PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Rosskopf, D; Bornhorst, A; Rimmbach, C; Schwahn, C; Kayser, A; Kruger, A; Tessmann, G; Geissler, I; Kroemer, HK; Volzke, H				Rosskopf, Dieter; Bornhorst, Alexa; Rimmbach, Christian; Schwahn, Christian; Kayser, Alexander; Krueger, Anne; Tessmann, Grietje; Geissler, Ingrid; Kroemer, Heyo K.; Voelzke, Henry			Comment on "A common genetic variant is associated with adult and childhood obesity"	SCIENCE			English	Editorial Material							INSIG-2	Contrary to the findings of Herbert et al. ( Reports, 14 April 2006, p. 279), homozygous carriers of the C allele of the rs7566605 variant near the INSIG2 gene did not exhibit a significantly increased risk for obesity in a large population-based cross-sectional German study. A subgroup analysis, however, revealed that this allele significantly increased the risk for obesity in already overweight individuals.	Ernst Moritz Arndt Univ Greifswald, Inst Pharmacol, Greifswald, Germany; Ernst Moritz Arndt Univ Greifswald, Inst Epidemiol & Social Med, Greifswald, Germany	Ernst Moritz Arndt Universitat Greifswald; Ernst Moritz Arndt Universitat Greifswald	Rosskopf, D (corresponding author), Ernst Moritz Arndt Univ Greifswald, Inst Pharmacol, Greifswald, Germany.	dieter.rosskopf@uni-greifswald.de	Meyre, David/D-7315-2011; Charles, Marie Aline/F-8567-2017; Jouret, Béatrice/AAC-8146-2019; Loos, Ruth/GON-5877-2022; Krüger, Anne/K-9539-2013; Charles, Marie Aline/S-1866-2019; Loos, Ruth J F/Q-2862-2016; O'Rahilly, Stephen/ABF-6509-2020; Dina, Christian R/D-3535-2015; FROGUEL, Philippe/O-6799-2017	Meyre, David/0000-0003-4850-7444; Charles, Marie Aline/0000-0003-4025-4390; Charles, Marie Aline/0000-0003-4025-4390; Loos, Ruth J F/0000-0002-8532-5087; O'Rahilly, Stephen/0000-0003-2199-4449; Dina, Christian R/0000-0002-7722-7348; FROGUEL, Philippe/0000-0003-2972-0784; Marre, Michel/0000-0002-3071-1837; Barroso, Ines/0000-0001-5800-4520	Medical Research Council [MC_U106179471, MC_U106188470, G9824984] Funding Source: Medline; Medical Research Council [G9824984, MC_U106179471, MC_U106188470] Funding Source: Medline; Medical Research Council [MC_U106188470, G9824984, MC_U106179471] Funding Source: Medline; Wellcome Trust [077016] Funding Source: Medline; MRC [MC_U106188470, G9824984] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Herbert A, 2006, SCIENCE, V312, P279, DOI 10.1126/science.1124779; John U, 2001, SOZ PRAVENTIV MED, V46, P186, DOI 10.1007/BF01324255; Sleight Peter, 2000, Curr Control Trials Cardiovasc Med, V1, P25, DOI 10.1186/CVM-1-1-025; Volzke H, 2004, J CLIN ENDOCR METAB, V89, P2145, DOI 10.1210/jc.2003-031028; Wolff B, 2005, J HYPERTENS, V23, P1361, DOI 10.1097/01.hjh.0000173518.06353.c2; Yabe D, 2003, P NATL ACAD SCI USA, V100, P3155, DOI 10.1073/pnas.0130116100; Yabe D, 2002, P NATL ACAD SCI USA, V99, P12753, DOI 10.1073/pnas.162488899	7	108	110	1	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 12	2007	315	5809								10.1126/science.1130571	http://dx.doi.org/10.1126/science.1130571			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124XZ	17218508				2022-12-28	WOS:000243407400024
J	Loos, RJF; Barroso, I; O'Rahilly, S; Wareham, NJ				Loos, Ruth J. F.; Barroso, Ines; O'Rahilly, Stephen; Wareham, Nicholas J.			Comment on "A common genetic variant is associated with adult and childhood obesity"	SCIENCE			English	Editorial Material								Herbert et al. ( Reports, 14 April 2006, p. 279) found that the rs7566605 genetic variant, located upstream of the INSIG2 gene, was consistently associated with increased body mass index. However, we found no evidence of association between rs7566605 and body mass index in two large ethnically homogeneous population-based cohorts. On the contrary, an opposite tendency was observed.	MRC, Epidemiol Unit, Cambridge, England; Wellcome Trust Res Labs, Metab Dis Grp, Sanger Inst, Hinxton, England; Univ Cambridge, Dept Clin Biochem, Cambridge Inst Med Res, Cambridge, England	Wellcome Trust Sanger Institute; University of Cambridge	Loos, RJF (corresponding author), MRC, Epidemiol Unit, Cambridge, England.	ruth.loos@mrc-epid.cam.ac.uk	Meyre, David/D-7315-2011; Charles, Marie Aline/F-8567-2017; Jouret, Béatrice/AAC-8146-2019; Loos, Ruth/GON-5877-2022; Krüger, Anne/K-9539-2013; Charles, Marie Aline/S-1866-2019; Loos, Ruth J F/Q-2862-2016; O'Rahilly, Stephen/ABF-6509-2020; Dina, Christian R/D-3535-2015; FROGUEL, Philippe/O-6799-2017	Meyre, David/0000-0003-4850-7444; Charles, Marie Aline/0000-0003-4025-4390; Charles, Marie Aline/0000-0003-4025-4390; Loos, Ruth J F/0000-0002-8532-5087; O'Rahilly, Stephen/0000-0003-2199-4449; Dina, Christian R/0000-0002-7722-7348; FROGUEL, Philippe/0000-0003-2972-0784; Marre, Michel/0000-0002-3071-1837; Barroso, Ines/0000-0001-5800-4520	Medical Research Council [MC_U106179471, MC_U106188470, G9824984] Funding Source: Medline; Medical Research Council [G9824984, MC_U106179471, MC_U106188470] Funding Source: Medline; Medical Research Council [MC_U106188470, G9824984, MC_U106179471] Funding Source: Medline; Wellcome Trust [077016] Funding Source: Medline; MRC [MC_U106188470, G9824984] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Day N, 1999, BRIT J CANCER, V80, P95; Herbert A, 2006, SCIENCE, V312, P279, DOI 10.1126/science.1124779; Wareham NJ, 1999, DIABETES CARE, V22, P262, DOI 10.2337/diacare.22.2.262	3	108	110	1	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 12	2007	315	5809								10.1126/science.1130012	http://dx.doi.org/10.1126/science.1130012			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124XZ	17218508	Green Accepted			2022-12-28	WOS:000243407400023
J	Dina, C; Meyre, D; Samson, C; Tichet, J; Marre, M; Jouret, B; Charles, MA; Balkau, B; Froguel, P				Dina, Christian; Meyre, David; Samson, Chantal; Tichet, Jean; Marre, Michel; Jouret, Beatrice; Charles, Marie Aline; Balkau, Beverley; Froguel, Philippe			Comment on "A common genetic variant is associated with adult and childhood obesity"	SCIENCE			English	Editorial Material							SUSCEPTIBILITY LOCUS	Herbert et al. ( Reports, 14 April 2006, p. 279) reported an association between the INSIG2 gene variant rs7566605 and obesity in four sample populations, under a recessive model. We attempted to replicate this result in 10,265 Caucasian individuals, combining family-based, case-control, and general population studies, but found no support for a major role of this variant in obesity.	Inst Pasteur, Inst Biol 8090, CNRS, F-59019 Lille, France; Inst Interreg Sante, Tours, France; Assistance Publ Hop Paris, Dept Diabetol, Hop Bichat Claude Bernard, Paris, France; Childrens Hosp, INSERM, U563, Toulouse, France; INSERM, U780, IFR69, Villejuif, France; Univ Paris Sud, Villejuif, France; Univ London Imperial Coll Sci Technol & Med, Dept Genom Med, London, England	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Imperial College London	Dina, C (corresponding author), Inst Pasteur, Inst Biol 8090, CNRS, F-59019 Lille, France.	dina@good.ibl.fr	Meyre, David/D-7315-2011; Charles, Marie Aline/F-8567-2017; Jouret, Béatrice/AAC-8146-2019; Loos, Ruth/GON-5877-2022; Krüger, Anne/K-9539-2013; Charles, Marie Aline/S-1866-2019; Loos, Ruth J F/Q-2862-2016; O'Rahilly, Stephen/ABF-6509-2020; Dina, Christian R/D-3535-2015; FROGUEL, Philippe/O-6799-2017	Meyre, David/0000-0003-4850-7444; Charles, Marie Aline/0000-0003-4025-4390; Charles, Marie Aline/0000-0003-4025-4390; Loos, Ruth J F/0000-0002-8532-5087; O'Rahilly, Stephen/0000-0003-2199-4449; Dina, Christian R/0000-0002-7722-7348; FROGUEL, Philippe/0000-0003-2972-0784; Marre, Michel/0000-0002-3071-1837; Barroso, Ines/0000-0001-5800-4520	Medical Research Council [MC_U106179471, MC_U106188470, G9824984] Funding Source: Medline; Medical Research Council [G9824984, MC_U106179471, MC_U106188470] Funding Source: Medline; Medical Research Council [MC_U106188470, G9824984, MC_U106179471] Funding Source: Medline; Wellcome Trust [077016] Funding Source: Medline; MRC [MC_U106188470, G9824984] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Balkau B, 1996, REV EPIDEMIOL SANTE, V44, P373; Bell CG, 2004, DIABETES, V53, P1857, DOI 10.2337/diabetes.53.7.1857; Bouatia-Naji N, 2006, DIABETES, V55, P545, DOI 10.2337/diabetes.55.02.06.db05-0971; GAUDERMAN MJ, 2005, QUANTO SOFTWARE; Hager J, 1998, NAT GENET, V20, P304, DOI 10.1038/3123; Herbert A, 2006, SCIENCE, V312, P279, DOI 10.1126/science.1124779; Heude B, 2004, OBES RES, V12, P499, DOI 10.1038/oby.2004.56; Lake SL, 2000, AM J HUM GENET, V67, P1515, DOI 10.1086/316895; Ott J, 2004, NEUROLOGY, V63, P955, DOI 10.1212/WNL.63.6.955; Tregouet DA, 1997, AM J HUM GENET, V61, P189, DOI 10.1086/513895; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	11	108	110	1	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 12	2007	315	5809								10.1126/science.1129402	http://dx.doi.org/10.1126/science.1129402			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124XZ	17218508				2022-12-28	WOS:000243407400022
J	Goldenfeld, N; Woese, C				Goldenfeld, Nigel; Woese, Carl			Biology's next revolution	NATURE			English	Editorial Material									Univ Illinois, Dept Phys, Urbana, IL 61801 USA; Univ Illinois, Inst Genom Biol, Urbana, IL 61801 USA; Univ Illinois, Dept Microbiol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Goldenfeld, N (corresponding author), Univ Illinois, Dept Phys, 1110 W Green St, Urbana, IL 61801 USA.							Frigaard NU, 2006, NATURE, V439, P847, DOI 10.1038/nature04435; Pedulla ML, 2003, CELL, V113, P171, DOI 10.1016/S0092-8674(03)00233-2; Sullivan MB, 2006, PLOS BIOL, V4, P1344, DOI 10.1371/journal.pbio.0040234; Vetsigian K, 2006, P NATL ACAD SCI USA, V103, P10696, DOI 10.1073/pnas.0603780103	4	170	181	1	74	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 25	2007	445	7126					369	369		10.1038/445369a	http://dx.doi.org/10.1038/445369a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	128WD	17251963	Green Submitted			2022-12-28	WOS:000243689500021
J	McCorry, D; McCorry, A				McCorry, Dougall; McCorry, Angea			Collapse with loss of awareness	BRITISH MEDICAL JOURNAL			English	Editorial Material									Walton Ctr, Dept Neurosci, Liverpool L9 7LJ, Merseyside, England; Mather Ave Surg, Liverpool, Merseyside, England	Walton Centre	McCorry, D (corresponding author), Walton Ctr, Dept Neurosci, Liverpool L9 7LJ, Merseyside, England.	d.j.mccorry@liv.ac.uk						Lempert T, 1996, J ROY SOC MED, V89, P372, DOI 10.1177/014107689608900705; National Institute for Health and Clinical Excellence, EP DIAGN MAN EP AD C	2	2	2	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 20	2007	334	7585					153	153		10.1136/bmj.39070.390961.DE	http://dx.doi.org/10.1136/bmj.39070.390961.DE			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	130LP	17235097	Green Published			2022-12-28	WOS:000243801400037
J	Tey, A; Grant, B; Harbison, D; Sutherand, S; Kearns, P; Sanders, R				Tey, Adrian; Grant, Barbara; Harbison, Dawn; Sutherand, Shona; Kearns, Patrick; Sanders, Roshini			Quality improvement report - Redesign and modernisation of an NHS cataract service (Fife 1997-2004): multifaceted approach	BRITISH MEDICAL JOURNAL			English	Article							VISUAL IMPAIRMENT; OF-LIFE; SURGERY; POPULATION	Better design of space and staffing can result in more operations and training opportunities and reduced waiting times.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Ophthalmol, Dundee DD1 9SY, Scotland; Queen Margaret Hosp, Cataract Unit, Dunfermline KY12 0SU, Fife, Scotland	University of Dundee	Tey, A (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Ophthalmol, Dundee DD1 9SY, Scotland.	atey7@yahoo.co.uk						BRENNER MH, 1993, ARCH OPHTHALMOL-CHIC, V111, P680, DOI 10.1001/archopht.1993.01090050114040; Desai P, 1999, BRIT J OPHTHALMOL, V83, P1336, DOI 10.1136/bjo.83.12.1336; Desai P, 1996, BRIT J OPHTHALMOL, V80, P868, DOI 10.1136/bjo.80.10.868; Desai P, 1999, BRIT J OPHTHALMOL, V83, P893, DOI 10.1136/bjo.83.8.893; Ferris JD, 2005, EYE, V19, P1090, DOI 10.1038/sj.eye.6702007; Gray CS, 1999, BRIT MED J, V318, P1367, DOI 10.1136/bmj.318.7195.1367; Guly C, 2005, BRIT MED J, V331, P1338, DOI 10.1136/bmj.331.7528.1338-b; Harrad R, 2002, BMJ-BRIT MED J, V325, P1033, DOI 10.1136/bmj.325.7371.1033; JAKKO L, 1999, ACTA OPHTHALMOL SCAN, V77, P681; Kelly SP, 2005, LANCET, V366, P1691, DOI 10.1016/S0140-6736(05)67686-6; Minassian DC, 2000, BRIT J OPHTHALMOL, V84, P4, DOI 10.1136/bjo.84.1.4; RAFERTY J, 1994, CATARACT SURG; Reidy A, 1998, BRIT MED J, V316, P1643, DOI 10.1136/bmj.316.7145.1643; *ROYAL COLL OPHTH, 2004, CAT SURG GUID; Taylor HR, 2000, BRIT J OPHTHALMOL, V84, P1, DOI 10.1136/bjo.84.1.1; *UK DEP HLTH, ACT CAT GOOD PRACT G; *UK DEP HLTH, HOSP ACT EP STAT	17	20	20	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 20	2007	334	7585					148	152		10.1136/bmj.39050.520069.BE	http://dx.doi.org/10.1136/bmj.39050.520069.BE			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	130LP	17235096	Green Published			2022-12-28	WOS:000243801400036
J	Brikci, N; Philips, M				Brikci, Nouria; Philips, Mit			User fees or equity funds in low-income countries	LANCET			English	Editorial Material							HEALTH-CARE; LESSONS		Med Sans Frontieres, Programmes Unit, London EC1N 8QX, England; Med Sans Frontieres, Brussels, Belgium	Doctors Without Borders; Doctors Without Borders	Brikci, N (corresponding author), Med Sans Frontieres, Programmes Unit, London EC1N 8QX, England.	nouria.brikci@london.msf.org						ABELSMITH B, 1992, HLTH POLICY PLAN, V7, P4; Ardeshir Sepehri, 2001, Journal of International Development, V13, P183, DOI 10.1002/jid.726; ATKIN J, 1986, SOC SCI MED, V22, P321; Ensor T, 2004, HEALTH POLICY PLANN, V19, P69, DOI 10.1093/heapol/czh009; GERTLER P, 1987, J ECONOMETRICS, V36, P67, DOI 10.1016/0304-4076(87)90044-3; Gilson L, 1997, HEALTH POLICY PLANN, V12, P273, DOI 10.1093/oxfordjournals.heapol.a018882; GRIFFIN C, 1987, 37 EDI WORLD BANK; Hsiao WC., 2001, UNMET HLTH NEEDS 2 B; KASSA A, 2005, ACCES SOINS MORTALIT; Kutzin J, 1998, CRITICAL CHALLENGES; Meessen B, 2006, LANCET, V368, P2253, DOI 10.1016/S0140-6736(06)69899-1; *MS BELG, 2006, ACC HEALTHC POST WAR; *MSB BELG, 2004, ACC SOINS SANT BUR R; Perin I, 2003, LANCET, V361, P1216, DOI 10.1016/S0140-6736(03)12956-X; Rice T, 1994, Med Care Rev, V51, P235, DOI 10.1177/107755879405100302; Robinson R, 2002, FUNDING HLTH CARE OP; Shaw RP, 1995, FINANCING HLTH CARE	17	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 6	2007	369	9555					10	11		10.1016/S0140-6736(07)60008-7	http://dx.doi.org/10.1016/S0140-6736(07)60008-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	125AK	17208624				2022-12-28	WOS:000243413700008
J	Kikkawa, M; Metlagel, Z				Kikkawa, Masahide; Metlagel, Zoltan			A molecular "Zipper" for Microtubules	CELL			English	Editorial Material							CRYOELECTRON TOMOGRAPHY; PLUS-END; ARCHITECTURE; LATTICE; SEAM; EB1	The dynamics of the microtubule cytoskeleton are controlled by microtubule-associated proteins (MAPs). In this issue, Sandblad et al. (2006) show that Mal3p, the yeast EB1 homolog, belongs to a new class of MAPs that "zipper" up the seam of the microtubule lattice.	Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Kikkawa, M (corresponding author), Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA.	masahide.kikkawa@utsouthwestern.edu	Kikkawa, Masahide/A-6692-2010	Kikkawa, Masahide/0000-0001-7656-8194				Austin JR, 2005, J CELL SCI, V118, P3895, DOI 10.1242/jcs.02512; BOUCHETMARQUIS C, 2006, BIOL CELL; KIKKAWA M, 1994, J CELL BIOL, V127, P1965, DOI 10.1083/jcb.127.6.1965; Lansbergen G, 2006, TRAFFIC, V7, P499, DOI 10.1111/j.1600-0854.2006.00400.x; MANDELKOW EM, 1986, J CELL BIOL, V102, P1067, DOI 10.1083/jcb.102.3.1067; Nicastro D, 2006, SCIENCE, V313, P944, DOI 10.1126/science.1128618; SANDBLAD L, 2006, CELL; SU LK, 1995, CANCER RES, V55, P2972; Sui HX, 2006, NATURE, V442, P475, DOI 10.1038/nature04816; Tirnauer JS, 2002, MOL BIOL CELL, V13, P3614, DOI 10.1091/mbc.E02-04-0210	10	7	7	0	0	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 29	2006	127	7					1302	1304		10.1016/j.cell.2006.12.009	http://dx.doi.org/10.1016/j.cell.2006.12.009			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	128WI	17190594	Bronze			2022-12-28	WOS:000243690000009
J	Zwaka, TP				Zwaka, Thomas P.			Keeping the noise down in ES cells	CELL			English	Editorial Material							EMBRYONIC STEM-CELLS; DEVELOPMENTAL REGULATORS; POLYCOMB	A new report (Szutorisz et al., 2006) suggests that embryonic stem (ES) cells adopt an unusual strategy to remain perpetually poised for differentiation. Apparently, ES cells use the proteasome to target transcriptional preinitiation complexes, thus minimizing transcriptional noise at genes that promote differentiation.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Ctr Cell & Genet Therapy, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Zwaka, TP (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Pl, Houston, TX 77030 USA.	tpzwaka@bcm.edu						Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Collins GA, 2006, CURR OPIN GENET DEV, V16, P197, DOI 10.1016/j.gde.2006.02.009; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Meshorer E, 2006, DEV CELL, V10, P105, DOI 10.1016/j.devcel.2005.10.017; SZUTORISZ H, 2006, CELL; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Zwaka TP, 2005, DEVELOPMENT, V132, P227, DOI 10.1242/dev.01586	10	7	8	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 29	2006	127	7					1301	1302		10.1016/j.cell.2006.12.011	http://dx.doi.org/10.1016/j.cell.2006.12.011			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	128WI	17190593	Bronze			2022-12-28	WOS:000243690000008
J	Allemann, Y; Hutter, D; Lipp, E; Sartori, C; Duplain, H; Egli, M; Cook, S; Scherrer, U; Seiler, C				Allemann, Yves; Hutter, Damian; Lipp, Ernst; Sartori, Claudio; Duplain, Herve; Egli, Marc; Cook, Stephane; Scherrer, Urs; Seiler, Christian			Patent Foramen ovale and high-altitude pulmonary edema	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DECOMPRESSION ILLNESS; HYPOXEMIA; CLOSURE; PREVENTION; PREVALENCE; PRESSURE	Context Individuals susceptible to high-altitude pulmonary edema ( HAPE) are characterized by exaggerated pulmonary hypertension and arterial hypoxemia at high altitude, but the underlying mechanism is incompletely understood. Anecdotal evidence suggests that shunting across a patent foramen ovale (PFO) may exacerbate hypoxemia in HAPE. Objective We hypothesized that PFO is more frequent in HAPE-susceptible individuals and may contribute to more severe arterial hypoxemia at high altitude. Design, Setting, and Participants Case-control study of 16 HAPE-susceptible participants and 19 mountaineers resistant to this condition ( repeated climbing to peaks above 4000 m and no symptoms of HAPE). Main Outcome Measures Presence of PFO determined by transesophageal echocardiography, estimated pulmonary artery pressure by Doppler echocardiography, and arterial oxygen saturation measured by pulse oximetry in HAPE-susceptible and HAPE-resistant participants at low ( 550 m) and high altitude ( 4559 m). Results The frequency of PFO was more than 4 times higher in HAPE-susceptible than in HAPE-resistant participants, both at low altitude (56% vs 11%, P=.004; odds ratio [ OR], 10.9 [95% confidence interval {CI}, 1.9-64.0]) and high altitude (69% vs 16%, P=. 001; OR, 11.7 [ 95% CI, 2.3-59.5]). At high altitude, mean (SD) arterial oxygen saturation prior to the onset of pulmonary edema was significantly lower in HAPE-susceptible participants than in the control group (73% [10%] vs 83% [7%], P=. 001). Moreover, in the HAPE-susceptible group, participants with a large PFO had more severe arterial hypoxemia (65% [6%] vs 77% [8%], P=. 02) than those with smaller or no PFO. Conclusions Patent foramen ovale was roughly 4 times more frequent in HAPE-susceptible mountaineers than in participants resistant to this condition. At high altitude, HAPE-susceptible participants with a large PFO had more severe hypoxemia. We speculate that at high altitude, a large PFO may contribute to exaggerated arterial hypoxemia and facilitate HAPE.	Univ Hosp Bern, Inselspital, Swiss Cardiovasc Ctr Bern, Dept Cardiol, CH-3010 Bern, Switzerland; CHU Vaudois, Dept Internal Med, Lausanne, Switzerland; CHU Vaudois, Botnar Ctr Extreme Med, Lausanne, Switzerland	University of Bern; University Hospital of Bern; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Allemann, Y (corresponding author), Univ Hosp Bern, Inselspital, Swiss Cardiovasc Ctr Bern, Dept Cardiol, CH-3010 Bern, Switzerland.	yves.allemann@insel.ch						Allemann Y, 2000, AM J PHYSIOL-HEART C, V279, pH2013, DOI 10.1152/ajpheart.2000.279.4.H2013; BARTSCH P, 1991, NEW ENGL J MED, V325, P1284, DOI 10.1056/NEJM199110313251805; Das BB, 2004, ARCH PEDIAT ADOL MED, V158, P1170, DOI 10.1001/archpedi.158.12.1170; Godart F, 2000, EUR HEART J, V21, P483, DOI 10.1053/euhj.1999.1944; HACKETT PH, 1988, J APPL PHYSIOL, V64, P1268, DOI 10.1152/jappl.1988.64.3.1268; HACKETT PH, 1992, INT J SPORTS MED, V13, pS68, DOI 10.1055/s-2007-1024599; Hegland DD, 2005, NEW ENGL J MED, V353, P2385, DOI 10.1056/NEJMcps050473; Kerut EK, 2001, J AM COLL CARDIOL, V38, P613, DOI 10.1016/S0735-1097(01)01427-9; Landzberg MJ, 2004, HEART, V90, P219, DOI 10.1136/hrt.2003.019315; LEVINE BD, 1991, ANN INTERN MED, V114, P569, DOI 10.7326/0003-4819-114-7-569; Maggiorini M, 2001, CIRCULATION, V103, P2078; Sartori C, 2004, EUR RESPIR J, V23, P916, DOI 10.1183/09031936.04.00115304; Sartori C, 2002, NEW ENGL J MED, V346, P1631, DOI 10.1056/NEJMoa013183; Scherrer U, 1996, NEW ENGL J MED, V334, P624, DOI 10.1056/NEJM199603073341003; Seiler C, 2004, HEART, V90, P1245, DOI 10.1136/hrt.2003.031500; Shanoudy H, 1998, CHEST, V113, P91, DOI 10.1378/chest.113.1.91; Soliman A, 1999, J AM SOC ECHOCARDIOG, V12, P99, DOI 10.1016/S0894-7317(99)70121-5; Torti SR, 2004, EUR HEART J, V25, P1014, DOI 10.1016/j.ehj.2004.04.028; WAGNER PD, 1987, J APPL PHYSIOL, V63, P2348, DOI 10.1152/jappl.1987.63.6.2348; Wilmshurst PT, 2000, LANCET, V356, P1648, DOI 10.1016/S0140-6736(00)03160-3	20	105	105	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	2006	296	24					2954	2958		10.1001/jama.296.24.2954	http://dx.doi.org/10.1001/jama.296.24.2954			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	120FD	17190896	Bronze			2022-12-28	WOS:000243069000027
J	Mari, F; Polettini, A; Lippi, D; Bertol, E				Mari, Francesco; Polettini, Aldo; Lippi, Donatella; Bertol, Elisabetta			The mysterious death of Francesco I de' Medici and Bianca Cappello: an arsenic murder?	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Florence, Dept Anat Histol & Legal Med, Chair Forens Toxicol, I-50134 Florence, Italy; Univ Florence, Dept Anat Histol & Legal Med, Chair Hist Med, I-50134 Florence, Italy; Univ Pavia, Dept Legal Med & Publ Hlth, Chair Forens Toxicol, I-27100 Pavia, Italy	University of Florence; University of Florence; University of Pavia	Mari, F (corresponding author), Univ Florence, Dept Anat Histol & Legal Med, Chair Forens Toxicol, I-50134 Florence, Italy.	Francesco.mari@unifi.it		BERTOL, ELISABETTA/0000-0003-3693-0552				BASELT RC, 2004, DIPOSITION TOXIC DRU; COOPMAN V, 1997, 35 TIAFT M AUG 24 28; DIDOMENICO C, 2005, MED DINASTIA RAGGI X; FEYNES G, 1937, RIV STORIA SCI MED N, V19, P1; Hindmarsh JT, 2002, CLIN BIOCHEM, V35, P1, DOI 10.1016/S0009-9120(01)00282-X; LINDH U, 1980, SCI TOTAL ENVIRON, V16, P109, DOI 10.1016/0048-9697(80)90018-2; MARI F, 2001, VELENI INTRIGHI DELI; SALTINI GE, 1863, ARCH STORICO ITAL, V18, P21; Saltini Guglielmo Enrico, 1898, BIANCA CAPPELLO FRAN; Wiechula D, 2003, BIOL TRACE ELEM RES, V92, P17, DOI 10.1385/BTER:92:1:17	10	22	23	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 23	2006	333	7582					1299	1301		10.1136/bmj.38996.682234.AE	http://dx.doi.org/10.1136/bmj.38996.682234.AE			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121MC	17185715	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000243160700013
J	Marson, A; Kretschmer, K; Frampton, GM; Jacobsen, ES; Polansky, JK; Maclsaac, KD; Levine, SS; Fraenkel, E; von Boehmer, H; Young, RA				Marson, Alexander; Kretschmer, Karsten; Frampton, Garrett M.; Jacobsen, Elizabeth S.; Polansky, Julia K.; Maclsaac, Kenzie D.; Levine, Stuart S.; Fraenkel, Ernest; von Boehmer, Harald; Young, Richard A.			Foxp3 occupancy and regulation of key target genes during T-cell stimulation	NATURE			English	Article							LYMPHOID TYROSINE PHOSPHATASE; TRANSCRIPTION; SCURFIN; ENTEROPATHY; EXPRESSION; PROTEIN	Foxp3(+) CD4(+) CD25(+) regulatory T (T-reg) cells are essential for the prevention of autoimmunity(1,2). T-reg cells have an attenuated cytokine response to T-cell receptor stimulation, and can suppress the proliferation and effector function of neighbouring T cells(3,4). The forkhead transcription factor Foxp3 ( forkhead box P3) is selectively expressed in T-reg cells, is required for T-reg development and function, and is sufficient to induce a Treg phenotype in conventional CD4(+) CD25(-) T cells(5-8). Mutations in Foxp3 cause severe, multi-organ autoimmunity in both human and mouse(9-11). FOXP3 can cooperate in a DNA-binding complex with NFAT ( nuclear factor of activated T cells) to regulate the transcription of several known target genes(12). However, the global set of genes regulated directly by Foxp3 is not known and consequently, how this transcription factor controls the gene expression programme for T-reg function is not understood. Here we identify Foxp3 target genes and report that many of these are key modulators of T-cell activation and function. Remarkably, the predominant, although not exclusive, effect of Foxp3 occupancy is to suppress the activation of target genes on T-cell stimulation. Foxp3 suppression of its targets appears to be crucial for the normal function of T-reg cells, because overactive variants of some target genes are known to be associated with autoimmune disease.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA; MIT, Biol Engn Div, Cambridge, MA 02139 USA; MIT, Comp Sci & Artificial Intelligence Lab, Cambridge, MA 02139 USA; Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Young, RA (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	Harald_von_Boehmer@dfci.harvard.edu; young@wi.mit.edu	Young, Richard A/F-6495-2012; Kretschmer, Karsten/E-8174-2010; Polansky-Biskup, Julia K./J-5937-2017	Young, Richard A/0000-0001-8855-8647; Kretschmer, Karsten/0000-0001-6770-4078; Polansky-Biskup, Julia K./0000-0003-4727-2540; Fraenkel, Ernest/0000-0001-9249-8181; Levine, Stuart/0000-0001-7363-562X; Frampton, Garrett/0000-0002-2361-2750	NATIONAL CANCER INSTITUTE [P01CA109901] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG002668] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA109901, P01 CA109901-067138] Funding Source: Medline; NHGRI NIH HHS [R01 HG002668-04A1, R01 HG002668] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Baecher-Allan C, 2006, IMMUNOL REV, V212, P203, DOI 10.1111/j.0105-2896.2006.00417.x; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Bottini N, 2004, NAT GENET, V36, P337, DOI 10.1038/ng1323; Bottini N, 2006, SEMIN IMMUNOL, V18, P207, DOI 10.1016/j.smim.2006.03.008; Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733; Bruder D, 2004, EUR J IMMUNOL, V34, P623, DOI 10.1002/eji.200324799; Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784; Chen CX, 2006, J BIOL CHEM, V281, P36828, DOI 10.1074/jbc.M608848200; Cobb BS, 2006, J EXP MED, V203, P2519, DOI 10.1084/jem.20061692; Fontenot JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; Harbison CT, 2004, NATURE, V431, P99, DOI 10.1038/nature02800; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Iellem A, 2001, J EXP MED, V194, P847, DOI 10.1084/jem.194.6.847; Jordan MS, 2001, NAT IMMUNOL, V2, P301, DOI 10.1038/86302; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; Klein L, 2003, P NATL ACAD SCI USA, V100, P8886, DOI 10.1073/pnas.1533365100; Kretschmer K, 2005, NAT IMMUNOL, V6, P1219, DOI 10.1038/ni1265; McHugh RS, 2002, IMMUNITY, V16, P311, DOI 10.1016/S1074-7613(02)00280-7; Myers LM, 2005, TRENDS IMMUNOL, V26, P440, DOI 10.1016/j.it.2005.06.003; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Schubert LA, 2001, J BIOL CHEM, V276, P37672, DOI 10.1074/jbc.M104521200; Shevach EM, 2002, NAT REV IMMUNOL, V2, P389, DOI 10.1038/nri821; Stanford WL, 1997, J EXP MED, V186, P705, DOI 10.1084/jem.186.5.705; Vang T, 2005, NAT GENET, V37, P1317, DOI 10.1038/ng1673; von Boehmer H, 2005, NAT IMMUNOL, V6, P338, DOI 10.1038/ni1180; Wildin RS, 2001, NAT GENET, V27, P18, DOI 10.1038/83707; Wu JS, 2006, J BIOL CHEM, V281, P11002, DOI 10.1074/jbc.M600498200; Wu YQ, 2006, CELL, V126, P375, DOI 10.1016/j.cell.2006.05.042	30	551	598	0	36	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	FEB 22	2007	445	7130					931	935		10.1038/nature05478	http://dx.doi.org/10.1038/nature05478			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	138CR	17237765	Green Accepted			2022-12-28	WOS:000244341200053
J	Cornely, OA; Maertens, J; Winston, DJ; Perfect, J; Ullmann, AJ; Walsh, TJ; Helfgott, D; Holowiecki, J; Stockelberg, D; Goh, Y; Petrini, M; Hardalo, C; Suresh, R; Angulo-Gonzalez, D				Cornely, Oliver A.; Maertens, Johan; Winston, Drew J.; Perfect, John; Ullmann, Andrew J.; Walsh, Thomas J.; Helfgott, David; Holowiecki, Jerzy; Stockelberg, Dick; Goh, Yeow-Tee; Petrini, Mario; Hardalo, Cathy; Suresh, Ramachandran; Angulo-Gonzalez, David			Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INVASIVE FUNGAL-INFECTIONS; ANTIFUNGAL PROPHYLAXIS; HEMATOLOGIC MALIGNANCY; ORAL FLUCONAZOLE; CONTROLLED-TRIAL; CANCER-PATIENTS; DOUBLE-BLIND; MULTICENTER; ASPERGILLOSIS; METAANALYSIS	BACKGROUND: Patients with neutropenia resulting from chemotherapy for acute myelogenous leukemia or the myelodysplastic syndrome are at high risk for difficult-to-treat and often fatal invasive fungal infections. METHODS: In this randomized, multicenter study involving evaluators who were unaware of treatment assignments, we compared the efficacy and safety of posaconazole with those of fluconazole or itraconazole as prophylaxis for patients with prolonged neutropenia. Patients received prophylaxis with each cycle of chemotherapy until recovery from neutropenia and complete remission, until occurrence of an invasive fungal infection, or for up to 12 weeks, whichever came first. We compared the incidence of proven or probable invasive fungal infections during treatment (the primary end point) between the posaconazole and fluconazole or itraconazole groups; death from any cause and time to death were secondary end points. RESULTS: A total of 304 patients were randomly assigned to receive posaconazole, and 298 patients were randomly assigned to receive fluconazole (240) or itraconazole (58). Proven or probable invasive fungal infections were reported in 7 patients (2%) in the posaconazole group and 25 patients (8%) in the fluconazole or itraconazole group (absolute reduction in the posaconazole group, -6%; 95% confidence interval, -9.7 to -2.5%; P<0.001), fulfilling statistical criteria for superiority. Significantly fewer patients in the posaconazole group had invasive aspergillosis (2 [1%] vs. 20 [7%], P<0.001). Survival was significantly longer among recipients of posaconazole than among recipients of fluconazole or itraconazole (P=0.04). Serious adverse events possibly or probably related to treatment were reported by 19 patients (6%) in the posaconazole group and 6 patients (2%) in the fluconazole or itraconazole group (P=0.01). The most common treatment-related adverse events in both groups were gastrointestinal tract disturbances. CONCLUSIONS: In patients undergoing chemotherapy for acute myelogenous leukemia or the myelodysplastic syndrome, posaconazole prevented invasive fungal infections more effectively than did either fluconazole or itraconazole and improved overall survival. There were more serious adverse events possibly or probably related to treatment in the posaconazole group.	Univ Cologne, Cologne, Germany; Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium; Univ Calif Los Angeles, Los Angeles, CA USA; Duke Univ, Med Ctr, Durham, NC USA; Johannes Gutenberg Univ Mainz, D-6500 Mainz, Germany; NCI, Bethesda, MD 20892 USA; Weill Cornell Med Coll, New York, NY USA; Silesian Med Univ, Katowice, Poland; Sahlgrens Univ Hosp, Gothenburg, Sweden; Singapore Gen Hosp, Singapore 0316, Singapore; Univ Pisa, Pisa, Italy; Schering Plough Corp, Res Inst, Kenilworth, NJ 07033 USA	University of Cologne; KU Leuven; University Hospital Leuven; University of California System; University of California Los Angeles; Duke University; Johannes Gutenberg University of Mainz; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Cornell University; Medical University Silesia; Sahlgrenska University Hospital; Singapore General Hospital; University of Pisa; Merck & Company; Schering Plough Corporation	Cornely, OA (corresponding author), Klinikum Univ Koln, Innere Med Klin, D-50924 Cologne, Germany.	oliver.cornely@uni-koeln.de	Cornely, Oliver A./J-5095-2013; Ullmann, AJ/AAQ-1724-2021; Holowiecki, Jerzy/AAW-7928-2021	Cornely, Oliver A./0000-0001-9599-3137; 	NATIONAL CANCER INSTITUTE [Z01SC006830, ZIASC006830] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ascioglu S, 2002, CLIN INFECT DIS, V34, P7, DOI 10.1086/323335; Boutati EI, 1997, BLOOD, V90, P999, DOI 10.1182/blood.V90.3.999.999_999_1008; BOW EJ, 1995, CLIN INFECT DIS, V21, P361, DOI 10.1093/clinids/21.2.361; Compas D, 1996, J CHROMATOGR B, V687, P453, DOI 10.1016/S0378-4347(96)00245-9; COOK RJ, 1995, BRIT MED J, V310, P1056; Cornely OA, 2003, BLOOD, V101, P3365, DOI 10.1182/blood-2002-05-1356; Denning DW, 1998, J INFECTION, V37, P173, DOI 10.1016/S0163-4453(98)80173-4; Glasmacher A, 2006, J ANTIMICROB CHEMOTH, V57, P317, DOI 10.1093/jac/dki440; Glasmacher A, 2003, J CLIN ONCOL, V21, P4615, DOI 10.1200/JCO.2003.04.052; GOODMAN JL, 1992, NEW ENGL J MED, V326, P845, DOI 10.1056/NEJM199203263261301; Groll Andreas H, 2005, Expert Rev Anti Infect Ther, V3, P467, DOI 10.1586/14787210.3.4.467; Hope WW, 2005, LANCET INFECT DIS, V5, P609, DOI 10.1016/S1473-3099(05)70238-3; Kanda Y, 2000, CANCER, V89, P1611, DOI 10.1002/1097-0142(20001001)89:7&lt;1611::AID-CNCR27&gt;3.0.CO;2-B; Lin SJ, 2001, CLIN INFECT DIS, V32, P358, DOI 10.1086/318483; Marr KA, 2004, BLOOD, V103, P1527, DOI 10.1182/blood-2003-08-2644; Moraes LA, 1999, THER DRUG MONIT, V21, P200, DOI 10.1097/00007691-199904000-00010; NCCLS, 2002, REF METH BROTH DIL A, V22; NCCLS, 2002, M38A NCCLS; *NCI CANC THER EV, 1999, COMM TOX CRIT MAN; Petraitiene R, 2001, ANTIMICROB AGENTS CH, V45, P857, DOI 10.1128/AAC.45.3.857-869.2001; Prentice HG, 2000, BRIT J HAEMATOL, V110, P273, DOI 10.1046/j.1365-2141.2000.02014.x; Raad II, 2006, CLIN INFECT DIS, V42, P1398, DOI 10.1086/503425; Roden MM, 2005, CLIN INFECT DIS, V41, P634, DOI 10.1086/432579; Rotstein C, 1999, CLIN INFECT DIS, V28, P331, DOI 10.1086/515128; Sabatelli F, 2006, ANTIMICROB AGENTS CH, V50, P2009, DOI 10.1128/AAC.00163-06; Shen JX, 2007, J PHARMACEUT BIOMED, V43, P228, DOI 10.1016/j.jpba.2006.06.011; SLAVIN MA, 1995, J INFECT DIS, V171, P1545, DOI 10.1093/infdis/171.6.1545; Ullmann AJ, 2006, ANTIMICROB AGENTS CH, V50, P658, DOI 10.1128/AAC.50.2.658-666.2006; van Burik JAH, 2006, CLIN INFECT DIS, V42, pE61, DOI 10.1086/500212; Vardakas KZ, 2006, BRIT J HAEMATOL, V132, P665, DOI 10.1111/j.1365-2141.2006.05966.x; Vardakas KZ, 2005, BRIT J HAEMATOL, V131, P22, DOI 10.1111/j.1365-2141.2005.05727.x; Viscoli C, 1999, CLIN INFECT DIS, V28, P1071, DOI 10.1086/514731; VONBIFF M, 1995, RESPIRATION, V62, P341; WINSTON DJ, 1993, ANN INTERN MED, V118, P495, DOI 10.7326/0003-4819-118-7-199304010-00003; Winston DJ, 2003, ANN INTERN MED, V138, P705, DOI 10.7326/0003-4819-138-9-200305060-00006	35	1231	1276	1	40	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 25	2007	356	4					348	359		10.1056/NEJMoa061094	http://dx.doi.org/10.1056/NEJMoa061094			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128FT	17251531				2022-12-28	WOS:000243644300005
J	Steinbrook, R				Steinbrook, Robert			Guidance for guidelines	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material												rsteinbrook@attglobal.net						Deyo RA, 1997, NEW ENGL J MED, V336, P1176, DOI 10.1056/NEJM199704173361611; Field MJ, 1990, CLIN PRACTICE GUIDEL; Hasenfeld R, 2003, QUAL SAF HEALTH CARE, V12, P428, DOI 10.1136/qhc.12.6.428; Taylor R, 2005, NATURE, V437, P1070, DOI 10.1038/4371070a; Wilensky GR, 2006, HEALTH AFFAIR, V25, pW572, DOI 10.1377/hlthaff.25.w572	5	87	95	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 25	2007	356	4					331	333		10.1056/NEJMp068282	http://dx.doi.org/10.1056/NEJMp068282			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128FT	17251529				2022-12-28	WOS:000243644300003
J	Lesperance, F; Frasure-Smith, N; Koszycki, D; Laliberte, MA; van Zyl, LT; Baker, B; Swenson, JR; Ghatavi, K; Abramson, BL; Dorian, P; Guertin, MC				Lesperance, Francois; Frasure-Smith, Nancy; Koszycki, Diana; Laliberte, Marc-Andre; van Zyl, Louis T.; Baker, Brian; Swenson, John Robert; Ghatavi, Kayhan; Abramson, Beth L.; Dorian, Paul; Guertin, Marie-Claude		CREATE Investigators	Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease - The Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							STAR-ASTERISK-D; SEQUENCED TREATMENT ALTERNATIVES; COLLABORATIVE RESEARCH-PROGRAM; MAJOR DEPRESSION; ENHANCING RECOVERY; DOUBLE-BLIND; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; CLINICAL MANAGEMENT; RISK-FACTOR	Context Few randomized controlled trials have evaluated the efficacy of treatments for major depression in patients with coronary artery disease ( CAD). None have simultaneously evaluated an antidepressant and short-term psychotherapy. Objective To document the short-term efficacy of a selective serotonin reuptake inhibitor ( citalopram) and interpersonal psychotherapy (IPT) in reducing depressive symptoms in patients with CAD and major depression. Design, Setting, and Participants The Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy, a randomized, controlled, 12-week, parallel-group, 2 x 2 factorial trial conducted May 1, 2002, to March 20, 2006, among 284 patients with CAD from 9 Canadian academic centers. All patients met Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria for diagnosis of major depression of 4 weeks' duration or longer and had baseline 24-item Hamilton Depression Rating Scale (HAM-D) scores of 20 or higher. Interventions Participants underwent 2 separate randomizations: ( 1) to receive 12 weekly sessions of IPT plus clinical management (n=142) or clinical management only (n=142) and ( 2) to receive 12 weeks of citalopram, 20 to 40 mg/d (n=142), or matching placebo (n=142). Main Outcome Measures The primary outcome measure was change between baseline and 12 weeks on the 24-item HAM-D, administered blindly during centralized telephone interviews ( tested at alpha=.033); the secondary outcome measure was self-reported Beck Depression Inventory II (BDI-II) score ( tested at alpha=.017). Results Citalopram was superior to placebo in reducing 12-week HAM-D scores ( mean difference, 3.3 points; 96.7% confidence interval [CI], 0.80-5.85; P=. 005), with a small to medium effect size of 0.33. Mean HAM-D response (52.8% vs 40.1%; P=. 03) and remission rates (35.9% vs 22.5%; P=. 01) and the reduction in BDI-II scores ( difference, 3.6 points; 98.3% CI, 0.58-6.64; P=. 005; effect size=0.33) also favored citalopram. There was no evidence of a benefit of IPT over clinical management, with the mean HAM-D difference favoring clinical management (- 2.26 points; 96.7% CI, - 4.78 to 0.27; P=. 06; effect size, 0.23). The difference on the BDI-II did not favor clinical management (1.13 points; 98.3% CI, - 1.90 to 4.16; P=. 37; effect size=0.11). Conclusions This trial documents the efficacy of citalopram administered in conjunction with weekly clinical management for major depression among patients with CAD and found no evidence of added value of IPT over clinical management. Based on these results and those of previous trials, citalopram or sertraline plus clinical management should be considered as a first-step treatment for patients with CAD and major depression.	Univ Montreal, Ctr Hosp, Res Ctr, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Dept Psychiat, Montreal, PQ H3C 3J7, Canada; Montreal Heart Inst, Res Ctr, Montreal, PQ H1T 1C8, Canada; Montreal Heart Inst, Dept Psychosomat Med, Montreal, PQ H1T 1C8, Canada; Montreal Heart Inst, Coordinating Ctr, Montreal, PQ H1T 1C8, Canada; McGill Univ, Dept Psychiat, Montreal, PQ, Canada; McGill Univ, Sch Nursing, Montreal, PQ, Canada; Univ Ottawa, Dept Psychiat, Ottawa, ON K1N 6N5, Canada; Univ Ottawa, Royal Ottawa Hosp, Mental Hlth Res Inst, Ottawa, ON, Canada; Univ Ottawa, Inst Heart, Ottawa, ON, Canada; Ottawa Hosp, Dept Psychiat, Ottawa, ON, Canada; Queens Univ, Dept Psychiat, Kingston, ON K7L 3N6, Canada; Kingston Gen Hosp, Kingston, ON K7L 2V7, Canada; Univ Hlth Network, Dept Psychiat, Toronto, ON, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada; St Michaels Hosp, Div Cardiol, Toronto, ON M5B 1W8, Canada; St Michaels Hosp, Cardiac Prevent Ctr, Toronto, ON M5B 1W8, Canada; Dalhousie Univ, Dept Psychiat, Capital Dist Hlth Author, Halifax, NS, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal; McGill University; McGill University; University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; Ottawa Hospital Research Institute; Queens University - Canada; Queens University - Canada; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; Dalhousie University	Lesperance, F (corresponding author), Univ Montreal, Ctr Hosp, Res Ctr, 1560 Sherbrooke E, Montreal, PQ H2L 4M1, Canada.	francois.lesperance@umontreal.ca	Lesperance, Francois/C-4716-2015	Lesperance, Francois/0000-0003-4604-2823				Alexopoulos GS, 2004, NEUROPSYCHOPHARMACOL, V29, P2278, DOI 10.1038/sj.npp.1300557; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Baskin TW, 2003, J CONSULT CLIN PSYCH, V71, P973, DOI 10.1037/0022-006X.71.6.973; BECH P, 1992, INT CLIN PSYCHOPHARM, V6, P45, DOI 10.1097/00004850-199206005-00005; Beck AT, 1996, PSYCHOL ASSESS; Berkman L, 2001, PSYCHOSOM MED, V63, P747; Berkman LF, 2003, JAMA-J AM MED ASSOC, V289, P3106; Califf RM, 2000, AM HEART J, V140, P1, DOI 10.1067/mhj.2000.107550; Campeau L, 2002, CAN J CARDIOL, V18, P371; Davis CE, 1997, CONTROL CLIN TRIALS, V18, P557, DOI 10.1016/S0197-2456(96)00133-X; de Mello MF, 2005, EUR ARCH PSY CLIN N, V255, P75, DOI 10.1007/s00406-004-0542-x; DeRubeis RJ, 2005, ARCH GEN PSYCHIAT, V62, P409, DOI 10.1001/archpsyc.62.4.409; DONNER A, 1984, STAT MED, V3, P199, DOI 10.1002/sim.4780030302; Dupont WD, 1997, CONTROL CLIN TRIALS, V18, P274, DOI 10.1016/S0197-2456(97)00074-3; ELKIN I, 1989, ARCH GEN PSYCHIAT, V46, P971; Fava M, 2003, PSYCHIAT CLIN N AM, V26, P457, DOI 10.1016/S0193-953X(02)00107-7; FAWCETT J, 1987, PSYCHOPHARMACOL BULL, V23, P309; First M.B., 2014, STRUCTURED CLIN INTE; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRANK E, 1991, ARCH GEN PSYCHIAT, V48, P851, DOI 10.1001/archpsyc.1991.01810330075011; Frasure-Smith N, 2006, PSYCHOSOM MED, V68, P87, DOI 10.1097/01.psy.0000195833.68482.27; Frasure-Smith N, 2003, JAMA-J AM MED ASSOC, V289, P3171, DOI 10.1001/jama.289.23.3171; Frasure-Smith N, 2005, PSYCHOSOM MED, V67, pS19, DOI 10.1097/01.psy.0000162253.07959.db; GLASSMAN AH, 1993, JAMA-J AM MED ASSOC, V269, P2673, DOI 10.1001/jama.269.20.2673; Glassman AH, 2006, ARCH GEN PSYCHIAT, V63, P283, DOI 10.1001/archpsyc.63.3.283; Glassman AH, 2002, JAMA-J AM MED ASSOC, V288, P701, DOI 10.1001/jama.288.6.701; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Klerman GL, 1984, INTERPERSONAL PSYCHO; Koszychi D, 2004, PSYCHOSOMATICS, V45, P319, DOI 10.1176/appi.psy.45.4.319; Leidy NK, 1999, NURS RES, V48, P20, DOI 10.1097/00006199-199901000-00004; Markowitz JC, 1998, ARCH GEN PSYCHIAT, V55, P452, DOI 10.1001/archpsyc.55.5.452; McAlister FA, 2003, JAMA-J AM MED ASSOC, V289, P2545, DOI 10.1001/jama.289.19.2545; Miller L, 2002, DEPRESS ANXIETY, V16, P114, DOI 10.1002/da.10047; Miller MD, 1999, AM J GERIAT PSYCHIAT, V7, P228, DOI 10.1097/00019442-199908000-00007; MILLER MD, 1998, MED CLIN TRAINING PR; Montgomery Alan A, 2003, BMC Med Res Methodol, V3, P26, DOI 10.1186/1471-2288-3-26; MONTGOMERY SA, 1979, BRIT J PSYCHIAT, V134, P382, DOI 10.1192/bjp.134.4.382; Ott MB, 2006, GUIDE GOOD CLIN PRAC; Reynolds CF, 1999, AM J PSYCHIAT, V156, P202; Rudisch B, 2003, BIOL PSYCHIAT, V54, P227, DOI 10.1016/S0006-3223(03)00587-0; Rumsfeld JS, 2005, CIRCULATION, V111, P250, DOI 10.1161/01.CIR.0000154573.62822.89; Rush AJ, 2004, CONTROL CLIN TRIALS, V25, P119, DOI 10.1016/S0197-2456(03)00112-0; RUSH AJ, 1986, PSYCHIAT RES, V18, P65; Schatzberg A, 2006, AM J GERIAT PSYCHIAT, V14, P361, DOI 10.1097/01.JGP.0000194645.70869.3b; Schneider LS, 2003, AM J PSYCHIAT, V160, P1277, DOI 10.1176/appi.ajp.160.7.1277; Schneiderman N, 2004, PSYCHOSOM MED, V66, P475, DOI 10.1097/01.psy.0000133217.96180.e8; Segal ZV, 2001, CAN J PSYCHIAT, V46, p29S; SOTSKY SM, 1991, AM J PSYCHIAT, V148, P997; Strik JTMH, 2000, PSYCHOSOM MED, V62, P783, DOI 10.1097/00006842-200011000-00007; Swenson JR, 2006, CAN J PSYCHIAT, V51, P923, DOI 10.1177/070674370605101408; TILDEN VP, 1990, NURS RES, V39, P337; Trivedi MH, 2006, AM J PSYCHIAT, V163, P28, DOI 10.1176/appi.ajp.163.1.28; Walsh BT, 2002, JAMA-J AM MED ASSOC, V287, P1840, DOI 10.1001/jama.287.14.1840; WEISSMAN MM, 2000, COMPREHENSIVE GUIDE; Whooley MA, 2006, JAMA-J AM MED ASSOC, V295, P2874, DOI 10.1001/jama.295.24.2874; Xiong GL, 2006, AM J CARDIOL, V98, P42, DOI 10.1016/j.amjcard.2006.01.051; YUSUF S, 1991, JAMA-J AM MED ASSOC, V266, P93, DOI 10.1001/jama.266.1.93	57	447	458	0	25	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 24	2007	297	4					367	379		10.1001/jama.297.4.367	http://dx.doi.org/10.1001/jama.297.4.367			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	128GE	17244833	Bronze			2022-12-28	WOS:000243645400022
J	Collins, FS; Manolio, TA				Collins, Francis S.; Manolio, Teri A.			Necessary but not sufficient	NATURE			English	Editorial Material									NHGRI, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Collins, FS (corresponding author), NHGRI, NIH, 31 Ctr Dr, Bethesda, MD 20892 USA.							Manolio TA, 2006, NAT REV GENET, V7, P812, DOI 10.1038/nrg1919; Willett WC, 2007, NATURE, V445, P257, DOI 10.1038/445257a	2	52	53	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 18	2007	445	7125					259	259		10.1038/445259a	http://dx.doi.org/10.1038/445259a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126HT	17230172	Bronze			2022-12-28	WOS:000243504700022
J	Deutsch, C; Sarmiento, JL; Sigman, DM; Gruber, N; Dunne, JP				Deutsch, Curtis; Sarmiento, Jorge L.; Sigman, Daniel M.; Gruber, Nicolas; Dunne, John P.			Spatial coupling of nitrogen inputs and losses in the ocean	NATURE			English	Article							PACIFIC SUBTROPICAL GYRE; TROPICAL NORTH PACIFIC; ATLANTIC OCEAN; FIXATION; DENITRIFICATION; NITRATE; REMINERALIZATION; TRICHODESMIUM; CYCLES; SEA	Nitrogen fixation is crucial for maintaining biological productivity in the oceans, because it replaces the biologically available nitrogen that is lost through denitrification. But, owing to its temporal and spatial variability, the global distribution of marine nitrogen fixation is difficult to determine from direct shipboard measurements. This uncertainty limits our understanding of the factors that influence nitrogen fixation, which may include iron, nitrogen-to-phosphorus ratios, and physical conditions such as temperature. Here we determine nitrogen fixation rates in the world's oceans through their impact on nitrate and phosphate concentrations in surface waters, using an ocean circulation model. Our results indicate that nitrogen fixation rates are highest in the Pacific Ocean, where water column denitrification rates are high but the rate of atmospheric iron deposition is low. We conclude that oceanic nitrogen fixation is closely tied to the generation of nitrogen-deficient waters in denitrification zones, supporting the view that nitrogen fixation stabilizes the oceanic inventory of fixed nitrogen over time.	Univ Washington, Sch Oceanog, Program Climate Change, Seattle, WA 98195 USA; Princeton Univ, Atmospher & Ocean Sci Program, Princeton, NJ 08544 USA; Princeton Univ, Dept Geosci, Princeton, NJ 08544 USA; Univ Calif Los Angeles, IGPP, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Atmospher & Ocean Sci, Los Angeles, CA 90095 USA; NOAA, Geophys Fluid Dynam Lab, Princeton, NJ 08542 USA	University of Washington; University of Washington Seattle; National Oceanic Atmospheric Admin (NOAA) - USA; Princeton University; Princeton University; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; National Oceanic Atmospheric Admin (NOAA) - USA	Deutsch, C (corresponding author), Univ Washington, Sch Oceanog, Program Climate Change, Seattle, WA 98195 USA.	cdeutsch@ocean.washington.edu	Deutsch, Curtis A/D-1703-2011; Sigman, Daniel M/A-2649-2008; Gruber, Nicolas/B-7013-2009; Dunne, John P/F-8086-2012	Sigman, Daniel M/0000-0002-7923-1973; Gruber, Nicolas/0000-0002-2085-2310; Dunne, John P/0000-0002-8794-0489				Abell J, 2000, J MAR RES, V58, P203, DOI 10.1357/002224000321511142; ANDERSON LA, 1994, GLOBAL BIOGEOCHEM CY, V8, P65, DOI 10.1029/93GB03318; Brandes JA, 2002, GLOBAL BIOGEOCHEM CY, V16, DOI 10.1029/2001GB001856; Brandes JA, 1998, LIMNOL OCEANOGR, V43, P1680, DOI 10.4319/lo.1998.43.7.1680; Broecker WS, 1998, PALEOCEANOGRAPHY, V13, P352, DOI 10.1029/98PA00920; Capone DG, 2005, GLOBAL BIOGEOCHEM CY, V19, DOI 10.1029/2004GB002331; Capone DG, 1997, SCIENCE, V276, P1221, DOI 10.1126/science.276.5316.1221; CODISPOTI LA, 1976, LIMNOL OCEANOGR, V21, P379, DOI 10.4319/lo.1976.21.3.0379; Codispoti LA, 2001, SCI MAR, V65, P85, DOI 10.3989/scimar.2001.65s285; CODISPOTI LA, 1995, NATURE, V376, P724, DOI 10.1038/376724a0; Conkright M. E., 2002, WORLD OCEAN ATLAS 20, P1; Deutsch C, 2001, GLOBAL BIOGEOCHEM CY, V15, P483, DOI 10.1029/2000GB001291; Deutsch C, 2004, GLOBAL BIOGEOCHEM CY, V18, DOI 10.1029/2003GB002189; Dunne JP, 2005, GLOBAL BIOGEOCHEM CY, V19, DOI 10.1029/2004GB002390; Falkowski PG, 1997, NATURE, V387, P272, DOI 10.1038/387272a0; Gnanadesikan A, 2001, DEEP-SEA RES PT II, V49, P363; Gruber N, 1997, GLOBAL BIOGEOCHEM CY, V11, P235, DOI 10.1029/97GB00077; Gruber N, 2003, CARBON CLIMATE INTER, P97; Hansell DA, 2004, MAR CHEM, V84, P243, DOI 10.1016/j.marchem.2003.08.004; Karl D, 2002, BIOGEOCHEMISTRY, V57, P47, DOI 10.1023/A:1015798105851; Karl D, 1997, NATURE, V388, P533, DOI 10.1038/41474; Lehmann MF, 2005, GLOBAL BIOGEOCHEM CY, V19, DOI 10.1029/2005GB002508; Letelier RM, 1998, AQUAT MICROB ECOL, V15, P265, DOI 10.3354/ame015265; Mahowald N, 1999, J GEOPHYS RES-ATMOS, V104, P15895, DOI 10.1029/1999JD900084; Redfield A. C, 1963, SEA, P26, DOI DOI 10.1016/J.ORGGEOCHEM.2014.06.002; SARMIENTO JL, 2006, OCEAN BIOGEOCHEMICAL, P118; Sigman DM, 2005, GLOBAL BIOGEOCHEM CY, V19, DOI 10.1029/2005GB002458; Tanaka T, 2004, CONT SHELF RES, V24, P1271, DOI 10.1016/j.csr.2004.04.004; Wu JF, 2000, SCIENCE, V289, P759, DOI 10.1126/science.289.5480.759; Zehr JP, 2001, NATURE, V412, P635, DOI 10.1038/35088063	30	513	527	6	258	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 11	2007	445	7124					163	167		10.1038/nature05392	http://dx.doi.org/10.1038/nature05392			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124QF	17215838				2022-12-28	WOS:000243384300042
J	Halperin, SA				Halperin, Scott A.			The control of pertussis - 2007 and beyond	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Dalhousie Univ, Dept Pediat, Halifax, NS, Canada; Dalhousie Univ, Dept Microbiol & Immunol, Halifax, NS, Canada	Dalhousie University; Dalhousie University	Halperin, SA (corresponding author), Dalhousie Univ, Dept Pediat, Halifax, NS, Canada.			Halperin, Scott/0000-0003-0525-589X				Lievano FA, 2002, J CLIN MICROBIOL, V40, P2801, DOI 10.1128/JCM.40.8.2801-2805.2002; Prevention and control of tuberculosis in correctional and detention facilities: recommendations from CDC, 2006, MMWR RECOMM REP, V55, P1; Skowronski DM, 2002, J INFECT DIS, V185, P1696; Skowronski DM, 2002, J INFECT DIS, V185, P1448, DOI 10.1086/340280; SMITH S, 2006, BOSTON GLOBE    1102; TALBOT EA, 2006, ANN M INF DIS SOC AM	6	74	81	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 11	2007	356	2					110	113		10.1056/NEJMp068288	http://dx.doi.org/10.1056/NEJMp068288			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	124NE	17215528				2022-12-28	WOS:000243373700003
J	Maccarone, TJ; Kundu, A; Zepf, SE; Rhode, KL				Maccarone, Thomas J.; Kundu, Arunav; Zepf, Stephen E.; Rhode, Katherine L.			A black hole in a globular cluster	NATURE			English	Article							X-RAY BINARIES; NGC-4472; CONNECTION; CATALOG	Globular star clusters contain thousands to millions of old stars packed within a region only tens of light years across. Their high stellar densities make it very probable that their member stars will interact or collide. There has accordingly been considerable debate about whether black holes should exist in these star clusters(1-3). Some theoretical work suggests that dynamical processes in the densest inner regions of globular clusters may lead to the formation of black holes of similar to 1,000 solar masses(3). Other numerical simulations instead predict that stellar interactions will eject most or all of the black holes that form in globular clusters(1,2). Here we report the X-ray signature of an accreting black hole in a globular cluster associated with the giant elliptical galaxy NGC 4472 ( in the Virgo cluster). This object has an X-ray luminosity of about 4 x 10(39) erg s(-1), which rules out any object other than a black hole in such an old stellar population. The X-ray luminosity varies by a factor of seven in a few hours, which excludes the possibility that the object is several neutron stars superposed.	Univ Southampton, Sch Phys & Astron, Southampton S017 1BJ, Hants, England; Michigan State Univ, Dept Phys & Astron, E Lansing, MI 48824 USA; Wesleyan Univ, Dept Astron, Middletown, CT 06459 USA; Yale Univ, Dept Astron, New Haven, CT 06520 USA	University of Southampton; Michigan State University; Wesleyan University; Yale University	Maccarone, TJ (corresponding author), Univ Southampton, Sch Phys & Astron, Southampton S017 1BJ, Hants, England.	tjm@phys.soton.ac.uk						ABRAMOWICZ MA, 1988, ASTROPHYS J, V332, P646, DOI 10.1086/166683; Blecha L, 2006, ASTROPHYS J, V642, P427, DOI 10.1086/500727; Colbert EJM, 2002, ASTROPHYS J SUPPL S, V143, P25, DOI 10.1086/342507; Hopman C, 2004, ASTROPHYS J, V604, pL101, DOI 10.1086/383616; Kalogera V, 2004, ASTROPHYS J, V601, pL171, DOI 10.1086/382042; King AR, 2003, MON NOT R ASTRON SOC, V345, P657, DOI 10.1046/j.1365-8711.2003.06980.x; KULKARNI SR, 1993, NATURE, V364, P421, DOI 10.1038/364421a0; Kundu A, 2002, ASTROPHYS J, V574, pL5, DOI 10.1086/342353; Lee JC, 2002, ASTROPHYS J, V567, P1102, DOI 10.1086/338588; Liu QZ, 2000, ASTRON ASTROPHYS SUP, V147, P25, DOI 10.1051/aas:2000288; MACCACARO T, 1988, ASTROPHYS J, V326, P680, DOI 10.1086/166127; Maccarone TJ, 2003, ASTROPHYS J, V586, P814, DOI 10.1086/367886; Madhusudhan N, 2006, ASTROPHYS J, V640, P918, DOI 10.1086/500238; Miller MC, 2002, MON NOT R ASTRON SOC, V330, P232, DOI 10.1046/j.1365-8711.2002.05112.x; Mukai K, 2003, ASTROPHYS J, V582, P184, DOI 10.1086/344639; Mushotzky RF, 2000, NATURE, V404, P459, DOI 10.1038/35006564; Oosterbroek T, 1997, ASTRON ASTROPHYS, V321, P776; Patruno A, 2005, MON NOT R ASTRON SOC, V364, P344, DOI 10.1111/j.1365-2966.2005.09568.x; Portegies Zwart S, 2004, MON NOT R ASTRON SOC, V355, P413, DOI 10.1111/j.1365-2966.2004.08327.x; Rhode KL, 2001, ASTRON J, V121, P210, DOI 10.1086/318039; SIGURDSSON S, 1993, NATURE, V364, P423, DOI 10.1038/364423a0; Smits M, 2006, ASTRON ASTROPHYS, V458, P477, DOI 10.1051/0004-6361:20065298; Truss M, 2006, MON NOT R ASTRON SOC, V368, pL25, DOI 10.1111/j.1745-3933.2006.00149.x; Williams RJ, 2002, ASTRON J, V124, P3042, DOI 10.1086/344765; Zycki PT, 1999, MON NOT R ASTRON SOC, V309, P561, DOI 10.1046/j.1365-8711.1999.02885.x; [No title captured]	26	177	179	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 11	2007	445	7124					183	185		10.1038/nature05434	http://dx.doi.org/10.1038/nature05434			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124QF	17203062	Green Submitted			2022-12-28	WOS:000243384300045
J	McFall-Ngai, M				McFall-Ngai, Margaret			Adaptive immunity - Care for the community	NATURE			English	Editorial Material									Univ Wisconsin, Symbiosis Cluster, Madison, WI 53706 USA; Univ Wisconsin, Dept Med Microbiol & Immunol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	McFall-Ngai, M (corresponding author), Univ Wisconsin, Symbiosis Cluster, Madison, WI 53706 USA.							Backhed F, 2005, SCIENCE, V307, P1915, DOI 10.1126/science.1104816; Dethlefsen L, 2006, TRENDS ECOL EVOL, V21, P517, DOI 10.1016/j.tree.2006.06.013; Hedrick SM, 2004, IMMUNITY, V21, P607, DOI 10.1016/j.immuni.2004.08.020; Weng L, 2006, GENOME RES, V16, P316, DOI 10.1101/gr.3676406	4	248	253	1	49	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 11	2007	445	7124					153	153		10.1038/445153a	http://dx.doi.org/10.1038/445153a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124QF	17215830				2022-12-28	WOS:000243384300032
J	Motoyama, EM; Yu, G; Vishik, IM; Vajk, OP; Mang, PK; Greven, M				Motoyama, E. M.; Yu, G.; Vishik, I. M.; Vajk, O. P.; Mang, P. K.; Greven, M.			Spin correlations in the electron-doped high-transition-temperature superconductor Nd2-xCexCuO4 +/-delta	NATURE			English	Article							MAGNETIC ORDER	High-transition-temperature (high-T-c) superconductivity develops near antiferromagnetic phases, and it is possible that magnetic excitations contribute to the superconducting pairing mechanism. To assess the role of antiferromagnetism, it is essential to understand the doping and temperature dependence of the two-dimensional antiferromagnetic spin correlations. The phase diagram is asymmetric with respect to electron and hole doping, and for the comparatively less-studied electron-doped materials, the antiferromagnetic phase extends much further with doping(1,2) and appears to overlap with the superconducting phase. The archetypal electron-doped compound Nd2-xCexCuO4+/-delta (NCCO) shows bulk superconductivity above x approximate to 0.13 ( refs 3, 4), while evidence for antiferromagnetic order has been found up to x approximate to 0.17 ( refs 2, 5, 6). Here we report inelastic magnetic neutron-scattering measurements that point to the distinct possibility that genuine long-range antiferromagnetism and superconductivity do not coexist. The data reveal a magnetic quantum critical point where superconductivity first appears, consistent with an exotic quantum phase transition between the two phases(7). We also demonstrate that the pseudogap phenomenon in the electron-doped materials, which is associated with pronounced charge anomalies(8-11), arises from a build-up of spin correlations, in agreement with recent theoretical proposals(12,13).	Stanford Univ, Dept Appl Phys, Stanford, CA 94305 USA; Stanford Synchrotron Radiat Lab, Stanford, CA 94309 USA; Natl Inst Stand & Technol, NIST Ctr Neutron Res, Gaithersburg, MD 20899 USA; Stanford Univ, Dept Phys, Stanford, CA 94305 USA	Stanford University; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory; National Institute of Standards & Technology (NIST) - USA; Stanford University	Greven, M (corresponding author), Stanford Univ, Dept Appl Phys, Stanford, CA 94305 USA.	greven@stanford.edu	Vishik, Inna/AGU-2119-2022; Yu, Guichuan/K-4025-2014					Armitage NP, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.257001; Blumberg G, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.107002; Dagan Y, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.057005; Eisaki H, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.064512; KEIMER B, 1992, PHYS REV B, V46, P14034, DOI 10.1103/PhysRevB.46.14034; Kyung B, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.147004; Mang PK, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.094507; Mang PK, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.027002; Markiewicz RS, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.174518; MATSUDA M, 1992, PHYS REV B, V45, P12548, DOI 10.1103/PhysRevB.45.12548; Matsui H, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.017003; Matsui H, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.047005; Motoyama EM, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.137002; Onose Y, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.024504; Park T, 2006, NATURE, V440, P65, DOI 10.1038/nature04571; Senthil T, 2004, SCIENCE, V303, P1490, DOI 10.1126/science.1091806; TAKAGI H, 1989, PHYS REV LETT, V62, P1197, DOI 10.1103/PhysRevLett.62.1197; Uefuji T, 2002, PHYSICA C, V378, P273, DOI 10.1016/S0921-4534(02)01426-0; Uefuji T, 2001, PHYSICA C, V357, P208, DOI 10.1016/S0921-4534(01)00208-8; Vajk OP, 2002, SCIENCE, V295, P1691, DOI 10.1126/science.1067110; Wang YY, 2003, SCIENCE, V299, P86, DOI 10.1126/science.1078422; Yamada K, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.137004; Zimmers A, 2005, EUROPHYS LETT, V70, P225, DOI 10.1209/epl/i2004-10480-2	24	179	181	0	52	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 11	2007	445	7124					186	189		10.1038/nature05437	http://dx.doi.org/10.1038/nature05437			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124QF	17215839	Green Submitted			2022-12-28	WOS:000243384300046
J	Tylianakis, JM; Tscharntke, T; Lewis, OT				Tylianakis, Jason M.; Tscharntke, Teja; Lewis, Owen T.			Habitat modification alters the structure of tropical host-parasitoid food webs	NATURE			English	Article							BIOLOGICAL-CONTROL; LAND-USE; COMMUNITY; DIVERSITY; DESCRIPTORS; STABILITY; SERVICES; GRADIENT; INSECTS; BEES	Global conversion of natural habitats to agriculture has led to marked changes in species diversity and composition(1). However, it is less clear how habitat modification affects interactions among species(2). Networks of feeding interactions ( food webs) describe the underlying structure of ecological communities, and might be crucially linked to their stability and function(3-7). Here, we analyse 48 quantitative food webs(8,9) for cavity-nesting bees, wasps and their parasitoids across five tropical habitat types. We found marked changes in food-web structure(10,11) across the modification gradient, despite little variation in species richness. The evenness of interaction frequencies declined with habitat modification, with most energy flowing along one or a few pathways in intensively managed agricultural habitats. In modified habitats there was a higher ratio of parasitoid to host species and increased parasitism rates, with implications for the important ecosystem services, such as pollination and biological control, that are performed by host bees and wasps(12). The most abundant parasitoid species was more specialized in modified habitats, with reduced attack rates on alternative hosts. Conventional community descriptors failed to discriminate adequately among habitats, indicating that perturbation of the structure and function of ecological communities might be overlooked in studies that do not document and quantify species interactions. Altered interaction structure therefore represents an insidious and functionally important hidden effect of habitat modification by humans.	Univ Gottingen, D-37073 Gottingen, Germany; Univ Oxford, Dept Zool, Oxford OX1 3PS, England	University of Gottingen; University of Oxford	Tylianakis, JM (corresponding author), Univ Canterbury, Sch Biol Sci, Private Bag 4800, Christchurch 8020, New Zealand.	jason.tylianakis@canterbury.ac.nz	Tscharntke, Teja/N-5123-2014; Tylianakis, Jason/B-6634-2011; Lewis, Owen T/B-9531-2011	Tylianakis, Jason/0000-0001-7402-5620; Lewis, Owen/0000-0001-7935-6111				Banasek-Richter C, 2004, J THEOR BIOL, V226, P23, DOI 10.1016/S0022-5193(03)00305-9; Bersier LF, 2002, ECOLOGY, V83, P2394, DOI 10.2307/3071801; COHEN JE, 1993, ECOLOGY, V74, P252, DOI 10.2307/1939520; Costanza R, 1997, NATURE, V387, P253, DOI 10.1038/387253a0; Foley JA, 2005, SCIENCE, V309, P570, DOI 10.1126/science.1111772; Goldwasser L, 1997, ECOLOGY, V78, P41; Hawkins BA, 1999, OIKOS, V86, P493, DOI 10.2307/3546654; Henneman ML, 2001, SCIENCE, V293, P1314, DOI 10.1126/science.1060788; Ives AR, 2004, NATURE, V429, P174, DOI 10.1038/nature02515; JANZEN DH, 1974, NAT HIST, V83, P48; Kearns CA, 1998, ANNU REV ECOL SYST, V29, P83, DOI 10.1146/annurev.ecolsys.29.1.83; Kremen C, 2002, P NATL ACAD SCI USA, V99, P16812, DOI 10.1073/pnas.262413599; Lewis OT, 2002, J ANIM ECOL, V71, P855, DOI 10.1046/j.1365-2656.2002.00651.x; Losey JE, 2006, BIOSCIENCE, V56, P311, DOI 10.1641/0006-3568(2006)56[311:TEVOES]2.0.CO;2; Martinez ND, 1999, ECOLOGY, V80, P1044, DOI 10.1890/0012-9658(1999)080[1044:EOSEOC]2.0.CO;2; McCann KS, 2000, NATURE, V405, P228, DOI 10.1038/35012234; Melian CJ, 2002, ECOL LETT, V5, P37, DOI 10.1046/j.1461-0248.2002.00280.x; Memmott J, 1999, ECOL LETT, V2, P276, DOI 10.1046/j.1461-0248.1999.00087.x; MEMMOTT J, 1994, J ANIM ECOL, V63, P521, DOI 10.2307/5219; Montoya JM, 2006, NATURE, V442, P259, DOI 10.1038/nature04927; Morris RJ, 2004, NATURE, V428, P310, DOI 10.1038/nature02394; Muller CB, 1999, J ANIM ECOL, V68, P346, DOI 10.1046/j.1365-2656.1999.00288.x; PAINE RT, 1988, ECOLOGY, V69, P1648, DOI 10.2307/1941141; Rand TA, 2006, ECOL LETT, V9, P603, DOI 10.1111/j.1461-0248.2006.00911.x; Rooney N, 2006, NATURE, V442, P265, DOI 10.1038/nature04887; Tilman D, 2001, SCIENCE, V292, P281, DOI 10.1126/science.1057544; Tylianakis JM, 2006, ECOLOGY, V87, P3047, DOI 10.1890/0012-9658(2006)87[3047:DEFASO]2.0.CO;2; Tylianakis JM, 2006, J BIOGEOGR, V33, P1295, DOI 10.1111/j.1365-2699.2006.01493.x; Tylianakis JM, 2005, ECOLOGY, V86, P3296, DOI 10.1890/05-0371; van der Putten WH, 2004, BASIC APPL ECOL, V5, P487, DOI 10.1016/j.baae.2004.09.003	30	619	643	10	457	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 11	2007	445	7124					202	205		10.1038/nature05429	http://dx.doi.org/10.1038/nature05429			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124QF	17215842				2022-12-28	WOS:000243384300050
J	Turner, MS				Turner, Michael S.			Quarks and the cosmos	SCIENCE			English	Editorial Material							COSMOLOGICAL CONSTANT; DARK-MATTER; UNIVERSE; SUPERNOVAE	Cosmology is in the midst of a period of revolutionary discovery, propelled by bold ideas from particle physics and by technological advances from gigapixel charge-coupled device cameras to peta-scale computing. The basic features of the universe have now been determined: It is 13.7 billion years old, spatially flat, and expanding at an accelerating rate; it is composed of atoms (4%), exotic dark matter (20%), and dark energy (76%); and there is evidence that galaxies and other structures were seeded by quantum fluctuations. Although we know much about the universe, we understand far less. Poised to dramatically advance our understanding of both the universe and the laws that govern it, cosmology is on the verge of a golden age.	Univ Chicago, Kavli Inst Cosmol Phys, Chicago, IL 60637 USA	University of Chicago	Turner, MS (corresponding author), Univ Chicago, Kavli Inst Cosmol Phys, 5640 S Ellis Ave, Chicago, IL 60637 USA.	mturner@uchicago.edu						BLUMENTHAL GR, 1984, NATURE, V311, P517, DOI 10.1038/311517a0; Carroll SM, 2004, PHYS REV D, V70, DOI 10.1103/PhysRevD.70.043528; COPELAND EJ, PREPRINT; Deffayet C, 2002, PHYS REV D, V65, DOI 10.1103/PhysRevD.65.044023; Glanz J, 1998, SCIENCE, V282, P2156; KOLB EW, 1990, EARLY UNIVERSE, pCH8; KRAUSS LM, 1995, GEN RELAT GRAVIT, V27, P1137, DOI 10.1007/BF02108229; Mather JC, 1999, ASTROPHYS J, V512, P511, DOI 10.1086/306805; OSTRIKER JP, 1995, NATURE, V377, P600, DOI 10.1038/377600a0; Perlmutter S, 1999, ASTROPHYS J, V517, P565, DOI 10.1086/307221; Riess AG, 1998, ASTRON J, V116, P1009, DOI 10.1086/300499; Sadoulet B, 2007, SCIENCE, V315, P61, DOI 10.1126/science.1136639; SANDAGE AR, 1970, PHYS TODAY, V23, P34, DOI 10.1063/1.3021960; SCOTT D, PREPRINT; Seife C, 2003, SCIENCE, V302, P2038, DOI 10.1126/science.302.5653.2038; SMOOT GF, 1992, ASTROPHYS J, V396, pL1, DOI 10.1086/186504; TEGMARK M, PREPRINT; WEINBERG S, 1989, REV MOD PHYS, V61, P1, DOI 10.1103/RevModPhys.61.1	18	10	10	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 5	2007	315	5808					59	61		10.1126/science.1136276	http://dx.doi.org/10.1126/science.1136276			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	122WU	17204637				2022-12-28	WOS:000243259100030
J	Wang, T; Overgaard, J				Wang, Tobias; Overgaard, Johannes			The heartbreak of adapting to global warming	SCIENCE			English	Editorial Material							CLIMATE-CHANGE; SHIFTS	Laboratory studies of basic physiological constraints on the cardiorespiratory system can be used to predict the impact of global warming on fish.	Aarhus Univ, Dept Zoophysiol, DK-8000 Aarhus, Denmark; Natl Environm Res Inst, Dept Terr Ecol, DK-8600 Silkeborg, Denmark	Aarhus University; Aarhus University	Wang, T (corresponding author), Aarhus Univ, Dept Zoophysiol, DK-8000 Aarhus, Denmark.	tobias.wang@biology.au.dk	Overgaard, Johannes/I-7493-2013; Wang, Tobias/I-7946-2013; Overgaard, Johannes/AAA-3922-2022	Overgaard, Johannes/0000-0002-2851-4551; Wang, Tobias/0000-0002-4350-3682; 				COSSINS AR, 1987, TEMPERATURE BIOL ANI, P210; Davis AJ, 1998, NATURE, V391, P783, DOI 10.1038/35842; FARRELL AP, 1993, VERTEBRATE GAS TRANSPORT CASCADE, P208; Frederich M, 2000, AM J PHYSIOL-REG I, V279, pR1531, DOI 10.1152/ajpregu.2000.279.5.R1531; HEATH AG, 1973, J EXP BIOL, V59, P323; Helmuth B, 2005, ANNU REV PHYSIOL, V67, P177, DOI 10.1146/annurev.physiol.67.040403.105027; Jensen MN, 2003, SCIENCE, V299, P38, DOI 10.1126/science.299.5603.38; Perry AL, 2005, SCIENCE, V308, P1912, DOI 10.1126/science.1111322; Portner HO, 2007, SCIENCE, V315, P95, DOI 10.1126/science.1135471; Stillman JH, 2003, SCIENCE, V301, P65, DOI 10.1126/science.1083073; Walther GR, 2002, NATURE, V416, P389, DOI 10.1038/416389a	11	96	97	1	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 5	2007	315	5808					49	50		10.1126/science.1137359	http://dx.doi.org/10.1126/science.1137359			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	122WU	17204631				2022-12-28	WOS:000243259100024
J	Haag-Liautard, C; Dorris, M; Maside, X; Macaskill, S; Halligan, DL; Charlesworth, B; Keightley, PD				Haag-Liautard, Cathy; Dorris, Mark; Maside, Xulio; Macaskill, Steven; Halligan, Daniel L.; Charlesworth, Brian; Keightley, Peter D.			Direct estimation of per nucleotide and genomic deleterious mutation rates in Drosophila	NATURE			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; EVOLUTION; RECOMBINATION; ACCUMULATION; FITNESS; DNA; INSERTIONS; SEX	Spontaneous mutations are the source of genetic variation required for evolutionary change, and are therefore important for many aspects of evolutionary biology. For example, the divergence between taxa at neutrally evolving sites in the genome is proportional to the per nucleotide mutation rate, u (ref. 1), and this can be used to date speciation events by assuming a molecular clock. The overall rate of occurrence of deleterious mutations in the genome each generation (U) appears in theories of nucleotide divergence and polymorphism(2), the evolution of sex and recombination(3), and the evolutionary consequences of inbreeding(2). However, estimates of U based on changes in allozymes(4) or DNA sequences(5) and fitness traits are discordant(6-8). Here we directly estimate u in Drosophila melanogaster by scanning 20 million bases of DNA from three sets of mutation accumulation lines by using denaturing high-performance liquid chromatography(9). From 37 mutation events that we detected, we obtained a mean estimate for u of 8.4 x 10(-9) per generation. Moreover, we detected significant heterogeneity in u among the three mutation-accumulation-line genotypes. By multiplying u by an estimate of the fraction of mutations that are deleterious in natural populations of Drosophila(10), we estimate that U is 1.2 per diploid genome. This high rate suggests that selection against deleterious mutations may have a key role in explaining patterns of genetic variation in the genome, and help to maintain recombination and sexual reproduction.	Univ Edinburgh, Sch Biol Sci, Inst Evolutionary Biol, Edinburgh EH9 3JT, Midlothian, Scotland	University of Edinburgh	Keightley, PD (corresponding author), Univ Edinburgh, Sch Biol Sci, Inst Evolutionary Biol, W Mains Rd, Edinburgh EH9 3JT, Midlothian, Scotland.	keightley.drosmutrate@spambob.net	Maside, Xulio/AAU-8864-2020; Halligan, Daniel/H-4459-2011; Maside, Xulio/AAA-6551-2019	Halligan, Daniel/0000-0003-4726-6343; Maside, Xulio/0000-0002-4494-8616	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Andolfatto P, 2005, NATURE, V437, P1149, DOI 10.1038/nature04107; Baer CF, 2005, P NATL ACAD SCI USA, V102, P5785, DOI 10.1073/pnas.0406056102; Charlesworth B, 1998, GENETICA, V102-3, P3, DOI 10.1023/A:1017066304739; CHARLESWORTH B, 1990, GENET RES, V55, P199, DOI 10.1017/S0016672300025532; Crow J.F., 1983, Genetics and Biology of Drosophila, V3c, P1; Denver DR, 2004, NATURE, V430, P679, DOI 10.1038/nature02697; Dobson-Stone C, 2000, EUR J HUM GENET, V8, P24, DOI 10.1038/sj.ejhg.5200409; Fernandez J, 1996, GENETICS, V143, P829; Fry JD, 2004, GENETICS, V166, P797, DOI 10.1534/genetics.166.2.797; Halligan DL, 2006, GENOME RES, V16, P875, DOI 10.1101/gr.5022906; Houle D, 2004, GENET RES, V83, P7, DOI 10.1017/S0016672303006505; Keightley PD, 1999, GENETICS, V153, P515; Keightley PD, 2006, NATURE, V443, P89, DOI 10.1038/nature05049; Kimura M., 1983, NEUTRAL THEORY MOL E; KONDRASHOV AS, 1988, NATURE, V336, P435, DOI 10.1038/336435a0; KONDRASHOV AS, 1993, HUM MUTAT, V2, P229, DOI 10.1002/humu.1380020312; Loewe L, 2006, BIOL LETTERS, V2, P426, DOI 10.1098/rsbl.2006.0481; Lynch M, 1999, EVOLUTION, V53, P645, DOI 10.1111/j.1558-5646.1999.tb05361.x; Maside X, 2001, GENET RES, V78, P121, DOI 10.1017/S0016672301005201; Moriyama EN, 1996, MOL BIOL EVOL, V13, P261, DOI 10.1093/oxfordjournals.molbev.a025563; MUKAI T, 1977, P NATL ACAD SCI USA, V74, P2514, DOI 10.1073/pnas.74.6.2514; Nachman MW, 2001, TRENDS GENET, V17, P481, DOI 10.1016/S0168-9525(01)02409-X; O'Donovan MC, 1998, GENOMICS, V52, P44, DOI 10.1006/geno.1998.5411; Oefner PJ, 2002, J CHROMATOGR B, V782, P27, DOI 10.1016/S1570-0232(02)00700-6; Petrov DA, 2002, GENETICA, V115, P81, DOI 10.1023/A:1016076215168; Presgraves DC, 2005, CURR BIOL, V15, P1651, DOI 10.1016/j.cub.2005.07.065; Ravnik-Glavac M, 2002, HUM MUTAT, V19, P374, DOI 10.1002/humu.10065; Salathe M, 2006, ECOL LETT, V9, P941, DOI 10.1111/j.1461-0248.2006.00942.x; Tamura K, 2004, MOL BIOL EVOL, V21, P36, DOI 10.1093/molbev/msg236; WOODRUFF RC, 1984, HEREDITY, V53, P223, DOI 10.1038/hdy.1984.78	30	280	282	0	65	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 4	2007	445	7123					82	85		10.1038/nature05388	http://dx.doi.org/10.1038/nature05388			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	122KG	17203060				2022-12-28	WOS:000243225100040
J	Brinar, VV; Habek, M				Brinar, Vesna V.; Habek, Mario			Dementia and white-matter demyelination in young patient with neurosyphilis	LANCET			English	Editorial Material							SYPHILIS		Univ Zagreb, Zagreb Sch Med, Univ Dept Neurol, Referral Ctr Demyelinating Dis Cent Nervous Syst, HR-10000 Zagreb, Croatia; Univ Zagreb, Univ Hosp Ctr, HR-10000 Zagreb, Croatia	University of Zagreb; University of Zagreb	Habek, M (corresponding author), Univ Zagreb, Zagreb Sch Med, Univ Dept Neurol, Referral Ctr Demyelinating Dis Cent Nervous Syst, HR-10000 Zagreb, Croatia.	mhabek@mef.hr						Borisenko KK, 1999, INT J STD AIDS, V10, P665, DOI 10.1258/0956462991913240; Fadil H, 2006, J NEUROIMAGING, V16, P286, DOI 10.1111/j.1552-6569.2006.00050.x; Knopman DS, 2001, NEUROLOGY, V56, P1143, DOI 10.1212/WNL.56.9.1143; Marinovic B, 2002, CLIN DERMATOL, V20, P141, DOI 10.1016/S0738-081X(01)00243-7; Peterman TA, 2005, SEX TRANSM DIS, V32, pS4, DOI 10.1097/01.olq.0000180455.79024.e9	5	9	9	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 23	2006	368	9554					2258	2258		10.1016/S0140-6736(06)69900-5	http://dx.doi.org/10.1016/S0140-6736(06)69900-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	120HY	17189039	Green Accepted			2022-12-28	WOS:000243076800035
J	Durga, J; van Boxtel, MPJ; Schouten, EG; Kok, FJ; Jolles, J; Katan, MB; Verhoef, P				Durga, Jane; van Boxtel, Martin P. J.; Schouten, Evert G.; Kok, Frans J.; Jolles, Jelle; Katan, Martijn B.; Verhoef, Petra			Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial	LANCET			English	Article							PARTICIPANTS AGED 24-81; NORMATIVE DATA; MEMORY PERFORMANCE; ELDERLY-PATIENTS; HOMOCYSTEINE; EDUCATION; FOLATE; VITAMIN-B-12; DECLINE; DEMENTIA	Background Low folate and raised homocysteine concentrations in blood are associated with poor cognitive performance in the general population. As part of the FACIT trial to assess the effect of folic acid on markers of atherosclerosis in men and women aged 50-70 years with raised plasma total homocysteine and normal serum vitamin B-12 at screening, we report here the findings for the secondary endpoint: the effect of folic acid supplementation on cognitive performance. Methods Our randomised, double blind, placebo controlled study took place between November, 1999, and December, 2004, in the Netherlands. We randomly assigned 818 participants 800 mu g daily oral folic acid or placebo for 3 years. The effect on cognitive performance was measured as the difference between the two groups in the 3-year change in performance for memory, sensorimotor speed, complex speed, information processing speed, and word fluency. Analysis was by intention-to-treat. This trial is registered with clinicaltrials.gov with trial number NCT00110604. Findings Serum folate concentrations increased by 576% (95% CI 539 to 614) and plasma total homocysteine concentrations decreased by 26% (24 to 28) in participants taking folic acid compared with those taking placebo. The 3-year change in memory (difference in Z scores 0.132, 95% CI 0.032 to 0.233), information processing speed (0.087, 0.016 to 0.158) and sensorimotor speed (0.064, -0.001 to 0.129) were significantly better in the folic acid group than in the placebo group. Interpretation Folic acid supplementation for 3 years significantly improved domains of cognitive function that tend to decline with age.	Univ Wageningen & Res Ctr, Div Human Nutr, NL-6700 EV Wageningen, Netherlands; Wageningen Ctr Food Sci, Wageningen, Netherlands; Maastricht Univ, Brain & Behav Inst, Dept Psychiat & Neuropsychol, Maastricht, Netherlands	Wageningen University & Research; Wageningen University & Research; Maastricht University	Durga, J (corresponding author), Nestle Res Ctr, Nutr & Hlth Dept, Vers Chez Blanc, CH-1000 Lausanne 26, Switzerland.	jane.durga@rdls.nestle.com	Katan, Martijn/ABB-6613-2021; Kennedy, Kristen M/B-4699-2008	Kennedy, Kristen M/0000-0001-5373-9026; Verhoef, Petra/0000-0002-6927-6182				BRAYNE C, 1988, LANCET, V1, P1265; Bryan J, 2002, J NUTR, V132, P1345, DOI 10.1093/jn/132.6.1345; Calvaresi E, 2001, J GERONTOL B-PSYCHOL, V56, pP327, DOI 10.1093/geronb/56.6.P327; Campbell NRC, 1996, ARCH INTERN MED, V156, P1638, DOI 10.1001/archinte.156.15.1638; Clarke R, 2003, J INTERN MED, V254, P67, DOI 10.1046/j.1365-2796.2003.01154.x; COONEY TM, 1988, J GERONTOL, V43, pP12, DOI 10.1093/geronj/43.1.P12; DEBIE SE, 1987, STANDARD QUESTIONS 1; den Heijer T, 2003, BRAIN, V126, P170, DOI 10.1093/brain/awg006; Durga J, 2006, NEUROBIOL AGING, V27, P334, DOI 10.1016/j.neurobiolaging.2005.01.003; Eussen SJ, 2006, AM J CLIN NUTR, V84, P361; Fillit HM, 2002, MAYO CLIN PROC, V77, P681, DOI 10.4065/77.7.681; Fioravanti M, 1997, ARCH GERONTOL GERIAT, V26, P1, DOI 10.1016/S0167-4943(97)00028-9; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111; HORN JL, 1967, ACTA PSYCHOL, V26, P107, DOI 10.1016/0001-6918(67)90011-X; Jolles J., 1995, MAASTRICHT AGING STU, P192; Kalmijn S, 2004, NEUROLOGY, V62, P275, DOI 10.1212/01.WNL.0000103860.75218.A5; Kaplan RJ, 2001, AM J CLIN NUTR, V74, P687; Lewerin C, 2005, AM J CLIN NUTR, V81, P1155; Lovden M, 2005, PSYCHOL AGING, V20, P303, DOI 10.1037/0882-7974.20.2.303; Malouf M, 2003, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD004514; Mattson MP, 2003, TRENDS NEUROSCI, V26, P137, DOI 10.1016/S0166-2236(03)00032-8; McMahon JA, 2006, NEW ENGL J MED, V354, P2764, DOI 10.1056/NEJMoa054025; Morris MC, 2005, ARCH NEUROL-CHICAGO, V62, P641, DOI 10.1001/archneur.62.4.641; Morrison JH, 1997, SCIENCE, V278, P412, DOI 10.1126/science.278.5337.412; OBIED R, 2005, CLIN CHEM LAB MED, V43, pA28; Petersen RC, 1999, ARCH NEUROL-CHICAGO, V56, P303, DOI 10.1001/archneur.56.3.303; Refsum H, 2004, CLIN CHEM, V50, P3, DOI 10.1373/clinchem.2003.021634; Salthouse TA, 1996, PSYCHOL REV, V103, P403, DOI 10.1037/0033-295X.103.3.403; Scarmeas N, 2006, J NEUROL NEUROSUR PS, V77, P308, DOI 10.1136/jnnp.2005.072306; Sommer BR, 2003, J GERIATR PSYCH NEUR, V16, P156, DOI 10.1177/0891988703256052; Stott DJ, 2005, AM J CLIN NUTR, V82, P1320, DOI 10.1093/ajcn/82.6.1320; Toole JF, 2004, JAMA-J AM MED ASSOC, V291, P565, DOI 10.1001/jama.291.5.565; van Boxtel MPJ, 1998, J GERONTOL A-BIOL, V53, pM147; Van der Elst W, 2006, ASSESSMENT, V13, P62, DOI 10.1177/1073191105283427; Van der Elst W, 2006, J INT NEUROPSYCH SOC, V12, P80, DOI 10.1017/S1355617706060115; Van der Elst W, 2005, J INT NEUROPSYCH SOC, V11, P290, DOI 10.1017/S1355617705050344; Van der Elst W, 2006, PSYCHOL ASSESSMENT, V18, P424, DOI 10.1037/1040-3590.18.4.424; van der Elst W, 2006, J CLIN EXP NEUROPSYC, V28, P998, DOI 10.1080/13803390591004428; Visser PJ, 2001, INT PSYCHOGERIATR, V13, P411, DOI 10.1017/S1041610201007839	40	515	546	1	49	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 20	2007	369	9557					208	216		10.1016/S0140-6736(07)60109-3	http://dx.doi.org/10.1016/S0140-6736(07)60109-3			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	128XG	17240287	Green Submitted			2022-12-28	WOS:000243692400029
J	Kauke, T; Reininger, AJ				Kauke, Teresa; Reininger, Armin J.			Livedo reticularis and cold agglutinins	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Clin Munich, D-80336 Munich, Germany	University of Munich	Kauke, T (corresponding author), Univ Clin Munich, D-80336 Munich, Germany.	armin.reininger@med.uni-muenchen.de							0	2	2	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 18	2007	356	3					284	284		10.1056/NEJMicm055304	http://dx.doi.org/10.1056/NEJMicm055304			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	126BV	17229955				2022-12-28	WOS:000243488100010
J	van den Bergh, S				van den Bergh, Sidney			Galaxy morphology - Out of order	NATURE			English	Editorial Material									Natl Res Council Canada, Herzberg Inst Astrophys, Dominion Astrophys Observ, Victoria, BC V9E 2E7, Canada	National Research Council Canada	van den Bergh, S (corresponding author), Natl Res Council Canada, Herzberg Inst Astrophys, Dominion Astrophys Observ, 5071 W Saanich Rd, Victoria, BC V9E 2E7, Canada.								0	6	6	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 18	2007	445	7125					265	265		10.1038/445265a	http://dx.doi.org/10.1038/445265a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126HT	17230178				2022-12-28	WOS:000243504700027
J	Grine, FE; Bailey, RM; Harvati, K; Nathan, RP; Morris, AG; Henderson, GM; Ribot, I; Pike, AWG				Grine, F. E.; Bailey, R. M.; Harvati, K.; Nathan, R. P.; Morris, A. G.; Henderson, G. M.; Ribot, I.; Pike, A. W. G.			Late Pleistocene human skull from Hofmeyr, South Africa, and modern human origins	SCIENCE			English	Article							MITOCHONDRIAL GENOMES; CHRONOLOGY; DISPERSALS	The lack of Late Pleistocene human fossils from sub-Saharan Africa has limited paleontological testing of competing models of recent human evolution. We have dated a skull from Hofmeyr, South Africa, to 36.2 +/- 3.3 thousand years ago through a combination of optically stimulated luminescence and uranium-series dating methods. The skull is morphologically modern overall but displays some archaic features. Its strongest morphometric affinities are with Upper Paleolithic ( UP) Eurasians rather than recent, geographically proximate people. The Hofmeyr cranium is consistent with the hypothesis that UP Eurasians descended from a population that emigrated from sub-Saharan Africa in the Late Pleistocene.	SUNY Stony Brook, Dept Anthropol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Anat Sci, Stony Brook, NY 11794 USA; Univ Oxford, Sch Geog & Environm, Oxford OX1 3QY, England; Max Planck Inst Evolutionary Anthropol, D-04103 Leipzig, Germany; Univ Oxford, Res Lab Archaeol & Hist Art, Oxford OX1 3QY, England; Univ Cape Town, Dept Human Biol, ZA-7925 Cape Town, South Africa; Univ Oxford, Dept Earth Sci, Oxford OX1 3PR, England; Univ Montreal, Dept Anthropol, Montreal, PQ H3C 3J7, Canada; Univ Bristol, Dept Archaeol & Anthropol, Bristol BS8 1UU, Avon, England	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Oxford; Max Planck Society; University of Oxford; University of Cape Town; University of Oxford; Universite de Montreal; University of Bristol	Grine, FE (corresponding author), SUNY Stony Brook, Dept Anthropol, Stony Brook, NY 11794 USA.	fgrine@notes.cc.sunysb.edu	Morris, Alan G/V-7363-2019; Rohlf, F J/A-8710-2008; Harvati, Katerina/A-5197-2008	Pike, Alistair/0000-0002-5610-8948; Henderson, Gideon/0000-0002-6279-7137				Aitken M.J., 1998, INTRO OPTICAL DATING; Ambrose SH, 1998, J ARCHAEOL SCI, V25, P377, DOI 10.1006/jasc.1997.0277; BRIESMEISTER JF, LA13709M LOS AL NAT; deVilliers H., 1968, SKULL S AFRICAN NEGR; Eswaran V, 2005, J HUM EVOL, V49, P1, DOI 10.1016/j.jhevol.2005.02.006; Forster P, 2004, PHILOS T R SOC B, V359, P255, DOI 10.1098/rstb.2003.1394; Garrigan D, 2005, MOL BIOL EVOL, V22, P189, DOI 10.1093/molbev/msi013; Harvati K, 2006, ANAT REC PART A, V288A, P1225, DOI 10.1002/ar.a.20395; Hawks JD, 2001, QUATERN INT, V75, P41, DOI 10.1016/S1040-6182(00)00076-8; HIGHARN T, COMMUNICATION; HOWELLS WW, 1989, PAPERS PEABODY MUSEU, V79; Ingman M, 2000, NATURE, V408, P708, DOI 10.1038/35047064; Kivisild T, 2006, GENETICS, V172, P373, DOI 10.1534/genetics.105.043901; Lahr M. M, 1996, EVOLUTION MODERN HUM; LUDWIG KR, 1993, 93531 USGS; Macaulay V, 2005, SCIENCE, V308, P1034, DOI 10.1126/science.1109792; Mellars P, 2006, NATURE, V439, P931, DOI 10.1038/nature04521; Nathan RP, 2003, RADIAT MEAS, V37, P305, DOI 10.1016/S1350-4487(03)00008-8; Ray N, 2005, GENOME RES, V15, P1161, DOI 10.1101/gr.3708505; Ribot Isabelle, 2004, Bulletins et Memoires de la Societe d'Anthropologie de Paris, V16, P143; Roseman CC, 2004, AM J PHYS ANTHROPOL, V125, P257, DOI 10.1002/ajpa.10424; SMITH FH, 1989, HUMAN REVOLUTION, P172; Szilvassy JV, 1987, ANN VIENNA NAT HIST, V89, P313; Takasaka T, 2006, AM J PHYS ANTHROPOL, V129, P465, DOI 10.1002/ajpa.20208; Trinkaus E, 2006, CURR ANTHROPOL, V47, P597, DOI 10.1086/504165; Turbon D, 1997, J HUM EVOL, V32, P449, DOI 10.1006/jhev.1996.0119; VOGEL JC, 1969, S AFRICAN ARCHAEOLOG, V24, P56	27	86	90	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 12	2007	315	5809					226	229		10.1126/science.1136294	http://dx.doi.org/10.1126/science.1136294			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	Science & Technology - Other Topics	124XZ	17218524				2022-12-28	WOS:000243407400043
J	Schlaitz, AL; Srayko, M; Dammermann, A; Quintin, S; Wielsch, N; MacLeod, I; de Robillard, Q; Zinke, A; Yates, JR; Muller-Reichert, T; Shevchenko, A; Oegema, K; Hyman, AA				Schlaitz, Anne-Lore; Srayko, Martin; Dammermann, Alexander; Quintin, Sohie; Wielsch, Natalie; MacLeod, Ian; de Robillard, Quentin; Zinke, Andrea; Yates, John R., III; Mueller-Reichert, Thomas; Shevchenko, Andrei; Oegema, Karen; Hyman, Anthony A.			The C-elegans RSA complex localizes protein phosphatase 2A to centrosomes and regulates mitotic spindle assembly	CELL			English	Article							AURORA-A KINASE; MICROTUBULE DYNAMICS; CAENORHABDITIS-ELEGANS; PHOSPHORYLATION; KINETOCHORE; MATURATION; MCAK; TARGET; GROWTH	Microtubule behavior changes during the cell cycle and during spindle assembly. However, it remains unclear how these changes are regulated and coordinated. We describe a complex that targets the Protein Phosphatase 2A holoenzyme (PP2A) to centrosomes in C. elegans embryos. This complex includes Regulator of Spindle Assembly 1 (RSA-1), a targeting subunit for PP2A, and RSA-2, a protein that binds and recruits RSA-1 to centrosomes. In contrast to the multiple functions of the PP2A catalytic subunit, RSA-1 and RSA-2 are specifically required for microtubule outgrowth from centrosomes and for spindle assembly. The centrosomally localized RSA-PP2A complex mediates these functions in part by regulating two critical mitotic effectors: the microtubule destabilizer KLP-7 and the C. elegans regulator of spindle assembly TPXL-1. By regulating a subset of PP2A functions at the centrosome, the RSA complex could therefore provide a means of coordinating microtubule outgrowth from centrosomes and kinetochore microtubule stability during mitotic spindle assembly.	MPI CBG, D-01307 Dresden, Germany; Univ Calif San Diego, Sch Med, Ludwig Inst Canc Res, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Max Planck Society; Ludwig Institute for Cancer Research; University of California System; University of California San Diego; Scripps Research Institute	Hyman, AA (corresponding author), MPI CBG, Pfotenhauerstr 108, D-01307 Dresden, Germany.	hyman@mpi-cbg.de	Hyman, Tony/F-1923-2011; Hyman, Anthony A/B-3917-2017; Srayko, Martin/A-3755-2014	Hyman, Anthony A/0000-0003-3664-154X; Srayko, Martin/0000-0003-0196-0364; QUINTIN, Sophie/0000-0003-4059-5486; Dammermann, Alexander/0000-0002-1251-0978	NIGMS NIH HHS [R01 GM074207, R01 GM074207-01A2] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM074207] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrews PD, 2004, DEV CELL, V6, P253, DOI 10.1016/S1534-5807(04)00025-5; Arnold HK, 2006, MOL CELL BIOL, V26, P2832, DOI 10.1128/MCB.26.7.2832-2844.2006; BRENNER S, 1974, GENETICS, V77, P71; Camilleri C, 2002, PLANT CELL, V14, P833, DOI 10.1105/tpc.010402; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Cassimeris L, 1999, CURR OPIN CELL BIOL, V11, P134, DOI 10.1016/S0955-0674(99)80017-9; Cassimeris L, 2001, INT REV CYTOL, V210, P163; Cheeseman IM, 2001, J CELL BIOL, V155, P1137, DOI 10.1083/jcb.200109063; Dagda RK, 2003, J BIOL CHEM, V278, P24976, DOI 10.1074/jbc.M302832200; Dammermann A, 2004, DEV CELL, V7, P815, DOI 10.1016/j.devcel.2004.10.015; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Desai A, 2003, GENE DEV, V17, P2421, DOI 10.1101/gad.1126303; Desai A, 1999, CELL, V96, P69, DOI 10.1016/S0092-8674(00)80960-5; Faux MC, 1996, TRENDS BIOCHEM SCI, V21, P312, DOI 10.1016/0968-0004(96)10040-2; GLIKSMAN NR, 1992, J CELL BIOL, V119, P1271, DOI 10.1083/jcb.119.5.1271; Grill SW, 2001, NATURE, V409, P630, DOI 10.1038/35054572; Grill SW, 2003, SCIENCE, V301, P518, DOI 10.1126/science.1086560; Gruss OJ, 2004, J CELL BIOL, V166, P949, DOI 10.1083/jcb.200312112; Hamill DR, 2002, DEV CELL, V3, P673, DOI 10.1016/S1534-5807(02)00327-1; Hannak E, 2002, J CELL BIOL, V157, P591, DOI 10.1083/jcb.200202047; Hannak E, 2001, J CELL BIOL, V155, P1109, DOI 10.1083/jcb.200108051; Harlow E., 1988, ANTIBODIES LAB MANUA; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kao GT, 2004, DEVELOPMENT, V131, P755, DOI 10.1242/dev.00987; Karsenti E, 2001, SCIENCE, V294, P543, DOI 10.1126/science.1063488; Kinoshita K, 2005, J CELL BIOL, V170, P1047, DOI 10.1083/jcb.200503023; Lan WJ, 2004, CURR BIOL, V14, P273, DOI 10.1016/j.cub.2004.01.055; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; O'Toole ET, 2003, J CELL BIOL, V163, P451, DOI 10.1083/jcb.200304035; Oegema K, 2001, J CELL BIOL, V153, P1209, DOI 10.1083/jcb.153.6.1209; OEGEMA K, 2006, C ELEGANS, DOI DOI 10.1895/WORMBOOK.1.72.1; Ohi R, 2004, MOL BIOL CELL, V15, P2895, DOI 10.1091/mbc.E04-02-0082; Ozlu N, 2005, DEV CELL, V9, P237, DOI 10.1016/j.devcel.2005.07.002; Praitis V, 2001, GENETICS, V157, P1217; Siddiqui SS, 2002, TRAFFIC, V3, P20, DOI 10.1034/j.1600-0854.2002.30104.x; Sonnichsen B, 2005, NATURE, V434, P462, DOI 10.1038/nature03353; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; Srayko M, 2005, DEV CELL, V9, P223, DOI 10.1016/j.devcel.2005.07.003; Srayko M, 2006, CURR BIOL, V16, P1944, DOI 10.1016/j.cub.2006.08.029; Stemple DL, 2004, NAT REV GENET, V5, P145, DOI 10.1038/nrg1273; Sumiyoshi E, 2002, J CELL SCI, V115, P1403; Tournebize R, 1997, EMBO J, V16, P5537, DOI 10.1093/emboj/16.18.5537; VERDE F, 1990, NATURE, V343, P233, DOI 10.1038/343233a0; Wittmann T, 2001, NAT CELL BIOL, V3, pE28, DOI 10.1038/35050669	44	71	87	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 12	2007	128	1					115	127		10.1016/j.cell.2006.10.050	http://dx.doi.org/10.1016/j.cell.2006.10.050			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	139GN	17218259	Green Accepted, Bronze			2022-12-28	WOS:000244420400017
J	Stark, J; Andl, T; Millar, SE				Stark, Jaroslav; Andl, Thomas; Millar, Sarah E.			Hairy math: Insights into hair-follicle spacing and orientation	CELL			English	Editorial Material							POLARITY; WNT	Hair follicles in the skin have a characteristic spacing and orientation. Two recent papers (Sick et al., 2006; Wang et al., 2006) report the use of contrasting mathematical models and experimental manipulations to gain insight into the mechanisms underlying patterns of hair-follicle distribution and orientation.	Univ Penn, Sch Med, Dept Dermatol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA; Univ London Imperial Coll Sci Technol & Med, Dept Math, London SW7 2AZ, England; Univ London Imperial Coll Sci Technol & Med, Ctr Integrat Syst Biol, London SW7 2AZ, England	University of Pennsylvania; University of Pennsylvania; Imperial College London; Imperial College London	Millar, SE (corresponding author), Univ Penn, Sch Med, Dept Dermatol, Philadelphia, PA 19104 USA.	millars@mail.med.upenn.edu		Andl, Thomas/0000-0002-5555-468X; Millar, Sarah/0000-0001-8792-6890				Amonlirdviman K, 2005, SCIENCE, V307, P423, DOI 10.1126/science.1105471; Andl T, 2002, DEV CELL, V2, P643, DOI 10.1016/S1534-5807(02)00167-3; Barrow JR, 2006, SEMIN CELL DEV BIOL, V17, P185, DOI 10.1016/j.semcdb.2006.04.002; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Jung HS, 1998, DEV BIOL, V196, P11, DOI 10.1006/dbio.1998.8850; Kuraguchi M, 2006, PLOS GENET, V2, P1362, DOI 10.1371/journal.pgen.0020146; Mao BY, 2003, GENE, V302, P179, DOI 10.1016/S0378-1119(02)01106-X; Sick S, 2006, SCIENCE, V314, P1447, DOI 10.1126/science.1130088; TURING AM, 1952, PHILOS T ROY SOC B, V237, P37, DOI 10.1098/rstb.1952.0012; Wang YS, 2006, P NATL ACAD SCI USA, V103, P19800, DOI 10.1073/pnas.0609712104	10	22	22	0	4	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 12	2007	128	1					17	20		10.1016/j.cell.2006.12.020	http://dx.doi.org/10.1016/j.cell.2006.12.020			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	139GN	17218249	Bronze			2022-12-28	WOS:000244420400007
J	Wegener, KL; Partridge, AW; Han, J; Pickford, AR; Liddington, RC; Ginsberg, MH; Campbell, ID				Wegener, Kate L.; Partridge, Anthony W.; Han, Jaewon; Pickford, Andrew R.; Liddington, Robert C.; Ginsberg, Mark H.; Campbell, Iain D.			Structural basis of integrin activation by talin	CELL			English	Article							MEMBRANE-PROXIMAL REGION; LIGAND-BINDING AFFINITY; FERM DOMAIN; TRANSMEMBRANE DOMAIN; SECONDARY STRUCTURE; CRYSTAL-STRUCTURE; CYTOPLASMIC FACE; PROTEIN; LINKAGE; COMPLEX	Regulation of integrin affinity (activation) is essential for metazoan development and for many pathological processes. Binding of the talin phosphotyrosine-binding (PTB) domain to integrin beta subunit cytoplasmic domains (tails) causes activation, whereas numerous other PTB-domain-containing proteins bind integrins without activating them. Here we define the structure of a complex between talin and the membrane-proximal integrin beta 3 cytoplasmic domain and identify specific contacts between talin and the integrin tail required for activation. We used structure-based mutagenesis to engineer talin and beta 3 variants that interact with comparable affinity to the wild-type proteins but inhibit integrin activation by competing with endogenous talin. These results reveal the structural basis of talin's unique ability to activate integrins, identify an interaction that could aid in the design of therapeutics to block integrin activation, and enable engineering of cells with defects in the activation of multiple classes of integrins.	Univ Oxford, Dept Biochem, Oxford OX1 3QU, England; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Burnham Inst, Ctr Canc, Program Cell Adhes, La Jolla, CA 92037 USA; Univ Portsmouth, Portsmouth PO1 2DY, Hants, England	University of Oxford; University of California System; University of California San Diego; Sanford Burnham Prebys Medical Discovery Institute; University of Portsmouth	Ginsberg, MH (corresponding author), Univ Oxford, Dept Biochem, Oxford OX1 3QU, England.	mhginsberg@ucsd.edu; iain.campbell@bioch.ox.ac.uk	Wegener, Kate/E-5077-2010; Pickford, Andy/AGB-6901-2022	Wegener, Kate/0000-0002-1562-6060; Ginsberg, Mark/0000-0002-5685-5417; Pickford, Andy/0000-0002-7237-0030	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABRAMS C, 1994, J BIOL CHEM, V269, P18781; Ayed A, 2001, NAT STRUCT BIOL, V8, P756, DOI 10.1038/nsb0901-756; Baker EK, 1997, P NATL ACAD SCI USA, V94, P1973, DOI 10.1073/pnas.94.5.1973; Bennett JS, 2005, J CLIN INVEST, V115, P3363, DOI 10.1172/JCI26989; Bersch B, 2003, J BIOMOL NMR, V27, P57, DOI 10.1023/A:1024746306675; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Calderwood DA, 2003, P NATL ACAD SCI USA, V100, P2272, DOI 10.1073/pnas.262791999; Calderwood DA, 2002, J BIOL CHEM, V277, P21749, DOI 10.1074/jbc.M111996200; Campbell ID, 2004, TRENDS BIOCHEM SCI, V29, P429, DOI 10.1016/j.tibs.2004.06.005; Chishti AH, 1998, TRENDS BIOCHEM SCI, V23, P281, DOI 10.1016/S0968-0004(98)01237-7; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Critchley DR, 2005, BIOCHEM SOC T, V33, P1308, DOI 10.1042/BST0331308; de Pereda JM, 2005, J BIOL CHEM, V280, P8381, DOI 10.1074/jbc.M413180200; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Edwards SD, 2001, BIOCHEMISTRY-US, V40, P7061, DOI 10.1021/bi010419h; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Garcia-Alvarez B, 2003, MOL CELL, V11, P49, DOI 10.1016/S1097-2765(02)00823-7; Ginsberg MH, 2005, CURR OPIN CELL BIOL, V17, P509, DOI 10.1016/j.ceb.2005.08.010; Gottschalk KE, 2005, STRUCTURE, V13, P703, DOI 10.1016/j.str.2005.02.014; Hamada K, 2000, EMBO J, V19, P4449, DOI 10.1093/emboj/19.17.4449; Hamada K, 2003, EMBO J, V22, P502, DOI 10.1093/emboj/cdg039; Han BG, 2000, NAT STRUCT BIOL, V7, P871; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; Huang CL, 2004, J BIOL CHEM, V279, P42279, DOI 10.1074/jbc.M402540200; HUGHES PE, 1995, J BIOL CHEM, V270, P12411, DOI 10.1074/jbc.270.21.12411; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Koradi R, 1996, J MOL GRAPHICS, V14, P29; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Li W, 2005, P NATL ACAD SCI USA, V102, P1424, DOI 10.1073/pnas.0409334102; Luo BH, 2005, P NATL ACAD SCI USA, V102, P3679, DOI 10.1073/pnas.0409440102; Papagrigoriou E, 2004, EMBO J, V23, P2942, DOI 10.1038/sj.emboj.7600285; PARDI A, 1984, J MOL BIOL, V180, P741, DOI 10.1016/0022-2836(84)90035-4; Partridge AW, 2005, J BIOL CHEM, V280, P7294, DOI 10.1074/jbc.M412701200; Pickford AR, 2001, EMBO J, V20, P1519, DOI 10.1093/emboj/20.7.1519; REDFIELD C, 1991, BIOCHEMISTRY-US, V30, P11029, DOI 10.1021/bi00110a004; REES DJG, 1990, NATURE, V347, P685, DOI 10.1038/347685a0; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; Smith WJ, 2003, J BIOL CHEM, V278, P4949, DOI 10.1074/jbc.M210601200; Stefansson A, 2004, J BIOL CHEM, V279, P21200, DOI 10.1074/jbc.M400771200; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; Tanentzapf G, 2006, NAT CELL BIOL, V8, P601, DOI 10.1038/ncb1411; Uhlik MT, 2005, J MOL BIOL, V345, P1, DOI 10.1016/j.jmb.2004.10.038; Ulmer TS, 2003, BIOCHEMISTRY-US, V42, P8307, DOI 10.1021/bi034384s; Vinogradova O, 2004, P NATL ACAD SCI USA, V101, P4094, DOI 10.1073/pnas.0400742101; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; Weljie AM, 2002, P NATL ACAD SCI USA, V99, P5878, DOI 10.1073/pnas.092515799	47	506	521	2	54	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 12	2007	128	1					171	182		10.1016/j.cell.2006.10.048	http://dx.doi.org/10.1016/j.cell.2006.10.048			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	139GN	17218263	Bronze			2022-12-28	WOS:000244420400021
J	Gilchrist, A; Resch, KJ; White, AG				Gilchrist, Alexei; Resch, Kevin J.; White, Andrew G.			Quantum information - Source of triggered entangled photon pairs?	NATURE			English	Letter									Univ Queensland, Dept Phys, Brisbane, Qld 4072, Australia; Univ Queensland, Ctr Quantum Comp Technol, Brisbane, Qld 4072, Australia	University of Queensland; University of Queensland	Gilchrist, A (corresponding author), Univ Queensland, Dept Phys, Brisbane, Qld 4072, Australia.	andrew.white@physics.uq.edu.au	White, Andrew G/A-1088-2009; White, Andrew G./AAI-1062-2020; Gilchrist, Alexei/B-9968-2009	White, Andrew G/0000-0001-9639-5200; Gilchrist, Alexei/0000-0003-0075-5174				Bennett CH, 1996, PHYS REV A, V54, P3824, DOI 10.1103/PhysRevA.54.3824; Coffman V, 2000, PHYS REV A, V61, DOI 10.1103/PhysRevA.61.052306; James DFV, 2001, PHYS REV A, V64, DOI 10.1103/PhysRevA.64.052312; MANDEL L, 1995, OPTICAL COHERENCE QU, P353; Munro WJ, 2001, PHYS REV A, V64, DOI 10.1103/PhysRevA.64.030302; Peres A, 1996, PHYS REV LETT, V77, P1413, DOI 10.1103/PhysRevLett.77.1413; Stevenson RM, 2006, NATURE, V439, P179, DOI 10.1038/nature04446; STOKES G G, 1851, CAMBRIDGE PHILOS SOC, V9, P399; Vasanelli A, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.216804; White AG, 2002, PHYS REV A, V65, DOI 10.1103/PhysRevA.65.012301; Wootters WK, 1998, PHYS REV LETT, V80, P2245, DOI 10.1103/PhysRevLett.80.2245; Young RJ, 2006, NEW J PHYS, V8, DOI 10.1088/1367-2630/8/2/029	12	6	6	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 11	2007	445	7124					E4	E5		10.1038/nature05546	http://dx.doi.org/10.1038/nature05546			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124QF	17215801	Green Submitted			2022-12-28	WOS:000243384300040
J	Coombes, R				Coombes, Rebecca			The week in medicine - Medical records: are patients' secrets up for grabs?	BRITISH MEDICAL JOURNAL			English	Editorial Material												rcoombes@bmjgroup.com							0	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JAN 6	2007	334	7583					16	17		10.1136/bmj.39084.441053.59	http://dx.doi.org/10.1136/bmj.39084.441053.59			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125CH	17204794	Green Published			2022-12-28	WOS:000243418600027
J	Buenz, EJ; Bauer, BA; Johnson, HE; Tavana, G; Beekman, EM; Frank, KL				Buenz, Eric J.; Bauer, Brent A.; Johnson, Holly E.; Tavana, Gaugau; Beekman, Eric M.; Frank, Kristi L.			Searching historical herbal texts for potential new drugs	BRITISH MEDICAL JOURNAL			English	Editorial Material									Mayo Clin, Coll Med, Complementary & Integrat Med Program, Rochester, MN 55905 USA; Natl Trop Bot Gardens, Inst Ethnomed, Kalaheo, HI USA; Univ Massachusetts, Amherst, MA 01003 USA	Mayo Clinic; University of Massachusetts System; University of Massachusetts Amherst	Buenz, EJ (corresponding author), Mayo Clin, Coll Med, Complementary & Integrat Med Program, Rochester, MN 55905 USA.	buenz@biosciential.com		, Eric/0000-0002-4053-7422; Howe, Charles/0000-0002-3889-8739				Buenz EJ, 2004, TRENDS PHARMACOL SCI, V25, P494, DOI 10.1016/j.tips.2004.07.003; Buenz EJ, 2005, J ETHNOPHARMACOL, V96, P57, DOI 10.1016/j.jep.2004.08.016; NCCLS, 2003, METH DIL ANT SUSC TE, V6th ed.; Prance GT, 2004, ECON BOT, V58, P470, DOI 10.1663/0013-0001(2004)058[0470:TUOARR]2.0.CO;2; Riddle JM, 2002, ADV EXP MED BIOL, V505, P89; RUMPHUIS G, 1941, HERBARIUM AMBOINENSE	6	20	23	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 23	2006	333	7582					1314	1315		10.1136/bmj.39008.492361.BE	http://dx.doi.org/10.1136/bmj.39008.492361.BE			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121MC	17185721	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000243160700019
J	Ferguson, N				Ferguson, Neil			Poverty, death, and a future influenza pandemic	LANCET			English	Editorial Material									Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, London W2 1PG, England	Imperial College London	Ferguson, N (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, London W2 1PG, England.	neil.ferguson@ic.ac.uk	Ferguson, Neil/B-8578-2008	Ferguson, Neil/0000-0002-1154-8093				Afkhami A, 2003, B HIST MED, V77, P367, DOI 10.1353/bhm.2003.0049; Beigel H, 2005, NEW ENGL J MED, V353, P1374, DOI 10.1056/NEJMra052211; Bell D, 2006, EMERG INFECT DIS, V12, P88; *I MED, 2006, ROL COMM BAS MIT STR; Johnson NPAS, 2002, B HIST MED, V76, P105, DOI 10.1353/bhm.2002.0022; Murray CJL, 2006, LANCET, V368, P2211, DOI 10.1016/S0140-6736(06)69895-4; Sydenstricker E, 1931, PUBLIC HEALTH REP, V46, P154, DOI 10.2307/4579923; World Health Organization, 2002, SCAL RESP INF DIS WA	8	13	14	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 23	2006	368	9554					2187	2188		10.1016/S0140-6736(06)69870-X	http://dx.doi.org/10.1016/S0140-6736(06)69870-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	120HY	17189012				2022-12-28	WOS:000243076800004
J	Finall, AI; McIntosh, SA; Thompson, WD				Finall, A. I.; McIntosh, S. A.; Thompson, W. D.			Subcutaneous inflammation mimicking metastatic malignancy induced by injection of mistletoe extract	BRITISH MEDICAL JOURNAL			English	Editorial Material							CLINICAL-TRIALS; PANNICULITIS; CANCER		Univ Wales Hosp, Cardiff & Vale NHS Trust, Dept Histopathol, Cardiff CF14 4XW, Wales; Aberdeen Royal Infirm, Unit Breast Surg, Aberdeen AB25 2ZD, Scotland	Cardiff University; University of Aberdeen	Finall, AI (corresponding author), Univ Wales Hosp, Cardiff & Vale NHS Trust, Dept Histopathol, Cardiff CF14 4XW, Wales.	Alison.Finall@CardiffandVale.wales.nhs.uk	McIntosh, Stuart/J-9512-2012	McIntosh, Stuart/0000-0002-4123-9611				Ernst E, 2003, INT J CANCER, V107, P262, DOI 10.1002/ijc.11386; Gorter R W, 1998, Am J Ther, V5, P181, DOI 10.1097/00045391-199805000-00009; HARRIS RB, 1999, ARCH DERMATOPATHOL, V21, P365; Hochberg MC, 1997, ARTHRITIS RHEUM, V40, P1725, DOI 10.1002/art.1780400928; Huber R, 2000, J ALTERN COMPLEM MED, V6, P305, DOI 10.1089/10755530050120664; JAFFE N, 1971, NEW ENGL J MED, V284, P366, DOI 10.1056/NEJM197102182840706; JANIS JF, 1968, ARCH DERMATOL, V97, P640, DOI 10.1001/archderm.97.6.640; Kaegi E, 1998, CAN MED ASSOC J, V158, P1157; Kienle GS, 2003, EUR J MED RES, V8, P109; Mabed M, 2004, BRIT J CANCER, V90, P65, DOI 10.1038/sj.bjc.6601463; *NAT CANC I, MISTL EXTR; PETERS MS, 1991, J CUTAN PATHOL, V18, P189, DOI 10.1111/j.1600-0560.1991.tb00151.x; PORTER R, 1997, MED HIST HUMANITY AN, P112; WINKELMANN RK, 1985, J AM ACAD DERMATOL, V13, P988, DOI 10.1016/S0190-9622(85)70250-2	14	5	5	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 23	2006	333	7582					1293	1294		10.1136/bmj.39044.460023.BE	http://dx.doi.org/10.1136/bmj.39044.460023.BE			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121MC	17185712	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000243160700010
J	Powell, M				Powell, Michael			Sir Victor Horsley - an inspiration	BRITISH MEDICAL JOURNAL			English	Editorial Material									UCL Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	Powell, M (corresponding author), UCL Natl Hosp Neurol & Neurosurg, Queen Sq, London WC1N 3BG, England.	michael.powell@ndh.nhs.ok						HORSLEY V, PUBLICATION LIST	1	4	4	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 23	2006	333	7582					1317	1319		10.1136/bmj.39056.527407.55	http://dx.doi.org/10.1136/bmj.39056.527407.55			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121MC	17185723	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000243160700021
J	Pan, F; Sun, L; Kardian, DB; Whartenby, KA; Pardoll, DM; Liu, JO				Pan, Fan; Sun, Luo; Kardian, David B.; Whartenby, Katharine A.; Pardoll, Drew M.; Liu, Jun O.			Feedback inhibition of calcineurin and Ras by a dual inhibitory protein Carabin	NATURE			English	Article							T-CELL-ACTIVATION; IDENTIFICATION; STIMULATION; LYMPHOCYTES; SELECTION; GTPASES; P21RAS; KINASE; FAMILY; CABIN1	Feedback regulation of adaptive immunity is a fundamental mechanism for controlling the overall output of different signal transduction pathways, including that mediated by the T-cell antigen receptor (TCR)(1). Calcineurin(2-4) and Ras(5-7) are known to have essential functions during T-cell activation. However, how the calcineurin signalling pathway is terminated in the process is still largely unknown. Although several endogenous inhibitors of calcineurin have been reported(8-13), none fulfils the criteria of a feedback inhibitor, as their expression is not responsive to TCR signalling. Here we identify an endogenous inhibitor of calcineurin, named Carabin, which also inhibits the Ras signalling pathway through its intrinsic Ras GTPase-activating protein (GAP) activity. Expression of Carabin is upregulated on TCR signalling in a manner that is sensitive to inhibitors of calcineurin, indicating that Carabin constitutes part of a negative regulatory loop for the intracellular TCR signalling pathway. Knockdown of Carabin by short interfering RNA led to a significant enhancement of interleukin-2 production by antigen-specific T cells in vitro and in vivo. Thus, Carabin is a negative feedback inhibitor of the calcineurin signalling pathway that also mediates crosstalk between calcineurin and Ras.	Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Solomon H Snyder Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Immunol & Hematopoiesis Div, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine	Liu, JO (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA.	joliu@jhu.edu						Albert S, 1999, EMBO J, V18, P5216, DOI 10.1093/emboj/18.19.5216; Anderson DH, 2005, METHOD ENZYMOL, V403, P552, DOI 10.1016/S0076-6879(05)03048-X; Cantrell DA, 2003, IMMUNOL REV, V192, P122, DOI 10.1034/j.1600-065X.2003.00028.x; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; Cui Y, 2003, NAT MED, V9, P952, DOI 10.1038/nm882; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FEARON ER, 1992, P NATL ACAD SCI USA, V89, P7958, DOI 10.1073/pnas.89.17.7958; Fischer AM, 2005, IMMUNITY, V23, P431, DOI 10.1016/j.immuni.2005.08.013; Gorlach J, 2000, EMBO J, V19, P3618, DOI 10.1093/emboj/19.14.3618; Han AD, 2003, NATURE, V422, P730, DOI 10.1038/nature01555; Kingsbury TJ, 2000, GENE DEV, V14, P1595; Lai MM, 1998, J BIOL CHEM, V273, P18325, DOI 10.1074/jbc.273.29.18325; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Liu Jun O, 2005, Sci STKE, V2005, pre1; MANALAN AS, 1983, P NATL ACAD SCI-BIOL, V80, P4291, DOI 10.1073/pnas.80.14.4291; Neilson JR, 2004, IMMUNITY, V20, P255, DOI 10.1016/S1074-7613(04)00052-4; Pan F, 2005, EMBO J, V24, P2104, DOI 10.1038/sj.emboj.7600685; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rothermel B, 2000, J BIOL CHEM, V275, P8719, DOI 10.1074/jbc.275.12.8719; Ryeom S, 2003, NAT IMMUNOL, V4, P874, DOI 10.1038/ni966; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; Sun L, 1998, IMMUNITY, V8, P703, DOI 10.1016/S1074-7613(00)80575-0; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; WOODROW M, 1993, J EXP MED, V178, P1517, DOI 10.1084/jem.178.5.1517; Youn HD, 1999, SCIENCE, V286, P790, DOI 10.1126/science.286.5440.790	27	44	49	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 25	2007	445	7126					433	436		10.1038/nature05476	http://dx.doi.org/10.1038/nature05476			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	128WD	17230191				2022-12-28	WOS:000243689500041
J	Smith, CGA; Aylward, AD; Millward, GH; Miller, S; Moore, LE				Smith, C. G. A.; Aylward, A. D.; Millward, G. H.; Miller, S.; Moore, L. E.			An unexpected cooling effect in Saturn's upper atmosphere	NATURE			English	Article							GRAVITY-WAVES	The upper atmospheres of the four Solar System giant planets exhibit high temperatures(1,2) that cannot be explained by the absorption of sunlight(2,3). In the case of Saturn the temperatures predicted by models of solar heating(2,4) are 200 K, compared to temperatures of similar to 400 K observed independently in the polar regions(5) and at 30 degrees latitude(6). This unexplained 'energy crisis' represents a major gap in our understanding of these planets' atmospheres. An important candidate for the source of the missing energy is the magnetosphere(1,2,4,7-9), which injects energy mostly in the polar regions of the planet. This polar energy input is believed to be sufficient to explain the observed temperatures(9), provided that it is efficiently redistributed globally by winds(4,8), a process that is not well understood. Here we show, using a numerical model(4), that the net effect of the winds driven by the polar energy inputs is not to heat but to cool the low-latitude thermosphere. This surprising result allows us to rule out known polar energy inputs as the solution to the energy crisis at Saturn. There is either an unknown - and large - source of polar energy, or, more probably, some other process heats low latitudes directly.	UCL, Dept Phys & Astron, London WC1E 6BT, England; Boston Univ, Ctr Space Phys, Boston, MA 02215 USA	University of London; University College London; Boston University	Aylward, AD (corresponding author), UCL, Dept Phys & Astron, Mortimer St, London WC1E 6BT, England.	a.aylward@ucl.ac.uk		Miller, Steven/0000-0002-7159-6871; Moore, Luke/0000-0003-4481-9862; Smith, Chris/0000-0002-9355-0401				Atreya S. K., 1984, SATURN, P239; ATREYA SK, 1982, PLANET SPACE SCI, V30, P849, DOI 10.1016/0032-0633(82)90117-9; ATREYA SK, 1986, ATMOSPHERE IONOSPHER, pCH2; Clarke JT, 2005, NATURE, V433, P717, DOI 10.1038/nature03331; CODRESCU MV, 1995, GEOPHYS RES LETT, V22, P2393, DOI 10.1029/95GL01909; Cowley SWH, 2004, J GEOPHYS RES-SPACE, V109, DOI 10.1029/2003JA010375; DAVIS L, 1990, J GEOPHYS RES-SPACE, V95, P15257, DOI 10.1029/JA095iA09p15257; FESTOU MC, 1982, GEOPHYS RES LETT, V9, P1147, DOI 10.1029/GL009i010p01147; Fuller-Rowell T.J., 1996, STEP REPORT, P217; Hickey MP, 2000, ICARUS, V148, P266, DOI 10.1006/icar.2000.6472; HICKEY MP, 2005, EOS S18, V86; Matcheva KI, 1999, ICARUS, V140, P328, DOI 10.1006/icar.1999.6151; MELIN H, 2006, THESIS U LONDON; Moore LE, 2004, ICARUS, V172, P503, DOI 10.1016/j.icarus.2004.07.007; Moses JI, 2000, ICARUS, V143, P244, DOI 10.1006/icar.1999.6270; Muller-Wodarg ICF, 2006, ICARUS, V180, P147, DOI 10.1016/j.icarus.2005.09.002; RICHARDSON JD, 1986, J GEOPHYS RES, V91, P1381, DOI 10.1029/JA091iA02p01381; Smith CGA, 2005, ANN GEOPHYS-GERMANY, V23, P2465, DOI 10.5194/angeo-23-2465-2005; Smith CGA, 2005, ANN GEOPHYS-GERMANY, V23, P1943, DOI 10.5194/angeo-23-1943-2005; SMITH GR, 1983, J GEOPHYS RES-SPACE, V88, P8667, DOI 10.1029/JA088iA11p08667; SMITH GR, 1990, REV GEOPHYS, V28, P117, DOI 10.1029/RG028i002p00117; Stallard TS, 2004, ICARUS, V167, P204, DOI 10.1016/j.icarus.2003.09.006; STROBEL DF, 1973, J ATMOS SCI, V30, P718, DOI 10.1175/1520-0469(1973)030<0718:OTTOTJ>2.0.CO;2; Yelle RV, 2004, CAMB PLANET, P185; Young LA, 1997, SCIENCE, V276, P108, DOI 10.1126/science.276.5309.108	25	48	49	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 25	2007	445	7126					399	401		10.1038/nature05518	http://dx.doi.org/10.1038/nature05518			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	128WD	17251972				2022-12-28	WOS:000243689500032
J	Alford, M; Blaschke, D; Drago, A; Klahn, T; Pagliara, G; Schaffner-Bielich, J				Alford, M.; Blaschke, D.; Drago, A.; Klaehn, T.; Pagliara, G.; Schaffner-Bielich, J.			Astrophysics - Quark matter in compact stars?	NATURE			English	Letter							STRANGE STARS		Washington Univ, Dept Phys, St Louis, MO 63130 USA; Univ Wroclaw, Inst Fizyki Teoretycznej, PL-50204 Wroclaw, Poland; Univ Rostock, Inst Phys, D-18051 Rostock, Germany; Univ Ferrara, Dipartimento Fis, I-44100 Ferrara, Italy; Ist Nazl Fis Nucl, Sez Ferrara, I-44100 Ferrara, Italy; GSI Darmstadt, D-64291 Darmstadt, Germany; Univ Frankfurt, Inst Theoret Phys, D-60438 Frankfurt, Germany	Washington University (WUSTL); University of Wroclaw; University of Rostock; University of Ferrara; Istituto Nazionale di Fisica Nucleare (INFN); Helmholtz Association; GSI Helmholtz-Center for Heavy Ion Research; Goethe University Frankfurt	Alford, M (corresponding author), Washington Univ, Dept Phys, St Louis, MO 63130 USA.	alford@wuphys.wustl.edu	Schaffner-Bielich, Juergen/L-9874-2018; Pagliara, Giuseppe/F-7650-2012; Blaschke, David/AAV-3413-2021; Drago, Alessandro/F-6347-2012; Blaschke, David/M-7009-2019	Schaffner-Bielich, Juergen/0000-0002-0079-6841; Blaschke, David/0000-0002-8399-5183; Drago, Alessandro/0000-0003-1302-8566; PAGLIARA, Giuseppe/0000-0003-3250-1398; Klahn, Thomas/0000-0001-5445-9528				Alford M, 1999, NUCL PHYS B, V537, P443, DOI 10.1016/S0550-3213(98)00668-3; Alford M, 2005, ASTROPHYS J, V629, P969, DOI 10.1086/430902; Alford M, 2001, PHYS REV D, V63, DOI 10.1103/PhysRevD.63.074016; ALPAR MA, 1987, PHYS REV LETT, V58, P2152, DOI 10.1103/PhysRevLett.58.2152; Fraga ES, 2001, PHYS REV D, V63, DOI 10.1103/PhysRevD.63.121702; Grigorian H, 2005, PHYS REV C, V71, DOI 10.1103/PhysRevC.71.045801; Klahn T, 2006, PHYS REV C, V74, DOI 10.1103/PhysRevC.74.035802; KLAHN T, 2006, ARXIVNUCLTH0609067; Link B, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.101101; Madsen J, 2000, PHYS REV LETT, V85, P10, DOI 10.1103/PhysRevLett.85.10; Ozel F, 2006, NATURE, V441, P1115, DOI 10.1038/nature04858; Page D, 2005, ASTROPHYS J, V635, pL157, DOI 10.1086/499520; Page D, 2006, NUCL PHYS A, V777, P497, DOI 10.1016/j.nuclphysa.2005.09.019; Ruster SB, 2004, PHYS REV D, V69, DOI 10.1103/PhysRevD.69.045011; WATTS AL, 2006, ARXIVASTROPH0609364	15	194	196	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 18	2007	445	7125					E7	E8		10.1038/nature05582	http://dx.doi.org/10.1038/nature05582			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126HT	17230145	Green Published, Green Submitted			2022-12-28	WOS:000243504700034
J	Paradise, JL; Feldman, HM; Campbell, TF; Dollaghan, CA; Rockette, HE; Pitcairn, DL; Smith, CG; Colborn, DK; Bernard, BS; Kurs-Lasky, M; Janosky, JE; Sabo, DL; O'Connor, RE; Pelham, WE				Paradise, Jack L.; Feldman, Heidi M.; Campbell, Thomas F.; Dollaghan, Christine A.; Rockette, Howard E.; Pitcairn, Dayna L.; Smith, Clyde G.; Colborn, D. Kathleen; Bernard, Beverly S.; Kurs-Lasky, Marcia; Janosky, Janine E.; Sabo, Diane L.; O'Connor, Rollanda E.; Pelham, William E., Jr.			Tympanostomy tubes and developmental outcomes at 9 to 11 years of age	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							1ST 3 YEARS; OTITIS-MEDIA; EARLY-CHILDHOOD; DELAYED INSERTION; LANGUAGE; CHILDREN; SPEECH; SKILLS; PERFORMANCE; IMPAIRMENT	BACKGROUND: Developmental impairments in children have been attributed to persistent middle-ear effusion in their early years of life. Previously, we reported that among children younger than 3 years of age with persistent middle-ear effusion, prompt as compared with delayed insertion of tympanostomy tubes did not result in improved cognitive, language, speech, or psychosocial development at 3, 4, or 6 years of age. However, other important components of development could not be assessed until the children were older. METHODS: We enrolled 6350 infants soon after birth and evaluated them regularly for middle-ear effusion. Before 3 years of age, 429 children with persistent effusion were randomly assigned to undergo the insertion of tympanostomy tubes either promptly or up to 9 months later if effusion persisted. We assessed literacy, attention, social skills, and academic achievement in 391 of these children at 9 to 11 years of age. RESULTS: Mean (+/-SD) scores on 48 developmental measures in the group of children who were assigned to undergo early insertion of tympanostomy tubes did not differ significantly from the scores in the group that was assigned to undergo delayed insertion. These measures included the Passage Comprehension subtest of the Woodcock Reading Mastery Tests (mean score, 98+/-12 in the early-treatment group and 99+/-12 in the delayed-treatment group); the Spelling, Writing Samples, and Calculation subtests of the Woodcock-Johnson III Tests of Achievement (96+/-13 and 97+/-16; 104+/-14 and 105+/-15; and 99+/-13 and 99+/-13, respectively); and inattention ratings on visual and auditory continuous performance tests. CONCLUSIONS: In otherwise healthy young children who have persistent middle-ear effusion, as defined in our study, prompt insertion of tympanostomy tubes does not improve developmental outcomes up to 9 to 11 years of age.	Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Pittsburgh, PA USA; Stanford Univ, Sch Med, Stanford, CA 94305 USA; Univ Texas Dallas, Dallas, TX 75230 USA; Univ Calif Riverside, Riverside, CA 92521 USA; SUNY Buffalo, Buffalo, NY 14260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Stanford University; University of Texas System; University of Texas Dallas; University of California System; University of California Riverside; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Paradise, JL (corresponding author), Childrens Hosp Pittsburgh, 3705 5th Ave, Pittsburgh, PA 15213 USA.	jpar@pitt.edu		Feldman, Heidi/0000-0002-4435-0913; E. PELHAM, JR., WILLIAM/0000-0002-3195-4478	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026026, R01HD042080] Funding Source: NIH RePORTER; NICHD NIH HHS [HD26026, HD42080] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Achenbach T., 1991, INTEGRATIVE GUIDE 19; ALLINDER M, 1988, PSYCHOL ASSESSMENT C, P106; *AM AC OT HEAD NEC, 2000, 2000 CLIN IND COMP; [Anonymous], 2001, WOODCOCKJOHNSON 3 TE; [Anonymous], 1998, WOODCOCK READING MAS; Asbjornsen A, 2000, DEV MED CHILD NEUROL, V42, P481, DOI 10.1017/S001216220000089X; Aylward GP, 2002, DEV NEUROPSYCHOL, V21, P285, DOI 10.1207/S15326942DN2103_5; Bennett KE, 2001, ARCH DIS CHILD, V85, P91, DOI 10.1136/adc.85.2.91; DENO SL, 1985, EXCEPT CHILDREN, V52, P219, DOI 10.1177/001440298505200303; Fabiano GA, 2006, J CLIN CHILD ADOLESC, V35, P369, DOI 10.1207/s15374424jccp3503_3; FEAGANS L, 1987, J PEDIATR PSYCHOL, V12, P581, DOI 10.1093/jpepsy/12.4.581; Feldman HM, 2003, J SPEECH LANG HEAR R, V46, P273, DOI 10.1044/1092-4388(2003/022); Gottfried AW, 2003, MON PARENT, P189; Gresham F.M., 1990, SOCIAL SKILLS RATING; Halperin JM., 1991, PSYCHOL ASSESS J CON, V3, P603, DOI [10.1037/1040-3590.3.4.603, DOI 10.1037/1040, DOI 10.1037/1040-3590.3.4.603]; HERSHER L, 1978, PERCEPT MOTOR SKILL, V47, P723, DOI 10.2466/pms.1978.47.3.723; Kindig JS, 2000, J PEDIATR PSYCHOL, V25, P15, DOI 10.1093/jpepsy/25.1.15; Luotonen M, 1996, PEDIATR INFECT DIS J, V15, P854, DOI 10.1097/00006454-199610000-00005; NILSSON M, 1994, J ACOUST SOC AM, V95, P1085, DOI 10.1121/1.408469; Nilsson M., 1996, DEV NORMING HEARING; Paradise JL, 2005, NEW ENGL J MED, V353, P576, DOI 10.1056/NEJMoa050406; Paradise JL, 1997, PEDIATRICS, V99, P318, DOI 10.1542/peds.99.3.318; Paradise JL, 2003, PEDIATRICS, V112, P265, DOI 10.1542/peds.112.2.265; Paradise JL, 2000, PEDIATRICS, V105, P1119, DOI 10.1542/peds.105.5.1119; Paradise JL, 2001, NEW ENGL J MED, V344, P1179, DOI 10.1056/NEJM200104193441601; PELHAM WE, 1992, J AM ACAD CHILD PSY, V31, P210, DOI 10.1097/00004583-199203000-00006; PELHAM WE, 1992, J AM ACAD CHILD PSY, V31, P1177; ROBERTS JE, 1994, J PEDIATR PSYCHOL, V19, P347, DOI 10.1093/jpepsy/19.3.347; ROBERTS JE, 1989, PEDIATRICS, V83, P477; Rosenfeld RM, 2004, PEDIATRICS, V113, P1412, DOI 10.1542/peds.113.5.1412; STOOL SE, 1994, AHCPR PUBLICATION; TEELE DW, 1990, J INFECT DIS, V162, P685, DOI 10.1093/infdis/162.3.685; UPDIKE C, 1992, ANN OTO RHINOL LARYN, V101, P530, DOI 10.1177/000348949210100615; Wagner R.K., 1999, COMPREHENSIVE TEST P; Wechsler D., 2007, WASI 2 WECHSLER ABBR; [No title captured]	36	95	101	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 18	2007	356	3					248	261		10.1056/NEJMoa062980	http://dx.doi.org/10.1056/NEJMoa062980			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	126BV	17229952				2022-12-28	WOS:000243488100007
J	Goebel, T				Goebel, Ted			The missing years for modern humans	SCIENCE			English	Editorial Material							MODERN HUMAN COLONIZATION; NEANDERTHALS; AFRICA; EUROPE; LEGACY; AGES; SITE		Texas A&M Univ, Ctr Study First Amer, Dept Anthropol, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station	Goebel, T (corresponding author), Texas A&M Univ, Ctr Study First Amer, Dept Anthropol, College Stn, TX 77843 USA.	goebel@tamu.edu	Goebel, Ted/A-7051-2009					Anikovich MV, 2007, SCIENCE, V315, P223, DOI 10.1126/science.1133376; Bar-Yosef O, 2002, ANNU REV ANTHROPOL, V31, P363, DOI 10.1146/annurev.anthro.31.040402.085416; Bowler JM, 2003, NATURE, V421, P837, DOI 10.1038/nature01383; Forster P, 2004, PHILOS T R SOC B, V359, P255, DOI 10.1098/rstb.2003.1394; Goebel T, 1999, EVOL ANTHROPOL, V8, P208; Gravina B, 2005, NATURE, V438, P51, DOI 10.1038/nature04006; Grine FE, 2007, SCIENCE, V315, P226, DOI 10.1126/science.1136294; McDougall I, 2005, NATURE, V433, P733, DOI 10.1038/nature03258; Mellars P, 2004, NATURE, V432, P461, DOI 10.1038/nature03103; Mellars P., 1990, EMERGENCE MODERN HUM; Mellars P, 2006, SCIENCE, V313, P796, DOI 10.1126/science.1128402; Mellars P, 2006, EVOL ANTHROPOL, V15, P167, DOI 10.1002/evan.20103; Mellars P, 2006, P NATL ACAD SCI USA, V103, P9381, DOI 10.1073/pnas.0510792103; Olivieri A, 2006, SCIENCE, V314, P1767, DOI 10.1126/science.1135566; Pitulko VV, 2004, SCIENCE, V303, P52, DOI 10.1126/science.1085219; Richards M, 2000, AM J HUM GENET, V67, P1251, DOI 10.1016/S0002-9297(07)62954-1; Semino O, 2000, SCIENCE, V290, P1155, DOI 10.1126/science.290.5494.1155; Zilhao J, 2006, EVOL ANTHROPOL, V15, P183, DOI 10.1002/evan.20110	18	34	36	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 12	2007	315	5809					194	196		10.1126/science.1137564	http://dx.doi.org/10.1126/science.1137564			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	124XZ	17218514				2022-12-28	WOS:000243407400031
J	Pedros-Alio, C				Pedros-Alio, Carlos			Dipping into the rare biosphere	SCIENCE			English	Editorial Material							DIVERSITY; MICROORGANISMS; PREDATION		CMIMA CSIC, Dept Marine Biol & Oceanog, Inst Ciencies Mar, E-08003 Barcelona, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Mediterraneo de Investigaciones Marinas y Ambientales (CMIMA); CSIC - Instituto de Ciencias del Mar (ICM)	Pedros-Alio, C (corresponding author), CMIMA CSIC, Dept Marine Biol & Oceanog, Inst Ciencies Mar, E-08003 Barcelona, Spain.	cpedros@icm.csic.es	Pedrós-Alió, Carlos/H-1222-2011	Pedrós-Alió, Carlos/0000-0003-1009-4277				Acinas SG, 2004, NATURE, V430, P551, DOI 10.1038/nature02649; Benlloch S, 2002, ENVIRON MICROBIOL, V4, P349, DOI 10.1046/j.1462-2920.2002.00306.x; Connon SA, 2002, APPL ENVIRON MICROB, V68, P3878, DOI 10.1128/AEM.68.8.3878-3885.2002; Curtis TP, 2002, P NATL ACAD SCI USA, V99, P10494, DOI 10.1073/pnas.142680199; Dykhuizen DE, 1998, ANTON LEEUW INT J G, V73, P25, DOI 10.1023/A:1000665216662; Jurgens K, 2002, ANTON LEEUW INT J G, V81, P413, DOI 10.1023/A:1020505204959; Markert S, 2007, SCIENCE, V315, P247, DOI 10.1126/science.1132913; Not F, 2007, SCIENCE, V315, P253, DOI 10.1126/science.1136264; PACE NR, 1986, ADV MICROB ECOL, V9, P1; Pedros-Alio C, 2006, TRENDS MICROBIOL, V14, P257, DOI 10.1016/j.tim.2006.04.007; Pernthaler J, 2005, NAT REV MICROBIOL, V3, P537, DOI 10.1038/nrmicro1180; Pommier T, 2007, MOL ECOL, V16, P867, DOI 10.1111/j.1365-294X.2006.03189.x; Sogin ML, 2006, P NATL ACAD SCI USA, V103, P12115, DOI 10.1073/pnas.0605127103; Venter JC, 2004, SCIENCE, V304, P66, DOI 10.1126/science.1093857; Ward BB, 2002, P NATL ACAD SCI USA, V99, P10234, DOI 10.1073/pnas.162359199; Zengler K, 2005, METHOD ENZYMOL, V397, P124, DOI 10.1016/S0076-6879(05)97007-9	16	97	99	1	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 12	2007	315	5809					192	193		10.1126/science.1135933	http://dx.doi.org/10.1126/science.1135933			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124XZ	17218512				2022-12-28	WOS:000243407400029
J	Escudier, B; Eisen, T; Stadler, WM; Szczylik, C; Oudard, S; Siebels, M; Negrier, S; Chevreau, C; Solska, E; Desai, AA; Rolland, F; Demkow, T; Hutson, TE; Gore, M; Freeman, S; Schwartz, B; Shan, MH; Simantov, R; Bukowski, RM				Escudier, Bernard; Eisen, Tim; Stadler, Walter M.; Szczylik, Cezary; Oudard, Stephane; Siebels, Michael; Negrier, Sylvie; Chevreau, Christine; Solska, Ewa; Desai, Apurva A.; Rolland, Frederic; Demkow, Tomasz; Hutson, Thomas E.; Gore, Martin; Freeman, Scott; Schwartz, Brian; Shan, Minghua; Simantov, Ronit; Bukowski, Ronald M.		TARGET Study Grp	Sorafenib in advanced clear-cell renal-cell carcinoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RECOMBINANT INTERLEUKIN-2; ANTITUMOR-ACTIVITY; PHASE-II; INHIBITOR; RECEPTOR; BEVACIZUMAB; INTERFERON; TARGETS; TRIAL	BACKGROUND: We conducted a phase 3, randomized, double-blind, placebo-controlled trial of sorafenib, a multikinase inhibitor of tumor-cell proliferation and angiogenesis, in patients with advanced clear-cell renal-cell carcinoma. METHODS: From November 2003 to March 2005, we randomly assigned 903 patients with renal-cell carcinoma that was resistant to standard therapy to receive either continuous treatment with oral sorafenib (at a dose of 400 mg twice daily) or placebo; 451 patients received sorafenib and 452 received placebo. The primary end point was overall survival. A single planned analysis of progression-free survival in January 2005 showed a statistically significant benefit of sorafenib over placebo. Consequently, crossover was permitted from placebo to sorafenib, beginning in May 2005. RESULTS: At the January 2005 cutoff, the median progression-free survival was 5.5 months in the sorafenib group and 2.8 months in the placebo group (hazard ratio for disease progression in the sorafenib group, 0.44; 95% confidence interval [CI], 0.35 to 0.55; P<0.01). The first interim analysis of overall survival in May 2005 showed that sorafenib reduced the risk of death, as compared with placebo (hazard ratio, 0.72; 95% CI, 0.54 to 0.94; P=0.02), although this benefit was not statistically significant according to the O'Brien-Fleming threshold. Partial responses were reported as the best response in 10% of patients receiving sorafenib and in 2% of those receiving placebo (P<0.001). Diarrhea, rash, fatigue, and hand-foot skin reactions were the most common adverse events associated with sorafenib. Hypertension and cardiac ischemia were rare serious adverse events that were more common in patients receiving sorafenib than in those receiving placebo. CONCLUSIONS: As compared with placebo, treatment with sorafenib prolongs progression-free survival in patients with advanced clear-cell renal-cell carcinoma in whom previous therapy has failed; however, treatment is associated with increased toxic effects.	Inst Gustave Roussy, Dept Med, F-94805 Villejuif, France; Cambridge Res Inst, Cambridge, England; Univ Chicago, Chicago, IL 60637 USA; Mil Med Acad, Warsaw, Poland; Hop Europeen Georges Pompidou, Paris, France; Univ Munich, Klinikum Grosshadern, D-8000 Munich, Germany; Ctr Leon Berard, F-69373 Lyon, France; Inst Claudius Regaud, Toulouse, France; Wojewodzka Przychodnia Onkol, Gdansk, Poland; Ctr Rene Gauducheau, St Herblain, France; Ctr Onkol, Warsaw, Poland; Baylor Charles A Sammons Canc Ctr, Dallas, TX USA; Royal Marsden Hosp, Surrey, England; Onyx Pharmaceut, Emeryville, CA USA; Bayer Pharmaceut, West Haven, CT USA; Cleveland Clin, Taussig Canc Ctr, Cleveland, OH 44106 USA	UNICANCER; Gustave Roussy; CRUK Cambridge Institute; University of Cambridge; University of Chicago; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Munich; UNICANCER; Centre Leon Berard; UNICANCER; Institut Claudius Regaud; UNICANCER; Institut de Cancerologie de l'Ouest (ICO); Baylor University Medical Center; Texas Oncology-Baylor Charles A Sammons Cancer Center; Royal Marsden NHS Foundation Trust; Bayer AG; Bayer Healthcare Pharmaceuticals; Cleveland Clinic Foundation	Escudier, B (corresponding author), Inst Gustave Roussy, Dept Med, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	escudier@igr.fr	Hutson, Thomas/AAS-9639-2020; Chevreau, Christine/A-5565-2015	Hutson, Thomas/0000-0002-4529-4212; Demkow, Tomasz/0000-0002-1737-4944; ROLLAND, FREDERIC/0000-0001-6957-0894; Schwartz, Brian/0000-0003-2632-6351; OUDARD, Stephane/0000-0003-0893-285X				Carlomagno F, 2006, JNCI-J NATL CANCER I, V98, P326, DOI 10.1093/jnci/djj069; CHANG YS, 2005, P AM ASS CANC RES, V46; Cohen HT, 2005, NEW ENGL J MED, V353, P2477, DOI 10.1056/NEJMra043172; Escudier B, 1999, J CLIN ONCOL, V17, P2039, DOI 10.1200/JCO.1999.17.7.2039; FYFE G, 1995, J CLIN ONCOL, V13, P688, DOI 10.1200/JCO.1995.13.3.688; Hainsworth JD, 2005, J CLIN ONCOL, V23, P7889, DOI 10.1200/JCO.2005.01.8234; Johnson JR, 2003, J CLIN ONCOL, V21, P1404, DOI 10.1200/JCO.2003.08.072; Levy Joan B., 2006, Proceedings of the American Association for Cancer Research Annual Meeting, V47, P213; Motzer RJ, 1996, NEW ENGL J MED, V335, P865, DOI 10.1056/NEJM199609193351207; Motzer RJ, 2006, J CLIN ONCOL, V24, P16, DOI 10.1200/JCO.2005.02.2574; Motzer RJ, 2004, J CLIN ONCOL, V22, P454, DOI 10.1200/JCO.2004.06.132; Motzer RJ, 2006, JAMA-J AM MED ASSOC, V295, P2516, DOI 10.1001/jama.295.21.2516; Negrier S, 1998, NEW ENGL J MED, V338, P1272, DOI 10.1056/NEJM199804303381805; Negrier S, 2000, CANCER J SCI AM, V6, pS93; Negrier S, 2005, J CLIN ONCOL, V23; Raftopoulos H, 2004, J CLIN ONCOL, V22, p414S; Ratain MJ, 2006, J CLIN ONCOL, V24, P2505, DOI 10.1200/JCO.2005.03.6723; Ratain MJ, 2004, J CLIN ONCOL, V22, P4442, DOI 10.1200/JCO.2004.07.960; Rini B, 2005, J CLIN ONCOL, V23, p380S; Ritchie A, 1999, LANCET, V353, P14; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491	22	3945	4123	7	47	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 11	2007	356	2					125	134		10.1056/NEJMoa060655	http://dx.doi.org/10.1056/NEJMoa060655			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	124NE	17215530	Bronze			2022-12-28	WOS:000243373700005
J	Mandavilli, A				Mandavilli, Apoorva			Reinventing an industry	NATURE			English	News Item																			0	2	2	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 11	2007	445	7124					138	139		10.1038/445138a	http://dx.doi.org/10.1038/445138a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124QF	17215817				2022-12-28	WOS:000243384300021
J	Keeley, EC; Hillis, LD				Keeley, Ellen C.; Hillis, L. David			Primary PCI for myocardial infarction with ST-segment elevation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PERCUTANEOUS-CORONARY-INTERVENTION; PRIMARY ANGIOPLASTY; CLINICAL CHARACTERISTICS; THROMBOLYTIC THERAPY; FIBRINOLYTIC THERAPY; REPERFUSION THERAPY; STENT THROMBOSIS; UNCOATED STENTS; POOLED ANALYSIS; UNITED-STATES		Univ Virginia, Sch Med, Dept Internal Med, Div Cardiol, Charlottesville, VA 22908 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Div Cardiol, Dallas, TX USA	University of Virginia; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Keeley, EC (corresponding author), Univ Virginia, Sch Med, Dept Internal Med, Div Cardiol, Charlottesville, VA 22908 USA.							Adams RJ, 2004, CIRCULATION, V110, P2512, DOI 10.1161/01.CIR.0000134791.68010.FA; Ahmed S, 2006, J THROMB THROMBOLYS, V21, P119, DOI 10.1007/s11239-006-5485-9; Almeda FQ, 2002, AM J CARDIOL, V89, P1151, DOI 10.1016/S0002-9149(02)02295-6; *AM HEART ASS, 2006, CARD DIS STAT; ANDERSON JL, 1993, CIRCULATION, V87, P1829, DOI 10.1161/01.CIR.87.6.1829; Antman EM, 2005, CIRCULATION, V111, P2013; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Aversano T, 2002, JAMA-J AM MED ASSOC, V287, P1943, DOI 10.1001/jama.287.15.1943; Aversano T, 2002, JAMA-J AM MED ASSOC, V287, P3212; Bartholomew BA, 2004, AM J CARDIOL, V93, P1515, DOI 10.1016/j.amjcard.2004.03.008; Bavry AA, 2005, J AM COLL CARDIOL, V45, P941, DOI 10.1016/j.jacc.2004.11.064; Cannon CP, 2004, NEW ENGL J MED, V350, P1495, DOI 10.1056/NEJMoa040583; Cannon CP, 2006, NEW ENGL J MED, V354, P778; Chen ZM, 2005, LANCET, V366, P1607, DOI 10.1016/s0140-6736(05)67660-x; COLLINS R, 1995, LANCET, V345, P669; Dalby M, 2003, CIRCULATION, V108, P1809, DOI 10.1161/01.CIR.0000091088.63921.8C; De Luca G, 2005, AM HEART J, V150, P557, DOI 10.1016/j.ahj.2004.10.044; DeGeare VS, 2000, AM J CARDIOL, V86, P30, DOI 10.1016/S0002-9149(00)00824-9; Fibrinolytic Therapy Trialists' (FTT) Collaborative Group, 1994, LANCET, V343, P311; Freedman JE, 2005, CIRCULATION, V112, P2725, DOI 10.1161/CIRCULATIONAHA.104.494468; Furman MI, 2001, J AM COLL CARDIOL, V37, P1571, DOI 10.1016/S0735-1097(01)01203-7; Gibson CM, 2003, J AM COLL CARDIOL, V42, P7, DOI 10.1016/S0735-1097(03)00506-0; Gibson CM, 2004, AM HEART J, V148, pS29, DOI 10.1016/j.ahj.2004.09.012; GOSS JE, 1995, CATHETER CARDIO DIAG, V34, P99, DOI 10.1002/ccd.1810340403; Grassman ED, 1997, J AM COLL CARDIOL, V30, P201, DOI 10.1016/S0735-1097(97)00102-2; Grines CL, 1999, NEW ENGL J MED, V341, P1949, DOI 10.1056/NEJM199912233412601; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; Halkin A, 2004, J AM COLL CARDIOL, V43, P1780, DOI 10.1016/j.jacc.2003.10.068; Hochman JS, 1999, NEW ENGL J MED, V341, P625, DOI 10.1056/NEJM199908263410901; Iakovou I, 2005, JAMA-J AM MED ASSOC, V293, P2126, DOI 10.1001/jama.293.17.2126; Juliard JM, 1997, J AM COLL CARDIOL, V30, P157, DOI 10.1016/S0735-1097(97)00119-8; Kandzari DE, 2006, AM HEART J, V151, P1288, DOI 10.1016/j.ahj.2005.08.017; Keeley EC, 2003, LANCET, V361, P13, DOI 10.1016/S0140-6736(03)12113-7; Keeley EC, 2005, CIRCULATION, V112, P3520; Keeley EC, 2006, LANCET, V367, P579, DOI 10.1016/S0140-6736(06)68148-8; Keeley EC, 2006, LANCET, V367, P1656; Kernis SJ, 2004, J AM COLL CARDIOL, V43, P1773, DOI 10.1016/j.jacc.2003.09.071; Laarman GJ, 2006, NEW ENGL J MED, V355, P1105, DOI 10.1056/NEJMoa062598; Libby P, 2001, CIRCULATION, V104, P365, DOI 10.1161/01.CIR.104.3.365; Libby P, 2005, CIRCULATION, V111, P3481, DOI 10.1161/CIRCULATIONAHA.105.537878; Matetzky S, 1999, J AM COLL CARDIOL, V34, P1932, DOI 10.1016/S0735-1097(99)00466-0; Mehta RH, 2004, J AM COLL CARDIOL, V43, P1765, DOI 10.1016/j.jacc.2003.09.072; Moreno R, 2005, J AM COLL CARDIOL, V45, P954, DOI 10.1016/j.jacc.2004.11.065; Nallamothu BK, 2006, CIRCULATION, V113, P222, DOI 10.1161/CIRCULATIONAHA.105.578195; Nallamothu BK, 2006, CIRCULATION, V113, P1189, DOI 10.1161/CIRCULATIONAHA.105.596346; Piper WD, 2003, AM HEART J, V145, P1022, DOI 10.1016/S0002-8703(03)00079-6; Prasad A, 2005, J AM COLL CARDIOL, V45, P508, DOI 10.1016/j.jacc.2004.10.054; REIMER KA, 1977, CIRCULATION, V56, P786, DOI 10.1161/01.CIR.56.5.786; Rogers WJ, 2000, J AM COLL CARDIOL, V36, P2056, DOI 10.1016/S0735-1097(00)00996-7; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; Sabatine MS, 2005, NEW ENGL J MED, V352, P1179, DOI 10.1056/NEJMoa050522; Sabatine MS, 2005, JAMA-J AM MED ASSOC, V294, P1224, DOI 10.1001/jama.294.10.1224; Sadeghi HM, 2003, CIRCULATION, V108, P2769, DOI 10.1161/01.CIR.0000103623.63687.21; Spaulding C, 2006, NEW ENGL J MED, V355, P1093, DOI 10.1056/NEJMoa062006; Stone GW, 2002, NEW ENGL J MED, V346, P957, DOI 10.1056/NEJMoa013404; Stone GW, 2002, J AM COLL CARDIOL, V39, P591, DOI 10.1016/S0735-1097(01)01779-X; Stone GW, 1998, J AM COLL CARDIOL, V31, P23, DOI 10.1016/S0735-1097(97)00439-7; Stone GW, 1997, J AM COLL CARDIOL, V29, P901, DOI 10.1016/S0735-1097(97)00041-7; Taher T, 2004, J AM COLL CARDIOL, V44, P38, DOI 10.1016/j.jacc.2004.03.041; Tarantini G, 2005, J AM COLL CARDIOL, V46, P1229, DOI 10.1016/j.jacc.2005.06.054; The GUSTO Angiographic Investigators, 1994, NEW ENGL J MED, V330, P516; Thune JJ, 2005, CIRCULATION, V112, P2017, DOI 10.1161/CIRCULATIONAHA.105.558676; Valgimigli M, 2005, JAMA-J AM MED ASSOC, V293, P2109, DOI 10.1001/jama.293.17.2109; Van de Werf F, 2003, EUR HEART J, V24, P28, DOI 10.1016/S0195-668X(02)00618-8; Weir RAP, 2006, AM J CARDIOL, V97, p13F, DOI 10.1016/j.amjcard.2006.03.005; Wharton TP, 2005, CIRCULATION, V112, P3509, DOI 10.1161/CIRCULATIONAHA.104.478362; Wharton TP, 2004, J AM COLL CARDIOL, V43, P1943, DOI 10.1016/j.jacc.2004.03.013; Yang EH, 2005, J AM COLL CARDIOL, V46, P2004, DOI 10.1016/j.jacc.2005.06.083; Zheng ZJ, 2001, CIRCULATION, V104, P2158, DOI 10.1161/hc4301.098254	69	119	128	1	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 4	2007	356	1					47	54		10.1056/NEJMct063503	http://dx.doi.org/10.1056/NEJMct063503			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	122EX	17202455				2022-12-28	WOS:000243209600008
J	Prevedel, R; Walther, P; Tiefenbacher, F; Bohl, P; Kaltenbaek, R; Jennewein, T; Zeilinger, A				Prevedel, Robert; Walther, Philip; Tiefenbacher, Felix; Bohl, Pascal; Kaltenbaek, Rainer; Jennewein, Thomas; Zeilinger, Anton			High-speed linear optics quantum computing using active feed-forward	NATURE			English	Article							TELEPORTATION; COMPUTATION; STATES; INFORMATION	As information carriers in quantum computing(1), photonic qubits have the advantage of undergoing negligible decoherence. However, the absence of any significant photon - photon interaction is problematic for the realization of non-trivial two-qubit gates. One solution is to introduce an effective nonlinearity by measurements resulting in probabilistic gate operations(2,3). In one-way quantum computation(4-8), the random quantum measurement error can be overcome by applying a feed-forward technique, such that the future measurement basis depends on earlier measurement results. This technique is crucial for achieving deterministic quantum computation once a cluster state ( the highly entangled multiparticle state on which one-way quantum computation is based) is prepared. Here we realize a concatenated scheme of measurement and active feed-forward in a one-way quantum computing experiment. We demonstrate that, for a perfect cluster state and no photon loss, our quantum computation scheme would operate with good fidelity and that our feed-forward components function with very high speed and low error for detected photons. With present technology, the individual computational step ( in our case the individual feed-forward cycle) can be operated in less than 150 ns using electro-optical modulators. This is an important result for the future development of one-way quantum computers, whose large-scale implementation will depend on advances in the production and detection of the required highly entangled cluster states.	Univ Vienna, Inst Expt Phys, A-1090 Vienna, Austria; Harvard Univ, Dept Phys, Cambridge, MA 02138 USA; Austrian Acad Sci, Inst Quantum Opt & Quantum Informat, A-1090 Vienna, Austria	University of Vienna; Harvard University; Austrian Academy of Sciences	Prevedel, R (corresponding author), Univ Vienna, Inst Expt Phys, Boltzmanngasse 5, A-1090 Vienna, Austria.	robert.prevedel@univie.ac.at; zeilinger-office@quantum.at	Zeilinger, Anton/A-1170-2011; Walther, Philip/D-6346-2018; Kaltenbaek, Rainer/C-8141-2015; Walther, Philip/O-2993-2019; Prevedel, Robert/L-3377-2014; Prevedel, Robert/AAP-2599-2020	Walther, Philip/0000-0002-4964-817X; Kaltenbaek, Rainer/0000-0002-9991-9919; Walther, Philip/0000-0002-4964-817X; Prevedel, Robert/0000-0003-3366-4703; Prevedel, Robert/0000-0003-3366-4703				Ahn J, 2000, SCIENCE, V287, P463, DOI 10.1126/science.287.5452.463; Aliferis P, 2004, PHYS REV A, V70, DOI 10.1103/PhysRevA.70.062314; Bennett CH, 2000, NATURE, V404, P247, DOI 10.1038/35005001; Coffman V, 2000, PHYS REV A, V61, DOI 10.1103/PhysRevA.61.052306; Giacomini S, 2002, PHYS REV A, V66, DOI 10.1103/PhysRevA.66.030302; Grover LK, 1997, PHYS REV LETT, V79, P325, DOI 10.1103/PhysRevLett.79.325; HORODECKI R, 1995, PHYS LETT A, V200, P340, DOI 10.1016/0375-9601(95)00214-N; James DFV, 2001, PHYS REV A, V64, DOI 10.1103/PhysRevA.64.052312; KIELSEL N, 2005, PHYS REV LETT, V95, DOI UNSP 210502; Knill E, 2001, NATURE, V409, P46, DOI 10.1038/35051009; Nielsen MA, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.040503; NIELSEN MA, 2003, J CLUB NOTES CLUSTER; Nielsen Michael A., 2002, QUANTUM COMPUTATION; Pittman TB, 2002, PHYS REV A, V66, DOI 10.1103/PhysRevA.66.052305; Raussendorf R, 2002, J MOD OPTIC, V49, P1299, DOI 10.1080/09500340110107487; Raussendorf R, 2003, PHYS REV A, V68, DOI 10.1103/PhysRevA.68.022312; Shor P. W., 1994, Proceedings. 35th Annual Symposium on Foundations of Computer Science (Cat. No.94CH35717), P124, DOI 10.1109/SFCS.1994.365700; SOUDAGAR Y, 2006, ARXIVORGQUANTPH06051; Toth G, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.060501; Ursin R, 2004, NATURE, V430, P849, DOI 10.1038/430849a; Vandersypen LMK, 2001, NATURE, V414, P883, DOI 10.1038/414883a; Walther P, 2005, NATURE, V434, P169, DOI 10.1038/nature03347; White AG, 1999, PHYS REV LETT, V83, P3103, DOI 10.1103/PhysRevLett.83.3103; Zhang AN, 2006, PHYS REV A, V73, DOI 10.1103/PhysRevA.73.022330	30	266	271	1	61	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 4	2007	445	7123					65	69		10.1038/nature05346	http://dx.doi.org/10.1038/nature05346			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	122KG	17203057				2022-12-28	WOS:000243225100036
J	Imboden, M; Swan, H; Denjoy, I; Van Langen, IM; Latinen-Forsblom, PJ; Napolitano, C; Fressart, V; Breithardt, G; Berthet, M; Priori, S; Hainque, B; Wilde, AAM; Schulze-Bahr, E; Feingold, J; Guicheney, P				Imboden, Medea; Swan, Heikki; Denjoy, Isabelle; Marijke Van Langen, Irene; Latinen-Forsblom, Paivi Johanna; Napolitano, Carlo; Fressart, Veronique; Breithardt, Guenter; Berthet, Myriam; Priori, Silvia; Hainque, Bernard; Wilde, Arthur Arnold Maria; Schulze-Bahr, Eric; Feingold, Josue; Guicheney, Pascale			Female predominance and transmission distortion in the long-QT syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CLINICAL-COURSE; RISK-FACTOR; DE-POINTES; GENDER; AGE; SEGREGATION; LQTS	BACKGROUND: Congenital long-QT syndrome is a disorder resulting in ventricular arrhythmias and sudden death. The most common forms of the long-QT syndrome, types 1 and 2, are caused by mutations in the potassium-channel genes KCNQ1 and KCNH2, respectively. Although inheritance of the long-QT syndrome is autosomal dominant, female predominance has often been observed and has been attributed to an increased susceptibility to cardiac arrhythmias in women. We investigated the possibility of an unbalanced transmission of the deleterious trait. METHODS: We investigated the distribution of alleles for the long-QT syndrome in 484 nuclear families with type 1 disease and 269 nuclear families with type 2 disease, all with fully genotyped offspring. The families were recruited in five European referral centers for the long-QT syndrome. Mutation segregation, sex ratio, and parental transmission were analyzed after correction for single ascertainment. RESULTS: Classic mendelian inheritance ratios were not observed in the offspring of either female carriers of the long-QT syndrome type 1 or male and female carriers of the long-QT syndrome type 2. Among the 1534 descendants, the proportion of genetically affected offspring was significantly greater than that expected according to mendelian inheritance: 870 were carriers of a mutation (57%), and 664 were noncarriers (43%, P<0.001). Among the 870 carriers, the allele for the long-QT syndrome was transmitted more often to female offspring (476 [55%]) than to male offspring (394 [45%], P=0.005). Increased maternal transmission of the long-QT syndrome mutations to daughters was also observed, possibly contributing to the excess of female patients with autosomal dominant long-QT syndrome. CONCLUSIONS: Positive selection of the mutated alleles that cause the long-QT syndrome leads to transmission distortion, with increased proportions of mutation carriers among the offspring of affected families. Alleles for the long-QT syndrome are more often transmitted to daughters than to sons.	Univ Paris 06, Assistance Publ Hop Paris,Inst Federatif Rech 14, Inst Myol, INSERM, Paris, France; Hop Lariboisiere, Assistance Publ Hop Paris, Serv Cardiol, F-75475 Paris, France; Grp Hosp Pitie Salpetriere, Assistance Publ Hop Paris, Serv Biochim, F-75634 Paris, France; Grp Hosp Pitie Salpetriere, Assistance Publ Hop Paris, Dept Genet, F-75634 Paris, France; Univ Zurich, Dept Mol Epidemiol, Inst Social & Prevent Med, Zurich, Switzerland; Univ Helsinki, Dept Med, Helsinki, Finland; Univ Amsterdam, Acad Med Ctr, Dept Clin Genet, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Expt & Mol Cardiol Grp, NL-1105 AZ Amsterdam, Netherlands; Univ Pavia, I-27100 Pavia, Italy; Fdn Salvatore Maugeri, Ist Ric & Cura Carattere Sci, Mol Cardiol Labs, Pavia, Italy; Univ Munster, Dept Mol Cardiol, Leibniz Inst Arteriosclerosis Res, D-4400 Munster, Germany; Hosp Univ Munster, Dept Cardiol & Angiol, Munster, Germany	Assistance Publique Hopitaux Paris (APHP); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite; University of Zurich; University of Helsinki; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Pavia; Istituti Clinici Scientifici Maugeri IRCCS; University of Munster; University of Munster	Imboden, M (corresponding author), Grp Hosp Pitie Salpetriere, Inst Myol, INSERM, U582, 47 Blvd Hop, F-75013 Paris, France.	imboden@medgen.unizh.ch	Napolitano, Carlo/K-4760-2016; Priori, Silvia G G/A-6116-2014; Guicheney, Pascale/D-1034-2017; Priori, Silvia G/ABH-6894-2020; napolitano, carlo/ABI-4608-2020	Napolitano, Carlo/0000-0002-7643-4628; Priori, Silvia G G/0000-0001-6877-0288; Guicheney, Pascale/0000-0002-7663-2050; Priori, Silvia G/0000-0001-6877-0288; napolitano, carlo/0000-0002-7643-4628; van Langen, Irene/0000-0002-0960-7154	Telethon [GGP04066] Funding Source: Medline	Telethon(Fondazione Telethon)		Conrath CE, 2002, CARDIOVASC RES, V53, P770, DOI 10.1016/S0008-6363(01)00477-1; Drici MD, 2001, DRUG SAFETY, V24, P575, DOI 10.2165/00002018-200124080-00002; Fodstad H, 2004, ANN MED, V36, P53, DOI 10.1080/17431380410032689; Gould TD, 1998, HUM MOL GENET, V7, P483, DOI 10.1093/hmg/7.3.483; HASHIBA K, 1992, ANN NY ACAD SCI, V644, P142, DOI 10.1111/j.1749-6632.1992.tb31008.x; Hashiba K, 1987, Heart Vessels Suppl, V2, P47; Ihaka R., 1996, J COMPUTATIONAL GRAP, V5, P299, DOI [10.2307/1390807, DOI 10.1080/10618600.1996.10474713]; Jiang S, 1998, GENOMICS, V53, P395, DOI 10.1006/geno.1998.5511; Kimbrough J, 2001, CIRCULATION, V104, P557, DOI 10.1161/hc3001.093501; Lehmann MH, 1997, J AM COLL CARDIOL, V29, P93, DOI 10.1016/S0735-1097(96)00454-8; Lehmann MH, 1996, CIRCULATION, V94, P2535, DOI 10.1161/01.CIR.94.10.2535; Li C, 1961, HUMAN GENETICS PRINC; Locati EH, 1998, CIRCULATION, V97, P2237, DOI 10.1161/01.CIR.97.22.2237; Lyon MF, 2003, ANNU REV GENET, V37, P393, DOI 10.1146/annurev.genet.37.110801.143030; LYTTLE TW, 1993, TRENDS GENET, V9, P205, DOI 10.1016/0168-9525(93)90120-7; Magee AC, 1998, J MED GENET, V35, P1045, DOI 10.1136/jmg.35.12.1045; MAKKAR RR, 1993, JAMA-J AM MED ASSOC, V270, P2590, DOI 10.1001/jama.270.21.2590; Malloy K J, 1999, J Gend Specif Med, V2, P37; MOSS AJ, 1991, CIRCULATION, V84, P1136, DOI 10.1161/01.CIR.84.3.1136; MOSS AJ, 1985, CIRCULATION, V71, P17, DOI 10.1161/01.CIR.71.1.17; Priori SG, 2003, NEW ENGL J MED, V348, P1866, DOI 10.1056/NEJMoa022147; Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554; Schollen E, 2004, J MED GENET, V41, P877, DOI 10.1136/jmg.2004.022350; Splawski I, 2000, CIRCULATION, V102, P1178, DOI 10.1161/01.CIR.102.10.1178; StrambaBadiale M, 1997, EUR HEART J, V18, P1000; ZAREBA W, 1995, J AM COLL CARDIOL, V26, P1685, DOI 10.1016/0735-1097(95)60383-2; Zareba W, 2003, J AM COLL CARDIOL, V42, P103, DOI 10.1016/S0735-1097(03)00554-0; Zareba W, 1998, NEW ENGL J MED, V339, P960, DOI 10.1056/NEJM199810013391404; Zollner S, 2004, AM J HUM GENET, V74, P62, DOI 10.1086/381131	29	59	64	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 28	2006	355	26					2744	2751		10.1056/NEJMoa042786	http://dx.doi.org/10.1056/NEJMoa042786			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	120UA	17192539	Green Accepted, Bronze			2022-12-28	WOS:000243110500006
J	Reeder, J; Orwoll, E				Reeder, Janet; Orwoll, Eric			Images in clinical medicine: Adults with osteogenesis imperfecta	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Oregon Hlth Sci Univ, Portland, OR 97239 USA	Oregon Health & Science University	Reeder, J (corresponding author), Oregon Hlth Sci Univ, Portland, OR 97239 USA.			Orwoll, Eric/0000-0002-8520-7355					0	2	2	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 28	2006	355	26					E28	E28		10.1056/NEJMicm062996	http://dx.doi.org/10.1056/NEJMicm062996			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	120UA	17192533				2022-12-28	WOS:000243110500011
J	Markowitz, AJ; Pantilat, SZ				Markowitz, Amy J.; Pantilat, Steven Z.			Palliative care for frail older adults: "There are things I can't do anymore that I wish I could"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material														Markowitz, Amy/0000-0001-9314-2814				Boockvar KS, 2006, JAMA-J AM MED ASSOC, V296, P2245, DOI 10.1001/jama.296.18.2245	1	1	1	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	2006	296	24					2967	2967		10.1001/jama.296.24.2967	http://dx.doi.org/10.1001/jama.296.24.2967			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	120FD	17190898				2022-12-28	WOS:000243069000029
J	Bolfan-Casanova, N				Bolfan-Casanova, Nathalie			Fuel for plate tectonics	SCIENCE			English	Editorial Material							UPPER-MANTLE; WATER; SOLUBILITY; OLIVINE; ORIGIN		Univ Clermont Ferrand, Lab Magmas & Volcans, F-63038 Clermont Ferrand, France		Bolfan-Casanova, N (corresponding author), Univ Clermont Ferrand, Lab Magmas & Volcans, F-63038 Clermont Ferrand, France.	n.bolfan@opgc.univ-bpclermont.fr						ANDERSON DL, 1989, THEORY EARTH; ARBAUD C, 2004, GEOPHYS RES LETT, V31, DOI DOI 10.1029/2004GL021341; BAI Q, 1992, NATURE, V357, P672, DOI 10.1038/357672a0; Bolfan-Casanova N, 2005, MINERAL MAG, V69, P229, DOI 10.1180/0026461056930248; Hirth G, 1996, EARTH PLANET SC LETT, V144, P93, DOI 10.1016/0012-821X(96)00154-9; HIRTH G, 2000, GEOCHEM GEOPHYS GEOS, V8; Karato S, 1998, EARTH PLANET SC LETT, V157, P193, DOI 10.1016/S0012-821X(98)00034-X; KOHLSTEDT DL, 2000, PHYS CHEM PARTIALLY; Mierdel K, 2007, SCIENCE, V315, P364, DOI 10.1126/science.1135422; Wang DJ, 2006, NATURE, V443, P977, DOI 10.1038/nature05256	10	5	6	1	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 19	2007	315	5810					338	339		10.1126/science.1137738	http://dx.doi.org/10.1126/science.1137738			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126SI	17234935				2022-12-28	WOS:000243535400026
J	Perry, B; Sones, K				Perry, Brian; Sones, Keith			Science for development - Poverty reduction through animal health	SCIENCE			English	Editorial Material							EPIDEMIOLOGY; VIRUS		Int Livestock Res Inst, Nairobi 00100, Kenya; Keith Sones Associates, Nairobi 00502, Kenya	CGIAR; International Livestock Research Institute (ILRI)	Perry, B (corresponding author), Int Livestock Res Inst, POB 30709, Nairobi 00100, Kenya.	b.perry@cgiar.org		Perry, Brian/0000-0002-6962-2102				ANDERSON R M, 1991; Baylis M, 2006, EFFECTS CLIMATE CHAN; Calvete C, 2006, VET REC, V158, P130, DOI 10.1136/vr.158.4.130; Catley A, 2004, PREV VET MED, V65, P17, DOI 10.1016/j.prevetmed.2004.06.007; Delgado CL, 2003, J NUTR, V133, p3907S, DOI 10.1093/jn/133.11.3907S; *DFID, 2004, 2 DFID; *DFID, AN HLTH PROGR; Eubank S, 2004, NATURE, V429, P180, DOI 10.1038/nature02541; Gardner MJ, 2005, SCIENCE, V309, P134, DOI 10.1126/science.1110439; Gulati A., 2005, S HIGH VAL AGR VERT; Hall A., 2002, Agricultural research policy in an era of privatization, P155, DOI 10.1079/9780851996004.0155; Harvell CD, 2002, SCIENCE, V296, P2158, DOI 10.1126/science.1063699; Jones P. G., COMMUNICATION; *LIV DEV, 1999, LIV POV FOC DEV; Mariner JC, 2003, VET REC, V152, P641, DOI 10.1136/vr.152.21.641; MCLEOD A, AN HLTH PROGR; Perry B, 2001, PREV VET MED, V48, P231, DOI 10.1016/S0167-5877(00)00203-8; Perry B. D, 2002, INVESTING ANIMAL HLT; Rogers DJ, 2000, SCIENCE, V289, P1763, DOI 10.1126/science.289.5485.1763; Thornton P.K., 2002, MAPPING POVERTY LIVE; *U PRET FAC VET EQ, 2006, IMP AFR HORS SICKN S; *UK FOR PROGR, 2006, INF DIS PREP FUT F 1; *UN FAO, AN PROD HLTH PROGR; WEARVER J, 2006, PARTICIPATORY DIS SU; *WOODD MACK LTD, 2005, ANN REP INT FED AN H	25	54	57	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 19	2007	315	5810					333	334		10.1126/science.1138614	http://dx.doi.org/10.1126/science.1138614			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	126SI	17234933				2022-12-28	WOS:000243535400023
J	Joshi, P; Islam, S; Pais, P; Reddy, S; Dorairaj, P; Kazmi, K; Pandey, MR; Haque, S; Mendis, S; Rangarajan, S; Yusuf, S				Joshi, Prashant; Islam, Shofiqul; Pais, Prem; Reddy, Srinath; Dorairaj, Prabhakaran; Kazmi, Khawar; Pandey, Mrigendra Raj; Haque, Sirajul; Mendis, Shanthi; Rangarajan, Sumathy; Yusuf, Salim			Risk factors for early myocardial infarction in South Asians compared with individuals in other countries	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-HEART-DISEASE; APOLIPOPROTEIN-A-I; CARDIOVASCULAR-DISEASE; PHYSICAL-ACTIVITY; ARTERY-DISEASE; FOLLOW-UP; ATTRIBUTABLE RISK; GLOBAL BURDEN; ETHNIC-GROUPS; HOMOCYSTEINE	Context South Asians have high rates of acute myocardial infarction ( AMI) at younger ages compared with individuals from other countries but the reasons for this are unclear. Objective To evaluate the association of risk factors for AMI in native South Asians, especially at younger ages, compared with individuals from other countries. Design, Setting, and Participants Standardized case-control study of 1732 cases with first AMI and 2204 controls matched by age and sex from 15 medical centers in 5 South Asian countries and 10 728 cases and 12 431 controls from other countries. Individuals were recruited to the study between February 1999 and March 2003. Main Outcome Measure Association of risk factors for AMI. Results The mean(SD) age for first AMI was lower in South Asian countries ( 53.0 [11.4] years) than in other countries ( 58.8 [12.2] years; P <. 001). Protective factors were lower in South Asian controls than in controls from other countries (moderate- or high-intensity exercise, 6.1% vs 21.6%; daily intake of fruits and vegetables, 26.5% vs 45.2%; alcohol consumption >= once/wk, 10.7% vs 26.9%). However, some harmful factors were more common in native South Asians than in individuals from other countries ( elevated apolipoprotein B-100/ apolipoprotein A-I ratio, 43.8% vs31.8%; history of diabetes, 9.5% vs 7.2%). Similar relative associations were found in South Asians compared with individuals from other countries for the risk factors of current and former smoking, apolipoprotein B100/ apolipoprotein A-I ratio for the top vs lowest tertile, waist-to-hip ratio for the top vs lowest tertile, history of hypertension, history of diabetes, psychosocial factors such as depression and stress at work or home, regular moderate- or high-intensity exercise, and daily intake of fruits and vegetables. Alcohol consumption was not found to be a risk factor for AMI in South Asians. The combined odds ratio for all 9 risk factors was similar in South Asians (123.3; 95% confidence interval [CI], 38.7-400.2] and in individuals from other countries (125.7; 95% CI, 88.5-178.4). The similarities in the odds ratios for the risk factors explained a high and similar degree of population attributable risk in both groups (85.8%[ 95% CI, 78.0%-93.7%] vs 88.2% [ 95% CI, 86.3%-89.9%], respectively). When stratified by age, South Asians had more risk factors at ages younger than 60 years. After adjusting for all 9 risk factors, the predictive probability of classifying an AMI case as being younger than 40 years was similar in individuals from South Asian countries and those from other countries. Conclusion The earlier age of AMI in South Asians can be largely explained by higher risk factor levels at younger ages.	Govt Med Coll, Dept Med, Nagpur, Maharashtra, India; McMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada; Hamilton Hlth Sci, Hamilton, ON, Canada; St Johns Med Coll, Dept Med, Bangalore, Karnataka, India; All India Inst Med Sci, New Delhi, India; Aga Khan Univ, Dept Cardiol, Karachi, Pakistan; Sheikh Med Univ, Dept Cardiol, Sheilkh, Bangladesh; WHO, CH-1211 Geneva, Switzerland	McMaster University; Population Health Research Institute; McMaster University; St. John's National Academy of Health Sciences; St. John's Medical College; All India Institute of Medical Sciences (AIIMS) New Delhi; Aga Khan University; World Health Organization	Yusuf, S (corresponding author), Hamilton Gen Hosp, Populat Hlth Res Inst, McMaster Clin, 2nd Floor,237 Barton St E, Hamilton, ON L8L 2X2, Canada.	yusufs@mcmaster.ca	Prabhakaran, Dorairaj/B-4147-2011; Mendis, Shanthi/GLT-0465-2022	Prabhakaran, Dorairaj/0000-0002-3172-834X; mendis, shanthi/0000-0002-8959-5738; Yusuf, Salim/0000-0003-4776-5601				Anand SS, 2000, LANCET, V356, P279, DOI 10.1016/S0140-6736(00)02502-2; BALARAJAN R, 1991, BMJ-BRIT MED J, V302, P560, DOI 10.1136/bmj.302.6776.560; BENICHOU J, 1990, BIOMETRICS, V46, P991, DOI 10.2307/2532443; Bhopal R, 1999, BRIT MED J, V319, P215, DOI 10.1136/bmj.319.7204.215; Bonaa KH, 2006, NEW ENGL J MED, V354, P1578, DOI 10.1056/NEJMoa055227; Brunner E, 1996, LANCET, V347, P1008, DOI 10.1016/S0140-6736(96)90147-6; ENAS EA, 1992, AM J CARDIOL, V70, P945, DOI 10.1016/0002-9149(92)90744-J; Ghiadoni L, 2000, CIRCULATION, V102, P2473, DOI 10.1161/01.CIR.102.20.2473; Hambrecht R, 2000, NEW ENGL J MED, V342, P454, DOI 10.1056/NEJM200002173420702; Ismail J, 2004, HEART, V90, P259, DOI 10.1136/hrt.2003.013631; JOSHI PP, 2003, S ASIAN J PREV CARDI, V7, P195; Joshipura KJ, 2001, ANN INTERN MED, V134, P1106, DOI 10.7326/0003-4819-134-12-200106190-00010; Krauss RM, 1996, CIRCULATION, V94, P1795, DOI 10.1161/01.CIR.94.7.1795; Lamarche B, 1996, CIRCULATION, V94, P273, DOI 10.1161/01.CIR.94.3.273; Lonn E, 2006, NEW ENGL J MED, V354, P1567, DOI 10.1056/NEJMoa060900; Luepker RV, 1996, JAMA-J AM MED ASSOC, V276, P241; MATTHEWS JH, 1984, CLIN LAB HAEMATOL, V6, P1; MCKEIGUE PM, 1988, BRIT MED J, V297, P903, DOI 10.1136/bmj.297.6653.903; MCKEIGUE PM, 1991, LANCET, V337, P382, DOI 10.1016/0140-6736(91)91164-P; Moss AJ, 1999, CIRCULATION, V99, P2517, DOI 10.1161/01.CIR.99.19.2517; Murray C.J, 1994, GLOBAL COMP ASSESSME; Murray C.J.L., 1996, GLOBAL BURDEN DIS IN, VII, P906; Pais P, 1996, LANCET, V348, P358, DOI 10.1016/S0140-6736(96)02507-X; Panagiotakos DB, 2003, NUTR J, V2, DOI 10.1186/1475-2891-2-2; Patil SS, 2004, NATL MED J INDIA, V17, P189; Pratt LA, 1996, CIRCULATION, V94, P3123, DOI 10.1161/01.CIR.94.12.3123; Rastogi T, 2004, INT J EPIDEMIOL, V33, P759, DOI 10.1093/ije/dyh042; Rastogi T, 2004, AM J CLIN NUTR, V79, P582; Reddy KS, 1998, CIRCULATION, V97, P596; Reddy KS, 2004, NEW ENGL J MED, V350, P2438, DOI 10.1056/NEJMp048024; Ridker PM, 2005, JAMA-J AM MED ASSOC, V294, P326, DOI 10.1001/jama.294.3.326; Rosengren A, 2004, LANCET, V364, P953, DOI 10.1016/S0140-6736(04)17019-0; Rosengren A, 1997, ANN EPIDEMIOL, V7, P69, DOI 10.1016/S1047-2797(96)00106-8; Rugulies R, 2002, AM J PREV MED, V23, P51, DOI 10.1016/S0749-3797(02)00439-7; Sniderman AD, 2003, LANCET, V361, P777, DOI 10.1016/S0140-6736(03)12663-3; Talmud PJ, 2002, ARTERIOSCL THROM VAS, V22, P1918, DOI 10.1161/01.ATV.0000035521.22199.C7; Toole JF, 2004, JAMA-J AM MED ASSOC, V291, P565, DOI 10.1001/jama.291.5.565; van't Veer P, 2000, PUBLIC HEALTH NUTR, V3, P103, DOI 10.1017/S1368980000000136; von Kanel R, 2001, PSYCHOSOM MED, V63, P531, DOI 10.1097/00006842-200107000-00003; Walldius G, 2001, LANCET, V358, P2026, DOI 10.1016/S0140-6736(01)07098-2; WALTER SD, 1975, BIOMETRIKA, V62, P371, DOI 10.1093/biomet/62.2.371; Wannamethee SG, 2000, ARCH INTERN MED, V160, P2108, DOI 10.1001/archinte.160.14.2108; Yusuf S, 2001, CIRCULATION, V104, P2746, DOI 10.1161/hc4601.099487; Yusuf S, 2005, LANCET, V366, P1640, DOI 10.1016/S0140-6736(05)67663-5; Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9; Yusuf S, 2001, CIRCULATION, V104, P2855, DOI 10.1161/hc4701.099488	46	562	570	0	27	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 17	2007	297	3					286	294		10.1001/jama.297.3.286	http://dx.doi.org/10.1001/jama.297.3.286			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125VT	17227980	Bronze			2022-12-28	WOS:000243472300023
J	Beukeboom, LW; Kamping, A; Louter, M; Pijnacker, LP; Katju, V; Ferree, PM; Werren, JH				Beukeboom, Leo W.; Kamping, Albert; Louter, Marina; Pijnacker, Laas P.; Katju, Vaishali; Ferree, Patrick M.; Werren, John H.			Haploid females in the parasitic wasp Nasonia vitripennis	SCIENCE			English	Article									Univ Groningen, Ctr Ecol & Evolut Studies, NL-9750 AA Haren, Netherlands; Univ Rochester, Dept Biol, Rochester, NY 14627 USA; Univ Calif Santa Cruz, Dept Mol Cell & Dev Biol, Santa Cruz, CA 95064 USA	University of Groningen; University of Rochester; University of California System; University of California Santa Cruz	Beukeboom, LW (corresponding author), Univ Groningen, Ctr Ecol & Evolut Studies, POB 14, NL-9750 AA Haren, Netherlands.	l.w.beukeboom@rug.nl	Beukeboom, L.W./D-1808-2012	Louter, Marina/0000-0002-9368-512X; Werren, John/0000-0001-9353-2070	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070026] Funding Source: NIH RePORTER; NIGMS NIH HHS [5 RO1 GM070026-02] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beukeboom LW, 2006, GENETICS, V172, P981, DOI 10.1534/genetics.105.044743; Beye M, 2003, CELL, V114, P419, DOI 10.1016/S0092-8674(03)00606-8; COOK JM, 1995, TRENDS ECOL EVOL, V10, P281, DOI 10.1016/0169-5347(95)90011-X; Weeks AR, 2001, SCIENCE, V292, P2479, DOI 10.1126/science.1060411	4	28	33	1	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 12	2007	315	5809					206	206		10.1126/science.1133388	http://dx.doi.org/10.1126/science.1133388			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124XZ	17218519	Green Submitted			2022-12-28	WOS:000243407400036
J	Fisher, CR; Girguis, P				Fisher, Charles R.; Girguis, Peter			A proteomic snapshot of life at a vent	SCIENCE			English	Editorial Material							TUBEWORM RIFTIA-PACHYPTILA; FOOD SOURCE; SYMBIONT; BLOOD; WORM		Penn State Univ, Dept Biol, University Pk, PA 16801 USA; Harvard Univ, Dept Organism & Evolut Biol, Cambridge, MA 02138 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Harvard University	Fisher, CR (corresponding author), Penn State Univ, Dept Biol, University Pk, PA 16801 USA.	cfisher@psu.edu; pgirguis@oeb.harvard.edu	Fisher, Charles/H-7912-2012	Girguis, Peter/0000-0002-3599-8160				Akashi H, 2002, P NATL ACAD SCI USA, V99, P3695, DOI 10.1073/pnas.062526999; ARP AJ, 1981, SCIENCE, V213, P342, DOI 10.1126/science.213.4505.342; ARP AJ, 1983, SCIENCE, V219, P295, DOI 10.1126/science.219.4582.295; CHILDRESS JJ, 1992, OCEANOGR MAR BIOL, V30, P337; FISHER CR, 1990, SCIENCE, V247, P1094, DOI 10.1126/science.247.4946.1094; Girguis PR, 2006, J EXP BIOL, V209, P3516, DOI 10.1242/jeb.02404; Markert S, 2007, SCIENCE, V315, P247, DOI 10.1126/science.1132913; RAU GH, 1980, CAN J FISH AQUAT SCI, V37, P742, DOI 10.1139/f80-098; RAU GH, 1979, SCIENCE, V203, P648, DOI 10.1126/science.203.4381.648; Robinson JJ, 1998, J BACTERIOL, V180, P1596, DOI 10.1128/JB.180.6.1596-1599.1998; Scott KM, 2003, ENVIRON MICROBIOL, V5, P424, DOI 10.1046/j.1462-2920.2003.00416.x	11	6	6	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 12	2007	315	5809					198	199		10.1126/science.1137739	http://dx.doi.org/10.1126/science.1137739			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124XZ	17218516				2022-12-28	WOS:000243407400033
J	Maerkl, SJ; Quake, SR				Maerkl, Sebastian J.; Quake, Stephen R.			A systems approach to measuring the binding energy landscapes of transcription factors	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; DNA; DISCOVERY; RECOGNITION; NETWORK; MOTIFS; SITES; MAX	A major goal of systems biology is to predict the function of biological networks. Although network topologies have been successfully determined in many cases, the quantitative parameters governing these networks generally have not. Measuring affinities of molecular interactions in high-throughput format remains problematic, especially for transient and low-affinity interactions. We describe a high-throughput microfluidic platform that measures such properties on the basis of mechanical trapping of molecular interactions. With this platform we characterized DNA binding energy landscapes for four eukaryotic transcription factors; these landscapes were used to test basic assumptions about transcription factor binding and to predict their in vivo function.	Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA; Stanford Univ, Howard Hughes Med Inst, Stanford, CA 94305 USA; CALTECH, Pasadena, CA 91125 USA	Stanford University; Howard Hughes Medical Institute; Stanford University; California Institute of Technology	Quake, SR (corresponding author), Stanford Univ, Dept Bioengn, 318 Campus Dr, Stanford, CA 94305 USA.	quake@stanford.edu	Maerkl, Sebastian J. J/C-5438-2008	Maerkl, Sebastian J. J/0000-0003-1917-5268				BAKER RE, 1990, MOL CELL BIOL, V10, P2458, DOI 10.1128/MCB.10.6.2458; Benos PV, 2002, NUCLEIC ACIDS RES, V30, P4442, DOI 10.1093/nar/gkf578; Bulyk ML, 2002, NUCLEIC ACIDS RES, V30, P1255, DOI 10.1093/nar/30.5.1255; Bulyk ML, 2001, P NATL ACAD SCI USA, V98, P7158, DOI 10.1073/pnas.111163698; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; Carroll AS, 2001, P NATL ACAD SCI USA, V98, P12578, DOI 10.1073/pnas.211195798; Cliften P, 2003, SCIENCE, V301, P71, DOI 10.1126/science.1084337; Djordjevic M, 2003, GENOME RES, V13, P2381, DOI 10.1101/gr.1271603; Elemento O, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-2-r18; Elowitz MB, 2000, NATURE, V403, P335, DOI 10.1038/35002125; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Granek JA, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-10-r87; Harbison CT, 2004, NATURE, V431, P99, DOI 10.1038/nature02800; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Jones RB, 2006, NATURE, V439, P168, DOI 10.1038/nature04177; Kellis M, 2003, NATURE, V423, P241, DOI 10.1038/nature01644; Kent NA, 2004, J BIOL CHEM, V279, P27116, DOI 10.1074/jbc.M403818200; Levens DL, 2003, GENE DEV, V17, P1071, DOI 10.1101/gad.1095203; Man TK, 2001, NUCLEIC ACIDS RES, V29, P2471, DOI 10.1093/nar/29.12.2471; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Mayo AE, 2006, PLOS BIOL, V4, P555, DOI 10.1371/journal.pbio.0040045; Mukherjee S, 2004, NAT GENET, V36, P1331, DOI 10.1038/ng1473; Ogawa N, 2000, MOL BIOL CELL, V11, P4309, DOI 10.1091/mbc.11.12.4309; Park S, 2004, BBA-GEN SUBJECTS, V1670, P217, DOI 10.1016/j.bbagen.2003.12.007; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Shimizu T, 1997, EMBO J, V16, P4689, DOI 10.1093/emboj/16.15.4689; Sinha S, 2002, NUCLEIC ACIDS RES, V30, P5549, DOI 10.1093/nar/gkf669; Spinner DS, 2002, J MOL BIOL, V317, P431, DOI 10.1006/jmbi.2002.5440; Thorsen T, 2002, SCIENCE, V298, P580, DOI 10.1126/science.1076996; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Unger MA, 2000, SCIENCE, V288, P113, DOI 10.1126/science.288.5463.113; Warren CL, 2006, P NATL ACAD SCI USA, V103, P867, DOI 10.1073/pnas.0509843102; Workman CT, 2006, SCIENCE, V312, P1054, DOI 10.1126/science.1122088; Xie XH, 2005, NATURE, V434, P338, DOI 10.1038/nature03441	36	409	439	0	78	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 12	2007	315	5809					233	237		10.1126/science.1131007	http://dx.doi.org/10.1126/science.1131007			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124XZ	17218526	Green Submitted			2022-12-28	WOS:000243407400045
J	Novack, DV; Faccio, R				Novack, Deborah Veis; Faccio, Roberta			Jawing about TNF: New hope for cherubism	CELL			English	Editorial Material							GENE; 3BP2	Mutations in the SH3-domain binding protein 2 (SH3BP2) are known to cause a rare childhood disorder called cherubism that is characterized by inflammation and bone loss in the jaw, but the mechanism has remained unclear. In this issue, Ueki et al. (Ueki et al., 2007) now demonstrate that a cherubism mutation activates mouse Sh3bp2 resulting in enhanced production of the cytokine TNF-alpha by myeloid cells, leading to both bone loss and inflammation.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Orthoped Surg, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Novack, DV (corresponding author), Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.	novack@wustl.edu; faccior@wustl.edu		Novack, Deborah/0000-0001-7101-5582				de la Fuente MA, 2006, MOL CELL BIOL, V26, P5214, DOI 10.1128/MCB.00087-06; Deckert M, 1998, IMMUNITY, V9, P595, DOI 10.1016/S1074-7613(00)80657-3; Hyckel P, 2005, J CRANIO MAXILL SURG, V33, P61, DOI 10.1016/j.jcms.2004.07.006; Imai Y, 2003, CLEFT PALATE-CRAN J, V40, P632, DOI 10.1597/1545-1569(2003)040<0632:AMMITS>2.0.CO;2; Kitaura H, 2005, J CLIN INVEST, V115, P3418, DOI 10.1172/JCI26132; Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444; Mao DL, 2006, J CLIN INVEST, V116, P2869, DOI 10.1172/JCI28775; Mocsai A, 2004, P NATL ACAD SCI USA, V101, P6158, DOI 10.1073/pnas.0401602101; Ueki Y, 2001, NAT GENET, V28, P125, DOI 10.1038/88832	9	25	25	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 12	2007	128	1					15	17		10.1016/j.cell.2006.12.019	http://dx.doi.org/10.1016/j.cell.2006.12.019			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	139GN	17218248	Bronze			2022-12-28	WOS:000244420400006
J	Gibney, EM				Gibney, Eric M.			Concurrent sentences - Dialysis in the state penitentiary	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Virginia Commonwealth Univ, Div Nephrol, Richmond, VA 23284 USA; Virginia Commonwealth Univ, Hume Lee Transplant Ctr, Richmond, VA USA	Virginia Commonwealth University; Virginia Commonwealth University	Gibney, EM (corresponding author), Virginia Commonwealth Univ, Div Nephrol, Med Coll Virginia Campus, Richmond, VA 23284 USA.								0	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 11	2007	356	2					108	110		10.1056/NEJMp068102	http://dx.doi.org/10.1056/NEJMp068102			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	124NE	17215527				2022-12-28	WOS:000243373700002
J	Motzer, RJ; Hutson, TE; Tomczak, P; Michaelson, MD; Bukowski, RM; Rixe, O; Oudard, S; Negrier, S; Szczylik, C; Kim, ST; Chen, I; Bycott, PW; Baum, CM; Figlin, RA				Motzer, Robert J.; Hutson, Thomas E.; Tomczak, Piotr; Michaelson, M. Dror; Bukowski, Ronald M.; Rixe, Olivier; Oudard, Stephane; Negrier, Sylvie; Szczylik, Cezary; Kim, Sindy T.; Chen, Isan; Bycott, Paul W.; Baum, Charles M.; Figlin, Robert A.			Sunitinib versus interferon alfa in metastatic renal-cell carcinoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; DOSE RECOMBINANT INTERLEUKIN-2; TYROSINE KINASE INHIBITOR; PHASE-III TRIAL; FUNCTIONAL ASSESSMENT; RANDOMIZED-TRIAL; FACTOR RECEPTOR; THERAPY; SU11248; VALIDATION	BACKGROUND: Since sunitinib malate has shown activity in two uncontrolled studies in patients with metastatic renal-cell carcinoma, a comparison of the drug with interferon alfa in a phase 3 trial is warranted. METHODS: We enrolled 750 patients with previously untreated, metastatic renal-cell carcinoma in a multicenter, randomized, phase 3 trial to receive either repeated 6-week cycles of sunitinib (at a dose of 50 mg given orally once daily for 4 weeks, followed by 2 weeks without treatment) or interferon alfa (at a dose of 9 MU given subcutaneously three times weekly). The primary end point was progression-free survival. Secondary end points included the objective response rate, overall survival, patient-reported outcomes, and safety. RESULTS: The median progression-free survival was significantly longer in the sunitinib group (11 months) than in the interferon alfa group (5 months), corresponding to a hazard ratio of 0.42 (95% confidence interval, 0.32 to 0.54; P<0.001). Sunitinib was also associated with a higher objective response rate than was interferon alfa (31% vs. 6%, P<0.001). The proportion of patients with grade 3 or 4 treatment-related fatigue was significantly higher in the group treated with interferon alfa, whereas diarrhea was more frequent in the sunitinib group (P<0.05). Patients in the sunitinib group reported a significantly better quality of life than did patients in the interferon alfa group (P<0.001). CONCLUSIONS: Progression-free survival was longer and response rates were higher in patients with metastatic renal-cell cancer who received sunitinib than in those receiving interferon alfa.	Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Baylor Sammons Canc Ctr Texas Oncol, Dallas, TX USA; Klin Onkol Oddzial Chemioterapii, Poznan, Poland; Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA; Cleveland Clin Fdn, Cleveland, OH 44195 USA; Hop La Pitie Salpetriere, Paris, France; Hop Europeen Georges Pompidou, Paris, France; Ctr Leon Berard, F-69373 Lyon, France; Mil Inst Med, Warsaw, Poland; Pfizer Global Res & Dev, La Jolla, CA USA; City Hope Comprehens Canc Ctr, Los Angeles, CA USA	Memorial Sloan Kettering Cancer Center; Baylor University Medical Center; Texas Oncology-Baylor Charles A Sammons Cancer Center; Harvard University; Massachusetts General Hospital; Cleveland Clinic Foundation; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; UNICANCER; Centre Leon Berard; Military Institute of Aviation Medicine; Pfizer; City of Hope	Motzer, RJ (corresponding author), Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.	motzerr@mskcc.org	Yang, Chen/G-1379-2010; Toon, Christopher W/G-3610-2012; Hutson, Thomas/AAS-9639-2020	Hutson, Thomas/0000-0002-4529-4212; Motzer, Robert/0000-0001-6925-2327; OUDARD, Stephane/0000-0003-0893-285X; Michaelson, Dror/0000-0001-9249-6338				Abrams TJ, 2003, MOL CANCER THER, V2, P1011; Brucker PS, 2005, EVAL HEALTH PROF, V28, P370, DOI 10.1177/0163278705279935; Brucker PS, 2005, EVAL HEALTH PROF, V28, P192, DOI 10.1177/0163278705275341; Cella David, 2006, J Support Oncol, V4, P191; CELLA DF, 1993, J CLIN ONCOL, V11, P570, DOI 10.1200/JCO.1993.11.3.570; Coppin C, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001425.pub2; Cox D.R., 1990, ANAL SURVIVAL DATA; Escudier B, 2005, J CLIN ONCOL, V23, p380S, DOI 10.1200/jco.2005.23.16_suppl.lba4510; Fisher RI, 2000, CANCER J SCI AM, V6, pS55; FITZMAURICE GM, 2004, APPL LONGITUDINAL AN, P187; Fyfe GA, 1996, J CLIN ONCOL, V14, P2410, DOI 10.1200/JCO.1996.14.8.2410; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Janzen NK, 2003, UROL CLIN N AM, V30, P843, DOI 10.1016/S0094-0143(03)00056-9; Kammula US, 1998, CANCER, V83, P797, DOI 10.1002/(SICI)1097-0142(19980815)83:4<797::AID-CNCR25>3.3.CO;2-2; Lam JS, 2005, WORLD J UROL, V23, P202, DOI 10.1007/s00345-004-0466-0; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; McDermott DF, 2005, J CLIN ONCOL, V23, P133, DOI 10.1200/JCO.2005.03.206; McDermott DF, 2005, J CLIN ONCOL, V23, P2877; Mekhail TM, 2005, J CLIN ONCOL, V23, P832, DOI 10.1200/JCO.2005.05.179; Mendel DB, 2003, CLIN CANCER RES, V9, P327; Motzer RJ, 2000, J UROLOGY, V163, P408, DOI 10.1016/S0022-5347(05)67889-5; Motzer RJ, 1996, NEW ENGL J MED, V335, P865, DOI 10.1056/NEJM199609193351207; Motzer RJ, 2006, J CLIN ONCOL, V24, P16, DOI 10.1200/JCO.2005.02.2574; Motzer RJ, 2002, J CLIN ONCOL, V20, P289, DOI 10.1200/JCO.20.1.289; Motzer RJ, 2000, J CLIN ONCOL, V18, P2972, DOI 10.1200/JCO.2000.18.16.2972; Motzer RJ, 2006, JAMA-J AM MED ASSOC, V295, P2516, DOI 10.1001/jama.295.21.2516; Na X, 2003, J UROLOGY, V170, P588, DOI 10.1097/01.ju.0000074870.54671.98; Negrier S, 2005, J CLIN ONCOL, V23, p380S; Negrier S, 1998, NEW ENGL J MED, V338, P1272, DOI 10.1056/NEJM199804303381805; O'Farrell AM, 2003, BLOOD, V101, P3597, DOI 10.1182/blood-2002-07-2307; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pyrhonen S, 1999, J CLIN ONCOL, V17, P2859, DOI 10.1200/JCO.1999.17.9.2859; Ritchie A, 1999, LANCET, V353, P14; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Willett JB, 2003, APPL LONGITUDINAL DA, P75, DOI DOI 10.1093/ACPROF:OSO/9780195152968.003.0004; Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491; Yang JC, 2003, J CLIN ONCOL, V21, P3127, DOI 10.1200/JCO.2003.02.122	40	4662	4768	7	336	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 11	2007	356	2					115	124		10.1056/NEJMoa065044	http://dx.doi.org/10.1056/NEJMoa065044			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	124NE	17215529				2022-12-28	WOS:000243373700004
J	Abrahamson, MJ				Abrahamson, Martin J.			A 74-year-old woman with diabetes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PEPTIDASE-4 INHIBITOR SITAGLIPTIN; IMPAIRED GLUCOSE-TOLERANCE; METFORMIN-TREATED PATIENTS; INTENSIVE INSULIN THERAPY; IMPROVES GLYCEMIC CONTROL; CORONARY-HEART-DISEASE; TO-TARGET TRIAL; DEGENERATIVE COMPLICATIONS; RISK-FACTORS; NPH INSULIN		Joslin Diabet Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School	Abrahamson, MJ (corresponding author), Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA.	martin.abrahamson@joslin.harvard.edu						Adler AI, 2000, BMJ-BRIT MED J, V321, P412, DOI 10.1136/bmj.321.7258.412; Alvarsson M, 2003, DIABETES CARE, V26, P2231, DOI 10.2337/diacare.26.8.2231; [Anonymous], 2005, DIABETES CARE, V28, pS4; Arias HR, 2003, INT REV NEUROBIOL, V54, P1, DOI 10.1016/S0074-7742(03)54002-8; Aschner P, 2006, DIABETES CARE, V29, P2632, DOI 10.2337/dc06-0703; Bai L, 2005, J ENDOCRINOL, V186, P343, DOI 10.1677/joe.1.06078; BECKNIELSEN H, 1994, J CLIN INVEST, V94, P1714, DOI 10.1172/JCI117518; BODEN G, 1995, J CLIN INVEST, V96, P1261, DOI 10.1172/JCI118160; Borch-Johnsen K, 1999, LANCET, V354, P617; Boule NG, 2001, JAMA-J AM MED ASSOC, V286, P1218, DOI 10.1001/jama.286.10.1218; Brown AF, 2003, J AM GERIATR SOC, V51, P665, DOI 10.1034/j.1600-0579.2003.00211.x; Carey DG, 1996, DIABETES, V45, P633, DOI 10.2337/diabetes.45.5.633; *CDCP, 2006, NAT VIT STAT REP; Chan JL, 2003, MAYO CLIN PROC, V78, P459, DOI 10.4065/78.4.459; Charbonnel B, 2006, DIABETES CARE, V29, P2638, DOI 10.2337/dc06-0706; DeFronzo RA, 2005, DIABETES CARE, V28, P1092, DOI 10.2337/diacare.28.5.1092; DeFronzo RA, 1999, ANN INTERN MED, V131, P281, DOI 10.7326/0003-4819-131-4-199908170-00008; DEFRONZO RA, 1995, NEW ENGL J MED, V333, P541, DOI 10.1056/NEJM199508313330902; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; Einhorn D, 2000, CLIN THER, V22, P1395, DOI 10.1016/S0149-2918(00)83039-8; Feinglos MN, 1999, DIABETES CARE, V22, pC61; Fonseca V, 2000, JAMA-J AM MED ASSOC, V283, P1695, DOI 10.1001/jama.283.13.1695; Ford ES, 1997, AM J EPIDEMIOL, V146, P214, DOI 10.1093/oxfordjournals.aje.a009256; FRANZ MJ, 1995, J AM DIET ASSOC, V95, P1009, DOI 10.1016/S0002-8223(95)00276-6; FULLER JH, 1983, BMJ-BRIT MED J, V287, P867, DOI 10.1136/bmj.287.6396.867; Gerich JE, 1996, HORM METAB RES, V28, P404, DOI 10.1055/s-2007-979828; Grundy SM, 2004, CIRCULATION, V109, P433, DOI 10.1161/01.CIR.0000111245.75752.C6; Grundy SM, 1999, CIRCULATION, V100, P1134, DOI 10.1161/01.CIR.100.10.1134; Hamdy O, 2001, ENDOCRIN METAB CLIN, V30, P883, DOI 10.1016/S0889-8529(05)70220-6; HARRIS MI, 1992, DIABETES CARE, V15, P815, DOI 10.2337/diacare.15.7.815; Harris MI, 1998, DIABETES CARE, V21, P518, DOI 10.2337/diacare.21.4.518; Hermansen K, 2006, DIABETES CARE, V29, P1269, DOI 10.2337/dc05-1365; Holman RR, 1998, DIABETES RES CLIN PR, V40, pS21; Horton ES, 1998, DIABETES CARE, V21, P1462, DOI 10.2337/diacare.21.9.1462; Horton ES, 2000, DIABETES CARE, V23, P1660, DOI 10.2337/diacare.23.11.1660; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Hurst RT, 2003, ANN INTERN MED, V139, P824, DOI 10.7326/0003-4819-139-10-200311180-00010; KAHN SE, 1997, ELLENBERG RIFKINS DI, P487; Kahn SE, 2006, NEW ENGL J MED, V355, P2427, DOI 10.1056/NEJMoa066224; Kendall DM, 2005, DIABETES CARE, V28, P1083, DOI 10.2337/diacare.28.5.1083; King H, 1998, DIABETES CARE, V21, P1414, DOI 10.2337/diacare.21.9.1414; Kipnes MS, 2001, AM J MED, V111, P10, DOI 10.1016/S0002-9343(01)00713-6; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P527, DOI 10.1001/archopht.1984.01040030405011; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P520, DOI 10.1001/archopht.1984.01040030398010; KOSKINEN P, 1992, DIABETES CARE, V15, P820, DOI 10.2337/diacare.15.7.820; Marcus MA, 1999, METABOLISM, V48, P194, DOI 10.1016/S0026-0495(99)90033-1; Monnier L, 2003, DIABETES CARE, V26, P881, DOI 10.2337/diacare.26.3.881; Monnier L, 2006, JAMA-J AM MED ASSOC, V295, P1681, DOI 10.1001/jama.295.14.1681; Moses R, 1999, DIABETES CARE, V22, P119, DOI 10.2337/diacare.22.1.119; Nathan DM, 2005, NEW ENGL J MED, V353, P2643, DOI 10.1056/nejmoa052187; OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K; Peyrot M, 2005, DIABETES CARE, V28, P2673, DOI 10.2337/diacare.28.11.2673; Phillips LS, 2001, ANN INTERN MED, V135, P825, DOI 10.7326/0003-4819-135-9-200111060-00012; PIRART J, 1977, DIABETES METAB, V3, P97; PIRART J, 1977, DIABETES METAB, V3, P173; PIRART J, 1977, DIABETES METAB, V3, P245; Purnell JQ, 1997, AM FAM PHYSICIAN, V56, P1835; Raskin P, 2005, DIABETES CARE, V28, P260, DOI 10.2337/diacare.28.2.260; Riddle MC, 1999, AM FAM PHYSICIAN, V60, P2613; Riddle MC, 2003, DIABETES CARE, V26, P3080, DOI 10.2337/diacare.26.11.3080; Robertson RP, 2003, DIABETES, V52, P581, DOI 10.2337/diabetes.52.3.581; Rosenstock J, 1998, DIABETES CARE, V21, P2050, DOI 10.2337/diacare.21.12.2050; Rosenstock J, 2006, CLIN THER, V28, P1556, DOI 10.1016/j.clinthera.2006.10.007; Ryan EA, 2004, DIABETES CARE, V27, P1028, DOI 10.2337/diacare.27.5.1028; Saudek CD, 2006, JAMA-J AM MED ASSOC, V295, P1688, DOI 10.1001/jama.295.14.1688; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Sjostrom L, 2004, NEW ENGL J MED, V351, P2683, DOI 10.1056/NEJMoa035622; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; The American Association of Clinical Endocrinologists, 2002, ENDOCR PRACT, V8, P1; Tominaga M, 1999, DIABETES CARE, V22, P920, DOI 10.2337/diacare.22.6.920; Turner RC, 1998, BMJ-BRIT MED J, V316, P823, DOI 10.1136/bmj.316.7134.823; Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140-6736(98)07037-8; Turner RC, 1999, JAMA-J AM MED ASSOC, V281, P2005, DOI 10.1001/jama.281.21.2005; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Weyer C, 1999, J CLIN INVEST, V104, P787, DOI 10.1172/JCI7231; Weyer C, 2000, DIABETOLOGIA, V43, P36, DOI 10.1007/s001250050005; Weyer C, 2001, J CLIN ENDOCR METAB, V86, P1930, DOI 10.1210/jc.86.5.1930; Willms B, 1999, DIABETIC MED, V16, P755, DOI 10.1046/j.1464-5491.1999.00149.x; Wright A, 2002, DIABETES CARE, V25, P330, DOI 10.2337/diacare.25.2.330; Yale JF, 2001, ANN INTERN MED, V134, P737, DOI 10.7326/0003-4819-134-9_Part_1-200105010-00010; Yki-Jarvinen H, 2000, DIABETES CARE, V23, P1130, DOI 10.2337/diacare.23.8.1130; NAT DIABETES STAT NA	82	10	11	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 10	2007	297	2					196	204		10.1001/jama.297.2.196	http://dx.doi.org/10.1001/jama.297.2.196			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	124GI	17213403				2022-12-28	WOS:000243355900029
J	Huang, B; Wu, HK; Bhaya, D; Grossman, A; Granier, S; Kobilka, BK; Zare, RN				Huang, Bo; Wu, Hongkai; Bhaya, Devaki; Grossman, Arthur; Granier, Sebastien; Kobilka, Brian K.; Zare, Richard N.			Counting low-copy number proteins in a single cell	SCIENCE			English	Article							CAPILLARY-ELECTROPHORESIS; ELECTROKINETIC TRANSPORT; FLUORESCENCE DETECTION; MOLECULE DETECTION; PHYCOBILISOME; POLY(DIMETHYLSILOXANE); NANOCHANNELS; ARCHITECTURE; CONFINEMENT; EXPRESSION	We have designed a microfluidic device in which we can manipulate, lyse, label, separate, and quantify the protein contents of a single cell using single-molecule fluorescence counting. Generic labeling of proteins is achieved through fluorescent-antibody binding. The use of cylindrical optics enables high-efficiency (approximate to 60%) counting of molecules in micrometer-sized channels. We used this microfluidic device to quantify beta(2) adrenergic receptors expressed in insect cells (SF9). We also analyzed phycobiliprotein contents in individual cyanobacterial cells ( Synechococcus sp. PCC 7942) and observed marked differences in the levels of specific complexes in cell populations that were grown under nitrogen-depleted conditions.	Stanford Univ, Dept Chem, Stanford, CA 94305 USA; Carnegie Inst Washington, Dept Plant Biol, Stanford, CA 94305 USA; Stanford Univ, Dept Mol & Cellular Physiol & Med, Stanford, CA 94305 USA	Stanford University; Carnegie Institution for Science; Stanford University	Zare, RN (corresponding author), Stanford Univ, Dept Chem, Stanford, CA 94305 USA.	zare@stanford.edu	Granier, Sebastien/J-1089-2016; Huang, Bo/D-4854-2009; Zare, Richard N./A-8410-2009	Kobilka, Brian/0000-0001-5958-3990; Zare, Richard/0000-0001-5266-4253				Cai L, 2006, NATURE, V440, P358, DOI 10.1038/nature04599; CASTRO A, 1993, ANAL CHEM, V65, P849, DOI 10.1021/ac00055a004; Chen DY, 1996, ANAL CHEM, V68, P690, DOI 10.1021/ac950651r; Cottingham K, 2004, ANAL CHEM, V76, p235A, DOI 10.1021/ac041584g; Foquet M, 2004, ANAL CHEM, V76, P1618, DOI 10.1021/ac035088o; GLAZER AN, 1983, ANN INST PASTEUR MIC, VB134, P159, DOI 10.1016/S0769-2609(83)80103-3; GROSSMAN AR, 1993, MICROBIOL REV, V57, P725, DOI 10.1128/MMBR.57.3.725-749.1993; Haab BB, 1999, ANAL CHEM, V71, P5137, DOI 10.1021/ac990644t; Hong JW, 2004, NAT BIOTECHNOL, V22, P435, DOI 10.1038/nbt951; Hu S, 2004, ANAL CHEM, V76, P4044, DOI 10.1021/ac0498314; Huang B, 2005, LAB CHIP, V5, P1005, DOI 10.1039/b509251e; KOBILKA BK, 1995, ANAL BIOCHEM, V231, P269, DOI 10.1006/abio.1995.1533; Lundqvist A, 2003, ELECTROPHORESIS, V24, P1737, DOI 10.1002/elps.200305429; Lyon WA, 1997, ANAL CHEM, V69, P3400, DOI 10.1021/ac9700742; Ma YF, 2001, ELECTROPHORESIS, V22, P421, DOI 10.1002/1522-2683(200102)22:3<421::AID-ELPS421>3.0.CO;2-W; Newman JRS, 2006, NATURE, V441, P840, DOI 10.1038/nature04785; Ocvirk G, 2000, ELECTROPHORESIS, V21, P107, DOI 10.1002/(SICI)1522-2683(20000101)21:1<107::AID-ELPS107>3.0.CO;2-Y; Pennathur S, 2005, ANAL CHEM, V77, P6772, DOI 10.1021/ac052141v; Pennathur S, 2005, ANAL CHEM, V77, P6782, DOI 10.1021/ac0508346; Whelan RJ, 2002, ANAL CHEM, V74, P4570, DOI 10.1021/ac025669y; Wu HK, 2004, P NATL ACAD SCI USA, V101, P12809, DOI 10.1073/pnas.0405299101; Wu JQ, 2005, SCIENCE, V310, P310, DOI 10.1126/science.1113230; YAMANAKA G, 1980, ARCH MICROBIOL, V124, P39, DOI 10.1007/BF00407026; Yu J, 2006, SCIENCE, V311, P1600, DOI 10.1126/science.1119623	24	316	340	1	194	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 5	2007	315	5808					81	84		10.1126/science.1133992	http://dx.doi.org/10.1126/science.1133992			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	122WU	17204646				2022-12-28	WOS:000243259100039
J	Skewgar, E; Boersma, PD; Harris, G; Caille, G				Skewgar, Elizabeth; Boersma, P. Dee; Harris, Graham; Caille, Guillermo			Sustainability - Anchovy fishery threat to Patagonian ecosystem	SCIENCE			English	Editorial Material								Unsustainable anchovy harvest could disrupt ecosystem function, other fisheries, and ecotourism revenues.	Univ Washington, Dept Biol, Seattle, WA 98195 USA; Fdn Patagonia Nat, RA-9120 Puerto Madryn, Chubut, Argentina	University of Washington; University of Washington Seattle	Skewgar, E (corresponding author), Univ Washington, Dept Biol, Seattle, WA 98195 USA.	skewes@u.washington.edu	Caille, Guillermo Martín/AAU-4135-2021					Bakun A, 2006, PROG OCEANOGR, V68, P271, DOI 10.1016/j.pocean.2006.02.004; DELCHUBUT G, 2006, TURISMO CHUBUT GENER; *FAO FISH DEP, 2001, INF ORD PESQ REP ARG; *FAO FISH DEP, 2004, STAT WORLD FISH AQ S; Frere E., 1996, Ornitologia Neotropical, V7, P35; Koen-Alonso M, 2005, CAN J FISH AQUAT SCI, V62, P1490, DOI 10.1139/F05-087; MAGNUSON JJ, 2006, DYNAMIC CHANGES MARI; *PRES REP OR UR, 2002, ADJ LIC PUBL FIRM IB; SCHONBERGER SN, 2001, 22816 WORLD BANK; *SECR AGR, 2006, DES CAPT MAR TOT	10	38	39	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 5	2007	315	5808					45	45		10.1126/science.1135767	http://dx.doi.org/10.1126/science.1135767			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	122WU	17204628				2022-12-28	WOS:000243259100021
J	Lalanda, M; Alonso, JA				Lalanda, Monica; Alonso, Juan Antonio			Daisy the doctor, Dr Dose, Dr Grizzly, Dr Amelia Bedelia, and colleagues	BRITISH MEDICAL JOURNAL			English	Editorial Material									Leeds Teaching Hosp, Leeds LS1 3EX, W Yorkshire, England; Stepping Hill Hosp, Stockport SK2 7JE, Lancs, England	University of Leeds	Lalanda, M (corresponding author), Leeds Teaching Hosp, Leeds LS1 3EX, W Yorkshire, England.	lalanda@doctors.org.uk							0	1	1	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 23	2006	333	7582					1330	1332		10.1136/bmj.333.7582.1330	http://dx.doi.org/10.1136/bmj.333.7582.1330			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121MC	17185732	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000243160700029
J	Moss, M; Burnham, EL				Moss, Marc; Burnham, Ellen Lyda			Alcohol abuse in the critically ill patient	LANCET			English	Review							INTENSIVE-CARE-UNIT; RESPIRATORY-DISTRESS-SYNDROME; DISORDERS IDENTIFICATION TEST; CARBOHYDRATE-DEFICIENT TRANSFERRIN; COMMUNITY-ACQUIRED PNEUMONIA; EPITHELIAL BARRIER FUNCTION; MULTIPLE ORGAN DYSFUNCTION; CHRONIC ETHANOL INGESTION; RISK-FACTORS; ATRIAL-FIBRILLATION	Alcohol abuse and dependence disorders are common in the 10% of hospitalised patients who need admission to the intensive care unit (ICU), but these disorders are often undiagnosed. The systemic effects from the excessive use of alcohol increase susceptibility to, or directly cause various important disorders in the critically ill. Early recognition of alcohol abuse and dependence is necessary and should prompt consideration of several alcohol-specific diagnoses that have important prognostic and therapeutic implications for these patients. We discuss the use of screening tests to improve the identification of alcohol abuse and dependence disorders, the epidemiology and pathogenesis of important alcohol-related disorders, differences in the presentation of several common alcohol-related diagnoses in the ICU, and important alcohol-specific therapies.	Univ Colorado, Div Pulm Sci & Crit Care Med, Denver, CO 80262 USA; Hlth Sci Ctr, Denver, CO 80262 USA	University of Colorado System; University of Colorado Denver	Moss, M (corresponding author), Univ Colorado, Div Pulm Sci & Crit Care Med, Denver, CO 80262 USA.	Marc.Moss@uchsc.edu			NCRR NIH HHS [M01-RR000039] Funding Source: Medline; NIAAA NIH HHS [R01-AA014435, P50-AA013757, K23-AA013918] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000039] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA013757, R01AA014435, K23AA013918] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Agabio R, 2005, ALCOHOL ALCOHOLISM, V40, P155, DOI 10.1093/alcalc/agh106; ANDREWS BE, 1987, Q J MED, V62, P195; BARTLETT JG, 1974, AM REV RESPIR DIS, V110, P56; Bechara RI, 2004, AM J RESP CRIT CARE, V170, P188, DOI 10.1164/rccm.200304-478OC; Bercault N, 2001, CRIT CARE MED, V29, P2303, DOI 10.1097/00003246-200112000-00012; Betrosian AP, 2004, AM J MED SCI, V327, P250, DOI 10.1097/00000441-200405000-00020; Blondell RD, 2003, JAMA-J AM MED ASSOC, V289, P552, DOI 10.1001/jama.289.5.552; Blondell RD, 2002, J STUD ALCOHOL, V63, P380, DOI 10.15288/jsa.2002.63.380; Boe DM, 2001, J INFECT DIS, V184, P1134, DOI 10.1086/323661; BRADEN GL, 1993, ARCH INTERN MED, V153, P2377, DOI 10.1001/archinte.153.20.2377; Brent J, 1999, NEW ENGL J MED, V340, P832, DOI 10.1056/NEJM199903183401102; Brent J, 2001, NEW ENGL J MED, V344, P424, DOI 10.1056/NEJM200102083440605; Brown CVR, 2004, J TRAUMA, V56, P1191, DOI 10.1097/01.TA.0000130761.78627.10; Brown LAS, 2001, ALCOHOL CLIN EXP RES, V25, P1078, DOI 10.1111/j.1530-0277.2001.tb02320.x; Burnham EL, 2003, ALCOHOL CLIN EXP RES, V27, P1167, DOI 10.1097/01.ALC.0000075821.34270.98; Burnham EL, 2004, CRIT CARE MED, V32, P675, DOI 10.1097/01.CCM.0000114824.65158.4E; Bush K, 1998, ARCH INTERN MED, V158, P1789, DOI 10.1001/archinte.158.16.1789; Cabre E, 2000, HEPATOLOGY, V32, P36, DOI 10.1053/jhep.2000.8627; Canagasaby A, 2005, ALCOHOL ALCOHOLISM, V40, P208, DOI 10.1093/alcalc/agh156; CARPENTER JL, 1991, SOUTHERN MED J, V84, P299, DOI 10.1097/00007611-199103000-00004; Chang PH, 2001, MED CLIN N AM, V85, P1191, DOI 10.1016/S0025-7125(05)70372-2; Conigrave KM, 2003, ADDICTION, V98, P31, DOI 10.1046/j.1359-6357.2003.00581.x; Connors GJ, 2003, ADDICTION, V98, P21, DOI 10.1046/j.1359-6357.2003.00585.x; Cook CCH, 1998, ALCOHOL ALCOHOLISM, V33, P317; D'Onofrio G, 1999, NEW ENGL J MED, V340, P915, DOI 10.1056/NEJM199903253401203; Dauphine C, 2004, ARCH SURG-CHICAGO, V139, P978, DOI 10.1001/archsurg.139.9.978; Djousse L, 2004, AM J CARDIOL, V93, P710, DOI 10.1016/j.amjcard.2003.12.004; Donovan DM, 2004, J TRAUMA, V56, P873, DOI 10.1097/01.TA.0000086650.27490.4B; Dufour MC, 2003, PANCREAS, V27, P286, DOI 10.1097/00006676-200311000-00002; ELISAF M, 1994, MINER ELECTROL METAB, V20, P274; Elisaf M, 2002, DRUG ALCOHOL REV, V21, P73, DOI 10.1080/09595230220119282a; Elisaf M, 1998, ALCOHOL CLIN EXP RES, V22, P134, DOI 10.1111/j.1530-0277.1998.tb03628.x; Elisaf MS, 1997, INT J CLIN PRACT, V51, P501; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; Ferguson JA, 1996, J GEN INTERN MED, V11, P410, DOI 10.1007/BF02600188; Fernandez-Sola J, 2000, ALCOHOL CLIN EXP RES, V24, P1830, DOI 10.1097/00000374-200012000-00012; FERNANDEZSOLA J, 1995, ARCH INTERN MED, V155, P1649, DOI 10.1001/archinte.155.15.1649; Fine MJ, 1996, JAMA-J AM MED ASSOC, V275, P134, DOI 10.1001/jama.275.2.134; FUXENCHLOPEZ Z, 1978, ARCH INTERN MED, V138, P1815, DOI 10.1001/archinte.138.12.1815; GABOW PA, 1982, MEDICINE, V61, P141, DOI 10.1097/00005792-198205000-00002; Gentilello LM, 1999, ANN SURG, V230, P473, DOI 10.1097/00000658-199910000-00003; Glaser DS, 1996, ANN EMERG MED, V27, P343, DOI 10.1016/S0196-0644(96)70271-8; GLUCKMAN SJ, 1978, BLOOD, V52, P551; Guidot DM, 2000, AM J PHYSIOL-LUNG C, V279, pL127, DOI 10.1152/ajplung.2000.279.1.L127; Hall W, 1997, LANCET, V349, P1897, DOI 10.1016/S0140-6736(97)04572-8; HALPERN NA, 1994, CRIT CARE MED, V22, P2001; Hasin D, 2003, ALCOHOL RES HEALTH, V27, P5; Hermans C, 1996, CLIN RHEUMATOL, V15, P193, DOI 10.1007/BF02230340; Herridge MS, 2003, NEW ENGL J MED, V348, P683, DOI 10.1056/NEJMoa022450; Hodges B, 2004, PHARMACOTHERAPY, V24, P1578, DOI 10.1592/phco.24.16.1578.50945; Hoffman R S, 1989, Emerg Med Clin North Am, V7, P943; Holguin F, 1998, J CLIN INVEST, V101, P761, DOI 10.1172/JCI1396; HOYUMPA AM, 1980, AM J CLIN NUTR, V33, P2750, DOI 10.1093/ajcn/33.12.2750; HOYUMPA AM, 1986, ALCOHOL CLIN EXP RES, V10, P573, DOI 10.1111/j.1530-0277.1986.tb05147.x; JENSEN NH, 1988, INTENS CARE MED, V15, P19; JURKOVICH GJ, 1993, JAMA-J AM MED ASSOC, V270, P51, DOI 10.1001/jama.270.1.51; Kershaw C, 2003, AM J RESP CRIT CARE, V167, pA251; KOLLS JK, 1995, AM J PHYSIOL-LUNG C, V268, pL991, DOI 10.1152/ajplung.1995.268.6.L991; KOSKINEN P, 1990, AM J CARDIOL, V66, P954, DOI 10.1016/0002-9149(90)90932-Q; KOSKINEN P, 1987, BRIT HEART J, V57, P468, DOI 10.1136/hrt.57.5.468; Kraemer Kevin L, 2003, Subst Abus, V24, P197, DOI 10.1023/A:1026099426602; Kraemer KL, 1997, ARCH INTERN MED, V157, P2234, DOI 10.1001/archinte.157.19.2234; Licker M, 2003, ANESTH ANALG, V97, P1558, DOI 10.1213/01.ANE.0000087799.85495.8A; Lingford-Hughes A, 2003, BRIT J PSYCHIAT, V182, P97, DOI 10.1192/bjp.182.2.97; Longabaugh R, 2001, J STUD ALCOHOL, V62, P806, DOI 10.15288/jsa.2001.62.806; Lukan JK, 2002, J TRAUMA, V53, P901, DOI 10.1097/00005373-200211000-00015; MACDONALD L, 1994, AM J EMERG MED, V12, P32, DOI 10.1016/0735-6757(94)90193-7; MacGregor R R, 1997, Curr Clin Top Infect Dis, V17, P291; MACGREGOR RR, 1974, NEW ENGL J MED, V291, P642, DOI 10.1056/NEJM197409262911302; MADDREY WC, 1990, SCAND J GASTROENTERO, V25, P118, DOI 10.3109/00365529009093136; Mandrekar P, 1999, INT IMMUNOL, V11, P1781, DOI 10.1093/intimm/11.11.1781; Marik P, 1996, ALCOHOL ALCOHOLISM, V31, P393; Martin GS, 2005, CRIT CARE, V9, pR74, DOI 10.1186/cc3025; Martin MJ, 2002, ALCOHOL CLIN EXP RES, V26, P836, DOI 10.1097/00000374-200206000-00013; Mathurin P, 2002, J HEPATOL, V36, P480, DOI 10.1016/S0168-8278(01)00289-6; Maxson PM, 1999, MAYO CLIN PROC, V74, P448; Mayo-Smith MF, 2004, ARCH INTERN MED, V164, P1405, DOI 10.1001/archinte.164.13.1405; MayoSmith MF, 1997, JAMA-J AM MED ASSOC, V278, P144, DOI 10.1001/jama.278.2.144; MCGILL V, 1995, J TRAUMA, V38, P931, DOI 10.1097/00005373-199506000-00019; Miller WR, 2006, ALCOHOL CLIN EXP RES, V30, P292, DOI 10.1111/j.1530-0277.2006.00027.x; Molina PE, 2004, ALCOHOL, V33, P217, DOI 10.1016/j.alcohol.2004.07.002; Monti PM, 1999, J CONSULT CLIN PSYCH, V67, P989, DOI 10.1037/0022-006X.67.6.989; Moss M, 2003, CRIT CARE MED, V31, P869, DOI 10.1097/01.CCM.0000055389.64497.11; Moss M, 1996, JAMA-J AM MED ASSOC, V275, P50, DOI 10.1001/jama.275.1.50; Moss M, 2000, AM J RESP CRIT CARE, V161, P414, DOI 10.1164/ajrccm.161.2.9905002; *NAT I ALC AB ALC, HELP PAT DRINK TOO M; Nelson S, 2002, NAT REV IMMUNOL, V2, P205, DOI 10.1038/nri744; NELSON S, 1989, J INFECT DIS, V160, P422, DOI 10.1093/infdis/160.3.422; Neuenschwander AU, 2002, EUR J CARDIO-THORAC, V22, P287, DOI 10.1016/S1010-7940(02)00263-4; Neumann T, 2004, ALCOHOL CLIN EXP RES, V28, P1693, DOI 10.1097/01.ALC.0000145696.58084.08; Neumann T, 2003, ADDICTION, V98, P81, DOI 10.1046/j.1359-6357.2003.00587.x; NILSSON E, 1991, J INFECT DIS, V163, P591, DOI 10.1093/infdis/163.3.591; O'Beirne J, 2000, POSTGRAD MED J, V76, P504, DOI 10.1136/pmj.76.898.504; ORTQVIST A, 1990, EUR RESPIR J, V3, P1105; Paull DE, 2004, AM J SURG, V188, P553, DOI 10.1016/j.amjsurg.2004.07.030; Puddey IB, 1999, ADDICTION, V94, P649, DOI 10.1046/j.1360-0443.1999.9456493.x; Reinert DF, 2002, ALCOHOL CLIN EXP RES, V26, P272, DOI 10.1111/j.1530-0277.2002.tb02534.x; REULER JB, 1985, NEW ENGL J MED, V312, P1035, DOI 10.1056/NEJM198504183121606; Richards JR, 2000, J EMERG MED, V19, P51, DOI 10.1016/S0736-4679(00)00180-3; Richardson JD, 2004, J AM COLL SURGEONS, V199, P133, DOI 10.1016/j.jamcollsurg.2004.02.023; RIVARA FP, 1993, JAMA-J AM MED ASSOC, V270, P1962, DOI 10.1001/jama.270.16.1962; RUBIN R, 1994, ALCOHOL CLIN EXP RES, V18, P105, DOI 10.1111/j.1530-0277.1994.tb00888.x; SACHS CW, 1990, AM REV RESPIR DIS, V141, P1249, DOI 10.1164/ajrccm/141.5_Pt_1.1249; Saitz R, 1997, MED CLIN N AM, V81, P881, DOI 10.1016/S0025-7125(05)70554-X; Saitz R, 1997, ARCH INTERN MED, V157, P1446, DOI 10.1001/archinte.157.13.1446; Saitz R, 2005, NEW ENGL J MED, V352, P596, DOI 10.1056/NEJMcp042262; Sander M, 2002, INTENS CARE MED, V28, P285, DOI 10.1007/s00134-001-1199-9; Santhosh-Kumar CR, 2000, AM J HEMATOL, V64, P71, DOI 10.1002/(SICI)1096-8652(200005)64:1&lt;71::AID-AJH13&gt;3.0.CO;2-Z; Schermer CR, 2003, J TRAUMA, V55, P849, DOI 10.1097/01.TA.0000091110.83692.38; Schiodt FV, 1997, NEW ENGL J MED, V337, P1112, DOI 10.1056/NEJM199710163371602; Servin FS, 2003, ANESTHESIOLOGY, V99, P576, DOI 10.1097/00000542-200309000-00012; Soderstrom CA, 1997, J TRAUMA, V43, P962, DOI 10.1097/00005373-199712000-00017; SONNE NM, 1992, BRIT J NEUROSURG, V6, P125, DOI 10.3109/02688699209002914; Spies C D, 2001, Curr Opin Crit Care, V7, P337; Spies CD, 1996, CRIT CARE MED, V24, P414, DOI 10.1097/00003246-199603000-00009; Spies CD, 2003, INTENS CARE MED, V29, P2230, DOI 10.1007/s00134-003-2033-3; Spies CD, 1998, ALCOHOL ALCOHOLISM, V33, P661, DOI 10.1093/alcalc/33.6.661; Spies CD, 1996, INTENS CARE MED, V22, P286, DOI 10.1007/s001340050082; SPIES CD, 1995, J TRAUMA, V39, P742, DOI 10.1097/00005373-199510000-00025; Spies CD, 2004, ANESTHESIOLOGY, V100, P1088, DOI 10.1097/00000542-200405000-00010; Spies CD, 1999, ANESTH ANALG, V88, P946, DOI 10.1097/00000539-199904000-00050; Spies CD, 1996, ACTA ANAESTH SCAND, V40, P649, DOI 10.1111/j.1399-6576.1996.tb04505.x; Stoltz DA, 2000, AM J RESP CRIT CARE, V161, P135, DOI 10.1164/ajrccm.161.1.9905016; SZABO G, 1995, J LEUKOCYTE BIOL, V58, P342, DOI 10.1002/jlb.58.3.342; Tayar J, 2002, NEW ENGL J MED, V346, P1253, DOI 10.1056/NEJM200204183461618; Thomson A D, 2000, Alcohol Alcohol Suppl, V35, P2; Thomson AD, 2002, ALCOHOL ALCOHOLISM, V37, P513, DOI 10.1093/alcalc/37.6.513; TONNESEN H, 1988, SCAND J UROL NEPHROL, V22, P175, DOI 10.1080/00365599.1988.11690408; Tonnesen H, 1999, BMJ-BRIT MED J, V318, P1311, DOI 10.1136/bmj.318.7194.1311; Tonnesen H, 1999, ALCOHOL ALCOHOLISM, V34, P148, DOI 10.1093/alcalc/34.2.148; Tonnesen H, 2003, DAN MED BULL, V50, P139; Tonnesen H, 1999, BRIT J SURG, V86, P869, DOI 10.1046/j.1365-2168.1999.01181.x; Tsai GC, 1998, ANNU REV MED, V49, P173; TURNER RC, 1989, J GEN INTERN MED, V4, P432, DOI 10.1007/BF02599697; URBANOMARQUEZ A, 1989, NEW ENGL J MED, V320, P409, DOI 10.1056/NEJM198902163200701; von Heymann C, 2002, J TRAUMA, V52, P95, DOI 10.1097/00005373-200201000-00017; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; Weisinger JR, 1998, LANCET, V352, P391, DOI 10.1016/S0140-6736(97)10535-9; WHANG R, 1992, ARCH INTERN MED, V152, P40, DOI 10.1001/archinte.152.1.40; WILSON A, 1984, ALCOHOL CLIN EXP RES, V8, P542, DOI 10.1111/j.1530-0277.1984.tb05726.x; WRENN KD, 1991, AM J MED, V91, P119, DOI 10.1016/0002-9343(91)90003-G; WRENN KD, 1992, AM J EMERG MED, V10, P165, DOI 10.1016/0735-6757(92)90054-2	142	73	73	1	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 23	2006	368	9554					2231	2242		10.1016/S0140-6736(06)69490-7	http://dx.doi.org/10.1016/S0140-6736(06)69490-7			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	120HY	17189035				2022-12-28	WOS:000243076800031
J	Bertram, TH; Perring, AE; Wooldridge, PJ; Crounse, JD; Kwan, AJ; Wennberg, PO; Scheuer, E; Dibb, J; Avery, M; Sachse, G; Vay, SA; Crawford, JH; McNaughton, CS; Clarke, A; Pickering, KE; Fuelberg, H; Huey, G; Blake, DR; Singh, HB; Hall, SR; Shetter, RE; Fried, A; Heikes, BG; Cohen, RC				Bertram, Timothy H.; Perring, Anne E.; Wooldridge, Paul J.; Crounse, John D.; Kwan, Alan J.; Wennberg, Paul O.; Scheuer, Eric; Dibb, Jack; Avery, Melody; Sachse, Glen; Vay, Stephanie A.; Crawford, James H.; McNaughton, Cameron S.; Clarke, Antony; Pickering, Kenneth E.; Fuelberg, Henry; Huey, Greg; Blake, Donald R.; Singh, Hanwant B.; Hall, Samuel R.; Shetter, Richard E.; Fried, Alan; Heikes, Brian G.; Cohen, Ronald C.			Direct measurements of the convective recycling of the upper troposphere	SCIENCE			English	Article							INDUCED FLUORESCENCE DETECTION; TRACE GAS-TRANSPORT; NITRIC-ACID; MIDLATITUDE CONVECTION; REACTIVE NITROGEN; OZONE PRODUCTION; ATMOSPHERIC NO2; HNO3/NOX RATIO; UNITED-STATES; PEM-TROPICS	We present a statistical representation of the aggregate effects of deep convection on the chemistry and dynamics of the upper troposphere ( UT) based on direct aircraft observations of the chemical composition of the UT over the eastern United States and Canada during summer. These measurements provide unique observational constraints on the chemistry occurring downwind of convection and the rate at which air in the UT is recycled. These results provide quantitative measures that can be used to evaluate global climate and chemistry models.	Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA; CALTECH, Div Engn & Appl Sci, Pasadena, CA 91125 USA; CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA; Univ New Hampshire, Inst Study Earth Oceans & Space, Durham, NH 03824 USA; NASA, Langley Res Ctr, Hampton, VA 23681 USA; Univ Hawaii Manoa, Sch Ocean & Earth Sci Technol, Honolulu, HI 96822 USA; Univ Maryland, Dept Atmospher & Ocean Sci, College Pk, MD 20742 USA; NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; Florida State Univ, Dept Meteorol, Tallahassee, FL 32306 USA; Georgia Inst Technol, Sch Earth & Atmospher Sci, Atlanta, GA 30332 USA; Univ Calif Irvine, Dept Chem, Irvine, CA 92697 USA; NASA, Ames Res Ctr, Moffett Field, CA 94035 USA; Natl Ctr Atmospher Res, Boulder, CO 80305 USA; Univ Rhode Isl, Grad Sch Oceanog, Narragansett, RI 02882 USA; Univ Calif Berkeley, Dept Earth & Planetary Sci, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; California Institute of Technology; California Institute of Technology; California Institute of Technology; University System Of New Hampshire; University of New Hampshire; National Aeronautics & Space Administration (NASA); NASA Langley Research Center; University of Hawaii System; University of Hawaii Manoa; University System of Maryland; University of Maryland College Park; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; State University System of Florida; Florida State University; University System of Georgia; Georgia Institute of Technology; University of California System; University of California Irvine; National Aeronautics & Space Administration (NASA); NASA Ames Research Center; National Center Atmospheric Research (NCAR) - USA; University of Rhode Island; University of California System; University of California Berkeley	Cohen, RC (corresponding author), Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.	cohen@cchem.berkeley.edu	Crounse, John/E-4622-2011; Crawford, James H/L-6632-2013; Wooldridge, Paul/AFP-4233-2022; Crounse, John D/C-3700-2014; Wennberg, Paul O/A-5460-2012; Hall, Samuel/AAG-9516-2020; Cohen, Ronald C/A-8842-2011; Pickering, Kenneth E/E-6274-2012; Affiliate, Anne Perring - NOAA/G-4597-2013; Avery, Melody A/C-6209-2019	Crawford, James H/0000-0002-6982-0934; Crounse, John D/0000-0001-5443-729X; Wennberg, Paul O/0000-0002-6126-3854; Hall, Samuel/0000-0002-2060-7112; Cohen, Ronald C/0000-0001-6617-7691; Affiliate, Anne Perring - NOAA/0000-0003-2231-7503; Blake, Donald/0000-0002-8283-5014; Bertram, Timothy H./0000-0002-3026-7588				CHAHINE MT, 1992, NATURE, V359, P373, DOI 10.1038/359373a0; CHATFIELD RB, 1984, J GEOPHYS RES-ATMOS, V89, P7111, DOI 10.1029/JD089iD05p07111; CHATFIELD RB, 1994, GEOPHYS RES LETT, V21, P2705, DOI 10.1029/94GL02659; Clarke AD, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2003JD004378; Clarke AD, 1999, J GEOPHYS RES-ATMOS, V104, P5735, DOI 10.1029/98JD02303; Cleary PA, 2002, APPL OPTICS, V41, P6950, DOI 10.1364/AO.41.006950; Cohan DS, 1999, J GEOPHYS RES-ATMOS, V104, P5717, DOI 10.1029/98JD01963; Collins WJ, 2002, Q J ROY METEOR SOC, V128, P991, DOI 10.1256/0035900021643629; Cooper OR, 2006, J GEOPHYS RES-ATMOS, V111, DOI 10.1029/2006JD007306; Crounse JD, 2006, ANAL CHEM, V78, P6726, DOI 10.1021/ac0604235; Davis DD, 1996, J GEOPHYS RES-ATMOS, V101, P2111, DOI 10.1029/95JD02755; DeCaria AJ, 2005, J GEOPHYS RES-ATMOS, V110, DOI 10.1029/2004JD005556; DENTENER FJ, 1993, J GEOPHYS RES-ATMOS, V98, P7149, DOI 10.1029/92JD02979; DICKERSON RR, 1987, SCIENCE, V235, P460, DOI 10.1126/science.235.4787.460; Dye JE, 2000, J GEOPHYS RES-ATMOS, V105, P10023, DOI 10.1029/1999JD901116; Faloona IC, 2004, J ATMOS CHEM, V47, P139, DOI 10.1023/B:JOCH.0000021036.53185.0e; Folkins I, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2002JD002185; Gauss M, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD002624; GIORGI F, 1985, J GEOPHYS RES-ATMOS, V90, P7872, DOI 10.1029/JD090iD05p07872; HAUF T, 1995, J GEOPHYS RES-ATMOS, V100, P22957, DOI 10.1029/95JD02324; Hauglustaine DA, 1996, GEOPHYS RES LETT, V23, P2609, DOI 10.1029/96GL02474; Huntrieser H, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2000JD000209; Huntrieser H, 1998, J GEOPHYS RES-ATMOS, V103, P28247, DOI 10.1029/98JD02353; Jacob DJ, 1996, J GEOPHYS RES-ATMOS, V101, P24235, DOI 10.1029/96JD00336; Jaegle L, 2005, FARADAY DISCUSS, V130, P407, DOI 10.1039/b502128f; Jaegle L, 1998, GEOPHYS RES LETT, V25, P1705, DOI 10.1029/97GL03591; Lawrence MG, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017644; LELIEVELD J, 1994, SCIENCE, V264, P1759, DOI 10.1126/science.264.5166.1759; MCKEEN SA, 1993, GEOPHYS RES LETT, V20, P2363, DOI 10.1029/93GL02527; Mullendore GL, 2005, J GEOPHYS RES-ATMOS, V110, DOI 10.1029/2004JD005059; PICKERING KE, 1990, J GEOPHYS RES-ATMOS, V95, P14049, DOI 10.1029/JD095iD09p14049; Pickering KE, 1998, J GEOPHYS RES-ATMOS, V103, P31203, DOI 10.1029/98JD02651; PICKERING KE, 1988, J GEOPHYS RES-ATMOS, V93, P759, DOI 10.1029/JD093iD01p00759; Prather MJ, 1997, GEOPHYS RES LETT, V24, P3189, DOI 10.1029/97GL03027; Ray EA, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2004JD004655; Ridley B, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2004JD004769; Rind D, 1996, J GEOPHYS RES-ATMOS, V101, P12667, DOI 10.1029/96JD00551; RUTLEDGE SA, 1988, MON WEATHER REV, V116, P1409, DOI 10.1175/1520-0493(1988)116<1409:TOMCSO>2.0.CO;2; SACHSE GW, 1987, J GEOPHYS RES-ATMOS, V92, P2071, DOI 10.1029/JD092iD02p02071; Sander R, 1999, COMPILATION HENRYS L; Shetter RE, 1999, J GEOPHYS RES-ATMOS, V104, P5647, DOI 10.1029/98JD01381; Singh HB, 2006, J GEOPHYS RES-ATMOS, V111, DOI 10.1029/2006JD007905; Smyth S, 1996, J GEOPHYS RES-ATMOS, V101, P1743, DOI 10.1029/95JD02861; Tabazadeh A, 1998, GEOPHYS RES LETT, V25, P4185, DOI 10.1029/1998GL900062; Talbot RW, 1999, GEOPHYS RES LETT, V26, P3057, DOI 10.1029/1999GL900589; THOMPSON AM, 1994, J GEOPHYS RES-ATMOS, V99, P18703, DOI 10.1029/94JD01244; Thornton JA, 2000, ANAL CHEM, V72, P528, DOI 10.1021/ac9908905; Vay SA, 1999, J GEOPHYS RES-ATMOS, V104, P5663, DOI 10.1029/98JD01420; Wang Y, 2000, GEOPHYS RES LETT, V27, P369, DOI 10.1029/1999GL010930; World Meteorological Organization, 1995, SCI ASS OZ DEPL	50	86	87	1	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 9	2007	315	5813					816	820		10.1126/science.1134548	http://dx.doi.org/10.1126/science.1134548			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	134FN	17204609	Green Submitted			2022-12-28	WOS:000244069000061
J	Rivera, MN; Kim, WJ; Wells, J; Driscoll, DR; Brannigan, BW; Han, M; Kim, JC; Feinberg, AP; Gerald, WL; Vargas, SO; Chin, L; Iafrate, AJ; Bell, DW; Haber, DA				Rivera, Miguel N.; Kim, Woo Jae; Wells, Julie; Driscoll, David R.; Brannigan, Brian W.; Han, Moonjoo; Kim, James C.; Feinberg, Andrew P.; Gerald, William L.; Vargas, Sara O.; Chin, Lynda; Iafrate, A. John; Bell, Daphne W.; Haber, Daniel A.			An X chromosome gene, WTX, is commonly inactivated in Wilms tumor	SCIENCE			English	Article							FANCONI-ANEMIA; HUMAN GENOME; CANCER; KIDNEY; MUTATIONS	Wilms tumor is a pediatric kidney cancer associated with inactivation of the WT1 tumor-suppressor gene in 5 to 10% of cases. Using a high-resolution screen for DNA copy-number alterations in Wilms tumor, we identified somatic deletions targeting a previously uncharacterized gene on the X chromosome. This gene, which we call WTX, is inactivated in approximately one-third of Wilms tumors (15 of 51 tumors). Tumors with mutations in WTX lack WT1 mutations, and both genes share a restricted temporal and spatial expression pattern in normal renal precursors. In contrast to biallelic inactivation of autosomal tumor-suppressor genes, WTX is inactivated by a monoallelic "single-hit" event targeting the single X chromosome in tumors from males and the active X chromosome in tumors from females.	Massachusetts Gen Hosp, Ctr Canc, Harvard Med Ctr, Boston, MA 02114 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA; Johns Hopkins Univ, Sch Med, Dept Med, Div Mol Med, Baltimore, MD 21205 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; Harvard Univ, Childrens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Johns Hopkins University; Memorial Sloan Kettering Cancer Center; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Haber, DA (corresponding author), Massachusetts Gen Hosp, Ctr Canc, Harvard Med Ctr, Boston, MA 02114 USA.	haber@helix.mgh.harvard.edu	Feinberg, Andrew/AAY-7666-2020	Feinberg, Andrew/0000-0002-8364-1991	NATIONAL CANCER INSTITUTE [R37CA058596, P50CA101942, R37CA054358, T32CA009216, R01CA054358] Funding Source: NIH RePORTER; NCI NIH HHS [R37 CA054358, R37 CA054358-17, P01-CA101942, T32-CA009216, R01 CA054358, R37-CA058596] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brennan C, 2004, CANCER RES, V64, P4744, DOI 10.1158/0008-5472.CAN-04-1241; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; Carrel L, 2005, NATURE, V434, P400, DOI 10.1038/nature03479; Dome JS, 2002, CURR OPIN PEDIATR, V14, P5, DOI 10.1097/00008480-200202000-00002; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; Heard E, 1999, MOL CELL BIOL, V19, P3156; Iafrate AJ, 2004, NAT GENET, V36, P949, DOI 10.1038/ng1416; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Maiti S, 2000, CANCER RES, V60, P6288; Meetei AR, 2004, NAT GENET, V36, P1219, DOI 10.1038/ng1458; Moore AW, 1999, DEVELOPMENT, V126, P1845; Nichols KE, 2005, IMMUNOL REV, V203, P180, DOI 10.1111/j.0105-2896.2005.00230.x; Pilia G, 1996, NAT GENET, V12, P241, DOI 10.1038/ng0396-241; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; Rahman N, 2004, NAT GENET, V36, P1142, DOI 10.1038/ng1104-1142; Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013; Rivera MN, 2005, NAT REV CANCER, V5, P699, DOI 10.1038/nrc1696; Sebat J, 2004, SCIENCE, V305, P525, DOI 10.1126/science.1098918; Spatz A, 2004, NAT REV CANCER, V4, P617, DOI 10.1038/nrc1413; Yuan E, 2005, MOL CANCER RES, V3, P493, DOI 10.1158/1541-7786.MCR-05-0082	22	244	300	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 2	2007	315	5812					642	645		10.1126/science.1137509	http://dx.doi.org/10.1126/science.1137509			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	131YR	17204608				2022-12-28	WOS:000243909400042
J	French, P				French, Patrick			Syphilis	BMJ-BRITISH MEDICAL JOURNAL			English	Review							SEXUALLY-TRANSMITTED-DISEASES; PENICILLIN TREATMENT; TREPONEMA-PALLIDUM; HIV; PREVENTION; BENZATHINE; TANZANIA; THERAPY; MANIFESTATIONS; PREGNANCY		UCL, Camden Primary Care Trust, London WC1E 6AUA, England	University of London; University College London	French, P (corresponding author), UCL, Camden Primary Care Trust, London WC1E 6AUA, England.	Patrick.French@camdenpct.nhs.uk	Donovan, Basil J/K-1246-2012; Scheetz, Marc H./A-8524-2009	Donovan, Basil J/0000-0001-8851-4126; Scheetz, Marc H./0000-0002-1091-6130				[Anonymous], ACTA DERMATO VEN S34; BERRY CD, 1987, NEW ENGL J MED, V316, P1587, DOI 10.1056/NEJM198706183162507; Celentano DD, 1998, AIDS, V12, pF29, DOI 10.1097/00002030-199805000-00004; Danielsen AG, 2004, ACTA DERM-VENEREOL, V84, P459, DOI 10.1080/00015550410017308; Egglestone S I, 2000, Commun Dis Public Health, V3, P158; Fraser CM, 1998, SCIENCE, V281, P375, DOI 10.1126/science.281.5375.375; GOEMAN J, 1995, GENITOURIN MED, V71, P275; HAHN RD, 1956, ARCH DERMATOL, V74, P355, DOI 10.1001/archderm.1956.01550100023006; JOHNS DR, 1987, NEW ENGL J MED, V316, P1569, DOI 10.1056/NEJM198706183162503; Lukehart SA, 2004, NEW ENGL J MED, V351, P154, DOI 10.1056/NEJMoa040216; Marra CM, 2004, J INFECT DIS, V189, P369, DOI 10.1086/381227; Mayaud P, 1997, AIDS, V11, P1873, DOI 10.1097/00002030-199715000-00013; Palmer HM, 2003, SEX TRANSM INFECT, V79, P479, DOI 10.1136/sti.79.6.479; Parkes R, 2004, INT J STD AIDS, V15, P73, DOI 10.1258/095646204322764253; Riedner G, 2005, NEW ENGL J MED, V353, P1236, DOI 10.1056/NEJMoa044284; Rolfs RT, 1997, NEW ENGL J MED, V337, P307, DOI 10.1056/NEJM199707313370504; Rompalo AM, 2001, SEX TRANSM DIS, V28, P448, DOI 10.1097/00007435-200108000-00004; Rompalo AM, 2001, SEX TRANSM DIS, V28, P158, DOI 10.1097/00007435-200103000-00007; Rottingen JA, 2001, SEX TRANSM DIS, V28, P579; Saloojee H, 2004, B WORLD HEALTH ORGAN, V82, P424; Simms I, 2005, SEX TRANSM DIS, V32, P220, DOI 10.1097/01.olq.0000149848.03733.c1; Watson-Jones D, 2002, J INFECT DIS, V186, P948, DOI 10.1086/342951; Watson-Jones D, 2002, J INFECT DIS, V186, P940, DOI 10.1086/342952; Wheeler HL, 2004, SEX TRANSM INFECT, V80, P411, DOI 10.1136/sti.2003.008821	24	86	98	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 20	2007	334	7585					143	147		10.1136/bmj.39085.518148.BE	http://dx.doi.org/10.1136/bmj.39085.518148.BE			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	130LP	17235095	Green Published			2022-12-28	WOS:000243801400035
J	Fisman, DN				Fisman, David N.			Syphilis resurgent in China	LANCET			English	Editorial Material									Hosp Sick Children, Res Inst, Toronto, ON M5G 1E2, Canada; Ontario Publ Hlth Labs Branch, Toronto, ON M5G 1E2, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Fisman, DN (corresponding author), Hosp Sick Children, Res Inst, Toronto, ON M5G 1E2, Canada.	david.fisman@sickkids.ca						Blumenthal D, 2005, NEW ENGL J MED, V353, P1165, DOI 10.1056/NEJMhpr051133; Chen ZQ, 2007, LANCET, V369, P132, DOI 10.1016/S0140-6736(07)60074-9; CHENG T, 1973, PUBLIC HLTH PEOPLES, P185; Garrett L., 2000, BETRAYAL TRUST COLLA; Hesketh T, 2005, AIDS CARE, V17, P958, DOI 10.1080/09540120500100676; Hualing Fu, 2005, CHINA QUART, V184, P811; KALOGERAKIS G, 2000, MONTREAL GAZETT 1129, pA1; PAYNE L, 2005, EURO SURVEILL, V10, DOI UNSP E051110.1; Pourbohloul B, 2003, SEX TRANSM DIS, V30, P297, DOI 10.1097/00007435-200304000-00005; QUETEL C, 1990, HIST SYPHILIS; Rompalo AM, 2001, CURR OPIN INFECT DIS, V14, P41, DOI 10.1097/00001432-200102000-00008; *US CENTR INT AG, 2006, WORLD FACTB; Weir E, 2002, CAN MED ASSOC J, V167, P1267	13	7	10	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 13	2007	369	9556					84	85		10.1016/S0140-6736(07)60044-0	http://dx.doi.org/10.1016/S0140-6736(07)60044-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	126TK	17223453				2022-12-28	WOS:000243538200006
J	Baulcombe, DC				Baulcombe, David C.			Amplified silencing	SCIENCE			English	Editorial Material							C-ELEGANS; RNAI; REVEALS; SIRNAS; PLANTS		John Innes Ctr, Sainsbury Lab, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Baulcombe, DC (corresponding author), John Innes Ctr, Sainsbury Lab, Norwich NR4 7UH, Norfolk, England.	david.baulcombe@sainsbury-laboratory.ac.uk		Baulcombe, David/0000-0003-0780-6878				Axtell MJ, 2006, CELL, V127, P565, DOI 10.1016/j.cell.2006.09.032; Fahlgren N, 2006, CURR BIOL, V16, P939, DOI 10.1016/j.cub.2006.03.065; Pak J, 2007, SCIENCE, V315, P241, DOI 10.1126/science.1132839; Ruby JG, 2006, CELL, V127, P1193, DOI 10.1016/j.cell.2006.10.040; Sijen T, 2007, SCIENCE, V315, P244, DOI 10.1126/science.1136699; Vagin VV, 2006, SCIENCE, V313, P320, DOI 10.1126/science.1129333; Vastenhouw NL, 2006, NATURE, V442, P882, DOI 10.1038/442882a; Voinnet O, 1998, CELL, V95, P177, DOI 10.1016/S0092-8674(00)81749-3; Yigit E, 2006, CELL, V127, P747, DOI 10.1016/j.cell.2006.09.033	9	83	86	1	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 12	2007	315	5809					199	200		10.1126/science.1138030	http://dx.doi.org/10.1126/science.1138030			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124XZ	17218517				2022-12-28	WOS:000243407400034
J	Torres-Padilla, ME; Parfitt, DE; Kouzarides, T; Zernicka-Goetz, M				Torres-Padilla, Maria-Elena; Parfitt, David-Emlyn; Kouzarides, Tony; Zernicka-Goetz, Magdalena			Histone arginine methylation regulates pluripotency in the early mouse embryo	NATURE			English	Article							PROTEIN METHYLTRANSFERASE; STEM-CELLS; BLASTOMERES; EXPRESSION; CLEAVAGE; RECEPTOR; H3; SPECIFICATION; EMBRYOGENESIS; TRANSCRIPTION	It has been generally accepted that the mammalian embryo starts its development with all cells identical, and only when inside and outside cells form do differences between cells first emerge. However, recent findings show that cells in the mouse embryo can differ in their developmental fate and potency as early as the four-cell stage(1-4). These differences depend on the orientation and order of the cleavage divisions that generated them(2,5). Because epigenetic marks are suggested to be involved in sustaining pluripotency(6,7), we considered that such developmental properties might be achieved through epigenetic mechanisms. Here we show that modification of histone H3, through the methylation of specific arginine residues, is correlated with cell fate and potency. Levels of H3 methylation at specific arginine residues are maximal in four-cell blastomeres that will contribute to the inner cell mass (ICM) and polar trophectoderm and undertake full development when combined together in chimaeras. Arginine methylation of H3 is minimal in cells whose progeny contributes more to the mural trophectoderm and that show compromised development when combined in chimaeras. This suggests that higher levels of H3 arginine methylation predispose blastomeres to contribute to the pluripotent cells of the ICM. We confirm this prediction by overexpressing the H3-specific arginine methyltransferase CARM1 in individual blastomeres and show that this directs their progeny to the ICM and results in a dramatic upregulation of Nanog and Sox2. Thus, our results identify specific histone modifications as the earliest known epigenetic marker contributing to development of ICM and show that manipulation of epigenetic information influences cell fate determination.	Univ Cambridge, Wellcome Trust Canc Res UK Gurdon Inst, Cambridge CB2 1QN, England	University of Cambridge	Zernicka-Goetz, M (corresponding author), Univ Cambridge, Wellcome Trust Canc Res UK Gurdon Inst, Tennis Court Rd, Cambridge CB2 1QN, England.	mzg@mole.bio.cam.ac.uk		Zernicka-Goetz, Magdalena/0000-0002-7004-2471; Kouzarides, Tony/0000-0002-8918-4162	Medical Research Council [G0300723, G0800784] Funding Source: Medline; Wellcome Trust [064421] Funding Source: Medline; MRC [G0300723] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503; Bannister AJ, 2005, NATURE, V436, P1103, DOI 10.1038/nature04048; Bauer UM, 2002, EMBO REP, V3, P39, DOI 10.1093/embo-reports/kvf013; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Cheng DH, 2004, J BIOL CHEM, V279, P23892, DOI 10.1074/jbc.M401853200; Deb K, 2006, SCIENCE, V311, P992, DOI 10.1126/science.1120925; Fujimori T, 2003, DEVELOPMENT, V130, P5113, DOI 10.1242/dev.00725; Gardner RL, 2001, DEVELOPMENT, V128, P839; Gardner RL, 2002, HUM REPROD, V17, P3178, DOI 10.1093/humrep/17.12.3178; Lee YH, 2002, MOL CELL BIOL, V22, P3621, DOI 10.1128/MCB.22.11.3621-3632.2002; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; Ma H, 2001, CURR BIOL, V11, P1981, DOI 10.1016/S0960-9822(01)00600-5; Meshorer E, 2006, DEV CELL, V10, P105, DOI 10.1016/j.devcel.2005.10.017; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Morgan HD, 2005, HUM MOL GENET, V14, pR47, DOI 10.1093/hmg/ddi114; Piotrowska K, 2001, DEVELOPMENT, V128, P3739; Piotrowska-Nitsche K, 2005, DEVELOPMENT, V132, P479, DOI 10.1242/dev.01602; Piotrowska-Nitsche K, 2005, MECH DEVELOP, V122, P487, DOI 10.1016/j.mod.2004.11.014; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; Schurter BT, 2001, BIOCHEMISTRY-US, V40, P5747, DOI 10.1021/bi002631b; Strahl BD, 2001, CURR BIOL, V11, P996, DOI 10.1016/S0960-9822(01)00294-9; Tassy O, 2006, CURR BIOL, V16, P345, DOI 10.1016/j.cub.2005.12.044; Torres-Padilla ME, 2006, J CELL BIOL, V174, P329, DOI 10.1083/jcb.200603146; Wang HB, 2001, SCIENCE, V293, P853, DOI 10.1126/science.1060781	25	430	455	1	49	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 11	2007	445	7124					214	218		10.1038/nature05458	http://dx.doi.org/10.1038/nature05458			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124QF	17215844	Green Accepted			2022-12-28	WOS:000243384300053
J	Goldsmith, BR; Coroneus, JG; Khalap, VR; Kane, AA; Weiss, GA; Collins, PG				Goldsmith, Brett R.; Coroneus, John G.; Khalap, Vaikunth R.; Kane, Alexander A.; Weiss, Gregory A.; Collins, Philip G.			Conductance-controlled point functionalization of single-walled carbon nanotubes	SCIENCE			English	Article							CHEMICAL FUNCTIONALIZATION; ELECTRONIC-STRUCTURE; CHEMISTRY; FABRICATION; TRANSISTORS; DEFECTS; TRANSPORT; OXIDATION; GRAPHITE; BUNDLES	We used covalent attachments to single-walled carbon nanotubes (SWNTs) to fabricate single-molecule electronic devices. The technique does not rely on submicrometer lithography or precision mechanical manipulation, but instead uses circuit conductance to monitor and control covalent attachment to an electrically connected SWNT. Discrete changes in the circuit conductance revealed chemical processes happening in real time and allowed the SWNT sidewalls to be deterministically broken, reformed, and conjugated to target species. By controlling the chemistry through electronically controlled electrochemical potentials, we were able to achieve single chemical attachments. We routinely functionalized pristine, defect-free SWNTs at one, two, or more sites and demonstrated three-terminal devices in which a single attachment controls the electronic response.	Univ Calif Irvine, Dept Phys & Astron, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Chem, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine	Collins, PG (corresponding author), Univ Calif Irvine, Dept Phys & Astron, Irvine, CA 92697 USA.	collinsp@uci.edu	Weiss, Gregory/AEN-4604-2022	Kane, Alexander/0000-0002-5901-5296	NIAID NIH HHS [R43 AI58365-01] Funding Source: Medline; NIGMS NIH HHS [R01 GM078528-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM078528] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1988, CARBON ELECTROCHEMIC, DOI DOI 10.1016/j.jpowsour.2007.12.091; Bachtold A, 2000, PHYS REV LETT, V84, P6082, DOI 10.1103/PhysRevLett.84.6082; Banerjee S, 2005, ADV MATER, V17, P17, DOI 10.1002/adma.200401340; BESENHARD JO, 1981, SYNTHETIC MET, V3, P187, DOI 10.1016/0379-6779(81)90007-2; Bockrath M, 2001, SCIENCE, V291, P283, DOI 10.1126/science.291.5502.283; Burghard M, 2005, SURF SCI REP, V58, P1, DOI 10.1016/j.surfrep.2005.07.001; Chiu PW, 2002, APPL PHYS LETT, V80, P3811, DOI 10.1063/1.1480487; Diehl MR, 2003, CHEMPHYSCHEM, V4, P1335, DOI 10.1002/cphc.200300871; Eom JH, 2006, PHYSICA B, V376, P7, DOI 10.1016/j.physb.2005.12.005; Fan YW, 2005, NAT MATER, V4, P906, DOI 10.1038/nmat1516; Freitag M, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.216801; Graupner R, 2003, PHYS CHEM CHEM PHYS, V5, P5472, DOI 10.1039/b311016h; Guo XF, 2006, SCIENCE, V311, P356, DOI 10.1126/science.1120986; Heller I, 2005, NANO LETT, V5, P137, DOI 10.1021/nl048200m; Ho W, 2002, J CHEM PHYS, V117, P11033, DOI 10.1063/1.1521153; Kruger M, 2001, APPL PHYS LETT, V78, P1291, DOI 10.1063/1.1350427; Lee YS, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.116801; Lu X, 2005, CHEM REV, V105, P3643, DOI 10.1021/cr030093d; Mannik J, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.016601; Maruccio G, 2004, ELECTROANAL, V16, P1853, DOI 10.1002/elan.200403073; METROT A, 1981, SYNTHETIC MET, V3, P201, DOI 10.1016/0379-6779(81)90009-6; Pan H, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.245425; Park H, 1999, APPL PHYS LETT, V75, P301, DOI 10.1063/1.124354; Park H, 2005, NANOTECHNOLOGY, V16, P635, DOI 10.1088/0957-4484/16/6/003; Rosenblatt S, 2002, NANO LETT, V2, P869, DOI 10.1021/nl025639a; Son YW, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.216602; Star A, 2003, NANO LETT, V3, P459, DOI 10.1021/nl0340172; STAROS JV, 1986, ANAL BIOCHEM, V156, P220, DOI 10.1016/0003-2697(86)90176-4; Strachan DR, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1857095; Sumanasekera GU, 1999, J PHYS CHEM B, V103, P4292, DOI 10.1021/jp984362t; Tans SJ, 2000, NATURE, V404, P834, DOI 10.1038/35009026; Tao NJ, 2005, J MATER CHEM, V15, P3260, DOI 10.1039/b503307a; Tseng AA, 2005, J VAC SCI TECHNOL B, V23, P877, DOI 10.1116/1.1926293; Wong SS, 1998, NATURE, V394, P52, DOI 10.1038/27873; Zhao JJ, 2005, CHEMPHYSCHEM, V6, P598, DOI 10.1002/cphc.200400593; Zhou YX, 2003, NANO LETT, V3, P1371, DOI 10.1021/nl034512y	37	202	216	1	80	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 5	2007	315	5808					77	81		10.1126/science.1135303	http://dx.doi.org/10.1126/science.1135303			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	122WU	17204645	Green Published			2022-12-28	WOS:000243259100038
J	Kondo, T; Tobe, S				Kondo, Takeshi; Tobe, Satoshi			Papillary fibroelastoma of the pulmonary artery	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Kobe Univ, Grad Sch Med, Kobe, Hyogo 6500017, Japan	Kobe University	Kondo, T (corresponding author), Kobe Univ, Grad Sch Med, Kobe, Hyogo 6500017, Japan.	kondo@med.kobe-u.ac.jp							0	2	2	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 4	2007	356	1					E1	E1		10.1056/NEJMicm053621	http://dx.doi.org/10.1056/NEJMicm053621			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	122EX	17202447				2022-12-28	WOS:000243209600011
J	Steinbrook, R				Steinbrook, Robert			Medicare and erythropoietic	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material												rsteinbrook@attglobal.net						*FDA PUBL HLTH ADV, 2006, EP ALF MARK PROCR EP; Singh AK, 2006, NEW ENGL J MED, V355, P2085, DOI 10.1056/NEJMoa065485; Steinbrook R, 2006, LANCET, V368, P2191, DOI 10.1016/S0140-6736(06)69707-9; US Renal Data System, 2006, USRDS 2006 ANN DAT R	4	35	35	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 4	2007	356	1					4	6		10.1056/NEJMp068296	http://dx.doi.org/10.1056/NEJMp068296			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	122EX	17202449				2022-12-28	WOS:000243209600002
J	Brent, DA; Mann, JJ				Brent, David A.; Mann, J. John			Familial pathways to suicidal behavior - Understanding and preventing suicide among adolescents	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Pittsburgh, Sch Med, Serv Teen Risk Ctr, Pittsburgh, PA 15261 USA; Columbia Univ, Coll Phys & Surg, New York, NY USA; New York State Psychiat Inst & Hosp, Dept Neurosci, New York, NY 10032 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Columbia University; New York State Psychiatry Institute	Brent, DA (corresponding author), Univ Pittsburgh, Sch Med, Serv Teen Risk Ctr, Pittsburgh, PA 15261 USA.							Baldessarini RJ, 2006, BIPOLAR DISORD, V8, P625, DOI 10.1111/j.1399-5618.2006.00344.x; Brent DA, 2005, AM J MED GENET C, V133C, P13, DOI 10.1002/ajmg.c.30042; Bridge JA, 2006, J CHILD PSYCHOL PSYC, V47, P372, DOI 10.1111/j.1469-7610.2006.01615.x; Comtois KA, 2006, J CLIN PSYCHOL, V62, P161, DOI 10.1002/jclp.20220; Mann JJ, 2003, NAT REV NEUROSCI, V4, P819, DOI 10.1038/nrn1220	5	90	91	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 28	2006	355	26					2719	2721		10.1056/NEJMp068195	http://dx.doi.org/10.1056/NEJMp068195			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	120UA	17192535				2022-12-28	WOS:000243110500002
J	Geyer, CE; Forster, J; Lindquist, D; Chan, S; Romieu, CG; Pienkowski, T; Jagiello-Gruszfeld, A; Crown, J; Chan, A; Kaufman, B; Skarlos, D; Campone, M; Davidson, N; Berger, M; Oliva, C; Rubin, SD; Stein, S; Cameron, D				Geyer, Charles E.; Forster, John; Lindquist, Deborah; Chan, Stephen; Romieu, C. Gilles; Pienkowski, Tadeusz; Jagiello-Gruszfeld, Agnieszka; Crown, John; Chan, Arlene; Kaufman, Bella; Skarlos, Dimosthenis; Campone, Mario; Davidson, Neville; Berger, Mark; Oliva, Cristina; Rubin, Stephen D.; Stein, Steven; Cameron, David			Lapatinib plus capecitabine for HER2-positive advanced breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ADJUVANT CHEMOTHERAPY; MONOCLONAL-ANTIBODY; KINASE INHIBITOR; TRASTUZUMAB; GROWTH; SAFETY; METASTASES; SURVIVAL; EFFICACY; GW572016	BACKGROUND: Lapatinib, a tyrosine kinase inhibitor of human epidermal growth factor receptor type 2 (HER2, also referred to as HER2/neu) and epidermal growth factor receptor (EGFR), is active in combination with capecitabine in women with HER2-positive metastatic breast cancer that has progressed after trastuzumab-based therapy. In this trial, we compared lapatinib plus capecitabine with capecitabine alone in such patients. METHODS: Women with HER2-positive, locally advanced or metastatic breast cancer that had progressed after treatment with regimens that included an anthracycline, a taxane, and trastuzumab were randomly assigned to receive either combination therapy (lapatinib at a dose of 1250 mg per day continuously plus capecitabine at a dose of 2000 mg per square meter of body-surface area on days 1 through 14 of a 21-day cycle) or monotherapy (capecitabine alone at a dose of 2500 mg per square meter on days 1 through 14 of a 21-day cycle). The primary end point was time to progression, based on an evaluation by independent reviewers under blinded conditions. RESULTS: The interim analysis of time to progression met specified criteria for early reporting on the basis of superiority in the combination-therapy group. The hazard ratio for the independently assessed time to progression was 0.49 (95% confidence interval, 0.34 to 0.71; P<0.001), with 49 events in the combination-therapy group and 72 events in the monotherapy group. The median time to progression was 8.4 months in the combination-therapy group as compared with 4.4 months in the monotherapy group. This improvement was achieved without an increase in serious toxic effects or symptomatic cardiac events. CONCLUSIONS: Lapatinib plus capecitabine is superior to capecitabine alone in women with HER2-positive advanced breast cancer that has progressed after treatment with regimens that included an anthracycline, a taxane, and trastuzumab.	Allegheny Gen Hosp, Allegheny Canc Ctr, Pittsburgh, PA 15212 USA; GlaxoSmithKline Inc, Greenford, Middx, England; US Oncol, Sedona, AZ USA; Univ Nottingham Hosp, Nottingham NG7 2UH, England; Ctr Reg Lutte Contre Canc Val dAurelle, Montpellier, France; Ctr Onkol Klin Nowotworow Piersi & Chirurg, Warsaw, Poland; Zaklad Opieki Zdrowotnej MSWiA, Olsztyn, Poland; Ireland Cooperat Oncol Res Grp, Dublin, Ireland; Mt Med Ctr, Perth, WA, Australia; Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel; Errikos Dynan Hosp, Athens, Greece; Ctr Rene Gauducheau, St Herblain, France; Broomfield Hosp, Chelmsford, Essex, England; GlaxoSmithKline Inc, Collegeville, PA USA; GlaxoSmithKline Inc, Greenford, Middx, England; Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland	Allegheny General Hospital; GlaxoSmithKline; US Oncology Network; University of Nottingham; All-Ireland Cooperative Oncology Research Group; Chaim Sheba Medical Center; Henry Dunant Hospital; UNICANCER; Institut de Cancerologie de l'Ouest (ICO); Mid Essex Hospital Services NHS Trust; Broomfield Hospital; GlaxoSmithKline; GlaxoSmithKline; University of Edinburgh	Geyer, CE (corresponding author), Allegheny Gen Hosp, Allegheny Canc Ctr, 320 E North Ave,5th Floor, Pittsburgh, PA 15212 USA.	cgeyer@wpahs.org	Geyer, Charles/AGY-0119-2022; Cameron, David A/C-7781-2013; Crown, John/AAL-3367-2020; Jagiello-Gruszfeld, Agnieszka i/S-6924-2018	Geyer, Charles/0000-0002-2379-5702; Cameron, David A/0000-0002-2717-7979; Jagiello-Gruszfeld, Agnieszka i/0000-0002-2698-5499; Pienkowski, Tadeusz/0000-0002-0110-5950; Crown, John/0000-0002-3125-7613; Oliva, Cristina/0000-0002-6772-8069; Chan, Stephen/0000-0001-8865-6618				Clayton AJ, 2004, BRIT J CANCER, V91, P639, DOI 10.1038/sj.bjc.6601970; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; *FOOD DRUG ADM, 2004, GUID IND DEV MED I 3; Konecny GE, 2006, CANCER RES, V66, P1630, DOI 10.1158/0008-5472.CAN-05-1182; Lin NU, 2004, J CLIN ONCOL, V22, P3608, DOI 10.1200/JCO.2004.01.175; Montemurro F, 2006, ONCOLOGIST, V11, P318, DOI 10.1634/theoncologist.11-4-318; PAMPALLONA S, 1994, J STAT PLAN INFER, V42, P19, DOI 10.1016/0378-3758(94)90187-2; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; Rusnak DW, 2001, MOL CANCER THER, V1, P85; SCHWARTZ G, 2004, P AM SOC CLIN O S14S, V23, pS212; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Spector NL, 2005, J CLIN ONCOL, V23, P2502, DOI 10.1200/JCO.2005.12.157; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Tripathy D, 2004, J CLIN ONCOL, V22, P1063, DOI 10.1200/JCO.2004.06.557; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719; Wood ER, 2004, CANCER RES, V64, P6652, DOI 10.1158/0008-5472.CAN-04-1168	19	2475	2571	6	188	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 28	2006	355	26					2733	2743		10.1056/NEJMoa064320	http://dx.doi.org/10.1056/NEJMoa064320			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	120UA	17192538				2022-12-28	WOS:000243110500005
J	Murray, CJL; Lopez, AD; Chin, B; Feehan, D; Hill, KH				Murray, Christopher J. L.; Lopez, Alan D.; Chin, Brian; Feehan, Dennis; Hill, Kenneth H.			Estimation of potential global pandemic influenza mortality on the basis of vital registry data from the 1918-20 pandemic: a quantitative analysis	LANCET			English	Article							UNITED-STATES; IMPACT; EPIDEMICS; VIRUSES; SEX	Background The threat of an avian influenza pandemic is causing widespread public concern and health policy response, especially in high-income countries. Our aim was to use high-quality vital registration data gathered during the 1918-20 pandemic to estimate global mortality should such a pandemic occur today. Methods We identified all countries with high-quality vital registration data for the 1918-20 pandemic and used these data to calculate excess mortality. We developed ordinary least squares regression models that related excess mortality to per-head income and absolute latitude and used these models to estimate mortality had there been an influenza pandemic in 2004. Findings Excess mortality data show that, even in 1918-20, population mortality varied over 30-fold across countries. Per-head income explained a large fraction of this variation in mortality. Extrapolation of 1918-20 mortality rates to the worldwide population of 2004 indicates that an estimated 62 million people (10th-90th percentile range 51 million-81 million) would be killed by a similar influenza pandemic; 96% (95% CI 95-98) of these deaths would occur in the developing world. if this mortality were concentrated in a single year, it would increase global mortality by 114%. Interpretation This analysis of the empirical record of the 1918-20 pandemic provides a plausible upper bound on pandemic mortality. Most deaths will occur in poor countries-ie, in societies whose scarce health resources are already stretched by existing health priorities.	Harvard Univ, Harvard Initiat Global Hlth, Cambridge, MA 02138 USA; Univ Queensland, Sch Populat Hlth, Brisbane, Qld, Australia; Johns Hopkins Bloomberg Sch Publ Hlth, Dept Populat & Family Hlth Sci, Baltimore, MD USA	Harvard University; University of Queensland; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Murray, CJL (corresponding author), Harvard Univ, Harvard Initiat Global Hlth, 104 Mt Auburn St, Cambridge, MA 02138 USA.	christopher-murray@harvard.edu	Lopez, Alan/AAA-2734-2022; Lopez, Alan D/F-1487-2010	Lopez, Alan D/0000-0001-5818-6512; Chin, Brian/0000-0002-1789-0359	NIA NIH HHS [P01-AG17625] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG017625] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADLER J, 2005, NEWSWEEK, V146, P38; *AUSTR GOV DEP HLT, AUSTR HLTH EM INFL P; *BUR CENS DEP COMM, 1918, MORT STAT 1916 17 AN; *BUR CENS DEP COMM, 1917, MORT STAT 1915 16 AN; *BUR CENS DEP COMM, 1921, MORT STAT 1919 20 AN; *BUR CENS DEP COMM, 1925, MORT STAT 1922 23 AN; *BUR CENS DEP COMM, 1924, MORT STAT 1921 22 AN; *BUR CENS DEP COMM, 1922, MORT STAT 1920 21 AN; *BUR CENS DEP COMM, 1919, MORT STAT 1917 18 AN; *BUR CENS DEP COMM, 1920, MORT STAT 1918 19 AN; BURNET FM, 1979, INTERVIROLOGY, V11, P201, DOI 10.1159/000149035; *CDCP NAT VACC PRO, FLUAID 2 0 EST STAT; COLLINS S, 1957, PUBLIC HLTH MONOGRAP, V48; Crosby A., 1989, AM FORGOTTEN PANDEMI; *DEP COMM BUR CENS, 1926, MORT STAT 1923 24 AN; Easterly William R., 2001, GLOBAL DEV NETWORK G; Ferguson NM, 2005, NATURE, V437, P209, DOI 10.1038/nature04017; Gani R, 2005, EMERG INFECT DIS, V11, P1355; GILL CA, 1928, GENESIS EPIDEMICS, P258; Glezen WP, 1996, EPIDEMIOL REV, V18, P64, DOI 10.1093/oxfordjournals.epirev.a017917; Hayden FG, 2001, PHILOS T R SOC B, V356, P1877, DOI 10.1098/rstb.2001.1007; Horimoto T, 2005, NAT REV MICROBIOL, V3, P591, DOI 10.1038/nrmicro1208; Hutton, 1933, CENSUS INDIA 1931 1, V1; Johnson NPAS, 2002, B HIST MED, V76, P105, DOI 10.1353/bhm.2002.0022; Knobler SL., 2005, THREAT PANDEMIC INFL; Kyncl J, 2005, EUR J EPIDEMIOL, V20, P365, DOI 10.1007/s10654-005-1067-y; Longini IM, 2005, SCIENCE, V309, P1083, DOI 10.1126/science.1115717; MADDISON A, 2001, WORLD EC HIST STAT; Marten, 1924, CENSUS INDIA 1921 1, V1; Mathers CD, 2005, B WORLD HEALTH ORGAN, V83, P171; MCQUEEN H, 1975, MED J AUSTRALIA, V1, P565, DOI 10.5694/j.1326-5377.1975.tb111588.x; Meltzer MI, 1999, EMERG INFECT DIS, V5, P659, DOI 10.3201/eid0505.990507; Mills ID, 1989, INDIAS HIST DEMOGRAP, P222; MITCHELL BR, 2003, INT HIST STAT SERIES; *MOSNEWS COM, 2004, RUSS EXP SAYS FLU EP; Mutsch M, 2005, CLIN INFECT DIS, V40, P1282, DOI 10.1086/429243; Nguyen-Van-Tam JS, 2003, VACCINE, V21, P1762, DOI 10.1016/S0264-410X(03)00069-0; Noymer A, 2000, POPUL DEV REV, V26, P565, DOI 10.1111/j.1728-4457.2000.00565.x; Olson DR, 2005, P NATL ACAD SCI USA, V102, P11059, DOI 10.1073/pnas.0408290102; Osterholm MT, 2005, NEW ENGL J MED, V352, P1839, DOI 10.1056/NEJMp058068; OSTERHOLM MT, 2005, INCREASING HLTH RISK; PATTERSON KD, 1983, SOC SCI MED, V17, P1299, DOI 10.1016/0277-9536(83)90022-9; PATTERSON KD, 1991, B HIST MED, V65, P4; PATTERSON KD, 1983, J AFR HIST, V24, P485, DOI 10.1017/S0021853700028012; Pool D I, 1973, Bull Hist Med, V47, P273; Preston SH, 1972, CAUSES DEATH LIFE TA; Reid AH, 1999, P NATL ACAD SCI USA, V96, P1651, DOI 10.1073/pnas.96.4.1651; Sattenspiel L, 2003, B MATH BIOL, V65, P1, DOI 10.1006/bulm.2002.0317; SCHOENBAUM SC, 1976, AM J EPIDEMIOL, V103, P166, DOI 10.1093/oxfordjournals.aje.a112214; SERFLING RE, 1967, AM J EPIDEMIOL, V86, P433, DOI 10.1093/oxfordjournals.aje.a120753; Smith RL, 2003, AM J EPIDEMIOL, V157, P1066, DOI 10.1093/aje/kwg088; Stephenson I, 2004, LANCET INFECT DIS, V4, P499, DOI 10.1016/S1473-3099(04)01105-3; SUMMERS R, 1985, PENN WORLD TABLE MAR; TOMKINS SM, 1992, J PAC HIST, V27, P181, DOI 10.1080/00223349208572706; *U CAL BERK M PLAN, HUM MORT DAT; *US DEP COMM BUR C, 1917, MORT STAT 1915 16 AN; Viboud C, 2005, J INFECT DIS, V192, P233, DOI 10.1086/431150; *WHIT HOUS, 2006, STAT US PLEDG 334 MI; WHO, 2005, INT STAT CLASS DIS R, V3; *WHO, 2005, WHOCDSCSRGIP20058; Woolhouse MEJ, 2002, NAT GENET, V32, P569, DOI 10.1038/ng1202-569; *WORLD BANK, DAT STAT FREQ ASK QU; *WORLD BANK, 2006, AV HUM INFL MULT FIN; World Health Organization, CUM NUMB CONF HUM CA; World Health Organization (WHO), 2006, WORLD HLTH REP 2006; Yen HL, 2005, ANTIMICROB AGENTS CH, V49, P4075, DOI 10.1128/AAC.49.10.4075-4084.2005; 2005, ABC NEWS        0930; [No title captured]	68	408	434	0	28	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 23	2006	368	9554					2211	2218		10.1016/S0140-6736(06)69895-4	http://dx.doi.org/10.1016/S0140-6736(06)69895-4			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	120HY	17189032				2022-12-28	WOS:000243076800028
J	O'Donnell, M				O'Donnell, Michael			The night Bernard Shaw taught us a lesson	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												mod@doctors.org.uk						GUINNESS A, 2000, COMMONPLACE BOOK, P29; ODONNELL M, 2005, MADNESS CREATIVITY L, P45; SHAW B, 1946, DOCTORS DILEMMA, P104; Skelton JR, 2005, BRIT J GEN PRACT, V55, P40	4	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 23	2006	333	7582					1338	1340		10.1136/bmj.39062.728900.55	http://dx.doi.org/10.1136/bmj.39062.728900.55			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121MC	17185735	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000243160700032
J	Witcombe, B; Meyer, D				Witcombe, Brian; Meyer, Dan			Sword swallowing and its side effects	BRITISH MEDICAL JOURNAL			English	Editorial Material							ESOPHAGEAL PERFORATIONS; MANAGEMENT		Gloucestershire Royal NHS Fdn Trust, Dept Radiol, Gloucester GL1 3NN, England; Sword Swallowers Assoc Int, Antioch, TN 37013 USA	Gloucestershire Hospitals NHS Foundation Trust	Witcombe, B (corresponding author), Gloucestershire Royal NHS Fdn Trust, Dept Radiol, Gloucester GL1 3NN, England.	brian.witcombe@glos.nhs.uk						Altorjay A, 1997, ANN SURG, V225, P415, DOI 10.1097/00000658-199704000-00011; DEVGAN BK, 1978, EAR NOSE THROAT J, V57, P445; HUIZINGA E, 1969, ANN OTO RHINOL LARYN, V78, P32, DOI 10.1177/000348946907800103; Kubba Haytham, 2003, Ear Nose Throat J, V82, P33; Lawrence DR, 1998, ANN ROY COLL SURG, V80, P115; Martin M, 2005, J TRAUMA, V59, P233, DOI 10.1097/01.TA.0000171446.09817.88; Scheinin SA, 2001, TEX HEART I J, V28, P65; Younes Z, 1999, J CLIN GASTROENTEROL, V29, P306, DOI 10.1097/00004836-199912000-00003	8	14	14	1	10	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 23	2006	333	7582					1285	1287		10.1136/bmj.39027.676690.55	http://dx.doi.org/10.1136/bmj.39027.676690.55			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121MC	17185708	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000243160700006
J	Lincoln, GA; Clarke, IJ; Hut, RA; Hazlerigg, DG				Lincoln, Gerald A.; Clarke, Iain J.; Hut, Roelof A.; Hazlerigg, David G.			Characterizing a mammalian circannual pacemaker	SCIENCE			English	Article							BEETLE ANTHRENUS-VERBASCI; PITUITARY-GLAND; PROLACTIN SECRETION; REPRODUCTIVE RHYTHM; MELATONIN SIGNAL; SYRIAN-HAMSTER; SEASONAL TIMER; CYCLES; PHOTOPERIOD; SHEEP	Many species express endogenous cycles in physiology and behavior that allow anticipation of the seasons. The anatomical and cellular bases of these circannual rhythms have not been defined. Here, we provide strong evidence using an in vivo Soay sheep model that the circannual regulation of prolactin secretion, and its associated biology, derive from a pituitary-based timing mechanism. Circannual rhythm generation is seen as the product of the interaction between melatonin-regulated timer cells and adjacent prolactin- secreting cells, which together function as an intrapituitary "pacemaker-slave" timer system. These new insights open the way for a molecular analysis of long-term timing mechanisms.	Univ Edinburgh, Ctr Reprod Biol, Edinburgh EH3 9EW, Midlothian, Scotland; Queens Med Res Inst, Edinburgh, Midlothian, Scotland; Univ Groningen, Dept Chronobiol, Haren, Netherlands; Monash Univ, Dept Physiol, Melbourne, Vic 3168, Australia; Univ Aberdeen, Sch Biol Sci, Aberdeen, Scotland	University of Edinburgh; University of Edinburgh; University of Groningen; Monash University; University of Aberdeen	Lincoln, GA (corresponding author), Univ Edinburgh, Ctr Reprod Biol, Edinburgh EH3 9EW, Midlothian, Scotland.	g.lincoln@hrsu.mrc.ac.uk	Hut, Roelof A./I-3483-2012	Clarke, Iain/0000-0002-6613-2757	Medical Research Council [G0600678] Funding Source: Medline; MRC [G0600678] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Bockers TM, 1997, ENDOCRINOLOGY, V138, P4101, DOI 10.1210/en.138.10.4101; Carmichael M S, 1986, J Biol Rhythms, V1, P277, DOI 10.1177/074873048600100402; GWINNER E, 2001, FRONTIERS LIFE, V4, P193; Gwinner E., 1986, CIRCANNUAL RHYTHMS E; Hazlerigg DG, 2004, CURR BIOL, V14, P334, DOI 10.1016/j.cub.2004.01.057; Jilg A, 2005, EUR J NEUROSCI, V22, P2845, DOI 10.1111/j.1460-9568.2005.04485.x; Johnston JD, 2003, FASEB J, V17, P810, DOI 10.1096/fj.02-0837com; Johnston JD, 2003, GEN COMP ENDOCR, V134, P182, DOI 10.1016/S0016-6480(03)00248-X; KARSCH FJ, 1989, BIOL REPROD, V41, P1034, DOI 10.1095/biolreprod41.6.1034; Kondo N, 2006, CELL, V125, P161, DOI 10.1016/j.cell.2006.03.017; LEDERC GM, 2005, ENDOCRINOLOGY, V146, P2782; Lincoln G, 1999, ADV EXP MED BIOL, V460, P137; Lincoln GA, 2005, ENDOCRINOLOGY, V146, P3782, DOI 10.1210/en.2005-0132; Lincoln GA, 2003, BIOL REPROD, V69, P1416, DOI 10.1095/biolreprod.103.017673; Lincoln GA, 1997, BIOL REPROD, V57, P460, DOI 10.1095/biolreprod57.2.460; LINCOLN GA, 1989, J REPROD FERTIL, V85, P687, DOI 10.1530/jrf.0.0850687; LINCOLN GA, 1994, J NEUROENDOCRINOL, V6, P251, DOI 10.1111/j.1365-2826.1994.tb00580.x; Lincoln GA, 1998, COMP BIOCHEM PHYS C, V119, P283, DOI 10.1016/S0742-8413(98)00017-6; Malpaux B, 2001, J BIOL RHYTHM, V16, P336, DOI 10.1177/074873001129002051; MARTINET L, 1992, J REPROD FERTIL, V95, P325, DOI 10.1530/jrf.0.0950325; McFerran DW, 2001, ENDOCRINOLOGY, V142, P3255, DOI 10.1210/en.142.7.3255; Miyazaki Y, 2005, J COMP PHYSIOL A, V191, P883, DOI 10.1007/s00359-005-0012-6; Nisimura T, 2002, BIOL RHYTHM RES, V33, P255, DOI 10.1076/brhm.33.3.255.8264; PENGELLY ET, 1974, CIRCANNUAL CLOCKS, P89; Stirland JA, 2001, J NEUROENDOCRINOL, V13, P147, DOI 10.1046/j.1365-2826.2001.00611.x; THRUN LA, 1995, J BIOL RHYTHM, V10, P42, DOI 10.1177/074873049501000104; Williams LM, 1997, J NEUROENDOCRINOL, V9, P639, DOI 10.1046/j.1365-2826.1997.00625.x; WOODFILL CJI, 1994, BIOL REPROD, V50, P965, DOI 10.1095/biolreprod50.4.965; Zucker Irving, 2001, Handbook of Behavioral Neurobiology, V12, P509	29	171	171	2	81	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 22	2006	314	5807					1941	1944		10.1126/science.1132009	http://dx.doi.org/10.1126/science.1132009			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	119EY	17185605				2022-12-28	WOS:000242996800054
J	Howerton, A; Byng, R; Campbell, J; Hess, D; Owens, C; Aitken, P				Howerton, Amanda; Byng, Richard; Campbell, John; Hess, David; Owens, Christabel; Aitken, Peter			Understanding help seeking behaviour among male offenders: qualitative interview study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEALTH-CARE; CONSULTATIONS; EXPERIENCES; PATHWAYS; SUICIDE; ILLNESS; PATIENT; DOCTOR; COHORT; TRUST	Objective To explore the factors that influence help seeking for mental distress by offenders. Design Qualitative study based on in-depth interviews with prisoners before and after release. Setting One category B local prison in southern England. Participants 35 male offenders aged 18-52, a quarter of whom had been flagged as being at risk of self harm. Results Most respondents reported that they would not seek help from a general practitioner or other healthcare professional if experiencing mental distress. When followed up after release, none had sought medical help despite the fact that many had considerable emotional problems. Many participants were hesitant to seek help because they feared being given a formal diagnosis of mental illness. Some of these men feared the stigma that such a diagnosis would bring, whereas others feared that a diagnosis would mean having to confront the problem. Lack of trust emerged as the most prominent theme in prisoners' discourse about not seeking help from health professionals. Distrust towards the "system" and authority figures in general was linked to adverse childhood experiences. Distrust directed specifically at healthcare professionals was often expressed as specific negative beliefs: many perceived that health professionals (most often doctors) "just don't care," "just want to medicate," and treat patients "superficially." Those men who would consider going to a general practitioner reported positive previous experiences of being respected and listened to. Conclusions Distrust is a major barrier to accessing health care among offenders. Like most people, the respondents in this study wanted to feel listened to, acknowledged, and treated as individuals by health professionals. By ensuring that a positive precedent is set, particularly for sceptical groups such as ex-prisoners, general practitioners and prison doctors may be able to encourage future help seeking. Information specifically designed for prisoners is needed to help to de-stigmatise mental illness, and preparation for release should include provision of information about access to health and social services. Awareness training for health professionals is recommended: trust might be fostered in this population by seemingly trivial gestures that indicate respect.	Peninsula Med Sch, Primary Care Res Grp, Exeter EX1 2LU, Devon, England; Peninsula Med Sch, Mental Hlth Res Grp, Exeter, Devon, England	University of Exeter; University of Exeter	Campbell, J (corresponding author), Peninsula Med Sch, Primary Care Res Grp, Exeter EX1 2LU, Devon, England.	john.campbell@pms.ac.uk	Guha, Sunni/E-8453-2011; Campbell, John/A-5792-2011; Lorente, Rosa/AAL-5850-2021	Campbell, John/0000-0002-6752-3493; Byng, Richard/0000-0001-7411-9467				Akhurst M., 1994, DYING HELP OFFENDERS; Armstrong D, 1983, POLITICAL ANATOMY BO; BENDAVID J, 1958, HUM RELAT, V11, P255, DOI 10.1177/001872675801100305; Biddle L, 2004, BRIT J GEN PRACT, V54, P248; Britten N, 2000, BMJ-BRIT MED J, V320, P484, DOI 10.1136/bmj.320.7233.484; DEANE FP, 1999, INT J ADV COUNS, V21, P55, DOI DOI 10.1023/A:1005346703753; Donovan JL, 2000, BRIT MED J, V320, P541, DOI 10.1136/bmj.320.7234.541; Freidson E., 1988, PROFESSION MED STUDY; Goffman E., 1971, RELATIONS PUBLIC MIC; GOVIER T, 1994, DIALOGUE-CAN PHILOS, V33, P237, DOI 10.1017/S0012217300010519; *HER MAJ CHIEF INS, 2001, PRIS GATE SUMM HM IN; LLOYD M, 1990, HOME OFFICE RES STUD, V115; Mays N, 2000, BMJ-BRIT MED J, V320, P50, DOI 10.1136/bmj.320.7226.50; McCabe R, 2002, BRIT MED J, V325, P1148, DOI 10.1136/bmj.325.7373.1148; MECHANIC D, 1962, J CHRON DIS, V15, P189, DOI 10.1016/0021-9681(62)90068-1; Morse JM, 1997, QUAL HEALTH RES, V7, P445, DOI 10.1177/104973239700700401; Oliver MI, 2005, BRIT J PSYCHIAT, V186, P297, DOI 10.1192/bjp.186.4.297; Pill R, 2001, BRIT MED BULL, V57, P207, DOI 10.1093/bmb/57.1.207; Pratt D, 2006, LANCET, V368, P119, DOI 10.1016/S0140-6736(06)69002-8; Prior L, 2003, SOC SCI MED, V56, P2191, DOI 10.1016/S0277-9536(02)00235-6; Pritchard C, 1997, J ROY SOC HEALTH, V117, P180, DOI 10.1177/146642409711700310; Rowe R, 2006, EUR J PUBLIC HEALTH, V16, P4, DOI 10.1093/eurpub/ckl004; Sattar Ghazala, 2003, Crisis, V24, P17, DOI 10.1027//0227-5910.24.1.17; Stewart M, 2004, ANN FAM MED, V2, P388, DOI 10.1370/afm.236; Strike C, 2006, CRISIS, V27, P31, DOI 10.1027/0227-5910.27.1.31; VIGGIANI N, 2005, BRIT MED J, V330, P918; Ziebland S, 2006, MED EDUC, V40, P405, DOI 10.1111/j.1365-2929.2006.02467.x; ZOLA IK, 1973, SOC SCI MED, V7, P677, DOI 10.1016/0037-7856(73)90002-4	28	69	69	0	27	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 10	2007	334	7588					303	306B		10.1136/bmj.39059.594444.AE	http://dx.doi.org/10.1136/bmj.39059.594444.AE			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	142MN	17223630	Green Published, Bronze			2022-12-28	WOS:000244654100034
J	Elliman, D; Bedford, H				Elliman, David; Bedford, Helen			Achieving the goal for global measles mortality	LANCET			English	Editorial Material									Great Ormond St Hosp Sick Children, Childrens Populat Hlth Unit, London WC1N 3JH, England; Inst Child Hlth, Ctr Paediat Epidemiol & Biostat, London, England	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London	Elliman, D (corresponding author), Great Ormond St Hosp Sick Children, Childrens Populat Hlth Unit, Great Ormond St, London WC1N 3JH, England.	EllimD@gosh.nhs.uk	Elliman, David/AAK-4595-2020					de Quadros CA, 2004, B WORLD HEALTH ORGAN, V82, P134; Meissner HC, 2004, PEDIATRICS, V114, P1065, DOI 10.1542/peds.2004-0440; UN, 2006, MILL DEV GOALS REP 2; *WHO, WILD POL 2000 2006; *WHO, 2005, IMM VACC BIOL VACC A; *WHO UN CHILDR FUN, 2004, CHILD HLTH COMM COMM; Wolfson LJ, 2007, LANCET, V369, P191, DOI 10.1016/S0140-6736(07)60107-X; World Health Organization, 2005, WORLD HLTH REP 2005; World Health Organization, 2000, WORLD HLTH REP 2000; World Health Organization United Nations Children's Fund, 2001, MEASL MORT RED REG E; World Health Organization (WHO), 2006, WORLD HLTH REP 2006	11	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 20	2007	369	9557					165	166		10.1016/S0140-6736(07)60082-8	http://dx.doi.org/10.1016/S0140-6736(07)60082-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	128XG	17240265				2022-12-28	WOS:000243692400004
J	Pasquale, LR				Pasquale, Louis R.			Genes involved in the pathogenesis of primary open-angle glaucoma - In search of the Holy Grail	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							INTRAOCULAR-PRESSURE; BLOOD-PRESSURE; LINKAGE; SCAN		Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary	Pasquale, LR (corresponding author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, 243 Charles St, Boston, MA 02114 USA.	louis_pasquale@meei.harvard.edu						Allayee H, 2001, HYPERTENSION, V38, P773, DOI 10.1161/hy1001.092617; Duggal P, 2007, ARCH OPHTHALMOL-CHIC, V125, P74, DOI 10.1001/archopht.125.1.74; Hewitt AW, 2006, CLIN EXP OPHTHALMOL, V34, P472, DOI 10.1111/j.1442-9071.2006.01268.x; KALENAK JW, 1995, OPHTHALMOLOGY, V102, P1559; Kass MA, 2002, ARCH OPHTHALMOL-CHIC, V120, P701; Lin DY, 2006, AM J HUM GENET, V78, P505, DOI 10.1086/500812; PEDERSON JE, 1984, ARCH OPHTHALMOL-CHIC, V102, P1689, DOI 10.1001/archopht.1984.01040031373030; Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224; Rice T, 2000, CIRCULATION, V102, P1956, DOI 10.1161/01.CIR.102.16.1956; SOMMER A, 1991, ARCH OPHTHALMOL-CHIC, V109, P1090, DOI 10.1001/archopht.1991.01080080050026	10	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 17	2007	297	3					306	307		10.1001/jama.297.3.306	http://dx.doi.org/10.1001/jama.297.3.306			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125VT	17230643				2022-12-28	WOS:000243472300026
J	Samuels, MA				Samuels, Martin A.			Update in neurology	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Samuels, MA (corresponding author), Brigham & Womens Hosp, Dept Neurol, 75 Francis St, Boston, MA 02115 USA.							[Anonymous], 2005, SLEEP, V28, P1049; Esteller M, 2000, NEW ENGL J MED, V343, P1350, DOI 10.1056/NEJM200011093431901; Hegi ME, 2004, CLIN CANCER RES, V10, P1871, DOI 10.1158/1078-0432.CCR-03-0384; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; Stupp R, 2002, J CLIN ONCOL, V20, P1375, DOI 10.1200/JCO.20.5.1375; Terayama Y, 1997, STROKE, V28, P1185, DOI 10.1161/01.STR.28.6.1185	6	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 16	2007	146	2					128	132		10.7326/0003-4819-146-2-200701160-00007	http://dx.doi.org/10.7326/0003-4819-146-2-200701160-00007			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	131WF	17227936				2022-12-28	WOS:000243901000006
J	Carlton, JM; Hirt, RP; Silva, JC; Delcher, AL; Schatz, M; Zhao, Q; Wortman, JR; Bidwell, SL; Alsmark, UCM; Besteiro, S; Sicheritz-Ponten, T; Noel, CJ; Dacks, JB; Foster, PG; Simillion, C; Van de Peer, Y; Miranda-Saavedra, D; Barton, GJ; Westrop, GD; Muller, S; Dessi, D; Fiori, PL; Ren, QH; Paulsen, I; Zhang, HB; Bastida-Corcuera, FD; Simoes-Barbosa, A; Brown, MT; Hayes, RD; Mukherjee, M; Okumura, CY; Schneider, R; Smith, AJ; Vanacova, S; Villalvazo, M; Haas, BJ; Pertea, M; Feldblyum, TV; Utterback, TR; Shu, CL; Osoegawa, K; de Jong, PJ; Hrdy, I; Horvathova, L; Zubacova, Z; Dolezal, P; Malik, SB; Logsdon, JM; Henze, K; Gupta, A; Wang, CC; Dunne, RL; Upcroft, JA; Upcroft, P; White, O; Salzberg, SL; Tang, P; Chiu, CH; Lee, YS; Embley, TM; Coombs, GH; Mottram, JC; Tachezy, J; Fraser-Liggett, CM; Johnson, PJ				Carlton, Jane M.; Hirt, Robert P.; Silva, Joana C.; Delcher, Arthur L.; Schatz, Michael; Zhao, Qi; Wortman, Jennifer R.; Bidwell, Shelby L.; Alsmark, U. Cecilia M.; Besteiro, Sebastien; Sicheritz-Ponten, Thomas; Noel, Christophe J.; Dacks, Joel B.; Foster, Peter G.; Simillion, Cedric; Van de Peer, Yves; Miranda-Saavedra, Diego; Barton, Geoffrey J.; Westrop, Gareth D.; Mueller, Sylke; Dessi, Daniele; Fiori, Pier Luigi; Ren, Qinghu; Paulsen, Ian; Zhang, Hanbang; Bastida-Corcuera, Felix D.; Simoes-Barbosa, Augusto; Brown, Mark T.; Hayes, Richard D.; Mukherjee, Mandira; Okumura, Cheryl Y.; Schneider, Rachel; Smith, Alias J.; Vanacova, Stepanka; Villalvazo, Maria; Haas, Brian J.; Pertea, Mihaela; Feldblyum, Tamara V.; Utterback, Terry R.; Shu, Chung-Li; Osoegawa, Kazutoyo; de Jong, Pieter J.; Hrdy, Ivan; Horvathova, Lenka; Zubacova, Zuzana; Dolezal, Pavel; Malik, Shehre-Banoo; Logsdon, John M., Jr.; Henze, Katrin; Gupta, Arti; Wang, Ching C.; Dunne, Rebecca L.; Upcroft, Jacqueline A.; Upcroft, Peter; White, Owen; Salzberg, Steven L.; Tang, Petrus; Chiu, Cheng-Hsun; Lee, Ying-Shiung; Embley, T. Martin; Coombs, Graham H.; Mottram, Jeremy C.; Tachezy, Jan; Fraser-Liggett, Claire M.; Johnson, Patricia J.			Draft genome sequence of the sexually transmitted pathogen Trichomonas vaginalis	SCIENCE			English	Article							ENTAMOEBA-HISTOLYTICA; TRITRICHOMONAS-FETUS; STRUCTURAL BASIS; DNA CONTENT; EUKARYOTES; CELLS; IDENTIFICATION; RESISTANCE; EVOLUTION; PROTEINS	We describe the genome sequence of the protist Trichomonas vaginalis, a sexually transmitted human pathogen. Repeats and transposable elements comprise about two-thirds of the similar to 160-megabase genome, reflecting a recent massive expansion of genetic material. This expansion, in conjunction with the shaping of metabolic pathways that likely transpired through lateral gene transfer from bacteria, and amplification of specific gene families implicated in pathogenesis and phagocytosis of host proteins may exemplify adaptations of the parasite during its transition to a urogenital environment. The genome sequence predicts previously unknown functions for the hydrogenosome, which support a common evolutionary origin of this unusual organelle with mitochondria.	Inst Genom Res, Rockville, MD 20850 USA; Univ Newcastle, Div Biol, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Univ Maryland, Ctr Bioinformat & Computat Biol, College Pk, MD 20742 USA; Univ Glasgow, Wellcome Ctr Mol Parasitol, Glasgow G12 8TA, Lanark, Scotland; Univ Glasgow, Div Infect & Immun, Glasgow Biomed Res Ctr, Glasgow G12 8TA, Lanark, Scotland; Tech Univ Denmark, Ctr Biol Sequence Anal, Biocentrum DTU, DK-2800 Lyngby, Denmark; Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada; Nat Hist Museum, Dept Zool, London SW7 5BD, England; Univ Antwerp VIB, Dept Plant Syst Biol, B-9052 Ghent, Belgium; Univ Dundee, Sch Life Sci Res, Dundee DD1 5EH, Scotland; Univ Sassari, Dept Biomed Sci, Div Exptl & Clin Microbiol, I-07100 Sassari, Italy; Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA; J Craig Venter Joint Technol Ctr, Rockville, MD 20850 USA; Childrens Hosp, Oakland Res Inst, Oakland, CA 94609 USA; Charles Univ Prague, Dept Parasitol, Fac Sci, CR-12844 Prague, Czech Republic; Univ Iowa, Dept Biol Sci, Roy J Carver Ctr Comparat Genom, Iowa City, IA 52242 USA; Univ Dusseldorf, Inst Bot, D-402225 Dusseldorf, Germany; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Queensland, Dept Microbiol & Parasitol, Brisbane, Qld 4072, Australia; Queensland Inst Med Res, Brisbane, Qld 4029, Australia; Chang Gung Univ, Bioinformat Ctr, Mol Med Res Ctr, Tao Yuan 333, Taiwan; Chang Gung Mem Hosp, Mol Infect Dis Res Ctr, Tao Yuan 333, Taiwan; Chang Gung Mem Hosp, Med Genom Ctr, Tao Yuan 333, Taiwan; Univ Strathclyde, Strathclyde Inst Pharm & Biomed Sci, Glasgow G4 0NR, Lanark, Scotland	J. Craig Venter Institute; Newcastle University - UK; University System of Maryland; University of Maryland College Park; University of Glasgow; University of Glasgow; Technical University of Denmark; University of Calgary; Natural History Museum London; Flanders Institute for Biotechnology (VIB); University of Antwerp; University of Dundee; University of Sassari; University of California System; University of California Los Angeles; J. Craig Venter Institute; Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute; Charles University Prague; University of Iowa; Heinrich Heine University Dusseldorf; University of California System; University of California San Francisco; University of Queensland; QIMR Berghofer Medical Research Institute; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; University of Strathclyde	Carlton, JM (corresponding author), NYU, Dept Med Parasitol, Sch Med, New York, NY 10011 USA.	jane.carlton@med.nyu.edu	Salzberg, Steven/Q-6514-2019; Paulsen, Ian T/K-3832-2012; Barton, Geoffrey J/C-6267-2011; Schatz, Michael/L-2690-2019; Pertea, Mihaela/AAT-2705-2021; Barton, Geoffrey/N-1037-2019; Salzberg, Steven L/F-6162-2011; Van de Peer, Yves/D-4388-2009; Dolezal, Pavel/V-1907-2017; Alsmark, Cecilia/AAO-1330-2021; Van de Peer, Yves/AAE-7666-2019; Silva, Joana/GVT-6441-2022; Vanacova, Stepanka/D-6858-2012; Miranda-Saavedra, Diego/C-2707-2012; Silva, Joana/GYQ-9526-2022; Besteiro, Sébastien/F-3622-2014; Hirt, Robert/R-5429-2017; Hrdý, Ivan/K-8931-2017; Logsdon, John M/B-7812-2009; Horváthová, Lenka/AAC-3119-2021; Malik, Shehre-Banoo/A-1385-2009; Fiori, Pier Luigi/GVU-9300-2022; Vanacova, Stepanka/AGO-9953-2022; Dacks, Joel/AAE-3308-2021; Sicheritz-Ponten, Thomas/A-4325-2017	Salzberg, Steven/0000-0002-8859-7432; Paulsen, Ian T/0000-0001-9015-9418; Schatz, Michael/0000-0002-4118-4446; Pertea, Mihaela/0000-0003-0762-8637; Barton, Geoffrey/0000-0002-9014-5355; Salzberg, Steven L/0000-0002-8859-7432; Van de Peer, Yves/0000-0003-4327-3730; Dolezal, Pavel/0000-0003-1285-9026; Van de Peer, Yves/0000-0003-4327-3730; Vanacova, Stepanka/0000-0001-8807-0684; Besteiro, Sébastien/0000-0003-1853-1494; Hirt, Robert/0000-0002-3760-9958; Hrdý, Ivan/0000-0002-5595-9177; Horváthová, Lenka/0000-0001-7618-8669; Fiori, Pier Luigi/0000-0001-6190-612X; Vanacova, Stepanka/0000-0001-8807-0684; Dacks, Joel/0000-0003-4520-5694; Fraser, Claire/0000-0003-1462-2428; Mottram, Jeremy/0000-0001-5574-3766; Embley, Thomas Martin/0000-0002-1484-340X; Foster, Peter/0000-0003-0194-9237; Simillion, Cedric/0000-0002-2026-6741; DESSI', Daniele/0000-0001-5713-741X; Malik, Shehre-Banoo/0000-0003-0833-0648; Westrop, Gareth/0000-0002-8011-6219; Tang, Petrus/0000-0002-2779-0116; Hayes, Richard/0000-0002-5236-7918; Bastida, Felix/0000-0003-1036-9787; Wortman, Jennifer/0000-0002-8713-1227; Sicheritz-Ponten, Thomas/0000-0001-6615-1141	MRC [G9722968, G0000508] Funding Source: UKRI; Medical Research Council [G9722968(65078), G9722968, G0000508(56841), G0000508] Funding Source: Medline; NIAID NIH HHS [U01 AI050913-02, U01 AI050913-01A1, UO1 AI50913-01, U01 AI050913] Funding Source: Medline; NLM NIH HHS [R01 LM007938, R01 LM006845, R01 LM007938-04, R01 LM006845-08] Funding Source: Medline; Wellcome Trust [072031] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI050913] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [R01LM007938, R01LM006845] Funding Source: NIH RePORTER	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); Wellcome Trust(Wellcome Trust); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Adl SM, 2005, J EUKARYOT MICROBIOL, V52, P399, DOI 10.1111/j.1550-7408.2005.00053.x; Bastida-Corcuera FD, 2005, EUKARYOT CELL, V4, P1951, DOI 10.1128/EC.4.11.1951-1958.2005; BEACH DH, 1991, MOL BIOCHEM PARASIT, V44, P97, DOI 10.1016/0166-6851(91)90225-U; Benchimol M, 2004, MICROSC MICROANAL, V10, P528, DOI 10.1017/S1431927604040905; Bradley PJ, 1997, EMBO J, V16, P3484, DOI 10.1093/emboj/16.12.3484; Cavalier-Smith T, 2005, ANN BOT-LONDON, V95, P147, DOI 10.1093/aob/mci010; Davis PH, 2006, MOL BIOCHEM PARASIT, V145, P111, DOI 10.1016/j.molbiopara.2005.08.017; DIAS FBP, 1992, MICROBIOS, V71, P55; Embley TM, 2006, NATURE, V440, P623, DOI 10.1038/nature04546; FIORI PL, 1993, FEMS MICROBIOL LETT, V109, P13, DOI 10.1111/j.1574-6968.1993.tb06136.x; Gregory TR, 2001, BIOL REV, V76, P65, DOI 10.1017/S1464793100005595; Honigberg B.M., 1990, P5; Ikegami A, 2004, INFECT IMMUN, V72, P4619, DOI 10.1128/IAI.72.8.4619-4627.2004; Klemba M, 2002, ANNU REV BIOCHEM, V71, P275, DOI 10.1146/annurev.biochem.71.090501.145453; Kleydman Y, 2004, MICROBIOL-SGM, V150, P1139, DOI 10.1099/mic.0.26939-0; Kutisova K, 2005, PARASITOLOGY, V131, P309, DOI 10.1017/S0031182005008000; Kwon DH, 2001, ANTIMICROB AGENTS CH, V45, P2609, DOI 10.1128/AAC.45.9.2609-2615.2001; Land KM, 2004, MOL MICROBIOL, V51, P115, DOI 10.1046/j.1365-2958.2003.03791.x; LEHKER MW, 1990, J EXP MED, V171, P2165, DOI 10.1084/jem.171.6.2165; Leiros HKS, 2004, J BIOL CHEM, V279, P55840, DOI 10.1074/jbc.M408044200; Loftus B, 2005, NATURE, V433, P865, DOI 10.1038/nature03291; LOWE PN, 1986, MOL BIOCHEM PARASIT, V21, P65, DOI 10.1016/0166-6851(86)90080-0; MUILER M, 1998, EVOLUTIONARY RELATIO, P109; Parsons M, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-127; Ramesh MA, 2005, CURR BIOL, V15, P185, DOI 10.1016/j.cub.2005.01.003; Rendon-Maldonado JG, 1998, EXP PARASITOL, V89, P241, DOI 10.1006/expr.1998.4297; Richards TA, 2005, NATURE, V436, P1113, DOI 10.1038/nature03949; Schmid G, 2001, J REPROD MED, V46, P545; Schumacher MA, 2003, CELL, V115, P413, DOI 10.1016/S0092-8674(03)00887-0; SHUTER BJ, 1983, AM NAT, V122, P26, DOI 10.1086/284116; Silva JC, 2005, MOL BIOL EVOL, V22, P126, DOI 10.1093/molbev/msh260; SINGH BN, 1994, ARCH BIOCHEM BIOPHYS, V309, P273, DOI 10.1006/abbi.1994.1113; Sutak R, 2004, P NATL ACAD SCI USA, V101, P10368, DOI 10.1073/pnas.0401319101; TURNER AC, 1988, EXP PARASITOL, V67, P47, DOI 10.1016/0014-4894(88)90007-0; Vanacova S, 2005, P NATL ACAD SCI USA, V102, P4430, DOI 10.1073/pnas.0407500102; Vogel C, 2006, PLOS COMPUT BIOL, V2, P370, DOI 10.1371/journal.pcbi.0020048; Westrop GD, 2006, J BIOL CHEM, V281, P25062, DOI 10.1074/jbc.M600688200; WHO World Health Organisation STD Statistics, 2001, GLOB PREV INC SEL CU; Yao CQ, 2003, MOL BIOCHEM PARASIT, V132, P1, DOI 10.1016/S0166-6851(03)00211-1; ZUO X, 1995, MICROBIOL-UK, V141, P2637, DOI 10.1099/13500872-141-10-2637	40	595	631	1	85	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 12	2007	315	5809					207	212		10.1126/science.1132894	http://dx.doi.org/10.1126/science.1132894			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124XZ	17218520	Green Accepted			2022-12-28	WOS:000243407400037
J	Farrell, B; Duley, L				Farrell, Barbara; Duley, Lelia			Doing the undoable: Magpie Trial long-term follow-up	LANCET			English	Editorial Material							MAGNESIUM-SULFATE; PREECLAMPSIA; WOMEN		Univ Oxford, Natl Perinatal Epidemiol Unit, Oxford, England; John Radcliffe Hosp, Nuffield Dept Med, Oxford OX3 9DU, England	University of Oxford; University of Oxford	Duley, L (corresponding author), Univ Oxford, Natl Perinatal Epidemiol Unit, Oxford, England.	lelia.duley@ndm.ox.ac.uk	Duley, Lelia/E-8107-2015	Duley, Lelia/0000-0001-6721-5178	MRC [G116/98] Funding Source: UKRI; Medical Research Council [G116/98] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Duley L, 2002, LANCET, V359, P1877, DOI 10.1016/s0140-6736(02)08778-0; *MAGP TRIAL FOLL U, 2006, BJOG            1212, DOI DOI 10.1111/J1471-0528.2006.01166.X; *MAGP TRIAL FOLL U, 2006, BJOG            1212, DOI DOI 10.1111/J.1471-0528.2006.01165.X; Sheth SS, 2002, LANCET, V359, P1872, DOI 10.1016/S0140-6736(02)08783-4; Simon J, 2006, BJOG-INT J OBSTET GY, V113, P144, DOI 10.1111/j.1471-0528.2005.00785.x	5	5	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 6	2007	369	9555					13	14		10.1016/S0140-6736(07)60010-5	http://dx.doi.org/10.1016/S0140-6736(07)60010-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125AK	17208626				2022-12-28	WOS:000243413700010
J	Hind, D; Pilgrim, H; Ward, S				Hind, Daniel; Pilgrim, Hazel; Ward, Sue			Questions about adjuvant trastuzumab still remain	LANCET			English	Editorial Material							CHEMOTHERAPY		Univ Sheffield, Sch Hlth & Related Res, Sheffield S1 4DA, S Yorkshire, England	University of Sheffield	Hind, D (corresponding author), Univ Sheffield, Sch Hlth & Related Res, Sheffield S1 4DA, S Yorkshire, England.	d.hind@sheffield.ac.uk	Hind, Daniel/AAE-1769-2020; Hind, Daniel/A-2180-2010	Hind, Daniel/0000-0002-6409-4793; Hind, Daniel/0000-0002-6409-4793; Ward, Sue/0000-0002-3344-0913; Squires, Hazel/0000-0002-2776-4014				Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; [Anonymous]; Barrett A, 2006, BRIT MED J, V333, P1118, DOI 10.1136/bmj.39008.624051.BE; Ewer MS, 2005, J CLIN ONCOL, V23, P7820, DOI 10.1200/JCO.2005.13.300; Joensuu H, 2006, NEW ENGL J MED, V354, P809, DOI 10.1056/NEJMoa053028; *NAT I HLTH CLIN E, 2006, TRAST ADJ TREAT EARL; *NAT I HLTH CLIN E, 2006, 2006042 NICE; National Institute for Health and Clinical Excellence, 2004, GUID METH TECHN APPR; *PHARMAC, 2006, HERC STAT UNCH FOLL; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; Rawlins M, 2005, J MED ETHICS, V31, P683, DOI 10.1136/jme.2005.013813; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; *SABCS, 2005, SAN ANTONIO BREAST C, V2, P2; SLAMON D, 2005, 28 SAN ANT BREAST CA, P1; Smith I, 2007, LANCET, V369, P29, DOI 10.1016/S0140-6736(07)60028-2; STEINHERZ LJ, 1991, JAMA-J AM MED ASSOC, V266, P1672, DOI 10.1001/jama.266.12.1672; *US GEN INC, 2006, ANN DRAFT LAB TEXT A	17	19	19	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 6	2007	369	9555					3	5		10.1016/S0140-6736(07)60004-X	http://dx.doi.org/10.1016/S0140-6736(07)60004-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125AK	17208620				2022-12-28	WOS:000243413700004
J	Fenollar, F; Puechal, X; Raoult, D				Fenollar, Florence; Puechal, Xavier; Raoult, Didier			Medical progress - Whipple's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							POLYMERASE-CHAIN-REACTION; TROPHERYMA-WHIPPELII DNA; CULTURE-NEGATIVE ENDOCARDITIS; OF-THE-LITERATURE; TERM FOLLOW-UP; CEREBROSPINAL-FLUID; ANTIBIOTIC SUSCEPTIBILITY; GASTROINTESTINAL-DISEASE; INTESTINAL-MUCOSA; Q-FEVER		Univ Mediterranee, Fac Med, F-13385 Marseille 5, France; CNRS, UMR 6020, IFR 48, Unite Rickettsies, Marseille, France; Le Mans Gen Hosp, Dept Rheumatol, Le Mans, France	UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); Centre Hospitalier Le Mans	Raoult, D (corresponding author), Univ Mediterranee, Fac Med, 27 Blvd Jean Moulin, F-13385 Marseille 5, France.	didier.raoult@medecine.univ-mrs.fr	RAOULT, Didier/A-8434-2008; Puéchal, Xavier/P-1555-2017	RAOULT, Didier/0000-0002-0633-5974; Puéchal, Xavier/0000-0003-3573-9203				Aiouaz H, 2005, REV MED INTERNE, V26, P784, DOI 10.1016/j.revmed.2005.07.012; Akar Z, 2002, J NEUROSURG, V97, P988, DOI 10.3171/jns.2002.97.4.0988; Amsler L, 2003, INFECTION, V31, P81, DOI 10.1007/s15010-002-3083-0; Apfalter P, 2005, J CLIN MICROBIOL, V43, P5835, DOI 10.1128/JCM.43.12.5835-5841.2005; BAI JC, 1991, J CLIN GASTROENTEROL, V13, P303, DOI 10.1097/00004836-199106000-00010; Baisden BL, 2002, AM J CLIN PATHOL, V118, P742; Bentley SD, 2003, LANCET, V361, P637, DOI 10.1016/S0140-6736(03)12597-4; BLACKSCHAFFER B, 1949, P SOC EXP BIOL MED, V72, P225; Boulos A, 2004, ANTIMICROB AGENTS CH, V48, P747, DOI 10.1128/AAC.48.3.747-752.2004; Boulos A, 2005, J ANTIMICROB CHEMOTH, V55, P178, DOI 10.1093/jac/dkh524; Bruhlmann P, 2000, RHEUMATOLOGY, V39, P1427, DOI 10.1093/rheumatology/39.12.1427; Cannon WR, 2003, LANCET, V361, P1916, DOI 10.1016/S0140-6736(03)13533-7; CHEARS WC, 1961, GASTROENTEROLOGY, V41, P129; CHEARS WC, 1961, AM J MED, V30, P226, DOI 10.1016/0002-9343(61)90094-8; Coria F, 2000, Neurologia, V15, P173; DeArment MC, 2003, J RHEUMATOL, V30, P1347; Desnues B, 2005, J INFECT DIS, V192, P1642, DOI 10.1086/491745; Desnues B, 2005, J IMMUNOL, V175, P4575, DOI 10.4049/jimmunol.175.7.4575; Dobbins 3rd WO, 1987, WHIPPLES DIS; Drancourt M, 2003, ANN INTERN MED, V139, P1046, DOI 10.7326/0003-4819-139-12-200312160-00025; Dreier J, 2004, J CLIN MICROBIOL, V42, P4487, DOI 10.1128/JCM.42.10.4487-4493.2004; Dumler JS, 2003, NEW ENGL J MED, V348, P1411, DOI 10.1056/NEJM200304033481425; Durand DV, 1997, MEDICINE, V76, P170, DOI 10.1097/00005792-199705000-00003; Dutly F, 2001, CLIN MICROBIOL REV, V14, P561, DOI 10.1128/CMR.14.3.561-583.2001; Dutly F, 2000, INFECTION, V28, P219, DOI 10.1007/s150100070039; Ehrbar HU, 1999, LANCET, V353, P2214, DOI 10.1016/S0140-6736(99)01776-6; Elssner A, 2004, J IMMUNOL, V172, P7721, DOI 10.4049/jimmunol.172.12.7721; ENZINGER FM, 1963, VIRCHOWS ARCH A, V336, P238, DOI 10.1007/BF00957912; FARR M, 1984, ANN RHEUM DIS, V43, P526, DOI 10.1136/ard.43.3.526; Fenollar F, 2001, CLIN DIAGN LAB IMMUN, V8, P1, DOI 10.1128/CDLI.8.1.1-8.2001; Fenollar F, 2001, Expert Rev Mol Diagn, V1, P299, DOI 10.1586/14737159.1.3.299; Fenollar F, 2001, CLIN INFECT DIS, V33, P1309, DOI 10.1086/322666; Fenollar F, 2004, J CLIN MICROBIOL, V42, P401, DOI 10.1128/JCM.42.1.401-403.2004; Fenollar F, 2002, J CLIN MICROBIOL, V40, P1119, DOI 10.1128/JCM.40.3.1119-1120.2002; Fenollar F, 2003, J INFECT DIS, V188, P828, DOI 10.1086/378093; Fenollar F, 2003, J CLIN MICROBIOL, V41, P3816, DOI 10.1128/JCM.41.8.3816-3822.2003; FEURLE GE, 1994, DIGEST DIS SCI, V39, P1642, DOI 10.1007/BF02087770; FLEMING JL, 1988, MAYO CLIN PROC, V63, P539, DOI 10.1016/S0025-6196(12)64884-8; Fresard A, 1996, CLIN INFECT DIS, V22, P575, DOI 10.1093/clinids/22.3.575; GEBOES K, 1992, ACTA GASTRO-ENT BELG, V55, P209; Geissdorfer W, 2001, INFECTION, V29, P44, DOI 10.1007/s15010-001-0135-9; Gerard A, 2002, MEDICINE, V81, P443, DOI 10.1097/00005792-200211000-00005; Ghigo E, 2002, INFECT IMMUN, V70, P1501, DOI 10.1128/IAI.70.3.1501-1506.2002; Goldenberger D, 1997, J CLIN MICROBIOL, V35, P2733, DOI 10.1128/JCM.35.11.2733-2739.1997; Gross M, 1999, ITAL J GASTROENTEROL, V31, P70; Gubler JGH, 1999, ANN INTERN MED, V131, P112, DOI 10.7326/0003-4819-131-2-199907200-00007; KEINATH RD, 1985, GASTROENTEROLOGY, V88, P1867, DOI 10.1016/0016-5085(85)90012-5; KELLY JJ, 1963, ARTHRITIS RHEUM-US, V6, P615, DOI 10.1002/art.1780060505; La Scola B, 2001, INT J SYST EVOL MICR, V51, P1471, DOI 10.1099/00207713-51-4-1471; Lee AG, 2002, J NEURO-OPHTHALMOL, V22, P18, DOI 10.1097/00041327-200203000-00006; Lepidi H, 2004, J INFECT DIS, V190, P935, DOI 10.1086/422845; Lepidi H, 2006, J INFECT DIS, V193, P1711, DOI 10.1086/504438; Lepidi H, 2003, HUM PATHOL, V34, P589, DOI 10.1016/S0046-8177(03)00126-6; Lohr M, 2004, J NEUROSURG, V101, P336, DOI 10.3171/jns.2004.101.2.0336; Louis ED, 1996, ANN NEUROL, V40, P561, DOI 10.1002/ana.410400404; Lynch T, 1997, ANN NEUROL, V42, P120, DOI 10.1002/ana.410420120; Mahnel R, 2005, AM J GASTROENTEROL, V100, P1167, DOI 10.1111/j.1572-0241.2005.40128.x; Maibach RC, 2002, J CLIN MICROBIOL, V40, P2466, DOI 10.1128/JCM.40.7.2466-2471.2002; Maiwald M, 2003, J INFECT DIS, V188, P801, DOI 10.1086/378073; Maiwald M, 1998, APPL ENVIRON MICROB, V64, P760; Maiwald M, 2001, ANN INTERN MED, V134, P115, DOI 10.7326/0003-4819-134-2-200101160-00011; MAIZEL H, 1993, MEDICINE, V72, P343, DOI 10.1097/00005792-199309000-00005; Marth T, 2003, LANCET, V361, P239, DOI 10.1016/S0140-6736(03)12274-X; Marth T, 1997, GASTROENTEROLOGY, V113, P442, DOI 10.1053/gast.1997.v113.pm9247462; Marth T, 1996, Semin Gastrointest Dis, V7, P41; Maurin M, 1999, CLIN MICROBIOL REV, V12, P518, DOI 10.1128/CMR.12.4.518; MCALLISTER HA, 1975, CIRCULATION, V52, P152, DOI 10.1161/01.CIR.52.1.152; Messori A, 2001, AM J NEURORADIOL, V22, P1004; Misbah SA, 2000, J CLIN PATHOL, V53, P750, DOI 10.1136/jcp.53.10.750; Misbah SA, 1999, QJM-MON J ASSOC PHYS, V92, P61, DOI 10.1093/qjmed/92.1.61; Misbah SA, 1997, QJM-MON J ASSOC PHYS, V90, P765; Muller SA, 2005, INFECTION, V33, P39, DOI 10.1007/s15010-005-4067-7; Naegeli B, 2000, STROKE, V31, P2002, DOI 10.1161/01.STR.31.8.2002; O'Duffy JD, 1999, ARTHRITIS RHEUM, V42, P812, DOI 10.1002/1529-0131(199904)42:4<812::AID-ANR27>3.0.CO;2-S; Olmos M, 2006, ALIMENT PHARM THER, V23, P833, DOI 10.1111/j.1365-2036.2006.02822.x; Papadopoulou Marianna, 2003, Mol Diagn, V7, P209, DOI 10.2165/00066982-200307030-00011; PAULLEY JW, 1952, GASTROENTEROLOGY, V22, P128; Peters G, 2002, J NEUROL NEUROSUR PS, V73, P336, DOI 10.1136/jnnp.73.3.336; POLICARD A, 1947, PRESSE MED, V55, P213; Posada IJ, 2004, REV NEUROLOGIA, V38, P196, DOI 10.33588/rn.3802.2003335; Puechal X, 2001, CURR OPIN RHEUMATOL, V13, P74, DOI 10.1097/00002281-200101000-00012; Puechal X, 2002, ARTHRITIS RHEUM, V46, P1130, DOI 10.1002/art.10099; Raoult D, 2001, JAMA-J AM MED ASSOC, V285, P1039, DOI 10.1001/jama.285.8.1039; Raoult D, 1999, ANN INTERN MED, V131, P144, DOI 10.7326/0003-4819-131-2-199907200-00012; Raoult D, 2000, NEW ENGL J MED, V342, P1538; Raoult D, 2003, GENOME RES, V13, P1800, DOI 10.1101/gr.1474603; Raoult D, 2006, NEW ENGL J MED, V355, P1503, DOI 10.1056/NEJMc061049; RELMAN DA, 1992, NEW ENGL J MED, V327, P293, DOI 10.1056/NEJM199207303270501; Renesto P, 2003, LANCET, V362, P447, DOI 10.1016/S0140-6736(03)14071-8; Richardson DC, 2003, J INFECTION, V47, P170, DOI 10.1016/S0163-4453(03)00015-X; RICKMAN LS, 1995, NEW ENGL J MED, V332, P363, DOI 10.1056/NEJM199502093320604; Schneider T, 1998, INFECTION, V26, P178, DOI 10.1007/BF02771847; Schneider T, 1998, ANN INTERN MED, V129, P875, DOI 10.7326/0003-4819-129-11_Part_1-199812010-00006; Schnider PJ, 1996, EUR J GASTROEN HEPAT, V8, P899; Schroter A, 2005, EUR J NEUROL, V12, P276, DOI 10.1111/j.1468-1331.2004.01035.x; Scollard DM, 2006, CLIN MICROBIOL REV, V19, P338, DOI 10.1128/CMR.19.2.338-381.2006; Smith MA, 2000, ANN INTERN MED, V132, P595, DOI 10.7326/0003-4819-132-7-200004040-00025; Street S, 1999, LANCET, V354, P1178, DOI 10.1016/S0140-6736(99)03065-2; Tran Huy A, 2006, BMC Endocr Disord, V6, P3, DOI 10.1186/1472-6823-6-3; vonHerbay A, 1997, GASTROENTEROLOGY, V113, P434, DOI 10.1053/gast.1997.v113.pm9247461; Weber U, 2003, CLIN RHEUMATOL, V22, P443, DOI 10.1007/s10067-003-0786-2; Whipple GH, 1907, B JOHNS HOPKINS HOSP, V18, P382; WILSON KH, 1991, LANCET, V338, P474, DOI 10.1016/0140-6736(91)90545-Z; YARDLEY JH, 1961, B JOHNS HOPKINS HOSP, V109, P80	104	337	347	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 4	2007	356	1					55	66		10.1056/NEJMra062477	http://dx.doi.org/10.1056/NEJMra062477			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	122EX	17202456				2022-12-28	WOS:000243209600009
J	Bibbins-Domingo, K; Fernandez, A				Bibbins-Domingo, Kirsten; Fernandez, Alicia			BiDil for heart failure in black patients: Implications of the U.S. Food and Drug Administration approval	ANNALS OF INTERNAL MEDICINE			English	Article							QUALITY-OF-CARE; ISOSORBIDE DINITRATE; RACIAL DISPARITIES; RANDOMIZED-TRIAL; RACE; HYDRALAZINE; MANAGEMENT; COMMITTEE; OUTCOMES; DISEASE	In 2005, the combination of hydralazine hydrochloride and isosorbide dinitrate was approved by the U. S. Food and Drug Administration (FDA) for treating heart failure in black patients. In departing from its long history of approving drugs for general clinical indications without regard to demographic classification, the FDA cited the need to address racial disparities in health as an important contributor to their decision. The authors argue that this decision, although perhaps well-intentioned, was based on flawed scientific interpretation of trial results that claimed differential drug response by race and ignored the considerable literature on the cause of racial disparities in health and health care. Because of its potential impact on future drug approvals, the FDA's decision is a setback in the scientific and policy discourse on medical therapeutics and race and specifically hinders the efforts aimed at eliminating health and health care disparities.	Univ Calif San Francisco, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Bibbins-Domingo, K (corresponding author), Univ Calif San Francisco, San Francisco Gen Hosp, Div Gen Internal Med, Box 1364, San Francisco, CA 94143 USA.	bibbinsk@medicine.ucsf.edu			NCRR NIH HHS [K23 RR01832401] Funding Source: Medline; NHLBI NIH HHS [N01-HC-95095] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC095095] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Agodoa LY, 2001, JAMA-J AM MED ASSOC, V285, P2719, DOI 10.1001/jama.285.21.2719; ALEXANDER M, 1995, JAMA-J AM MED ASSOC, V274, P1037, DOI 10.1001/jama.274.13.1037; Barnato AE, 2005, MED CARE, V43, P308, DOI 10.1097/01.mlr.0000156848.62086.06; BROOKS J, 2006, HATTIESBURG AM  0718; Burchard EG, 2003, NEW ENGL J MED, V348, P1170, DOI 10.1056/NEJMsb025007; CARLSON RJ, 2005, HLTH AFF MILLWO 1011; Carson P, 1999, J Card Fail, V5, P178, DOI 10.1016/S1071-9164(99)90001-5; COHN JN, 1986, NEW ENGL J MED, V314, P1547, DOI 10.1056/NEJM198606123142404; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; Dries DL, 1999, NEW ENGL J MED, V340, P609, DOI 10.1056/NEJM199902253400804; Eichhorn E, 2001, NEW ENGL J MED, V344, P1659; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; Hertz RP, 2005, ARCH INTERN MED, V165, P2098, DOI 10.1001/archinte.165.18.2098; Hjalmarson A, 1999, LANCET, V353, P2001; Hunt SA, 2005, CIRCULATION, V112, pE154, DOI 10.1161/CIRCULATIONAHA.105.167586; Hunt SA, 2001, CIRCULATION, V104, P2996, DOI 10.1161/hc4901.102568; Kahn J, 2005, NAT GENET, V37, P655, DOI 10.1038/ng0705-655; Kahn J, 2003, PERSPECT BIOL MED, V46, P473, DOI 10.1353/pbm.2003.0087; KAHN J, 2005, HASTING CENT REP, V35; Kahn JD, 2005, BRIT MED J, V330, P1508, DOI 10.1136/bmj.330.7506.1508-a; Kahn Jonathan, 2004, Yale J Health Policy Law Ethics, V4, P1; Kalinowski L, 2004, CIRCULATION, V109, P2511, DOI 10.1161/01.CIR.0000129087.81352.7A; LECHAT P, 1994, CIRCULATION, V90, P1765, DOI 10.1161/01.CIR.90.4.1765; Liggett SB, 2006, P NATL ACAD SCI USA, V103, P11288, DOI 10.1073/pnas.0509937103; Lillie-Blanton M, 2004, J AM COLL CARDIOL, V44, P503, DOI 10.1016/j.jacc.2004.04.043; Mathew J, 2005, AM HEART J, V150, P968, DOI 10.1016/j.ahj.2005.03.060; Meade TW, 1998, LANCET, V351, P233; Moran AE, 2005, NEW ENGL J MED, V352, P1041; NAINGGOLAN L, 2006, HEART WIRE      0711; *NIH, 2005, INCL WOM MIN PART RE; Nissen SE, 2005, CIRCULATION, V112, P2043, DOI 10.1161/CIRCULATIONAHA.105.573105; Packer M, 2001, NEW ENGL J MED, V344, P1651, DOI 10.1056/NEJM200105313442201; PETO R, 1988, BRIT MED J, V296, P313, DOI 10.1136/bmj.296.6618.313; POCOCK SJ, 1987, NEW ENGL J MED, V317, P426, DOI 10.1056/NEJM198708133170706; Rathore SS, 2003, JAMA-J AM MED ASSOC, V289, P2517, DOI 10.1001/jama.289.19.2517; Ridker PM, 2005, NEW ENGL J MED, V352, P1293, DOI 10.1056/NEJMoa050613; Sankar P, 2004, JAMA-J AM MED ASSOC, V291, P2985, DOI 10.1001/jama.291.24.2985; SANKAR P, 2005, HLTH AFF MILLWO 1011; SAUL S, 2006, NY TIMES        0522; Saul Stephanie, 2005, N Y Times Web, pC4; Saul Stephanie, 2005, N Y Times Web, pC3; Schneider EC, 2001, ANN INTERN MED, V135, P328, DOI 10.7326/0003-4819-135-5-200109040-00009; Sehgal AR, 2004, HYPERTENSION, V43, P566, DOI 10.1161/01.HYP.0000118019.28487.9c; Taylor AL, 2004, NEW ENGL J MED, V351, P2049, DOI 10.1056/NEJMoa042934; Thom T, 2006, CIRCULATION, V113, pE85, DOI 10.1161/CIRCULATIONAHA.105.171600; Trivedi AN, 2005, NEW ENGL J MED, V353, P692, DOI 10.1056/NEJMsa051207; *US FDA, 2005, SUMM MIN CARD REN DR; Wright JT, 2002, JAMA-J AM MED ASSOC, V288, P2421, DOI 10.1001/jama.288.19.2421; YUSUF S, 1991, JAMA-J AM MED ASSOC, V266, P93, DOI 10.1001/jama.266.1.93	49	35	35	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 2	2007	146	1					52	W8		10.7326/0003-4819-146-1-200701020-00009	http://dx.doi.org/10.7326/0003-4819-146-1-200701020-00009			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188BK	17200222				2022-12-28	WOS:000247893300007
J	Botuyan, MV; Lee, J; Ward, IM; Kim, JE; Thompson, JR; Chen, JJ; Mer, G				Botuyan, Maria Victoria; Lee, Joseph; Ward, Irene M.; Kim, Ja-Eun; Thompson, James R.; Chen, Junjie; Mer, Georges			Structural basis for the methylation state-specific recognition of histone H4-K20 by 53BP1 and Crb2 in DNA repair	CELL			English	Article							DOUBLE-STRAND BREAKS; CHECKPOINT PROTEIN CRB2; TANDEM BRCT DOMAINS; H4 LYS-20; LYSINE METHYLATION; HISTIDINE KINASES; CRYSTAL-STRUCTURE; SILENT CHROMATIN; TUDOR DOMAIN; H3 TAIL	Histone lysine methylation has been linked to the recruitment of mammalian DNA repair factor 53BP1 and putative fission yeast homolog Crb2 to DNA double-strand breaks (DSBs), but how histone recognition is achieved has not been established. Here we demonstrate that this link occurs through direct binding of 53BP1 and Crb2 to histone H4. Using X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy, we show that, despite low amino acid sequence conservation, both 53BP1 and Crb2 contain tandem tudor domains that interact with histone H4 specifically dimethylated at Lys20 (W-K20me2). The structure of 53BP1/H4-K20me2 complex uncovers a unique five-residue 53BP1 binding cage, remarkably conserved in the structure of Crb2, that best accommodates a dimethyllysine but excludes a trimethyllysine, thus explaining the methylation state-specific recognition of H4-K20. This study reveals an evolutionarily conserved molecular mechanism of targeting DNA repair proteins to DSBs by direct recognition of H4-K20me2.	Mayo Clin, Coll Med, Dept Oncol, Rochester, MN 55905 USA; Mayo Clin, Coll Med, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin, Coll Med, Dept Physiol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Chen, JJ (corresponding author), Mayo Clin, Coll Med, Dept Oncol, Rochester, MN 55905 USA.	junjie.chen@yale.edu; mer.georges@mayo.edu	Mer, Georges/AAT-4946-2021; Kim, Ja-Eun/AAI-1896-2020	Mer, Georges/0000-0002-1900-1578; Kim, Ja-Eun/0000-0002-9132-1277	NCI NIH HHS [R01 CA109449, CA100109, R01 CA100109] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA109449, R01CA100109] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bekker-Jensen S, 2005, J CELL BIOL, V170, P201, DOI 10.1083/jcb.200503043; Besant PG, 2005, BBA-PROTEINS PROTEOM, V1754, P281, DOI 10.1016/j.bbapap.2005.07.026; Botuyan MVE, 2004, STRUCTURE, V12, P1137, DOI 10.1016/j.str.2004.06.002; Charier G, 2004, STRUCTURE, V12, P1551, DOI 10.1016/j.str.2004.06.014; Couture JF, 2005, GENE DEV, V19, P1455, DOI 10.1101/gad.1318405; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DeLano W.L, PYMOL MOL GRAPHICS S; Du LL, 2006, GENE DEV, V20, P1583, DOI 10.1101/gad.1422606; Du LL, 2004, J BIOL CHEM, V279, P38409, DOI 10.1074/jbc.M403326200; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fang J, 2002, CURR BIOL, V12, P1086, DOI 10.1016/S0960-9822(02)00924-7; Feng Q, 2002, CURR BIOL, V12, P1052, DOI 10.1016/S0960-9822(02)00901-6; Ferentz AE, 2000, Q REV BIOPHYS, V33, P29, DOI 10.1017/S0033583500003589; Flanagan JF, 2005, NATURE, V438, P1181, DOI 10.1038/nature04290; FUJITAKI JM, 1981, BIOCHEMISTRY-US, V20, P3658, DOI 10.1021/bi00515a055; Ghosh A, 2004, MOL CELL, V15, P727, DOI 10.1016/j.molcel.2004.07.017; Huang Y, 2006, SCIENCE, V312, P748, DOI 10.1126/science.1125162; Huyen Y, 2004, NATURE, V432, P406, DOI 10.1038/nature03114; Iwabuchi K, 2003, J BIOL CHEM, V278, P36487, DOI 10.1074/jbc.M304066200; Jacobs SA, 2002, SCIENCE, V295, P2080, DOI 10.1126/science.1069473; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Karachentsev D, 2005, GENE DEV, V19, P431, DOI 10.1101/gad.1263005; Kim J, 2006, EMBO REP, V7, P397, DOI 10.1038/sj.embor.7400625; Li G, 2005, NAT STRUCT MOL BIOL, V12, P46, DOI 10.1038/nsmb869; Li HT, 2006, NATURE, V442, P91, DOI 10.1038/nature04802; Lou ZK, 2006, MOL CELL, V21, P187, DOI 10.1016/j.molcel.2005.11.025; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761; Maurer-Stroh S, 2003, TRENDS BIOCHEM SCI, V28, P69, DOI 10.1016/S0968-0004(03)00004-5; MAVRI J, 1994, PROTEINS, V18, P381, DOI 10.1002/prot.340180408; Mer G, 2000, CELL, V103, P449, DOI 10.1016/S0092-8674(00)00136-7; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nakamura TM, 2005, MOL CELL BIOL, V25, P10721, DOI 10.1128/MCB.25.24.10721-10730.2005; Nielsen PR, 2002, NATURE, V416, P103, DOI 10.1038/nature722; Nishioka K, 2002, MOL CELL, V9, P1201, DOI 10.1016/S1097-2765(02)00548-8; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pena PV, 2006, NATURE, V442, P100, DOI 10.1038/nature04814; Pryde F, 2005, J CELL SCI, V118, P2043, DOI 10.1242/jcs.02336; Rice JC, 2002, GENE DEV, V16, P2225, DOI 10.1101/gad.1014902; Sanders SL, 2004, CELL, V119, P603, DOI 10.1016/j.cell.2004.11.009; Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704; Sims JK, 2006, J BIOL CHEM, V281, P12760, DOI 10.1074/jbc.M513462200; SMITH DL, 1973, NATURE, V246, P103, DOI 10.1038/246103a0; Steeg PS, 2003, CANCER LETT, V190, P1, DOI 10.1016/S0304-3835(02)00499-8; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Stucki M, 2005, CELL, V123, P1213, DOI 10.1016/j.cell.2005.09.038; Turnbull WB, 2003, J AM CHEM SOC, V125, P14859, DOI 10.1021/ja036166s; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; van Attikum H, 2005, NAT REV MOL CELL BIO, V6, P757, DOI 10.1038/nrm1737; Vidanes GM, 2005, CELL, V121, P973, DOI 10.1016/j.cell.2005.06.013; Ward IM, 2003, J BIOL CHEM, V278, P19579, DOI 10.1074/jbc.C300117200; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Xiao B, 2005, GENE DEV, V19, P1444, DOI 10.1101/gad.1315905	53	747	769	1	42	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 29	2006	127	7					1361	1373		10.1016/j.cell.2006.10.043	http://dx.doi.org/10.1016/j.cell.2006.10.043			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	128WI	17190600	Green Accepted, Bronze			2022-12-28	WOS:000243690000016
J	Green, RJ; Pierce, JMT				Green, R. J.; Pierce, J. M. T.			A novel use for disposable laryngoscope blades	BRITISH MEDICAL JOURNAL			English	Editorial Material									Southampton Gen Hosp, Southampton SO16 6YD, Hants, England	University of Southampton	Pierce, JMT (corresponding author), Southampton Gen Hosp, Southampton SO16 6YD, Hants, England.	tom.pierce@suht.swest.nhs.uk						Gaiser RR, 2004, BRIT J ANAESTH, V92, P584, DOI 10.1093/bja/aeh103; Goldberg ME, 1996, J CLIN ANESTH, V8, P475, DOI 10.1016/0952-8180(96)00127-4; *MDA, 2000, SINGL US MED DEV IMP; Miller DM, 2001, ANAESTHESIA, V56, P1069, DOI 10.1046/j.1365-2044.2001.02277.x	4	0	0	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 23	2006	333	7582					1297	1298		10.1136/bmj.39031.653160.AE	http://dx.doi.org/10.1136/bmj.39031.653160.AE			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121MC	17185714	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000243160700012
J	Vergassola, M; Villermaux, E; Shraiman, BI				Vergassola, Massimo; Villermaux, Emmanuel; Shraiman, Boris I.			'Infotaxis' as a strategy for searching without gradients	NATURE			English	Article							FINE-SCALE STRUCTURE; ODOR PLUMES; INSECT ORIENTATION; MOBILE ROBOT; PHEROMONE; CHEMOTAXIS; TRACKING; MOTHS	Chemotactic bacteria rely on local concentration gradients to guide them towards the source of a nutrient(1). Such local cues pointing towards the location of the source are not always available at macroscopic scales because mixing in a flowing medium breaks up regions of high concentration into random and disconnected patches. Thus, animals sensing odours in air or water detect them only intermittently as patches sweep by on the wind or currents(2-6). A macroscopic searcher must devise a strategy of movement based on sporadic cues and partial information. Here we propose a search algorithm, which we call 'infotaxis', designed to work under such conditions. Any search process can be thought of as acquisition of information on source location; for infotaxis, information plays a role similar to concentration in chemotaxis. The infotaxis strategy locally maximizes the expected rate of information gain. We demonstrate its efficiency using a computational model of odour plume propagation and experimental data on mixing flows(7). Infotactic trajectories feature 'zigzagging' and 'casting' paths similar to those observed in the flight of moths(8). The proposed search algorithm is relevant to the design of olfactory robots(9-11), but the general idea of infotaxis can be applied more broadly in the context of searching with sparse information.	Univ Calif Santa Barbara, Kavli Inst Theoret Phys, Santa Barbara, CA 93106 USA; Inst Pasteur, CNRS, URA 2171, F-75724 Paris 15, France; Univ Aix Marseille 1, F-13384 Marseille, France	University of California System; University of California Santa Barbara; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Aix-Marseille Universite	Shraiman, BI (corresponding author), Univ Calif Santa Barbara, Kavli Inst Theoret Phys, Santa Barbara, CA 93106 USA.	shraiman@kitp.ucsb.edu		Vergassola, Massimo/0000-0002-7212-8244; Villermaux, Emmanuel/0000-0001-5130-4862				Balkovsky E, 2002, P NATL ACAD SCI USA, V99, P12589, DOI 10.1073/pnas.192393499; Belanger JH, 1998, J COMP PHYSIOL A, V183, P345, DOI 10.1007/s003590050261; Berg B.C., 1993, RANDOM WALKS BIOL; BERG HC, 1977, BIOPHYS J, V20, P193, DOI 10.1016/S0006-3495(77)85544-6; COVER TM, 1991, SERIES TELECOMMUNICA; Dusenbery D.B., 1992, SENSORY ECOLOGY ORGA; Falkovich G, 2001, REV MOD PHYS, V73, P913, DOI 10.1103/RevModPhys.73.913; Farrell JA, 2005, IEEE J OCEANIC ENG, V30, P428, DOI 10.1109/JOE.2004.838066; Farrell JA, 2003, IEEE T SYST MAN CY B, V33, P850, DOI 10.1109/TSMCB.2003.810873; Grasso FW, 2000, ROBOT AUTON SYST, V30, P115, DOI 10.1016/S0921-8890(99)00068-8; Hansson B.S., 1999, INSECT OLFACTION; Ishida H, 2005, IEEE SENS J, V5, P537, DOI 10.1109/JSEN.2004.839597; Ishida H, 1996, SENSOR ACTUAT B-CHEM, V33, P115, DOI 10.1016/0925-4005(96)01907-7; Kaupp UB, 2003, NAT CELL BIOL, V5, P109, DOI 10.1038/ncb915; Kennedy JS, 1983, PHYSIOL ENTOMOL, V27, P58; Kuwana Y, 1999, BIOSENS BIOELECTRON, V14, P195, DOI 10.1016/S0956-5663(98)00106-7; Li W, 2001, ADAPT BEHAV, V9, P143, DOI 10.1177/10597123010093003; MAFRANETO A, 1994, NATURE, V369, P142, DOI 10.1038/369142a0; Marques L, 2006, AUTON ROBOT, V20, P183, DOI 10.1007/s10514-006-7536-7; MURLIS J, 1981, PHYSIOL ENTOMOL, V6, P71, DOI 10.1111/j.1365-3032.1981.tb00262.x; MURLIS J, 1992, ANNU REV ENTOMOL, V37, P505, DOI 10.1146/annurev.en.37.010192.002445; PANG S, IN PRESS IEEE T SY B; Payne T.L., 1986, MECH INSECT OLFACTIO; Russell R.A., 1999, ODOR DETECTION MOBIL; Russell RA, 2003, ROBOT AUTON SYST, V45, P83, DOI 10.1016/S0921-8890(03)00120-9; SHANNON CE, 1948, BELL SYST TECH J, V27, P379, DOI 10.1002/j.1538-7305.1948.tb01338.x; SHANNON CE, 1948, BELL SYST TECH J, V27, P623, DOI 10.1002/j.1538-7305.1948.tb00917.x; Shraiman BI, 2000, NATURE, V405, P639, DOI 10.1038/35015000; Villermaux E, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.184501; Webb B, 2002, NATURE, V417, P359, DOI 10.1038/417359a	31	478	494	4	142	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 25	2007	445	7126					406	409		10.1038/nature05464	http://dx.doi.org/10.1038/nature05464			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	128WD	17251974				2022-12-28	WOS:000243689500034
J	Thiam, S; LeFevre, AM; Hane, F; Ndiaye, A; Ba, F; Fielding, KL; Ndir, M; Lienhardt, C				Thiam, Sylla; LeFevre, Andrea M.; Hane, Fatoumata; Ndiaye, Alimatou; Ba, Fatoumata; Fielding, Katherine L.; Ndir, Moustapha; Lienhardt, Christian			Effectiveness of a strategy to improve adherence to tuberculosis treatment in a resource-poor setting - A cluster randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OBSERVED TREATMENT DOT; SOUTH-AFRICA; COMMUNITY; DECENTRALIZATION; DISTRICT	Context Poor adherence to treatment remains a major obstacle to efficient tuberculosis ( TB) control in developing countries. Innovative strategies to improve access and adherence to treatment are needed. Objectives To assess the effectiveness of a contextualized intervention strategy aimed at improving patients' adherence to treatment and to evaluate its impact on TB control in a resource-poor country in Africa with prevalent TB infection. Design, Setting, and Patients A cluster randomized controlled trial, conducted between June 2003 and January 2005, at 16 government district health centers in Senegal. Patients older than 15 years with newly diagnosed sputum smear - positive pulmonary TB were randomly assigned to the intervention or control group. Intervention The intervention strategy included reinforced counseling through improved communication between health personnel and patients, decentralization of treatment, choice of directly observed therapy ( DOT) supporter by the patient, and reinforcement of supervision activities. In the control group, the usual TB control program procedures remained unchanged. Main Outcome Measure Proportion of patients successfully completing the 8-month course of treatment and the proportion of patients defaulting from treatment. Results A total of 1522 patients were recruited into the study. Treatment was successful for 682 (88%) of 778 patients recruited in the intervention group, and for 563 (76%) of 744 patients recruited in the control group ( adjusted risk ratio [RR], 1.18; 95% confidence interval [CI], 1.03-1.34). The proportion of patients defaulting was reduced in the intervention group to 5.5% (n=43) compared with 16.8% (n=125) in the control group ( adjusted RR, 0.43; 95% CI, 0.21-0.89). Conclusion The intervention package based on improved patients counseling and communication, decentralization of treatment, patient choice of DOT supporter, and reinforcement of supervision activities led to improvement in patient outcomes compared with the usual TB control procedures. This approach may be generalized in the context of TB control programs in resource-poor countries.	Int Union TB & Lung Dis, F-75006 Paris, France; IRD, Programme TB, Dakar, Senegal; London Sch Hyg & Trop Med, Infect Dis Epidemiol Unit, London WC1, England; Programme Natl Lutte AntiTB, Dakar, Senegal	Institut de Recherche pour le Developpement (IRD); University of London; London School of Hygiene & Tropical Medicine	Lienhardt, C (corresponding author), IRD, 68 Blvd St Michel, F-75006 Paris, France.	clienhardt@iuatld.org	Lienhardt, Christian/AAU-4969-2021; Rehman, Andrea/AAP-3172-2020; HANE, Fatoumata/GQA-9196-2022	Lienhardt, Christian/0000-0003-0233-893X; Rehman, Andrea/0000-0001-9967-5822; Fielding, Katherine/0000-0002-6524-3754	Medical Research Council [G0700837] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Adatu F, 2003, INT J TUBERC LUNG D, V7, pS63; Bennett S, 2002, INT J EPIDEMIOL, V31, P839, DOI 10.1093/ije/31.4.839; Clarke M, 2005, INT J TUBERC LUNG D, V9, P673; Comolet TM, 1998, INT J TUBERC LUNG D, V2, P891; Enarson D.A., 2000, MANAGEMENT TUBERCULO; HANE F, IN PRESS INT J TUBER; Hayes RJ, 1999, INT J EPIDEMIOL, V28, P319, DOI 10.1093/ije/28.2.319; Hill RC, 2005, INT J TUBERC LUNG D, V9, P1349; Jaiswal A, 2003, TROP MED INT HEALTH, V8, P625, DOI 10.1046/j.1365-3156.2003.01061.x; Kamolratanakul P, 1999, T ROY SOC TROP MED H, V93, P552, DOI 10.1016/S0035-9203(99)90379-6; Kangangi JK, 2003, INT J TUBERC LUNG D, V7, pS5; Lienhardt C, 2004, TROP MED INT HEALTH, V9, P833, DOI 10.1111/j.1365-3156.2004.01273.x; Lienhardt C, 2006, LANCET, V367, P949, DOI 10.1016/S0140-6736(06)68390-6; LIENHARDT C, 2003, RETURN WHITE PLAGUE; Macq JCM, 2003, INT J TUBERC LUNG D, V7, P103; MENZIES R, 1993, TUBERCLE LUNG DIS, V74, P32, DOI 10.1016/0962-8479(93)90066-7; *MIN SANT PREV SEN, 2002, B EP MIN SANT PREV S, V9; Newell JN, 2006, LANCET, V367, P903, DOI 10.1016/S0140-6736(06)68380-3; Nyirenda TE, 2003, INT J TUBERC LUNG D, V7, pS21; Organization WH, 2003, ADHERENCE LONG TERM; Snider, 1982, B INT UNION TUBERC, V57, P247; SUMARTOJO E, 1993, AM REV RESPIR DIS, V147, P1311, DOI 10.1164/ajrccm/147.5.1311; Thiam S, 2005, Med Trop (Mars), V65, P43; THOMSON A, 2006, SOC CLIN TRIALS C MA; Volmink J, 2000, LANCET, V355, P1345, DOI 10.1016/S0140-6736(00)02124-3; Walley JD, 2001, LANCET, V357, P664, DOI 10.1016/S0140-6736(00)04129-5; *WHO, 2004, GLOB TUB CONTR SURV; World Health Organization, 2002, WHOCDSTB2002297; World Health Organization, 1994, WHOTB94179; Zwarenstein M, 1998, LANCET, V352, P1340, DOI 10.1016/S0140-6736(98)04022-7	31	111	113	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 24	2007	297	4					380	386		10.1001/jama.297.4.380	http://dx.doi.org/10.1001/jama.297.4.380			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128GE	17244834	Green Accepted			2022-12-28	WOS:000243645400023
J	Mizuno, D; Tardin, C; Schmidt, CF; MacKintosh, FC				Mizuno, Daisuke; Tardin, Catherine; Schmidt, C. F.; MacKintosh, F. C.			Nonequilibrium mechanics of active cytoskeletal networks	SCIENCE			English	Article							2-POINT MICRORHEOLOGY; MYOSIN; VISCOELASTICITY; ELASTICITY; MOTION; MODULI	Cells both actively generate and sensitively react to forces through their mechanical framework, the cytoskeleton, which is a nonequilibrium composite material including polymers and motor proteins. We measured the dynamics and mechanical properties of a simple three-component model system consisting of myosin II, actin filaments, and cross-linkers. In this system, stresses arising from motor activity controlled the cytoskeletal network mechanics, increasing stiffness by a factor of nearly 100 and qualitatively changing the viscoelastic response of the network in an adenosine triphosphate-dependent manner. We present a quantitative theoretical model connecting the large-scale properties of this active gel to molecular force generation.	Vrije Univ Amsterdam, Dept Phys & Astron, NL-1081 HV Amsterdam, Netherlands; Univ Gottingen, Fak Phys, Inst Phys 3, D-37077 Gottingen, Germany	Vrije Universiteit Amsterdam; University of Gottingen	MacKintosh, FC (corresponding author), Vrije Univ Amsterdam, Dept Phys & Astron, NL-1081 HV Amsterdam, Netherlands.	cfs@nat.vu.nl; fcm@nat.vu.nl	MacKintosh, Fred C/A-9450-2008; Schmidt, Christoph F/G-3787-2011; 水野, 大介/O-1812-2018; MacKintosh, Frederick/AAB-9332-2021	MacKintosh, Fred C/0000-0002-2607-9541; Schmidt, Christoph F/0000-0003-2864-6973; 水野, 大介/0000-0001-7749-3681; MacKintosh, Frederick/0000-0002-2607-9541				Bray D, 2001, CELL MOVEMENTS MOL M; Buchanan M, 2005, MACROMOLECULES, V38, P8840, DOI 10.1021/ma0500990; Caspi A, 1998, PHYS REV LETT, V80, P1106, DOI 10.1103/PhysRevLett.80.1106; Crocker JC, 2000, PHYS REV LETT, V85, P888, DOI 10.1103/PhysRevLett.85.888; D'Anna G, 2003, NATURE, V424, P909, DOI 10.1038/nature01867; Discher DE, 2005, SCIENCE, V310, P1139, DOI 10.1126/science.1116995; Einstein A, 1905, ANN PHYS-BERLIN, V17, P549, DOI 10.1002/andp.19053220806; Gardel ML, 2004, SCIENCE, V304, P1301, DOI 10.1126/science.1095087; Gittes F, 1997, PHYS REV LETT, V79, P3286, DOI 10.1103/PhysRevLett.79.3286; Gittes F, 1998, PHYS REV E, V58, pR1241, DOI 10.1103/PhysRevE.58.R1241; HAYASHI T, 1975, J BIOCHEM-TOKYO, V78, P1031, DOI 10.1093/oxfordjournals.jbchem.a130980; Hough LA, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.021906; Humphrey D, 2002, NATURE, V416, P413, DOI 10.1038/416413; Janmey PA, 2004, TRENDS BIOCHEM SCI, V29, P364, DOI 10.1016/j.tibs.2004.05.003; Koenderink GH, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysLettRev.96.138307; Laevsky G, 2003, J CELL SCI, V116, P3761, DOI 10.1242/jcs.00684; Lau AWC, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.198101; Le Goff L, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.018101; Levine AJ, 2000, PHYS REV LETT, V85, P1774, DOI 10.1103/PhysRevLett.85.1774; MACKINTOSH FC, 1995, PHYS REV LETT, V75, P4425, DOI 10.1103/PhysRevLett.75.4425; MASON TG, 1995, PHYS REV LETT, V74, P1250, DOI 10.1103/PhysRevLett.74.1250; Mizuno D, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.088104; Morse DC, 1998, MACROMOLECULES, V31, P7044, DOI 10.1021/ma980304u; REISLER E, 1980, J MOL BIOL, V143, P129, DOI 10.1016/0022-2836(80)90127-8; Storm C, 2005, NATURE, V435, P191, DOI 10.1038/nature03521; Veigel C, 1999, NATURE, V398, P530, DOI 10.1038/19104	26	651	657	3	193	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 19	2007	315	5810					370	373		10.1126/science.1134404	http://dx.doi.org/10.1126/science.1134404			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126SI	17234946				2022-12-28	WOS:000243535400040
J	Scharfman, HE; Hen, R				Scharfman, Helen E.; Hen, Rene			Is more Neurogenesis always better?	SCIENCE			English	Editorial Material							SEIZURE-INDUCED NEUROGENESIS; HIPPOCAMPAL NEUROGENESIS; DENTATE GYRUS; ADULT; REPLACEMENT; PRECURSORS; NEOCORTEX; NEURONS; MEMORY; STROKE		Columbia Univ, Dept Pharmacol, New York, NY 10032 USA; Columbia Univ, Dept Neurol, New York, NY 10032 USA; Helen Hayes Hosp, Ctr Neural Recovery & Rehabil Res, W Haverstraw, NY 10993 USA; Columbia Univ, Dept Psychiat, New York, NY 10032 USA; Columbia Univ, Ctr Neurobiol & Behav, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University; Columbia University	Scharfman, HE (corresponding author), Columbia Univ, Dept Pharmacol, New York, NY 10032 USA.	scharfmanh@helenhayeshosp.org			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037562] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS037562] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Bannerman DM, 2004, NEUROSCI BIOBEHAV R, V28, P273, DOI 10.1016/j.neubiorev.2004.03.004; Dayer AG, 2005, J CELL BIOL, V168, P415, DOI 10.1083/jcb.200407053; Dayer AG, 2003, J COMP NEUROL, V460, P563, DOI 10.1002/cne.10675; Doetsch F, 2005, CURR OPIN NEUROBIOL, V15, P121, DOI 10.1016/j.conb.2005.01.018; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Jin K, 2006, BRAIN RES, V1085, P183, DOI 10.1016/j.brainres.2006.02.081; Keilhoff G, 2004, BIOL PSYCHIAT, V56, P317, DOI 10.1016/j.biopsych.2004.06.010; KEMPERMANN G, 2006, ADULT NEUROGENESIS S; Kokoeva MV, 2005, SCIENCE, V310, P679, DOI 10.1126/science.1115360; Kuhn HG, 2001, EUR ARCH PSY CLIN N, V251, P152, DOI 10.1007/s004060170035; Longo Frank M., 2006, Current Alzheimer Research, V3, P5, DOI 10.2174/156720506775697089; Malberg JE, 2000, J NEUROSCI, V20, P9104, DOI 10.1523/jneurosci.20-24-09104.2000; Meshi D, 2006, NAT NEUROSCI, V9, P729, DOI 10.1038/nn1696; Parent JM, 2006, ANN NEUROL, V59, P81, DOI 10.1002/ana.20699; Parent JM, 2002, ANN NEUROL, V52, P802, DOI 10.1002/ana.10393; Rakic P, 2002, NAT REV NEUROSCI, V3, P65, DOI 10.1038/nrn700; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; SAXE M, 2006, 2666 SOC NEUR; Saxe MD, 2006, P NATL ACAD SCI USA, V103, P17501, DOI 10.1073/pnas.0607207103; Scharfman HE, 2004, ADV EXP MED BIOL, V548, P192; Shors TJ, 2002, HIPPOCAMPUS, V12, P578, DOI 10.1002/hipo.10103; Winocur G, 2006, HIPPOCAMPUS, V16, P296, DOI 10.1002/hipo.20163; Zhao M, 2003, P NATL ACAD SCI USA, V100, P7925, DOI 10.1073/pnas.1131955100	24	93	99	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 19	2007	315	5810					336	338		10.1126/science.1138711	http://dx.doi.org/10.1126/science.1138711			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126SI	17234934	Green Accepted			2022-12-28	WOS:000243535400025
J	Markowitz, AJ; McPhee, SJ				Markowitz, Amy J.; McPhee, Stephen J.			End-of-life care for homeless patients: "She says she is there to help me in any situation"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material														Markowitz, Amy/0000-0001-9314-2814				Kushel MB, 2006, JAMA-J AM MED ASSOC, V296, P2959, DOI 10.1001/jama.296.24.2959	1	2	2	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 17	2007	297	3					305	305		10.1001/jama.297.3.305	http://dx.doi.org/10.1001/jama.297.3.305			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125VT	17227982				2022-12-28	WOS:000243472300025
J	Brouilette, SW; Moore, JS; D McMahon, A; Thompson, JR; Ford, I; Shepherd, J; Packard, CJ; Samani, NJ				Brouilette, Scott W.; Moore, Jasbir S.; D McMahon, Alex; Thompson, John R.; Ford, Ian; Shepherd, James; Packard, Chris J.; Samani, Nilesh J.		W Scotland Coronary Prevention Stu	Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study	LANCET			English	Article							WHITE BLOOD-CELLS; ATHEROSCLEROSIS; ENDOTHELIUM; MORTALITY; THERAPY; PLAQUES	Background Inter-individual differences in biological ageing could affect susceptibility to coronary heart disease. Our aim was to determine whether mean leucocyte telomere length is a predictor of the development of coronary heart disease. Methods We compared telomere lengths at recruitment in 484 individuals in the West of Scotland Primary Prevention Study (WOSCOPS) who went on to develop coronary heart disease events with those from 1058 matched controls who remained event free. We also investigated whether there was any association between telomere length and observed clinical benefit of statin treatment in WOSCOPS. Findings Mean telomere length decreased with age by 9% per decade (95% CI 3.6-14.1; p=0.001) in controls; much the same trend was seen in cases (-5.9% per decade, -3.1 to 14.1; p=0.1902). Individuals in the middle and the lowest tertiles of telomere length were more at risk of developing a coronary heart disease event than were individuals in the highest tertile (odds ratio [OR] for coronary heart disease: 1.51, 95% CI 1.15-1.98; p=0.0029 in the middle tertile; 1.44, 1.10-1.90, p=0.0090 in the lowest). In placebo-treated patients, the risk of coronary heart disease was almost double in those in the lower two tertiles of telomere length compared with those in the highest tertile (1.93, 1.33-2.80, p=0.0005 in the middle tertile; 1.94, 1.33-2.84, p=0.0006 in the lowest). By contrast, in patients treated with pravastatin, the increased risk with shorter telomeres was substantially attenuated (1.12, 0.75-1.69, p=0.5755 in the middle tertile; 1.02, 0.68-1.52, p=0.9380 in the lowest). Interpretation Mean leucocyte telomere length is a predictor of future coronary heart disease events in middle-aged, high-risk men and could identify individuals who would benefit most from statin treatment. Our findings lend support to the hypothesis that differences in biological ageing might contribute to the risk-and variability in age of onset-of coronary heart disease.	Univ Leicester, Dept Cardiovasc Sci, Leicester, Leics, England; Univ Leicester, Dept Hlth Sci, Leicester, Leics, England; Univ Glasgow, Robertson Ctr Biostat, Glasgow, Lanark, Scotland; Univ Glasgow, Dept Vasc Biochem, Glasgow, Lanark, Scotland	University of Leicester; University of Leicester; University of Glasgow; University of Glasgow	Samani, NJ (corresponding author), Univ Leicester, Dept Cardiovasc Sci, Glenfield Hosp, Clin Sci Wing,Groby Rd, Leicester LE3 9QP, Leics, England.	njs@le.ac.uk	Ford, Ian/ABE-6145-2020					ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; ALLSOPP RC, 1995, EXP CELL RES, V219, P130, DOI 10.1006/excr.1995.1213; Andrew T, 2006, AM J HUM GENET, V78, P480, DOI 10.1086/500052; [Anonymous], 1995, Am J Cardiol, V76, P485; Brouilette S, 2003, ARTERIOSCL THROM VAS, V23, P842, DOI 10.1161/01.ATV.0000067426.96344.32; BURRIG KF, 1991, ARTERIOSCLER THROMB, V11, P1678, DOI 10.1161/01.ATV.11.6.1678; Cawthon RM, 2003, LANCET, V361, P393, DOI 10.1016/S0140-6736(03)12384-7; Cawthon RM, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e47; Chan SRWL, 2004, PHILOS T R SOC B, V359, P109, DOI 10.1098/rstb.2003.1370; CHANG E, 1995, P NATL ACAD SCI USA, V92, P11190, DOI 10.1073/pnas.92.24.11190; DAVIES MJ, 1988, BRIT HEART J, V60, P459; Epel ES, 2004, P NATL ACAD SCI USA, V101, P17312, DOI 10.1073/pnas.0407162101; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Harrison D, 1998, Can J Cardiol, V14 Suppl D, p30D; Jeanclos E, 1998, DIABETES, V47, P482, DOI 10.2337/diabetes.47.3.482; Martin-Ruiz C, 2004, J BIOL CHEM, V279, P17826, DOI 10.1074/jbc.M311980200; Martin-Ruiz CM, 2005, AGING CELL, V4, P287, DOI 10.1111/j.1474-9726.2005.00171.x; Minamino T, 2002, CIRCULATION, V105, P1541, DOI 10.1161/01.CIR.0000013836.85741.17; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; Packard CJ, 2000, NEW ENGL J MED, V343, P1148, DOI 10.1056/NEJM200010193431603; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Samani NJ, 2001, LANCET, V358, P472, DOI 10.1016/S0140-6736(01)05633-1; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SLAGBOOM PE, 1994, AM J HUM GENET, V55, P876; Spyridopoulos I, 2004, CIRCULATION, V110, P3136, DOI 10.1161/01.CIR.0000142866.50300.EB; Takubo K, 2002, EXP GERONTOL, V37, P523, DOI 10.1016/S0531-5565(01)00218-2; Valdes AM, 2005, LANCET, V366, P662, DOI 10.1016/S0140-6736(05)66630-5; Vasa M, 2001, CIRCULATION, V103, P2885, DOI 10.1161/hc2401.092816; Vasa-Nicotera M, 2005, AM J HUM GENET, V76, P147, DOI 10.1086/426734; VAZIRI H, 1994, P NATL ACAD SCI USA, V91, P9857, DOI 10.1073/pnas.91.21.9857; Von Zglinicki T, 2000, ANN NY ACAD SCI, V908, P99, DOI 10.1111/j.1749-6632.2000.tb06639.x; Walter DH, 2002, CIRCULATION, V105, P3017, DOI 10.1161/01.CIR.0000018166.84319.55; Warton K, 2004, GENE, V342, P85, DOI 10.1016/j.gene.2004.07.027; Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9	34	579	602	0	49	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 13	2007	369	9556					107	114		10.1016/S0140-6736(07)60071-3	http://dx.doi.org/10.1016/S0140-6736(07)60071-3			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	126TK	17223473				2022-12-28	WOS:000243538200029
J	Conter, V; Valsecchi, MG; Silvestri, D; Campbell, M; Dibar, E; Magyarosy, E; Gadner, H; Stary, J; Benoit, Y; Zimmermann, M; Reiter, A; Riehm, H; Masera, G; Schrappe, M				Conter, Valentino; Valsecchi, Maria Grazia; Silvestri, Daniela; Campbell, Myriam; Dibar, Eduardo; Magyarosy, Edina; Gadner, Helmut; Stary, Jan; Benoit, Yves; Zimmermann, Martin; Reiter, Alfred; Riehm, Hansjoerg; Masera, Giuseppe; Schrappe, Martin			Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial	LANCET			English	Article							BFM STUDY-GROUP; IN-VITRO; CHILDHOOD; PREDNISONE; INTENSIFICATION; CLASSIFICATION; THERAPY	Background Studies in the 1970s and 1980s suggested that the outcome of childhood acute lymphoblastic leukaemia (ALL) could be improved by intensification of conventional continuation chemotherapy with pulses of vincristine sulfate and steroids. We aimed to investigate the efficacy and toxic effects of vincristine-dexamethasone pulses as an addition to the continuation-therapy phase in a large cohort of children with intermediate-risk disease who were treated with the Berlin-Frankfyrt-Munster (BFM) treatment strategy. Methods 3109 children, diagnosed with ALL and intermediate-risk features, were enrolled by eight participating organisations in eleven countries. All were treated with very similar protocols based on the BFM treatment strategy, which included induction, consolidation, reinduction, and continuation-therapy phases. At the beginning of the continuation-therapy phase, those patients in complete remission were randomly assigned to either a treatment or a control group. Control patients were given conventional mercaptopurine and methotrexate chemotherapy only. Patients in the treatment arm were also given pulses of vincristine (1.5 mg/m(2) weekly for 2 weeks) and dexamethasone (6 mg/m(2) daily for 7 days) every 10 weeks for six cycles. The primary outcome measure was disease-free survival. Analysis was by intention to treat. The study is registered at http://www.clinicaltrials.gov with the identifier NCT00411541. Findings 174 patients (5.6%) relapsed or died in complete remission before randomisation. Of the remaining 2935 patients, 2618 (89.2%) were randomly assigned: 1325 to the treatment group and 1293 to the control group. With median follow-up of 4.8 years, 240 children in the treatment group and 241 in the control group had relapses; 15 in the treatment group and 14 controls died in complete remission or developed second malignant neoplasms. The 5-year and 7-year disease-free survival estimates were 79.8% (SE 1.2) and 77.5% (1.5) in the treatment group and 79.2% (1.2) and 78.4% (1.3.) in the control group, respectively. Treatment with pulses of vincristine and dexamethasone was associated with a non-significant 3% relative-risk reduction (hazard ratio 0.97; 95% CI 0.81-1.15; p=0.70). Interpretation Children with intermediate-risk ALL who received intensive chemotherapy based on BFM protocols did not benefit from intensification of the continuation-therapy phase with a schedule of pulses of vincristine and dexamethasone.	Univ Milano Bicocca, Osped San Gerardo, Dept Paediat, Monza, Italy; Univ Milano Bicocca, Med Stat Unit, Dept Clin Med Biotechnol & Prevent, Monza, Italy; Hosp Roberto Del Rio, PINDA, Dept Paediat Haematol & Oncol, Santiago, Chile; Italian Hosp, Dept Paediat Haematol & Oncol, Buenos Aires, DF, Argentina; Semmelweis Univ, Dept Paediat, Budapest, Hungary; St Anna Childrens Hosp, Childrens Canc Res Inst, Vienna, Austria; Univ Hosp Motol, Dept Paediat Haematol & Oncol, Prague, Czech Republic; Ghent Univ Hosp, Dept Paediat Haematooncol, B-9000 Ghent, Belgium; European Org Res Treatment Canc, Childrens Leukemia Grp, Brussels, Belgium; Hannover Med Sch, Dept Paediat Haematol & Oncol, D-3000 Hannover, Germany; Univ Childrens Hosp, Dept Paediat Haematol & Oncol, Giessen, Germany; Univ Med Ctr Schleswig Holstein, Dept Paediat, Kiel, Germany	San Gerardo Hospital; University of Milano-Bicocca; University of Milano-Bicocca; Universidad de Chile; Hospital Italiano de Buenos Aires; Semmelweis University; Saint Anna Children's Hospital; Motol University Hospital; Ghent University; Ghent University Hospital; European Organisation for Research & Treatment of Cancer; Hannover Medical School; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Kiel; Schleswig Holstein University Hospital	Conter, V (corresponding author), Univ Milano Bicocca, Osped San Gerardo, Dept Paediat, Monza, Italy.	valentino.conter@pediatriamonza.it	Schrappe, Martin/A-8109-2010; Stary, Jan/AAB-9635-2020; Schrappe, Martin/ABA-6144-2020; Valsecchi, Maria Grazia/K-8891-2016	Valsecchi, Maria Grazia/0000-0001-5574-3504				Arico M, 2005, Leukemia, V19, P1145, DOI 10.1038/sj.leu.2403783; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BLEYER WA, 1991, J CLIN ONCOL, V9, P1012, DOI 10.1200/JCO.1991.9.6.1012; Bostrom BC, 2003, BLOOD, V101, P3809, DOI 10.1182/blood-2002-08-2454; Carroll William L, 2003, Hematology Am Soc Hematol Educ Program, P102; CHESSELLS JM, 1995, LANCET, V345, P143, DOI 10.1016/S0140-6736(95)90164-7; CLAVELL LA, 1986, NEW ENGL J MED, V315, P657, DOI 10.1056/NEJM198609113151101; Conter V, 1997, J CLIN ONCOL, V15, P2786, DOI 10.1200/JCO.1997.15.8.2786; Conter V, 2000, LEUKEMIA, V14, P2196, DOI 10.1038/sj.leu.2401963; COX DR, 1972, J R STAT SOC B, V34, P187; Gaynon PS, 2000, LEUKEMIA, V14, P2223, DOI 10.1038/sj.leu.2401939; Henze G, 1990, Haematol Blood Transfus, V33, P483; HOLLAND JF, 1972, CANCER-AM CANCER SOC, V30, P1480, DOI 10.1002/1097-0142(197212)30:6<1480::AID-CNCR2820300611>3.0.CO;2-3; JONES B, 1991, MED PEDIATR ONCOL, V19, P269, DOI 10.1002/mpo.2950190411; Kaspers GJL, 1996, MED PEDIATR ONCOL, V27, P114; KLUMPER E, 1995, BLOOD, V86, P3861, DOI 10.1182/blood.V86.10.3861.bloodjournal86103861; Masera G, 1998, INT J PEDIAT HEM ONC, V5, P141; PINKEL D, 1971, CANCER-AM CANCER SOC, V27, P247, DOI 10.1002/1097-0142(197102)27:2<247::AID-CNCR2820270202>3.0.CO;2-C; Pui CH, 2000, LEUKEMIA, V14, P2286, DOI 10.1038/sj.leu.2401938; REITER A, 1994, BLOOD, V84, P3122, DOI 10.1182/blood.V84.9.3122.3122; Richards S, 1996, LANCET, V347, P1783; Riehm H, 1990, Haematol Blood Transfus, V33, P439; Sallan S E, 1990, Haematol Blood Transfus, V33, P459; Schrappe M, 2000, LEUKEMIA, V14, P2205, DOI 10.1038/sj.leu.2401973; TUBERGEN DG, 1993, J CLIN ONCOL, V11, P527, DOI 10.1200/JCO.1993.11.3.527; Valsecchi MG, 1996, ANN ONCOL, V7, P1005; VANDERDOESVANDENBERG A, 1992, MED PEDIATR ONCOL, V20, P497, DOI 10.1002/mpo.2950200603; Veerman AJP, 1996, J CLIN ONCOL, V14, P911, DOI 10.1200/JCO.1996.14.3.911	28	79	84	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 13	2007	369	9556					123	131		10.1016/S0140-6736(07)60073-7	http://dx.doi.org/10.1016/S0140-6736(07)60073-7			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	126TK	17223475				2022-12-28	WOS:000243538200031
J	Sheikh, A; Esmail, A				Sheikh, Aziz; Esmail, Aneez			Should Muslims have faith based health services?	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Edinburgh, Div Community Hlth Sci, Edinburgh EH8 9DX, Midlothian, Scotland	University of Edinburgh	Sheikh, A (corresponding author), Univ Edinburgh, Div Community Hlth Sci, Edinburgh EH8 9DX, Midlothian, Scotland.	Aziz.Sheikh@ed.ac.uk; aneezesmail@manchester.ac.uk	Sheikh, Aziz/D-2818-2009; Esmail, Aneez/I-6903-2013	Sheikh, Aziz/0000-0001-7022-3056; 					0	15	15	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JAN 13	2007	334	7584					74	75		10.1136/bmj.39072.347720.68	http://dx.doi.org/10.1136/bmj.39072.347720.68			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	127DZ	17218711	Green Published, Green Submitted			2022-12-28	WOS:000243566800028
J	Shen, WH; Balajee, AS; Wang, JL; Wu, H; Eng, C; Pandolfi, PP; Yin, YX				Shen, Wen Hong; Balajee, Adayabalam S.; Wang, Jianli; Wu, Hong; Eng, Charis; Pandolfi, Pier Paolo; Yin, Yuxin			Essential role for nuclear PTEN in maintaining chromosomal integrity	CELL			English	Article							TUMOR-SUPPRESSOR GENE; CENP-C; CELL-SURVIVAL; KINETOCHORE; PROTEIN; AMPLIFICATION; INSTABILITY; NEOPLASIA; CANCER; REPAIR	A broad spectrum of mutations in PTEN, encoding a lipid phosphatase that inactivates the P13-K/AKT pathway, is found associated with primary tumors. Some of these mutations occur outside the phosphatase domain, suggesting that additional activities of PTEN function in tumor suppression. We report a nuclear function for PTEN in controlling chromosomal integrity. Disruption of Pten leads to extensive centromere breakage and chromosomal translocations. PTEN was found localized at centromeres and physically associated with CENP-C, an integral component of the kinetochore. C-terminal PTEN mutants disrupt the association of PTEN with centromeres and cause centromeric instability. Furthermore, Pten null cells exhibit spontaneous DNA double-strand breaks (DSBs). We show that PTEN acts on chromatin and regulates expression of Rad51, which reduces the incidence of spontaneous DSBs. Our results demonstrate that PTEN plays a fundamental role in the maintenance of chromosomal stability through the physical interaction with centromeres and control of DNA repair. We propose that PTEN acts as a guardian of genome integrity.	Columbia Univ, Coll Phys & Surg, Dept Radiat Oncol, New York, NY 10032 USA; Univ Calif Los Angeles, Sch Med, Dept Med & Mol Pharmacol, Los Angeles, CA 90095 USA; Cleveland Clin Fdn, Genom Med Inst, Cleveland, OH 44195 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Canc Biol & Genet Program, New York, NY 10021 USA	Columbia University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cleveland Clinic Foundation; Memorial Sloan Kettering Cancer Center	Yin, YX (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Radiat Oncol, 630 W 168th St, New York, NY 10032 USA.	yy151@columbia.edu	wang, jian/GVS-0711-2022	Eng, Charis/0000-0002-3693-5145; SHEN, WEN/0000-0002-5830-6518	NCI NIH HHS [R01 CA093677, R01 CA102447] Funding Source: Medline; NIGMS NIH HHS [R01 GM100478] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA093677, R01CA102447] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agrawal S, 2005, HUM MOL GENET, V14, P2459, DOI 10.1093/hmg/ddi246; Albertson DG, 2003, NAT GENET, V34, P369, DOI 10.1038/ng1215; Carroll CW, 2006, TRENDS CELL BIOL, V16, P70, DOI 10.1016/j.tcb.2005.12.008; Choo KHA, 2000, TRENDS CELL BIOL, V10, P182, DOI 10.1016/S0962-8924(00)01739-6; Cleveland DW, 2003, CELL, V112, P407, DOI 10.1016/S0092-8674(03)00115-6; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; EARNSHAW WC, 1985, CHROMOSOMA, V91, P313, DOI 10.1007/BF00328227; Eng C, 2003, HUM MUTAT, V22, P183, DOI 10.1002/humu.10257; Foster ER, 2005, FEBS J, V272, P3231, DOI 10.1111/j.1742-4658.2005.04741.x; Fukagawa T, 1999, EMBO J, V18, P4196, DOI 10.1093/emboj/18.15.4196; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; HAYS SL, 1995, P NATL ACAD SCI USA, V92, P6925, DOI 10.1073/pnas.92.15.6925; Henikoff S, 2001, SCIENCE, V293, P1098, DOI 10.1126/science.1062939; Kalitsis P, 1998, P NATL ACAD SCI USA, V95, P1136, DOI 10.1073/pnas.95.3.1136; Levine AJ, 1995, ANN NY ACAD SCI, V768, P111, DOI 10.1111/j.1749-6632.1995.tb12115.x; Li G, 2002, DEVELOPMENT, V129, P4159; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Mills KD, 2003, IMMUNOL REV, V194, P77, DOI 10.1034/j.1600-065X.2003.00060.x; MOROI Y, 1980, P NATL ACAD SCI-BIOL, V77, P1627, DOI 10.1073/pnas.77.3.1627; Pastink A, 2001, MUTAT RES-FUND MOL M, V480, P37, DOI 10.1016/S0027-5107(01)00167-1; Pierce AJ, 2001, TRENDS CELL BIOL, V11, pS52, DOI 10.1016/S0962-8924(01)02149-3; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Puc J, 2005, CANCER CELL, V7, P193, DOI 10.1016/j.ccr.2005.01.009; Regnier V, 2005, MOL CELL BIOL, V25, P3967, DOI 10.1128/MCB.25.10.3967-3981.2005; SAITOH H, 1992, CELL, V70, P115, DOI 10.1016/0092-8674(92)90538-N; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Smiraldo PG, 2005, CANCER RES, V65, P2089, DOI 10.1158/0008-5472.CAN-04-2079; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stambolic V, 2000, CANCER RES, V60, P3605; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Thacker J, 2005, CANCER LETT, V219, P125, DOI 10.1016/j.canlet.2004.08.018; Thiriet C, 2005, MOL CELL, V18, P617, DOI 10.1016/j.molcel.2005.05.008; TOMKIEL J, 1994, J CELL BIOL, V125, P531, DOI 10.1083/jcb.125.3.531; Tutt A, 2002, TRENDS MOL MED, V8, P571, DOI 10.1016/S1471-4914(02)02434-6; Vlietstra RJ, 1998, CANCER RES, V58, P2720; Waite KA, 2002, AM J HUM GENET, V70, P829, DOI 10.1086/340026; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yilmaz OH, 2006, NATURE, V441, P475, DOI 10.1038/nature04703; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; Yuen KWY, 2005, CURR OPIN CELL BIOL, V17, P576, DOI 10.1016/j.ceb.2005.09.012	48	738	780	2	33	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 12	2007	128	1					157	170		10.1016/j.cell.2006.11.042	http://dx.doi.org/10.1016/j.cell.2006.11.042			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	139GN	17218262	Bronze			2022-12-28	WOS:000244420400020
J	Farnan, I; Cho, H; Weber, WJ				Farnan, Ian; Cho, Herman; Weber, William J.			Quantification of actinide alpha-radiation damage in minerals and ceramics	NATURE			English	Article							NUCLEAR-WASTE FORMS; CRYSTALLINE CERAMICS; ZIRCON; SI-29; IMMOBILIZATION; PLUTONIUM; METAMICTIZATION; AMORPHIZATION	There are large amounts of heavy alpha-emitters in nuclear waste and nuclear materials inventories stored in various sites around the world(1). These include plutonium and minor actinides such as americium and curium. In preparation for geological disposal there is consensus(2) that actinides that have been separated from spent nuclear fuel should be immobilized within mineral-based ceramics rather than glass(2-4) because of their superior aqueous durability and lower risk of accidental criticality. However, in the long term, the alpha-decay taking place in these ceramics will severely disrupt their crystalline structure(2-4) and reduce their durability(5,6). A fundamental property in predicting cumulative radiation damage is the number of atoms permanently displaced per alpha-decay. At present, this number is estimated to be 1,000 - 2,000 atoms/alpha in zircon(4). Here we report nuclear magnetic resonance, spin-counting experiments that measure close to 5,000 atoms/alpha in radiation-damaged natural zircons. New radiological nuclear magnetic resonance measurements on highly radioactive, Pu-239 zircon show damage similar to that caused by U-238 and Th-232 in mineral zircons at the same dose, indicating no significant effect of half-life or loading levels ( dose rate). On the basis of these measurements, the initially crystalline structure of a 10 weight per cent Pu-239 zircon would be amorphous after only 1,400 years in a geological repository ( desired immobilization timescales are of the order of 250,000 years). These measurements establish a basis for assessing the long-term structural durability of actinide-containing ceramics in terms of an atomistic understanding of the fundamental damage event.	Univ Cambridge, Dept Earth Sci, Cambridge CB2 3EQ, England; Pacific NW Natl Lab, Richland, WA 99352 USA	University of Cambridge; United States Department of Energy (DOE); Pacific Northwest National Laboratory	Farnan, I (corresponding author), Univ Cambridge, Dept Earth Sci, Cambridge CB2 3EQ, England.	ifarnan@esc.cam.ac.uk	Farnan, Ian/M-3881-2014; Weber, William J./A-4177-2008	Farnan, Ian/0000-0001-7844-5112; Weber, William J./0000-0002-9017-7365				Ashbrook SE, 2004, SOLID STATE NUCL MAG, V26, P105, DOI 10.1016/j.ssnmr.2004.06.003; Balan E, 2003, AM MINERAL, V88, P1769, DOI 10.2138/am-2003-11-1217; Balan E, 2001, AM MINERAL, V86, P1025; DEVANATHAN R, IN PRESS MOL SIMUL; Ewing RC, 2004, J APPL PHYS, V95, P5949, DOI 10.1063/1.1707213; Ewing RC, 2003, REV MINERAL GEOCHEM, V53, P387, DOI 10.2113/0530387; Ewing RC, 1999, P NATL ACAD SCI USA, V96, P3432, DOI 10.1073/pnas.96.7.3432; Ewing RC, 2001, CAN MINERAL, V39, P697, DOI 10.2113/gscanmin.39.3.697; Farnan I, 1999, PHASE TRANSIT, V69, P47, DOI 10.1080/01411599908208007; Farnan I, 2004, REV SCI INSTRUM, V75, P5232, DOI 10.1063/1.1818512; Farnan I, 2003, AM MINERAL, V88, P1663, DOI 10.2138/am-2003-11-1205; Farnan I, 2001, J APPL PHYS, V89, P2084, DOI 10.1063/1.1343523; GIBBONS JF, 1972, PR INST ELECTR ELECT, V60, P1062, DOI 10.1109/PROC.1972.8854; HOLLAND HD, 1955, ACTA CRYSTALLOGR, V8, P291, DOI 10.1107/S0365110X55000947; *IAEA, 2003, GUID MAN PLUT INFCIR; Larsen FH, 2002, CHEM PHYS LETT, V357, P403, DOI 10.1016/S0009-2614(02)00520-1; MAGI M, 1984, J PHYS CHEM-US, V88, P1518, DOI 10.1021/j150652a015; Meldrum A, 1998, NATURE, V395, P56, DOI 10.1038/25698; MILLER ML, 1993, ULTRAMICROSCOPY, V48, P203, DOI 10.1016/0304-3991(93)90183-X; Muller I, 2001, MRS BULL, V26, P698, DOI 10.1557/mrs2001.180; MURAKAMI T, 1991, AM MINERAL, V76, P1510; Rios S, 2000, J PHYS-CONDENS MAT, V12, P2401, DOI 10.1088/0953-8984/12/11/306; Trachenko K, 2003, J PHYS-CONDENS MAT, V15, pL1, DOI 10.1088/0953-8984/15/2/101; Trachenko K, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.180102; WEBER WJ, 1991, RADIAT EFF DEFECT S, V115, P341, DOI 10.1080/10420159108220580; Weber WJ, 1997, J MATER RES, V12, P1946, DOI 10.1557/JMR.1997.0266; WEBER WJ, 1993, J AM CERAM SOC, V76, P1729, DOI 10.1111/j.1151-2916.1993.tb06641.x; Weber WJ, 1998, J MATER RES, V13, P1434, DOI 10.1557/JMR.1998.0205; Wilde SA, 2001, NATURE, V409, P175, DOI 10.1038/35051550; Zhang M, 2000, J PHYS-CONDENS MAT, V12, P1915, DOI 10.1088/0953-8984/12/8/333	30	127	128	2	123	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 11	2007	445	7124					190	193		10.1038/nature05425	http://dx.doi.org/10.1038/nature05425			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124QF	17215840				2022-12-28	WOS:000243384300047
J	Rasmussen, JN; Chong, A; Alter, DA				Rasmussen, Jeppe N.; Chong, Alice; Alter, David A.			Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DRUG-THERAPY; MEDICATION NONADHERENCE; SECONDARY PREVENTION; PHARMACY RECORDS; ELDERLY-PATIENTS; STATIN THERAPY; BLOOD-PRESSURE; BETA-BLOCKERS; IMPACT; CARE	Context The extent to which drug adherence may affect survival remains unclear, in part because mortality differences may be attributable to "healthy adherer" behavioral attributes more so than to pharmacological benefits. Objective To explore the relationship between drug adherence and mortality in survivors of acute myocardial infarction (AMI). Design, Setting, and Participants Population-based, observational, longitudinal study of 31 455 elderly AMI survivors between 1999 and 2003 in Ontario. All patients filled a prescription for statins, beta-blockers, or calcium channel blockers, with the latter drug considered a control given the absence of clinical trial-proven survival benefits. Main Outcome Measures Patient adherence was subdivided a priori into 3 categories - high (proportion of days covered, >= 80%), intermediate (proportion of days covered, 40%-79%), and low (proportion of days covered, <40%) - and compared with long-term mortality (median of 2.4 years of follow-up) using multivariable survival models (and propensity analyses) adjusted for sociodemographic factors, illness severity, comorbidities, and concomitant use of evidence-based therapies. Results Among statin users, compared with their high-adherence counterparts, the risk of mortality was greatest for low adherers (deaths in 261/1071 (24%) vs 2310/14345 (16%); adjusted hazard ratio, 1.25; 95% confidence interval, 1.09-1.42; P = .001) and was intermediary for intermediate adherers (deaths in 472/2407 (20%); adjusted hazard ratio, 1.12; 95% confidence interval, 1.01-1.25; P = .03). A similar but less pronounced dose-response - type adherence-mortality association was observed for beta-blockers. Mortality was not associated with adherence to calcium channel blockers. Moreover, sensitivity analyses demonstrated no relationships between drug adherence and cancer-related admissions, outcomes for which biological plausibility do not exist. Conclusion The long-term survival advantages associated with improved drug adherence after AMI appear to be class-specific, suggesting that adherence outcome benefits are mediated by drug effects and do not merely reflect an epiphenomenon of "healthy adherer" behavioral attributes.	Univ Toronto, Inst Clin Evaluat Sci, Toronto, ON M4N 3M5, Canada; Univ Toronto, Sunnybrook Hlth Sci Ctr, Clin Epidemiol Unit, Toronto, ON M4N 3M5, Canada; Univ Toronto, Div Cardiol, Li Ka Shing Knowledge Inst, St Michaels Hosp, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Med & Hlth Policy, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Management, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Evaluat, Toronto, ON M4N 3M5, Canada; Natl Inst Publ Hlth, Copenhagen, Denmark	University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University of Toronto; University of Toronto	Alter, DA (corresponding author), Univ Toronto, Inst Clin Evaluat Sci, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	david.alter@ices.on.ca						Adams RJ, 2004, CIRCULATION, V110, P2512, DOI 10.1161/01.CIR.0000134791.68010.FA; Alter DA, 2004, JAMA-J AM MED ASSOC, V291, P1100, DOI 10.1001/jama.291.9.1100; ANDRADE SE, 1995, NEW ENGL J MED, V332, P1125, DOI 10.1056/NEJM199504273321703; Benner JS, 2002, JAMA-J AM MED ASSOC, V288, P455, DOI 10.1001/jama.288.4.455; Bertolet BD, 1999, DRUG AGING, V15, P461, DOI 10.2165/00002512-199915060-00006; Braunwald E, 2000, J AM COLL CARDIOL, V36, P970, DOI 10.1016/S0735-1097(00)00889-5; Dargie HJ, 2001, LANCET, V357, P1385, DOI 10.1016/s0140-6736(00)04560-8; DiMatteo MR, 2002, MED CARE, V40, P794, DOI 10.1097/01.MLR.0000024612.61915.2D; Dobbels F, 2004, J HEART LUNG TRANSPL, V23, P1245, DOI 10.1016/j.healun.2003.09.016; Freemantle N, 1999, BMJ-BRIT MED J, V318, P1730, DOI 10.1136/bmj.318.7200.1730; FRIEDMAN LM, 1982, JAMA-J AM MED ASSOC, V247, P1707; Garcia R, 2002, ENZYME MICROB TECH, V30, P110, DOI 10.1016/S0141-0229(01)00462-8; Gislason GH, 2006, EUR HEART J, V27, P1153, DOI 10.1093/eurheartj/ehi705; Ho PM, 2006, ARCH INTERN MED, V166, P1836, DOI 10.1001/archinte.166.17.1836; Ho PM, 2006, ARCH INTERN MED, V166, P1842, DOI 10.1001/archinte.166.17.1842; Jackevicius CA, 2002, JAMA-J AM MED ASSOC, V288, P462, DOI 10.1001/jama.288.4.462; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Johnson ES, 2002, AM J MANAG CARE, V8, pS249; Ko DT, 2004, JAMA-J AM MED ASSOC, V291, P1864, DOI 10.1001/jama.291.15.1864; LaRosa JC, 1999, JAMA-J AM MED ASSOC, V282, P2340, DOI 10.1001/jama.282.24.2340; Lau HS, 1997, J CLIN EPIDEMIOL, V50, P619, DOI 10.1016/S0895-4356(97)00040-1; Law M, 2006, AM J CARDIOL, V97, p52C, DOI 10.1016/j.amjcard.2005.12.010; Law MR, 2003, BRIT MED J, V326, P1427, DOI 10.1136/bmj.326.7404.1427; Lee JK, 2006, JAMA-J AM MED ASSOC, V296, P2563, DOI 10.1001/jama.296.21.joc60162; LIN DY, 1989, J AM STAT ASSOC, V84, P1074, DOI 10.2307/2290085; Mackillop WJ, 2000, CANCER-AM CANCER SOC, V89, P901, DOI 10.1002/1097-0142(20000815)89:4<901::AID-CNCR25>3.0.CO;2-I; McDermott MM, 1997, ARCH INTERN MED, V157, P1921, DOI 10.1001/archinte.157.17.1921; Mickley H, 2004, EUR HEART J, V25, P96, DOI 10.1016/j.ehj.2003.06.011; Newby LK, 2006, CIRCULATION, V113, P203, DOI 10.1161/CIRCULATIONAHA.105.505636; Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100; Peterson AM, 2005, PHARMACOECONOMICS, V23, P13, DOI 10.2165/00019053-200523010-00002; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Simpson E, 2003, AM HEART J, V145, P438, DOI 10.1067/mhj.2003.143; Simpson SH, 2006, BMJ-BRIT MED J, V333, P15, DOI 10.1136/bmj.38875.675486.55; Steiner JF, 1997, J CLIN EPIDEMIOL, V50, P105, DOI 10.1016/S0895-4356(96)00268-5; Tu JV, 2001, J AM COLL CARDIOL, V37, P992, DOI 10.1016/S0735-1097(01)01109-3; Tu JV., 1999, CARDIOVASCULAR HLTH, P83; Wei L, 2002, HEART, V88, P229, DOI 10.1136/heart.88.3.229; Wei L, 2004, PHARMACOEPIDEM DR S, V13, P761, DOI 10.1002/pds.963; WEST SL, 1995, AM J EPIDEMIOL, V142, P1103, DOI 10.1093/oxfordjournals.aje.a117563	40	738	757	0	28	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 10	2007	297	2					177	186		10.1001/jama.297.2.177	http://dx.doi.org/10.1001/jama.297.2.177			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	124GI	17213401				2022-12-28	WOS:000243355900027
J	Padwal, RS; Majumdar, SR				Padwal, Raj S.; Majumdar, Sumit R.			Drug treatments for obesity: orlistat, sibutramine, and rimonabant	LANCET			English	Article							CANNABINOID-1 RECEPTOR BLOCKER; ENDOCANNABINOID SYSTEM; RISK-FACTORS; OVERWEIGHT PATIENTS; RANDOMIZED-TRIAL; WEIGHT; PHARMACOTHERAPY; ANTAGONIST; MANAGEMENT; POTENT	Antiobesity treatment is recommended for selected patients in whom lifestyle modification is unsuccessful. Two antiobesity drugs are currently licensed for long-term use. Orlistat, a gastrointestinal lipase inhibitor, reduces weight by around 3 kg on average and decreases progression to diabetes in high-risk patients; adverse gastrointestinal effects are common. Sibutramine, a monoamine-reuptake inhibitor, results in mean weight losses of 4-5 kg, but is associated with increases in blood pressure and pulse rate. Rimonabant, the first of the endocannabinoid receptor antagonists, reduces weight by 4-5 kg on average and improves waist circumference and concentrations of HDL cholesterol and triglyceride; however, an increased incidence of mood-related disorders has been reported. To date, all antiobesity drug trials have been limited by their high attrition rates and lack of long-term morbidity and mortality data. Other promising antiobesity drugs, including those acting within the central melanocortin pathway, are in development, but are years away from clinical use. In light of the lack of successful weight-loss treatments and the public-health implications of the obesity pandemic, the development of safe and effective drugs should be a priority. However, as new drugs are developed we suggest that the assessment processes should include both surrogate endpoints (ie, weight loss) and clinical outcomes (ie, major obesity-related morbidity and mortality). Only then can patients and their physicians be confident that the putative benefits of such drugs outweigh their risks and costs.	Univ Alberta Hosp, Dept Med, Edmonton, AB T6G 2B7, Canada	University of Alberta	Padwal, RS (corresponding author), Univ Alberta Hosp, Dept Med, 2E3-22 Walter C Mackenzie HSC, Edmonton, AB T6G 2B7, Canada.	rpadwal@ualberta.ca	Eckhardt, Erik/G-1567-2010; Padwal, Raj/G-6903-2016	Padwal, Raj/0000-0003-3541-2817				Abenhaim L, 1996, NEW ENGL J MED, V335, P609, DOI 10.1056/NEJM199608293350901; [Anonymous], 1989, NEW ENGL J MED, V321, P406; Arbeeny CM, 2004, OBES RES, V12, P1191, DOI 10.1038/oby.2004.150; Avenell A, 2004, HEALTH TECHNOL ASSES, V8, P1; Bach DS, 1999, OBES RES, V7, P363, DOI 10.1002/j.1550-8528.1999.tb00419.x; Bays HE, 2004, OBES RES, V12, P1197, DOI 10.1038/oby.2004.151; Blanck HM, 2004, PREV MED, V39, P1243, DOI 10.1016/j.ypmed.2004.04.040; Boyd ST, 2005, ANN PHARMACOTHER, V39, P684, DOI 10.1345/aph.1E499; Carai MAM, 2005, LIFE SCI, V77, P2339, DOI 10.1016/j.lfs.2005.04.017; *CLINICALTRIALS GO, 2005, ATH UND DEV ASS INT; *CLINICALTRIALS GO, 2005, STRADIVARIUS STRAT R; ClinicalTrials.gov, 2005, CRESCENDO COMPR RIM; Connolly HM, 1997, NEW ENGL J MED, V337, P581, DOI 10.1056/NEJM199708283370901; Correia Marcelo L G, 2005, Expert Opin Emerg Drugs, V10, P643, DOI 10.1517/14728214.10.3.643; Cota D, 2003, J CLIN INVEST, V112, P423, DOI 10.1172/JCI17725; Curioni C, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006162.pub2; De Petrocellis L, 2004, BRIT J PHARMACOL, V141, P765, DOI 10.1038/sj.bjp.0705666; Department of Health and Human Services. National Heart Lung and Blood Institute, 1998, CLIN GUID ID EV TREA; Despres JP, 2005, NEW ENGL J MED, V353, P2121, DOI 10.1056/NEJMoa044537; Di Marzo V, 2004, NAT REV DRUG DISCOV, V3, P771, DOI 10.1038/nrd1495; Di Marzo V, 2005, NAT NEUROSCI, V8, P585, DOI 10.1038/nn1457; *EUR AG EV MED PRO, 2006, RIM SUMM PROD CHAR; *EUR AG EV MED PRO, 1997, NOT GUID CLIN INV DR; *EUR MED AG, 2005, XEN SCI DISC; European Agency for the Evaluation of Medicinal Products, 2002, COMM PROPR MED PROD; Farrigan C, 2002, NAT REV DRUG DISCOV, V1, P257, DOI 10.1038/nrd781; Gardner G, 2000, OVERFED UNDERFED GLO; Gary-Bobo M, 2006, MOL PHARMACOL, V69, P471, DOI 10.1124/mol.105.015040; GOLDSTEIN DJ, 1992, INT J OBESITY, V16, P397; Gomez R, 2002, J NEUROSCI, V22, P9612; Haddock CK, 2002, INT J OBESITY, V26, P262, DOI 10.1038/sj.ijo.0801889; Halford JCG, 2006, APPETITE, V46, P6, DOI 10.1016/j.appet.2005.07.010; Haslam DW, 2005, LANCET, V366, P1197, DOI 10.1016/S0140-6736(05)67483-1; HAUPTMAN JB, 1992, AM J CLIN NUTR, V55, P309; Hill JO, 2005, J NUTR EDUC BEHAV, V37, P206, DOI 10.1016/S1499-4046(06)60248-0; Horvath TL, 2003, J CLIN INVEST, V112, P323, DOI [10.1172/JCI19376, 10.1172/JCI200319376]; Howlett AC, 2004, NEUROPHARMACOLOGY, V47, P345, DOI 10.1016/j.neuropharm.2004.07.030; Lambert DM, 2005, J MED CHEM, V48, P5059, DOI 10.1021/jm058183t; Lean MEJ, 2001, INT J OBESITY, V25, pS8, DOI 10.1038/sj.ijo.0801931; LEIBEL RL, 1995, NEW ENGL J MED, V332, P621, DOI 10.1056/NEJM199503093321001; Liu YL, 2005, INT J OBESITY, V29, P183, DOI 10.1038/sj.ijo.0802847; LUSCOMBE GP, 1989, NEUROPHARMACOLOGY, V28, P129, DOI 10.1016/0028-3908(89)90048-8; Mackie K, 2006, ANNU REV PHARMACOL, V46, P101, DOI 10.1146/annurev.pharmtox.46.120604.141254; MacWalter RS, 2003, ANN PHARMACOTHER, V37, P510, DOI 10.1345/aph.1C122; McNeely W, 1998, DRUGS, V56, P1093, DOI 10.2165/00003495-199856060-00019; McNeely W, 1998, DRUGS, V56, P241, DOI 10.2165/00003495-199856020-00007; McNulty SJ, 2003, DIABETES CARE, V26, P125, DOI 10.2337/diacare.26.1.125; Mechoulam R., 1986, CANNABINOIDS THERAPE, DOI [10.1201/9780429260667, DOI 10.1201/9780429260667]; Nisoli E, 2003, DRUG SAFETY, V26, P1027, DOI 10.2165/00002018-200326140-00004; Nissen SE, 2005, JAMA-J AM MED ASSOC, V294, P2581, DOI 10.1001/JAMA.294.20.JOC50147; Osei-Hyiaman D, 2005, NEUROENDOCRINOLOGY, V81, P273, DOI 10.1159/000087925; Osei-Hyiaman D, 2005, J CLIN INVEST, V115, P1298, DOI 10.1172/JCI200523057; Padwal R, 2003, INT J OBESITY, V27, P1437, DOI 10.1038/sj.ijo.0802475; Padwal RS, 2005, OBES RES, V13, P1905, DOI 10.1038/oby.2005.234; Padwal RS, 2003, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD004094.pub2, DOI 10.1002/14651858.CD004094.PUB2]; Pagotto U, 2005, ANN MED, V37, P270, DOI 10.1080/07853890510037419; Parmentier-Batteur S, 2002, J NEUROSCI, V22, P9771, DOI 10.1523/jneurosci.22-22-09771.2002; Pi-Sunyer F, 2006, JAMA-J AM MED ASSOC, V295, P761, DOI 10.1001/jama.295.7.761; RINALDICARMONA M, 1995, LIFE SCI, V56, P1941, DOI 10.1016/0024-3205(95)00174-5; RINALDICARMONA M, 1994, FEBS LETT, V350, P240, DOI 10.1016/0014-5793(94)00773-X; Rosenbaum M, 1997, NEW ENGL J MED, V337, P396, DOI 10.1056/NEJM199708073370606; Sanchez-Reyes L, 2004, CLIN THER, V26, P1427, DOI 10.1016/j.clinthera.2004.09.017; Sari R, 2004, ENDOCR RES, V30, P159, DOI 10.1081/ERC-200027356; Scheen AJ, 2006, LANCET, V368, P1660, DOI 10.1016/S0140-6736(06)69571-8; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Torgerson JS, 2004, DIABETES CARE, V27, P155, DOI 10.2337/diacare.27.1.155; Underdown NJ, 2005, BRIT J PHARMACOL, V146, P809, DOI 10.1038/sj.bjp.0706391; Van Gaal LF, 2005, LANCET, V365, P1389, DOI 10.1016/S0140-6736(05)66374-X; Wadden TA, 2005, NEW ENGL J MED, V353, P2111, DOI 10.1056/NEJMoa050156; Wadden TA, 2000, OBES RES, V8, P431, DOI 10.1038/oby.2000.53; WEIBEL EK, 1987, J ANTIBIOT, V40, P1081, DOI 10.7164/antibiotics.40.1081; Wooltorton E, 2002, CAN MED ASSOC J, V166, P1307; Zannad F, 2002, AM HEART J, V144, P508, DOI 10.1067/mhj.2002.124403; Zhi JG, 2003, J CLIN PHARMACOL, V43, P428, DOI 10.1177/0091270003252236; Zhi JG, 2002, J CLIN PHARMACOL, V42, P1011; 2004, MED NEWS TODAY   MAY	77	517	536	1	98	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 6	2007	369	9555					71	77		10.1016/S0140-6736(07)60033-6	http://dx.doi.org/10.1016/S0140-6736(07)60033-6			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125AK	17208644				2022-12-28	WOS:000243413700031
J	Halzen, F				Halzen, Francis			Neutrino astrophysics experiments beneath the sea and ice	SCIENCE			English	Editorial Material							TELESCOPE; ASTRONOMY; PROJECT	Neutrino astronomy beyond the Sun was first imagined in the late 1950s. A neutrino detector at the bottom of Lake Baikal, the deployment of detectors in the Mediterranean Sea, and the construction of a kilometer-scale neutrino telescope at the South Pole exemplify current efforts to realize this dream.	Univ Wisconsin, Dept Phys, Madison, WI 53703 USA	University of Wisconsin System; University of Wisconsin Madison	Halzen, F (corresponding author), Univ Wisconsin, Dept Phys, Madison, WI 53703 USA.	francis.halzen@icecube.wisc.edu						Achterberg A, 2006, ASTROPART PHYS, V26, P155, DOI 10.1016/j.astropartphys.2006.06.007; Aggouras G, 2005, ASTROPART PHYS, V23, P377, DOI 10.1016/j.astropartphys.2005.02.001; Aguilar JA, 2006, ASTROPART PHYS, V26, P314, DOI 10.1016/j.astropartphys.2006.07.004; Balkanov V, 2003, NUCL PHYS B-PROC SUP, V118, P363, DOI 10.1016/S0920-5632(03)01334-3; Cronin J. W., 1997, SCI AM, V276, P32; ROBERTS A, 1992, REV MOD PHYS, V64, P259, DOI 10.1103/RevModPhys.64.259	7	15	15	1	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 5	2007	315	5808					66	68		10.1126/science.1136504	http://dx.doi.org/10.1126/science.1136504			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	122WU	17204640				2022-12-28	WOS:000243259100033
J	Deppmann, CD; Ginty, DD				Deppmann, Christopher D.; Ginty, David D.			Retrograde control of neural circuit formation	CELL			English	Editorial Material							GROWTH	Glial-derived neurotrophic factor (GDNF), secreted by skeletal muscle, triggers expression of the ETS transcription factor Pea3 in a subset of motor neurons in the spinal cord. In this issue, Vrieseling and Arber (2006) find that this retrograde GDNF-Pea3 signal controls dendrite patterning and assembly of a sensory-motor reflex circuit.	Johns Hopkins Univ, Sch Med, Solomon H Snyder Dept Neurosci, Howard Huges Med Inst, Baltimore, MD 21205 USA	Johns Hopkins University	Ginty, DD (corresponding author), Johns Hopkins Univ, Sch Med, Solomon H Snyder Dept Neurosci, Howard Huges Med Inst, Baltimore, MD 21205 USA.	dginty@jhmi.edu						Chen HH, 2003, CURR OPIN NEUROBIOL, V13, P96, DOI 10.1016/S0959-4388(03)00006-0; Cowan WM, 2001, ANNU REV NEUROSCI, V24, P551, DOI 10.1146/annurev.neuro.24.1.551; FRANK E, 1993, NEURON, V10, P779, DOI 10.1016/0896-6273(93)90194-V; Glebova NO, 2005, ANNU REV NEUROSCI, V28, P191, DOI 10.1146/annurev.neuro.28.061604.135659; Haase G, 2002, NEURON, V35, P893, DOI 10.1016/S0896-6273(02)00864-4; Howe CL, 2005, CURR OPIN NEUROBIOL, V15, P40, DOI 10.1016/j.conb.2005.01.010; VRIESELING E, 2006, CELL	7	1	1	0	0	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 29	2006	127	7					1306	1307		10.1016/j.cell.2006.12.013	http://dx.doi.org/10.1016/j.cell.2006.12.013			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	128WI	17190596	Bronze			2022-12-28	WOS:000243690000011
J	Moroz, LL; Edwards, JR; Puthanveettil, SV; Kohn, AB; Hla, T; Heyland, A; Knudsen, L; Sahni, A; Yu, FH; Liu, L; Jezzini, S; Lovell, P; Iannucculli, W; Chen, MC; Nguyen, T; Sheng, HT; Shaw, R; Kalachikov, S; Panchin, YV; Farmerie, W; Russo, JJ; Ju, JY; Kandel, ER				Moroz, Leonid L.; Edwards, John R.; Puthanveettil, Sathyanarayanan V.; Kohn, Andrea B.; Hla, Thomas; Heyland, Andreas; Knudsen, Ljame; Sahni, Anuj; Yu, Fahong; Liu, Li; Jezzini, Sami; Lovell, Peter; Iannucculli, William; Chen, Minchen; Nguyen, Tuan; Sheng, Huitao; Shaw, Regina; Kalachikov, Sergey; Panchin, Yuri V.; Farmerie, William; Russo, James J.; Ju, Jingyue; Kandel, Eric R.			Neuronal transcriptome of Aplysia: neuronal compartments and circuitry	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; OPISTHOBRANCHIA MOLLUSCA; PHYLOGENETIC ANALYSIS; ABDOMINAL GANGLION; METACEREBRAL CELLS; ANIMAL PHYLOGENY; GENE-SEQUENCES; CDNA LIBRARY; CALIFORNICA; EVOLUTION	Molecular analyses of Aplysia, a well-established model organism for cellular and systems neural science, have been seriously handicapped by a lack of adequate genomic information. By sequencing cDNA libraries from the central nervous system (CNS), we have identified over 175,000 expressed sequence tags (ESTs), of which 19,814 are unique neuronal gene products and represent 50%-70% of the total Aplysia neuronal transcriptome. We have characterized the transcriptome at three levels: (1) the central nervous system, (2) the elementary components of a simple behavior: the gill-withdrawal reflex-by analyzing sensory, motor, and serotonergic modulatory neurons, and (3) processes of individual neurons. In addition to increasing the amount of available gene sequences of Aplysia by two orders of magnitude, this collection represents the largest database available for any member of the Lophotrochozoa and therefore provides additional insights into evolutionary strategies used by this highly successful diversified lineage, one of the three proposed super-clacles of bilateral animals.	Univ Florida, Whitney Lab Marine Biosci, St Augustine, FL 32080 USA; Univ Florida, Dept Neurosci, McKnight Brain Inst, Gainesville, FL 32611 USA; Columbia Univ, Columbia Genome Ctr, Coll Phys & Surg, New York, NY 10032 USA; Columbia Univ, Ctr Neurobiol & Behav, New York, NY 10032 USA; Columbia Univ, New York State Psychiat Inst, New York, NY 10032 USA; Univ Florida, Interdisciplinary Ctr Biotechnol Res, Gainesville, FL 32611 USA; Columbia Univ, Howard Hughes Med Inst, New York, NY 10032 USA; Columbia Univ, Dept Chem Engn, New York, NY 10027 USA; Columbia Univ, Kavli Inst Brain Sci, New York, NY 10032 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; Columbia University; Columbia University; Columbia University; New York State Psychiatry Institute; State University System of Florida; University of Florida; Columbia University; Howard Hughes Medical Institute; Columbia University; Columbia University	Moroz, LL (corresponding author), Univ Florida, Whitney Lab Marine Biosci, 9505 Ocean Shore Blvd, St Augustine, FL 32080 USA.	moroz@whitney.ufl.edu; erk5@columbia.edu		Panchin, Yuri/0000-0002-8006-2839; Heyland, Andreas/0000-0002-7592-4473; Moroz, Leonid/0000-0002-1333-3176	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P50HG002806] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH075026] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039103] Funding Source: NIH RePORTER; NHGRI NIH HHS [P50 HG002806] Funding Source: Medline; NIMH NIH HHS [R01 MH075026] Funding Source: Medline; NINDS NIH HHS [R01 NS039103, NS39103] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aguinaldo AMA, 1997, NATURE, V387, P489, DOI 10.1038/387489a0; Brannvall K, 2003, BIOCHEM BIOPH RES CO, V308, P369, DOI 10.1016/S0006-291X(03)01386-X; Brusca RC, 2003, INVERTEBRATES; CASH D, 1989, J NEUROBIOL, V20, P25, DOI 10.1002/neu.480200104; Cheney-Choker S, 2004, POETRY WALES, V40, P55; CLEARY LJ, 1993, J NEUROPHYSIOL, V70, P1767, DOI 10.1152/jn.1993.70.5.1767; Cravchik A, 2001, ARCH NEUROL-CHICAGO, V58, P1772, DOI 10.1001/archneur.58.11.1772; de Rosa R, 1999, NATURE, V399, P772, DOI 10.1038/21631; Diaz-Rios M, 1999, J COMP NEUROL, V413, P255, DOI 10.1002/(SICI)1096-9861(19991018)413:2<255::AID-CNE7>3.0.CO;2-E; Fantappie MR, 2001, EXP PARASITOL, V98, P162, DOI 10.1006/expr.2001.4630; Fitzgerald KK, 1997, LEARN MEMORY, V3, P366, DOI 10.1101/lm.3.5.366; FU GK, 2002, Patent No. 6387624; Fujisawa Y, 1999, J NEUROSCI, V19, P9618; GILLER E, 1971, J NEUROPHYSIOL, V34, P93, DOI 10.1152/jn.1971.34.1.93; Giribet G, 2006, P NATL ACAD SCI USA, V103, P7723, DOI 10.1073/pnas.0602578103; Goll MG, 2006, SCIENCE, V311, P395, DOI 10.1126/science.1120976; Grande C, 2004, MOL PHYLOGENET EVOL, V33, P378, DOI 10.1016/j.ympev.2004.06.008; Grande C, 2004, MOL BIOL EVOL, V21, P303, DOI 10.1093/molbev/msh016; Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520; Haag ES, 1999, DEV BIOL, V211, P77, DOI 10.1006/dbio.1999.9283; Halanych KM, 2004, ANNU REV ECOL EVOL S, V35, P229, DOI 10.1146/annurev.ecolsys.35.112202.130124; Haszprunar G, 2000, AM MALACOL BULL, V15, P115; HENING WA, 1979, BRAIN RES, V179, P231, DOI 10.1016/0006-8993(79)90441-4; Heyland A, 2006, J EXP ZOOL PART B, V306B, P551, DOI 10.1002/jez.b.21113; Holland ND, 2003, NAT REV NEUROSCI, V4, P617, DOI 10.1038/nrn1175; JAHANPARWAR B, 1979, BEHAV NEURAL BIOL, V27, P39, DOI 10.1016/S0163-1047(79)92744-4; Jezzini SH, 2005, J NEUROSCI METH, V149, P15, DOI 10.1016/j.jneumeth.2005.05.007; Jezzini SH, 2004, MOL BRAIN RES, V127, P27, DOI 10.1016/j.molbrainres.2004.05.007; JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275, DOI 10.1093/bioinformatics/8.3.275; KANDEL E.R., 1979, BEHAV BIOL APLYSIA; KANDEL ER, 1966, J PHYSIOL-LONDON, V183, P287, DOI 10.1113/jphysiol.1966.sp007867; Kandel ER, 2001, SCIENCE, V294, P1030, DOI 10.1126/science.1067020; Kandel ER., 1976, CELLULAR BASIS BEHAV; Knudsen B, 2006, MOL PHYLOGENET EVOL, V38, P459, DOI 10.1016/j.ympev.2005.08.017; Kortschak RD, 2003, CURR BIOL, V13, P2190, DOI 10.1016/j.cub.2003.11.030; KUPFERMANN I, 1974, BEHAV BIOL, V10, P1, DOI 10.1016/S0091-6773(74)91644-7; KUPFERMANN I, 1982, BRAIN RES, V241, P334, DOI 10.1016/0006-8993(82)91072-1; KUPFERMANN I, 1969, SCIENCE, V164, P847, DOI 10.1126/science.164.3881.847; Kurosu H, 2005, SCIENCE, V309, P1829, DOI 10.1126/science.1112766; Kusserow A, 2005, NATURE, V433, P156, DOI 10.1038/nature03158; Lehesjoki AE, 2003, EMBO J, V22, P3473, DOI 10.1093/emboj/cdg338; Lovell P, 2006, INTEGR COMP BIOL, V46, P847, DOI 10.1093/icb/icl042; Lydeard C, 2000, MOL PHYLOGENET EVOL, V15, P83, DOI 10.1006/mpev.1999.0719; Miller DJ, 2005, TRENDS GENET, V21, P536, DOI 10.1016/j.tig.2005.08.002; Moccia R, 2003, J NEUROSCI, V23, P9409; Nachin L, 2005, J BACTERIOL, V187, P6265, DOI 10.1128/JB.187.18.6265-6272.2005; Nielsen C, 2005, EVOL DEV, V7, P483, DOI 10.1111/j.1525-142X.2005.05051.x; Nielsen C, 2012, ANIMAL EVOLUTION: INTERRELATIONSHIPS OF THE LIVING PHYLA, 3RD EDITION, P1; Passamaneck Y, 2006, MOL PHYLOGENET EVOL, V40, P20, DOI 10.1016/j.ympev.2006.02.001; Passamaneck YJ, 2004, MOL PHYLOGENET EVOL, V32, P25, DOI 10.1016/j.ympev.2003.12.016; Peterson KJ, 2001, EVOL DEV, V3, P170, DOI 10.1046/j.1525-142x.2001.003003170.x; Philip GK, 2005, MOL BIOL EVOL, V22, P1175, DOI 10.1093/molbev/msi102; Philippe H, 2005, MOL BIOL EVOL, V22, P1246, DOI 10.1093/molbev/msi111; Pojeta J. Jr, 1987, P270; RAE PMM, 1979, NUCLEIC ACIDS RES, V6, P2987, DOI 10.1093/nar/6.9.2987; Raible F, 2005, SCIENCE, V310, P1325, DOI 10.1126/science.1119089; Rokas A, 2005, SCIENCE, V310, P1933, DOI 10.1126/science.1116759; ROSEN SC, 1989, J NEUROSCI, V9, P1562; Sakharov D A, 1974, J Neural Transm, VSuppl 11, P43; Sheng GJ, 2003, CELL, V115, P603, DOI 10.1016/S0092-8674(03)00927-9; SIMPSON VJ, 1986, NUCLEIC ACIDS RES, V14, P6711, DOI 10.1093/nar/14.16.6711; SOARES MB, 1994, P NATL ACAD SCI USA, V91, P9228, DOI 10.1073/pnas.91.20.9228; Tatusov RL, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-41; Technau U, 2005, TRENDS GENET, V21, P633, DOI 10.1016/j.tig.2005.09.007; VALENTINE JW, 2004, ORIGIN PHYLA; Vonnemann V, 2005, J MOLLUS STUD, V71, P113, DOI 10.1093/mollus/eyi014; WEISS KR, 1976, BRAIN RES, V117, P33, DOI 10.1016/0006-8993(76)90554-0; Wolf YI, 2004, GENOME RES, V14, P29, DOI 10.1101/gr.1347404; YANG ZB, 1994, J MOL EVOL, V39, P105; Zhulidov PA, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh031	70	246	251	2	36	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 29	2006	127	7					1453	1467		10.1016/j.cell.2006.09.052	http://dx.doi.org/10.1016/j.cell.2006.09.052			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	128WI	17190607	Bronze, Green Accepted			2022-12-28	WOS:000243690000023
J	Barnes, AM; Chang, WZ; Morello, R; Cabral, WA; Weis, MA; Eyre, DR; Leikin, S; Makareeva, E; Kuznetsova, N; Uveges, TE; Ashok, A; Flor, AW; Mulvihill, JJ; Wilson, PL; Sundaram, UT; Lee, B; Marini, JC				Barnes, Aileen M.; Cliang, Weizhong; Morello, Roy; Cabral, Wayne A.; Weis, MaryAnn; Eyre, David R.; Leikin, Sergey; Makareeva, Elena; Kuznetsova, Natalia; Uveges, Thomas E.; Ashok, Aarthi; Flor, Armando W.; Mulvihill, John J.; Wilson, Patrick L.; Sundaram, Usha T.; Lee, Brendan; Marini, Joan C.			Brief report: Deficiency of cartilage-associated protein in recessive lethal osteogenesis imperfecta	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BRITTLE BONE-DISEASE; I PROCOLLAGEN; CDNA CLONING; TRIPLE-HELIX; COLLAGEN; MUTATIONS; GENES; CRTAP; FORM; ENZYME	Classic osteogenesis imperfecta, an autosomal dominant disorder associated with osteoporosis and bone fragility, is caused by mutations in the genes for type I collagen. A recessive form of the disorder has long been suspected. Since the loss of cartilage-associated protein (CRTAP), which is required for post-translational prolyl 3-hydroxylation of collagen, causes severe osteoporosis in mice, we investigated whether CRTAP deficiency is associated with recessive osteogenesis imperfecta. Three of 10 children with lethal or severe osteogenesis imperfecta, who did not have a primary collagen defect yet had excess post-translational modification of collagen, were found to have a recessive condition resulting in CRTAP deficiency, suggesting that prolyl 3-hydroxylation of type I collagen is important for bone formation.	NICHHD, NIH, Bethesda, MD 20892 USA; Baylor Coll Med, Houston, TX 77030 USA; Univ Washington, Orthopaed Res Labs, Seattle, WA 98195 USA; Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA; Virginia Commonwealth Univ, Med Coll Virginia, Richmond, VA 23298 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Baylor College of Medicine; University of Washington; University of Washington Seattle; University of Oklahoma System; University of Oklahoma Health Sciences Center; Virginia Commonwealth University	Marini, JC (corresponding author), NICHD, Bone & Extracellular Matrix Branch, NIH, Bldg 10,Rm 10N260,9000 Rockville Pike, Bethesda, MD 20892 USA.	oidoc@helix.nih.gov	Leikin, Sergey/A-5518-2008; Makareeva, Elena/F-5183-2011	Leikin, Sergey/0000-0001-7095-0739; Makareeva, Elena/0000-0002-5815-0760; Barnes, Aileen/0000-0001-8021-4997	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD008830] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD022657, Z01HD008830] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR037318, R01AR036794, R01AR037318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE016990] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 HD008830] Funding Source: Medline; NIAMS NIH HHS [R01 AR036794, AR37318, R37 AR037318, R01 AR037318] Funding Source: Medline; NICHD NIH HHS [P01 HD022657, HD22657] Funding Source: Medline; NIDCR NIH HHS [DE016990, R01 DE016990] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AITCHISON K, 1988, HUM GENET, V78, P233, DOI 10.1007/BF00291667; BONADIO J, 1985, J BIOL CHEM, V260, P1734; BRUCKNER P, 1984, EUR J BIOCHEM, V140, P391, DOI 10.1111/j.1432-1033.1984.tb08114.x; Byers P, 2002, CONNECTIVE TISSUE IT, P385, DOI DOI 10.1002/0471221929.CH8; BYERS PH, 1988, AM J HUM GENET, V42, P237; Castagnola P, 1997, J CELL SCI, V110, P1351; Fietzek P P, 1976, Int Rev Connect Tissue Res, V7, P1; FIETZEK PP, 1972, EUR J BIOCHEM, V30, P163, DOI 10.1111/j.1432-1033.1972.tb02083.x; Glorieux FH, 2002, J BONE MINER RES, V17, P30, DOI 10.1359/jbmr.2002.17.1.30; Glorieux FH, 2000, J BONE MINER RES, V15, P1650, DOI 10.1359/jbmr.2000.15.9.1650; Grant ME, 2002, COLLAGEN FAMILY STRU, P159, DOI DOI 10.1002/0471221929.CH2; KIVIRIKKO KI, 1980, ENZYMOLOGY POST TRAN, P53; Labuda M, 2002, BONE, V31, P19, DOI 10.1016/S8756-3282(02)00808-6; Marini JC, 2004, NELSON TXB PEDIAT, P2336; MARINI JC, IN PRESS HUM MUTAT; Morello R, 1999, MATRIX BIOL, V18, P319, DOI 10.1016/S0945-053X(99)00002-5; Morello R, 2006, CELL, V127, P291, DOI 10.1016/j.cell.2006.08.039; RAGHUNATH M, 1994, J MOL BIOL, V236, P940, DOI 10.1006/jmbi.1994.1199; RISTELI J, 1977, EUR J BIOCHEM, V73, P485, DOI 10.1111/j.1432-1033.1977.tb11341.x; SILLENCE DO, 1979, J MED GENET, V16, P101, DOI 10.1136/jmg.16.2.101; Tonachini L, 1999, CYTOGENET CELL GENET, V87, P191, DOI 10.1159/000015463; Vranka JA, 2004, J BIOL CHEM, V279, P23615, DOI 10.1074/jbc.M312807200; WALLIS GA, 1993, J MED GENET, V30, P492, DOI 10.1136/jmg.30.6.492; Ward LM, 2002, BONE, V31, P12, DOI 10.1016/S8756-3282(02)00790-1; WILLIAMS EM, 1989, CLIN GENET, V35, P181	25	225	240	1	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 28	2006	355	26					2757	2764		10.1056/NEJMoa063804	http://dx.doi.org/10.1056/NEJMoa063804			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	120UA	17192541	Green Published, Green Accepted			2022-12-28	WOS:000243110500008
J	Tomba, P; Vigano, A; Menarini, C; Picci, P				Tomba, P.; Vigano, A.; Menarini, C.; Picci, P.			From a 16th century monastery to a 21st century orthopaedic hospital	BRITISH MEDICAL JOURNAL			English	Editorial Material							PUTTI,VITTORIO		Inst Orthoped Rizzoli, Lib, Bologna, Italy; Inst Orthoped Rizzoli, Sci Direct, Bologna, Italy		Tomba, P (corresponding author), Inst Orthoped Rizzoli, Lib, Bologna, Italy.	patrizia.tomba@ior.it	; Picci, Piero/J-5979-2016; Tomba, patrizia/C-7904-2019	vigano, anna/0000-0003-4770-9095; Picci, Piero/0000-0002-8519-4101; Tomba, patrizia/0000-0002-3347-4486				Benini A, 1996, SPINE, V21, P1388, DOI 10.1097/00007632-199606010-00024; Bertram C, 1999, CHIRURG, V70, P1374, DOI 10.1007/s001040050797; Campanacci M, 1998, Chir Organi Mov, V83, P317; CANUTI SSD, 1996, RIZZOLI ORTHOPAEDIC, P213; DALENDINARA PR, ARCH STORICO ABBAZIA; FURFARO D, 1964, Chir Organi Mov, V53, P75; GARRISON FH, 1917, INTRO HIST MED, P144; Kaplan E B, 1966, Clin Orthop Relat Res, V44, P65; Merlini L, 2003, NEUROMUSCULAR DISORD, V13, P421, DOI 10.1016/S0960-8966(03)00032-4; MOUTIER G, 1923, PARIS MED, V18, P51; PALLARDY G, 1995, J RADIOL, V76, P1033; PELTIER LF, 1969, J BONE JOINT SURG AM, VA 51, P1433, DOI 10.2106/00004623-196951070-00026; PLATT H, 1950, J BONE JOINT SURG BR, V32, P570, DOI 10.1302/0301-620X.32B4.570; PUTTI V, 1941, J BONE JOINT SURG, V23, P187; STEINDLER A, 1923, J BONE JOINT SURG, V21, P127; TONDI B, 1684, I FASTI OLIVETANI, P162; TOWER P, 1956, ARCH OPHTHALMOL-CHIC, V56, P57; Vigano A, 1995, Chir Organi Mov, V80, P101; Vigano A, 1999, ACTA ORTHOP SCAND, V70, P531, DOI 10.3109/17453679908997838; 1940, N ENGL MED J, V233, P955	20	1	1	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 23	2006	333	7582					1328	1330		10.1136/bmj.39006.748634.47	http://dx.doi.org/10.1136/bmj.39006.748634.47			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121MC	17185731	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000243160700028
J	Perlo, J; Casanova, F; Blumich, B				Perlo, Juan; Casanova, Federico; Bluemich, Bernhard			Ex situ NMR in highly homogeneous fields: H-1 spectroscopy	SCIENCE			English	Article							SINGLE-SIDED SENSOR; RESOLUTION	Portable single-sided nuclear magnetic resonance (NMR) magnets used for nondestructive studies of large samples are believed to generate inherently inhomogeneous magnetic fields. We demonstrated experimentally that the field of an open magnet can be shimmed to high homogeneity in a large volume external to the sensor. This technique allowed us to measure localized high-resolution proton spectra outside a portable open magnet with a spectral resolution of 0.25 part per million. The generation of these experimental conditions also simplifies the implementation of such powerful methodologies as multidimensional NMR spectroscopy and imaging.	Rhein Westfal TH Aachen, Inst Tech Chem & Makromol Chem, D-52056 Aachen, Germany	RWTH Aachen University	Blumich, B (corresponding author), Rhein Westfal TH Aachen, Inst Tech Chem & Makromol Chem, D-52056 Aachen, Germany.	bluemich@mc.rwth-aachen.de	Bluemich, Bernhard P/B-4378-2016	Bluemich, Bernhard P/0000-0002-1152-4438				Appelt S, 2006, NAT PHYS, V2, P105, DOI 10.1038/nphys211; Blumich B, 2000, NMR IMAGING MAT; Brill TM, 2002, SCIENCE, V297, P369, DOI 10.1126/science.1072245; Hurlimann MD, 2002, J MAGN RESON, V157, P31, DOI 10.1006/jmre.2002.2567; Meriles CA, 2001, SCIENCE, V293, P82, DOI 10.1126/science.1061498; Perlo J, 2005, SCIENCE, V308, P1279, DOI 10.1126/science.1108944; Perlo J, 2005, J MAGN RESON, V173, P254, DOI 10.1016/j.jmr.2004.12.010; Perlo J, 2004, J MAGN RESON, V166, P228, DOI 10.1016/j.jmr.2003.10.018; Shapira B, 2004, J AM CHEM SOC, V126, P7184, DOI 10.1021/ja048859u; Song YQ, 2000, NATURE, V406, P178, DOI 10.1038/35018057; Topgaard D, 2004, P NATL ACAD SCI USA, V101, P17576, DOI 10.1073/pnas.0408296102	11	110	116	3	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 23	2007	315	5815					1110	1112		10.1126/science.1135499	http://dx.doi.org/10.1126/science.1135499			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	138UA	17218492				2022-12-28	WOS:000244387600032
J	Gavin, MA; Rasmussen, JP; Fontenot, JD; Vasta, V; Manganiello, VC; Beavo, JA; Rudensky, AY				Gavin, Marc A.; Rasmussen, Jeffrey P.; Fontenot, Jason D.; Vasta, Valeria; Manganiello, Vincent C.; Beavo, Joseph A.; Rudensky, Alexander Y.			Foxp3-dependent programme of regulatory T-cell differentiation	NATURE			English	Article							TRANSCRIPTION FACTOR FOXP3; HELPER-CELLS; INFLAMMATION; ACTIVATION; RECEPTORS	Regulatory CD4(+) T cells (T-R cells), the development of which is critically dependent on X-linked transcription factor Foxp3 ( forkhead box P3), prevent self-destructive immune responses(1). Despite its important role, molecular and functional features conferred by Foxp3 to T-R precursor cells remain unknown. It has been suggested that Foxp3 expression is required for both survival of T-R precursors as well as their inability to produce interleukin (IL)-2 and independently proliferate after T-cell-receptor engagement, raising the possibility that such 'anergy' and T-R suppressive capacity are intimately linked(2-4). Here we show, by dissociating Foxp3-dependent features from those induced by the signals preceding and promoting its expression in mice, that the latter signals include several functional and transcriptional hallmarks of T-R cells. Although its function is required for T-R cell suppressor activity, Foxp3 to a large extent amplifies and fixes pre-established molecular features of T-R cells, including anergy and dependence on paracrine IL-2. Furthermore, Foxp3 solidifies T-R cell lineage stability through modification of cell surface and signalling molecules, resulting in adaptation to the signals required to induce and maintain T-R cells. This adaptation includes Foxp3-dependent repression of cyclic nucleotide phosphodiesterase 3B, affecting genes responsible for T-R cell homeostasis.	Univ Washington, Dept Immunol, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA; NHLBI, NIH, Bethesda, MD 20892 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Rudensky, AY (corresponding author), Amgen Corp, Seattle, WA 98101 USA.	aruden@u.washington.edu		Rasmussen, Jeffrey/0000-0001-6997-3773	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL002540, Z01HL002540] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Batten M, 2006, NAT IMMUNOL, V7, P929, DOI 10.1038/ni1375; Chan CWY, 2003, J IMMUNOL, V170, P4036, DOI 10.4049/jimmunol.170.8.4036; Choi YH, 2006, J CLIN INVEST, V116, P3240, DOI 10.1172/JCI24867; Erdmann AA, 2005, BLOOD, V105, P4707, DOI 10.1182/blood-2004-04-1407; Fontenot JD, 2005, NAT IMMUNOL, V6, P331, DOI 10.1038/ni1179; Fontenot JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Hsieh CS, 2006, NAT IMMUNOL, V7, P401, DOI 10.1038/ni1318; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; Ohta A, 2001, NATURE, V414, P916, DOI 10.1038/414916a; Roncarolo MG, 2006, IMMUNOL REV, V212, P28; Sheppard FR, 2005, J LEUKOCYTE BIOL, V78, P1025, DOI 10.1189/jlb.0804442; Stumhofer JS, 2006, NAT IMMUNOL, V7, P937, DOI 10.1038/ni1376; Torgersen KM, 2002, CELL SIGNAL, V14, P1, DOI 10.1016/S0898-6568(01)00214-5; van Santen HM, 2004, J EXP MED, V200, P1221, DOI 10.1084/jem.20041022; WILLIAMS LM, IN PRESS NATURE IMMU; Yegutkin GG, 2006, J BIOL CHEM, V281, P29441, DOI 10.1074/jbc.M602480200; Yegutkin GG, 2002, BIOCHEM J, V367, P121, DOI 10.1042/BJ20020439; Zhang W, 2000, BLOOD, V95, P3380, DOI 10.1182/blood.V95.11.3380.011k25_3380_3386; ZHENG Y, NATURE IN PRESS	23	872	926	2	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 15	2007	445	7129					771	775		10.1038/nature05543	http://dx.doi.org/10.1038/nature05543			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	136EK	17220874	Bronze			2022-12-28	WOS:000244205200046
J	Haines, JL; Pericak-Vance, MA				Haines, Jonathan L.; Pericak-Vance, Margaret A.			Rapid dissection of the genetic risk of age-related macular degeneration - Achieving the promise of the genomic era - Commentary	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							COMPLEMENT FACTOR-H; COMMON HAPLOTYPE; DISEASE; POLYMORPHISM; ASSOCIATION; LOC387715; VARIANT		Univ Miami, Miller Sch Med, Miami Inst Human Genom, Miami, FL 33101 USA; Vanderbilt Univ, Med Ctr, Ctr Human Genet Res, Nashville, TN USA	University of Miami; Vanderbilt University	Pericak-Vance, MA (corresponding author), Univ Miami, Miller Sch Med, Miami Inst Human Genom, POB 019132, Miami, FL 33101 USA.	mpericak@med.miami.edu						Arking DE, 2006, NAT GENET, V38, P644, DOI 10.1038/ng1790; Collins FS, 2003, NATURE, V422, P835, DOI 10.1038/nature01626; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Duerr RH, 2006, SCIENCE, V314, P1461, DOI 10.1126/science.1135245; Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189; Gorin MB, 1999, MOL VIS, V5, pU31; Graham RR, 2006, NAT GENET, V38, P550, DOI 10.1038/ng1782; Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102; Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359; *J HOPK U MCKUS NA, ONL MEND INH MAN OMI; Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437; Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069; Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557; *PREV BLINDN AM, 2003, VIS PROBL US 2002; Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353; Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55; Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822	17	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 24	2007	297	4					401	402		10.1001/jama.297.4.401	http://dx.doi.org/10.1001/jama.297.4.401			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128GE	17252632				2022-12-28	WOS:000243645400026
J	Konradsen, F; Dawson, AH; Eddleston, M; Gunnell, D				Konradsen, Flemming; Dawson, Andrew H.; Eddleston, Michael; Gunnell, David			Pesticide self-poisoning: thinking outside the box	LANCET			English	Editorial Material							DEVELOPING-COUNTRIES; SUICIDE		Univ Copenhagen, Dept Int Hlth, DK-1014 Copenhagen K, Denmark; Univ Peradeniya, S Asian Clin Toxicol Res Collaborat, Peradeniya, Sri Lanka; Univ Newcastle, Sch Populat Hlth Sci, Fac Med & Hlth Sci, Newcastle, NSW 2308, Australia; Univ Oxford, Nuffield Dept Clin Med, Ctr Trop Med, Oxford, England; Univ Bristol, Dept Social Med, Bristol, Avon, England	University of Copenhagen; University of Peradeniya; University of Newcastle; University of Oxford; University of Bristol	Konradsen, F (corresponding author), Univ Copenhagen, Dept Int Hlth, DK-1014 Copenhagen K, Denmark.	f.konradsen@pubhealth.ku.dk	Dawson, Andrew H/U-8041-2019; Gunnell, David/ABE-6653-2020; Dawson, Andrew/D-5085-2012	Dawson, Andrew H/0000-0002-8047-397X; Gunnell, David/0000-0002-0829-6470; Dawson, Andrew/0000-0002-8047-397X; Konradsen, Flemming/0000-0003-1036-6949	Wellcome Trust [063560, 071669] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bertolote JM, 2006, B WORLD HEALTH ORGAN, V84, P260; *CROPL INT, 1998, GUID SAF EFF US CROP; Eddleston M, 2006, INJURY PREV, V12, P333, DOI 10.1136/ip.2006.012641; Gunnell D, 2003, INT J EPIDEMIOL, V32, P902, DOI 10.1093/ije/dyg307; Konradsen F, 2003, TOXICOLOGY, V192, P249, DOI 10.1016/S0300-483X(03)00339-1; MISHARA BL, 2005, ANN C INT ASS SUIC P; PIERIS R, 2005, FINAL REPORT USE SUR; *SYNG, 2006, SOC RES PROD STEW; WHO, 2001, WORLD HLTH REPORT 20; , 2004, IMP PEST HLTH PREV I; 2006, IASP NEWS B      APR	11	34	34	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 20	2007	369	9557					169	170		10.1016/S0140-6736(07)60085-3	http://dx.doi.org/10.1016/S0140-6736(07)60085-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	128XG	17240268	Bronze, Green Published, Green Accepted			2022-12-28	WOS:000243692400007
J	Berg, RW; Alaburda, A; Hounsgaard, J				Berg, Rune W.; Alaburda, Aidas; Hounsgaard, Jorn			Balanced inhibition and excitation drive spike activity in spinal half-centers	SCIENCE			English	Article							NEURONS IN-VIVO; NETWORK ACTIVITY; CORTICAL-NEURONS; SYNAPTIC INPUT; CONDUCTANCE; CORD; MOTONEURONS; VARIABILITY; MODULATION; MODELS	Many limb movements are composed of alternating flexions and extensions. However, the underlying spinal network mechanisms remain poorly defined. Here, we show that the intensity of synaptic excitation and inhibition in limb motoneurons varies in phase rather than out of phase during rhythmic scratchlike network activity in the turtle. Inhibition and excitation peak with the total neuron conductance during the depolarizing waves of scratch episodes. Furthermore, spike activity is driven by depolarizing synaptic transients rather than pacemaker properties. These findings show that balanced excitation and inhibition and irregular firing are fundamental motifs in certain spinal network functions.	Univ Copenhagen, Panum Inst, Dept Neurosci & Pharmacol, DK-2200 Copenhagen, Denmark; Vilnius State Univ, Fac Nat Sci, Dept Biochem & Biophys, LT-03101 Vilnius, Lithuania	University of Copenhagen; Vilnius University	Hounsgaard, J (corresponding author), Univ Copenhagen, Panum Inst, Dept Neurosci & Pharmacol, DK-2200 Copenhagen, Denmark.	j.hounsgaard@mfi.ku.dk	Berg, Rune W/C-9717-2014; Berg, Rune W./X-7293-2019	Berg, Rune W/0000-0001-6376-9368; Berg, Rune W./0000-0001-6376-9368; hounsgaard, jorn/0000-0003-1523-0485				Alaburda A, 2005, J NEUROSCI, V25, P6316, DOI 10.1523/JNEUROSCI.0843-05.2005; Alaburda A, 2003, J NEUROSCI, V23, P8625; Anderson JS, 2000, J NEUROPHYSIOL, V84, P909, DOI 10.1152/jn.2000.84.2.909; Borg-Graham LJ, 1998, NATURE, V393, P369, DOI 10.1038/30735; Brown TG, 1911, P R SOC LOND B-CONTA, V84, P308, DOI 10.1098/rspb.1911.0077; CALVIN WH, 1968, J NEUROPHYSIOL, V31, P574, DOI 10.1152/jn.1968.31.4.574; Chance FS, 2002, NEURON, V35, P773, DOI 10.1016/S0896-6273(02)00820-6; Delgado-Lezama R, 1999, PROG BRAIN RES, V123, P57, DOI 10.1016/S0079-6123(08)62844-7; Destexhe A, 2003, NAT REV NEUROSCI, V4, P739, DOI 10.1038/nrn1198; Diba K, 2004, J NEUROSCI, V24, P9723, DOI 10.1523/JNEUROSCI.1721-04.2004; GERSTEIN GL, 1964, BIOPHYS J, V4, P41, DOI 10.1016/S0006-3495(64)86768-0; Grillner S, 2003, NAT REV NEUROSCI, V4, P573, DOI 10.1038/nrn1137; Grillner S., 1981, HDB PHYSL NERVOUS SY, P1179, DOI DOI 10.1002/CPHY.CP010226; Haider B, 2006, J NEUROSCI, V26, P4535, DOI 10.1523/JNEUROSCI.5297-05.2006; HOUNSGAARD J, 1988, J PHYSIOL-LONDON, V398, P575, DOI 10.1113/jphysiol.1988.sp017058; JANKOWSKA E, 1965, NATURE, V206, P198, DOI 10.1038/206198a0; KEIFER J, 1983, BRAIN RES, V266, P148, DOI 10.1016/0006-8993(83)91318-5; Kiehn O, 2000, BRAIN RES BULL, V53, P649, DOI 10.1016/S0361-9230(00)00398-1; Marder E, 1996, PHYSIOL REV, V76, P687, DOI 10.1152/physrev.1996.76.3.687; Marino J, 2005, NAT NEUROSCI, V8, P194, DOI 10.1038/nn1391; Salinas E, 2000, J NEUROSCI, V20, P6193, DOI 10.1523/JNEUROSCI.20-16-06193.2000; Shadlen MN, 1998, J NEUROSCI, V18, P3870; Sherrington C., 1947, INTEGRATIVE ACTION N, V2nd; Shu YS, 2003, NATURE, V423, P288, DOI 10.1038/nature01616; SOFTKY WR, 1993, J NEUROSCI, V13, P334; Stein PSG, 2005, J COMP PHYSIOL A, V191, P213, DOI 10.1007/s00359-004-0568-6; Stern EA, 1997, J NEUROPHYSIOL, V77, P1697, DOI 10.1152/jn.1997.77.4.1697; van Vreeswijk C, 1998, NEURAL COMPUT, V10, P1321, DOI 10.1162/089976698300017214; vanVreeswijk C, 1996, SCIENCE, V274, P1724, DOI 10.1126/science.274.5293.1724	29	181	181	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 19	2007	315	5810					390	393		10.1126/science.1134960	http://dx.doi.org/10.1126/science.1134960			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126SI	17234950				2022-12-28	WOS:000243535400046
J	Goldston, D				Goldston, David			Climate of opportunity	NATURE			English	Editorial Material									Princeton Univ, Woodrow Wilson Sch Publ & Int Affairs, Princeton, NJ 08544 USA	Princeton University	Goldston, D (corresponding author), Princeton Univ, Woodrow Wilson Sch Publ & Int Affairs, Princeton, NJ 08544 USA.								0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 18	2007	445	7125					248	248		10.1038/445248a	http://dx.doi.org/10.1038/445248a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126HT	17230163	Bronze			2022-12-28	WOS:000243504700012
J	Smith, R				Smith, Roger			Mechanisms of disease - Parturition	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CORTICOTROPIN-RELEASING HORMONE; FACTOR-KAPPA-B; ADENOSINE-3',5'-MONOPHOSPHATE REGULATORY ELEMENT; MESSENGER-RNA EXPRESSION; PROGESTERONE-RECEPTOR-A; BINDING PROTEIN; FETAL LUNG; HUMAN MYOMETRIUM; PLASMA-CORTISOL; GENE-EXPRESSION		John Hunter Hosp, Hunter Med Res Inst, Mothers & Babies Res Ctr, Newcastle, NSW 2310, Australia	Hunter Medical Research Institute; John Hunter Hospital; University of Newcastle	Smith, R (corresponding author), John Hunter Hosp, Hunter Med Res Inst, Mothers & Babies Res Ctr, Lookout Rd, Newcastle, NSW 2310, Australia.	roger.smith@newcastle.edu.au		Smith, Roger/0000-0003-4720-0280				Alvi SA, 1999, MOL HUM REPROD, V5, P476, DOI 10.1093/molehr/5.5.476; ASA SL, 1991, NEUROENDOCRINOLOGY, V53, P562, DOI 10.1159/000125775; Asboth Gergely, 1997, Acta Physiologica Hungarica, V85, P39; BENEDETTO C, 1994, AM J OBSTET GYNECOL, V171, P126, DOI 10.1016/0002-9378(94)90457-X; Bernal AL, 2003, BJOG-INT J OBSTET GY, V110, P39, DOI 10.1016/S1470-0328(03)00023-5; Bievenue AM, 2002, J SOC GYNECOL INVEST, V9, P27, DOI 10.1016/S1071-5576(01)00141-1; Bisits AM, 2005, PLOS COMPUT BIOL, V1, P132, DOI 10.1371/journal.pcbi.0010019; Blanks AM, 2003, BJOG-INT J OBSTET GY, V110, P46, DOI 10.1016/S1470-0328(03)00024-7; Bowman ME, 2001, AM J PRIMATOL, V53, P123, DOI 10.1002/1098-2345(200103)53:3<123::AID-AJP3>3.0.CO;2-V; Brainard AM, 2005, AM J PHYSIOL-CELL PH, V289, pC49, DOI 10.1152/ajpcell.00399.2004; Challis John R. G., 1994, P985; Challis JRG, 2001, BIOL NEONATE, V79, P163; Chanrachakul B, 2004, AM J PHYSIOL-CELL PH, V287, pC1747, DOI 10.1152/ajpcell.00236.2004; Chanrachakul B, 2003, REPRODUCTION, V126, P43, DOI 10.1530/reprod/126.1.43; Chapman NR, 2005, ENDOCRINOLOGY, V146, P4994, DOI 10.1210/en.2005-0533; Cheng YH, 2000, J CLIN ENDOCR METAB, V85, P1937, DOI 10.1210/jc.85.5.1937; Cheng Z, 2005, NATURE, V437, P88, DOI 10.1038/nature04000; *CHIMP SEQ AN CONS, 2005, NATURE, V0437; Condon JC, 2006, MOL ENDOCRINOL, V20, P764, DOI 10.1210/me.2005-0242; Condon JC, 2004, P NATL ACAD SCI USA, V101, P4978, DOI 10.1073/pnas.0401124101; Condon JC, 2003, P NATL ACAD SCI USA, V100, P9518, DOI 10.1073/pnas.1633616100; CONNEELY OM, 1987, BIOCHEM BIOPH RES CO, V149, P493, DOI 10.1016/0006-291X(87)90395-0; COOKE RG, 1980, J REPROD FERTIL, V59, P347, DOI 10.1530/jrf.0.0590347; CSAPO A, 1956, AM J ANAT, V98, P273, DOI 10.1002/aja.1000980206; CSAPO AI, 1971, AM J OBSTET GYNECOL, V110, P630, DOI 10.1016/0002-9378(71)90242-0; Doheny HC, 2005, J CLIN ENDOCR METAB, V90, P5786, DOI 10.1210/jc.2005-0574; Duquette RA, 2005, BIOL REPROD, V72, P276, DOI 10.1095/biolreprod.104.033506; Ellis MJ, 2002, AM J OBSTET GYNECOL, V186, P94, DOI 10.1067/mob.2002.119188; Elovitz MA, 2001, AM J OBSTET GYNECOL, V185, P1059, DOI 10.1067/mob.2001.117638; EMANUEL RL, 1994, CLIN ENDOCRINOL, V40, P257, DOI 10.1111/j.1365-2265.1994.tb02477.x; Emanuel RL, 2000, PEPTIDES, V21, P1819, DOI 10.1016/S0196-9781(00)00343-0; Eswaran H, 2004, AM J OBSTET GYNECOL, V190, P1598, DOI 10.1016/j.ajog.2004.03.063; Garbrecht MR, 2006, BIOL NEONATE, V89, P109, DOI 10.1159/000088653; Garfield RE, 2005, AM J OBSTET GYNECOL, V193, P23, DOI 10.1016/j.ajog.2005.01.050; Giangrande PH, 2000, MOL CELL BIOL, V20, P3102, DOI 10.1128/MCB.20.9.3102-3115.2000; Giles W, 2000, AM J OBSTET GYNECOL, V182, P439, DOI 10.1016/S0002-9378(00)70236-5; GOLAND RS, 1993, J CLIN ENDOCR METAB, V77, P1174, DOI 10.1210/jc.77.5.1174; GOLAND RS, 1992, ENDOCRINOLOGY, V131, P1782, DOI 10.1210/en.131.4.1782; GRAMMATOPOULOS D, 1995, J CLIN ENDOCR METAB, V80, P2388, DOI 10.1210/jc.80.8.2388; Grammatopoulos DK, 1999, LANCET, V354, P1546, DOI 10.1016/S0140-6736(99)03418-2; HAIG D, 1993, Q REV BIOL, V68, P495, DOI 10.1086/418300; Hillhouse EW, 2006, ENDOCR REV, V27, P260, DOI 10.1210/er.2005-0034; Himmelmann K, 2005, ACTA PAEDIATR, V94, P287, DOI 10.1111/j.1651-2227.2005.tb03071.x; Hobel CJ, 1999, AM J OBSTET GYNECOL, V180, pS257, DOI 10.1016/S0002-9378(99)70712-X; Hobel CJ, 1999, ANN NY ACAD SCI, V897, P54, DOI 10.1111/j.1749-6632.1999.tb07878.x; Johnson RF, 2004, J CLIN ENDOCR METAB, V89, P5639, DOI 10.1210/jc.2004-0540; Keelan JA, 1999, AM J OBSTET GYNECOL, V181, P1530, DOI 10.1016/S0002-9378(99)70400-X; Korebrits C, 1998, BRIT J OBSTET GYNAEC, V105, P556, DOI 10.1111/j.1471-0528.1998.tb10158.x; LAATIKAINEN TJ, 1988, AM J OBSTET GYNECOL, V159, P891, DOI 10.1016/S0002-9378(88)80163-7; Ledingham MA, 1999, HUM REPROD, V14, P2089, DOI 10.1093/humrep/14.8.2089; Leung TN, 2001, BRIT J OBSTET GYNAEC, V108, P527, DOI 10.1016/S0306-5456(00)00112-1; Li W, 2005, J CLIN ENDOCR METAB, V90, P6569, DOI 10.1210/jc.2005-1445; LIGGINS GC, 1968, J ENDOCRINOL, V42, P323, DOI 10.1677/joe.0.0420323; LIGGINS GC, 1977, CIBA F S, V47, P5; Lindstrom TM, 2005, REPRODUCTION, V130, P569, DOI 10.1530/rep.1.00197; LINTON EA, 1990, J CLIN ENDOCR METAB, V70, P1574, DOI 10.1210/jcem-70-6-1574; LINTON EA, 1993, J CLIN ENDOCR METAB, V76, P260, DOI 10.1210/jc.76.1.260; LOCKWOOD CJ, 1994, AM J OBSTET GYNECOL, V171, P1; Loudon JAZ, 2004, MOL HUM REPROD, V10, P895, DOI 10.1093/molehr/gah112; Lowery C L, 2003, J Ark Med Soc, V100, P90; Lye SJ, 2001, FRONT HORM RES, V27, P165; Lye SJ, 1998, FETAL MATERNAL MED R, V10, P121, DOI DOI 10.1017/S096553959800031X); MacDorman MF, 2005, INT J HEALTH SERV, V35, P415, DOI 10.2190/TJ2N-DADV-1EP5-5C7F; MacDougall MWJ, 2003, J CLIN ENDOCR METAB, V88, P2194, DOI 10.1210/jc.2002-021862; Macphee DJ, 2000, ENDOCRINOLOGY, V141, P274, DOI 10.1210/en.141.1.274; Mazouni C, 2006, CONTRACEPTION, V73, P244, DOI 10.1016/j.contraception.2005.09.007; McGrath S, 2002, AM J OBSTET GYNECOL, V186, P257, DOI 10.1067/mob.2002.119635; MCLEAN M, 1995, NAT MED, V1, P460, DOI 10.1038/nm0595-460; Mesiano S, 2004, J SOC GYNECOL INVEST, V11, P193, DOI 10.1016/j.jsgi.2003.12.004; Mesiano S, 2002, J CLIN ENDOCR METAB, V87, P2924, DOI 10.1210/jc.87.6.2924; Moran CJ, 2002, MOL HUM REPROD, V8, P196, DOI 10.1093/molehr/8.2.196; MORGAN MA, 1992, BIOL REPROD, V46, P1158, DOI 10.1095/biolreprod46.6.1158; Ni X, 2004, J CLIN ENDOCR METAB, V89, P2312, DOI 10.1210/jc.2003-030948; Ni X, 2004, CELL MOL LIFE SCI, V61, P1114, DOI 10.1007/s00018-004-4030-2; Ni X, 1997, J CLIN ENDOCR METAB, V82, P4171, DOI 10.1210/jc.82.12.4171; Nodwell A, 1999, PLACENTA, V20, P197, DOI 10.1053/plac.1998.0357; Oldenhof AD, 2002, AM J PHYSIOL-CELL PH, V283, pC1530, DOI 10.1152/ajpcell.00607.2001; Osman I, 2003, MOL HUM REPROD, V9, P41, DOI 10.1093/molehr/gag001; OWENS PC, 1987, LIFE SCI, V41, P1745, DOI 10.1016/0024-3205(87)90603-5; Parkington HC, 2001, FRONT HORM RES, V27, P179; Patel RR, 2004, INT J EPIDEMIOL, V33, P107, DOI 10.1093/ije/dyg238; PETRAGLIA F, 1989, AM J OBSTET GYNECOL, V160, P247, DOI 10.1016/0002-9378(89)90130-0; Petrou S, 2005, BJOG-INT J OBSTET GY, V112, P10, DOI 10.1111/j.1471-0528.2005.00577.x; Power ML, 2006, AM J PRIMATOL, V68, P181, DOI 10.1002/ajp.20215; QUARTERO HWP, 1989, PLACENTA, V10, P439, DOI 10.1016/0143-4004(89)90054-4; Renfree MB, 2000, REV REPROD, V5, P6, DOI 10.1530/ror.0.0050006; ROBINSON BG, 1988, P NATL ACAD SCI USA, V85, P5244, DOI 10.1073/pnas.85.14.5244; Rosenberg KR, 2001, SCI AM, V285, P72, DOI 10.1038/scientificamerican1101-72; Sanborn BM, 2005, J SOC GYNECOL INVEST, V12, P479, DOI 10.1016/j.jsgi.2005.07.002; Sandman CA, 1997, ANN NY ACAD SCI, V814, P266, DOI 10.1111/j.1749-6632.1997.tb46162.x; Sandman CA, 1999, ANN NY ACAD SCI, V897, P66, DOI 10.1111/j.1749-6632.1999.tb07879.x; Sheehan PM, 2005, MOL HUM REPROD, V11, P495, DOI 10.1093/molehr/gah201; Shlykov SG, 2003, BIOL REPROD, V69, P647, DOI 10.1095/biolreprod.103.015396; SIGGER JN, 1984, J REPROD FERTIL, V70, P103, DOI 10.1530/jrf.0.0700103; Slattery MM, 2002, LANCET, V360, P1489, DOI 10.1016/S0140-6736(02)11476-0; SMITH R, 1993, J CLIN ENDOCR METAB, V76, P1063, DOI 10.1210/jc.76.4.1063; SMITH R, 1990, J PSYCHOSOM RES, V34, P53, DOI 10.1016/0022-3999(90)90008-R; Smith R, 1998, J CLIN ENDOCR METAB, V83, P2916, DOI 10.1210/jc.83.8.2916; Smith R, 1999, J CLIN ENDOCR METAB, V84, P2820, DOI 10.1210/jc.84.8.2820; Thomson AJ, 1999, HUM REPROD, V14, P229, DOI 10.1093/humrep/14.1.229; Torricelli M, 2006, EUR J ENDOCRINOL, V154, P281, DOI 10.1530/eje.1.02091; Wadhwa PD, 1998, AM J OBSTET GYNECOL, V179, P1079, DOI 10.1016/S0002-9378(98)70219-4; WARREN WB, 1992, AM J OBSTET GYNECOL, V166, P1198, DOI 10.1016/S0002-9378(11)90606-1; Wei LL, 1996, MOL ENDOCRINOL, V10, P1379, DOI 10.1210/me.10.11.1379; Whittle WL, 2001, BIOL REPROD, V64, P1019, DOI 10.1095/biolreprod64.4.1019; WOLFE C, 1987, LANCET, V1, P335; WOOD C, 1964, J OBSTET GYN BR COMM, V71, P360; Yoon BH, 1998, AM J OBSTET GYNECOL, V179, P1107, DOI 10.1016/S0002-9378(98)70114-0; Young RC, 2005, J SOC GYNECOL INVEST, V12, p354A; Yu JTHT, 1998, J REPROD FERTIL, V112, P185	110	339	345	1	32	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 18	2007	356	3					271	283		10.1056/NEJMra061360	http://dx.doi.org/10.1056/NEJMra061360			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	126BV	17229954				2022-12-28	WOS:000243488100009
J	Stukel, TA; Fisher, ES; Wennberg, DE; Alter, DA; Gottlieb, DJ; Vermeulen, MJ				Stukel, Therese A.; Fisher, Elliott S.; Wennberg, David E.; Alter, David A.; Gottlieb, Daniel J.; Vermeulen, Marian J.			Analysis of observational studies in the presence of treatment selection bias - Effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; CORONARY-ANGIOGRAPHY; REGIONAL-VARIATIONS; ELDERLY-PATIENTS; THROMBOLYTIC THERAPY; MEDICARE PATIENTS; OUTCOMES; REGRESSION; RISK; STRATEGIES	Context Comparisons of outcomes between patients treated and untreated in observational studies may be biased due to differences in patient prognosis between groups, often because of unobserved treatment selection biases. Objective To compare 4 analytic methods for removing the effects of selection bias in observational studies: multivariable model risk adjustment, propensity score risk adjustment, propensity-based matching, and instrumental variable analysis. Design, Setting, and Patients A national cohort of 122 124 patients who were elderly ( aged 65-84 years), receiving Medicare, and hospitalized with acute myocardial infarction ( AMI) in 1994-1995, and who were eligible for cardiac catheterization. Baseline chart reviews were taken from the Cooperative Cardiovascular Project and linked to Medicare health administrative data to provide a rich set of prognostic variables. Patients were followed up for 7 years through December 31, 2001, to assess the association between long-term survival and cardiac catheterization within 30 days of hospital admission. Main Outcome Measure Risk-adjusted relative mortality rate using each of the analytic methods. Results Patients who received cardiac catheterization (n = 73 238) were younger and had lower AMI severity than those who did not. After adjustment for prognostic factors by using standard statistical risk-adjustment methods, cardiac catheterization was associated with a 50% relative decrease in mortality ( for multivariable model risk adjustment: adjusted relative risk [RR], 0.51; 95% confidence interval [CI], 0.50-0.52; for propensity score risk adjustment: adjusted RR, 0.54; 95% CI, 0.53-0.55; and for propensity-based matching: adjusted RR, 0.54; 95% CI, 0.52-0.56). Using regional catheterization rate as an instrument, instrumental variable analysis showed a 16% relative decrease in mortality ( adjusted RR, 0.84; 95% CI, 0.79-0.90). The survival benefits of routine invasive care from randomized clinical trials are between 8% and 21%. Conclusions Estimates of the observational association of cardiac catheterization with long-term AMI mortality are highly sensitive to analytic method. All standard risk-adjustment methods have the same limitations regarding removal of unmeasured treatment selection biases. Compared with standard modeling, instrumental variable analysis may produce less biased estimates of treatment effects, but is more suited to answering policy questions than specific clinical questions.	Inst Clin Evaluat Sci, Toronto, ON, Canada; Dartmouth Med Sch, Ctr Evaluat Clin Sci, Hanover, NH USA; Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada; Sunnybrook Hlth Sci Ctr, Clin Epidemiol & Hlth Care Res Program, Toronto, ON, Canada; Vet Adm Outcomes Grp, White River Jct, VT USA; Maine Med Ctr, Ctr Outcomes Res & Evaluat, Portland, ME 04102 USA; St Michaels Hosp, Toronto Rehabil Inst, Div Cardiol, Toronto, ON M5B 1W8, Canada; St Michaels Hosp, Toronto Rehabil Inst, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada	University of Toronto; Dartmouth College; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Maine Medical Center; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University Health Network Toronto; Toronto Rehabilitation Institute; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; University Health Network Toronto; Toronto Rehabilitation Institute; University of Toronto	Stukel, TA (corresponding author), Inst Clin Evaluat Sci, Toronto, ON, Canada.	stukel@ices.on.ca	Potter, Joseph E/A-3122-2008	Stukel, Therese/0000-0002-2951-1360	NIA NIH HHS [P01 AG019783-06, P01 AG019783, 1P01-AG19783-01] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG019783] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Angrist JD, 1996, J AM STAT ASSOC, V91, P444, DOI 10.2307/2291629; Austin PC, 2005, STAT MED, V24, P1563, DOI 10.1002/sim.2053; Benson K, 2000, NEW ENGL J MED, V342, P1878, DOI 10.1056/NEJM200006223422506; Braitman LE, 2002, ANN INTERN MED, V137, P693, DOI 10.7326/0003-4819-137-8-200210150-00015; Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507; Cox D. R., 1984, ANAL SURVIVAL DATA; COX DR, 1968, J ROY STAT SOC B, V30, P248, DOI 10.1111/j.2517-6161.1968.tb00724.x; D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B; Fisher ES, 2003, ANN INTERN MED, V138, P288, DOI 10.7326/0003-4819-138-4-200302180-00007; Fisher ES, 2003, ANN INTERN MED, V138, P273, DOI 10.7326/0003-4819-138-4-200302180-00006; Goodman DC, 2002, NEW ENGL J MED, V346, P1538, DOI 10.1056/NEJMoa011921; Harrell F.E., 2015, REGRESSION MODELING, DOI [10.1007/978-3-319-19425-7, DOI 10.1007/978-3-319-19425-7, 10.1007/978-1-4757-3462-1]; Harris KM, 1998, HEALTH SERV RES, V33, P1337; Keeley EC, 2003, LANCET, V361, P13, DOI 10.1016/S0140-6736(03)12113-7; Ko DT, 2004, JAMA-J AM MED ASSOC, V291, P1864, DOI 10.1001/jama.291.15.1864; Krumholz HM, 1997, JAMA-J AM MED ASSOC, V277, P1683, DOI 10.1001/jama.277.21.1683; LANDRUM MB, 2001, HLTH SERV OUTCOMES R, V2, P221, DOI DOI 10.1023/A:1020367111374; Lee DS, 2005, JAMA-J AM MED ASSOC, V294, P1240, DOI 10.1001/jama.294.10.1240; LIN DY, 1994, STAT MED, V13, P2233, DOI 10.1002/sim.4780132105; Mamdani M, 2004, LANCET, V363, P1751, DOI 10.1016/S0140-6736(04)16299-5; Marciniak TA, 1998, JAMA-J AM MED ASSOC, V279, P1351, DOI 10.1001/jama.279.17.1351; MCCLELLAN M, 1994, JAMA-J AM MED ASSOC, V272, P859, DOI 10.1001/jama.272.11.859; Mehta SR, 2005, JAMA-J AM MED ASSOC, V293, P2908, DOI 10.1001/jama.293.23.2908; Newhouse JP, 1998, ANNU REV PUBL HEALTH, V19, P17, DOI 10.1146/annurev.publhealth.19.1.17; Normand SLT, 2001, J CLIN EPIDEMIOL, V54, P387, DOI 10.1016/S0895-4356(00)00321-8; Parsons L, REDUCING BIAS PROPEN; Pilote L, 1996, NEW ENGL J MED, V335, P1198, DOI 10.1056/NEJM199610173351606; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; ROSENBAUM PR, 1984, J AM STAT ASSOC, V79, P516, DOI 10.2307/2288398; ROSENBAUM PR, 1985, AM STAT, V39, P33, DOI 10.2307/2683903; ROSENBAUM PR, 1991, ANN INTERN MED, V115, P901, DOI 10.7326/0003-4819-115-11-901; Ryan TJ, 1999, J AM COLL CARDIOL, V34, P890, DOI 10.1016/S0735-1097(99)00351-4; SCHOENFELD D, 1982, BIOMETRIKA, V69, P239, DOI 10.1093/biomet/69.1.239; Selby JV, 1996, NEW ENGL J MED, V335, P1888, DOI 10.1056/NEJM199612193352506; Shah BR, 2005, J CLIN EPIDEMIOL, V58, P550, DOI 10.1016/j.jclinepi.2004.10.016; Staiger D, 1997, ECONOMETRICA, V65, P557, DOI 10.2307/2171753; *STAT CORP, 2004, STATA STAT SOFTW REL; Stukel TA, 2005, JAMA-J AM MED ASSOC, V293, P1329, DOI 10.1001/jama.293.11.1329; U.S. Food and Drug Administration U.S. Department of Health and Human Services, FDA PUBL HLTH ADV DE; Wang PS, 2005, NEW ENGL J MED, V353, P2335, DOI 10.1056/NEJMoa052827; Wennberg D.E, 1999, DARTMOUTH ATLAS CARD; Wooldridge J.M., 2000, INTRO ECONOMETRICS M	42	590	604	3	66	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 17	2007	297	3					278	285		10.1001/jama.297.3.278	http://dx.doi.org/10.1001/jama.297.3.278			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125VT	17227979	Green Accepted, Bronze			2022-12-28	WOS:000243472300022
J	Saha, V				Saha, Vaskar			Simplifying treatment for children with ALL	LANCET			English	Editorial Material							ACUTE LYMPHOBLASTIC-LEUKEMIA; DELAYED INTENSIFICATION; DEXAMETHASONE; SURVIVAL		Univ Manchester, Paterson Inst Canc Res, Canc Res UK Childrens Canc Grp, Manchester M20 4BX, Lancs, England	Cancer Research UK; Paterson Institute for Cancer Research; University of Manchester	Saha, V (corresponding author), Univ Manchester, Paterson Inst Canc Res, Canc Res UK Childrens Canc Grp, Manchester M20 4BX, Lancs, England.	vaskar.saha@cancer.org.uk		Saha, Vaskar/0000-0002-2916-9649				Arico M, 2005, HAEMATOLOGICA, V90, P1186; Bostrom BC, 2003, BLOOD, V101, P3809, DOI 10.1182/blood-2002-08-2454; Conter V, 2007, LANCET, V369, P123, DOI 10.1016/S0140-6736(07)60073-7; Eden OB, 2000, LEUKEMIA, V14, P2307, DOI 10.1038/sj.leu.2401962; Lange BJ, 2002, BLOOD, V99, P825, DOI 10.1182/blood.V99.3.825; Mitchell CD, 2005, BRIT J HAEMATOL, V129, P734, DOI 10.1111/j.1365-2141.2005.05509.x; *MRC UKALL TRIALS, 1986, LANCET, V327, P408; Pui CH, 2006, NEW ENGL J MED, V354, P166, DOI 10.1056/NEJMra052603; Richards S, 1996, LANCET, V347, P1783; Roy A, 2005, BRIT J HAEMATOL, V129, P35, DOI 10.1111/j.1365-2141.2005.05425.x; Schrappe M, 2000, LEUKEMIA, V14, P2193, DOI 10.1038/sj.leu.2401977; TUBERGEN DG, 1993, J CLIN ONCOL, V11, P527, DOI 10.1200/JCO.1993.11.3.527	12	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 13	2007	369	9556					82	83		10.1016/S0140-6736(07)60043-9	http://dx.doi.org/10.1016/S0140-6736(07)60043-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	126TK	17223452				2022-12-28	WOS:000243538200005
J	Ferraz, G; Nichols, JD; Hines, JE; Stouffer, PC; Bierregaard, RO; Lovejoy, TE				Ferraz, Goncalo; Nichols, James D.; Hines, James E.; Stouffer, Philip C.; Bierregaard, Richard O., Jr.; Lovejoy, Thomas E.			A large-scale deforestation experiment: Effects of patch area and isolation on Amazon birds	SCIENCE			English	Article								As compared with extensive contiguous areas, small isolated habitat patches lack many species. Some species disappear after isolation; others are rarely found in any small patch, regardless of isolation. We used a 13-year data set of bird captures from a large landscape-manipulation experiment in a Brazilian Amazon forest to model the extinction-colonization dynamics of 55 species and tested basic predictions of island biogeography and metapopulation theory. From our models, we derived two metrics of species vulnerability to changes in isolation and patch area. We found a strong effect of area and a variable effect of isolation on the predicted patch occupancy by birds.	Inst Nacl de Pesquisas da Amazonia, Biol Dynam Forest Fragments Project, BR-69011 Manaus, Amazonas, Brazil; US Fish & Wildlife Serv, Patuxent Wildlife Res Ctr, Laurel, MD 20708 USA; Louisiana State Univ, Sch Renewable Nat Resources, Baton Rouge, LA 70803 USA; Louisiana State Univ, AgCenter, Baton Rouge, LA 70803 USA; Univ N Carolina, Dept Biol, Charlotte, NC 28223 USA; H John Heinz III Ctr Sci Econ Environm, Washington, DC 20004 USA	Institute Nacional de Pesquisas da Amazonia; United States Department of the Interior; US Fish & Wildlife Service; Louisiana State University System; Louisiana State University; Louisiana State University System; Louisiana State University; University of North Carolina; University of North Carolina Charlotte	Ferraz, G (corresponding author), Inst Nacl de Pesquisas da Amazonia, Biol Dynam Forest Fragments Project, BR-69011 Manaus, Amazonas, Brazil.	gferraz@inpa.gov.br	stouffer, phil/AAF-7281-2020; Ferraz, Gonçalo/C-3860-2008	Ferraz, Gonçalo/0000-0001-8748-0462				Bierregaard R., 2001, LESSONS AMAZONIA ECO; BROWN JH, 1977, ECOLOGY, V58, P445, DOI 10.2307/1935620; Burnham K.P., 2002, MODEL SELECTION MULT, VSecond edition; Cohn-Haft Mario, 1997, Ornithological Monographs, V48, P205; Fahrig L, 2003, ANNU REV ECOL EVOL S, V34, P487, DOI 10.1146/annurev.ecolsys.34.011802.132419; Gascon Claude, 2001, P31; Hanski I., 1999, METAPOPULATION ECOLO; Hines JE, 2004, PRESENCE VERSION 2 0; LAURANCE WF, 2006, EMERGING THREATS TRO; MAC ARTHUR ROBERT H., 1967; MacKenzie D. I., 2017, OCCUPANCY ESTIMATION; MacKenzie DI, 2003, ECOLOGY, V84, P2200, DOI 10.1890/02-3090; ROBBINS CS, 1989, WILDLIFE MONOGR, P1; STOUFFER PC, 1995, ECOLOGY, V76, P2429, DOI 10.2307/2265818; Trzcinski MK, 1999, ECOL APPL, V9, P586, DOI 10.1890/1051-0761(1999)009[0586:IEOFCA]2.0.CO;2; Van Houtan KS, 2006, EVOL ECOL RES, V8, P129	16	219	225	6	156	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 12	2007	315	5809					238	241		10.1126/science.1133097	http://dx.doi.org/10.1126/science.1133097			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124XZ	17218527	Green Submitted			2022-12-28	WOS:000243407400046
J	Shimada, K; Gasser, SM				Shimada, Kenji; Gasser, Susan M.			The origin recognition complex functions in sister-chromatid cohesion in Saccharomyces cerevisiae	CELL			English	Article							DNA-DAMAGE CHECKPOINT; BUDDING YEAST; MCM PROTEINS; HETEROCHROMATIN PROTEIN-1; CHROMOSOME CONDENSATION; PRECOCIOUS SEPARATION; CELL-CYCLE; S-PHASE; REPLICATION; ORC	High-fidelity chromosomal segregation requires the properly timed establishment of sisterchromatid cohesion mediated by the Cohesin complex, and its resolution at the metaphaseto-anaphase transition. We have examined cell-cycle progression in a yeast strain from which the origin recognition complex protein Orc2 was depleted after the assembly of prereplication complexes. We find that Orc2 depletion causes a delay in progression through mitosis, reflecting activation of both the DNAdamage and Mad2-spindle checkpoints. Surprisingly, sister-chromatid cohesion is impaired in Orc2-depleted cells, although Cohesin subunits are properly associated with chromatin. Reexpression of Orc2 in late G2/M phase restores chromatid cohesion. Finally, the targeting of Orc2 to a specific chromosomal locus suppresses premature sister-chromatid separation locally in a temperature-sensitive cohesin mutant. We conclude that ORG mediates sisterchromatid interaction on a pathway that is additive with Cohesin-mediated pairing.	Friedrich Miescher Inst, CH-4058 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Gasser, SM (corresponding author), Friedrich Miescher Inst, Maulbeerstr 66, CH-4058 Basel, Switzerland.	susan.gasser@fmi.ch		Gasser, Susan/0000-0003-3610-9123				Badugu R, 2003, J BIOL CHEM, V278, P34491, DOI 10.1074/jbc.M305262200; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Bell SP, 2002, GENE DEV, V16, P659, DOI 10.1101/gad.969602; Bowers JL, 2004, MOL CELL, V16, P967, DOI 10.1016/j.molcel.2004.11.038; Cenci G, 2003, NAT CELL BIOL, V5, P82, DOI 10.1038/ncb902; Chang CR, 2005, GENE DEV, V19, P3031, DOI 10.1101/gad.1356305; Chastain PD, 2004, J BIOL CHEM, V279, P36354, DOI 10.1074/jbc.M403501200; Clarke DJ, 2000, BIOESSAYS, V22, P351, DOI 10.1002/(SICI)1521-1878(200004)22:4<351::AID-BIES5>3.0.CO;2-W; D'Amours D, 2004, CELL, V117, P455, DOI 10.1016/S0092-8674(04)00413-1; de Gramont A, 2005, TRENDS BIOCHEM SCI, V30, P559, DOI 10.1016/j.tibs.2005.08.008; Dillin A, 1998, SCIENCE, V279, P1733, DOI 10.1126/science.279.5357.1733; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; Du YCN, 2002, CELL, V109, P835, DOI 10.1016/S0092-8674(02)00773-0; Garber PM, 2002, GENETICS, V161, P521; Gasser SM, 2001, GENE, V279, P1, DOI 10.1016/S0378-1119(01)00741-7; Giannattasio M, 2004, EMBO J, V23, P429, DOI 10.1038/sj.emboj.7600051; Gillespie PJ, 2004, CURR BIOL, V14, P1598, DOI 10.1016/j.cub.2004.07.053; Glynn EF, 2004, PLOS BIOL, V2, P1325, DOI 10.1371/journal.pbio.0020259; Goshima G, 2000, CELL, V100, P619, DOI 10.1016/S0092-8674(00)80699-6; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; He XW, 2000, CELL, V101, P763, DOI 10.1016/S0092-8674(00)80888-0; Hiragami K, 2005, CELL MOL LIFE SCI, V62, P2711, DOI 10.1007/s00018-005-5287-9; Hua XQH, 1998, J CELL BIOL, V140, P271, DOI 10.1083/jcb.140.2.271; Irlbacher H, 2005, GENE DEV, V19, P1811, DOI 10.1101/gad.334805; Ivanov D, 2002, CURR BIOL, V12, P323, DOI 10.1016/S0960-9822(02)00681-4; Kawasaki Y, 2006, GENES CELLS, V11, P745, DOI 10.1111/j.1365-2443.2006.00975.x; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Lam WW, 2006, GENE DEV, V20, P2973, DOI 10.1101/gad.1468806; Lengronne A, 2004, NATURE, V430, P573, DOI 10.1038/nature02742; Liang C, 1997, GENE DEV, V11, P3375, DOI 10.1101/gad.11.24.3375; Loupart ML, 2000, CURR BIOL, V10, P1547, DOI 10.1016/S0960-9822(00)00844-7; Mayer ML, 2001, MOL CELL, V7, P959, DOI 10.1016/S1097-2765(01)00254-4; Megee PC, 1999, MOL CELL, V4, P445, DOI 10.1016/S1097-2765(00)80347-0; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; Moore LL, 2005, MOL CELL BIOL, V25, P2583, DOI 10.1128/MCB.25.7.2583-2592.2005; Nasmyth K, 2005, ANNU REV BIOCHEM, V74, P595, DOI 10.1146/annurev.biochem.74.082803.133219; NEWTON CS, 1993, COLD SPRING HARB SYM, V58, P415; Pak DTS, 1997, CELL, V91, P311, DOI 10.1016/S0092-8674(00)80415-8; Pasero P, 1999, GENE DEV, V13, P2159, DOI 10.1101/gad.13.16.2159; Pellicioli A, 1999, EMBO J, V18, P6561, DOI 10.1093/emboj/18.22.6561; Pflumm MF, 2001, DEVELOPMENT, V128, P1697; Prasanth SG, 2004, EMBO J, V23, P2651, DOI 10.1038/sj.emboj.7600255; Prasanth SG, 2002, SCIENCE, V297, P1026, DOI 10.1126/science.1072802; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; Schleiffer A, 2003, MOL CELL, V11, P571, DOI 10.1016/S1097-2765(03)00108-4; Shimada K, 2002, GENE DEV, V16, P3236, DOI 10.1101/gad.239802; Skibbens RV, 1999, GENE DEV, V13, P307, DOI 10.1101/gad.13.3.307; Sonoda E, 2001, DEV CELL, V1, P759, DOI 10.1016/S1534-5807(01)00088-0; Straight AF, 1996, CURR BIOL, V6, P1599, DOI 10.1016/S0960-9822(02)70783-5; Strom L, 2004, MOL CELL, V16, P1003, DOI 10.1016/j.molcel.2004.11.026; STRUNNIKOV AV, 1993, J CELL BIOL, V123, P1635, DOI 10.1083/jcb.123.6.1635; Sullivan M, 2004, CELL, V117, P471, DOI 10.1016/S0092-8674(04)00415-5; Suter B, 2004, GENETICS, V167, P579, DOI 10.1534/genetics.103.024851; Takahashi TS, 2004, NAT CELL BIOL, V6, P991, DOI 10.1038/ncb1177; Tanaka TU, 2000, NAT CELL BIOL, V2, P492, DOI 10.1038/35019529; Thomas SE, 2005, CELL, V123, P555, DOI 10.1016/j.cell.2005.08.043; Uhlmann F, 1998, CURR BIOL, V8, P1095, DOI 10.1016/S0960-9822(98)70463-4; Uhlmann F, 2004, EXP CELL RES, V296, P80, DOI 10.1016/j.yexcr.2004.03.005; Unal E, 2004, MOL CELL, V16, P991, DOI 10.1016/j.molcel.2004.11.027; Wyrick JJ, 2001, SCIENCE, V294, P2357, DOI 10.1126/science.1066101	61	79	79	0	5	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 12	2007	128	1					85	99		10.1016/j.cell.2006.11.045	http://dx.doi.org/10.1016/j.cell.2006.11.045			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	139GN	17218257	Bronze			2022-12-28	WOS:000244420400015
J	Iglehart, JK				Iglehart, John K.			Health care on the hill - Democrats set the agenda	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		Biles B, 2006, COST PRIVATIZATION E; FREKING K, 2006, WASHINGTON POST 1114, pA14; Lee C, 2006, WASHINGTON POST 1121, pA	3	5	6	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 4	2007	356	1					1	4		10.1056/NEJMp068276	http://dx.doi.org/10.1056/NEJMp068276			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	122EX	17202448				2022-12-28	WOS:000243209600001
J	Simon, GE				Simon, Gregory E.			The antidepressant quandray - Considering suicide risk whem treating adolescent depression	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA	Group Health Cooperative	Simon, GE (corresponding author), Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA.							Gibbons RD, 2006, AM J PSYCHIAT, V163, P1898, DOI 10.1176/appi.ajp.163.11.1898; Hammad TA, 2006, ARCH GEN PSYCHIAT, V63, P332, DOI 10.1001/archpsyc.63.3.332; National Committee for Quality Assurance, 2006, STAT HLTH CAR QUAL 2; ROSACK J, 2004, PSYCHIAT NEWS, V39, P9; Simon GE, 2006, AM J PSYCHIAT, V163, P41, DOI 10.1176/appi.ajp.163.1.41	5	21	22	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 28	2006	355	26					2722	2723		10.1056/NEJMp068270	http://dx.doi.org/10.1056/NEJMp068270			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	120UA	17192536				2022-12-28	WOS:000243110500003
J	Bradbeer, C; Soni, S; Ekbote, A; Martin, T				Bradbeer, C.; Soni, S.; Ekbote, A.; Martin, T.			You're not going to give me the umbrella, are you?	BRITISH MEDICAL JOURNAL			English	Editorial Material									St Thomas Hosp, Dept Genitourinary Med, London SE1 7EH, England	Guy's & St Thomas' NHS Foundation Trust	Bradbeer, C (corresponding author), St Thomas Hosp, Dept Genitourinary Med, London SE1 7EH, England.	caroline.bradbeer@gstt.nhs.uk							0	2	2	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 23	2006	333	7582					1287	1288		10.1136/bmj.39043.717245.F7	http://dx.doi.org/10.1136/bmj.39043.717245.F7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121MC	17185709	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000243160700007
J	Meessen, B; Van Damme, W; Tashobya, CK; Tibouti, A				Meessen, Bruno; Van Damme, Wim; Tashobya, Christine Kirunga; Tibouti, Abdelmajid			Poverty and user fees for public health care in low-income countries: lessons from Uganda and Cambodia	LANCET			English	Editorial Material							SERVICES; ACCESS; POOR; AFRICA; EQUITY; IMPACT		Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium; Catholic Univ Louvain, Dept Econ, B-1348 Louvain, Belgium; Minist Hlth, Kampala, Uganda; UNICEF, New York, NY USA	Institute of Tropical Medicine (ITM); Universite Catholique Louvain; UNICEF	Meessen, B (corresponding author), Inst Trop Med, Dept Publ Hlth, Natl Str 155, B-2000 Antwerp, Belgium.	bmeessen@itg.be	Van Damme, Wim/F-7404-2011	Van Damme, Wim/0000-0002-6344-3007; Meessen, Bruno/0000-0002-0359-8621				ABELSMITH B, 1992, HEALTH POLICY PLANN, V7, P329, DOI 10.1093/heapol/7.4.329; BURUNDI, SIDE EFFECTS FREE MA; Castro-Leal F, 2000, B WORLD HEALTH ORGAN, V78, P66; Coady D., 2004, TARGETING TRANSFERS; Gilson L, 2005, BMJ-BRIT MED J, V331, P762, DOI 10.1136/bmj.331.7519.762; Gilson L, 2001, HEALTH POLICY, V58, P37, DOI 10.1016/S0168-8510(01)00153-1; Gilson L., 1995, J INT DEVEL, V7, P369, DOI 10.1002/jid.3380070305; Gottret P. E., 2006, HLTH FINANCING REVIS; Gwatkin D. R., 2005, REACHING POOR HLTH N; Gwatkin DR, 2004, LANCET, V364, P1273, DOI 10.1016/S0140-6736(04)17145-6; Hardeman W, 2004, HEALTH POLICY PLANN, V19, P22, DOI 10.1093/heapol/czh003; Jacobs B, 2006, HEALTH POLICY PLANN, V21, P27, DOI 10.1093/heapol/czj001; James C, 2005, BMJ-BRIT MED J, V331, P747, DOI 10.1136/bmj.331.7519.747; JARRETT SW, 1992, HEALTH POLICY PLANN, V7, P164, DOI 10.1093/heapol/7.2.164; KAUFMANN D, 2005, WORLD BANK POLICY RE, V4; Kawabata K, 2002, B WORLD HEALTH ORGAN, V80, P612; Meessen B, 2006, TROP MED INT HEALTH, V11, P1303, DOI 10.1111/j.1365-3156.2006.01680.x; Nabyonga J, 2005, HEALTH POLICY PLANN, V20, P100, DOI 10.1093/heapol/czi012; NOIRHOMME M, 2006, ASSURANCE MALADIE AF, P432; Palmer N, 2004, LANCET, V364, P1365, DOI 10.1016/S0140-6736(04)17195-X; Pearson Mark, 2004, ISSUES PAPER CASE AB; Sachs JD, 2005, LANCET, V365, P347, DOI 10.1016/S0140-6736(05)70201-4; *SAV CHILDR, 2005, UNN EV US FEES HEALT; Soeters R, 2003, HEALTH POLICY PLANN, V18, P74, DOI 10.1093/heapol/18.1.74; Stierle F, 1999, INT J HEALTH PLAN M, V14, P81, DOI 10.1002/(SICI)1099-1751(199904/06)14:2<81::AID-HPM543>3.0.CO;2-P; Tashobya CK, 2006, HLTH SYSTEMS REFORMS; Van Damme W, 2004, TROP MED INT HEALTH, V9, P273, DOI 10.1046/j.1365-3156.2003.01194.x; WILLIS CY, 1995, HEALTH POLICY PLANN, V10, P241, DOI 10.1093/heapol/10.3.241; Xu K, 2006, SOC SCI MED, V62, P866, DOI 10.1016/j.socscimed.2005.07.004	29	67	67	0	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 23	2006	368	9554					2253	2257		10.1016/S0140-6736(06)69899-1	http://dx.doi.org/10.1016/S0140-6736(06)69899-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	120HY	17189038	Green Submitted			2022-12-28	WOS:000243076800034
J	Turegano-Fuentes, F; Perez-Diaz, D				Turegano-Fuentes, Fernando; Perez-Diaz, Dolores			Medical response to the 2005 terrorist bombings in London	LANCET			English	Editorial Material							MANAGEMENT; CASUALTIES		Univ Gen Hosp Gregorio Maranon, Madrid, Spain	General University Gregorio Maranon Hospital	Turegano-Fuentes, F (corresponding author), Univ Gen Hosp Gregorio Maranon, Madrid, Spain.	fturegano@inicia.es						Aylwin CJ, 2006, LANCET, V368, P2219, DOI 10.1016/S0140-6736(06)69896-6; Costich Julia Field, 2004, J Public Health Manag Pract, V10, P225; de Ceballos JPG, 2005, CRIT CARE, V9, P104, DOI 10.1186/cc2995; Frykberg ER, 2002, J TRAUMA, V53, P201, DOI 10.1097/00005373-200208000-00001; Frykberg ER, 2005, CRIT CARE, V9, P20, DOI 10.1186/cc2997; Hirshberg A, 2005, J TRAUMA, V58, P686, DOI 10.1097/01.TA.0000159243.70507.86; Stein M, 2005, SCAND J SURG, V94, P286, DOI 10.1177/145749690509400407	7	11	11	0	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 23	2006	368	9554					2188	2189		10.1016/S0140-6736(06)69871-1	http://dx.doi.org/10.1016/S0140-6736(06)69871-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	120HY	17189013				2022-12-28	WOS:000243076800005
J	Shuchman, M				Shuchman, Miriam			Debating the risks of drug-eluting stents	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		Antman Elliott M, 2004, J Am Coll Cardiol, V44, P671, DOI 10.1016/j.jacc.2004.07.002; ANTMAN EM, 2005, J AM COLL CARDIOL, V45, P1376; EISENSTEIN EL, IN PRESS JAMA; Hauser RG, 2005, CIRCULATION, V112, P2040, DOI 10.1161/CIRCULATIONAHA.105.580381; Shuchman M, 2006, NEW ENGL J MED, V355, P1949, DOI 10.1056/NEJMp068234; WALLENTIN L, 2006, M CIRC SYST DEV PAN	6	65	71	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 25	2007	356	4					325	328		10.1056/NEJMp068300	http://dx.doi.org/10.1056/NEJMp068300			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128FT	17251527				2022-12-28	WOS:000243644300001
J	Krumholz, H; Ross, JS; Presler, AH; Egilman, DS				Krumholz, Harlan; Ross, Joseph S.; Presler, Amos H.; Egilman, David S.			What have we learnt from Vioxx?	BMJ-BRITISH MEDICAL JOURNAL			English	Article							UPPER GASTROINTESTINAL TOXICITY; CARDIOVASCULAR OUTCOMES; RHEUMATOID-ARTHRITIS; COX-2 INHIBITORS; ROFECOXIB; OSTEOARTHRITIS; EXPRESSION; NAPROXEN; EVENTS; MANAGEMENT	In October UK patients who had cardiovascular events while taking rofecoxib lost the right to fight Merck in the US for compensation. But researchers and journals can still benefit from this case if they learn from the mistakes, write Harlan Krumholz and colleagues.	Yale Univ, Sch Med, Dept Med, New Haven, CT 06520 USA; Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY USA; Never Again Consulting, Attleboro, MA USA; Brown Univ, Dept Biomed Community Hlth, Providence, RI 02912 USA	Yale University; Icahn School of Medicine at Mount Sinai; Brown University	Krumholz, H (corresponding author), Yale Univ, Sch Med, Dept Med, 333 Cedar St,POB 208088, New Haven, CT 06520 USA.	harlan.krumholz@yale.edu	, Harlan/AAI-2875-2020	Ross, Joseph/0000-0002-9218-3320				Antman EM, 2005, CIRCULATION, V112, P759, DOI 10.1161/CIRCULATIONAHA.105.568451; Berenson Alex, 2004, N Y Times Web, pA32; Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103; Braunstein N, 2005, ANN INTERN MED, V143, P158, DOI 10.7326/0003-4819-143-2-200507190-00118; Bresalier RS, 2006, NEW ENGL J MED, V355, P221; Bresalier RS, 2005, NEW ENGL J MED, V352, P1092, DOI 10.1056/NEJMoa050493; Cannon CP, 2006, LANCET, V368, P1771, DOI 10.1016/S0140-6736(06)69666-9; Catella-Lawson F, 1999, J PHARMACOL EXP THER, V289, P735; Claire B, 2000, NEW ENGL J MED, V343, P1520, DOI [DOI 10.1056/NEJME058314, 10.1056/NEJM200011233432103]; Curfman GD, 2006, NEW ENGL J MED, V354, P1193, DOI 10.1056/NEJMe068054; Curfman GD, 2005, NEW ENGL J MED, V353, P2813, DOI 10.1056/NEJMe058314; DRACEN JM, 2006, WALL STREET J   0519, pA11; Drazen JM, 2005, NEW ENGL J MED, V352, P1131, DOI 10.1056/NEJMe058038; Egilman DS, 2006, ANN INTERN MED, V144, P781, DOI 10.7326/0003-4819-144-10-200605160-00016; Eisenberg RS, 2005, NEW ENGL J MED, V352, P1285, DOI 10.1056/NEJMp048358; FitzGerald GA, 2001, NEW ENGL J MED, V345, P433, DOI 10.1056/NEJM200108093450607; FitzGerald GA, 2004, NEW ENGL J MED, V351, P1709, DOI 10.1056/NEJMp048288; FitzGerald GA, 2000, ANN MED, V32, P21; Flanagin A, 1998, JAMA-J AM MED ASSOC, V280, P222, DOI 10.1001/jama.280.3.222; *FOOD DRUG ADM, 1999, HFD550 FOOD DRUG ADM; *FOOD DRUG ADM, 2001, 21042 NDA FDA ADV CO; FRIES JF, 2001, COMMUNICATION   0109; Furberg, 2005, DATA MONITORING CLIN; Furberg CD, 2006, NEW ENGL J MED, V355, P204; Garnett WR, 2001, PHARMACOTHERAPY, V21, P1223, DOI 10.1592/phco.21.15.1223.33891; Gloth FM, 2001, J AM GERIATR SOC, V49, P188, DOI 10.1046/j.1532-5415.2001.49041.x; HAWTHORNE F, 2003, MERCK DRUGGEMAUT INS; Hochberg MC, 2002, AM J MANAG CARE, V8, pS502; *IMS HLTH, 2004, NAT PRESCR AUD PLUS; Konstam MA, 2001, CIRCULATION, V104, P2280, DOI 10.1161/hc4401.100078; Lagakos SW, 2006, NEW ENGL J MED, V355, P113, DOI 10.1056/NEJMp068137; Laine C, 2005, ANN INTERN MED, V143, P611, DOI 10.7326/0003-4819-143-8-200510180-00013; Lisse JR, 2003, ANN INTERN MED, V139, P539, DOI 10.7326/0003-4819-139-7-200310070-00005; McAdam BF, 2000, J CLIN INVEST, V105, P1473, DOI 10.1172/JCI9523; Meier Barry, 2005, N Y Times Web, pC3; Meier Barry, 2004, N Y Times Web, pA16; *MERCK, 2000, VIOXX RESP YOUR QUES; *MERCK, 1999, MED AFF PROC POL PRO; *MERCK CO, 2000, MULT STRAT ADV BOARD; MORRISON BW, 1998, MEMO A NIES B GERTZ; MORRISON BW, 2001, EMAIL COMMUNICATION; Mukherjee D, 2001, JAMA-J AM MED ASSOC, V286, P954, DOI 10.1001/jama.286.8.954; Nissen SE, 2006, NEW ENGL J MED, V355, P203; Oberholzer-Gee F, 2004, NEW ENGL J MED, V351, P2147, DOI 10.1056/NEJMp048284; Okie S, 2005, NEW ENGL J MED, V352, P1063, DOI 10.1056/NEJMp058003; Okie S, 2005, NEW ENGL J MED, V352, P1283, DOI 10.1056/NEJMp058055; Pratico D, 2000, BLOOD, V96, P3823, DOI 10.1182/blood.V96.12.3823.h8003823_3823_3826; Psaty BM, 2005, NEW ENGL J MED, V352, P1133, DOI 10.1056/NEJMe058042; REICIN AS, 2000, LETT FINANCIAL DISCL; RENNIE D, 1994, JAMA-J AM MED ASSOC, V271, P469, DOI 10.1001/jama.271.6.469; Schnitzer TJ, 2001, CLIN THER, V23, P313, DOI 10.1016/S0149-2918(01)80041-2; SCOLNICK EM, 2000, EMAIL COMMUNICATION; TARGUM SL, 2001, NDA21042 FDA; Topol EJ, 2004, NEW ENGL J MED, V351, P1707, DOI 10.1056/NEJMp048286; *US SEC EXCH COMM, 2006, FORM 10 Q Q REP PURS; WAXMAN HA, 2005, MEMO MARKETING VIOXX; WAXMAN HA, 2005, MERCK DOCUMENTS SHOW; Weaver AL, 2001, CLIN THER, V23, P1323, DOI 10.1016/S0149-2918(01)80112-0; WEINBLATT M, 1999, MEMO BJORKMAN NEATON	59	151	155	1	18	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 20	2007	334	7585					120	123		10.1136/bmj.39024.487720.68	http://dx.doi.org/10.1136/bmj.39024.487720.68			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	130LP	17235089	Green Published, Bronze			2022-12-28	WOS:000243801400027
J	Lomas, J				Lomas, Jonathan			The in-between world of knowledge brokering	BRITISH MEDICAL JOURNAL			English	Editorial Material							ORGANIZATIONS; MANAGEMENT; POLICY					jonathan.lomas@chsrf.ca	Robles-Sardin, Alma E/M-7714-2015	Robles-Sardin, Alma E/0000-0003-2044-7793				*AUSTR GOV LAND WA, 2006, KNOWL REG NRM CONN R; *CAN HLTH SERV RES, 2006, KNOWL BROK; Canadian Health Services Research Foundation, 2003, THEOR PRACT KNOWL BR; Clark G., 2005, NEW DIRECTIONS KNOWL; David AS, 2001, BRIT MED J, V323, P1462, DOI 10.1136/bmj.323.7327.1462; Ferlie E, 2000, J Health Serv Res Policy, V5, P96; Gabbay J, 2004, BRIT MED J, V329, P1013, DOI 10.1136/bmj.329.7473.1013; Greenhalgh T, 2004, MILBANK Q, V82, P581, DOI 10.1111/j.0887-378X.2004.00325.x; HAYNES RB, 1990, ANN INTERN MED, V113, P724, DOI 10.7326/0003-4819-113-9-724; Hutchings Andrew, 2006, J Health Serv Res Policy, V11, P218, DOI 10.1258/135581906778476553; Innvaer Simon, 2002, J Health Serv Res Policy, V7, P239, DOI 10.1258/135581902320432778; Lavis JN, 2003, MILBANK Q, V81, P221, DOI 10.1111/1468-0009.t01-1-00052; Lomas J, 2003, MILBANK Q, V81, P363, DOI 10.1111/1468-0009.t01-1-00060; Lomas J, 2000, HEALTH AFFAIR, V19, P236, DOI 10.1377/hlthaff.19.3.236; Lomas J, 1997, IMPROVING RES DISSEM; *M LOCK CTR, 1998, INT KNOWL TRANSF EXC; McLean R., 1997, APPROACHES KNOWLEDGE; Murmann Johann Peter, 2003, KNOWLEDGE COMPETITIV; *SCOTT EX, 2005, NEW DIR KNOWL TRANSF; Tomlinson S, 2000, BRIT MED J, V320, P636, DOI 10.1136/bmj.320.7235.636; van Kammen J, 2006, B WORLD HEALTH ORGAN, V84, P608, DOI 10.2471/BLT.05.028308; Walshe K, 2001, MILBANK Q, V79, P429, DOI 10.1111/1468-0009.00214; WARD D, 1992, EDUC REC, V73, P12; World Health Organization, 2004, WORLD REP KNOWL BETT	24	324	326	1	45	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 20	2007	334	7585					129	132		10.1136/bmj.39038.593380.AE	http://dx.doi.org/10.1136/bmj.39038.593380.AE			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	130LP	17235094	Green Published			2022-12-28	WOS:000243801400031
J	Pavlu, J; Ahmed, RE; O'Regan, DP; Partridge, J; Lefroy, DC; Layton, DM				Pavlu, Jiri; Ahmed, Riaz E.; O'Regan, Declan P.; Partridge, John; Lefroy, David C.; Layton, D. Mark			Myocardial infarction in sickle-cell disease	LANCET			English	Editorial Material									Univ London Imperial Coll Sci & Technol, Dept Haematol, London W12 0NN, England; Univ London Imperial Coll Sci & Technol, Imaging Sci Dept, London W12 0NN, England; Univ London Imperial Coll Sci & Technol, Dept Cardiol, London W12 0NN, England	Imperial College London; Imperial College London; Imperial College London	Pavlu, J (corresponding author), Univ London Imperial Coll Sci & Technol, Dept Haematol, Hammersmith Canpus,Du Cane Rd, London W12 0NN, England.	pavluj@yahoo.com		O'Regan, Declan/0000-0002-0691-0270				Dang NC, 2005, AM J HEMATOL, V80, P133, DOI 10.1002/ajh.20385; Hunold P, 2005, AM J ROENTGENOL, V184, P1420, DOI 10.2214/ajr.184.5.01841420; James TN, 2000, CIRCULATION, V101, P1874, DOI 10.1161/01.CIR.101.15.1874; Mansi IA, 2002, J NATL MED ASSOC, V94, P448; Martin CR, 1996, J NATL MED ASSOC, V88, P428	5	23	25	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 20	2007	369	9557					246	246		10.1016/S0140-6736(07)60114-7	http://dx.doi.org/10.1016/S0140-6736(07)60114-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128XG	17240292				2022-12-28	WOS:000243692400034
J	Walker, FO				Walker, Francis O.			Huntington's disease	LANCET			English	Review							AGE-OF-ONSET; CAG REPEAT LENGTH; MUTANT HUNTINGTIN; MOUSE MODEL; DNA ANALYSIS; INTRANUCLEAR INCLUSIONS; NEURONAL DYSFUNCTION; TRINUCLEOTIDE REPEAT; POLYGLUTAMINE TRACT; ANDROGEN RECEPTOR	Huntington's disease is an autosomal-dominant, progressive neurodegenerative disorder with a distinct phenotype, including chorea and dystonia, incoordination, cognitive decline, and behavioural difficulties. Typically, onset of symptoms is in middle-age after affected individuals have had children, but the disorder can manifest at any time between infancy and senescence. The mutant protein in Huntington's disease-huntingtin-results from an expanded CAG repeat leading to a polyglutamine strand of variable length at the N-terminus. Evidence suggests that this tail confers a toxic gain of function. The precise pathophysiological mechanisms of Huntington's disease are poorly understood, but research in transgenic animal models of the disorder is providing insight into causative factors and potential treatments.	Wake Forest Univ, Dept Neurol, Winston Salem, NC 27157 USA	Wake Forest University	Walker, FO (corresponding author), Wake Forest Univ, Dept Neurol, Med Ctr Blvd, Winston Salem, NC 27157 USA.	fwalker@wfubmc.edu	Longo, Kenneth A/A-5631-2010	Walker, Francis/0000-0002-7817-9421				Almqvist EW, 1999, AM J HUM GENET, V64, P1293, DOI 10.1086/302374; Almqvist EW, 2001, CLIN GENET, V60, P198, DOI 10.1034/j.1399-0004.2001.600305.x; Almqvist EW, 2003, CLIN GENET, V64, P300, DOI 10.1034/j.1399-0004.2003.00157.x; AMBROSE CM, 1994, SOMAT CELL MOLEC GEN, V20, P27, DOI 10.1007/BF02257483; Anca MH, 2004, AM J MED GENET A, V124A, P89, DOI 10.1002/ajmg.a.20328; ANDREW SE, 1993, NAT GENET, V4, P398, DOI 10.1038/ng0893-398; [Anonymous], 1994, Neurology, V44, P1533; [Anonymous], 2003, GENETICS MOVEMENT DI, DOI [10.1016/b978-012566652-7/50035-6, DOI 10.1016/B978-012566652-7/50035-6]; Arrasate M, 2004, NATURE, V431, P805, DOI 10.1038/nature02998; Aylward EH, 2004, NEUROLOGY, V63, P66, DOI 10.1212/01.WNL.0000132965.14653.D1; Bae BI, 2005, NEURON, V47, P29, DOI 10.1016/j.neuron.2005.06.005; Baliko L, 2004, NEUROEPIDEMIOLOGY, V23, P258, DOI 10.1159/000079953; Bates G. P., 2002, HUNTINGTONS DIS, P429; Bates GP, 2002, HUNTINGTONS DIS, P387; BEAL MF, 1993, J NEUROCHEM, V61, P1147, DOI 10.1111/j.1471-4159.1993.tb03633.x; Bodner RA, 2006, P NATL ACAD SCI USA, V103, P4246, DOI 10.1073/pnas.0511256103; Borovecki F, 2005, P NATL ACAD SCI USA, V102, P11023, DOI 10.1073/pnas.0504921102; Busch A, 2003, J BIOL CHEM, V278, P41452, DOI 10.1074/jbc.M303354200; Cha JHJ, 2000, TRENDS NEUROSCI, V23, P387, DOI 10.1016/S0166-2236(00)01609-X; Charrin NC, 2005, PATHOL BIOL, V53, P189, DOI 10.1016/j.patbio.2004.12.008; Chattopadhyay B, 2005, NEUROSCI LETT, V374, P81, DOI 10.1016/j.neulet.2004.10.018; Chattopadhyay B, 2003, NEUROSCI LETT, V345, P93, DOI 10.1016/S0304-3940(03)00436-1; CHICUREL M, A PARV FDN WORKSH; COYLE JT, 1976, NATURE, V263, P244, DOI 10.1038/263244a0; Craufurd D., 2002, HUNTINGTONS DIS, P62; Danek A, 2005, CURR OPIN NEUROL, V18, P386, DOI 10.1097/01.wco.0000173464.01888.e9; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DIFIGLIA M, 1995, NEURON, V14, P1075, DOI 10.1016/0896-6273(95)90346-1; DIMAIO L, 1993, J MED GENET, V30, P293, DOI 10.1136/jmg.30.4.293; DiProspero NA, 2004, J NEUROCYTOL, V33, P517, DOI 10.1007/s11068-004-0514-8; Djousse L, 2004, NEUROGENETICS, V5, P109, DOI 10.1007/s10048-004-0175-2; Djousse L, 2002, NEUROLOGY, V59, P1325, DOI 10.1212/01.WNL.0000031791.10922.CF; ELLIOTSON J, 1832, LANCET, V1, P161; Evers-Kiebooms G, 2002, EUR J HUM GENET, V10, P167, DOI 10.1038/sj.ejhg.5200781; FARRER LA, 1986, AM J MED GENET, V24, P305, DOI 10.1002/ajmg.1320240211; Folstein S.E., 1989, HUNTINGTONS DIS DISO; Foroud T, 1999, J NEUROL NEUROSUR PS, V66, P52, DOI 10.1136/jnnp.66.1.52; Freeman W, 2004, BRAIN RES BULL, V63, P45, DOI 10.1016/j.brainresbull.2003.12.004; Gardian G, 2005, J BIOL CHEM, V280, P556, DOI 10.1074/jbc.M410210200; Gauthier LR, 2004, CELL, V118, P127, DOI 10.1016/j.cell.2004.06.018; Georgiou N, 1999, MOVEMENT DISORD, V14, P320, DOI 10.1002/1531-8257(199903)14:2<320::AID-MDS1018>3.0.CO;2-Z; Geschwind DH, 1997, AM J HUM GENET, V60, P842; Geschwind DH, 1997, NEUROLOGY, V49, P1247, DOI 10.1212/WNL.49.5.1247; Gomez-Tortosa E, 2001, ANN NEUROL, V49, P29, DOI 10.1002/1531-8249(200101)49:1<29::AID-ANA7>3.0.CO;2-B; Gordon AM, 2000, EXP NEUROL, V163, P136, DOI 10.1006/exnr.2000.7348; Graham RK, 2006, CELL, V125, P1179, DOI 10.1016/j.cell.2006.04.026; Gutekunst CA, 2002, HUNTINGTONS DIS, P251; Harper P., 2002, HUNTINGTONS DIS, P3; Harper P.S., 2002, OXF MONOGR MED GENET, V45, P113; Harper PS, 2004, LANCET NEUROL, V3, P249, DOI 10.1016/S1474-4422(04)00711-2; Harper PS, 2002, HUNTINGTONS DIS, P159; Hayden MR, 2003, LANCET NEUROL, V2, P141, DOI 10.1016/S1474-4422(03)00317-X; Hayden MR., 1981, HUNTINGTONS CHOREA, P45; Heinsen H, 1999, ACTA NEUROPATHOL, V97, P613, DOI 10.1007/s004010051037; Hersch SM, 2006, NEUROLOGY, V66, P250, DOI 10.1212/01.wnl.0000194318.74946.b6; Hickey MA, 2003, PROG NEURO-PSYCHOPH, V27, P255, DOI 10.1016/S0278-5846(03)00021-6; Higgins Donald S Jr, 2006, Curr Treat Options Neurol, V8, P236, DOI 10.1007/s11940-006-0014-x; HUGGINS M, 1992, AM J MED GENET, V42, P508, DOI 10.1002/ajmg.1320420417; *HUNT PROJ, 2006, SET HD UPD SEPT 28; *HUNT STUD GROUP, CLIN TRIALS RES STUD; Hunt V P, 1989, J Neurosci Nurs, V21, P92; Huntington G., 1872, MED SURG REP, V26, P320; JESTE DV, 1984, EXP NEUROL, V85, P78, DOI 10.1016/0014-4886(84)90162-6; JONES L, 2002, HUNTINGTONS DIS, P348; Kambouris M, 2000, AM J HUM GENET, V66, P445, DOI 10.1086/302744; Kaytor MD, 2004, J NEUROCHEM, V89, P962, DOI 10.1111/j.1471-4159.2004.02376.x; Kehoe P, 1999, J MED GENET, V36, P108; Kieburtz K, 2001, NEUROLOGY, V57, P397; Kipps CM, 2005, J NEUROL NEUROSUR PS, V76, P650, DOI 10.1136/jnnp.2004.047993; KOMURE O, 1995, NEUROLOGY, V45, P143, DOI 10.1212/WNL.45.1.143; KREMER B, 1995, AM J HUM GENET, V57, P343; KREMER B, 2002, HUNTINGTONS DIS, P3; KREMER HPH, 1991, NEUROSCI LETT, V132, P101, DOI 10.1016/0304-3940(91)90443-W; KREMER HPH, 1992, PROG BRAIN RES, V93, P249; Kunig G, 2000, ANN NEUROL, V47, P644; Laccone F, 1999, NEUROLOGY, V53, P801, DOI 10.1212/WNL.53.4.801; Lawrence AD, 1998, BRAIN, V121, P1343, DOI 10.1093/brain/121.7.1343; Lunkes A, 1998, HUM MOL GENET, V7, P1355, DOI 10.1093/hmg/7.9.1355; MacDonald ME, 1999, NEUROLOGY, V53, P1330, DOI 10.1212/WNL.53.6.1330; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Macdonald V, 2002, NEUROBIOL DIS, V10, P378, DOI 10.1006/nbdi.2002.0528; Macdonald V, 1997, NEUROPATH APPL NEURO, V23, P492, DOI 10.1046/j.1365-2990.1997.00076.x; Mahant N, 2003, NEUROLOGY, V61, P1085, DOI 10.1212/01.WNL.0000086373.32347.16; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Margolis RL, 2004, ANN NEUROL, V56, P670, DOI 10.1002/ana.20248; Margolis RL, 2001, TRENDS MOL MED, V7, P479, DOI 10.1016/S1471-4914(01)02179-7; Mariotti C, 2000, NEUROMUSCULAR DISORD, V10, P391, DOI 10.1016/S0960-8966(99)00132-7; Maris RW, 2002, LANCET, V360, P319, DOI 10.1016/S0140-6736(02)09556-9; Marsh JL, 2003, HUM MOL GENET, V12, pR187, DOI 10.1093/hmg/ddg271; Marshall FJ, 2006, NEUROLOGY, V66, P366, DOI 10.1212/01.wnl.0000198586.85250.13; McNeil SM, 1997, HUM MOL GENET, V6, P775, DOI 10.1093/hmg/6.5.775; Menalled LB, 2003, J COMP NEUROL, V465, P11, DOI 10.1002/cne.10776; Mills IG, 2005, J CELL BIOL, V170, P191, DOI 10.1083/jcb.200503106; Mizuno H, 2000, CLIN NEUROPATHOL, V19, P94; Modregger J, 2002, HUM MOL GENET, V11, P2547, DOI 10.1093/hmg/11.21.2547; Moutou C, 2004, EUR J HUM GENET, V12, P1007, DOI 10.1038/sj.ejhg.5201291; Mukai H, 2005, P NATL ACAD SCI USA, V102, P10887, DOI 10.1073/pnas.0409283102; Muller DJ, 2005, EUR PSYCHIAT, V20, P65, DOI 10.1016/j.eurpsy.2004.06.024; MYERS RH, 1991, J NEUROPATH EXP NEUR, V50, P729, DOI 10.1097/00005072-199111000-00005; Myers Richard H, 2004, NeuroRx, V1, P255, DOI 10.1602/neurorx.1.2.255; Nakano T, 1985, No To Shinkei, V37, P767; O'Hearn E, 2001, NEUROLOGY, V56, P299, DOI 10.1212/WNL.56.3.299; Panov AV, 2003, ARCH BIOCHEM BIOPHYS, V410, P1, DOI 10.1016/S0003-9861(02)00585-4; Paulsen JS, 2004, AM J NEURORADIOL, V25, P1715; Paulsen JS, 2005, AM J PSYCHIAT, V162, P725, DOI 10.1176/appi.ajp.162.4.725; Paulsen JS, 2001, J NEUROL NEUROSUR PS, V71, P310, DOI 10.1136/jnnp.71.3.310; Peters MF, 1999, MOL CELL NEUROSCI, V14, P121, DOI 10.1006/mcne.1999.0773; Piccioni F, 2001, BRAIN RES BULL, V56, P215, DOI 10.1016/S0361-9230(01)00652-9; POST SG, 1992, J MED ETHICS, V18, P75, DOI 10.1136/jme.18.2.75; PRIDMORE SA, 1990, MED J AUSTRALIA, V153, P593, DOI 10.5694/j.1326-5377.1990.tb126270.x; Pulst S.-M., 2003, GENETICS MOVEMENT DI; Pulst SM, 1996, NAT GENET, V14, P269, DOI 10.1038/ng1196-269; RANEN NG, 1995, AM J HUM GENET, V57, P593; Rangone H, 2004, PATHOL BIOL, V52, P338, DOI 10.1016/j.patbio.2003.06.004; Reilmann R, 2001, NEUROLOGY, V57, P920, DOI 10.1212/WNL.57.5.920; Rosas HD, 2003, NEUROLOGY, V60, P1615, DOI 10.1212/01.WNL.0000065888.88988.6E; Rosenblatt A, 2001, AM J MED GENET, V105, P399, DOI 10.1002/ajmg.1400; Rubinsztein DC, 1996, AM J HUM GENET, V59, P16; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Siesling S, 2000, J NEUROL NEUROSUR PS, V69, P54, DOI 10.1136/jnnp.69.1.54; Snowden JS, 1998, ARCH NEUROL-CHICAGO, V55, P801, DOI 10.1001/archneur.55.6.801; Sorensen SA, 1999, CANCER, V86, P1342, DOI 10.1002/(SICI)1097-0142(19991001)86:7<1342::AID-CNCR33>3.3.CO;2-V; SPARGO E, 1993, J NEUROL NEUROSUR PS, V56, P487, DOI 10.1136/jnnp.56.5.487; Squitieri F, 2003, BRAIN, V126, P946, DOI 10.1093/brain/awg077; Squitieri F, 2002, NEUROL SCI, V23, pS107, DOI 10.1007/s100720200092; Stevanin G, 2000, EUR J HUM GENET, V8, P4, DOI 10.1038/sj.ejhg.5200403; STOBER T, 1984, NEURORADIOLOGY, V26, P25, DOI 10.1007/BF00328198; Strand AD, 2005, HUM MOL GENET, V14, P1863, DOI 10.1093/hmg/ddi192; Takano H, 1998, AM J HUM GENET, V63, P1060, DOI 10.1086/302067; Thompson JC, 2002, J NEUROPSYCH CLIN N, V14, P37, DOI 10.1176/appi.neuropsych.14.1.37; TIBBEN A, 1990, LANCET, V335, P553, DOI 10.1016/0140-6736(90)90796-8; TIBBEN A, 2002, HUNTINGTONS DIS, P198; Tilley BC, 2006, NEUROLOGY, V66, P628, DOI 10.1212/01.wnl.0000201251.33253.fb; Toyoshima Y, 2004, ANN NEUROL, V55, P281, DOI 10.1002/ana.10824; TROTTIER Y, 1994, J MED GENET, V31, P377, DOI 10.1136/jmg.31.5.377; Van Raamsdonk JM, 2005, J NEUROSCI, V25, P4169, DOI 10.1523/JNEUROSCI.0590-05.2005; Vonsattel JPG, 1998, J NEUROPATH EXP NEUR, V57, P369; Wahlin TBR, 2000, ACTA NEUROL SCAND, V102, P150, DOI 10.1034/j.1600-0404.2000.102003150.x; WANKER E, 2002, HUNTINGTONS DIS, P327; Watts R. L., 1997, MOVEMENT DISORDERS N; WEINER WJ, 1989, MOVEMENT DISORDERS C; Wellington CL, 2000, J NEURAL TRANSM-SUPP, P1; WEXLER NS, 1987, NATURE, V326, P194, DOI 10.1038/326194a0; Wexler NS, 2004, P NATL ACAD SCI USA, V101, P3498, DOI 10.1073/pnas.0308479101; WRIGHT HH, 1981, ARCH NEUROL-CHICAGO, V38, P412, DOI 10.1001/archneur.1981.00510070046005; Yamamoto A, 2000, CELL, V101, P57, DOI 10.1016/S0092-8674(00)80623-6; YOUNG AB, 1986, NEUROLOGY, V36, P244, DOI 10.1212/WNL.36.2.244; Zuccato C, 2005, PHARMACOL RES, V52, P133, DOI 10.1016/j.phrs.2005.01.001	148	1242	1303	9	424	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 20	2007	369	9557					218	228		10.1016/S0140-6736(07)60111-1	http://dx.doi.org/10.1016/S0140-6736(07)60111-1			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128XG	17240289				2022-12-28	WOS:000243692400031
J	Martell, BA; O'Connor, PG; Kerns, RD; Becker, WC; Morales, KH; Kosten, TR; Fiellin, DA				Martell, Bridget A.; O'Connor, Patrick G.; Kerns, Robert D.; Becker, William C.; Morales, Knashawn H.; Kosten, Thomas R.; Fiellin, David A.			Systematic review: Opioid treatment for chronic back pain: Prevalence, efficacy, and association with addiction	ANNALS OF INTERNAL MEDICINE			English	Review							RANDOMIZED CONTROLLED-TRIALS; CHRONIC NONCANCER PAIN; PRIMARY-CARE; TRANSDERMAL FENTANYL; NONMALIGNANT PAIN; PATIENT CHARACTERISTICS; CONTROLLED-RELEASE; CONSORT STATEMENT; NEUROPATHIC PAIN; CLINICAL-TRIALS	Background: The prevalence, efficacy, and risk for addiction for persons receiving opioids for chronic back pain are unclear. Purpose: To determine the prevalence of opioid treatment, whether opioid medications are effective, and the prevalence of substance use disorders among patients receiving opioid medications for chronic back pain. Data Sources: English-language studies from MEDLINE (1966-March 2005), EMBASE (1966-March 2005), Cochrane Central Register of Controlled Clinical Trials (to 4th quarter 2004), Psychinfo (1966-March 2005), and retrieved references. Study Selection: Articles that studied an adult, nonobstetric sample; used oral, topical, or transdermal opioids; and focused on treatment for chronic back pain. Data Extraction: Two investigators independently extracted data and determined study quality. Data Synthesis: Opioid prescribing varied by treatment setting (range, 3% to 66%). Meta-analysis of the 4 studies assessing the efficacy of opioids compared with placebo or a nonopioid control did not show reduced pain with opioids (g, -0.199 composite standardized mean difference [95% CI, -0.49 to 0.11]; P = 0.136). Meta-analysis of the 5 studies directly comparing the efficacy of different opioids demonstrated a nonsignificant reduction in pain from baseline (g, -0.93 composite standardized mean difference [CI, -1.89 to -0,03]; P = 0.055). The prevalence of lifetime substance use disorders ranged from 36% to 56%, and the estimates of the prevalence of current substance use disorders were as high as 43%. Aberrant medication-taking behaviors ranged from 5% to 24%. Limitations: Retrieval and publication biases and poor study quality. No trial evaluating the efficacy of opioids was longer than 16 weeks. Conclusions: Opioids are commonly prescribed for chronic back pain and may be efficacious for short-term pain relief. Long-term efficacy (>= 16 weeks) is unclear. Substance use disorders are common in patients taking opioids for back pain, and aberrant medication-taking behaviors occur in up to 24% of cases.	Yale Univ, Sch Med, New Haven, CT 06520 USA; VA Connecticut Hlth Care Syst, West Haven, CT USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA	Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; University of Pennsylvania	Fiellin, DA (corresponding author), Yale Univ, Sch Med, 333 Cedar St,POB 208025, New Haven, CT 06520 USA.	david.fiellin@yale.edu	Kosten, Thomas/AAI-5998-2021	Fiellin, David/0000-0002-4006-010X; Becker, William/0000-0002-0788-1467				Abrams KR, 2000, METHODS METAANALYSIS; Adams NJ, 2001, J PAIN SYMPTOM MANAG, V22, P791, DOI 10.1016/S0885-3924(01)00320-7; Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; Bramley-Moore Susan R., 1998, Australian Journal of Hospital Pharmacy, V28, P83; Breckenridge J, 2003, J PAIN, V4, P344, DOI 10.1016/S1526-5900(03)00638-2; BRETT AS, 2004, J WATCH, V24, P157; Brown RL, 1996, J FAM PRACTICE, V43, P152; Cassidy JD, 1998, SPINE, V23, P1860, DOI 10.1097/00007632-199809010-00012; Chabal C, 1997, CLIN J PAIN, V13, P150, DOI 10.1097/00002508-199706000-00009; Chou R, 2003, J PAIN SYMPTOM MANAG, V26, P1026, DOI 10.1016/j.jpainsymman.2003.03.003; CLARK ME, 2005, OPIOID THERAPY CHRON; Compton P, 1998, J PAIN SYMPTOM MANAG, V16, P355, DOI 10.1016/S0885-3924(98)00110-9; Compton P, 2003, J PAIN, V4, P511, DOI 10.1016/j.jpain.2003.08.003; Coste J, 1999, MED CARE, V37, P1294, DOI 10.1097/00005650-199912000-00012; Cox DR., 1970, ANAL BINARY DATA; Dellemijn PLI, 2001, EUR J PAIN-LONDON, V5, P333, DOI 10.1053/eujp.2001.0240; DEYO RA, 1988, ARCH PHYS MED REHAB, V69, P174; Deyo RA, 2001, NEW ENGL J MED, V344, P363, DOI 10.1056/NEJM200102013440508; Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377; Eisenberg E, 2005, JAMA-J AM MED ASSOC, V293, P3043, DOI 10.1001/jama.293.24.3043; Elliott AM, 1999, LANCET, V354, P1248, DOI 10.1016/S0140-6736(99)03057-3; Fanciullo GJ, 2002, SPINE, V27, P201, DOI 10.1097/00007632-200201150-00016; Fillingim RB, 2003, SPINE, V28, P143, DOI 10.1097/00007632-200301150-00010; FRANCE RD, 1984, SOC SCI MED, V19, P1379, DOI 10.1016/0277-9536(84)90027-3; Fries JF, 2004, ARTHRITIS RES THER, V6, pR250, DOI 10.1186/ar1170; Gammaitoni AR, 2003, PAIN MED, V4, P21, DOI 10.1046/j.1526-4637.2003.03002.x; Gilron I, 2005, NEW ENGL J MED, V352, P1324, DOI 10.1056/NEJMoa042580; GRAVEN S, 2000, P 9 WORLD C PAIN PRO, V16, P554; HALE M, 1997, PAIN RES MANAG, V2, P33; Hale ME, 2005, J PAIN, V6, P21, DOI 10.1016/j.jpain.2004.09.005; Hale ME, 1999, CLIN J PAIN, V15, P179, DOI 10.1097/00002508-199909000-00004; HART LG, 1995, SPINE, V20, P11, DOI 10.1097/00007632-199501000-00003; HEDGES LV, 1985, STAT METHODS META AN; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; *IMMPAACT, 2005, PAIN, V113, P9; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jamison RN, 1998, SPINE, V23, P2591, DOI 10.1097/00007632-199812010-00014; Kuntz D, 1996, PRESSE MED, V25, P1171; Lexchin J, 2003, BMJ-BRIT MED J, V326, P1167, DOI 10.1136/bmj.326.7400.1167; Libretto SE, 2002, CLIN DRUG INVEST, V22, P473, DOI 10.2165/00044011-200222070-00009; Long DM, 1996, J SPINAL DISORD, V9, P40; Mahowald ML, 2005, ARTHRITIS RHEUM-US, V52, P312, DOI 10.1002/art.20784; Manchikanti Laxmaiah, 2004, Pain Physician, V7, P431; Manchikanti Laxmaiah, 2004, Pain Physician, V7, P71; Moher D, 1996, LANCET, V347, P363, DOI 10.1016/S0140-6736(96)90538-3; Mohler D.M., 2001, LANCET, V357, P1191; Moulin Y, 2001, Infirm Que, V9, P53; Muller FO, 1998, ARZNEIMITTEL-FORSCH, V48, P675; Normand SLT, 1999, STAT MED, V18, P321, DOI 10.1002/(SICI)1097-0258(19990215)18:3<321::AID-SIM28>3.0.CO;2-P; Nyiendo J, 2001, J MANIP PHYSIOL THER, V24, P543, DOI 10.1067/mmt.2001.118978; Ossipov MH, 2005, BIOPOLYMERS, V80, P319, DOI 10.1002/bip.20254; Pitkala KH, 2002, J AM GERIATR SOC, V50, P1861, DOI 10.1046/j.1532-5415.2002.50517.x; POLATIN PB, 1993, SPINE, V18, P66, DOI 10.1097/00007632-199301000-00011; READY LB, 1982, PAIN, V12, P285, DOI 10.1016/0304-3959(82)90160-9; Reid MC, 2002, J GEN INTERN MED, V17, P173, DOI 10.1046/j.1525-1497.2002.10435.x; Richards P, 2002, PAIN MED, V3, P176; Ringe JD, 2002, RHEUMATOL INT, V22, P199, DOI 10.1007/s00296-002-0217-8; Salzman RT, 1999, J PAIN SYMPTOM MANAG, V18, P271, DOI 10.1016/S0885-3924(99)00079-2; *SAMHSA OFF APPL S, 2004, NAT SURV DRUG AB HLT; Sanchez-Meca J, 2003, PSYCHOL METHODS, V8, P448, DOI 10.1037/1082-989X.8.4.448; Savage SR, 1999, MED CLIN N AM, V83, P761, DOI 10.1016/S0025-7125(05)70133-4; Schnitzer TJ, 2004, J PAIN SYMPTOM MANAG, V28, P72, DOI 10.1016/j.jpainsymman.2003.10.015; Schofferman J, 1999, CLIN J PAIN, V15, P136, DOI 10.1097/00002508-199906000-00011; Simpson RK, 1997, J PAIN SYMPTOM MANAG, V14, P218, DOI 10.1016/S0885-3924(97)00183-8; SORENSEN HT, 1992, DAN MED BULL, V39, P464; TENNANT F, 1993, LANCET, V342, P1047, DOI 10.1016/0140-6736(93)92900-E; THUREL C, 1991, CURR THER RES CLIN E, V50, P463; Trafton JA, 2004, DRUG ALCOHOL DEPEN, V73, P23, DOI 10.1016/j.drugalcdep.2003.08.007; Turk DC, 1997, CLIN J PAIN, V13, P330, DOI 10.1097/00002508-199712000-00011; *VA NAT PAIN MAN, 2005, VA OFF QUAL PERF OP; van Tulder MW, 2000, SPINE, V25, P2501, DOI 10.1097/00007632-200010010-00013; *WHO, 2005, WHOS PAIN REL LADD; Zacny J, 2003, DRUG ALCOHOL DEPEN, V69, P215, DOI 10.1016/S0376-8716(03)00003-6; ZENZ M, 1992, J PAIN SYMPTOM MANAG, V7, P69, DOI 10.1016/0885-3924(92)90116-Y; 2004, LETT DRUGS THER, V47, P97	77	536	555	0	48	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 16	2007	146	2					116	127		10.7326/0003-4819-146-2-200701160-00006	http://dx.doi.org/10.7326/0003-4819-146-2-200701160-00006			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	131WF	17227935				2022-12-28	WOS:000243901000005
J	Bibbins-Domingo, K; Gupta, R; Na, B; Wu, AHB; Schiller, NB; Whooley, MA				Bibbins-Domingo, Kirsten; Gupta, Reena; Na, Beeya; Wu, Alan H. B.; Schiller, Nelson B.; Whooley, Mary A.			N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							C-REACTIVE PROTEIN; PROGNOSTIC VALUE; VENTRICULAR DYSFUNCTION; MYOCARDIAL-INFARCTION; ARTERY-DISEASE; RISK; FAILURE; PREDICTORS; PREVENTION; COMMITTEE	Context Identification of individuals at high risk for cardiovascular events is important for the optimal use of primary and secondary prevention measures. Objective To determine whether plasma levels of amino terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP) predict cardiovascular events or death independent of other available prognostic tests. Design, Setting, and Participants Prospective cohort study (2000-2002) of 987 individuals in California with stable coronary heart disease in the Heart and Soul Study, who were followed up for a mean of 3.7 (range, 0.1-5.3) years. Main Outcome Measures The association of baseline NT-proBNP levels with death or cardiovascular events (myocardial infarction, stroke, or heart failure). Traditional clinical risk factors, echocardiographic measures, ischemia, other biomarkers, and New York Heart Association classification were adjusted for to determine whether NT-proBNP levels were independent of other prognostic factors. Receiver operating characteristic (ROC) curves were used to assess the incremental prognostic value of adding NT-proBNP level to these other measures. Results A total of 256 participants (26.2%) had a cardiovascular event or died. Each increasing quartile of NT-proBNP level (range of quartile 1, 8.06-73.95 pg/mL; quartile 2, 74-174.5 pg/mL; quartile 3, 175.1-459 pg/mL; quartile 4, >= 460 pg/mL) was associated with a greater risk of cardiovascular events or death, ranging from 23 of 247 (annual event rate, 2.6%) in the lowest quartile to 134 of 246 (annual event rate, 19.6%) in the highest quartile (unadjusted hazard ratio [HR] for quartile 4 vs quartile 1, 7.8; 95% confidence interval [CI], 5.0-12.1; P < .001). Each SD increase in log NT-proBNP level (1.3 pg/mL) was associated with a 2.3-fold increased rate of adverse cardiovascular outcomes (unadjusted HR, 2.3; 95% CI, 2.0-2.6; P < .001), and this association persisted after adjustment for all of the other prognostic measures (adjusted HR, 1.7; 95% CI, 1.3-2.2; P < .001). The addition of NT-proBNP level to standard clinical assessment and complete echocardiographic parameters significantly improved the area under the ROC curves for predicting subsequent adverse cardiovascular outcomes (0.80 for clinical risk factors and echocardiographic parameters plus log NT-proBNP vs 0.76 for clinical risk factors and echocardiographic parameters only; P = .006). Conclusions Elevated levels of NT-proBNP predict cardiovascular morbidity and mortality, independent of other prognostic markers, and identify at-risk individuals even in the absence of systolic or diastolic dysfunction by echocardiography. Level of NT-proBNP may help guide risk stratification of high-risk individuals, such as those with coronary heart disease.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; San Francisco Gen Hosp, Div Gen Internal Med, San Francisco, CA USA; San Francisco Vet Adm Med Ctr, San Francisco, CA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center	Bibbins-Domingo, K (corresponding author), Univ Calif San Francisco, Dept Med, Box 1364, San Francisco, CA 94143 USA.	bibbinsk@medicine.ucsf.edu			DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC095095] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079235] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC-95095, N01HC95095, R01 HL079235, R01 HL079235-01A1] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		American College of Sports Medicine, 2000, GUID EX TEST PRESCR; Berger R, 2002, CIRCULATION, V105, P2392, DOI 10.1161/01.CIR.0000016642.15031.34; Bibbins-Domingo K, 2003, CIRCULATION, V108, P2987, DOI 10.1161/01.CIR.0000103681.04726.9C; Blankenberg S, 2006, CIRCULATION, V114, P201, DOI 10.1161/CIRCULATIONAHA.105.590927; D'Souza SP, 2004, PHARMACOL THERAPEUT, V101, P113, DOI 10.1016/j.pharmthera.2003.11.001; de Lemos JA, 2001, NEW ENGL J MED, V345, P1014, DOI 10.1056/NEJMoa011053; Gardner RS, 2003, EUR HEART J, V24, P1735, DOI 10.1016/j.ehj.2003.07.005; Gibbons RJ, 2002, CIRCULATION, V106, P1883, DOI 10.1161/01.CIR.0000034670.06526.15; Groenning BA, 2004, HEART, V90, P297, DOI 10.1136/hrt.2003.026021; James SK, 2003, CIRCULATION, V108, P275, DOI 10.1161/01.CIR.0000079170.10579.DC; Kistorp C, 2005, JAMA-J AM MED ASSOC, V293, P1609, DOI 10.1001/jama.293.13.1609; Kragelund C, 2005, NEW ENGL J MED, V352, P666, DOI 10.1056/NEJMoa042330; Luepker RV, 2003, CIRCULATION, V108, P2543, DOI 10.1161/01.CIR.0000100560.46946.EA; McDonagh TA, 2001, HEART, V86, P21, DOI 10.1136/heart.86.1.21; Mega JL, 2004, J AM COLL CARDIOL, V44, P335, DOI 10.1016/j.jacc.2004.04.033; Morrow DA, 2003, J AM COLL CARDIOL, V41, P1264, DOI 10.1016/S0735-1097(03)00168-2; Morrow DA, 2005, JAMA-J AM MED ASSOC, V294, P2866, DOI 10.1001/jama.294.22.2866; Ndrepepa G, 2005, CIRCULATION, V112, P2102, DOI 10.1161/CIRCULATIONAHA.105.550715; Omland T, 2002, CIRCULATION, V106, P2913, DOI 10.1161/01.CIR.0000041661.63285.AE; Omland T, 2005, AM J CARDIOL, V95, P24, DOI 10.1016/j.amjcard.2004.08.058; Redfield MM, 2003, JAMA-J AM MED ASSOC, V289, P194, DOI 10.1001/jama.289.2.194; Richards AM, 1998, CIRCULATION, V97, P1921, DOI 10.1161/01.CIR.97.19.1921; Rubattu S, 2004, STROKE, V35, P814, DOI 10.1161/01.STR.0000119381.52589.AB; Ruo B, 2003, JAMA-J AM MED ASSOC, V290, P215, DOI 10.1001/jama.290.2.215; Schnabel R, 2005, EUR HEART J, V26, P241, DOI 10.1093/eurheartj/ehi036; Tsutamoto T, 1997, CIRCULATION, V96, P509; Wang TJ, 2004, NEW ENGL J MED, V350, P655, DOI 10.1056/NEJMoa031994	28	209	222	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 10	2007	297	2					169	176		10.1001/jama.297.2.169	http://dx.doi.org/10.1001/jama.297.2.169			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	124GI	17213400	Green Accepted, Bronze			2022-12-28	WOS:000243355900026
J	Fixler, JB; Foster, GT; McGuirk, JM; Kasevich, MA				Fixler, J. B.; Foster, G. T.; McGuirk, J. M.; Kasevich, M. A.			Atom interferometer measurement of the newtonian constant of gravity	SCIENCE			English	Article							FUNDAMENTAL PHYSICAL CONSTANTS; CODATA RECOMMENDED VALUES; GRAVITATIONAL CONSTANT; GRADIOMETER; BALANCE	We measured the Newtonian constant of gravity, G, using a gravity gradiometer based on atom interferometry. The gradiometer measures the differential acceleration of two samples of laser-cooled Cs atoms. The change in gravitational field along one dimension is measured when a well-characterized Pb mass is displaced. Here, we report a value of G = 6.693 x 10-(11) cubic meters per kilogram second squared, with a standard error of the mean of +/- 0.027 x 10(-11) and a systematic error of +/- 0.021 x 10(-11) cubic meters per kilogram second squared. The possibility that unknown systematic errors still exist in traditional measurements makes it important to measure G with independent methods.	Stanford Univ, Dept Phys, Stanford, CA 94305 USA; CUNY Hunter Coll, Dept Phys & Astron, New York, NY 10021 USA; Simon Fraser Univ, Dept Phys, Burnaby, BC V5A 1S6, Canada	Stanford University; City University of New York (CUNY) System; Hunter College (CUNY); Simon Fraser University	Kasevich, MA (corresponding author), Stanford Univ, Dept Phys, Stanford, CA 94305 USA.	kasevich@stanford.edu						Berman P., 1996, ATOM INTERFEROMETRY; Bertoldi A, 2006, EUR PHYS J D, V40, P271, DOI 10.1140/epjd/e2006-00212-2; BONGS K, 2006, APPL PHYS B, V85, P602; Boys C. V. I., 1895, PHILOS T R SOC A, V186, P1; Foster GT, 2002, OPT LETT, V27, P951, DOI 10.1364/OL.27.000951; Gillies GT, 1997, REP PROG PHYS, V60, P151, DOI 10.1088/0034-4885/60/2/001; Gundlach JH, 2000, PHYS REV LETT, V85, P2869, DOI 10.1103/PhysRevLett.85.2869; Heyl PR, 1942, J RES NAT BUR STAND, V29, P1, DOI 10.6028/jres.029.001; KASEVICH M, 1991, PHYS REV LETT, V66, P2297, DOI 10.1103/PhysRevLett.66.2297; Kleinevoss U, 1999, MEAS SCI TECHNOL, V10, P492, DOI 10.1088/0957-0233/10/6/313; Kuroda K, 1999, MEAS SCI TECHNOL, V10, P435, DOI 10.1088/0957-0233/10/6/304; McGuirk JM, 2002, PHYS REV A, V65, DOI 10.1103/PhysRevA.65.033608; McGuirk JM, 2001, OPT LETT, V26, P364, DOI 10.1364/OL.26.000364; Michaelis W, 2004, METROLOGIA, V41, pL29, DOI 10.1088/0026-1394/41/6/L01; MICHAELIS W, 1995, METROLOGIA, V32, P267; Mohr PJ, 2005, REV MOD PHYS, V77, P1, DOI 10.1103/RevModPhys.77.1; Mohr PJ, 2000, REV MOD PHYS, V72, P351, DOI 10.1103/RevModPhys.72.351; Nolting F, 1999, MEAS SCI TECHNOL, V10, P487, DOI 10.1088/0957-0233/10/6/312; Peters A, 2001, METROLOGIA, V38, P25, DOI 10.1088/0026-1394/38/1/4; Quinn TJ, 2001, PHYS REV LETT, V87, part. no., DOI 10.1103/PhysRevLett.87.111101; RAAB EL, 1987, PHYS REV LETT, V59, P2631, DOI 10.1103/PhysRevLett.59.2631; Schwarz JP, 1998, SCIENCE, V282, P2230, DOI 10.1126/science.282.5397.2230; Snadden MJ, 1998, PHYS REV LETT, V81, P971, DOI 10.1103/PhysRevLett.81.971; STOREY P, 1994, J PHYS II, V4, P1999, DOI 10.1051/jp2:1994103	24	362	377	0	74	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 5	2007	315	5808					74	77		10.1126/science.1135459	http://dx.doi.org/10.1126/science.1135459			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	122WU	17204644				2022-12-28	WOS:000243259100037
J	Doebley, JF; Gaut, BS; Smith, BD				Doebley, John F.; Gaut, Brandon S.; Smith, Bruce D.			The molecular genetics of crop domestication	CELL			English	Review							LINKAGE DISEQUILIBRIUM; ARTIFICIAL SELECTION; QUANTITATIVE TRAIT; POPULATION-GENETICS; FRUIT SIZE; MAIZE; EVOLUTION; RICE; TOMATO; DIVERSITY	Ten thousand years ago human societies around the globe began to transition from hunting and gathering to agriculture. By 4000 years ago, ancient peoples had completed the domestication of all major crop species upon which human survival is dependent, including rice, wheat, and maize. Recent research has begun to reveal the genes responsible for this agricultural revolution. The list of genes to date tentatively suggests that diverse plant developmental pathways were the targets of Neolithic "genetic tinkering," and we are now closer to understanding how plant development was redirected to meet the needs of a hungry world.	Univ Wisconsin, Dept Genet, Madison, WI 53706 USA; Univ Calif Irvine, Dept Ecol & Evolutionary Biol, Irvine, CA USA; Smithsonian Inst, Museum Natl Hist Nat, Archaeobiol Program, Washington, DC 20013 USA	University of Wisconsin System; University of Wisconsin Madison; University of California System; University of California Irvine; Smithsonian Institution; Smithsonian National Museum of Natural History	Doebley, JF (corresponding author), Univ Wisconsin, Dept Genet, Madison, WI 53706 USA.	jdoebley@wisc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058816] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM58816] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akey JM, 2004, PLOS BIOL, V2, P1591, DOI 10.1371/journal.pbio.0020286; Al-Babili S, 2005, TRENDS PLANT SCI, V10, P565, DOI 10.1016/j.tplants.2005.10.006; Anderson E., 1969, PLANTS MAN LIFE; Ashikari M, 2005, SCIENCE, V309, P741, DOI 10.1126/science.1113373; Benz BF, 2001, P NATL ACAD SCI USA, V98, P2104, DOI 10.1073/pnas.98.4.2104; BHATTACHARYYA MK, 1990, CELL, V60, P115, DOI 10.1016/0092-8674(90)90721-P; BLAKE M, 2006, HIST MAIZE; Bomblies K, 2003, DEVELOPMENT, V130, P2385, DOI 10.1242/dev.00457; Bomblies K, 2005, MOL BIOL EVOL, V22, P1082, DOI 10.1093/molbev/msi095; Bommert P, 2005, DEVELOPMENT, V132, P1235, DOI 10.1242/dev.01671; Burke JM, 2005, GENETICS, V171, P1933, DOI 10.1534/genetics.104.039057; Cardon G, 1999, GENE, V237, P91, DOI 10.1016/S0378-1119(99)00308-X; Casa AM, 2005, THEOR APPL GENET, V111, P23, DOI 10.1007/s00122-005-1952-5; Clark RM, 2004, P NATL ACAD SCI USA, V101, P700, DOI 10.1073/pnas.2237049100; Cong B, 2002, P NATL ACAD SCI USA, V99, P13606, DOI 10.1073/pnas.172520999; Cubas P, 1999, PLANT J, V18, P215, DOI 10.1046/j.1365-313X.1999.00444.x; Doebley J, 2004, ANNU REV GENET, V38, P37, DOI 10.1146/annurev.genet.38.072902.092425; Doebley J, 1997, NATURE, V386, P485, DOI 10.1038/386485a0; Doebley J., 1989, Isozymes in plant biology., P165; Doebley J, 1998, PLANT CELL, V10, P1075, DOI 10.1105/tpc.10.7.1075; Dorweiler JE, 1997, AM J BOT, V84, P1313, DOI 10.2307/2446130; Eyre-Walker A, 1998, P NATL ACAD SCI USA, V95, P4441, DOI 10.1073/pnas.95.8.4441; Frary A, 2000, SCIENCE, V289, P85, DOI 10.1126/science.289.5476.85; Fridman E, 2004, SCIENCE, V305, P1786, DOI 10.1126/science.1101666; Hamblin MT, 2006, GENETICS, V173, P953, DOI 10.1534/genetics.105.054312; Hamblin MT, 2004, GENETICS, V167, P471, DOI 10.1534/genetics.167.1.471; HAMMER K, 1984, Kulturpflanze, V32, P11; Hanson MA, 1996, GENETICS, V143, P1395; Harris DR, 1996, ORIGINS SPREAD AGR P; Henry AM, 2005, J MOL EVOL, V61, P551, DOI 10.1007/s00239-005-0003-9; Heun M, 1997, SCIENCE, V278, P1312, DOI 10.1126/science.278.5341.1312; Innan H, 2004, P NATL ACAD SCI USA, V101, P10667, DOI 10.1073/pnas.0401720101; Jaenicke-Despres V, 2003, SCIENCE, V302, P1206, DOI 10.1126/science.1089056; Konishi S, 2006, SCIENCE, V312, P1392, DOI 10.1126/science.1126410; Kosugi S, 2002, PLANT J, V30, P337, DOI 10.1046/j.1365-313X.2002.01294.x; Lev-Yadun S, 2002, NAT BIOTECHNOL, V20, P337, DOI 10.1038/nbt0402-337b; Li CB, 2006, SCIENCE, V311, P1936, DOI 10.1126/science.1123604; Li CX, 2005, P NATL ACAD SCI USA, V102, P12978, DOI 10.1073/pnas.0504039102; Liu JP, 2002, P NATL ACAD SCI USA, V99, P13302, DOI 10.1073/pnas.162485999; Londo JP, 2006, P NATL ACAD SCI USA, V103, P9578, DOI 10.1073/pnas.0603152103; Matsuoka Y, 2002, P NATL ACAD SCI USA, V99, P6080, DOI 10.1073/pnas.052125199; Maynard-Smith J, 1974, GENET RES, V23, P23, DOI [10.1017/S0016672308009579, 10.1017/S0016672300014634]; Messing J, 2004, P NATL ACAD SCI USA, V101, P14349, DOI 10.1073/pnas.0406163101; Nesbitt TC, 2002, GENETICS, V162, P365; Nielsen R, 2005, PLOS BIOL, V3, P976, DOI 10.1371/journal.pbio.0030170; Nielsen R, 2005, ANNU REV GENET, V39, P197, DOI 10.1146/annurev.genet.39.073003.112420; Olsen KM, 2006, GENETICS, V173, P975, DOI 10.1534/genetics.106.056473; Ostergaard L, 2006, PLANT BIOTECHNOL J, V4, P45, DOI 10.1111/j.1467-7652.2005.00156.x; Palaisa K, 2004, P NATL ACAD SCI USA, V101, P9885, DOI 10.1073/pnas.0307839101; Palaisa KA, 2003, PLANT CELL, V15, P1795, DOI 10.1105/tpc.012526; Piperno D.R., 1998, ORIGINS AGR LOWLAND; Piperno DR, 2001, P NATL ACAD SCI USA, V98, P2101, DOI 10.1073/pnas.98.4.2101; Pollinger JP, 2005, GENOME RES, V15, P1809, DOI 10.1101/gr.4374505; Przeworski M, 2005, EVOLUTION, V59, P2312, DOI 10.1554/05-273.1; Purugganan MD, 2000, GENETICS, V155, P855; RICK CM, 1975, B TORREY BOT CLUB, V102, P376, DOI 10.2307/2484764; Simons KJ, 2006, GENETICS, V172, P547, DOI 10.1534/genetics.105.044727; Smith B. D., 1998, EMERGENCE AGR; Smith BD, 2001, P NATL ACAD SCI USA, V98, P1324, DOI 10.1073/pnas.98.4.1324; Smith LB, 2000, MOL BREEDING, V6, P603, DOI 10.1023/A:1011370525688; Tanksley SD, 1997, SCIENCE, V277, P1063, DOI 10.1126/science.277.5329.1063; Tenaillon MI, 2004, MOL BIOL EVOL, V21, P1214, DOI 10.1093/molbev/msh102; Thornton K, 2006, GENETICS, V172, P1607, DOI 10.1534/genetics.105.048223; Vigouroux Y, 2002, P NATL ACAD SCI USA, V99, P9650, DOI 10.1073/pnas.112324299; Wang H, 2005, NATURE, V436, P714, DOI 10.1038/nature03863; Wang RL, 1999, NATURE, V398, P236, DOI 10.1038/18435; WANG ZY, 1995, PLANT J, V7, P613, DOI 10.1046/j.1365-313X.1995.7040613.x; Wright SI, 2005, SCIENCE, V308, P1310, DOI 10.1126/science.1107891; Wright SI, 2005, MOL BIOL EVOL, V22, P506, DOI 10.1093/molbev/msi035; Yamasaki M, 2005, PLANT CELL, V17, P2859, DOI 10.1105/tpc.105.037242; Zeder MA, 2006, TRENDS GENET, V22, P139, DOI 10.1016/j.tig.2006.01.007	71	1208	1285	17	510	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 29	2006	127	7					1309	1321		10.1016/j.cell.2006.12.006	http://dx.doi.org/10.1016/j.cell.2006.12.006			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	128WI	17190597	Bronze			2022-12-28	WOS:000243690000012
J	Lee, JY; Yang, W				Lee, Jae Young; Yang, Wei			UvrD helicase unwinds DNA one base pair at a time by a two-part power stroke	CELL			English	Article							ESCHERICHIA-COLI UVRD; SINGLE-STRANDED-DNA; CRYSTAL-STRUCTURE; REP HELICASE; STEP-SIZE; ATP HYDROLYSIS; RECBCD ENZYME; PCRA HELICASE; GENE-PRODUCT; DUPLEX DNA	Helicases use the energy derived from nucleoside triphosphate hydrolysis to unwind double helices in essentially every metabolic pathway involving nucleic acids. Earlier crystal structures have suggested that DNA helicases translocate along a single-stranded DNA in an inchworm fashion, We report here a series of crystal structures of the UvrD helicase complexed with DNA and ATP hydrolysis intermediates. These structures reveal that ATP binding alone leads to unwinding of 1 base pair by directional rotation and translation of the DNA duplex, and ADP and Pi release leads to translocation of the developing single strand. Thus DNA unwinding is achieved by a two-part power stroke in a combined wrench-and-inchworm mechanism. The rotational angle and translational distance of DNA define the unwinding step to be 1 base pair per ATP hydrolyzed. Finally, a gateway for ssDNA translocation and an alternative strand-displacement mode may explain the varying step sizes reported previously.	NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Yang, W (corresponding author), NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.	wei.yang@nih.gov	Yang, Wei/D-4926-2011; Yang, Wei/ABB-4785-2020	Yang, Wei/0000-0002-3591-2195; Yang, Wei/0000-0002-3591-2195	Intramural NIH HHS Funding Source: Medline; NIDDK NIH HHS [Z01 DK036119-10] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK036119] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABDELMONEM M, 1977, EUR J BIOCHEM, V79, P33, DOI 10.1111/j.1432-1033.1977.tb11780.x; Ali JA, 1997, SCIENCE, V275, P377, DOI 10.1126/science.275.5298.377; ARTHUR HM, 1980, MOL GEN GENET, V180, P185, DOI 10.1007/BF00267368; Becker PB, 2002, ANNU REV BIOCHEM, V71, P247, DOI 10.1146/annurev.biochem.71.110601.135400; Bernstein DA, 2003, EMBO J, V22, P4910, DOI 10.1093/emboj/cdg500; Brendza KM, 2005, P NATL ACAD SCI USA, V102, P10076, DOI 10.1073/pnas.0502886102; Bruand C, 2000, MOL MICROBIOL, V35, P204, DOI 10.1046/j.1365-2958.2000.01700.x; Bruger AT, 1998, ACTA CRYSTALLOGR D, V54, P905; Byrd AK, 2005, BIOCHEMISTRY-US, V44, P12990, DOI 10.1021/bi050703z; Cheng W, 2002, P NATL ACAD SCI USA, V99, P16006, DOI 10.1073/pnas.242479399; Dao V, 1998, J BIOL CHEM, V273, P9202, DOI 10.1074/jbc.273.15.9202; Dillingham MS, 2000, BIOCHEMISTRY-US, V39, P205, DOI 10.1021/bi992105o; Dillingham MS, 1999, NUCLEIC ACIDS RES, V27, P3310, DOI 10.1093/nar/27.16.3310; Durr H, 2005, CELL, V121, P363, DOI 10.1016/j.cell.2005.03.026; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fischer CJ, 2004, J MOL BIOL, V344, P1287, DOI 10.1016/j.jmb.2004.10.005; GEORGE JW, 1994, J MOL BIOL, V235, P424, DOI 10.1006/jmbi.1994.1003; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; Graham DL, 2002, CHEM BIOL, V9, P375, DOI 10.1016/S1074-5521(02)00112-6; Guarne A, 2004, EMBO J, V23, P4134, DOI 10.1038/sj.emboj.7600412; HICKSON ID, 1983, MOL GEN GENET, V190, P265, DOI 10.1007/BF00330649; HODGMAN TC, 1988, NATURE, V333, P22, DOI 10.1038/333022b0; Iyer LM, 2004, J STRUCT BIOL, V146, P11, DOI 10.1016/j.jsb.2003.10.010; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; Korolev S, 1998, PROTEIN SCI, V7, P605, DOI 10.1002/pro.5560070309; LOHMAN TM, 2003, ENERGY COUPLING MOL, P304; Lucius AL, 2004, J MOL BIOL, V339, P751, DOI 10.1016/j.jmb.2004.04.010; Macris MA, 2005, BIOCHEM SOC T, V33, P1447, DOI 10.1042/BST0331447; Maluf NK, 2003, J MOL BIOL, V325, P913, DOI 10.1016/S0022-2836(02)01277-9; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MATSON SW, 1987, J BIOL CHEM, V262, P2066; Mechanic LE, 1999, J BIOL CHEM, V274, P12488, DOI 10.1074/jbc.274.18.12488; Myong S, 2005, NATURE, V437, P1321, DOI 10.1038/nature04049; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; OGAWA H, 1968, MOL GEN GENET, V101, P227, DOI 10.1007/BF00271625; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pfander B, 2005, NATURE, V436, P428, DOI 10.1038/nature03665; Rasnik I, 2004, J MOL BIOL, V336, P395, DOI 10.1016/j.jmb.2003.12.031; RICHET E, 1976, J BIOL CHEM, V251, P808; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2873, DOI 10.1021/bi00433a019; Singleton MR, 2004, NATURE, V432, P187, DOI 10.1038/nature02988; Singleton MR, 2002, J BACTERIOL, V184, P1819, DOI 10.1128/JB.184.7.1819-1826.2002; Soultanas P, 2000, EMBO J, V19, P3799, DOI 10.1093/emboj/19.14.3799; Tanner NK, 2003, MOL CELL, V11, P127, DOI 10.1016/S1097-2765(03)00006-6; Theis K, 1999, EMBO J, V18, P6899, DOI 10.1093/emboj/18.24.6899; VANDEPUT.P, 1965, MUTAT RES, V2, P97, DOI 10.1016/0027-5107(65)90041-2; Veaute X, 2005, EMBO J, V24, P180, DOI 10.1038/sj.emboj.7600485; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; von Hippel PH, 2003, BIOESSAYS, V25, P1168, DOI 10.1002/bies.10369; WICKNER S, 1974, P NATL ACAD SCI USA, V71, P783, DOI 10.1073/pnas.71.3.783; Zhang G, 1998, J BACTERIOL, V180, P377, DOI 10.1128/JB.180.2.377-387.1998	52	293	295	0	15	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 29	2006	127	7					1349	1360		10.1016/j.cell.2006.10.049	http://dx.doi.org/10.1016/j.cell.2006.10.049			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	128WI	17190599	Green Accepted, Bronze			2022-12-28	WOS:000243690000015
J	Bailey, MS; de Silva, HJ				Bailey, Mark S.; de Silva, H. Janaka			Sri Lankan sanni masks: an ancient classification of disease	BRITISH MEDICAL JOURNAL			English	Editorial Material									Army Med Directorate, Surrey GU15 4NP, England; Univ Kelaniya, Dept Med, Ragama, Sri Lanka	University Kelaniya	Bailey, MS (corresponding author), Army Med Directorate, Surrey GU15 4NP, England.	mark@ramc.org	Bailey, Mark S./D-3854-2013	Bailey, Mark S./0000-0003-4840-5093				Bartlett A, 1989, Int J Soc Psychiatry, V35, P245, DOI 10.1177/002076408903500305; Kapferer B., 2005, TOVIL EXORCISM HEALI; Kapferer Bruce, 1991, CELEBRATION DEMONS E; OBEYESEKERE G, 1969, COMP STUD SOC HIST, V11, P174, DOI 10.1017/S0010417500005260; PERTOLD O, 1930, CEREMONIAL DANCES SI; Wijesuriya B., 2001, TRADITIONAL SINHALES; Wirz Paul, 1954, EXORCISM ART HEALING	7	6	6	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 23	2006	333	7582					1327	1328		10.1136/bmj.39055.445417.BE	http://dx.doi.org/10.1136/bmj.39055.445417.BE			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121MC	17185730	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000243160700027
J	Steinbrook, R				Steinbrook, Robert			Haernoglobin concentrations in chronic kidney disease	LANCET			English	Editorial Material									Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Hanover, NH 03756 USA; VA Outcomes Grp, White River Jct, VT 05009 USA	Dartmouth College; VA Outcomes Group	Steinbrook, R (corresponding author), Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Hanover, NH 03756 USA.	rsteinbrook@attglobal.net						*AMG, 2006, AR SINGL DARB ALF; *AMG, 2006, EP EP ALF REC PROD I; Besarab A, 1998, NEW ENGL J MED, V339, P584, DOI 10.1056/NEJM199808273390903; COTTER D, 2006, HLTH AFF MILWOOD, V26, P1249; COYNE DW, IN PRESS CLIN J AM S; *DAVITA, 2005 ANN REP; Drueke TB, 2006, NEW ENGL J MED, V355, P2071, DOI 10.1056/NEJMoa062276; *NAT KIDN FDN, 2006, AM J KIDNEY DIS S, V27, pS11; *NAT KIDN FDN, 2005 ANN REP; *NAT KIDN FDN, 2006, KIDN DIS OUTC QUAL I; *ORTH BIOT PROD, 2006, PROCR EP ALF; Singh AK, 2006, NEW ENGL J MED, V355, P2085, DOI 10.1056/NEJMoa065485; Strippoli GFM, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003967.pub2; US Renal Data System, 2006, USRDS 2006 ANN DAT R	14	28	30	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 23	2006	368	9554					2191	2193		10.1016/S0140-6736(06)69707-9	http://dx.doi.org/10.1016/S0140-6736(06)69707-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	120HY	17189015				2022-12-28	WOS:000243076800007
J	Xin, HW; Liu, D; Wan, M; Safari, A; Kim, H; Sun, W; O'Connor, MS; Zhou, SY				Xin, Huawei; Liu, Dan; Wan, Ma; Safari, Amin; Kim, Hyeung; Sun, Wen; O'Connor, Matthew S.; Zhou Songyang			TPP1 is a homologue of ciliate TEBP-beta and interacts with POT1 to recruit telomerase	NATURE			English	Article							END-BINDING-PROTEIN; DNA-DAMAGE; LENGTH REGULATOR; COMPLEX; MAINTENANCE; SUBUNIT; PROTECTION; TERMINI; ENZYME; YEAST	Telomere dysfunction may result in chromosomal abnormalities, DNA damage responses, and even cancer(1). Early studies in lower organisms have helped to establish the crucial role of telomerase and telomeric proteins in maintaining telomere length and protecting telomere ends(2-7). In Oxytricha nova, telomere G-overhangs are protected by the TEBP-alpha/beta heterodimer(3,4). Human telomeres contain duplex telomeric repeats with 3' single-stranded G-overhangs, and may fold into a t-loop structure that helps to shield them from being recognized as DNA breaks(8,9). Additionally, the TEBP-alpha homologue, POT1, which binds telomeric single-stranded DNA (ssDNA)(10), associates with multiple telomeric proteins ( for example, TPP1, TIN2, TRF1, TRF2 and RAP1) to form the six-protein telosome/shelterin(11,12) and other subcomplexes. These telomeric protein complexes in turn interact with diverse pathways to form the telomere interactome(13) for telomere maintenance. However, the mechanisms by which the POT1-containing telosome communicates with telomerase to regulate telomeres remain to be elucidated. Here we demonstrate that TPP1 is a putative mammalian homologue of TEBP-beta and contains a predicted amino-terminal oligonucleotide/ oligosaccharide binding (OB) fold. TPP1-POT1 association enhanced POT1 affinity for telomeric ssDNA. In addition, the TPP1 OB fold, as well as POT1 - TPP1 binding, seemed critical for POT1-mediated telomerelength control and telomere-end protection in human cells. Disruption of POT1 - TPP1 interaction by dominant negative TPP1 expression or RNA interference (RNAi) resulted in telomerelength alteration and DNA damage responses. Furthermore, we offer evidence that TPP1 associates with the telomerase in a TPP1-OB-fold-dependent manner, providing a physical link between telomerase and the telosome/shelterin complex. Our findings highlight the critical role of TPP1 in telomere maintenance, and support a yin - yang model in which TPP1 and POT1 function as a unit to protect human telomeres, by both positively and negatively regulating telomerase access to telomere DNA.	Baylor Coll Med, Verna & Marrs Mclean Dept Biochem & Mol Biol, Houston, TX 77030 USA	Baylor College of Medicine	Zhou, SY (corresponding author), Baylor Coll Med, Verna & Marrs Mclean Dept Biochem & Mol Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	songyang@bcm.tmc.edu						Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Bertuch AA, 2006, CURR OPIN CELL BIOL, V18, P247, DOI 10.1016/j.ceb.2006.04.005; Chadwick D., 1997, TELOMERES TELOMERASE; Chen JL, 2003, EMBO J, V22, P304, DOI 10.1093/emboj/cdg024; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; di Fagagna FD, 2003, NATURE, V426, P194, DOI 10.1038/nature02118; FANG GW, 1993, P NATL ACAD SCI USA, V90, P6056, DOI 10.1073/pnas.90.13.6056; FANG GW, 1993, CELL, V74, P875, DOI 10.1016/0092-8674(93)90467-5; GOTTSCHLING DE, 1986, CELL, V47, P195, DOI 10.1016/0092-8674(86)90442-3; GRAY JT, 1991, CELL, V67, P807, DOI 10.1016/0092-8674(91)90075-A; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; HENDERSON E, 1987, CELL, V51, P899, DOI 10.1016/0092-8674(87)90577-0; Hockemeyer D, 2006, CELL, V126, P63, DOI 10.1016/j.cell.2006.04.044; Horvath MP, 1998, CELL, V95, P963, DOI 10.1016/S0092-8674(00)81720-1; Houghtaling BR, 2004, CURR BIOL, V14, P1621, DOI 10.1016/j.cub.2004.08.052; Lei M, 2004, NAT STRUCT MOL BIOL, V11, P1223, DOI 10.1038/nsmb867; Lingner J, 1998, CURR OPIN GENET DEV, V8, P226, DOI 10.1016/S0959-437X(98)80145-7; Liu D, 2004, J BIOL CHEM, V279, P51338, DOI 10.1074/jbc.M409293200; Liu D, 2004, NAT CELL BIOL, V6, P673, DOI 10.1038/ncb1142; Loayza D, 2003, NATURE, V423, P1013, DOI 10.1038/nature01688; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; O'Connor MS, 2006, P NATL ACAD SCI USA, V103, P11874, DOI 10.1073/pnas.0605303103; Shore D, 1997, BIOL CHEM, V378, P591; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; Verdun RE, 2005, MOL CELL, V20, P551, DOI 10.1016/j.molcel.2005.09.024; Wu L, 2006, CELL, V126, P49, DOI 10.1016/j.cell.2006.05.037; Yang Q, 2005, MOL CELL BIOL, V25, P1070, DOI 10.1128/MCB.25.3.1070-1080.2005; Ye JZS, 2004, GENE DEV, V18, P1649, DOI 10.1101/gad.1215404; Zhou SY, 2006, CRIT REV EUKAR GENE, V16, P103, DOI 10.1615/CritRevEukarGeneExpr.v16.i2.10	30	377	391	0	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 1	2007	445	7127					559	562		10.1038/nature05469	http://dx.doi.org/10.1038/nature05469			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	131KI	17237767				2022-12-28	WOS:000243867300048
J	Hueso, LE; Pruneda, JM; Ferrari, V; Burnell, G; Valdes-Herrera, JP; Simons, BD; Littlewood, PB; Artacho, E; Fert, A; Mathur, ND				Hueso, Luis E.; Pruneda, Jose M.; Ferrari, Valeria; Burnell, Gavin; Valdes-Herrera, Jose P.; Simons, Benjamin D.; Littlewood, Peter B.; Artacho, Emilio; Fert, Albert; Mathur, Neil D.			Transformation of spin information into large electrical signals using carbon nanotubes	NATURE			English	Article							TRANSPORT; LA2/3SR1/3MNO3	Spin electronics (spintronics) exploits the magnetic nature of electrons, and this principle is commercially applied in, for example, the spin valves of disk-drive read heads. There is currently widespread interest in developing new types of spintronic devices based on industrially relevant semiconductors, in which a spin-polarized current flows through a lateral channel between a spin-polarized source and drain(1,2). However, the transformation of spin information into large electrical signals is limited by spin relaxation, so that the magnetoresistive signals are below 1% ( ref. 2). Here we report large magnetoresistance effects (61% at 5 K), which correspond to large output signals ( 65 mV), in devices where the non-magnetic channel is a multiwall carbon nanotube that spans a 1.5 mu m gap between epitaxial electrodes of the highly spin polarized(3,4) manganite La0.7Sr0.3MnO3. This spintronic system combines a number of favourable properties that enable this performance; the long spin lifetime in nanotubes due to the small spin - orbit coupling of carbon; the high Fermi velocity in nanotubes that limits the carrier dwell time; the high spin polarization in the manganite electrodes, which remains high right up to the manganite - nanotube interface; and the resistance of the interfacial barrier for spin injection. We support these conclusions regarding the interface using density functional theory calculations. The success of our experiments with such chemically and geometrically different materials should inspire new avenues in materials selection for future spintronics applications.	Univ Cambridge, Dept Mat Sci, Cambridge CB2 3QZ, England; Univ Cambridge, Dept Earth Sci, Cambridge CB2 3EQ, England; CSIC, Inst Ciencia Mat Barcelona, E-08193 Barcelona, Spain; Univ Cambridge, Cavendish Lab, Cambridge CB3 0HE, England; Univ Cambridge, Nanosci Ctr, Cambridge CB3 0FF, England; CNRS Thales TRT, Unite Mixte Phys, F-91405 Orsay, France	University of Cambridge; University of Cambridge; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Ciencia de Materiales de Barcelona (ICMAB); University of Cambridge; University of Cambridge; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Mathur, ND (corresponding author), Univ Cambridge, Dept Mat Sci, Pembroke St, Cambridge CB2 3QZ, England.	ndm12@cam.ac.uk	Littlewood, Peter/M-4960-2019; Simons, Benjamin/AAY-8920-2020; Hueso, Luis E/C-8713-2009; Artacho, Emilio/G-2616-2015; Burnell, Gavin/C-8950-2009; Littlewood, Peter B/B-7746-2008; Pruneda, Miguel/A-4077-2008; Pruneda, Miguel/GQH-9515-2022	Simons, Benjamin/0000-0002-3875-7071; Hueso, Luis E/0000-0002-7918-8047; Artacho, Emilio/0000-0001-9357-1547; Burnell, Gavin/0000-0002-9486-0639; Pruneda, Miguel/0000-0002-3621-6095; Pruneda, Miguel/0000-0002-3621-6095	Engineering and Physical Sciences Research Council [GR/S02174/01] Funding Source: researchfish	Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))		Bowen M, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.137203; Bowen M, 2003, APPL PHYS LETT, V82, P233, DOI 10.1063/1.1534619; Buitelaar MR, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.156801; DATTA S, 1990, APPL PHYS LETT, V56, P665, DOI 10.1063/1.102730; Dresselhaus MS, 2001, CARBON NANOTUBES; Ferrari V, 2006, PHYS STATUS SOLIDI A, V203, P1437, DOI 10.1002/pssa.200566183; Fert A, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.184420; FERT A, 2006, IN PRESS IEEE T ELEC; George J. M., 2004, Molecular Physics Reports, V40, P23; Hueso LE, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2170431; Jedema FJ, 2002, NATURE, V416, P713, DOI 10.1038/416713a; Jensen A, 2005, PHYS REV B, V72, DOI 10.1103/PhysRevB.72.035419; Joachim C, 2000, NATURE, V408, P541, DOI 10.1038/35046000; Jonker BT, 2006, CONT CONCEPT CONDENS, P227, DOI 10.1016/S1572-0934(05)01007-3; Jorgensen HI, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.207003; KOHN W, 1965, PHYS REV, V140, P1133, DOI 10.1103/PhysRev.140.A1133; Mattana R, 2003, PHYS REV LETT, V90, DOI [10.1103/PhysRevLett.90.166601, 10.1103/PhysRevLett.166601]; MESERVEY R, 1994, PHYS REP, V238, P173, DOI 10.1016/0370-1573(94)90105-8; Mieville L, 1998, APPL PHYS LETT, V73, P1736, DOI 10.1063/1.122261; Park JH, 1998, NATURE, V392, P794, DOI 10.1038/33883; Pasupathy AN, 2004, SCIENCE, V306, P86, DOI 10.1126/science.1102068; Petta JR, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.136601; Rashba EI, 2000, PHYS REV B, V62, pR16267, DOI 10.1103/PhysRevB.62.R16267; Sahoo S, 2005, NAT PHYS, V1, P99, DOI 10.1038/nphys149; Schmidt G, 2000, PHYS REV B, V62, pR4790, DOI 10.1103/PhysRevB.62.R4790; Smith DL, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.045323; Soler JM, 2002, J PHYS-CONDENS MAT, V14, P2745, DOI 10.1088/0953-8984/14/11/302; Tombros N, 2006, PHYS REV B, V73, DOI 10.1103/PhysRevB.73.233403; Tsukagoshi K, 1999, NATURE, V401, P572, DOI 10.1038/44108; Zutic I, 2004, REV MOD PHYS, V76, P323, DOI 10.1103/RevModPhys.76.323	30	285	288	2	146	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 25	2007	445	7126					410	413		10.1038/nature05507	http://dx.doi.org/10.1038/nature05507			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	128WD	17251975				2022-12-28	WOS:000243689500035
J	Jeltes, T; McNamara, JM; Hogervorst, W; Vassen, W; Krachmalnicoff, V; Schellekens, M; Perrin, A; Chang, H; Boiron, D; Aspect, A; Westbrook, CI				Jeltes, T.; McNamara, J. M.; Hogervorst, W.; Vassen, W.; Krachmalnicoff, V.; Schellekens, M.; Perrin, A.; Chang, H.; Boiron, D.; Aspect, A.; Westbrook, C. I.			Comparison of the Hanbury Brown-Twiss effect for bosons and fermions	NATURE			English	Article							INTENSITY INTERFEROMETRY; IMPENETRABLE BOSONS; ELECTRONS; PHYSICS; GAS	Fifty years ago, Hanbury Brown and Twiss (HBT) discovered photon bunching in light emitted by a chaotic source(1), highlighting the importance of two-photon correlations(2) and stimulating the development of modern quantum optics(3). The quantum interpretation of bunching relies on the constructive interference between amplitudes involving two indistinguishable photons, and its additive character is intimately linked to the Bose nature of photons. Advances in atom cooling and detection have led to the observation and full characterization of the atomic analogue of the HBT effect with bosonic atoms(4-6). By contrast, fermions should reveal an antibunching effect ( a tendency to avoid each other). Antibunching of fermions is associated with destructive two-particle interference, and is related to the Pauli principle forbidding more than one identical fermion to occupy the same quantum state. Here we report an experimental comparison of the fermionic and bosonic HBT effects in the same apparatus, using two different isotopes of helium: He-3 ( a fermion) and He-4 ( a boson). Ordinary attractive or repulsive interactions between atoms are negligible; therefore, the contrasting bunching and antibunching behaviour that we observe can be fully attributed to the different quantum statistics of each atomic species. Our results show how atom - atom correlation measurements can be used to reveal details in the spatial density(7,8) or momentum correlations(9) in an atomic ensemble. They also enable the direct observation of phase effects linked to the quantum statistics of a many-body system, which may facilitate the study of more exotic situations(10).	Univ Paris Sud, Lab Charles Fabry, Inst Opt, CNRS, F-91127 Palaiseau, France; Vrije Univ Amsterdam, Ctr Laser, NL-1081 HV Amsterdam, Netherlands	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Vrije Universiteit Amsterdam	Vassen, W (corresponding author), Univ Paris Sud, Lab Charles Fabry, Inst Opt, CNRS, Campus Polytech RD 128, F-91127 Palaiseau, France.	w.vassen@few.vu.nl; christoph.westbrook@institutoptique.fr	Westbrook, Christoph I/B-6092-2009; Perrin, Aurélien/C-2109-2008	Westbrook, Christoph I/0000-0002-6490-0468; Perrin, Aurélien/0000-0001-5195-438X; Chang, Hong/0000-0001-7806-9698; Vassen, Wim/0000-0002-3785-4865; Krachmalnicoff, Valentina/0000-0002-5484-5338				Altman E, 2004, PHYS REV A, V70, DOI 10.1103/PhysRevA.70.013603; Baym G, 1998, ACTA PHYS POL B, V29, P1839; BOAL DH, 1990, REV MOD PHYS, V62, P553, DOI 10.1103/RevModPhys.62.553; BROWN RH, 1956, NATURE, V177, P27, DOI 10.1038/177027a0; Esteve J, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.130403; FANO U, 1961, AM J PHYS, V29, P539, DOI 10.1119/1.1937827; Folling S, 2005, NATURE, V434, P481, DOI 10.1038/nature03500; GIRARDEAU M, 1960, J MATH PHYS, V1, P516, DOI 10.1063/1.1703687; GLAUBER RJ, 1965, QUANTUM OPTICS ELECT, P63; Gomes JV, 2006, PHYS REV A, V74, DOI 10.1103/PhysRevA.74.053607; Greiner M, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.110401; Grondalski J, 1999, OPT EXPRESS, V5, P249, DOI 10.1364/OE.5.000249; HANBURYBROWN R, 1956, NATURE, V178, P1046, DOI DOI 10.1038/1781046A0; Hellweg D, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.010406; Henny M, 1999, SCIENCE, V284, P296, DOI 10.1126/science.284.5412.296; Iannuzzi M, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.080402; Jagutzki O, 2002, NUCL INSTRUM METH A, V477, P244, DOI 10.1016/S0168-9002(01)01839-3; Kiesel H, 2002, NATURE, V418, P392, DOI 10.1038/nature00911; KIMBLE HJ, 1977, PHYS REV LETT, V39, P691, DOI 10.1103/PhysRevLett.39.691; Loudon R., 2000, QUANTUM THEORY LIGHT; McNamara JM, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.080404; Oliver WD, 1999, SCIENCE, V284, P299, DOI 10.1126/science.284.5412.299; Olshanii M, 1998, PHYS REV LETT, V81, P938, DOI 10.1103/PhysRevLett.81.938; Ottl A, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.090404; Schellekens M, 2005, SCIENCE, V310, P648, DOI 10.1126/science.1118024; Scully M.O., 1997, QUANTUM OPT; SPIELMAN IB, 2006, MOTT INSULATOR TRANS; Tychkov AS, 2006, PHYS REV A, V73, DOI 10.1103/PhysREvA.73.031603; Yasuda M, 1996, PHYS REV LETT, V77, P3090, DOI 10.1103/PhysRevLett.77.3090	30	264	264	5	65	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 25	2007	445	7126					402	405		10.1038/nature05513	http://dx.doi.org/10.1038/nature05513			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	128WD	17251973	Green Submitted			2022-12-28	WOS:000243689500033
J	Liu, H; Bravata, DM; Olkin, I; Nayak, S; Roberts, B; Garber, AM; Hoffman, AR				Liu, Hau; Bravata, Dena M.; Olkin, Ingram; Nayak, Smita; Roberts, Brian; Garber, Alan M.; Hoffman, Andrew R.			Systematic review: The safety and efficacy of growth hormone in the healthy elderly	ANNALS OF INTERNAL MEDICINE			English	Review							PLACEBO-CONTROLLED TRIAL; GH REPLACEMENT THERAPY; ABDOMINALLY OBESE MEN; BODY-COMPOSITION; RESISTANCE EXERCISE; BONE-DENSITY; AGED WOMEN; OLDER MEN; POSTMENOPAUSAL WOMEN; HYPOPITUITARY ADULTS	Background: Human growth hormone (GH) is widely used as an antiaging therapy, although its use for this purpose has not been approved by the U.S. Food and Drug Administration and its distribution as an antiaging agent is illegal in the United States. Purpose: To evaluate the safety and efficacy of GH therapy in the healthy elderly. Data Sources: The authors searched MEDLINE and EMBASE databases for English-language studies published through 21 November 2005 by using such terms as growth hormone and aging. Study Selection: The authors included randomized, controlled trials that compared GH therapy with no GH therapy or GH and lifestyle interventions (exercise with or without diet) with lifestyle interventions alone. Included trials provided GH for 2 weeks or more to community-dwelling participants with a mean age of 50 years or more and a body mass index of 35 kg/m(2) or less. The authors excluded studies that evaluated GH as treatment for a specific illness. Data Extraction: Two authors independently reviewed articles and abstracted data. Data Synthesis: 31 articles describing 18 unique study populations met the inclusion criteria. A total of 220 participants who received GH (107 person-years) completed their respective studies. Study participants were elderly (mean age, 69 years [SD, 6]) and overweight (mean body mass index, 28 kg/m(2) [SD, 2]). Initial daily GH dose (mean, 14 kg per kg of body weight [SD, 71) and treatment duration (mean, 27 weeks [SD, 16]) varied. In participants treated with GH compared with those not treated with GH, overall fat mass decreased (change in fat mass, -2.1 kg [95% CI, -2.8 to -1.35] and overall lean body mass increased (change in lean body mass, 2.1 kg [CI, 1.3 to 2.9]) (P < 0.001), and their weight did not change significantly (change in weight, 0.1 kg [CI, -0.7 to 0.8]; P = 0.87). Total cholesterol levels decreased (change in cholesterol, -0.29 mmol/L [-11.21 mg/dL]; P = 0.006), although not significantly after adjustment for body composition changes. Other outcomes, including bone density and other serum lipid levels, did not change. Persons treated with GH were significantly more likely to experience soft tissue edema, arthralgias, carpal tunnel syndrome, and gynecomastia and were somewhat more likely to experience the onset of diabetes mellitus and impaired fasting glucose. Limitations: Some important outcomes were infrequently or heterogeneously measured and could not be synthesized. Most included studies had small sample sizes. Conclusions: The literature published on randomized, controlled trials evaluating GH therapy in the healthy elderly is limited but suggests that it is associated with small changes in body composition and increased rates of adverse events. On the basis of this evidence, GH cannot be recommended as an antiaging therapy.	Stanford Univ, Stanford, CA 94305 USA; Palo Alto Hlth Care Syst, Palo Alto, CA USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Liu, H (corresponding author), Stanford Univ, 117 Encina Commons, Stanford, CA 94305 USA.	hauliu@stanford.edu	Garber, Alan M/F-1476-2010	Hoffman, Andrew/0000-0002-0145-1917	AHRQ HHS [HS000028-19] Funding Source: Medline; NIA NIH HHS [AG17253] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [T32HS000028, F32HS000028] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG017253] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abs R, 1999, CLIN ENDOCRINOL, V50, P703, DOI 10.1046/j.1365-2265.1999.00695.x; Altman DG, 2001, BRIT MED J, V323, P446, DOI 10.1136/bmj.323.7310.446; *AM AC ANT AG MED, 2003, A4M SAF UPD HUM GROW; *AM AC ANT AG MED, 2003, A4M ANT AG KUVR EFF; *ANT AG GROUP HLTH, 2006, HGH INF; Baum HBA, 1996, ANN INTERN MED, V125, P883, DOI 10.7326/0003-4819-125-11-199612010-00003; BENGTSSON BA, 1993, J CLIN ENDOCR METAB, V76, P309, DOI 10.1210/jc.76.2.309; Biller BMK, 2000, J CLIN ENDOCR METAB, V85, P970, DOI 10.1210/jc.85.3.970; Blackman MB, 2002, JAMA-J AM MED ASSOC, V288, P2282, DOI 10.1001/jama.288.18.2282; BOSTEN M, 2006, DOCTOR SPEAKS HONEST; Carroll PV, 1998, J CLIN ENDOCR METAB, V83, P382, DOI 10.1210/jc.83.2.382; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; Christmas C, 2002, J GERONTOL A-BIOL, V57, pM12, DOI 10.1093/gerona/57.1.M12; CLEMMESEN B, 1993, OSTEOPOROSIS INT, V3, P330, DOI 10.1007/BF01637319; *COCHR COLL, 2004, REVM 4 2 US GUID; COHN L, 1993, CLIN ENDOCRINOL, V39, P417, DOI 10.1111/j.1365-2265.1993.tb02388.x; DEBOER H, 1995, ENDOCR REV, V16, P63, DOI 10.1210/er.16.1.63; DERAY G, 1987, NEW ENGL J MED, V316, P575, DOI 10.1056/NEJM198703053161003; Drake WM, 1998, J CLIN ENDOCR METAB, V83, P3913, DOI 10.1210/jc.83.11.3913; Drazen JM, 2003, NEW ENGL J MED, V348, P777, DOI 10.1056/NEJMp030021; ELKINS R, 1999, HGH AGE REVERSING MI; Ezzat S, 2002, J CLIN ENDOCR METAB, V87, P2725, DOI 10.1210/jc.87.6.2725; Feldt-Rasmussen U, 2004, GROWTH HORM IGF RES, V14, pS51, DOI 10.1016/j.ghir.2004.03.013; Franco C, 2005, J CLIN ENDOCR METAB, V90, P1466, DOI 10.1210/jc.2004-1657; Gharib Hossein, 2003, Endocr Pract, V9, P64; GILBERT E, 1999, STAYING YOUNG GROWTH; Hameed M, 2004, J PHYSIOL-LONDON, V555, P231, DOI 10.1113/jphysiol.2003.051722; Hennessey JV, 2001, J AM GERIATR SOC, V49, P852, DOI 10.1046/j.1532-5415.2001.49173.x; HERMANUSSEN M, 1991, Z GERONTOL, V24, P337; Hertoghe T, 2006, JAMA-J AM MED ASSOC, V295, P888, DOI 10.1001/jama.295.8.888; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Hoffman A. R., 1999, Journal of Endocrinological Investigation, V22, P4; Hoffman AR, 2004, J CLIN ENDOCR METAB, V89, P2048, DOI 10.1210/jc.2003-030346; HOLLOWAY L, 1994, J CLIN ENDOCR METAB, V79, P470, DOI 10.1210/jc.79.2.470; HOLMES SJ, 1995, CLIN ENDOCRINOL, V43, P143, DOI 10.1111/j.1365-2265.1995.tb01908.x; *HOLT MED GROUP IN, 2006, HUM GROWTH HORM; Huang X, 2005, METABOLISM, V54, P1162, DOI 10.1016/j.metabol.2005.03.023; Johannsson G, 1997, J CLIN ENDOCR METAB, V82, P727, DOI 10.1210/jc.82.3.727; JOHANNSSON G, 1996, ENDOCRINOL METAB SA, V3, P3; Jorgensen J. O. L., 1999, Journal of Endocrinological Investigation, V22, P150; JORGENSEN JOL, 1994, EUR J ENDOCRINOL, V130, P224, DOI 10.1530/eje.0.1300224; Jurgens G, 2002, CLIN PHARMACOL THER, V71, P162, DOI 10.1067/mcp.2002.121373; Kann P, 1996, MED KLIN, V91, P46; Karlsson C, 1998, EUR J ENDOCRINOL, V138, P408, DOI 10.1530/eje.0.1380408; KAUFMAN M, 2002, WASHINGTON POST 1113, V2; Kehely A, 2002, J CLIN ENDOCR METAB, V87, P1974, DOI 10.1210/jc.87.5.1974; KLATZ R, 2003, NEW ANTI AGING REVOL; Klatz R, 1998, GROW YOUNG HGH AMAZI; Kozakowski J, 1998, Pol Arch Med Wewn, V100, P306; KUNZ R, 2006, COCHRANE DATABASE ME, DOI DOI 10.1002/14651858.MR00012; Lamberts SWJ, 2000, HORM RES, V53, P42, DOI 10.1159/000023532; Lange KHW, 2000, AM J PHYSIOL-ENDOC M, V279, pE989, DOI 10.1152/ajpendo.2000.279.5.E989; Lange KHW, 2002, J CLIN ENDOCR METAB, V87, P513, DOI 10.1210/jc.87.2.513; Lange KHW, 2001, CLIN ENDOCRINOL, V55, P77, DOI 10.1046/j.1365-2265.2001.01344.x; Lange KHW, 2001, AM J PHYSIOL-ENDOC M, V280, pE886, DOI 10.1152/ajpendo.2001.280.6.E886; LANGRETH R, 2006, SWEET SYRINGE FORBES; Lyle WG, 2002, PLAST RECONSTR SURG, V110, P1585, DOI 10.1097/00006534-200211000-00032; Martin F, 1999, GROWTH HORM IGF RES, V9, P3; Monson JP, 2003, EUR J ENDOCRINOL, V148, pS9, DOI 10.1530/eje.0.148S009; Munzer T, 2001, J CLIN ENDOCR METAB, V86, P3604, DOI 10.1210/jc.86.8.3604; Noakes M, 2004, CURR OPIN LIPIDOL, V15, P31, DOI 10.1097/00041433-200402000-00007; Orwin R.G., 1994, HDB RES SYNTHESIS; Papadakis MA, 1996, ANN INTERN MED, V124, P708, DOI 10.7326/0003-4819-124-8-199604150-00002; PERLS T, 2006, HUMAN GROWTH HORMONE; Perls TT, 2005, JAMA-J AM MED ASSOC, V294, P2086, DOI 10.1001/jama.294.16.2086; RUDMAN D, 1990, NEW ENGL J MED, V323, P1, DOI 10.1056/NEJM199007053230101; RUDMAN D, 1991, HORM RES, V36, P73, DOI 10.1159/000182193; Savine R., 1999, Journal of Endocrinological Investigation, V22, P142; Savine R, 2000, HORM RES, V53, P37, DOI 10.1159/000023531; Sowers JR, 2003, AM J MED, V115, P37, DOI 10.1016/j.amjmed.2003.08.012; Svensson J, 2000, GROWTH HORM IGF RES, V10, P118, DOI 10.1054/ghir.2000.0148; TAAFFE DR, 1994, CLIN SCI, V87, P581, DOI 10.1042/cs0870581; Taaffe DR, 1996, J CLIN ENDOCR METAB, V81, P421, DOI 10.1210/jc.81.1.421; TAAFFE DR, 1994, J CLIN ENDOCR METAB, V79, P1361, DOI 10.1210/jc.79.5.1361; Taaffe DR, 2001, HORM METAB RES, V33, P156, DOI 10.1055/s-2001-14930; Thompson JL, 1998, J CLIN ENDOCR METAB, V83, P1477, DOI 10.1210/jc.83.5.1477; Toogood AA, 1998, GROWTH HORM IGF RES, V8, P47, DOI 10.1016/S1096-6374(98)80009-9; Torgerson DJ, 1999, BRIT MED J, V319, P375, DOI 10.1136/bmj.319.7206.375; TSOUVALAS D, 2005, SEARCH ETERNAL YOUTH; Vance ML, 2003, NEW ENGL J MED, V348, P779, DOI 10.1056/NEJMp020186; Verhagen AP, 1998, J CLIN EPIDEMIOL, V51, P1235, DOI 10.1016/S0895-4356(98)00131-0; Viikari J, 1998, Duodecim, V114, P867; West S, 2002, AHRQ PUBLICATION, V02-E016; YARASHESKI KE, 1995, AM J PHYSIOL-ENDOC M, V268, pE268, DOI 10.1152/ajpendo.1995.268.2.E268; Yarasheski KE, 1997, CLIN ENDOCRINOL, V47, P223, DOI 10.1046/j.1365-2265.1997.2461060.x; YARASHESKI KE, 1993, JAMA-J AM MED ASSOC, V270, P1694, DOI 10.1001/jama.270.14.1694; Yuen K, 2004, EUR J ENDOCRINOL, V151, P39, DOI 10.1530/eje.0.1510039; Zachwieja JJ, 1996, METABOLISM, V45, P254, DOI 10.1016/S0026-0495(96)90063-3	88	226	238	0	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 16	2007	146	2					104	115		10.7326/0003-4819-146-2-200701160-00005	http://dx.doi.org/10.7326/0003-4819-146-2-200701160-00005			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	131WF	17227934				2022-12-28	WOS:000243901000004
J	Wagner, AK; Ross-Degnan, D; Gurwitz, JH; Zhang, F; Gilden, DB; Cosler, L; Soumerai, SB				Wagner, Anita K.; Ross-Degnan, Dennis; Gurwitz, Jerry H.; Zhang, Fang; Gilden, Daniel B.; Cosler, Leon; Soumerai, Stephen B.			Effect of New York state regulatory action on benzodiazepine prescribing and hip fracture rates	ANNALS OF INTERNAL MEDICINE			English	Article							TRIPLICATE PRESCRIPTION PROGRAM; RISK-FACTORS; MEDICATION USE; OLDER-PEOPLE; HALF-LIFE; FALLS; SURVEILLANCE; PATTERNS; DOSAGE; IMPACT	Background: Medicare Part D excludes benzodiazepines from coverage, and numerous state government policies limit use of benzodiazepines. No data indicate that such policies have decreased the incidence of hip fracture. Objective: To assess whether a statewide policy that decreased the use of benzodiazepines among elderly persons by more than 50% has decreased the incidence of hip fracture. Design: A quasi-experiment comparing changes in outcomes before and after a policy change in a study U.S. state (New York) and a control state (New Jersey). Setting: Two U.S. state Medicaid programs, 1988-1990. Patients: Medicaid enrollees in New York (n = 51529) and New Jersey (n = 42 029) who received or did not receive a benzodiazepine. Measurements: Benzodiazepine prescribing and hazard ratios for hip fracture, adjusted for age and eligibility category. Intervention: A statewide policy, implemented in New York in 1989, that required triplicate forms for benzodiazepine prescribing to allow surveillance by health authorities. Results: The triplicate prescription policy immediately resulted in a 60.3% (95% CI, -66.3% to -54.2%) reduction in benzodiazepine use among women and 58.5% (-64.3% to -52.8%) among men. Benzodiazepine use in New Jersey remained stable. Hazard ratios for hip fracture that were adjusted for age and eligibility category did not change in New York or New Jersey when the periods before and after use of the triplicate prescription policy were compared (change from 1.2 to 1.1 among female benzodiazepine recipients [P = 0.70], 1.3 to 1.1 [P = 0.08] among female nonrecipients, 0.8 to 1.1 [P = 0.56] among male recipients, and 1.1 to 1.3 [P = 0.46] among male nonrecipients). Limitations: Information was lacking on race, benzodiazepine dose, and other potential determinants of continued benzodiazepine prescribing. Conclusions: Policies that lead to substantial reductions in the use of benzodiazepines among elderly persons do not necessarily lead to decreased incidence of hip fracture. Limitations on coverage of benzodiazepines under Medicare Part D may not achieve this widely assumed clinical benefit.	Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA 02215 USA; Harvard Pilgrim Hlth Care, Boston, MA 02215 USA; Univ Massachusetts, Sch Med, Meyers Primary Care Inst, Fallon Fdn, Worcester, MA 01605 USA; Fallon Community Hlth Plan, Worcester, MA USA; JEN Associates Inc, Cambridge, MA USA; New York State Dept Hlth, Albany Coll Pharm & Management Reports & Res Unit, Off Medicaid Management, Albany, NY USA	Harvard University; Harvard Medical School; Harvard Pilgrim Health Care; University of Massachusetts System; University of Massachusetts Worcester; State University of New York (SUNY) System	Soumerai, SB (corresponding author), Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA 02215 USA.	ssoumerai@hms.harvard.edu	Zhang, Fang/HHN-2153-2022		AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [U18HS011843] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG019808] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA010371] Funding Source: NIH RePORTER; AHRQ HHS [U 18 HS 11843] Funding Source: Medline; NIA NIH HHS [R01 AG19808-01A1] Funding Source: Medline; NIDA NIH HHS [R01DA10 371-01] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		[Anonymous], 1979, QUASIEXPERIMENTATION; Bambauer KZ, 2005, PSYCHIAT SERV, V56, P1143, DOI 10.1176/appi.ps.56.9.1143; CUMMING RG, 1993, MED J AUSTRALIA, V158, P414, DOI 10.5694/j.1326-5377.1993.tb121839.x; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; EADIE JL, 1993, IMPACT PRESCRIPTION, V179; ENSRUD KE, 1996, EPIDEMIOLOGY, V7, P335; FEDERSPIEL CF, 1976, MED CARE, V14, P166, DOI 10.1097/00005650-197602000-00006; GALES BJ, 1995, ANN PHARMACOTHER, V29, P354, DOI 10.1177/106002809502900402; GRISSO JA, 1991, NEW ENGL J MED, V324, P1326, DOI 10.1056/NEJM199105093241905; HENNESSEY S, 2005, PHARMACOEPIDEMIOLOGY; HERINGS RMC, 1995, ARCH INTERN MED, V155, P1801, DOI 10.1001/archinte.155.16.1801; Hosmer D. W., 1999, APPL SURVIVAL ANAL; Karagas MR, 1996, AM J EPIDEMIOL, V143, P677; KEENE GS, 1993, BRIT MED J, V307, P1248, DOI 10.1136/bmj.307.6914.1248; Kleinbaum DG, 1996, SURVIVAL ANAL SELF L; Koski K, 1998, GERONTOLOGY, V44, P232, DOI 10.1159/000022017; LIU BA, 1995, J AM GERIATR SOC, V43, P1141, DOI 10.1111/j.1532-5415.1995.tb07016.x; LURIE P, 1992, JAMA-J AM MED ASSOC, V268, P472; *NAT PHARM COUNC, 2003, PHARM BEN STAT MED A; Neutel CI, 1996, AGE AGEING, V25, P273, DOI 10.1093/ageing/25.4.273; NEVITT MC, 1989, JAMA-J AM MED ASSOC, V261, P2663, DOI 10.1001/jama.261.18.2663; Pearson SA, 2006, ARCH INTERN MED, V166, P572, DOI 10.1001/archinte.166.5.572; Pierfitte C, 2001, BMJ-BRIT MED J, V322, P704, DOI 10.1136/bmj.322.7288.704; RAY WA, 1992, J CLIN EPIDEMIOL, V45, P703, DOI 10.1016/0895-4356(92)90047-Q; RAY WA, 1989, JAMA-J AM MED ASSOC, V262, P3303, DOI 10.1001/jama.262.23.3303; RAY WA, 1987, NEW ENGL J MED, V316, P363, DOI 10.1056/NEJM198702123160702; Ray WA, 2000, J AM GERIATR SOC, V48, P682, DOI 10.1111/j.1532-5415.2000.tb04729.x; Ross-Degnan D, 2004, INT J PSYCHIAT MED, V34, P103, DOI 10.2190/8FR4-QYY1-7MYG-2AGJ; ROSSDEGNAN D, 1993, JAMA-J AM MED ASSOC, V270, P1937, DOI 10.1001/jama.270.16.1937; SAS Institute Inc, 1999, SAS STAT US GUID VER; Schneeweiss S, 2005, J AM GERIATR SOC, V53, P948, DOI 10.1111/j.1532-5415.2005.53303.x; Sgadari A, 2000, J CLIN PSYCHOPHARM, V20, P234, DOI 10.1097/00004714-200004000-00017; Simoni-Wastila L, 2004, CLIN THER, V26, P322, DOI 10.1016/S0149-2918(04)90030-6; Sloan FA, 1999, AM J PUBLIC HEALTH, V89, P935, DOI 10.2105/AJPH.89.6.935; SOROCK GS, 1988, ARCH INTERN MED, V148, P2441, DOI 10.1001/archinte.148.11.2441; TAGGART HM, 1988, J AM GERIATR SOC, V36, P1006, DOI 10.1111/j.1532-5415.1988.tb04367.x; Tamblyn R, 2005, J AM GERIATR SOC, V53, P233, DOI 10.1111/j.1532-5415.2005.53108.x; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; VanHaaren AM, 2001, PHARMACOTHERAPY, V21, P1159, DOI 10.1592/phco.21.15.1159.33898; WADHWANI A, 2006, TENNESSEAN      0223; Wagner AK, 2004, ARCH INTERN MED, V164, P1567, DOI 10.1001/archinte.164.14.1567; Wagner AK, 2002, J CLIN PHARM THER, V27, P299, DOI 10.1046/j.1365-2710.2002.00430.x; Wang PS, 2001, AM J PSYCHIAT, V158, P892, DOI 10.1176/appi.ajp.158.6.892; WEINTRAUB M, 1991, JAMA-J AM MED ASSOC, V266, P2392, DOI 10.1001/jama.266.17.2392; WEINTRAUB M, 1993, CLIN PHARMACOL THER, V54, P252, DOI 10.1038/clpt.1993.145; ZULLICH SG, 1992, ANN PHARMACOTHER, V26, P539	46	52	53	1	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 16	2007	146	2					96	103		10.7326/0003-4819-146-2-200701160-00004	http://dx.doi.org/10.7326/0003-4819-146-2-200701160-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	131WF	17227933				2022-12-28	WOS:000243901000003
J	Watts, G				Watts, Geoff			Quite reasonably emotional	LANCET			English	Editorial Material											Watts, G (corresponding author), 28 New End Sq, London NW3 1LS, England.	geoff@scileg.freeserve.co.uk						Greene JD, 2001, SCIENCE, V293, P2105, DOI 10.1126/science.1062872; Moll J, 2002, J NEUROSCI, V22, P2730, DOI 10.1523/JNEUROSCI.22-07-02730.2002; Zhong CB, 2006, SCIENCE, V313, P1451, DOI 10.1126/science.1130726	3	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 13	2007	369	9556					90	91		10.1016/S0140-6736(07)60048-8	http://dx.doi.org/10.1016/S0140-6736(07)60048-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	126TK	17223457				2022-12-28	WOS:000243538200010
J	Young, J; Forster, A				Young, John; Forster, Anne			Rehabilitation after stroke	BMJ-BRITISH MEDICAL JOURNAL			English	Review							TRAINING CARE GIVERS; EXERCISE THERAPY; TIME		Univ Leeds, Aca Unit Elderly Care & Rehabil, Bradford BD5 0NA, W Yorkshire, England; Bradford Teaching Hosp NHS Fdn Trust, Bradford BD5 0NA, W Yorkshire, England	University of Leeds	Young, J (corresponding author), Univ Leeds, Aca Unit Elderly Care & Rehabil, Bradford BD5 0NA, W Yorkshire, England.	john.young@bradfordhospitals.nhs.uk		young, john/0000-0003-4085-9306; Forster, Anne/0000-0001-7466-4414				Anderson C, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000443.pub2; Brady MC, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000425.pub4; Department of Health, 2001, NAT SERV FRAM OLD PE; Duncan PW, 2005, STROKE, V36, pE100, DOI 10.1161/01.STR.0000180861.54180.FF; ELLIS G, 2006, CEREBROVASC DIS, V21, P120; FORSTER A, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001919; Hackett ML, 2005, STROKE, V36, P2296, DOI 10.1161/01.STR.0000183622.75135.a4; Han B, 1999, STROKE, V30, P1478, DOI 10.1161/01.STR.30.7.1478; Intercollegiate working Party for Stroke, 2004, NAT CLIN GUID STROK; JORGENSEN HS, 1995, ARCH PHYS MED REHAB, V76, P406, DOI 10.1016/S0003-9993(95)80568-0; KALRA L, 1993, STROKE, V24, P1462, DOI 10.1161/01.STR.24.10.1462; Kalra L, 2004, BMJ-BRIT MED J, V328, P1099, DOI 10.1136/bmj.328.7448.1099; Kwakkel G, 2004, STROKE, V35, P2529, DOI 10.1161/01.STR.0000143153.76460.7d; Langhorne P, 2002, AGE AGEING, V31, P365, DOI 10.1093/ageing/31.5.365; Langhorne P, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000197.pub3; McKevitt C, 2004, STROKE, V35, P1499, DOI 10.1161/01.STR.0000127532.64840.36; Outpatient Service Trialists, 2003, COCHRANE DB SYST REV, DOI [10.1002/14651858.cd002925, 10.1002/14651858.CD002925, DOI 10.1002/14651858.CD002925]; Patel A, 2004, BMJ-BRIT MED J, V328, P1102, DOI 10.1136/bmj.328.7448.1102; POLLOCK A, 2007, IN PRESS COCHRANE DA; *SIGN, 2002, SIGN PUBL, V64; van der Lee JH, 2001, CLIN REHABIL, V15, P20, DOI 10.1191/026921501677557755; Van Peppen RPS, 2004, CLIN REHABIL, V18, P833, DOI 10.1191/0269215504cr843oa; Walker MF, 2004, STROKE, V35, P2226, DOI 10.1161/01.STR.0000137766.17092.fb; World Health Organization, 2000, WORLD HLTH REP 2000; Young J, 2003, REV CLIN GERONTOL, V13, P55	25	97	102	0	20	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 13	2007	334	7584					86	90		10.1136/bmj.39059.456794.68	http://dx.doi.org/10.1136/bmj.39059.456794.68			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	127DZ	17218714	Green Published			2022-12-28	WOS:000243566800032
J	Doyle, M; Fookes, M; Ivens, A; Mangan, MW; Wain, J; Dorman, CJ				Doyle, Marie; Fookes, Maria; Ivens, Al; Mangan, Michael W.; Wain, John; Dorman, Charles J.			An H-NS-like stealth protein aids horizontal DNA transmission in bacteria	SCIENCE			English	Article							PLASMID; SEQUENCE; GENES; COLI; LER; R27; SFH	The Sfh protein is encoded by self-transmissible plasmids involved in human typhoid and is closely related to the global regulator H-NS. We have found that Sfh provides a stealth function that allows the plasmids to be transmitted to new bacterial hosts with minimal effects on their fitness. Introducing the plasmid without the sfh gene imposes a mild H-NS- phenotype and a severe loss of fitness due to titration of the cellular pool of H-NS by the A+T-rich plasmid. This stealth strategy seems to be used widely to aid horizontal DNA transmission and has important implications for bacterial evolution.	Trinity Coll Dublin, Dept Microbiol, Moyne Inst Prevent Med, Dublin 2, Ireland; Wellcome Trust Res Labs, Sanger Inst, Cambridge CB10 1SA, England	Trinity College Dublin; Wellcome Trust Sanger Institute	Dorman, CJ (corresponding author), Trinity Coll Dublin, Dept Microbiol, Moyne Inst Prevent Med, Dublin 2, Ireland.	cjdorman@tcd.ie	Wain, John/B-3446-2013; Dorman, Charles J/N-9867-2015; Dorman, Charles/P-3481-2019	Wain, John/0000-0002-1257-1148; Dorman, Charles J/0000-0002-6018-9170; Dorman, Charles/0000-0002-6018-9170; Ivens, Al/0000-0002-0112-3876; Mangan, Michael/0000-0001-9428-0397	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Beloin C, 2003, MOL GENET GENOMICS, V270, P66, DOI 10.1007/s00438-003-0897-0; Berdichevsky T, 2005, J BACTERIOL, V187, P349, DOI 10.1128/JB.187.1.349-357.2005; Bertin P, 1999, MOL MICROBIOL, V31, P319, DOI 10.1046/j.1365-2958.1999.01176.x; BOUMA JE, 1988, NATURE, V335, P351, DOI 10.1038/335351a0; Bustamante VH, 2001, MOL MICROBIOL, V39, P664, DOI 10.1046/j.1365-2958.2001.02209.x; Chen I, 2005, SCIENCE, V310, P1456, DOI 10.1126/science.1114021; Dahlberg C, 2003, GENETICS, V165, P1641; Deighan P, 2003, MOL MICROBIOL, V48, P1401, DOI 10.1046/j.1365-2958.2003.03515.x; Dobrindt U, 2004, NAT REV MICROBIOL, V2, P414, DOI 10.1038/nrmicro884; Dorman CJ, 2004, NAT REV MICROBIOL, V2, P391, DOI 10.1038/nrmicro883; Forns N, 2005, J BACTERIOL, V187, P3950, DOI 10.1128/JB.187.12.3950-3959.2005; LENSKI RE, 1994, J BACTERIOL, V176, P3140, DOI 10.1128/jb.176.11.3140-3147.1994; Lucchini S, 2006, PLOS PATHOG, V2, P746, DOI 10.1371/journal.ppat.0020081; More MI, 1996, J BACTERIOL, V178, P4392, DOI 10.1128/jb.178.15.4392-4399.1996; Navarre WW, 2006, SCIENCE, V313, P236, DOI 10.1126/science.1128794; Rimsky S, 2004, CURR OPIN MICROBIOL, V7, P109, DOI 10.1016/j.mib.2004.02.001; Sherburne CK, 2000, NUCLEIC ACIDS RES, V28, P2177, DOI 10.1093/nar/28.10.2177; TIETZE E, 1994, J BASIC MICROB, V34, P105, DOI 10.1002/jobm.3620340206; Wain J, 2004, T ROY SOC TROP MED H, V98, P423, DOI 10.1016/j.trstmh.2003.10.015; Wain J, 1998, J CLIN MICROBIOL, V36, P1683, DOI 10.1128/JCM.36.6.1683-1687.1998; Wei J, 2003, INFECT IMMUN, V71, P2775, DOI 10.1128/IAI.71.5.2775-2786.2003	21	161	162	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 12	2007	315	5809					251	252		10.1126/science.1137550	http://dx.doi.org/10.1126/science.1137550			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124XZ	17218529				2022-12-28	WOS:000243407400050
J	Fradkin, E; Kivelson, SA; Oganesyan, V				Fradkin, Eduardo; Kivelson, Steven A.; Oganesyan, Vadim			Electron nematic phase in a transition metal oxide	SCIENCE			English	Editorial Material							SUPERCONDUCTIVITY; FLUID		Univ Illinois, Dept Phys, Urbana, IL 61801 USA; Stanford Univ, Dept Phys, Stanford, CA 93105 USA; Yale Univ, Dept Phys, New Haven, CT 06520 USA	University of Illinois System; University of Illinois Urbana-Champaign; Stanford University; Yale University	Fradkin, E (corresponding author), Univ Illinois, Dept Phys, 1110 W Green St, Urbana, IL 61801 USA.	kivelson@stanford.edu	Fradkin, Eduardo H/B-5612-2013	Fradkin, Eduardo/0000-0001-6837-463X; Kivelson, Steven/0000-0001-9149-9502; OGANESYAN, Vadim/0000-0002-6716-9498	Division Of Materials Research [0758462] Funding Source: National Science Foundation	Division Of Materials Research(National Science Foundation (NSF)NSF - Directorate for Mathematical & Physical Sciences (MPS))		Ando Y, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.137005; Borzi RA, 2007, SCIENCE, V315, P214, DOI 10.1126/science.1134796; Cooper KB, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.241313; Dell'Anna L, 2006, PHYS REV B, V73, DOI 10.1103/PhysRevB.73.045127; Halboth CJ, 2000, PHYS REV LETT, V85, P5162, DOI 10.1103/PhysRevLett.85.5162; Kee HY, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.245109; Kee HY, 2005, PHYS REV B, V71, DOI 10.1103/PhysRevB.71.184402; Kivelson SA, 1998, NATURE, V393, P550, DOI 10.1038/31177; Mackenzie AP, 2003, REV MOD PHYS, V75, P657, DOI 10.1103/RevModPhys.75.657; Oganesyan V, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.195109	11	26	26	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 12	2007	315	5809					196	197		10.1126/science.1137172	http://dx.doi.org/10.1126/science.1137172			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124XZ	17218515				2022-12-28	WOS:000243407400032
J	Mignot, E; Takahashi, JS				Mignot, Emmanuel; Takahashi, Joseph S.			A circadian sleep disorder reveals a complex clock	CELL			English	Editorial Material							PHASE SYNDROME; PHOSPHORYLATION; MUTATION	Circadian rhythms are established by transcription of clock genes and autoregulatory transcriptional feedback loops. In this issue, Xu et al. (2007) characterize mice expressing a human Per2 mutation identified in patients with familial advanced sleep phase syndrome. Their results reveal that PER2 phosphorylation, by CK1 delta and other kinases, is surprisingly complex and has opposite effects on PER2 levels and period length.	Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94304 USA; Northwestern Univ, Howard Hughes Med Inst, Evanston, IL 60208 USA	Howard Hughes Medical Institute; Stanford University; Howard Hughes Medical Institute; Northwestern University	Mignot, E (corresponding author), Stanford Univ, Sch Med, Howard Hughes Med Inst, 701-B Welch Rd, Stanford, CA 94304 USA.	mignot@stanford.edu	Takahashi, Joseph S/E-8482-2012; Takahashi, Joseph S./Y-2781-2019	Takahashi, Joseph S/0000-0003-0384-8878; Takahashi, Joseph S./0000-0003-0384-8878	Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		Gallego M, 2006, P NATL ACAD SCI USA, V103, P10618, DOI 10.1073/pnas.0604511103; Jones CR, 1999, NAT MED, V5, P1062, DOI 10.1038/12502; Kondratov RV, 2006, CELL CYCLE, V5, P890, DOI 10.4161/cc.5.8.2684; Kwon I, 2006, MOL CELL BIOL, V26, P7318, DOI 10.1128/MCB.00337-06; Lowrey PL, 2004, ANNU REV GENOM HUM G, V5, P407, DOI 10.1146/annurev.genom.5.061903.175925; Toh KL, 2001, SCIENCE, V291, P1040, DOI 10.1126/science.1057499; Vanselow K, 2006, GENE DEV, V20, P2660, DOI 10.1101/gad.397006; Xu Y, 2005, NATURE, V434, P640, DOI 10.1038/nature03453	8	23	25	1	7	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 12	2007	128	1					22	23		10.1016/j.cell.2006.12.024	http://dx.doi.org/10.1016/j.cell.2006.12.024			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	139GN	17218251	Bronze, Green Accepted			2022-12-28	WOS:000244420400009
J	Armstead, I; Donnison, I; Aubry, S; Harper, J; Hortensteiner, S; James, C; Mani, J; Moffet, M; Ougham, H; Roberts, L; Thomas, A; Weeden, N; Thomas, H; King, I				Armstead, Ian; Donnison, Iain; Aubry, Sylvain; Harper, John; Hortensteiner, Stefan; James, Caron; Mani, Jan; Moffet, Matt; Ougham, Helen; Roberts, Luned; Thomas, Ann; Weeden, Norman; Thomas, Howard; King, Ian			Cross-species identification of Mendel's/locus	SCIENCE			English	Article							STAY GREEN		Inst Grassland & Environm Res, Aberystwyth SY23 3EB, Dyfed, Wales; Univ Bern, Inst Plant Sci, CH-3013 Bern, Switzerland; Montana State Univ, Dept Plant Sci & Plant Pathol, Bozeman, MT 59717 USA	Aberystwyth University; University of Bern; Montana State University System; Montana State University Bozeman	Armstead, I (corresponding author), Inst Grassland & Environm Res, Aberystwyth SY23 3EB, Dyfed, Wales.	ian.armstead@bbsrc.ac.uk	Donnison, Iain S/K-6138-2014; Thomas, Howard/G-6812-2011; Aubry, Sylvain/V-6364-2019; King, Ian/N-4500-2014	Donnison, Iain S/0000-0001-6276-555X; Aubry, Sylvain/0000-0002-7598-3609; 	Biotechnology and Biological Sciences Research Council [BBS/E/G/00003001] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Armstead I, 2006, NEW PHYTOL, V172, P592, DOI 10.1111/j.1469-8137.2006.01922.x; Cha KW, 2002, THEOR APPL GENET, V104, P526, DOI 10.1007/s001220100750; Hortensteiner S, 2006, ANNU REV PLANT BIOL, V57, P55, DOI 10.1146/annurev.arplant.57.032905.105212; Mendel G., 1866, VERHAND NATURF VER B, V4, P3, DOI DOI 10.5962/BHL.TITLE.61004; THOMAS H, 1993, ANN APPL BIOL, V123, P193, DOI 10.1111/j.1744-7348.1993.tb04086.x; Thomas H, 1996, BOT ACTA, V109, P3, DOI 10.1111/j.1438-8677.1996.tb00862.x	6	137	154	5	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 5	2007	315	5808					73	73		10.1126/science.1132912	http://dx.doi.org/10.1126/science.1132912			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	122WU	17204643				2022-12-28	WOS:000243259100036
J	Sapienza, C				Sapienza, Carmen			Do Watson and Crick motor from X to Z?	SCIENCE			English	Editorial Material							SEGREGATION	A protein that determines left-right body asymmetry in the mouse is involved in the nonrandom segregation of duplicated chromosomes to daughter cells.	Temple Univ, Sch Med, Fels Inst Canc Res, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Pathol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Sapienza, C (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res, 3307 N Broad St, Philadelphia, PA 19140 USA.	sapienza@temple.edu						Armakolas A, 2006, SCIENCE, V311, P1146, DOI 10.1126/science.1120519; Armakolas A, 2007, SCIENCE, V315, P100, DOI 10.1126/science.1129429; Beumer KJ, 1998, GENETICS, V150, P173; CAIRNS J, 1975, NATURE, V255, P197, DOI 10.1038/255197a0; Haber JE, 2006, SCIENCE, V313, DOI 10.1126/science.1127836; KLAR AJS, 1994, TRENDS GENET, V10, P392, DOI 10.1016/0168-9525(94)90055-8; Liu PT, 2002, NAT GENET, V30, P66, DOI 10.1038/ng788	7	4	4	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 5	2007	315	5808					46	47		10.1126/science.1137587	http://dx.doi.org/10.1126/science.1137587			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	122WU	17204629				2022-12-28	WOS:000243259100022
J	Kroeger, A; Nathan, MB				Kroeger, Axel; Nathan, Michael B.			Dengue: setting the global research agenda	LANCET			English	Editorial Material							CLASSIFICATION		UNICEF UNDP World Bank WHO Special Programme Res, CH-1211 Geneva 27, Switzerland; Dept Control Neglected Trop Dis Vector Ecol & Man, CH-1211 Geneva 27, Switzerland	The World Bank; World Health Organization	Kroeger, A (corresponding author), UNICEF UNDP World Bank WHO Special Programme Res, CH-1211 Geneva 27, Switzerland.	kroegera@who.int		Kroeger, Axel/0000-0001-8438-2904				Bandyopadhyay S, 2006, TROP MED INT HEALTH, V11, P1238, DOI 10.1111/j.1365-3156.2006.01678.x; Deen JL, 2006, LANCET, V368, P170, DOI 10.1016/S0140-6736(06)69006-5; Focks DA, 2006, MULTICOUNTRY STUDY A; Kroeger A, 2006, BMJ-BRIT MED J, V332, P1247, DOI 10.1136/bmj.332.7552.1247; *UN, WORLD URB PRSP 2001; *WORLD HLTH ASS, DENG FEV DENG HAEM F	6	60	63	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 23	2006	368	9554					2193	2195		10.1016/S0140-6736(06)69873-5	http://dx.doi.org/10.1016/S0140-6736(06)69873-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	120HY	17189016				2022-12-28	WOS:000243076800008
J	Wong, KL; Pawin, G; Kwon, KY; Lin, X; Jiao, T; Solanki, U; Fawcett, RHJ; Bartels, L; Stolbov, S; Rahman, TS				Wong, K. L.; Pawin, G.; Kwon, K. -Y.; Lin, X.; Jiao, T.; Solanki, U.; Fawcett, R. H. J.; Bartels, L.; Stolbov, S.; Rahman, T. S.			A molecule carrier	SCIENCE			English	Article							LARGE ORGANIC-MOLECULES; SINGLE-MOLECULE; SURFACE; DYNAMICS; DIFFUSION; HYDROGEN; METALS; ENERGY	We found that anthraquinone diffuses along a straight line across a flat, highly symmetric Cu(111) surface. It can also reversibly attach one or two CO2 molecules as "cargo" and act as a "molecule carrier," thereby transforming the diffusive behavior of the CO2 molecules from isotropic to linear. Density functional theory calculations indicated a substrate-mediated attraction of similar to 0.12 electron volt (eV). Scanning tunneling microscopy revealed individual steps of the molecular complex on its diffusion pathway, with increases of similar to 0.03 and similar to 0.02 eV in the diffusion barrier upon attachment of the first and second CO2 molecule, respectively.	Univ Calif Riverside, Riverside, CA 92521 USA; Univ Cent Florida, Dept Phys, Orlando, FL 32816 USA	University of California System; University of California Riverside; State University System of Florida; University of Central Florida	Bartels, L (corresponding author), Univ Calif Riverside, Pierce Hall, Riverside, CA 92521 USA.	ludwig.bartels@ucr.edu	bartelsdoe, ludwig/F-8008-2011; Wong, Kin L/F-6907-2011; Bartels, Ludwig/C-2764-2008	Wong, Kin L/0000-0001-6776-3852; 				Balzani V, 2000, ANGEW CHEM INT EDIT, V39, P3348, DOI 10.1002/1521-3773(20001002)39:19<3348::AID-ANIE3348>3.0.CO;2-X; Barth JV, 2005, NATURE, V437, P671, DOI 10.1038/nature04166; Brune H, 1998, NATURE, V394, P451, DOI 10.1038/28804; Collin JP, 2001, ACCOUNTS CHEM RES, V34, P477, DOI 10.1021/ar0001766; Ernst KH, 1999, PHYS CHEM CHEM PHYS, V1, P4105, DOI 10.1039/a904169i; Gimzewski JK, 1998, SCIENCE, V281, P531, DOI 10.1126/science.281.5376.531; Gross L, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.056103; Heinrich AJ, 2002, SCIENCE, V298, P1381, DOI 10.1126/science.1076768; Horch S, 1999, NATURE, V398, P134, DOI 10.1038/18185; Kelly TR, 1999, NATURE, V401, P150, DOI 10.1038/43639; Kottas GS, 2005, CHEM REV, V105, P1281, DOI 10.1021/cr0300993; KRESSE G, 1993, PHYS REV B, V47, P558, DOI 10.1103/PhysRevB.47.558; Kwon KY, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.166101; Lukas S, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.028301; McCarty GS, 2004, J AM CHEM SOC, V126, P16772, DOI 10.1021/ja038930g; Mitsui T, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.036101; Moore JS, 1997, ACCOUNTS CHEM RES, V30, P402, DOI 10.1021/ar950232g; Otero R, 2004, NAT MATER, V3, P779, DOI 10.1038/nmat1243; Otero R, 2004, ANGEW CHEM INT EDIT, V43, P2092, DOI 10.1002/anie.200353586; Pawin G, 2006, SCIENCE, V313, P961, DOI 10.1126/science.1129309; PAYNE MC, 1992, REV MOD PHYS, V64, P1045, DOI 10.1103/RevModPhys.64.1045; PERDEW JP, 1992, PHYS REV B, V45, P13244, DOI 10.1103/PhysRevB.45.13244; Repp J, 2000, PHYS REV LETT, V85, P2981, DOI 10.1103/PhysRevLett.85.2981; Rosei F, 2003, PROG SURF SCI, V71, P95, DOI 10.1016/S0079-6816(03)00004-2; Shirai Y, 2005, NANO LETT, V5, P2330, DOI 10.1021/nl051915k; STRANICK SJ, 1994, SCIENCE, V266, P99, DOI 10.1126/science.266.5182.99; Sykes ECH, 2003, ACCOUNTS CHEM RES, V36, P945, DOI 10.1021/ar970286l; Theobald JA, 2003, NATURE, V424, P1029, DOI 10.1038/nature01915; van Delden RA, 2005, NATURE, V437, P1337, DOI 10.1038/nature04127; VANDERBILT D, 1990, PHYS REV B, V41, P7892, DOI 10.1103/PhysRevB.41.7892	30	58	59	1	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 9	2007	315	5817					1391	1393		10.1126/science.1135302	http://dx.doi.org/10.1126/science.1135302			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	143UP	17234916				2022-12-28	WOS:000244752200027
J	Westfall, JM; Mold, J; Fagnan, L				Westfall, John M.; Mold, James; Fagnan, Lyle			Practice-based research - "Blue Highways" on the NIH roadmap	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PRIMARY-CARE; UNITED-STATES; MEDICAL-CARE; PERFORMANCE; GUIDELINES; QUALITY; ECOLOGY; RATES		Univ Colorado, Hlth Sci Ctr, Dept Family Med, High Plains Res Network, Denver, CO 80045 USA; Univ Oklahoma, Hlth Sci Ctr, Oklahoma Phys Resource Res Network, Dept Family & Prevent Med, Oklahoma City, OK USA; Oregon Hlth Sci Univ, Dept Family Med, Oregon Rural Practice Based Res Network, Portland, OR 97201 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Oklahoma System; University of Oklahoma Health Sciences Center; Oregon Health & Science University	Westfall, JM (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Family Med, High Plains Res Network, POB 6508,Mail Stop F496, Denver, CO 80045 USA.	jack.westfall@uchsc.edu	Westfall, John/AAD-3570-2021; Duran, Bonnie m/A-3029-2009					*AG HEALTHC RES QU, FACT SHEET AHRQ SUPP; [Anonymous], 2000, YB MED INFORM MANAGI; BECKER L, 1988, J FAM PRACTICE, V27, P41; Bradley EH, 2005, MED CARE, V43, P282, DOI 10.1097/00005650-200503000-00011; Coughlin SS, 2004, J RURAL HEALTH, V20, P118, DOI 10.1111/j.1748-0361.2004.tb00017.x; *FAM PHYS INQ NETW, FPIN; Graham RP, 2000, J CLIN EPIDEMIOL, V53, P949, DOI 10.1016/S0895-4356(99)00224-3; Green LA, 2001, NEW ENGL J MED, V344, P2021, DOI 10.1056/NEJM200106283442611; Green LA, 2006, J AM BOARD FAM MED, V19, P1, DOI 10.3122/jabfm.19.1.1; Heat-Moon, 1999, BLUE HIGHWAYS JOURNE; *I MED COMM Q UAL, 2001, CROSS QUAL CHASM NEW; Katz DA, 1999, HEALTH SERV RES, V34, P377; Katzan IL, 2000, JAMA-J AM MED ASSOC, V283, P1151, DOI 10.1001/jama.283.9.1151; Main D S, 1993, Arch Fam Med, V2, P1061, DOI 10.1001/archfami.2.10.1061; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; O'Connor PJ, 1999, J FAM PRACTICE, V48, P690; Stange KC, 2000, PREV MED, V31, P167, DOI 10.1006/pmed.2000.0700; Sung NS, 2003, JAMA-J AM MED ASSOC, V289, P1278, DOI 10.1001/jama.289.10.1278; Taylor JA, 2005, PEDIATR INFECT DIS J, V24, P489, DOI 10.1097/01.inf.0000164706.91337.5d; Westfall JM, 2006, ANN FAM MED, V4, P153, DOI 10.1370/afm.403; WHITE KL, 1961, NEW ENGL J MED, V265, P885, DOI 10.1056/NEJM196111022651805; Zerhouni E, 2003, SCIENCE, V302, P63, DOI 10.1126/science.1091867; CLIN TRIALS NETWORKS	23	780	795	3	50	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 24	2007	297	4					403	406		10.1001/jama.297.4.403	http://dx.doi.org/10.1001/jama.297.4.403			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128GE	17244837				2022-12-28	WOS:000243645400027
J	Braiteh, F; Cohen, PR; Kurzrock, R				Braiteh, Fadi; Cohen, Philip R.; Kurzrock, Razelle			CAT scan reveals BAT sign	LANCET			English	Editorial Material									Univ Texas, MD Anderson Canc Ctr, Div Canc Med, Phase Program 1, Houston, TX 77030 USA; Univ Texas, Houston Med Sch, Dept Dermatol, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston	Braiteh, F (corresponding author), Univ Texas, MD Anderson Canc Ctr, Div Canc Med, Phase Program 1, 1515 Holcombe Blvd, Houston, TX 77030 USA.	fbraiteh@mdanderson.org	Kurzrock, Razelle/AAU-9782-2020					[Anonymous], 2005, GRAYS ANATOMY ANATOM, V39th; Rogers LF, 2003, AM J ROENTGENOL, V180, P1501, DOI 10.2214/ajr.180.6.1801501	2	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 20	2007	369	9557					217	217		10.1016/S0140-6736(07)60110-X	http://dx.doi.org/10.1016/S0140-6736(07)60110-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128XG	17240288				2022-12-28	WOS:000243692400030
J	Coombes, R				Coombes, Rebecca			The week in medicine - No quick fix for the NHS	BRITISH MEDICAL JOURNAL			English	Editorial Material												rcoombes@bmjgroup.com							0	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JAN 20	2007	334	7585					124	125		10.1136/bmj.39097.690428.59	http://dx.doi.org/10.1136/bmj.39097.690428.59			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	130LP	17235090	Green Published			2022-12-28	WOS:000243801400028
J	Wolfson, LJ; Strebel, PM; Gacic-Dobo, M; Hoekstra, EJ; McFarland, JW; Hersh, BS				Wolfson, Lara J.; Strebel, Peter M.; Gacic-Dobo, Marta; Hoekstra, Edward J.; McFarland, Jeffrey W.; Hersh, Bradley S.		Measles Initiative	Has the 2005 measles mortality reduction goal been achieved? A natural history modelling study	LANCET			English	Article							UPPER RIVER DIVISION; CHILD-MORTALITY; RESPIRATORY-INFECTIONS; VACCINATION CAMPAIGN; CASE-FATALITY; RURAL AREA; DEATHS; ERADICATION; COMMUNITY; OUTBREAK	Background In 2002, the UN General Assembly Special Session on Children adopted a goal to reduce deaths owing to measles by half by the end of 2005, compared with 1999 estimates. We describe efforts and progress made towards this goal. Methods We assessed trends in immunisation against measles on the basis of national implementation of the WHO/UNICEF comprehensive strategy for measles mortality reduction, and the provision of a second opportunity for measles immunisation. We used a natural history model to evaluate trends in mortality due to measles. Results Between 1999 and 2005, according to our model mortality owing to measles was reduced by 60%, from an estimated 873 000 deaths (uncertainty bounds 634000-1140 000) in 1999 to 345 000 deaths (247 000-458 000) in 2005. The largest percentage reduction in estimated measles mortality during this period was in the western Pacific region (81%), followed by Africa (75%) and the eastern Mediterranean region (62%). Africa achieved the largest total reduction, contributing 72% of the global reduction in measles mortality. Nearly 7.5 million deaths from measles were prevented through immunisation between 1999 and 2005, with supplemental immunisation activities and improved routine immunisation accounting for 2.3 million of these prevented deaths. Interpretation The achievement of the 2005 global measles mortality reduction goal is evidence of what can be accomplished for child survival in countries with high childhood mortality when safe, cost-effective, and affordable interventions are backed by country-level political commitment and an effective international partnership.	WHO, Initiat Vaccine Res, CH-1211 Geneva 27, Switzerland; WHO, Dept Immunisat Vaccines & Biol, CH-1211 Geneva 27, Switzerland; UNICEF, New York, NY USA; US Ctr Dis Control & Prevent, Phnom Penh, Cambodia	World Health Organization; World Health Organization; UNICEF	Wolfson, LJ (corresponding author), WHO, Initiat Vaccine Res, 20 Ave Appia, CH-1211 Geneva 27, Switzerland.	wolfsonl@who.int	Wolfson, Lara/AAC-1400-2019	Wolfson, Lara/0000-0002-6454-3368				ANDERSON R M, 1991; ANDERSON RM, 1983, J HYG-CAMBRIDGE, V90, P259, DOI 10.1017/S002217240002893X; ANDERSON RM, 1985, J HYG-CAMBRIDGE, V94, P365, DOI 10.1017/S002217240006160X; [Anonymous], 2004, Wkly Epidemiol Rec, V79, P130; Antunes JLF, 2002, B WORLD HEALTH ORGAN, V80, P391; ASSAAD F, 1983, REV INFECT DIS, V5, P452; ATKINSON WL, 1991, SEMIN PEDIATR INFECT, V2, P100; Awasthi Shally, 1996, Indian Journal of Pediatrics, V63, P363, DOI 10.1007/BF02751529; BAGENHOLM GC, 1989, ANN TROP PAEDIATR, V9, P75, DOI 10.1080/02724936.1989.11748602; BANG AT, 1990, LANCET, V336, P201, DOI 10.1016/0140-6736(90)91733-Q; Baqui AH, 1998, B WORLD HEALTH ORGAN, V76, P161; Baqui AH, 2001, ACTA PAEDIATR, V90, P682, DOI 10.1080/080352501750258775; BARCLAY AJG, 1987, BMJ-BRIT MED J, V294, P296; BARKIN RM, 1975, AM J EPIDEMIOL, V102, P341, DOI 10.1093/oxfordjournals.aje.a112170; BHATIA S, 1989, STUD FAMILY PLANN, V20, P136, DOI 10.2307/1966568; BHUIYA A, 1987, SOC SCI MED, V24, P439, DOI 10.1016/0277-9536(87)90217-6; Bilous J, 2006, LANCET, V367, P1464, DOI 10.1016/S0140-6736(06)68625-X; BLACK FL, 1959, J IMMUNOL, V83, P74; Brenzel L, 2006, DISEASE CONTROL PRIORITIES IN DEVELOPING COUNTRIES, 2ND EDITION, P389; Bryce J, 2005, LANCET, V365, P1147, DOI 10.1016/S0140-6736(05)71877-8; BURSTROM B, 1993, SCAND J INFECT DIS, V25, P763, DOI 10.3109/00365549309008576; CHEN RT, 1994, INT J EPIDEMIOL, V23, P185, DOI 10.1093/ije/23.1.185; CHOUDHARY S R, 1989, Indian Pediatrics, V26, P544; Christensen R., 1990, LOG LINEAR MODELS; CLEMENS JD, 1988, AM J EPIDEMIOL, V128, P1330, DOI 10.1093/oxfordjournals.aje.a115086; Clements C. J., 2004, GLOBAL EPIDEMIOLOGY; CUTTS FT, 1995, BIOLOGICALS, V23, P95; de Quadros CA, 2004, B WORLD HEALTH ORGAN, V82, P134; de Quadros CA, 2004, J INFECT DIS, V189, pS227, DOI 10.1086/377741; DEFRANCISCO A, 1993, ANN TROP PAEDIATR, V13, P345, DOI 10.1080/02724936.1993.11747669; degli Atti MLC, 2006, VACCINE, V24, P1332, DOI 10.1016/j.vaccine.2005.09.031; deQuadros CA, 1996, JAMA-J AM MED ASSOC, V275, P224, DOI 10.1001/jama.275.3.224; Dowdle W R, 1998, Bull World Health Organ, V76 Suppl 2, P22; EKANEM EE, 1994, TROP GEOGR MED, V46, P305; FAUVEAU V, 1991, INT J EPIDEMIOL, V20, P729, DOI 10.1093/ije/20.3.729; *GAVI, IFFIM PROGR OV; GESSNER BD, 1994, JAMA-J AM MED ASSOC, V272, P382, DOI 10.1001/jama.272.5.382; Gounder C, 1998, HEALTH POLICY PLANN, V13, P212, DOI 10.1093/heapol/13.3.212; Grabowsky M, 2005, TROP MED INT HEALTH, V10, P1151, DOI 10.1111/j.1365-3156.2005.01502.x; Hedrich AW, 1933, AM J HYG, V17, P613, DOI 10.1093/oxfordjournals.aje.a117929; Henao-Restrepo AM, 2003, J INFECT DIS, V187, pS15, DOI 10.1086/368273; HETHCOTE HW, 1995, MODELS INFECTIOUS HU, P215; HINMAN AR, 1982, REV INFECT DIS, V4, P933; Hirve S, 1997, Indian Pediatr, V34, P995; Hodges M, 1998, West Afr J Med, V17, P95; HOPKINS DR, 1982, LANCET, V1, P1396; Hussain A, 1999, TROP MED INT HEALTH, V4, P758, DOI 10.1046/j.1365-3156.1999.00485.x; Jaffar S, 1997, TROP MED INT HEALTH, V2, P28, DOI 10.1046/j.1365-3156.1997.d01-131.x; Kabir Z, 2002, J TROP PEDIATRICS, V48, P178, DOI 10.1093/tropej/48.3.178; Kadane JB, 1998, J ROY STAT SOC D-STA, V47, P3; Kahn K, 1999, TROP MED INT HEALTH, V4, P433, DOI 10.1046/j.1365-3156.1999.00415.x; KEJA K, 1988, World Health Statistics Quarterly, V41, P59; KHAN AJ, 1990, B WORLD HEALTH ORGAN, V68, P577; LANGMUIR AD, 1962, AM J DIS CHILD, V103, P224, DOI 10.1001/archpedi.1962.02080020236005; Lindsey J.K., 2000, APPL GEN LINEAR MODE; McCullagh P., 1989, GEN LINEAR MODELS, V2nd; *MEASL PARTN, 2005, MEASL INV CAS 2; Meissner HC, 2004, PEDIATRICS, V114, P1065, DOI 10.1542/peds.2004-0440; MIRZA NM, 1990, E AFR MED J, V67, P823; MOLBAK K, 1992, T ROY SOC TROP MED H, V86, P216, DOI 10.1016/0035-9203(92)90580-6; Morris SS, 2003, INT J EPIDEMIOL, V32, P1041, DOI 10.1093/ije/dyg241; Orenstein WA, 2000, AM J PUBLIC HEALTH, V90, P1521, DOI 10.2105/AJPH.90.10.1521; Otten M, 2005, LANCET, V366, P832, DOI 10.1016/S0140-6736(05)67216-9; *PAHO, 2005, SCI TECHN PUBL PAHO, V605; PANDEY MR, 1991, LANCET, V338, P993, DOI 10.1016/0140-6736(91)91847-N; Perry Robert T., 2004, Journal of Infectious Diseases, V189, pS4, DOI 10.1086/377712; PISON G, 1993, INT J EPIDEMIOL, V22, P72, DOI 10.1093/ije/22.1.72; PREBLUD SR, 1982, JAMA-J AM MED ASSOC, V247, P1134, DOI 10.1001/jama.247.8.1134; Reddaiah V. P., 1992, Indian Journal of Pediatrics, V59, P567, DOI 10.1007/BF02832992; ROSS DA, 1993, LANCET, V342, P7, DOI 10.1016/0140-6736(93)91879-Q; Samb B, 1997, AM J EPIDEMIOL, V145, P51, DOI 10.1093/oxfordjournals.aje.a009031; SHAMEBO D, 1991, J TROP PEDIATRICS, V37, P254, DOI 10.1093/tropej/37.5.254; Slutsker L, 1996, AM J TROP MED HYG, V55, P77, DOI 10.4269/ajtmh.1996.55.77; SMEDMAN L, 1986, ANN TROP PAEDIATR, V6, P67, DOI 10.1080/02724936.1986.11748414; SNYDER MJ, 1962, AM J DIS CHILD, V103, P250, DOI 10.1001/archpedi.1962.02080020262012; SPENCER H C, 1987, Annals of Tropical Medicine and Parasitology, V81, P36; SPIKA JS, 1989, ANN TROP PAEDIATR, V9, P33, DOI 10.1080/02724936.1989.11748592; Stein CE, 2003, J INFECT DIS, V187, pS8, DOI 10.1086/368114; Stittelaar Koert J, 2002, Expert Rev Vaccines, V1, P151, DOI 10.1586/14760584.1.2.151; Strebel P, 2003, J INFECT DIS, V187, pS1, DOI 10.1086/368226; SUTRISNA B, 1993, LANCET, V342, P787, DOI 10.1016/0140-6736(93)91545-W; UN, MILL DEV GOALS; UNICEF, 2002, WORLD FIT CHILDR; UNPD, 2005, WORLD POP PROSP 2004; VANDENBROECK J, 1993, LANCET, V341, P1491, DOI 10.1016/0140-6736(93)90632-Q; *WHO, 1974, HDB RES, V1, P1; *WHO, 2006, WKLY EPIDEMIOL REC, V81, P365; *WHO, 2003, 5220 WHO; *WHO, 2002, STAT WORLDS VACC IMM; *WHO, 2005, WHO VACC PREV DIS MO; *WHO UNICEF, 2005, GLOB IMM VIS STRAT; WHO (World Health Organization), 2004, WKLY EPIDEMIOL REC; World Health Organization, MEASL REP CAS; World Health Organization, WHO UNICEF EST NAT I; World Health Organization, 2005, WORLD HLTH REP 2005; World Health Organization United Nations Children's Fund, 2001, MEASL MORT RED REG E; Yameogo KR, 2005, INT J EPIDEMIOL, V34, P556, DOI 10.1093/ije/dyi001	98	180	189	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 20	2007	369	9557					191	200		10.1016/S0140-6736(07)60107-X	http://dx.doi.org/10.1016/S0140-6736(07)60107-X			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128XG	17240285				2022-12-28	WOS:000243692400027
J	Mason, MF; Norton, MI; Van Horn, JD; Wegner, DM; Grafton, ST; Macrae, CN				Mason, Malia F.; Norton, Michael I.; Van Horn, John D.; Wegner, Daniel M.; Grafton, Scott T.; Macrae, C. Neil			Wandering minds: The default network and stimulus-independent thought	SCIENCE			English	Article							BRAIN ACTIVITY; MEMORY; CONSCIOUSNESS; SELF; MODE; FMRI	Despite evidence pointing to a ubiquitous tendency of human minds to wander, little is known about the neural operations that support this core component of human cognition. Using both thought sampling and brain imaging, the current investigation demonstrated that mind-wandering is associated with activity in a default network of cortical regions that are active when the brain is "at rest." In addition, individuals' reports of the tendency of their minds to wander were correlated with activity in this network.	Dartmouth Coll, Dept Psychol & Brain Sci, Hanover, NH 03755 USA; Harvard Univ, Harvard Business Sch, Boston, MA 02163 USA; Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA; Univ Aberdeen, Sch Psychol, Aberdeen AB24 2UB, Scotland	Dartmouth College; Harvard University; Harvard University; University of Aberdeen	Mason, MF (corresponding author), Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.	malia@nmr.mgh.harvard.edu	Macrae, Neil/C-4761-2008; Kennedy, Kristen M/B-4699-2008	Kennedy, Kristen M/0000-0001-5373-9026; Van Horn, John Darrell/0000-0003-1537-0816	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH049127] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033504] Funding Source: NIH RePORTER; NIMH NIH HHS [MH49127] Funding Source: Medline; NINDS NIH HHS [R01 NS050614, R01 NS033504] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANTROBUS JS, 1966, PERCEPT MOTOR SKILL, V23, P399, DOI 10.2466/pms.1966.23.2.399; Buckner RL, 2005, J NEUROSCI, V25, P7709, DOI 10.1523/JNEUROSCI.2177-05.2005; Cabeza R, 2004, J COGNITIVE NEUROSCI, V16, P1583, DOI 10.1162/0898929042568578; Christoff K, 2004, CORTEX, V40, P623, DOI 10.1016/S0010-9452(08)70158-8; Craig AD, 2003, CURR OPIN NEUROBIOL, V13, P500, DOI 10.1016/S0959-4388(03)00090-4; Damasio A. R., 1983, NEUROPSYCHOLOGY HUMA, P85; Damasio AR, 2000, NAT NEUROSCI, V3, P1049, DOI 10.1038/79871; GIAMBRA LM, 1989, PSYCHOL AGING, V4, P136, DOI 10.1037/0882-7974.4.2.136; Gusnard DA, 2001, P NATL ACAD SCI USA, V98, P4259, DOI 10.1073/pnas.071043098; Gusnard DA, 2001, NAT REV NEUROSCI, V2, P685, DOI 10.1038/35094500; Kelley WM, 2002, J COGNITIVE NEUROSCI, V14, P785, DOI 10.1162/08989290260138672; Klinger E., 1971, STRUCTURE FUNCTIONS; Maguire EA, 2001, PHILOS T R SOC B, V356, P1441, DOI 10.1098/rstb.2001.0944; McGuire PK, 1996, NEUROREPORT, V7, P2095; McKiernan KA, 2003, J COGNITIVE NEUROSCI, V15, P394, DOI 10.1162/089892903321593117; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Schooler JW, 2004, THINKING AND SEEING, P203; Schooler JW, 2002, TRENDS COGN SCI, V6, P339, DOI 10.1016/S1364-6613(02)01949-6; SHIFFRIN RM, 1977, PSYCHOL REV, V84, P127, DOI 10.1037/0033-295X.84.2.127; Singer J. L., 1972, FUNCTION NATURE IMAG, P175; SINGER JL, 1962, INT J SOC PSYCHIATR, V8, P272, DOI 10.1177/002076406200800404; Singer JL., 1966, DAYDREAMING; Smallwood J, 2006, PSYCHOL BULL, V132, P946, DOI 10.1037/0033-2909.132.6.946; TEASDALE JD, 1995, MEM COGNITION, V23, P551, DOI 10.3758/BF03197257; TULVING E, 1985, CAN PSYCHOL, V26, P1, DOI 10.1037/h0080017; Vincent JL, 2006, J NEUROPHYSIOL, V96, P3517, DOI 10.1152/jn.00048.2006; Wegner DM, 1997, CARN S COGN, P295	27	1860	1898	6	358	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 19	2007	315	5810					393	395		10.1126/science.1131295	http://dx.doi.org/10.1126/science.1131295			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	126SI	17234951	Green Submitted, Green Accepted			2022-12-28	WOS:000243535400047
J	Lohse, N; Hansen, ABE; Pedersen, G; Kronborg, G; Gerstoft, J; Sorensen, HT; Vaeth, M; Obel, N				Lohse, Nicolai; Hansen, Ann-Brit Eg; Pedersen, Gitte; Kronborg, Gifte; Gerstoft, Jan; Sorensen, Henrik Toft; Vaeth, Michael; Obel, Niels			Survival of persons with and without HIV infection in Denmark, 1995-2005	ANNALS OF INTERNAL MEDICINE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; ALL-CAUSE MORTALITY; GENERAL-POPULATION; COHORT; INDIVIDUALS; DEMOGRAPHICS; EUROSIDA; DEATH; RISK	Background: The expected survival of HIV-infected patients is of major public health interest. Objective: To estimate survival time and age-specific mortality rates of an HIV-infected population compared with that of the general population. Design: Population-based cohort study. Setting: All HIV-infected persons receiving care in Denmark from 1995 to 2005. Patients: Each member of the nationwide Danish HIV Cohort Study was matched with as many as 99 persons from the general population according to sex, date of birth, and municipality of residence. Measurements: The authors computed Kaplan-Meier life tables with age as the time scale to estimate survival from age 25 years. Patients with HIV infection and corresponding persons from the general population were observed from the date of the patient's HIV diagnosis until death, emigration, or 1 May 2005. Results: 3990 HIV-infected patients and 379 872 persons from the general population were included in the study, yielding 22 744 (median, 5.8 y/person) and 2 689 287 (median, 8.4 years/person) person-years of observation. Three percent of participants were lost to follow-up. From age 25 years, the median survival was 19.9 years (95% CI, 18.5 to 21.3) among patients with HIV infection and 51.1 years (CI, 50.9 to 51.5) among the general population. For HIV-infected patients, survival increased to 32.5 years (CI, 29.4 to 34.7) during the 2000 to 2005 period. In the subgroup that excluded persons with known hepatitis C coinfection (16%), median survival was 38.9 years (CI, 35.4 to 40.1) during this same period. The relative mortality rates for patients with HIV infection compared with those for the general population decreased with increasing age, whereas the excess mortality rate increased with increasing age. Limitations: The observed mortality rates are assumed to apply beyond the current maximum observation time of 10 years. Conclusions: The estimated median survival is more than 35 years for a young person diagnosed with HIV infection in the late highly active antiretroviral therapy era. However, an ongoing effort is still needed to further reduce mortality rates for these persons compared with the general population.	Odense Univ Hosp, Dept Infect Dis, DK-5000 Odense C, Denmark; Univ So Denmark, Odense, Denmark; Aarhus Univ Hosp, DK-8000 Aarhus, Denmark; Univ Aarhus, Aarhus, Denmark; Hvidovre Univ Hosp, Hvidovre, Denmark; Rigshosp, DK-2100 Copenhagen, Denmark; Boston Univ, Boston, MA 02215 USA	University of Southern Denmark; Odense University Hospital; University of Southern Denmark; Aarhus University; Aarhus University; University of Copenhagen; Rigshospitalet; University of Copenhagen; Boston University	Lohse, N (corresponding author), Odense Univ Hosp, Dept Infect Dis, Sdr Blvd 29, DK-5000 Odense C, Denmark.	nl@dce.au.dk	Sorensen, Henrik Toft/Z-6181-2019; Kronborg, Gitte/E-4757-2010; Lohse, Nicolai/ABE-5884-2020; Hansen, Ann-Brit/ABA-1921-2020; Vaeth, Michael/T-6882-2017	Sorensen, Henrik Toft/0000-0003-4299-7040; Vaeth, Michael/0000-0002-0134-5006; Lohse, Nicolai/0000-0001-8403-8759; Hansen, Ann-Brit Eg/0000-0003-4228-3822				Braithwaite RS, 2005, AM J MED, V118, P890, DOI 10.1016/j.amjmed.2004.12.034; Christensen P B, 1998, Ugeskr Laeger, V160, P3529; Dorrucci M, 2005, AIDS, V19, P331; Frank L, 2000, SCIENCE, V287, P2398, DOI 10.1126/science.287.5462.2398; Galvan FH, 2002, J STUD ALCOHOL, V63, P179, DOI 10.15288/jsa.2002.63.179; Jaggy C, 2003, LANCET, V362, P877, DOI 10.1016/S0140-6736(03)14307-3; Jensen-Fangel S, 2004, AIDS, V18, P89, DOI 10.1097/00002030-200401020-00011; Jensen-Fangel S, 2001, SCAND J INFECT DIS, V33, P765, DOI 10.1080/003655401317074590; Keiser O, 2004, AIDS, V18, P1835, DOI 10.1097/00002030-200409030-00013; Laing SP, 1999, DIABETIC MED, V16, P459, DOI 10.1046/j.1464-5491.1999.00075.x; Lohse N, 2005, AIDS, V19, P815, DOI 10.1097/01.aids.0000168976.51843.9f; Lohse N, 2005, SCAND J INFECT DIS, V37, P338, DOI 10.1080/00365540510031692; Lohse N, 2004, SCAND J INFECT DIS, V36, P738, DOI 10.1080/00365540410020974a; Lundgren JD, 2002, J INFECT DIS, V185, P178, DOI 10.1086/338267; Mamary EM, 2002, AIDS PATIENT CARE ST, V16, P39, DOI 10.1089/108729102753429389; Mocroft A, 2003, LANCET, V362, P22, DOI 10.1016/S0140-6736(03)13802-0; *NAT CTR HLTH STAT, 2002, UN STAT LIF TABL; Press N, 2002, JAIDS-J ACQ IMM DEF, V31, pS112, DOI 10.1097/00126334-200212153-00005; Saves M, 2003, CLIN INFECT DIS, V37, P292, DOI 10.1086/375844; van Sighem A, 2005, JAIDS-J ACQ IMM DEF, V40, P212, DOI 10.1097/01.qai.0000165911.97085.d0; Zwahlen M, 2005, INT J EPIDEMIOL, V34, P130, DOI 10.1093/ije./dyh402	21	561	589	0	26	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 16	2007	146	2					87	95		10.7326/0003-4819-146-2-200701160-00003	http://dx.doi.org/10.7326/0003-4819-146-2-200701160-00003			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	131WF	17227932				2022-12-28	WOS:000243901000002
J	Spyridopoulos, I; Dimmeler, S				Spyridopoulos, Ioakim; Dimmeler, Stefanie			Can telomere length predict cardiovascular risk?	LANCET			English	Editorial Material							ENDOTHELIAL PROGENITOR CELLS; DISEASE		Univ Frankfurt, Dept Internal Med 3, D-60590 Frankfurt, Germany	Goethe University Frankfurt	Dimmeler, S (corresponding author), Univ Frankfurt, Dept Internal Med 3, D-60590 Frankfurt, Germany.	dimmeler@em.uni-frankfurt.de		Dimmeler, Stefanie/0000-0002-1045-2436; Spyridopoulos, Ioakim/0000-0002-2750-2444				Assmus B, 2003, CIRC RES, V92, P1049, DOI 10.1161/01.RES.0000070067.64040.7C; Blasco MA, 2005, NAT REV GENET, V6, P611, DOI 10.1038/nrg1656; Brouilette SW, 2007, LANCET, V369, P107, DOI 10.1016/S0140-6736(07)60071-3; Brummendorf TH, 2001, BLOOD, V97, P895, DOI 10.1182/blood.V97.4.895; Cawthon RM, 2003, LANCET, V361, P393, DOI 10.1016/S0140-6736(03)12384-7; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; Rufer N, 1999, J EXP MED, V190, P157, DOI 10.1084/jem.190.2.157; Schmidt-Lucke C, 2005, CIRCULATION, V111, P2981, DOI 10.1161/CIRCULATIONAHA.104.504340; Spyridopoulos I, 2004, CIRCULATION, V110, P3136, DOI 10.1161/01.CIR.0000142866.50300.EB; Valdes AM, 2005, LANCET, V366, P662, DOI 10.1016/S0140-6736(05)66630-5; Werner N, 2005, NEW ENGL J MED, V353, P999, DOI 10.1056/NEJMoa043814; Wong JMY, 2003, LANCET, V362, P983, DOI 10.1016/S0140-6736(03)14369-3	12	8	8	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 13	2007	369	9556					81	82		10.1016/S0140-6736(07)60042-7	http://dx.doi.org/10.1016/S0140-6736(07)60042-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	126TK	17223451				2022-12-28	WOS:000243538200004
J	Wallace, HAC; Marques-Kranc, F; Richardson, M; Luna-Crespo, F; Sharpe, JA; Hughes, J; Wood, WG; Higgs, DR; Smith, AJH				Wallace, Helen A. C.; Marques-Kranc, Fatima; Richardson, Melville; Luna-Crespo, Francisco; Sharpe, Jackie A.; Hughes, Jim; Wood, William G.; Higgs, Douglas R.; Smith, Andrew J. H.			Manipulating the mouse genome to engineer precise functional syntenic replacements with human sequence	CELL			English	Article							EMBRYONIC STEM-CELLS; BACTERIAL ARTIFICIAL CHROMOSOMES; GENE-EXPRESSION; ES CELLS; REGULATORY ELEMENTS; GLOBIN CLUSTER; RECOMBINATION; DNA; MICE; IDENTIFICATION	We have devised a strategy (called recombinase-mediated genomic replacement, RMGR) to allow the replacement of large segments (> 100 kb) of the mouse genome with the equivalent human syntenic region. The technique involves modifying a mouse ES cell chromosome and a human BAC by inserting heterotypic lox sites to flank the proposed exchange interval and then using Cre recombinase to achieve segmental exchange. We have demonstrated the feasibility of this approach by replacing the mouse alpha globin regulatory domain with the human syntenic region and generating homozygous mice that produce only human a globin chains. Furthermore, modified ES cells can be used iteratively for functional studies, and here, as an example, we have used RMGR to produce an accurate mouse model of human alpha thalassemia. RMGR has general applicability and will overcome limitations inherent in current transgenic technology when studying the expression of human genes and modeling human genetic diseases.	Univ Edinburgh, Inst Stem Cell Res, Edinburgh EH9 3JQ, Midlothian, Scotland; Univ Oxford, John Radcliffe Hosp, MRC, Weatherall Inst Mol Med,Mol Haematol Unit, Oxford OX3 9DS, England	University of Edinburgh; University of Oxford	Smith, AJH (corresponding author), Univ Edinburgh, Inst Stem Cell Res, Kings Bldg,W Mains Rd, Edinburgh EH9 3JQ, Midlothian, Scotland.	andrew.smith@ed.ac.uk		Higgs, Douglas/0000-0003-3579-8705	Medical Research Council [G0300058B] Funding Source: researchfish; MRC [MC_U137961145, MC_U137961144] Funding Source: UKRI; Medical Research Council [MC_U137961144, MC_U137961145] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Alami R, 2000, HUM MOL GENET, V9, P631, DOI 10.1093/hmg/9.4.631; Anguita E, 2004, EMBO J, V23, P2841, DOI 10.1038/sj.emboj.7600274; Anguita E, 2002, BLOOD, V100, P3450, DOI 10.1182/blood-2002-05-1409; Anguita E, 2001, P NATL ACAD SCI USA, V98, P12114, DOI 10.1073/pnas.201413098; Baer A, 2001, CURR OPIN BIOTECH, V12, P473, DOI 10.1016/S0958-1669(00)00248-2; Belteki G, 2003, NAT BIOTECHNOL, V21, P321, DOI 10.1038/nbt787; Bethke B, 1997, NUCLEIC ACIDS RES, V25, P2828, DOI 10.1093/nar/25.14.2828; Brown JM, 2006, J CELL BIOL, V172, P177, DOI 10.1083/jcb.200507073; COLLEDGE WH, 1995, NAT GENET, V10, P445, DOI 10.1038/ng0895-445; Copeland NG, 2001, NAT REV GENET, V2, P769, DOI 10.1038/35093556; De Gobbi M, 2006, SCIENCE, V312, P1215, DOI 10.1126/science.1126431; Engle SJ, 1996, HUM MOL GENET, V5, P1607, DOI 10.1093/hmg/5.10.1607; Flint J, 1997, NAT GENET, V15, P252, DOI 10.1038/ng0397-252; Flint J, 2001, HUM MOL GENET, V10, P371, DOI 10.1093/hmg/10.4.371; Garrick D, 2006, PLOS GENET, V2, P438, DOI 10.1371/journal.pgen.0020058; Higgs DR, 1998, SEMIN HEMATOL, V35, P93; Hughes JR, 2005, P NATL ACAD SCI USA, V102, P9830, DOI 10.1073/pnas.0503401102; Kaufman RM, 1999, BLOOD, V94, P3178, DOI 10.1182/blood.V94.9.3178.421k23_3178_3184; Kielman MF, 1996, GENOMICS, V32, P341, DOI 10.1006/geno.1996.0128; Kleinjan DA, 2005, AM J HUM GENET, V76, P8, DOI 10.1086/426833; Lee EC, 2001, GENOMICS, V73, P56, DOI 10.1006/geno.2000.6451; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; Muyrers JPP, 2001, TRENDS BIOCHEM SCI, V26, P325, DOI 10.1016/S0968-0004(00)01757-6; Nagy A., 2003, MANIPULATING MOUSE E; NICHOLS J, 1990, DEVELOPMENT, V110, P1341; PASZTY C, 1995, NAT GENET, V11, P33, DOI 10.1038/ng0995-33; Peterson KR, 1998, HUM MOL GENET, V7, P2079, DOI 10.1093/hmg/7.13.2079; Schaft J, 2001, GENESIS, V31, P6, DOI 10.1002/gene.1076; SCHLAKE T, 1994, BIOCHEMISTRY-US, V33, P12746, DOI 10.1021/bi00209a003; Shen W, 2005, MOL BIOTECHNOL, V31, P181, DOI 10.1385/MB:31:3:181; Smith AJH, 2002, ONCOGENE, V21, P4521, DOI 10.1038/sj.onc.1205530; SMITH AJH, 1995, NAT GENET, V9, P376, DOI 10.1038/ng0495-376; Testa G, 2003, NAT BIOTECHNOL, V21, P443, DOI 10.1038/nbt804; Valenzuela DM, 2003, NAT BIOTECHNOL, V21, P652, DOI 10.1038/nbt822; YAGI T, 1990, P NATL ACAD SCI USA, V87, P9918, DOI 10.1073/pnas.87.24.9918; Yang Y, 2003, NAT BIOTECHNOL, V21, P447, DOI 10.1038/nbt803; Yu YJ, 2001, NAT REV GENET, V2, P780, DOI 10.1038/35093564	37	120	151	0	15	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 12	2007	128	1					197	209		10.1016/j.cell.2006.11.044	http://dx.doi.org/10.1016/j.cell.2006.11.044			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	139GN	17218265	Bronze			2022-12-28	WOS:000244420400023
J	Yen, TJ				Yen, Tim J.			Polo delivers a PICH to the kinetochore	CELL			English	Editorial Material								In this issue, Baumann et al. (2007) identify a helicase PICH that localizes to "threads" that remain connected between sister kinetochores after they have separated in anaphase. These threads are thought to be catenated centromeric DNA. PICH contributes to the mitotic checkpoint by recruiting Mad2 to kinetochores and is proposed to regulate checkpoint signaling by monitoring tension at centromeres.	Fox Chase Canc Ctr, Philadelphia, PA 19083 USA	Fox Chase Cancer Center	Yen, TJ (corresponding author), Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19083 USA.	timothy.yen@fccc.edu		Yen, Tim/0000-0003-2159-0997				Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Chan GK, 2005, TRENDS CELL BIOL, V15, P589, DOI 10.1016/j.tcb.2005.09.010; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; Flaus A, 2006, NUCLEIC ACIDS RES, V34, P2887, DOI 10.1093/nar/gkl295; Gruber S, 2003, CELL, V112, P765, DOI 10.1016/S0092-8674(03)00162-4; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; Vagnarelli P, 2004, CHROMOSOMA, V113, P211, DOI 10.1007/s00412-004-0307-3	7	4	4	0	3	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 12	2007	128	1					20	21		10.1016/j.cell.2006.12.022	http://dx.doi.org/10.1016/j.cell.2006.12.022			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	139GN	17218250	Bronze			2022-12-28	WOS:000244420400008
J	Wilcken, B; Haas, M; Joy, P; Wiley, V; Chaplin, M; Black, C; Fletcher, J; McGill, J; Boneh, A				Wilcken, Bridget; Haas, Marion; Joy, Pamela; Wiley, Veronica; Chaplin, Meredyth; Black, Carly; Fletcher, Janice; McGill, Jim; Boneh, Avihu			Outcome of neonatal screening for medium-chain aryl-CoA dehydrogenase deficiency in Australia: a cohort study	LANCET			English	Article							TANDEM MASS-SPECTROMETRY; INBORN-ERRORS; CLINICAL SYMPTOMS; METABOLISM; MUTATION; IDENTIFICATION; POPULATION; EXPERIENCE; NEWBORNS	Background Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency is the disorder thought most to justify neonatal screening by tandem-mass spectrometry because, without screening, there seems to be substantial morbidity and mortality. Our aim was to assess the overall effectiveness of neonatal screening for MCAD deficiency in Australia. Methods We identified MCAD-deficient patients from a total population of 2495000 Australian neonates (810000 screened) born between April 1, 1994, and March 31, 2004. Those from a cohort of 1995000 (460000 screened) were followed up for at least 4 years, and we recorded number of deaths and severe episodes, medical and neuropsychological outcome, and hospital admissions within the screened and unscreened groups. Findings In cohorts aged at least 4 years there were 35 MCAD-deficient patients in those not screened (2.28 per 100 000 total population) and 24 in the screened population (5.2 per 100000). We estimated that patients with this disorder in the unscreened cohort remained undiagnosed. Before 4 years of age, three screened patients had an episode of severe decompensation (including one neonatal death) versus 23 unscreened patients (including five deaths). At the most conservative estimate, relative risk of an adverse event was 0.44 (95% CI 0.13-1.45). In the larger cohort the relative risk (screened vs unscreened) of an adverse event by age 2 years was 0.26 (95% CI 0.07-0.97), also a conservative estimate. 38 of 52 living patients had neuropsychological testing, with no suggestions of significant differences in general cognitive outcome between the groups. Interpretation Screening is effective in patients with MCAD deficiency since early diagnosis reduces deaths and severe adverse events in children up to the age of 4 years.	Childrens Hosp Westmead, Westmead, NSW 2145, Australia; Univ Sydney, Sydney, NSW 2006, Australia; Univ Technol Sydney, Ctr Hlth Econ Res & Evaluat, Sydney, NSW 2007, Australia; Womens & Childrens Hosp, Adelaide, SA, Australia; Royal Childrens Hosp, Brisbane, Qld, Australia; Univ Melbourne, Melbourne, Vic, Australia; Murdoch Childrens Res Inst, Genet Hlth Serv Victoria, Melbourne, Vic, Australia	University of Sydney; University of Sydney; University of Technology Sydney; Womens & Childrens Hospital Australia; Royal Children's Hospital Brisbane; University of Melbourne; Murdoch Children's Research Institute	Wilcken, B (corresponding author), Childrens Hosp Westmead, Locked Bag 4001, Westmead, NSW 2145, Australia.	bridgetw@chw.edu.au	Haas, Marion Ruth/H-2732-2017					Andresen BS, 2001, AM J HUM GENET, V68, P1408, DOI 10.1086/320602; Derks TGJ, 2006, J PEDIATR-US, V148, P665, DOI 10.1016/j.jpeds.2005.12.028; Dezateux C, 2003, EUR J PEDIATR, V162, pS25, DOI 10.1007/s00431-003-1346-0; Ensenauer R, 2005, GENET MED, V7, P339, DOI 10.1097/01.GIM.0000164548.54482.9D; Frazier DM, 2006, J INHERIT METAB DIS, V29, P76, DOI 10.1007/s10545-006-0228-9; Grosse SD, 2006, GENET MED, V8, P205, DOI 10.1097/01.gim.0000204472.25153.8d; IAFOLLA AK, 1994, J PEDIATR-US, V124, P409, DOI 10.1016/S0022-3476(94)70363-9; Maier EM, 2005, HUM MUTAT, V25, P443, DOI 10.1002/humu.20163; *MAT CHILD HLTH BU, 2005, NEWB SCREEN UN SCREE; MATSUBARA Y, 1991, LANCET, V338, P552, DOI 10.1016/0140-6736(91)91110-G; Nennstiel-Ratzel U, 2005, MOL GENET METAB, V85, P157, DOI 10.1016/j.ymgme.2004.12.010; Pandor A, 2004, HEALTH TECHNOL ASSES, V8, P1; Pollitt RI, 1997, HEALTH TECHNOL ASSES, V1, pi; Pollitt RJ, 1998, ARCH DIS CHILD, V79, P116, DOI 10.1136/adc.79.2.116; Pourfarzam M, 2001, LANCET, V358, P1063, DOI 10.1016/S0140-6736(01)06199-2; ROE CR, 2005, METABOLIC MOL BASES, P2297; Schulze A, 2003, PEDIATRICS, V111, P1399, DOI 10.1542/peds.111.6.1399; SEYMOUR CA, 2001, HEALTH TECHNOL ASSES, V1, P23; Sparrow S.S., 2005, VINELAND 2 ADAPTIVE; Tanaka K., 1992, Human Mutation, V1, P271, DOI 10.1002/humu.1380010402; TOUMA EH, 1992, ARCH DIS CHILD, V67, P142, DOI 10.1136/adc.67.1.142; Waddell L, 2006, MOL GENET METAB, V87, P32, DOI 10.1016/j.ymgme.2005.09.020; Waisbren SE, 2002, J INHERIT METAB DIS, V25, P599, DOI 10.1023/A:1022003726224; WILCKEN B, 1994, ARCH DIS CHILD, V70, P410, DOI 10.1136/adc.70.5.410; Wilcken B, 2003, NEW ENGL J MED, V348, P2304, DOI 10.1056/NEJMoa025225; Wiley V, 1999, ACTA PAEDIATR, V88, P48, DOI 10.1080/080352599750029376; Wilson CJ, 1999, ARCH DIS CHILD, V80, P459, DOI 10.1136/adc.80.5.459; Woodcock R. W., 2001, WOODCOCK JOHNSON; ZIADEH R, 1995, PEDIATR RES, V37, P675, DOI 10.1203/00006450-199505000-00021; Zytkovicz TH, 2001, CLIN CHEM, V47, P1945	30	117	120	1	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 6	2007	369	9555					37	42		10.1016/S0140-6736(07)60029-4	http://dx.doi.org/10.1016/S0140-6736(07)60029-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125AK	17208640				2022-12-28	WOS:000243413700027
J	Baroni, M; Thiemens, MH; Delmas, RJ; Savarino, J				Baroni, Melanie; Thiemens, Mark H.; Delmas, Robert J.; Savarino, Joel			Mass-independent sulfur isotopic compositions in stratospheric volcanic eruptions	SCIENCE			English	Article							ATMOSPHERIC SULFUR; FRACTIONATION; RECORDS; SNOW	The observed mass-independent sulfur isotopic composition (Delta S-33) of volcanic sulfate from the Agung ( March 1963) and Pinatubo ( June 1991) eruptions recorded in the Antarctic snow provides a mechanism for documenting stratospheric events. The sign of Delta S-33 changes over time from an initial positive component to a negative value. Delta S-33 is created during photochemical oxidation of sulfur dioxide to sulfuric acid on a monthly time scale, which indicates a fast process. The reproducibility of the results reveals that Delta S-33 is a reliable tracer to chemically identify atmospheric processes involved during stratospheric volcanism.	Univ Grenoble 1, CNRS, Lab Glaciol & Geophys Environm, F-38400 St Martin Dheres, France; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); University of California System; University of California San Diego	Savarino, J (corresponding author), Univ Grenoble 1, CNRS, Lab Glaciol & Geophys Environm, F-38400 St Martin Dheres, France.	jsavarino@lgge.obs.ujf-grenoble.fr	Savarino, Joel/H-9730-2012	Savarino, Joel/0000-0002-6708-9623				BEKKI S, 1994, J GEOPHYS RES-ATMOS, V99, P18861, DOI 10.1029/94JD00667; BLUTH GJS, 1993, NATURE, V366, P327, DOI 10.1038/366327a0; Burkholder JB, 1997, GEOPHYS RES LETT, V24, P3201, DOI 10.1029/97GL03255; Castellano E, 2005, J GEOPHYS RES-ATMOS, V110, DOI 10.1029/2004JD005259; CASTLEMAN AW, 1974, TELLUS, V26, P222, DOI 10.1111/j.2153-3490.1974.tb01970.x; CHUNG K, 1975, INT J CHEM KINET, V7, P161, DOI 10.1002/kin.550070202; COLEDAI J, 1999, ANN GLACIOL, V29, P99, DOI DOI 10.3189/172756499781821319; Doiron S. D., 1991, EOS T AGU, V72, P489, DOI [10.1029/90EO00354, DOI 10.1029/90EO00354]; Farquhar J, 2000, SCIENCE, V289, P756, DOI 10.1126/science.289.5480.756; Farquhar J, 2000, NATURE, V404, P50, DOI 10.1038/35003517; Farquhar J, 2003, EARTH PLANET SC LETT, V213, P1, DOI 10.1016/S0012-821X(03)00296-6; Farquhar J, 2001, J GEOPHYS RES-PLANET, V106, P32829, DOI 10.1029/2000JE001437; Legrand M, 1999, J GEOPHYS RES-ATMOS, V104, P1581, DOI 10.1029/1998JD100032; LEGRAND MR, 1984, ATMOS ENVIRON, V18, P1867, DOI 10.1016/0004-6981(84)90363-9; Leung FY, 2001, J PHYS CHEM A, V105, P8073, DOI 10.1021/jp011014+; Mojzsis SJ, 2003, GEOCHIM COSMOCHIM AC, V67, P1635, DOI 10.1016/S0016-7037(03)00059-0; Ohmoto H, 2006, NATURE, V442, P908, DOI 10.1038/nature05044; Ono S, 2003, EARTH PLANET SC LETT, V213, P15, DOI 10.1016/S0012-821X(03)00295-4; Patris N, 2000, J GEOPHYS RES-ATMOS, V105, P7071, DOI 10.1029/1999JD900974; Pavlov AA, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL022784; Pavlov AA, 2002, ASTROBIOLOGY, V2, P27, DOI 10.1089/153110702753621321; Romero AB, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2003JD003660; Savarino J, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL018134; Zielinski GA, 2000, QUATERNARY SCI REV, V19, P417, DOI 10.1016/S0277-3791(99)00073-6	24	112	114	5	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 5	2007	315	5808					84	87		10.1126/science.1131754	http://dx.doi.org/10.1126/science.1131754			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	122WU	17204647				2022-12-28	WOS:000243259100040
J	Hwang, HW; Wentzel, EA; Mendell, JT				Hwang, Hun-Way; Wentzel, Erik A.; Mendell, Joshua T.			A hexanucleotide element directs microRNA nuclear import	SCIENCE			English	Article							BIOGENESIS; TARGETS; SIRNAS; MIRNAS	MicroRNAs ( miRNAs) negatively regulate partially complementary target messenger RNAs. Target selection in animals is dictated primarily by sequences at the miRNA 5' end. We demonstrated that despite their small size, specific miRNAs contain additional sequence elements that control their posttranscriptional behavior, including their subcellular localization. We showed that human miR-29b, in contrast to other studied animal miRNAs, is predominantly localized to the nucleus. The distinctive hexanucleotide terminal motif of miR-29b acts as a transferable nuclear localization element that directs nuclear enrichment of miRNAs or small interfering RNAs to which it is attached. Our results indicate that miRNAs sharing common 5' sequences, considered to be largely redundant, might have distinct functions because of the influence of cis-acting regulatory motifs.	Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Program Human Genet & Mol Biol, Baltimore, MD 21205 USA	Johns Hopkins University	Mendell, JT (corresponding author), Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Program Human Genet & Mol Biol, Baltimore, MD 21205 USA.	jmendell@jhmi.edu		Hwang, Hun-Way/0000-0003-0522-1577				Abbott AL, 2005, DEV CELL, V9, P403, DOI 10.1016/j.devcel.2005.07.009; Brennecke J, 2005, PLOS BIOL, V3, P404, DOI 10.1371/journal.pbio.0030085; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Cullen BR, 2004, MOL CELL, V16, P861, DOI 10.1016/j.molcel.2004.12.002; Cummins JM, 2006, P NATL ACAD SCI USA, V103, P3687, DOI 10.1073/pnas.0511155103; Du TT, 2005, DEVELOPMENT, V132, P4645, DOI 10.1242/dev.02070; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Kim VN, 2005, NAT REV MOL CELL BIO, V6, P376, DOI 10.1038/nrm1644; Lai EC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-115; Leaman D, 2005, CELL, V121, P1097, DOI 10.1016/j.cell.2005.04.016; Lee Y, 2002, EMBO J, V21, P4663, DOI 10.1093/emboj/cdf476; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Meister G, 2004, MOL CELL, V15, P185, DOI 10.1016/j.molcel.2004.07.007; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Pauley KM, 2006, EMBO REP, V7, P904, DOI 10.1038/sj.embor.7400783; Valencia-Sanchez MA, 2006, GENE DEV, V20, P515, DOI 10.1101/gad.1399806	16	515	559	2	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 5	2007	315	5808					97	100		10.1126/science.1136235	http://dx.doi.org/10.1126/science.1136235			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	122WU	17204650				2022-12-28	WOS:000243259100044
J	Yancheva, G; Nowaczyk, NR; Mingram, J; Dulski, P; Schettler, G; Negendank, JFW; Liu, JQ; Sigman, DM; Peterson, LC; Haug, GH				Yancheva, Gergana; Nowaczyk, Norbert R.; Mingram, Jens; Dulski, Peter; Schettler, Georg; Negendank, Jorg F. W.; Liu, Jiaqi; Sigman, Daniel M.; Peterson, Larry C.; Haug, Gerald H.			Influence of the intertropical convergence zone on the East Asian monsoon	NATURE			English	Article							SOUTH CHINA SEA; HIGH-RESOLUTION; SURFACE TEMPERATURE; LAST DEGLACIATION; MILLENNIAL SCALE; LATE PLEISTOCENE; INDIAN MONSOON; CLIMATE-CHANGE; EL-NINO; HOLOCENE	The Asian - Australian monsoon is an important component of the Earth's climate system that influences the societal and economic activity of roughly half the world's population. The past strength of the rain-bearing East Asian summer monsoon can be reconstructed with archives such as cave deposits(1-3), but the winter monsoon has no such signature in the hydrological cycle and has thus proved difficult to reconstruct. Here we present high-resolution records of the magnetic properties and the titanium content of the sediments of Lake Huguang Maar in coastal southeast China over the past 16,000 years, which we use as proxies for the strength of the winter monsoon winds. We find evidence for stronger winter monsoon winds before the Bolling - Allerod warming, during the Younger Dryas episode and during the middle and late Holocene, when cave stalagmites suggest weaker summer monsoons(1-3). We conclude that this anticorrelation is best explained by migrations in the intertropical convergence zone. Similar migrations of the intertropical convergence zone have been observed in Central America for the period AD 700 to 900 (refs 4 - 6), suggesting global climatic changes at that time. From the coincidence in timing, we suggest that these migrations in the tropical rain belt could have contributed to the declines of both the Tang dynasty in China and the Classic Maya in Central America.	Geoforschungszentrum Potsdam, Sect 3 3, D-14473 Potsdam, Germany; Chinese Acad Sci, Inst Geol & Geophys, Beijing 100029, Peoples R China; Princeton Univ, Dept Geosci, Princeton, NJ 08544 USA; Univ Miami, Rosenstiel Sch Marine & Atmospher Sci, Miami, FL 33149 USA	Helmholtz Association; Helmholtz-Center Potsdam GFZ German Research Center for Geosciences; Chinese Academy of Sciences; Institute of Geology & Geophysics, CAS; Princeton University; University of Miami	Haug, GH (corresponding author), Geoforschungszentrum Potsdam, Sect 3 3, D-14473 Potsdam, Germany.	haug@gfz-potsdam.de	Sigman, Daniel M/A-2649-2008	Sigman, Daniel M/0000-0002-7923-1973				BLOEMENDAL J, 1992, J GEOPHYS RES-SOL EA, V97, P4361, DOI 10.1029/91JB03068; Cane MA, 2005, EARTH PLANET SC LETT, V230, P227, DOI 10.1016/j.epsl.2004.12.003; deMenocal PB, 2001, SCIENCE, V292, P667, DOI 10.1126/science.1059827; DIAMOND J, 2005, COLLAPSE; DING ZL, 1992, PALAEOGEOGR PALAEOCL, V94, P223; Dykoski CA, 2005, EARTH PLANET SC LETT, V233, P71, DOI 10.1016/j.epsl.2005.01.036; Elvin Blunden C., 1998, CULTURAL ATLAS CHINA; FAGAN BM, 2000, FLOODS FAMINES EMPER; Fleitmann D, 2003, SCIENCE, V300, P1737, DOI 10.1126/science.1083130; HASTENRATH S, 1993, J GEOPHYS RES-ATMOS, V98, P5093, DOI 10.1029/92JD02646; Haug GH, 2003, SCIENCE, V299, P1731, DOI 10.1126/science.1080444; Haug GH, 2001, SCIENCE, V293, P1304, DOI 10.1126/science.1059725; Heslop D, 1999, PHYS CHEM EARTH PT A, V24, P785, DOI 10.1016/S1464-1895(99)00115-5; Hodell DA, 2001, SCIENCE, V292, P1367, DOI 10.1126/science.1057759; Hughen KA, 1996, NATURE, V380, P51, DOI 10.1038/380051a0; Ivanochko TS, 2005, EARTH PLANET SC LETT, V235, P302, DOI 10.1016/j.epsl.2005.04.002; Koutavas A, 2002, SCIENCE, V297, P226, DOI 10.1126/science.1072376; Kumar KK, 1999, SCIENCE, V284, P2156, DOI 10.1126/science.284.5423.2156; Liu TS, 1998, ANNU REV EARTH PL SC, V26, P111, DOI 10.1146/annurev.earth.26.1.111; Mingram J, 2004, QUATERN INT, V122, P85, DOI 10.1016/j.quaint.2004.02.001; Oppo DW, 2005, GEOLOGY, V33, P785, DOI 10.1130/G21867.1; PORTER SC, 1995, NATURE, V375, P305, DOI 10.1038/375305a0; Sirocko F, 1996, SCIENCE, V272, P526, DOI 10.1126/science.272.5261.526; Thompson LG, 1997, SCIENCE, V276, P1821, DOI 10.1126/science.276.5320.1821; Wang B., 2006, ASIAN MONSOON, P1; Wang L, 1999, MAR GEOL, V156, P245, DOI 10.1016/S0025-3227(98)00182-0; Wang LJ, 1999, GEOPHYS RES LETT, V26, P2889, DOI 10.1029/1999GL900443; Wang XF, 2004, NATURE, V432, P740, DOI 10.1038/nature03067; Wang YJ, 2001, SCIENCE, V294, P2345, DOI 10.1126/science.1064618; Yuan DX, 2004, SCIENCE, V304, P575, DOI 10.1126/science.1091220	30	635	791	22	359	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 4	2007	445	7123					74	77		10.1038/nature05431	http://dx.doi.org/10.1038/nature05431			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	122KG	17203059	Green Submitted			2022-12-28	WOS:000243225100038
J	Arnold, DM; Dentali, F; Crowther, MA; Meyer, RM; Cook, RJ; Sigouin, C; Fraser, GA; Lim, W; Kelton, JG				Arnold, Donald M.; Dentali, Francesco; Crowther, Mark A.; Meyer, Ralph M.; Cook, Richard J.; Sigouin, Christopher; Fraser, Graeme A.; Lim, Wendy; Kelton, John G.			Systematic review: Efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura	ANNALS OF INTERNAL MEDICINE			English	Review							ANTI-CD20 MONOCLONAL-ANTIBODY; AUTOIMMUNE HEMOLYTIC-ANEMIA; B-CELL DEPLETION; ELDERLY-PATIENTS; IN-VITRO; COMPLEMENT; THERAPY; LYMPHOMA; CHILDREN; CD55	Background: Rituximab, a monoclonal anti-CD20 antibody, is increasingly used to treat idiopathic thrombocytopenic purpura (ITP). Purpose: To systematically review the literature on the efficacy and safety of rituximab for the treatment of adults with ITP. Data Sources: MEDLINE, EMBASE, the Cochrane Library, abstracts from the American Societies of Hematology and Clinical Oncology annual meetings, and bibliographies of relevant articles and reviews were searched in duplicate until April 2006. Study Selection: Descriptive and comparative studies in any language that met predefined inclusion criteria were eligible. Efficacy analysis was restricted to studies enrolling 5 or more patients. Data Extraction: Platelet count response, toxicities, dose, previous treatments, baseline platelet count, duration of ITP, study design, and sources of funding were extracted in duplicate. Data Synthesis: We identified 19 eligible reports on efficacy (313 patients) and 29 on safety (306 patients). Weighted means for complete response (platelet count > 150 x 10(9) cells/L) and overall response (platelet count > 50 x 10(9) cells/L) with rituximab were 43.6% (95% CI, 29.5% to 57.7%) and 62.5% (CI, 52.6% to 72.5%), respectively. Responses lasted from 2 to 48 months. Nearly all patients had received corticosteroids, and 53.8% had undergone splenectomy. Nine patients (2.9%) died. Limitations: There were no controlled studies, and no studies met all criteria for study quality. Reported deaths could not necessarily be attributed to rituximab. Overall, the number of rituximab-treated patients with ITP reported in the literature is small. Conclusions: Rituximab resulted in an overall platelet count response in 62.5% of adults with ITP. However, this finding derives from uncontrolled studies that also reported significant toxicities, including death in 2.9% of cases. These data suggest that providers should avoid indiscriminate use of rituximab and that randomized, controlled trials of rituximab for ITP are urgently needed.	McMaster Univ, Hlth Sci Ctr, Hamilton, ON L8N 3Z5, Canada; Juravinski Canc Ctr, Hamilton, ON, Canada; Insubria Univ, Varese, Italy; Natl Canc Inst Canada, Clin Trials Grp, Kingston, ON, Canada; Queens Univ, Kingston, ON K7L 3N6, Canada; Univ Waterloo, Waterloo, ON N2L 3G1, Canada	McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba; McMaster University; University of Insubria; Queens University - Canada; Canadian Cancer Trials Group; Queens University - Canada; University of Waterloo	Arnold, DM (corresponding author), McMaster Univ, Hlth Sci Ctr, Room 3N-43,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	arnold@mcmaster.ca		Arnold, Donald/0000-0003-0943-8853; Cook, Richard/0000-0002-1414-4908; Crowther, Mark/0000-0003-4986-4873				AHN ER, 2005, BLOOD, V106; Ahrens N, 2002, INFUS THER TRANSFUS, V29, P277; [Anonymous], NAT CANC I COMM TERM; Beck CE, 2005, J PEDIATR-US, V147, P521, DOI 10.1016/j.jpeds.2005.04.032; Braendstrup P, 2005, AM J HEMATOL, V78, P275, DOI 10.1002/ajh.20276; CASE DC, 2005, BLOOD, V106; Cines DB, 2005, BLOOD, V106, P2244, DOI 10.1182/blood-2004-12-4598; Cines DB, 2005, ANNU REV MED, V56, P425, DOI 10.1146/annurev.med.56.082103.104644; Cohen YC, 2000, ARCH INTERN MED, V160, P1630, DOI 10.1001/archinte.160.11.1630; Coiffier B, 2002, NEW ENGL J MED, V346, P235, DOI 10.1056/NEJMoa011795; Cook DJ, 1997, ANN INTERN MED, V126, P376, DOI 10.7326/0003-4819-126-5-199703010-00006; Cooper N, 2004, BRIT J HAEMATOL, V125, P232, DOI 10.1111/j.1365-2141.2004.04889.x; D'Arena G, 2003, LEUKEMIA LYMPHOMA, V44, P561, DOI 10.1080/1042819021000055020; Delgado J, 2002, HAEMATOLOGICA, V87, P215; Di Gaetano N, 2003, J IMMUNOL, V171, P1581, DOI 10.4049/jimmunol.171.3.1581; Edwards JCW, 2004, NEW ENGL J MED, V350, P2572, DOI 10.1056/NEJMoa032534; Feugier P, 2005, J CLIN ONCOL, V23, P4117, DOI 10.1200/JCO.2005.09.131; Garcia-Chavez J, 2005, BLOOD, V106, p81B; George JN, 2006, J CLIN APHERESIS, V21, P49, DOI 10.1002/jca.20091; George JN, 1996, BLOOD, V88, P3, DOI 10.1182/blood.V88.1.3.3; Giagounidis AAN, 2002, EUR J HAEMATOL, V69, P95, DOI 10.1034/j.1600-0609.2002.02686.x; Golay J, 2000, BLOOD, V95, P3900; Golay J, 2002, BRIT J HAEMATOL, V119, P923, DOI 10.1046/j.1365-2141.2002.03935.x; Golay J, 2001, BLOOD, V98, P3383, DOI 10.1182/blood.V98.12.3383; Grillo-Lopez AJ, 2002, SEMIN ONCOL, V29, P105, DOI 10.1053/sonc.2002.30145; Grossi A, 2000, BLOOD, V96, p253A; *ITP, 2006, ANN HEMATOL, V85, P400; JACOUB J, 2004, BLOOD, V104, P3950; Kimby E, 2005, CANCER TREAT REV, V31, P456, DOI 10.1016/j.ctrv.2005.05.007; Lalayanni Chrisavgi, 2004, Hematology, V9, P287, DOI 10.1080/10245330410001714248; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Leandro MJ, 2005, RHEUMATOLOGY, V44, P1542, DOI 10.1093/rheumatology/kei080; Lieb JV, 2003, BLOOD, V102, p83B; Maloney DG, 1997, J CLIN ONCOL, V15, P3266, DOI 10.1200/JCO.1997.15.10.3266; Maloney DG, 1997, BLOOD, V90, P2188; MOM B, 1999, BLOOD S, V94, pB82; Narang M, 2003, AM J HEMATOL, V74, P263, DOI 10.1002/ajh.10413; Narat S, 2005, HAEMATOLOGICA, V90, P1273; Perotta A, 1999, BLOOD, V94, p14A; Portielje JEA, 2001, BLOOD, V97, P2549, DOI 10.1182/blood.V97.9.2549; Riksen NP, 2003, NETH J MED, V61, P262; Rosenthal E, 2001, BLOOD, V98, p525A; Saleh MN, 2000, SEMIN ONCOL, V27, P99; Sanal SM, 2004, BLOOD, V104, p75B, DOI 10.1182/blood.V104.11.3956.3956; Serratrice CD, 2002, REV MED INTERNE, V23, P869, DOI 10.1016/S0248-8663(02)00700-2; Shanafelt TD, 2003, MAYO CLIN PROC, V78, P1340, DOI 10.4065/78.11.1340; Slim K, 2003, ANZ J SURG, V73, P712, DOI 10.1046/j.1445-2197.2003.02748.x; STASI R, 1995, AM J MED, V98, P436, DOI 10.1016/S0002-9343(99)80342-8; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Swords R, 2004, AM J HEMATOL, V77, P103, DOI 10.1002/ajh.20135; Thude H, 2004, ACTA HAEMATOL-BASEL, V111, P221, DOI 10.1159/000077570; Wang J, 2005, J PEDIATR-US, V146, P217, DOI 10.1016/j.jpeds.2004.09.004; Zaja F, 2003, HAEMATOLOGICA, V88, P538; Zaja FF, 2005, BLOOD, V106, p77B; ZAJA FF, 2001, BLOOD, V98, pB41; Zalzaleh G, 2004, BLOOD, V104, p69B, DOI 10.1182/blood.V104.11.3930.3930; Zhou Nong, 2005, Zhonghua Yi Xue Za Zhi, V85, P432	57	386	419	0	31	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 2	2007	146	1					25	W5		10.7326/0003-4819-146-1-200701020-00006	http://dx.doi.org/10.7326/0003-4819-146-1-200701020-00006			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188BK	17200219				2022-12-28	WOS:000247893300004
J	Pasrija, S; Sharma, N				Pasrija, Shikha; Sharma, Nayantara			Images in clinical medicine: Benign diffuse breast hyperplasia during pregnancy	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Tagore Garden, New Delhi 110027, India		Pasrija, S (corresponding author), Tagore Garden, New Delhi 110027, India.	shikhapasrija@hotmail.com							0	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 28	2006	355	26					2771	2771		10.1056/NEJMicm040539	http://dx.doi.org/10.1056/NEJMicm040539			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	120UA	17192543				2022-12-28	WOS:000243110500010
J	Yang, YX; Lewis, JD; Epstein, S; Metz, DC				Yang, Yu-Xiao; Lewis, James D.; Epstein, Solomon; Metz, David C.			Long-term proton pump inhibitor therapy and risk of hip fracture	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							L-LACTIC ACID; ORAL CORTICOSTEROIDS; CALCIUM-ABSORPTION; BONE-RESORPTION; K+-ATPASE; OMEPRAZOLE; OSTEOPOROSIS; POPULATION; H+; CARBONATE	Context Proton pump inhibitors (PPIs) may interfere with calcium absorption through induction of hypochlorhydria but they also may reduce bone resorption through inhibition of osteoclastic vacuolar proton pumps. Objective To determine the association between PPI therapy and risk of hip fracture. Design, Setting, and Patients A nested case-control study was conducted using the General Practice Research Database (1987-2003), which contains information on patients in the United Kingdom. The study cohort consisted of users of PPI therapy and nonusers of acid suppression drugs who were older than 50 years. Cases included all patients with an incident hip fracture. Controls were selected using incidence density sampling, matched for sex, index date, year of birth, and both calendar period and duration of up-to-standard follow-up before the index date. For comparison purposes, a similar nested case-control analysis for histamine 2 receptor antagonists was performed. Main Outcome Measure The risk of hip fractures associated with PPI use. Results There were 13 556 hip fracture cases and 135 386 controls. The adjusted odds ratio (AOR) for hip fracture associated with more than 1 year of PPI therapy was 1.44 (95% confidence interval [CI], 1.30-1.59). The risk of hip fracture was significantly increased among patients prescribed long-term high-dose PPIs ( AOR, 2.65; 95% CI, 1.80-3.90; P <. 001). The strength of the association increased with increasing duration of PPI therapy ( AOR for 1 year, 1.22 [ 95% CI, 1.15-1.30]; 2 years, 1.41 [ 95% CI, 1.28-1.56]; 3 years, 1.54 [ 95% CI, 1.37-1.73]; and 4 years, 1.59 [ 95% CI, 1.39-1.80]; P <. 001 for all comparisons). Conclusion Long-term PPI therapy, particularly at high doses, is associated with an increased risk of hip fracture.	Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Div Gastroenterol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Div Endocrinol, Philadelphia, PA 19104 USA; Doylestown Hosp Res Ctr, Dept Med, Doylestown, PA USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Yang, YX (corresponding author), Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, 722 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.	yangy@mail.med.upenn.edu	yang, yx/GZM-0464-2022		NIDDK NIH HHS [K08 DK062978] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK062978] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOLINN GW, 1984, J CLIN INVEST, V73, P640, DOI 10.1172/JCI111254; Chonan O, 1998, J NUTR SCI VITAMINOL, V44, P473, DOI 10.3177/jnsv.44.473; Chonan O, 1998, J NUTR SCI VITAMINOL, V44, P869, DOI 10.3177/jnsv.44.869; CHRISCHILLES EA, 1991, ARCH INTERN MED, V151, P2026, DOI 10.1001/archinte.151.10.2026; Cumming RG, 1997, EPIDEMIOL REV, V19, P244, DOI 10.1093/oxfordjournals.epirev.a017956; Dawson-Hughes B, 2002, OSTEOPOROSIS INT, V13, P657, DOI 10.1007/s001980200089; DONALDSON LJ, 1990, J EPIDEMIOL COMMUN H, V44, P241, DOI 10.1136/jech.44.3.241; Farina C, 2002, CURR PHARM DESIGN, V8, P2033, DOI 10.2174/1381612023393369; GOERSS JB, 1992, J BONE MINER RES, V7, P573; Hollowell J, 1997, Popul Trends, P36; IVANOVIC.P, 1967, ANN INTERN MED, V66, P917, DOI 10.7326/0003-4819-66-5-917; Jacobson BC, 2003, AM J GASTROENTEROL, V98, P51, DOI 10.1111/j.1572-0241.2003.07186.x; Johansson S, 2003, ALIMENT PHARM THER, V18, P973, DOI 10.1046/j.1365-2036.2003.01798.x; LANDAHL S, 1992, CLIN PHARMACOKINET, V23, P469, DOI 10.2165/00003088-199223060-00006; Leibson CL, 2002, J AM GERIATR SOC, V50, P1644, DOI 10.1046/j.1532-5415.2002.50455.x; Lewis JD, 2005, PHARMACOEPIDEM DR S, V14, P443, DOI 10.1002/pds.1115; LUBIN JH, 1984, BIOMETRICS, V40, P63, DOI 10.2307/2530744; MARSHALL BJ, 1994, AM J GASTROENTEROL, V89, pS116; MIZUNASHI K, 1993, CALCIFIED TISSUE INT, V53, P21, DOI 10.1007/BF01352010; NILAS L, 1985, GUT, V26, P252, DOI 10.1136/gut.26.3.252; Nordin BEC, 1997, NUTRITION, V13, P664, DOI 10.1016/S0899-9007(97)00136-6; O'Connell MB, 2005, AM J MED, V118, P778, DOI 10.1016/j.amjmed.2005.02.007; *OFF NAT STAT, 1996, STUD MED POP SUBJ, V60; Perry J, 1978, OXMIS PROBLEM CODES; RECKER RR, 1985, NEW ENGL J MED, V313, P70, DOI 10.1056/NEJM198507113130202; RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605; Schoofs MWCJ, 2003, ANN INTERN MED, V139, P476, DOI 10.7326/0003-4819-139-6-200309160-00010; SERFATYLACROSNIERE C, 1995, J AM COLL NUTR, V14, P364; SHEIKH MS, 1987, NEW ENGL J MED, V317, P532, DOI 10.1056/NEJM198708273170903; Shin JM, 2004, J AM CHEM SOC, V126, P7800, DOI 10.1021/ja049607w; TUUKKANEN J, 1986, CALCIFIED TISSUE INT, V38, P123, DOI 10.1007/BF02556841; Van Staa TP, 2000, J BONE MINER RES, V15, P993, DOI 10.1359/jbmr.2000.15.6.993; Van Staa TP, 2000, PHARMACOEPIDEM DR S, V9, P359, DOI 10.1002/1099-1557(200009/10)9:5<359::AID-PDS507>3.0.CO;2-E; van Staa TP, 2001, JAMA-J AM MED ASSOC, V285, P1850, DOI 10.1001/jama.285.14.1850; Vestergaard P, 2006, CALCIFIED TISSUE INT, V79, P76, DOI 10.1007/s00223-006-0021-7; ZAIDI M, 1990, BIOSCIENCE REP, V10, P547, DOI 10.1007/BF01116615	37	833	886	1	37	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	2006	296	24					2947	2953		10.1001/jama.296.24.2947	http://dx.doi.org/10.1001/jama.296.24.2947			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	120FD	17190895	Bronze			2022-12-28	WOS:000243069000026
J	Combs, CD				Combs, C. Donald			Startling technologies promise to transform medicine	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Eastern Virginia Med Sch, Dept Planning & Hlth Profess, Norfolk, VA 23505 USA	Eastern Virginia Medical School	Combs, CD (corresponding author), Eastern Virginia Med Sch, Dept Planning & Hlth Profess, POB 1980, Norfolk, VA 23505 USA.	combscd@evms.edu						ATALA A, 2005, 2 C STRAT ENG NEGL S; *BETH ISR DEAC MED, 2002, NEW RAD WAV TREATM C; CARROLL FA, 2006, DAILY PRESS     0413, pA1; COMBS CD, 2006, OUR NATION TODAY 202; DAVIS J, 2006, WIRED, V11, P40; Drake RR, 2005, EXPERT REV PROTEOMIC, V2, P203, DOI 10.1586/14789450.2.2.203; Gallagher AG, 2004, JAMA-J AM MED ASSOC, V292, P3024, DOI 10.1001/jama.292.24.3024; GORSS J, 2003, EUREKALERT      0210; GRENDA E, 2005, MED APPL RAPID PROTO; *INTOUCH TECHN, VIRT TECHN; KOLB JF, 2006, NUCL PLASMA SCI SOC, V3, P30; L'Heureux N, 2006, NAT MED, V12, P361, DOI 10.1038/nm1364; Lymberis A, 2003, TELEMED J E-HEALTH, V9, P379, DOI 10.1089/153056203772744716; *MCG I REG MED, I COLL NAT TISS ENG; *NAN, 1974, MIT MAT STOPS BLEED; SCHMIDT EA, 2006, HUMAN FACTORS ERGONO, P2697; *STER, STER MAD EAS WHAT IS; Toffler A., 1980, 3 WAVE; 2006, MED NEWS TODAY  1015	19	6	8	1	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 23	2006	333	7582					1308	1311		10.1136/bmj.39049.453877.BE	http://dx.doi.org/10.1136/bmj.39049.453877.BE			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121MC	17185719	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000243160700017
J	Pennington, DJ; Silva-Santos, B; Silberzahn, T; Escorcio-Correia, M; Woodward, MJ; Roberts, SJ; Smith, AL; Dyson, PJ; Hayday, AC				Pennington, Daniel J.; Silva-Santos, Bruno; Silberzahn, Tobias; Escorcio-Correia, Monica; Woodward, Martin J.; Roberts, Scott J.; Smith, Adrian L.; Dyson, P. Julian; Hayday, Adrian C.			Early events in the thymus affect the balance of effector and regulatory T cells	NATURE			English	Article							TRANSCRIPTION FACTOR FOXP3; ALPHA-BETA; ANTIGEN 4; TOLERANCE; LINEAGE; GENE; INFLAMMATION; PROGENITORS; ENRICHMENT; SELECTION	In cellular immunology the critical balance between effector and regulatory mechanisms is highlighted by serious immunopathologies attributable to mutations in Foxp3, a transcription factor required for a major subset of regulatory T (T(R)) cells(1-3). Thus, many studies have focused on the developmental origin of T(R) cells, with the prevailing view that they emerge in the thymus from late-stage T-cell progenitors whose T-cell receptors (TCRs) engage high affinity (agonist) ligands(4-6). This study questions the completeness of that interpretation. Here we show that without any obvious effect on TCR-mediated selection, the normal differentiation of mouse gamma delta T cells into potent cytolytic and interferon-gamma-secreting effector cells is switched towards an aggregate regulatory phenotype by limiting the capacity of CD4(+) CD8(+) T-cell progenitors to influence in trans early gamma delta cell progenitors. Unexpectedly, we found that the propensity of early TCR-alpha beta(+) progenitors to differentiate into Foxp3 1 T(R) cells is also regulated in trans by CD4(+) CD8(+) T-cell progenitor cells, before agonist selection.	Guys Hosp, Kings Coll London Sch Med, Peter Gorer Dept Immunobiol, London SE1 9RT, England; Queen Mary Coll, London & Barts Sch Med & Dent, Inst Cell & Mol Sci, London E1 2AT, England; Fac Med Lisbon, Inst Mol Med, P-1649028 Lisbon, Portugal; Inst Child Hlth, Mol Haematol & Canc Biol Unit, Camelia Botnar Labs, London WC1N 1EH, England; Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06510 USA; Inst Anim Hlth, Compton Lab, Newbury RG20 7NN, Berks, England; Hammersmith Hosp, Imperial Coll, Div Med, London W12 0HS, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of London; Queen Mary University London; Universidade de Lisboa; University of London; University College London; Yale University; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute; Imperial College London	Pennington, DJ (corresponding author), Guys Hosp, Kings Coll London Sch Med, Peter Gorer Dept Immunobiol, London SE1 9RT, England.	d.pennington@qmul.ac.uk; adrian.hayday@kcl.ac.uk	England, Philip C/A-1920-2010	England, Philip C/0000-0002-9024-8901; Smith, Adrian/0000-0002-7657-6191; Silva-Santos, Bruno/0000-0003-4141-9302; HAYDAY, ADRIAN/0000-0002-9495-5793; Escorcio Correia Wang, Monica/0000-0002-9205-1993; Pennington, Daniel/0000-0001-7889-9923	Biotechnology and Biological Sciences Research Council [BBS/E/I/00001048, BBS/E/I/00001160] Funding Source: Medline; Wellcome Trust [071534] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission)		Aluvihare VR, 2004, NAT IMMUNOL, V5, P266, DOI 10.1038/ni1037; Apostolou I, 2002, NAT IMMUNOL, V3, P756, DOI 10.1038/ni816; Bosco N, 2006, J IMMUNOL, V177, P5014, DOI 10.4049/jimmunol.177.8.5014; Buer J, 1997, J EXP MED, V185, P1541, DOI 10.1084/jem.185.9.1541; Carter JD, 2005, J IMMUNOL, V174, P6627, DOI 10.4049/jimmunol.174.11.6627; FEHLING HJ, 1995, NATURE, V375, P795, DOI 10.1038/375795a0; Fontenot JD, 2005, NAT IMMUNOL, V6, P1142, DOI 10.1038/ni1263; Fontenot JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; Futterer A, 1998, IMMUNITY, V9, P59, DOI 10.1016/S1074-7613(00)80588-9; Gibbons D, 2001, J EXP MED, V194, P695, DOI 10.1084/jem.194.5.695; Girardi M, 2002, J EXP MED, V195, P855, DOI 10.1084/jem.20012000; HAVRAN WL, 1990, NATURE, V344, P68, DOI 10.1038/344068a0; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Jordan MS, 2001, NAT IMMUNOL, V2, P301, DOI 10.1038/86302; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; Lerman MA, 2004, J IMMUNOL, V173, P236, DOI 10.4049/jimmunol.173.1.236; Livak F, 1997, EUR J IMMUNOL, V27, P2948, DOI 10.1002/eji.1830271130; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; Passoni L, 1997, IMMUNITY, V7, P83, DOI 10.1016/S1074-7613(00)80512-9; PHILPOTT KL, 1992, SCIENCE, V256, P1448, DOI 10.1126/science.1604321; Prockop SE, 2004, J IMMUNOL, V173, P1604, DOI 10.4049/jimmunol.173.3.1604; Read S, 2000, J EXP MED, V192, P295, DOI 10.1084/jem.192.2.295; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Silva-Santos B, 2005, SCIENCE, V307, P925, DOI 10.1126/science.1103978; Suri-Payer E, 1998, J IMMUNOL, V160, P1212; Takahashi T, 2000, J EXP MED, V192, P303, DOI 10.1084/jem.192.2.303; van Santen HM, 2004, J EXP MED, V200, P1221, DOI 10.1084/jem.20041022; WISE E, UNPUB J IMMUNOL; Zelenika D, 2002, J IMMUNOL, V168, P1069, DOI 10.4049/jimmunol.168.3.1069	30	84	86	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 21	2006	444	7122					1073	1077		10.1038/nature06051	http://dx.doi.org/10.1038/nature06051			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	118VH	17190001				2022-12-28	WOS:000242971100057
J	Frey, BJ; Dueck, D				Frey, Brendan J.; Dueck, Delbert			Clustering by passing messages between data points	SCIENCE			English	Article								Clustering data by identifying a subset of representative examples is important for processing sensory signals and detecting patterns in data. Such "exemplars" can be found by randomly choosing an initial subset of data points and then iteratively refining it, but this works well only if that initial choice is close to a good solution. We devised a method called "affinity propagation," which takes as input measures of similarity between pairs of data points. Real-valued messages are exchanged between data points until a high-quality set of exemplars and corresponding clusters gradually emerges. We used affinity propagation to cluster images of faces, detect genes in microarray data, identify representative sentences in this manuscript, and identify cities that are efficiently accessed by airline travel. Affinity propagation found clusters with much lower error than other methods, and it did so in less than one-hundredth the amount of time.	Univ Toronto, Dept Elect & Comp Engn, Toronto, ON M5S 3G4, Canada	University of Toronto	Frey, BJ (corresponding author), Univ Toronto, Dept Elect & Comp Engn, 10 Kings Coll Rd, Toronto, ON M5S 3G4, Canada.	frey@psi.toronto.edu						Charikar M, 2002, J COMPUT SYST SCI, V65, P129, DOI 10.1006/jcss.2002.1882; Dasgupta S., 2000, P 16 C UNC ART INT, P152; DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1, DOI 10.1111/j.2517-6161.1977.tb01600.x; Frey BJ, 2005, NAT GENET, V37, P991, DOI 10.1038/ng1630; FREY BJ, 2002, P 14 C NIPS, P737; HOPFIELD JJ, 1982, P NATL ACAD SCI-BIOL, V79, P2554, DOI 10.1073/pnas.79.8.2554; Jain S, 2004, J COMPUT GRAPH STAT, V13, P158, DOI 10.1198/1061860043001; MacKay DJC, 1999, IEEE T INFORM THEORY, V45, P399, DOI 10.1109/18.748992; MacQueen J., 1967, P 5 BERK S MATH STAT, V1, P281, DOI DOI 10.1007/S11665-016-2173-6; Manning C, 1999, FDN STAT NATURAL LAN; Meltzer T, 2005, IEEE I CONF COMP VIS, P428; Mezard M, 2003, SCIENCE, V301, P1685, DOI 10.1126/science.1086309; Mezard M, 2002, SCIENCE, V297, P812, DOI 10.1126/science.1073287; Pearl J., 1988, PROBABILISTIC REASON, DOI 10.1016/B978-0-08-051489-5.50008-4; Pruitt KD, 2003, NUCLEIC ACIDS RES, V31, P34, DOI 10.1093/nar/gkg111; Shi JB, 2000, IEEE T PATTERN ANAL, V22, P888, DOI 10.1109/34.868688; SOKAL RR, 1958, U KANSAS SCI B, V38, P1409; VEDIDIA JS, 2005, IEEE T INFORM THEORY, V51, P2282	19	3895	4309	48	628	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 16	2007	315	5814					972	976		10.1126/science.1136800	http://dx.doi.org/10.1126/science.1136800			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	136MW	17218491	Bronze			2022-12-28	WOS:000244229800037
J	Macpherson, LJ; Dubin, AE; Evans, MJ; Marr, F; Schultz, PG; Cravatt, BF; Patapoutian, A				Macpherson, Lindsey J.; Dubin, Adrienne E.; Evans, Michael J.; Marr, Felix; Schultz, Peter G.; Cravatt, Benjamin F.; Patapoutian, Ardem			Noxious compounds activate TRPA1 ion channels through covalent modification of cysteines	NATURE			English	Article							CLICK CHEMISTRY; S-NITROSYLATION; COLD; KEAP1; PROTEIN; ELECTROPHILE; NOCICEPTION; REACTIVITY; SENSATION; INDUCERS	The nervous system senses peripheral damage through nociceptive neurons that transmit a pain signal(1,2). TRPA1 is a member of the Transient Receptor Potential (TRP) family of ion channels and is expressed in nociceptive neurons(3-5). TRPA1 is activated by a variety of noxious stimuli, including cold temperatures, pungent natural compounds, and environmental irritants(6-11). How such diverse stimuli activate TRPA1 is not known. We observed that most compounds known to activate TRPA1 are able to covalently bind cysteine residues. Here we use click chemistry to show that derivatives of two such compounds, mustard oil and cinnamaldehyde, covalently bind mouse TRPA1. Structurally unrelated cysteine-modifying agents such as iodoacetamide (IA) and (2-aminoethyl) methanethiosulphonate ( MTSEA) also bind and activate TRPA1. We identified by mass spectrometry fourteen cytosolic TRPA1 cysteines labelled by IA, three of which are required for normal channel function. In excised patches, reactive compounds activated TRPA1 currents that were maintained at least 10 min after washout of the compound in calcium-free solutions. Finally, activation of TRPA1 by disulphide-bond-forming MTSEA is blocked by the reducing agent dithiothreitol (DTT). Collectively, our data indicate that covalent modification of reactive cysteines within TRPA1 can cause channel activation, rapidly signalling potential tissue damage through the pain pathway.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; Novartis	Patapoutian, A (corresponding author), Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA.	ardem@scripps.edu		Macpherson, Lindsey/0000-0002-1089-3733				Bandell M, 2004, NEURON, V41, P849, DOI 10.1016/S0896-6273(04)00150-3; Bautista DM, 2006, CELL, V124, P1269, DOI 10.1016/j.cell.2006.02.023; Brauchi S, 2004, P NATL ACAD SCI USA, V101, P15494, DOI 10.1073/pnas.0406773101; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Dhaka A, 2006, ANNU REV NEUROSCI, V29, P135, DOI 10.1146/annurev.neuro.29.051605.112958; Dinkova-Kostova AT, 2001, P NATL ACAD SCI USA, V98, P3404, DOI 10.1073/pnas.051632198; Dinkova-Kostova AT, 2005, CHEM RES TOXICOL, V18, P1779, DOI 10.1021/tx050217c; Eggler AL, 2005, P NATL ACAD SCI USA, V102, P10070, DOI 10.1073/pnas.0502402102; Evans MJ, 2005, NAT BIOTECHNOL, V23, P1303, DOI 10.1038/nbt1149; Fearon IM, 1999, J PHYSIOL-LONDON, V514, P629, DOI 10.1111/j.1469-7793.1999.629ad.x; Getz EB, 1999, ANAL BIOCHEM, V273, P73, DOI 10.1006/abio.1999.4203; GRABAREK Z, 1990, ANAL BIOCHEM, V185, P131, DOI 10.1016/0003-2697(90)90267-D; Hess DT, 2005, NAT REV MOL CELL BIO, V6, P150, DOI 10.1038/nrm1569; Hinman A, 2006, P NATL ACAD SCI USA, V103, P19564, DOI 10.1073/pnas.0609598103; Hong F, 2005, CHEM RES TOXICOL, V18, P1917, DOI 10.1021/tx0502138; Jordt SE, 2004, NATURE, V427, P260, DOI 10.1038/nature02282; Julius D, 2001, NATURE, V413, P203, DOI 10.1038/35093019; Kolb HC, 2001, ANGEW CHEM INT EDIT, V40, P2004, DOI 10.1002/1521-3773(20010601)40:11<2004::AID-ANIE2004>3.3.CO;2-X; Kwan KY, 2006, NEURON, V50, P277, DOI 10.1016/j.neuron.2006.03.042; Macpherson LJ, 2006, MOL CELL NEUROSCI, V32, P335, DOI 10.1016/j.mcn.2006.05.005; Macpherson LJ, 2005, CURR BIOL, V15, P929, DOI 10.1016/j.cub.2005.04.018; Matalon S, 2003, AM J PHYSIOL-LUNG C, V285, pL1184, DOI 10.1152/ajplung.00281.2003; Montell Craig, 2005, Sci STKE, V2005, pre3, DOI 10.1126/stke.2722005re3; Nagata K, 2005, J NEUROSCI, V25, P4052, DOI 10.1523/JNEUROSCI.0013-05.2005; Shapiro TA, 2001, CANCER EPIDEM BIOMAR, V10, P501; Speers AE, 2004, CHEM BIOL, V11, P535, DOI 10.1016/j.chembiol.2004.03.012; Story GM, 2003, CELL, V112, P819, DOI 10.1016/S0092-8674(03)00158-2; Voets T, 2004, NATURE, V430, P748, DOI 10.1038/nature02732; Wakabayashi N, 2004, P NATL ACAD SCI USA, V101, P2040, DOI 10.1073/pnas.0307301101; Wood JN, 1997, ANNU REV PHYSIOL, V59, P457, DOI 10.1146/annurev.physiol.59.1.457; Yoshida T, 2006, NAT CHEM BIOL, V2, P596, DOI 10.1038/nchembio821	31	857	903	4	143	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 1	2007	445	7127					541	545		10.1038/nature05544	http://dx.doi.org/10.1038/nature05544			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	131KI	17237762				2022-12-28	WOS:000243867300044
J	Day, JMD; Pearson, DG; Taylor, LA				Day, James M. D.; Pearson, D. Graham; Taylor, Lawrence A.			Highly siderophile element constraints on accretion and differentiation of the Earth-Moon system	SCIENCE			English	Article							MANTLE; IMPACT; FRACTIONATION; HYPOTHESIS; ORIGIN; CRUST; AGE	A new combined rhenium-osmium- and platinum-group element data set for basalts from the Moon establishes that the basalts have uniformly low abundances of highly siderophile elements. The data set indicates a lunar mantle with long-term, chondritic, highly siderophile element ratios, but with absolute abundances that are over 20 times lower than those in Earth's mantle. The results are consistent with silicate-metal equilibrium during a giant impact and core formation in both bodies, followed by post-core-formation late accretion that replenished their mantles with highly siderophile elements. The lunar mantle experienced late accretion that was similar in composition to that of Earth but volumetrically less than (similar to 0.02% lunar mass) and terminated earlier than for Earth.	Univ Tennessee, Dept Earth & Planetary Sci, Knoxville, TN 37996 USA; Univ Durham, Dept Earth Sci, Durham DH1 3LE, England	University of Tennessee System; University of Tennessee Knoxville; Durham University	Day, JMD (corresponding author), Univ Tennessee, Dept Earth & Planetary Sci, Knoxville, TN 37996 USA.	jday13@utk.edu	Day, James/A-5099-2010; Pearson, Graham/AAN-5507-2020	Day, James/0000-0001-9520-3465; 				Anbar AD, 2001, J GEOPHYS RES-PLANET, V106, P3219, DOI 10.1029/2000JE001272; BIRCK JL, 1994, EARTH PLANET SC LETT, V124, P139, DOI 10.1016/0012-821X(94)00086-7; Bombardieri DJ, 2005, METEORIT PLANET SCI, V40, P679, DOI 10.1111/j.1945-5100.2005.tb00973.x; Boyet M, 2005, SCIENCE, V309, P576, DOI 10.1126/science.1113634; CAMERON AGW, 1991, ICARUS, V92, P204, DOI 10.1016/0019-1035(91)90046-V; Canup RM, 2001, NATURE, V412, P708, DOI 10.1038/35089010; CARLSON RW, 1988, EARTH PLANET SC LETT, V90, P119, DOI 10.1016/0012-821X(88)90095-7; Chou CL, 1978, P LUNAR PLANET SCI, V9, P219; Cohen BA, 2000, SCIENCE, V290, P1754, DOI 10.1126/science.290.5497.1754; Day JMD, 2006, GEOCHIM COSMOCHIM AC, V70, P1581, DOI 10.1016/j.gca.2005.11.015; DAY JMD, 2006, LUN PLAN SCI C, V37; Kleine T, 2005, SCIENCE, V310, P1671, DOI 10.1126/science.1118842; Morgan JW, 2001, METEORIT PLANET SCI, V36, P1257, DOI 10.1111/j.1945-5100.2001.tb01959.x; Puchtel IS, 2001, GEOCHIM COSMOCHIM AC, V65, P2979, DOI 10.1016/S0016-7037(01)00642-1; Rehkamper M, 1999, GEOCHIM COSMOCHIM AC, V63, P3915, DOI 10.1016/S0016-7037(99)00219-7; Rhodes J. M., 1976, P LUN PLAN SCI C, VXII, P1467; Rhodes J.M., 1973, P 4 LUNAR SCI C, V2, P1127; Righter K, 2000, ORIGIN EARTH MOON, P291; Shirey SB, 1998, ANNU REV EARTH PL SC, V26, P423, DOI 10.1146/annurev.earth.26.1.423; Snyder G. A., 2000, ORIGIN EARTH MOON, p361 395; Sun WD, 2003, NATURE, V422, P294, DOI 10.1038/nature01482; Walker RJ, 2004, EARTH PLANET SC LETT, V224, P399, DOI 10.1016/j.epsl.2004.05.036	22	149	153	1	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 12	2007	315	5809					217	219		10.1126/science.1133355	http://dx.doi.org/10.1126/science.1133355			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124XZ	17218521				2022-12-28	WOS:000243407400040
J	Laposata, M; Van Cott, EM; Lev, MH; Chien, AJ; Harris, NL; Ellman, L				Laposata, Michael; Van Cott, Elizabeth M.; Lev, Michael H.; Chien, Amy Jo; Harris, Nancy Lee; Ellman, Leonard			A woman with epistaxis, hematemesis, and altered mental status - Multiple vitamin K-dependent coagulation-factor deficiencies due to ingestion of brodifacoum	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUPERWARFARIN; COAGULOPATHY		Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Radiol, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University	Laposata, M (corresponding author), Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.							*A WOOD COMP, COUM DAT SHEET; Bruno GR, 2000, ANN EMERG MED, V36, P262, DOI 10.1067/mem.2000.108317; Chua JD, 1998, ARCH INTERN MED, V158, P1929, DOI 10.1001/archinte.158.17.1929; HAMPTON KK, 1991, BLOOD COAGUL FIBRIN, V2, P637, DOI 10.1097/00001721-199110000-00008; HOFFMAN RS, 1988, J TOXICOL-CLIN TOXIC, V26, P233, DOI 10.3109/15563658809000350; Ingels M, 2002, ANN EMERG MED, V40, P75, DOI 10.1067/mem.2002.125449; *INT PROGR CHEM SA, BROM PEST DAT SHEET; *INT PROGR CHEM SA, DIF HLTH SAF GUID; *INT PROGR CHEM SA, BROD PEST DAT SHEET; JONES EC, 1984, JAMA-J AM MED ASSOC, V252, P3005, DOI 10.1001/jama.252.21.3005; LaRosa FG, 1997, ARCH PATHOL LAB MED, V121, P67; LUSHER JM, 1993, SEMIN HEMATOL, V30, P36; Mullins ME, 2000, PEDIATRICS, V105, P402, DOI 10.1542/peds.105.2.402; Pavlu F, 2005, LANCET, V365, P628; SCULLY M, 2002, BIOCHEMIST, V24, P15; Sharma P, 2005, LANCET, V365, P552; SHEEN SR, 1994, VET HUM TOXICOL, V36, P216; Tsutaoka BT, 2003, PHARMACOTHERAPY, V23, P1186, DOI 10.1592/phco.23.10.1186.32755; Waien SA, 2001, NEW ENGL J MED, V345, P1860; Waien SA, 2001, NEW ENGL J MED, V345, P700, DOI 10.1056/NEJM200108303450916; WATTS RG, 1990, PEDIATRICS, V86, P883; WEITZEL JN, 1990, BLOOD, V76, P2555	22	25	28	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 11	2007	356	2					174	182		10.1056/NEJMcpc069032	http://dx.doi.org/10.1056/NEJMcpc069032			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	124NE	17215536				2022-12-28	WOS:000243373700012
J	Lockman, S; Shapiro, RL; Smeaton, LM; Wester, C; Thior, I; Stevens, L; Chand, F; Makhema, J; Moffat, C; Asmelash, A; Ndase, P; Arimi, P; van Widenfelt, E; Mazhani, L; Novitsky, V; Lagakos, S; Essex, M				Lockman, Shahin; Shapiro, Roger L.; Smeaton, Laura M.; Wester, Carolyn; Thior, Ibou; Stevens, Lisa; Chand, Fatima; Makhema, Joseph; Moffat, Claire; Asmelash, Aida; Ndase, Patrick; Arimi, Peter; van Widenfelt, Erik; Mazhani, Loeto; Novitsky, Vladimir; Lagakos, Stephen; Essex, Max			Response to antiretroviral therapy after a single, peripartum dose of nevirapine	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TO-CHILD TRANSMISSION; HIV-1 VERTICAL TRANSMISSION; K103N RESISTANCE MUTATION; RANDOMIZED-TRIAL; SUBTYPE-C; RECEIVING NEVIRAPINE; WOMEN; PREVENTION; ZIDOVUDINE; PROPHYLAXIS	BACKGROUND: A single dose of nevirapine during labor reduces perinatal transmission of human immunodeficiency virus type 1 (HIV-1) but often leads to viral nevirapine resistance mutations in mothers and infants. METHODS: We studied the response to nevirapine-based antiretroviral treatment among women and infants who had previously been randomly assigned to a single, peripartum dose of nevirapine or placebo in a trial in Botswana involving the prevention of the transmission of HIV-1 from mother to child. All women were treated with antenatal zidovudine. The primary end point for mothers and infants was virologic failure by the 6-month visit after initiation of antiretroviral treatment, estimated within groups by the Kaplan-Meier method. RESULTS: Of 218 women who started antiretroviral treatment, 112 had received a single dose of nevirapine and 106 had received placebo. By the 6-month visit after the initiation of antiretroviral treatment, 5.0% of the women who had received placebo had virologic failure, as compared with 18.4% of those who had received a single dose of nevirapine (P=0.002). Among 60 women starting antiretroviral treatment within 6 months after receiving placebo or a single dose of nevirapine, no women in the placebo group and 41.7% in the nevirapine group had virologic failure (P<0.001). In contrast, virologic failure rates did not differ significantly between the placebo group and the nevirapine group among 158 women starting antiretroviral treatment 6 months or more post partum (7.8% and 12.0%, respectively; P=0.39). Thirty infants also began antiretroviral treatment (15 in the placebo group and 15 in the nevirapine group). Virologic failure by the 6-month visit occurred in significantly more infants who had received a single dose of nevirapine than in infants who had received placebo (P<0.001). Maternal and infant findings did not change qualitatively by 12 and 24 months after the initiation of antiretroviral treatment. CONCLUSIONS: Women who received a single dose of nevirapine to prevent perinatal transmission of HIV-1 had higher rates of virologic failure with subsequent nevirapine-based antiretroviral therapy than did women without previous exposure to nevirapine. However, this applied only when nevirapine-based antiretroviral therapy was initiated within 6 months after receipt of a single, peripartum dose of nevirapine.	Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA; Botswana Harvard Sch Publ Hlth AIDS Initiat Partn, Gaborone, Botswana; Botswana Minist Hlth, Gaborone, Botswana	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Beth Israel Deaconess Medical Center	Lockman, S (corresponding author), Brigham & Womens Hosp, Div Infect Dis, 15 Francis St,PBB-A4, Boston, MA 02115 USA.	slockman@hsph.harvard.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD037793, R01HD044391] Funding Source: NIH RePORTER; FOGARTY INTERNATIONAL CENTER [D43TW000004] Funding Source: NIH RePORTER; FIC NIH HHS [D43 TW00004] Funding Source: Medline; NICHD NIH HHS [R01 HD44391, R01 HD37793] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BEDIKOU G, 2005, 3 IS C HIV PATH TREA; Chaix ML, 2006, J INFECT DIS, V193, P482, DOI 10.1086/499966; COOVADIA H, 2006, 13 C RETR OPP INF DE; Eshleman SH, 2006, J INFECT DIS, V193, P479, DOI 10.1086/499967; Eshleman SH, 2005, AIDS, V19, P2167, DOI 10.1097/01.aids.0000194800.43799.94; Eshleman SH, 2005, J INFECT DIS, V192, P30, DOI 10.1086/430764; Eshleman SH, 2001, AIDS, V15, P1951, DOI 10.1097/00002030-200110190-00006; Flys T, 2005, J INFECT DIS, V192, P24, DOI 10.1086/430742; Flys TS, 2006, JAIDS-J ACQ IMM DEF, V42, P610, DOI 10.1097/01.qai.0000221686.67810.20; Guay LA, 1999, LANCET, V354, P795, DOI 10.1016/S0140-6736(99)80008-7; Jackson JB, 2000, AIDS, V14, pF111, DOI 10.1097/00002030-200007280-00001; Jackson JB, 2003, LANCET, V362, P859, DOI 10.1016/S0140-6736(03)14341-3; Jourdain G, 2004, NEW ENGL J MED, V351, P229, DOI 10.1056/NEJMoa041305; Lallemant M, 2005, 3 IAS C HIV PATH TRE; Lee EJ, 2005, J INFECT DIS, V192, P1260, DOI 10.1086/444424; Loubser S, 2006, AIDS, V20, P995, DOI 10.1097/01.aids.0000222071.60620.1d; McCutchan FE, 2006, J MED VIROL, V78, pS7, DOI 10.1002/jmv.20599; MCINTYRE JA, 2005, 3 IAS C HIV PATH TRE; Palmer S, 2006, P NATL ACAD SCI USA, V103, P7094, DOI 10.1073/pnas.0602033103; PILLAY CCN, 2004, 15 INT AIDS C BANGK; Shapiro RL, 2006, AIDS, V20, P1281, DOI 10.1097/01.aids.0000232236.26630.35; Stanford University, STANF U HIV DRUG RES; Thior I, 2006, JAMA-J AM MED ASSOC, V296, P794, DOI 10.1001/jama.296.7.794; WHO, 2006, ANT DRUGS TREAT PREG; World Health Organization, 2006, ANT THER HIV INF AD; VIRAMUNE DONATION PR	26	309	320	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 11	2007	356	2					135	147		10.1056/NEJMoa062876	http://dx.doi.org/10.1056/NEJMoa062876			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	124NE	17215531	Green Published, Green Accepted			2022-12-28	WOS:000243373700006
J	Dudziak, D; Kamphorst, AO; Heidkamp, GF; Buchholz, VR; Trumpfheller, C; Yamazaki, S; Cheong, C; Liu, K; Lee, HW; Park, CG; Steinman, RM; Nussenzweig, MC				Dudziak, Diana; Kamphorst, Alice O.; Heidkamp, Gordon F.; Buchholz, Veit R.; Trumpfheller, Christine; Yamazaki, Sayuri; Cheong, Cheolho; Liu, Kang; Lee, Han-Woong; Park, Chae Gyu; Steinman, Ralph M.; Nussenzweig, Michel C.			Differential antigen processing by dendritic cell subsets in vivo	SCIENCE			English	Article							MONOCLONAL-ANTIBODY; CROSS-PRESENTATION; LYMPH-NODE; T-CELLS; CD8(+); MOUSE; COMPLEXES; PROTEOLYSIS; ACTIVATION; RECEPTOR	Dendritic cells (DCs) process and present self and foreign antigens to induce tolerance or immunity. In vitro models suggest that induction of immunity is controlled by regulating the presentation of antigen, but little is known about how DCs control antigen presentation in vivo. To examine antigen processing and presentation in vivo, we specifically targeted antigens to two major subsets of DCs by using chimeric monoclonal antibodies. Unlike CD8(+) DCs that express the cell surface protein CD205, CD8(-) DCs, which are positive for the 33D1 antigen, are specialized for presentation on major histocompatibility complex (MHC) class II. This difference in antigen processing is intrinsic to the DC subsets and is associated with increased expression of proteins involved in MHC processing.	Rockefeller Univ, Lab Mol Immunol, New York, NY 10021 USA; Rockefeller Univ, Cellular Physiol & Immunol Lab, New York, NY 10021 USA; Yonsei Univ, Coll Sci, Dept Biochem, Seoul 120749, South Korea; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA	Rockefeller University; Rockefeller University; Yonsei University; Howard Hughes Medical Institute; Rockefeller University	Nussenzweig, MC (corresponding author), Rockefeller Univ, Lab Mol Immunol, 1230 York Ave, New York, NY 10021 USA.	nussen@rockefeller.edu	Nussenzweig, Michel/AAE-7292-2019; Steinman, Ralph/F-7729-2012; Buchholz, Veit R./AAF-6966-2021; Dudziak, Diana/B-2432-2017	Buchholz, Veit R./0000-0003-0441-3913; Park, Chae Gyu/0000-0003-1906-1308; Dudziak, Diana/0000-0001-9358-134X; Kamphorst, Alice/0000-0002-9230-9501				Allan RS, 2003, SCIENCE, V301, P1925, DOI 10.1126/science.1087576; Bonifaz L, 2002, J EXP MED, V196, P1627, DOI 10.1084/jem.20021598; Bryant P, 2004, CURR OPIN IMMUNOL, V16, P96, DOI 10.1016/j.coi.2003.11.011; Cresswell P, 1999, IMMUNOL REV, V172, P21, DOI 10.1111/j.1600-065X.1999.tb01353.x; Dadaglio G, 1997, IMMUNITY, V6, P727, DOI 10.1016/S1074-7613(00)80448-3; Delamarre L, 2005, SCIENCE, V307, P1630, DOI 10.1126/science.1108003; den Haan JMM, 2002, J EXP MED, V196, P817, DOI 10.1084/jem.20020295; den Haan JMM, 2000, J EXP MED, V192, P1685, DOI 10.1084/jem.192.12.1685; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; Guo M, 2000, HUM IMMUNOL, V61, P729, DOI 10.1016/S0198-8859(00)00144-0; Hawiger D, 2001, J EXP MED, V194, P769, DOI 10.1084/jem.194.6.769; Inaba K, 2000, J EXP MED, V191, P927, DOI 10.1084/jem.191.6.927; Iyoda T, 2002, J EXP MED, V195, P1289, DOI 10.1084/jem.20020161; Liu YJ, 2001, CELL, V106, P259, DOI 10.1016/S0092-8674(01)00456-1; NUSSENZWEIG MC, 1982, P NATL ACAD SCI-BIOL, V79, P161, DOI 10.1073/pnas.79.1.161; Pierre P, 1998, CELL, V93, P1135, DOI 10.1016/S0092-8674(00)81458-0; Pooley JL, 2001, J IMMUNOL, V166, P5327, DOI 10.4049/jimmunol.166.9.5327; Scheinecker C, 2002, J EXP MED, V196, P1079, DOI 10.1084/jem.20020991; Schnorrer P, 2006, P NATL ACAD SCI USA, V103, P10729, DOI 10.1073/pnas.0601956103; Shastri N, 2005, IMMUNOL REV, V207, P31, DOI 10.1111/j.0105-2896.2005.00321.x; Shortman K, 2002, NAT REV IMMUNOL, V2, P151, DOI 10.1038/nri746; Steinman RM, 2003, ANNU REV IMMUNOL, V21, P685, DOI 10.1146/annurev.immunol.21.120601.141040; Trombetta ES, 2005, ANNU REV IMMUNOL, V23, P975, DOI 10.1146/annurev.immunol.22.012703.104538; Turley SJ, 2000, SCIENCE, V288, P522, DOI 10.1126/science.288.5465.522; VREMEC D, 1992, J EXP MED, V176, P47, DOI 10.1084/jem.176.1.47; WITMER MD, 1984, AM J ANAT, V170, P465, DOI 10.1002/aja.1001700318; Yewdell JW, 1999, ADV IMMUNOL, V73, P1, DOI 10.1016/S0065-2776(08)60785-3	27	1018	1042	1	111	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 5	2007	315	5808					107	111		10.1126/science.1136080	http://dx.doi.org/10.1126/science.1136080			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	122WU	17204652				2022-12-28	WOS:000243259100048
J	Lam, YC; Bowman, AB; Jafar-Neiad, P; Lim, J; Richman, R; Fryer, JD; Hyun, ED; Duvick, LA; Brr, HT; Botas, J; Zoghbi, HY				Lam, Yung C.; Bowman, Aaron B.; Jafar-Neiad, Paymaan; Lim, Janghoo; Richman, Ronald; Fryer, John D.; Hyun, Eric D.; Duvick, Lisa A.; Brr, Harry T.; Botas, Juan; Zoghbi, Huda Y.			ATAXIN-1 interacts with the repressor capicua in its native complex to cause SCA1 neuropathology	CELL			English	Article							BULBAR MUSCULAR-ATROPHY; HISTONE ACETYLTRANSFERASE ACTIVITY; TRANSGENIC MOUSE MODEL; DISEASE GENE HOMOLOG; HUNTINGTONS-DISEASE; MUTANT HUNTINGTIN; MEDIATES NEURODEGENERATION; EMBRYONIC LETHALITY; EXPANDED ATAXIN-7; AXH DOMAIN	Spinocerebellar ataxia type 1 (SCA1) is one of several neurodegenerative diseases caused by expansion of a polyglutamine tract in the disease protein, in this case, ATAXIN-1 (ATXN1). A key question in the field is whether neurotoxicity is mediated by aberrant, novel interactions with the expanded protein or whether its wild-type functions are augmented to a deleterious degree. We examined soluble protein complexes from mouse cerebellum and found that the majority of wild-type and expanded ATXN1 assembles into large stable complexes containing the transcriptional repressor Capicua. ATXN1 directly binds Capicua and modulates Capicua repressor activity in Drosophila and mammalian cells, and its loss decreases the steady-state level of Capicua. Interestingly, the S776A mutation, which abrogates the neurotoxicity of expanded ATXN1, substantially reduces the association of mutant ATXN1 with Capicua in vivo. These data provide insight into the function of ATXN1 and suggest that SCA1 neuropathology depends on native, not novel, protein interactions.	Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Program Dev Biol, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Biochem, Minneapolis, MN 55455 USA; Univ Minnesota, Inst Human Genet, Minneapolis, MN 55455 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Zoghbi, HY (corresponding author), Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA.	hzoghbi@bcm.tmc.edu		Bowman, Aaron/0000-0001-8728-3346; Orr, Harry/0000-0001-6118-741X; Zoghbi, Huda/0000-0002-0700-3349	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD024064] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS022920, R01NS022920, R01NS027699, R01NS045667] Funding Source: NIH RePORTER; NICHD NIH HHS [HD024064] Funding Source: Medline; NINDS NIH HHS [NS45667, NS22920, NS27699] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Atkey MR, 2006, DEVELOPMENT, V133, P2115, DOI 10.1242/dev.02369; BURRIGHT EN, 1995, CELL, V82, P937, DOI 10.1016/0092-8674(95)90273-2; Cattaneo E, 2005, NAT REV NEUROSCI, V6, P919, DOI 10.1038/nrn1806; Chen HK, 2003, CELL, V113, P457, DOI 10.1016/S0092-8674(03)00349-0; Chen SM, 2004, HUM MOL GENET, V13, P53, DOI 10.1093/hmg/ddh005; Chen-Plotkin AS, 2006, NEUROBIOL DIS, V22, P233, DOI 10.1016/j.nbd.2005.11.001; Chevalier-Larsen ES, 2004, J NEUROSCI, V24, P4778, DOI 10.1523/JNEUROSCI.0808-04.2004; de Chiara C, 2005, J MOL BIOL, V354, P883, DOI 10.1016/j.jmb.2005.09.083; Doss-Pepe EW, 2003, MOL CELL BIOL, V23, P6469, DOI 10.1128/MCB.23.18.6469-6483.2003; Dunah AW, 2002, SCIENCE, V296, P2238, DOI 10.1126/science.1072613; DUYAO MP, 1995, SCIENCE, V269, P407, DOI 10.1126/science.7618107; Emamian ES, 2003, NEURON, V38, P375, DOI 10.1016/S0896-6273(03)00258-7; Eriksen JL, 2005, TRENDS MOL MED, V11, P91, DOI 10.1016/j.molmed.2005.01.001; Fernandez-Funez P, 2000, NATURE, V408, P101, DOI 10.1038/35040584; Gatchel JR, 2005, NAT REV GENET, V6, P743, DOI 10.1038/nrg1691; Gauthier LR, 2004, CELL, V118, P127, DOI 10.1016/j.cell.2004.06.018; Graham RK, 2006, CELL, V125, P1179, DOI 10.1016/j.cell.2006.04.026; Harjes P, 2003, TRENDS BIOCHEM SCI, V28, P425, DOI 10.1016/S0968-0004(03)00168-3; Helmlinger D, 2006, PLOS BIOL, V4, P432, DOI 10.1371/journal.pbio.0040067; Ikeda Y, 2005, J BIOL CHEM, V280, P29661, DOI 10.1074/jbc.M411694200; Jimenez G, 2000, GENE DEV, V14, P224; Katsuno M, 2002, NEURON, V35, P843, DOI 10.1016/S0896-6273(02)00834-6; Kawamura-Saito M, 2006, HUM MOL GENET, V15, P2125, DOI 10.1093/hmg/ddl136; Kegel KB, 2002, J BIOL CHEM, V277, P7466, DOI 10.1074/jbc.M103946200; Li SH, 2004, TRENDS GENET, V20, P146, DOI 10.1016/j.tig.2004.01.008; Li SH, 2002, MOL CELL BIOL, V22, P1277, DOI 10.1128/MCB.22.5.1277-1287.2002; Lim J, 2006, CELL, V125, P801, DOI 10.1016/j.cell.2006.03.032; Luo SQ, 2005, J CELL BIOL, V169, P647, DOI 10.1083/jcb.200412071; MACDONALD ME, 2003, SCI STKE, V207, pPE48; Matilla A, 1998, J NEUROSCI, V18, P5508, DOI 10.1523/JNEUROSCI.18-14-05508.1998; Matsumoto T, 2005, J BIOCHEM, V138, P105, DOI 10.1093/jb/mvi118; McMahon SJ, 2005, P NATL ACAD SCI USA, V102, P8478, DOI 10.1073/pnas.0503493102; McManamny P, 2002, HUM MOL GENET, V11, P2103, DOI 10.1093/hmg/11.18.2103; NASIR J, 1995, CELL, V81, P811, DOI 10.1016/0092-8674(95)90542-1; Okazawa H, 2002, NEURON, V34, P701, DOI 10.1016/S0896-6273(02)00697-9; Palhan VB, 2005, P NATL ACAD SCI USA, V102, P8472, DOI 10.1073/pnas.0503505102; Pardo R, 2006, J NEUROSCI, V26, P1635, DOI 10.1523/JNEUROSCI.3706-05.2006; Rangone H, 2004, EUR J NEUROSCI, V19, P273, DOI 10.1111/j.0953-816X.2003.03131.x; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Roch F, 2002, DEVELOPMENT, V129, P993; Ross CA, 2004, NAT MED, V10, pS10, DOI 10.1038/nm1066; Rovelet-Lecrux A, 2006, NAT GENET, V38, P24, DOI 10.1038/ng1718; Schaffar G, 2004, MOL CELL, V15, P95, DOI 10.1016/j.molcel.2004.06.029; Steffan JS, 2004, SCIENCE, V304, P100, DOI 10.1126/science.1092194; Strom AL, 2005, NEUROBIOL DIS, V20, P646, DOI 10.1016/j.nbd.2005.04.018; Tsai CC, 2004, P NATL ACAD SCI USA, V101, P4047, DOI 10.1073/pnas.0400615101; Tsuda H, 2005, CELL, V122, P633, DOI 10.1016/j.cell.2005.06.012; Van Raamsdonk JM, 2005, HUM MOL GENET, V14, P1379, DOI 10.1093/hmg/ddi147; Warby SC, 2005, HUM MOL GENET, V14, P1569, DOI 10.1093/hmg/ddi165; Warrick JM, 2005, MOL CELL, V18, P37, DOI 10.1016/j.molcel.2005.02.030; Watase K, 2002, NEURON, V34, P905, DOI 10.1016/S0896-6273(02)00733-X; YEH E, 1995, P NATL ACAD SCI USA, V92, P7036, DOI 10.1073/pnas.92.15.7036; ZEITLIN S, 1995, NAT GENET, V11, P155, DOI 10.1038/ng1095-155; Zhai WG, 2005, CELL, V123, P1241, DOI 10.1016/j.cell.2005.10.030; Zuccato C, 2003, NAT GENET, V35, P76, DOI 10.1038/ng1219	55	226	232	2	16	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	DEC 29	2006	127	7					1335	1347		10.1016/j.cell.2006.11.038	http://dx.doi.org/10.1016/j.cell.2006.11.038			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	128WI	17190598	Bronze			2022-12-28	WOS:000243690000014
J	Larsen, FJ; Ekblom, B; Sahlin, K; Lundberg, JO; Weitzberg, E				Larsen, Filip J.; Ekblom, Bjorn; Sahlin, Kent; Lundberg, Jon O.; Weitzberg, Eddie			Effects of dietary nitrate on blood pressure in healthy volunteers	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter							NITRITE; TRIAL		Swedish Sch Sport & Hlth Sci, S-11433 Stockholm, Sweden; Karolinska Inst, S-17177 Stockholm, Sweden	Swedish School of Sport & Health Sciences; Karolinska Institutet	Larsen, FJ (corresponding author), Swedish Sch Sport & Hlth Sci, S-11433 Stockholm, Sweden.	eddie.weitzberg@ki.se		Lundberg, Jon/0000-0002-0174-5210				Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601; Gladwin MT, 2005, NAT CHEM BIOL, V1, P308, DOI 10.1038/nchembio1105-308; Gladwin MT, 2006, NAT CHEM BIOL, V2, P110, DOI 10.1038/nchembio0206-110; Lundberg JO, 2005, ARTERIOSCL THROM VAS, V25, P915, DOI 10.1161/01.ATV.0000161048.72004.c2; Lundberg JO, 2004, NAT REV MICROBIOL, V2, P681, DOI 10.1038/nrmicro982; ROUSE IL, 1983, LANCET, V1, P5	6	421	429	0	64	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 28	2006	355	26					2792	2793		10.1056/NEJMc062800	http://dx.doi.org/10.1056/NEJMc062800			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	120UA	17192551	Green Published			2022-12-28	WOS:000243110500030
J	Boudker, O; Ryan, RM; Yernool, D; Shimamoto, K; Gouaux, E				Boudker, Olga; Ryan, Renae M.; Yernool, Dinesh; Shimamoto, Keiko; Gouaux, Eric			Coupling substrate and ion binding to extracellular gate of a sodium-dependent aspartate transporter	NATURE			English	Article							SCANNING MUTAGENESIS REVEALS; AMINO-ACID TRANSPORTER; GLUTAMATE TRANSPORTERS; REENTRANT LOOP; GLT-1; NA+; EXPRESSION; CLONING; GENE; COTRANSPORT	Secondary transporters are integral membrane proteins that catalyse the movement of substrate molecules across the lipid bilayer by coupling substrate transport to one or more ion gradients, thereby providing a mechanism for the concentrative uptake of substrates. Here we describe crystallographic and thermodynamic studies of Glt(Ph), a sodium (Na+)-coupled aspartate transporter, defining sites for aspartate, two sodium ions and D, L-threo-beta-benzyloxyaspartate, an inhibitor. We further show that helical hairpin 2 is the extracellular gate that controls access of substrate and ions to the internal binding sites. At least two sodium ions bind in close proximity to the substrate and these sodium-binding sites, together with the sodium-binding sites in another sodium-coupled transporter, LeuT, define an unwound alpha-helix as the central element of the ion-binding motif, a motif well suited to the binding of sodium and to participation in conformational changes that accompany ion binding and unbinding during the transport cycle.	Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Columbia Univ, Howard Hughes Med Inst, New York, NY 10032 USA; Suntory Inst Bioorgan Res, Osaka 6188503, Japan	Columbia University; Columbia University; Howard Hughes Medical Institute; Suntory Holdings Ltd	Gouaux, E (corresponding author), Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97239 USA.	gouauxe@ohsu.edu	Ryan, Renae/AAC-3540-2021; Gouaux, Eric/Y-4370-2019	Ryan, Renae/0000-0002-8680-4610; Gouaux, Eric/0000-0002-8549-2360				ARRIZA JL, 1993, J BIOL CHEM, V268, P15329; ARRIZA JL, 1994, J NEUROSCI, V14, P5559; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brocke L, 2002, J BIOL CHEM, V277, P3985, DOI 10.1074/jbc.M107735200; Chen NH, 2004, PFLUG ARCH EUR J PHY, V447, P519, DOI 10.1007/s00424-003-1064-5; ENGELKE T, 1989, J BACTERIOL, V171, P5551, DOI 10.1128/jb.171.10.5551-5560.1989; Gaillard I, 1996, BIOCHEMISTRY-US, V35, P6150, DOI 10.1021/bi953005v; Grewer C, 2005, BIOCHEMISTRY-US, V44, P11913, DOI 10.1021/bi050987n; Grewer C, 2005, J MEMBRANE BIOL, V203, P1, DOI 10.1007/s00232-004-0731-6; Grunewald M, 2002, J BIOL CHEM, V277, P26074, DOI 10.1074/jbc.M202248200; Grunewald M, 1998, NEURON, V21, P623, DOI 10.1016/S0896-6273(00)80572-3; Grunewald M, 2000, J BIOL CHEM, V275, P9684, DOI 10.1074/jbc.275.13.9684; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P3949, DOI 10.1021/bi00612a011; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; Kanner BI, 2002, BBA-BIOENERGETICS, V1555, P92, DOI 10.1016/S0005-2728(02)00260-8; KANNER BI, 1982, BIOCHEMISTRY-US, V21, P6327, DOI 10.1021/bi00267a044; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; Koch HP, 2005, J NEUROSCI, V25, P1730, DOI 10.1523/JNEUROSCI.4138-04.2005; Lauger P., 1991, ELECTROGENIC ION PUM; Levy LM, 1998, J NEUROSCI, V18, P9620, DOI 10.1523/jneurosci.18-23-09620.1998; Mudring AV, 2005, INORG CHEM, V44, P6240, DOI 10.1021/ic050547k; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; Ogawa W, 1998, J BACTERIOL, V180, P6749, DOI 10.1128/JB.180.24.6749-6752.1998; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; QUICK M, 2002, TRANSMEMBRANE TRANSP; Seal RP, 1998, NEURON, V21, P1487, DOI 10.1016/S0896-6273(00)80666-2; SHAFQAT S, 1993, J BIOL CHEM, V268, P15351; Shimamoto K, 1998, MOL PHARMACOL, V53, P195, DOI 10.1124/mol.53.2.195; Slotboom DJ, 1999, MICROBIOL MOL BIOL R, V63, P293, DOI 10.1128/MMBR.63.2.293-307.1999; Slotboom DJ, 1999, P NATL ACAD SCI USA, V96, P14282, DOI 10.1073/pnas.96.25.14282; Slotboom DJ, 1996, J BIOL CHEM, V271, P31317, DOI 10.1074/jbc.271.49.31317; Slotboom DJ, 2001, TRENDS BIOCHEM SCI, V26, P534, DOI 10.1016/S0968-0004(01)01925-9; Slotboom DJ, 2001, J BIOL CHEM, V276, P10775, DOI 10.1074/jbc.M011064200; Sobczak M, 2005, CURR OPIN MICROBIOL, V8, P161, DOI 10.1016/j.mib.2005.02.005; Tao Z, 2006, J BIOL CHEM, V281, P10263, DOI 10.1074/jbc.M510739200; Wilson TH, 2001, BBA-BIOENERGETICS, V1505, P121, DOI 10.1016/S0005-2728(00)00282-6; Wright EM, 2004, PFLUG ARCH EUR J PHY, V447, P510, DOI 10.1007/s00424-003-1063-6; Yamashita A, 2005, NATURE, V437, P215, DOI 10.1038/nature03978; Yernool D, 2004, NATURE, V431, P811, DOI 10.1038/nature03018; Yurgel SN, 2005, J BACTERIOL, V187, P1161, DOI 10.1128/JB.187.3.1161-1172.2005; Zarbiv R, 1998, J BIOL CHEM, V273, P14231, DOI 10.1074/jbc.273.23.14231; ZERANGUE N, 1995, J BIOL CHEM, V270, P6433, DOI 10.1074/jbc.270.12.6433; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0; Zhang YM, 1999, P NATL ACAD SCI USA, V96, P1710, DOI 10.1073/pnas.96.4.1710	45	386	393	0	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 25	2007	445	7126					387	393		10.1038/nature05455	http://dx.doi.org/10.1038/nature05455			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	128WD	17230192				2022-12-28	WOS:000243689500030
J	Cobey, FC; Takayama, H				Cobey, Fred C.; Takayama, Hiroo			Contraceptive failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Washington, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Cobey, FC (corresponding author), Univ Washington, Seattle, WA 98195 USA.	fcobey@partners.org							0	0	0	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 25	2007	356	4					397	397		10.1056/NEJMicm055402	http://dx.doi.org/10.1056/NEJMicm055402			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	128FT	17251536				2022-12-28	WOS:000243644300010
J	Epstein, RM				Epstein, Ronald M.			Medical education - Assessment in medical education	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PATIENT-CENTERED COMMUNICATION; PEER ASSESSMENT; PROFESSIONAL COMPETENCE; GENERAL-PRACTITIONERS; PERFORMANCE; PHYSICIAN; RATINGS; ISSUES; SKILLS; CARE	As an attending physician working with a student for a week, you receive a form that asks you to evaluate the student's fund of knowledge, procedural skills, professionalism, interest in learning, and "systems-based practice." You wonder which of these attributes you can reliably assess and how the data you provide will be used to further the student's education. You also wonder whether other tests of knowledge and competence that students must undergo before they enter practice are equally problematic.	Univ Rochester, Sch Med & Dent, Dept Family Med, Rochester, NY USA; Univ Rochester, Sch Med & Dent, Dept Psychiat, Rochester, NY USA; Univ Rochester, Sch Med & Dent, Dept Oncol, Rochester, NY USA; Univ Rochester, Sch Med & Dent, Rochester Ctr Improve Commun Hlth Care, Rochester, NY USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester	Epstein, RM (corresponding author), 1381 South Ave, Rochester, NY 14620 USA.	ronald_epstein@urmc.rochester.edu						ANASTAKIS DJ, 1991, AM J SURG, V162, P67, DOI 10.1016/0002-9610(91)90205-R; [Anonymous], 2001, CROSSING QUALITY CHA, DOI DOI 10.17226/10027; Batalden P, 2002, HEALTH AFFAIR, V21, P103, DOI 10.1377/hlthaff.21.5.103; Batmangelich Sorush, 2004, J Contin Educ Health Prof, V24, P134, DOI 10.1002/chp.1340240303; Ben-David MF, 2000, MED TEACH, V22, P472, DOI 10.1080/01421590050110731; BORDAGE G, 1984, MED EDUC, V18, P406, DOI 10.1111/j.1365-2923.1984.tb01295.x; Borrell-Carrio F, 2004, ANN FAM MED, V2, P310, DOI 10.1370/afm.80; Bowen JL, 2006, NEW ENGL J MED, V355, P2217, DOI 10.1056/NEJMra054782; Brailovsky C, 2001, MED EDUC, V35, P430, DOI 10.1046/j.1365-2923.2001.00911.x; BUTTERFIELD PS, 1991, J GEN INTERN MED, V6, P155, DOI 10.1007/BF02598316; Calhoun J G, 1984, Res Med Educ, V23, P205; Carney PA, 1999, J FAM PRACTICE, V48, P958; Carraccio C, 2004, TEACH LEARN MED, V16, P381, DOI 10.1207/s15328015tlm1604_13; CASE S, 2000, CONSTRUCTING WRITTEN; Chang JT, 2006, ANN INTERN MED, V144, P665, DOI 10.7326/0003-4819-144-9-200605020-00010; Charlin B, 2000, TEACH LEARN MED, V12, P189, DOI 10.1207/S15328015TLM1204_5; COLLIVER JA, 1992, ACAD MED, V67, P592, DOI 10.1097/00001888-199209000-00010; Dannefer EF, 2005, MED EDUC, V39, P713, DOI 10.1111/j.1365-2929.2005.02193.x; DREYFUS HL, 2001, INTERNET THINKING AC; Epstein RM, 2002, JAMA-J AM MED ASSOC, V287, P226, DOI 10.1001/jama.287.2.226; Epstein RM, 1999, JAMA-J AM MED ASSOC, V282, P833, DOI 10.1001/jama.282.9.833; Epstein RM, 2005, SOC SCI MED, V61, P1516, DOI 10.1016/j.socscimed.2005.02.001; Epstein RM, 2005, ANN FAM MED, V3, P415, DOI 10.1370/afm.348; Epstein RM, 2004, TEACH LEARN MED, V16, P186, DOI 10.1207/s15328015tlm1602_12; Epstein RM, 2003, FAM SYST HEALTH, V21, P11, DOI DOI 10.1037/H0089495; ERAUT M, 1994, DEV PROFESSIONAL KNO, P100; Ericsson KA, 2004, ACAD MED, V79, pS70, DOI 10.1097/00001888-200410001-00022; Eva KW, 2005, ACAD MED, V80, pS46, DOI 10.1097/00001888-200510001-00015; Eva KW, 2004, ACAD MED, V79, pS40, DOI 10.1097/00001888-200410001-00012; Farmer EA, 2005, MED EDUC, V39, P1188, DOI 10.1111/j.1365-2929.2005.02339.x; Fraser SW, 2001, BRIT MED J, V323, P799, DOI 10.1136/bmj.323.7316.799; FREDERIKSEN N, 1984, AM PSYCHOL, V39, P193, DOI 10.1037/0003-066X.39.3.193; Friedman MH, 1998, ACAD MED, V73, pS19, DOI 10.1097/00001888-199810000-00033; Ginsburg S, 2004, ACAD MED, V79, pS1, DOI 10.1097/00001888-200410001-00001; Graber ML, 2005, ARCH INTERN MED, V165, P1493, DOI 10.1001/archinte.165.13.1493; Gruppen LD, 2002, INT HDB RES MED ED, P205; HAKSTIAN AR, 1971, J EDUC RES, V64, P319, DOI 10.1080/00220671.1971.10884175; Hall JA, 1998, HEALTH PSYCHOL, V17, P70, DOI 10.1037/0278-6133.17.1.70; Hodges B, 2003, MED EDUC, V37, P1012, DOI 10.1046/j.1365-2923.2003.01674.x; Klass D, 2000, AM J PHYS MED REHAB, V79, P481, DOI 10.1097/00002060-200009000-00018; KLESSIG J, 1989, J GEN INTERN MED, V4, P514, DOI 10.1007/BF02599551; Kravitz RL, 2005, JAMA-J AM MED ASSOC, V294, P2436; Kravitz RL, 2005, JAMA-J AM MED ASSOC, V293, P1995, DOI 10.1001/jama.293.16.1995; Leach DC, 2002, JAMA-J AM MED ASSOC, V287, P243, DOI 10.1001/jama.287.2.243; Leung WC, 2002, BRIT MED J, V325, P693, DOI 10.1136/bmj.325.7366.693; LURIE S, IN PRESS REL DEANS L; Lurie SJ, 2006, MED EDUC, V40, P840, DOI 10.1111/j.1365-2929.2006.02540.x; Lypson ML, 2004, ACAD MED, V79, P564, DOI 10.1097/00001888-200406000-00013; NEWBLE DI, 1983, MED EDUC, V17, P165, DOI 10.1111/j.1365-2923.1983.tb00657.x; NOFZIGER AC, 2002, OTT C MED ED ASS OTT; Norcini JJ, 2003, MED EDUC, V37, P539, DOI 10.1046/j.1365-2923.2003.01536.x; Norcini JJ, 2003, ANN INTERN MED, V138, P476, DOI 10.7326/0003-4819-138-6-200303180-00012; Norman G, 2002, BRIT MED J, V324, P748, DOI 10.1136/bmj.324.7340.748; NORMAN GR, 1991, MED EDUC, V25, P119, DOI 10.1111/j.1365-2923.1991.tb00037.x; Papadakis MA, 2004, NEW ENGL J MED, V350, P1703, DOI 10.1056/NEJMp038246; Pulito AR, 2006, TEACH LEARN MED, V18, P99, DOI 10.1207/s15328015tlm1802_2; Ram P, 1999, MED EDUC, V33, P447; RAMSEY PG, 1993, JAMA-J AM MED ASSOC, V269, P1655, DOI 10.1001/jama.269.13.1655; Reznick RK, 2006, NEW ENGL J MED, V355, P2664, DOI 10.1056/NEJMra054785; REZNICK RK, 1993, ACAD MED, V68, pS4, DOI 10.1097/00001888-199310000-00028; Schirmer JM, 2005, FAM MED, V37, P184; SCHMIDT HG, 1992, ACAD MED, V67, P287; SCHMIDT HG, 1990, ACAD MED, V65, P611, DOI 10.1097/00001888-199010000-00001; Schon D.A., 1987, ED REFLECTIVE PRACTI; Schuwirth L, 2004, MED EDUC, V38, P1208, DOI 10.1111/j.1365-2929.2004.02055.x; Schuwirth LWT, 2004, MED EDUC, V38, P974, DOI 10.1111/j.1365-2929.2004.01916.x; Schuwirth LWT, 1996, MED EDUC, V30, P44, DOI 10.1111/j.1365-2923.1996.tb00716.x; Schuwirth LWT, 2001, MED EDUC, V35, P348, DOI 10.1046/j.1365-2923.2001.00771.x; Shanafelt TD, 2002, ANN INTERN MED, V136, P358, DOI 10.7326/0003-4819-136-5-200203050-00008; Sullivan WM, 2005, WORK INTEGRITY CRISI; Tamblyn R, 2002, JAMA-J AM MED ASSOC, V288, P3019, DOI 10.1001/jama.288.23.3019; Tamblyn RM, 1998, CAN MED ASSOC J, V158, P205; Van der Vleuten CPM, 1996, ADV HEALTH SCI EDUC, V1, P41, DOI 10.1007/BF00596229; VANDERVLEUTEN CPM, 1991, MED EDUC, V25, P110; Violato C, 1997, ACAD MED, V72, pS82, DOI 10.1097/00001888-199710001-00028; Wass V, 2001, MED EDUC, V35, P321, DOI 10.1046/j.1365-2923.2001.00928.x; Wass V, 2001, LANCET, V357, P945, DOI 10.1016/S0140-6736(00)04221-5	77	972	1019	4	157	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 25	2007	356	4					387	396		10.1056/NEJMra054784	http://dx.doi.org/10.1056/NEJMra054784			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	128FT	17251535				2022-12-28	WOS:000243644300009
J	Frith, L				Frith, Lucy			HIV self-testing: a time to revise current policy	LANCET			English	Article							HOME; NORMALIZATION; PREFERENCES; COLLECTION; PREVENTION		Univ Liverpool, Div Primary Care, Liverpool L69 3GB, Merseyside, England	University of Liverpool	Frith, L (corresponding author), Univ Liverpool, Div Primary Care, Whelan Bldg,Brownlow Hill, Liverpool L69 3GB, Merseyside, England.	L.J.Frith@liverpool.ac.uk	Frith, Lucy/AAW-6711-2020	Frith, Lucy/0000-0002-8506-0699				[Anonymous], 2000, CAN MED ASSOC J, V162, P1545; Branson BM, 1998, JAMA-J AM MED ASSOC, V280, P1699, DOI 10.1001/jama.280.19.1699; *BRIT ASS SEX HLTH, 2005, UK NAT GUID HIV TEST; De Cock KM, 1998, BMJ-BRIT MED J, V316, P290, DOI 10.1136/bmj.316.7127.290; *FDA, 2005, APPR VAL OV THE COUN; Marks G, 2005, JAIDS-J ACQ IMM DEF, V39, P446, DOI 10.1097/01.qai.0000151079.33935.79; Phillips KA, 2003, AM J PREV MED, V24, P340, DOI 10.1016/S0749-3797(03)00019-9; Rogstad KE, 2003, SEX TRANSM INFECT, V79, P243, DOI 10.1136/sti.79.3.243; Rosenbrock R, 2000, SOC SCI MED, V50, P1607, DOI 10.1016/S0277-9536(99)00469-4; Spielberg F, 2004, LANCET INFECT DIS, V4, P640, DOI 10.1016/S1473-3099(04)01150-8; Spielberg F, 2003, JAIDS-J ACQ IMM DEF, V32, P318, DOI 10.1097/00126334-200303010-00012; Spielberg F, 2001, SEX TRANSM DIS, V28, P51, DOI 10.1097/00007435-200101000-00012; Spielberg F, 2003, HOME SELF TESTING HI; *UK DEP HLTH, 2004, CHOOS HLTH MAK HLTH; *UK GEN MED COUNC, 2000, ANT TEST HIV; *UK HUM GEN COMM, 2005, NONC DNA TEST; US Food and Drug Administration, 2004, FDA APPR 1 OR FLUID; Wright AA, 2006, NEW ENGL J MED, V354, P437, DOI 10.1056/NEJMp058302	18	38	39	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 20	2007	369	9557					243	245		10.1016/S0140-6736(07)60113-5	http://dx.doi.org/10.1016/S0140-6736(07)60113-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	128XG	17240291				2022-12-28	WOS:000243692400033
J	Li, X; Grubisic, A; Stokes, ST; Cordes, J; Gantefor, GF; Bowen, KH; Kiran, B; Willis, M; Jena, P; Burgert, R; Schnockel, H				Li, X.; Grubisic, A.; Stokes, S. T.; Cordes, J.; Gantefoer, G. F.; Bowen, K. H.; Kiran, B.; Willis, M.; Jena, P.; Burgert, R.; Schnoeckel, H.			Unexpected stability of Al4H6: A borane analog?	SCIENCE			English	Article							INFRARED-SPECTRUM; MAIN GROUP; CLUSTERS; HYDROGEN; ALUMINUM; ANIONS; AL2H6; ALH3	Whereas boron has many hydrides, aluminum has been thought to exhibit relatively few. A combined anion photoelectron and density functional theory computational study of the Al4H6- anion and its corresponding neutral, Al4H6, showed that Al4H6 can be understood in terms of the Wade-Mingos rules for electron counting, suggesting that it may be a borane analog. The data support an Al4H6 structure with a distorted tetrahedral aluminum atom framework, four terminal Al-H bonds, and two sets of counter-positioned Al-H-Al bridging bonds. The large gap between the highest occupied and the lowest unoccupied molecular orbitals found for Al4H6, together with its exceptionally high heat of combustion, further suggests that Al4H6 may be an important energetic material if it can be prepared in bulk.	Johns Hopkins Univ, Dept Chem & Mat Sci, Baltimore, MD 21218 USA; Univ Konstanz, Dept Phys, D-7750 Constance, Germany; Virginia Commonwealth Univ, Dept Phys, Richmond, VA 23284 USA; Univ Karlsruhe TH, Inst Inorgan Chem, D-76128 Karlsruhe, Germany	Johns Hopkins University; University of Konstanz; Virginia Commonwealth University; Helmholtz Association; Karlsruhe Institute of Technology	Bowen, KH (corresponding author), Johns Hopkins Univ, Dept Chem & Mat Sci, Baltimore, MD 21218 USA.	kbowen@jhu.edu	Ganteför, Gerd/AAU-2721-2021; Li, Xuelong/Z-3785-2019; li, xiang/GWM-6319-2022; Grubisic, Andrej/P-2717-2014; Li, Xuelong/ABF-3381-2020; Li, Xiang/G-3886-2011; Li, Xiang/F-4539-2012	Ganteför, Gerd/0000-0003-4591-6381; Grubisic, Andrej/0000-0001-8236-0007; Jena, Purusottam/0000-0002-2316-859X				Ahlrichs R, 1999, PHYS CHEM CHEM PHYS, V1, P13, DOI 10.1039/a807713d; Andrews L, 2003, SCIENCE, V299, P2049, DOI 10.1126/science.1082456; [Anonymous], CHEM COMMUN; [Anonymous], [No title captured]; [Anonymous], 1996, ANGEW CHEM, V108, P141; Balakrishnarajan MM, 2004, J AM CHEM SOC, V126, P13119, DOI 10.1021/ja0467420; Breisacher P, 1964, J AM CHEM SOC, V86, P5053; Burkart S, 1999, CHEM PHYS LETT, V301, P546, DOI 10.1016/S0009-2614(98)01428-6; CAVANAUGH MA, 1985, POLYHEDRON, V4, P687, DOI 10.1016/S0277-5387(00)86684-X; Cotton F.A., 1998, ADV INORG CHEM; Cui LF, 2006, J CHEM PHYS, V124, DOI 10.1063/1.2166633; Gerhards M, 2002, J CHEM PHYS, V116, P10247, DOI 10.1063/1.1477924; Greenwood N.N., 1997, CHEM ELEMENTS; HILLER W, 1991, ANGEW CHEM INT EDIT, V30, P179; Jemmis ED, 2001, J AM CHEM SOC, V123, P4313, DOI 10.1021/ja003233z; KURTH FA, 1993, J CHEM SOC CHEM COMM, P1302, DOI 10.1039/c39930001302; LAUHER JW, 1978, J AM CHEM SOC, V100, P5305, DOI 10.1021/ja00485a011; LINTI G, 2002, MOL CLUSTERS MAIN GR; Lipscomb W. N., 1963, BORON HYDRIDES; MINGOS DMP, 1972, NATURE-PHYS SCI, V236, P99, DOI 10.1038/physci236099a0; Neu A, 1999, INORG CHIM ACTA, V289, P58, DOI 10.1016/S0020-1693(99)00058-4; Neu A, 1997, ANGEW CHEM INT EDIT, V36, P2117, DOI 10.1002/anie.199721171; Rao BK, 2001, PHYS REV LETT, V86, P692, DOI 10.1103/PhysRevLett.86.692; Schleyer PV, 1998, INORG CHEM, V37, P3454, DOI 10.1021/ic980110v; SIEKMANN HR, 1991, Z PHYS D ATOM MOL CL, V20, P417, DOI 10.1007/BF01544026; Wade K., 1976, ADV INORG CHEM RAD, V18, P1, DOI DOI 10.1016/S0065-2792(08)60027-8; WILLIAMS RE, 1992, CHEM REV, V92, P177, DOI 10.1021/cr00010a001; YANG SH, 1987, CHEM PHYS LETT, V139, P233, DOI 10.1016/0009-2614(87)80548-1	28	161	166	2	85	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 19	2007	315	5810					356	358		10.1126/science.1133767	http://dx.doi.org/10.1126/science.1133767			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126SI	17234942				2022-12-28	WOS:000243535400035
J	Chaudhuri, O; Parekh, SH; Fletcher, DA				Chaudhuri, Ovijit; Parekh, Sapun H.; Fletcher, Daniel A.			Reversible stress softening of actin networks	NATURE			English	Article							ARP2/3 COMPLEX; DENDRITIC ORGANIZATION; MECHANICAL-PROPERTIES; CROSS-LINKING; CELLS; FILAMENTS; MICRORHEOLOGY; MICROTUBULES; ELASTICITY; MOTILITY	The mechanical properties of cells play an essential role in numerous physiological processes. Organized networks of semiflexible actin filaments determine cell stiffness and transmit force during mechanotransduction, cytokinesis, cell motility and other cellular shape changes(1-3). Although numerous actin-binding proteins have been identified that organize networks, the mechanical properties of actin networks with physiological architectures and concentrations have been difficult to measure quantitatively. Studies of mechanical properties in vitro have found that crosslinked networks of actin filaments formed in solution exhibit stress stiffening arising from the entropic elasticity of individual filaments or crosslinkers resisting extension(4-8). Here we report reversible stress-softening behaviour in actin networks reconstituted in vitro that suggests a critical role for filaments resisting compression. Using a modified atomic force microscope to probe dendritic actin networks ( like those formed in the lamellipodia of motile cells), we observe stress stiffening followed by a regime of reversible stress softening at higher loads. This softening behaviour can be explained by elastic buckling of individual filaments under compression that avoids catastrophic fracture of the network. The observation of both stress stiffening and softening suggests a complex interplay between entropic and enthalpic elasticity in determining the mechanical properties of actin networks.	Univ Calif Berkeley, UC San Francisco UC Berkeley Joint Grad Grp Bioen, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Bioengn, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley	Fletcher, DA (corresponding author), Univ Calif Berkeley, UC San Francisco UC Berkeley Joint Grad Grp Bioen, Berkeley, CA 94720 USA.	fletch@berkeley.edu	Ladoux, Benoit/A-9879-2013	Chaudhuri, Ovijit/0000-0002-9287-3401	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM074751, R01GM072736] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM072736-05, R01 GM072736, R01 GM074751-01A2, R01 GM074751] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alcaraz J, 2003, BIOPHYS J, V84, P2071, DOI 10.1016/S0006-3495(03)75014-0; Brangwynne CP, 2006, J CELL BIOL, V173, P733, DOI 10.1083/jcb.200601060; BUSTAMANTE C, 1994, SCIENCE, V265, P1599, DOI 10.1126/science.8079175; Cameron LA, 1999, P NATL ACAD SCI USA, V96, P4908, DOI 10.1073/pnas.96.9.4908; Cameron LA, 2001, CURR BIOL, V11, P130, DOI 10.1016/S0960-9822(01)00022-7; Coughlin MF, 1998, J BIOMECH ENG-T ASME, V120, P770, DOI 10.1115/1.2834892; Fabry B, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.148102; FRICKE J, 1988, J NON-CRYST SOLIDS, V100, P169, DOI 10.1016/0022-3093(88)90014-2; Gardel ML, 2006, P NATL ACAD SCI USA, V103, P1762, DOI 10.1073/pnas.0504777103; Gardel ML, 2004, SCIENCE, V304, P1301, DOI 10.1126/science.1095087; GITTES F, 1993, J CELL BIOL, V120, P923, DOI 10.1083/jcb.120.4.923; Head DA, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.108102; Janmey PA, 2004, TRENDS BIOCHEM SCI, V29, P364, DOI 10.1016/j.tibs.2004.05.003; Kroy K, 1996, PHYS REV LETT, V77, P306, DOI 10.1103/PhysRevLett.77.306; Landau LD, 1986, THEORY ELASTICITY, DOI 10.1016/C2009-0-25521-8; MACKINTOSH FC, 1995, PHYS REV LETT, V75, P4425, DOI 10.1103/PhysRevLett.75.4425; Mahaffy RE, 2000, PHYS REV LETT, V85, P880, DOI 10.1103/PhysRevLett.85.880; Marcy Y, 2004, P NATL ACAD SCI USA, V101, P5992, DOI 10.1073/pnas.0307704101; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; Nakamura F, 2002, J BIOL CHEM, V277, P9148, DOI 10.1074/jbc.M111297200; Onck PR, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.178102; Parekh SH, 2005, NAT CELL BIOL, V7, P1219, DOI 10.1038/ncb1336; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; Satcher RL, 1996, BIOPHYS J, V71, P109, DOI 10.1016/S0006-3495(96)79206-8; Stamenovic D, 2004, J APPL PHYSIOL, V96, P1600, DOI 10.1152/japplphysiol.00595.2003; Storm C, 2005, NATURE, V435, P191, DOI 10.1038/nature03521; Svitkina TM, 1999, J CELL BIOL, V145, P1009, DOI 10.1083/jcb.145.5.1009; Tseng Y, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.258104; Xu JY, 2000, J BIOL CHEM, V275, P35886, DOI 10.1074/jbc.M002377200	30	292	303	6	120	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 18	2007	445	7125					295	298		10.1038/nature05459	http://dx.doi.org/10.1038/nature05459			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126HT	17230186	Green Accepted			2022-12-28	WOS:000243504700040
J	Keays, DA; Tian, G; Poirier, K; Huang, GJ; Siebold, C; Cleak, J; Oliver, PL; Fray, M; Harvey, RJ; Molnar, Z; Pinon, MC; Dear, N; Valdar, W; Brown, SDM; Davies, KE; Rawlins, JNP; Cowan, NJ; Nolan, P; Chelly, J; Flint, J				Keays, David A.; Tian, Guoling; Poirier, Karine; Huang, Guo-Jen; Siebold, Christian; Cleak, James; Oliver, Peter L.; Fray, Martin; Harvey, Robert J.; Molnar, Zoltan; Pinon, Maria C.; Dear, Neil; Valdar, William; Brown, Steve D. M.; Davies, Kay E.; Rawlins, J. Nicholas P.; Cowan, Nicholas J.; Nolan, Patrick; Chelly, Jamel; Flint, Jonathan			Mutations in alpha-tubulin cause abnormal neuronal migration in mice and lissencephaly in humans	CELL			English	Article							CEREBELLAR HYPOPLASIA; CORTICAL DEVELOPMENT; BETA-TUBULIN; GENE; DOUBLECORTIN; PROTEIN; CHAPERONIN; MOUSE; HETERODIMER; HIPPOCAMPUS	The development of the mammalian brain is dependent on extensive neuronal migration. Mutations in mice and humans that affect neuronal migration result in abnormal lamination of brain structures with associated behavioral deficits. Here, we report the identification of a hyperactive N-ethyl-N-nitrosourea (ENU)induced mouse mutant with abnormalities in the laminar architecture of the hippocampus and cortex, accompanied by impaired neuronal migration. We show that the causative mutation lies in the guanosine triphosphate (GTP) binding pocket of alpha-1 tubulin (Tuba 1) and affects tubulin heterodimer formation. Phenotypic similarity with existing mouse models of lissencephaly led us to screen a cohort of patients with developmental brain anomalies. We identified two patients with cle novo mutations in TUBA3, the human homolog of Tubal. This study demonstrates the utility of ENU mutagenesis in the mouse as a means to discover the basis of human neurodevelopmental disorders.	Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; NYU, Med Ctr, Dept Biochem, New York, NY 10016 USA; MRC, Funct Genet Unit, Oxford OX1 3QX, England; MRC, Mammalian Genet Unit, Didcot OX11 0RD, Oxon, England; Univ London, Sch Pharm, Dept Pharmacol, London WC1N 1AX, England; Univ Oxford, Dept Physiol Anat & Genet, Oxford OX1 3QX, England; Univ Oxford, Dept Expt Psychol, Oxford OX1 3UD, England; Univ Paris 05, Fac Med Rene Descartes, Inst Cochin, INSERM,Unite 567,CNRS,UMR 8104, F-75014 Paris, France	University of Oxford; Wellcome Centre for Human Genetics; New York University; MRC Harwell; University of London; University College London; University of London School of Pharmacy; University of Oxford; University of Oxford; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Flint, J (corresponding author), Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.	jf@well.ox.ac.uk	Harvey, Robert/D-3994-2016; Oliver, Peter/F-1453-2010; Chelly, Jamel/J-7528-2015; Nolan, Patrick/W-3918-2019; POIRIER, Karine/N-3009-2018; Molnar, Zoltan/J-7281-2012; Valdar, William/AAE-4354-2019	Harvey, Robert/0000-0001-5956-6664; Chelly, Jamel/0000-0002-0939-8719; Nolan, Patrick/0000-0001-5550-0334; POIRIER, Karine/0000-0002-7928-2906; Molnar, Zoltan/0000-0002-6852-6004; Huang, Guo-Jen/0000-0002-6392-2155; Oliver, Peter/0000-0003-3347-2461; Flint, Jonathan/0000-0002-9427-4429	MRC [MC_U137761449, MC_U142684173, MC_UP_1502/1, G0300200, MC_U142684175, MC_U142684172] Funding Source: UKRI; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047234] Funding Source: NIH RePORTER; Medical Research Council [MC_UP_1502/1, MC_U142684175, MC_U142684172, MC_U142684173, MC_U137761449, G0300200] Funding Source: Medline; NIDDK NIH HHS [R01 DK047234, R01 DK47234] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Wellcome Trust(Wellcome Trust)		ANGEVINE JAY B., 1965, EXP NEUROL SUPPL, V2, P1; Bannerman DM, 2004, BEHAV NEUROSCI, V118, P643, DOI 10.1037/0735-7044.118.3.643; Bartolini F, 2002, J BIOL CHEM, V277, P14629, DOI 10.1074/jbc.M200128200; BASTEN CJ, 1996, PLANT GENOME, V4; Boycott KM, 2005, AM J HUM GENET, V77, P477, DOI 10.1086/444400; Buhot MC, 2001, BEHAV NEUROSCI, V115, P455, DOI 10.1037/0735-7044.115.2.455; CHURCHILL GA, 1994, GENETICS, V138, P963; Corbo JC, 2002, J NEUROSCI, V22, P7548; Deacon RMJ, 2002, BEHAV BRAIN RES, V132, P203, DOI 10.1016/S0166-4328(01)00401-6; Demyanenko GP, 2004, NEURON, V44, P423, DOI 10.1016/j.neuron.2004.10.016; des Portes V, 1998, CELL, V92, P51; DOBYNS WB, 1995, NEUROPEDIATRICS, V26, P132, DOI 10.1055/s-2007-979744; Farr SA, 2002, PHYSIOL BEHAV, V76, P531, DOI 10.1016/S0031-9384(02)00749-7; Francis F, 2006, EUR J NEUROSCI, V23, P877, DOI 10.1111/j.1460-9568.2006.04649.x; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; Gleeson JG, 1998, CELL, V92, P63, DOI 10.1016/S0092-8674(00)80899-5; Gloster A, 1999, J COMP NEUROL, V405, P45, DOI 10.1002/(SICI)1096-9861(19990301)405:1<45::AID-CNE4>3.0.CO;2-M; GU W, 1989, MOL CELL BIOL, V9, P3418, DOI 10.1128/MCB.9.8.3418; Gupta A, 2002, NAT REV GENET, V3, P342, DOI 10.1038/nrg799; Hong SE, 2000, NAT GENET, V26, P93, DOI 10.1038/79246; Huang GJ, 2005, NEUROPSYCHOPHARMACOL, V30, P231, DOI 10.1038/sj.npp.1300609; Kappeler C, 2006, HUM MOL GENET, V15, P1387, DOI 10.1093/hmg/ddl062; Kikkawa M, 2006, EMBO J, V25, P4187, DOI 10.1038/sj.emboj.7601299; Leventer RJ, 2005, J CHILD NEUROL, V20, P307, DOI 10.1177/08830738050200040701; Lewis SA, 1996, J CELL BIOL, V132, P1, DOI 10.1083/jcb.132.1.1; Lowe J, 2001, J MOL BIOL, V313, P1045, DOI 10.1006/jmbi.2001.5077; Moores CA, 2004, MOL CELL, V14, P833, DOI 10.1016/j.molcel.2004.06.009; Nolan PM, 2000, NAT GENET, V25, P440, DOI 10.1038/78140; Paylor R, 1999, LEARN MEMORY, V6, P521, DOI 10.1101/lm.6.5.521; Phillips JB, 2004, CELL MOTIL CYTOSKEL, V58, P112, DOI 10.1002/cm.20003; Pinheiro J, 2001, MIXED EFFECTS MODELS; QIU S, 2005, NEUROBIOLOGY LEARNIN, V85, P228; *R DEV COR TEAM, 2004, LANG ENV STAT COMP; REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0; Solberg LC, 2006, MAMM GENOME, V17, P129, DOI 10.1007/s00335-005-0112-1; SPIEGELMAN BM, 1977, CELL, V12, P587, DOI 10.1016/0092-8674(77)90259-8; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Takahashi T, 1999, J NEUROSCI, V19, P10357; Thornton CE, 1999, MAMM GENOME, V10, P987, DOI 10.1007/s003359901145; TIAN GL, 1995, J BIOL CHEM, V270, P23910, DOI 10.1074/jbc.270.41.23910; Tian GL, 1999, J BIOL CHEM, V274, P24054, DOI 10.1074/jbc.274.34.24054; Tian GL, 2006, P NATL ACAD SCI USA, V103, P13491, DOI 10.1073/pnas.0602798103; Vega LR, 1998, MOL BIOL CELL, V9, P2349, DOI 10.1091/mbc.9.9.2349; VILLASANTE A, 1986, MOL CELL BIOL, V6, P2409, DOI 10.1128/MCB.6.7.2409; WILLINS DA, 1995, GENETICS, V141, P1287; ZENG ZB, 1994, GENETICS, V136, P1457	46	318	325	2	29	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 12	2007	128	1					45	57		10.1016/j.cell.2006.12.017	http://dx.doi.org/10.1016/j.cell.2006.12.017			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	139GN	17218254	Green Published, hybrid			2022-12-28	WOS:000244420400012
J	Friedman, RA				Friedman, Richard A.			Uncovering an epidemic - Screening for mental illness in teens	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PREVALENCE; CHILDREN		Weill Cornell Med Coll, Psychopharmacol Clin, New York, NY 10021 USA	Cornell University	Friedman, RA (corresponding author), Weill Cornell Med Coll, Psychopharmacol Clin, New York, NY 10021 USA.							Gould MS, 2005, JAMA-J AM MED ASSOC, V293, P1635, DOI 10.1001/jama.293.13.1635; GOULD MS, 1990, AM J EPIDEMIOL, V131, P71, DOI 10.1093/oxfordjournals.aje.a115487; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P768; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Shaffer D, 1996, J AM ACAD CHILD PSY, V35, P865, DOI 10.1097/00004583-199607000-00012; VELEZ CN, 1988, J AM ACAD CHILD PSY, V27, P349, DOI 10.1097/00004583-198805000-00014	6	55	55	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 28	2006	355	26					2717	2719		10.1056/NEJMp068262	http://dx.doi.org/10.1056/NEJMp068262			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	120UA	17192534				2022-12-28	WOS:000243110500001
J	Goldman, L; Kumar, P; Souhami, B				Goldman, Lee; Kumar, Parveen; Souhami, Bob			Why medicine inspires me	BRITISH MEDICAL JOURNAL			English	Editorial Material									Columbia Univ, Med Ctr, New York, NY 10032 USA	Columbia University	Goldman, L (corresponding author), Columbia Univ, Med Ctr, New York, NY 10032 USA.	lgoldman@columbia.edu							0	0	0	1	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	DEC 23	2006	333	7582					1320	1321		10.1136/bmj.39058.497060.BE	http://dx.doi.org/10.1136/bmj.39058.497060.BE			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121MC	17185724	Green Published			2022-12-28	WOS:000243160700022
J	Wilbanks, J				Wilbanks, John			Another reason for opening access to research	BRITISH MEDICAL JOURNAL			English	Editorial Material									MIT, Comp Sci & Artificial Intelligence Lab, Creat Commons, Sci Commons Project, Cambridge, MA 02127 USA	Massachusetts Institute of Technology (MIT)	Wilbanks, J (corresponding author), MIT, Comp Sci & Artificial Intelligence Lab, Creat Commons, Sci Commons Project, Cambridge, MA 02127 USA.	wilbanks@creativecommons.org		wilbanks, john/0000-0002-4510-0385				Butler D, 2006, NATURE, V441, P914, DOI 10.1038/441914a; DAVIES K, 2006, SEARCH DEPLOY; MCVEIGH M, 2004, OPEN ACCESS J ISI CI; MORRISON H, 2006, J INTERLIBRARY LOAN, V16, P3; OReilly T., WHAT IS WEB 2 0 DESI; *PUBL LIB SCI, 2005, PLOS BIOL 13 9; *SCI COMM, SCHOL COPYR PROJ; Suber P, OPEN ACCESS OVERVIEW; Willinsky J, 2003, J Postgrad Med, V49, P263; *WORLD WID WEB CON, W3C SEM WEB ACT	10	4	5	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 23	2006	333	7582					1306	1308		10.1136/sbmj.39063.730660.F7	http://dx.doi.org/10.1136/sbmj.39063.730660.F7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121MC	17185718	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000243160700016
J	Martianov, I; Ramadass, A; Barros, AS; Chow, N; Akoulitchev, A				Martianov, Igor; Ramadass, Aroul; Barros, Ana Serra; Chow, Natalie; Akoulitchev, Alexandre			Repression of the human dihydrofolate reductase gene by a non-coding interfering transcript	NATURE			English	Article							RNA-POLYMERASE-II; CRYSTAL-STRUCTURE; TATA-ELEMENT; COMPLEX; EXPRESSION; CELLS; TFIIB; SPECIFICITY; PROMOTER; SITE	Alternative promoters within the same gene are a general phenomenon in gene expression(1,2). Mechanisms of their selective regulation vary from one gene to another and are still poorly understood. Here we show that in quiescent cells the mechanism of transcriptional repression of the major promoter of the gene encoding dihydrofolate reductase depends on a non-coding transcript initiated from the upstream minor promoter and involves both the direct interaction of the RNA and promoter-specific interference. The specificity and efficiency of repression is ensured by the formation of a stable complex between non-coding RNA and the major promoter, direct interaction of the non-coding RNA with the general transcription factor IIB and dissociation of the preinitiation complex from the major promoter. By using in vivo and in vitro assays such as inducible and reconstituted transcription, RNA bandshifts, RNA interference, chromatin immunoprecipitation and RNA immunoprecipitation, we show that the regulatory transcript produced from the minor promoter has a critical function in an epigenetic mechanism of promoter-specific transcriptional repression.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France; Univ Aveiro, Dept Biol, P-3810193 Aveiro, Portugal	University of Oxford; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Universidade de Aveiro	Akoulitchev, A (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.	alexandre.akoulitchev@path.ox.ac.uk		Martiyanov, Igor/0000-0001-6108-2036	MRC [G0200452] Funding Source: UKRI; Medical Research Council [G0200452] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		AKOULITCHEV S, 1995, NATURE, V377, P557, DOI 10.1038/377557a0; Ayoubi TAY, 1996, FASEB J, V10, P453, DOI 10.1096/fasebj.10.4.8647344; Blume SW, 2003, J CELL BIOCHEM, V88, P165, DOI 10.1002/jcb.10326; Carbone GM, 2003, NUCLEIC ACIDS RES, V31, P833, DOI 10.1093/nar/gkg198; GEE JE, 1992, J BIOL CHEM, V267, P11163; Gilbert C, 2004, MOL CELL, V14, P457, DOI 10.1016/S1097-2765(04)00239-4; HENDRICKSON SL, 1980, P NATL ACAD SCI-BIOL, V77, P5140, DOI 10.1073/pnas.77.9.5140; Janowski BA, 2006, NAT STRUCT MOL BIOL, V13, P787, DOI 10.1038/nsmb1140; Kazmi MA, 1996, BIOTECHNIQUES, V21, P304; Kim DH, 2006, NAT STRUCT MOL BIOL, V13, P793, DOI 10.1038/nsmb1142; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; Lagrange T, 1996, P NATL ACAD SCI USA, V93, P10620, DOI 10.1073/pnas.93.20.10620; LETAI AG, 1988, BIOCHEMISTRY-US, V27, P9108, DOI 10.1021/bi00426a007; MARCK C, 1978, NUCLEIC ACIDS RES, V5, P1017, DOI 10.1093/nar/5.3.1017; Martens JA, 2004, NATURE, V429, P571, DOI 10.1038/nature02538; MASTERS JN, 1985, MOL CELL BIOL, V5, P493, DOI 10.1128/MCB.5.3.493; MORGAN AR, 1968, J MOL BIOL, V37, P63, DOI 10.1016/0022-2836(68)90073-9; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; ROBERTS SGE, 1994, NATURE, V371, P717, DOI 10.1038/371717a0; Xu ZL, 2003, GENE, V309, P145, DOI 10.1016/S0378-1119(03)00506-7	21	559	617	2	77	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 8	2007	445	7128					666	670		10.1038/nature05519	http://dx.doi.org/10.1038/nature05519			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	133UM	17237763				2022-12-28	WOS:000244039400048
J	Psaty, BM; Weiss, NS				Psaty, Bruce M.; Weiss, Noel S.			NSAID trials and the choice of comparators - Questions of public health importance	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							INHIBITORS; RISK		Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA; Univ Washington, Dept Epidemiol, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA; Univ Washington, Dept Hlth Serv, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA; Grp Hlth, Ctr Hlth Studies, Seattle, WA USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Psaty, BM (corresponding author), Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA.							Cannon CP, 2006, LANCET, V368, P1771, DOI 10.1016/S0140-6736(06)69666-9; *COMM ASS US DRUG, IN PRESS FUT DRUG SA; Kearney PM, 2006, BMJ-BRIT MED J, V332, P1302, DOI 10.1136/bmj.332.7553.1302; McGettigan P, 2006, JAMA-J AM MED ASSOC, V296, P1633, DOI 10.1001/jama.296.13.jrv60011; Psaty BM, 2006, JAMA-J AM MED ASSOC, V295, P1704, DOI 10.1001/jama.295.14.1704	5	22	22	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 25	2007	356	4					328	330		10.1056/NEJMp068286	http://dx.doi.org/10.1056/NEJMp068286			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128FT	17251528				2022-12-28	WOS:000243644300002
J	Oettle, H; Post, S; Neuhaus, P; Gellert, K; Langrehr, J; Ridwelski, K; Schramm, H; Fahlke, J; Zuelke, C; Burkart, C; Gutberlet, K; Kettner, E; Schmalenberg, H; Weigang-Koehler, K; Bechstein, WO; Niedergethmann, M; Schmidt-Wolf, I; Roll, L; Doerken, B; Riess, H				Oettle, Helmut; Post, Stefan; Neuhaus, Peter; Gellert, Klaus; Langrehr, Jan; Ridwelski, Karsten; Schramm, Harald; Fahlke, Joerg; Zuelke, Carl; Burkart, Christof; Gutberlet, Klaus; Kettner, Erika; Schmalenberg, Harald; Weigang-Koehler, Karin; Bechstein, Wolf-Otto; Niedergethmann, Marco; Schmidt-Wolf, Ingo; Roll, Lars; Doerken, Bernd; Riess, Hanno			Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer - A Randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BREAST-CANCER; COMBINATION CHEMOTHERAPY; RADICAL RESECTION; THERAPY; 5-FLUOROURACIL; MULTICENTER; CARCINOMA; ADENOCARCINOMA; STATISTICS; RECURRENCE	Context The role of adjuvant therapy in resectable pancreatic cancer is still uncertain, and no recommended standard exists. Objective To test the hypothesis that adjuvant chemotherapy with gemcitabine administered after complete resection of pancreatic cancer improves disease-free survival by 6 months or more. Design, Setting, and Patients Open, multicenter, randomized controlled phase 3 trial with stratification for resection, tumor, and node status. Conducted from July 1998 to December 2004 in the outpatient setting at 88 academic and community-based oncology centers in Germany and Austria. A total of 368 patients with gross complete (R0 or R1) resection of pancreatic cancer and no prior radiation or chemotherapy were enrolled into 2 groups. Intervention Patients received adjuvant chemotherapy with 6 cycles of gemcitabine on days 1, 8, and 15 every 4 weeks (n = 179), or observation ([ control] n = 175). Main Outcome Measures Primary end point was disease-free survival, and secondary end points were overall survival, toxicity, and quality of life. Survival analysis was based on all eligible patients (intention-to-treat). Results More than 80% of patients had R0 resection. The median number of chemotherapy cycles in the gemcitabine group was 6 ( range, 0-6). Grade 3 or 4 toxicities rarely occurred with no difference in quality of life ( by Spitzer index) between groups. During median follow-up of 53 months, 133 patients (74%) in the gemcitabine group and 161 patients (92%) in the control group developed recurrent disease. Median disease-free survival was 13.4 months in the gemcitabine group (95% confidence interval, 11.4-15.3) and 6.9 months in the control group ( 95% confidence interval, 6.1-7.8; P <. 001, log-rank). Estimated disease-free survival at 3 and 5 years was 23.5% and 16.5% in the gemcitabine group, and 7.5% and 5.5% in the control group, respectively. Subgroup analyses showed that the effect of gemcitabine on disease-free survival was significant in patients with either R0 or R1 resection. There was no difference in overall survival between the gemcitabine group ( median, 22.1 months; 95% confidence interval, 18.4-25.8; estimated survival, 34% at 3 years and 22.5% at 5 years) and the control group ( median, 20.2 months; 95% confidence interval, 17-23.4; estimated survival, 20.5% at 3 years and 11.5% at 5 years; P=. 06, log-rank). Conclusions Postoperative gemcitabine significantly delayed the development of recurrent disease after complete resection of pancreatic cancer compared with observation alone. These results support the use of gemcitabine as adjuvant chemotherapy in resectable carcinoma of the pancreas.	Charite Sch Med, Dept Med Oncol & Hematol, D-13353 Berlin, Germany; Univ Hosp, Dept Surg, Mannheim, Germany; Charite Sch Med, Dept Gen Visceral & Transplantat Surg, D-13353 Berlin, Germany; Sana Hosp Lichtenberg, Dept Gen & Visceral Surg, Berlin, Germany; City Hosp, Dept Gen & Visceral Surg, Magdeburg, Germany; City Hosp, Altstadt Hosp, Magdeburg, Germany; Waldklinikum, Dept Gen Visceral & Pediat Surg, Gera, Germany; Univ Hosp, Dept Surg, Magdeburg, Germany; Univ Hosp, Regensburg, Germany; Univ Hosp, Dept Med 2, Tubingen, Germany; Bremen Mitte Hosp, Bremen, Germany; Univ Hosp, Dept Med 2, Jena, Germany; Nord Hosp, Nurnberg, Germany; Univ Hosp, Dept Visceral & Vasc Surg, Frankfurt, Germany; Univ Hosp, Dept Med, Bonn, Germany; Univ Hosp, Outpatient Clin 1, Bonn, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Ruprecht Karls University Heidelberg; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University Hospital Magdeburg; University of Regensburg; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Klinikum Bremen-Mitte; Friedrich Schiller University of Jena; Klinikum Nurnberg Nord; Goethe University Frankfurt; Goethe University Frankfurt Hospital; University of Bonn; University of Bonn	Oettle, H (corresponding author), Charite Sch Med, Dept Med Oncol & Hematol, Campus Virchow Klinikum,Augustenburger Pl 1, D-13353 Berlin, Germany.	helmut.oettle@charite.de	Bechstein, Wolf/H-5457-2019	Bechstein, Wolf/0000-0002-3267-8145				Aapro MS, 1998, ANTI-CANCER DRUG, V9, P191, DOI 10.1097/00001813-199803000-00001; BAKKEVOLD KE, 1993, EUR J CANCER, V29A, P698, DOI 10.1016/S0959-8049(05)80349-1; Bonadonna G, 2005, BRIT MED J, V330, P217, DOI 10.1136/bmj.38314.622095.8F; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Citron ML, 2003, J CLIN ONCOL, V21, P1431, DOI 10.1200/JCO.2003.09.081; Ducreux M, 2002, ANN ONCOL, V13, P1185, DOI 10.1093/annonc/mdf197; Gonzalez RJ, 2005, SURG CLIN N AM, V85, P1033, DOI 10.1016/j.suc.2005.05.004; Gramont Aimery de, 2005, Semin Oncol, V32, P11, DOI 10.1053/j.seminoncol.2005.06.004; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; KALSER MH, 1985, ARCH SURG-CHICAGO, V120, P899; KAYAHARA M, 1993, CANCER, V72, P2118, DOI 10.1002/1097-0142(19931001)72:7<2118::AID-CNCR2820720710>3.0.CO;2-4; Klinkenbijl JH, 1999, ANN SURG, V230, P776, DOI 10.1097/00000658-199912000-00006; Kosuge T, 2006, JPN J CLIN ONCOL, V36, P159, DOI 10.1093/jjco/hyi234; Leichman CG, 2006, SURG ONCOL CLIN N AM, V15, P159, DOI 10.1016/j.soc.2005.09.006; Martin M, 2005, NEW ENGL J MED, V352, P2302, DOI 10.1056/NEJMoa043681; Neoptolemos JP, 2004, NEW ENGL J MED, V350, P1200, DOI 10.1056/NEJMoa032295; Oettle H, 2002, CANCER-AM CANCER SOC, V95, P912, DOI 10.1002/cncr.10758; Oettle H, 2000, ANTI-CANCER DRUG, V11, P771, DOI 10.1097/00001813-200011000-00001; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Regine WF, 2006, J CLIN ONCOL, V24, p180S; Sener SF, 1999, J AM COLL SURGEONS, V189, P1, DOI 10.1016/S1072-7515(99)00075-7; Sperti C, 1997, WORLD J SURG, V21, P195, DOI 10.1007/s002689900215; SPITZER WO, 1981, J CHRON DIS, V34, P585, DOI 10.1016/0021-9681(81)90058-8; Staley CA, 1996, AM J SURG, V171, P118, DOI 10.1016/S0002-9610(99)80085-3; Takada T, 2002, CANCER, V95, P1685, DOI 10.1002/cncr.10831; Tempero Margaret A, 2005, J Natl Compr Canc Netw, V3, P598	26	1792	1865	0	80	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 17	2007	297	3					267	277		10.1001/jama.297.3.267	http://dx.doi.org/10.1001/jama.297.3.267			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125VT	17227978	Bronze			2022-12-28	WOS:000243472300021
J	Sujeet, K; Shankar, S				Sujeet, Kumar; Shankar, Stuti			Prevertebral emphysema after a dental procedure	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Good Samaritan Hosp, Baltimore, MD 21239 USA		Sujeet, K (corresponding author), Good Samaritan Hosp, Baltimore, MD 21239 USA.	kumar.sujeet@medstar.net							0	13	13	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 11	2007	356	2					173	173		10.1056/NEJMicm053300	http://dx.doi.org/10.1056/NEJMicm053300			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	124NE	17215535				2022-12-28	WOS:000243373700010
J	Glantz, L				Glantz, Leonard			Should smokers be refused surgery? No	BRITISH MEDICAL JOURNAL			English	Editorial Material									Boston Univ, Sch Publ Hlth, Boston, MA 02118 USA	Boston University		lglantz@bu.edu		Glantz, Leonard/0000-0003-4591-2305					0	15	15	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JAN 6	2007	334	7583					21	21		10.1136/bmj.39059.532095.68	http://dx.doi.org/10.1136/bmj.39059.532095.68			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	125CH	17204800	Green Published			2022-12-28	WOS:000243418600032
J	Andreae, MO				Andreae, Meinrat O.			Aerosols before pollution	SCIENCE			English	Editorial Material							CLOUD CONDENSATION NUCLEI; VERTICAL PROFILES	No unpolluted regions remain in today's atmosphere. How can we estimate the aerosol content of the atmosphere before there was human activity?	Max Planck Inst Chem, D-55020 Mainz, Germany	Max Planck Society	Andreae, MO (corresponding author), Max Planck Inst Chem, D-55020 Mainz, Germany.	andreae@mpch-mainz.mpg.de	Andreae, Meinrat O./B-1068-2008	Andreae, Meinrat O./0000-0003-1968-7925				Delene DJ, 2001, J GEOPHYS RES-ATMOS, V106, P12579, DOI 10.1029/2000JD900800; HOPPEL WA, 1973, J ATMOS SCI, V30, P1410, DOI 10.1175/1520-0469(1973)030<1410:VPOCAV>2.0.CO;2; Komppula M, 2005, J GEOPHYS RES-ATMOS, V110, DOI 10.1029/2004JD005200; Lohmann U, 2005, ATMOS CHEM PHYS, V5, P715, DOI 10.5194/acp-5-715-2005; Putaud JP, 2004, ATMOS ENVIRON, V38, P2579, DOI 10.1016/j.atmosenv.2004.01.041; Roberts MC, 2001, GEOPHYS RES LETT, V28, P2807, DOI 10.1029/2000GL012585; Stier P, 2006, ATMOS CHEM PHYS, V6, P3059, DOI 10.5194/acp-6-3059-2006; Tunved P, 2006, SCIENCE, V312, P261, DOI 10.1126/science.1123052; TWOMEY S, 1978, J ATMOS SCI, V35, P650, DOI 10.1175/1520-0469(1978)035<0650:ROFYOO>2.0.CO;2	9	159	165	1	91	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 5	2007	315	5808					50	51		10.1126/science.1136529	http://dx.doi.org/10.1126/science.1136529			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	122WU	17204632				2022-12-28	WOS:000243259100025
J	Hu, K; Ji, L; Applegate, KT; Danuser, G; Waterman-Storer, CM				Hu, Ke; Ji, Lin; Applegate, Kathryn T.; Danuser, Gaudenz; Waterman-Storer, Clare M.			Differential transmission of actin motion within focal adhesions	SCIENCE			English	Article							EXTRACELLULAR-MATRIX; CELL-MIGRATION; STRESS FIBERS; ALPHA-ACTININ; PROTEIN; CYTOSKELETON; VINCULIN; TALIN; CONTRACTILITY; ASSOCIATION	Cell migration requires the transmission of motion generated in the actin cytoskeleton to the extracellular environment through a complex assembly of proteins in focal adhesions. We developed correlational fluorescent speckle microscopy to measure the coupling of focal-adhesion proteins to actin filaments. Different classes of focal-adhesion structural and regulatory molecules exhibited varying degrees of correlated motions with actin filaments, indicating hierarchical transmission of actin motion through focal adhesions. Interactions between vinculin, talin, and actin filaments appear to constitute a slippage interface between the cytoskeleton and integrins, generating a molecular clutch that is regulated during the morphodynamic transitions of cell migration.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Waterman-Storer, CM (corresponding author), Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA.	gdanuser@scripps.edu; waterman@scripps.edu		Waterman, Clare/0000-0001-6142-6775; Danuser, Gaudenz/0000-0001-8583-2014	NIGMS NIH HHS [GM67230, U54GM64346] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM064346, R01GM067230, U01GM067230] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beckerle MC, 1997, BIOESSAYS, V19, P949, DOI 10.1002/bies.950191104; BURRIDGE K, 1984, NATURE, V308, P744, DOI 10.1038/308744a0; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Edlund M, 2001, CELL MOTIL CYTOSKEL, V48, P190, DOI 10.1002/1097-0169(200103)48:3<190::AID-CM1008>3.0.CO;2-C; Ezzell RM, 1997, EXP CELL RES, V231, P14, DOI 10.1006/excr.1996.3451; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; GEIGER B, 1979, CELL, V18, P193, DOI 10.1016/0092-8674(79)90368-4; Giannone G, 2003, J CELL BIOL, V163, P409, DOI 10.1083/jcb.200302001; Giannone G, 2004, CELL, V116, P431, DOI 10.1016/S0092-8674(04)00058-3; Gupton SL, 2005, J CELL BIOL, V168, P619, DOI 10.1083/jcb.200406063; Ji L, 2005, J MICROSC-OXFORD, V220, P150, DOI 10.1111/j.1365-2818.2005.01522.x; Jiang GY, 2003, NATURE, V424, P334, DOI 10.1038/nature01805; JOHNSON RP, 1995, NATURE, V373, P261, DOI 10.1038/373261a0; Katsumi A, 2004, J BIOL CHEM, V279, P12001, DOI 10.1074/jbc.R300038200; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LIN CH, 1995, NEURON, V14, P763, DOI 10.1016/0896-6273(95)90220-1; MARUYAMA K, 1965, J BIOCHEM-TOKYO, V58, P13, DOI 10.1093/oxfordjournals.jbchem.a128158; MUGURUMA M, 1990, BIOCHEM BIOPH RES CO, V171, P1217, DOI 10.1016/0006-291X(90)90815-5; Pelham RJ, 1997, P NATL ACAD SCI USA, V94, P13661, DOI 10.1073/pnas.94.25.13661; Ponti A, 2004, SCIENCE, V305, P1782, DOI 10.1126/science.1100533; Schlaepfer DD, 1996, CELL STRUCT FUNCT, V21, P445, DOI 10.1247/csf.21.445; Tanaka T, 1996, FEBS LETT, V399, P53, DOI 10.1016/S0014-5793(96)01280-X; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3	26	389	395	2	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 5	2007	315	5808					111	115		10.1126/science.1135085	http://dx.doi.org/10.1126/science.1135085			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	122WU	17204653				2022-12-28	WOS:000243259100049
J	Kumar, P				Kumar, Parveen			The greatest joy: the patient's thanks	BRITISH MEDICAL JOURNAL			English	Editorial Material									British Med Assoc, London WC1H 9JP, England		Kumar, P (corresponding author), British Med Assoc, Tavistock Sq, London WC1H 9JP, England.	pkumar@bma.org.uk							0	1	1	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	DEC 23	2006	333	7582					1321	1322		10.1136/bmj.39062.411875.80	http://dx.doi.org/10.1136/bmj.39062.411875.80			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121MC	17185726	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000243160700023
J	Fuerstman, MJ; Garstecki, P; Whitesides, GM				Fuerstman, Michael J.; Garstecki, Piotr; Whitesides, George M.			Coding/decoding and reversibility of droplet trains in microfluidic networks	SCIENCE			English	Article							LONG BUBBLES; MOTION; FLOW; MICROCHANNELS; PRESSURE	Droplets of one liquid suspended in a second, immiscible liquid move through a microfluidic device in which a channel splits into two branches that reconnect downstream. The droplets choose a path based on the number of droplets that occupy each branch. The interaction among droplets in the channels results in complex sequences of path selection. The linearity of the flow through the microchannels, however, ensures that the behavior of the system can be reversed. This reversibility makes it possible to encrypt and decrypt signals coded in the intervals between droplets. The encoding/decoding device is a functional microfluidic system that requires droplets to navigate a network in a precise manner without the use of valves, switches, or other means of external control.	Polish Acad Sci, Inst Phys Chem, PL-01224 Warsaw, Poland; Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA	Polish Academy of Sciences; Institute of Physical Chemistry of the Polish Academy of Sciences; Harvard University	Garstecki, P (corresponding author), Polish Acad Sci, Inst Phys Chem, Kasprzaka 44-52, PL-01224 Warsaw, Poland.	garst@ichf.edu.pl; gwhitesides@gmwgroup.harvard.edu	Garstecki, Piotr/ABA-9188-2020	Garstecki, Piotr/0000-0001-9101-7163				Anna SL, 2003, APPL PHYS LETT, V82, P364, DOI 10.1063/1.1537519; BRETHERTON FP, 1961, J FLUID MECH, V10, P166, DOI 10.1017/S0022112061000160; Cubaud T, 2004, PHYS FLUIDS, V16, P4575, DOI 10.1063/1.1813871; Engl W, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.208304; Ganan-Calvo AM, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.274501; Garstecki P, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.234502; Garstecki P, 2006, LAB CHIP, V6, P437, DOI 10.1039/b510841a; Garstecki P, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1946902; Garstecki P, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.164501; Garstecki P, 2005, NAT PHYS, V1, P168, DOI 10.1038/nphys176; Guillot P, 2005, PHYS REV E, V72, DOI 10.1103/PhysRevE.72.066301; Hodges SR, 2004, J FLUID MECH, V501, P279, DOI 10.1017/S0022112003007213; Jousse F, 2006, PHYS REV E, V74, DOI 10.1103/PhysRevE.74.036311; Link DR, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.054503; Pine DJ, 2005, NATURE, V438, P997, DOI 10.1038/nature04380; Squires TM, 2005, REV MOD PHYS, V77, P977, DOI 10.1103/RevModPhys.77.977; Stone HA, 2004, ANNU REV FLUID MECH, V36, P381, DOI 10.1146/annurev.fluid.36.050802.122124; TAYLOR GI, 1966, NATL COMMITTEE FLUID; Thorsen T, 2001, PHYS REV LETT, V86, P4163, DOI 10.1103/PhysRevLett.86.4163; Ward T, 2005, ELECTROPHORESIS, V26, P3716, DOI 10.1002/elps.200500173; WONG H, 1995, J FLUID MECH, V292, P95, DOI 10.1017/S0022112095001455	21	183	198	2	165	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 9	2007	315	5813					828	832		10.1126/science.1134514	http://dx.doi.org/10.1126/science.1134514			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	134FN	17204610				2022-12-28	WOS:000244069000064
J	Gewin, V				Gewin, Virginia			Crunch time for multiple-gene tests	NATURE			English	News Item																			0	6	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 25	2007	445	7126					354	355		10.1038/445354a	http://dx.doi.org/10.1038/445354a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	128WD	17251949				2022-12-28	WOS:000243689500010
J	Mahoney, MR; Sargent, DJ				Mahoney, Michelle R.; Sargent, Daniel J.			Adverse-event rates: journals versus databases	LANCET			English	Editorial Material							CANCER CLINICAL-TRIALS		Mayo Clin, Div Biostat, Rochester, MN 55905 USA	Mayo Clinic	Mahoney, MR (corresponding author), Mayo Clin, Div Biostat, Rochester, MN 55905 USA.	mahoney.michelle@mayo.edu		Sargent, Daniel/0000-0002-2684-4741				Anderson SJ, 2006, J CLIN ONCOL, V24, P3821, DOI 10.1200/JCO.2006.06.9856; FOOTE M, 2005, AM MED WRITERS ASS J, V20, P47; Goldberg RM, 2002, J CLIN ONCOL, V20, P4591, DOI 10.1200/JCO.2002.03.039; HILLMAN SL, 2006, J CLIN ONCOL S, V185, P6006; Ioannidis JPA, 2006, ANN INTERN MED, V144, P298, DOI 10.7326/0003-4819-144-4-200602210-00013; Ioannidis JPA, 2004, ANN INTERN MED, V141, P781, DOI 10.7326/0003-4819-141-10-200411160-00009; Keech AC, 2004, MED J AUSTRALIA, V181, P215, DOI 10.5694/j.1326-5377.2004.tb06241.x; Korn D, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010001; Mahoney MR, 2005, J CLIN ONCOL, V23, P9275, DOI 10.1200/JCO.2004.00.0588; Mann H, 2002, LANCET, V360, P406, DOI 10.1016/S0140-6736(02)09613-7; Morse MA, 2001, JAMA-J AM MED ASSOC, V285, P1201, DOI 10.1001/jama.285.9.1201; *NCI, 2005, CTEP NCI GUID ADV EV; *NCI, 2003, CLIN DAT UPD SYST CD; *NCI, CTEP FORMS TEMPL DOC; *NCI, MON CLIN TRIALS; Plint AC, 2006, MED J AUSTRALIA, V185, P263, DOI 10.5694/j.1326-5377.2006.tb00557.x; Raisch DW, 2001, CLIN THER, V23, P2011, DOI 10.1016/S0149-2918(01)80153-3; Scharf O, 2006, J CLIN ONCOL, V24, P3933, DOI 10.1200/JCO.2005.05.3959	18	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 20	2007	369	9557					171	172		10.1016/S0140-6736(07)60086-5	http://dx.doi.org/10.1016/S0140-6736(07)60086-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128XG	17240269				2022-12-28	WOS:000243692400008
J	Mierdel, K; Keppler, H; Smyth, JR; Langenhorst, F				Mierdel, Katrin; Keppler, Hans; Smyth, Joseph R.; Langenhorst, Falko			Water solubility in aluminous orthopyroxene and the origin of Earth's asthenosphere	SCIENCE			English	Article							LOW-VELOCITY ZONE; UPPER-MANTLE; SYSTEM MGO-AL2O3-SIO2; ENSTATITE; TEMPERATURE; PERIDOTITE; HYDROGEN; GARNET; LITHOSPHERE; DEPENDENCE	Plate tectonics is based on the concept of rigid lithosphere plates sliding on a mechanically weak asthenosphere. Many models assume that the weakness of the asthenosphere is related to the presence of small amounts of hydrous melts. However, the mechanism that may cause melting in the asthenosphere is not well understood. We show that the asthenosphere coincides with a zone where the water solubility in mantle minerals has a pronounced minimum. The minimum is due to a sharp decrease of water solubility in aluminous orthopyroxene with depth, whereas the water solubility in olivine continuously increases with pressure. Melting in the asthenosphere may therefore be related not to volatile enrichment but to a minimum in water solubility, which causes excess water to form a hydrous silicate melt.	Univ Tubingen, Inst Geowissensch, D-72074 Tubingen, Germany; Univ Bayreuth, Bayer Geoinst, D-95440 Bayreuth, Germany; Univ Colorado, Dept Geol Sci, Boulder, CO 80309 USA; Univ Jena, Inst Geowissensch, D-07749 Jena, Germany	Eberhard Karls University of Tubingen; University of Bayreuth; University of Colorado System; University of Colorado Boulder; Friedrich Schiller University of Jena	Keppler, H (corresponding author), Univ Tubingen, Inst Geowissensch, Wilheimstr 56, D-72074 Tubingen, Germany.	hans.keppler@uni-bayreuth.de		Langenhorst, Falko/0000-0003-4892-7713				Anderson D.L., 1970, PHYS EARTH PLANET IN, V3, P41, DOI DOI 10.1016/0031-9201(70)90042-7; ANDERSON DL, 1989, THEORY EARTH; BELL DR, 1995, AM MINERAL, V80, P465; Bell DR, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2001JB000679; BELL DR, 1992, SCIENCE, V255, P1391, DOI 10.1126/science.255.5050.1391; Bolfan-Casanova N, 2005, MINERAL MAG, V69, P229, DOI 10.1180/0026461056930248; CAMERON M, 1980, REV MINERAL, V7, P5; DANCKWERTH PA, 1978, CONTRIB MINERAL PETR, V66, P189, DOI 10.1007/BF00372158; Gasparik T., 2003, ATLAS EARTHS INTERIO, DOI [10.1007/978-3-540-38352-9, DOI 10.1007/978-3-540-38352-9]; Hirth G, 1996, EARTH PLANET SC LETT, V144, P93, DOI 10.1016/0012-821X(96)00154-9; Ingrin J, 2000, EUR J MINERAL, V12, P543; Karato S, 1998, EARTH PLANET SC LETT, V157, P193, DOI 10.1016/S0012-821X(98)00034-X; Kawamoto T, 1997, SCIENCE, V276, P240, DOI 10.1126/science.276.5310.240; Kohlstedt DL, 1996, CONTRIB MINERAL PETR, V123, P345, DOI 10.1007/s004100050161; KUSHIRO I, 1968, J GEOPHYS RES, V73, P6023, DOI 10.1029/JB073i018p06023; LAMBERT IB, 1968, NATURE, V219, P1240, DOI 10.1038/2191240a0; LAMBERT IB, 1970, SCIENCE, V169, P764, DOI 10.1126/science.169.3947.764; Lu R, 1997, CONTRIB MINERAL PETR, V129, P35, DOI 10.1007/s004100050321; Mierdel K, 2004, CONTRIB MINERAL PETR, V148, P305, DOI 10.1007/s00410-004-0605-z; PAIERSON MS, 1982, B MINERAL, V105, P20; PERKINS D, 1981, CONTRIB MINERAL PETR, V78, P99, DOI 10.1007/BF00371147; PITZER KS, 1994, J CHEM PHYS, V101, P3111, DOI 10.1063/1.467624; Rauch M, 2002, CONTRIB MINERAL PETR, V143, P525, DOI 10.1007/s00410-002-0365-6; Rychert CA, 2005, NATURE, V436, P542, DOI 10.1038/nature03904; Stalder R, 2002, EUR J MINERAL, V14, P1139, DOI 10.1127/0935-1221/2002/0014-1139; Turcotte D.L., 2002, GEODYNAMICS, DOI DOI 10.1002/GJ.987; Zhao YH, 2004, CONTRIB MINERAL PETR, V147, P155, DOI 10.1007/s00410-003-0524-4	27	204	221	4	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 19	2007	315	5810					364	368		10.1126/science.1135422	http://dx.doi.org/10.1126/science.1135422			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126SI	17234945				2022-12-28	WOS:000243535400038
J	Anderson, GF; Chu, E				Anderson, Gerard F.; Chu, Edward			Expanding priorities - Confronting chronic disease in countries with low income	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA; Johns Hopkins Sch Med, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Medicine	Anderson, GF (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA.		Thorpe, Allison/A-2705-2011					[Anonymous], 2005, PREV CHRON DIS VIT I; World Bank. Oxford University, 2006, DIS CONTR PRIOR DEV; 2006, GATES BUFFETT GIFT M	3	135	141	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 18	2007	356	3					209	211		10.1056/NEJMp068182	http://dx.doi.org/10.1056/NEJMp068182			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	126BV	17229946				2022-12-28	WOS:000243488100001
J	Buetow, S; Elwyn, G				Buetow, Stephen; Elwyn, Glyn			Patient safety and patient error	LANCET			English	Article							NONCOMPLIANCE; EVENTS		Univ Auckland, Dept Gen Practice & Primary Hlth Care, Auckland 1, New Zealand; Cardiff Univ, Ctr Hlth Sci Res, Dept Gen Practice, Cardiff, S Glam, Wales	University of Auckland; Cardiff University	Buetow, S (corresponding author), Univ Auckland, Dept Gen Practice & Primary Hlth Care, Private Bag 92019, Auckland 1, New Zealand.	s.buetow@auckland.ac.nz	Elwyn, Glyn/B-4798-2009; Elwyn, G./L-4292-2015	Elwyn, Glyn/0000-0002-0917-6286; Buetow, Stephen/0000-0002-9771-248X				Barber N, 2002, QUAL SAF HEALTH CARE, V11, P81, DOI 10.1136/qhc.11.1.81; Brennan TA, 2000, NEW ENGL J MED, V342, P1123, DOI 10.1056/NEJM200004133421510; Buetow S, 2006, J MED ETHICS, V32, P260, DOI 10.1136/jme.2005.012245; DARCY PF, 1976, ROY SOC HEALTH J, V96, P277; DONOVAN JL, 1992, SOC SCI MED, V34, P507, DOI 10.1016/0277-9536(92)90206-6; Elwyn G, 2001, EVIDENCE BASED PATIE; ELY JW, 1995, J FAM PRACTICE, V40, P337; Hardmeier B, 2004, SWISS MED WKLY, V134, P664; HIBBARD JH, 2003, MED CARE S1, V41, P61, DOI DOI 10.1097/00005650-200301001-00007; Hussain-Gambles M, 2004, BRIT J GEN PRACT, V54, P108; Kennedy I, 2003, BRIT MED J, V326, P1276, DOI 10.1136/bmj.326.7402.1276; Kinney ED, 2000, AM J LAW MED, V26, P335; Kohn KT, 2000, ERR IS HUMAN BUILDIN; Leape LL, 2000, BMJ-BRIT MED J, V320, P725, DOI 10.1136/bmj.320.7237.725; Loh CY, 2004, ALLERGY, V59, P1168, DOI 10.1111/j.1398-9995.2004.00554.x; Lundeen JM, 2003, FAM MED, V35, P355; MEYER G, 2003, INT J QUAL HEALTH C, V15, P125; Nieva VF, 2003, QUAL SAF HEALTH CARE, V12, pII17, DOI 10.1136/qhc.12.suppl_2.ii17; OSSERMAN KE, 1953, NEW YORK STATE J MED, V53, P1637; Parsons T., 1951, SOCIAL SYSTEM; REASON J, 2002, HUMAN ERROR; Rubin G, 2003, QUAL SAF HEALTH CARE, V12, P443, DOI 10.1136/qhc.12.6.443; STEINBERG A, 2005, BOSTON GLOBE BO 0530; Thomas EJ, 2003, J GEN INTERN MED, V18, P61, DOI 10.1046/j.1525-1497.2003.20147.x; Vincent CA, 2002, QUAL SAF HEALTH CARE, V11, P76, DOI 10.1136/qhc.11.1.76; World Health Organization, 2004, WORLD ALLIANCE PATIE; Zaghloul SS, 2004, ARCH DERMATOL, V140, P408, DOI 10.1001/archderm.140.4.408	27	29	29	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 13	2007	369	9556					158	161		10.1016/S0140-6736(07)60077-4	http://dx.doi.org/10.1016/S0140-6736(07)60077-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	126TK	17223479				2022-12-28	WOS:000243538200035
J	Nguyen, T; Vazquez, M; Toto, R				Nguyen, Thai; Vazquez, Miguel; Toto, Robert			Living kidney donation and hypertension risk	LANCET			English	Editorial Material							DONOR; TRANSPLANTATION; NEPHRECTOMY		Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Toto, R (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA.	Robert.toto@utsouthwestern.edu	Toto, Robert/AAQ-3336-2021					Boudville N, 2006, ANN INTERN MED, V145, P185, DOI 10.7326/0003-4819-145-3-200608010-00006; Cohen DJ, 2006, AM J TRANSPLANT, V6, P1153, DOI 10.1111/j.1600-6143.2006.01272.x; Davis CL, 2005, J AM SOC NEPHROL, V16, P2098, DOI 10.1681/ASN.2004100824; Davis CL, 2004, AM J KIDNEY DIS, V43, P508, DOI 10.1053/j.ajkd.2003.10.044; HOSTETTER T, 1981, AM J PHYSIOL, V241, P85; Johnson EM, 1997, TRANSPLANTATION, V64, P1124, DOI 10.1097/00007890-199710270-00007; KASISKE BL, 1995, KIDNEY INT, V48, P814, DOI 10.1038/ki.1995.355; McCune TR, 2004, CLIN TRANSPLANT, V18, P33, DOI 10.1111/j.1399-0012.2004.00215.x; NAJARIAN JS, 1992, LANCET, V340, P807, DOI 10.1016/0140-6736(92)92683-7; Praga M, 2000, KIDNEY INT, V58, P2111, DOI 10.1046/j.1523-1755.2000.00384.x; Waterman Amy D, 2006, Prog Transplant, V16, P17	11	4	4	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 13	2007	369	9556					87	88		10.1016/S0140-6736(07)60046-4	http://dx.doi.org/10.1016/S0140-6736(07)60046-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	126TK	17223455				2022-12-28	WOS:000243538200008
J	Collins, FS				Collins, Francis S.		Int Mouse Knockout Consortium	A mouse for all reasons	CELL			English	Editorial Material							MULTIPURPOSE; ALLELES; GENOME	Three major mouse knockout programs are underway worldwide, working together to mutate all protein-encoding genes in the mouse using a combination of gene trapping and gene targeting in mouse embryonic stem (ES) cells. Although the current emphasis is on production of this valuable resource, there are significant efforts to facilitate program coordination, to enhance the availability of this resource, and to plan for future efforts in mouse genetics research.	Univ Toronto, Hosp Sick Children, Toronto, ON M5G 1X8, Canada; Tech Univ Munich, GSF, Natl Res Ctr Environm & Hlth, D-8000 Munich, Germany	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; University of Munich		francisc@mail.nih.gov	Lefebvre, Louis/O-9309-2016; Nagy, Andras/G-6465-2013	Lefebvre, Louis/0000-0001-5664-9480; Nagy, Andras/0000-0003-4311-0413				Austin CP, 2004, NAT GENET, V36, P921, DOI 10.1038/ng0904-921; Auwerx J, 2004, NAT GENET, V36, P925, DOI 10.1038/ng0904-925; Copeland NG, 2001, NAT REV GENET, V2, P769, DOI 10.1038/35093556; Friedel RH, 2005, P NATL ACAD SCI USA, V102, P13188, DOI 10.1073/pnas.0505474102; Schnutgen F, 2005, P NATL ACAD SCI USA, V102, P7221, DOI 10.1073/pnas.0502273102; Skarnes WC, 2004, NAT GENET, V36, P543, DOI 10.1038/ng0604-543; Testa G, 2004, GENESIS, V38, P151, DOI 10.1002/gene.20012; Valenzuela DM, 2003, NAT BIOTECHNOL, V21, P652, DOI 10.1038/nbt822; Zhang YM, 1998, NAT GENET, V20, P123, DOI 10.1038/2417	9	324	354	0	12	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 12	2007	128	1					9	13		10.1016/j.cell.2006.12.018	http://dx.doi.org/10.1016/j.cell.2006.12.018			5	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	139GN	17218247	Bronze			2022-12-28	WOS:000244420400005
J	Leonard, DC				Leonard, Douglas C.			A supernova riddle	SCIENCE			English	Editorial Material							IA SUPERNOVAE; SPECTROPOLARIMETRY; ASPHERICITY		San Diego State Univ, Dept Astron, San Diego, CA 92182 USA	California State University System; San Diego State University	Leonard, DC (corresponding author), San Diego State Univ, Dept Astron, San Diego, CA 92182 USA.	leonard@sciences.sdsu.edu						Gamezo VN, 2005, ASTROPHYS J, V623, P337, DOI 10.1086/428767; Glanz J, 1998, SCIENCE, V282, P2156; Howell DA, 2001, ASTROPHYS J, V556, P302, DOI 10.1086/321584; Leonard DC, 2005, ASTROPHYS J, V632, P450, DOI 10.1086/432866; Li WD, 2001, ASTROPHYS J, V546, P734, DOI 10.1086/318299; Phillips M.M., 1993, ASTROPHYS J LETT, V413, P105; Reinecke M, 2002, ASTRON ASTROPHYS, V391, P1167, DOI 10.1051/0004-6361:20020885; WANG L, IN PRESS ASTROPHYS J; Wang LF, 2003, ASTROPHYS J, V591, P1110, DOI 10.1086/375444; Wang LF, 2007, SCIENCE, V315, P212, DOI 10.1126/science.1121656	11	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 12	2007	315	5809					193	194		10.1126/science.1123373	http://dx.doi.org/10.1126/science.1123373			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124XZ	17218513	Green Submitted			2022-12-28	WOS:000243407400030
J	Samardzija, MR				Samardzija, Michael R.			Science and law - The obvious war	SCIENCE			English	Editorial Material									Univ Texas, MD Anderson Canc Ctr, Off Technol Commercializat, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Samardzija, MR (corresponding author), Univ Texas, MD Anderson Canc Ctr, Off Technol Commercializat, 1515 Holcombe Blvd, Houston, TX 77030 USA.	michaels@mdanderson.org						Janicke PM, 2002, ANTITRUST LAW J, V69, P645; LERNER J, 1995, J LAW ECON, V38, P463, DOI 10.1086/467339; MANDEL G, 2006, IN PRESS YALE J LAW; Shapiro C, 2001, INNOV POLICY EC, V1, P119, DOI DOI 10.1086/ipe.1.25056143; *USPTO, 2006, TRANSF M CHALL 21 CE, P64; WAGNER RP, IN PRESS TEXAS LAW R, V85	6	2	2	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 12	2007	315	5809					190	191		10.1126/science.1136053	http://dx.doi.org/10.1126/science.1136053			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	124XZ	17218511				2022-12-28	WOS:000243407400028
J	Hack, M; Costello, DW				Hack, Maureen; Costello, Deanne Wilson			Decrease in frequency of cerebral palsy in preterm infants	LANCET			English	Editorial Material							EPIDEMIOLOGY		Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Case Med Ctr, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital	Hack, M (corresponding author), Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Case Med Ctr, Cleveland, OH 44106 USA.	mxh7@po.cwru.edu						Bax M, 2005, DEV MED CHILD NEUROL, V47, P571, DOI 10.1017/S001216220500112X; Blair E, 2006, SEMIN FETAL NEONAT M, V11, P117, DOI 10.1016/j.siny.2005.10.010; Hagberg B, 1996, ACTA PAEDIATR, V85, P954, DOI 10.1111/j.1651-2227.1996.tb14193.x; Martin JA, 2005, PRELIMINARY BIRTHS 2; PALLISANO R, 1997, DEV MED CHILD NEUROL, V39, P214; Paneth N, 2006, CLIN PERINATOL, V33, P251, DOI 10.1016/j.clp.2006.03.011; Platt MJ, 2007, LANCET, V369, P43, DOI 10.1016/S0140-6736(07)60030-0; WILSONCOSTELLO D, IN PRESS PEDIATRICS	8	5	7	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 6	2007	369	9555					7	8		10.1016/S0140-6736(07)60006-3	http://dx.doi.org/10.1016/S0140-6736(07)60006-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125AK	17208622				2022-12-28	WOS:000243413700006
J	Gottar, M; Gobert, V; Matskevich, AA; Reichhart, JM; Wang, CS; Butt, TM; BeIvin, M; Hoffmann, JA; Ferrandon, D				Gottar, Marie; Gobert, Vanessa; Matskevich, Alexey A.; Reichhart, Jean-Marc; Wang, Chengshu; Butt, Tariq M.; BeIvin, Marcia; Hoffmann, Jules A.; Ferrandon, Dominique			Dual detection of fungal infections in Drosophila via recognition of glucans and sensing of virulence factors	CELL			English	Article							POSITIVE BACTERIAL-INFECTIONS; GRAM-NEGATIVE BACTERIA; IMMUNE-RESPONSE; METARHIZIUM-ANISOPLIAE; ANTIMICROBIAL PEPTIDE; DEFICIENT DROSOPHILA; MANDUCA-SEXTA; TOLL PATHWAY; HOST-DEFENSE; PROTEIN	The Drosophila immune system discriminates between various types of infections and activates appropriate signal transduction pathways to combat the invading microorganisms. The Toll pathway is required for the host response against fungal and most Gram-positive bacterial infections. The sensing of Gram-positive bacteria is mediated by the pattern recognition receptors PGRP-SA and GNBP1 that cooperate to detect the presence of infections in the host. Here, we report that GNBP3 is a pattern recognition receptor that is required for the detection of fungal cell wall components. Strikingly, we find that there is a second, parallel pathway acting jointly with GNBP3. The Drosophila Persephone protease activates the Toll pathway when proteolytically matured by the secreted fungal virulence factor PR1. Thus, the detection of fungal infections in Drosophila relies both on the recognition of invariant microbial patterns and on monitoring the effects of virulence factors on the host.	CNRS, Inst Biol Mol & Cellulaire, UPR 9022, F-67084 Strasbourg, France; Exelixis Inc, San Francisco, CA 94083 USA; Univ Wales Swansea, Dept Biol Sci, Swansea SA2 8PP, W Glam, Wales	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Exelixis, Inc.; Swansea University	Ferrandon, D (corresponding author), CNRS, Inst Biol Mol & Cellulaire, UPR 9022, F-67084 Strasbourg, France.	d.ferrandon@ibmc.u-strasbg.fr	Wang, Chengshu/A-1656-2011	Wang, Chengshu/0000-0003-1477-1466; Butt, Tariq/0000-0002-8789-9543; FERRANDON, Dominique/0000-0001-7680-7773	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI044220] Funding Source: NIH RePORTER; NIAID NIH HHS [P01 AI44220, P01 AI044220, P01 AI044220-08] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alarco AM, 2004, J IMMUNOL, V172, P5622, DOI 10.4049/jimmunol.172.9.5622; Bagga S, 2004, GENE, V324, P159, DOI 10.1016/j.gene.2003.09.031; Bischoff V, 2004, NAT IMMUNOL, V5, P1175, DOI 10.1038/ni1123; Brown GD, 2001, NATURE, V413, P36, DOI 10.1038/35092620; Chung WO, 2004, J IMMUNOL, V173, P5165, DOI 10.4049/jimmunol.173.8.5165; Clarkson JM, 1996, TRENDS MICROBIOL, V4, P197, DOI 10.1016/0966-842X(96)10022-6; Dangl JL, 2001, NATURE, V411, P826, DOI 10.1038/35081161; FEHLBAUM P, 1994, J BIOL CHEM, V269, P33159; Ferrandon D, 2004, SEMIN IMMUNOL, V16, P43, DOI 10.1016/j.smim.2003.10.008; Fontaine T, 2000, J BIOL CHEM, V275, P27594; Gobert V, 2003, SCIENCE, V302, P2126, DOI 10.1126/science.1085432; Gottar M, 2002, NATURE, V416, P640, DOI 10.1038/nature734; Hansen KK, 2005, P NATL ACAD SCI USA, V102, P8363, DOI 10.1073/pnas.0409535102; Hoffmann JA, 2003, NATURE, V426, P33, DOI 10.1038/nature02021; Jang IH, 2006, DEV CELL, V10, P45, DOI 10.1016/j.devcel.2005.11.013; Jung AC, 2001, BIOTECHNIQUES, V30, P594, DOI 10.2144/01303rr04; Kambris Z, 2006, CURR BIOL, V16, P808, DOI 10.1016/j.cub.2006.03.020; Kaneko T, 2005, CELL MICROBIOL, V7, P461, DOI 10.1111/j.1462-5822.2005.00504.x; Kaneko T, 2006, NAT IMMUNOL, V7, P715, DOI 10.1038/ni1356; Kerfoot SM, 2004, J IMMUNOL, V173, P7070, DOI 10.4049/jimmunol.173.11.7070; Kim MG, 2005, CELL, V121, P749, DOI 10.1016/j.cell.2005.03.025; Kim YS, 2000, J BIOL CHEM, V275, P32721, DOI 10.1074/jbc.M003934200; Lee MH, 2004, J BIOL CHEM, V279, P3218, DOI 10.1074/jbc.M309821200; Lee SH, 2006, PROTEIN SCI, V15, P304, DOI 10.1110/ps.051813506; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Lemaitre B, 1997, P NATL ACAD SCI USA, V94, P14614, DOI 10.1073/pnas.94.26.14614; Levashina EA, 1999, SCIENCE, V285, P1917, DOI 10.1126/science.285.5435.1917; Ligoxygakis P, 2002, SCIENCE, V297, P114, DOI 10.1126/science.1072391; Ma CC, 2000, J BIOL CHEM, V275, P7505, DOI 10.1074/jbc.275.11.7505; Malley R, 2003, P NATL ACAD SCI USA, V100, P1966, DOI 10.1073/pnas.0435928100; Michel T, 2001, NATURE, V414, P756, DOI 10.1038/414756a; Mota LJ, 2005, ANN MED, V37, P234, DOI 10.1080/07853890510037329; Ochiai M, 2000, J BIOL CHEM, V275, P4995, DOI 10.1074/jbc.275.7.4995; Park JM, 2004, J EXP MED, V200, P1647, DOI 10.1084/jem.20041215; Roberts D.W., 1981, BIOL CONIDIAL FUNGI, P201; Rooney HCE, 2005, SCIENCE, V308, P1783, DOI 10.1126/science.1111404; Rutschmann S, 2000, NAT IMMUNOL, V1, P342, DOI 10.1038/79801; Rutschmann S, 2000, IMMUNITY, V12, P569, DOI 10.1016/S1074-7613(00)80208-3; Rutschmann S, 2002, J IMMUNOL, V168, P1542, DOI 10.4049/jimmunol.168.4.1542; Shao F, 2003, SCIENCE, V301, P1230, DOI 10.1126/science.1085671; STLEGER RJ, 1992, EUR J BIOCHEM, V204, P991, DOI 10.1111/j.1432-1033.1992.tb16721.x; Tauszig-Delamasure S, 2002, NAT IMMUNOL, V3, P91, DOI 10.1038/ni747; Thibault ST, 2004, NAT GENET, V36, P283, DOI 10.1038/ng1314; Tzou P, 2002, P NATL ACAD SCI USA, V99, P2152, DOI 10.1073/pnas.042411999; Viboud GI, 2005, ANNU REV MICROBIOL, V59, P69, DOI 10.1146/annurev.micro.59.030804.121320; Wang CS, 2005, FUNGAL GENET BIOL, V42, P704, DOI 10.1016/j.fgb.2005.04.006; Wang CS, 2002, FEMS MICROBIOL LETT, V213, P251, DOI 10.1111/j.1574-6968.2002.tb11314.x	47	299	311	3	58	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 29	2006	127	7					1425	1437		10.1016/j.cell.2006.10.046	http://dx.doi.org/10.1016/j.cell.2006.10.046			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	128WI	17190605	Green Accepted, Bronze			2022-12-28	WOS:000243690000021
J	Phillips, JA				Phillips, John A.			Is Burkitt's lymphoma sexy enough?	LANCET			English	Editorial Material											Phillips, JA (corresponding author), 60 Old Rossorry Rd, Enniskillen BT74 7LF, Fermanagh, North Ireland.	jnsphillips@tiscali.co.uk							0	5	5	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 23	2006	368	9554					2251	2252		10.1016/S0140-6736(06)69898-X	http://dx.doi.org/10.1016/S0140-6736(06)69898-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	120HY	17189037				2022-12-28	WOS:000243076800033
J	Stepney, R				Stepney, Rob			Back to the future: how good are doctors at gazing in the crystal ball?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												walcot2@freenetname.co.uk						ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; *CANC RES UK, 2005, TRENDS CANC SURV RAT; *CDCP, 2006, CANC SURV; *CDCP, PROGR BRIEF GLOB HLT; *CDCP, 2006, BAS STAT; Kane JM, 2006, AM J PSYCHIAT, V163, P1316, DOI 10.1176/appi.ajp.163.8.1316; Lucas FL, 2006, CIRCULATION, V113, P374, DOI 10.1161/CIRCULATIONAHA.105.560433; TAYLOR H, 1987, BRISTOL MYERS REPORT	8	2	2	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 23	2006	333	7582					1311	1313		10.1136/bmj.39049.751701.47	http://dx.doi.org/10.1136/bmj.39049.751701.47			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121MC	17185720	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000243160700018
J	Trilla, A; Aymerich, M; Lacy, AM; Bertran, MJ				Trilla, Antoni; Aymerich, Marta; Lacy, Antonio M.; Bertran, Maria J.			Phenotypic differences between male physicians, surgeons, and film stars: comparative study	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Barcelona, Hosp Clin, Prevent Med & Epidemiol Unit, E-08036 Barcelona, Spain; Univ Barcelona, Hosp Clin, Haemopathol Unit, E-08036 Barcelona, Spain; Univ Barcelona, Hosp Clin, Gen & Digest Tract Surg Unit, E-08036 Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona	Trilla, A (corresponding author), Univ Barcelona, Hosp Clin, Prevent Med & Epidemiol Unit, E-08036 Barcelona, Spain.	atrilla@clinic.ub.es	Trilla, Antoni/G-2446-2018					Gordon PM, 1995, BRIT MED J, V311, P1704, DOI 10.1136/bmj.311.7021.1704; Isaacs D, 1999, BRIT MED J, V319, P1618, DOI 10.1136/bmj.319.7225.1618; Rowland Pamela A, 2005, Curr Surg, V62, P214, DOI 10.1016/j.cursur.2004.08.008; *WIK, SNOW WHIT	4	14	14	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 23	2006	333	7582					1291	1293		10.1136/bmj.39015.672373.80	http://dx.doi.org/10.1136/bmj.39015.672373.80			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121MC	17185711	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000243160700009
J	Oransky, I				Oransky, Ivan			Richard Joseph Mulvaney - Obituary	LANCET			English	Biographical-Item												ivan-oransky@erols.com							0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 16	2006	368	9553					2120	2120		10.1016/S0140-6736(06)69851-6	http://dx.doi.org/10.1016/S0140-6736(06)69851-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	117EZ	17195298				2022-12-28	WOS:000242856900010
J	Stamenkovic, VR; Fowler, B; Mun, BS; Wang, GF; Ross, PN; Lucas, CA; Markovic, NM				Stamenkovic, Vojislav R.; Fowler, Ben; Mun, Bongjin Simon; Wang, Guofeng; Ross, Philip N.; Lucas, Christopher A.; Markovic, Nenad M.			Improved oxygen reduction activity on Pt3Ni(111) via increased surface site availability	SCIENCE			English	Article							ELECTRONIC-STRUCTURE; ALLOY; ELECTROCATALYSIS; CATALYSIS; KINETICS; NI	The slow rate of the oxygen reduction reaction (ORR) in the polymer electrolyte membrane fuel cell ( PEMFC) is the main limitation for automotive applications. We demonstrated that the Pt3Ni( 111) surface is 10-fold more active for the ORR than the corresponding Pt(111) surface and 90-fold more active than the current state-of-the- art Pt/C catalysts for PEMFC. The Pt3Ni( 111) surface has an unusual electronic structure (d-band center position) and arrangement of surface atoms in the near-surface region. Under operating conditions relevant to fuel cells, its near-surface layer exhibits a highly structured compositional oscillation in the outermost and third layers, which are Pt-rich, and in the second atomic layer, which is Ni-rich. The weak interaction between the Pt surface atoms and nonreactive oxygenated species increases the number of active sites for O-2 adsorption.	Argonne Natl Lab, Div Mat Sci, Argonne, IL 60439 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Sci Mat, Berkeley, CA 94720 USA; Univ Liverpool, Dept Phys, Oliver Lodge Lab, Liverpool L69 7ZE, Merseyside, England; Univ S Carolina, Dept Chem & Phys, Aiken, SC 29801 USA	United States Department of Energy (DOE); Argonne National Laboratory; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of Liverpool; University of South Carolina	Stamenkovic, VR (corresponding author), Argonne Natl Lab, Div Mat Sci, 9700 S Cass Ave, Argonne, IL 60439 USA.	vrstamenkovic@anl.gov; nmmarkovic@anl.gov	Stamenkovic, Vojislav/ABD-5466-2021; Mun, Bongjin/G-1701-2013; Stamenkovic, Vojislav/AAF-1435-2019	Stamenkovic, Vojislav/0000-0002-1149-3563; Lucas, Christopher/0000-0001-5743-3868	EPSRC [EP/F000766/1] Funding Source: UKRI; Engineering and Physical Sciences Research Council [EP/D034892/1, EP/F000766/1] Funding Source: researchfish	EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))		Adzic R, 1998, FRONT ELECT, P197; APPLEBY AJ, 1970, CATALY REV, V4, P221; Besenbacher F, 1998, SCIENCE, V279, P1913, DOI 10.1126/science.279.5358.1913; CAMPBELL CT, 1990, ANNU REV PHYS CHEM, V41, P775; Gasteiger HA, 2005, APPL CATAL B-ENVIRON, V56, P9, DOI 10.1016/j.apcatb.2004.06.021; Gauthier Y, 1996, SURF REV LETT, V3, P1663, DOI 10.1142/S0218625X9600262X; GAUTHIER Y, 1985, PHYS REV B, V31, P6216, DOI 10.1103/PhysRevB.31.6216; Gottesfeld S., 1997, ADV ELECTROCHEMICAL, V5; Greeley J, 2002, ANNU REV PHYS CHEM, V53, P319, DOI 10.1146/annurev.physchem.53.100301.131630; Hammer B, 2000, ADV CATAL, V45, P71; Kinoshita K., 1992, ELECTROCHEMICAL OXYG; Lucas CA, 2006, ADV ELECTROCHEMICAL, V9; LUCZAK FJ, 1987, Patent No. 4711829; Markovic NM, 2002, SURF SCI REP, V45, P121, DOI 10.1016/S0167-5729(01)00022-X; MARKOVIC NM, 1995, J PHYS CHEM-US, V99, P3411, DOI 10.1021/j100011a001; MUKERJEE S, 1993, J ELECTROANAL CHEM, V357, P201, DOI 10.1016/0022-0728(93)80380-Z; Mun BS, 2005, PHYS REV B, V71, DOI 10.1103/PhysRevB.71.115420; Norskov JK, 2006, SCIENCE, V312, P1322, DOI 10.1126/science.1127180; Paulus UA, 2002, J PHYS CHEM B, V106, P4181, DOI 10.1021/jp013442l; ROBINSON IK, 1989, PHYS REV LETT, V63, P2578, DOI 10.1103/PhysRevLett.63.2578; Stamenkovic V, 2003, J ELECTROANAL CHEM, V554, P191, DOI 10.1016/S0022-0728(03)00177-3; Stamenkovic V, 2002, J PHYS CHEM B, V106, P11970, DOI 10.1021/jp021182h; Stamenkovic V, 2006, ANGEW CHEM INT EDIT, V45, P2897, DOI 10.1002/anie.200504386; Stamenkovic VR, 2006, J AM CHEM SOC, V128, P8813, DOI 10.1021/ja0600476; TARASEVICH MR, 1983, COMPR TREAT, pCH6; Thiel P. A., 1995, HDB SURFACE IMAGING; Toda T, 1999, J ELECTROCHEM SOC, V146, P3750, DOI 10.1149/1.1392544; Vielstich W, 2003, HDB FUEL CELLS FUNDA; Zhang JL, 2005, ANGEW CHEM INT EDIT, V44, P2132, DOI 10.1002/anie.200462335	29	3421	3493	82	3183	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 26	2007	315	5811					493	497		10.1126/science.1135941	http://dx.doi.org/10.1126/science.1135941			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	129JU	17218494	Green Submitted			2022-12-28	WOS:000243726600040
J	Morris, MC; Tangney, CC				Morris, Martha Clare; Tangney, Christine C.			Is dietary intake of folate too low?	LANCET			English	Editorial Material							FORTIFICATION; POPULATION		Rush Inst Healthy Aging, Chicago, IL 60612 USA; Rush Univ, Med Ctr, Dept Nutr, Chicago, IL 60612 USA	Rush University; Rush University	Morris, MC (corresponding author), Rush Inst Healthy Aging, Chicago, IL 60612 USA.	Martha_C_Morris@rush.edu			NIA NIH HHS [R01 AG021972] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG021972] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		deBree A, 1997, EUR J CLIN NUTR, V51, P643, DOI 10.1038/sj.ejcn.1600467; Dietrich M, 2005, J AM COLL NUTR, V24, P266, DOI 10.1080/07315724.2005.10719474; Durga J, 2007, LANCET, V369, P208, DOI 10.1016/S0140-6736(07)60109-3; *FOOD NUTR BOARD I, 1998, DIET REF INT THIAM R; Herbert V, 1994, MODERN NUTR HLTH DIS, V1, P402; Kafatos A, 2000, J AM DIET ASSOC, V100, P1487, DOI 10.1016/S0002-8223(00)00416-8; Pfeiffer CM, 2005, AM J CLIN NUTR, V82, P442, DOI 10.1093/ajcn/82.2.442; SAUBERLICH HE, 1999, FOLATE FOLIC ACID PT, P103; SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693; Ulrich CM, 2006, CANCER EPIDEM BIOMAR, V15, P189, DOI 10.1158/1055-9965.EPI-152CO	10	17	17	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 20	2007	369	9557					166	167		10.1016/S0140-6736(07)60083-X	http://dx.doi.org/10.1016/S0140-6736(07)60083-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128XG	17240266	Green Accepted			2022-12-28	WOS:000243692400005
J	Benton, TG				Benton, Tim G.			Ecology - Managing farming's footprint on biodiversity	SCIENCE			English	Editorial Material							FARMLAND BIRD POPULATIONS; AGRICULTURAL INTENSIFICATION; ABUNDANCE		Univ Leeds, Inst Integrat & Comparat Biol, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Benton, TG (corresponding author), Univ Leeds, Inst Integrat & Comparat Biol, Leeds LS2 9JT, W Yorkshire, England.	t.g.benton@leeds.ac.uk	Benton, Tim G/C-6493-2009	Benton, Tim G/0000-0002-7448-1973	Economic and Social Research Council [RES-227-25-0006] Funding Source: researchfish	Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC))		Bengtsson J, 2005, J APPL ECOL, V42, P261, DOI 10.1111/j.1365-2664.2005.01005.x; Benton TG, 2006, P R SOC B, V273, P1173, DOI 10.1098/rspb.2006.3495; Butler SJ, 2007, SCIENCE, V315, P381, DOI 10.1126/science.1136607; Casula P, 2006, ECOL LETT, V9, P995, DOI 10.1111/j.1461-0248.2006.00945.x; Chamberlain DE, 2000, J APPL ECOL, V37, P771, DOI 10.1046/j.1365-2664.2000.00548.x; Donald PF, 2001, P ROY SOC B-BIOL SCI, V268, P25, DOI 10.1098/rspb.2000.1325; Donald PF, 2006, J APPL ECOL, V43, P209, DOI 10.1111/j.1365-2664.2006.01146.x; Gabriel D, 2006, ECOL APPL, V16, P2011, DOI 10.1890/1051-0761(2006)016[2011:BDADSS]2.0.CO;2; Green RE, 2005, SCIENCE, V307, P550, DOI 10.1126/science.1106049; Krebs JR, 1999, NATURE, V400, P611, DOI 10.1038/23127; Loehle C, 2006, J APPL ECOL, V43, P957, DOI 10.1111/j.1365-2664.2006.01208.x; Robinson RA, 2002, J APPL ECOL, V39, P157, DOI 10.1046/j.1365-2664.2002.00695.x; Stephens PA, 2003, J APPL ECOL, V40, P970, DOI 10.1111/j.1365-2664.2003.00865.x; Sutherland WJ, 2006, J APPL ECOL, V43, P617, DOI 10.1111/j.1365-2664.2006.01188.x; Tilman D, 2001, SCIENCE, V292, P281, DOI 10.1126/science.1057544; *UN ENV PROGR, GLOB ENV OUTL 1	16	42	43	1	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 19	2007	315	5810					341	342		10.1126/science.1137650	http://dx.doi.org/10.1126/science.1137650			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	126SI	17234937				2022-12-28	WOS:000243535400028
J	Goodson, KE				Goodson, K. E.			Ordering up the minimum thermal conductivity of solids	SCIENCE			English	Editorial Material									Stanford Univ, Dept Mech Engn, Stanford, CA 94305 USA	Stanford University	Goodson, KE (corresponding author), Stanford Univ, Dept Mech Engn, Stanford, CA 94305 USA.	goodson@stanford.edu	Goodson, Kenneth E/C-3545-2011					[Anonymous], 1979, SOLID STATE PHYS, DOI 10.1016/S0081-1947(08)60359-8; CAHILL DG, 1992, PHYS REV B, V46, P6131, DOI 10.1103/PhysRevB.46.6131; CHIRITESCU C, 2006, SCIENCE         1214, DOI DOI 10.1126/SCIENCE.1136494; Chiritescu C, 2007, SCIENCE, V315, P351, DOI 10.1126/science.1136494; Costescu RM, 2004, SCIENCE, V303, P989, DOI 10.1126/science.1093711; Jain A, 2002, J APPL PHYS, V91, P3275, DOI 10.1063/1.1448407; Kelly MJ, 2006, INT J APPL CERAM TEC, V3, P81, DOI 10.1111/j.1744-7402.2006.02073.x; Kim P, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.215502; OLSON JR, 1993, PHYS REV B, V47, P14850, DOI 10.1103/PhysRevB.47.14850; Pirovano A, 2004, IEEE T ELECTRON DEV, V51, P452, DOI 10.1109/TED.2003.823243; Venkatasubramanian R, 2001, NATURE, V413, P597, DOI 10.1038/35098012	12	59	62	2	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 19	2007	315	5810					342	343		10.1126/science.1138067	http://dx.doi.org/10.1126/science.1138067			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126SI	17234938				2022-12-28	WOS:000243535400029
J	Kristan, WB				Kristan, William B.			A push-me pull-you neural design	SCIENCE			English	Editorial Material							INHIBITION; EXCITATION		Univ Calif San Diego, Div Biol Sci, Neurobiol Sect, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Kristan, WB (corresponding author), Univ Calif San Diego, Div Biol Sci, Neurobiol Sect, La Jolla, CA 92093 USA.	wkristan@ucsd.edu						Attwell D, 2001, J CEREBR BLOOD F MET, V21, P1133, DOI 10.1097/00004647-200110000-00001; Berg RW, 2007, SCIENCE, V315, P390, DOI 10.1126/science.1134960; Berkowitz A, 2005, J NEUROPHYSIOL, V94, P4455, DOI 10.1152/jn.00229.2005; BROCK LG, 1952, J PHYSIOL-LONDON, V117, P431, DOI 10.1113/jphysiol.1952.sp004759; CARR CE, 1990, J NEUROSCI, V10, P3227; Chance FS, 2002, NEURON, V35, P773, DOI 10.1016/S0896-6273(02)00820-6; Gabernet L, 2005, NEURON, V48, P315, DOI 10.1016/j.neuron.2005.09.022; Haider B, 2006, J NEUROSCI, V26, P4535, DOI 10.1523/JNEUROSCI.5297-05.2006; Higley MJ, 2006, J NEUROSCI, V26, P448, DOI 10.1523/JNEUROSCI.3506-05.2006; Litvak V, 2003, J NEUROSCI, V23, P3006; Salinas E, 2000, J NEUROSCI, V20, P6193, DOI 10.1523/JNEUROSCI.20-16-06193.2000; Sherrington C.S., 1906, INTEGRATIVE ACTION N	12	6	6	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 19	2007	315	5810					339	340		10.1126/science.1138110	http://dx.doi.org/10.1126/science.1138110			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126SI	17234936				2022-12-28	WOS:000243535400027
J	Massey, R; Rhodes, J; Ellis, R; Scoville, N; Leauthaud, A; Finoguenov, A; Capak, P; Bacon, D; Aussel, H; Kneib, JP; Koekemoer, A; McCracken, H; Mobasher, B; Pires, S; Refregier, A; Sasaki, S; Starck, JL; Taniguchi, Y; Taylor, A; Taylor, J				Massey, Richard; Rhodes, Jason; Ellis, Richard; Scoville, Nick; Leauthaud, Alexie; Finoguenov, Alexis; Capak, Peter; Bacon, David; Aussel, Herve; Kneib, Jean-Paul; Koekemoer, Anton; McCracken, Henry; Mobasher, Bahram; Pires, Sandrine; Refregier, Alexandre; Sasaki, Shunji; Starck, Jean-Luc; Taniguchi, Yoshi; Taylor, Andy; Taylor, James			Dark matter maps reveal cosmic scaffolding	NATURE			English	Article							WEAK; EVOLUTION; GALAXIES; SPACE	Ordinary baryonic particles ( such as protons and neutrons) account for only one-sixth of the total matter in the Universe(1-3). The remainder is a mysterious 'dark matter' component, which does not interact via electromagnetism and thus neither emits nor reflects light. As dark matter cannot be seen directly using traditional observations, very little is currently known about its properties. It does interact via gravity, and is most effectively probed through gravitational lensing: the deflection of light from distant galaxies by the gravitational attraction of foreground mass concentrations(4,5). This is a purely geometrical effect that is free of astrophysical assumptions and sensitive to all matter - whether baryonic or dark(6,7). Here we show high-fidelity maps of the large-scale distribution of dark matter, resolved in both angle and depth. We find a loose network of filaments, growing over time, which intersect in massive structures at the locations of clusters of galaxies. Our results are consistent with predictions of gravitationally induced structure formation(8,9), in which the initial, smooth distribution of dark matter collapses into filaments then into clusters, forming a gravitational scaffold into which gas can accumulate, and stars can be built(10).	CALTECH, Pasadena, CA 91125 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Lab Astrophys Marseille, F-13376 Marseille 12, France; Max Planck Inst Extraterr Phys, D-85748 Garching, Germany; Inst Astron, Edinburgh EH9 3HJ, Midlothian, Scotland; CNRS, CEA, Unite Mixte Rech, AIM, F-91191 Gif Sur Yvette, France; Univ Paris 07, CE Saclay, UMR 7158, F-91191 Gif Sur Yvette, France; Space Telescope Sci Inst, Baltimore, MD 21218 USA; Univ Paris 06, Inst Astrophys Paris, F-75014 Paris, France; Ctr Etud Saclay, CEA, DSM, DAPNIA,SEDI, F-91191 Gif Sur Yvette, France; Ehime Univ, Dept Phys, Matsuyama, Ehime 7908577, Japan; Univ Waterloo, Dept Phys & Astron, Waterloo, ON N2L 3G1, Canada	California Institute of Technology; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); UDICE-French Research Universities; Aix-Marseille Universite; Max Planck Society; University of Edinburgh; UDICE-French Research Universities; Universite Paris Cite; CEA; Centre National de la Recherche Scientifique (CNRS); Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); UDICE-French Research Universities; Universite Paris Cite; CEA; Universite Paris Saclay; Space Telescope Science Institute; UDICE-French Research Universities; Sorbonne Universite; CEA; UDICE-French Research Universities; Universite Paris Saclay; Ehime University; University of Waterloo	Massey, R (corresponding author), CALTECH, MC105-24,1200 E Calif Blvd, Pasadena, CA 91125 USA.	rjm@astro.caltech.edu	Starck, Jean-Luc/D-9467-2011; McCracken, Henry Joy/AAA-1489-2019; Kneib, Jean-Paul/A-7919-2015; Koekemoer, Anton M./F-8400-2014; Capak, Peter/AAK-4282-2020	Starck, Jean-Luc/0000-0003-2177-7794; McCracken, Henry Joy/0000-0002-9489-7765; Kneib, Jean-Paul/0000-0002-4616-4989; Koekemoer, Anton M./0000-0002-6610-2048; Capak, Peter/0000-0003-3578-6843; Aussel, Herve/0000-0002-1371-5705; Taylor, James/0000-0002-6639-4183				Bacon DJ, 2003, MON NOT R ASTRON SOC, V344, P1307, DOI 10.1046/j.1365-8711.2003.06922.x; Bartelmann M, 2001, PHYS REP, V340, P291, DOI 10.1016/S0370-1573(00)00082-X; Benitez N, 2000, ASTROPHYS J, V536, P571, DOI 10.1086/308947; Bergstrom L, 2000, REP PROG PHYS, V63, P793, DOI 10.1088/0034-4885/63/5/2r3; CAPAK P, UNPUB ASTROPHYS J; Clowe D, 2006, ASTROPHYS J, V648, pL109, DOI 10.1086/508162; DAVIS M, 1985, ASTROPHYS J, V292, P371, DOI 10.1086/163168; Dekel A, 1999, ASTROPHYS J, V520, P24, DOI 10.1086/307428; GUZZO G, UNPUB ASTROPHYS J; HASINGER G, IN PRESS ASTROPHYS J; Hopkinson GR, 1996, IEEE T NUCL SCI, V43, P614, DOI 10.1109/23.490905; KAISER N, 1992, ASTROPHYS J, V388, P272, DOI 10.1086/171151; KAISER N, 1993, ASTROPHYS J, V404, P441, DOI 10.1086/172297; LEAUTHAUD A, UNPUB ASTROPHYS J; Massey R, 2004, ASTRON J, V127, P3089, DOI 10.1086/420985; MOBASHER B, UNPUB ASTROPHYS J; Refregier A, 2003, ANNU REV ASTRON ASTR, V41, P645, DOI 10.1146/annurev.astro.41.111302.102207; Rhodes J, 2000, ASTROPHYS J, V536, P79, DOI 10.1086/308902; RHODES J, UNPUB ASTROPHYS J; SAUNDERS W, 1999, ASP C SER, V201, P228; Schneider P, 2002, ASTRON ASTROPHYS, V389, P729, DOI 10.1051/0004-6361:20020626; SCOVILLE N, IN PRESS ASTROPHYS J; Shen JJ, 2006, ASTROPHYS J, V645, P783, DOI 10.1086/504513; Springel V, 2005, NATURE, V435, P629, DOI 10.1038/nature03597; Starck J-L, 2002, ASTRONOMICAL IMAGE D; Starck JL, 2006, ASTRON ASTROPHYS, V451, P1139, DOI 10.1051/0004-6361:20052997; Steidel CC, 2004, ASTROPHYS J, V604, P534, DOI 10.1086/381960; Taylor AN, 2004, MON NOT R ASTRON SOC, V353, P1176, DOI 10.1111/j.1365-2966.2004.08138.x; Zwicky F., 1933, HELV PHYS ACTA, V6, P110, DOI [DOI 10.1007/S10714-008-0707-4, 10.1007/s10714-008-0707-4]	30	258	263	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 18	2007	445	7125					286	290		10.1038/nature05497	http://dx.doi.org/10.1038/nature05497			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126HT	17206154	Green Accepted, Green Submitted			2022-12-28	WOS:000243504700038
J	Markert, S; Arndt, C; Felbeck, H; Becher, D; Sievert, SM; Hugler, M; Albrecht, D; Robidart, J; Bench, S; Feldman, RA; Hecker, M; Schweder, T				Markert, Stephanie; Arndt, Cordelia; Felbeck, Horst; Becher, Dorte; Sievert, Stefan M.; Huegler, Michael; Albrecht, Dirk; Robidart, Julie; Bench, Shellie; Feldman, Robert A.; Hecker, Michael; Schweder, Thomas			Physiological proteomics of the uncultured endosymbiont of Riftia pachyptila	SCIENCE			English	Article							DEEP-SEA VENTS; CHEMOAUTOTROPHIC SYMBIONTS; CARBON FIXATION; PURIFICATION; TROPHOSOME; BACTERIA; ANIMALS; JONES; WORM	The bacterial endosymbiont of the deep-sea tube worm Riftia pachyptila has never been successfully cultivated outside its host. In the absence of cultivation data, we have taken a proteomic approach based on the metagenome sequence to study the metabolism of this peculiar microorganism in detail. As one result, we found that three major sulfide oxidation proteins constitute similar to 12% of the total cytosolic proteome, which highlights the essential role of these enzymes for the symbiont's energy metabolism. Unexpectedly, the symbiont uses the reductive tricarboxylic acid cycle in addition to the previously identified Calvin cycle for CO2 fixation.	Scripps Inst Oceanog, La Jolla, CA 92093 USA; Inst Marine Biotechnol, D-17489 Greifswald, Germany; Max Planck Inst Infect Biol, D-10117 Berlin, Germany; Woods Hole Oceanog Inst, Woods Hole, MA 02543 USA; Univ Greifswald, D-17487 Greifswald, Germany; Univ Calif Santa Cruz, Santa Cruz, CA 95064 USA; Synbio Corp, Menlo Pk, CA 94025 USA	University of California System; University of California San Diego; Scripps Institution of Oceanography; Max Planck Society; Woods Hole Oceanographic Institution; Ernst Moritz Arndt Universitat Greifswald; University of California System; University of California Santa Cruz	Schweder, T (corresponding author), Scripps Inst Oceanog, La Jolla, CA 92093 USA.	schweder@uni-greifswald.de	Bench, Shellie R/E-7679-2010; Markert, Stephanie/AAL-5591-2021; Hügler, Michael/A-9155-2018; Becher, Doerte/B-4454-2015	Markert, Stephanie/0000-0003-0923-3305; Hügler, Michael/0000-0002-2820-0333; Becher, Doerte/0000-0002-9630-5735; Schweder, Thomas/0000-0002-7213-3596; Robidart, Julie/0000-0001-9805-3570; Sievert, Stefan/0000-0002-9541-2707				BLUM J, 1984, ARCH BIOCHEM BIOPHYS, V228, P617, DOI 10.1016/0003-9861(84)90030-4; CAVANAUGH CM, 1981, SCIENCE, V213, P340, DOI 10.1126/science.213.4505.340; CHILDRESS JJ, 1992, OCEANOGR MAR BIOL, V30, P337; DISTEL DL, 1988, J EXP ZOOL, V247, P1, DOI 10.1002/jez.1402470102; FELBECK H, 1981, NATURE, V293, P291, DOI 10.1038/293291a0; Felbeck Horst, 1988, Oceanologica Acta Special Issue, V8, P131; FISHER CR, 1989, BIOL BULL, V177, P372, DOI 10.2307/1541597; JANNASCH HW, 1985, SCIENCE, V229, P717, DOI 10.1126/science.229.4715.717; JONES ML, 1981, SCIENCE, V213, P333, DOI 10.1126/science.213.4505.333; LUTZ RA, 1994, NATURE, V371, P663, DOI 10.1038/371663a0; Nelson D.C., 1995, DEEP SEA HYDROTHERMA, P125; Pflugfelder B, 2005, MAR BIOL, V146, P895, DOI 10.1007/s00227-004-1500-x; Robinson JJ, 2003, LIMNOL OCEANOGR, V48, P48, DOI 10.4319/lo.2003.48.1.0048; SCHEDEL M, 1979, ARCH MICROBIOL, V121, P29, DOI 10.1007/BF00409202; Sorgo A, 2002, MAR ECOL PROG SER, V231, P115, DOI 10.3354/meps231115; STAHL DA, 1984, SCIENCE, V224, P409, DOI 10.1126/science.224.4647.409; TABITA FR, 1988, MICROBIOL REV, V52, P155, DOI 10.1128/MMBR.52.2.155-189.1988; WILMOT DB, 1990, MAR BIOL, V106, P273, DOI 10.1007/BF01314811	18	153	159	7	114	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 12	2007	315	5809					247	250		10.1126/science.1132913	http://dx.doi.org/10.1126/science.1132913			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124XZ	17218528	Green Submitted			2022-12-28	WOS:000243407400049
J	Oldroyd, GED				Oldroyd, Giles E. D.			Nodules and hormones	SCIENCE			English	Editorial Material							CYTOKININ; RHIZOBIUM; ORGANOGENESIS; INDUCTION; MELILOTI; GENE	A hormone-signaling pathway is crucial to the ability of certain plants to form nodules when stimulated by nitrogen-fixing bacteria.	John Innes Ctr Plant Sci Res, Dept Dis & Stress Biol, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Oldroyd, GED (corresponding author), John Innes Ctr Plant Sci Res, Dept Dis & Stress Biol, Norwich Res Pk, Norwich NR4 7UH, Norfolk, England.	giles.oldroyd@bbsrc.ac.uk	Oldroyd, Giles/ABA-7501-2020; Oldroyd, Giles/ABD-8143-2021	Oldroyd, Giles/0000-0002-5245-6355				COOPER JB, 1994, PLANT CELL, V6, P215, DOI 10.1105/tpc.6.2.215; Fang YW, 1998, PLANT PHYSIOL, V116, P53, DOI 10.1104/pp.116.1.53; Gleason C, 2006, NATURE, V441, P1149, DOI 10.1038/nature04812; Goedhart J, 2000, PLANT J, V21, P109, DOI 10.1046/j.1365-313x.2000.00656.x; Gonzalez-Rizzo S, 2006, PLANT CELL, V18, P2680, DOI 10.1105/tpc.106.043778; Kalo P, 2005, SCIENCE, V308, P1786, DOI 10.1126/science.1110951; Lohar DP, 2004, PLANT J, V38, P203, DOI 10.1111/j.1365-313X.2004.02038.x; Mathesius U, 2000, MOL PLANT MICROBE IN, V13, P617, DOI 10.1094/MPMI.2000.13.6.617; Murray JD, 2007, SCIENCE, V315, P101, DOI 10.1126/science.1132514; Oldroyd GED, 2003, PLANT PHYSIOL, V131, P1027, DOI 10.1104/pp.102.010710; Tirichine L, 2007, SCIENCE, V315, P104, DOI 10.1126/science.1132397; Tirichine L, 2006, NATURE, V441, P1153, DOI 10.1038/nature04862	12	51	55	1	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 5	2007	315	5808					52	53		10.1126/science.1137588	http://dx.doi.org/10.1126/science.1137588			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	122WU	17204633				2022-12-28	WOS:000243259100026
J	Sadoulet, B				Sadoulet, Bernard			Particle dark matter in the universe: At the brink of discovery?	SCIENCE			English	Editorial Material								The nature of dark matter is one of the central problems of cosmology, particle physics, and gravity. It may be made of still unknown particles produced in the early universe. Much progress has been made in attempts to detect these particles and in the development of the required experimental techniques. Results from direct searches, the Large Hadron Collider, and the Gamma-ray Large Area Space Telescope offer promising opportunities within the next decade to find the missing dark matter.	Univ Calif Berkeley, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Sadoulet, B (corresponding author), Univ Calif Berkeley, Berkeley, CA 94720 USA.	sadoulet@cosmology.berkeley.edu						Baltz EA, 2004, J HIGH ENERGY PHYS; Duffy LD, 2006, PHYS REV D, V74, DOI 10.1103/PhysRevD.74.012006; FILIPPINI JP, COMMUNICATION; Seljak U, 2005, PHYS REV D, V71, DOI 10.1103/PhysRevD.71.103515; Turner MS, 2007, SCIENCE, V315, P59, DOI 10.1126/science.1136276	6	13	13	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 5	2007	315	5808					61	63		10.1126/science.1136639	http://dx.doi.org/10.1126/science.1136639			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	122WU	17204638				2022-12-28	WOS:000243259100031
J	Armstrong, PW; Granger, CB; Adams, PX; Hamm, C; Holmes, D; O'Neill, WW; Todaro, TG; Vahanian, A; Van de Werf, F				Armstrong, Paul W.; Granger, Christopher B.; Adams, Peter X.; Hamm, Christian; Jr, David Holmes; O'Neill, William W.; Todaro, Thomas G.; Vahanian, Alec; Van de Werf, Frans		APEX AMI Investigators	Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRIMARY ANGIOPLASTY; SEGMENT ELEVATION; DOUBLE-BLIND; REPERFUSION; INHIBITION; ANTIBODY; THERAPY; BLOCKADE; SURGERY; INJURY	Context Reperfusion with percutaneous transluminal coronary intervention (PCI) is effective at improving outcomes in patients with acute ST-elevation myocardial infarction (STEMI). However, in patients without prompt reestablishment of brisk coronary flow and tissue perfusion, mortality remains high, providing an opportunity for novel treatments, including anti-inflammatory agents. Objective To evaluate the effectiveness of pexelizumab, a humanized monoclonal antibody that binds the C5 component of complement, as an adjunct to PCI in improving 30-day mortality from STEMI. Design, Setting, and Patients This trial was a prospective, multicenter, double-blind, placebo-controlled, phase 3 study of the intravenous administration of pexelizumab in conjunction with primary PCI in STEMI with prespecified high-risk electrocardiographic findings. The trial was intended to enroll 8500 patients, but in conjunction with the US Food and Drug Administration enrollment was modified to 5745 patients presenting from 296 hospitals in 17 countries from July 13, 2004, to May 11, 2006. Interventions Two thousand eight hundred eighty-five patients were randomly assigned to receive placebo and 2860 to receive pexelizumab given as a 2-mg/kg intravenous bolus prior to PCI followed by 0.05-mg/kg per hour infusion over the subsequent 24 hours. Patients were randomized within 6 hours of symptom onset. Main Outcome Measures The primary end point was all-cause mortality through day 30. Secondary end points were death through day 90 and the composite of death, cardiogenic shock, or congestive heart failure through days 30 and 90. Results No difference in mortality through day 30 was observed between the pexelizumab and placebo treatment groups, with 116 patients (4.06%) and 113 patients (3.92%) who died in the respective groups ( hazard ratio [HR], 1.04; 95% confidence interval [CI], 0.80-1.35; log-rank P=. 78). The composite end points of death, shock, or heart failure were also similar with 257 patients (8.99%) receiving pexelizumab and 265 patients (9.19%) receiving placebo at 30 days ( HR, 0.98; 95% CI, 0.83-1.16; P=. 81) and 293 patients (10.24%) receiving pexelizumab and 293 patients (10.16%) receiving placebo at 90 days ( HR, 1.01; 95% CI, 0.86-1.19; P=. 91). Conclusion In this large clinical trial of patients treated with primary PCI for STEMI, mortality was low and unaffected by administration of pexelizumab.	Univ Alberta, Dept Med, Edmonton, AB T6G 2H7, Canada; Duke Univ, Med Ctr, Durham, NC USA; Alex Pharmaceut, Cheshire, CT USA; Kerckhoff Heart Ctr, Bad Nauheim, Germany; Mayo Clin, Rochester, MN USA; Univ Miami, Miami, FL 33152 USA; Procter & Gamble Co, Pharmaceut, Cincinnati, OH USA; Hosp Bichat, Paris, France; Univ Hosp Gasthuisberg, Dept Cardiol, B-3000 Louvain, Belgium	University of Alberta; Duke University; Kerckhoff Clinic; Mayo Clinic; University of Miami; Procter & Gamble; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; KU Leuven; University Hospital Leuven	Armstrong, PW (corresponding author), Univ Alberta, Dept Med, 2-51 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.	paul.armstrong@ualberta.ca	Granger, Christopher B/D-3458-2014; Hamm, Christian W./I-3155-2017; Stasek, Josef/R-6400-2017	Granger, Christopher B/0000-0002-0045-3291; Hamm, Christian W./0000-0001-6763-4161; Marques, Koen/0000-0001-7156-9147; Violini, Roberto/0000-0003-1997-7439; LO, Sing Kai/0000-0001-8401-1759; Van de Werf, Frans/0000-0001-9479-7767; Armstrong, Paul/0000-0002-0460-3445; Welsh, Robert/0000-0003-2613-9142; Chew, Derek/0000-0003-3593-296X; STEG, Philippe Gabriel/0000-0001-6896-2941; Schampaert, Erick/0000-0002-7607-1214; Stasek, Josef/0000-0001-5619-9248				Antman Elliott M., 2004, J Am Coll Cardiol, V44, pE1, DOI 10.1016/j.jacc.2004.07.014; Armstrong PW, 2006, AM HEART J, V152, P407, DOI 10.1016/j.ahj.2006.06.006; Armstrong PW, 2005, AM HEART J, V149, P402, DOI 10.1016/j.ahj.2004.12.015; Baran KW, 2001, CIRCULATION, V104, P2778, DOI 10.1161/hc4801.100236; Claeys MJ, 1999, CIRCULATION, V99, P1972, DOI 10.1161/01.CIR.99.15.1972; Faxon DP, 2002, J AM COLL CARDIOL, V40, P1199, DOI 10.1016/S0735-1097(02)02136-8; Granger CB, 2003, CIRCULATION, V108, P1184, DOI 10.1161/01.CIR.0000087447.12918.85; Kloner RA, 2006, EUR HEART J, V27, P2400, DOI 10.1093/eurheartj/ehl094; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; Mahaffey KW, 2006, AM HEART J, V152, P291, DOI 10.1016/j.ahj.2006.03.027; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Schouten HJA, 1995, BIOMETRICS, V51, P1529, DOI 10.2307/2533283; SMITH PK, 2006, AM COLL CARD C MARCH; Theroux P, 2005, EUR HEART J, V26, P1964, DOI 10.1093/eurheartj/ehi292; Thomas TC, 1996, MOL IMMUNOL, V33, P1389, DOI 10.1016/S0161-5890(96)00078-8; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; VAKEVA A, 1994, AM J PATHOL, V144, P1357; Vakeva AP, 1998, CIRCULATION, V97, P2259, DOI 10.1161/01.CIR.97.22.2259; Van de Werf F, 2003, EUR HEART J, V24, P28, DOI 10.1016/S0195-668X(02)00618-8; vantHof AWJ, 1997, LANCET, V350, P615, DOI 10.1016/S0140-6736(96)07120-6; Verrier ED, 2004, JAMA-J AM MED ASSOC, V291, P2319, DOI 10.1001/jama.291.19.2319; Yusuf S, 2001, CIRCULATION, V104, P2746, DOI 10.1161/hc4601.099487	22	349	361	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 3	2007	297	1					43	51						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	123BS	17200474				2022-12-28	WOS:000243271900020
J	Gostin, LO				Gostin, Lawrence O.			Law as a tool to facilitate healthier lifestyles and prevent obesity	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							UNITED-STATES; PUBLIC-HEALTH; PREVALENCE; OVERWEIGHT; ADULTS; INCOME		Georgetown Univ, Ctr Law, ONeill Inst Natl & Global Hlth Law, Washington, DC 20001 USA; Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA	Georgetown University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Gostin, LO (corresponding author), Georgetown Univ, Ctr Law, ONeill Inst Natl & Global Hlth Law, 600 New Jersey Ave NW, Washington, DC 20001 USA.	gostin@law.georgetown.edu						Adams KF, 2006, NEW ENGL J MED, V355, P763, DOI 10.1056/NEJMoa055643; [Anonymous], FREQ ASK QUEST WHO G; Blanck H. M., 2006, Morbidity and Mortality Weekly Report, V55, P985; Block JP, 2004, AM J PREV MED, V27, P211, DOI 10.1016/j.amepre.2004.06.007; BURROS M, 2006, NY TIMES        1007; Chang VW, 2005, ARCH INTERN MED, V165, P2122, DOI 10.1001/archinte.165.18.2122; Epstein RA, 2005, GEORGETOWN LAW J, V93, P1361; Finkelstein EA, 2004, OBES RES, V12, P18, DOI 10.1038/oby.2004.4; Frieden TR, 2004, AM J PUBLIC HEALTH, V94, P2059, DOI 10.2105/AJPH.94.12.2059; Hedley AA, 2004, JAMA-J AM MED ASSOC, V291, P2847, DOI 10.1001/jama.291.23.2847; *HLTH CAN, TRANSFORMING FOOD SU; Institute of Medicine, 2005, DIET REF INT EN CARB; Institute of Medicine, 2006, FOOD MARK CHILDR YOU; Jacobson MF, 2000, AM J PUBLIC HEALTH, V90, P854, DOI 10.2105/AJPH.90.6.854; Mair J.S., 2005, USE ZONING RESTRICT; Mello MM, 2006, NEW ENGL J MED, V354, P2601, DOI 10.1056/NEJMhpr060227; *NAT REST ASS, STAT FRIV LAWS LEG; Olshansky SJ, 2005, NEW ENGL J MED, V352, P1138, DOI 10.1056/NEJMsr043743; Perdue WC, 2003, AM J PUBLIC HEALTH, V93, P1390, DOI 10.2105/AJPH.93.9.1390; *TRUST AM HLTH, 2004, F FAT OB POL ARE FAI; US Department of Health and Human Services, 2010, HLTH PEOPL 2010, V2; *US GOV ACC OFF, 2003, GAO03506; *WHO REG OFF EUR, EUR CHART COUNT OB	23	87	87	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 3	2007	297	1					87	90		10.1001/jama.297.1.87	http://dx.doi.org/10.1001/jama.297.1.87			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	123BS	17200479	Green Published			2022-12-28	WOS:000243271900025
J	Gregori, L; Gurgel, PV; Lathrop, JT; Edwardson, P; Lambert, BC; Carbonell, RG; Burton, SJ; Hammond, DJ; Rohwer, RG				Gregori, Luisa; Gurgel, Patrick V.; Lathrop, Julia T.; Edwardson, Peter; Lambert, Brian C.; Carbonell, Ruben G.; Burton, Steven J.; Hammond, David J.; Rohwer, Robert G.			Reduction in infectivity of endogenous transmissible spongiform encephalopathies present in blood by adsorption to selective affinity resins	LANCET			English	Article							CREUTZFELDT-JAKOB-DISEASE; PRION PROTEIN; TRANSFUSION; COMPONENTS; TESTS	Background Transmissible spongiform encephalopathies (TSE) can be contracted through blood transfusion. Selective adsorption of the causative agent from donated blood might be one of the best ways of managing this risk. In our study, affinity resin L13, which reduces brain-derived infectivity spiked into human red blood cell concentrate by around 4 log(10)ID(50), and its equivalent, L13A, produced on a manufacturing scale, were assessed for their ability to remove TSE infectivity endogenously present in blood. Methods 500 mL of scrapie-infected hamster whole blood was leucoreduced at full scale before passage through the affinity resins. Infectivity of whole blood, leucoreduced whole blood (challenge), and the recovered blood from each flow-through was measured by limiting dilution titration. Findings Leutcoreduction removed 72% of input infectivity. 15 of 99 animals were infected by the challenge, whereas none of the 96 or 100 animals inoculated with the final flow-throughs from either resin developed the disease after 540 days. The limit of detection of the bioassay was 0 center dot 2 infectious doses per mL. The overall reduction of the challenge infectivity was more than 1 center dot 22 log(10)ID. The results showed removal of endogenous TSE infectivity from leucoreduced whole blood by affinity ligands. The same resins adsorb normal and abnormal prion protein from human infections with variant, sporadic, and familial Creutzfeldt-jakob disease, in the presence of blood components. Interpretation TSE affinity ligands, when incorporated into appropriate devices, can be used to mitigate the risks from TSE-infected blood, blood products, and other materials exposed to TSE infectivity.	Univ Maryland, Vet Affairs Med Ctr, Vet Affairs Maryland Hlth Care Syst, Baltimore, MD 21201 USA; ProMet BioSci Ltd, Cambridge, England; Amer Red Cross Biomed R&D, Plasma Derivat Dept, Rockville, MD USA; N Carolina State Univ, Dept Chem & Biomol Engn, Raleigh, NC 27695 USA	University System of Maryland; University of Maryland Baltimore; US Department of Veterans Affairs; Veterans Health Administration (VHA); American Red Cross; University of North Carolina; North Carolina State University	Rohwer, RG (corresponding author), Univ Maryland, Vet Affairs Med Ctr, Vet Affairs Maryland Hlth Care Syst, Baltimore, MD 21201 USA.	rrohwer@umaryland.edu	Gurgel, Patrick/M-9749-2019; Gurgel, Patrick/C-2181-2008					BAUMBACH GA, 1992, BIOPHARM         MAY, P24; Brown P, 1999, TRANSFUSION, V39, P1169, DOI 10.1046/j.1537-2995.1999.39111169.x; Brown P, 2005, VOX SANG, V89, P63, DOI 10.1111/j.1423-0410.2005.00683.x; Brown P, 1998, TRANSFUSION, V38, P810, DOI 10.1046/j.1537-2995.1998.38998408999.x; FURKA A, 1991, INT J PEPT PROT RES, V37, P487, DOI 10.1111/j.1399-3011.1991.tb00765.x; Gregori L, 2004, LANCET, V364, P529, DOI 10.1016/S0140-6736(04)16812-8; Gregori L, 2006, TRANSFUSION, V46, P1152, DOI 10.1111/j.1537-2995.2006.00865.x; HAMMOND D, Patent No. 2004050851; Hilton DA, 2004, J PATHOL, V203, P733, DOI 10.1002/path.1580; Houston F, 2000, LANCET, V356, P999, DOI 10.1016/S0140-6736(00)02719-7; Hunter N, 2002, J GEN VIROL, V83, P2897, DOI 10.1099/0022-1317-83-11-2897; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; Llewelyn CA, 2004, LANCET, V363, P417, DOI 10.1016/S0140-6736(04)15486-X; MacGregor I, 1999, VOX SANG, V77, P88; Minor PD, 2004, VOX SANG, V86, P164, DOI 10.1111/j.0042-9007.2004.00411.x; *NAT CREUTZF JAK D, 2006, VAR CREUTZF JAK DIS; Peden AH, 2004, LANCET, V364, P527, DOI 10.1016/S0140-6736(04)16811-6; *US DEP HHS, 2002, GUID IND REV PREV ME; Wroe SJ, 2006, LANCET, V368, P2061, DOI 10.1016/S0140-6736(06)69835-8	19	70	73	1	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 23	2006	368	9554					2226	2230		10.1016/S0140-6736(06)69897-8	http://dx.doi.org/10.1016/S0140-6736(06)69897-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	120HY	17189034				2022-12-28	WOS:000243076800030
J	Wakabayashi, Y; Mao, JH; Brown, K; Girardi, M; Balmain, A				Wakabayashi, Yuichi; Mao, Jian-Hua; Brown, Ken; Girardi, Michael; Balmain, Allan			Promotion of Hras-induced squamous carcinomas by a polymorphic variant of the Patched gene in FVB mice	NATURE			English	Article							BASAL-CELL CARCINOMAS; HUMAN HOMOLOG; SKIN TUMORS; SIGNALING PATHWAY; INDUCED APOPTOSIS; SONIC HEDGEHOG; DROSOPHILA; MUTATIONS; CANCER; RAS	Mice of the C57BL/6 strain are resistant to the development of skin squamous carcinomas (SCCs) induced by an activated Ras oncogene, whereas FVB/N mice are highly susceptible(1). The genetic basis of this difference in phenotype is unknown. Here we show that susceptibility to SCC is under the control of a carboxyterminal polymorphism in the mouse Ptch gene. F-1 hybrids between C57BL/6 and FVB/N strains ((B6FVB)F-1) are resistant to Ras-induced SCCs, but resistance can be overcome either by elimination of the C57BL/6 Ptch allele (Ptch(B6)) or by overexpression of the FVB/N Ptch allele (Ptch(FVB)) in the epidermis of K5Hras-transgenic (B6FVB) F-1 hybrid mice. The human Patched (PTCH) gene is a classical tumour suppressor gene for basal cell carcinomas and medulloblastomas, the loss of which causes increased signalling through the Sonic Hedgehog (SHH) pathway(2-5). SCCs that develop in Ptch(B6+/-) mice do not lose the wild-type Ptch gene or show evidence of increased SHH signalling. Although Ptch(FVB) overexpression can promote SCC formation, continued expression is not required for tumour maintenance, suggesting a role at an early stage of tumour cell lineage commitment. The Ptch polymorphism affects Hras-induced apoptosis, and binding to Tid1, the mouse homologue of the Drosophila l( 2) tid tumour suppressor gene. We propose that Ptch occupies a critical niche in determining basal or squamous cell lineage, and that both tumour types can arise from the same target cell depending on carcinogen exposure and host genetic background.	Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA; Univ Glasgow, CRC Dept Med Oncol, Glasgow G61 1BD, Lanark, Scotland; Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06520 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of Glasgow; Yale University; University of California System; University of California San Francisco	Balmain, A (corresponding author), Univ Calif San Francisco, Canc Res Inst, 2340 Sutter St, San Francisco, CA 94143 USA.	abalmain@cc.ucsf.edu	Mao, Jian-Hua/EIZ-8595-2022	Mao, Jian-Hua/0000-0001-9320-6021; Girardi, Michael/0000-0003-1887-9343				ARBEIT JM, 1994, J VIROL, V68, P4358, DOI 10.1128/JVI.68.7.4358-4368.1994; Aszterbaum M, 1999, NAT MED, V5, P1285, DOI 10.1038/15242; Barnes EA, 2001, EMBO J, V20, P2214, DOI 10.1093/emboj/20.9.2214; Brown K, 1998, CURR BIOL, V8, P516, DOI 10.1016/S0960-9822(98)70203-9; Canamasas I, 2003, J BIOL CHEM, V278, P30952, DOI 10.1074/jbc.M304225200; Cheng H, 2005, MOL CELL BIOL, V25, P44, DOI 10.1128/MCB.25.1.44-59.2005; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Guerrero I, 2003, SCIENCE, V301, P774, DOI 10.1126/science.1088625; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; HENNINGS H, 1993, CARCINOGENESIS, V14, P2353, DOI 10.1093/carcin/14.11.2353; Hooper JE, 2005, NAT REV MOL CELL BIO, V6, P306, DOI 10.1038/nrm1622; Janes KA, 2005, SCIENCE, V310, P1646, DOI 10.1126/science.1116598; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Li XX, 2005, BLOOD, V105, P3465, DOI 10.1182/blood-2004-06-2483; Mao JH, 2003, CURR OPIN GENET DEV, V13, P14, DOI 10.1016/S0959-437X(03)00005-4; NAGASE H, 1995, NAT GENET, V10, P424, DOI 10.1038/ng0895-424; Perez-Losada J, 2003, NAT REV CANCER, V3, P434, DOI 10.1038/nrc1095; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; Sarkar S, 2001, J BIOL CHEM, V276, P49034, DOI 10.1074/jbc.M103683200; Syken J, 1999, P NATL ACAD SCI USA, V96, P8499, DOI 10.1073/pnas.96.15.8499; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Tarunina M, 2004, MOL CELL BIOL, V24, P10792, DOI 10.1128/MCB.24.24.10792-10801.2004; Thibert C, 2003, SCIENCE, V301, P843, DOI 10.1126/science.1085405; Trentin GA, 2001, J BIOL CHEM, V276, P13087, DOI 10.1074/jbc.M009267200; Unden AB, 1996, CANCER RES, V56, P4562; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096	29	89	90	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 15	2007	445	7129					761	765		10.1038/nature05489	http://dx.doi.org/10.1038/nature05489			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	136EK	17230190				2022-12-28	WOS:000244205200044
J	Prochnow, C; Bransteitter, R; Klein, MG; Goodman, MF; Chen, XJS				Prochnow, Courtney; Bransteitter, Ronda; Klein, Michael G.; Goodman, Myron F.; Chen, Xiaojiang S.			The APOBEC-2 crystal structure and functional implications for the deaminase AID	NATURE			English	Article							INDUCED CYTIDINE DEAMINASE; ANTIVIRAL ACTIVITY; EDITING ENZYMES; RESOLUTION; MUTATIONS; MECHANISM; FAMILY; HIV-1; DNA	APOBEC-2 (APO2) belongs to the family of apolipoprotein B messenger RNA-editing enzyme catalytic ( APOBEC) polypeptides, which deaminates mRNA and single-stranded DNA(1,2). Different APOBEC members use the same deamination activity to achieve diverse human biological functions. Deamination by an APOBEC protein called activation-induced cytidine deaminase ( AID) is critical for generating high-affinity antibodies(3), and deamination by APOBEC-3 proteins can inhibit retrotransposons and the replication of retroviruses such as human immunodeficiency virus and hepatitis B virus(4-7). Here we report the crystal structure of APO2. APO2 forms a rod-shaped tetramer that differs markedly from the square-shaped tetramer of the free nucleotide cytidine deaminase, with which APOBEC proteins share considerable sequence homology. In APO2, two long alpha-helices of a monomer structure prevent the formation of a square-shaped tetramer and facilitate formation of the rod-shaped tetramer via head-to-head interactions of two APO2 dimers. Extensive sequence homology among APOBEC family members allows us to test APO2 structure-based predictions using AID. We show that AID deamination activity is impaired by mutations predicted to interfere with oligomerization and substrate access. The structure suggests how mutations in patients with hyper-IgM-2 syndrome inactivate AID, resulting in defective antibody maturation.	Univ So Calif, Los Angeles, CA 90089 USA	University of Southern California	Chen, XJS (corresponding author), Univ So Calif, Los Angeles, CA 90089 USA.	xiaojiang.chen@usc.edu						Anant S, 2001, AM J PHYSIOL-CELL PH, V281, pC1904, DOI 10.1152/ajpcell.2001.281.6.C1904; BETTS L, 1994, J MOL BIOL, V235, P635, DOI 10.1006/jmbi.1994.1018; Bonvin M, 2006, HEPATOLOGY, V43, P1364, DOI 10.1002/hep.21187; Bransteitter R, 2003, P NATL ACAD SCI USA, V100, P4102, DOI 10.1073/pnas.0730835100; Bransteitter R, 2006, J BIOL CHEM, V281, P16833, DOI 10.1074/jbc.R600006200; Chiu YL, 2006, TRENDS IMMUNOL, V27, P291, DOI 10.1016/j.it.2006.04.003; Chung SJ, 2005, J MED CHEM, V48, P658, DOI 10.1021/jm0496279; Conticello SG, 2005, MOL BIOL EVOL, V22, P367, DOI 10.1093/molbev/msi026; Cullen BR, 2006, J VIROL, V80, P1067, DOI 10.1128/JVI.80.3.1067-1076.2006; Durandy A, 2006, CURR OPIN RHEUMATOL, V18, P369, DOI 10.1097/01.bor.0000231905.12172.b5; Franca R, 2006, MED SCI MONITOR, V12, pRA92; Jarmuz A, 2002, GENOMICS, V79, P285, DOI 10.1006/geno.2002.6718; Johansson E, 2002, BIOCHEMISTRY-US, V41, P2563, DOI 10.1021/bi011849a; Minegishi Y, 2000, CLIN IMMUNOL, V97, P203, DOI 10.1006/clim.2000.4956; Navarro F, 2005, VIROLOGY, V333, P374, DOI 10.1016/j.virol.2005.01.011; Opi S, 2006, J VIROL, V80, P4673, DOI 10.1128/JVI.80.10.4673-4682.2006; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pham P, 2005, BIOCHEMISTRY-US, V44, P2703, DOI 10.1021/bi047481+; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Shindo K, 2003, J BIOL CHEM, V278, P44412, DOI 10.1074/jbc.C300376200; SMITH AA, 1994, BIOCHEMISTRY-US, V33, P6468, DOI 10.1021/bi00187a012; Teh AH, 2006, BIOCHEMISTRY-US, V45, P7825, DOI 10.1021/bi060345f; Teng BB, 1999, J LIPID RES, V40, P623; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; WANG J, IN PRESS J BIOL CHEM; Wiegand HL, 2004, EMBO J, V23, P2451, DOI 10.1038/sj.emboj.7600246; Xie KF, 2004, P NATL ACAD SCI USA, V101, P8114, DOI 10.1073/pnas.0400493101	28	163	175	2	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 25	2007	445	7126					447	451		10.1038/nature05492	http://dx.doi.org/10.1038/nature05492			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	128WD	17187054				2022-12-28	WOS:000243689500044
J	Hellmann, DB; Grand, DJ; Freischlag, JA				Hellmann, David B.; Grand, David J.; Freischlag, Julie A.			Inflammatory abdominal aortic aneurysm	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHRONIC PERIAORTITIS; MANAGEMENT; EXPERIENCE; SPECTRUM; FIBROSIS; DISEASE	Inflammatory abdominal aortic aneurysm ( AAA) accounts for 5% to 10% of all cases of AAA and differs from typical atherosclerotic AAA in many important ways. Although both inflammatory and atherosclerotic AAA most commonly affect the infrarenal portion of the abdominal aorta, patients with the inflammatory variant are younger and usually symptomatic, chiefly from back or abdominal pain. Unlike patients with atherosclerotic AAA, most with the inflammatory variant have an elevated erythrocyte sedimentation rate or abnormalities of other serum inflammatory markers. Computed tomography and magnetic resonance imaging are both sensitive for demonstrating the cuff of soft tissue inflammation surrounding the aneurysm that is characteristic of inflammatory AAA. In contrast to atherosclerotic AAA, the inflammatory variant is characterized pathologically by marked thickening of the aneurysm wall, fibrosis of the adjacent retroperitoneum, and rigid adherence of the adjacent structures to the anterior aneurysm wall. An extraordinary expansion of the adventitia due to inflammation also distinguishes inflammatory from atherosclerotic AAA. Although the pathogenesis of inflammatory AAA appears to involve an immune response localized to the vessel wall, the etiology of the inflammatory reaction is unknown. Inflammatory AAA is almost never associated with inflammation of other arteries. Male sex and smoking, the main risk factors for atherosclerotic AAA, are even stronger risk factors for the inflammatory variant. Smoking cessation is the first step of medical therapy. Corticosteroids or immunosuppressive therapies may also have roles. Although inflammatory AAA appears less likely to rupture than atherosclerotic AAA, surgical intervention appears prudent once the diameter of the aneurysm exceeds 5.5 cm. Knowing the features of inflammatory AAA should allow physicians to distinguish it from atherosclerotic AAA or from systemic vasculitis and to treat it with the appropriate combination of medical and surgical therapies.	Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Radiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Hellmann, DB (corresponding author), Johns Hopkins Bayview Med Ctr, Dept Med, 4940 Eastern Ave, Baltimore, MD 21224 USA.	hellmann@jhmi.edu						Blockmans D, 2002, CLIN NUCL MED, V27, P211, DOI 10.1097/00003072-200203000-00016; BOONTJE AH, 1990, J CARDIOVASC SURG, V31, P611; Drieskens O, 2002, CLIN NUCL MED, V27, P413, DOI 10.1097/00003072-200206000-00005; FELNER HD, 1984, HUM PATHOL, V15, P454; FIORANI P, 1986, INT ANGIOL, V5, P49; Fleming C, 2005, ANN INTERN MED, V142, P203, DOI 10.7326/0003-4819-142-3-200502010-00012; Hallett JW, 2000, MAYO CLIN PROC, V75, P395, DOI 10.4065/75.4.395; Haug ES, 2003, J VASC SURG, V38, P492, DOI 10.1016/S0741-5214(03)00340-9; Hellmann DB, 2002, JAMA-J AM MED ASSOC, V287, P2996, DOI 10.1001/jama.287.22.2996; Hill J, 1988, Ann Vasc Surg, V2, P352, DOI 10.1016/S0890-5096(06)60815-7; Iino M, 2002, J COMPUT ASSIST TOMO, V26, P1006, DOI 10.1097/00004728-200211000-00026; Jois RN, 2004, RHEUMATOLOGY, V43, P1441, DOI 10.1093/rheumatology/keh326; Karlsson L, 2000, EUR J VASC ENDOVASC, V19, P630, DOI 10.1053/ejvs.1999.1057; LINDBLAD B, 1991, J VASC SURG, V13, P231, DOI 10.1016/0741-5214(91)90215-G; Nitecki SS, 1996, J VASC SURG, V23, P860, DOI 10.1016/S0741-5214(96)70249-5; PARUMS DV, 1986, ATHEROSCLEROSIS, V61, P117, DOI 10.1016/0021-9150(86)90070-5; PARUMS DV, 1990, HISTOPATHOLOGY, V16, P423; PASQUINELLI G, 1993, J SUBMICR CYTOL PATH, V25, P103; PENNELL RC, 1985, J VASC SURG, V2, P859, DOI 10.1067/mva.1985.avs0020859; RAMSHAW AL, 1994, HISTOPATHOLOGY, V24, P23, DOI 10.1111/j.1365-2559.1994.tb01267.x; Rasmussen TE, 2001, J VASC SURG, V34, P84, DOI 10.1067/mva.2001.115603; Rasmussen TE, 1997, ANN SURG, V225, P155, DOI 10.1097/00000658-199702000-00003; Sakalihasan N, 2005, LANCET, V365, P1577, DOI 10.1016/S0140-6736(05)66459-8; STERPETTI AV, 1989, J VASC SURG, V9, P643, DOI 10.1067/mva.1989.vs0090643; Sultan S, 1999, EUR J VASC ENDOVASC, V18, P510, DOI 10.1053/ejvs.1999.0923; Tambyraja AL, 2004, J VASC SURG, V39, P400, DOI 10.1016/j.jvs.2003.07.029; TANAKA S, 1994, J VASC SURG, V20, P235, DOI 10.1016/0741-5214(94)90011-6; Tang T, 2005, EUR J VASC ENDOVASC, V29, P353, DOI 10.1016/j.ejvs.2004.12.009; Vaglio A, 2003, AM J MED, V114, P454, DOI 10.1016/S0002-9343(03)00056-1; Vaglio A, 2005, CURR OPIN RHEUMATOL, V17, P34, DOI 10.1097/01.bor.0000145517.83972.40; WALKER DI, 1972, BRIT J SURG, V59, P609, DOI 10.1002/bjs.1800590807	31	82	85	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 24	2007	297	4					395	400		10.1001/jama.297.4.395	http://dx.doi.org/10.1001/jama.297.4.395			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128GE	17244836				2022-12-28	WOS:000243645400025
J	Jones, L; Wells, K				Jones, Loretta; Wells, Kenneth			Strategies for academic and clinician engagement in community-participatory partnered research	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HEALTH		Healthy African Amer Families, Los Angeles, CA USA; Charles R Drew Univ Med & Sci, Univ Med & Sci, Lynwood, CA USA; RAND Corp, Santa Monica, CA USA; Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, David Geffen Sch Med, Sch Publ Hlth, Los Angeles, CA USA; Univ Calif Los Angeles, Dept Hlth Serv, David Geffen Sch Med, Sch Publ Hlth, Los Angeles, CA USA; Semel Inst, Los Angeles, CA USA	Charles R. Drew University of Medicine & Science; RAND Corporation; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Wells, K (corresponding author), 10920 Wilshire Blvd,Suite 300, Los Angeles, CA 90024 USA.	kwells@ucla.edu	Duran, Bonnie m/A-3029-2009		NCRR NIH HHS [RR11145, G12RR03026] Funding Source: Medline; NIMHD NIH HHS [MD000148, 263-MD-517172, MD00182] Funding Source: Medline; NIMH NIH HHS [P30MH068639] Funding Source: Medline; PHS HHS [200-92-0564] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [G12RR003026] Funding Source: NIH RePORTER; NATIONAL CENTER ON MINORITY HEALTH AND HEALTH DISPARITIES [P20MD000148] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P30MH068639] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [P20MD000182] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIMHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER ON MINORITY HEALTH AND HEALTH DISPARITIES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))		Asch SM, 2006, NEW ENGL J MED, V354, P1147, DOI 10.1056/NEJMsa044464; Chung Bowen, 2006, Ethn Dis, V16, pS67; FETTERMAN DM, 2004, PRACTICE; Freimuth VS, 2001, SOC SCI MED, V52, P797, DOI 10.1016/S0277-9536(00)00178-7; Green L, 2001, PUBLIC HEALTH REP, V116, P20, DOI 10.1093/phr/116.S1.20; *I MED, 2003, UN TREATM CONFR RAC; Institute of Medicine, 2001, CROSSING QUALITY CHA; Israel B A, 2001, Educ Health (Abingdon), V14, P182; Israel BA, 2005, METHODS COMMUNITY BA, P31; Macaulay AC, 1999, BRIT MED J, V319, P774, DOI 10.1136/bmj.319.7212.774; Metzler MM, 2003, AM J PUBLIC HEALTH, V93, P803, DOI 10.2105/AJPH.93.5.803; Minkler M, 2003, COMMUNITY BASED PART, P53; Moini M., 2005, COMMUNITY ENGAGEMENT; Patel Kavita K, 2006, Ethn Dis, V16, pS35; Pechura CM, 2006, ETHNIC DIS, V16, P154; Tunis SR, 2003, JAMA-J AM MED ASSOC, V290, P1624, DOI 10.1001/jama.290.12.1624; Wallerstein N, 2006, ETHNIC DIS, V16, P146; Wells K, 2004, AM J PSYCHIAT, V161, P955, DOI 10.1176/appi.ajp.161.6.955; Wells KB, 2000, JAMA-J AM MED ASSOC, V283, P212, DOI 10.1001/jama.283.2.212; Wells Kenneth B, 2006, Ethn Dis, V16, pS3; Zerhouni EA, 2005, NEW ENGL J MED, V353, P1621, DOI 10.1056/NEJMsb053723	21	356	357	2	33	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 24	2007	297	4					407	410		10.1001/jama.297.4.407	http://dx.doi.org/10.1001/jama.297.4.407			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128GE	17244838				2022-12-28	WOS:000243645400028
J	Barham, K; Shah, T				Barham, Kalleen; Shah, Tina			Phlegmasia cerulea dolens	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Albert Einstein Med Ctr, Philadelphia, PA 19141 USA	Yeshiva University	Barham, K (corresponding author), Albert Einstein Med Ctr, Philadelphia, PA 19141 USA.	barhamk@einstein.edu							0	5	5	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 18	2007	356	3					E3	E3		10.1056/NEJMicm054730	http://dx.doi.org/10.1056/NEJMicm054730			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	126BV	17229945				2022-12-28	WOS:000243488100011
J	Farooqi, IS; Wangensteen, T; Collins, S; Kimber, W; Matarese, G; Keogh, JM; Lank, E; Bottomley, B; Lopez-Fernandez, J; Ferraz-Amaro, I; Dattani, MT; Ercan, O; Myhre, AG; Retterstol, L; Stanhope, R; Edge, JA; McKenzie, S; Lessan, N; Ghodsi, M; De Rosa, V; Perna, F; Fontana, S; Barroso, I; Undlien, DE; O'Rahilly, S				Farooqi, I. Sadaf; Wangensteen, Teresia; Collins, Stephan; Kimber, Wendy; Matarese, Giuseppe; Keogh, Julia M.; Lank, Emma; Bottomley, Bill; Lopez-Fernandez, Judith; Ferraz-Amaro, Ivan; Dattani, Mehul T.; Ercan, Oya; Myhre, Anne Grethe; Retterstol, Lars; Stanhope, Richard; Edge, Julie A.; McKenzie, Sheila; Lessan, Nader; Ghodsi, Maryam; De Rosa, Veronica; Perna, Francesco; Fontana, Silvia; Barroso, Ines; Undlien, Dag E.; O'Rahilly, Stephen			Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EARLY-ONSET OBESITY; BODY-MASS INDEX; MORBID-OBESITY; MISSENSE MUTATION; METABOLIC-RATE; HYPOGONADISM; DYSFUNCTION; HUMANS; GROWTH; ASSOCIATION	BACKGROUND: A single family has been described in which obesity results from a mutation in the leptin-receptor gene (LEPR), but the prevalence of such mutations in severe, early-onset obesity has not been systematically examined. METHODS: We sequenced LEPR in 300 subjects with hyperphagia and severe early-onset obesity, including 90 probands from consanguineous families, and investigated the extent to which mutations cosegregated with obesity and affected receptor function. We evaluated metabolic, endocrine, and immune function in probands and affected relatives. RESULTS: Of the 300 subjects, 8 (3%) had nonsense or missense LEPR mutations -- 7 were homozygotes, and 1 was a compound heterozygote. All missense mutations resulted in impaired receptor signaling. Affected subjects were characterized by hyperphagia, severe obesity, alterations in immune function, and delayed puberty due to hypogonadotropic hypogonadism. Serum leptin levels were within the range predicted by the elevated fat mass in these subjects. Their clinical features were less severe than those of subjects with congenital leptin deficiency. CONCLUSIONS: The prevalence of pathogenic LEPR mutations in a cohort of subjects with severe, early-onset obesity was 3%. Circulating levels of leptin were not disproportionately elevated, suggesting that serum leptin cannot be used as a marker for leptin-receptor deficiency. Congenital leptin-receptor deficiency should be considered in the differential diagnosis in any child with hyperphagia and severe obesity in the absence of developmental delay or dysmorphism.	Univ Cambridge, Addenbrookes Hosp, Dept Clin Biochem, Cambridge Inst Med Res, Cambridge CB2 2QQ, England; Wellcome Trust Sanger Inst, Cambridge, England; Inst Child Hlth, London, England; Great Ormond St Hosp Sick Children, London WC1N 3JH, England; UCL, London, England; John Radcliffe Hosp, Oxford OX3 9DU, England; Royal London Hosp, London E1 1BB, England; Univ Oslo, Ulleval Univ Hosp, Oslo, Norway; Rikshosp Radiumhosp Med Ctr, Oslo, Norway; Univ Naples Federico 2, Naples, Italy; CNR, Ist Endocrinol & Oncol Sperimentale, I-80125 Naples, Italy; Hosp Univ Canarias, Tenerife, Spain; Istanbul Univ, Cerrahpasa Med Fac, Fatih Istanbul, Turkey; Univ Tehran Med Sci, Shariati Hosp, Tehran, Iran	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Wellcome Trust Sanger Institute; University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; University of Oxford; Barts Health NHS Trust; Royal London Hospital; University of Oslo; University of Oslo; University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); Universidad de la Laguna; Istanbul University; Istanbul University - Cerrahpasa; Tehran University of Medical Sciences	Farooqi, IS (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Clin Biochem, Cambridge Inst Med Res, Hills Rd,Box 232, Cambridge CB2 2QQ, England.	isf20@cam.ac.uk	Ghodsi, Maryam/HGB-1575-2022; Ghodsi, Masoud/A-9403-2017; O'Rahilly, Stephen/ABF-6509-2020; Ercan, Oya/A-9654-2018; Matarese, Giuseppe/AAO-4077-2021; Ferraz-Amaro, Ivan/X-1489-2019; Farooqi, Ismaa Sadaf/AAZ-3046-2020; De Rosa, Veronica/K-6534-2016; ercan, oya/AAS-5035-2020; DATTANI, MEHUL/C-5401-2008; collins, stephan c/P-4409-2016	Ghodsi, Maryam/0000-0001-8940-3970; Ghodsi, Masoud/0000-0002-9127-8635; O'Rahilly, Stephen/0000-0003-2199-4449; Ercan, Oya/0000-0001-7397-2837; Matarese, Giuseppe/0000-0001-9429-0616; Ferraz-Amaro, Ivan/0000-0003-0197-5267; De Rosa, Veronica/0000-0002-9477-0991; collins, stephan c/0000-0002-1533-3380; Barroso, Ines/0000-0001-5800-4520; PERNA, Francesco/0000-0001-5319-0977; Farooqi, Sadaf/0000-0001-7609-3504	MRC [G0502115] Funding Source: UKRI; Medical Research Council [G0502115] Funding Source: Medline; Telethon [GJT04008] Funding Source: Medline; Wellcome Trust [077016, 067457, 068086] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Telethon(Fondazione Telethon); Wellcome Trust(Wellcome Trust)		BRAY GA, 1990, PROG NEUROENDOCRINOL, V4, P128; Casanueva FF, 1998, BAILLIERE CLIN ENDOC, V12, P297, DOI 10.1016/S0950-351X(98)80024-4; Chung WK, 1998, AM J PHYSIOL-REG I, V274, pR985, DOI 10.1152/ajpregu.1998.274.4.R985; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; COLE TJ, 1995, ARCH DIS CHILD, V73, P25, DOI 10.1136/adc.73.1.25; CUNNINGHAM JJ, 1991, AM J CLIN NUTR, V54, P963, DOI 10.1093/ajcn/54.6.963; Echwald SM, 1997, BIOCHEM BIOPH RES CO, V233, P248, DOI 10.1006/bbrc.1997.6430; Farooqi IS, 2005, ANNU REV MED, V56, P443, DOI 10.1146/annurev.med.56.062904.144924; Farooqi IS, 1999, NEW ENGL J MED, V341, P879, DOI 10.1056/NEJM199909163411204; Farooqi IS, 2003, NEW ENGL J MED, V348, P1085, DOI 10.1056/NEJMoa022050; Farooqi IS, 2002, J CLIN INVEST, V110, P1093, DOI 10.1172/JCI200215693; Farooqi IS, 2001, NATURE, V414, P34, DOI 10.1038/35102112; FOMON SJ, 1982, AM J CLIN NUTR    S1, V35, P169; Gibson WT, 2004, J CLIN ENDOCR METAB, V89, P4821, DOI 10.1210/jc.2004-0376; HAMILL PVV, 1979, AM J CLIN NUTR, V32, P607, DOI 10.1093/ajcn/32.3.607; HAYTER JE, 1993, EUR J CLIN NUTR, V47, P724; Heo M, 2002, INT J OBESITY, V26, P640, DOI 10.1038/sj.ijo.0801990; Jackson RS, 1997, NAT GENET, V16, P303, DOI 10.1038/ng0797-303; Kelestimur F, 2006, CLIN ENDOCRINOL, V64, P667, DOI 10.1111/j.1365-2265.2006.02525.x; Kiess W, 2001, Obes Rev, V2, P29, DOI 10.1046/j.1467-789x.2001.00017.x; Krude H, 1998, NAT GENET, V19, P155, DOI 10.1038/509; Lahlou N, 2000, DIABETES, V49, P1347, DOI 10.2337/diabetes.49.8.1347; Licinio J, 2004, P NATL ACAD SCI USA, V101, P4531, DOI 10.1073/pnas.0308767101; Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795; MOLNAR D, 1995, J PEDIATR-US, V127, P571, DOI 10.1016/S0022-3476(95)70114-1; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; Ozata M, 2000, J CLIN ENDOCR METAB, V85, P416; Ozata M, 1999, J CLIN ENDOCR METAB, V84, P3686, DOI 10.1210/jc.84.10.3686; Semple RK, 2005, J CLIN ENDOCR METAB, V90, P1849, DOI 10.1210/jc.2004-1418; Speiser PW, 2005, J CLIN ENDOCR METAB, V90, P1871, DOI 10.1210/jc.2004-1389; Strobel A, 1998, NAT GENET, V18, P213, DOI 10.1038/ng0398-213; WILLIAMS DRR, 1995, DIABETIC MED, V12, P30, DOI 10.1111/j.1464-5491.1995.tb02058.x	32	425	445	1	35	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 18	2007	356	3					237	247		10.1056/NEJMoa063988	http://dx.doi.org/10.1056/NEJMoa063988			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	126BV	17229951	Green Accepted			2022-12-28	WOS:000243488100006
J	Huttenlocher, A; Horwitz, AR				Huttenlocher, Anna; Horwitz, Alan Rick			Wound healing with electric potential	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Wisconsin, Sch Med, Dept Pediat, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Dept Pharmacol, Madison, WI USA; Univ Virginia, Sch Med, Dept Cell Biol, Charlottesville, VA 22908 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Virginia	Huttenlocher, A (corresponding author), Univ Wisconsin, Sch Med, Dept Pediat, Madison, WI 53706 USA.							Chung CY, 2001, TRENDS BIOCHEM SCI, V26, P557, DOI 10.1016/S0968-0004(01)01934-X; McCaig CD, 2005, PHYSIOL REV, V85, P943, DOI 10.1152/physrev.00020.2004; Mycielska ME, 2004, J CELL SCI, V117, P1631, DOI 10.1242/jcs.01125; Van Haastert PJM, 2004, NAT REV MOL CELL BIO, V5, P626, DOI 10.1038/nrm1435; Zhao M, 2006, NATURE, V442, P457, DOI 10.1038/nature04925	5	48	51	0	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 18	2007	356	3					303	304		10.1056/NEJMcibr066496	http://dx.doi.org/10.1056/NEJMcibr066496			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	126BV	17229960				2022-12-28	WOS:000243488100016
J	Yennurajalingam, S; Bruera, E				Yennurajalingam, Sriram; Bruera, Eduardo			Palliative management of fatigue at the close of life - "It feels like my body is just worn out"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							QUALITY-OF-LIFE; CANCER-RELATED FATIGUE; PATIENT-CONTROLLED METHYLPHENIDATE; DOUBLE-BLIND; MULTIPLE-SCLEROSIS; COGNITIVE IMPAIRMENT; PHYSICAL-ACTIVITY; HEMOGLOBIN LEVEL; CONTROLLED-TRIAL; UNITED-STATES	Fatigue is the most common chronic symptom associated with cancer and other chronic progressive diseases. The assessment and treatment of fatigue at or near the end of life can be complex. Some of the challenges include its subjective nature, with great variability in its source, how it is expressed, and how it is perceived, requiring treatment to be based on patient report of frequency and severity; its multidimensional character; and the limited understanding of its pathophysiology. Using the case of an 82-year-old retired nurse with fatigue that could be explained by a number of concurrent conditions, including anemia, weight loss, depression and isolation, dyspnea, deconditioning, and medications, the authors illustrate the clinical approach to assess and treat fatigue at the end of life.	Univ Texas, MD Anderson Canc Ctr, Dept Palliat Care & Rehabil Med, Unit 008, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Bruera, E (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Palliat Care & Rehabil Med, Unit 008, 1515 Holcombe Blvd, Houston, TX 77030 USA.	ebruera@mdanderson.org	Bruera, Eduardo/AAA-1550-2022					Adler HL, 1999, J UROLOGY, V161, P182, DOI 10.1016/S0022-5347(01)62092-5; Agteresch HJ, 2000, J NATL CANCER I, V92, P321, DOI 10.1093/jnci/92.4.321; ARMITAGE JO, 1998, CLIN ONCOL UPDATES, V1, P1; BEAL JE, 1995, J PAIN SYMPTOM MANAG, V10, P89, DOI 10.1016/0885-3924(94)00117-4; Belza B, 2001, NURS RES, V50, P195, DOI 10.1097/00006199-200107000-00003; Berman RS, 1999, ANN SURG, V229, P1, DOI 10.1097/00000658-199901000-00001; Block SD, 2006, J PALLIAT MED, V9, P751, DOI 10.1089/jpm.2006.9.751; Breitbart W, 1997, J PAIN SYMPTOM MANAG, V13, P128, DOI 10.1016/S0885-3924(96)00316-8; Bruera E, 2003, J CLIN ONCOL, V21, P4439, DOI 10.1200/JCO.2003.06.156; Bruera E, 2006, J CLIN ONCOL, V24, P2073, DOI 10.1200/JCO.2005.02.8506; Bruera E, 1998, Cancer Prev Control, V2, P74; Bruera E, 2003, J PAIN SYMPTOM MANAG, V26, P1049, DOI 10.1016/S0885-3924(03)00332-4; BRUERA E, 1985, CANCER TREAT REP, V69, P751; BRUERA E, 1992, PAIN, V48, P163, DOI 10.1016/0304-3959(92)90053-E; Bruera E, 2000, J PAIN SYMPTOM MANAG, V19, P427, DOI 10.1016/S0885-3924(00)00138-X; Bruera E, 1991, J Palliat Care, V7, P6; CALMAN KC, 1984, J MED ETHICS, V10, P124, DOI 10.1136/jme.10.3.124; CARDENAS DD, 1982, NEPHRON, V30, P336, DOI 10.1159/000182512; Cella D, 2001, J CLIN ONCOL, V19, P3385, DOI 10.1200/JCO.2001.19.14.3385; Cella D, 1997, MANUAL FUNCTIONAL AS; Chang VT, 2000, CANCER, V88, P2164, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2164::AID-CNCR24>3.0.CO;2-5; Coats AJS, 2002, INT J CARDIOL, V85, P133, DOI 10.1016/S0167-5273(02)00242-5; Conill C, 1997, J PAIN SYMPTOM MANAG, V14, P328, DOI 10.1016/S0885-3924(97)00263-7; Coodley GO, 1997, AIDS, V11, P1347, DOI 10.1097/00002030-199711000-00008; Courneya KS, 2003, J CLIN ONCOL, V21, P1660, DOI 10.1200/JCO.2003.04.093; DELLACUNA GR, 1989, EUR J CANCER CLIN ON, V25, P1817; Demetri GD, 1998, J CLIN ONCOL, V16, P3412, DOI 10.1200/JCO.1998.16.10.3412; Dimeo FC, 1999, CANCER, V85, P2273, DOI 10.1002/(SICI)1097-0142(19990515)85:10<2273::AID-CNCR24>3.0.CO;2-B; Dittner AJ, 2004, J PSYCHOSOM RES, V56, P157, DOI 10.1016/S0022-3999(03)00371-4; Drueke TB, 2006, NEW ENGL J MED, V355, P2071, DOI 10.1056/NEJMoa062276; Dunst J, 2000, SEMIN ONCOL, V27, P4; Eisenstaedt R, 2006, BLOOD REV, V20, P213, DOI 10.1016/j.blre.2005.12.002; Fishbain DA, 2005, PAIN MED, V6, P299, DOI 10.1111/j.1526-4637.2005.00044.x; Fishbain DA, 2003, PAIN MED, V4, P51, DOI 10.1046/j.1526-4637.2003.03008.x; Glaus A, 1996, SUPPORT CARE CANCER, V4, P82, DOI 10.1007/BF01845757; Guralnik JM, 2004, BLOOD, V104, P2263, DOI 10.1182/blood-2004-05-1812; Gutstein HB, 2001, CANCER-AM CANCER SOC, V92, P1678, DOI 10.1002/1097-0142(20010915)92:6+<1678::AID-CNCR1496>3.0.CO;2-R; Hamerman D, 1999, J AM GERIATR SOC, V47, P1016, DOI 10.1111/j.1532-5415.1999.tb01299.x; Hann DM, 1998, QUAL LIFE RES, V7, P301, DOI 10.1023/A:1024929829627; Hardy JR, 2001, PALLIATIVE MED, V15, P3, DOI 10.1191/026921601673324846; Homsi J, 2001, Am J Hosp Palliat Care, V18, P403, DOI 10.1177/104990910101800610; Inoue A, 2003, SUPPORT CARE CANCER, V11, P528, DOI 10.1007/s00520-003-0488-y; INOUYE SK, 1990, ANN INTERN MED, V113, P941, DOI 10.7326/0003-4819-113-12-941; Jason L A, 1999, J Health Psychol, V4, P9, DOI 10.1177/135910539900400103; Jenkins C, 1998, J PALLIATIVE CARE, V14, P18, DOI 10.1177/082585979801400104; Jenkins CA, 1998, J PALLIATIVE CARE, V14, P55, DOI 10.1177/082585979801400410; Johnson SK, 1999, ANN BEHAV MED, V21, P258, DOI 10.1007/BF02884843; Kasper S, 2005, AM J GERIAT PSYCHIAT, V13, P884, DOI 10.1176/appi.ajgp.13.10.884; Krupp LB, 2003, CNS DRUGS, V17, P225, DOI 10.2165/00023210-200317040-00002; Lander M, 2000, CLIN GERIATR MED, V16, P335, DOI 10.1016/S0749-0690(05)70060-4; Lawlor PG, 2000, ARCH INTERN MED, V160, P786, DOI 10.1001/archinte.160.6.786; Lawlor PG, 2002, CANCER-AM CANCER SOC, V94, P1836, DOI 10.1002/cncr.10389; Lawrence D.P., 2004, J NATL CANC I MONOGR, V32, P40, DOI [DOI 10.1093/JNCIM0N0GRAPHS/LGH027, DOI 10.1093/JNCIMONOGRAPHS/LGH027]; Lee BN, 2004, NEUROIMMUNOMODULAT, V11, P279, DOI 10.1159/000079408; Liao S, 2000, J AM GERIATR SOC, V48, P426, DOI 10.1111/j.1532-5415.2000.tb04702.x; Lissoni P, 1996, EUR J CANCER, V32A, P1340, DOI 10.1016/0959-8049(96)00136-0; MacDonald N, 2003, J AM COLL SURGEONS, V197, P143, DOI 10.1016/S1072-7515(03)00382-X; MACVICAR MG, 1986, CANC B, V385, P235; Mendoza TR, 1999, CANCER-AM CANCER SOC, V85, P1186, DOI 10.1002/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N; Meyers CA, 2005, CANCER-AM CANCER SOC, V104, P788, DOI 10.1002/cncr.21234; Michalaki V, 2004, BRIT J CANCER, V90, P2312, DOI 10.1038/sj.bjc.6601814; Mock V, 2001, CANCER PRACT, V9, P119, DOI 10.1046/j.1523-5394.2001.009003119.x; Mock V, 2005, PSYCHO-ONCOL, V14, P464, DOI 10.1002/pon.863; MOERTEL CG, 1974, CANCER-AM CANCER SOC, V33, P1607, DOI 10.1002/1097-0142(197406)33:6<1607::AID-CNCR2820330620>3.0.CO;2-V; Morley JE, 1999, NUTRITION, V15, P499, DOI 10.1016/S0899-9007(99)00057-X; Morrison RS, 2003, J GERONTOL A-BIOL, V58, P76; Moss RB, 1999, J CLIN IMMUNOL, V19, P314, DOI 10.1023/A:1020595709352; Munch TN, 2005, J PALLIAT MED, V8, P1144, DOI 10.1089/jpm.2005.8.1144; Murtagh John, 2003, Aust Fam Physician, V32, P873; *NAT COMPR CANC NE, 2006, NAT COMPRE CANC NETW; Nemeth E, 2004, J CLIN INVEST, V113, P1271, DOI 10.1172/JCI200420945; Neuenschwander H, 1997, SUPPORT CARE CANCER, V5, P252, DOI 10.1007/s005200050069; Oldervoll LM, 2006, J PAIN SYMPTOM MANAG, V31, P421, DOI 10.1016/j.jpainsymman.2005.10.004; Ooi WL, 1997, JAMA-J AM MED ASSOC, V277, P1299, DOI 10.1001/jama.277.16.1299; Osterborg A, 2002, J CLIN ONCOL, V20, P2486, DOI 10.1200/JCO.2002.10.101; Penninx BWJH, 2003, AM J MED, V115, P104, DOI 10.1016/S0002-9343(03)00263-8; Pereira J, 1997, CANCER-AM CANCER SOC, V79, P835; Piper B F, 1998, Oncol Nurs Forum, V25, P677; Plioplys AV, 1997, NEUROPSYCHOBIOLOGY, V35, P16, DOI 10.1159/000119325; POPIELA T, 1989, EUR J CANCER CLIN ON, V25, P1823; Portenoy R K, 1999, Oncologist, V4, P1; Prue G, 2006, EUR J CANCER, V42, P846, DOI 10.1016/j.ejca.2005.11.026; Rammohan KW, 2002, J NEUROL NEUROSUR PS, V72, P179, DOI 10.1136/jnnp.72.2.179; Ream E, 1996, INT J NURS STUD, V33, P519, DOI 10.1016/0020-7489(96)00004-1; REIFE CM, 1995, MED CLIN N AM, V79, P299, DOI 10.1016/S0025-7125(16)30069-4; Respini D, 2003, CRIT REV ONCOL HEMAT, V47, P273, DOI 10.1016/S1040-8428(02)00176-2; ReyesTeran G, 1996, AIDS, V10, P1501, DOI 10.1097/00002030-199611000-00007; ROCKEY DC, 1993, NEW ENGL J MED, V329, P1691, DOI 10.1056/NEJM199312023292303; Schwartz A, 1999, J Nurs Meas, V7, P35; Schwartz Anna L, 2002, Oncol Nurs Forum, V29, pE85, DOI 10.1188/02.ONF.E85-E90; Segal RJ, 2003, J CLIN ONCOL, V21, P1653, DOI 10.1200/JCO.2003.09.534; SHARPE MC, 1991, J ROY SOC MED, V84, P118, DOI 10.1177/014107689108400224; Shasha D, 2003, CANCER, V98, P1072, DOI 10.1002/cncr.11616; Slatkin Neal E, 2003, J Support Oncol, V1, P53; SMETS EMA, 1995, J PSYCHOSOM RES, V39, P315, DOI 10.1016/0022-3999(94)00125-O; SMETS EMA, 1993, BRIT J CANCER, V68, P220, DOI 10.1038/bjc.1993.319; Somogyi-Zalud E, 2000, J AM GERIATR SOC, V48, pS131, DOI 10.1111/j.1532-5415.2000.tb03122.x; Stein KD, 1998, CANCER PRACT, V6, P143, DOI 10.1046/j.1523-5394.1998.006003143.x; Stone P, 2000, ANN ONCOL, V11, P561, DOI 10.1023/A:1008331230608; Strasser F, 2002, HEMATOL ONCOL CLIN N, V16, P589, DOI 10.1016/S0889-8588(02)00011-4; Tisdale MJ, 1997, NUTRITION, V13, P1, DOI 10.1016/S0899-9007(96)00313-9; Tomassini V, 2004, J NEUROL SCI, V218, P103, DOI 10.1016/j.jns.2003.11.005; Valentine AD, 1998, SEMIN ONCOL, V25, P39; Walke LM, 2004, ARCH INTERN MED, V164, P2321, DOI 10.1001/archinte.164.21.2321; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Webster K, 1998, ONCOLOGY-NY, V12, P697; Wigmore SJ, 2000, NUTR CANCER, V36, P177, DOI 10.1207/S15327914NC3602_6; Winningham ML, 2001, CANCER-AM CANCER SOC, V92, P988, DOI 10.1002/1097-0142(20010815)92:4+<988::AID-CNCR1411>3.0.CO;2-O; Wolfe F, 1996, J RHEUMATOL, V23, P1407; Working Group of the Royal Australasian College of Physicians, 2002, MED J AUST S, V176, pS23; WYSENBEEK AJ, 1993, BRIT J RHEUMATOL, V32, P633; Yavuzsen T, 2005, J CLIN ONCOL, V23, P8500, DOI 10.1200/JCO.2005.01.8010; Zakai NA, 2005, ARCH INTERN MED, V165, P2214, DOI 10.1001/archinte.165.19.2214	113	46	46	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 17	2007	297	3					295	304		10.1001/jama.297.3.295	http://dx.doi.org/10.1001/jama.297.3.295			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	125VT	17227981				2022-12-28	WOS:000243472300024
J	Wilson, JF				Wilson, Jennifer Fisher			Facing an uncertain climate	ANNALS OF INTERNAL MEDICINE			English	News Item							HUMAN HEALTH					jenwilson@acponline.org	Wilson, Jennifer/Q-3623-2019	Wilson, Jennifer/0000-0003-4025-3136				Epstein PR, 2005, NEW ENGL J MED, V353, P1433, DOI 10.1056/NEJMp058079; Houghton J. T., 2001, CLIMATE CHANGE 2001; Kovats RS, 2000, CLIMATE CHANGE HUMAN; Lindgren E, 2000, ENVIRON HEALTH PERSP, V108, P119, DOI 10.2307/3454509; McMichael A. J, 1996, WHOEHG967; McMichael AJ, 2006, LANCET, V367, P859, DOI 10.1016/S0140-6736(06)68079-3; MCMICHAEL AJ, 2006, CLIMATE CHANGE HUMAN; Mohan JE, 2006, P NATL ACAD SCI USA, V103, P9086, DOI 10.1073/pnas.0602392103; Stern N. H., 2006, STERN REV EC CLIMATE; Stott PA, 2004, NATURE, V432, P610, DOI 10.1038/nature03089; Thomas CD, 2004, NATURE, V427, P145, DOI 10.1038/nature02121; Wayne P, 2002, ANN ALLERG ASTHMA IM, V88, P279, DOI 10.1016/S1081-1206(10)62009-1	12	7	7	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 16	2007	146	2					153	156		10.7326/0003-4819-146-2-200701160-00022	http://dx.doi.org/10.7326/0003-4819-146-2-200701160-00022			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	131WF	17227946				2022-12-28	WOS:000243901000017
J	Anikovich, MV; Sinitsyn, AA; Hoffecker, JF; Holliday, VT; Popov, VV; Lisitsyn, SN; Forman, SL; Levkovskaya, GM; Pospelova, GA; Kuz'mina, IE; Burova, ND; Goldberg, P; Macphail, RI; Giaccio, B; Praslov, ND				Anikovich, M. V.; Sinitsyn, A. A.; Hoffecker, John F.; Holliday, Vance T.; Popov, V. V.; Lisitsyn, S. N.; Forman, Steven L.; Levkovskaya, G. M.; Pospelova, G. A.; Kuz'mina, I. E.; Burova, N. D.; Goldberg, Paul; Macphail, Richard I.; Giaccio, Biagio; Praslov, N. D.			Early Upper Paleolithic in Eastern Europe and implications for the dispersal of modern humans	SCIENCE			English	Article							CALIBRATION; DATES	Radiocarbon and optically stimulated luminescence dating and magnetic stratigraphy indicate Upper Paleolithic occupation-probably representing modern humans-at archaeological sites on the Don River in Russia 45,000 to 42,000 years ago. The oldest levels at Kostenki underlie a volcanic ash horizon identified as the Campanian Ignimbrite Y5 tephra that is dated elsewhere to about 40,000 years ago. The occupation layers contain bone and ivory artifacts, including possible figurative art, and fossil shells imported more than 500 kilometers. Thus, modern humans appeared on the central plain of Eastern Europe as early as anywhere else in northern Eurasia.	Univ Colorado, Inst Arctic & Alpine Res, Boulder, CO 80309 USA; Russian Acad Sci, Inst Hist Mat Culture, St Petersburg 191186, Russia; Univ Arizona, Dept Anthropol, Tucson, AZ 85721 USA; Univ Arizona, Dept Geosci, Tucson, AZ 85721 USA; Kostenki Museum Preserve, Voronezh 396355, Russia; Univ Illinois, Luminescence Dating Res Lab, Dept Earth & Environm Sci, Chicago, IL 60607 USA; Russian Acad Sci, Inst Earth Phys, Moscow 123995, Russia; Russian Acad Sci, Inst Zool, St Petersburg 199034, Russia; Boston Univ, Dept Archaeol, Boston, MA 02215 USA; UCL, Inst Archaeol, London WC1H 0PY, England; CNR, Ist Geol Ambientale & Geoingn, I-00133 Rome, Italy	University of Colorado System; University of Colorado Boulder; Russian Academy of Sciences; Institute for the History of Material Culture, Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; University of Arizona; University of Arizona; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Russian Academy of Sciences; Russian Academy of Sciences; Zoological Institute of the Russian Academy of Sciences; Boston University; University of London; University College London; Consiglio Nazionale delle Ricerche (CNR); Istituto di Geologia Ambientale e Geoingegneria (IGAG-CNR)	Hoffecker, JF (corresponding author), Univ Colorado, Inst Arctic & Alpine Res, Boulder, CO 80309 USA.	john.hoffecker@colorado.edu	Giaccio, Biagio/B-2561-2017; Forman, Steven/ABD-7720-2021	Giaccio, Biagio/0000-0002-7007-9127; HOFFECKER, JOHN/0000-0001-6132-3012; Forman, Steven/0000-0002-2080-7915; Lisitsyn, Sergey/0000-0002-9953-6969				ANIKOVICH MV, 2003, ARCHAEOL ETHNOL ANTH, V2, P15; [Anonymous], 2002, DESOLATE LANDSCAPES; BORISKOVSKII PI, 1963, MAT ISSLED ARKHEOL S, V121; Conard NJ, 2004, NATURE, V430, P198, DOI 10.1038/nature02690; Efimenko PP, 1958, KOSTENKI 1; Fairbanks RG, 2005, QUATERNARY SCI REV, V24, P1781, DOI 10.1016/j.quascirev.2005.04.007; FEDELE FG, 2003, GEOPHYS MONOGR SER, V139, P301, DOI DOI 10.1029/139GM20; GRISHCHENKO MI, 1961, T KOM IZUCH CHETVERT, V17, P62; Hughen K, 2004, SCIENCE, V303, P202, DOI 10.1126/science.1090300; KHOLMOVOI GV, 2001, PLEISTOTSENOVYE OTLO; Klein R. G., 1969, MAN CULTURE LATE PLE; Lazukov G. I., 1982, PALEOLIT KOSTENKOVSK, P13; LAZUKOV GI, 1957, MAT ISSLEDOVANIYA AR, V59, P135; Levkovskaya G. M., 1977, PALEOEKOLOGIYA DREVN, P74; Melekeszev I. V., 1984, VULCANOLOGIA SEISMOL, V3, P35; Mellars P, 2006, NATURE, V439, P931, DOI 10.1038/nature04521; Pospelova GA, 1998, FIZ ZEMLI+, P65; POSPELOVA GA, 2005, PROBLEMY RANNEI PORY, P87; Praslov N. D., 1982, PALEOLIT KOSTENKOVSK; PYLE DM, 2003, 16 INQUA C PROGR ABS, P147; ROGACHEV AN, 1957, MATERIALY ISSLEDOVAN, V59, P9; Shackleton NJ, 2004, QUATERNARY SCI REV, V23, P1513, DOI 10.1016/j.quascirev.2004.03.006; Sinitsyn AA, 2003, ANTIQUITY, V77, P9, DOI 10.1017/S0003598X00061299; SINITSYN AA, 2002, KOSTENKI KONTEKSTE P, P190; SINITSYN AA, 1997, RADIOUGLERODNAYA KHR, P21; SPIRIDONOVA EA, 1991, EVOLUTSIYA RASTITELN; Ton-That T, 2001, EARTH PLANET SC LETT, V184, P645, DOI 10.1016/S0012-821X(00)00358-7; Velichko A. A., 1961, GEOLOGICHESKII VOZRA; Vereshchagin N. K., 1982, MAMONTOBAYA FAUNA AZ, V11, P3	29	111	112	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 12	2007	315	5809					223	226		10.1126/science.1133376	http://dx.doi.org/10.1126/science.1133376			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	Science & Technology - Other Topics	124XZ	17218523				2022-12-28	WOS:000243407400042
J	Ueki, Y; Lin, CY; Senoo, M; Ebihara, T; Agata, N; Onji, M; Saheki, Y; Kawai, T; Mukherjee, PM; Reichenberger, E; Olsen, BR				Ueki, Yasuyoshi; Lin, Chin-Yu; Senoo, Makoto; Ebihara, Takeshi; Agata, Naoki; Onji, Masahiro; Saheki, Yasunori; Kawai, Toshihisa; Mukherjee, Padma M.; Reichenberger, Ernst; Olsen, Bjorn R.			Increased myeloid cell responses to M-CSF and RANKL cause bone loss and inflammation in SH3BP2 "cherubism" mice	CELL			English	Article							ADAPTER PROTEIN 3BP2; COLONY-STIMULATING FACTOR; TYROSINE KINASE; KAPPA-B; TRANSCRIPTION FACTOR; ANTIGEN RECEPTOR; LINKER REGION; IMMUNE-SYSTEM; ACTIVATION; SYK	While studies of the adaptor SH3BP2 have implicated a role in receptor-mediated signaling in mast cells and lymphocytes, they have failed to identify its function or explain why SH3BP2 missense mutations cause bone loss and inflammation in patients with cherubism. We demonstrate that Sh3bp2 "cherubism" mice exhibit trabecular bone loss, TNF-alpha-dependent systemic inflammation, and cortical bone erosion. The mutant phenotype is lymphocyte independent and can be transferred to mice carrying wild-type Sh3bp2 alleles through mutant fetal liver cells. Mutant myeloid cells show increased responses to M-CSF and RANKL stimulation, and, through mechanisms of increased ERK 1/2 and SYK phosphorylation/activation, they form macrophages that express high levels of TNF-alpha and osteoclasts; that are unusually large. M-CSF and RANKL stimulation of myeloid cells that overexpress wild-type SH3BP2 results in similar large osteoclasts. This indicates that the mutant phenotype reflects gain of SH3BP2 function and suggests that SH3BP2 is a critical regulator of myeloid cell responses to M-CSF and RANKL stimulation.	Harvard Univ, Sch Dent Med, Dept Dev Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Forsyth Inst, Dept Immunol, Boston, MA 02115 USA; Univ Connecticut, Ctr Hlth, Ctr Restorat Med & Skeletal Dev, Dept Oral Rehabil Biomat & Skeletal Dev, Farmington, CT 06030 USA	Harvard University; Harvard School of Dental Medicine; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Forsyth Institute; University of Connecticut	Olsen, BR (corresponding author), Harvard Univ, Sch Dent Med, Dept Dev Biol, Boston, MA 02115 USA.	bjorn_olsen@hms.harvard.edu	Ebihara, Takeshi/GYU-7579-2022; Saheki, Yasunori/D-5430-2016	Saheki, Yasunori/0000-0002-1229-6668; Senoo, Makoto/0000-0002-0155-0683	NIAMS NIH HHS [AR36820, AR36819] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR036819, R01AR036819, R01AR036820, R37AR036820] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		CECCHINI MG, 1994, DEVELOPMENT, V120, P1357; CHITU V, 2005, CURR OPIN IMMUNOL, V17, P1; de la Fuente MA, 2006, MOL CELL BIOL, V26, P5214, DOI 10.1128/MCB.00087-06; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; Deckert M, 1998, IMMUNITY, V9, P595, DOI 10.1016/S1074-7613(00)80657-3; Dumitru CD, 2000, CELL, V103, P1071, DOI 10.1016/S0092-8674(00)00210-5; Eliopoulos AG, 2006, J BIOL CHEM, V281, P1371, DOI 10.1074/jbc.M506790200; Faccio R, 2003, J CELL BIOCHEM, V90, P871, DOI 10.1002/jcb.10694; Faccio R, 2005, NAT MED, V11, P284, DOI 10.1038/nm1194; Foucault I, 2005, BLOOD, V105, P1106, DOI 10.1182/blood-2003-08-2965; Foucault I, 2003, J BIOL CHEM, V278, P7146, DOI 10.1074/jbc.M209509200; Hong JJ, 2002, J BIOL CHEM, V277, P31703, DOI 10.1074/jbc.M201362200; Humphrey MB, 2005, IMMUNOL REV, V208, P50, DOI 10.1111/j.0105-2896.2005.00325.x; Jevremovic D, 2001, J IMMUNOL, V166, P7219, DOI 10.4049/jimmunol.166.12.7219; Jimi E, 2005, IMMUNOL REV, V208, P80, DOI 10.1111/j.0105-2896.2005.00329.x; Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054; Kitaura H, 2005, J CLIN INVEST, V115, P3418, DOI 10.1172/JCI26132; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; Law CL, 1996, MOL CELL BIOL, V16, P1305; Maeno K, 2003, J BIOL CHEM, V278, P24912, DOI 10.1074/jbc.M301201200; Miah SMS, 2004, GENES CELLS, V9, P993, DOI 10.1111/j.1365-2443.2004.00784.x; Mocsai A, 2004, P NATL ACAD SCI USA, V101, P6158, DOI 10.1073/pnas.0401602101; Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320; Niida S, 2005, P NATL ACAD SCI USA, V102, P14016, DOI 10.1073/pnas.0503544102; Qu XJ, 2005, BIOCHEMISTRY-US, V44, P3891, DOI 10.1021/bi048353o; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Ross FP, 2005, IMMUNOL REV, V208, P88, DOI 10.1111/j.0105-2896.2005.00331.x; Sada K, 2002, BLOOD, V100, P2138, DOI 10.1182/blood-2001-12-0340; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; Smolen JS, 2003, NAT REV DRUG DISCOV, V2, P473, DOI 10.1038/nrd1109; Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6; Takeshita S, 2002, NAT MED, V8, P943, DOI 10.1038/nm752; Tanaka S, 2005, IMMUNOL REV, V208, P30, DOI 10.1111/j.0105-2896.2005.00327.x; Tiziani V, 1999, AM J HUM GENET, V65, P158, DOI 10.1086/302456; Ueki Y, 2001, NAT GENET, V28, P125, DOI 10.1038/88832; Xing LP, 2005, IMMUNOL REV, V208, P19, DOI 10.1111/j.0105-2896.2005.00336.x; Yao ZQ, 2006, J BIOL CHEM, V281, P11846, DOI 10.1074/jbc.M512624200; Zollino M, 2000, AM J MED GENET, V94, P254, DOI 10.1002/1096-8628(20000918)94:3<254::AID-AJMG13>3.0.CO;2-7	38	139	146	0	14	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 12	2007	128	1					71	83		10.1016/j.cell.2006.10.047	http://dx.doi.org/10.1016/j.cell.2006.10.047			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	139GN	17218256	Bronze			2022-12-28	WOS:000244420400014
J	Grantham-McGregor, S; Cheung, YB; Cueto, S; Glewwe, P; Richter, L; Strupp, B				Grantham-McGregor, Sally; Cheung, Yin Bun; Cueto, Santiago; Glewwe, Paul; Richter, Linda; Strupp, Barbara		Int Child Dev Steering Grp	Child development in developing countries 1 - Developmental potential in the first 5 years for children in developing countries	LANCET			English	Review							COGNITIVE-DEVELOPMENT; PRIMARY-SCHOOL; ZINC SUPPLEMENTATION; SOCIOECONOMIC-STATUS; MENTAL-DEVELOPMENT; MOTOR DEVELOPMENT; MATERNAL-CARE; FAMILY CHARACTERISTICS; NUTRITIONAL-STATUS; JAMAICAN CHILDREN	Many children younger than 5 years in developing countries are exposed to multiple risks, including poverty, malnutrition, poor health, and unstimulating home environments, which detrimentally affect their cognitive, motor, and social-emotional development. There are few national statistics on the development of young children in developing countries. We therefore identified two factors with available worldwide data-the prevalence of early childhood stunting and the number of people living in absolute poverty-to use as indicators of poor development. We show that both indicators are closely associated with poor cognitive and educational performance in children and use them to estimate that over 200 million children under 5 years are not fulfilling their developmental potential. Most of these children live in south Asia and sub-Saharan Africa. These disadvantaged children are likely to do poorly in school and subsequently have low incomes, high fertility, and provide poor care for their children, thus contributing to the intergenerational transmission of poverty.	UCL, Inst Child Hlth, Ctr Int Child Hlth, London WC1N 1EH, England; London Sch Hyg & Trop Med, London WC1, England; Grp Anal Dev, Lima, Peru; Univ Minnesota, Dept Appl Econ, Minneapolis, MN 55455 USA; Human Sci Res Council, Cape Town, South Africa; Cornell Univ, Dept Psychol, Ithaca, NY 14853 USA; Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA	University of London; University College London; University of London; London School of Hygiene & Tropical Medicine; University of Minnesota System; University of Minnesota Twin Cities; Human Sciences Research Council-South Africa; Cornell University; Cornell University	Grantham-McGregor, S (corresponding author), UCL, Inst Child Hlth, Ctr Int Child Hlth, London WC1N 1EH, England.	s.mcgregor@ich.ucl.ac.uk	Fahimifar, Sepideh/M-5303-2019; Cueto, Santiago/Q-7168-2019	Cueto, Santiago/0000-0002-0639-3429	Medical Research Council [G0700837] Funding Source: Medline; Wellcome Trust [068599] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Adair LS, 1999, J NUTR, V129, P1140, DOI 10.1093/jn/129.6.1140; AGARWAL DK, 1987, 6 NUTR FDN IND; Aldaz-Carroll E., 2001, CUAD ECON, V38, P155, DOI [10.4067/S0717-68212001011400003, DOI 10.4067/S0717-68212001011400003]; Alderman H, 1997, ECON DEV CULT CHANGE, V46, P97, DOI 10.1086/452323; [Anonymous], 2005, STAT WORLDS CHILDR 2; Baker-Henningham H, 2003, EUR J CLIN NUTR, V57, P786, DOI 10.1038/sj.ejcn.1601611; BAKERHENNINGHAM H, 2006, SPECIAL ED NEEDS STU; Basilio CS, 2005, REV SAUDE PUBL, V39, P725, DOI 10.1590/S0034-89102005000500005; Beasley NMR, 2000, ACTA TROP, V76, P223, DOI 10.1016/S0001-706X(00)00101-7; Behrman JR, 1999, WORLD BANK ECON REV, V13, P211, DOI 10.1093/wber/13.2.211; BEHRMAN JR, 2005, WHAT DETERMINES ADUL; Berkman DS, 2002, LANCET, V359, P564, DOI 10.1016/S0140-6736(02)07744-9; Bhandari N, 2002, B WORLD HEALTH ORGAN, V80, P189; Bhargava A, 2000, AM J PHYS ANTHROPOL, V111, P89, DOI 10.1002/(SICI)1096-8644(200001)111:1&lt;89::AID-AJPA6&gt;3.0.CO;2-X; BLACK J, 1998, HDB CHILD ADOLESCENT, V1, P31; Black MM, 2004, PEDIATRICS, V113, P1297, DOI 10.1542/peds.113.5.1297; BOGIN B, 1983, CHILD DEV, V54, P115, DOI 10.2307/1129868; Bradley RH, 2002, ANNU REV PSYCHOL, V53, P371, DOI 10.1146/annurev.psych.53.100901.135233; Bredy TW, 2003, NEUROSCIENCE, V118, P571, DOI 10.1016/S0306-4522(02)00918-1; Brito GNO, 2004, ARQ NEURO-PSIQUIAT, V62, P949, DOI 10.1590/S0004-282X2004000600004; Brooker S, 1999, SOC SCI MED, V48, P675, DOI 10.1016/S0277-9536(98)00382-7; BrooksGunn J, 1997, FUTURE CHILD, V7, P55, DOI 10.2307/1602387; BYAMUGISHA A, 2005, SACMEQ II PROJECT UG; CHEN S, 2004, 3341 WPS; Cheung YB, 2001, INT J EPIDEMIOL, V30, P66, DOI 10.1093/ije/30.1.66; Cheung YB, 2006, STAT MED, V25, P3011, DOI 10.1002/sim.2467; CHIMOMBO J, 2005, SACMEQ II PROJECT MA; *CHRON POV RES CTR, 2006, CHRON POV REP 2004 0; CLARKE NMA, 1990, ECOL FOOD NUTR, V26, P1; *COMM INT SCI CHIL, 2000, NEUR NEIGHB SCI CHIL; Cueto Santiago, 2005, Food and Nutrition Bulletin, V26, pS251; Currie J., 1999, 6943 NAT BUR EC RES; Daniels MC, 2004, J NUTR, V134, P1439, DOI 10.1093/jn/134.6.1439; de Onis M, 2004, INT J EPIDEMIOL, V33, P1260, DOI 10.1093/ije/dyh202; De Onis M, 2006, WHO CHILD GROWTH STA; Deaton A, 2001, WORLD BANK RES OBSER, V16, P125, DOI 10.1093/wbro/16.2.125; Drewett R, 2001, J CHILD PSYCHOL PSYC, V42, P181, DOI 10.1111/1469-7610.00709; Duflo E, 2001, AM ECON REV, V91, P795, DOI 10.1257/aer.91.4.795; Espy KA, 2001, MERRILL PALMER QUART, V47, P42, DOI 10.1353/mpq.2001.0001; Feinstein L, 2003, ECONOMICA, V70, P73, DOI 10.1111/1468-0335.t01-1-00272; Filmer D, 1999, POPUL DEV REV, V25, P85, DOI 10.1111/j.1728-4457.1999.00085.x; Filmer D, 2001, DEMOGRAPHY, V38, P115, DOI 10.2307/3088292; FLORENCIO C, 1988, NUTR HLTH OTHER DETE; FRANKENBERG E, 1995, J POPULAT, V1, P21; Garza C, 2006, ACTA PAEDIATR, V95, P56, DOI 10.1080/08035320500495514; GLEWWE P, 1995, REV ECON STAT, V77, P156, DOI 10.2307/2110001; Glewwe P, 2001, J PUBLIC ECON, V81, P345, DOI 10.1016/S0047-2727(00)00118-3; GONZALEZ P, 2004, HIGHLIGHTS TRENDS IN; GORDON G, 2003, CHILD POVERTY DEV WO; Gorman KS, 1996, CHILD DEV, V67, P314; Grantham-McGregor SM., 2004, REPORT FAMILY CARE I, DOI [10.7249/rb4545-1, DOI 10.7249/RB4545-1]; Griffiths R., 1970, ABILITIES YOUNG CHIL; GUNNAR M, IN PRESS W ED; Hall A, 2001, EUR J CLIN NUTR, V55, P801, DOI 10.1038/sj.ejcn.1601229; Hamadani JD, 2001, AM J CLIN NUTR, V74, P381; Hamadani JD, 2002, LANCET, V360, P290, DOI 10.1016/S0140-6736(02)09551-X; Hamill PV, 1977, VITAL HLTH STAT 11, V11, P1; Hatt LE, 2006, SOC SCI MED, V62, P375, DOI 10.1016/j.socscimed.2005.06.007; Hutchinson SE, 1997, EUR J CLIN NUTR, V51, P729, DOI 10.1038/sj.ejcn.1600473; Ivanovic DA, 2004, NUTRITION, V20, P878, DOI 10.1016/j.nut.2004.06.009; JAMISON DT, 1986, J DEV ECON, V20, P299, DOI 10.1016/0304-3878(86)90026-X; JOHNSTON FE, 1987, AM J PHYS ANTHROPOL, V73, P501, DOI 10.1002/ajpa.1330730412; Jones G, 2003, LANCET, V362, P65, DOI 10.1016/S0140-6736(03)13811-1; Kariger PK, 2005, J NUTR, V135, P814; KEITHEILE M, 2005, SACMEQ II PROJECT BO; KIRKSEY A, 1994, AM J CLIN NUTR, V60, P782, DOI 10.1093/ajcn/60.5.782; Kuklina EV, 2004, J NUTR, V134, P3296; KULPOO D, 2005, SACMEQ II PROJECT MA; Lam D, 1999, J HUM RESOUR, V34, P160, DOI 10.2307/146306; LASKY RE, 1981, CHILD DEV, V52, P219; Liddell C, 2001, BRIT J EDUC PSYCHOL, V71, P413, DOI 10.1348/000709901158596; Lima MC, 2004, ACTA PAEDIATR, V93, P969, DOI 10.1111/j.1651-2227.2004.tb18257.x; Liu D, 2000, NAT NEUROSCI, V3, P799, DOI 10.1038/77702; Lozoff B, 2004, PEDIATR RES, V55, p23A; Maitra P, 2004, J HEALTH POPUL NUTR, V22, P84; MAKUWA D, 2005, SACMEQ II PROJECT NA; MARTORELL R, 1995, J NUTR, V125, pS1060; Martorell R, 1992, HUMAN GROWTH BASIC C, P143; Meaney MJ, 2001, ANNU REV NEUROSCI, V24, P1161, DOI 10.1146/annurev.neuro.24.1.1161; MEANEY MJ, 1991, PSYCHONEUROENDOCRINO, V16, P85, DOI 10.1016/0306-4530(91)90072-2; Mendez MA, 1999, J NUTR, V129, P1555, DOI 10.1093/jn/129.8.1555; Mistry RS, 2004, DEV PSYCHOL, V40, P727, DOI 10.1037/0012-1649.40.5.727; MOLO I, 2005, SACMEQ II PROJECT S; MONCKEBERG F, 1972, SCI PUBLICATION, V251, P48; MOOCK PR, 1986, J DEV ECON, V20, P33, DOI 10.1016/0304-3878(86)90004-0; Morgan RE, 2001, NEUROTOXICOL TERATOL, V23, P519, DOI 10.1016/S0892-0362(01)00171-4; MOTHIBELI A, 2005, SACMEQ II PROJECT LE; MRUTU AS, 2005, SACMEQ II PROJECT TA; NASSOR SM, 2005, SACMEQ II PROJECT ZA; *NICHD EARL CHILD, 2001, EARLY ED DEV, V0012; ONSOMU E, 2005, SACMEQ II PROJECT KE; Ozmert EN, 2005, J TROP PEDIATRICS, V51, P25, DOI 10.1093/tropej/fmh070; PASSOS A, 2005, SACMEQ II PROJECT MO; Pianta RC, 1997, J APPL DEV PSYCHOL, V18, P1, DOI 10.1016/S0193-3973(97)90011-3; POLLITT E, 1993, MON SOC CHILD DEV, V58; POPKIN BM, 1982, SOC SCI MED, V16, P53, DOI 10.1016/0277-9536(82)90423-3; POWELL CA, 1985, AM J CLIN NUTR, V41, P1322, DOI 10.1093/ajcn/41.6.1322; PSACHAROPOULOS G, 1989, ECON DEV CULT CHANGE, V37, P683, DOI 10.1086/451755; Psacharopoulos G., 2004, EDUC ECON, V12, P111, DOI [DOI 10.1080/0964529042000239140, 10.1080/0964529042000239140]; Raven J., 1998, COLOURED PROGR MATRI; RICHTER L, 1998, VIEW SCH PREPARATION; RICHTER LM, 1995, PAEDIATR PERINAT EP, V9, P109, DOI 10.1111/j.1365-3016.1995.tb00124.x; Rodier PM, 2004, PEDIATRICS, V113, P1076; ROSENZWEIG MR, 1994, J HUM RESOUR, V29, P670, DOI 10.2307/146115; Rutter M, 2004, DEV PSYCHOL, V40, P81, DOI 10.1037/0012-1649.40.1.81; RUTTER M, 1989, J CHILD PSYCHOL PSYC, V30, P23, DOI 10.1111/j.1469-7610.1989.tb00768.x; Sattler, 1986, STANFORD BINET INTEL; Schady N, 2005, 3605 WORLD BANK; SHABALALA J, 2005, SACMEQ II PROJECT SW; Shariff ZM, 2000, ASIA PAC J CLIN NUTR, V9, P264, DOI 10.1046/j.1440-6047.2000.00191.x; Shrimpton R, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.5.e75; Siegel EH, 2005, J NUTR, V135, P2840, DOI 10.1093/jn/135.12.2840; SIGMAN M, 1989, J PEDIATR-US, V115, P357, DOI 10.1016/S0022-3476(89)80832-7; SIGMAN M, 1991, J CHILD PSYCHOL PSYC, V32, P307, DOI 10.1111/j.1469-7610.1991.tb00309.x; SIGMAN M, 1989, CHILD DEV, V60, P1463, DOI 10.2307/1130935; STEEGMANN AT, 1992, AM J HUM BIOL, V4, P247, DOI 10.1002/ajhb.1310040209; Stein Aryeh D., 2005, Food and Nutrition Bulletin, V26, pS46; Stith AY, 2003, APPL PSYCHOL-INT REV, V52, P614, DOI 10.1111/1464-0597.00154; Thompson RA, 2001, AM PSYCHOL, V56, P5, DOI 10.1037//0003-066X.56.1.5; *UN, 2002, ROAD MAP IMPL UN MIL; UNESCO, 2005, EFA GLOBAL MONITORIN; *UNICEF, 2006, MULT IND CLUST SURV, V2; Vazir S, 1998, Indian Pediatr, V35, P959; Victora CG, 2003, LANCET, V362, P233, DOI 10.1016/S0140-6736(03)13917-7; VICTORA CG, 2003, CAD SAUDE PUBLICA, P1241; VICTORA MD, 1990, CHILD CARE HLTH DEV, V16, P151, DOI 10.1111/j.1365-2214.1990.tb00647.x; Wachs T., 2000, NECESSARY NOT SUFFIC; WALKER SP, 1990, W INDIAN MED J, V39, P12; Walker SP, 2005, LANCET, V366, P1804, DOI 10.1016/S0140-6736(05)67574-5; Webb KE, 2005, EUR J CLIN NUTR, V59, P618, DOI 10.1038/sj.ejcn.1602103; Webb SJ, 2001, DEV NEUROPSYCHOL, V19, P147, DOI 10.1207/S15326942DN1902_2; Wechsler D., 2008, WAIS 4 WECHSLER ADUL; Wechsler DW., 1999, INTELLIGENCE SCALE C; WHO, 2006, GLOB DAT CHILD GROWT; Wilson MA, 2000, P NATL ACAD SCI USA, V97, P5540, DOI 10.1073/pnas.97.10.5540; *WORLD BANK, 2005, WORLD DEV IND 2005; World Health Organization, 2006, INT STAT CLASS DIS R; *YOUNG LIV, 2002, JUST CONT 7 5 8 5 YE	138	1785	1839	15	352	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 6	2007	369	9555					60	70		10.1016/S0140-6736(07)60032-4	http://dx.doi.org/10.1016/S0140-6736(07)60032-4			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	125AK	17208643	Green Published, Green Accepted			2022-12-28	WOS:000243413700030
J	Keidan, J				Keidan, Jane			Medicine and the media - Sucked into the Herceptin maelstrom	BRITISH MEDICAL JOURNAL			English	Editorial Material									Queen Elizabeth Hosp, Kings Lynn NHS Trust, Kings Lynn, England		Keidan, J (corresponding author), Queen Elizabeth Hosp, Kings Lynn NHS Trust, Kings Lynn, England.	Jane.Keidan@qehkl.nhs.uk							0	6	6	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JAN 6	2007	334	7583					18	18		10.1136/bmj.39080.481551.47	http://dx.doi.org/10.1136/bmj.39080.481551.47			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125CH	17204797	Green Published			2022-12-28	WOS:000243418600029
J	Peters, MJ				Peters, Matthew J.			Should smokers be refused surgery? Yes	BRITISH MEDICAL JOURNAL			English	Editorial Material									Concord Repatriat Gen Hosp, Dept Thorac Med, Concord, NSW 2139, Australia	Concord Repatriation General Hospital	Peters, MJ (corresponding author), Concord Repatriat Gen Hosp, Dept Thorac Med, Concord, NSW 2139, Australia.	matthew.peters@cs.nsw.gov.au		Peters, Matthew/0000-0002-9649-8741					0	14	15	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JAN 6	2007	334	7583					20	20		10.1136/bmj.39059.503495.68	http://dx.doi.org/10.1136/bmj.39059.503495.68			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	125CH	17204799	Green Published			2022-12-28	WOS:000243418600031
J	Calabrese, LH; Dodick, DW; Schwedt, TJ; Singhal, AB				Calabrese, Leonard H.; Dodick, David W.; Schwedt, Todd J.; Singhal, Aneesh B.			Narrative review: Reversible cerebral vasoconstriction syndromes	ANNALS OF INTERNAL MEDICINE			English	Review							CALL-FLEMING-SYNDROME; CENTRAL-NERVOUS-SYSTEM; THUNDERCLAP HEADACHE; TRANSCRANIAL DOPPLER; PRIMARY ANGIITIS; POSTERIOR LEUKOENCEPHALOPATHY; INTRACRANIAL VASOSPASM; POSTPARTUM ANGIOPATHY; UNRUPTURED ANEURYSM; AMPHETAMINE ABUSE	Reversible cerebral vasoconstriction syndromes (RCVS) comprise a group of diverse conditions, all characterized by reversible multifocal narrowing of the cerebral arteries heralded by sudden (thunderclap), severe headaches with or without associated neurologic deficits. Reversible cerebral vasoconstriction syndromes are clinically important because they affect young persons and can be complicated by ischemic or hemorrhagic strokes. The differential diagnosis of RCVS includes conditions associated with thunderclap headache and conditions that cause irreversible or progressive cerebral artery narrowing, such as intracranial atherosclerosis and cerebral vasculitis. Misdiagnosis as primary cerebral vasculitis and aneurysmal subarachnoid hemorrhage is common because of overlapping clinical and angiographic features. However, unlike these more ominous conditions, RCVS is usually self-limited: Resolution of headaches and vasoconstriction occurs over a period of days to weeks. In this review, we describe our current understanding of RCVS; summarize its key clinical, laboratory, and imaging features; and discuss strategies for diagnostic evaluation and treatment.	Case Western Reserve Univ, Cleveland Clin, Lerner Coll Med, Dept Rheumat & Immunol Dis, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Cleveland, OH 44195 USA; Mayo Clin, Scottsdale, AZ USA; Massachusetts Gen Hosp, Boston, MA 02114 USA	Case Western Reserve University; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Mayo Clinic; Mayo Clinic Phoenix; Harvard University; Massachusetts General Hospital	Calabrese, LH (corresponding author), Case Western Reserve Univ, Cleveland Clin, Lerner Coll Med, Dept Rheumat & Immunol Dis, 9500 Euclid Ave,Desk A50, Cleveland, OH 44195 USA.	Calabrl@ccf.org		Schwedt, Todd/0000-0002-7780-7086	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS051412, P50NS051343] Funding Source: NIH RePORTER; NINDS NIH HHS [P50NS051343, R01NS051412] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aggarwal SK, 1996, NEUROLOGY, V46, P1741, DOI 10.1212/WNL.46.6.1741; ALHALABI M, 1994, NEUROLOGY, V44, P1221, DOI 10.1212/WNL.44.7.1221; BETTONI L, 1984, ACTA NEUROL BELG, V84, P161; BLACK KS, 1995, AM J NEURORADIOL, V16, P1650; BLOOMFIELD SM, 1985, NEUROSURGERY, V17, P792, DOI 10.1227/00006123-198511000-00011; BOGOUSSLAVSKY J, 1989, EUR NEUROL, V29, P102, DOI 10.1159/000116388; Borel CO, 2003, STROKE, V34, P427, DOI 10.1161/01.STR.0000053848.06436.AB; BUCKLE RM, 1964, J NEUROL NEUROSUR PS, V27, P440, DOI 10.1136/jnnp.27.5.440; Buxton N, 2000, J ROY SOC MED, V93, P472, DOI 10.1177/014107680009300906; CALABRESE LH, 1993, J RHEUMATOL, V20, P2046; Calabrese LH, 1997, ARTHRITIS RHEUM, V40, P1189, DOI 10.1002/1529-0131(199707)40:7<1189::AID-ART2>3.0.CO;2-4; Calabrese LH, 2003, CLIN EXP RHEUMATOL, V21, pS127; Calado S, 2004, CEREBROVASC DIS, V18, P340, DOI 10.1159/000080976; CALL GK, 1988, STROKE, V19, P1159, DOI 10.1161/01.STR.19.9.1159; Chen D, 2002, NEUROL RES, V24, P215, DOI 10.1179/016164102101199639; Chu CT, 1998, J NEUROPATH EXP NEUR, V57, P30, DOI 10.1097/00005072-199801000-00005; DAY JW, 1986, LANCET, V2, P1247; Dietrich HH, 2000, NEUROSURGERY, V46, P517, DOI 10.1097/00006123-200003000-00001; Dodick DW, 1999, CEPHALALGIA, V19, P118, DOI 10.1046/j.1468-2982.1999.019002118.x; Dodick DW, 2003, CEPHALALGIA, V23, P994, DOI 10.1046/j.1468-2982.2003.00577.x; Dodick DW, 2003, CEPHALALGIA, V23, P163, DOI 10.1046/j.1468-2982.2003.00506.x; Dodick DW, 2002, HEADACHE, V42, P309, DOI 10.1046/j.1526-4610.2002.02084.x; Doss-Esper CE, 2005, J NEUROIMAGING, V15, P188, DOI 10.1177/1051228404273820; DUNA GF, 1995, J RHEUMATOL, V22, P662; FARINE D, 1984, OBSTET GYNECOL, V63, P586; Fisher C M, 1983, Clin Neurosurg, V31, P32; FREDERICKS RK, 1991, STROKE, V22, P1437, DOI 10.1161/01.STR.22.11.1437; GARNIC JD, 1983, NEURORADIOLOGY, V24, P273, DOI 10.1007/BF00333180; Geocadin RG, 2002, J NEUROL SCI, V205, P29, DOI 10.1016/S0022-510X(02)00245-9; GERAGHTY JJ, 1991, NEUROLOGY, V41, P1145, DOI 10.1212/WNL.41.7.1145; Gilbert GJ, 2002, NEUROLOGY, V59, P651, DOI 10.1212/WNL.59.4.651-a; Goldstein M., 1991, VASCULITIS HYPERTENS; GOMEZ CR, 1991, ANGIOLOGY, V42, P152, DOI 10.1177/000331979104200211; Hajj-Ali RA, 2002, ARTHRIT RHEUM-ARTHR, V47, P662, DOI 10.1002/art.10797; HENRY PY, 1984, CEPHALALGIA, V4, P171, DOI 10.1046/j.1468-2982.1984.0403171.x; HYDEROWAN MD, 1983, SURG NEUROL, V20, P120, DOI 10.1016/0090-3019(83)90461-5; Ihara M, 2000, J NEUROIMAGING, V10, P230, DOI 10.1111/jon2000104230; JACKSON M, 1993, CEPHALALGIA, V13, P427, DOI 10.1046/j.1468-2982.1993.1306427.x; JANSSENS E, 1995, STROKE, V26, P128, DOI 10.1161/01.STR.26.1.128; Kadkhodayan Y, 2004, RADIOLOGY, V233, P878, DOI 10.1148/radiol.2333031621; Kaplan PW, 1998, CLIN ELECTROENCEPHAL, V29, P120, DOI 10.1177/155005949802900302; KAYE BR, 1987, JAMA-J AM MED ASSOC, V258, P2104, DOI 10.1001/jama.258.15.2104; Konstantinopoulos PA, 2004, AM J OBSTET GYNECOL, V191, P375, DOI 10.1016/j.ajog.2004.03.028; KONTOS HA, 1978, AM J PHYSIOL, V234, pH371, DOI 10.1152/ajpheart.1978.234.4.H371; Kubo S, 2002, HEADACHE, V42, P297, DOI 10.1046/j.1526-4610.2002.02087.x; LECOZ P, 1988, REV NEUROL, V144, P295; LEROUX PD, 1991, SURG NEUROL, V36, P25, DOI 10.1016/0090-3019(91)90128-V; LEVINE SR, 1987, NEUROLOGY, V37, P1849, DOI 10.1212/WNL.37.12.1849; LIEBERMAN AN, 1984, HEADACHE, V24, P245; LopezValdes E, 1997, NEUROLOGY, V49, P303, DOI 10.1212/WNL.49.1.303; Lu SR, 2004, NEUROLOGY, V62, P1414, DOI 10.1212/01.WNL.0000120669.85649.77; MartinAraguz A, 1997, REV NEUROLOGIA, V25, P225; MASUZAWA T, 1983, NEURORADIOLOGY, V24, P277, DOI 10.1007/BF00333181; MERKEL PA, 1995, SEMIN ARTHRITIS RHEU, V25, P172, DOI 10.1016/S0049-0172(95)80029-8; Modi M, 2000, HEADACHE, V40, P677, DOI 10.1046/j.1526-4610.2000.040008677.x; MONTEIRO P, 1985, HEADACHE, V25, P429; Nighoghossian N, 1998, HEADACHE, V38, P478, DOI 10.1046/j.1526-4610.1998.3806478.x; NIGHOGHOSSIAN N, 1994, EUR NEUROL, V34, P288, DOI 10.1159/000117059; Nolte KB, 1996, NEUROLOGY, V46, P1291, DOI 10.1212/WNL.46.5.1291; Noskin O, 2006, NEUROLOGY, V67, P159, DOI 10.1212/01.wnl.0000223648.76430.27; Nowak DA, 2003, CEPHALALGIA, V23, P218, DOI 10.1046/j.1468-2982.2003.00507.x; RAROQUE HG, 1993, STROKE, V24, P2108, DOI 10.1161/01.STR.24.12.2108; RAYNOR RB, 1980, NEUROSURGERY, V6, P92, DOI 10.1227/00006123-198001000-00014; Razavi M, 1999, NEUROLOGY, V52, P1088, DOI 10.1212/WNL.52.5.1088; RUMBAUGH CL, 1971, RADIOLOGY, V101, P345, DOI 10.1148/101.2.345; SANIN LC, 1993, CEPHALALGIA, V13, P289, DOI 10.1046/j.1468-2982.1993.1304289.x; Schaafsma A, 2002, EUR J VASC ENDOVASC, V23, P17, DOI 10.1053/ejvs.2001.1545; Schluter A, 2002, NEUROLOGY, V59, P1772, DOI 10.1212/01.WNL.0000033278.68801.22; SCHON F, 1987, J NEUROL NEUROSUR PS, V50, P492, DOI 10.1136/jnnp.50.4.492; Schwedt TJ, 2006, LANCET NEUROL, V5, P621, DOI 10.1016/S1474-4422(06)70497-5; SERDARU M, 1984, J NEUROL NEUROSUR PS, V47, P73, DOI 10.1136/jnnp.47.1.73; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; Singhai AB, 2002, NEUROLOGY, V59, P652; Singhal AB, 2005, NEUROCRIT CARE, V3, P91, DOI 10.1385/NCC:3:1:091; Singhal AB, 2004, ARCH NEUROL-CHICAGO, V61, P411, DOI 10.1001/archneur.61.3.411; Singhal AB, 2003, STROKE, V34, P264; Singhal AB, 2002, J NEUROL NEUROSUR PS, V73, P96, DOI 10.1136/jnnp.73.1.96-a; Singhal AB, 2002, NEUROLOGY, V58, P130, DOI 10.1212/WNL.58.1.130; SINGHAL AB, 2001, UNCOMMON CAUSES STRO, P114; SINGHAL AB, 2002, ANN NEUROL, VS, P59; SINGHAL AB, 2004, TOP STROKE REHABIL, V11, P1, DOI DOI 10.1310/ATK7-QTP7-7NE2-5G8X; SLIVKA A, 1995, HEADACHE, V35, P1, DOI 10.1111/j.1526-4610.1995.hed3501001.x; SNYDER BD, 1978, ARCH NEUROL-CHICAGO, V35, P612, DOI 10.1001/archneur.1978.00500330060012; SOLOMON S, 1990, HEADACHE, V30, P52, DOI 10.1111/j.1526-4610.1990.hed3002052.x; Sommer Claudia, 2006, Curr Pain Headache Rep, V10, P101, DOI 10.1007/s11916-006-0020-4; Song JK, 2004, NEURORADIOLOGY, V46, P1022, DOI 10.1007/s00234-003-1129-3; Sturm JW, 2000, CEPHALALGIA, V20, P132, DOI 10.1046/j.1468-2982.2000.00053.x; SUWANWELA C, 1972, J NEUROSURG, V36, P314, DOI 10.3171/jns.1972.36.3.0314; Sztajzel R, 1999, EUR NEUROL, V41, P153, DOI 10.1159/000008040; Tani Eiichi, 2002, Neurosurg Focus, V12, pECP1; TROMMER BL, 1988, STROKE, V19, P326, DOI 10.1161/01.STR.19.3.326; Voltz R, 1996, NEUROLOGY, V46, P250, DOI 10.1212/WNL.46.1.250; WALKER GL, 1980, J NEUROL NEUROSUR PS, V43, P464, DOI 10.1136/jnnp.43.5.464; WILKINS RH, 1970, J NEUROSURG, V32, P626, DOI 10.3171/jns.1970.32.6.0626; Yamamoto Y, 1999, ARCH NEUROL-CHICAGO, V56, P824, DOI 10.1001/archneur.56.7.824; YARNELL PR, 1986, STROKE, V17, P1022, DOI 10.1161/01.STR.17.5.1022; Younger DS, 1997, NEUROL CLIN, V15, P821, DOI 10.1016/S0733-8619(05)70349-2	97	547	568	0	29	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 2	2007	146	1					34	W6		10.7326/0003-4819-146-1-200701020-00007	http://dx.doi.org/10.7326/0003-4819-146-1-200701020-00007			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188BK	17200220				2022-12-28	WOS:000247893300005
J	Davies, KE; Grounds, MD				Davies, Kay E.; Grounds, Miranda D.			Treating muscular dystrophy with stem cells?	CELL			English	Editorial Material							MUSCLE; MESOANGIOBLASTS	There is currently no effective treatment for the devastating muscle-wasting disease Duchenne muscular dystrophy (DMD). Cossu and colleagues report in a recent Nature paper that transplantation of mesoangioblast stem cells may hold promise for treating DMD. Further studies are required to fully evaluate the clinical potential of these blood-vessel-associated stem cells.	Univ Oxford, MRC Funct Genet Unit, Oxford, England; Univ Western Australia, Sch Anat & Human Biol, Nedlands, WA 6009, Australia	University of Oxford; University of Western Australia	Davies, KE (corresponding author), Univ Oxford, MRC Funct Genet Unit, Oxford, England.	kay.davies@anat.ox.ac.uk		Grounds, Miranda/0000-0002-4530-9402				De Luca A, 2005, AM J PATHOL, V166, P477, DOI 10.1016/S0002-9440(10)62270-5; Galvez BG, 2006, J CELL BIOL, V174, P231, DOI 10.1083/jcb.200512085; Lee-Pullen TF, 2005, IUBMB LIFE, V57, P731, DOI 10.1080/15216540500352748; Miller RG, 1997, MUSCLE NERVE, V20, P469, DOI 10.1002/(SICI)1097-4598(199704)20:4<469::AID-MUS10>3.3.CO;2-1; Morosetti R, 2006, P NATL ACAD SCI USA, V103, P16995, DOI 10.1073/pnas.0603386103; Nowak KJ, 2004, EMBO REP, V5, P872, DOI 10.1038/sj.embor.7400221; RADLEY H, 2006, INT J BIOCHEM CELL B, DOI DOI 10.1016/BIOCEL.2006.09.009; Sampaolesi M, 2006, NATURE, V444, P574, DOI 10.1038/nature05282; SHARMA KR, 1993, NEUROLOGY, V43, P527, DOI 10.1212/WNL.43.3_Part_1.527; Stupka N, 2004, ACTA NEUROPATHOL, V107, P299, DOI 10.1007/s00401-003-0807-x	10	31	34	1	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 29	2006	127	7					1304	1306		10.1016/j.cell.2006.12.010	http://dx.doi.org/10.1016/j.cell.2006.12.010			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	128WI	17190595	Bronze			2022-12-28	WOS:000243690000010
J	Vrieseling, E; Arber, S				Vrieseling, Eline; Arber, Silvia			Target-induced transcriptional control of dendritic patterning and connectivity in motor neurons by the ETS gene Pea3	CELL			English	Article							LUMBOSACRAL SPINAL-CORD; SENSORY NEURONS; MOTONEURONS; POOLS; SPECIFICATION; INNERVATION; AFFERENTS; ARBORIZATION; EXPRESSION; BULLFROG	The apposition of axon terminals and dendrites, is critical for the control of neuronal activation, but how distinct neuronal subpopulations establish selective dendrite patterns and acquire specific presynaptic inputs remains unclear. Spinal motor neuron (MN) pools project to specific target muscles and are activated by selective synaptic inputs from group la proprioceptive afferents (IaPAs). Here, we show that MN pools with radially projecting dendrites respond to sensory stimulation with monosynaptic latency and are strikingly different from MN pools with dendrites that avoid the central gray matter, which are only activated through indirect connections. We provide genetic evidence that the induction of the ETS transcription factor Pea3 by GDNF is essential in two cervical MN pools to control dendrite patterning and selectivity of IaPA connectivity. These findings suggest that target-induced transcriptional programs control MN dendrite orientation and play a crucial role in the establishment of sensory-motor connections in the spinal cord.	Univ Basel, Biozentrum, Dept Cell Biol, CH-4056 Basel, Switzerland; Friedrich Miescher Inst, CH-4058 Basel, Switzerland	University of Basel; Friedrich Miescher Institute for Biomedical Research	Arber, S (corresponding author), Univ Basel, Biozentrum, Dept Cell Biol, Klingelbergstr 70, CH-4056 Basel, Switzerland.	silvia.arber@unibas.ch	Pecho-Vrieseling, Eline/AAP-7239-2020	Arber, Silvia/0000-0002-6261-250X; Pecho-Vrieseling, Eline/0000-0001-6712-775X				Arber S, 2000, CELL, V101, P485, DOI 10.1016/S0092-8674(00)80859-4; BALDISSERA F, 1981, HDB PHYSL INTEGRATIO; BAULAC M, 1981, ACTA ANAT, V109, P209; BLASER PF, 1990, DEV BRAIN RES, V57, P139, DOI 10.1016/0165-3806(90)90193-3; BROWN AG, 1978, J PHYSIOL-LONDON, V274, P111, DOI 10.1113/jphysiol.1978.sp012137; Brown AG, 1981, ORG SPINAL CORD; Clandinin TR, 2002, NEURON, V35, P827, DOI 10.1016/S0896-6273(02)00876-0; Dasen JS, 2005, CELL, V123, P477, DOI 10.1016/j.cell.2005.09.009; ECCLES JC, 1957, J PHYSIOL-LONDON, V137, P22, DOI 10.1113/jphysiol.1957.sp005794; FRANK E, 1993, NEURON, V10, P779, DOI 10.1016/0896-6273(93)90194-V; FRANK E, 1988, STRATEGIES SELECTIVE; Goulding M, 2005, CURR OPIN NEUROBIOL, V15, P14, DOI 10.1016/j.conb.2005.01.017; Haase G, 2002, NEURON, V35, P893, DOI 10.1016/S0896-6273(02)00864-4; Hausser M, 2000, SCIENCE, V290, P739, DOI 10.1126/science.290.5492.739; Hippenmeyer S, 2005, PLOS BIOL, V3, P878, DOI 10.1371/journal.pbio.0030159; Hippenmeyer S, 2004, TRENDS NEUROSCI, V27, P482, DOI 10.1016/j.tins.2004.05.012; Jan YN, 2003, NEURON, V40, P229, DOI 10.1016/S0896-6273(03)00631-7; Jessell TM, 2000, NAT REV GENET, V1, P20, DOI 10.1038/35049541; KALB RG, 1994, DEVELOPMENT, V120, P3063; Landgraf M, 2003, PLOS BIOL, V1, P221, DOI 10.1371/journal.pbio.0000041; LANDMESSER L, 1978, J PHYSIOL-LONDON, V284, P371, DOI 10.1113/jphysiol.1978.sp012545; LICHTMAN JW, 1984, J NEUROSCI, V4, P1754; LICHTMAN JW, 1984, J NEUROSCI, V4, P1745; Liebl DJ, 1997, J NEUROSCI, V17, P9113; Lin JH, 1998, CELL, V95, P393, DOI 10.1016/S0092-8674(00)81770-5; Livet J, 2002, NEURON, V35, P877, DOI 10.1016/S0896-6273(02)00863-2; Mears SC, 1997, J NEUROSCI, V17, P3128; MEL BW, 1994, NEURAL COMPUT, V6, P1031, DOI 10.1162/neco.1994.6.6.1031; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; OKADO N, 1990, ANAT EMBRYOL, V182, P113; Oliveira ALR, 2003, SYNAPSE, V50, P117, DOI 10.1002/syn.10249; Polleux F, 2000, NATURE, V404, P567, DOI 10.1038/35007001; RALL W, 1962, ANN NY ACAD SCI, V96, P1071, DOI 10.1111/j.1749-6632.1962.tb54120.x; RALL W, 1967, J NEUROPHYSIOL, V30, P1169, DOI 10.1152/jn.1967.30.5.1169; ROMANES GJ, 1951, J COMP NEUROL, V94, P313, DOI 10.1002/cne.900940209; Ryan JM, 1998, BRAIN BEHAV EVOLUT, V51, P90; Salie R, 2005, NEURON, V45, P189, DOI 10.1016/j.neuron.2005.01.002; Shirasaki R, 2002, ANNU REV NEUROSCI, V25, P251, DOI 10.1146/annurev.neuro.25.112701.142916; SZEKELY G, 1980, ACTA BIOL ACAD SCI H, V31, P305; Wenner P, 1995, J NEUROSCI, V15, P8191; Wong ROL, 2002, NAT REV NEUROSCI, V3, P803, DOI 10.1038/nrn941; Yang X, 2001, NEURON, V30, P399, DOI 10.1016/S0896-6273(01)00287-2; Yu TW, 2001, NAT NEUROSCI, V4, P1169, DOI 10.1038/nn748	43	134	136	0	10	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 29	2006	127	7					1439	1452		10.1016/j.cell.2006.10.042	http://dx.doi.org/10.1016/j.cell.2006.10.042			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	128WI	17190606	Bronze			2022-12-28	WOS:000243690000022
J	Pronovost, P; Needham, D; Berenholtz, S; Sinopoli, D; Chu, HT; Cosgrove, S; Sexton, B; Hyzy, R; Welsh, R; Roth, G; Bander, J; Kepros, J; Goeschel, C				Pronovost, Peter; Needham, Dale; Berenholtz, Sean; Sinopoli, David; Chu, Haitao; Cosgrove, Sara; Sexton, Bryan; Hyzy, Robert; Welsh, Robert; Roth, Gary; Bander, Joseph; Kepros, John; Goeschel, Christine			An intervention to decrease catheter-related bloodstream infections in the ICU	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EDUCATION-PROGRAM; CARE; PREVENTION	BACKGROUND: Catheter-related bloodstream infections occurring in the intensive care unit (ICU) are common, costly, and potentially lethal. METHODS: We conducted a collaborative cohort study predominantly in ICUs in Michigan. An evidence-based intervention was used to reduce the incidence of catheter-related bloodstream infections. Multilevel Poisson regression modeling was used to compare infection rates before, during, and up to 18 months after implementation of the study intervention. Rates of infection per 1000 catheter-days were measured at 3-month intervals, according to the guidelines of the National Nosocomial Infections Surveillance System. RESULTS: A total of 108 ICUs agreed to participate in the study, and 103 reported data. The analysis included 1981 ICU-months of data and 375,757 catheter-days. The median rate of catheter-related bloodstream infection per 1000 catheter-days decreased from 2.7 infections at baseline to 0 at 3 months after implementation of the study intervention (P <= 0.002), and the mean rate per 1000 catheter-days decreased from 7.7 at baseline to 1.4 at 16 to 18 months of follow-up (P<0.002). The regression model showed a significant decrease in infection rates from baseline, with incidence-rate ratios continuously decreasing from 0.62 (95% confidence interval [CI], 0.47 to 0.81) at 0 to 3 months after implementation of the intervention to 0.34 (95% CI, 0.23 to 0.50) at 16 to 18 months. CONCLUSIONS: An evidence-based intervention resulted in a large and sustained reduction (up to 66%) in rates of catheter-related bloodstream infection that was maintained throughout the 18-month study period.	Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Profess Studies Business & Educ, Baltimore, MD USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA; Univ Michigan, Ann Arbor, MI 48109 USA; William Beaumont Hosp, Royal Oak, MI 48072 USA; Ingham Reg Med Ctr, Lansing, MI USA; Harper Univ Hosp, Detroit, MI USA; Sparrow Hlth Syst, Lansing, MI USA; Michigan Hlth & Hosp Assoc Keystone Ctr Patient S, Lansing, MI USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of Michigan System; University of Michigan; Beaumont Health	Pronovost, P (corresponding author), Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA.		Chu, Haitao/J-7576-2012; Goeschel, Christine/AAA-6783-2020	Chu, Haitao/0000-0003-0932-598X	AHRQ HHS [1UC1HS14246] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [UC1HS014246] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Altman DE, 2004, NEW ENGL J MED, V351, P2041, DOI 10.1056/NEJMp048243; Berenholtz Sean M, 2004, Jt Comm J Qual Saf, V30, P195; Berenholtz SM, 2004, CRIT CARE MED, V32, P2014, DOI 10.1097/01.CCM.0000142399.70913.2F; Brennan TA, 2005, NEW ENGL J MED, V353, P1405, DOI 10.1056/NEJMsb051157; Burke JP, 2003, NEW ENGL J MED, V348, P651, DOI 10.1056/NEJMhpr020557; Cardo D, 2004, AM J INFECT CONTROL, V32, P470, DOI 10.1016/j.ajic.2004.10.001; Cohran J, 1996, HEART LUNG, V25, P161, DOI 10.1016/S0147-9563(96)80120-8; Eggimann P, 2000, LANCET, V355, P1864, DOI 10.1016/S0140-6736(00)02291-1; Leape LL, 2005, JAMA-J AM MED ASSOC, V293, P2384, DOI 10.1001/jama.293.19.2384; Mermel LA, 2000, ANN INTERN MED, V133, P395; Mermel LA, 2000, ANN INTERN MED, V132, P391, DOI 10.7326/0003-4819-132-5-200003070-00009; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Panageas KS, 2003, ANN INTERN MED, V139, P658, DOI 10.7326/0003-4819-139-8-200310210-00009; Pronovost P, 2003, J CRIT CARE, V18, P71, DOI 10.1053/jcrc.2003.50008; Pronovost Peter, 2005, Healthc Exec, V20, P14; Pronovost Peter J, 2004, Jt Comm J Qual Saf, V30, P59; PRONOVOST PJ, 2005, J PATIENT SAF, V1, P33; Rabe-Hesketh S.S.A., 2005, MULTILEVEL LONGITUDI; Sherertz RJ, 2000, ANN INTERN MED, V132, P641, DOI 10.7326/0003-4819-132-8-200004180-00007; Skrondal A., 2004, GEN LATENT VARIABLE; WACHTER R, 2004, HLTH AFF MILLWOOD S2, V23; Warren DK, 2006, INFECT CONT HOSP EP, V27, P662, DOI 10.1086/506184; Warren DK, 2006, CRIT CARE MED, V34, P2084, DOI 10.1097/01.CCM.0000227648.15804.2D; Warren DK, 2004, CHEST, V126, P1612, DOI 10.1378/chest.126.5.1612; 2000, MMWR MORB MORTAL WKL, V49, P149; 2000, MMWR MORB MORTAL WKL, V49, P189; 2005, MMWR MORB MORTAL WKL, V54, P1013	27	2710	2789	1	138	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 28	2006	355	26					2725	2732		10.1056/NEJMoa061115	http://dx.doi.org/10.1056/NEJMoa061115			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	120UA	17192537	Bronze			2022-12-28	WOS:000243110500004
J	Doumouchtsis, SK; Martin, NS; Robins, JB				Doumouchtsis, Stergios K.; Martin, Nigel S.; Robins, James B.			"Veterinary" diagnosis of lead poisoning in pregnancy	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							EXPOSURE		Inverclyde Royal Hosp, Rankin Matern Unit, Dept Obstet & Gynaecol, Greenock PA16 0XN, Scotland; Shore Vet Ctr, Gourock, Scotland		Doumouchtsis, SK (corresponding author), Royal Surrey Cty Hosp, Dept Obstet & Gynaecol, Egerton Rd, Surrey GU2 7XX, England.	sdoum@yahoo.com	Doumouchtsis, Stergios/I-5984-2014	Doumouchtsis, Stergios/0000-0002-0404-6335				Gardella C, 2001, OBSTET GYNECOL SURV, V56, P231, DOI 10.1097/00006254-200104000-00024; Knight TE, 2003, J FELINE MED SURG, V5, P249, DOI 10.1016/S1098-612X(03)00047-0; Shannon M, 2003, AMBUL PEDIATR, V3, P37, DOI 10.1367/1539-4409(2003)003<0037:SLPIP>2.0.CO;2; Yang YX, 2003, EXP NEUROL, V184, P489, DOI 10.1016/S0014-4886(03)00272-3	4	5	5	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 23	2006	333	7582					1302	1303		10.1136/bmj.39024.611366.AE	http://dx.doi.org/10.1136/bmj.39024.611366.AE			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121MC	17185716	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000243160700014
J	Letelier, LM; Bedregal, P				Letelier, Luz M.; Bedregal, Paula			Health reform in Chile	LANCET			English	Editorial Material									Pontificia Univ Catolica Chile, Dept Internal Med, Santiago, Chile; Pontificia Univ Catolica Chile, Dept Publ Hlth, Santiago, Chile	Pontificia Universidad Catolica de Chile; Pontificia Universidad Catolica de Chile	Letelier, LM (corresponding author), Pontificia Univ Catolica Chile, Dept Internal Med, Alameda 340, Santiago, Chile.	lmletel@med.puc.cl	Letelier, Luz M/HCJ-0044-2022	Letelier, Luz M/0000-0002-4150-2985				*CHIL MIN HLTH, 2004, RES NAT POP HLTH SUR; *DEP STAT HLTH INF, MAT MORT AB MORT CHI; *DEP STAT HLTH INF, 2004, MORT CAUS GEND; Ham C, 1997, HEALTH POLICY, V42, P49, DOI 10.1016/S0168-8510(97)00054-7; *INE, 2004, PROJ EST CHIL POP; Ministerio de Salud de Chile. Division de Rectoria y Regulacion, 2002, OBJ SAN DEC 2000 201, VFirst; VEGA J, 2002, CHALLENGING INEQUITI; World Health Organization, WORLD HLTH REP 2005	8	30	31	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 23	2006	368	9554					2197	2198		10.1016/S0140-6736(06)69875-9	http://dx.doi.org/10.1016/S0140-6736(06)69875-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	120HY	17189018				2022-12-28	WOS:000243076800010
J	Souhami, R				Souhami, Robert			The certainty that we will know more	BRITISH MEDICAL JOURNAL			English	Editorial Material									UCL, London WC1E 6BE, England	University of London; University College London	Souhami, R (corresponding author), UCL, London WC1E 6BE, England.	robert.souhami@btinternet.com							0	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 23	2006	333	7582					1322	1323		10.1136/bmj.39062.508067.80	http://dx.doi.org/10.1136/bmj.39062.508067.80			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121MC	17185727	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000243160700024
J	Hossain, P; Kawar, B; Nahas, ME				Hossain, Parvez; Kawar, Bisher; Nahas, Meguid El			Obesity and diabetes in the developing world - A growing challenge	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Sheffield, Sheffield Kidney Inst, Acad Nephrol Unit, Sheffield, S Yorkshire, England	University of Sheffield	Hossain, P (corresponding author), Univ Sheffield, Sheffield Kidney Inst, Acad Nephrol Unit, Sheffield, S Yorkshire, England.							Haslam DW, 2005, LANCET, V366, P1197, DOI 10.1016/S0140-6736(05)67483-1; Kearney PM, 2005, LANCET, V365, P217, DOI 10.1016/S0140-6736(05)70151-3; Lee G, 2003, SEMIN NEPHROL, V23, P107, DOI 10.1053/snep.2003.50009; Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047; World Health Organization (WHO), 2006, WORLD HLTH REP 2006	5	1380	1418	2	82	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 18	2007	356	3					213	215		10.1056/NEJMp068177	http://dx.doi.org/10.1056/NEJMp068177			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	126BV	17229948				2022-12-28	WOS:000243488100003
J	Thompson, JF; Hodi, FS; Zembowicz, A				Thompson, J. F.; Hodi, F. S.; Zembowicz, A.			A 49-year-old woman with a pigmented lesion on the arm - Malignant melanoma, invasive to 0.9 mm, with metastasis to one of two sentinel lymph nodes.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AMERICAN JOINT COMMITTEE; CUTANEOUS MELANOMA; STAGE-I; MICROSCOPIC SATELLITES; DOSE INTERFERON-ALPHA-2B; PROGNOSTIC-FACTORS; SURGICAL MARGINS; ADJUVANT THERAPY; GROWTH-PHASE; THICKNESS		Royal Prince Alfred Hosp, Sydney Canc Ctr, Sydney Melanoma Unit, Sydney, NSW, Australia; Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Melanoma Institute Australia; University of Sydney; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Thompson, JF (corresponding author), Royal Prince Alfred Hosp, Sydney Canc Ctr, Sydney Melanoma Unit, Sydney, NSW, Australia.			Thompson, John/0000-0002-2816-2496				Azzola MF, 2003, CANCER-AM CANCER SOC, V97, P1488, DOI 10.1002/cncr.11196; BALCH CM, 1993, ANN SURG, V218, P262, DOI 10.1097/00000658-199309000-00005; BALCH CM, 1982, ANN SURG, V196, P677, DOI 10.1097/00000658-198212001-00011; Balch CM, 2001, J CLIN ONCOL, V19, P3635, DOI 10.1200/JCO.2001.19.16.3635; BRESLOW A, 1970, ANN SURG, V172, P902, DOI 10.1097/00000658-197011000-00017; Cascinelli N, 2001, LANCET, V358, P866, DOI 10.1016/S0140-6736(01)06068-8; CLARK WH, 1989, JNCI-J NATL CANCER I, V81, P1893, DOI 10.1093/jnci/81.24.1893; Clary BM, 2001, ANN SURG ONCOL, V8, P328, DOI 10.1245/aso.2001.8.4.328; Clemente CG, 1996, CANCER, V77, P1303, DOI 10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5; Cohn-Cedermark G, 2000, CANCER-AM CANCER SOC, V89, P1495, DOI 10.1002/1097-0142(20001001)89:7<1495::AID-CNCR12>3.0.CO;2-D; DAY CL, 1981, ANN SURG, V194, P108, DOI 10.1097/00000658-198107000-00019; Essner R, 1999, ANN SURG ONCOL, V6, P442, DOI 10.1007/s10434-999-0442-4; Gershenwald JE, 1998, J CLIN ONCOL, V16, P2253, DOI 10.1200/JCO.1998.16.6.2253; Gershenwald JE, 1999, J CLIN ONCOL, V17, P976, DOI 10.1200/JCO.1999.17.3.976; GUERRY D, 1993, J INVEST DERMATOL, V100, pS342, DOI 10.1111/1523-1747.ep12470248; Guitart J, 2002, ARCH DERMATOL, V138, P603, DOI 10.1001/archderm.138.5.603; HALL WH, 1992, JAMA-J AM MED ASSOC, V268, P1314, DOI 10.1001/jama.1992.03490100112037; HARRIST TJ, 1984, CANCER, V53, P2183, DOI 10.1002/1097-0142(19840515)53:10<2183::AID-CNCR2820531029>3.0.CO;2-9; Kashani-Sabet M, 2002, J CLIN ONCOL, V20, P1826, DOI 10.1200/JCO.2002.07.082; Khayat D, 2003, CANCER-AM CANCER SOC, V97, P1941, DOI 10.1002/cncr.11272; Kirkwood JM, 2000, J CLIN ONCOL, V18, P2444, DOI 10.1200/JCO.2000.18.12.2444; Kirkwood JM, 1996, J CLIN ONCOL, V14, P7, DOI 10.1200/JCO.1996.14.1.7; Kirkwood JM, 2001, J CLIN ONCOL, V19, P2370, DOI 10.1200/JCO.2001.19.9.2370; LEON P, 1991, ARCH SURG-CHICAGO, V126, P1461; Morton DL, 2005, J CLIN ONCOL, V23, p710S; Morton DL, 1999, ANN SURG, V230, P453, DOI 10.1097/00000658-199910000-00001; MORTON DL, 1992, ARCH SURG-CHICAGO, V127, P392; REINTGEN D, 1994, ANN SURG, V220, P759, DOI 10.1097/00000658-199412000-00009; Retsas S, 2002, EUR J CANCER, V38, P511, DOI 10.1016/S0959-8049(01)00394-X; RONAN SG, 1988, SEMIN ONCOL, V15, P558; Shaikh L, 2005, ARCH DERMATOL, V141, P739, DOI 10.1001/archderm.141.6.739; Taran JM, 2001, CANCER, V91, P1822, DOI 10.1002/1097-0142(20010501)91:9<1822::AID-CNCR1202>3.0.CO;2-Y; Thomas JM, 2004, NEW ENGL J MED, V350, P757, DOI 10.1056/NEJMoa030681; THOMPSON JF, 1995, MELANOMA RES, V5, P255, DOI 10.1097/00008390-199508000-00008; UREN RF, 1994, MELANOMA RES, V4, P395, DOI 10.1097/00008390-199412000-00009; VERONESI U, 1991, ARCH SURG-CHICAGO, V126, P438; Wong SL, 2005, AM J SURG, V190, P196, DOI 10.1016/j.amjsurg.2005.05.011; Yee, 2005, ANN SURG ONCOL, V12, P843, DOI 10.1245/ASO.2005.07.916; Yee VSK, 2005, ANN SURG ONCOL, V12, P429, DOI 10.1245/ASO.2005.03.074	39	0	0	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 18	2007	356	3					285	292		10.1056/NEJMcpc069034	http://dx.doi.org/10.1056/NEJMcpc069034			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	126BV	17229956				2022-12-28	WOS:000243488100012
J	Smellie, WSA				Smellie, W. Stuart A.			Testing pitfalls and summary of guidance on sex hormone testing	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PRIMARY-CARE PATHOLOGY; WOMEN; DIAGNOSIS; ESTRADIOL		Gen Hosp, Clin Lab, Bishop Auckland DL14 6AD, England		Smellie, WSA (corresponding author), Gen Hosp, Clin Lab, Bishop Auckland DL14 6AD, England.	info@smellie.com						FOX R, 1991, CLIN ENDOCRINOL, V34, P127, DOI 10.1111/j.1365-2265.1991.tb00282.x; GANGAR K, 1989, BRIT MED J, V299, P601, DOI 10.1136/bmj.299.6699.601-a; Kim YK, 1997, HUM REPROD, V12, P1152, DOI 10.1093/humrep/12.6.1152; *NAT I CLIN EXC, 2004, CLIN GUID, V11; ROBINSON S, 1992, BRIT J OBSTET GYNAEC, V99, P232, DOI 10.1111/j.1471-0528.1992.tb14505.x; *ROYAL COLL OBST G, 1998, IN INV MAN INF COUPL; SCOTT RT, 1989, FERTIL STERIL, V51, P651; Smellie WSA, 2006, J CLIN PATHOL, V59, P893, DOI 10.1136/jcp.2005.035212; Smellie WS, 2006, J CLIN PATHOL, V59, P113, DOI 10.1136/jcp.2005.031526	9	0	0	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 13	2007	334	7584					91	94		10.1136/bmj.39038.614317.AE	http://dx.doi.org/10.1136/bmj.39038.614317.AE			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	127DZ	17218715	Green Published			2022-12-28	WOS:000243566800033
J	Not, F; Valentin, K; Romari, K; Lovejoy, C; Massana, R; Tobe, K; Vaulot, D; Medlin, LK				Not, Fabrice; Valentin, Klaus; Romari, Khadidja; Lovejoy, Connie; Massana, Ramon; Toebe, Kerstin; Vaulot, Daniel; Medlin, Linda K.			Picobiliphytes: A marine picoplanktonic algal group with unknown affinities to other eukaryotes	SCIENCE			English	Article							COASTAL SITE; 18S RDNA; DIVERSITY	Environmental sequencing has revealed unimagined diversity among eukaryotic picoplankton. A distinct picoplanktonic algal group, initially detected from 18S ribosomal DNA ( rDNA) sequences, was hybridized with rRNA lambda-targeted (rRNA-targeted) probes, detected by tyramide signal amplification-fluorescent in situ hybridization, and showed an organelle-like body with orange fluorescence indicative of phycobilins. Using this fluorescence signal, cells were sorted by flow cytometry and probed. Hybridized cells contained a 4',6'-diamidino-2-phenylindole-stained organelle resembling a plastid with a nucleomorph. This suggests that they may be secondary endosymbiotic algae. Pending the isolation of living cells and their formal description, these algae have been termed picobiliphytes.	CNRS, Stn Biol Roscoff, CNRS, UMR 7144, F-29682 Roscoff, France; Alfred Wegener Inst Polar & Marine Res, D-27570 Bremerhaven, Germany; Univ Laval, Quebec Ocean, Dept Biol, Ste Foy, PQ G1K 7P4, Canada; Inst Ciencies Mar, Barcelona 08003, Spain	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); UDICE-French Research Universities; Sorbonne Universite; Helmholtz Association; Alfred Wegener Institute, Helmholtz Centre for Polar & Marine Research; Laval University; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Mediterraneo de Investigaciones Marinas y Ambientales (CMIMA); CSIC - Instituto de Ciencias del Mar (ICM)	Not, F (corresponding author), Inst Ciencies Mar, Passeig Martim Barceloneta 37-49, Barcelona 08003, Spain.	not@icm.csic.es; lkmedlin@awi-bremerhaven.de	Massana, Ramon/F-4205-2016; Vaulot, Daniel/T-6649-2019; medlin, linda k/G-4820-2010; Lovejoy, Connie/A-3756-2008; Valentin, Klaus/G-5862-2014	Vaulot, Daniel/0000-0002-0717-5685; Lovejoy, Connie/0000-0001-8027-2281; Valentin, Klaus/0000-0001-7401-9423; Massana, Ramon/0000-0001-9172-5418				Adl SM, 2005, J EUKARYOT MICROBIOL, V52, P399, DOI 10.1111/j.1550-7408.2005.00053.x; Countway PD, 2005, J EUKARYOT MICROBIOL, V52, P95, DOI 10.1111/j.1550-7408.2005.05202006.x; Diez B, 2001, APPL ENVIRON MICROB, V67, P2932, DOI 10.1128/AEM.67.7.2932-2941.2001; Jeffrey S.W., 1997, PHYTOPLANKTON PIGMEN; Li WKW, 2001, CYTOMETRY, V44, P236, DOI 10.1002/1097-0320(20010701)44:3<236::AID-CYTO1116>3.0.CO;2-5; Lopez-Garcia P, 2001, NATURE, V409, P603, DOI 10.1038/35054537; Lovejoy C, 2006, APPL ENVIRON MICROB, V72, P3085, DOI 10.1128/AEM.72.5.3085-3095.2006; Marin B, 2005, PROTIST, V156, P425, DOI 10.1016/j.protis.2005.09.001; Massana R, 2004, FEMS MICROBIOL ECOL, V50, P231, DOI 10.1016/j.femsec.2004.07.001; Massana R, 2006, ENVIRON MICROBIOL, V8, P1515, DOI 10.1111/j.1462-2920.2006.01042.x; MCFADDEN G, 1995, TRENDS ECOL EVOL, V10, P12, DOI 10.1016/S0169-5347(00)88954-5; MEDLIN LK, 2006, MICROB ECOL, V167, P1432; Moon-van der Staay SY, 2001, NATURE, V409, P607, DOI 10.1038/35054541; Moreira D, 2000, NATURE, V405, P69, DOI 10.1038/35011054; Not F, 2002, AQUAT MICROB ECOL, V28, P157, DOI 10.3354/ame028157; Romari K, 2004, LIMNOL OCEANOGR, V49, P784, DOI 10.4319/lo.2004.49.3.0784; Vaulot D, 2004, NOVA HEDWIGIA, V79, P49, DOI 10.1127/0029-5035/2004/0079-0049	17	153	160	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 12	2007	315	5809					253	255		10.1126/science.1136264	http://dx.doi.org/10.1126/science.1136264			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124XZ	17218530	Green Published			2022-12-28	WOS:000243407400051
J	Shen, JS; Tareste, DC; Paumet, F; Rothman, JE; Melia, TJ				Shen, Jingshi; Tareste, David C.; Paumet, Fabienne; Rothman, James E.; Melia, Thomas J.			Selective activation of cognate SNAREpins by Sec1/Munc18 proteins	CELL			English	Article							MEMBRANE-FUSION; NEUROTRANSMITTER RELEASE; 3-DIMENSIONAL STRUCTURE; T-SNARE; SYNTAXIN; EXOCYTOSIS; COMPLEX; SPECIFICITY; BINDS; GOLGI	Sec1/Muncl 8 (SM) proteins are required for every step of intracellular membrane fusion, but their molecular mechanism of action has been unclear. In this work, we demonstrate a fundamental role of the SM protein: to act as a stimulatory subunit of its cognate SNARE fusion machinery. In a reconstituted system, mammalian SNARE pairs assemble between bilayers to drive a basal fusion reaction. Munc18-1/nSec1, a synaptic SM protein required for neurotransmitter release, strongly accelerates this reaction through direct contact with both t- and v-SNAREs. Munc18-1 accelerates fusion only for the cognate SNAREs for exocytosis, therefore enhancing fusion specificity.	Columbia Univ, Dept Physiol & Cellular Biophys, New York, NY 10032 USA	Columbia University	Rothman, JE (corresponding author), Columbia Univ, Dept Physiol & Cellular Biophys, New York, NY 10032 USA.	jr2269@columbia.edu; tm2176@columbia.edu	Tareste, David/P-9249-2019; Tareste, David/L-2639-2017	Tareste, David/0000-0002-8744-7598; Tareste, David/0000-0002-8744-7598; SHEN, JINGSHI/0000-0001-9595-1148; Paumet, Fabienne/0000-0003-4466-6966				Antonin W, 2000, EMBO J, V19, P6453, DOI 10.1093/emboj/19.23.6453; Bhattacharya S, 2002, P NATL ACAD SCI USA, V99, P13867, DOI 10.1073/pnas.202335999; Bock JB, 2001, NATURE, V409, P839, DOI 10.1038/35057024; Borisovska M, 2005, EMBO J, V24, P2114, DOI 10.1038/sj.emboj.7600696; Bracher A, 2002, EMBO J, V21, P6114, DOI 10.1093/emboj/cdf608; Brandhorst D, 2006, P NATL ACAD SCI USA, V103, P2701, DOI 10.1073/pnas.0511138103; BRENNER S, 1974, GENETICS, V77, P71; Brunger AT, 2005, Q REV BIOPHYS, V38, P1, DOI 10.1017/S0033583505004051; Bryant NJ, 2001, EMBO J, V20, P3380, DOI 10.1093/emboj/20.13.3380; Carpp LN, 2006, J CELL BIOL, V173, P927, DOI 10.1083/jcb.200512024; Carr CM, 1999, J CELL BIOL, V146, P333, DOI 10.1083/jcb.146.2.333; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Ciufo LF, 2005, MOL BIOL CELL, V16, P470, DOI 10.1091/mbc.E04-08-0685; Dulubova I, 2003, P NATL ACAD SCI USA, V100, P32, DOI 10.1073/pnas.232701299; Dulubova I, 2002, EMBO J, V21, P3620, DOI 10.1093/emboj/cdf381; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; Fernandez I, 1998, CELL, V94, P841, DOI 10.1016/S0092-8674(00)81742-0; Fisher RJ, 2001, SCIENCE, V291, P875, DOI 10.1126/science.291.5505.875; Gallwitz D, 2003, TRENDS BIOCHEM SCI, V28, P113, DOI 10.1016/S0968-0004(03)00028-8; Giraudo CG, 2006, SCIENCE, V313, P676, DOI 10.1126/science.1129450; Graham ME, 1997, J NEUROCHEM, V69, P2369; HARRISON SD, 1994, NEURON, V13, P555, DOI 10.1016/0896-6273(94)90025-6; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; Holthuis JCM, 1998, MOL BIOL CELL, V9, P3383, DOI 10.1091/mbc.9.12.3383; Hu C, 2003, SCIENCE, V300, P1745, DOI 10.1126/science.1084909; Jackson MB, 2006, ANNU REV BIOPH BIOM, V35, P135, DOI 10.1146/annurev.biophys.35.040405.101958; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Jahn R, 2006, NAT REV MOL CELL BIO, V7, P631, DOI 10.1038/nrm2002; Koh TW, 2003, TRENDS NEUROSCI, V26, P413, DOI 10.1016/S0166-2236(03)00195-4; Latham CF, 2006, TRAFFIC, V7, P1408, DOI 10.1111/j.1600-0854.2006.00474.x; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; Melia TJ, 2002, J CELL BIOL, V158, P929, DOI 10.1083/jcb.200112081; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; NOVICK P, 1979, P NATL ACAD SCI USA, V76, P1858, DOI 10.1073/pnas.76.4.1858; Parlati F, 1999, P NATL ACAD SCI USA, V96, P12565, DOI 10.1073/pnas.96.22.12565; Paumet F, 2005, J BIOL CHEM, V280, P21137, DOI 10.1074/jbc.M500841200; Paumet F, 2004, P NATL ACAD SCI USA, V101, P3376, DOI 10.1073/pnas.0400271101; Paumet F, 2001, J CELL BIOL, V155, P961, DOI 10.1083/jcb.200104092; Peng RW, 2005, THESCIENTIFICWORLDJO, V5, P471, DOI 10.1100/tsw.2005.53; Peng RW, 2004, EMBO J, V23, P3939, DOI 10.1038/sj.emboj.7600410; Peng RW, 2002, J CELL BIOL, V157, P645, DOI 10.1083/jcb.200202006; Pryor PR, 2004, EMBO REP, V5, P590, DOI 10.1038/sj.embor.7400150; Richmond JE, 2001, NATURE, V412, P338, DOI 10.1038/35085583; Rickman C, 2005, CHEM BIOL, V12, P545, DOI 10.1016/j.chembiol.2005.03.004; Rizo J, 2002, NAT REV NEUROSCI, V3, P641, DOI 10.1038/nrn898; Schaub JR, 2006, NAT STRUCT MOL BIOL, V13, P748, DOI 10.1038/nsmb1124; SCHEKMAN R, 2004, CELL, V116, pS19; Schekman Randy, 2004, Cell, VS116, pS13, DOI 10.1016/S0092-8674(03)00972-3; Schutz D, 2005, EUR J NEUROSCI, V21, P2419, DOI 10.1111/j.1460-9568.2005.04095.x; Scott BL, 2004, J CELL BIOL, V167, P75, DOI 10.1083/jcb.200405018; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Sorensen JB, 2002, P NATL ACAD SCI USA, V99, P1627, DOI 10.1073/pnas.251673298; Sudhof TC, 2004, ANNU REV NEUROSCI, V27, P509, DOI 10.1146/annurev.neuro.26.041002.131412; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Takamori S, 2006, CELL, V127, P831, DOI 10.1016/j.cell.2006.10.030; ter Beest MBA, 2005, MOL BIOL CELL, V16, P5784, DOI 10.1091/mbc.E05-070-0661; Toonen RFG, 2005, J NEUROCHEM, V93, P1393, DOI 10.1111/j.1471-4159.2005.03128.x; Toonen RFG, 2003, TRENDS CELL BIOL, V13, P177, DOI 10.1016/S0962-8924(03)00031-X; Tucker WC, 2004, SCIENCE, V304, P435, DOI 10.1126/science.1097196; Ungar D, 2003, ANNU REV CELL DEV BI, V19, P493, DOI 10.1146/annurev.cellbio.19.110701.155609; Verhage M, 2000, SCIENCE, V287, P864, DOI 10.1126/science.287.5454.864; Voets T, 2001, NEURON, V31, P581, DOI 10.1016/S0896-6273(01)00391-9; Weber T, 2000, J CELL BIOL, V149, P1063, DOI 10.1083/jcb.149.5.1063; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Weimer RM, 2003, NAT NEUROSCI, V6, P1023, DOI 10.1038/nn1118; Williams AL, 2004, MOL BIOL CELL, V15, P162, DOI 10.1091/mbc.E03-07-0535; Wu MN, 1998, EMBO J, V17, P127, DOI 10.1093/emboj/17.1.127; Yamaguchi T, 2002, DEV CELL, V2, P295, DOI 10.1016/S1534-5807(02)00125-9; Yang B, 2000, J CELL BIOL, V148, P247, DOI 10.1083/jcb.148.2.247; Zilly FE, 2006, PLOS BIOL, V4, P1789, DOI 10.1371/journal.pbio.0040330	70	349	365	0	48	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 12	2007	128	1					183	195		10.1016/j.cell.2006.12.016	http://dx.doi.org/10.1016/j.cell.2006.12.016			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	139GN	17218264	Bronze			2022-12-28	WOS:000244420400022
J	Xu, Y; Toh, KL; Jones, CR; Shin, JY; Fu, YH; Ptacek, LJ				Xu, Y.; Toh, K. L.; Jones, C. R.; Shin, J. -Y.; Fu, Y. -H.; Ptacek, L. J.			Modeling of a human circadian mutation yields insights into clock regulation by PER2	CELL			English	Article							MOLECULAR ANALYSIS; GENE-EXPRESSION; CKI-EPSILON; PHOSPHORYLATION; PERIOD; MPER2; TRANSCRIPTION; DELTA; DROSOPHILA; COMPONENT	Circadian rhythms are endogenous oscillations of physiological and behavioral phenomena with period length of -24 hr. A mutation in human Period 2 (hPER2), a gene crucial for resetting the central clock in response to light, is associated with familial advanced sleep phase syndrome (FASPS), an autosomal dominant condition with early morning awakening and early sleep times. The FASPS hPER2 S662G mutation resulted in PER2 being hypophosphorylated by casein kinase I (CKI) in vitro. We generated transgenic mice carrying the FASPS hPER2 S662G mutation and faithfully recapitulate the human phenotype. We show that phosphorylation at S662 leads to increased PER2 transcription and suggest that phosphorylation at another site leads to PER2 degradation. Altering CK1 delta dosage modulates the S662 phenotype demonstrating that CK1 delta can regulate period through PER2 in vivo. Modeling a naturally occurring human variant in mice has yielded novel insights into PER2 regulation.	Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94158 USA; Univ Utah, Dept Neurol, Salt Lake City, UT 84132 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94158 USA	University of California System; University of California San Francisco; Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Fu, YH (corresponding author), Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94158 USA.	yhf@neugenes.org; ljp@ucsf.edu	Xu, Ying/A-3009-2013; Xu, Ying/AAF-3081-2019	Xu, Ying/0000-0002-6689-7768; Xu, Ying/0000-0002-6689-7768	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059596] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH074924] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL059596] Funding Source: Medline; NIMH NIH HHS [P50 MH074924] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ABBONDANZO SJ, 1993, METHOD ENZYMOL, V225, P803; Akashi M, 2002, MOL CELL BIOL, V22, P1693, DOI 10.1128/MCB.22.6.1693-1703.2002; Albrecht U, 1997, CELL, V91, P1055, DOI 10.1016/S0092-8674(00)80495-X; [Anonymous], [No title captured], DOI [DOI 10.1126/SCIENCE.284.5423.2177, 10.1126/science.284.5423.2177]; Bae K, 2001, NEURON, V30, P525, DOI 10.1016/S0896-6273(01)00302-6; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; Camacho F, 2001, FEBS LETT, V489, P159, DOI 10.1016/S0014-5793(00)02434-0; Campbell S, 2000, SCIENCE, V288, P1174, DOI 10.1126/science.288.5469.1174; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; Eide EJ, 2005, MOL CELL BIOL, V25, P2795, DOI 10.1128/MCB.25.7.2795-2807.2005; Emery P, 2004, NEURON, V43, P443, DOI 10.1016/j.neuron.2004.08.009; Gallego M, 2006, P NATL ACAD SCI USA, V103, P10618, DOI 10.1073/pnas.0604511103; Harms E, 2004, J BIOL RHYTHM, V19, P361, DOI 10.1177/0748730404268111; Hastings MH, 2004, J BIOL RHYTHM, V19, P400, DOI 10.1177/0748730404268786; Jin XW, 1999, CELL, V96, P57, DOI 10.1016/S0092-8674(00)80959-9; Jones CR, 1999, NAT MED, V5, P1062, DOI 10.1038/12502; Klerman EB, 1996, AM J PHYSIOL-REG I, V270, pR271, DOI 10.1152/ajpregu.1996.270.1.R271; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Lee C, 2001, CELL, V107, P855, DOI 10.1016/S0092-8674(01)00610-9; Lowrey PL, 2004, ANNU REV GENOM HUM G, V5, P407, DOI 10.1146/annurev.genom.5.061903.175925; Lowrey PL, 2000, SCIENCE, V288, P483, DOI 10.1126/science.288.5465.483; Miyazaki K, 2004, BIOCHEM J, V380, P95, DOI 10.1042/BJ20031308; Nawathean P, 2004, MOL CELL, V13, P213, DOI 10.1016/S1097-2765(03)00503-3; Preitner N, 2002, CELL, V110, P251, DOI 10.1016/S0092-8674(02)00825-5; Reppert SM, 2001, ANNU REV PHYSIOL, V63, P647, DOI 10.1146/annurev.physiol.63.1.647; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; Ripperger JRA, 2006, NAT GENET, V38, P369, DOI 10.1038/ng1738; Sato TK, 2004, NEURON, V43, P527, DOI 10.1016/j.neuron.2004.07.018; Shearman LP, 2000, SCIENCE, V288, P1013, DOI 10.1126/science.288.5468.1013; Tamanini F, 2005, METHOD ENZYMOL, V393, P418, DOI 10.1016/S0076-6879(05)93020-6; Toh KL, 2001, SCIENCE, V291, P1040, DOI 10.1126/science.1057499; Ueda HR, 2005, NAT GENET, V37, P187, DOI 10.1038/ng1504; Ueda HR, 2002, NATURE, V418, P534, DOI 10.1038/nature00906; Xu Y, 2005, NATURE, V434, P640, DOI 10.1038/nature03453; Yagita K, 2002, EMBO J, V21, P1301, DOI 10.1093/emboj/21.6.1301; Yamamoto T, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-18; Young MW, 2001, NAT REV GENET, V2, P702, DOI 10.1038/35088576; Yu WJ, 2002, BIOCHEM BIOPH RES CO, V290, P933, DOI 10.1006/bbrc.2001.6300; Zheng BH, 1999, NATURE, V400, P169, DOI 10.1038/22118; Zylka MJ, 1998, NEURON, V21, P1115, DOI 10.1016/S0896-6273(00)80628-5	41	283	293	5	25	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 12	2007	128	1					59	70		10.1016/j.cell.2006.11.043	http://dx.doi.org/10.1016/j.cell.2006.11.043			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	139GN	17218255	Bronze, Green Accepted, Green Submitted			2022-12-28	WOS:000244420400013
J	Zhang, J; Sasaki, K; Sutter, E; Adzic, RR				Zhang, J.; Sasaki, K.; Sutter, E.; Adzic, R. R.			Stabilization of platinum oxygen-reduction electrocatalysts using gold clusters	SCIENCE			English	Article							METAL-CLUSTERS; CATALYTIC-ACTIVITY; FUEL-CELLS; CO; ADSORPTION; OXIDATION; SURFACES; O-2	We demonstrated that platinum (Pt) oxygen-reduction fuel-cell electrocatalysts can be stabilized against dissolution under potential cycling regimes ( a continuing problem in vehicle applications) by modifying Pt nanoparticles with gold (Au) clusters. This behavior was observed under the oxidizing conditions of the O-2 reduction reaction and potential cycling between 0.6 and 1.1 volts in over 30,000 cycles. There were insignificant changes in the activity and surface area of Au-modified Pt over the course of cycling, in contrast to sizable losses observed with the pure Pt catalyst under the same conditions. In situ x-ray absorption near-edge spectroscopy and voltammetry data suggest that the Au clusters confer stability by raising the Pt oxidation potential.	Brookhaven Natl Lab, Dept Chem, Upton, NY 11973 USA; Brookhaven Natl Lab, Ctr Funct Nanomat, Upton, NY 11973 USA	United States Department of Energy (DOE); Brookhaven National Laboratory; United States Department of Energy (DOE); Brookhaven National Laboratory	Zhang, J (corresponding author), Brookhaven Natl Lab, Dept Chem, Upton, NY 11973 USA.		Sutter, Eli A./AAD-7878-2019					Adzic R, 1998, FRONT ELECT, P197; Brankovic SR, 2001, J SERB CHEM SOC, V66, P887; Chen MS, 2006, CATAL TODAY, V111, P22, DOI 10.1016/j.cattod.2005.10.007; Christoffersen E, 2001, J CATAL, V199, P123, DOI 10.1006/jcat.2000.3136; Chusuei CC, 2001, TOP CATAL, V14, P71; Comotti M, 2006, J AM CHEM SOC, V128, P917, DOI 10.1021/ja0561441; de Mongeot FB, 1998, SURF SCI, V411, P249, DOI 10.1016/S0039-6028(98)00286-6; Del Popolo MG, 2005, SURF SCI, V597, P133, DOI 10.1016/j.susc.2004.04.063; Ferreira PJ, 2005, J ELECTROCHEM SOC, V152, pA2256, DOI 10.1149/1.2050347; Gasteiger HA, 2005, APPL CATAL B-ENVIRON, V56, P9, DOI 10.1016/j.apcatb.2004.06.021; Greeley J, 2002, ANNU REV PHYS CHEM, V53, P319, DOI 10.1146/annurev.physchem.53.100301.131630; Hammer B, 2006, TOP CATAL, V37, P3, DOI 10.1007/s11244-006-0004-y; Hammer B, 2000, ADV CATAL, V45, P71; Iizuka Y, 1997, CATAL TODAY, V36, P115, DOI 10.1016/S0920-5861(96)00204-0; Kim YD, 2003, CHEM PHYS LETT, V377, P170, DOI 10.1016/S0009-2614(03)01130-8; Lopez N, 2002, J AM CHEM SOC, V124, P11262, DOI 10.1021/ja026998a; Meier DC, 2004, J AM CHEM SOC, V126, P1892, DOI 10.1021/ja030359y; Meyer R, 2004, GOLD BULL, V37, P72, DOI 10.1007/BF03215519; Min BK, 2006, SURF SCI, V600, pL7, DOI 10.1016/j.susc.2005.10.024; RODRIGUEZ JA, 1992, SCIENCE, V257, P897, DOI 10.1126/science.257.5072.897; Roudgar A, 2004, SURF SCI, V559, pL180, DOI 10.1016/j.susc.2004.04.032; Salisbury BE, 2000, CHEM PHYS, V262, P131, DOI 10.1016/S0301-0104(00)00272-X; Stolcic D, 2003, J AM CHEM SOC, V125, P2848, DOI 10.1021/ja0293406; Strbac S, 1996, J ELECTROANAL CHEM, V403, P169, DOI 10.1016/0022-0728(95)04389-6; Valden M, 1998, SCIENCE, V281, P1647, DOI 10.1126/science.281.5383.1647; WOODS R, 1976, ELECTROANALYTICAL CH, V9; Xu Y, 2004, J AM CHEM SOC, V126, P4717, DOI 10.1021/ja031701+; Yoon B, 2003, J PHYS CHEM A, V107, P4066, DOI 10.1021/jp027596s; Zhang JL, 2005, ANGEW CHEM INT EDIT, V44, P2132, DOI 10.1002/anie.200462335	29	1541	1590	19	1117	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 12	2007	315	5809					220	222		10.1126/science.1134569	http://dx.doi.org/10.1126/science.1134569			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124XZ	17218522				2022-12-28	WOS:000243407400041
J	Weber, F; Xu, YM; Zhang, L; Patocs, A; Shen, L; Platzer, P; Eng, C				Weber, Frank; Xu, Yaomin; Zhang, Li; Patocs, Attila; Shen, Lei; Platzer, Petra; Eng, Charis			Microenvironmental genomic alterations and clinicopathological behavior in head and neck squamous cell carcinoma	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROSTATE-CANCER-AGGRESSIVENESS; FIELD CANCERIZATION; TUMOR PROGRESSION; BREAST-CANCER; STROMA; EXPRESSION; PROTEIN; EPITHELIUM; LUNG; DIFFERENTIATION	Context Carcinogens associated with head and neck squamous cell carcinoma (SCC) genesis should inflict genomic alterations not only on the epithelium but also the mesenchyme of the aerodigestive tract. Therefore, the apparently nonmalignant stroma surrounding the tumor epithelium can acquire genomic alterations and contribute to cancer initiation and progression. Objectives To determine compartment-specific loci of loss of heterozygosity or allelic imbalance (LOH/AI) and to identify which genomic alterations restricted to the stroma cell population contribute to aggressiveness of head and neck SCC disease. Design, Setting, and Patients Tumor epithelium and surrounding stroma were isolated from 122 US patients with oral cavity and oropharyngeal or hypopharyngeal SCC and subjected to whole-genome LOH/AI analysis using 366 microsatellite markers. Samples, collected between 2001 and 2004, were pulled and transferred in batches of 10 to 30 between 2002 and 2005. Laser capture microdissection DNA extraction and technical genotyping occurred on a rolling model between 2002 and November 2005. Main Outcome Measures Compartment-specific frequency and distribution of LOH/AI were determined, and hot spots of genomic alterations identified. Compartment-specific LOH/AI events were correlated with presenting clinicopathologic characteristics. Results Tumor-associated stroma of head and neck SCC from smokers were found to have a high degree of genomic alterations. A correlation between tumor aggressiveness could be found for a specific set of 5 loci. Three stroma-specific loci (D4S2417, D3S360, and D19555) were associated with tumor size (pT) and regional nodal metastases (pN). Furthermore, 2 epithelial-specific LOH/AI hot spots were positively correlated with pN status and clinical stage. Conclusions Stroma-specific genetic alterations are associated with smoking-related head and neck SCC genesis. These findings suggest novel prognostic or diagnostic biomarkers and identify potential new molecular targets for therapeutic and preventive intervention.	Cleveland Clin Lerner Res Inst, Genom Med Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Sect Stat Genet, Dept Quantitat Hlth Sci, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Taussig Canc Ctr, Cleveland, OH 44195 USA; Ohio State Univ, Div Biostat, Sch Publ Hlth, Columbus, OH 43210 USA; Case Western Reserve Univ, Dept Stat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA; Case Western Reserve Univ, CASE Comprehens Canc Ctr, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; University System of Ohio; Ohio State University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Eng, C (corresponding author), Cleveland Clin Lerner Res Inst, Genom Med Inst, 9500 Euclid Ave,NE-50, Cleveland, OH 44195 USA.	engc@ccf.org	Weber, Frank/A-1883-2012	Weber, Frank/0000-0002-0995-667X; Eng, Charis/0000-0002-3693-5145; Patocs, Attila/0000-0001-7506-674X				*AM CANC SOC, 2006, OR CANC FACTS FIG; [Anonymous], 2006, SEER CANC STAT REV 1; Appelhoff RJ, 2004, J BIOL CHEM, V279, P38458, DOI 10.1074/jbc.M406026200; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Bockmuhl U, 2002, GENE CHROMOSOME CANC, V33, P29, DOI 10.1002/gcc.1209.abs; Bockmuhl U, 1998, HEAD NECK-J SCI SPEC, V20, P145, DOI 10.1002/(SICI)1097-0347(199803)20:2<145::AID-HED8>3.0.CO;2-2; Braakhuis BJM, 2005, SEMIN CANCER BIOL, V15, P113, DOI 10.1016/j.semcancer.2004.08.004; Braakhuis BJM, 2003, CANCER RES, V63, P1727; Climent J, 2002, CLIN CANCER RES, V8, P3863; Condon MS, 2005, SEMIN CANCER BIOL, V15, P132, DOI 10.1016/j.semcancer.2004.08.002; Dacic S, 2005, AM J SURG PATHOL, V29, P897, DOI 10.1097/01.pas.0000164367.96379.66; Dai MS, 2002, J BIOL CHEM, V277, P26327, DOI 10.1074/jbc.M201834200; Denison SR, 2003, GENE CHROMOSOME CANC, V38, P40, DOI 10.1002/gcc.10236; Edlund M, 2004, J CELL BIOCHEM, V91, P686, DOI 10.1002/jcb.10702; FARAWAY JJ, 2006, EXTENDING LINEAR MOD, V1; Forastiere A, 2001, NEW ENGL J MED, V345, P1890, DOI 10.1056/NEJMra001375; Fukino K, 2004, CANCER RES, V64, P7231, DOI 10.1158/0008-5472.CAN-04-2866; Gotte A, 2005, ADV OTO-RHINO-LARYNG, V62, P38; GREEN FL, 1997, AJCC CANC STAGING MA; Hill R, 2005, CELL, V123, P1001, DOI 10.1016/j.cell.2005.09.030; Hoatlin ME, 1999, BLOOD, V94, P3737, DOI 10.1182/blood.V94.11.3737.423k39_3737_3747; Horvath B, 2005, HEAD NECK-J SCI SPEC, V27, P585, DOI 10.1002/hed.20188; Huang Q, 2002, GENE CHROMOSOME CANC, V34, P224, DOI 10.1002/gcc.10062; Hunter KD, 2005, NAT REV CANCER, V5, P127, DOI 10.1038/nrc1549; Hussain S, 2004, HUM MOL GENET, V13, P1241, DOI 10.1093/hmg/ddh135; Jang SJ, 2001, ONCOGENE, V20, P2235, DOI 10.1038/sj.onc.1204311; Jukkola T, 2004, GENE EXPR PATTERNS, V4, P755, DOI 10.1016/j.modgep.2004.03.006; Kurose K, 2001, HUM MOL GENET, V10, P1907, DOI 10.1093/hmg/10.18.1907; Leng K, 2006, J ORAL PATHOL MED, V35, P19, DOI 10.1111/j.1600-0714.2005.00365.x; Marsh DJ, 1997, CANCER RES, V57, P500; McCawley LJ, 2001, CURR BIOL, V11, pR25, DOI 10.1016/S0960-9822(00)00038-5; McCullagh P., 1989, GEN LINEAR MODELS, V(2nd), DOI [10.1007/978-1-4899-3242-6, https://doi.org/10.1007/978-1-4899-3242-6, DOI 10.1007/978-1-4899-3242-6]; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; Naguibneva I, 2006, NAT CELL BIOL, V8, P278, DOI 10.1038/ncb1373; Nelson HH, 2005, CARCINOGENESIS, V26, P1770, DOI 10.1093/carcin/bgi125; Perez-Ordonez B, 2006, J CLIN PATHOL, V59, P445, DOI 10.1136/jcp.2003.007641; Riccil F, 2005, CANCER BIOL THER, V4, P302, DOI 10.4161/cbt.4.3.1501; Rosenquist TA, 2003, DNA REPAIR, V2, P581, DOI 10.1016/S1568-7864(03)00025-9; Rosenthal E, 2004, MOL CARCINOGEN, V40, P116, DOI 10.1002/mc.20024; Slager SL, 2003, AM J HUM GENET, V72, P759, DOI 10.1086/368230; SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q; Taniguchi T, 2002, BLOOD, V100, P2414, DOI 10.1182/blood-2002-01-0278; Tran Y, 1998, ONCOGENE, V17, P3499, DOI 10.1038/sj.onc.1202258; van Oijen MGCT, 2000, CANCER EPIDEM BIOMAR, V9, P249; Wacholder S, 2004, J NATL CANCER I, V96, P434, DOI 10.1093/jnci/djh075; Weber F, 2005, BRIT J CANCER, V92, P1922, DOI 10.1038/sj.bjc.6602557; Weber F, 2006, AM J HUM GENET, V78, P961, DOI 10.1086/504090; Williams HK, 2000, J CLIN PATHOL-MOL PA, V53, P165, DOI 10.1136/mp.53.4.165; Witte JS, 2000, AM J HUM GENET, V67, P92, DOI 10.1086/302960; Worsham MJ, 2006, ARCH OTOLARYNGOL, V132, P409, DOI 10.1001/archotol.132.4.409; XU Y, 2005, C NONP INF PROB APPL	51	71	74	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 10	2007	297	2					187	195		10.1001/jama.297.2.187	http://dx.doi.org/10.1001/jama.297.2.187			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	124GI	17213402	Bronze			2022-12-28	WOS:000243355900028
J	Shah, R				Shah, Rupal			BMJ masterclass for GPs - Dyspepsia and Helicobacter pylori	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; INFECTION; ERADICATION; REFLUX					roo.tindall@hotmail.com						[Anonymous], 2005, Drug Ther Bull, V43, P37; *BRIT SOC GASTR, 2002, GUID MAN OES GASTR C; Chiba N, 2002, BRIT MED J, V324, P1012, DOI 10.1136/bmj.324.7344.1012; Delaney B, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001961.pub2; Harvey RF, 2004, BMJ-BRIT MED J, V328, P1417, DOI 10.1136/bmj.38082.626725.EE; Hippisley-Cox J, 2005, BMJ-BRIT MED J, V331, P1310, DOI 10.1136/bmj.331.7528.1310; Hooper L, 2004, BRIT MED J, V329, P948, DOI 10.1136/bmj.38232.680567.EB; Labenz J, 1997, GASTROENTEROLOGY, V112, P1442, DOI 10.1016/S0016-5085(97)70024-6; Lane JA, 2006, BMJ-BRIT MED J, V332, P199, DOI 10.1136/bmj.38702.662546.55; *NIH CLIN EXC, 2005, MAN DYSP AD PRIM CAR	10	5	7	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 6	2007	334	7583					41	43		10.1136/bmj.39014.468900.BE	http://dx.doi.org/10.1136/bmj.39014.468900.BE			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125CH	17204803	Green Published			2022-12-28	WOS:000243418600042
J	Tan, HL; Meregalli, PG				Tan, Hanno L.; Meregalli, Paola G.			Lethal ECG changes hidden by therapeutic hypothermia	LANCET			English	Editorial Material							BRUGADA-SYNDROME		Univ Amsterdam, Acad Med Ctr, Dept Cardiol, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	Tan, HL (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Cardiol, NL-1105 AZ Amsterdam, Netherlands.	h.l.tan@amc.uva.nl						Antzelevitch C, 2005, CIRCULATION, V111, P659, DOI 10.1161/01.CIR.0000152479.54298.51; Miyazaki T, 1996, J AM COLL CARDIOL, V27, P1061, DOI 10.1016/0735-1097(95)00613-3; Smith J, 2003, HEART, V89, P272, DOI 10.1136/heart.89.3.272; Tan HL, 2005, CIRCULATION, V112, P207, DOI 10.1161/CIRCULATIONAHA.104.522581; Wilde AAM, 2002, CIRCULATION, V106, P2514, DOI 10.1161/01.CIR.0000034169.45752.4A	5	15	15	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 6	2007	369	9555					78	78		10.1016/S0140-6736(07)60034-8	http://dx.doi.org/10.1016/S0140-6736(07)60034-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125AK	17208645				2022-12-28	WOS:000243413700032
J	Soukoulis, CM; Linden, S; Wegener, M				Soukoulis, Costas M.; Linden, Stefan; Wegener, Martin			Negative refractive index at optical wavelengths	SCIENCE			English	Editorial Material							MAGNETIC RESPONSE; METAMATERIALS; PERMEABILITY; LIGHT	Metamaterials are designed to have structures that provide optical properties not found in nature. If their capacity can be extended, new kinds of devices for imaging and control of light will be possible.	Iowa State Univ, Ames Lab, Ames, IA 50011 USA; Iowa State Univ, Dept Phys & Astron, Ames, IA 50011 USA; Fdn Res & Technol Hellas, Inst Elect Struct & Laser, Iraklion 71110, Greece; Univ Crete, Iraklion 71409, Crete, Greece; Univ Karlsruhe, Ctr Funct Nanostruct, D-76128 Karlsruhe, Germany; Forschungszentrum Karlsruhe, D-76128 Karlsruhe, Germany	Iowa State University; United States Department of Energy (DOE); Ames National Laboratory; Iowa State University; Foundation for Research & Technology - Hellas (FORTH); University of Crete; Helmholtz Association; Karlsruhe Institute of Technology; Helmholtz Association; Karlsruhe Institute of Technology	Soukoulis, CM (corresponding author), Iowa State Univ, Ames Lab, Ames, IA 50011 USA.	soukoulis@ameslab.gov	Wegener, Martin/ABD-5353-2021; Soukoulis, Costas M./A-5295-2008; Wegener, Martin/S-5456-2016	Wegener, Martin/0000-0002-9770-2441; Wegener, Martin/0000-0002-9770-2441				Bayindir M, 2002, APPL PHYS LETT, V81, P120, DOI 10.1063/1.1492009; Dolling G, 2005, OPT LETT, V30, P3198, DOI 10.1364/OL.30.003198; Dolling G, 2006, SCIENCE, V312, P892, DOI 10.1126/science.1126021; Dolling G, 2007, OPT LETT, V32, P53, DOI 10.1364/OL.32.000053; Dolling G, 2006, OPT LETT, V31, P1800, DOI 10.1364/OL.31.001800; Enkrich C, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.203901; Greegor RB, 2003, APPL PHYS LETT, V82, P2356, DOI 10.1063/1.1563726; Grigorenko AN, 2006, OPT LETT, V31, P2483, DOI 10.1364/OL.31.002483; Grigorenko AN, 2005, NATURE, V438, P335, DOI 10.1038/nature04242; Katsarakis N, 2005, OPT LETT, V30, P1348, DOI 10.1364/OL.30.001348; Linden S, 2004, SCIENCE, V306, P1351, DOI 10.1126/science.1105371; Parazzoli CG, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.107401; Pendry JB, 2000, PHYS REV LETT, V85, P3966, DOI 10.1103/PhysRevLett.85.3966; Shalaev VM, 2005, OPT LETT, V30, P3356, DOI 10.1364/OL.30.003356; Shelby RA, 2001, SCIENCE, V292, P77, DOI 10.1126/science.1058847; Smith DR, 2004, SCIENCE, V305, P788, DOI 10.1126/science.1096796; Smith DR, 2000, PHYS REV LETT, V84, P4184, DOI 10.1103/PhysRevLett.84.4184; SMITH DR, 2004, PHYS TODAY       JUN, P37; Soukoulis CM, 2006, OPT PHOTONICS NEWS, V17, P16, DOI 10.1364/OPN.17.6.000016; Soukoulis CM, 2006, ADV MATER, V18, P1941, DOI 10.1002/adma.200600106; VESELAGO VG, 1968, SOV PHYS USPEKHI, V10, P509, DOI 10.1070/PU1968v010n04ABEH003699; Yen TJ, 2004, SCIENCE, V303, P1494, DOI 10.1126/science.1094025; Zhang S, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.137404; Zhang S, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.037402	24	789	812	8	218	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 5	2007	315	5808					47	49		10.1126/science.1136481	http://dx.doi.org/10.1126/science.1136481			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	122WU	17204630	Green Published			2022-12-28	WOS:000243259100023
J	Nunez-Smith, M; Curry, LA; Bigby, J; Berg, D; Krumholz, HM; Bradley, EH				Nunez-Smith, Marcella; Curry, Leslie A.; Bigby, JudyAnn; Berg, David; Krumholz, Harlan M.; Bradley, Elizabeth H.			Impact of race on the professional lives of physicians of African descent	ANNALS OF INTERNAL MEDICINE			English	Article							ACADEMIC MEDICINE; QUALITATIVE RESEARCH; MINORITY FACULTY; DIVERSITY; DISCRIMINATION; EXPERIENCE; PROMOTION; SCHOOLS	Background: Increasing the racial and ethnic diversity of the physician workforce is a national priority. However, insight into the professional experiences of minority physicians is limited. This knowledge is fundamental to developing effective strategies to recruit, retain, and support a diverse physician workforce. Objective: To characterize how physicians of African descent experience race in the workplace. Design: Qualitative study based on in-person and in-depth racially concordant interviews using a standard discussion guide. Setting: The 6 New England states in the United States. Participants: 25 practicing physicians of African descent representing a diverse range of primary practice settings, specialties, and ages. Measurements: Professional experiences of physicians of African descent. Results: 1) Awareness of race permeates the experience of physicians of African descent in the health care workplace; 2) race-related experiences shape interpersonal interactions and define the institutional climate; 3) responses to perceived racism at work vary along a spectrum from minimization to confrontation; 4) the health care workplace is often silent on issues of race; and 5) collective race-related experiences can result in "racial fatigue," with personal and professional consequences for physicians. Limitations: The study was restricted to New England and may not reflect the experiences of physicians in other geographic regions. The findings are meant to be hypothesis-generating and require additional follow-up studies. Conclusions: The issue of race remains a pervasive influence in the work lives of physicians of African descent. Without sufficient attention to the specific ways in which race shapes physicians' work experiences, health care organizations are unlikely to create environments that successfully foster and sustain a diverse physician workforce.	Yale Univ, Sch Med, Robert Wood Johnson Clin Scholars Program, New Haven, CT 06520 USA; Yale Univ, Sch Eipidemiol & Publ Hlth, New Haven, CT 06520 USA; Univ Connecticut, Sch Med, Farmington, CT USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA	Yale University; Yale University; University of Connecticut; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Nunez-Smith, M (corresponding author), Yale Univ, Sch Med, Robert Wood Johnson Clin Scholars Program, IE-61,POB 208088, New Haven, CT 06520 USA.	marcella.nunez-smith@yale.edu	, Harlan/AAI-2875-2020; Curry, Leslie A/ABA-1890-2021; curry, leslie/AAA-6100-2022	curry, leslie/0000-0002-3419-4654; Nunez-Smith, Marcella/0000-0003-2797-4756				Alderfer C. P., 2003, HDB PSYCHOL, P595; American Medical Association, 2006, PHYS CHAR DISTR US; [Anonymous], 2005, HOLDING FAST STRUGGL; Bright CM, 1998, J NATL MED ASSOC, V90, P681; BRITTEN N, 1995, BRIT MED J, V311, P251, DOI 10.1136/bmj.311.6999.251; BULLOCK SC, 1987, J NATL MED ASSOC, V79, P601; BYRD MW, 2001, AM HLTH DILEMMA RACE, V2; Coombs AAT, 2005, J NATL MED ASSOC, V97, P467; Corbie-Smith G, 1999, ACAD MED, V74, P695, DOI 10.1097/00001888-199906000-00018; DIPBOYE RL, 2005, DISCRIMINATION WORK, V22; Fang D, 2000, JAMA-J AM MED ASSOC, V284, P1085, DOI 10.1001/jama.284.9.1085; Glaser B., 1992, BASICS GROUNDED THEO; Glaser B.G., 1965, AWARENESS DYING; Malterud K, 2001, LANCET, V358, P397, DOI 10.1016/S0140-6736(01)05548-9; MAYS N, 1995, BRIT MED J, V311, P109, DOI 10.1136/bmj.311.6997.109; Miles M.B., 1994, RES METHODS PUBLIC A, V4, P162, DOI [https://doi.org/10.4324/9781315701134-11, DOI 10.4324/9781315701134-11]; Muhr T., 2004, USERS MANUAL ATLAS 5; Nickens H W, 1992, JAMA, V267, P2395, DOI 10.1001/jama.267.17.2390; NICKENS HW, 1994, NEW ENGL J MED, V331, P472, DOI 10.1056/NEJM199408183310712; Palepu A, 1998, JAMA-J AM MED ASSOC, V280, P767, DOI 10.1001/jama.280.9.767; Palepu A, 2000, ACAD MED, V75, P157, DOI 10.1097/00001888-200002000-00014; Patton MQ., 2015, QUALITATIVE RES EVAL, V3; Peterson NB, 2004, J GEN INTERN MED, V19, P259, DOI 10.1111/j.1525-1497.2004.20409.x; Price EG, 2005, J GEN INTERN MED, V20, P565, DOI 10.1111/j.1525-1497.2005.0127.x; SMEDLEY BD, 2004, NATL COMPELLING INTE; Strauss A., 1990, BASICS QUALITATIVE R; Strauss A., 1998, BASICS QUALITATIVE R; Sullivan Commission on Diversity in the Health Workforce, 2004, MISS PERS MIN HLTH P; Tekian A, 1997, ACAD MED, V72, pS140, DOI 10.1097/00001888-199710001-00047; Thomson WA, 1999, ACAD MED, V74, P312, DOI 10.1097/00001888-199904000-00010	30	77	77	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 2	2007	146	1					45	W7		10.7326/0003-4819-146-1-200701020-00008	http://dx.doi.org/10.7326/0003-4819-146-1-200701020-00008			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188BK	17200221				2022-12-28	WOS:000247893300006
J	Murali, MR; Kratz, A; Finberg, KE; Hopkins, CM; Wakem, C				Murali, Mandakolathur R.; Kratz, Alexander; Finberg, Karin E.; Hopkins, Carolyn M.; Wakem, Christopher			A man with anemia and a low level of HDL cholesterol - Lymphoplasmacytic lymphoma with Waldenstrom's macroglobulinemia and biclonal gammopathy. Falsely low serum HDL cholesterol test result due to the presence of the paraprotein	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MONOCLONAL IMMUNOGLOBULINS		Massachusetts Gen Hosp, Div Clin Immunol & Allergy, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital	Murali, MR (corresponding author), Massachusetts Gen Hosp, Div Clin Immunol & Allergy, Boston, MA 02114 USA.							Baca A, 2004, CLIN CHEM, V50, P255, DOI 10.1373/clinchem.2003.027813; Berth M, 2004, ACTA CLIN BELG, V59, P263, DOI 10.1179/acb.2004.039; Blade J, 2006, NEW ENGL J MED, V355, P2765, DOI 10.1056/NEJMcp052790; BONEWALD L, 1985, CLIN CHIM ACTA, V146, P53, DOI 10.1016/0009-8981(85)90123-8; Ciric B, 2001, BLOOD, V97, P321, DOI 10.1182/blood.V97.1.321; Ganz T, 2002, ISRAEL MED ASSOC J, V4, P1043; Guralnik JM, 2004, BLOOD, V104, P2263, DOI 10.1182/blood-2004-05-1812; Kadri N, 2002, CLIN CHEM, V48, P964; Kyle RA, 1999, HEMATOL ONCOL CLIN N, V13, P1181, DOI 10.1016/S0889-8588(05)70120-9; KYLE RA, 1981, AM J MED, V71, P999, DOI 10.1016/0002-9343(81)90326-0; KYLE RA, 1993, MAYO CLIN PROC, V68, P26, DOI 10.1016/S0025-6196(12)60015-9; MERLINI G, 1986, SEMIN ONCOL, V13, P350; Nemeth E, 2004, J CLIN INVEST, V113, P1271, DOI 10.1172/JCI200420945; Pantanowitz L, 2003, ARCH PATHOL LAB MED, V127, P55; Rifai N., 1999, TIETZ TXB CLIN CHEM, V3rd; Sahota SS, 2002, BLOOD, V100, P1505, DOI 10.1182/blood.V100.4.1505.h81602001505_1505_1507; Schulz, 1996, Mol Diagn, V1, P159, DOI 10.1016/S1084-8592(96)70001-2; Smogorzewska A, 2004, CLIN CHEM, V50, P1691, DOI 10.1373/clinchem.2004.037499; Tsai LY, 2005, CLIN CHIM ACTA, V358, P192, DOI 10.1016/j.cccn.2005.02.008; Vardiman J., 2001, WHO CLASSIFICATION T, V3	20	8	8	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 28	2006	355	26					2772	2779		10.1056/NEJMcpc069031	http://dx.doi.org/10.1056/NEJMcpc069031			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	120UA	17192544				2022-12-28	WOS:000243110500012
J	Ventura, A; Kirsch, DG; McLaughlin, ME; Tuveson, DA; Grimm, J; Lintault, L; Newman, J; Reczek, EE; Weissleder, R; Jacks, T				Ventura, Andrea; Kirsch, David G.; McLaughlin, Margaret E.; Tuveson, David A.; Grimm, Jan; Lintault, Laura; Newman, Jamie; Reczek, Elizabeth E.; Weissleder, Ralph; Jacks, Tyler			Restoration of p53 function leads to tumour regression in vivo	NATURE			English	Article							LUNG-CANCER; MUTANT P53; SUPPRESSION; MICE; ANGIOGENESIS; RECOMBINASES; EXPRESSION; MUTATIONS; GEFITINIB; EFFICACY	Tumorigenesis is a multi-step process that requires activation of oncogenes and inactivation of tumour suppressor genes(1). Mouse models of human cancers have recently demonstrated that continuous expression of a dominantly acting oncogene ( for example, Hras, Kras and Myc) is often required for tumour maintenance(2-5); this phenotype is referred to as oncogene addiction(6). This concept has received clinical validation by the development of active anticancer drugs that specifically inhibit the function of oncoproteins such as BCR-ABL, c-KIT and EGFR(7-10). Identifying additional gene mutations that are required for tumour maintenance may therefore yield clinically useful targets for new cancer therapies. Although loss of p53 function is a common feature of human cancers(11), it is not known whether sustained inactivation of this or other tumour suppressor pathways is required for tumour maintenance. To explore this issue, we developed a Cre-loxP-based strategy to temporally control tumour suppressor gene expression in vivo. Here we show that restoring endogenous p53 expression leads to regression of autochthonous lymphomas and sarcomas in mice without affecting normal tissues. The mechanism responsible for tumour regression is dependent on the tumour type, with the main consequence of p53 restoration being apoptosis in lymphomas and suppression of cell growth with features of cellular senescence in sarcomas. These results support efforts to treat human cancers by way of pharmacological reactivation of p53.	MIT, Ctr Canc Res, Cambridge, MA 02142 USA; Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02129 USA; Massachusetts Gen Hosp, Ctr Mol Imaging Res, Boston, MA 02129 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Howard Hughes Med Inst, Chevy Chase, MD 20815 USA	Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Jacks, T (corresponding author), MIT, Ctr Canc Res, Cambridge, MA 02142 USA.	tjacks@mit.edu	Grimm, Jan/B-1937-2008; Ventura, Andrea/F-1789-2011	/0000-0003-0828-4143; Ventura, Andrea/0000-0003-4320-9907				Branda CS, 2004, DEV CELL, V6, P7, DOI 10.1016/S1534-5807(03)00399-X; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Christophorou MA, 2006, NATURE, V443, P214, DOI 10.1038/nature05077; Christophorou MA, 2005, NAT GENET, V37, P718, DOI 10.1038/ng1572; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Dickins RA, 2005, NAT GENET, V37, P1289, DOI 10.1038/ng1651; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Fisher GH, 2001, GENE DEV, V15, P3249, DOI 10.1101/gad.947701; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Haupt S, 2004, SEMIN CANCER BIOL, V14, P244, DOI 10.1016/j.semcancer.2004.04.003; Indra AK, 1999, NUCLEIC ACIDS RES, V27, P4324, DOI 10.1093/nar/27.22.4324; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Snyder EL, 2004, PLOS BIOL, V2, P186, DOI 10.1371/journal.pbio.0020036; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Teodoro JG, 2006, SCIENCE, V313, P968, DOI 10.1126/science.1126391; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; XUE W, 2007, NATURE          0124; Zhang LL, 2000, CANCER RES, V60, P3655	31	1342	1397	2	191	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 8	2007	445	7128					661	665		10.1038/nature05541	http://dx.doi.org/10.1038/nature05541			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	133UM	17251932				2022-12-28	WOS:000244039400047
J	Tombola, F; Pathak, MM; Gorostiza, P; Isacoff, EY				Tombola, Francesco; Pathak, Medha M.; Gorostiza, Pau; Isacoff, Ehud Y.			The twisted ion-permeation pathway of a resting voltage-sensing domain	NATURE			English	Article							FOCUSED ELECTRIC-FIELD; SHAKER K+ CHANNEL; POTASSIUM CHANNEL; TRANSMEMBRANE MOVEMENT; SENSOR; PORE; DISPLACEMENT; ACTIVATION; MECHANISM; MODELS	Proteins containing voltage-sensing domains (VSDs) translate changes in membrane potential into changes in ion permeability or enzymatic activity(1-3). In channels, voltage change triggers a switch in conformation of the VSD, which drives gating in a separate pore domain, or, in channels lacking a pore domain, directly gates an ion pathway within the VSD4,5. Neither mechanism is well understood(6). In the Shaker potassium channel, mutation of the first arginine residue of the S4 helix to a smaller uncharged residue makes the VSD permeable to ions ('omega current') in the resting conformation ('S4 down')(7). Here we perform a structure-guided perturbation analysis of the omega conductance to map its VSD permeation pathway. We find that there are four omega pores per channel, which is consistent with one conduction path per VSD. Permeating ions from the extracellular medium enter the VSD at its peripheral junction with the pore domain, and then plunge into the core of the VSD in a curved conduction pathway. Our results provide a model of the resting conformation of the VSD.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Phys Biosci Div, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Isacoff, EY (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.	ehud@berkeley.edu	Tombola, Francesco/C-7311-2011; Gorostiza, Pau/Q-2544-2015; isacoff, ehud/AAP-1459-2020; Tombola, Francesco/ABA-6002-2020	Gorostiza, Pau/0000-0002-7268-5577; Tombola, Francesco/0000-0002-9315-0352; Isacoff, Ehud Y./0000-0003-4775-9359				Ahern CA, 2005, NEURON, V48, P25, DOI 10.1016/j.neuron.2005.08.020; Bezanilla F, 2000, PHYSIOL REV, V80, P555, DOI 10.1152/physrev.2000.80.2.555; Cha A, 1999, NATURE, V402, P809, DOI 10.1038/45552; Chanda B, 2005, NATURE, V436, P852, DOI 10.1038/nature03888; Durell SR, 2004, BIOPHYS J, V87, P2116, DOI 10.1529/biophysj.104.040618; Gandhi CS, 2003, NEURON, V40, P515, DOI 10.1016/S0896-6273(03)00646-9; Glauner KS, 1999, NATURE, V402, P813, DOI 10.1038/45561; Islas LD, 2001, J GEN PHYSIOL, V117, P69, DOI 10.1085/jgp.117.1.69; Larsson HP, 1996, NEURON, V16, P387, DOI 10.1016/S0896-6273(00)80056-2; Lee SY, 2004, NATURE, V430, P232, DOI 10.1038/nature02632; Long SB, 2005, SCIENCE, V309, P897, DOI 10.1126/science.1116269; Minor DL, 2006, NAT STRUCT MOL BIOL, V13, P388, DOI 10.1038/nsmb0506-388; Murata Y, 2005, NATURE, V435, P1239, DOI 10.1038/nature03650; Phillips LR, 2005, NATURE, V436, P857, DOI 10.1038/nature03873; Ramsey IS, 2006, NATURE, V440, P1213, DOI 10.1038/nature04700; Ruta V, 2005, CELL, V123, P463, DOI 10.1016/j.cell.2005.08.041; Sasaki M, 2006, SCIENCE, V312, P589, DOI 10.1126/science.1122352; SIGWORTH FJ, 1980, J PHYSIOL-LONDON, V307, P97, DOI 10.1113/jphysiol.1980.sp013426; Starace DM, 2004, NATURE, V427, P548, DOI 10.1038/nature02270; Tombola F, 2005, NEURON, V45, P379, DOI 10.1016/j.neuron.2004.12.047; Tombola F, 2006, ANNU REV CELL DEV BI, V22, P23, DOI 10.1146/annurev.cellbio.21.020404.145837; Yang NB, 1996, NEURON, V16, P113, DOI 10.1016/S0896-6273(00)80028-8; Yarov-Yarovoy V, 2006, P NATL ACAD SCI USA, V103, P7292, DOI 10.1073/pnas.0602350103; YU FH, 2004, SCI STKE; Yusaf SP, 1996, PFLUG ARCH EUR J PHY, V433, P91, DOI 10.1007/s004240050253	25	114	115	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 1	2007	445	7127					546	549		10.1038/nature05396	http://dx.doi.org/10.1038/nature05396			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	131KI	17187057				2022-12-28	WOS:000243867300045
J	Van Voorhis, BJ				Van Voorhis, Bradley J.			In vitro fertilization	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PREIMPLANTATION GENETIC DIAGNOSIS; DOUBLE-EMBRYO-TRANSFER; ASSISTED REPRODUCTIVE TECHNOLOGY; INTRACYTOPLASMIC SPERM INJECTION; PROSPECTIVE RANDOMIZED-TRIAL; COST-EFFECTIVENESS ANALYSIS; POOR OVARIAN RESPONSE; MULTIPLE BIRTHS; UNITED-STATES; INTRAUTERINE INSEMINATION		Univ Iowa, Sch Med, Div Reprod Endocrinol & Infertil, Iowa City, IA 52242 USA	University of Iowa	Van Voorhis, BJ (corresponding author), Univ Iowa Hosp & Clin, Dept Obstet & Gynecol, 200 Hawkins Dr, Iowa City, IA 52242 USA.	brad-van-voorhis@uiowa.edu		Van Voorhis, Brad/0000-0002-1455-0164				Baart EB, 2006, HUM REPROD, V21, P223, DOI 10.1093/humrep/dei291; Bancsi LFJMM, 2003, FERTIL STERIL, V79, P1091, DOI 10.1016/S0015-0282(03)00078-5; Battaglia DE, 1996, HUM REPROD, V11, P2217; Brinton LA, 2005, FERTIL STERIL, V83, P261, DOI 10.1016/j.fertnstert.2004.09.016; CALLAHAN TL, 1994, NEW ENGL J MED, V331, P244, DOI 10.1056/NEJM199407283310407; *CDCP, 2003, 2003 ASS REPR TECHN; Centers for Disease Control and Prevention (CDC), 2000, MMWR Morb Mortal Wkly Rep, V49, P535; COLLINS JA, 1995, FERTIL STERIL, V64, P22, DOI 10.1016/s0015-0282(16)57650-x; Evers JLH, 1998, HUM REPROD, V13, P1206, DOI 10.1093/humrep/13.5.1206; Gardner DK, 2004, FERTIL STERIL, V81, P551, DOI 10.1016/j.fertnstert.2003.07.023; Gnoth C, 2005, HUM REPROD, V20, P1144, DOI 10.1093/humrep/deh870; Gnoth C, 2003, HUM REPROD, V18, P1959, DOI 10.1093/humrep/deg366; Goverde AJ, 2000, LANCET, V355, P13, DOI 10.1016/S0140-6736(99)04002-7; Hamilton BE, 2006, INT J ANDROL, V29, P34, DOI 10.1111/j.1365-2605.2005.00638.x; Hendriks DJ, 2005, FERTIL STERIL, V83, P291, DOI 10.1016/j.fertnstert.2004.10.011; Jackson RA, 2004, OBSTET GYNECOL, V103, P551, DOI 10.1097/01.AOG.0000114989.84822.51; Jain T, 2002, NEW ENGL J MED, V347, P661, DOI 10.1056/NEJMsa013491; Karande VC, 1999, FERTIL STERIL, V71, P468, DOI 10.1016/S0015-0282(98)00490-7; Katalinic A, 2004, FERTIL STERIL, V81, P1604, DOI 10.1016/j.fertnstert.2003.10.053; Kjellberg AT, 2006, HUM REPROD, V21, P210, DOI 10.1093/humrep/dei298; Kurinczuk JJ, 2004, CURR OPIN OBSTET GYN, V16, P201, DOI 10.1097/00001703-200406000-00002; Lukassen HGM, 2005, HUM REPROD, V20, P702, DOI 10.1093/humrep/deh672; Martin Joyce A, 2003, Natl Vital Stat Rep, V52, P1; Munne S, 2006, FERTIL STERIL, V85, P326, DOI 10.1016/j.fertnstert.2005.10.014; Munne S, 2006, REPROD BIOMED ONLINE, V12, P234, DOI 10.1016/S1472-6483(10)60866-8; Niemitz EL, 2004, AM J HUM GENET, V74, P599, DOI 10.1086/382897; Olson CK, 2005, FERTIL STERIL, V84, P1308, DOI 10.1016/j.fertnstert.2005.03.086; Papanikolaou EG, 2006, NEW ENGL J MED, V354, P1139, DOI 10.1056/NEJMoa053524; Pinborg A, 2003, HUM REPROD, V18, P1234, DOI 10.1093/humrep/deg257; Retzloff MG, 2003, FERTIL STERIL, V80, P851, DOI 10.1016/S0015-0282(03)01014-8; Reynolds MA, 2003, PEDIATRICS, V111, P1159; Russell RB, 2003, OBSTET GYNECOL, V101, P129, DOI 10.1016/S0029-7844(02)02316-5; Ryan GL, 2004, FERTIL STERIL, V81, P500, DOI 10.1016/j.fertnstert.2003.05.035; Schoen R, 2005, POP STUD-J DEMOG, V59, P135, DOI 10.1080/00324720500099124; Shahine LK, 2006, FERTIL STERIL, V85, P51, DOI 10.1016/j.fertnstert.2005.06.045; SOLIMAN S, 1993, FERTIL STERIL, V59, P1239; Staessen C, 2004, HUM REPROD, V19, P2849, DOI 10.1093/humrep/deh536; STEPTOE PC, 1978, LANCET, V2, P366; Stromberg B, 2002, LANCET, V359, P461, DOI 10.1016/S0140-6736(02)07674-2; Thurin A, 2004, NEW ENGL J MED, V351, P2392, DOI 10.1056/NEJMoa041032; Van Voorhis BJ, 1999, FERTIL STERIL, V71, P604, DOI 10.1016/S0015-0282(98)00545-7; Van Voorhis BJ, 2001, FERTIL STERIL, V75, P661, DOI 10.1016/S0015-0282(00)01783-0; VANVOORHIS BJ, 1995, FERTIL STERIL, V64, P647, DOI 10.1016/S0015-0282(16)57808-X; Venn A, 1999, LANCET, V354, P1586, DOI 10.1016/S0140-6736(99)05203-4; WENSTROM KD, 1993, FERTIL STERIL, V60, P510; 2006, FERTIL STERIL S4, V86	46	103	114	1	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 25	2007	356	4					379	386		10.1056/NEJMcp065743	http://dx.doi.org/10.1056/NEJMcp065743			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128FT	17251534				2022-12-28	WOS:000243644300008
J	Teichman, PG; Donchin, Y; Kot, RJ				Teichman, Peter G.; Donchin, Yoel; Kot, Raphael J.			Current concepts - International aeromedical evacuation	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ACUTE MYOCARDIAL-INFARCTION; SERIOUS DIVING ACCIDENTS; AIR-TRAVEL; CRITICALLY-ILL; MEDICAL REPATRIATION; OXYGEN-SATURATION; ADVERSE EVENTS; INTENSIVE-CARE; TRANSPORT; DISEASE		Victoria Healthcare Int, Ho Chi Minh City, Vietnam; Family Med Practice Vietnam, Ho Chi Minh City, Vietnam; Hadassah Med Org, Patient Safety Unit, Jerusalem, Israel	Hebrew University of Jerusalem; Hadassah University Medical Center	Teichman, PG (corresponding author), Victoria Healthcare Int, 79 Dien Bien Phu St,Da Kao Ward,Dist 1, Ho Chi Minh City, Vietnam.	keqfap@yahoo.co.nz						Aerospace Med Assoc, 2003, AVIAT SPACE ENVIR MD, V74, pA1; *AIR MED PHYS ASS, 1999, AIR MED PHYS HDB, V7, P4; *AM AIRL, ACC PASS MISC MED CO; Andersson N, 2003, AVIAT SPACE ENVIR MD, V74, P138; [Anonymous], 2004, WORLD REP ROAD TRAFF; *ASS AIR MED SERV, ATL DAT AIR MED SERV; BENDRICK GA, 1995, AVIAT SPACE ENVIR MD, V66, P40; Buckland L, 2003, ARCH DIS CHILD-FETAL, V88, pF513, DOI 10.1136/fn.88.6.F513; Caldwell J A, 2001, Air Med J, V20, P25; Carey MJ, 1996, ANN EMERG MED, V28, P424, DOI 10.1016/S0196-0644(96)70009-4; Castillo CY, 1999, AVIAT SPACE ENVIR MD, V70, P103; *CDCP, QUEST ANSW EX ORD AD; Christopher GW, 1999, EMERG INFECT DIS, V5, P241, DOI 10.3201/eid0502.990208; Coker RK, 2002, THORAX, V57, P289; CRIPPEN D, 1990, AM J EMERG MED, V8, P551, DOI 10.1016/0735-6757(90)90163-T; Davis DP, 2005, ANN EMERG MED, V46, P115, DOI 10.1016/j.annemergmed.2005.01.024; *DEP STAT, 2005, US DEP STAT FOR AFF, V7; Dewhurst AT, 2001, ANAESTHESIA, V56, P882, DOI 10.1046/j.1365-2044.2001.02059-2.x; DILLARD TA, 1993, CHEST, V103, P422, DOI 10.1378/chest.103.2.422; Dinges DF, 1995, J SLEEP RES, V4, P4, DOI 10.1111/j.1365-2869.1995.tb00220.x; Edgington B H, 1992, J Air Med Transp, V11, P11, DOI 10.1016/S1046-9095(05)80058-3; Essebag V, 2003, CHEST, V124, P1937, DOI 10.1378/chest.124.5.1937; FLEETER JS, 1998, AC SOC AM 136 M NORF; *FLIGHT SAF FDN, INT NON SCHED PASS A; *FLIGHT SAF FDN, 2002, REP SHOW DIFF RESP I; Gilligan JE, 1999, MED J AUSTRALIA, V171, P617, DOI 10.5694/j.1326-5377.1999.tb123822.x; GONG H, 1992, CHEST, V101, P1104, DOI 10.1378/chest.101.4.1104; GORE JM, 1989, ARCH INTERN MED, V149, P353, DOI 10.1001/archinte.149.2.353; Grines CL, 2002, J AM COLL CARDIOL, V39, P1713, DOI 10.1016/S0735-1097(02)01870-3; Humphreys S, 2005, ANAESTHESIA, V60, P458, DOI 10.1111/j.1365-2044.2005.04124.x; *IATA, 2005, INT AIR TRANSP ASS P; JOHNSON A, 1977, AVIAT SPACE ENVIR MD, V48, P546; KAPLAN L, 1987, ANN EMERG MED, V16, P55, DOI 10.1016/S0196-0644(87)80287-1; Kashani KB, 2006, CURR OPIN CRIT CARE, V12, P43, DOI 10.1097/01.ccx.0000198057.35212.3e; KRAMER MR, 1995, CHEST, V108, P1292, DOI 10.1378/chest.108.5.1292; LAVERNHE JP, 1985, AVIAT SPACE ENVIR MD, V56, P367; Leggat PA, 2002, J TRAVEL MED, V9, P59, DOI 10.2310/7060.2002.21444; LYONS TJ, 1995, AVIAT SPACE ENVIR MD, V66, P927; Lyznicki JM, 2000, AVIAT SPACE ENVIR MD, V71, P827; MACDONALD E, 2002, AIR MED PHYS HDB S, P64; Maegele M, 2005, CRIT CARE MED, V33, P1136, DOI 10.1097/01.CCM.0000163269.42524.50; McInnes R, 2002, J TRAVEL MED, V9, P297, DOI 10.2310/7060.2002.30168; MELAMED Y, 1981, AVIAT SPACE ENVIR MD, V52, P480; Mortazavi A, 2003, AVIAT SPACE ENVIR MD, V74, P922; PARSONS CJ, 1982, CAN MED ASSOC J, V126, P237; Patel D, 2000, J TRAVEL MED, V7, P64; Schroder S, 2004, ANAESTHESIST, V53, P1093, DOI 10.1007/s00101-004-0748-3; Shelton S L, 2000, Prehosp Emerg Care, V4, P361, DOI 10.1080/10903120090941128; Shibolet O, 2005, LIVER TRANSPLANT, V11, P650, DOI 10.1002/lt.20399; Shirley PJ, 2000, HOSP MED, V61, P406, DOI 10.12968/hosp.2000.61.6.1356; Straumann E, 1999, HEART, V82, P415, DOI 10.1136/hrt.82.4.415; Thomson David P, 2003, Prehosp Emerg Care, V7, P265, DOI 10.1080/10903120390936923; VANN RD, 1993, AVIAT SPACE ENVIR MD, V64, P801; Veldman Alex, 2004, Air Med J, V23, P24, DOI 10.1016/j.amj.2003.12.009; VIELLETTE PR, 2001, FLIGHT SAFETY DI APR, P39; Wallace PGM, 1999, BRIT MED J, V319, P368, DOI 10.1136/bmj.319.7206.368; *WHO, WHO GLOB OUTBR AL RE; *WHO DEP COMM DIS, 2004, TRANSP INF SUBST; Wilde H, 2003, J TRAVEL MED, V10, P315; World Health Organization (WHO), 2005, INT TRAV HLTH; Wright MC, 2006, QUAL SAF HEALTH CARE, V15, P258, DOI 10.1136/qshc.2005.017566; 2006, UN AIRLINES CONTRACT	62	45	48	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 18	2007	356	3					262	270		10.1056/NEJMra063651	http://dx.doi.org/10.1056/NEJMra063651			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	126BV	17229953				2022-12-28	WOS:000243488100008
J	Kesselheim, AS; Avorn, J				Kesselheim, Aaron S.; Avorn, Jerry			The role of litigation in defining drug risks	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02120 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Kesselheim, AS (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Pharmacoepidemiol & Pharmacoecon, 1620 Tremont St,Suite 3030, Boston, MA 02120 USA.	akesselheim@partners.org	Kesselheim, Aaron/R-6793-2017	Kesselheim, Aaron/0000-0002-8867-2666	PHS HHS [6T32HP1101] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Avorn J, 2005, POWERFUL MED BENEFIT; BACIU A, 2006, FUTURE DRUG SAFETY P; BERENSON A, 2003, NY TIMES        0921, pA1; Berenson Alex, 2006, N Y Times Web, pC2; BRENT RL, 1995, REPROD TOXICOL, V9, P337, DOI 10.1016/0890-6238(95)00020-B; Curfman GD, 2005, NEW ENGL J MED, V353, P2813, DOI 10.1056/NEJMe058314; DeAngelis CD, 2006, JAMA-J AM MED ASSOC, V296, P996, DOI 10.1001/jama.296.8.jed60051; Food and Drug Administration HHS, 2006, Fed Regist, V71, P3921; FR (Federal Register), 1985, FED REGISTER, V50, P7452; Harris G., 2005, NY TIMES 0225, pA1; JOHANNES L, 1997, WALL ST J       1211, pA1; JOHANNES L, 1999, WALL ST J       0928, pA1; KAY J, 2003, MIAMI DAILY BUS 0226; Koller EA, 2002, PHARMACOTHERAPY, V22, P841, DOI 10.1592/phco.22.11.841.33629; Struve Catherine T, 2005, Yale J Health Policy Law Ethics, V5, P587; U.S. Food and Drug Administration, 2004, FDA PUBL HLTH ADV WO; Watkins PB, 1998, NEW ENGL J MED, V338, P916, DOI 10.1056/NEJM199803263381314; 2004, PUBLIC CITIZEN WORST	18	49	50	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 17	2007	297	3					308	311		10.1001/jama.297.3.308	http://dx.doi.org/10.1001/jama.297.3.308			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125VT	17227983				2022-12-28	WOS:000243472300027
J	Grosse, SD; Dezateux, C				Grosse, Scott D.; Dezateux, Carol			Newborn screening for inherited metabolic disease	LANCET			English	Editorial Material							COA DEHYDROGENASE-DEFICIENCY; TANDEM MASS-SPECTROMETRY; COST-EFFECTIVENESS		Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA; UCL, MRC, Ctr Epidemiol Child Hlth, Inst Child Hlth, London, England	Centers for Disease Control & Prevention - USA; University of London; University College London	Grosse, SD (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA.	SGrosse@cdc.gov	Dezateux, Carol/A-3416-2009	Grosse, Scott/0000-0003-1078-6855; Dezateux, Carol/0000-0001-9787-6276				Autti-Ramo I, 2005, ACTA PAEDIATR, V94, P1126, DOI 10.1080/08035250510029497; Carroll AE, 2006, PEDIATRICS, V117, pS287, DOI 10.1542/peds.2005-2633H; Derks TGJ, 2006, J PEDIATR-US, V148, P665, DOI 10.1016/j.jpeds.2005.12.028; Feuchtbaum L, 2006, PEDIATRICS, V117, pS280, DOI 10.1542/peds.2005-2633G; Grosse SD, 2006, GENET MED, V8, P205, DOI 10.1097/01.gim.0000204472.25153.8d; Pandor A, 2004, HEALTH TECHNOL ASSES, V8, P1; Pollitt RJ, 1998, ARCH DIS CHILD, V79, P116, DOI 10.1136/adc.79.2.116; Pourfarzam M, 2001, LANCET, V358, P1063, DOI 10.1016/S0140-6736(01)06199-2; Tin W, 1998, ARCH DIS CHILD-FETAL, V79, pF83, DOI 10.1136/fn.79.2.F83; Venditti LN, 2003, PEDIATRICS, V112, P1005, DOI 10.1542/peds.112.5.1005; Waddell L, 2006, MOL GENET METAB, V87, P32, DOI 10.1016/j.ymgme.2005.09.020; Waisbren SE, 2003, JAMA-J AM MED ASSOC, V290, P2564, DOI 10.1001/jama.290.19.2564; WILCKEN B, 1994, ARCH DIS CHILD, V70, P410, DOI 10.1136/adc.70.5.410; Wilcken B, 2007, LANCET, V369, P37, DOI 10.1016/S0140-6736(07)60029-4	14	8	8	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 6	2007	369	9555					5	6		10.1016/S0140-6736(07)60005-1	http://dx.doi.org/10.1016/S0140-6736(07)60005-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125AK	17208621				2022-12-28	WOS:000243413700005
J	Higgins, J				Higgins, Joan			Health policy: a new took at NHS commissioning	BRITISH MEDICAL JOURNAL			English	Editorial Material												joan.higgins@manchester.ac.uk						Department of Health, 2006, HLTH REF ENGL UPD CO; Enthoven A.C., 1985, REFLECTIONS MANAGEME; Mays N., 1998, LEARNING INTERNAL MA; Propper C, 1998, J HEALTH ECON, V17, P645, DOI 10.1016/S0167-6296(98)00029-0; RIESBERG A, 2004, EURO OBSERVER, V6, P6; Robinson R, 1994, EVALUATING NHS REFOR; SHEAFF R, 2006, ACHIEVING HIGH PERFO; Smith J, 2004, REV EFFECTIVENESS PR; *THAM VALL STRAT H, 2005, 6205 THAM VALL STRAT; *THAM VALL STRAT H, 2005, 6305 THAM VALL STRAT; Thome C, 2006, J NEUROSURG-SPINE, V4, P1, DOI 10.3171/spi.2006.4.1.1	11	5	5	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JAN 6	2007	334	7583					22	24		10.1136/bmj.39038.476435.68	http://dx.doi.org/10.1136/bmj.39038.476435.68			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125CH	17204801	Green Published			2022-12-28	WOS:000243418600033
J	Genet, C; Ebbesen, TW				Genet, C.; Ebbesen, T. W.			Light in tiny holes	NATURE			English	Review							EXTRAORDINARY INFRARED TRANSMISSION; SINGLE SUBWAVELENGTH APERTURE; OPTICAL-TRANSMISSION; SURFACE-PLASMONS; METAL-FILMS; ENHANCED TRANSMISSION; ARRAYS; DIFFRACTION; NANOHOLES; FLUORESCENCE	The presence of tiny holes in an opaque metal film, with sizes smaller than the wavelength of incident light, leads to a wide variety of unexpected optical properties such as strongly enhanced transmission of light through the holes and wavelength filtering. These intriguing effects are now known to be due to the interaction of the light with electronic resonances in the surface of the metal film, and they can be controlled by adjusting the size and geometry of the holes. This knowledge is opening up exciting new opportunities in applications ranging from subwavelength optics and optoelectronics to chemical sensing and biophysics.	Univ Strasbourg, ISIS, F-67000 Strasbourg, France; Univ Strasbourg, CNRS, UMR 7006, F-67000 Strasbourg, France	UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Ebbesen, TW (corresponding author), Univ Strasbourg, ISIS, 8 Allee G Monge, F-67000 Strasbourg, France.	ebbesen@isis-ulp.org	Genet, Cyriaque/AAE-6711-2022	Genet, Cyriaque/0000-0003-0672-7406				Altewischer E, 2003, J OPT SOC AM B, V20, P1927, DOI 10.1364/JOSAB.20.001927; Altewischer E, 2002, NATURE, V418, P304, DOI 10.1038/nature00869; Baida FI, 2002, OPT COMMUN, V209, P17, DOI 10.1016/S0030-4018(02)01690-5; Barbara A, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.161403; Barnes WL, 2003, NATURE, V424, P824, DOI 10.1038/nature01937; Barnes WL, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.107401; Bethe HA, 1944, PHYS REV, V66, P163, DOI 10.1103/PhysRev.66.163; BETZIG E, 1992, SCIENCE, V257, P189, DOI 10.1126/science.257.5067.189; Bonod N, 2003, OPT EXPRESS, V11, P482, DOI 10.1364/OE.11.000482; Bravo-Abad J, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.227401; Bravo-Abad J, 2006, NAT PHYS, V2, P120, DOI 10.1038/nphys213; Brolo AG, 2004, NANO LETT, V4, P2015, DOI 10.1021/nl048818w; Brolo AG, 2005, J AM CHEM SOC, V127, P14936, DOI 10.1021/ja0548687; Brolo AG, 2004, LANGMUIR, V20, P4813, DOI 10.1021/la0493621; Chang CW, 2005, LASER PHYS LETT, V2, P351, DOI 10.1002/lapl.200510006; Chang SH, 2005, OPT EXPRESS, V13, P3150, DOI 10.1364/OPEX.13.003150; Chyan JY, 2006, NANOTECHNOLOGY, V17, P40, DOI 10.1088/0957-4484/17/1/008; Coe JV, 2006, ANAL CHEM, V78, P1384, DOI 10.1021/ac069371+; de Abajo FJG, 2006, OPT EXPRESS, V14, P7, DOI 10.1364/OPEX.14.000007; de Abajo FJGI, 2002, OPT EXPRESS, V10, P1475, DOI 10.1364/OE.10.001475; Dechant A, 2004, APPL PHYS LETT, V84, P4678, DOI 10.1063/1.1760215; Degiron A, 2005, J OPT A-PURE APPL OP, V7, pS90, DOI 10.1088/1464-4258/7/2/012; Degiron A, 2004, OPT COMMUN, V239, P61, DOI 10.1016/j.optcom.2004.05.058; Degiron A, 2004, OPT EXPRESS, V12, P3694, DOI 10.1364/OPEX.12.003694; Degiron A, 2002, APPL PHYS LETT, V81, P4327, DOI 10.1063/1.1526162; Dintinger J, 2006, ADV MATER, V18, P1645, DOI 10.1002/adma.200600366; Dintinger J, 2006, ADV MATER, V18, P1267, DOI 10.1002/adma.200502393; Dogariu A, 2001, OPT LETT, V26, P450, DOI 10.1364/OL.26.000450; Ebbesen TW, 1998, NATURE, V391, P667, DOI 10.1038/35570; Egorov D, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.033404; Fasel S, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.110501; Fujikata J., 2004, T MAGN SOC JPN, V4, P255; Garcia-Vidal FJ, 2005, J OPT A-PURE APPL OP, V7, pS97, DOI 10.1088/1464-4258/7/2/013; Garcia-Vidal FJ, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.103901; Garcia-Vidal FJ, 2003, APPL PHYS LETT, V83, P4500, DOI 10.1063/1.1631384; Garcia-Vidal FJ, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.213901; Gbur G, 2005, APPL PHYS LETT, V87, DOI 10.1063/1.2128061; Genet C, 2003, OPT COMMUN, V225, P331, DOI 10.1016/j.optcom.2003.07.037; Ghaemi HF, 1998, PHYS REV B, V58, P6779, DOI 10.1103/PhysRevB.58.6779; Gordon R, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.037401; Gordon R, 2005, OPT EXPRESS, V13, P1933, DOI 10.1364/OPEX.13.001933; GRIMALDI FM, 1665, PHYSICOMATHESIS LUMI, V9; GRUHLKE RW, 1986, PHYS REV LETT, V56, P2838, DOI 10.1103/PhysRevLett.56.2838; Halte V, 2005, PHYS STATUS SOLIDI B, V242, P1872, DOI 10.1002/pssb.200461830; Ishi T, 2005, JPN J APPL PHYS 2, V44, pL364, DOI 10.1143/JJAP.44.L364; Ishi T, 2005, JPN J APPL PHYS 2, V44, pL170, DOI 10.1143/JJAP.44.L170; Kim DS, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.143901; Kim KY, 2006, OPT EXPRESS, V14, P320, DOI 10.1364/OPEX.14.000320; Kim TJ, 1999, OPT LETT, V24, P256, DOI 10.1364/OL.24.000256; Koerkamp KJK, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.183901; Krasavin AV, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1925759; Kwak ES, 2005, NANO LETT, V5, P1963, DOI 10.1021/nl051339s; Lalanne P, 2006, NAT PHYS, V2, P551, DOI 10.1038/nphys364; Lalanne P, 2005, J OPT A-PURE APPL OP, V7, P422, DOI 10.1088/1464-4258/7/8/013; Lee KG, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.103902; Levene MJ, 2003, SCIENCE, V299, P682, DOI 10.1126/science.1079700; Lezec HJ, 2002, SCIENCE, V297, P820, DOI 10.1126/science.1071895; Liu C, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1895481; Liu W., 2005, PHYS REV B, V65; Liu Y, 2004, NANOTECHNOLOGY, V15, P1368, DOI 10.1088/0957-4484/15/9/043; Lockyear MJ, 2004, APPL PHYS LETT, V84, P2040, DOI 10.1063/1.1688001; Lomakin V, 2005, PHYS REV B, V71, DOI 10.1103/PhysRevB.71.235117; Luo XG, 2004, JPN J APPL PHYS 1, V43, P4017, DOI 10.1143/JJAP.43.4017; MAGDE D, 1972, PHYS REV LETT, V29, P705, DOI 10.1103/PhysRevLett.29.705; Marquier F, 2005, OPT EXPRESS, V13, P70, DOI 10.1364/OPEX.13.000070; Martin-Moreno L, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.167401; Martin-Moreno L, 2001, PHYS REV LETT, V86, P1114, DOI 10.1103/PhysRevLett.86.1114; Moran CE, 2004, NANO LETT, V4, P1497, DOI 10.1021/nl049635c; Moreno E, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.170406; Muller R, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.205415; Nahata A, 2003, OPT LETT, V28, P423, DOI 10.1364/OL.28.000423; OBERMULLER C, 1995, APPL PHYS LETT, V67, P3408, DOI 10.1063/1.115262; Pendry JB, 2004, SCIENCE, V305, P847, DOI 10.1126/science.1098999; Popov E, 2005, APPL OPTICS, V44, P2332, DOI 10.1364/AO.44.002332; Popov E, 2000, PHYS REV B, V62, P16100, DOI 10.1103/PhysRevB.62.16100; Porto JA, 1999, PHYS REV LETT, V83, P2845, DOI 10.1103/PhysRevLett.83.2845; Prikulis J, 2004, NANO LETT, V4, P1003, DOI 10.1021/nl0497171; Rigneault H, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.117401; Rindzevicius T, 2005, NANO LETT, V5, P2335, DOI 10.1021/nl0516355; RITCHIE RH, 1957, PHYS REV, V106, P874, DOI 10.1103/PhysRev.106.874; Rivas JG, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.201306; ROBERTS A, 1987, J OPT SOC AM A, V4, P1970, DOI 10.1364/JOSAA.4.001970; Ropers C, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.113901; Sarrazin M, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.085415; Sarychev AK, 2002, IEEE J QUANTUM ELECT, V38, P956, DOI 10.1109/JQE.2002.1017614; Schouten HF, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.053901; Shao DB, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1951052; Shen JT, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.197401; Shipman SP, 2005, PHYS REV E, V71, DOI 10.1103/PhysRevE.71.026611; Shou X, 2005, OPT EXPRESS, V13, P9834, DOI 10.1364/OPEX.13.009834; Skigin DC, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.217402; Srituravanich W, 2004, NANO LETT, V4, P1085, DOI 10.1021/nl049573q; Stark PRH, 2005, METHODS, V37, P37, DOI 10.1016/j.ymeth.2005.05.006; Strelniker YM, 1999, PHYS REV B, V59, P12763, DOI 10.1103/PhysRevB.59.R12763; Sun ZJ, 2004, APPL PHYS LETT, V85, P642, DOI 10.1063/1.1776327; Sun ZJ, 2003, APPL PHYS LETT, V83, P3021, DOI 10.1063/1.1618021; Takakura Y, 2001, PHYS REV LETT, V86, P5601, DOI 10.1103/PhysRevLett.86.5601; Thio T, 2001, OPT LETT, V26, P1972, DOI 10.1364/OL.26.001972; Visser TD, 2006, NAT PHYS, V2, P509, DOI 10.1038/nphys372; Wang QJ, 2005, APPL PHYS LETT, V87, DOI 10.1063/1.2034120; Webb KJ, 2006, PHYS REV B, V73, DOI 10.1103/PhysRevB.73.033401; Williams SM, 2004, J PHYS CHEM B, V108, P11833, DOI 10.1021/jp0489368; Williams SM, 2004, NANOTECHNOLOGY, V15, pS495, DOI 10.1088/0957-4484/15/10/001; Xie Y, 2004, OPT EXPRESS, V12, P6106, DOI 10.1364/OPEX.12.006106; Ye YH, 2005, OPT LETT, V30, P1521, DOI 10.1364/OL.30.001521; Yin L, 2004, APPL PHYS LETT, V85, P467, DOI 10.1063/1.1773362; Yu LB, 2005, PHYS REV B, V71, DOI 10.1103/PhysRevB.71.041405; Zayats AV, 2003, J MICROSC-OXFORD, V210, P344, DOI 10.1046/j.1365-2818.2003.01161.x	108	1761	1842	14	781	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 4	2007	445	7123					39	46		10.1038/nature05350	http://dx.doi.org/10.1038/nature05350			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	122KG	17203054				2022-12-28	WOS:000243225100031
J	Schacter, DL; Addis, DR				Schacter, Daniel L.; Addis, Donna Rose			The ghosts of past and future	NATURE			English	Editorial Material							MIND		Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA	Harvard University	Schacter, DL (corresponding author), Harvard Univ, Dept Psychol, 33 Kirkland St, Cambridge, MA 02138 USA.		Addis, Donna Rose/AEZ-1941-2022; Addis, Donna Rose/AAF-2307-2022	Addis, Donna Rose/0000-0002-6231-1491; Schacter, Daniel/0000-0002-2460-6061				Schacter D.L., 2001, 7 SINS MEMORY; Suddendorf T, 1997, GENET SOC GEN PSYCH, V123, P133; Tulving E, 2002, ANNU REV PSYCHOL, V53, P1, DOI 10.1146/annurev.psych.53.100901.135114	3	273	281	1	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 4	2007	445	7123					27	27		10.1038/445027a	http://dx.doi.org/10.1038/445027a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	122KG	17203045	Bronze			2022-12-28	WOS:000243225100020
J	Schade, R; Andersohn, F; Suissa, S; Haverkamp, W; Garbe, E				Schade, Rene; Andersohn, Frank; Suissa, Samy; Haverkamp, Wilhelm; Garbe, Edeltraut			Dopamine agonists and the risk of cardiac-valve regurgitation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VALVULAR HEART-DISEASE; PRACTICE RESEARCH DATABASE; PARKINSONS-DISEASE; 5-HT2B RECEPTORS; MONOAMINERGIC RECEPTOR; ANTIPARKINSON AGENTS; DIFFERENTIAL ACTIONS; MULTIPLE CLASSES; PERGOLIDE; FENFLURAMINE	BACKGROUND: Case reports and echocardiographic studies suggest that the ergot-derived dopamine agonists pergolide and cabergoline, used in the treatment of Parkinson's disease and the restless legs syndrome, may increase the risk of cardiac-valve regurgitation. METHODS: We used data from the United Kingdom General Practice Research Database to identify a population-based cohort comprising 11,417 subjects 40 to 80 years of age who were prescribed antiparkinsonian drugs between 1988 and 2005. We conducted a nested case-control analysis within this cohort in which each patient with newly diagnosed cardiac-valve regurgitation was matched with up to 25 control subjects from the cohort, according to age, sex, and year of entry into the cohort. Incidence-rate ratios for cardiac-valve regurgitation with the use of different dopamine agonists were estimated by conditional logistic-regression analysis. RESULTS: Of 31 case patients with newly diagnosed cardiac-valve regurgitation, 6 were currently exposed to pergolide, 6 were currently exposed to cabergoline, and 19 had not been exposed to any dopamine agonist within the previous year. The rate of cardiac-valve regurgitation was increased with current use of pergolide (incidence-rate ratio, 7.1; 95% confidence interval [CI], 2.3 to 22.3) and cabergoline (incidence-rate ratio, 4.9; 95% CI, 1.5 to 15.6), but not with current use of other dopamine agonists. CONCLUSIONS: In this study, use of the dopamine agonists pergolide and cabergoline was associated with an increased risk of newly diagnosed cardiac-valve regurgitation.	Charite Univ Med Berlin, Dept Clin Pharmacol, Berlin, Germany; Charite Univ Med Berlin, Dept Cardiol, Berlin, Germany; McGill Univ, Ctr Hlth, Royal Victoria Hosp, Div Clin Epidemiol,McGill Pharmacoepidemiol Res U, Montreal, PQ, Canada	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; McGill University; Royal Victoria Hospital	Schade, R (corresponding author), Charite Univ Med Berlin, Dept Clin Pharmacol, Charite Campus Mitte, Berlin, Germany.		Greiver, Michelle/N-8764-2015	Greiver, Michelle/0000-0001-8957-0285				Baseman DG, 2004, NEUROLOGY, V63, P301, DOI 10.1212/01.WNL.0000129842.49926.07; Chung EJ, 2006, MOVEMENT DISORD, V21, P586, DOI 10.1002/mds.20813; Committee on Safety of Medicines, 2003, CURRENT PROBLEMS PHA, V29, P7; Dhawan V, 2005, J NEURAL TRANSM, V112, P661, DOI 10.1007/s00702-005-0289-1; Earley CJ, 2003, NEW ENGL J MED, V348, P2103, DOI 10.1056/NEJMcp021288; Fitzgerald LW, 2000, MOL PHARMACOL, V57, P75; Flowers CM, 2003, MAYO CLIN PROC, V78, P730, DOI 10.4065/78.6.730; Horvath J, 2004, MOVEMENT DISORD, V19, P656, DOI 10.1002/mds.20201; Jahnichen S, 2005, EUR J PHARMACOL, V513, P225, DOI 10.1016/j.ejphar.2005.03.010; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; Jick H, 1998, NEW ENGL J MED, V339, P719, DOI 10.1056/NEJM199809103391102; Jick SS, 2003, PHARMACOTHERAPY, V23, P686, DOI 10.1592/phco.23.5.686.32205; Lopez-Ilasaca M, 1998, BIOCHEM PHARMACOL, V56, P269, DOI 10.1016/S0006-2952(98)00059-8; Millan MJ, 2002, J PHARMACOL EXP THER, V303, P791, DOI 10.1124/jpet.102.039867; Newman-Tancredi A, 2002, J PHARMACOL EXP THER, V303, P815, DOI 10.1124/jpet.102.039883; Nutt JG, 2005, NEW ENGL J MED, V353, P1021, DOI 10.1056/NEJMcp043908; Peralta C, 2006, MOVEMENT DISORD, V21, P1109, DOI 10.1002/mds.20887; Pinero A, 2005, NEW ENGL J MED, V353, P1976, DOI 10.1056/NEJM200511033531822; Pritchett AM, 2002, MAYO CLIN PROC, V77, P1280, DOI 10.4065/77.12.1280; Rothman RB, 2000, CIRCULATION, V102, P2836; Serratrice Jacques, 2002, Cardiol Rev, V10, P334, DOI 10.1097/00045415-200211000-00005; Setola V, 2003, MOL PHARMACOL, V63, P1223, DOI 10.1124/mol.63.6.1223; Van Camp G, 2003, NEUROLOGY, V61, P859, DOI 10.1212/01.WNL.0000083985.00343.F2; Van Camp G, 2004, LANCET, V363, P1179, DOI 10.1016/S0140-6736(04)15945-X; Walley T, 1997, LANCET, V350, P1097, DOI 10.1016/S0140-6736(97)04248-7	25	501	515	0	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 4	2007	356	1					29	38		10.1056/NEJMoa062222	http://dx.doi.org/10.1056/NEJMoa062222			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	122EX	17202453				2022-12-28	WOS:000243209600006
J	Tronetti, PS				Tronetti, Pamela S.			A place in the sun	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												Pam.Tronetti@physicianpm.com							0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 3	2007	297	1					17	18		10.1001/jama.297.1.17	http://dx.doi.org/10.1001/jama.297.1.17			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	123BS	17200463				2022-12-28	WOS:000243271900001
J	Cheng, H; Dufu, K; Lee, CS; Hsu, JL; Dias, A; Reed, R				Cheng, Hong; Dufu, Kobina; Lee, Chung-Sheng; Hsu, Jeanne L.; Dias, Anusha; Reed, Robin			Human mRNA export machinery recruited to the 5 ' end of mRNA	CELL			English	Article							EXON JUNCTION COMPLEX; NONSENSE-MEDIATED DECAY; CAP-BINDING-PROTEIN; GENOME-WIDE ANALYSIS; NUCLEAR EXPORT; RIBONUCLEOPROTEIN PARTICLE; COUPLING TRANSCRIPTION; BIOCHEMICAL-ANALYSIS; MAMMALIAN-CELLS; POLYMERASE-II	Pre-mRNAs undergo splicing to remove introns, and the spliced mRNA is exported to the cytoplasm for translation. Here we investigated the mechanism for recruitment of the conserved mRNA export machinery (TREX complex) to mRNA. We show that the human TREX complex is recruited to a region near the 5' end of mRNA, with the TREX component Aly bound closest to the 5' cap. Both TREX recruitment and mRNA export require the cap, and these roles for the cap are splicing dependent. CBP80, which is bound to the cap, associates efficiently with TREX, and Aly mediates this interaction. Together, these data indicate that the CBP80-Aly interaction results in recruitment of TREX to the 5' end of mRNA, where it functions in mRNA export. As a consequence, the mRNA would be exported in a 5' to 3' direction through the nuclear pore, as observed in early electron micrographs of giant Balbiani ring mRNPs.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Reed, R (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.	rreed@hms.harvard.edu		Dufu, Kobina/0000-0001-5450-4157				Abruzzi KC, 2004, EMBO J, V23, P2620, DOI 10.1038/sj.emboj.7600261; Ballut L, 2005, NAT STRUCT MOL BIOL, V12, P861, DOI 10.1038/nsmb990; Bentley D, 2002, CURR OPIN CELL BIOL, V14, P336, DOI 10.1016/S0955-0674(02)00333-2; Bentley DL, 2005, CURR OPIN CELL BIOL, V17, P251, DOI 10.1016/j.ceb.2005.04.006; Bruhn L, 1997, GENE DEV, V11, P640, DOI 10.1101/gad.11.5.640; Chan CC, 2004, RNA, V10, P200, DOI 10.1261/rna.5230104; Chin SY, 2004, GENE DEV, V18, P745, DOI 10.1101/gad.1170204; Culbertson MR, 2003, CURR OPIN GENET DEV, V13, P207, DOI 10.1016/S0959-437X(03)00014-5; Dahlberg JE, 2004, CURR OPIN CELL BIOL, V16, P335, DOI 10.1016/j.ceb.2004.03.006; Daneholt B, 1997, CELL, V88, P585, DOI 10.1016/S0092-8674(00)81900-5; Ferraiuolo MA, 2004, P NATL ACAD SCI USA, V101, P4118, DOI 10.1073/pnas.0400933101; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Gatfield D, 2003, EMBO J, V22, P3960, DOI 10.1093/emboj/cdg371; Gatfield D, 2001, CURR BIOL, V11, P1716, DOI 10.1016/S0960-9822(01)00532-2; Gehring NH, 2003, MOL CELL, V11, P939, DOI 10.1016/S1097-2765(03)00142-4; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; Harlow L, 1988, ANTIBODIES LAB MANUA; Herold A, 2003, EMBO J, V22, P2472, DOI 10.1093/emboj/cdg233; Hirose Y, 2000, GENE DEV, V14, P1415; Ishigaki Y, 2001, CELL, V106, P607, DOI 10.1016/S0092-8674(01)00475-5; IZAURRALDE E, 1992, J CELL BIOL, V118, P1287, DOI 10.1083/jcb.118.6.1287; IZAURRALDE E, 1994, CELL, V78, P657, DOI 10.1016/0092-8674(94)90530-4; IZAURRALDE E, 1995, NATURE, V376, P709, DOI 10.1038/376709a0; JARMOLOWSKI A, 1994, J CELL BIOL, V124, P627, DOI 10.1083/jcb.124.5.627; Jimeno S, 2002, EMBO J, V21, P3526, DOI 10.1093/emboj/cdf335; Kim VN, 2001, SCIENCE, V293, P1832, DOI 10.1126/science.1062829; Kim VN, 2001, EMBO J, V20, P2062, DOI 10.1093/emboj/20.8.2062; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; Le Hir H, 2000, EMBO J, V19, P6860, DOI 10.1093/emboj/19.24.6860; Le Hir H, 2000, GENE DEV, V14, P1098; Le Hir H, 2001, EMBO J, V20, P4987, DOI 10.1093/emboj/20.17.4987; Lejeune F, 2002, EMBO J, V21, P3536, DOI 10.1093/emboj/cdf345; Lewis JD, 2000, SCIENCE, V288, P1385, DOI 10.1126/science.288.5470.1385; Lewis JD, 1997, EUR J BIOCHEM, V247, P461, DOI 10.1111/j.1432-1033.1997.00461.x; Luo MJ, 2001, NATURE, V413, P644, DOI 10.1038/35098106; Luo MJ, 1999, P NATL ACAD SCI USA, V96, P14937, DOI 10.1073/pnas.96.26.14937; Lykke-Andersen J, 2001, SCIENCE, V293, P1836, DOI 10.1126/science.1062786; MACQUAT LE, 2000, TRANSLATIONAL CONTRO, P827; Masuda S, 2005, GENE DEV, V19, P1512, DOI 10.1101/gad.1302205; Masuyama K, 2004, GENE DEV, V18, P2074, DOI 10.1101/gad.1216204; MEHLIN H, 1992, CELL, V69, P605, DOI 10.1016/0092-8674(92)90224-Z; Moore MJ, 2005, SCIENCE, V309, P1514, DOI 10.1126/science.1111443; Ohno M, 2000, CELL, V101, P187, DOI 10.1016/S0092-8674(00)80829-6; Palacios IM, 2004, NATURE, V427, P753, DOI 10.1038/nature02351; PELTZ SW, 1993, GENE DEV, V7, P1737, DOI 10.1101/gad.7.9.1737; Reed R, 2003, CURR OPIN CELL BIOL, V15, P326, DOI 10.1016/S0955-0674(03)00048-6; Reed R, 2005, CURR OPIN CELL BIOL, V17, P269, DOI 10.1016/j.ceb.2005.04.011; Rehwinkel J, 2004, NAT STRUCT MOL BIOL, V11, P558, DOI 10.1038/nsmb759; Rodrigues JP, 2001, P NATL ACAD SCI USA, V98, P1030, DOI 10.1073/pnas.98.3.1030; Schell T, 2002, GENOME BIOL, V3; Shibuya T, 2004, NAT STRUCT MOL BIOL, V11, P346, DOI 10.1038/nsmb750; Singh G, 2003, TRENDS BIOCHEM SCI, V28, P464, DOI 10.1016/S0968-0004(03)00176-2; Strasser K, 2002, NATURE, V417, P304, DOI 10.1038/nature746; Strasser K, 2001, NATURE, V413, P648, DOI 10.1038/35098113; Stutz F, 2000, RNA, V6, P638, DOI 10.1017/S1355838200000078; Tange TO, 2005, RNA, V11, P1869, DOI 10.1261/rna.2155905; Tange TO, 2004, CURR OPIN CELL BIOL, V16, P279, DOI 10.1016/j.ceb.2004.03.012; Visa N, 1996, CELL, V84, P253, DOI 10.1016/S0092-8674(00)80980-0; Visa N, 1996, J CELL BIOL, V133, P5, DOI 10.1083/jcb.133.1.5; Wagner E, 2002, J CELL SCI, V115, P3033; Zenklusen D, 2002, MOL CELL BIOL, V22, P8241, DOI 10.1128/MCB.22.23.8241-8253.2002; Zhou ZL, 2000, NATURE, V407, P401, DOI 10.1038/35030160; Zhou ZL, 2002, P NATL ACAD SCI USA, V99, P12203, DOI 10.1073/pnas.182427099	64	331	350	0	27	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 29	2006	127	7					1389	1400		10.1016/j.cell.2006.10.044	http://dx.doi.org/10.1016/j.cell.2006.10.044			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	128WI	17190602	Bronze			2022-12-28	WOS:000243690000018
J	Golinko, MS				Golinko, Michael S.			A bump in the neck	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												msg1@alum.mit.edu							0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	2006	296	24					2901	2902		10.1001/jama.296.24.2901	http://dx.doi.org/10.1001/jama.296.24.2901			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	120FD	17190881				2022-12-28	WOS:000243069000001
J	Heaton, KW				Heaton, Kenneth W.			Faints, fits, and fatalities from emotion in Shakespeare's characters: survey of the canon	BRITISH MEDICAL JOURNAL			English	Editorial Material									Claverham House, Bristol BS49 4QD, Avon, England		Heaton, KW (corresponding author), Claverham House, Bristol BS49 4QD, Avon, England.	kenheaton@compuserve.com						ADAMS JC, 2000, SHAKESPEARES PHYSIC; [Anonymous], 1997, NORTON SHAKESPEARE; Bergfeldt L, 2003, HEART, V89, P353, DOI 10.1136/heart.89.3.353; Bloom Harold, 1999, SHAKESPEARE INVENTIO; *CARD RISK YOUNG, 2003, SUDD ARRH WHAT CAUS; Crystal David, 2003, SHAKESPEARES WORDS; Darwin C., 1998, EXPRESSION EMOTION M; EDGAR II, 1971, SHAKESEPARE MED PSYC; FOSTER J, 2001, DOCTORS SHAKESPEARE; Heaton K, 2006, GROATS WORTH WIT J O, V17, P32; Hoeniger F. D., 1992, MED SHAKESPEARE ENGL; Kail A. C., 1986, MED MIND SHAKESPEARE; MELCHIORI G, 1998, SHAKESPEARES EDWARD; Plutchik R., 1980, EMOTION PSYCHOEVOLUT; Simpson RR., 1959, SHAKESPEARE MED; Stroebe Margaret S., 1993, P175, DOI 10.1017/CBO9780511664076.013; Wittstein IS, 2005, NEW ENGL J MED, V352, P539, DOI 10.1056/NEJMoa043046	17	14	14	2	7	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 23	2006	333	7582					1335	1338		10.1136/bmj.39045.690556.AE	http://dx.doi.org/10.1136/bmj.39045.690556.AE			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121MC	17185734	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000243160700031
J	Jalan, R; Williams, R; Bernuau, J				Jalan, Rajiv; Williams, Roger; Bernuau, Jacques			Paracetarnol: are therapeutic doses entirely safe?	LANCET			English	Editorial Material							ACUTE LIVER-FAILURE; ACETAMINOPHEN		UCL, UCL Inst Hepatol, London WC1E 6HX, England; Hop Beaujon, APHP, Pole Malad Appareil Digest, Clichy, France	University of London; University College London; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite	Jalan, R (corresponding author), UCL, UCL Inst Hepatol, London WC1E 6HX, England.	r.j.jalan@ucl.ac.uk						Bernuau JR, 2004, HEPATOLOGY, V40, p499A; CRITCHLEY JAJH, 1986, BRIT J CLIN PHARMACO, V22, P649, DOI 10.1111/j.1365-2125.1986.tb02953.x; KWAN D, 1995, DIGEST DIS SCI, V40, P1951, DOI 10.1007/BF02208663; Larson AM, 2005, HEPATOLOGY, V42, P1364, DOI 10.1002/hep.20948; Moynihan R, 2002, BRIT MED J, V325, P678, DOI 10.1136/bmj.325.7366.678; OGRADY JG, 1993, LANCET, V342, P273; Ostapowicz G, 2002, ANN INTERN MED, V137, P947, DOI 10.7326/0003-4819-137-12-200212170-00007; Polson J, 2006, GASTROENTEROLOGY, V130, pA772; PRESCOTT LF, 1983, DRUGS, V25, P290, DOI 10.2165/00003495-198325030-00002; *US FOOD DRUG ADM, 2006, CDER 2002 M DOC AUG; Watkins PB, 2006, JAMA-J AM MED ASSOC, V296, P87, DOI 10.1001/jama.296.1.87; Yaghi Cesar, 2006, Gastroenterol Clin Biol, V30, P763, DOI 10.1016/S0399-8320(06)73311-5; Yin OQP, 2001, INT J PHARM, V222, P305, DOI 10.1016/S0378-5173(01)00712-8	13	39	39	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 23	2006	368	9554					2195	2196		10.1016/S0140-6736(06)69874-7	http://dx.doi.org/10.1016/S0140-6736(06)69874-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	120HY	17189017				2022-12-28	WOS:000243076800009
J	Cordenonsi, M; Montagner, M; Adorno, M; Zacchigna, L; Martello, G; Mamidi, A; Soligo, S; Dupont, S; Piccolo, S				Cordenonsi, Michelangelo; Montagner, Marco; Adorno, Maddalena; Zacchigna, Luca; Martello, Graziano; Mamidi, Anant; Soligo, Sandra; Dupont, Sirio; Piccolo, Stefano			Integration of TGF-beta and Ras/MAPK signaling through p53 phosphorylation	SCIENCE			English	Article							MESODERM INDUCTION; REQUIRES FGF; TRANSDUCTION; ACTIVATION; KINASE	During development and tissue homeostasis, cells must integrate different signals. We investigated how cell behavior is controlled by the combined activity of transforming growth factor-beta (TGF-beta) and receptor tyrosine kinase (RTK) signaling, whose integration mechanism is unknown. We find that RTK/Ras/ MAPK (mitogen-activated protein kinase) activity induces p53 N-terminal phosphorylation, enabling the interaction of p53 with the TGF-beta-activated Smads. This mechanism confines mesoderm specification in Xenopus embryos and promotes TGF-beta cytostasis in human cells. These data indicate a mechanism to allow extracellular cues to specify the TGF-beta gene-expression program.	Univ Padua, Dept Med Biotechnol, Sect Histol & Embryol, Padua, Italy	University of Padua	Piccolo, S (corresponding author), Univ Padua, Dept Med Biotechnol, Sect Histol & Embryol, Padua, Italy.	piccolo@civ.bio.unipd.it	Montagner, Marco/AAY-3236-2020; Cordenonsi, Michelangelo/K-7692-2016; Dupont, Sirio/AAP-8133-2021	Montagner, Marco/0000-0003-3080-2138; Cordenonsi, Michelangelo/0000-0002-8253-5724; PICCOLO, STEFANO/0000-0002-2037-0004; Dupont, Sirio/0000-0002-6869-1966; Martello, Graziano/0000-0001-5520-085X; Mamidi, Anant/0000-0001-7953-7991	Telethon [GGP04030] Funding Source: Medline	Telethon(Fondazione Telethon)		Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Bottcher RT, 2005, ENDOCR REV, V26, P63, DOI 10.1210/er.2003-0040; Cordenonsi M, 2003, CELL, V113, P301, DOI 10.1016/S0092-8674(03)00308-8; CORNELL RA, 1994, DEVELOPMENT, V120, P453; Davidson G, 2005, NATURE, V438, P867, DOI 10.1038/nature04170; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; LABONNE C, 1994, DEVELOPMENT, V120, P463; LABONNE C, 1995, DEVELOPMENT, V121, P1475; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Roper E, 2001, EMBO REP, V2, P145, DOI 10.1093/embo-reports/kve020; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Zeng X, 2005, NATURE, V438, P873, DOI 10.1038/nature04185	15	171	183	1	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 9	2007	315	5813					840	843		10.1126/science.1135961	http://dx.doi.org/10.1126/science.1135961			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	134FN	17234915	Bronze			2022-12-28	WOS:000244069000068
J	Sergina, NV; Rausch, M; Wang, DH; Blair, J; Hann, B; Shokat, KM; Moasser, MM				Sergina, Natalia V.; Rausch, Megan; Wang, Donghui; Blair, Jimmy; Hann, Byron; Shokat, Kevan M.; Moasser, Mark M.			Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3	NATURE			English	Article							EPIDERMAL-GROWTH-FACTOR; FACTOR RECEPTOR EGFR; BREAST-CANCER CELLS; ZD1839 IRESSA; TUMOR-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; NEU ONCOGENE; IN-VIVO; PROTEIN; GEFITINIB	Oncogenic tyrosine kinases have proved to be promising targets for the development of highly effective anticancer drugs. However, tyrosine kinase inhibitors (TKIs) against the human epidermal growth factor receptor ( HER) family show only limited activity against HER2-driven breast cancers, despite effective inhibition of epidermal growth factor receptor (EGFR) and HER2 in vivo(1-8). The reasons for this are unclear. Signalling in trans is a key feature of this multimember family and the critically important phosphatidylinositol-3- OH kinase ( PI( 3) K)/Akt pathway is driven predominantly through transphosphorylation of the kinase-inactive HER3 (refs 9, 10). Here we show that HER3 and consequently PI( 3) K/Akt signalling evade inhibition by current HER-family TKIs in vitro and in tumours in vivo. This is due to a compensatory shift in the HER3 phosphorylation - dephosphorylation equilibrium, driven by increased membrane HER3 expression driving the phosphorylation reaction and by reduced HER3 phosphatase activity impeding the dephosphorylation reaction. These compensatory changes are driven by Akt-mediated negative-feedback signalling. Although HER3 is not a direct target of TKIs, HER3 substrate resistance undermines their efficacy and has thus far gone undetected. The experimental abrogation of HER3 resistance by small interfering RNA knockdown restores potent pro-apoptotic activity to otherwise cytostatic HER TKIs, re-affirming the oncogene-addicted nature of HER2-driven tumours and the therapeutic promise of this oncoprotein target. However, because HER3 signalling is buffered against an incomplete inhibition of HER2 kinase, much more potent TKIs or combination strategies are required to silence oncogenic HER2 signalling effectively. The biologic marker with which to assess the efficacy of HER TKIs should be the transphosphorylation of HER3 rather than autophosphorylation.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Moasser, MM (corresponding author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.	mmoasser@medicine.ucsf.edu		Blair, Jimmy/0000-0003-0303-5981	NATIONAL CANCER INSTITUTE [R01CA122216] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044009] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA122216, R01 CA122216-01A1] Funding Source: Medline; NIAID NIH HHS [R01 AI044009] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akita RW, 2003, SEMIN ONCOL, V30, P15, DOI 10.1016/S0093-7754(03)00187-8; Anderson NG, 2001, INT J CANCER, V94, P774, DOI 10.1002/ijc.1557; BACUS SS, 2003, P AM SOC CLIN ONCOL, V22; Baselga J, 2005, J CLIN ONCOL, V23, P5323, DOI 10.1200/JCO.2005.08.326; Bianco R, 2003, ONCOGENE, V22, P2812, DOI 10.1038/sj.onc.1206388; BLACKWELL K, 2004, P AM SOC CLIN ONCOL, V23; BURRIS HA, 2003, BREAST CANC RES T S1, V82; Campiglio M, 2004, J CELL PHYSIOL, V198, P259, DOI 10.1002/jcp.10411; CAMPOS SM, 2004, P AM SOC CLIN ONCOL, V23; DEES EC, 2004, P AM SOC CLIN ONCOL, V23; Fry DW, 1998, P NATL ACAD SCI USA, V95, P12022, DOI 10.1073/pnas.95.20.12022; Haas-Kogan DA, 2005, JNCI-J NATL CANCER I, V97, P880, DOI 10.1093/jnci/dji161; Huron DR, 2003, CLIN CANCER RES, V9, P1267; Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573; KIM HH, 1994, J BIOL CHEM, V269, P24747; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; McKillop D, 2005, MOL CANCER THER, V4, P641, DOI 10.1158/1535-7163.MCT-04-0329; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Moasser MM, 2001, CANCER RES, V61, P7184; Moody SE, 2002, CANCER CELL, V2, P451, DOI 10.1016/S1535-6108(02)00212-X; Moulder SL, 2001, CANCER RES, V61, P8887; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Offterdinger M, 2002, J CELL BIOL, V157, P929, DOI 10.1083/jcb.200109033; She QB, 2003, CLIN CANCER RES, V9, P4340; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Spector NL, 2005, J CLIN ONCOL, V23, P2502, DOI 10.1200/JCO.2005.12.157; Tonks NK, 2005, CELL, V121, P667, DOI 10.1016/j.cell.2005.05.016; Tsou HR, 2001, J MED CHEM, V44, P2719, DOI 10.1021/jm0005555; WINER E, 2002, BREAST CANC RES T S1, V76	30	750	809	0	60	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 25	2007	445	7126					437	441		10.1038/nature05474	http://dx.doi.org/10.1038/nature05474			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	128WD	17206155	Green Accepted			2022-12-28	WOS:000243689500042
J	Ullmann, AJ; Lipton, JH; Vesole, DH; Chandrasekar, P; Langston, A; Tarantolo, SR; Greinix, H; Morais de Azevedo, W; Reddy, V; Boparai, N; Pedicone, L; Patino, H; Durrant, S				Ullmann, Andrew J.; Lipton, Jeffrey H.; Vesole, David H.; Chandrasekar, Pranatharthi; Langston, Amelia; Tarantolo, Stefano R.; Greinix, Hildegard; Morais de Azevedo, Wellington; Reddy, Vijay; Boparai, Navdeep; Pedicone, Lisa; Patino, Hernando; Durrant, Simon			Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INVASIVE FUNGAL-INFECTIONS; CELL TRANSPLANT RECIPIENTS; IN-VITRO ACTIVITIES; RISK-FACTORS; AMPHOTERICIN-B; MARROW-TRANSPLANTATION; ASPERGILLUS INFECTIONS; CONTROLLED-TRIAL; EPIDEMIOLOGY; ITRACONAZOLE	BACKGROUND: Invasive fungal infections are an important cause of morbidity and mortality after allogeneic hematopoietic stem-cell transplantation. METHODS: In an international, randomized, double-blind trial, we compared oral posaconazole with oral fluconazole for prophylaxis against invasive fungal infections in patients with graft-versus-host disease (GVHD) who were receiving immunosuppressive therapy. The primary end point was the incidence of proven or probable invasive fungal infections from randomization to day 112 of the fixed treatment period of the study. RESULTS: Of a total of 600 patients, 301 were assigned to posaconazole and 299 to fluconazole. At the end of the fixed 112-day treatment period, posaconazole was found to be as effective as fluconazole in preventing all invasive fungal infections (incidence, 5.3% and 9.0%, respectively; odds ratio, 0.56; 95 percent confidence interval [CI], 0.30 to 1.07; P=0.07) and was superior to fluconazole in preventing proven or probable invasive aspergillosis (2.3% vs. 7.0%; odds ratio, 0.31; 95% CI, 0.13 to 0.75; P=0.006). While patients were receiving study medications (exposure period), in the posaconazole group, as compared with the fluconazole group, there were fewer breakthrough invasive fungal infections (2.4% vs. 7.6%, P=0.004), particularly invasive aspergillosis (1.0% vs. 5.9%, P=0.001). Overall mortality was similar in the two groups, but the number of deaths from invasive fungal infections was lower in the posaconazole group (1%, vs. 4% in the fluconazole group; P=0.046). The incidence of treatment-related adverse events was similar in the two groups (36% in the posaconazole group and 38% in the fluconazole group), and the rates of treatment-related serious adverse events were 13% and 10%, respectively. CONCLUSIONS: Posaconazole was similar to fluconazole for prophylaxis against fungal infections among patients with GVHD. It was superior in preventing invasive aspergillosis and reducing the rate of deaths related to fungal infections.	Johannes Gutenberg Univ Mainz, Med Klin & Poliklin 3, D-55101 Mainz, Germany; Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada; Med Coll Wisconsin, Milwaukee, WI 53226 USA; Harper Grace Hosp, Detroit, MI USA; Emory Univ, Atlanta, GA 30322 USA; Univ Nebraska, Med Ctr, Omaha, NE USA; Med Univ Vienna, Vienna, Austria; Univ Fed Minas Gerais, Hosp Clin, Belo Horizonte, MG, Brazil; Univ Florida, Gainesville, FL USA; Schering Plough Corp, Res Inst, Kenilworth, NJ 07033 USA; Royal Brisbane Hosp, Brisbane, Qld 4029, Australia	Johannes Gutenberg University of Mainz; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Medical College of Wisconsin; Emory University; University of Nebraska System; University of Nebraska Medical Center; Medical University of Vienna; Universidade Federal de Minas Gerais; State University System of Florida; University of Florida; Merck & Company; Schering Plough Corporation; Royal Brisbane & Women's Hospital	Ullmann, AJ (corresponding author), Johannes Gutenberg Univ Mainz, Med Klin & Poliklin 3, Langenbeckstr 1, D-55101 Mainz, Germany.	ullmann@uni-mainz.de	Ullmann, AJ/AAQ-1724-2021					Albengres E, 1998, DRUG SAFETY, V18, P83, DOI 10.2165/00002018-199818020-00001; [Anonymous], 2000, MMWR Recomm Rep, V49, P1; Ascioglu S, 2002, CLIN INFECT DIS, V34, P7, DOI 10.1086/323335; Barry AL, 2000, J CLIN MICROBIOL, V38, P3457, DOI 10.1128/JCM.38.9.3457-3459.2000; DEREPENTIGNY L, 1987, J CLIN MICROBIOL, V25, P863, DOI 10.1128/JCM.25.5.863-867.1987; Espinel-Ingroff A, 2001, ANTIMICROB AGENTS CH, V45, P1828, DOI 10.1128/AAC.45.6.1828-1835.2001; Espinel-Ingroff A, 1998, J CLIN MICROBIOL, V36, P2950, DOI 10.1128/JCM.36.10.2950-2956.1998; FERRARA JLM, 1991, NEW ENGL J MED, V324, P667; Fukuda T, 2003, BLOOD, V102, P827, DOI 10.1182/blood-2003-02-0456; GOODMAN JL, 1992, NEW ENGL J MED, V326, P845, DOI 10.1056/NEJM199203263261301; Grow WB, 2002, BONE MARROW TRANSPL, V29, P15, DOI 10.1038/sj.bmt.1703332; Herbrecht R, 2002, NEW ENGL J MED, V347, P408, DOI 10.1056/NEJMoa020191; Jantunen E, 1997, BONE MARROW TRANSPL, V19, P801, DOI 10.1038/sj.bmt.1700737; Marr KA, 2004, BLOOD, V103, P1527, DOI 10.1182/blood-2003-08-2644; Marr KA, 2004, CLIN INFECT DIS, V39, pS170, DOI 10.1086/421952; Marr KA, 2000, BLOOD, V96, P2055; Marr KA, 2002, BLOOD, V100, P4358, DOI 10.1182/blood-2002-05-1496; Marr KA, 2002, CLIN INFECT DIS, V34, P909, DOI 10.1086/339202; Martino R, 2002, BRIT J HAEMATOL, V116, P475, DOI 10.1046/j.1365-2141.2002.03259.x; MEYERS JD, 1990, SEMIN ONCOL, V17, P10; Morgenstern GR, 1999, BRIT J HAEMATOL, V105, P901, DOI 10.1046/j.1365-2141.1999.01465.x; MORRISON VA, 1994, AM J MED, V96, P497, DOI 10.1016/0002-9343(94)90088-4; Pfaller MA, 2002, ANTIMICROB AGENTS CH, V46, P1032, DOI 10.1128/AAC.46.4.1032-1037.2002; PRZEPIORKA D, 1995, BONE MARROW TRANSPL, V15, P825; Raad II, 2006, CLIN INFECT DIS, V42, P1398, DOI 10.1086/503425; Ribaud P, 1999, CLIN INFECT DIS, V28, P322, DOI 10.1086/515116; Sabatelli F, 2006, ANTIMICROB AGENTS CH, V50, P2009, DOI 10.1128/AAC.00163-06; SAUGIERVEBER P, 1993, BONE MARROW TRANSPL, V12, P121; Shen JX, 2007, J PHARMACEUT BIOMED, V43, P228, DOI 10.1016/j.jpba.2006.06.011; SLAVIN MA, 1995, J INFECT DIS, V171, P1545, DOI 10.1093/infdis/171.6.1545; Thursky K, 2004, BONE MARROW TRANSPL, V34, P115, DOI 10.1038/sj.bmt.1704543; Ullmann AJ, 2006, ANTIMICROB AGENTS CH, V50, P658, DOI 10.1128/AAC.50.2.658-666.2006; van Burik JAH, 2006, CLIN INFECT DIS, V43, P1376; van Burik JAH, 2006, CLIN INFECT DIS, V42, pE61, DOI 10.1086/500212; van Burik JAH, 2004, CLIN INFECT DIS, V39, P1407, DOI 10.1086/422312; Wald A, 1997, J INFECT DIS, V175, P1459, DOI 10.1086/516480; Walsh TJ, 2007, CLIN INFECT DIS, V44, P2, DOI 10.1086/508774; WINGARD JR, 1987, BONE MARROW TRANSPL, V2, P175; Winston DJ, 2003, ANN INTERN MED, V138, P705, DOI 10.7326/0003-4819-138-9-200305060-00006; 2004, MMWR RECOMM REP, V53, P396	40	931	969	0	25	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 25	2007	356	4					335	347		10.1056/NEJMoa061098	http://dx.doi.org/10.1056/NEJMoa061098			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128FT	17251530				2022-12-28	WOS:000243644300004
J	Crowley, WF				Crowley, William Francis, Jr.			Drug development and clinical research in the UK	LANCET			English	Editorial Material							RESEARCH ENTERPRISE		Massachusetts Gen Hosp, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Crowley, WF (corresponding author), Massachusetts Gen Hosp, Boston, MA 02114 USA.	crowley.william@mgh.harvard.edu						Crowley WF, 2004, JAMA-J AM MED ASSOC, V291, P1120, DOI 10.1001/jama.291.9.1120; DiMasi JA, 2003, J HEALTH ECON, V22, P151, DOI 10.1016/S0167-6296(02)00126-1; Sung NS, 2003, JAMA-J AM MED ASSOC, V289, P1278, DOI 10.1001/jama.289.10.1278; UK Clinical Research Collaboration, 2005, CLIN RES UK SINGL SY; Zerhouni EA, 2005, NEW ENGL J MED, V353, P1621, DOI 10.1056/NEJMsb053723	5	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 20	2007	369	9557					174	175		10.1016/S0140-6736(07)60088-9	http://dx.doi.org/10.1016/S0140-6736(07)60088-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	128XG	17240271				2022-12-28	WOS:000243692400010
J	Vukusic, P; Hallam, B; Noyes, J				Vukusic, Pete; Hallam, Benny; Noyes, Joe			Brilliant whiteness in ultrathin beetle scales	SCIENCE			English	Article							SCATTERING		Univ Exeter, Sch Phys, Exeter EX4 4QL, Devon, England; Imerys Minerals Ltd, Par PL24 2SQ, Cornwall, England	University of Exeter	Vukusic, P (corresponding author), Univ Exeter, Sch Phys, Exeter EX4 4QL, Devon, England.	P.Vukusic@ex.ac.uk			BBSRC [BB/E000177/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/E000177/1, JF16983] Funding Source: Medline	BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		FITZWATER S, 1985, J COATING TECHNOL, V57, P39; GANZ E, 1976, APPL OPTICS, V15, P2039, DOI 10.1364/AO.15.002039; Kinoshita S., 2005, STRUCTURAL COLORS BI; McNeil LE, 2000, ACTA MATER, V48, P4571, DOI 10.1016/S1359-6454(00)00243-3; Srinivasarao M, 1999, CHEM REV, V99, P1935, DOI 10.1021/cr970080y; Vukusic P, 2003, NATURE, V424, P852, DOI 10.1038/nature01941	6	192	196	4	97	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 19	2007	315	5810					348	348		10.1126/science.1134666	http://dx.doi.org/10.1126/science.1134666			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126SI	17234940				2022-12-28	WOS:000243535400031
J	Lu, HL; Seo, YT; Lee, JW; Moudrakovski, I; Ripmeester, JA; Chapman, NR; Coffin, RB; Gardner, G; Pohlman, J				Lu, Hailong; Seo, Yu-taek; Lee, Jong-won; Moudrakovski, Igor; Ripmeester, John A.; Ross Chapman, N.; Coffin, Richard B.; Gardner, Graeme; Pohlman, John			Complex gas hydrate from the Cascadia margin	NATURE			English	Article							BLACK-SEA; GULF; RIDGE; CLIMATE	Natural gas hydrates are a potential source of energy(1) and may play a role in climate change(2) and geological hazards(3). Most natural gas hydrate appears to be in the form of 'structure I', with methane as the trapped guest molecule(4), although 'structure II' hydrate has also been identified, with guest molecules such as isobutane and propane, as well as lighter hydrocarbons(5,6). A third hydrate structure, 'structure H', which is capable of trapping larger guest molecules, has been produced in the laboratory(7), but it has not been confirmed that it occurs in the natural environment. Here we characterize the structure, gas content and composition, and distribution of guest molecules in a complex natural hydrate sample recovered from Barkley canyon, on the northern Cascadia margin(8). We show that the sample contains structure H hydrate, and thus provides direct evidence for the natural occurrence of this hydrate structure. The structure H hydrate is intimately associated with structure II hydrate, and the two structures contain more than 13 different hydrocarbon guest molecules. We also demonstrate that the stability field of the complex gas hydrate lies between those of structure II and structure H hydrates, indicating that this form of hydrate is more stable than structure I and may thus potentially be found in a wider pressure - temperature regime than can methane hydrate deposits.	Natl Res Council Canada, Steacie Inst Mol Sci, Ottawa, ON K1A 0R6, Canada; Univ Victoria, Sch Earth & Ocean Sci, Victoria, BC V8W 3P6, Canada; USN, Res Lab, Washington, DC 20375 USA; Natl Res Council Canada, Inst Natl Measurement Stand, Ottawa, ON K1A 0R6, Canada	National Research Council Canada; University of Victoria; United States Department of Defense; United States Navy; Naval Research Laboratory; National Research Council Canada	Ripmeester, JA (corresponding author), Natl Res Council Canada, Steacie Inst Mol Sci, 100 Sussex Dr, Ottawa, ON K1A 0R6, Canada.	john.ripmeester@nrc-cnrc.gc.ca	Ripmeester, John A/G-1950-2011; Seo, Yutaek/B-3384-2012	Seo, Yutaek/0000-0001-8537-579X; Moudrakovski, Igor/0000-0002-8919-4766				BERNARD BB, 1976, EARTH PLANET SC LETT, V31, P48, DOI 10.1016/0012-821X(76)90095-9; Chapman N., 2004, EOS T AM GEOPHYS UN, V85, P361, DOI DOI 10.1029/2004EO380001; DAVIDSON DW, 1986, GEOCHIM COSMOCHIM AC, V50, P619, DOI 10.1016/0016-7037(86)90110-9; Diaconescu CC, 2001, MAR PETROL GEOL, V18, P209, DOI 10.1016/S0264-8172(00)00061-1; DILLON WP, 2001, AM GEOPHYSICAL UNION, V124, P211; Ginsburg G. D., 1998, SUBMARINE GAS HYDRAT; Kleinberg RL, 2001, AM SCI, V89, P244, DOI 10.1511/2001.3.244; KVENVOLDEN KA, 1983, INITIAL REP DEEP SEA, V76, P353; Lambeck K, 2002, NATURE, V419, P199, DOI 10.1038/nature01089; Lee J, 2006, ANGEW CHEM INT EDIT, V45, P2456, DOI 10.1002/anie.200504366; LU H, 2005, GEOL SURV CAN B, V585, P89; Lu HL, 2005, J GEOPHYS RES-SOL EA, V110, DOI 10.1029/2005JB003900; MATSUMOTO R, 2005, EOS T S, V86; Mazzini A, 2004, MAR GEOL, V212, P153, DOI 10.1016/j.margeo.2004.08.001; Milkov AV, 2005, GEOCHIM COSMOCHIM AC, V69, P1007, DOI 10.1016/j.gca.2004.08.021; Milkov AV, 2004, ORG GEOCHEM, V35, P1067, DOI 10.1016/j.orggeochem.2004.04.003; Pohlman JW, 2005, ORG GEOCHEM, V36, P703, DOI 10.1016/j.orggeochem.2005.01.011; Ripmeester J. A., 2005, GEOL SURV CAN B, P106; RIPMEESTER JA, 1990, J PHYS CHEM-US, V94, P8773, DOI 10.1021/j100388a006; RIPMEESTER JA, 1987, NATURE, V325, P135, DOI 10.1038/325135a0; SASSEN R, 1994, ORG GEOCHEM, V22, P1029, DOI 10.1016/0146-6380(94)90036-1; Sassen R, 2004, CHEM GEOL, V205, P195, DOI 10.1016/j.chemgeo.2003.12.032; Spence G. D., 2001, EOS T AM GEOPHYS UN, V82, P621, DOI [DOI 10.1029/01E000358, DOI 10.1029/01EO00358]; TULK CA, 1999, GSC B, V544, P263; Woodside JM, 2003, GEO-MAR LETT, V23, P269, DOI 10.1007/s00367-003-0149-7; Xu WY, 2001, J GEOPHYS RES-SOL EA, V106, P26413, DOI 10.1029/2001JB000420	26	225	244	5	104	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 18	2007	445	7125					303	306		10.1038/nature05463	http://dx.doi.org/10.1038/nature05463			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126HT	17230188				2022-12-28	WOS:000243504700042
J	Chen, ZQ; Zhang, GC; Gong, XD; Lin, C; Gao, X; Liang, GJ; Yue, XL; Chen, XS; Cohen, MS				Chen, Zhi-Qiang; Zhang, Guo-Cheng; Gong, Xiang-Dong; Lin, Charles; Gao, Xing; Liang, Guo-Jun; Yue, Xiao-Li; Chen, Xiang-Sheng; Cohen, Myron S.			Syphilis in China: results of a national surveillance programme	LANCET			English	Article							SEXUALLY-TRANSMITTED-DISEASES; HIGH PREVALENCE; HEALTH-CARE; SEX WORKERS; HIV; SPREAD; INFECTION; TRANSMISSION; TRENDS; MEN	Background After a massive syphilis epidemic in the first half of the 20th century, China was able to eliminate this infection for 20 years (1960-80). However, substantial changes in Chinese society have been followed by a resurgent epidemic of sexually transmitted diseases. Sporadic reports have provided clues to the magnitude of the spread of syphilis, but a national surveillance effort is needed to provide data for planning and intervention. Methods We collected and assessed case report data from China's national sexually transmitted disease surveillance system and sentinel site network. Findings In 1993, the reported total rate of cases of syphilis in China was 0.2 cases per 100000, whereas primary and secondary syphilis alone represented 5.7 cases per 100000 persons in 2005. The rate of congenital syphilis increased greatly with an average yearly rise of 71.9%, from 0.01 cases per 100000 livebirths in 1991 to 19.68 cases per 100000 livebirths in 2005. Interpretation The results suggest that a range of unique biological and social forces are driving the spread of syphilis in China. A national campaign for detection and treatment of syphilis, and a credible prevention strategy, are urgently needed.	Chinese Acad Med Sci, Natl Ctr STD Control, Nanjing 210042, Peoples R China; Peking Union Med Coll Inst, Nanjing 210042, Peoples R China; Univ Calif San Francisco, Sch Med, San Francisco, CA USA; Univ N Carolina, Ctr Infect Dis, Chapel Hill, NC USA	Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; University of California System; University of California San Francisco; University of North Carolina; University of North Carolina Chapel Hill	Chen, XS (corresponding author), Chinese Acad Med Sci, Natl Ctr STD Control, 12 Jiangwangmiao St, Nanjing 210042, Peoples R China.	chenxs@vip.163.com		Lin, Charles/0000-0002-5347-4811				Anonymous, 2006, Morbidity and Mortality Weekly Report, V55, P269; [Anonymous], 2006, Wkly Epidemiol Rec, V81, P108; Blumenthal D, 2005, NEW ENGL J MED, V353, P1165, DOI 10.1056/NEJMhpr051133; Borisenko KK, 1999, INT J STD AIDS, V10, P665, DOI 10.1258/0956462991913240; Brown AE, 2004, SEX TRANSM INFECT, V80, P159, DOI 10.1136/sti.2004.009571; Buchacz K, 2004, AIDS, V18, P2075, DOI 10.1097/00002030-200410210-00012; Chang ZQ, 2004, HDB SEXUALLY TRANSMI; Chen J, 2000, EXP THERM FLUID SCI, V21, P206, DOI 10.1016/S0894-1777(00)00004-2; Chen XS, 2000, SEX TRANSM DIS, V27, P138, DOI 10.1097/00007435-200003000-00003; CHEN YL, 2001, CHIN J STD AIDS PREV, V8, P237; Choi KH, 1999, INT J STD AIDS, V10, P309, DOI 10.1258/0956462991914177; Cohen MS, 2000, SEX TRANSM DIS, V27, P143, DOI 10.1097/00007435-200003000-00004; Cohen MS, 1996, J INFECT DIS, V174, pS223, DOI 10.1093/infdis/174.Supplement_2.S223; COHEN MS, 1984, CHINESE HOSP SOCIALI; Ding YP, 2005, JAIDS-J ACQ IMM DEF, V38, P314; Galvin SR, 2004, NAT REV MICROBIOL, V2, P33, DOI 10.1038/nrmicro794; Gil VE, 1996, SOC SCI MED, V42, P141, DOI 10.1016/0277-9536(95)00064-X; Golden MR, 2003, JAMA-J AM MED ASSOC, V290, P1510, DOI 10.1001/jama.290.11.1510; GONG XD, 2001, CHIN J SEX TRANSM IN, V1, P1; Grassly NC, 2005, NATURE, V433, P417, DOI 10.1038/nature03072; Hershatter Gail, 1997, DANGEROUS PLEASURES; Hesketh T, 2005, INT J STD AIDS, V16, P262, DOI 10.1258/0956462053420257; Ho D, 2005, NATURE, V435, P421, DOI 10.1038/435421a; Hopkins S, 2001, SEX TRANSM INFECT, V77, P316, DOI 10.1136/sti.77.5.316; HORN J, 1974, AWAY ALL PESTS ENGLI; HU CK, 1964, BEIJ SCI C, P167; Hu CKYG, 1959, CHINESE J DERMATOL, V7, P290; Jiang J, 2006, SEX TRANSM DIS, V33, P118, DOI 10.1097/01.olq.0000199763.14766.2b; Jing F, 2004, HEALTH POLICY PLANN, V19, pI40, DOI 10.1093/heapol/czh044; Lim MK, 2004, HEALTH AFFAIR, V23, P222, DOI 10.1377/hlthaff.23.6.222; Lin CC, 2006, SEX TRANSM DIS, V33, P726, DOI 10.1097/01.olq.0000222703.12018.58; Lin Z, 2001, CHIN J STD AIDS PREV, V7, P273; LIU M, 1958, CHINESE J DERMATOL, V6, P76; Mwapasa V, 2006, AIDS, V20, P1869, DOI 10.1097/01.aids.0000244206.41500.27; *NAT BUR STAT CHIN, NAT YEARL STAT DAT; Parish WL, 2003, JAMA-J AM MED ASSOC, V289, P1265, DOI 10.1001/jama.289.10.1265; Peeling RW, 2004, LANCET, V364, P1561, DOI 10.1016/S0140-6736(04)17327-3; Reynolds SJ, 2006, SEX TRANSM INFECT, V82, P121, DOI 10.1136/sti.2005.015040; *S BTS MOH, 1996, GB159741995 SBTSMOH; SIDEL VW, 1972, NEW ENGL J MED, V286, P1292, DOI 10.1056/NEJM197206152862404; Tucker JD, 2005, AIDS, V19, P539, DOI 10.1097/01.aids.0000163929.84154.87; van den Hoek A, 2001, AIDS, V15, P753, DOI 10.1097/00002030-200104130-00011; WANG J, 1923, CHUNG HUA I HSUEH TS, V9, P17; World Health Organisation (WHO), 2004, EXP 100 COND US PROG; Yu AL, 1999, CHIN J AIDS STD, V6, P33; Zhang HJ, 2002, CHIN J FAMILY PLAN, V5, P273; Zhang K, 1999, AIDS CARE, V11, P581, DOI 10.1080/09540129947730; Zhao RL, 2003, CHIN J AIDS STD S, P98	48	242	287	0	36	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 13	2007	369	9556					132	138		10.1016/S0140-6736(07)60074-9	http://dx.doi.org/10.1016/S0140-6736(07)60074-9			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	126TK	17223476	Green Published, Bronze			2022-12-28	WOS:000243538200032
J	Malipeddi, AS; Kallarackal, G				Malipeddi, Aruna S.; Kallarackal, George			Disseminated tuberculosis after anti-TNF alpha treatment	LANCET			English	Editorial Material							MYCOBACTERIUM-TUBERCULOSIS; INFECTION		Gen Hosp Kettering, Dept Rheumatol, Kettering NN16 8UZ, England		Malipeddi, AS (corresponding author), Gen Hosp Kettering, Dept Rheumatol, Kettering NN16 8UZ, England.	arunam@doctors.org.uk						Ferrara G, 2006, LANCET, V367, P1328, DOI 10.1016/S0140-6736(06)68579-6; Keane J, 2001, NEW ENGL J MED, V345, P1098, DOI 10.1056/NEJMoa011110; Mohan AK, 2004, CLIN INFECT DIS, V39, P295, DOI 10.1086/421494; Ormerod LP, 2005, THORAX, V60, P800, DOI 10.1136/thx.2005.046797; Schiff MH, 2006, ANN RHEUM DIS, V65, P889, DOI 10.1136/ard.2005.043166	5	24	25	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 13	2007	369	9556					162	162		10.1016/S0140-6736(07)60078-6	http://dx.doi.org/10.1016/S0140-6736(07)60078-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	126TK	17223480				2022-12-28	WOS:000243538200036
J	Elliott, EJ				Elliott, Elizabeth Jane			Acute gastroenteritis in children	BMJ-BRITISH MEDICAL JOURNAL			English	Review							YOUNG-CHILDREN; METAANALYSIS; MANAGEMENT; DIARRHEA; EFFICACY; SAFETY; CARE		Univ Sydney, Discipline Paediat & Child Hlth, Sydney, NSW 2006, Australia	University of Sydney	Elliott, EJ (corresponding author), Childrens Hosp Westmead, Westmead, NSW 2145, Australia.	elizabe2@chw.edu.au		Elliott, Elizabeth/0000-0002-6501-5487				*AC GASTR GUID TEA, 2005, EV BAS CAR GUID GAST; ALLEN SJ, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003048.PUB2; Bahl R, 2001, J HEALTH POPUL NUTR, V19, P338; BROWN KH, 1994, PEDIATRICS, V93, P17; ELLIOTT E, 2005, PROBLEMS CHILD ADOLE, V35, P310; ELLIOTT E, 2006, CLIN EVID, V15, P1; ELLIOTT EJ, IN PRESS EVIDENCE BA; Fonseca BK, 2004, ARCH PEDIAT ADOL MED, V158, P483, DOI 10.1001/archpedi.158.5.483; Galati JC, 2006, AUST NZ J PUBL HEAL, V30, P416, DOI 10.1111/j.1467-842X.2006.tb00456.x; GORE SM, 1992, BMJ-BRIT MED J, V304, P287, DOI 10.1136/bmj.304.6822.287; Guerrant RL, 2001, CLIN INFECT DIS, V32, P331, DOI 10.1086/318514; Hahn S., 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002847; Harting L, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004390.pub2; King Caleb K, 2003, MMWR Recomm Rep, V52, P1; Kirkwood CD, 2006, COMMUN DIS INTELL, V30, P434; McConnochie KM, 1999, ARCH PEDIAT ADOL MED, V153, P1233, DOI 10.1001/archpedi.153.12.1233; Murphy C, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003754.PUB2; Ruben AR, 1998, MED J AUSTRALIA, V169, pS6, DOI 10.5694/j.1326-5377.1998.tb123468.x; Ruiz-Palacios GM, 2006, NEW ENGL J MED, V354, P11, DOI 10.1056/NEJMoa052434; Steiner MJ, 2004, JAMA-J AM MED ASSOC, V291, P2746, DOI 10.1001/jama.291.22.2746; Tham EBA, 1996, J PAEDIATR CHILD H, V32, P504, DOI 10.1111/j.1440-1754.1996.tb00963.x; Thomas DR, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002968.pub2; *US FOOD DRUG ADM, BACT EXPL BACT TEST; Vesikari T, 2006, NEW ENGL J MED, V354, P23, DOI 10.1056/NEJMoa052664; *WHO UNICEF, JOINT STAT OR REH SA; World Health Organization, 2005, TREATM DIARRH MAN PH	26	168	177	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 6	2007	334	7583					35	40		10.1136/bmj.39036.406169.80	http://dx.doi.org/10.1136/bmj.39036.406169.80			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125CH	17204802	Green Published			2022-12-28	WOS:000243418600038
J	Heath, I				Heath, Iona			Life and death - In defence of a National Sickness Service	BRITISH MEDICAL JOURNAL			English	Editorial Material												iona.heath@dst.pipex.com							0	12	19	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JAN 6	2007	334	7583					19	19		10.1136/bmj.39066.541678.B7	http://dx.doi.org/10.1136/bmj.39066.541678.B7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	125CH	17204798	Green Published			2022-12-28	WOS:000243418600030
J	Smith, I; Procter, M; D Gelber, R; Guillaume, S; Feyereislova, A; Dowsett, M; Goldhirsch, A; Untch, M; Mariani, G; Baselga, J; Kaufmann, M; Cameron, D; Bell, R; Bergh, J; Coleman, R; Wardley, A; Harbeck, N; Lopez, RI; Mallmann, P; Gelmon, K; Wilcken, N; Wist, E; Rovira, PS; Piccart-Gebhart, M				Smith, Ian; Procter, Marion; D Gelber, Richard; Guillaume, Sebastien; Feyereislova, Andrea; Dowsett, Mitch; Goldhirsch, Aron; Untch, Michael; Mariani, Gabriella; Baselga, Jose; Kaufmann, Manfred; Cameron, David; Bell, Richard; Bergh, Jonas; Coleman, Robert; Wardley, Andrew; Harbeck, Nadia; Lopez, Roberto I.; Mallmann, Peter; Gelmon, Karen; Wilcken, Nicholas; Wist, Erik; Sanchez Rovira, Pedro; Piccart-Gebhart, Martine		HERA Study Team	2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial	LANCET			English	Article							POSTMENOPAUSAL WOMEN; 1ST-LINE TREATMENT; PHASE-II; TAMOXIFEN; EFFICACY; SAFETY; COMBINATION; DOCETAXEL; SURVIVAL; THERAPY	Background Trastuzumab-a humanised monoclonal antibody against HER2-has been shown to improve disease-free survival after chemotherapy in women with HER2-positive early breast cancer. We investigated the drug's effect on overall survival after a median follow-up of 2 years in the Herceptin Adjuvant (HERA) study. Methods HERA is an international multicentre randomised trial that compared 1 or 2 years of trastuzumab treatment with observation alone after standard neoadjuvant or adjuvant chemotherapy in women with HER2-positive node positive or high-risk node negative breast cancer. 5102 women participated in the trial; we analysed data from 1703 women who had been randomised for treatment with trastuzumab for 1 year and 1698 women from the control group, with median follow-up of 23.5 months (range 0-48 months). The primary endpoint of the trial was disease-free survival. Here, we assess overall survival, a secondary endpoint. Analyses were done on an intent-to-treat basis. This trial is registered with the European Clinical Trials Database, number 2005-002385-11. Findings 97 (5.7%) patients randomised to observation alone and 58 (3.4%) patients randomised to 1 year of treatment with trastuzumab were lost to follow-up. 172 women stopped trastuzumab prematurely. 59 deaths were reported for trastuzumab and 90 in the control group. The unadjusted hazard ratio (HR) for the risk of death with trastuzumab compared with observation alone was 0.66 (95% CI 0.47-0.91; p=0.0115). 218 disease-free survival events were reported with trastuzumab compared with 321 in the control group. The unadjusted HR for the risk of an event with trastuzumab compared with observation alone was 0.64 (0.54-0.76; p<0.0001). Interpretation Our results show that 1 year of treatment with trastuzumab after adjuvant chemotherapy has a significant overall survival benefit after a median follow-up of 2 years. The emergence of this benefit after only 2 years reinforces the importance of trastuzumab in the treatment of women with HER2-positive early breast cancer.	Royal Marsden Hosp, Breast Unit, London SW3 6JJ, England; Inst Canc Res, London SW3 6JB, England; Frontier Sci Scotland, Kingussie, Scotland; Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA; Univ Libre Bruxelles, Inst Jules Bordet, Breast Data Ctr, Brussels, Belgium; Univ Libre Bruxelles, Inst Jules Bordet, Dept Med, Brussels, Belgium; Roche, Basel, Switzerland; European Inst Oncol, Dept Med, Milan, Italy; Oncol Inst So Switzerland, Bellinzona, Switzerland; Univ Munich, Klin Frauenheilkunde & Geburtshilfe, Munich, Germany; Ist Nazl Studio & Cura Tumori, I-20133 Milan, Italy; Vall Hebron Univ Hosp, Med Oncol Serv, Barcelona, Spain; Goethe Univ Frankfurt, Dept Obstet & Gynaecol, D-6000 Frankfurt, Germany; Western Gen Hosp, Dept Oncol, Edinburgh EH4 2XU, Midlothian, Scotland; Geelong Hosp, Andrew Love Canc Ctr, Geelong, Vic, Australia; Karolinska Inst, Dept Oncol, Stockholm, Sweden; Univ Hosp, Stockholm, Sweden; Weston Pk Hosp, Canc Res Ctr, Acad Unit Clin Oncol, Sheffield, S Yorkshire, England; Christie Hosp, Manchester, Lancs, England; Tech Univ Munich, Klinikum Rechts Isar, Frauenklin, D-8000 Munich, Germany; Inst Oncol Nacl Panama, Panama City, Panama; Univ Hosp Cologne, Dept Obstet & Gynaecol, Cologne, Germany; British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada; Westmead Hosp, Dept Med Oncol & Palliat Care, Westmead, NSW 2145, Australia; Ullevaal Univ Hosp, Dept Oncol, Oslo, Norway; Complejo Hosp Jaen, Jaen, Spain	Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Harvard University; Dana-Farber Cancer Institute; Institut Jules Bordet; Universite Libre de Bruxelles; Institut Jules Bordet; Universite Libre de Bruxelles; Roche Holding; IRCCS European Institute of Oncology (IEO); Institute of Oncology Research (IOR); University of Munich; Fondazione IRCCS Istituto Nazionale Tumori Milan; Hospital Universitari Vall d'Hebron; Goethe University Frankfurt; University of Edinburgh; Geelong Hospital; Karolinska Institutet; Weston Park Hospital; Christie NHS Foundation Trust; Christie Hospital; Technical University of Munich; University of Cologne; British Columbia Cancer Agency; University of Sydney; University of Oslo; Complejo Hospitalario de Jaen	Smith, I (corresponding author), Royal Marsden Hosp, Breast Unit, Fulham Rd, London SW3 6JJ, England.	ian.smith@rmh.nhs.uk	Wardley, Andrew/N-8135-2015; Mariani, Gabriella/J-4223-2017; Mallmann, Peter/B-1220-2010; Cameron, David A/C-7781-2013; Coleman, Robert/E-4346-2019; Wardley, Andrew Michael/GLU-5636-2022	Wardley, Andrew/0000-0002-9639-0888; Mariani, Gabriella/0000-0001-7733-3143; Cameron, David A/0000-0002-2717-7979; Wardley, Andrew Michael/0000-0002-9639-0888; Bergh, Jonas/0000-0001-5526-1847				Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; [Anonymous], 2005, LANCET, V366, P1673; Baselga J, 2005, J CLIN ONCOL, V23, P2162, DOI 10.1200/JCO.2005.01.014; Baum M, 2002, LANCET, V359, P2131; BAUM M, 1983, LANCET, V2, P450; BONADONNA G, 1976, NEW ENGL J MED, V294, P405, DOI 10.1056/NEJM197602192940801; Coombes RC, 2004, NEW ENGL J MED, V350, P1081, DOI 10.1056/NEJMoa040331; Gschwind A, 2004, NAT REV CANCER, V4, P361, DOI 10.1038/nrc1360; Guarneri V, 2006, J CLIN ONCOL, V24, P4107, DOI 10.1200/JCO.2005.04.9551; *HERA STUD TEAM, 2005, 28 ANN SAN ANT BREAS; Hortobagyi GN, 2005, NEW ENGL J MED, V353, P1734, DOI 10.1056/NEJMe058196; Joensuu H, 2006, NEW ENGL J MED, V354, P809, DOI 10.1056/NEJMoa053028; Marty M, 2005, J CLIN ONCOL, V23, P4265, DOI 10.1200/JCO.2005.04.173; PEREZ E, 2005, 41 ANN M AM SOC CLIN; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; SLAMON D, 2005, 28 ANN SAN ANT BREAS; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Tan-Chiu E, 2005, J CLIN ONCOL, V23, P7811, DOI 10.1200/JCO.2005.02.4091; Thurlimann B, 2005, NEW ENGL J MED, V353, P2747; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719	23	1147	1217	1	88	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 6	2007	369	9555					29	36		10.1016/S0140-6736(07)60028-2	http://dx.doi.org/10.1016/S0140-6736(07)60028-2			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125AK	17208639				2022-12-28	WOS:000243413700026
J	Armakolas, A; Klar, AJS				Armakolas, Athanasios; Klar, Amar J. S.			Left-right dynein motor implicated in selective chromatid segregation in mouse cells	SCIENCE			English	Article							MOUSE-CHROMOSOME-7 DNA STRANDS; LEFT-RIGHT ASYMMETRY	During cell division, copies of mouse chromosome 7 are segregated selectively or randomly to daughter cells depending on the cell type. The mechanism for differential segregation is unknown. Because mouse left-right dynein (LRD) gene mutations result in randomization of visceral organs' laterality, we hypothesized that LRD may also function in selective chromatid segregation. Indeed, upon knock-down by RNA interference methods, LRD depletion disrupts biased segregation. LRD messenger RNA presence or absence correlates with the observed segregation patterns. This work supports the claim that LRD functions in a mechanism for selective chromatid segregation.	NCI, Gene Regulat & Chromosome Biol Lab, Ctr Canc Res, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Klar, AJS (corresponding author), NCI, Gene Regulat & Chromosome Biol Lab, Ctr Canc Res, POB B, Frederick, MD 21702 USA.	klar@ncifcrf.gov			Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [ZIABC010386, Z01BC010386] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Armakolas A, 2006, SCIENCE, V311, P1146, DOI 10.1126/science.1120519; Haber JE, 2006, SCIENCE, V313, DOI 10.1126/science.1127836; Hummel K. P., 1959, Journal of Heredity, V50, P9; Klar AJS, 2004, GENETICS, V167, P1833, DOI 10.1534/genetics.104.028217; KLAR AJS, 1994, TRENDS GENET, V10, P392, DOI 10.1016/0168-9525(94)90055-8; Klar AJS, 2006, SCIENCE, V313, DOI 10.1126/science.1128552; Liu PT, 2002, NAT GENET, V30, P66, DOI 10.1038/ng788; MESELSON M, 1958, P NATL ACAD SCI USA, V44, P671, DOI 10.1073/pnas.44.7.671; Supp DM, 1997, NATURE, V389, P963, DOI 10.1038/40140; Tabin C, 2005, J MOL HISTOL, V36, P317, DOI 10.1007/s10735-005-9000-y; WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0	11	60	60	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 5	2007	315	5808					100	101		10.1126/science.1129429	http://dx.doi.org/10.1126/science.1129429			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	122WU	17204651				2022-12-28	WOS:000243259100045
J	Waxman, E				Waxman, Eli			Neutrino astrophysics: A new tool for exploring the universe	SCIENCE			English	Editorial Material							MASSES	In the past four decades a new type of astronomy has emerged, where instead of looking up into the sky, "telescopes" are buried miles underground or deep under water or ice and search not for photons ( that is, light), but rather for particles called neutrinos. Neutrinos are nearly massless particles that interact very weakly with matter. The detection of neutrinos emitted by the Sun and by a nearby supernova provided direct tests of the theory of stellar evolution and led to modifications of the standard model describing the properties of elementary particles. At present, several very large neutrino detectors are being constructed, aiming at the detection of the most powerful sources of energy and particles in the universe. The hope is that the detection of neutrinos from these sources, which are extra-Galactic and are most likely powered by mass accretion onto black holes, will not only allow study of the sources, but, much like solar neutrinos, will also provide new information about fundamental properties of matter.	Weizmann Inst Sci, Fac Phys, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Waxman, E (corresponding author), Weizmann Inst Sci, Fac Phys, IL-76100 Rehovot, Israel.	waxman@wicc.weizmann.ac.il	WAXMAN, ELI/K-1557-2012					Bahcall J N, 1989, NEUTRINO ASTROPHYSIC; Bilenky SM, 2005, PHYS SCRIPTA, VT121, P17, DOI 10.1088/0031-8949/2005/T121/001; Elgaroy O, 2005, NEW J PHYS, V7, DOI 10.1088/1367-2630/7/1/061; Halzen F, 2007, SCIENCE, V315, P66, DOI 10.1126/science.1136504; Lindner M, 2005, PHYS SCRIPTA, VT121, P78, DOI 10.1088/0031-8949/2005/T121/011; Sadoulet B, 2007, SCIENCE, V315, P61, DOI 10.1126/science.1136639; Waxman E, 2005, PHYS SCRIPTA, VT121, P147, DOI 10.1088/0031-8949/2005/T121/022; Weinheimer C, 2005, PHYS SCRIPTA, VT121, P166, DOI 10.1088/0031-8949/2005/T121/026; Winter W, 2006, PHYS REV D, V74, DOI 10.1103/PhysRevD.74.033015; Yanagida T, 2005, PHYS SCRIPTA, VT121, P137, DOI 10.1088/0031-8949/2005/T121/020	11	11	11	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 5	2007	315	5808					63	65		10.1126/science.1136638	http://dx.doi.org/10.1126/science.1136638			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	122WU	17204639	Green Submitted			2022-12-28	WOS:000243259100032
J	Zheng, Y; Josefowicz, SZ; Kas, A; Chu, TT; Gavin, MA; Rudensky, AY				Zheng, Ye; Josefowicz, Steven Z.; Kas, Arnold; Chu, Tin-Tin; Gavin, Marc A.; Rudensky, Alexander Y.			Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells	NATURE			English	Article							TRANSCRIPTION FACTOR FOXP3; PHOSPHORYLATION; OCCUPANCY; LYMPHOMAS; BINDING; MICE; RNA	Transcription factor Foxp3 ( forkhead box P3), restricted in its expression to a specialized regulatory CD4(+) T-cell subset (T-R) with a dedicated suppressor function, controls T-R lineage development. In humans and mice, Foxp3 deficiency results in a paucity of T-R cells and a fatal breach in immunological tolerance, causing highly aggressive multi-organ autoimmune pathology(1-3). Here, through genome-wide analysis combining chromatin immunoprecipitation with mouse genome tiling array profiling, we identify Foxp3 binding regions for 700 genes and for an intergenically encoded microRNA. We find that a large number of Foxp3-bound genes are up-or downregulated in Foxp3(+) T cells, suggesting that Foxp3 acts as both a transcriptional activator and repressor. Foxp3-mediated regulation unique to the thymus affects, among others, genes encoding nuclear factors that control gene expression and chromatin remodelling. In contrast, Foxp3 target genes shared by the thymic and peripheral T-R cells encode primarily plasma membrane proteins, as well as cell signalling proteins. Together, our studies suggest that distinct transcriptional sub-programmes implemented by Foxp3 establish T-R lineage during differentiation and its proliferative and functional competence in the periphery.	Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA; Univ Washington, Dept Immunol, Seattle, WA 98195 USA	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Rudensky, AY (corresponding author), Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA.	aruden@u.washington.edu	Zheng, Ye/G-4866-2015; Josefowicz, Steven Z/B-8716-2011	Zheng, Ye/0000-0001-5012-4309; josefowicz, steven/0000-0001-7453-779X				Beima KM, 2006, J BIOL CHEM, V281, P11992, DOI 10.1074/jbc.M513613200; Chen CX, 2006, J BIOL CHEM, V281, P36828, DOI 10.1074/jbc.M608848200; Cobb BS, 2006, J EXP MED, V203, P2519, DOI 10.1084/jem.20061692; Costinean S, 2006, P NATL ACAD SCI USA, V103, P7024, DOI 10.1073/pnas.0602266103; Couronne O, 2003, GENOME RES, V13, P73, DOI 10.1101/gr.762503; Eis PS, 2005, P NATL ACAD SCI USA, V102, P3627, DOI 10.1073/pnas.0500613102; Fontenot JD, 2005, NAT IMMUNOL, V6, P331, DOI 10.1038/ni1179; Fontenot JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; Gavin MA, 2002, NAT IMMUNOL, V3, P33, DOI 10.1038/ni743; GAVIN MA, IN PRESS NATURE; Johnson WE, 2006, P NATL ACAD SCI USA, V103, P12457, DOI 10.1073/pnas.0601180103; Michael LF, 2000, MOL CELL BIOL, V20, P1596, DOI 10.1128/MCB.20.5.1596-1603.2000; Sakaguchi S, 2006, IMMUNOL REV, V212, P8, DOI 10.1111/j.0105-2896.2006.00427.x; Tam W, 2002, J VIROL, V76, P4275, DOI 10.1128/JVI.76.9.4275-4286.2002; Wu YQ, 2006, CELL, V126, P375, DOI 10.1016/j.cell.2006.05.042; Zhang XM, 2005, P NATL ACAD SCI USA, V102, P4459, DOI 10.1073/pnas.0501076102; Ziegler SF, 2006, ANNU REV IMMUNOL, V24, P209, DOI 10.1146/annurev.immunol.24.021605.090547	18	651	694	2	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 22	2007	445	7130					936	940		10.1038/nature05563	http://dx.doi.org/10.1038/nature05563			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	138CR	17237761				2022-12-28	WOS:000244341200054
J	Grabe, M; Lai, HC; Jain, M; Jan, YN; Jan, LY				Grabe, Michael; Lai, Helen C.; Jain, Monika; Jan, Yuh Nung; Jan, Lily Yeh			Structure prediction for the down state of a potassium channel voltage sensor	NATURE			English	Article							DEPENDENT K+ CHANNEL; GATING-CHARGE; PORE DOMAIN; MOLECULAR-MOVEMENT; CRYSTAL-STRUCTURE; S4; DISPLACEMENT; KAT1	Voltage-gated potassium (Kv) channels, essential for regulating potassium uptake and cell volume in plants and electrical excitability in animals, switch between conducting and non-conducting states as a result of conformational changes in the four voltage-sensing domains (VSDs) that surround the channel pore(1\). This process, known as gating, is initiated by a cluster of positively charged residues on the fourth transmembrane segment (S4) of each VSD, which drives the VSD into a 'down state' at negative voltages and an 'up state' at more positive voltages(2). The crystal structure of Kv1.2 probably corresponds to the up state(3), but the local environment of S4 in the down state and its motion in voltage gating remains unresolved(4-6). Here we employed several conditional lethal/second-site suppressor yeast screens to determine the transmembrane packing of the VSD in the down state. This screen relies on the ability of KAT1, a eukaryotic Kv channel, to conduct potassium when its VSDs are in the down state, thereby rescuing potassium-transport-deficient yeast(7). Starting with KAT1 channels bearing conditional lethal mutations, we identified second-site suppressor mutations throughout the VSD that recover yeast growth. We then constructed a down state model of the channel using six pairs of interacting residues as structural constraints and verified this model by engineering suppressor mutations on the basis of spatial considerations. A comparison of this down state model with the up state Kv1.2 structure suggests that the VSDs undergo large rearrangements during gating, whereas the S4 segment remains positioned between the central pore and the remainder of the VSD in both states.	Univ Calif San Francisco, Howard Hughes Med Inst, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Biochem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Grad Grp Biophys, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Jan, LY (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, Dept Physiol, San Francisco, CA 94143 USA.	lily.jan@ucsf.edu	Grabe, Michael/B-3705-2009	Lai, Helen/0000-0003-4334-0243; Jan, Lily/0000-0003-3938-8498				ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; Baker OS, 1998, NEURON, V20, P1283, DOI 10.1016/S0896-6273(00)80507-3; Broomand A, 2003, J GEN PHYSIOL, V122, P741, DOI 10.1085/jgp.200308927; CATTERALL WA, 1986, ANNU REV BIOCHEM, V55, P953, DOI 10.1146/annurev.biochem.55.1.953; Gandhi CS, 2003, NEURON, V40, P515, DOI 10.1016/S0896-6273(03)00646-9; Grabe M, 2004, P NATL ACAD SCI USA, V101, P17640, DOI 10.1073/pnas.0408116101; GUY HR, 1986, P NATL ACAD SCI USA, V83, P508, DOI 10.1073/pnas.83.2.508; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; Jiang YX, 2003, NATURE, V423, P42, DOI 10.1038/nature01581; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Kale L, 1999, J COMPUT PHYS, V151, P283, DOI 10.1006/jcph.1999.6201; Kuo AL, 2003, SCIENCE, V300, P1922, DOI 10.1126/science.1085028; Lai HC, 2005, NEURON, V47, P395, DOI 10.1016/j.neuron.2005.06.019; Laine M, 2003, NEURON, V39, P467, DOI 10.1016/S0896-6273(03)00468-9; Latorre R, 2003, J GEN PHYSIOL, V122, P459, DOI 10.1085/jgp.200308818; Li-Smerin YY, 2000, NEURON, V25, P411, DOI 10.1016/S0896-6273(00)80904-6; Long SB, 2005, SCIENCE, V309, P897, DOI 10.1126/science.1116269; Long SB, 2005, SCIENCE, V309, P903, DOI 10.1126/science.1116270; Minor DL, 1999, CELL, V96, P879, DOI 10.1016/S0092-8674(00)80597-8; Neale EJ, 2003, J BIOL CHEM, V278, P29079, DOI 10.1074/jbc.M301991200/6493; Posson DJ, 2005, NATURE, V436, P848, DOI 10.1038/nature03819; Ruta V, 2005, CELL, V123, P463, DOI 10.1016/j.cell.2005.08.041; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SCHOPPA NE, 1992, SCIENCE, V255, P1712, DOI 10.1126/science.1553560; SCHREIBER G, 1995, J MOL BIOL, V248, P478, DOI 10.1006/jmbi.1995.0235; Serrano R, 2001, CURR OPIN CELL BIOL, V13, P399, DOI 10.1016/S0955-0674(00)00227-1; Starace DM, 2004, NATURE, V427, P548, DOI 10.1038/nature02270; Tombola F, 2005, NEURON, V45, P379, DOI 10.1016/j.neuron.2004.12.047	28	62	63	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 1	2007	445	7127					550	553		10.1038/nature05494	http://dx.doi.org/10.1038/nature05494			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	131KI	17187053				2022-12-28	WOS:000243867300046
J	Huang, DT; Hunt, HW; Zhuang, M; Ohi, MD; Holton, JM; Schulman, BA				Huang, Danny T.; Hunt, Harold W.; Zhuang, Min; Ohi, Melanie D.; Holton, James M.; Schulman, Brenda A.			Basis for a ubiquitin-like protein thioester switch toggling E1-E2 affinity	NATURE			English	Article							ACTIVATING ENZYME; CRYSTAL-STRUCTURE; MECHANISM; BINDING; E1; NEDD8; CONJUGATION; INSIGHTS; COMPLEX; SYSTEM	Ubiquitin-like proteins (UBLs) are conjugated by dynamic E1-E2-E3 enzyme cascades. E1 enzymes activate UBLs by catalysing UBL carboxy-terminal adenylation, forming a covalent E1, UBL thioester intermediate, and generating a thioester-linked E2 similar to UBL product, which must be released for subsequent reactions. Here we report the structural analysis of a trapped UBL activation complex for the human NEDD8 pathway, containing NEDD8's heterodimeric E1 (APPBP1-UBA3), two NEDD8s ( one thioester-linked to E1, one noncovalently associated for adenylation), a catalytically inactive E2 (Ubc12), and MgATP. The results suggest that a thioester switch toggles E1 - E2 affinities. Two E2 binding sites depend on NEDD8 being thioester-linked to E1. One is unmasked by a striking E1 conformational change. The other comes directly from the thioester-bound NEDD8. After NEDD8 transfer to E2, reversion to an alternate E1 conformation would facilitate release of the E2, NEDD8 thioester product. Thus, transferring the UBL's thioester linkage between successive conjugation enzymes can induce conformational changes and alter interaction networks to drive consecutive steps in UBL cascades.	St Jude Childrens Hosp, Howard Hughes Med Inst, Memphis, TN 38105 USA; St Jude Childrens Hosp, Dept Struct Biol & Genet, Memphis, TN 38105 USA; St Jude Childrens Hosp, Dept Tumor Cell Biol, Memphis, TN 38105 USA; Univ Tennessee, Ctr Hlth Sci, Interdisciplinary Program, Memphis, TN 38163 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Phys Biosci Div, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; Harvard University; Harvard Medical School; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Schulman, BA (corresponding author), St Jude Childrens Hosp, Howard Hughes Med Inst, 332 N Lauderdale St, Memphis, TN 38105 USA.	brenda.schulman@stjude.org	Huang, Danny/AAM-3631-2021	Huang, Danny/0000-0002-6192-259X	Howard Hughes Medical Institute Funding Source: Medline; NCI NIH HHS [P30 CA021765, P30 CA021765-31] Funding Source: Medline; NIGMS NIH HHS [R01 GM069530, R01 GM077053-02, R01 GM077053, R01 GM069530-04] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM077053, R01GM069530] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bencsath KP, 2002, J BIOL CHEM, V277, P47938, DOI 10.1074/jbc.M207442200; Bohnsack RN, 2003, J BIOL CHEM, V278, P26823, DOI 10.1074/jbc.M303177200; Brzovic PS, 2006, MOL CELL, V21, P873, DOI 10.1016/j.molcel.2006.02.008; CIECHANOVER A, 1982, J BIOL CHEM, V257, P2537; Eletr ZM, 2005, NAT STRUCT MOL BIOL, V12, P933, DOI 10.1038/nsmb984; HAAS AL, 1982, J BIOL CHEM, V257, P2543; HAAS AL, 1982, J BIOL CHEM, V257, P329; HAAS AL, 1988, J BIOL CHEM, V263, P13268; Hamilton KS, 2001, STRUCTURE, V9, P897, DOI 10.1016/S0969-2126(01)00657-8; Harper JW, 2006, CELL, V124, P1133, DOI 10.1016/j.cell.2006.03.009; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 2005, NAT REV MOL CELL BIO, V6, P610, DOI 10.1038/nrm1701; Hicke L, 2001, CELL, V106, P527, DOI 10.1016/S0092-8674(01)00485-8; Hochstrasser M, 2000, SCIENCE, V289, P563, DOI 10.1126/science.289.5479.563; Hochstrasser M, 2006, CELL, V124, P27, DOI 10.1016/j.cell.2005.12.025; Huang DT, 2005, MOL CELL, V17, P341, DOI 10.1016/j.molcel.2004.12.020; Huang DT, 2004, NAT STRUCT MOL BIOL, V11, P927, DOI 10.1038/nsmb826; Hurley JH, 2006, ANNU REV BIOPH BIOM, V35, P277, DOI 10.1146/annurev.biophys.35.040405.102126; Kerscher O, 2006, ANNU REV CELL DEV BI, V22, P159, DOI 10.1146/annurev.cellbio.22.010605.093503; Lois LM, 2005, EMBO J, V24, P439, DOI 10.1038/sj.emboj.7600552; Miura T, 1999, J MOL BIOL, V290, P213, DOI 10.1006/jmbi.1999.2859; Morita E, 2004, ANNU REV CELL DEV BI, V20, P395, DOI 10.1146/annurev.cellbio.20.010403.102350; Osaka F, 1998, GENE DEV, V12, P2263, DOI 10.1101/gad.12.15.2263; PICKART CM, 1985, J BIOL CHEM, V260, P1573; Pickart CM, 2004, BBA-MOL CELL RES, V1695, P55, DOI 10.1016/j.bbamcr.2004.09.019; PICKART CM, 1994, J BIOL CHEM, V269, P7115; Reverter D, 2005, NATURE, V435, P687, DOI 10.1038/nature03588; Szczepanowski RH, 2005, J BIOL CHEM, V280, P22006, DOI 10.1074/jbc.M502583200; Tokgoz Z, 2006, J BIOL CHEM, V281, P14729, DOI 10.1074/jbc.M513562200; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6; Walden H, 2003, MOL CELL, V12, P1427, DOI 10.1016/S1097-2765(03)00452-0; Walden H, 2003, NATURE, V422, P330, DOI 10.1038/nature01456; Whitby FG, 1998, J BIOL CHEM, V273, P34983, DOI 10.1074/jbc.273.52.34983	34	164	167	1	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 25	2007	445	7126					394	398		10.1038/nature05490	http://dx.doi.org/10.1038/nature05490			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	128WD	17220875	Green Accepted			2022-12-28	WOS:000243689500031
J	Elliott, WJ; Meyer, PM				Elliott, William J.; Meyer, Peter M.			Incident diabetes in clinical trials of anti hypertensive drugs: a network meta-analysis	LANCET			English	Article							ISOLATED SYSTOLIC HYPERTENSION; CONVERTING ENZYME-INHIBITORS; CHRONIC HEART-FAILURE; END-POINT REDUCTION; ANTIHYPERTENSIVE DRUGS; CARDIOVASCULAR MORBIDITY; RANDOMIZED-TRIAL; LONG-TERM; LOSARTAN INTERVENTION; GLUCOSE-TOLERANCE	Background The effect of different classes of antihypertensive drugs on incident diabetes mellitus is controversial because traditional meta-analyses are hindered by heterogeneity across trials and the absence of trials comparing angiotensin-converting-enzyme (ACE) inhibitors with angiotensin-receptor blockers (ARB). We therefore undertook a network meta-analysis, which accounts for both direct and indirect comparisons to assess the effects of antihypertensive agents on incident diabetes. Methods We undertook a systematic review up to Sept 15, 2006, and identified 48 randomised groups of 22 clinical trials with 143 153 participants who did not have diabetes at randomisation and so were eligible for inclusion in our analysis. 17 trials enrolled patients with hypertension, three enrolled high-risk patients, and one enrolled those with heart failure. The main outcome was the proportion of patients who developed diabetes. Findings Intitial drug therapy used in the trials (and the number of patients with diabetes of the total number at risk) included: an ARB (1189 of 14185, or 8.38%), ACE inhibitor (1618 of 22941, or 7.05%), calcium-channel blocker (CCB, 2791 of 38 607, or 7.23%), placebo (1686 of 24 767, or 6.81%), beta blocker (2705 of 35 745, or 7.57%), or diuretic (998 of 18 699, or 5.34%). With an initial diuretic as the standard of comparison (eight groups), the degree of incoherence (a measure of how closely the entire network fits together) was small (omega=0.000017, eight degrees of freedom). The odds ratios were: ARB (five groups) 0.57 (95% CI 0.46-0.72, p<0.0001); ACE inhibitor (eight groups) 0.67 (0.56-0.80, p<0.0001); CCB (nine groups): 0.75 (0.62-0.90, p=0.002); placebo (nine groups) 0.77 (0.63-0.94, p = 0.009); beta blocker (nine groups) 0.90 (0.75-1.09, p=0.30). These estimates changed little in many sensitivity analyses. Interpretation The association of antihypertensive drugs with incident diabetes is therefore lowest for ARB and ACE inhibitors followed by CCB and placebo, beta blockers and diuretics in rank order.	Rush Univ, Rush Med Coll, Med Ctr, Dept Prevent Med, Chicago, IL 60612 USA	Rush University	Elliott, WJ (corresponding author), Rush Univ, Rush Med Coll, Med Ctr, Dept Prevent Med, Chicago, IL 60612 USA.	welliott@rush.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K25HL068139] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abuissa H, 2005, J AM COLL CARDIOL, V46, P821, DOI 10.1016/j.jacc.2005.05.051; Amer Diabet Assoc, 2013, DIABETES CARE, V36, pS67, DOI [10.2337/dc10-S062, 10.2337/dc13-S067, 10.2337/dc12-s064, 10.2337/dc11-S062]; Appel LJ, 2002, JAMA-J AM MED ASSOC, V288, P3039, DOI 10.1001/jama.288.23.3039; Bakris G, 2006, DIABETES CARE, V29, P2592, DOI 10.2337/dc06-1373; Bakris GL, 2004, JAMA-J AM MED ASSOC, V292, P2227, DOI 10.1001/jama.292.18.2227; BENGTSSON C, 1984, BMJ-BRIT MED J, V289, P1495, DOI 10.1136/bmj.289.6457.1495; Bosch J, 2005, CIRCULATION, V112, P1339, DOI 10.1161/CIRCULATIONAHA.105.548461; Bosch J, 2006, NEW ENGL J MED, V355, P1551; Braunwald E, 2004, NEW ENGL J MED, V351, P2058; Brown MJ, 2000, LANCET, V356, P366, DOI 10.1016/S0140-6736(00)02527-7; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Dahlof B, 2002, LANCET, V359, P995, DOI 10.1016/S0140-6736(02)08089-3; Dahlof B, 2005, LANCET, V366, P895, DOI 10.1016/S0140-6736(05)67185-1; Elliott WJ, 2005, CURR HYPERTENS REP, V7, P249, DOI 10.1007/s11906-005-0021-4; FLETCHER A, 1991, J HYPERTENS, V9, P225, DOI 10.1097/00004872-199103000-00005; Gillespie EL, 2005, DIABETES CARE, V28, P2261, DOI 10.2337/diacare.28.9.2261; GOLDNER MG, 1960, NEW ENGL J MED, V262, P403, DOI 10.1056/NEJM196002252620807; Gress TW, 2000, NEW ENGL J MED, V342, P905, DOI 10.1056/NEJM200003303421301; GURWITZ JH, 1993, ANN INTERN MED, V118, P273, DOI 10.7326/0003-4819-118-4-199302150-00005; Hansson L, 2000, LANCET, V356, P359, DOI 10.1016/S0140-6736(00)02526-5; Hansson L, 1999, LANCET, V353, P611, DOI 10.1016/S0140-6736(98)05012-0; Hansson L, 1999, LANCET, V354, P1751, DOI 10.1016/S0140-6736(99)10327-1; HOLLIS HC, 1961, JAMA-J AM MED ASSOC, V176, P947; Jandeleit-Dahm KAM, 2005, J HYPERTENS, V23, P463, DOI 10.1097/01.hjh.0000160198.05416.72; Julius S, 2006, NEW ENGL J MED, V354, P1685, DOI 10.1056/NEJMoa060838; Julius S, 2004, LANCET, V363, P2022, DOI 10.1016/S0140-6736(04)16451-9; Kostis JB, 2005, AM J CARDIOL, V95, P29, DOI 10.1016/j.amjcard.2004.08.059; Kurtz TW, 2004, J HYPERTENS, V22, P2253, DOI 10.1097/00004872-200412000-00003; Lindholm LH, 2002, J HYPERTENS, V20, P1879, DOI 10.1097/00004872-200209000-00035; Lindholm LH, 2003, J HYPERTENS, V21, P1563, DOI 10.1097/00004872-200308000-00022; Lithell H, 2003, J HYPERTENS, V21, P875, DOI 10.1097/00004872-200305000-00011; Liu LS, 2005, J HYPERTENS, V23, P2157, DOI 10.1097/01.hjh.0000194120.42722.ac; Lumley T, 2002, STAT MED, V21, P2313, DOI 10.1002/sim.1201; Luna B, 2001, JAMA-J AM MED ASSOC, V286, P1945, DOI 10.1001/jama.286.16.1945; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; *NAT I HLTH CLIN E, 2006, HYP MAN HYP AD PRIM, V18; Opie LH, 2004, J HYPERTENS, V22, P1453, DOI 10.1097/01.hjh.0000133732.24501.9e; Padwal R, 2005, DIABETES CARE, V28, P736, DOI 10.2337/diacare.28.3.736; Padwal R, 2004, DIABETES CARE, V27, P247, DOI 10.2337/diacare.27.1.247; Pepine CJ, 2003, JAMA-J AM MED ASSOC, V290, P2805, DOI 10.1001/jama.290.21.2805; Pfeffer MA, 2003, LANCET, V362, P759, DOI 10.1016/S0140-6736(03)14282-1; POLLARE T, 1989, NEW ENGL J MED, V321, P868, DOI 10.1056/NEJM198909283211305; Prisant LM, 2004, J CLIN PHARMACOL, V44, P406, DOI 10.1177/0091270004263018; Psaty BM, 2006, JAMA-J AM MED ASSOC, V295, P1704, DOI 10.1001/jama.295.14.1704; Psaty BN, 2003, JAMA-J AM MED ASSOC, V289, P2534, DOI 10.1001/jama.289.19.2534; Qiao Q, 2003, DIABETES CARE, V26, P2910, DOI 10.2337/diacare.26.10.2910; SAMAAN N, 1963, LANCET, V2, P1244; Savage PJ, 1998, ARCH INTERN MED, V158, P741, DOI 10.1001/archinte.158.7.741; Scheen AJ, 2004, DIABETES METAB, V30, P487, DOI 10.1016/S1262-3636(07)70146-5; Scheen AJ, 2004, DRUGS, V64, P2537, DOI 10.2165/00003495-200464220-00004; Taylor EN, 2006, DIABETES CARE, V29, P1065, DOI 10.2337/dc05-2366; Teo KK, 2004, AM HEART J, V148, P52, DOI 10.1016/j.ahj.2004.03.020; The AO, 2002, JAMA-J AM MED ASSOC, V288, P2981, DOI DOI 10.1001/JAMA.288.23.2981; Thornley-Brown D, 2006, ARCH INTERN MED, V166, P797, DOI 10.1001/archinte.166.7.797; Verdecchia P, 2004, HYPERTENSION, V43, P963, DOI 10.1161/01.HYP.0000125726.92964.ab; Vermes E, 2003, CIRCULATION, V107, P1291, DOI 10.1161/01.CIR.0000054611.89228.92; WILHELMSEN L, 1987, J HYPERTENS, V5, P561, DOI 10.1097/00004872-198710000-00009; WILKINS RW, 1959, ANN INTERN MED, V50, P1, DOI 10.7326/0003-4819-50-1-1; Yusuf S, 2005, CIRCULATION, V112, P48, DOI 10.1161/CIRCULATIONAHA.104.528166; Yusuf S, 2001, JAMA-J AM MED ASSOC, V286, P1882, DOI 10.1001/jama.286.15.1882	60	702	753	3	57	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 20	2007	369	9557					201	207		10.1016/S0140-6736(07)60108-1	http://dx.doi.org/10.1016/S0140-6736(07)60108-1			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128XG	17240286				2022-12-28	WOS:000243692400028
J	Gourlay, CM; Dahle, AK				Gourlay, C. M.; Dahle, A. K.			Dilatant shear bands in solidifying metals	NATURE			English	Article							ALUMINUM-ALLOYS; SEMISOLID STATE; MUSHY ZONE; BEHAVIOR; SAND; DEFORMATION; FAILURE; STRAIN; SOLIDIFICATION; THICKNESS	Compacted granular materials expand in response to shear(1), and can exhibit different behaviour from that of the solids, liquids and gases of which they are composed. Application of the physics of granular materials has increased the understanding of avalanches(2), geological faults 3,4, flow in hoppers and silos 5, and soil mechanics(6,7). During the equiaxed solidification of metallic alloys, there exists a range of solid fractions where the microstructure consists of a geometrically crowded disordered assembly of crystals saturated with liquid. It is therefore natural to ask if such a microstructure deforms as a granular material and what relevance this might have to solidification processing. Here we show that partially solidified alloys can exhibit the characteristics of a cohesionless granular material, including Reynolds' dilatancy(1) and strain localization in dilatant shear bands 7 - 18 mean crystals wide. We show that this behaviour is important in defect formation during high pressure die casting of Al and Mg alloys, a global industry that contributes over $7.3 billion to the USA's economy alone(8) and is used in the manufacture of products that include mobile-phone covers and steering wheels. More broadly, these findings highlight the potential to apply the principles and modelling approaches developed in granular mechanics to the field of solidification processing, and also indicate the possible benefits that might be gained from exploring and exploiting further synergies between these fields.	Univ Queensland, CAST CRC, Brisbane, Qld 4072, Australia; Univ Queensland, Australian Res Council CoE Design Light Met Mat E, Brisbane, Qld 4072, Australia	University of Queensland; University of Queensland	Gourlay, CM (corresponding author), Univ Queensland, CAST CRC, Brisbane, Qld 4072, Australia.	c.gourlay@minmet.uq.edu.au; a.dahle@minmet.uq.edu.au	Gourlay, Christopher M/D-9584-2011	Gourlay, Christopher M/0000-0002-4588-6007				Alshibli KA, 1999, J COMPUT CIVIL ENG, V13, P103, DOI 10.1061/(ASCE)0887-3801(1999)13:2(103); [Anonymous], 1998, FUNDAMENTALS SOLIDIF; [Anonymous], 2005, SHAPING AM FUTURE; ARNBERG L, 1993, MAT SCI ENG A-STRUCT, V173, P101, DOI 10.1016/0921-5093(93)90195-K; BRIDGWATER J, 1980, GEOTECHNIQUE, V30, P533, DOI 10.1680/geot.1980.30.4.533; Daerr A, 1999, NATURE, V399, P241, DOI 10.1038/20392; Dahle AK, 1997, ACTA MATER, V45, P547, DOI 10.1016/S1359-6454(96)00203-0; Desrues J, 2004, INT J NUMER ANAL MET, V28, P279, DOI 10.1002/nag.338; DURAN J, 2000, SANDS POWDERS GRAINS; Eskin DG, 2004, PROG MATER SCI, V49, P629, DOI 10.1016/S0079-6425(03)00037-9; FLEMINGS MC, 1991, METALL TRANS A, V22, P957, DOI 10.1007/BF02661090; MARONE C, 1993, NATURE, V362, P618, DOI 10.1038/362618a0; Martin CL, 2002, MAT SCI ENG A-STRUCT, V325, P292, DOI 10.1016/S0921-5093(01)01528-3; MARTIN CL, 1994, ACTA METALL MATER, V42, P3603, DOI 10.1016/0956-7151(94)90427-8; Martin CL, 1997, INT J PLASTICITY, V13, P215, DOI 10.1016/S0749-6419(97)00009-0; Metz S.A., 1969, AFS T, V77, P329; MUHLHAUS HB, 1987, GEOTECHNIQUE, V37, P271; Nemat-Nasser S, 2001, GEOTECHNIQUE, V51, P753, DOI 10.1680/geot.51.9.753.41039; Oda M, 1998, GEOTECHNIQUE, V48, P465, DOI 10.1680/geot.1998.48.4.465; Rappaz M, 2003, METALL MATER TRANS A, V34, P467, DOI 10.1007/s11661-003-0083-3; Reynolds O., 1885, PHILOS MAG, V20, P469, DOI [10.1080/14786448508627791, DOI 10.1080/14786448508627791]; ROSCOE KH, 1970, GEOTECHNIQUE, V20, P129, DOI 10.1680/geot.1970.20.2.129; Scott DR, 1996, NATURE, V381, P592, DOI 10.1038/381592a0; Stangeland A, 2004, METALL MATER TRANS A, V35A, P2903, DOI 10.1007/s11661-004-0238-x; STEPHENS DJ, 1978, POWDER TECHNOL, V21, P17, DOI 10.1016/0032-5910(78)80104-1; Sumitomo T, 2000, MAT SCI ENG A-STRUCT, V289, P18, DOI 10.1016/S0921-5093(00)00936-9; Terzaghi K., 1943, THEORETICAL SOIL MEC; Vardoulakis I, 1996, GEOTECHNIQUE, V46, P457, DOI 10.1680/geot.1996.46.3.457; Wong RCK, 2000, GEOTECH TEST J, V23, P158; Wood DM, 2002, INT J SOLIDS STRUCT, V39, P3429	30	169	172	6	133	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 4	2007	445	7123					70	73		10.1038/nature05426	http://dx.doi.org/10.1038/nature05426			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	122KG	17203058				2022-12-28	WOS:000243225100037
J	McCormick, DA; Shu, YS; Yu, YG				McCormick, David A.; Shu, Yousheng; Yu, Yuguo			Hodgkin and Huxley model - still standing?	NATURE			English	Letter							ACTION-POTENTIAL INITIATION; SYNAPTIC ACTIVITY; SEGMENT		Yale Univ, Sch Med, Kavli Inst Neurosci, Dept Neurobiol, New Haven, CT 06510 USA	Yale University	McCormick, DA (corresponding author), Yale Univ, Sch Med, Kavli Inst Neurosci, Dept Neurobiol, 333 Cedar St, New Haven, CT 06510 USA.	david.mccormick@yale.edu	Shu, Yousheng/AAC-3881-2020; Kobelt, Liza/F-5926-2011	Shu, Yousheng/0000-0002-2834-2876; Yu, Yuguo/0000-0003-0603-2890				Baranauskas G, 2006, J NEUROSCI, V26, P671, DOI 10.1523/JNEUROSCI.2283-05.2006; Colbert CM, 1996, J NEUROSCI, V16, P6676; Colbert CM, 2002, NAT NEUROSCI, V5, P533, DOI 10.1038/nn857; COOMBS JS, 1957, J PHYSIOL-LONDON, V139, P232, DOI 10.1113/jphysiol.1957.sp005888; Inda MC, 2006, P NATL ACAD SCI USA, V103, P2920, DOI 10.1073/pnas.0511197103; Komada M, 2002, J CELL BIOL, V156, P337, DOI 10.1083/jcb.200110003; Mainen ZF, 1996, NATURE, V382, P363, DOI 10.1038/382363a0; Naundorf B, 2006, NATURE, V440, P1060, DOI 10.1038/nature04610; Palmer LM, 2006, J NEUROSCI, V26, P1854, DOI 10.1523/JNEUROSCI.4812-05.2006; Pare D, 1998, J NEUROPHYSIOL, V79, P1450, DOI 10.1152/jn.1998.79.3.1450; Shu YS, 2007, J NEUROPHYSIOL, V97, P746, DOI 10.1152/jn.00922.2006; Shu YS, 2006, NATURE, V441, P761, DOI 10.1038/nature04720; Shu YS, 2003, J NEUROSCI, V23, P10388; Stuart G, 1997, J PHYSIOL-LONDON, V505, P617, DOI 10.1111/j.1469-7793.1997.617ba.x	14	94	96	3	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 4	2007	445	7123					E1	E2		10.1038/nature05523	http://dx.doi.org/10.1038/nature05523			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	122KG	17203021				2022-12-28	WOS:000243225100029
J	Crosas, B; Hanna, J; Kirkpatrick, DS; Zhang, DP; Tone, Y; Hathaway, NA; Buecker, C; Leggett, DS; Schmidt, M; King, RW; Gygi, SP; Finley, D				Crosas, Bernat; Hanna, John; Kirkpatrick, Donald S.; Zhang, Dan Phoebe; Tone, Yoshiko; Hathaway, Nathaniel A.; Buecker, Christa; Leggett, David S.; Schmidt, Marion; King, Randall W.; Gygi, Steven P.; Finley, Daniel			Ubiquitin chains are remodeled at the proteasome by opposing ubiquitin ligase and deubiquitinating activities	CELL			English	Article							26 S-PROTEASOME; SACCHAROMYCES-CEREVISIAE; QUANTITATIVE-ANALYSIS; CONJUGATING ENZYMES; PROTEIN COMPLEXES; DEGRADATION; SUBSTRATE; IDENTIFICATION; RECEPTORS; RAD23	The ubiquitin ligase Hul5 was recently identified as a component of the proteasome, a multisubunit protease that degrades ubiquitin-protein conjugates. We report here a proteasome-dependent conjugating activity of Hul5 that endows proteasomes with the capacity to extend ubiquitin chains. hul5 mutants show reduced degradation of multiple proteasome substrates in vivo, suggesting that the polyubiquitin signal that targets substrates to the proteasome can be productively amplified at the proteasome. However, the products of Hul5 conjugation are subject to disassembly by a proteasome-bound deubiquitinating enzyme, Ubp6. A hul5 null mutation suppresses a ubp6 null mutation, suggesting that a balance of chain-extending and chain-trimming activities is required for proper proteasome function. As the association of Hul5 with proteasomes was found to be strongly stabilized by Ubp6, these enzymes may be situated in proximity to one another. We propose that through dynamic remodeling of ubiquitin chains, proteasomes actively regulate substrate commitment to degradation.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; CSIC, Inst Biol Mol Barcelona, ES-08034 Barcelona, Spain	Harvard University; Harvard Medical School; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB)	Finley, D (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.	daniel_finley@hms.harvard.edu		King, Randall/0000-0001-7882-8180; Kirkpatrick, Donald/0000-0003-3091-2804; Buecker, Christa/0000-0003-3055-2642	NIGMS NIH HHS [GM65592, GM67945, GM66492] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067945, R01GM066492, R56GM066492, R01GM065592] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amerik AY, 2000, MOL BIOL CELL, V11, P3365, DOI 10.1091/mbc.11.10.3365; Cagney G, 2001, PHYSIOL GENOMICS, V7, P27, DOI 10.1152/physiolgenomics.2001.7.1.27; Chen L, 2002, MOL CELL BIOL, V22, P4902, DOI 10.1128/MCB.22.13.4902-4913.2002; Chuang SM, 2005, GENETICS, V171, P1477, DOI 10.1534/genetics.105.046888; Di Fiore PP, 2003, NAT REV MOL CELL BIO, V4, P491, DOI 10.1038/nrm1124; Elsasser S, 2002, NAT CELL BIOL, V4, P725, DOI 10.1038/ncb845; Elsasser S, 2005, NAT CELL BIOL, V7, P742, DOI 10.1038/ncb0805-742; Elsasser S, 2004, J BIOL CHEM, V279, P26817, DOI 10.1074/jbc.M404020200; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Gorbea C, 2000, J BIOL CHEM, V275, P875, DOI 10.1074/jbc.275.2.875; Guerrero C, 2006, MOL CELL PROTEOMICS, V5, P366, DOI 10.1074/mcp.M500303-MCP200; Hanna J, 2006, CELL, V127, P99, DOI 10.1016/j.cell.2006.07.038; Hoeller D, 2006, NAT CELL BIOL, V8, P163, DOI 10.1038/ncb1354; Ju DH, 2004, BIOCHEM BIOPH RES CO, V321, P51, DOI 10.1016/j.bbrc.2004.06.105; Kajava AV, 2002, J BIOL CHEM, V277, P49791, DOI 10.1074/jbc.M204982200; Kee Y, 2005, EMBO J, V24, P2414, DOI 10.1038/sj.emboj.7600710; Kirkpatrick DS, 2006, NAT CELL BIOL, V8, P700, DOI 10.1038/ncb1436; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Kumar S, 1999, J BIOL CHEM, V274, P18785, DOI 10.1074/jbc.274.26.18785; Leggett DS, 2002, MOL CELL, V10, P495, DOI 10.1016/S1097-2765(02)00638-X; London MK, 2004, FEBS LETT, V567, P259, DOI 10.1016/j.febslet.2004.04.078; Madura K, 2004, TRENDS BIOCHEM SCI, V29, P637, DOI 10.1016/j.tibs.2004.10.008; Meimoun A, 2000, MOL BIOL CELL, V11, P915, DOI 10.1091/mbc.11.3.915; Pickart CM, 2004, NAT REV MOL CELL BIO, V5, P177, DOI 10.1038/nrm1336; Richly H, 2005, CELL, V120, P73, DOI 10.1016/j.cell.2004.11.013; Rumpf S, 2006, MOL CELL, V21, P261, DOI 10.1016/j.molcel.2005.12.014; Saeki Y, 2002, BIOCHEM BIOPH RES CO, V296, P813, DOI 10.1016/S0006-291X(02)02002-8; Schmidt M, 2005, BIOL CHEM, V386, P725, DOI 10.1515/BC.2005.085; Seeger M, 2003, J BIOL CHEM, V278, P16791, DOI 10.1074/jbc.M208281200; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; Shih SC, 2003, EMBO J, V22, P1273, DOI 10.1093/emboj/cdg140; Stone M, 2004, J MOL BIOL, V344, P697, DOI 10.1016/j.jmb.2004.09.057; Swanson R, 2001, GENE DEV, V15, P2660, DOI 10.1101/gad.933301; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Tongaonkar P, 2000, MOL CELL BIOL, V20, P4691, DOI 10.1128/MCB.20.13.4691-4698.2000; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898; Verma R, 2004, CELL, V118, P99, DOI 10.1016/j.cell.2004.06.014; Verma R, 2000, MOL BIOL CELL, V11, P3425, DOI 10.1091/mbc.11.10.3425; Wang M, 2005, EMBO J, V24, P4324, DOI 10.1038/sj.emboj.7600895; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Xie YM, 2000, P NATL ACAD SCI USA, V97, P2497, DOI 10.1073/pnas.060025497; Xie YM, 2002, NAT CELL BIOL, V4, P1003, DOI 10.1038/ncb889; Xie YM, 2001, P NATL ACAD SCI USA, V98, P3056, DOI 10.1073/pnas.071022298; Yao TT, 2002, NATURE, V419, P403, DOI 10.1038/nature01071; You JX, 2001, J BIOL CHEM, V276, P19871, DOI 10.1074/jbc.M100034200	47	235	252	1	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 29	2006	127	7					1401	1413		10.1016/j.cell.2006.09.051	http://dx.doi.org/10.1016/j.cell.2006.09.051			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	128WI	17190603	Bronze			2022-12-28	WOS:000243690000019
J	Trelle, S; Shang, AJ; Nartey, L; Cassell, JA; Low, N				Trelle, Sven; Shang, Aijing; Nartey, Linda; Cassell, Jackie A.; Low, Nicola			Improved effectiveness of partner notification for patients with sexually transmitted infections: systematic review	BMJ-BRITISH MEDICAL JOURNAL			English	Review							CHEST-PAIN; CHLAMYDIA-TRACHOMATIS; GENERAL-PRACTICE; FOLLOW-UP; REASSURANCE; METAANALYSIS; MANAGEMENT; DIAGNOSIS	Objective To examine the effectiveness of methods to improve partner notification by patient referral (index patient has responsibility for informing sex partners of their exposure to a sexually transmitted infection). Design Systematic review of randomised trials of any intervention to supplement simple patient referral. Data sources Seven electronic databases searched (January 1990 to December 2005) without language restriction, and reference lists of retrieved articles. Review methods Selection of trials, data extraction, and quality assessment were done by two independent reviewers. The primary outcome was a reduction of incidence or prevalence of sexually transmitted infections in index patients. If this was not reported data were extracted according to a hierarchy of secondary outcomes: number of partners treated; number of partners tested or testing positive; and number of partners notified, located, or elicited. Random effects meta-analysis was carried out when appropriate. Results 14 trials were included with 12 389 women and men diagnosed as having gonorrhoea, chlamydia, non-gonococcal urethritis, trichomoniasis, or a sexually transmitted infection syndrome. All studies had methodological weaknesses that could have biased their results. Three strategies were used. Six trials examined patient delivered partner therapy. Meta-analysis of five of these showed a reduced risk of persistent or recurrent infection in patients with chlamydia or gonorrhoea (summary risk ratio 0.73, 95% confidence interval 0.57 to 0.93). Supplementing patient referral with information for partners was as effective as patient delivered partner therapy. Neither strategy was effective in women with trichomoniasis. Two trials found that providing index patients with chlamydia with sampling kits for their partners increased the number of partners who got treated. Conclusions Involving index patients in shared responsibility for the management of sexual partners improves outcomes. Health professionals should consider the following strategies for the management of individual patients: patient delivered partner therapy, home sampling for partners, and providing additional information for partners.	Univ Bern, Dept Social & Prevent Med, CH-3012 Bern, Switzerland; UCL Royal Free & Univ Coll Med Sch, Ctr Sexual Hlth & HIV Res, London, England	University of Bern; University of London; University College London; UCL Medical School	Low, N (corresponding author), Univ Bern, Dept Social & Prevent Med, Finkenhubelweg 11, CH-3012 Bern, Switzerland.	low@ispm.unibe.ch	Low, Nicola/H-4718-2019; Trelle, Sven/D-3760-2009	Low, Nicola/0000-0003-4817-8986; Trelle, Sven/0000-0002-8162-8910; Cassell, Jackie/0000-0003-0777-0385				Andersen B, 1998, FAM PRACT, V15, P223, DOI 10.1093/fampra/15.3.223; Apoola A, 2006, SEX TRANSM INFECT, V82, P327, DOI 10.1136/sti.2005.018119; Arthur G, 2005, SEX TRANSM DIS, V32, P734, DOI 10.1097/01.olq.0000175376.62297.73; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; BRUCE RA, 1983, J AM COLL CARDIOL, V2, P565, DOI 10.1016/S0735-1097(83)80286-1; Cassell JA, 2006, BMJ-BRIT MED J, V332, P332, DOI 10.1136/bmj.38726.404120.7C; Centers for Disease Control and Prevention,, 2006, EXP PARTN THER MAN S; CHANNER KS, 1987, Q J MED, V63, P315; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Donkin L, 2006, PSYCHOL HEALTH, V21, P421, DOI 10.1080/14768320500329292; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; FITZPATRICK R, 1981, J NEUROL NEUROSUR PS, V44, P1061, DOI 10.1136/jnnp.44.12.1061; Hawkes S, 2003, BRIT MED J, V327, P633, DOI 10.1136/bmj.327.7416.633; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hintze J., 2004, NCSS PASS SOFTWARE; Hogben M, 2005, SEX TRANSM DIS, V32, P101, DOI 10.1097/01.olq.0000151417.43230.18; Hogben M, 2004, SEX TRANSM INFECT, V80, P30, DOI 10.1136/sti.2003.004937; Howard LM, 1996, J PSYCHOSOM RES, V41, P307, DOI 10.1016/S0022-3999(96)00164-X; Low N, 2006, BRIT MED J, V332, P14, DOI 10.1136/bmj.38678.405370.7C; Low N, 2004, SEX TRANSM INFECT, V80, P223, DOI 10.1136/sti.2003.005165; Low N, 2006, LANCET, V368, P2001, DOI 10.1016/S0140-6736(06)69482-8; Lucock MP, 1997, BRIT MED J, V315, P572; Macke BA, 1999, AM J PREV MED, V17, P230, DOI 10.1016/S0749-3797(99)00076-8; MATHEWS C, 2001, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD002843; McDonald IG, 1996, BRIT MED J, V313, P329, DOI 10.1136/bmj.313.7053.329; Meechan GT, 2005, PSYCHO-ONCOLOGY, V14, P239, DOI 10.1002/pon.841; Moher D, 2001, ANN INTERN MED, V134, P657, DOI 10.7326/0003-4819-134-8-200104170-00011; *NAT I CLIN EXC, 2005, GUID DEV METH INF NA; Nijher GJ, 2001, BRIT MED J, V323, P1319, DOI 10.1136/bmj.323.7325.1319; OXMAN AD, 1994, CAN J PUBLIC HEALTH, V85, pS41; POTTS SG, 1995, PSYCHOL MED, V25, P339, DOI 10.1017/S0033291700036242; Sanders D, 1997, PSYCHOL MED, V27, P1033, DOI 10.1017/S0033291797005266; *SOC SEX HLTH ADV, 2004, MAN SEX HLTH ADV; St Lawrence JS, 2002, AM J PUBLIC HEALTH, V92, P1784, DOI 10.2105/AJPH.92.11.1784; World Health Organisation, 1999, SEX TRANSM DIS POL P; Wright A, 2002, SEX TRANSM INFECT, V78, P422, DOI 10.1136/sti.78.6.422	36	140	143	0	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 17	2007	334	7589					354	357		10.1136/bmj.39079.460741.7C	http://dx.doi.org/10.1136/bmj.39079.460741.7C			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	141EJ	17237298	Green Published, Bronze, Green Accepted			2022-12-28	WOS:000244560400033
J	Zheng, Y; Danilenko, DM; Valdez, P; Kasman, I; Eastham-Anderson, J; Wu, JF; Ouyang, WJ				Zheng, Yan; Danilenko, Dimitry M.; Valdez, Patricia; Kasman, Ian; Eastham-Anderson, Jeffrey; Wu, Jianfeng; Ouyang, Wenjun			Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis	NATURE			English	Article							CYTOTOXIC T-LYMPHOCYTE; PSORIASIS-VULGARIS; DENDRITIC CELLS; EPIDERMAL DIFFERENTIATION; HUMAN KERATINOCYTES; INTERFERON-GAMMA; TRANSGENIC MICE; GROWTH-FACTOR; FACTOR-ALPHA; EXPRESSION	Psoriasis is a chronic inflammatory skin disease characterized by hyperplasia of the epidermis ( acanthosis), infiltration of leukocytes into both the dermis and epidermis, and dilation and growth of blood vessels(1). The underlying cause of the epidermal acanthosis in psoriasis is still largely unknown. Recently, interleukin (IL)-23, a cytokine involved in the development of IL-17-producing T helper cells (T(H)17 cells)(2,3), was found to have a potential function in the pathogenesis of psoriasis(4,5). Here we show that IL-22 is preferentially produced by T(H)17 cells and mediates the acanthosis induced by IL-23. We found that IL-23 or IL-6 can directly induce the production of IL-22 from both murine and human naive T cells. However, the production of IL-22 and IL-17 from T(H)17 cells is differentially regulated. Transforming growth factor-beta, although crucial for IL-17 production, actually inhibits IL-22 production. Furthermore, IL-22 mediates IL-23-induced acanthosis and dermal inflammation through the activation of Stat3 ( signal transduction and activators of transcription 3) in vivo. Our results suggest that T(H)17 cells, through the production of both IL-22 and IL-17, might have essential functions in host defence and in the pathogenesis of autoimmune diseases such as psoriasis. IL-22, as an effector cytokine produced by T cells, mediates the crosstalk between the immune system and epithelial cells.	Genentech Inc, Dept Immunol, San Francisco, CA 94080 USA; Genentech Inc, Dept Pathol, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech	Ouyang, WJ (corresponding author), Genentech Inc, Dept Immunol, San Francisco, CA 94080 USA.	ouyang.wenjun@gene.com	Ouyang, Wenjun/ABA-8763-2020; Zheng, Yan/A-6993-2008	Zheng, Yan/0000-0002-7002-277X; Danilenko, Dimitry/0000-0002-8326-1921; Ouyang, Wenjun/0000-0002-1811-5864				Abrams JR, 2000, J EXP MED, V192, P681, DOI 10.1084/jem.192.5.681; Austin LM, 1999, J INVEST DERMATOL, V113, P752, DOI 10.1046/j.1523-1747.1999.00749.x; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Boniface K, 2005, J IMMUNOL, V174, P3695, DOI 10.4049/jimmunol.174.6.3695; Chan JR, 2006, J EXP MED, V203, P2577, DOI 10.1084/jem.20060244; Gurney AL, 2004, INT IMMUNOPHARMACOL, V4, P669, DOI 10.1016/j.intimp.2004.01.016; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; JIANG CK, 1993, P NATL ACAD SCI USA, V90, P6786, DOI 10.1073/pnas.90.14.6786; Kauffman CL, 2004, J INVEST DERMATOL, V123, P1037, DOI 10.1111/j.0022-202X.2004.23448.x; Komine M, 2001, J INVEST DERMATOL, V116, P330, DOI 10.1046/j.1523-1747.2001.01249.x; Kopp T, 2003, J IMMUNOL, V170, P5438, DOI 10.4049/jimmunol.170.11.5438; Kopp T, 2001, J INVEST DERMATOL, V117, P618, DOI 10.1046/j.1523-1747.2001.01441.x; Lee E, 2004, J EXP MED, V199, P125, DOI 10.1084/jem.20030451; Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308; Lowes MA, 2005, P NATL ACAD SCI USA, V102, P19057, DOI 10.1073/pnas.0509736102; Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754; McKenzie BS, 2006, TRENDS IMMUNOL, V27, P17, DOI 10.1016/j.it.2005.10.003; NESTLE FO, 1994, J CLIN INVEST, V94, P202, DOI 10.1172/JCI117308; Nickoloff BJ, 2004, J CLIN INVEST, V113, P1664, DOI 10.1172/JCI200422147; Parham C, 2002, J IMMUNOL, V168, P5699, DOI 10.4049/jimmunol.168.11.5699; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Pestka S, 2004, ANNU REV IMMUNOL, V22, P929, DOI 10.1146/annurev.immunol.22.012703.104622; Sano S, 2005, NAT MED, V11, P43, DOI 10.1038/nm1162; SCHLAAK JF, 1994, J INVEST DERMATOL, V102, P145, DOI 10.1111/1523-1747.ep12371752; STOLER A, 1988, J CELL BIOL, V107, P427, DOI 10.1083/jcb.107.2.427; Teunissen MBM, 1998, J INVEST DERMATOL, V111, P645, DOI 10.1046/j.1523-1747.1998.00347.x; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001; Weaver CT, 2006, IMMUNITY, V24, P677, DOI 10.1016/j.immuni.2006.06.002; Wolk K, 2004, IMMUNITY, V21, P241, DOI 10.1016/j.immuni.2004.07.007; Wolk K, 2006, EUR J IMMUNOL, V36, P1309, DOI 10.1002/eji.200535503	30	1445	1570	3	93	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 8	2007	445	7128					648	651		10.1038/nature05505	http://dx.doi.org/10.1038/nature05505			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	133UM	17187052				2022-12-28	WOS:000244039400044
J	Edwards, RD; Moss, JG; Lumsden, MA; Wu, O; Murray, LS; Twaddle, S; Murray, GD				Edwards, Richard D.; Moss, Jonathan G.; Lumsden, Marry Ann; Wu, Olivia; Murray, Lilian S.; Twaddle, Sara; Murray, Gordon D.		REST Investigators	Uterine-artery embolization versus surgery for symptomatic uterine fibroids	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COST-EFFECTIVENESS; HYSTERECTOMY; TRIAL	BACKGROUND: The efficacy and safety of uterine-artery embolization, as compared with standard surgical methods, for the treatment of symptomatic uterine fibroids remain uncertain. METHODS: We conducted a randomized trial comparing uterine-artery embolization and surgery in women with symptomatic uterine fibroids. The primary outcome was quality of life at 1 year of follow-up, as measured by the Medical Outcomes Study 36-Item Short-Form General Health Survey (SF-36). RESULTS: Patients were randomly assigned in a 2:1 ratio to undergo either uterine-artery embolization or surgery, with 106 patients undergoing embolization and 51 undergoing surgery (43 hysterectomies and 8 myomectomies). There were no significant differences between groups in any of the eight components of the SF-36 scores at 1 year. The embolization group had a shorter median duration of hospitalization than the surgical group (1 day vs. 5 days, P<0.001) and a shorter time before returning to work (P<0.001). At 1 year, symptom scores were better in the surgical group (P=0.03). During the first year of follow-up, there were 13 major adverse events in the embolization group (12%) and 10 in the surgical group (20%) (P=0.22), mostly related to the intervention. Ten patients in the embolization group (9%) required repeated embolization or hysterectomy for inadequate symptom control. After the first year of follow-up, 14 women in the embolization group (13%) required hospitalization, 3 of them for major adverse events and 11 for reintervention for treatment failure. CONCLUSIONS: In women with symptomatic fibroids, the faster recovery after embolization must be weighed against the need for further treatment in a minority of patients.	Gartnavel Hosp, N Glasgow Hosp, Dept Radiol, Glasgow G12 OYN, Lanark, Scotland; Univ Glasgow, Glasgow, Lanark, Scotland; Scottish Intercollegiate Guidelines Network, Edinburgh, Midlothian, Scotland; Univ Edinburgh, Sch Med, Edinburgh, Midlothian, Scotland	University of Glasgow; University of Edinburgh	Moss, JG (corresponding author), Gartnavel Hosp, N Glasgow Hosp, Dept Radiol, 1053 GReat Western Rd, Glasgow G12 OYN, Lanark, Scotland.		Wu, Olivia/AAH-4621-2019; moss, jon george/GWN-0387-2022; Wu, Olivia/A-5011-2010	Wu, Olivia/0000-0002-0570-6016; Wu, Olivia/0000-0002-0570-6016; Murray, Gordon/0000-0001-9866-4734				*AM COLL OBST GYN, 2004, OBSTET GYNECOL, V103, P403; Beinfeld MT, 2002, ACAD RADIOL, V9, P1300, DOI 10.1016/S1076-6332(03)80563-9; Briggs AH, 1997, HEALTH ECON, V6, P327, DOI 10.1002/(SICI)1099-1050(199707)6:4<327::AID-HEC282>3.0.CO;2-W; Edozien LC, 2005, BMJ-BRIT MED J, V330, P1457, DOI 10.1136/bmj.330.7506.1457; Fletcher J, 1999, BRIT J RADIOL, V72, P432, DOI 10.1259/bjr.72.857.10505004; Garry R, 2004, HEALTH TECHNOL ASSES, V8, P1; Garside R, 2004, HEALTH TECHNOL ASSES, V8, P1; Goodwin SC, 2001, J VASC INTERV RADIOL, V12, P1011, DOI 10.1016/S1051-0443(07)61586-3; Hehenkamp WJK, 2005, AM J OBSTET GYNECOL, V193, P1618, DOI 10.1016/j.ajog.2005.05.017; Henderson J, 2002, ULTRASOUND OBST GYN, V20, P154, DOI 10.1046/j.1469-0705.2002.00724.x; Jenkinson C, 1996, QUAL HEALTH CARE, V5, P9, DOI 10.1136/qshc.5.1.9; Jennison C, 2000, GROUP SEQUENTIAL MET; Kind P., 1996, QUAL LIFE PHARMACOEC, V25, P3110, DOI [10.1097/00007632-200012150-00005, DOI 10.1097/00007632-200012150-00005]; Lumsden MA, 1998, BAILLIERE CLIN OB GY, V12, P177, DOI 10.1016/S0950-3552(98)80060-6; Marret H, 2005, BJOG-INT J OBSTET GY, V112, P461, DOI 10.1111/j.1471-0528.2004.00487.x; Marret H, 2004, J VASC INTERV RADIOL, V15, P1483, DOI 10.1097/01.RVI.0000141445.13873.7D; *NHS NAT SERV SCOT, 2005, SCOTT HLTH SERV COST; *NIH CLIN EXC, 2004, UT ART EMB TREATM FI; Pinto I, 2003, RADIOLOGY, V226, P425, DOI 10.1148/radiol.2262011716; RAVINA JH, 1995, LANCET, V346, P671, DOI 10.1016/S0140-6736(95)92282-2; Sculpher MJ, 1996, BRIT J OBSTET GYNAEC, V103, P142, DOI 10.1111/j.1471-0528.1996.tb09666.x; Torrance GW, 1987, METHODS EC EVALUATIO; Worthington-Kirsch R, 2005, OBSTET GYNECOL, V106, P52, DOI 10.1097/01.AOG.0000165828.68787.a9; WORTHINGTONKIRS.R, 2005, OBSTET GYNECOL, V106, P869; ZELEN M, 1979, NEW ENGL J MED, V300, P1242, DOI 10.1056/NEJM197905313002203	25	254	271	1	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 25	2007	356	4					360	370						11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128FT	17251532				2022-12-28	WOS:000243644300006
J	Grosenick, L; Clement, TS; Fernald, RD				Grosenick, Logan; Clement, Tricia S.; Fernald, Russell D.			Fish can infer social rank by observation alone	NATURE			English	Article							TRANSITIVE INFERENCE; HAPLOCHROMIS-BURTONI; INFORMATION; MEMORY; RATS	Transitive inference (TI) involves using known relationships to deduce unknown ones ( for example, using A. B and B. C to infer A. C), and is thus essential to logical reasoning. First described as a developmental milestone in children(1), TI has since been reported in nonhuman primates(2-4), rats(5,6) and birds(7-10). Still, how animals acquire and represent transitive relationships and why such abilities might have evolved remain open problems. Here we show that male fish (Astatotilapia burtoni) can successfully make inferences on a hierarchy implied by pairwise fights between rival males. These fish learned the implied hierarchy vicariously ( as 'bystanders'), by watching fights between rivals arranged around them in separate tank units. Our findings show that fish use TI when trained on socially relevant stimuli, and that they can make such inferences by using indirect information alone. Further, these bystanders seem to have both spatial and featural representations related to rival abilities, which they can use to make correct inferences depending on what kind of information is available to them. Beyond extending TI to fish and experimentally demonstrating indirect TI learning in animals, these results indicate that a universal mechanism underlying TI is unlikely. Rather, animals probably use multiple domain-specific representations adapted to different social and ecological pressures that they encounter during the course of their natural lives.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA; Stanford Univ, Ctr Study Language & Informat, Stanford, CA 94305 USA	Stanford University; Stanford University	Grosenick, L (corresponding author), Stanford Univ, Ctr Study Language & Informat, Ventura Hall,200 Panama St, Stanford, CA 94305 USA.	logang@stanford.edu						Allen C., 2006, RATIONAL ANIMALS, P175, DOI DOI 10.1093/ACPROF:OSO/9780198528272.003.0007; Bond AB, 2003, ANIM BEHAV, V65, P479, DOI 10.1006/anbe.2003.2101; BRYANT PE, 1971, NATURE, V232, P456, DOI 10.1038/232456a0; Chase ID, 2002, P NATL ACAD SCI USA, V99, P5744, DOI 10.1073/pnas.082104199; Clement TS, 2005, BEHAV ECOL, V16, P83, DOI 10.1093/beheco/arh134; DAVIS H, 1992, J COMP PSYCHOL, V106, P342, DOI 10.1037/0735-7036.106.4.342; DELILLO C, 2001, ANIMAL COGNITION, V4, P61, DOI DOI 10.1007/S100710100092; Dusek JA, 1997, P NATL ACAD SCI USA, V94, P7109, DOI 10.1073/pnas.94.13.7109; FERNALD R D, 1977, Environmental Biology of Fishes, V2, P299, DOI 10.1007/BF00005997; FERNALD RD, 1977, ANIM BEHAV, V25, P964, DOI 10.1016/0003-3472(77)90048-3; FERNALD RD, 1977, ANIM BEHAV, V25, P643, DOI 10.1016/0003-3472(77)90115-4; GILLAN DJ, 1981, J EXP PSYCHOL ANIM B, V7, P1, DOI 10.1037/0097-7403.7.1.1; Hofmann HA, 1999, P NATL ACAD SCI USA, V96, P14171, DOI 10.1073/pnas.96.24.14171; Lazareva OF, 2004, J EXP ANAL BEHAV, V82, P1, DOI 10.1901/jeab.2004.82-1; MCGONIGLE B, 1992, Q J EXP PSYCHOL-B, V45, P189; MCGONIGLE BO, 1977, NATURE, V267, P694, DOI 10.1038/267694a0; MCGONIGLE BO, 1986, REASONING DISCOURSE, P141; Oliveira RF, 1998, P ROY SOC B-BIOL SCI, V265, P1045, DOI 10.1098/rspb.1998.0397; Paz-y-Mino G, 2004, NATURE, V430, P778, DOI 10.1038/nature02723; Piaget J., 1928, JUDGEMENT REASONING; R Development Core Team, 2006, R LANG ENV STAT COMP; Rapp PR, 1996, BEHAV NEUROSCI, V110, P887, DOI 10.1037/0735-7044.110.5.887; ROBERTS WA, 1994, PSYCHOL SCI, V5, P368, DOI 10.1111/j.1467-9280.1994.tb00287.x; STEIRN JN, 1995, ANIM LEARN BEHAV, V23, P76, DOI 10.3758/BF03198018; Vargas JP, 2004, J COMP PSYCHOL, V118, P206, DOI 10.1037/0735-7036.118.2.206; VONFERSEN L, 1991, J EXP PSYCHOL ANIM B, V17, P334, DOI 10.1037/0097-7403.17.3.334; White SA, 2002, J EXP BIOL, V205, P2567; Wynne CDL, 1998, MODELS OF ACTION: MECHANISMS FOR ADAPTIVE BEHAVIOR, P269; Zentall TR, 2001, BEHAV PROCESS, V54, P65, DOI 10.1016/S0376-6357(01)00150-4	29	330	337	3	142	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 25	2007	445	7126					429	432		10.1038/nature05511	http://dx.doi.org/10.1038/nature05511			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	128WD	17251980				2022-12-28	WOS:000243689500040
J	Halkic, N; Ksontini, R				Halkic, Nermin; Ksontini, Riadh			Hepatosplenic candidiasis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Lausanne, Sch Med, CH-1101 Lausanne, Switzerland	University of Lausanne	Halkic, N (corresponding author), Univ Lausanne, Sch Med, CH-1101 Lausanne, Switzerland.	nermin.halkic@chuv.ch	Halkic, Nermin/J-6670-2017	Halkic, Nermin/0000-0002-0117-0453					0	7	7	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 25	2007	356	4					E4	E4		10.1056/NEJMicm040112	http://dx.doi.org/10.1056/NEJMicm040112			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128FT	17251526	Green Published			2022-12-28	WOS:000243644300011
J	Reddy, KS				Reddy, K. Srinath			The preventive polypill - Much promise, insufficent evidence	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CARDIOVASCULAR-DISEASE		Publ Hlth Fdn India, New Delhi, India; All India Inst Med Sci, New Delhi, India	Public Health Foundation of India; All India Institute of Medical Sciences (AIIMS) New Delhi	Reddy, KS (corresponding author), Publ Hlth Fdn India, New Delhi, India.							Gaziano TA, 2006, LANCET, V368, P679, DOI 10.1016/S0140-6736(06)69252-0; Reddy KS, 2004, NEW ENGL J MED, V350, P2438, DOI 10.1056/NEJMp048024; Wald NJ, 2003, BRIT MED J, V327, P586	3	35	40	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 18	2007	356	3					212	212		10.1056/NEJMp068219	http://dx.doi.org/10.1056/NEJMp068219			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	126BV	17229947				2022-12-28	WOS:000243488100002
J	Hawkes, N				Hawkes, Nigel			Body politic - Fat chance of hitting obesity targets	BRITISH MEDICAL JOURNAL			English	Editorial Material												nigel.hawkes@thetimes.co.uk							0	2	2	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JAN 13	2007	334	7584					71	71		10.1136/bmj.39086.625822.59	http://dx.doi.org/10.1136/bmj.39086.625822.59			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	127DZ	17218708	Green Published			2022-12-28	WOS:000243566800025
J	Baker, SJ				Baker, Suzanne J.			PTEN enters the nuclear age	CELL			English	Review							TUMOR-SUPPRESSOR; PHOSPHORYLATION; LOCALIZATION; STABILITY; PROTEIN; GROWTH; DOMAIN; CHK1	Regulation of the PTEN tumor suppressor protein is poorly understood. In this issue, Wang et al. (2007) and Trotman et al. (2007) describe how ubiquitination regulates PTEN stability and its nuclear localization. Additionally, Shen et al. (2007) report that a nuclear pool of PTEN helps to maintain chromosomal stability.	St Jude Childrens Hosp, Dept Dev Neurobiol, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Baker, SJ (corresponding author), St Jude Childrens Hosp, Dept Dev Neurobiol, 332 N Lauderdale St, Memphis, TN 38105 USA.	suzanne.baker@stjude.org	Baker, Suzanne J/N-8167-2018					Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Chow LML, 2006, CANCER LETT, V241, P184, DOI 10.1016/j.canlet.2005.11.042; Deleris P, 2006, J CELL BIOCHEM, V98, P469, DOI 10.1002/jcb.20695; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Georgescu MM, 2000, CANCER RES, V60, P7033; Gil A, 2006, MOL BIOL CELL, V17, P4002, DOI 10.1091/mbc.E06-05-0380; KIM JS, 2006, MOL CELL BIOL; Li AG, 2006, MOL CELL, V23, P575, DOI 10.1016/j.molcel.2006.06.028; Lian ZL, 2005, ONCOGENE, V24, P7394, DOI 10.1038/sj.onc.1209089; Lindsay Y, 2006, J CELL SCI, V119, P5160, DOI 10.1242/jcs.000133; Okahara F, 2004, J BIOL CHEM, V279, P45300, DOI 10.1074/jbc.C400377200; Okumura K, 2006, J BIOL CHEM, V281, P26562, DOI 10.1074/jbc.M605391200; Puc J, 2005, CANCER CELL, V7, P193, DOI 10.1016/j.ccr.2005.01.009; Puc J, 2005, CELL CYCLE, V4, P927, DOI 10.4161/cc.4.7.1795; Trotman LC, 2003, PLOS BIOL, V1, P385, DOI 10.1371/journal.pbio.0000059; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000	16	130	146	0	7	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 12	2007	128	1					25	28		10.1016/j.cell.2006.12.023	http://dx.doi.org/10.1016/j.cell.2006.12.023			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	139GN	17218252	Bronze			2022-12-28	WOS:000244420400010
J	Baumann, C; Korner, R; Hofmann, K; Nigg, EA				Baumann, Christoph; Koerner, Roman; Hofmann, Kay; Nigg, Erich A.			PICH, a centromere-associated SNF2 family ATPase, is regulated by Plk1 and required for the spindle checkpoint	CELL			English	Article							ANAPHASE-PROMOTING COMPLEX; PROTEIN PHOSPHATASE 2A; CELL-CYCLE CHECKPOINT; POLO-LIKE KINASES; TOPOISOMERASE-II; SACCHAROMYCES-CEREVISIAE; MITOTIC CHECKPOINT; BUDDING YEAST; BOX DOMAIN; KINETOCHORE	We identify PICH (PIk1 -interacting checkpoint "helicase"), a member of the SNF2 ATPase family, as an interaction partner and substrate of PIk1. Following phosphorylation of PICH on the Cdk1 site T1 063, PIk1 is recruited to PICH and controls its localization. Starting in prometaphase, PICH accumulates at kinetochores and inner centromeres. Moreover, it decorates threads that form during metaphase before increasing in length and progressively diminishing during anaphase. PICH-positive threads connect sister kinetochores and are dependent on tension, sensitive to DNase, and exacerbated in response to premature loss of cohesins or inhibition of topoisomerase II, suggesting that they represent stretched centromeric chromatin. Depletion of PICH causes the selective loss of Mad2 from kinetochores and completely abrogates the spindle checkpoint, resulting in massive chromosome missegregation. These data identify PICH as a novel essential component of checkpoint signaling. We propose that PICH binds to catenated centromere-related DNA to monitor tension developing between sister kinetochores.	Max Planck Inst Biochem, Dept Cell Biol, D-82152 Martinsried, Germany; Miltenyi Biotec GmbH, Bioinformat Grp, D-50829 Cologne, Germany	Max Planck Society; Miltenyi Biotec	Nigg, EA (corresponding author), Max Planck Inst Biochem, Dept Cell Biol, D-82152 Martinsried, Germany.	nigg@biochem.mpg.de	Körner, Roman/G-8565-2011; Hofmann, Kay/D-6714-2011	Körner, Roman/0000-0001-9285-9290; Hofmann, Kay/0000-0002-2289-9083; nigg, erich/0000-0003-4835-5719				Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Becker PB, 2002, ANNU REV BIOCHEM, V71, P247, DOI 10.1146/annurev.biochem.71.110601.135400; Beerens N, 2005, J BIOL CHEM, V280, P4722, DOI 10.1074/jbc.M409147200; Ciferri C, 2005, J BIOL CHEM, V280, P29088, DOI 10.1074/jbc.M504070200; Cleveland DW, 2003, CELL, V112, P407, DOI 10.1016/S0092-8674(03)00115-6; DeLuca JG, 2005, MOL BIOL CELL, V16, P519, DOI 10.1091/mbc.E04-09-0852; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Flaus A, 2006, NUCLEIC ACIDS RES, V34, P2887, DOI 10.1093/nar/gkl295; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; Haering CH, 2003, BIOESSAYS, V25, P1178, DOI 10.1002/bies.10361; Hanisch A, 2006, MOL BIOL CELL, V17, P448, DOI 10.1091/mbc.E05-08-0801; Hauf S, 2005, PLOS BIOL, V3, P419, DOI 10.1371/journal.pbio.0030069; Havas K, 2000, CELL, V103, P1133, DOI 10.1016/S0092-8674(00)00215-4; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Indjeian VB, 2005, SCIENCE, V307, P130, DOI 10.1126/science.1101366; Jang YJ, 2002, P NATL ACAD SCI USA, V99, P1984, DOI 10.1073/pnas.042689299; Kitajima TS, 2006, NATURE, V441, P46, DOI 10.1038/nature04663; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; Lia G, 2006, MOL CELL, V21, P417, DOI 10.1016/j.molcel.2005.12.013; Losada A, 2002, GENE DEV, V16, P3004, DOI 10.1101/gad.249202; Lowery DM, 2005, ONCOGENE, V24, P248, DOI 10.1038/sj.onc.1208280; Maiato H, 2004, J CELL SCI, V117, P5461, DOI 10.1242/jcs.01536; Mapelli M, 2006, EMBO J, V25, P1273, DOI 10.1038/sj.emboj.7601033; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Neef R, 2003, J CELL BIOL, V162, P863, DOI 10.1083/jcb.200306009; NICKLAS RB, 1995, J CELL BIOL, V130, P929, DOI 10.1083/jcb.130.4.929; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Owen-Hughes T, 2006, E SCHERING RES FDN W, V57, P47; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Pines J, 2006, TRENDS CELL BIOL, V16, P55, DOI 10.1016/j.tcb.2005.11.006; Pinsky BA, 2005, TRENDS CELL BIOL, V15, P486, DOI 10.1016/j.tcb.2005.07.005; Riedel CG, 2006, NATURE, V441, P53, DOI 10.1038/nature04664; RIEDER CL, 1994, J CELL BIOL, V127, P1301, DOI 10.1083/jcb.127.5.1301; RIEDER CL, 1995, J CELL BIOL, V130, P941, DOI 10.1083/jcb.130.4.941; Salic A, 2004, CELL, V118, P567, DOI 10.1016/j.cell.2004.08.016; Seong YS, 2002, J BIOL CHEM, V277, P32282, DOI 10.1074/jbc.M202602200; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; Shiratori A, 1999, YEAST, V15, P219, DOI 10.1002/(SICI)1097-0061(199902)15:3<219::AID-YEA349>3.3.CO;2-V; Stern BM, 2001, CURR BIOL, V11, P1462, DOI 10.1016/S0960-9822(01)00451-1; Stucke VM, 2004, CHROMOSOMA, V113, P1, DOI 10.1007/s00412-004-0288-2; Sumara I, 2002, MOL CELL, V9, P515, DOI 10.1016/S1097-2765(02)00473-2; Svejstrup JQ, 2003, J CELL SCI, V116, P447, DOI 10.1242/jcs.00271; Tang ZY, 2006, DEV CELL, V10, P575, DOI 10.1016/j.devcel.2006.03.010; Toyoda Y, 2006, MOL BIOL CELL, V17, P2287, DOI 10.1091/mbc.E05-11-1089; Uhlmann F, 2000, CELL, V103, P375, DOI 10.1016/S0092-8674(00)00130-6; Vagnarelli P, 2004, CHROMOSOMA, V113, P211, DOI 10.1007/s00412-004-0307-3; YANAGIDA N, 1995, BIOESSAYS, V17, P519, DOI 10.1002/bies.950170608; Yu HT, 2006, J CELL BIOL, V173, P153, DOI 10.1083/jcb.200601172	54	251	261	1	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 12	2007	128	1					101	114		10.1016/j.cell.2006.11.041	http://dx.doi.org/10.1016/j.cell.2006.11.041			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	139GN	17218258	Bronze			2022-12-28	WOS:000244420400016
J	Okie, S				Okie, Susan			Sex, drugs, prisons, and HIV	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		[Anonymous], 2006, CRIMINOL PUBLIC POL, DOI DOI 10.1111/J.1745-9133.2006.00101.X; Dolan K, 2003, ADDICTION, V98, P153, DOI 10.1046/j.1360-0443.2003.00309.x; Hammett TM, 2002, AM J PUBLIC HEALTH, V92, P1789, DOI 10.2105/AJPH.92.11.1789; MARUSCHAK LM, 2006, HIV PRISONS 2004; 2006, MMWR MORB MORTAL WKL, V55, P421	5	37	38	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 11	2007	356	2					105	108		10.1056/NEJMp068277	http://dx.doi.org/10.1056/NEJMp068277			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	124NE	17215526	Bronze			2022-12-28	WOS:000243373700001
J	Jolly, R				Jolly, Richard			Early childhood development: the global challenge	LANCET			English	Editorial Material									Univ Sussex, Inst Dev Studies, Brighton BN1 9RE, E Sussex, England	University of Sussex	Jolly, R (corresponding author), Univ Sussex, Inst Dev Studies, Brighton BN1 9RE, E Sussex, England.	R.Jolly@ids.ac.uk						ENGLE PL, IN PRESS LANCET; GAUTAM K, 2001, UNICEF VISIONARY, P137; Grantham-McGregor S, 2007, LANCET, V369, P60, DOI 10.1016/S0140-6736(07)60032-4; JOLLY R, 2001, UNICEF VISIONARY, V15, P50; *UNDP, 1993, HUM DEV REP 1993, P141; *UNICEF, 1992, STAT WORLDS CHILDR R, P12; *UNICEF, 2001, PROGR WORLD SUMM CHI, P19; WALKER SP, IN PRESS LANCET	8	19	21	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 6	2007	369	9555					8	9		10.1016/S0140-6736(07)60007-5	http://dx.doi.org/10.1016/S0140-6736(07)60007-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	125AK	17208623				2022-12-28	WOS:000243413700007
J	Montanez, IP; Tabor, NJ; Niemeier, D; DiMichele, WA; Frank, TD; Fielding, CR; Isbell, JL; Birgenheier, LP; Rygel, MC				Montanez, Isabel P.; Tabor, Neil J.; Niemeier, Deb; DiMichele, William A.; Frank, Tracy D.; Fielding, Christopher R.; Isbell, John L.; Birgenheier, Lauren P.; Rygel, Michael C.			CO2-forced climate and vegetation instability during late paleozoic deglaciation	SCIENCE			English	Article							ATMOSPHERIC CO2; ISOTOPIC COMPOSITION; CARBON-DIOXIDE; NORTH-AMERICA; GLACIATION; RECORD; OXYGEN; EVOLUTION; PALEOCLIMATE; DELTA-O-18	The late Paleozoic deglaciation is the vegetated Earth's only recorded icehouse-to-greenhouse transition, yet the climate dynamics remain enigmatic. By using the stable isotopic compositions of soil-formed minerals, fossil-plant matter, and shallow-water brachiopods, we estimated atmospheric partial pressure of carbon dioxide (pCO(2)) and tropical marine surface temperatures during this climate transition. Comparison to southern Gondwanan glacial records documents covariance between inferred shifts in pCO(2), temperature, and ice volume consistent with greenhouse gas forcing of climate. Major restructuring of paleotropical flora in western Euramerica occurred in step with climate and pCO(2) shifts, illustrating the biotic impact associated with past CO2-forced turnover to a permanent ice-free world.	Univ Calif Davis, Dept Geol, Davis, CA 95616 USA; So Methodist Univ, Dept Geol Sci, Dallas, TX 75275 USA; Univ Calif Davis, Dept Civil & Environm Engn, Davis, CA 95616 USA; Smithsonian Museum Nat Hist, Dept Paleobiol, Washington, DC 20560 USA; Univ Nebraska, Dept Geosci, Lincoln, NE 68588 USA; Univ Wisconsin, Dept Geosci, Milwaukee, WI 53201 USA	University of California System; University of California Davis; Southern Methodist University; University of California System; University of California Davis; Smithsonian Institution; Smithsonian National Museum of Natural History; University of Nebraska System; University of Nebraska Lincoln; University of Wisconsin System; University of Wisconsin Milwaukee	Montanez, IP (corresponding author), Univ Calif Davis, Dept Geol, Davis, CA 95616 USA.	montanez@geology.ucdavis.edu	DiMichele, William/K-4301-2012	Rygel, Michael/0000-0002-6453-6205; Birgenheier, Lauren/0000-0001-6951-0939; Montanez, Isabel/0000-0003-0492-3796; Frank, Tracy/0000-0002-8422-7389				Arens NC, 2000, PALEOBIOLOGY, V26, P137, DOI 10.1666/0094-8373(2000)026&lt;0137:CCPFRT&gt;2.0.CO;2; Bangert B, 1999, J AFR EARTH SCI, V29, P33, DOI 10.1016/S0899-5362(99)00078-0; Banks M.R., 1981, EARTHS PREPLEISTOCEN, P495; Beck WC, 2005, GEOCHIM COSMOCHIM AC, V69, P3493, DOI 10.1016/j.gca.2005.02.003; Berner RA, 2001, AM J SCI, V301, P182, DOI 10.2475/ajs.301.2.182; CECIL C.B., 2003, SEPM SPECIAL PUBLICA, V77, P151; Cerling TE, 1999, PALAEOWEATHERING PAL, V27, P43, DOI DOI 10.1002/9781444304190.CH2; Dickins JM, 1996, PALAEOGEOGR PALAEOCL, V125, P185, DOI 10.1016/S0031-0182(96)00030-2; DIMICHELE WA, 1992, EVOLUTION, V46, P807, DOI 10.1111/j.1558-5646.1992.tb02086.x; DiMichele WA, 2000, PALAIOS, V15, P524, DOI 10.2307/3515616; DiMichele WA, 2006, GEOL SOC AM SPEC PAP, V399, P223, DOI 10.1130/2006.2399(11); Ekart DD, 1999, AM J SCI, V299, P805, DOI 10.2475/ajs.299.10.805; Frakes L. A, 1992, CLIMATE MODES PHANER; GONZALEZ CR, 1990, PALAEOGEOGR PALAEOCL, V79, P275, DOI 10.1016/0031-0182(90)90022-Y; Gradstein F., 2005, GEOLOGIC TIME SCALE, DOI [10.1017/CBO9780511536045, DOI 10.1017/CBO9780511536045]; Isbell J.L., 2003, EXTREME DEPOSITIONAL, V370, P5; Jones AT, 2004, GEOLOGY, V32, P153, DOI 10.1130/G20112.1; Kim ST, 1997, GEOCHIM COSMOCHIM AC, V61, P3461, DOI 10.1016/S0016-7037(97)00169-5; Korte C, 2005, PALAEOGEOGR PALAEOCL, V224, P333, DOI 10.1016/j.palaeo.2005.03.015; Kump LR, 2005, NATURE, V436, P333, DOI 10.1038/436333a; Kump LR, 2002, NATURE, V419, P188, DOI 10.1038/nature01087; Lopez-Gamundi O. R, 1997, LATE GLACIAL POSTGLA, P147; MAMAY SH, 1992, AM J BOT, V79, P1092, DOI 10.2307/2445207; MAMAY SH, 1967, 575C US GEOL SURV, P120; Mii HS, 1999, GEOL SOC AM BULL, V111, P960, DOI 10.1130/0016-7606(1999)111<0960:CISONA>2.3.CO;2; Mora CI, 1996, SCIENCE, V271, P1105, DOI 10.1126/science.271.5252.1105; Pagani M, 2005, SCIENCE, V309, P600, DOI 10.1126/science.1110063; Panchuk KM, 2006, J SEDIMENT RES, V76, P200, DOI 10.2110/jsr.2006.017; Petit JR, 1999, NATURE, V399, P429, DOI 10.1038/20859; Ross C. A., 1988, SOC ECON PALEONT MIN, P227, DOI 10.2110/pec.88.01.0227; Royer D.L., 2004, GSA TODAY, V14, P4, DOI DOI 10.1130/1052-5173(2004)014; Royer DL, 2001, EARTH-SCI REV, V54, P349, DOI 10.1016/S0012-8252(00)00042-8; Saltzman MR, 2003, GEOLOGY, V31, P151, DOI 10.1130/0091-7613(2003)031<0151:LPIAOG>2.0.CO;2; Scheffler K, 2003, GEOLOGY, V31, P605, DOI 10.1130/0091-7613(2003)031<0605:GCDCGO>2.0.CO;2; Schrag DP, 2002, QUATERNARY SCI REV, V21, P331, DOI 10.1016/S0277-3791(01)00110-X; Siegenthaler U, 2005, SCIENCE, V310, P1313, DOI 10.1126/science.1120130; Stollhofen H, 2000, PALAEOGEOGR PALAEOCL, V161, P127, DOI 10.1016/S0031-0182(00)00120-6; Tabor NJ, 2005, PALAEOGEOGR PALAEOCL, V223, P127, DOI 10.1016/j.palaeo.2005.04.009; Tabor NJ, 2004, SEDIMENTOLOGY, V51, P851, DOI 10.1111/j.1365-3091.2004.00655.x; Tabor NJ, 2004, GEOCHIM COSMOCHIM AC, V68, P1503, DOI 10.1016/S0016-7037(03)00497-6; TABOR NJ, IN PRESS EARTH PLANE; Tripati A, 2005, NATURE, V436, P341, DOI 10.1038/nature03874; Veizer J, 1999, CHEM GEOL, V161, P59, DOI 10.1016/S0009-2541(99)00081-9; Visser JNJ, 1997, SEDIMENTOLOGY, V44, P507, DOI 10.1046/j.1365-3091.1997.d01-35.x; Winguth AME, 2002, PALEOCEANOGRAPHY, V17, DOI 10.1029/2001PA000646; YAPP CJ, 1992, NATURE, V355, P342, DOI 10.1038/355342a0; Zhang H, 1999, ACTA GEOL SIN-ENGL, V73, P111	47	393	409	4	107	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 5	2007	315	5808					87	91		10.1126/science.1134207	http://dx.doi.org/10.1126/science.1134207			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	122WU	17204648	Green Published			2022-12-28	WOS:000243259100041
J	Jones, J; Vellend, H; Detsky, AS; Mourad, O				Jones, Jeremy; Vellend, Hillar; Detsky, Allan S.; Mourad, Ophyr			A stain in time	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							POLYMERASE-CHAIN-REACTION; WHIPPLES-DISEASE; TROPHERYMA-WHIPPELII; DIAGNOSIS		St Michaels Hosp, Dept Med, Toronto, ON M5B 1W8, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada; Mt Sinai Hosp, Dept Med, Toronto, ON M5G 1X5, Canada; Univ Hlth Network, Dept Med, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Mourad, O (corresponding author), St Michaels Hosp, Dept Med, 30 Bond St, Toronto, ON M5B 1W8, Canada.	mourado@smh.toronto.on.ca						Alkan S, 2001, AM J CLIN PATHOL, V116, P898; Durand DV, 1997, MEDICINE, V76, P170, DOI 10.1097/00005792-199705000-00003; Ehrbar HU, 1999, LANCET, V353, P2214, DOI 10.1016/S0140-6736(99)01776-6; FLEMING JL, 1988, MAYO CLIN PROC, V63, P539, DOI 10.1016/S0025-6196(12)64884-8; Gerard A, 2002, MEDICINE, V81, P443, DOI 10.1097/00005792-200211000-00005; Mahnel R, 2004, CLIN EXP MED, V4, P39, DOI 10.1007/s10238-004-0036-1; Marth T, 2003, LANCET, V361, P239, DOI 10.1016/S0140-6736(03)12274-X; Ramzan NN, 1997, ANN INTERN MED, V126, P520, DOI 10.7326/0003-4819-126-7-199704010-00004; Ratnaike RN, 2000, POSTGRAD MED J, V76, P760, DOI 10.1136/pmj.76.902.760; vonHerbay A, 1997, GASTROENTEROLOGY, V113, P434, DOI 10.1053/gast.1997.v113.pm9247461; vonHerbay A, 1996, GASTROENTEROLOGY, V110, P1735, DOI 10.1053/gast.1996.v110.pm8964398	11	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 4	2007	356	1					68	74		10.1056/NEJMcps052579	http://dx.doi.org/10.1056/NEJMcps052579			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	122EX	17202458				2022-12-28	WOS:000243209600012
J	Pine, M; Jordan, HS; Elixhauser, A; Fry, DE; Hoaglin, DC; Jones, B; Meimban, R; Warner, D; Gonzales, J				Pine, Michael; Jordan, Harmon S.; Elixhauser, Anne; Fry, Donald E.; Hoaglin, David C.; Jones, Barbara; Meimban, Roger; Warner, David; Gonzales, Junius			Enhancement of claims data to improve risk adjustment of hospital mortality	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VETERANS-AFFAIRS; CABG SURGERY; SEVERITY; QUALITY; RATES; PREDICTIONS; VALIDATION; MORBIDITY; DATABASES; ACCESS	Context Comparisons of risk-adjusted hospital performance often are important components of public reports, pay-for-performance programs, and quality improvement initiatives. Risk-adjustment equations used in these analyses must contain sufficient clinical detail to ensure accurate measurements of hospital quality. Objective To assess the effect on risk-adjusted hospital mortality rates of adding present on admission codes and numerical laboratory data to administrative claims data. Design, Setting, and Patients Comparison of risk-adjustment equations for inpatient mortality from July 2000 through June 2003 derived by sequentially adding increasingly difficult-to-obtain clinical data to an administrative database of 188 Pennsylvania hospitals. Patients were hospitalized for acute myocardial infarction, congestive heart failure, cerebrovascular accident, gastrointestinal tract hemorrhage, or pneumonia or underwent an abdominal aortic aneurysm repair, coronary artery bypass graft surgery, or craniotomy. Main Outcome Measures C statistics as a measure of the discriminatory power of alternative risk-adjustment models ( administrative, present on admission, laboratory, and clinical for each of the 5 conditions and 3 procedures). Results The mean (SD) c statistic for the administrative model was 0.79 (0.02). Adding present on admission codes and numerical laboratory data collected at the time of admission resulted in substantially improved risk-adjustment equations ( mean [ SD] c statistic of 0.84 [0.01] and 0.86 [ 0.01], respectively). Modest additional improvements were obtained by adding more complex and expensive to collect clinical data such as vital signs, blood culture results, key clinical findings, and composite scores abstracted from patients' medical records ( mean [ SD] c statistic of 0.88 [ 0.01]). Conclusions This study supports the value of adding present on admission codes and numerical laboratory values to administrative databases. Secondary abstraction of difficult-to-obtain key clinical findings adds little to the predictive power of risk-adjustment equations.	Michael Pine & Associates Inc, Chicago, IL USA; Univ Chicago, Pritzker Sch Med, Dept Med, Chicago, IL 60637 USA; Abt Associates Inc, Cambridge, MA 02138 USA; Tufts Univ, Sch Med, Boston, MA 02111 USA; Agcy Healthcare Res & Qual, Rockville, MD USA	University of Chicago; ABT Associates; Tufts University; Agency for Healthcare Research & Quality	Pine, M (corresponding author), 1210 Chicago Ave,Suite 503, Evanston, IL 60202 USA.	mpine@aol.com						*AG HEALTHC RES QU, QUAL IND SOFTW SAS Z; *AG HEALTHC RES QU, 2006, INP QUAL IND TECHN S; Berner ES, 2005, J AM MED INFORM ASSN, V12, P3, DOI 10.1197/jamia.M1664; BREWSTER AC, 1985, INQUIRY-J HEALTH CAR, V22, P377; COFFEY R, 2006, US AGENCY HEALTHCARE; DALEY J, 1988, JAMA-J AM MED ASSOC, V260, P3617, DOI 10.1001/jama.260.24.3617; Garets D, 2006, ELECT MED RECORDS VS; Ghali WA, 2002, ANN INTERN MED, V136, P723, DOI 10.7326/0003-4819-136-10-200205210-00007; Gibbs J, 1999, ARCH SURG-CHICAGO, V134, P36, DOI 10.1001/archsurg.134.1.36; Grover FL, 2001, ANN SURG, V234, P464, DOI 10.1097/00000658-200110000-00006; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HANNAN EL, 1990, JAMA-J AM MED ASSOC, V264, P2768, DOI 10.1001/jama.264.21.2768; Hannan EL, 1997, HEALTH SERV RES, V31, P659; HANNAN EL, 1992, MED CARE, V30, P892, DOI 10.1097/00005650-199210000-00002; Hastie T., 2009, ELEMENTS STAT LEARNI, DOI 10.1007/978-0-387-84858-7_7; HIGGINS TL, 1992, JAMA-J AM MED ASSOC, V267, P2344, DOI 10.1001/jama.267.17.2344; HOSMER DW, 2000, WILEY PS TX, P1; IEZZONI LI, 1995, ANN INTERN MED, V123, P763, DOI 10.7326/0003-4819-123-10-199511150-00004; IEZZONI LI, 1992, MED CARE, V30, P347, DOI 10.1097/00005650-199204000-00005; JOLLIS JG, 1993, ANN INTERN MED, V119, P844, DOI 10.7326/0003-4819-119-8-199310150-00011; Khuri SF, 1998, ANN SURG, V228, P491, DOI 10.1097/00000658-199810000-00006; KNAUS WA, 1981, CRIT CARE MED, V9, P591, DOI 10.1097/00003246-198108000-00008; Krumholz HM, 2006, CIRCULATION, V113, P1683, DOI 10.1161/CIRCULATIONAHA.105.611186; Krumholz HM, 2006, CIRCULATION, V113, P1693, DOI 10.1161/CIRCULATIONAHA.105.611194; Lee DS, 2003, JAMA-J AM MED ASSOC, V290, P2581, DOI 10.1001/jama.290.19.2581; Lee SJ, 2006, JAMA-J AM MED ASSOC, V295, P801, DOI 10.1001/jama.295.7.801; Lee TH, 2004, NEW ENGL J MED, V350, P2409, DOI 10.1056/NEJMsb041193; LEMESHOW S, 1993, JAMA-J AM MED ASSOC, V270, P2478, DOI 10.1001/jama.270.20.2478; McKay NL, 2005, HEALTH CARE MANAGE R, V30, P347, DOI 10.1097/00004010-200510000-00009; Moscucci M, 2005, J AM COLL CARDIOL, V45, P1759, DOI 10.1016/j.jacc.2005.01.055; Naessens J M, 1991, Qual Assur Health Care, V3, P257; Narins CR, 2005, ARCH INTERN MED, V165, P83, DOI 10.1001/archinte.165.1.83; *NAT HLTH CAR PURC, 2002, STAT REP CONS PURCH; *NAT UN BILL COMM, UB 04 DAT SPEC MAN B; *PENNS HEALTHC COS, 2004, IND ACC PAR RAND REP; Pine M, 1997, ANN INTERN MED, V126, P347, DOI 10.7326/0003-4819-126-5-199703010-00002; Pine M, 1998, INT J QUAL HEALTH C, V10, P491, DOI 10.1093/intqhc/10.6.491; Regenstreif Institute, LOG OBS ID NAM COD L; Schneider EC, 1996, NEW ENGL J MED, V335, P251, DOI 10.1056/NEJM199607253350406; SCHWARZ G, 1978, ANN STAT, V6, P461, DOI 10.1214/aos/1176344136; SMITH DW, 1991, MED CARE, V29, P1108, DOI 10.1097/00005650-199111000-00004; VANRUISWYK J, 1993, MED DECIS MAKING, V13, P152, DOI 10.1177/0272989X9301300209	42	230	230	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 3	2007	297	1					71	76		10.1001/jama.297.1.71	http://dx.doi.org/10.1001/jama.297.1.71			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	123BS	17200477	Bronze			2022-12-28	WOS:000243271900023
J	Temple, R; Stockbridge, NL				Temple, Robert; Stockbridge, Norman L.			BiDil for heart failure in black patients: The U.S. Food and Drug Administration perspective	ANNALS OF INTERNAL MEDICINE			English	Article							ISOSORBIDE DINITRATE; MORTALITY; HYDRALAZINE; RACE	Critics of the U. S. Food and Drug Administration (FDA) approval of the fixed combination of hydralazine hydrochloride, 37.5 mg, and isosorbide dinitrate, 20 mg, for treating heart failure in black patients have suggested that data were insufficient to distinguish treatment effects in black and white people; that distinctions based on race, rather than pathophysiology, were scientifically unreasonable; and that a "race-based" approval could be a commercial ploy to avoid a more expensive and prolonged full evaluation of a drug. The criticisms acknowledge that data supporting the approval came from a well-designed clinical trial in which self-identified black patients with heart failure who took hydralazine hydrochloride-isosorbide dinitrate with standard therapy experienced a statistically significant 43% (95% CI, 11% to 63%) reduction in mortality compared with those who took only the standard therapy. The criticisms do not always recognize that the decision to conduct the trial in only black patients reflected careful analyses of 2 previous trials in racially mixed patient populations that compared hydralazine hydrochloride-isosorbide dinitrate with placebo or with enalapril. Both trials showed little or no overall effect of hydralazine hydrochloride-isosorbide dinitrate in the mostly white patient population but hinted at a substantial effect in subsets of black patients. Perhaps most critically, the criticisms do not appreciate the urgency of strong scientific evidence of a substantial survival benefit in black patients. A serious attempt to avoid race-based approval by mandating study of a mixed population to identify a possible white patient-responder subset, particularly without a plausible hypothesis as to what that subset might be, would have required years of work, many thousands of patients, and wholly unreasonable delay in approval of a treatment whose effectiveness had been well-documented in the group for which it was intended.	US FDA, Silver Spring, MD 20993 USA	US Food & Drug Administration (FDA)	Temple, R (corresponding author), US FDA, 10903 New Hampshire Ave, Silver Spring, MD 20993 USA.	robert.temple@fda.hhs.gov						[Anonymous], 1990, Lancet, V336, P1; Avorn J, 2005, NEW ENGL J MED, V353, P969, DOI 10.1056/NEJMp058174; Bloche MG, 2004, NEW ENGL J MED, V351, P2035, DOI 10.1056/NEJMp048271; Brown NJ, 1996, CLIN PHARMACOL THER, V60, P8, DOI 10.1016/S0009-9236(96)90161-7; COHN JN, 1986, NEW ENGL J MED, V314, P1547, DOI 10.1056/NEJM198606123142404; Cohn JN, 1998, NEW ENGL J MED, V339, P1810, DOI 10.1056/NEJM199812173392503; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; Davis BR, 1996, AM J HYPERTENS, V9, P342, DOI 10.1016/0895-7061(96)00037-4; Food and Drug Administration, 1988, GUID FORM CONT CLIN; Food and Drug Administration HHS, 2006, Fed Regist, V71, P3921; Haga SB, 2006, J AM COLL CARDIOL, V48, P12, DOI 10.1016/j.jacc.2006.04.017; Harty L, 2006, J CLIN PHARMACOL, V46, P405, DOI 10.1177/0091270005286028; JUST H, 1995, CIRCULATION S1, V92, P722; Kahn Jonathan, 2004, Yale J Health Policy Law Ethics, V4, P1; *NITROMED INC, 2005, BIDIL; PACKER M, 1993, CIRCULATION, V88, P301; PACKER M, 1991, NEW ENGL J MED, V325, P1468, DOI 10.1056/NEJM199111213252103; Perry G, 1997, NEW ENGL J MED, V336, P525; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; Taylor AL, 2004, NEW ENGL J MED, V351, P2049, DOI 10.1056/NEJMoa042934; Temple R, 2000, ANN INTERN MED, V133, P455, DOI 10.7326/0003-4819-133-6-200009190-00014; TEMPLE RJ, 1994, COMMUN STAT THEORY, V23, P499, DOI 10.1080/03610929408831269; U.S. Food and Drug Administration, 1993, Fed Regist, V58, P39406; *US FDA, 1989, GUID STUD DRUGS LIK; *US FDA, 2005, P US FDA CTR DRUG EV; YUSUF S, 1991, JAMA-J AM MED ASSOC, V266, P93, DOI 10.1001/jama.266.1.93	26	81	81	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 2	2007	146	1					57	W9		10.7326/0003-4819-146-1-200701020-00010	http://dx.doi.org/10.7326/0003-4819-146-1-200701020-00010			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188BK	17200223				2022-12-28	WOS:000247893300008
J	Black, N				Black, Nick			The challenging isle: a walk through Soho	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Black, N (corresponding author), Univ London London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.	nick.black@lshtm.ac.uk						Black Nick., 2006, WALKING LONDONS MEDI	1	1	1	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 23	2006	333	7582					1325	1326		10.1136/bmj.39056.530995.BE	http://dx.doi.org/10.1136/bmj.39056.530995.BE			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121MC	17185729	Green Published, Bronze, Green Accepted, Green Submitted			2022-12-28	WOS:000243160700026
J	Collier, J				Collier, Joe			Getting new drugs to market: how individuals,could do this without leaving their desks	BRITISH MEDICAL JOURNAL			English	Editorial Material									St George Hosp, Sch Med, Dept Basic Med Sci, London SW17 0RE, England	St Georges University London	Collier, J (corresponding author), St George Hosp, Sch Med, Dept Basic Med Sci, London SW17 0RE, England.	jcollier@sgul.ac.uk						Henry D, 2002, LANCET, V360, P1590, DOI 10.1016/S0140-6736(02)11527-3; JACK A, 2006, FINANCIAL TIMES 0929	2	1	1	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 23	2006	333	7582					1315	1317		10.1136/bmj.39055.610764.47	http://dx.doi.org/10.1136/bmj.39055.610764.47			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121MC	17185722	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000243160700020
J	Willich, SN				Willich, Stefan N.			Physicians in opera - reflection of medical history and public perception	BRITISH MEDICAL JOURNAL			English	Editorial Material							MITRAL-VALVE; DEATH		Humboldt Univ, Charite Univ Med Ctr, Inst Social Med Epidemiol & Hlth Econ, D-1086 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Willich, SN (corresponding author), Humboldt Univ, Charite Univ Med Ctr, Inst Social Med Epidemiol & Hlth Econ, D-1086 Berlin, Germany.	stefan.willich@charite.de						BAAS HJ, 1986, GESCH ENTWICKLUNG AR; BEDFORD DE, 1951, BRIT HEART J, V13, P423; BOUDOULAS H, 1980, CIRCULATION, V61, P1200, DOI 10.1161/01.CIR.61.6.1200; CARMODY J, 1991, MED J AUSTRALIA, V155, P783, DOI 10.5694/j.1326-5377.1991.tb94038.x; CHESLER E, 1983, CIRCULATION, V67, P632, DOI 10.1161/01.CIR.67.3.632; DAUBER LG, 1992, AM J CARDIOL, V70, P838, DOI 10.1016/0002-9149(92)90582-J; ESTES JW, 1994, OPERA Q, V10, P143; FIELDING JF, 1990, IRISH J MED SCI, V159, P77, DOI 10.1007/BF02946673; GOLDOVSKY B, 1986, CLEV CLIN J MED, V53, P39, DOI 10.3949/ccjm.53.1.39; KLASEN EM, 1984, THESIS U MAINZ MAINZ; KUMMEL WF, 1977, MUSIK MED; LEDERMAN RJ, 1989, NEW ENGL J MED, V320, P246, DOI 10.1056/NEJM198901263200410; MALBECK ES, 1971, THESIS U DUSSELDORF; Ober W B, 1976, Practitioner, V216, P110; Sadie Stanley, 1992, NEW GROVE DICT OPERA; Schmiedebach Heinz-Peter, 1989, GANZE MENSCH MED, V162, P33; St Louis E K, 1992, Pharos Alpha Omega Alpha Honor Med Soc, V55, P15; WILLICH SN, 1993, CIRCULATION, V87, P1442, DOI 10.1161/01.CIR.87.5.1442	18	8	8	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 23	2006	333	7582					1333	1335		10.1136/bmj.39056.464074.55	http://dx.doi.org/10.1136/bmj.39056.464074.55			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121MC	17185733	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000243160700030
J	Prideaux, GJ; Long, JA; Ayliffe, LK; Hellstrom, JC; Pillans, B; Boles, WE; Hutchinson, MN; Roberts, RG; Cupper, ML; Arnold, LJ; Devine, PD; Warburton, NM				Prideaux, Gavin J.; Long, John A.; Ayliffe, Linda K.; Hellstrom, John C.; Pillans, Brad; Boles, Walter E.; Hutchinson, Mark N.; Roberts, Richard G.; Cupper, Matthew L.; Arnold, Lee J.; Devine, Paul D.; Warburton, Natalie M.			An arid-adapted middle Pleistocene vertebrate fauna from south-central Australia	NATURE			English	Article							QUATERNARY; EXTINCTION; MEGAFAUNA; AGES	How well the ecology, zoogeography and evolution of modern biotas is understood depends substantially on knowledge of the Pleistocene(1,2). Australia has one of the most distinctive, but least understood, Pleistocene faunas. Records from the western half of the continent are especially rare(3). Here we report on a diverse and exceptionally well preserved middle Pleistocene vertebrate assemblage from caves beneath the arid, treeless Nullarbor plain of south-central Australia. Many taxa are represented by whole skeletons, which together serve as a template for identifying fragmentary, hitherto indeterminate, remains collected previously from Pleistocene sites across southern Australia. A remarkable eight of the 23 Nullarbor kangaroos are new, including two tree-kangaroos. The diverse herbivore assemblage implies substantially greater floristic diversity than that of the modern shrub steppe, but all other faunal and stable-isotope data indicate that the climate was very similar to today. Because the 21 Nullarbor species that did not survive the Pleistocene were well adapted to dry conditions, climate change ( specifically, increased aridity) is unlikely to have been significant in their extinction.	Western Australian Museum, Dept Earth & Planetary Sci, Perth, WA 6000, Australia; Museum Victoria, Melbourne, Vic 3001, Australia; Univ Utah, Dept Geol & Geophys, Salt Lake City, UT 84112 USA; Australian Natl Univ, Res Sch Earth Sci, Canberra, ACT 0200, Australia; Univ Melbourne, Sch Earth Sci, Melbourne, Vic 3010, Australia; Australian Museum, Sydney, NSW 2010, Australia; S Australian Museum, Herpetol Sect, Adelaide, SA 5000, Australia; Univ Wollongong, Geoquest Res Ctr, Sch Earth & Environm Sci, Wollongong, NSW 2522, Australia; Speleol Res Grp Western Australia, E Victoria Pk, WA 6981, Australia	Western Australian Museum; Museum Victoria; Utah System of Higher Education; University of Utah; Australian National University; University of Melbourne; Australian Museum; University of Wollongong	Prideaux, GJ (corresponding author), Western Australian Museum, Dept Earth & Planetary Sci, Perth, WA 6000, Australia.	gavin.prideaux@museum.wa.gov.au	Roberts, Richard Graham/B-8245-2013; Ayliffe, Linda/C-3627-2009; Hellstrom, John C/B-1770-2008; Arnold, Lee J/J-4356-2018	Roberts, Richard Graham/0000-0002-0128-4119; Ayliffe, Linda/0000-0001-7662-5494; Hellstrom, John C/0000-0001-9427-3525; Arnold, Lee J/0000-0001-9603-3824; Pillans, Bradley/0000-0002-8373-635X; Warburton, Natalie/0000-0002-8498-3053; Prideaux, Gavin/0000-0002-9958-0265; Long, John/0000-0001-8012-0114				Baynes A., 1987, BIOL SURVEY NULLARBO, P139; *BUR MET, 1989, CLIM AUSTR; BURBRIDGE NANCY T., 1960, AUSTRALIAN JOUR BOT, V8, P75, DOI 10.1071/BT9600075; CERLING TE, IN PRESS OECOLOGIA; Graham RW, 1996, SCIENCE, V272, P1601; Horton D.R., 1984, P639; Johnson CN, 2004, AUSTRAL ECOL, V29, P553, DOI 10.1111/j.1442-9993.2004.01389.x; Keast A., 1981, ECOLOGICAL BIOGEOGRA, P1891; Koch PL, 1998, ANNU REV EARTH PL SC, V26, P573, DOI 10.1146/annurev.earth.26.1.573; Lian OB, 2006, QUATERNARY SCI REV, V25, P2449, DOI 10.1016/j.quascirev.2005.11.013; Lister AM, 2004, PHILOS T R SOC B, V359, P221, DOI 10.1098/rstb.2003.1436; Lowry D. C., 1970, Bull. geol. Surv. West. Aust., VNo. 122, P1; Lundelius E. L. J., 1989, FIELDIANA GEOLOGY, V17, P1; McKenzie N., 2004, AUSTR SOILS LANDSCAP, DOI [10.1071/9780643100732, DOI 10.1071/9780643100732]; Miller GH, 2005, SCIENCE, V309, P287, DOI 10.1126/science.1111288; MITCHELL AA, 1998, ARID SHRUBLAND PLANT; Murray Paul, 2004, SHADOW DRACULA LIFE; Passey BH, 2005, J ARCHAEOL SCI, V32, P1459, DOI 10.1016/j.jas.2005.03.015; Prideaux GJ, 2007, GEOLOGY, V35, P33, DOI 10.1130/G23070A.1; Prideaux Gavin J., 2000, Journal of Vertebrate Paleontology, V20, p62A; PRIDEAUX GJ, 2004, U CALIF PUBL GEOL SC, V146; PRIDEAUX GJ, 2006, ENCY QUATERNARY SCI, P1518; Roberts RG, 2001, SCIENCE, V292, P1888, DOI 10.1126/science.1060264; ROBERTS RG, 1996, AUST ARCHAEOL, V42, P7; Solem A., 1986, Journal of the Malacological Society of Australia, V7, P95; Strahan R., 1995, MAMMALS AUSTR, V2nd; Woodhead J, 2006, QUAT GEOCHRONOL, V1, P208, DOI 10.1016/j.quageo.2006.08.002; Wroe S, 2006, QUATERNARY SCI REV, V25, P2692, DOI 10.1016/j.quascirev.2006.03.005	28	91	97	1	56	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JAN 25	2007	445	7126					422	425		10.1038/nature05471	http://dx.doi.org/10.1038/nature05471			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	128WD	17251978				2022-12-28	WOS:000243689500038
J	Perera, R; Heneghan, C; Yudkin, P				Perera, Rafael; Heneghan, Carl; Yudkin, Patricia			A graphical method for depicting randomised trials of complex interventions	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Oxford, Dept Primary Hlth Care, Ctr Evidence Based Med, Oxford OX3 7LF, England	University of Oxford	Yudkin, P (corresponding author), Univ Oxford, Dept Primary Hlth Care, Ctr Evidence Based Med, Oxford OX3 7LF, England.	pat.yudkin@dphpc.ox.ac.uk		Perera, Rafael/0000-0003-2418-2091				Aveyard P, 2003, ADDICTION, V98, P345, DOI 10.1046/j.1360-0443.2003.00302.x; Jarman B, 2002, BRIT MED J, V324, P1072, DOI 10.1136/bmj.324.7345.1072; Lewin RJP, 2002, BRIT J GEN PRACT, V52, P194; *MED RES COUNC, 2000, FRAM DEV EV RCTS COM; Paterson C, 2005, BMJ-BRIT MED J, V330, P1202, DOI 10.1136/bmj.330.7501.1202	5	121	122	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 20	2007	334	7585					127	129		10.1136/bmj.39045.396817.68	http://dx.doi.org/10.1136/bmj.39045.396817.68			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	130LP	17235093	Green Published			2022-12-28	WOS:000243801400030
J	Boyd, NF; Guo, H; Martin, LJ; Sun, LM; Stone, J; Fishell, E; Jong, RA; Hislop, G; Chiarelli, A; Minkin, S; Yaffe, MJ				Boyd, Norman F.; Guo, Helen; Martin, Lisa J.; Sun, Limei; Stone, Jennifer; Fishell, Eve; Jong, Roberta A.; Hislop, Greg; Chiarelli, Anna; Minkin, Salomon; Yaffe, Martin J.			Mammographic density and the risk and detection of breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PARENCHYMAL PATTERNS; SCREENING-PROGRAM; WOMEN; INTERVAL; CLASSIFICATION; FEATURES; FAILURE; SIGNS	BACKGROUND: Extensive mammographic density is associated with an increased risk of breast cancer and makes the detection of cancer by mammography difficult, but the influence of density on risk according to method of cancer detection is unknown. METHODS: We carried out three nested case-control studies in screened populations with 1112 matched case-control pairs. We examined the association of the measured percentage of density in the baseline mammogram with risk of breast cancer, according to method of cancer detection, time since the initiation of screening, and age. RESULTS: As compared with women with density in less than 10% of the mammogram, women with density in 75% or more had an increased risk of breast cancer (odds ratio, 4.7; 95% confidence interval [CI], 3.0 to 7.4), whether detected by screening (odds ratio, 3.5; 95% CI, 2.0 to 6.2) or less than 12 months after a negative screening examination (odds ratio, 17.8; 95% CI, 4.8 to 65.9). Increased risk of breast cancer, whether detected by screening or other means, persisted for at least 8 years after study entry and was greater in younger than in older women. For women younger than the median age of 56 years, 26% of all breast cancers and 50% of cancers detected less than 12 months after a negative screening test were attributable to density in 50% or more of the mammogram. CONCLUSIONS: Extensive mammographic density is strongly associated with the risk of breast cancer detected by screening or between screening tests. A substantial fraction of breast cancers can be attributed to this risk factor.	Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Campbell Family Inst Breast Canc Res, Toronto, ON, Canada; Womens Hosp Med Ctr, Dept Radiol, Toronto, ON, Canada; Womens Hosp Med Ctr, Dept Imaging Res, Toronto, ON, Canada; Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; Canc Care Ontario, Ontario Breast Screening Program, Toronto, ON, Canada; British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Womens College Hospital; University of Toronto; University Toronto Affiliates; Womens College Hospital; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Cancer Care Ontario; British Columbia Cancer Agency	Boyd, NF (corresponding author), Ontario Canc Inst, 610 Univ Ave,Room 10-415, Toronto, ON M5G 2M9, Canada.	boyd@uhnres.utoronto.ca	Stone, Jennifer/AAS-3805-2020	Stone, Jennifer/0000-0001-5077-0124				Boyd NF, 2005, LANCET ONCOL, V6, P798, DOI 10.1016/S1470-2045(05)70390-9; BOYD NF, 1995, J NATL CANCER I, V87, P670, DOI 10.1093/jnci/87.9.670; BOYD NF, 1982, BRIT J CANCER, V45, P185, DOI 10.1038/bjc.1982.32; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; Buist DSM, 2004, JNCI-J NATL CANCER I, V96, P1432, DOI 10.1093/jnci/djh269; BYNG JW, 1994, PHYS MED BIOL, V39, P1629, DOI 10.1088/0031-9155/39/10/008; Byrne C, 2001, CANCER CAUSE CONTROL, V12, P103, DOI 10.1023/A:1008935821885; BYRNE C, 1995, J NATL CANCER I, V87, P1622, DOI 10.1093/jnci/87.21.1622; Crystal P, 2003, AM J ROENTGENOL, V181, P177, DOI 10.2214/ajr.181.1.1810177; Gilliland FD, 2000, J NATL CANCER I, V92, P743, DOI 10.1093/jnci/92.9.743; Harvey JA, 2004, RADIOLOGY, V230, P29, DOI 10.1148/radiol.2301020870; JOHNS PC, 1987, PHYS MED BIOL, V32, P675, DOI 10.1088/0031-9155/32/6/002; Jong R, 1996, EUR J CANCER PREV, V5, P281, DOI 10.1097/00008469-199608000-00008; Knight JA, 1998, BREAST CANCER RES TR, V48, P65, DOI 10.1023/A:1005990806919; MA L, 1992, J NATL CANCER I, V84, P781, DOI 10.1093/jnci/84.10.781; Mandelson MT, 2000, J NATL CANCER I, V92, P1081, DOI 10.1093/jnci/92.13.1081; McCormack VA, 2006, CANCER EPIDEM BIOMAR, V15, P1159, DOI 10.1158/1055-9965.EPI-06-0034; MEYER JE, 1984, RADIOLOGY, V150, P335, DOI 10.1148/radiology.150.2.6691085; MILLER AB, 1992, CAN MED ASSOC J, V147, P1477; MILLER AB, 1993, CAN MED ASSOC J, V148, P718; Pisano ED, 2005, NEW ENGL J MED, V353, P1773, DOI 10.1056/NEJMoa052911; Porter PL, 1999, J NATL CANCER I, V91, P2020, DOI 10.1093/jnci/91.23.2020; Rothman K., 1998, MODERN EPIDEMIOLOGY; Roubidoux MA, 2004, RADIOLOGY, V230, P42, DOI 10.1148/radiol.2301020589; SAFTLAS AF, 1991, CANCER, V67, P2833, DOI 10.1002/1097-0142(19910601)67:11<2833::AID-CNCR2820671121>3.0.CO;2-U; Sala E, 1998, J MED SCREEN, V5, P207, DOI 10.1136/jms.5.4.207; SICKLES EA, 1986, AM J ROENTGENOL, V146, P661, DOI 10.2214/ajr.146.4.661; Ursin G, 2003, CANCER EPIDEM BIOMAR, V12, P332; van Gils CH, 1998, EUR J EPIDEMIOL, V14, P315, DOI 10.1023/A:1007423824675; WHITEHEAD J, 1985, CANCER, V56, P1280, DOI 10.1002/1097-0142(19850915)56:6<1280::AID-CNCR2820560610>3.0.CO;2-8; WOLFE JN, 1987, AM J ROENTGENOL, V148, P1087, DOI 10.2214/ajr.148.6.1087; WOLFE JN, 1976, CANCER, V37, P2486, DOI 10.1002/1097-0142(197605)37:5<2486::AID-CNCR2820370542>3.0.CO;2-8; WOLFE JN, 1976, AM J ROENTGENOL, V126, P1130, DOI 10.2214/ajr.126.6.1130; Wright H, 2005, AM J SURG, V190, P572, DOI 10.1016/j.amjsurg.2005.06.014	34	1542	1574	3	95	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 18	2007	356	3					227	236		10.1056/NEJMoa062790	http://dx.doi.org/10.1056/NEJMoa062790			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	126BV	17229950				2022-12-28	WOS:000243488100005
J	Thiebaut, R; Leproust, S; Chene, G; Gilbert, R				Thiebaut, Rodolphe; Leproust, Sandy; Chene, Genevie; Gilbert, Ruth		SYROCOT Study Grp	Effectiveness of prenatal treatment for congenital toxoplasmosis: a meta-analysis of individual patients' data	LANCET			English	Article							TO-CHILD TRANSMISSION; PREGNANT-WOMEN; CLINICAL-MANIFESTATIONS; GONDII INFECTION; MULTICENTER; SONOGRAPHY; PREVENTION; COHORT; RISK; CT	Background Despite three decades of prenatal screening for congenital toxoplasmosis in some European countries, uncertainty remains about the effectiveness of prenatal treatment. Methods We did a systematic review of cohort studies based on universal screening for congenital toxoplasmosis. We did a meta-analysis using individual patients' data to assess the effect of timing and type of prenatal treatment on mother-to-child transmission of infection and clinical manifestations before age 1 year. Analyses were adjusted for gestational age at maternal seroconversion and other covariates. Findings We included 26 cohorts in the review. In 1438 treated mothers identified by prenatal screening, we found weak evidence that treatment started within 3 weeks of seroconversion reduced mother-to-child transmission compared with treatment started after 8 or more weeks (adjusted odds ratio [OR] 0.48, 95% CI 0.28-0.80; p=0.05). In 550 infected liveborn infants identified by prenatal or neonatal screening, we found no evidence that prenatal treatment significantly reduced the risk of clinical manifestations (adjusted OR for treated vs not treated 1.11, 95% CI 0.61-2.02). Increasing gestational age at seroconversion was strongly associated with increased risk of mother-to-child transmission (OR 1.15, 95% CI 1.12-1.17) and decreased risk of intracranial lesions (0.91, 0.87-0.95), but not with eye lesions (0.97, 0.93-1.00). Interpretation We found weak evidence for an association between early treatment and reduced risk of congenital toxoplasmosis. Further evidence from observational studies is unlikely to change these results and would not distinguish whether the association is due to treatment or to biases caused by confounding. Only a large randomised controlled clinical trial would provide clinicians and patients with valid evidence of the potential benefit of prenatal treatment.	Univ Bordeaux 2, INSERM, U875, F-33076 Bordeaux, France; UCL, Inst Child Hlth, London, England	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; University of London; University College London	Thiebaut, R (corresponding author), Univ Bordeaux 2, INSERM, U875, 2 Victor Segalen,146 Rue Leo Saignat, F-33076 Bordeaux, France.	rodolphe.thiebaut@isped.u-bordeaux2.fr	Thiebaut, Rodolphe/T-6803-2019; Gomez Marin, Jorge/L-9793-2013; Bahia-Oliveira, Lilian M.G./A-8464-2013; chene, genevieve/H-8665-2014; SAVASI, VALERIA MARIA/K-8433-2016	Thiebaut, Rodolphe/0000-0002-5235-3962; Gomez Marin, Jorge/0000-0001-6472-3329; Bahia-Oliveira, Lilian M.G./0000-0003-3001-8079; chene, genevieve/0000-0002-8368-6460; Gilbert, Ruth/0000-0001-9347-2709; SAVASI, VALERIA MARIA/0000-0002-1476-7689				Bahia-Oliveira L. M. G., 2001, INT J PARASITOL, V31, P133; Blankenberg FG, 2000, AM J NEURORADIOL, V21, P213; Cook AJC, 2000, BRIT MED J, V321, P142, DOI 10.1136/bmj.321.7254.142; Dunn D, 1999, LANCET, V353, P1829, DOI 10.1016/S0140-6736(98)08220-8; Eskild A, 1996, J Med Screen, V3, P188; Evengard B, 2001, EPIDEMIOL INFECT, V127, P121, DOI 10.1017/S0950268801005775; Foulon W, 1999, AM J OBSTET GYNECOL, V180, P410, DOI 10.1016/S0002-9378(99)70224-3; Gallego C, 2006, ACTA TROP, V97, P161, DOI 10.1016/j.actatropica.2005.10.001; GHIDINI A, 1991, J REPROD MED, V36, P270; Gilbert R, 2003, BJOG-INT J OBSTET GY, V110, P112, DOI 10.1016/S1470-0328(02)02325-X; Gilbert R, 2001, EPIDEMIOL INFECT, V127, P113, DOI 10.1017/S095026880100560X; Gilbert RE, 2001, INT J EPIDEMIOL, V30, P1303, DOI 10.1093/ije/30.6.1303; Gomez G, 2003, STAT MED, V22, P409, DOI 10.1002/sim.1326; GRANT EG, 1985, RADIOLOGY, V157, P63, DOI 10.1148/radiology.157.1.2994172; Gras L, 2005, ACTA PAEDIATR, V94, P1721, DOI 10.1080/08035250500251999; Gras L, 2001, INT J EPIDEMIOL, V30, P1309, DOI 10.1093/ije/30.6.1309; GUERINA NG, 1994, NEW ENGL J MED, V330, P1858, DOI 10.1056/NEJM199406303302604; Holland GN, 2003, AM J OPHTHALMOL, V136, P973, DOI 10.1016/j.ajo.2003.09.040; Lebech M, 1996, EUR J CLIN MICROBIOL, V15, P799, DOI 10.1007/BF01701522; Lehmann T, 2006, P NATL ACAD SCI USA, V103, P11423, DOI 10.1073/pnas.0601438103; Logar J, 2002, SCAND J INFECT DIS, V34, P201, DOI 10.1080/00365540110080386; MARIN JEG, 2005, INFECTIO, V9, P16; MAYER HO, 1986, ZBL GYNAKOL, V108, P1482; Ndong Obame T., 1997, Bulletin de la Societe Francaise de Parasitologie, V15, P141; Neto EC, 2000, INT J EPIDEMIOL, V29, P941, DOI 10.1093/ije/29.5.941; PATISSIER G, 2001, REV PRAT GYNECOL OBS, V52, P33; RAEBER PA, 1995, SCHWEIZ MED WSCHR, V125, pS96; Remington JS, 2001, INFECT DIS FETUS NEW, P205; Salt A, 2005, BMC Pediatr, V5, P21, DOI 10.1186/1471-2431-5-21; Szenasi Z, 1997, INT J EPIDEMIOL, V26, P428, DOI 10.1093/ije/26.2.428; Thiebaut R, 2006, EUR J OBSTET GYN R B, V124, P3, DOI 10.1016/j.ejogrb.2005.07.019; THIEBAUT R, 2003, COCHRANE LIB; Wallon M, 1999, BRIT MED J, V318, P1511, DOI 10.1136/bmj.318.7197.1511; Wallon M, 1999, EUR J PEDIATR, V158, P645, DOI 10.1007/s004310051168	34	289	313	2	20	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 13	2007	369	9556					115	122						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	126TK	17223474	Green Submitted			2022-12-28	WOS:000243538200030
J	Yeung, RSM				Yeung, Rae S. M.			Phenotype and coronary outcome in Kawasaki's disease	LANCET			English	Editorial Material							ASSOCIATION; ANEURYSMS		Univ Toronto, Hosp Sick Children, Dept Paediat, Div Rheumatol, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Yeung, RSM (corresponding author), Univ Toronto, Hosp Sick Children, Dept Paediat, Div Rheumatol, Toronto, ON M5G 1X8, Canada.	rae.yeung@sickkids.ca		Yeung, Rae/0000-0003-2361-725X				Beiser AS, 1998, AM J CARDIOL, V81, P1116, DOI 10.1016/S0002-9149(98)00116-7; Benseler SM, 2006, ANN RHEUM DIS, V65, P245; Benseler SM, 2005, PEDIATRICS, V116, pE760, DOI 10.1542/peds.2005-0559; BURNS JC, 1991, J PEDIATR-US, V118, P680, DOI 10.1016/S0022-3476(05)80026-5; DANIELS SR, 1987, AM J DIS CHILD, V141, P205, DOI 10.1001/archpedi.1987.04460020095035; Gong GWK, 2006, J PEDIATR-US, V148, P800, DOI 10.1016/j.jpeds.2006.01.039; Harada Kensuke, 1991, Acta Paediatrica Japonica, V33, P805; Kobayashi T, 2006, CIRCULATION, V113, P2606, DOI 10.1161/CIRCULATIONAHA.105.592865; KOREN G, 1986, J PEDIATR-US, V108, P388, DOI 10.1016/S0022-3476(86)80878-2; Newburger JW, 2004, CIRCULATION, V110, P2747, DOI 10.1161/01.CIR.0000145143.19711.78; Rowley A H, 1991, Adv Pediatr, V38, P51; Sung RYT, 2006, PEDIATR INFECT DIS J, V25, P521, DOI 10.1097/01.inf.0000215263.96289.1c	12	9	9	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 13	2007	369	9556					85	87		10.1016/S0140-6736(07)60045-2	http://dx.doi.org/10.1016/S0140-6736(07)60045-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	126TK	17223454				2022-12-28	WOS:000243538200007
J	Mitro, N; Mak, PA; Vargas, L; Godio, C; Hampton, E; Molteni, V; Kreusch, A; Saez, E				Mitro, Nico; Mak, Puiying A.; Vargas, Leo; Godio, Cristina; Hampton, Eric; Molteni, Valentina; Kreusch, Andreas; Saez, Enrique			The nuclear receptor LXR is a glucose sensor	NATURE			English	Article							ELEMENT-BINDING PROTEIN-1C; X-RECEPTOR; LIVER; METABOLISM; ALPHA; TRANSCRIPTION; MICE; HOMEOSTASIS; LIPOGENESIS; DEFICIENCY	The liver has a central role in glucose homeostasis, as it has the distinctive ability to produce and consume glucose(1). On feeding, glucose influx triggers gene expression changes in hepatocytes to suppress endogenous glucose production and convert excess glucose into glycogen or fatty acids to be stored in adipose tissue(2). This process is controlled by insulin, although debate exists as to whether insulin acts directly or indirectly on the liver(3). In addition to stimulating pancreatic insulin release, glucose also regulates the activity of ChREBP, a transcription factor that modulates lipogenesis(4). Here we describe another mechanism whereby glucose determines its own fate: we show that glucose binds and stimulates the transcriptional activity of the liver X receptor (LXR), a nuclear receptor that coordinates hepatic lipid metabolism. D-Glucose and D-glucose-6-phosphate are direct agonists of both LXR-alpha and LXR-beta. Glucose activates LXR at physiological concentrations expected in the liver and induces expression of LXR target genes with efficacy similar to that of oxysterols, the known LXR ligands. Cholesterol homeostasis genes that require LXR for expression are upregulated in liver and intestine of fasted mice re-fed with a glucose diet, indicating that glucose is an endogenous LXR ligand. Our results identify LXR as a transcriptional switch that integrates hepatic glucose metabolism and fatty acid synthesis.	Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA; Scripps Res Inst, La Jolla, CA 92037 USA	Novartis; Scripps Research Institute	Saez, E (corresponding author), Novartis Res Fdn, Genom Inst, 10675 John Hopkins Dr, San Diego, CA 92121 USA.	esaez@scripps.edu		Godio, Cristina/0000-0003-2639-6368; Mitro, Nico/0000-0002-5000-3619				Cao GQ, 2003, J BIOL CHEM, V278, P1131, DOI 10.1074/jbc.M210208200; Chen GX, 2004, P NATL ACAD SCI USA, V101, P11245, DOI 10.1073/pnas.0404297101; Cherrington AD, 2005, J CLIN INVEST, V115, P1136, DOI 10.1172/JCI200525152; DEBLASI A, 1989, TRENDS PHARMACOL SCI, V10, P227, DOI 10.1016/0165-6147(89)90266-6; Eberle D, 2004, BIOCHIMIE, V86, P839, DOI 10.1016/j.biochi.2004.09.018; Fehr M, 2004, J FLUORESC, V14, P603, DOI 10.1023/B:JOFL.0000039347.94943.99; Iizuka K, 2004, P NATL ACAD SCI USA, V101, P7281, DOI 10.1073/pnas.0401516101; Janowski BA, 1999, P NATL ACAD SCI USA, V96, P266, DOI 10.1073/pnas.96.1.266; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Joseph SB, 2002, P NATL ACAD SCI USA, V99, P7604, DOI 10.1073/pnas.112059299; Joseph SB, 2004, CELL, V119, P299, DOI 10.1016/j.cell.2004.09.032; Laffitte BA, 2003, P NATL ACAD SCI USA, V100, P5419, DOI 10.1073/pnas.0830671100; Liang GS, 2002, J BIOL CHEM, V277, P9520, DOI 10.1074/jbc.M111421200; Lin JD, 2005, CELL, V120, P261, DOI 10.1016/j.cell.2004.11.043; Moore MC, 2003, BEST PRACT RES CL EN, V17, P343, DOI 10.1016/S1521-690X(03)00036-8; Parks EJ, 2002, P NUTR SOC, V61, P281, DOI 10.1079/PNS2002148; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; Shulman AI, 2005, NEW ENGL J MED, V353, P604, DOI 10.1056/NEJMra043590; STEHNOBITTEL L, 1995, SCIENCE, V270, P1835, DOI 10.1126/science.270.5243.1835; Yamashita H, 2001, P NATL ACAD SCI USA, V98, P9116, DOI 10.1073/pnas.161284298; Zierler K, 1999, AM J PHYSIOL-ENDOC M, V276, pE409, DOI 10.1152/ajpendo.1999.276.3.E409	24	411	439	1	56	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 11	2007	445	7124					219	223		10.1038/nature05449	http://dx.doi.org/10.1038/nature05449			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124QF	17187055				2022-12-28	WOS:000243384300054
J	Aharonian, F				Aharonian, Felix			The very-high-energy gamma-ray sky	SCIENCE			English	Editorial Material							SUPERNOVA REMNANT; DISCOVERY; BINARY; ACCELERATION; HESS	Over the past few years, very-high-energy gamma-ray astronomy has emerged as a truly observational discipline, with many detected sources representing different galactic and extragalactic source populations-supernova remnants, pulsar wind nebulae, giant molecular clouds, star formation regions, compact binary systems, and active galactic nuclei. It is expected that observations with the next generation of stereoscopic arrays of imaging atmospheric Cherenkov telescopes over a very broad energy range from 10(10) to 10(15) electron volts will dramatically increase the number of very-high-energy gamma-ray sources, thus having a huge impact on the development of astrophysics, cosmology, and particle astrophysics.	Dublin Inst Adv Studies, Dublin 4, Ireland; Max Planck Inst Kernphys, D-69117 Heidelberg, Germany	Dublin Institute for Advanced Studies; Max Planck Society	Aharonian, F (corresponding author), Dublin Inst Adv Studies, 10 Burlington Rd, Dublin 4, Ireland.	Felix.Aharonian@mpi-hd.mpg.de						Aharonian F, 2006, ASTRON ASTROPHYS, V460, P365, DOI 10.1051/0004-6361:20065546; Aharonian F, 2006, ASTRON ASTROPHYS, V460, P743, DOI 10.1051/0004-6361:20065940; Aharonian F, 2006, SCIENCE, V314, P1424, DOI 10.1126/science.1134408; Aharonian F, 2006, NATURE, V440, P1018, DOI 10.1038/nature04680; Aharonian F, 2006, ASTRON ASTROPHYS, V449, P223, DOI 10.1051/0004-6361:20054279; Aharonian F, 2006, NATURE, V439, P695, DOI 10.1038/nature04467; Aharonian F, 2005, ASTRON ASTROPHYS, V442, P1, DOI 10.1051/0004-6361:20052983; Aharonian F, 2005, SCIENCE, V309, P746, DOI 10.1126/science.1113764; Aharonian FA, 2004, NATURE, V432, P75, DOI 10.1038/nature02960; Aharonian FA, 1997, ANNU REV NUCL PART S, V47, P273, DOI 10.1146/annurev.nucl.47.1.273; Albert J, 2006, SCIENCE, V312, P1771, DOI 10.1126/science.1128177; DEGRANGE B, 2005, P C NETW ATM CHER DE; Enomoto R, 2002, NATURE, V416, P823, DOI 10.1038/416823a; PUNCH M, 1992, NATURE, V358, P477, DOI 10.1038/358477a0; Sinnis G, 2005, AIP CONF PROC, V745, P234, DOI 10.1063/1.1878412; WEEKES TC, 1989, ASTROPHYS J, V342, P379, DOI 10.1086/167599	16	14	15	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 5	2007	315	5808					70	72		10.1126/science.1136395	http://dx.doi.org/10.1126/science.1136395			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	122WU	17204642				2022-12-28	WOS:000243259100035
J	Portner, HO; Knust, R				Poertner, Hans O.; Knust, Rainer			Climate change affects marine fishes through the oxygen limitation of thermal tolerance	SCIENCE			English	Article							TEMPERATURE-DEPENDENT BIOGEOGRAPHY; PHYSIOLOGICAL-BASIS; GADUS-MORHUA; TRADE-OFFS; COD; RECRUITMENT; PERFORMANCE; EVOLUTION; GROWTH; SEA	A cause-and-effect understanding of climate influences on ecosystems requires evaluation of thermal limits of member species and of their ability to cope with changing temperatures. Laboratory data available for marine fish and invertebrates from various climatic regions led to the hypothesis that, as a unifying principle, a mismatch between the demand for oxygen and the capacity of oxygen supply to tissues is the first mechanism to restrict whole-animal tolerance to thermal extremes. We show in the eelpout, Zoarces viviparus, a bioindicator fish species for environmental monitoring from North and Baltic Seas (Helcom), that thermally limited oxygen delivery closely matches environmental temperatures beyond which growth performance and abundance decrease. Decrements in aerobic performance in warming seas will thus be the first process to cause extinction or relocation to cooler waters.	Alfred Wegener Inst Polar & Marine Res, D-27515 Bremerhaven, Germany	Helmholtz Association; Alfred Wegener Institute, Helmholtz Centre for Polar & Marine Research	Portner, HO (corresponding author), Alfred Wegener Inst Polar & Marine Res, Postfach 12 01 61, D-27515 Bremerhaven, Germany.	hpoertner@awi-bremerhaven.de	Pörtner, Hans-O./K-9429-2016	Pörtner, Hans-O./0000-0001-6535-6575				Beaugrand G, 2003, NATURE, V426, P661, DOI 10.1038/nature02164; Fonds M, 1989, G31 INT COUNC EXPL S; Frederich M, 2000, AM J PHYSIOL-REG I, V279, pR1531, DOI 10.1152/ajpregu.2000.279.5.R1531; Hardewig I, 1999, J COMP PHYSIOL B, V169, P597, DOI 10.1007/s003600050260; HELAOUET P, IN PRESS MAR ECOL PR; Jensen MN, 2003, SCIENCE, V299, P38, DOI 10.1126/science.299.5603.38; Johnston IA, 1998, J EXP BIOL, V201, P1; KUNDZEWICZ ZW, 2001, IMPACTS ADAPTATION V, P641; Lannig G, 2004, AM J PHYSIOL-REG I, V287, pR902, DOI 10.1152/ajpregu.00700.2003; Linton TK, 1998, CAN J FISH AQUAT SCI, V55, P576, DOI 10.1139/cjfas-55-3-576; Mark FC, 2002, AM J PHYSIOL-REG I, V283, pR1254, DOI 10.1152/ajpregu.00167.2002; Perry AL, 2005, SCIENCE, V308, P1912, DOI 10.1126/science.1111322; Portner HO, 2006, DEEP-SEA RES PT II, V53, P1071, DOI 10.1016/j.dsr2.2006.02.015; Portner H.-O., 2005, FISH PHYSIOL, V22, P79, DOI DOI 10.1016/S1546-5098(04)22003-9; Portner HO, 2002, COMP BIOCHEM PHYS A, V132, P739, DOI 10.1016/S1095-6433(02)00045-4; Portner HO, 2006, PHYSIOL BIOCHEM ZOOL, V79, P295, DOI 10.1086/499986; Portner HO, 2004, PHYSIOL BIOCHEM ZOOL, V77, P959, DOI 10.1086/423742; Portner HO, 2004, RESP PHYSIOL NEUROBI, V141, P243, DOI 10.1016/j.resp.2004.03.011; Portner HO, 2001, NATURWISSENSCHAFTEN, V88, P137; Portner HO, 2002, J EXP BIOL, V205, P2217; Portner HO, 2001, CONT SHELF RES, V21, P1975, DOI 10.1016/S0278-4343(01)00038-3; Rodnick KJ, 2004, J FISH BIOL, V64, P310, DOI 10.1111/j.0022-1112.2004.00292.x; Sartoris FJ, 2003, J FISH BIOL, V62, P1239, DOI 10.1046/j.1095-8649.2003.00099.x; Sheppard C, 2004, MAR POLLUT BULL, V49, P12, DOI 10.1016/j.marpolbul.2004.05.011; Sogard SM, 1997, B MAR SCI, V60, P1129; *SYST SOFTW INT, SIGMAPLOT; TIEWS K, 1983, ARCH FISCHEREIWISS, V34, P4; TIEWS K, 1990, VEROFF I KUST BINNEN, V103, P1; ULLEWEIT J, 1995, THESIS U BREMEN BREM; Van Dijk PLM, 1999, J EXP BIOL, V202, P3611; Wiltshire KH, 2004, HELGOLAND MAR RES, V58, P269, DOI 10.1007/s10152-004-0196-0; Zakhartsev MV, 2003, J COMP PHYSIOL B, V173, P365, DOI 10.1007/s00360-003-0342-z	32	1323	1346	7	641	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 5	2007	315	5808					95	97		10.1126/science.1135471	http://dx.doi.org/10.1126/science.1135471			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	122WU	17204649				2022-12-28	WOS:000243259100043
J	Chen, HY; Yu, SL; Chen, CH; Chang, GC; Chen, CY; Yuan, A; Cheng, CL; Wang, CH; Terng, HJ; Kao, SF; Chan, WK; Li, HN; Liu, CC; Singh, S; Chen, WJ; Chen, JJW; Yang, PC				Chen, Hsuan-Yu; Yu, Sung-Liang; Chen, Chun-Houh; Chang, Gee-Chen; Chen, Chih-Yi; Yuan, Ang; Cheng, Chiou-Ling; Wang, Chien-Hsun; Terng, Harn-Jing; Kao, Shu-Fang; Chan, Wing-Kai; Li, Han-Ni; Liu, Chun-Chi; Singh, Sher; Chen, Wei J.; Chen, Jeremy J. W.; Yang, Pan-Chyr			A five-gene signature and clinical outcome in non-small-cell lung cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GENE-EXPRESSION; PLASMINOGEN-ACTIVATOR; TYROSINE KINASE; MICROARRAY DATA; ADENOCARCINOMA; SURVIVAL; CLASSIFICATION; METASTASIS; INVASION; PREDICTION	BACKGROUND: Current staging methods are inadequate for predicting the outcome of treatment of non-small-cell lung cancer (NSCLC). We developed a five-gene signature that is closely associated with survival of patients with NSCLC. METHODS: We used computer-generated random numbers to assign 185 frozen specimens for microarray analysis, real-time reverse-transcriptase polymerase chain reaction (RT-PCR) analysis, or both. We studied gene expression in frozen specimens of lung-cancer tissue from 125 randomly selected patients who had undergone surgical resection of NSCLC and evaluated the association between the level of expression and survival. We used risk scores and decision-tree analysis to develop a gene-expression model for the prediction of the outcome of treatment of NSCLC. For validation, we used randomly assigned specimens from 60 other patients. RESULTS: Sixteen genes that correlated with survival among patients with NSCLC were identified by analyzing microarray data and risk scores. We selected five genes (DUSP6, MMD, STAT1, ERBB3, and LCK) for RT-PCR and decision-tree analysis. The five-gene signature was an independent predictor of relapse-free and overall survival. We validated the model with data from an independent cohort of 60 patients with NSCLC and with a set of published microarray data from 86 patients with NSCLC. CONCLUSIONS: Our five-gene signature is closely associated with relapse-free and overall survival among patients with NSCLC.	Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan; Natl Taiwan Univ, Coll Publ Hlth, Taipei 10764, Taiwan; Natl Taiwan Univ, Coll Med, Taipei 10764, Taiwan; Acad Sinica, Taipei 115, Taiwan; Advpharma, Taipei, Taiwan; Taichung Vet Gen Hosp, Taichung, Taiwan; Natl Chung Hsing Univ, Taichung 40227, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University; Academia Sinica - Taiwan; Taichung Veterans General Hospital; National Chung Hsing University	Yang, PC (corresponding author), Natl Taiwan Univ Hosp, Dept Internal Med, 7 Chung Shan S Rd, Taipei 100, Taiwan.	pcyang@ha.mc.ntu.edu.tw	Yang, Pan-Chyr/B-8808-2009; Chen, Hsuan-Yu/AAE-8428-2019; Chen, Chun-houh/AAP-2640-2021	Chen, Chun-houh/0000-0003-0899-7477; Chen, Jeremy J.W./0000-0003-1049-3825; Chan, Wing-Kai/0000-0002-5328-548X; YANG, PAN-CHYR/0000-0001-6330-6048; YUAN, ANG/0000-0002-5664-1339; Chen, Wei Jen/0000-0001-5899-5870; YU, SUNG-LIANG/0000-0003-4535-9036				Bast RC, 2004, NEW ENGL J MED, V351, P2865, DOI 10.1056/NEJMe048300; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Bieche I, 1999, CLIN CHEM, V45, P1148; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Chen JJW, 2005, J CLIN ONCOL, V23, P953, DOI 10.1200/JCO.2005.12.172; Chen JJW, 1998, GENOMICS, V51, P313, DOI 10.1006/geno.1998.5354; Chen JJW, 2001, CANCER RES, V61, P5223; COX DR, 1972, J R STAT SOC B, V34, P187; Endoh H, 2004, J CLIN ONCOL, V22, P811, DOI 10.1200/JCO.2004.04.109; Furukawa T, 2003, AM J PATHOL, V162, P1807, DOI 10.1016/S0002-9440(10)64315-5; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Garber ME, 2002, P NATL ACAD SCI USA, V99, P1098; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Gordon GJ, 2002, CANCER RES, V62, P4963; Granville CA, 2005, AM J RESP CELL MOL, V32, P169, DOI 10.1165/rcmb.F290; Hoffman PC, 2000, LANCET, V355, P1280; Hoheisel JD, 2006, NAT REV GENET, V7, P200, DOI 10.1038/nrg1809; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Koziol JA, 2003, CLIN CANCER RES, V9, P5120; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Le Chevalier T, 2004, NEW ENGL J MED, V350, P351, DOI 10.1056/nejmoa031644; Lossos IS, 2004, NEW ENGL J MED, V350, P1828, DOI 10.1056/NEJMoa032520; Ludwig JA, 2005, NAT REV CANCER, V5, P845, DOI 10.1038/nrc1739; Mahabeleshwar GH, 2004, J BIOL CHEM, V279, P9733, DOI 10.1074/jbc.M311400200; Mahabeleshwar GH, 2003, J BIOL CHEM, V278, P52598, DOI 10.1074/jbc.M308941200; Muller-Tidow C, 2005, CANCER RES, V65, P1778, DOI 10.1158/0008-5472.CAN-04-3388; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Ramaswamy S, 2004, NEW ENGL J MED, V350, P1814, DOI 10.1056/NEJMp048059; Rehli M, 1995, BIOCHEM BIOPH RES CO, V217, P661, DOI 10.1006/bbrc.1995.2825; ROSNER R, 2000, FUNDAMENTALS BIOSTAT; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; SHAFER J, 1996, P 22 INT C VER LARG; Shih JY, 2001, JNCI-J NATL CANCER I, V93, P1392, DOI 10.1093/jnci/93.18.1392; *STRAND GEN PVT LT, 2004, AV US MAN; Tsao MS, 2005, NEW ENGL J MED, V353, P133, DOI 10.1056/NEJMoa050736; Wang CC, 2005, ONCOGENE, V24, P4081, DOI 10.1038/sj.onc.1208573; Wigle DA, 2002, CANCER RES, V62, P3005; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Zamoyska R, 2003, IMMUNOL REV, V191, P107, DOI 10.1034/j.1600-065X.2003.00015.x; Zhang HP, 2001, P NATL ACAD SCI USA, V98, P6730, DOI 10.1073/pnas.111153698	41	717	744	4	82	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 4	2007	356	1					11	20		10.1056/NEJMoa060096	http://dx.doi.org/10.1056/NEJMoa060096			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	122EX	17202451	Green Published, Bronze			2022-12-28	WOS:000243209600004
J	Greenaway, C; Dongier, P; Boivin, JF; Tapiero, B; Miller, M; Schwartzman, K				Greenaway, Christina; Dongier, Pierre; Boivin, Jean-Francois; Tapiero, Bruce; Miller, Mark; Schwartzman, Kevin			Susceptibility to measles, mumps, and rubella in newly arrived adult immigrants and refugees	ANNALS OF INTERNAL MEDICINE			English	Article							VISITING FRIENDS; UNITED-STATES; EPIDEMIOLOGY; ELIMINATION	Background: Despite effective vaccination programs for measles, mumps, and rubella in the United States and Canada, outbreaks continue to occur in susceptible subgroups, such as foreign-born persons. Objective: To determine the susceptibility of newly arrived immigrants and refugees to measles, mumps, and rubella. Design: Seroprevalence study. etting: Two hospitals and three community clinics in Montreal, Quebec, Canada. Patients: 1480 adult immigrants and refugees who were recruited from October 2002 to December 2004. Measurements: Sociodemographic and clinical data and serology for measles, mumps, and rubella. Results: Thirty-six percent (range, 22% to 54%) of the study population was nonimmune to at least 1 of the 3 diseases. This proportion varied by age, sex, and region of origin. In multivariate analysis and after adjustment for region of origin, age, and socioeconomic factors, immigrant women had higher odds (odds ratio, 2.1) of being immune to measles (95% CI, 1.2 to 3.8) and an odds ratio of 1.7 of being nonimmune to rubella (CI, 1.2 to 2.6) compared with immigrant men. Limitations: The results from the community-based convenience sample of immigrants may not be generalizable to all immigrant populations. Conclusions: Many new immigrants and refugees, particularly women, are susceptible to measles, mumps, or rubella and may benefit from targeted vaccination programs.	McGill Univ, Sir Mortimer B Davis Jewish Hosp, Cote des Neiges Local Community Hlth Ctr, Div Infect Dis, Montreal, PQ H3T 1E2, Canada; Hop St Justine, Montreal, PQ H3T 1C5, Canada	McGill University; Universite de Montreal	Greenaway, C (corresponding author), McGill Univ, Sir Mortimer B Davis Jewish Hosp, Cote des Neiges Local Community Hlth Ctr, Div Infect Dis, 3755 Cote St Catherine Rd,Room G-143, Montreal, PQ H3T 1E2, Canada.	ca.greenaway@mcgill.ca						Angell SY, 2005, ANN INTERN MED, V142, P67, DOI 10.7326/0003-4819-142-1-200501040-00013; Centers of Disease Control and Prevention, 2001, MMWR Recomm Rep, V50, P1, DOI 10.1103/PhysRevE.106.055304; Bacaner N, 2004, JAMA-J AM MED ASSOC, V291, P2856, DOI 10.1001/jama.291.23.2856; Barnett ED, 2002, CLIN INFECT DIS, V35, P403, DOI 10.1086/341772; *CAN NAT REP IMM, 1999, PEADIAT CHILD HL SC, V4, pC5; *CDC, TECHN INSTR PAN PHYS; Gershman K., 2006, Morbidity and Mortality Weekly Report, V55, P559; *IMM QUEB GOV QUEB, 2001, PORTR IMM POP 2001 C; King A, 2004, J INFECT DIS, V189, pS236, DOI 10.1086/378499; Oster NV, 2004, J INFECT DIS, V189, pS48, DOI 10.1086/374854; Papania MJ, 2004, J INFECT DIS, V189, pS61, DOI 10.1086/381557; Reef SE, 2002, JAMA-J AM MED ASSOC, V287, P464, DOI 10.1001/jama.287.4.464; *STAT CAN, 2001, IMM CIT 2001 CENS OT; U.S. Census Bureau, 2000 CENS POP HOUS; United Nations, 2002, INT MIGR REP 2002; *WHO, 2004, WHO VACC PREV DIS MO; Willis Bayo C., 2005, Morbidity and Mortality Weekly Report, V54, P1; 1994, MMWR MORB MORTAL WKL, V43, P391; 1994, MMWR MORB MORTAL WKL, V43, P397	19	33	33	1	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 2	2007	146	1					20	W4		10.7326/0003-4819-146-1-200701020-00005	http://dx.doi.org/10.7326/0003-4819-146-1-200701020-00005			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188BK	17200218				2022-12-28	WOS:000247893300003
J	Sandblad, L; Busch, KE; Tittmann, P; Gross, H; Brunner, D; Hoenger, A				Sandblad, Linda; Busch, Karl Emanuel; Tittmann, Peter; Gross, Heinz; Brunner, Damian; Hoenger, Andreas			The Schizosaccharomyces pombe EB1 homolog Mal3p binds and stabilizes the microtubule lattice seam	CELL			English	Article							END-TRACKING PROTEINS; 3-DIMENSIONAL STRUCTURE; STRUCTURAL INSIGHTS; BETA-TUBULIN; IN-VITRO; KINESIN; TIP1P; DECORATION; COOPERATE; DYNAMICS	End binding 1 (EB1) proteins are highly conserved regulators of microtubule dynamics. Using electron microscopy (EM) and high-resolution surface shadowing we have studied the microtubule-binding properties of the fission yeast EB1 homolog Mal3p. This allowed for a direct visualization of Mal3p bound on the surface of microtubules. Mal3p particles usually formed a single line on each microtubule along just one of the multiple grooves that are formed by adjacent protofilaments. We provide structural data showing that the alignment of Mal3p molecules coincides with the microtubule lattice seam as well as data suggesting that Mal3p not only binds but also stabilizes this seam. Accordingly, Mal3p stabilizes microtubules through a specific interaction with what is potentially the weakest part of the microtubule in a way not previously demonstrated. Our findings further suggest that microtubules exhibit two distinct reaction platforms on their surface that can independently interact with target structures such as microtubule-associated proteins, motors, kinetochores, or membranes.	European Mol Biol Lab, Cell Biol & Biophys Unit, D-69117 Heidelberg, Germany; European Mol Biol Lab, Struct & Computat Biol Unit, D-69117 Heidelberg, Germany; ETH, Swiss Fed Inst Technol, Electron Microscopy Ctr, CH-8093 Zurich, Switzerland; Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA	European Molecular Biology Laboratory (EMBL); European Molecular Biology Laboratory (EMBL); Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Colorado System; University of Colorado Boulder	Brunner, D (corresponding author), European Mol Biol Lab, Cell Biol & Biophys Unit, D-69117 Heidelberg, Germany.	brunner@embl.de; andreas.hoenger@colorado.edu	Brunner, Damian/F-2024-2011	Busch, Karl Emanuel/0000-0001-7886-3226; Brunner, Damian/0000-0001-5250-492X; Hoenger, Andreas/0000-0001-9176-6658				AFZELIUS BA, 1990, J CELL SCI, V95, P207; Akhmanova A, 2005, CURR OPIN CELL BIOL, V17, P47, DOI 10.1016/j.ceb.2004.11.001; AMOS LA, 1979, NATURE, V279, P607, DOI 10.1038/279607a0; AMOS LA, 1974, J CELL SCI, V14, P523; Arnal I, 2004, CURR BIOL, V14, P2086, DOI 10.1016/j.cub.2004.11.055; Austin JR, 2005, J CELL SCI, V118, P3895, DOI 10.1242/jcs.02512; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Beinhauer JD, 1997, J CELL BIOL, V139, P717, DOI 10.1083/jcb.139.3.717; BEURON F, 2001, STRUCTURAL ANAL MICR, V164; Browning H, 2003, NAT CELL BIOL, V5, P812, DOI 10.1038/ncb1034; Brunner D, 2000, CELL, V102, P695, DOI 10.1016/S0092-8674(00)00091-X; Busch KE, 2004, CURR BIOL, V14, P548, DOI 10.1016/j.cub.2004.03.029; Busch KE, 2004, DEV CELL, V6, P831, DOI 10.1016/j.devcel.2004.05.008; CHRETIEN D, 1991, BIOL CELL, V71, P161, DOI 10.1016/0248-4900(91)90062-R; Chretien D, 1996, STRUCTURE, V4, P1031, DOI 10.1016/S0969-2126(96)00110-4; CHRETIEN D, 1995, J CELL BIOL, V129, P1311, DOI 10.1083/jcb.129.5.1311; Dias DP, 1999, J MOL BIOL, V287, P287, DOI 10.1006/jmbi.1999.2597; Ebneth A, 1998, J CELL BIOL, V143, P777, DOI 10.1083/jcb.143.3.777; GASKIN F, 1974, J MOL BIOL, V89, P737, DOI 10.1016/0022-2836(74)90048-5; Gimona M, 2002, FEBS LETT, V513, P98, DOI 10.1016/S0014-5793(01)03240-9; GROSS H, 1990, 12TH P INT C MICR, V1, P510; Hayashi I, 2003, J BIOL CHEM, V278, P36430, DOI 10.1074/jbc.M305773200; Hoenger A, 2000, J MOL BIOL, V297, P1087, DOI 10.1006/jmbi.2000.3627; Hoenger A, 2000, BIOL CHEM, V381, P1001, DOI 10.1515/BC.2000.123; HOENGER A, 1995, NATURE, V376, P271, DOI 10.1038/376271a0; Honnappa S, 2005, EMBO J, V24, P261, DOI 10.1038/sj.emboj.7600529; KIKKAWA M, 1994, J CELL BIOL, V127, P1965, DOI 10.1083/jcb.127.6.1965; Ligon LA, 2006, FEBS LETT, V580, P1327, DOI 10.1016/j.febslet.2006.01.050; Ligon LA, 2003, MOL BIOL CELL, V14, P1405, DOI 10.1091/mbc.E02-03-0155; Liu Q, 2004, J NEUROSCI, V24, P6427, DOI 10.1523/JNEUROSCI.1335-04.2004; MANDELKOW EM, 1985, J MOL BIOL, V181, P123, DOI 10.1016/0022-2836(85)90330-4; Mennella V, 2005, NAT CELL BIOL, V7, P235, DOI 10.1038/ncb1222; Mimori-Kiyosue Y, 2000, CURR BIOL, V10, P865, DOI 10.1016/S0960-9822(00)00600-X; Muller-Reichert T, 1998, P NATL ACAD SCI USA, V95, P3661, DOI 10.1073/pnas.95.7.3661; Nakamura M, 2001, CURR BIOL, V11, P1062, DOI 10.1016/S0960-9822(01)00297-4; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; Nogales E, 2006, CURR OPIN CELL BIOL, V18, P179, DOI 10.1016/j.ceb.2006.02.009; Oliva MA, 2004, NAT STRUCT MOL BIOL, V11, P1243, DOI 10.1038/nsmb855; Santarella RA, 2004, J MOL BIOL, V339, P539, DOI 10.1016/j.jmb.2004.04.008; Seitz A, 2002, EMBO J, V21, P4896, DOI 10.1093/emboj/cdf503; SMITH PR, 1977, J ULTRA MOL STRUCT R, V61, P124, DOI 10.1016/S0022-5320(77)90011-9; SONG YH, 1995, J CELL BIOL, V128, P81, DOI 10.1083/jcb.128.1.81; SONG YH, 1993, P NATL ACAD SCI USA, V90, P1671, DOI 10.1073/pnas.90.5.1671; Song YH, 2001, EMBO J, V20, P6213, DOI 10.1093/emboj/20.22.6213; Sosa H, 1996, J MOL BIOL, V260, P743, DOI 10.1006/jmbi.1996.0434; SU LK, 1995, CANCER RES, V55, P2972; Wang HW, 2005, CELL CYCLE, V4, P1157, DOI 10.4161/cc.4.9.2042	47	123	125	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 29	2006	127	7					1415	1424		10.1016/j.cell.2006.11.025	http://dx.doi.org/10.1016/j.cell.2006.11.025			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	128WI	17190604	Bronze			2022-12-28	WOS:000243690000020
J	Varshavsky, A				Varshavsky, Alexander			Discovering the RNA double helix and hybridization	CELL			English	Editorial Material							HYBRID HELIX; POLYNUCLEOTIDES; ACIDS; DNA	The discovery, 50 years ago, that RNA could form a double helix made possible a number of advances, including an understanding that led, decades later, to the discovery of microRNAs and RNA interference. Remarkably, the first nucleic acid hybridization reaction was also described in the same report.	CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology	Varshavsky, A (corresponding author), CALTECH, Div Biol, Pasadena, CA 91125 USA.	avarsh@caltech.edu						DAY RO, 1973, P NATL ACAD SCI USA, V70, P849, DOI 10.1073/pnas.70.3.849; DOTY P, 1960, P NATL ACAD SCI USA, V46, P461, DOI 10.1073/pnas.46.4.461; FELSENFELD G, 1957, BIOCHIM BIOPHYS ACTA, V26, P457, DOI 10.1016/0006-3002(57)90091-4; FELSENFELD G, 1957, J AM CHEM SOC, V79, P2023, DOI 10.1021/ja01565a074; GRUNBERGMANAGO M, 1955, SCIENCE, V122, P907, DOI 10.1126/science.122.3176.907; HALL BD, 1961, P NATL ACAD SCI USA, V47, P137, DOI 10.1073/pnas.47.2.137; Rich A, 2006, J BIOL CHEM, V281, P7693, DOI 10.1074/JBC.X600003200; Rich A, 2004, ANNU REV BIOCHEM, V73, P1, DOI 10.1146/annurev.biochem.73.011303.073945; RICH A, 1954, NATURE, V173, P995, DOI 10.1038/173995a0; Rich A, 1956, J AM CHEM SOC, V78, P3548, DOI 10.1021/ja01595a086; RICH A, 1960, P NATL ACAD SCI USA, V46, P1044, DOI 10.1073/pnas.46.8.1044; RICH A, 1954, P NATL ACAD SCI USA, V40, P759, DOI 10.1073/pnas.40.8.759; ROSENBERG JM, 1973, NATURE, V243, P150, DOI 10.1038/243150a0; WARNER RC, 1956, FED PROC, V15, P379; WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0	15	9	10	3	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 29	2006	127	7					1295	1297		10.1016/j.cell.2006.12.008	http://dx.doi.org/10.1016/j.cell.2006.12.008			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	128WI	17190591	Bronze			2022-12-28	WOS:000243690000006
J	Kushel, MB; Miaskowski, C				Kushel, Margot B.; Miaskowski, Christine			End-of-life care for homeless patients - "She says she is there to help me in any situation"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SEVERE MENTAL-ILLNESS; NEW-YORK-CITY; UNITED-STATES; MEDICAL-CARE; RISK-FACTORS; CONTROLLED SUBSTANCES; SUSTAINING TREATMENT; OPIOID DEPENDENCE; PAIN MANAGEMENT; ADULTS	Homelessness annually affects an estimated 2.3 million to 3.5 million individuals living in the United States. Homeless people face difficulties in meeting their basic needs. Many have substance abuse problems and mental illness, lack social support, and have no medical insurance. These challenges complicate the homeless patient's ability to engage in end-of-life advanced planning, adhere to medications, and find an adequate site to receive terminal care. Employing a multidisciplinary team to care for homeless patients can help address their needs and improve care. For patients who continue to use illicit substances while receiving end-of-life care, experts recommend scheduling frequent clinic visits, using long-acting pain medications, dispensing small quantities of medications at a time, and using a written pain agreement. Homeless people are less likely to have a surrogate decision maker. Clinicians should have frequent, well-documented conversations with these patients about end-of-life wishes. Homeless people can rarely use hospice services because they lack the financial resources for inpatient hospice and have neither the home nor the social support required for home hospice. Developing inpatient palliative care services at hospitals that serve many homeless people could improve the end-of-life care homeless people receive.	Univ Calif San Francisco, Sch Nursing, Dept Physiol Nursing, San Francisco, CA 94143 USA; Univ Calif San Francisco, San Francisco Gen Hosp, Div Gen Internal Med, San Francisco, CA USA	University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	Kushel, MB (corresponding author), Univ Calif San Francisco, Sch Nursing, Dept Physiol Nursing, Box 1364, San Francisco, CA 94143 USA.	mkushel@medsfgh.ucsf.edu		Kushel, Margot/0000-0002-1361-6889	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [K08HS011415] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA107091] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR003923] Funding Source: NIH RePORTER; AHRQ HHS [K08 HS011415] Funding Source: Medline; NCI NIH HHS [CA107091] Funding Source: Medline; NINR NIH HHS [NR03923] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		ASCH DA, 1995, AM J RESP CRIT CARE, V151, P288, DOI 10.1164/ajrccm.151.2.7842181; Ashburn MA, 2003, PRINCIPLES ANALGESIC; Bamberger JD, 2000, AM J PUBLIC HEALTH, V90, P699, DOI 10.2105/AJPH.90.5.699; Barrow SM, 1999, AM J PUBLIC HEALTH, V89, P529, DOI 10.2105/AJPH.89.4.529; Blendon RJ, 1998, JAMA-J AM MED ASSOC, V279, P827, DOI 10.1001/jama.279.11.827; Bonin E., 2004, ADAPTING YOUR PRACTI; Buchanan D, 2006, AM J PUBLIC HEALTH, V96, P1278, DOI 10.2105/AJPH.2005.067850; Burt M. R., 2006, CHARACTERISTICS TRAN; BURT MR, 1999, HOMELESSNESS PROGRAM; Burt MR, 2001, HELPING AM HOMELESS; Caton CLM, 2005, AM J PUBLIC HEALTH, V95, P1753, DOI 10.2105/AJPH.2005.063321; Caton CLM, 2000, AM J PUBLIC HEALTH, V90, P258, DOI 10.2105/AJPH.90.2.258; Cicero TJ, 2005, J PAIN, V6, P662, DOI 10.1016/j.jpain.2005.05.004; Culhane DP, 2002, HOUS POLICY DEBATE, V13, P107, DOI 10.1080/10511482.2002.9521437; Cunningham WE, 1999, MED CARE, V37, P1270, DOI 10.1097/00005650-199912000-00010; Dumais A, 2005, AM J PSYCHIAT, V162, P2116, DOI 10.1176/appi.ajp.162.11.2116; *FED STAT MED BOAR, PAIN POL RES CTR WEB; *FED STAT MED BOAR, 2004, MOD POL US CONTR SUB; Fishman SM, 1999, J PAIN SYMPTOM MANAG, V18, P27, DOI 10.1016/S0885-3924(99)00035-4; Fishman SM, 2002, CLIN J PAIN, V18, pS70, DOI 10.1097/00002508-200207001-00008; Friedmann PD, 2006, MED CARE, V44, P8, DOI 10.1097/01.mlr.0000188913.50489.77; Gelberg L, 1997, AM J PUBLIC HEALTH, V87, P217, DOI 10.2105/AJPH.87.2.217; GELBERG L, 1989, JAMA-J AM MED ASSOC, V262, P1973, DOI 10.1001/jama.262.14.1973; Gilson AM, 2001, J PAIN SYMPTOM MANAG, V21, P227, DOI 10.1016/S0885-3924(00)00263-3; Grant BF, 2005, J CLIN PSYCHIAT, V66, P1205, DOI 10.4088/JCP.v66n1001; Hernandez M, 2005, CURR OPIN ANESTHESIO, V18, P315, DOI 10.1097/01.aco.0000169241.21680.0b; HIBBS JR, 1994, NEW ENGL J MED, V331, P304, DOI 10.1056/NEJM199408043310506; *HLTH CAR HOM CLIN, 2004, HEAL HANDS HCH CLIN; Hwang SW, 2000, CAN MED ASSOC J, V163, P161; Hwang SW, 1997, ANN INTERN MED, V126, P625, DOI 10.7326/0003-4819-126-8-199704150-00007; Hwang SW, 2000, JAMA-J AM MED ASSOC, V283, P2152, DOI 10.1001/jama.283.16.2152; Johnson RE, 2000, NEW ENGL J MED, V343, P1290, DOI 10.1056/NEJM200011023431802; Joranson DE, 2002, J PAIN SYMPTOM MANAG, V23, P138, DOI 10.1016/S0885-3924(01)00403-1; KARP N, 2003, INCAPACITATED HLTH C; Kertesz SG, 2005, MED CARE, V43, P574, DOI 10.1097/01.mlr.0000163652.91463.b4; Kessell ER, 2006, J URBAN HEALTH, V83, P860, DOI 10.1007/s11524-006-9083-0; Kirkpatrick AF, 1998, J CLIN ANESTH, V10, P435, DOI 10.1016/S0952-8180(98)00062-2; Korkeila JA, 2005, COMPR PSYCHIAT, V46, P447, DOI 10.1016/j.comppsych.2005.03.008; Krantz MJ, 2004, ARCH INTERN MED, V164, P277, DOI 10.1001/archinte.164.3.277; Kushel MB, 2001, JAMA-J AM MED ASSOC, V285, P200, DOI 10.1001/jama.285.2.200; Kushel MB, 2002, AM J PUBLIC HEALTH, V92, P778, DOI 10.2105/AJPH.92.5.778; LING W, 1994, J PSYCHOACTIVE DRUGS, V26, P119, DOI 10.1080/02791072.1994.10472259; LINHORST DM, 1991, COMMUNITY MENT HLT J, V27, P135, DOI 10.1007/BF00752816; Lipton FR, 2000, PSYCHIATR SERV, V51, P479, DOI 10.1176/appi.ps.51.4.479; Loas G, 2005, PSYCHIAT RES, V137, P103, DOI 10.1016/j.psychres.2004.06.022; MARTELL JV, 1992, ANN INTERN MED, V116, P299, DOI 10.7326/0003-4819-116-4-299; Merrill J, 2002, J GEN INTERN MED, V17, P327, DOI 10.1046/j.1525-1497.2002.10625.x; MIASKOWSKI C, 2005, CLIN PRACTICE GUIDEL, V3; Morrison RS, 2005, J PALLIAT MED, V8, P1127, DOI 10.1089/jpm.2005.8.1127; Moss AR, 2004, CLIN INFECT DIS, V39, P1190, DOI 10.1086/424008; Norris WM, 2005, CHEST, V127, P2180, DOI 10.1378/chest.127.6.2180; O'Connor PG, 2000, ANN INTERN MED, V133, P40, DOI 10.7326/0003-4819-133-1-200007040-00008; Passik S. D., 2002, PRINCIPLES PRACTICE; Passik SD, 2001, J PAIN SYMPTOM MANAG, V21, P359, DOI 10.1016/S0885-3924(01)00279-2; Passik Steven D, 2002, J Pain Palliat Care Pharmacother, V16, P39; Passik Steven D, 2004, Curr Pain Headache Rep, V8, P289, DOI 10.1007/s11916-004-0010-3; Rosenheck R, 2003, ARCH GEN PSYCHIAT, V60, P940, DOI 10.1001/archpsyc.60.9.940; Rosenheck R, 1998, MED CARE, V36, P1256, DOI 10.1097/00005650-199808000-00013; Salit SA, 1998, NEW ENGL J MED, V338, P1734, DOI 10.1056/NEJM199806113382406; Song J, 2005, J CLIN ETHIC, V16, P251; Tarzian Anita J, 2005, J Palliat Med, V8, P36, DOI 10.1089/jpm.2005.8.36; Tsai M, 2005, J HEALTH CARE POOR U, V16, P297, DOI 10.1353/hpu.2005.0042; Tsemberis S, 2000, PSYCHIATR SERV, V51, P487, DOI 10.1176/appi.ps.51.4.487; Tsemberis S, 2005, PSYCHIAT SERV, V56, P1303; Tulsky JP, 2004, INT J TUBERC LUNG D, V8, P83; *US DEP HOUS URB D, SUPP HOUS PROGR; *US DEP HOUS URB D, HOUS CHOIC VOCH FACT; US Department of Housing and Urban Development, HUDS PUBL HOUS PROGR; WEISSMAN DE, 1989, PAIN, V36, P363, DOI 10.1016/0304-3959(89)90097-3; White DB, 2006, CRIT CARE MED, V34, P2053, DOI 10.1097/01.CCM.0000227654.38708.C1; White KR, 2002, MED CARE, V40, P17, DOI 10.1097/00005650-200201000-00004; Zacny J, 2003, DRUG ALCOHOL DEPEN, V69, P215, DOI 10.1016/S0376-8716(03)00003-6; Zlotnick C, 2003, SUBST USE MISUSE, V38, P577, DOI 10.1081/JA-120017386	73	37	38	0	17	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	2006	296	24					2959	2966		10.1001/jama.296.24.2959	http://dx.doi.org/10.1001/jama.296.24.2959			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	120FD	17190897				2022-12-28	WOS:000243069000028
J	Aylwin, CJ; Konig, TC; Brennan, NW; Shirley, PJ; Davies, G; Walsh, MS; Brohi, K				Aylwin, Christopher J.; Koenig, Thomas C.; Brennan, Nora W.; Shirley, Peter J.; Davies, Gareth; Walsh, Michael S.; Brohi, Karim			Reduction in critical mortality in urban mass casualty incidents: analysis of triage, surge, and resource use after the London bombings on July 7, 2005	LANCET			English	Article							TERRORIST BOMBINGS; TRAUMA CARE; INJURIES; MANAGEMENT; CITY	Background The terrorist bombings in London on July 7, 2005, produced the largest mass casualty event in the UK since World War 2. The aim of this study was to analyse the prehospital and in-hospital response to the incident and identify system processes that optimise resource use and reduce critical mortality. Methods This study was a retrospective analysis of the London-wide prehospital response and the in-hospital response of one academic trauma Centre. Data for injuries, outcome, triage, patient flow, and resource use were obtained by the review of emergency services and hospital records. Findings There were 775 casualties and 56 deaths, 53 at scene. 55 patients were triaged to priority dispatch and 20 patients were critically injured. Critical mortality was low at 15% and not due to poor availability of resources. Over-triage rates were reduced where advanced prehospital teams did initial scene triage. The Royal London Hospital received 194 casualties, 27 arrived as seriously injured. Maximum surge rate was 18 seriously injured patients per hour and resuscitation room capacity was reached within 15 min. 17 patients needed surgery and 264 units of blood products were used in the first 15 h, close to the hospital's routine daily blood use. Interpretation Critical mortality was reduced by rapid advanced major incident management and seems unrelated to over-triage. Hospital surge capacity can be maintained by repeated effective triage and implementing a hospital-wide damage control philosophy, keeping investigations to a minimum, and transferring patients rapidly to definitive care.	Royal London Hosp, Dept Trauma Surg, London E1 1BB, England; Royal London Hosp, Dept Intens Care Med, London E1 1BB, England; Royal London Hosp, Dept Emergency Med & Prehosp Care, London E1 1BB, England	Barts Health NHS Trust; Royal London Hospital; Barts Health NHS Trust; Royal London Hospital; Barts Health NHS Trust; Royal London Hospital	Brohi, K (corresponding author), Royal London Hosp, Dept Trauma Surg, London E1 1BB, England.	karim@trauma.org						[Anonymous], EMERGO TRAIN SYSTEM; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Biancolini CA, 1999, J TRAUMA, V47, P728, DOI 10.1097/00005373-199910000-00019; Christie P M, 1998, J Med Syst, V22, P289; Cushman JG, 2003, J TRAUMA, V54, P147, DOI 10.1097/00005373-200301000-00018; de Ceballos JPG, 2005, CRIT CARE, V9, P104, DOI 10.1186/cc2995; FRYKBERG ER, 1988, ANN SURG, V208, P569, DOI 10.1097/00000658-198811000-00005; Frykberg ER, 2002, J TRAUMA, V53, P201, DOI 10.1097/00005373-200208000-00001; FRYKBERG ER, 1987, MIL MED, V152, P563; Hirshberg A, 1999, J TRAUMA, V47, P545, DOI 10.1097/00005373-199909000-00020; Hirshberg A, 2001, ANN EMERG MED, V37, P647, DOI 10.1067/mem.2001.115650; Hirshberg A, 2005, J TRAUMA, V58, P686, DOI 10.1097/01.TA.0000159243.70507.86; Leibovici D, 1996, J TRAUMA, V41, P1030, DOI 10.1097/00005373-199612000-00015; Lockey DJ, 2005, RESUSCITATION, V66, pIX, DOI 10.1016/j.resuscitation.2005.07.005; *LOND EM SERV LIAI, MAJ INC PROC MAN; Mackway-Jones K, 2019, MAJOR INCIDENT MEDIC, V2; Mallonee S, 1996, JAMA-J AM MED ASSOC, V276, P382, DOI 10.1001/jama.276.5.382; Moore FA, 2004, LANCET, V363, P1988, DOI 10.1016/S0140-6736(04)16415-5; Schmidt PJ, 2002, NEW ENGL J MED, V346, P617, DOI 10.1056/NEJM200202213460813; *WHO, 2005, WHO ANN REP HLTH ACT	20	270	279	2	34	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 23	2006	368	9554					2219	2225		10.1016/S0140-6736(06)69896-6	http://dx.doi.org/10.1016/S0140-6736(06)69896-6			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	120HY	17189033				2022-12-28	WOS:000243076800029
J	Christensen, K; Herskind, AM; Vaupel, JW				Christensen, Kaare; Herskind, Anne Maria; Vaupel, James W.			Why Danes are smug: comparative study of life satisfaction in the European Union	BRITISH MEDICAL JOURNAL			English	Editorial Material							POPULATION; MORTALITY; HAPPINESS; DEATH		Univ So Denmark, Inst Publ Hlth, DK-5000 Odense C, Denmark; Odense Univ Hosp, Dept Paediat, Odense, Denmark; Max Planck Inst Demog Res, D-18057 Rostock, Germany	University of Southern Denmark; University of Southern Denmark; Odense University Hospital; Max Planck Society	Christensen, K (corresponding author), Univ So Denmark, Inst Publ Hlth, JB Winslowsvej 9B, DK-5000 Odense C, Denmark.	kchristensen@health.sdu.dk	Christensen, Kaare/C-2360-2009	Christensen, Kaare/0000-0002-5429-5292; Vaupel, James/0000-0003-0783-3905				[Anonymous], 2005, ESTIMATING LIFE CYCL; DIENER E, 1995, J PERS SOC PSYCHOL, V69, P851, DOI 10.1037/0022-3514.69.5.851; Easterlin RA, 2003, P NATL ACAD SCI USA, V100, P11176, DOI 10.1073/pnas.1633144100; GINI V, 1955, MEMORIE METODOLOGICA; INGLEHART R, 2000, CULTURE SUBJECTIVE W; Jacobsen R, 2004, EUR J EPIDEMIOL, V19, P117, DOI 10.1023/B:EJEP.0000017834.35943.bd; Kirkup W, 2003, J EPIDEMIOL COMMUN H, V57, P429, DOI 10.1136/jech.57.6.429; Kohler HP, 2005, POPUL DEV REV, V31, P407, DOI 10.1111/j.1728-4457.2005.00078.x; LYKKEN D, 1996, PSYCHOL SCI, V6, P10; Lyubomirsky S, 2001, AM PSYCHOL, V56, P239, DOI 10.1037/0003-066X.56.3.239; SUTER D, 1979, ANN HUM BIOL, V6, P89, DOI 10.1080/03014467900003401; *UNDP, 2005, UNDP PUBL; Witte DR, 2000, BMJ-BRIT MED J, V321, P1552, DOI 10.1136/bmj.321.7276.1552	13	33	33	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 23	2006	333	7582					1289	1291		10.1136/bmj.39028.665602.55	http://dx.doi.org/10.1136/bmj.39028.665602.55			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	121MC	17185710	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000243160700008
J	Sprangers, R; Kay, LE				Sprangers, Remco; Kay, Lewis E.			Quantitative dynamics and binding studies of the 20S proteasome by NMR	NATURE			English	Article							MOLECULAR-WEIGHT PROTEINS; 723-RESIDUE ENZYME; METHYL-GROUPS; SPECTROSCOPY; RELAXATION; DEGRADATION; RESOLUTION; COMPLEX; ASSIGNMENTS; PARTICLE	The machinery used by the cell to perform essential biological processes is made up of large molecular assemblies. One such complex, the proteasome, is the central molecular machine for removal of damaged and misfolded proteins from the cell. Here we show that for the 670-kilodalton 20S proteasome core particle it is possible to overcome the molecular weight limitations that have traditionally hampered quantitative nuclear magnetic resonance (NMR) spectroscopy studies of such large systems. This is achieved by using an isotope labelling scheme where isoleucine, leucine and valine methyls are protonated in an otherwise highly deuterated background in concert with experiments that preserve the lifetimes of the resulting NMR signals. The methodology has been applied to the 20S core particle to reveal functionally important motions and interactions by recording spectra on complexes with molecular weights of up to a megadalton. Our results establish that NMR spectroscopy can provide detailed insight into supra-molecular structures over an order of magnitude larger than those routinely studied using methodology that is generally applicable.	Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med Genet, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Chem, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto; University of Toronto	Kay, LE (corresponding author), Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada.	kay@pound.med.utoronto.ca						Adams J, 2004, NAT REV CANCER, V4, P349, DOI 10.1038/nrc1361; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Benaroudj N, 2003, MOL CELL, V11, P69, DOI 10.1016/S1097-2765(02)00775-X; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Fiaux J, 2002, NATURE, V418, P207, DOI 10.1038/nature00860; Forster A, 2005, MOL CELL, V18, P589, DOI 10.1016/j.molcel.2005.04.016; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Groll M, 2000, NAT STRUCT BIOL, V7, P1062, DOI 10.1038/80992; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Korzhnev DM, 2004, J AM CHEM SOC, V126, P3964, DOI 10.1021/ja039587i; Kwon YD, 2004, J MOL BIOL, V335, P233, DOI 10.1016/j.jmb.2003.08.029; Liu CW, 2003, SCIENCE, V299, P408, DOI 10.1126/science.1079293; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Mittermaier A, 2006, SCIENCE, V312, P224, DOI 10.1126/science.1124964; Nederlof PM, 1995, P NATL ACAD SCI USA, V92, P12060, DOI 10.1073/pnas.92.26.12060; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366; Pickart CM, 2004, NAT REV MOL CELL BIO, V5, P177, DOI 10.1038/nrm1336; Salzmann M, 1998, P NATL ACAD SCI USA, V95, P13585, DOI 10.1073/pnas.95.23.13585; Sharon M, 2006, J BIOL CHEM, V281, P9569, DOI 10.1074/jbc.M511951200; Tugarinov V, 2005, BIOCHEMISTRY-US, V44, P15970, DOI 10.1021/bi0519809; Tugarinov V, 2005, J AM CHEM SOC, V127, P8214, DOI 10.1021/ja0508830; Tugarinov V, 2004, ANNU REV BIOCHEM, V73, P107, DOI 10.1146/annurev.biochem.73.011303.074004; Tugarinov V, 2003, J AM CHEM SOC, V125, P13868, DOI 10.1021/ja030345s; Tugarinov V, 2003, J AM CHEM SOC, V125, P10420, DOI 10.1021/ja030153x; Unno M, 2002, STRUCTURE, V10, P609, DOI 10.1016/S0969-2126(02)00748-7; Whitby FG, 2000, NATURE, V408, P115, DOI 10.1038/35040607; ZWICKL P, 1994, NAT STRUCT BIOL, V1, P765, DOI 10.1038/nsb1194-765	29	386	394	0	87	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 8	2007	445	7128					618	622		10.1038/nature05512	http://dx.doi.org/10.1038/nature05512			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	133UM	17237764				2022-12-28	WOS:000244039400037
J	Xue, W; Zender, L; Miething, C; Dickins, RA; Hernando, E; Krizhanovsky, V; Cordon-Cardo, C; Lowe, SW				Xue, Wen; Zender, Lars; Miething, Cornelius; Dickins, Ross A.; Hernando, Eva; Krizhanovsky, Valery; Cordon-Cardo, Carlos; Lowe, Scott W.			Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas	NATURE			English	Article							CELL SENESCENCE; ONCOGENIC RAS; KILLER-CELLS; SUPPRESSION; CANCER; TUMORIGENESIS; PATHWAY; NEVI	Although cancer arises from a combination of mutations in oncogenes and tumour suppressor genes, the extent to which tumour suppressor gene loss is required for maintaining established tumours is poorly understood. p53 is an important tumour suppressor that acts to restrict proliferation in response to DNA damage or deregulation of mitogenic oncogenes, by leading to the induction of various cell cycle checkpoints, apoptosis or cellular senescence(1,2). Consequently, p53 mutations increase cell proliferation and survival, and in some settings promote genomic instability and resistance to certain chemotherapies(3). To determine the consequences of reactivating the p53 pathway in tumours, we used RNA interference (RNAi) to conditionally regulate endogenous p53 expression in a mosaic mouse model of liver carcinoma(4,5). We show that even brief reactivation of endogenous p53 in p53-deficient tumours can produce complete tumour regressions. The primary response to p53 was not apoptosis, but instead involved the induction of a cellular senescence program that was associated with differentiation and the upregulation of inflammatory cytokines. This program, although producing only cell cycle arrest in vitro, also triggered an innate immune response that targeted the tumour cells in vivo, thereby contributing to tumour clearance. Our study indicates that p53 loss can be required for the maintenance of aggressive carcinomas, and illustrates how the cellular senescence program can act together with the innate immune system to potently limit tumour growth.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Cold Spring Harbor Lab, Howard Hughes Med Inst, Cold Spring Harbor, NY 11724 USA; Mem Sloan Kettering Canc Ctr, Div Mol Pathol, New York, NY 10021 USA	Cold Spring Harbor Laboratory; Cold Spring Harbor Laboratory; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	Lowe, SW (corresponding author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.	lowe@cshl.edu	Dickins, Ross A/K-2852-2012; Miething, Cornelius/F-9498-2014; Krizhanovsky, Valery/D-1336-2010	Dickins, Ross A/0000-0003-4112-5304; Miething, Cornelius/0000-0003-4699-3805; Hernando, Eva/0000-0003-1023-0312; Krizhanovsky, Valery/0000-0002-3977-5482; Xue, Wen/0000-0002-9797-8042	NATIONAL CANCER INSTITUTE [P01CA087497, P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA087497, P30 CA008748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Christophorou MA, 2006, NATURE, V443, P214, DOI 10.1038/nature05077; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Dickins RA, 2005, NAT GENET, V37, P1289, DOI 10.1038/ng1651; Ghiringhelli F, 2006, IMMUNOL REV, V214, P229, DOI 10.1111/j.1600-065X.2006.00445.x; Gorgoulis VG, 2005, LAB INVEST, V85, P502, DOI 10.1038/labinvest.3700241; Gray-Schopfer VC, 2006, BRIT J CANCER, V95, P496, DOI 10.1038/sj.bjc.6603283; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Hong F, 2003, CANCER RES, V63, P9023; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Minamino T, 2003, CIRCULATION, V108, P2264, DOI 10.1161/01.CIR.0000093274.82929.22; Mundt B, 2002, FASEB J, V16, P94, DOI 10.1096/fj.02-0537fje; Roninson IB, 2003, CANCER RES, V63, P2705; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shelton DN, 1999, CURR BIOL, V9, P939, DOI 10.1016/S0960-9822(99)80420-5; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; SHULTZ LD, 1995, J IMMUNOL, V154, P180; Silva JM, 2005, NAT GENET, V37, P1281, DOI 10.1038/ng1650; Staib F, 2003, HUM MUTAT, V21, P201, DOI 10.1002/humu.10176; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; VENTURA A, 2007, NATURE          0124, DOI DOI 10.1038/NATURE05541; Zender L, 2005, COLD SH Q B, V70, P251, DOI 10.1101/sqb.2005.70.059; Zender L, 2006, CELL, V125, P1253, DOI 10.1016/j.cell.2006.05.030	30	1777	1841	14	214	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 8	2007	445	7128					656	660		10.1038/nature05529	http://dx.doi.org/10.1038/nature05529			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	133UM	17251933	Green Accepted			2022-12-28	WOS:000244039400046
J	Yu, JK; Satou, Y; Holland, ND; Shin-I, T; Kohara, Y; Satoh, N; Bronner-Fraser, M; Holland, LZ				Yu, Jr-Kai; Satou, Yutaka; Holland, Nicholas D.; Shin-, Tadasu, I; Kohara, Yuji; Satoh, Noriyuki; Bronner-Fraser, Marianne; Holland, Linda Z.			Axial patterning in cephalochordates and the evolution of the organizer	NATURE			English	Article							TWISTED GASTRULATION; AMPHIOXUS EMBRYOS; NEURAL INDUCTION; XENOPUS EMBRYOS; HEAD ORGANIZER; GENE; MESODERM; ANTAGONISM; EXPRESSION; PHYLOGENY	The organizer of the vertebrate gastrula is an important signalling centre that induces and patterns dorsal axial structures. Although a topic of long-standing interest, the evolutionary origin of the organizer remains unclear. Here we show that the gastrula of the cephalochordate amphioxus expresses dorsal/ventral (D/V) patterning genes (for example, bone morphogenetic proteins (BMPs), Nodal and their antagonists) in patterns reminiscent of those of their vertebrate orthlogues, and that amphioxus embryos, like those of vertebrates, are ventralized by exogenous BMP protein. In addition, Wnt-antagonists (for example, Dkks and sFRP2-like) are expressed anteriorly, whereas Wnt genes themselves are expressed posteriorly, consistent with a role for Wnt signalling in anterior/posterior (A/P) patterning. These results suggest evolutionary conservation of the mechanisms for both D/V and A/P patterning of the early gastrula. In light of recent phylogenetic analyses placing cephalochordates basally in the chordate lineage, we propose that separate signalling centres for patterning the D/V and A/P axes may be an ancestral chordate character.	Scripps Inst Oceanog, Div Marine Biol Res, La Jolla, CA 92037 USA; Kyoto Univ, Grad Sch Sci, Dept Zool, Sakyo Ku, Kyoto 6068502, Japan; Natl Inst Genet, Shizuoka 4118540, Japan; CALTECH, Div Biol 139 74, Pasadena, CA 91125 USA	University of California System; University of California San Diego; Scripps Institution of Oceanography; Kyoto University; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; California Institute of Technology	Holland, LZ (corresponding author), Scripps Inst Oceanog, Div Marine Biol Res, La Jolla, CA 92037 USA.	lzholland@ucsd.edu	Yu, Jr-Kai/H-4822-2019; Satou, Yutaka/K-7131-2012; Satou, Yutaka/AAJ-2194-2021; Satoh, Nori/C-4123-2009	Yu, Jr-Kai/0000-0001-8591-0529; Satou, Yutaka/0000-0001-5193-0708; Satou, Yutaka/0000-0001-5193-0708; Satoh, Nori/0000-0002-4480-3572; Bronner, Marianne/0000-0003-4274-1862				Blair JE, 2005, MOL BIOL EVOL, V22, P2275, DOI 10.1093/molbev/msi225; Bourlat SJ, 2006, NATURE, V444, P85, DOI 10.1038/nature05241; Broun M, 2005, DEVELOPMENT, V132, P2907, DOI 10.1242/dev.01848; Chang CB, 2001, NATURE, V410, P483, DOI 10.1038/35068583; DALE L, 1992, DEVELOPMENT, V115, P573; Darras S, 2001, DEV BIOL, V236, P271, DOI 10.1006/dbio.2001.0339; De Robertis EM, 2004, ANNU REV CELL DEV BI, V20, P285, DOI 10.1146/annurev.cellbio.20.011403.154124; De Robertis EM, 2000, NAT REV GENET, V1, P171, DOI 10.1038/35042039; Delsuc F, 2006, NATURE, V439, P965, DOI 10.1038/nature04336; Ferrier DEK, 2001, DEV BIOL, V237, P270, DOI 10.1006/dbio.2001.0375; Gerhart J, 2001, INT J DEV BIOL, V45, P133; Hoang BH, 2004, CANCER RES, V64, P2734, DOI 10.1158/0008-5472.CAN-03-1952; Holland LZ, 2005, DEV DYNAM, V233, P1430, DOI 10.1002/dvdy.20473; Holland LZ, 2002, DEV BIOL, V241, P209, DOI 10.1006/dbio.2001.0503; Hufton AL, 2006, BMC DEV BIOL, V6, DOI 10.1186/1471-213X-6-27; Imai KS, 2006, SCIENCE, V312, P1183, DOI 10.1126/science.1123404; JOLY JS, 1993, DEVELOPMENT, V119, P1261; Jones CM, 1999, CURR BIOL, V9, P946, DOI 10.1016/S0960-9822(99)80421-7; Kourakis MJ, 2005, TRENDS GENET, V21, P506, DOI 10.1016/j.tig.2005.07.002; Kozmik Z, 2001, GENESIS, V29, P172, DOI 10.1002/gene.1021; Kusserow A, 2005, NATURE, V433, P156, DOI 10.1038/nature03158; Langeland JA, 2006, INT J BIOL SCI, V2, P110; Levin M, 2005, MECH DEVELOP, V122, P3, DOI 10.1016/j.mod.2004.08.006; Lowe CJ, 2006, PLOS BIOL, V4, P1603, DOI 10.1371/journal.pbio.0040291; Matus DQ, 2006, P NATL ACAD SCI USA, V103, P11195, DOI 10.1073/pnas.0601257103; Matus DQ, 2006, CURR BIOL, V16, P499, DOI 10.1016/j.cub.2006.01.052; Neidert AH, 2000, EVOL DEV, V2, P303, DOI 10.1046/j.1525-142x.2000.00073.x; Niehrs C, 2004, NAT REV GENET, V5, P425, DOI 10.1038/nrg1347; Nikaido M, 1997, MECH DEVELOP, V61, P75, DOI 10.1016/S0925-4773(96)00625-9; Passamaneck YJ, 2005, DEV DYNAM, V233, P1, DOI 10.1002/dvdy.20300; Pera EM, 2000, MECH DEVELOP, V96, P183, DOI 10.1016/S0925-4773(00)00394-4; Philippe H, 2005, MOL BIOL EVOL, V22, P1246, DOI 10.1093/molbev/msi111; Reversade B, 2005, CELL, V123, P1147, DOI 10.1016/j.cell.2005.08.047; Schubert M., 2003, WNT SIGNALING DEV, P210; Scott IC, 2001, NATURE, V410, P475, DOI 10.1038/35068572; Stern CD, 2001, NAT REV NEUROSCI, V2, P92, DOI 10.1038/35053563; TUNG TC, 1962, SCI SINICA, V11, P805; Yu JK, 2002, EVOL DEV, V4, P418, DOI 10.1046/j.1525-142X.2002.02030.x; Zhang SC, 1997, DEV GENES EVOL, V206, P532, DOI 10.1007/s004270050083	39	186	195	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 8	2007	445	7128					613	617		10.1038/nature05472	http://dx.doi.org/10.1038/nature05472			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	133UM	17237766				2022-12-28	WOS:000244039400036
J	Green, JE; Choi, JW; Boukai, A; Bunimovich, Y; Johnston-Halperin, E; DeIonno, E; Luo, Y; Sheriff, BA; Xu, K; Shin, YS; Tseng, HR; Stoddart, JF; Heath, JR				Green, Jonathan E.; Choi, Jang Wook; Boukai, Akram; Bunimovich, Yuri; Johnston-Halperin, Ezekiel; DeIonno, Erica; Luo, Yi; Sheriff, Bonnie A.; Xu, Ke; Shin, Young Shik; Tseng, Hsian-Rong; Stoddart, J. Fraser; Heath, James R.			A 160-kilobit molecular electronic memory patterned at 10(11) bits per square centimetre	NATURE			English	Article							ONE-DIMENSIONAL NANOSTRUCTURES; CARBON NANOTUBE; NANOIMPRINT LITHOGRAPHY; HALF-PITCH; CIRCUITS; ARCHITECTURE; FABRICATION; TRANSISTORS; JUNCTIONS; NETWORKS	The primary metric for gauging progress in the various semiconductor integrated circuit technologies is the spacing, or pitch, between the most closely spaced wires within a dynamic random access memory (DRAM) circuit(1). Modern DRAM circuits have 140 nm pitch wires and a memory cell size of 0.0408 mu m(2). Improving integrated circuit technology will require that these dimensions decrease over time. However, at present a large fraction of the patterning and materials requirements that we expect to need for the construction of new integrated circuit technologies in 2013 have 'no known solution'(1). Promising ingredients for advances in integrated circuit technology are nanowires(2), molecular electronics(3) and defect-tolerant architectures(4), as demonstrated by reports of single devices(5-7) and small circuits(8,9). Methods of extending these approaches to large-scale, high-density circuitry are largely undeveloped. Here we describe a 160,000-bit molecular electronic memory circuit, fabricated at a density of 10(11) bits cm(-2) ( pitch 33 nm; memory cell size 0.0011 mu m(2)), that is, roughly analogous to the dimensions of a DRAM circuit(1) projected to be available by 2020. A monolayer of bistable, [ 2] rotaxane molecules(10) served as the data storage elements. Although the circuit has large numbers of defects, those defects could be readily identified through electronic testing and isolated using software coding. The working bits were then configured to form a fully functional random access memory circuit for storing and retrieving information.	CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA; CALTECH, Kavli Nanosci Inst, Pasadena, CA 91125 USA; Univ Calif Los Angeles, Calif Nanosyst Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA	California Institute of Technology; California Institute of Technology; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Heath, JR (corresponding author), CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA.	heath@caltech.edu	Choi, Jang Wook/C-1821-2011; Xu, Ke/A-9476-2011; Johnston-Halperin, Ezekiel/B-5902-2012; Stoddart, James Fraser/H-1518-2011; Johnston-Halperin, Ezekiel/AAM-2564-2021; Tseng, Hsian-Rong/G-2222-2010	Choi, Jang Wook/0000-0001-8783-0901; Xu, Ke/0000-0002-2788-194X; Stoddart, James Fraser/0000-0003-3161-3697; Johnston-Halperin, Ezekiel/0000-0002-6240-3505; Tseng, Hsian-Rong/0000-0003-0942-5905; Bunimovich, Yuri/0000-0002-7920-8781				Allwood DA, 2005, SCIENCE, V309, P1688, DOI 10.1126/science.1108813; Beckman R, 2005, SCIENCE, V310, P465, DOI 10.1126/science.1114757; Chen Y, 2003, NANOTECHNOLOGY, V14, P462, DOI 10.1088/0957-4484/14/4/311; Chen ZH, 2006, SCIENCE, V311, P1735, DOI 10.1126/science.1122797; Choi JW, 2006, CHEM-EUR J, V12, P261, DOI 10.1002/chem.200500934; DeHon A, 2005, IEEE DES TEST COMPUT, V22, P306, DOI 10.1109/MDT.2005.94; DeHon A, 2005, IEEE T NANOTECHNOL, V4, P215, DOI 10.1109/TNANO.2004.837849; Diehl MR, 2002, ANGEW CHEM INT EDIT, V41, P353, DOI 10.1002/1521-3773(20020118)41:2<353::AID-ANIE353>3.0.CO;2-Y; Heath JR, 2003, PHYS TODAY, V56, P43, DOI 10.1063/1.1583533; Heath JR, 1998, SCIENCE, V280, P1716, DOI 10.1126/science.280.5370.1716; Huang Y, 2001, SCIENCE, V291, P630, DOI 10.1126/science.291.5504.630; Jung GY, 2006, NANO LETT, V6, P351, DOI 10.1021/nl052110f; Katz E, 2005, CHEMPHYSCHEM, V6, P2179, DOI 10.1002/cphc.200500162; Lee MH, 2004, IEEE T NANOTECHNOL, V3, P152, DOI 10.1109/TNANO.2004.824011; Luo Y, 2002, CHEMPHYSCHEM, V3, P519, DOI 10.1002/1439-7641(20020617)3:6<519::AID-CPHC519>3.0.CO;2-2; McCreery RL, 2004, CHEM MATER, V16, P4477, DOI 10.1021/cm049517q; Melosh NA, 2003, SCIENCE, V300, P112, DOI 10.1126/science.1081940; Parkin SSP, 1999, J APPL PHYS, V85, P5828, DOI 10.1063/1.369932; Pop E, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.155505; Semiconductor industry association, 2005, INT TECHN ROADM SEM; Snider G, 2005, APPL PHYS A-MATER, V80, P1183, DOI 10.1007/s00339-004-3154-4; Stan MR, 2003, P IEEE, V91, P1940, DOI 10.1109/JPROC.2003.818327; Vieu C, 2000, APPL SURF SCI, V164, P111, DOI 10.1016/S0169-4332(00)00352-4; Waser R, 2004, NAT MATER, V3, P81, DOI 10.1038/nmat1067; Wu W, 2005, APPL PHYS A-MATER, V80, P1173, DOI 10.1007/s00339-004-3176-y; Xiang J, 2006, NATURE, V441, P489, DOI 10.1038/nature04796; Yang PD, 2002, CHEMPHYSCHEM, V3, P503, DOI 10.1002/1439-7641(20020617)3:6<503::AID-CPHC503>3.0.CO;2-U; Zhong ZH, 2003, SCIENCE, V302, P1377, DOI 10.1126/science.1090899; Zhou XJ, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.146805	29	1011	1029	5	331	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 25	2007	445	7126					414	417		10.1038/nature05462	http://dx.doi.org/10.1038/nature05462			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	128WD	17251976				2022-12-28	WOS:000243689500036
J	Poelwijk, FJ; Kiviet, DJ; Weinreich, DM; Tans, SJ				Poelwijk, Frank J.; Kiviet, Daniel J.; Weinreich, Daniel M.; Tans, Sander J.			Empirical fitness landscapes reveal accessible evolutionary paths	NATURE			English	Article							PROTEIN-DNA RECOGNITION; FLUCTUATING ENVIRONMENTS; ISOCITRATE DEHYDROGENASE; LAC REPRESSOR; MUTANT; ADAPTATION; ROBUSTNESS; DYNAMICS; EVOLVABILITY; SPECIFICITY		FOM Inst AMOLF, NL-1098 SJ Amsterdam, Netherlands; Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA	AMOLF; Harvard University	Tans, SJ (corresponding author), FOM Inst AMOLF, Kruislaan 407, NL-1098 SJ Amsterdam, Netherlands.	tans@amolf.nl	Tans, Sander/AAS-2901-2020; Weinreich, Dan/AAZ-6606-2021	Poelwijk, Frank/0000-0002-5696-4357				Arnold FH, 2001, TRENDS BIOCHEM SCI, V26, P100, DOI 10.1016/S0968-0004(00)01755-2; Barkai N, 1997, NATURE, V387, P913, DOI 10.1038/43199; Bloom JD, 2006, P NATL ACAD SCI USA, V103, P5869, DOI 10.1073/pnas.0510098103; Bridgham JT, 2006, SCIENCE, V312, P97, DOI 10.1126/science.1123348; Counago R, 2006, MOL CELL, V22, P441, DOI 10.1016/j.molcel.2006.04.012; DARWIN C, 1859, ORIGIN SPECIES, pCH6; Dekel E, 2005, NATURE, V436, P588, DOI 10.1038/nature03842; DePristo MA, 2005, NAT REV GENET, V6, P678, DOI 10.1038/nrg1672; Elena SF, 2003, NAT REV GENET, V4, P457, DOI 10.1038/nrg1088; Gavrilets S, 2004, FITNESS LANDSCAPES O; Gillespie J.H., 1992, CAUSES MOL EVOLUTION; Hurley JH, 1996, BIOCHEMISTRY-US, V35, P5670, DOI 10.1021/bi953001q; HURLEY JH, 1991, BIOCHEMISTRY-US, V30, P8671, DOI 10.1021/bi00099a026; Kalodimos CG, 2002, EMBO J, V21, P2866, DOI 10.1093/emboj/cdf318; Kauffman S.A., 1993, ORIGINS ORDER; KIMURA M, 1962, GENETICS, V47, P713; Kirschner M, 1998, P NATL ACAD SCI USA, V95, P8420, DOI 10.1073/pnas.95.15.8420; Kitano H, 2004, NAT REV GENET, V5, P826, DOI 10.1038/nrg1471; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kussell E, 2005, SCIENCE, V309, P2075, DOI 10.1126/science.1114383; LEHMING N, 1990, EMBO J, V9, P615, DOI 10.1002/j.1460-2075.1990.tb08153.x; LENSKI RE, 1994, P NATL ACAD SCI USA, V91, P6808, DOI 10.1073/pnas.91.15.6808; Lunzer M, 2005, SCIENCE, V310, P499, DOI 10.1126/science.1115649; MALCOLM BA, 1990, NATURE, V345, P86, DOI 10.1038/345086a0; PAULING L, 1963, ACTA CHEM SCAND, V17, pS9; Poelwijk FJ, 2006, PLOS COMPUT BIOL, V2, P467, DOI 10.1371/journal.pcbi.0020058; Salinas RK, 2005, CHEMBIOCHEM, V6, P1628, DOI 10.1002/cbic.200500049; SMITH JM, 1970, NATURE, V225, P563, DOI 10.1038/225563a0; STACKHOUSE J, 1990, FEBS LETT, V262, P104, DOI 10.1016/0014-5793(90)80164-E; Stelling J, 2004, CELL, V118, P675, DOI 10.1016/j.cell.2004.09.008; Thattai M, 2004, GENETICS, V167, P523, DOI 10.1534/genetics.167.1.523; Thornton JW, 2004, NAT REV GENET, V5, P366, DOI 10.1038/nrg1324; Ugalde JA, 2004, SCIENCE, V305, P1433, DOI 10.1126/science.1099597; Van Nimwegen E, 2000, B MATH BIOL, V62, P799, DOI 10.1006/bulm.2000.0180; Weinreich DM, 2006, SCIENCE, V312, P111, DOI 10.1126/science.1123539; Weinreich DM, 2005, EVOLUTION, V59, P1165; WRIGHT SEWALL, 1932, PROC SIXTH INTERNAT CONGR GENETICS ITHACA NEW YORK, V1, P356; Zhu GP, 2005, SCIENCE, V307, P1279, DOI 10.1126/science.1106974	38	345	347	1	86	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 25	2007	445	7126					383	386		10.1038/nature05451	http://dx.doi.org/10.1038/nature05451			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	128WD	17251971				2022-12-28	WOS:000243689500029
J	Dearing, A				Dearing, Andrew			Enabling Europe to innovate	SCIENCE			English	Review								As activities that relate to innovation become increasingly global and open and so draw the private and public sectors into complex networks of partnerships, these activities also tend to concentrate where the ecosystem is most supportive. European public policy, which in recent years has emphasized the importance of research and development (R&D) in achieving competitive knowledge-based societies, is shifting toward approaches that address the broader qualities required of favorable ecosystems for innovation in a global economy, thereby incorporating the roles of market demand, public procurement, and regulation, as well as science, education, and industrial R&D, as part of determining effective innovation policies.	European Ind Res Management Associat, F-75116 Paris, France		Dearing, A (corresponding author), European Ind Res Management Associat, 46 Rue Lauriston, F-75116 Paris, France.	adearing@eirma.asso.fr						Aho Esko, 2006, CREATING INNOVATIVE; Chesbrough H., 2002, OPEN INNOVATION NEW; Coombs R, 2002, SCIENCE, V296, P471, DOI 10.1126/science.1068350; *EC, 2006, MON IND RES 2005 EU, P10; GOLDBRUNNER T, 2006, WELL DESIGNED GLOBAL; Huston L, 2006, HARVARD BUS REV, V84, P58; *IR GOV ADV COUNC, 2005, NAT COD PRACT MAN CO; National Council of University Research Administrators, 2006, GUID PRINC U IND END; Thursby J., 2006, HERE THERE SURVEY FA	9	6	6	1	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 19	2007	315	5810					344	347		10.1126/science.1131373	http://dx.doi.org/10.1126/science.1131373			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126SI	17234939				2022-12-28	WOS:000243535400030
J	Jain, R; Kabir, K; Gilroy, JB; Mitchell, KAR; Wong, KC; Hicks, RG				Jain, Rajsapan; Kabir, Khayrul; Gilroy, Joe B.; Mitchell, Keith A. R.; Wong, Kin-Chung; Hicks, Robin G.			High-temperature metal-organic magnets	NATURE			English	Article							MOLECULE-BASED MAGNETS; PRUSSIAN BLUE; NICKEL NANOPARTICLES; = TCNE; FE; NI; CO; CHEMISTRY; BEHAVIOR; SALTS	For over two decades there have been intense efforts aimed at the development of alternatives to conventional magnets, particularly materials comprised in part or wholly of molecular components(1,2). Such alternatives offer the prospect of realizing magnets fabricated through controlled, low-temperature, solution-based chemistry, as opposed to high-temperature metallurgical routes, and also the possibility of tuning magnetic properties through synthesis. However, examples of magnetically ordered molecular materials at or near room temperature are extremely rare 3, and the properties of these materials are often capricious and difficult to reproduce. Here we present a versatile solution-based route to a new class of metal - organic materials exhibiting magnetic order well above room temperature. Reactions of the metal ( M) precursor complex bis(1,5-cyclooctadiene) nickel with three different organics A - TCNE ( tetracyanoethylene), TCNQ (7,7,8,8-tetracyanoquinodimethane) or DDQ (2,3-dichloro-5,6-dicyano-1,4-benzoquinone) - proceed via electron transfer from nickel to A and lead to materials containing Ni(II) ions and reduced forms of A in a 2: 1 Ni: A ratio - that is, opposite to that of conventional ( low Curie temperature) MA(2)-type magnets. These materials also contain oxygen-based species within their architectures. Magnetic characterization of the three compounds reveals spontaneous field-dependent magnetization and hysteresis at room temperature, with ordering temperatures well above ambient. The unusual stoichiometry and striking magnetic properties highlight these three compounds as members of a class of stable magnets that are at the interface between conventional inorganic magnets and genuine molecule-based magnets.	Univ Victoria, Dept Chem, Victoria, BC V8W 3V6, Canada; Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z1, Canada	University of Victoria; University of British Columbia	Hicks, RG (corresponding author), Univ Victoria, Dept Chem, POB 3065 STN CSC, Victoria, BC V8W 3V6, Canada.	rhicks@uvic.ca						BELL SE, 1992, INORG CHEM, V31, P3269, DOI 10.1021/ic00041a020; Buschmann WE, 1999, CHEM-EUR J, V5, P3019; Clerac R, 2003, CHEM MATER, V15, P1840, DOI 10.1021/cm021053d; Cordente N, 2001, NANO LETT, V1, P565, DOI 10.1021/nl0100522; ENGLAND SJ, 1980, J CHEM SOC CHEM COMM, P840, DOI 10.1039/c39800000840; FERLAY S, 1995, NATURE, V378, P701, DOI 10.1038/378701a0; Ferraro J. R., 1987, INTRO SYNTHETIC ELEC; Fitzgerald JP, 2000, CHEM COMMUN, P49, DOI 10.1039/a907535f; Kahn O., 1993, MOL MAGNETISM; KAIM W, 1994, COORDIN CHEM REV, V129, P157, DOI 10.1016/0010-8545(94)85020-8; Khadar MA, 2003, MATER RES BULL, V38, P1341, DOI 10.1016/S0025-5408(03)00139-9; Koltypin Y, 1999, CHEM MATER, V11, P1331, DOI 10.1021/cm981111o; LesliePelecky DL, 1996, CHEM MATER, V8, P1770, DOI 10.1021/cm960077f; Long G, 2001, INORG CHIM ACTA, V313, P1, DOI 10.1016/S0020-1693(00)00260-7; MANRIQUEZ JM, 1991, SCIENCE, V252, P1415, DOI 10.1126/science.252.5011.1415; Miller JS, 2000, INORG CHEM, V39, P4392, DOI 10.1021/ic000540x; Miller JS, 2000, MRS BULL, V25, P21, DOI 10.1557/mrs2000.221; Miller JS, 1998, CHEM COMMUN, P1319, DOI 10.1039/a800922h; MILLER JS, 1987, SCIENCE, V235, P871, DOI 10.1126/science.235.4791.871; MILLER JS, 1986, J AM CHEM SOC, V108, P4459, DOI 10.1021/ja00275a036; MURPHY VJ, 1994, INORG CHEM, V33, P1833, DOI 10.1021/ic00087a018; Osan J, 2001, X-RAY SPECTROM, V30, P419, DOI 10.1002/xrs.523; Pokhodnya KI, 2002, INORG CHEM, V41, P1996, DOI 10.1021/ic011288b; POKHODNYA VI, 2001, PHYS REV B, V63, DOI UNSP 174408; SCHRAUZER GN, 1962, Z NATURFORSCH PT B, VB 17, P73, DOI 10.1515/znb-1962-0201; Vickers EB, 2005, CHEM MATER, V17, P1667, DOI 10.1021/cm047869r; Vickers EB, 2004, INORG CHIM ACTA, V357, P3889, DOI 10.1016/j.ica.2004.04.030; Vickers EB, 2004, J AM CHEM SOC, V126, P3716, DOI 10.1021/ja0397308; Yang DQ, 2005, J PHYS CHEM B, V109, P19329, DOI 10.1021/jp0536504; Zhang J, 1998, ANGEW CHEM INT EDIT, V37, P657, DOI 10.1002/(SICI)1521-3773(19980316)37:5<657::AID-ANIE657>3.0.CO;2-L	30	137	140	1	111	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 18	2007	445	7125					291	294		10.1038/nature05439	http://dx.doi.org/10.1038/nature05439			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126HT	17230185				2022-12-28	WOS:000243504700039
J	Stein, DJ; Seedat, S; Iversen, A; Wessely, S				Stein, Dan J.; Seedat, Soraya; Iversen, Amy; Wessely, Simon			Post-traumatic stress disorder: medicine and politics	LANCET			English	Review							HIPPOCAMPAL VOLUME; RECONCILIATION COMMISSION; WAR; HEALTH; WORLD; RISK; VULNERABILITY; METAANALYSIS; PSYCHIATRY; PREVENTION	Regrettably, exposure to trauma is common worldwide, and can have serious adverse psychological results. The introduction of the notion of post-traumatic stress disorder has led to increasing medicalisation of the problem. This awareness has helped popular acceptance of the reality of post-traumatic psychiatric sequelae, which has boosted research into the pathogenesis of the disorder, leading to improved pharmacological and psychological management. The subjective experience of trauma and subsequent expression of symptoms vary considerably over space and time, and we emphasise that not all psychological distress or psychiatric disorders after trauma should be termed post-traumatic stress disorder. There are limits to the medicalisation of distress and there is value in focusing on adaptive coping during and after traumas. Striking a balance between a focus on heroism and resilience versus victimhood and pathological change is a crucial and constant issue after trauma for both clinicians and society. In this Review we discuss the advantages and disadvantages of medicalising trauma response, using examples from South Africa, the Armed Services, and post-disaster, to draw attention to our argument.	Groote Schuur Hosp, UCT Dept Psychiat, ZA-7925 Cape Town, South Africa; Univ Stellenbosch, Dept Psychiat, Cape Town, South Africa; Inst Psychiat, London, England	University of Cape Town; Stellenbosch University; University of London; King's College London	Stein, DJ (corresponding author), Groote Schuur Hosp, UCT Dept Psychiat, J-2,Anzio Rd, ZA-7925 Cape Town, South Africa.	dan.stein@uct.ac.za	Wessely, Simon C/A-8713-2008; Stein, Dan/A-1752-2008; Iversen, Amy/D-1112-2011	Stein, Dan/0000-0001-7218-7810; Wessely, Simon Charles/0000-0002-6743-9929; Seedat, Soraya/0000-0002-5118-786X				American Psychiatric Association, 1980, DIAGN STAT MAN MENT, V3; Ballenger JC, 2000, J CLIN PSYCHIAT, V61, P60; BARSKY AJ, 1988, NEW ENGL J MED, V318, P414, DOI 10.1056/NEJM198802183180705; Basoglu M, 1997, PSYCHOL MED, V27, P1421, DOI 10.1017/S0033291797005679; Bradley R, 2005, AM J PSYCHIAT, V162, P214, DOI 10.1176/appi.ajp.162.2.214; Bremner JD, 2000, AM J PSYCHIAT, V157, P1120, DOI 10.1176/appi.ajp.157.7.1120; Brewin CR, 2000, J CONSULT CLIN PSYCH, V68, P748, DOI 10.1037/0022-006X.68.5.748; Charney DS, 2004, AM J PSYCHIAT, V161, P195, DOI 10.1176/appi.ajp.161.2.195; Cheng MH, 2006, LANCET, V367, P15, DOI 10.1016/S0140-6736(06)67904-X; CONNOR KM, 1998, CNS SPECTRUMS S2, V3, P43; DEBOER M, 1992, PSYCHOTHER PSYCHOSOM, V57, P158, DOI 10.1159/000288593; Demyttenaere K, 2004, JAMA-J AM MED ASSOC, V291, P2581, DOI 10.1001/jama.291.21.2581; Emsley RA, 2003, J NERV MENT DIS, V191, P237, DOI 10.1097/00005053-200304000-00004; Finestone AJ, 1997, ARCH INTERN MED, V157, P491, DOI 10.1001/archinte.157.5.491; Frueh BC, 2005, BRIT J PSYCHIAT, V186, P467, DOI 10.1192/bjp.186.6.467; Furedi Frank, 2003, THERAPY CULTURE CULT; Gilbertson MW, 2002, NAT NEUROSCI, V5, P1242, DOI 10.1038/nn958; Harvey BH, 2004, PSYCHOPHARMACOLOGY, V175, P494, DOI 10.1007/s00213-004-1836-4; Herman Judith, 2001, TRAUMA RECOVERY; Hobbes T., 1998, LEVIATHAN; Hughes JH, 2005, BRIT J PSYCHIAT, V186, P536, DOI 10.1192/bjp.186.6.536; Huibers MJH, 2006, PSYCHOL MED, V36, P895, DOI 10.1017/S0033291705006926; Jones E, 2003, BRIT J PSYCHIAT, V182, P158, DOI 10.1192/bjp.182.2.158; Jones E, 2002, BMJ-BRIT MED J, V324, P321, DOI 10.1136/bmj.324.7333.321; Kaminer D, 2001, BRIT J PSYCHIAT, V178, P373, DOI 10.1192/bjp.178.4.373; Kaplan Z, 2005, J CLIN PSYCHIAT, V66, P1146, DOI 10.4088/JCP.v66n0910; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Kitayama N, 2005, J AFFECT DISORDERS, V88, P79, DOI 10.1016/j.jad.2005.05.014; Kleinman Arthur, 1998, RETHINKING PSYCHIAT; LEE KA, 1995, AM J PSYCHIAT, V152, P516; Marsella A.J., 1996, ETHNOCULTURAL ASPECT; MOSSMAN D, 2005, B AM ACAD PSYCH LAW, V24, P27; NELL V, IN PRESS BEHAV BRAIN; NERIA Y, 2005, MENTAL HLTH WAKE TER; Pitman RK, 2002, BIOL PSYCHIAT, V51, P189, DOI 10.1016/S0006-3223(01)01279-3; Pupavac V, 2002, ALTERNATIVES, V27, P489, DOI 10.1177/030437540202700404; Pupavac V., 2004, EUR J SOC THEORY, V7, P149, DOI [DOI 10.1177/1368431004041749, 10.1177/1368431004041749]; Rose S, 2003, PSYCHOTHER PSYCHOSOM, V72, P176, DOI 10.1159/000070781; Rose S, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000560; Sadler J Z, 1994, PHILOS PERSPECTIVES; Seedat S, 2004, J AFFECT DISORDERS, V80, P45, DOI 10.1016/S0165-0327(03)00047-8; SHAY J, 1995, ARCHILLES VIETNAM CO; Shephard B, 1999, HIST PSYCHIATR, V10, P491, DOI 10.1177/0957154X9901004005; Shephard Ben, 2000, WAR NERVES SOLDIERS; Sommers C.H., 2005, ONE NATION THERAPY H; Stein DJ, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002795.pub2; Stein DJ, 2004, LANCET, V364, P233, DOI 10.1016/S0140-6736(04)16693-2; Stein DJ, 1998, BRIT J PSYCHIAT, V173, P455, DOI 10.1192/bjp.173.6.455; STEIN DJ, 1991, COMPR PSYCHIAT, V32, P404, DOI 10.1016/0010-440X(91)90017-7; Summerfield D, 2001, BRIT MED J, V322, P95, DOI 10.1136/bmj.322.7278.95; Summerfield D, 2002, BRIT MED J, V325, P1105, DOI 10.1136/bmj.325.7372.1105; van Ommeren M, 2005, B WORLD HEALTH ORGAN, V83, P71; Vermetten E, 2003, BIOL PSYCHIAT, V54, P693, DOI 10.1016/S0006-3223(03)00634-6; Wessely S, 2005, NEW ENGL J MED, V353, P548, DOI 10.1056/NEJMp058180; Wessely S, 2005, BRIT J PSYCHIAT, V186, P459, DOI 10.1192/bjp.186.6.459; Wessely S., 2005, J MENTAL HLTH, V14, P106, DOI [10.1080/09638230500048099, DOI 10.1080/09638230500048099, 10.1080/09638230500048099.]; Yehuda R, 2004, J CLIN PSYCHIAT, V65, P29; Yehuda R, 2002, PSYCHIAT CLIN N AM, V25, P341, DOI 10.1016/S0193-953X(02)00002-3; YEHUDA R, 1995, AM J PSYCHIAT, V152, P1705; Young Allan., 1995, HARMONY ILLUSIONS IN; [No title captured]; 2002, LANCET, V360, P729	62	105	106	0	27	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 13	2007	369	9556					139	144		10.1016/S0140-6736(07)60075-0	http://dx.doi.org/10.1016/S0140-6736(07)60075-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	126TK	17223477				2022-12-28	WOS:000243538200033
J	Binswanger, IA; Stern, MF; Deyo, RA; Heagerty, PJ; Cheadle, A; Elmore, JG; Koepsell, TD				Binswanger, Ingrid A.; Stern, Marc F.; Deyo, Richard A.; Heagerty, Patrick J.; Cheadle, Allen; Elmore, Joann G.; Koepsell, Thomas D.			Release from prison - A high risk of death for former inmates	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VITAL STATUS; MORTALITY; OVERDOSE; HEALTH; USERS	BACKGROUND: The U.S. population of former prison inmates is large and growing. The period immediately after release may be challenging for former inmates and may involve substantial health risks. We studied the risk of death among former inmates soon after their release from Washington State prisons. METHODS: We conducted a retrospective cohort study of all inmates released from the Washington State Department of Corrections from July 1999 through December 2003. Prison records were linked to the National Death Index. Data for comparison with Washington State residents were obtained from the Wide-ranging OnLine Data for Epidemiologic Research system of the Centers for Disease Control and Prevention. Mortality rates among former inmates were compared with those among other state residents with the use of indirect standardization and adjustment for age, sex, and race. RESULTS: Of 30,237 released inmates, 443 died during a mean follow-up period of 1.9 years. The overall mortality rate was 777 deaths per 100,000 person-years. The adjusted risk of death among former inmates was 3.5 times that among other state residents (95% confidence interval [CI], 3.2 to 3.8). During the first 2 weeks after release, the risk of death among former inmates was 12.7 (95% CI, 9.2 to 17.4) times that among other state residents, with a markedly elevated relative risk of death from drug overdose (129; 95% CI, 89 to 186). The leading causes of death among former inmates were drug overdose, cardiovascular disease, homicide, and suicide. CONCLUSIONS: Former prison inmates were at high risk for death after release from prison, particularly during the first 2 weeks. Interventions are necessary to reduce the risk of death after release from prison.	Univ Colorado, Hlth Sci Ctr, Dept Med, Div Gen Internal Med, Denver, CO 80262 USA; Puget Sound Vet Affairs Med Ctr, Seattle, WA USA; Univ Washington, Dept Med, Seattle, WA USA; Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; Washington State Dept Correct, Olympia, WA USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Binswanger, IA (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Med, Div Gen Internal Med, 4200 E 9th Ave,B180, Denver, CO 80262 USA.	ingrid.binswanger@uchsc.edu	Binswanger, Ingrid/X-4496-2019	Binswanger, Ingrid/0000-0001-8862-8078	NCI NIH HHS [1 K05 CA104699, K05 CA104699-01, K05 CA104699] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K05CA104699] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bird SM, 2003, ADDICTION, V98, P185, DOI 10.1046/j.1360-0443.2003.00264.x; BOYLE CA, 1990, AM J EPIDEMIOL, V131, P160, DOI 10.1093/oxfordjournals.aje.a115470; *BUR JUST STAT, 2005, CRIM OFF STAT; Bureau of Justice Statistics, 2006, CORR STAT; *CDCP, 2005, CDC WONDER COMPR MOR; Clayton D, 2002, STAT MODELS EPIDEMIO; COLSHER PL, 1992, AM J PUBLIC HEALTH, V82, P881, DOI 10.2105/AJPH.82.6.881; Cropsey K, 2004, ADDICT BEHAV, V29, P425, DOI 10.1016/j.addbeh.2003.08.014; Darke S, 2000, DRUG ALCOHOL DEPEN, V60, P141, DOI 10.1016/S0376-8716(99)00147-7; Hammett TM, 2002, AM J PUBLIC HEALTH, V92, P1789, DOI 10.2105/AJPH.92.11.1789; HARDINGPINK D, 1990, MED SCI LAW, V30, P12, DOI 10.1177/002580249003000104; Harlow C.W., 2003, ED CORRECTIONAL POPU; HARRISON PM, 2004, BUREAU JUSTICE STAT; Iguchi MY, 2002, PUBLIC HEALTH REP, V117, pS146; Jones R, 2002, ADDICTION, V97, P1517, DOI 10.1046/j.1360-0443.2002.00244.x; Joukamaa M, 1998, FORENSIC SCI INT, V96, P11, DOI 10.1016/S0379-0738(98)00098-X; Mumola C, 2005, SUICIDE HOMICIDE STA; *NAT CTR HLTH STAT, 2000, NAT DEATH IND US MAN; *NAT CTR HLTH STAT, 1999, NAT DEATH IND US M S; Petersilia J, 2003, PRISONERS COME HOME; Seal KH, 2001, AM J PUBLIC HEALTH, V91, P1842, DOI 10.2105/AJPH.91.11.1842; Seaman SR, 1998, BRIT MED J, V316, P426, DOI 10.1136/bmj.316.7129.426; Stewart LM, 2004, AUST NZ J PUBL HEAL, V28, P32, DOI 10.1111/j.1467-842X.2004.tb00629.x; Verger P, 2003, J FORENSIC SCI, V48, P614; WENTWORTH DN, 1983, AM J PUBLIC HEALTH, V73, P1270, DOI 10.2105/AJPH.73.11.1270; World Health Organization, 2006, INT STAT CLASS DIS R	26	957	961	1	88	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 11	2007	356	2					157	165		10.1056/NEJMsa064115	http://dx.doi.org/10.1056/NEJMsa064115			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	124NE	17215533	Green Accepted			2022-12-28	WOS:000243373700008
J	Jacobson, PD; Parmet, WE				Jacobson, Peter D.; Parmet, Wendy E.			A new era of unapproved drugs - The case of Abigail Alliance v Von Eschenbach	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							RATES		Univ Michigan, Sch Publ Hlth, Ctr Law Eth & Hlth, Ann Arbor, MI 48109 USA; Northeastern Univ, Sch Law, Boston, MA 02115 USA	University of Michigan System; University of Michigan; Northeastern University	Jacobson, PD (corresponding author), Univ Michigan, Sch Publ Hlth, Ctr Law Eth & Hlth, 109 Observ, Ann Arbor, MI 48109 USA.	pdj@umich.edu						*AB ALL, AB STOR; Costanza ME, 1995, CLIN CANCER RES, V1, P699; DiMasi JA, 2001, CLIN PHARMACOL THER, V69, P297, DOI 10.1067/mcp.2001.115446; Institute of Medicine, 2006, FUT DRUG SAF PROM PR; Kola I, 2004, NAT REV DRUG DISCOV, V3, P711, DOI 10.1038/nrd1470; Mayer M, 2006, CLIN TRIALS, V3, P149, DOI 10.1191/1740774506cn144oa; PILON R, 2006, WALL STREET J   0603, P9; 2005, WALL STREET J   1115, pA22	8	41	41	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 10	2007	297	2					205	208		10.1001/jama.297.2.205	http://dx.doi.org/10.1001/jama.297.2.205			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	124GI	17213404				2022-12-28	WOS:000243355900030
J	Blade, J				Blade, Joan			Clinical practice: Monoclonal gammopathy of undetermined significance	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							20-YEAR FOLLOW-UP; MULTIPLE-MYELOMA; MALIGNANT-TRANSFORMATION; NATURAL-HISTORY; LONG-TERM; RISK; MGUS		Univ Barcelona Hosp Clin, Dept Hematol, ICMHO,IDIBAPS, Postgrad Sch Hematol Farreras Valenti, E-08036 Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Blade, J (corresponding author), Univ Barcelona Hosp Clin, Dept Hematol, ICMHO,IDIBAPS, Postgrad Sch Hematol Farreras Valenti, Villarroel 170, E-08036 Barcelona, Spain.	jblade@clinic.ub.es						AXELSSON U, 1986, ACTA MED SCAND, V219, P519; Baldini L, 1996, BLOOD, V87, P912, DOI 10.1182/blood.V87.3.912.bloodjournal873912; BERGSAGEL PL, 2004, MYELOMA BIOL MANAGEM, P35; BLADE J, 1992, BRIT J HAEMATOL, V81, P391, DOI 10.1111/j.1365-2141.1992.tb08245.x; Blade J, 2004, MAYO CLIN PROC, V79, P855, DOI 10.4065/79.7.855; Blade J, 1998, ARCH INTERN MED, V158, P1889, DOI 10.1001/archinte.158.17.1889; Blade Joan, 2006, Curr Treat Options Oncol, V7, P237, DOI 10.1007/s11864-006-0016-7; Cesana C, 2002, J CLIN ONCOL, V20, P1625, DOI 10.1200/JCO.20.6.1625; FONSECA R, 2004, MYELOMA BIOL MANAGEM, P67; Gregersen H, 2001, HAEMATOLOGICA, V86, P1172; Hallek M, 1998, BLOOD, V91, P3, DOI 10.1182/blood.V91.1.3.3_3_21; Hideshima T, 2004, BLOOD, V104, P607, DOI 10.1182/blood-2004-01-0037; HIDESHIMA T, 2004, MULTIPLE MYELOMA BIO, P59; Katzmann JA, 2002, CLIN CHEM, V48, P1437; Kyle RA, 2003, BRIT J HAEMATOL, V121, P749; KYLE RA, 1978, AM J MED, V64, P814, DOI 10.1016/0002-9343(78)90522-3; Kyle RA, 2002, NEW ENGL J MED, V346, P564, DOI 10.1056/NEJMoa01133202; KYLE RA, 1984, JAMA-J AM MED ASSOC, V251, P1849, DOI 10.1001/jama.251.14.1849; KYLE RA, 1993, MAYO CLIN PROC, V68, P26, DOI 10.1016/S0025-6196(12)60015-9; Kyle RA, 2004, MAYO CLIN PROC, V79, P859, DOI 10.4065/79.7.859; Kyle RA, 2006, NEW ENGL J MED, V354, P1362, DOI 10.1056/NEJMoa054494; Kyle RA, 2004, MYELOMA BIOL MANAGEM, P315; Landgren O, 2006, BLOOD, V107, P904, DOI 10.1182/blood-2005-08-3449; Magrangeas F, 2003, BLOOD, V101, P4998, DOI 10.1182/blood-2002-11-3385; Montoto S, 2002, NEW ENGL J MED, V346, P2087; Ocqueteau M, 1998, AM J PATHOL, V152, P1655; Pasqualetti P, 1997, ACTA HAEMATOL-BASEL, V97, P174; Rajkumar SV, 2005, BLOOD, V106, P812, DOI 10.1182/blood-2005-03-1038; RAWSTRON AC, 2005, HAEMATOLOGICA S1, V90, P196; WALDENSTROM J, 1960, Harvey Lect, V56, P211; Zhan FH, 2002, BLOOD, V99, P1745, DOI 10.1182/blood.V99.5.1745	31	77	79	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 28	2006	355	26					2765	2770		10.1056/NEJMcp052790	http://dx.doi.org/10.1056/NEJMcp052790			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	120UA	17192542				2022-12-28	WOS:000243110500009
J	Carandang, R; Seshadri, S; Beiser, A; Kelly-Hayes, M; Kase, CS; Kannel, WB; Wolf, PA				Carandang, Raphael; Seshadri, Sudha; Beiser, Alexa; Kelly-Hayes, Margaret; Kase, Carlos S.; Kannel, William B.; Wolf, Philip A.			Trends in incidence, lifetime risk, severity, and 30-day mortality of stroke over the past 50 years	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RANDOMIZED CONTROLLED-TRIAL; ACUTE ISCHEMIC-STROKE; CASE-FATALITY; INCIDENCE RATES; CARDIOVASCULAR-DISEASE; INTERNATIONAL TRENDS; PRIMARY PREVENTION; UNITED-STATES; NEW-ZEALAND; LUND-ORUP	Context Prior estimates of long-term trends in the incidence and severity of stroke have varied; trends in lifetime risk have not been reported. Objective To determine long-term trends in the incidence, lifetime risk, severity, and 30-day mortality of clinical stroke. Design, Setting, and Participants Prospective evaluation of the community-based Framingham Study original and offspring cohorts. Participants were 9152 men and women free of prevalent stroke and undergoing follow-up for up to 50 years over 3 consecutive periods (1950-1977, 1978-1989, and 1990-2004), with biennial ascertainment of stroke risk factor data and active surveillance for incident clinical stroke and cause-specific mortality. Main Outcome Measures Incidence (age-adjusted, sex-specific), severity, 30-day mortality, and mortality-adjusted 10-year and lifetime risk of stroke in each of the specified periods. Results There were 1030 incident clinical strokes ( 450 [44%] in men, 629 atherothrombotic brain infarctions [61%]) in 9152 persons 55 years or older over 174 917 person-years of follow-up. The age-adjusted incidence of first stroke per 1000 person-years in each of the 3 periods was 7.6, 6.2, and 5.3, respectively, in men (P=. 02 for trend) and 6.2, 5.8, and 5.1 in women ( P=. 01 for trend). The lifetime risk at age 65 years decreased from 19.5% to 14.5% in men ( P=. 11) and from 18.0% to 16.1% in women ( P=. 61). Age-adjusted stroke severity did not vary across periods; however, 30-day mortality decreased significantly in men ( from 23% to 14%; P=. 01) but not significantly in women ( from 21% to 20%; P=. 32). Conclusions In this cohort of men and women free of prevalent clinical stroke at initial examination, incidence of stroke has decreased over the past 50 years but the lifetime risk has not declined to the same degree, perhaps due to improved life expectancy. The results of this study suggest that improved control of risk factors has lowered stroke incidence but emphasize the need for continued primary prevention efforts.	Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA; NHLBI, Framingham Heart Study, Framingham, MA USA	Boston University; Boston University; Framingham Heart Study; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Wolf, PA (corresponding author), Boston Univ, Sch Med, Dept Neurol, 715 Albany St,B-608, Boston, MA 02118 USA.	pawolf@bu.edu		Kelly-Hayes, Margaret/0000-0001-5938-8052; Kase, Carlos/0000-0002-3047-5010; Seshadri, Sudha/0000-0001-6135-2622; Beiser, Alexa/0000-0001-8551-7778; Wolf, Philip/0000-0002-3628-301X	NHLBI NIH HHS [N01-HC-25195] Funding Source: Medline; NINDS NIH HHS [5R01-NS17950, R01 NS017950] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC025195] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017950] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		American Heart Association, 2006, HEART DIS STROK STAT; Anderson CS, 2005, STROKE, V36, P2087, DOI 10.1161/01.STR.0000181079.42690.bf; Baigent C, 2005, LANCET, V366, P1267, DOI 10.1016/S0140-6736(05)67394-1; Beiser A, 2000, STAT MED, V19, P1495, DOI 10.1002/(SICI)1097-0258(20000615/30)19:11/12<1495::AID-SIM441>3.0.CO;2-E; Benatru I, 2006, STROKE, V37, P1674, DOI 10.1161/01.STR.0000226979.56456.a8; BONITA R, 1993, LANCET, V342, P1470, DOI 10.1016/0140-6736(93)92938-P; Broderick J, 1998, STROKE, V29, P415, DOI 10.1161/01.STR.29.2.415; Broderick J P, 1993, Ann Epidemiol, V3, P476; BRODERICK JP, 1989, STROKE, V20, P577, DOI 10.1161/01.STR.20.5.577; Carolei A, 1997, STROKE, V28, P2500, DOI 10.1161/01.STR.28.12.2500; CHENG XM, 1995, STROKE, V26, P1990, DOI 10.1161/01.STR.26.11.1990; COOPER R, 1990, STROKE, V21, P1274, DOI 10.1161/01.STR.21.9.1274; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; Derby CA, 2000, STROKE, V31, P875, DOI 10.1161/01.STR.31.4.875; Diener HC, 1996, J NEUROL SCI, V143, P1, DOI 10.1016/S0022-510X(96)00308-5; DRURY I, 1984, NEUROLOGY, V34, P653, DOI 10.1212/WNL.34.5.653; EISENBLATTER D, 1995, STROKE, V26, P919, DOI 10.1161/01.STR.26.6.919; Fang J, 2001, STROKE, V32, P2221, DOI 10.1161/hs1001.096193; Fogelholm R, 2003, STROKE, V34, P1840, DOI 10.1161/01.STR.0000085565.91317.4C; Furlan A, 1999, JAMA-J AM MED ASSOC, V282, P2003, DOI 10.1001/jama.282.21.2003; Goldstein LB, 2001, STROKE, V32, P280, DOI 10.1161/01.STR.32.1.280; Halliday A, 2004, LANCET, V363, P1491; Hallstrom B, 2002, STROKE, V33, P1624, DOI 10.1161/01.STR.0000017222.48968.6E; HARMSEN P, 1992, STROKE, V23, P1410, DOI 10.1161/01.STR.23.10.1410; Hollander M, 2003, J NEUROL NEUROSUR PS, V74, P317, DOI 10.1136/jnnp.74.3.317; Howard G, 2001, STROKE, V32, P2213, DOI 10.1161/hs1001.096047; Jamrozik K, 1999, STROKE, V30, P2105, DOI 10.1161/01.STR.30.10.2105; Johansson B, 2000, STROKE, V31, P481, DOI 10.1161/01.STR.31.2.481; KAGAN A, 1994, STROKE, V25, P1170, DOI 10.1161/01.STR.25.6.1170; Kapral MK, 2005, STROKE, V36, P809, DOI 10.1161/01.STR.0000157662.09551.e5; Kelly-Hayes Margaret, 2003, J Stroke Cerebrovasc Dis, V12, P119, DOI 10.1016/S1052-3057(03)00042-9; Kubo M, 2003, STROKE, V34, P2349, DOI 10.1161/01.STR.0000090348.52943.A2; Kubo M, 2006, NEUROLOGY, V66, P1539, DOI 10.1212/01.wnl.0000216132.95207.b4; Kwan J, 2001, CME J GERIATR MED, V3, P94; LAURIA G, 1995, STROKE, V26, P1787, DOI 10.1161/01.STR.26.10.1787; MacMahon S, 2001, LANCET, V358, P1033, DOI 10.1016/S0140-6736(01)06178-5; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Morikawa Y, 2000, STROKE, V31, P1583, DOI 10.1161/01.STR.31.7.1583; Muntner P, 2002, STROKE, V33, P1209, DOI 10.1161/01.STR.0000015031.57955.D1; NAKAYAMA H, 1994, STROKE, V25, P808, DOI 10.1161/01.STR.25.4.808; Numminen H, 1996, STROKE, V27, P1487, DOI 10.1161/01.STR.27.9.1487; Pessah-Rasmussen H, 2003, STROKE, V34, P913, DOI 10.1161/01.STR.0000063365.10841.43; Ridker PM, 2005, NEW ENGL J MED, V352, P1293, DOI 10.1056/NEJMoa050613; Rothwell PM, 2004, LANCET, V363, P1925, DOI 10.1016/S0140-6736(04)16405-2; Sarti C, 2000, STROKE, V31, P1588, DOI 10.1161/01.STR.31.7.1588; Seshadri S, 2006, STROKE, V37, P345, DOI 10.1161/01.STR.0000199613.38911.b2; Shahar E, 1997, STROKE, V28, P275, DOI 10.1161/01.STR.28.2.275; Sivenius J, 2004, STROKE, V35, P420, DOI 10.1161/01.STR.0000110220.63212.59; Smadja D, 2001, STROKE, V32, P2741, DOI 10.1161/hs1201.099385; Stegmayr B, 1999, STROKE, V30, P709, DOI 10.1161/01.STR.30.4.709; Thorvaldsen P, 1999, STROKE, V30, P2529, DOI 10.1161/01.STR.30.12.2529; THORVALDSEN P, 1995, STROKE; Thrift AG, 2001, STROKE, V32, P1732, DOI 10.1161/01.STR.32.8.1732; WOLF PA, 1991, STROKE, V22, P312, DOI 10.1161/01.STR.22.3.312; WOLF PA, 1992, STROKE, V23, P1551, DOI 10.1161/01.STR.23.11.1551; WOLF PA, 2004, STROKE PATHOPHYSIOLO, P13	56	369	375	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	2006	296	24					2939	2946		10.1001/jama.296.24.2939	http://dx.doi.org/10.1001/jama.296.24.2939			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	120FD	17190894	Bronze			2022-12-28	WOS:000243069000025
J	Wang, F; Podell, ER; Zaug, AJ; Yang, YT; Baciu, P; Cech, TR; Lei, M				Wang, Feng; Podell, Elaine R.; Zaug, Arthur J.; Yang, Yuting; Baciu, Paul; Cech, Thomas R.; Lei, Ming			The POT1-TPP1 telomere complex is a telomerase processivity factor	NATURE			English	Article							END-BINDING-PROTEIN; HUMAN POT1; LENGTH REGULATOR; OXYTRICHA-NOVA; DNA-BINDING; IN-VITRO; CHROMOSOME; SUBUNIT; TRF1; TIN2	Telomeres were originally defined as chromosome caps that prevent the natural ends of linear chromosomes from undergoing deleterious degradation and fusion events. POT1 ( protection of telomeres) protein binds the single-stranded G-rich DNA overhangs at human chromosome ends and suppresses unwanted DNA repair activities. TPP1 is a previously identified binding partner of POT1 that has been proposed to form part of a six-protein shelterin complex at telomeres. Here, the crystal structure of a domain of human TPP1 reveals an oligonucleotide/oligosaccharide-binding fold that is structurally similar to the beta-subunit of the telomere end-binding protein of a ciliated protozoan, suggesting that TPP1 is the missing beta-subunit of human POT1 protein. Telomeric DNA end-binding proteins have generally been found to inhibit rather than stimulate the action of the chromosome end-replicating enzyme, telomerase. In contrast, we find that TPP1 and POT1 form a complex with telomeric DNA that increases the activity and processivity of the human telomerase core enzyme. We propose that POT1 - TPP1 switches from inhibiting telomerase access to the telomere, as a component of shelterin, to serving as a processivity factor for telomerase during telomere extension.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Colorado, Howard Hughes Med Inst, Dept Chem & Biochem, Boulder, CO 80309 USA	University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder	Lei, M (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, MSRBIII 5301D,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	leim@umich.edu	Wang, Feng/B-2474-2012					Baumann P, 2002, MOL CELL BIOL, V22, P8079, DOI 10.1128/MCB.22.22.8079-8087.2002; Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; Cech TR, 2004, CELL, V116, P273, DOI 10.1016/S0092-8674(04)00038-8; Chen JL, 2003, EMBO J, V22, P304, DOI 10.1093/emboj/cdg024; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; Dietmann S, 2001, NAT STRUCT BIOL, V8, P953, DOI 10.1038/nsb1101-953; FANG GW, 1991, NUCLEIC ACIDS RES, V19, P5515, DOI 10.1093/nar/19.20.5515; FANG GW, 1993, GENE DEV, V7, P870, DOI 10.1101/gad.7.5.870; FANG GW, 1993, CELL, V74, P875, DOI 10.1016/0092-8674(93)90467-5; GRAY JT, 1991, CELL, V67, P807, DOI 10.1016/0092-8674(91)90075-A; HICKE BJ, 1990, P NATL ACAD SCI USA, V87, P1481, DOI 10.1073/pnas.87.4.1481; Hockemeyer D, 2006, CELL, V126, P63, DOI 10.1016/j.cell.2006.04.044; Horvath MP, 1998, CELL, V95, P963, DOI 10.1016/S0092-8674(00)81720-1; Houghtaling BR, 2004, CURR BIOL, V14, P1621, DOI 10.1016/j.cub.2004.08.052; Kim S, 2004, J BIOL CHEM, V279, P43799, DOI 10.1074/jbc.M408650200; Kim SH, 1999, NAT GENET, V23, P405, DOI 10.1038/70508; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; Lei M, 2004, NAT STRUCT MOL BIOL, V11, P1223, DOI 10.1038/nsmb867; Lei M, 2005, J BIOL CHEM, V280, P20449, DOI 10.1074/jbc.M502212200; Li BB, 2000, CELL, V101, P471, DOI 10.1016/S0092-8674(00)80858-2; Liu D, 2004, J BIOL CHEM, V279, P51338, DOI 10.1074/jbc.M409293200; Liu D, 2004, NAT CELL BIOL, V6, P673, DOI 10.1038/ncb1142; Loayza D, 2004, J BIOL CHEM, V279, P13241, DOI 10.1074/jbc.M312309200; Loayza D, 2003, NATURE, V423, P1013, DOI 10.1038/nature01688; O'Connor MS, 2006, P NATL ACAD SCI USA, V103, P11874, DOI 10.1073/pnas.0605303103; Paeschke K, 2005, NAT STRUCT MOL BIOL, V12, P847, DOI 10.1038/nsmb982; Shay JW, 2002, CANCER CELL, V2, P257, DOI 10.1016/S1535-6108(02)00159-9; Teixeira MT, 2004, CELL, V117, P323, DOI 10.1016/S0092-8674(04)00334-4; Theobald DL, 2003, ANNU REV BIOPH BIOM, V32, P115, DOI 10.1146/annurev.biophys.32.110601.142506; Wu L, 2006, CELL, V126, P49, DOI 10.1016/j.cell.2006.05.037; Ye JZS, 2004, J BIOL CHEM, V279, P47264, DOI 10.1074/jbc.M409047200; Ye JZS, 2004, GENE DEV, V18, P1649, DOI 10.1101/gad.1215404; Zaug AJ, 2005, P NATL ACAD SCI USA, V102, P10864, DOI 10.1073/pnas.0504744102	38	499	520	0	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 1	2007	445	7127					506	510		10.1038/nature05454	http://dx.doi.org/10.1038/nature05454			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	131KI	17237768	Green Published			2022-12-28	WOS:000243867300036
J	Sharp, D				Sharp, David			A device before its time	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England		Sharp, D (corresponding author), The Lancet, London NW1 7BY, England.							Charette F, 2006, NATURE, V444, P551, DOI 10.1038/444551a; Freeth T, 2006, NATURE, V444, P587, DOI 10.1038/nature05357; HANCOCK G, 1996, FINGERPRINTS GODS QU, P389; PRICE DJD, 1959, SCI AM           JUN; *WIK, BAGHD BATT; WRIGHT MT, UNDERSTANDING ANTIKY	6	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 20	2007	369	9557					176	176		10.1016/S0140-6736(07)60089-0	http://dx.doi.org/10.1016/S0140-6736(07)60089-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128XG	17240272				2022-12-28	WOS:000243692400011
J	Butler, SJ; Vickery, JA; Norris, K				Butler, S. J.; Vickery, J. A.; Norris, K.			Farmland biodiversity and the footprint of agriculture	SCIENCE			English	Article							GENETICALLY-MODIFIED CROPS; AGRI-ENVIRONMENT SCHEMES; CONSERVATION; DECLINES; BRITAIN; IMPACTS; ECOLOGY; BIRDS	Sustainable development requires the reconciliation of demands for biodiversity conservation and increased agricultural production. Assessing the impact of novel farming practices on biodiversity and ecosystem services is fundamental to this process. Using farmland birds as a model system, we present a generic risk assessment framework that accurately predicts each species' current conservation status and population growth rate associated with past changes in agriculture. We demonstrate its value by assessing the potential impact on biodiversity of two controversial land uses, genetically modified herbicide-tolerant crops and agri-environment schemes. This framework can be used to guide policy and land management decisions and to assess progress toward sustainability targets.	Univ Reading, Sch Agr Policy & Dev, Ctr Agrienvironm Res, Reading RG6 6AR, Berks, England; British Trust Ornithol, Thetford IP24 2PU, Norfolk, England	University of Reading; British Trust for Ornithology	Butler, SJ (corresponding author), Univ Reading, Sch Agr Policy & Dev, Ctr Agrienvironm Res, Reading RG6 6AR, Berks, England.	s.j.butler@reading.ac.uk	Butler, Simon/H-1703-2011	Butler, Simon/0000-0002-5111-5639				*ACRE, 2006, MAN FOOTPR AGR COMP; Adams WM, 2004, SCIENCE, V306, P1146, DOI 10.1126/science.1097920; Balmford A, 2002, SCIENCE, V297, P950, DOI 10.1126/science.1073947; Biesmeijer JC, 2006, SCIENCE, V313, P351, DOI 10.1126/science.1127863; Chapin FS, 2000, NATURE, V405, P234, DOI 10.1038/35012241; Costanza R, 1997, NATURE, V387, P253, DOI 10.1038/387253a0; *DEFR, 2005, ENTR LEV STEW HDB; Freckleton RP, 2004, P ROY SOC B-BIOL SCI, V271, P325, DOI 10.1098/rspb.2003.2603; Green RE, 2005, SCIENCE, V307, P550, DOI 10.1126/science.1106049; GREEN RE, 2004, SCIENCE         1223, DOI DOI 10.1126/SCIENCE.1106049; Gregory R.D., 2003, Ornis Hungarica, V12-13, P11; Gregory Richard D., 2002, British Birds, V95, P410; Hails RS, 2002, NATURE, V418, P685, DOI 10.1038/nature01016; Kleijn D, 2003, J APPL ECOL, V40, P947, DOI 10.1111/j.1365-2664.2003.00868.x; Kleijn D, 2001, NATURE, V413, P723, DOI 10.1038/35099540; Krebs JR, 1999, NATURE, V400, P611, DOI 10.1038/23127; Loreau M, 2001, SCIENCE, V294, P804, DOI 10.1126/science.1064088; Newton I, 2004, IBIS, V146, P579, DOI 10.1111/j.1474-919X.2004.00375.x; Norris K, 2004, P ROY SOC B-BIOL SCI, V271, P123, DOI 10.1098/rspb.2003.2576; Owens IPF, 2000, P NATL ACAD SCI USA, V97, P12144, DOI 10.1073/pnas.200223397; Perry JN, 2004, NATURE, V428, P313, DOI 10.1038/nature02374; *RUR DEV SERV STRA, 2006, ES OPT UPT REP; Siriwardena GM, 1998, J APPL ECOL, V35, P24, DOI 10.1046/j.1365-2664.1998.00275.x; Tilman D, 2001, SCIENCE, V292, P281, DOI 10.1126/science.1057544; Tilman D, 1999, P NATL ACAD SCI USA, V96, P5995, DOI 10.1073/pnas.96.11.5995; Whitfield J, 2006, NATURE, V439, P908, DOI 10.1038/439908a; Zeki S, 2003, PHILOS T ROY SOC B, V358, P1775, DOI 10.1098/rstb.2003.1412	27	295	309	6	337	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 19	2007	315	5810					381	384		10.1126/science.1136607	http://dx.doi.org/10.1126/science.1136607			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126SI	17234947				2022-12-28	WOS:000243535400043
J	Weisheit, M; Fahler, S; Marty, A; Souche, Y; Poinsignon, C; Givord, D				Weisheit, Martin; Faehler, Sebastian; Marty, Alain; Souche, Yves; Poinsignon, Christiane; Givord, Dominique			Electric field-induced modification of magnetism in thin-film ferromagnets	SCIENCE			English	Article							REVERSAL; METAL	A large electric field at the surface of a ferromagnetic metal is expected to appreciably change its electron density. In particular, the metal's intrinsic magnetic properties, which are commonly regarded as fixed material constants, will be affected. This requires, however, that the surface has a strong influence on the material's properties, as is the case with ultrathin films. We demonstrated that the magnetocrystalline anisotropy of ordered iron-platinum (FePt) and iron-palladium (FePd) intermetallic compounds can be reversibly modified by an applied electric field when immersed in an electrolyte. A voltage change of -0.6 volts on 2-nanometer-thick films altered the coercivity by -4.5 and +1% in FePt and FePd, respectively. The modification of the magnetic parameters was attributed to a change in the number of unpaired d electrons in response to the applied electric field. Our device structure is general and should be applicable for characterization of other thin-film magnetic systems.	Inst Neel, F-38042 Grenoble 9, France; IFW Dresden, Inst Met Mat, D-01171 Dresden, Germany; CEA Grenoble, Dept Rech Fondamentale Mat Condensee, Serv Phys Mat & Microstruct, F-38054 Grenoble 9, France; Ecole Natl Super Electrochim & Electromet, Lab Electrochim Physiocochim Mat & Interfaces, F-38402 St Martin Dheres, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Institute for Integrative Nanosciences (IIN); Leibniz Institute for Solid State & Materials Research Dresden; CEA; Communaute Universite Grenoble Alpes; Institut National Polytechnique de Grenoble	Weisheit, M (corresponding author), AMD Saxony LLC & Co KG, Dept Mat Anal, Wilschdorfer Landstr 101, D-01109 Dresden, Germany.	martin.weisheit@amd.com	marty, alain/H-7941-2014; Fähler, Sebastian/U-3649-2017	marty, alain/0000-0001-5709-6945; Fähler, Sebastian/0000-0001-9450-4952				Chernyak Y, 2006, J CHEM ENG DATA, V51, P416, DOI 10.1021/je050341y; Chiba D, 2003, SCIENCE, V301, P943, DOI 10.1126/science.1086608; DAALDEROP GHO, 1991, PHYS REV B, V44, P12054, DOI 10.1103/PhysRevB.44.12054; Gleiter H, 2001, ACTA MATER, V49, P737, DOI 10.1016/S1359-6454(00)00221-4; Hemberger J, 2005, NATURE, V434, P364, DOI 10.1038/nature03348; Hur N, 2004, NATURE, V429, P392, DOI 10.1038/nature02572; Ohno H, 2000, NATURE, V408, P944, DOI 10.1038/35050040; Okamoto S, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.094422; Trasatti S, 1996, ELECTROCHIM ACTA, V41, P2069, DOI 10.1016/S0013-4686(96)90003-1; Weissmuller J, 2003, SCIENCE, V300, P312, DOI 10.1126/science.1081024	10	916	935	8	328	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 19	2007	315	5810					349	351		10.1126/science.1136629	http://dx.doi.org/10.1126/science.1136629			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126SI	17234941				2022-12-28	WOS:000243535400032
J	Abram, NJ; Gagan, MK; Liu, ZY; Hantoro, WS; McCulloch, MT; Suwargadi, BW				Abram, Nerilie J.; Gagan, Michael K.; Liu, Zhengyu; Hantoro, Wahyoe S.; McCulloch, Malcolm T.; Suwargadi, Bambang W.			Seasonal characteristics of the Indian Ocean Dipole during the Holocene epoch	NATURE			English	Article							SEA-SURFACE TEMPERATURE; SUMMER MONSOON; EL-NINO; ASIAN MONSOON; ENSO; PACIFIC; PRECIPITATION; OSCILLATION; MIDHOLOCENE; VARIABILITY	The Indian Ocean Dipole(1,2) (IOD) - an oscillatory mode of coupled ocean - atmosphere variability - causes climatic extremes and socio-economic hardship throughout the tropical Indian Ocean region(1-5). There is much debate about how the IOD interacts with the El Nino/Southern Oscillation (ENSO) and the Asian monsoon, and recent changes in the historic ENSO - monsoon relationship(6) raise the possibility that the properties of the IOD may also be evolving. Improving our understanding of IOD events and their climatic impacts thus requires the development of records defining IOD activity in different climatic settings, including prehistoric times when ENSO and the Asian monsoon behaved differently from the present day. Here we use coral geochemical records from the equatorial eastern Indian Ocean to reconstruct surface-ocean cooling and drought during individual IOD events over the past similar to 6,500 years. We find that IOD events during the middle Holocene were characterized by a longer duration of strong surface ocean cooling, together with droughts that peaked later than those expected by El Nino forcing alone. Climate model simulations suggest that this enhanced cooling and drying was the result of strong cross-equatorial winds driven by the strengthened Asian monsoon of the middle Holocene. These IOD - monsoon connections imply that the socioeconomic impacts of projected future changes in Asian monsoon strength may extend throughout Australasia.	Australian Natl Univ, Res Sch Earth Sci, Canberra, ACT 0200, Australia; Univ Wisconsin, Ctr Climat Res, Madison, WI 53706 USA; Chinese Acad Sci, Earth Environm Inst, Xian 710075, Peoples R China; Ocean Univ China, Qingdao 266003, Peoples R China; Indonesian Inst Sci, Res & Dev Ctr Geotechnol, Bandung 40135, Indonesia	Australian National University; University of Wisconsin System; University of Wisconsin Madison; Chinese Academy of Sciences; Ocean University of China; Indonesian Institute of Sciences	Abram, NJ (corresponding author), British Antarctic Survey, NERC, Cambridge CB3 0ET, England.	nabr@bas.ac.uk; michael.gagan@anu.edu.au	McCulloch, Malcolm T/C-3651-2009; Gagan, Michael/L-5014-2018; Abram, Nerilie/AAT-5171-2021	McCulloch, Malcolm T/0000-0003-1538-1558; Gagan, Michael/0000-0002-8279-323X; Abram, Nerilie/0000-0003-1246-2344				Abram NJ, 2003, SCIENCE, V301, P952, DOI 10.1126/science.1083841; Anderson DM, 2002, SCIENCE, V297, P596, DOI 10.1126/science.1072881; Ashok K, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017926; Ashrit RG, 2001, GEOPHYS RES LETT, V28, P1727, DOI 10.1029/2000GL012489; BECK JW, 1992, SCIENCE, V257, P644, DOI 10.1126/science.257.5070.644; Behera SK, 2006, J CLIMATE, V19, P1688, DOI 10.1175/JCLI3797.1; Birkett C, 1999, GEOPHYS RES LETT, V26, P1031, DOI 10.1029/1999GL900165; Briggs RW, 2006, SCIENCE, V311, P1897, DOI 10.1126/science.1122602; Charles CD, 2003, MAR GEOL, V201, P207, DOI 10.1016/S0025-3227(03)00217-2; Charles CD, 1997, SCIENCE, V277, P925, DOI 10.1126/science.277.5328.925; Dai A, 2000, GEOPHYS RES LETT, V27, P1283, DOI 10.1029/1999GL011140; EATON P, 2001, FOREST FIRES REGIONA; Fischer AS, 2005, J CLIMATE, V18, P3428, DOI 10.1175/JCLI3478.1; Gagan MK, 2004, QUATERN INT, V118, P127, DOI 10.1016/S1040-6182(03)00134-4; Gagan MK, 1998, SCIENCE, V279, P1014, DOI 10.1126/science.279.5353.1014; Hu ZZ, 2000, GEOPHYS RES LETT, V27, P2681, DOI 10.1029/2000GL011550; Koutavas A, 2002, SCIENCE, V297, P226, DOI 10.1126/science.1072376; Kumar KK, 2006, SCIENCE, V314, P115, DOI 10.1126/science.1131152; Kumar KK, 1999, SCIENCE, V284, P2156, DOI 10.1126/science.284.5423.2156; Liu Z, 2003, PALEOCEANOGRAPHY, V18, DOI 10.1029/2002PA000819; Liu Z, 2004, CLIM DYNAM, V22, P157, DOI 10.1007/s00382-003-0372-y; Moy CM, 2002, NATURE, V420, P162, DOI 10.1038/nature01194; REYNOLDS RW, 1994, J CLIMATE, V7, P929, DOI 10.1175/1520-0442(1994)007<0929:IGSSTA>2.0.CO;2; Saji NH, 1999, NATURE, V401, P360, DOI 10.1038/43854; SONTAKKE NA, 1993, J CLIMATE, V6, P1807, DOI 10.1175/1520-0442(1993)006<1807:COAISM>2.0.CO;2; Webster PJ, 1999, NATURE, V401, P356, DOI 10.1038/43848; Xie PP, 1996, J CLIMATE, V9, P840, DOI 10.1175/1520-0442(1996)009<0840:AOGMPU>2.0.CO;2; Yuan DX, 2004, SCIENCE, V304, P575, DOI 10.1126/science.1091220; Zickfeld K, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL022771	29	135	139	2	76	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 18	2007	445	7125					299	302		10.1038/nature05477	http://dx.doi.org/10.1038/nature05477			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126HT	17230187				2022-12-28	WOS:000243504700041
J	Fletcher, J				Fletcher, John			What is heterogeneity and is it important?	BMJ-BRITISH MEDICAL JOURNAL			English	Article									BMJ, London WC1H 9JR, England		Fletcher, J (corresponding author), BMJ, London WC1H 9JR, England.	jfletcher@bmj.com						Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Macdonald GM, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub2; Oliver D, 2007, BRIT MED J, V334, P82, DOI 10.1136/bmj.39049.706493.55; Tramer MR, 2006, BRIT MED J, V333, P675, DOI 10.1136/bmj.38905.634132.AE; Winzenberg T, 2006, BMJ-BRIT MED J, V333, P775, DOI 10.1136/bmj.38950.561400.55	5	234	236	1	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 13	2007	334	7584					94	96		10.1136/bmj.39057.406644.68	http://dx.doi.org/10.1136/bmj.39057.406644.68			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	127DZ	17218716	Green Published			2022-12-28	WOS:000243566800034
J	Melichar, HJ; Narayan, K; Der, SD; Hiraoka, Y; Gardiol, N; Jeannet, G; Held, W; Chambers, CA; Kang, JS				Melichar, Heather J.; Narayan, Kavitha; Der, Sandy D.; Hiraoka, Yoshiki; Gardiol, Noemie; Jeannet, Gregoire; Held, Werner; Chambers, Cynthia A.; Kang, Joonsoo			Regulation of gamma delta versus alpha beta T lymphocyte differentiation by the transcription factor SOX13	SCIENCE			English	Article							CELL-RECEPTOR; COLON-CARCINOMA; CATENIN; GENE; EXPRESSION; PATHWAY; TCF-1; PROTEINS	alpha beta and gamma delta T cells originate from a common, multipotential precursor population in the thymus, but the molecular mechanisms regulating this lineage-fate decision are unknown. We have identified Sox13 as a gamma delta-specific gene in the immune system. Using Sox13 transgenic mice, we showed that this transcription factor promotes gd T cell development while opposing ab T cell differentiation. Conversely, mice deficient in Sox13 expression exhibited impaired development of gd T cells but not ab T cells. One mechanism of SOX13 function is the inhibition of signaling by the developmentally important Wnt/T cell factor (TCF) pathway. Our data thus reveal a dominant pathway regulating the developmental fate of these two lineages of T lymphocytes.	Univ Massachusetts, Sch Med, Dept Pathol, Grad Program Immunol & Virol, Worcester, MA 01655 USA; Univ Toronto, Dept Lab Med & Pathobiol, Program Proteom & Bioinformat, Toronto, ON, Canada; Keio Univ, Sch Med, Dept Anat, Shinjuku Ku, Tokyo 1608582, Japan; Ludwig Inst Canc Res, Lausanne Branch, CH-1066 Epalinges, Switzerland; Univ Lausanne, CH-1066 Epalinges, Switzerland	University of Massachusetts System; University of Massachusetts Worcester; University of Toronto; Keio University; Ludwig Institute for Cancer Research; University of Lausanne	Kang, JS (corresponding author), Univ Massachusetts, Sch Med, Dept Pathol, Grad Program Immunol & Virol, 55 Lake Ave N, Worcester, MA 01655 USA.	Joonsoo.Kang@umassmed.edu		kang, joonsoo/0000-0001-8419-7995	NATIONAL CANCER INSTITUTE [R01CA100382] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA100382/92614] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLISON JP, 1987, IMMUNOL TODAY, V8, P293, DOI 10.1016/0167-5699(87)90014-4; Ciofani M, 2006, IMMUNITY, V25, P105, DOI 10.1016/j.immuni.2006.05.010; Hayday AC, 2000, ANNU REV IMMUNOL, V18, P975, DOI 10.1146/annurev.immunol.18.1.975; Held W, 1999, IMMUNITY, V11, P433, DOI 10.1016/S1074-7613(00)80118-1; Huang ZF, 2006, J IMMUNOL, V176, P4880, DOI 10.4049/jimmunol.176.8.4880; Ioannidis V, 2001, NAT IMMUNOL, V2, P691, DOI 10.1038/90623; ISHIDA I, 1990, P NATL ACAD SCI USA, V87, P3067, DOI 10.1073/pnas.87.8.3067; Kan LX, 2004, DEV BIOL, V269, P580, DOI 10.1016/j.ydbio.2004.02.005; Kang J, 1997, Semin Immunol, V9, P171, DOI 10.1006/smim.1997.0069; Kang J, 2001, J EXP MED, V193, P689, DOI 10.1084/jem.193.6.689; Kaufmann SHE, 1996, P NATL ACAD SCI USA, V93, P2272, DOI 10.1073/pnas.93.6.2272; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Roose J, 1998, NUCLEIC ACIDS RES, V26, P469, DOI 10.1093/nar/26.2.469; Saint-Ruf C, 2000, NATURE, V406, P524, DOI 10.1038/35020093; Sampson EM, 2001, EMBO J, V20, P4500, DOI 10.1093/emboj/20.16.4500; Schilham MW, 1998, J IMMUNOL, V161, P3984; Silva-Santos B, 2005, SCIENCE, V307, P925, DOI 10.1126/science.1103978; Staal FJT, 2001, EUR J IMMUNOL, V31, P285, DOI 10.1002/1521-4141(200101)31:1<285::AID-IMMU285>3.3.CO;2-4; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; VERBEEK S, 1995, NATURE, V374, P70, DOI 10.1038/374070a0; Wegner M, 1999, NUCLEIC ACIDS RES, V27, P1409, DOI 10.1093/nar/27.6.1409; Zorn AM, 1999, MOL CELL, V4, P487, DOI 10.1016/S1097-2765(00)80200-2	23	127	128	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 12	2007	315	5809					230	233		10.1126/science.1135344	http://dx.doi.org/10.1126/science.1135344			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124XZ	17218525				2022-12-28	WOS:000243407400044
J	Easton, G				Easton, Graham			Clicking for pills	BRITISH MEDICAL JOURNAL			English	Article												Gp.easton@virgin.net	Easton, Graham/K-8359-2019					[Anonymous], 2006, GOOD PRACT PRESCR ME; *MED HEALTHC PROD, BUYING MED INT; *ROYAL PHARM SOC G, COD ETH STAND; *US FOOD DRUG ADM, BUYING MED PROD ONL; WHO, COUNT MED	5	9	9	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JAN 6	2007	334	7583					14	15		10.1136/bmj.39063.418391.68	http://dx.doi.org/10.1136/bmj.39063.418391.68			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125CH	17204793	Green Published			2022-12-28	WOS:000243418600026
J	Olinto, AV				Olinto, Angela V.			Cosmic rays: The highest-energy messengers	SCIENCE			English	Editorial Material							SPECTRUM	The origin of the most energetic particles ever observed, cosmic rays, will begin to be revealed in the next few years. Newly constructed ultrahigh-energy cosmic ray observatories together with high-energy gamma-ray and neutrino observatories are well positioned to unveil this mystery before the centenary of their discovery in 2012. Cosmic ray sources are likely to involve the most energetic phenomena ever witnessed in the universe.	Univ Chicago, Enrico Fermi Inst, Kavli Inst Cosmol Phys, Dept Astron & Astrophys, Chicago, IL 60637 USA	University of Chicago	Olinto, AV (corresponding author), Univ Chicago, Enrico Fermi Inst, Kavli Inst Cosmol Phys, Dept Astron & Astrophys, 5640 S Ellis Ave, Chicago, IL 60637 USA.	olinto@kicp.uchicago.edu						Abbasi RU, 2005, ASTROPART PHYS, V23, P157, DOI 10.1016/j.astropartphys.2004.12.006; Abbasi RU, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.151101; Abraham J, 2004, NUCL INSTRUM METH A, V523, P50, DOI 10.1016/j.nima.2003.12.012; Aharonian F, 2006, ASTRON ASTROPHYS, V449, P223, DOI 10.1051/0004-6361:20054279; Antoni T, 2005, ASTROPART PHYS, V24, P1, DOI 10.1016/j.astropartphys.2005.04.001; ARMANGAUD E, COMMUNICATION; De Marco D, 2003, ASTROPART PHYS, V20, P53, DOI 10.1016/S0927-6505(03)00148-8; Gaisser TK, 2006, NUCL PHYS A, V777, P98, DOI 10.1016/j.nuclphysa.2005.01.024; GREISEN K, 1966, PHYS REV LETT, V16, P748, DOI 10.1103/PhysRevLett.16.748; HAYASHIDA N, 1994, PHYS REV LETT, V73, P3491, DOI 10.1103/PhysRevLett.73.3491; HILLAS AM, 2006, IN PRESS COSMOLOGY G; Volk HJ, 2005, ASTRON ASTROPHYS, V433, P229, DOI 10.1051/0004-6361:20042015; ZATSEPIN GT, 1966, JETP LETT, V4, P81966	13	2	2	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 5	2007	315	5808					68	70		10.1126/science.1136640	http://dx.doi.org/10.1126/science.1136640			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	122WU	17204641				2022-12-28	WOS:000243259100034
J	Ferrer, M; Golyshina, OV; Beloqui, A; Golyshin, PN; Timmis, KN				Ferrer, Manuel; Golyshina, Olga V.; Beloqui, Ana; Golyshin, Peter N.; Timmis, Kenneth N.			The cellular machinery of Ferroplasma acidiphilum is iron-protein-dominated	NATURE			English	Article							SOUTHERN-OCEAN; WALL-LACKING; SP-NOV.; ENVIRONMENTS; PROKARYOTES; CLUSTERS; ARCHAEA; ACID	Ferroplasma is a genus of the Archaea, one of the three branches of the tree of life, and belongs to the order Thermoplasmatales ( Euryarchaeota), which contains the most acidophilic microbes yet known. Ferroplasma species live in acid mine drainage, acidic pools and environments containing sulphidic ores such as pyrite and characterized by pH values of 0 - 2 and high concentrations of ferrous iron and other heavy metals(1-3). F. acidiphilum strain Y-T is a chemoautotroph that grows optimally at pH 1.7 and gains energy by oxidizing ferrous iron and carbon by the fixation of carbon dioxide(1). Here we show that 86% of 189 investigated cellular proteins of F. acidiphilum are iron-metalloproteins. These include proteins with deduced structural, chaperone and catalytic roles, not described as iron-metalloproteins in any other organism so far investigated. The iron atoms in the proteins seem to organize and stabilize their three-dimensional structures, to act as 'iron rivets'. Analysis of proteins of the phylogenetic neighbour Picrophilus torridus and of the habitat neighbour Acidithiobacillus ferrooxidans revealed far fewer and only typical metalloproteins. F. acidiphilum therefore has a currently unique iron-protein-dominated cellular machinery and biochemical phylogeny.	CSIC, Inst Catalysis, Madrid 28049, Spain; HZI Helmholtz Ctr Infect Res, Dept Environm Microbiol, D-38124 Braunschweig, Germany; Tech Univ Carolo Wilhelmina Braunschweig, Inst Microbiol, D-38106 Braunschweig, Germany; Univ Essex, Dept Biol Sci, Colchester CO4 3SQ, Essex, England	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Catalisis y Petroleoquimica (ICP); Helmholtz Association; Helmholtz-Center for Infection Research; Braunschweig University of Technology; University of Essex	Ferrer, M (corresponding author), CSIC, Inst Catalysis, Madrid 28049, Spain.	mferrer@icp.csic.es	Beloqui, Ana/C-4512-2012; Ferrer, Manuel/K-4535-2014	Beloqui, Ana/0000-0002-7693-4163; Ferrer, Manuel/0000-0003-4962-4714; Golyshin, Peter/0000-0002-5433-0350; Golyshina, Olga/0000-0001-5132-6850				Agarwalla S, 2004, J BIOL CHEM, V279, P34123, DOI 10.1074/jbc.M405702200; BLOCHL E, 1992, P NATL ACAD SCI USA, V89, P8117, DOI 10.1073/pnas.89.17.8117; Boal AK, 2005, BIOCHEMISTRY-US, V44, P8397, DOI 10.1021/bi047494n; Buesseler KO, 2004, SCIENCE, V304, P414, DOI 10.1126/science.1086895; Dopson M, 2004, APPL ENVIRON MICROB, V70, P2079, DOI 10.1128/AEM.70.4.2079-2088.2004; Ferrer M, 2005, BIOCHEM J, V391, P269, DOI 10.1042/BJ20050346; Giometti CS, 2003, PROTEOMICS, V3, P777, DOI 10.1002/pmic.200300406; Golyshina OV, 2000, INT J SYST EVOL MICR, V50, P997, DOI 10.1099/00207713-50-3-997; Golyshina OV, 2005, ENVIRON MICROBIOL, V7, P1277, DOI 10.1111/j.1462-2920.2005.00861.x; Golyshina OV, 2006, ENVIRON MICROBIOL, V8, P416, DOI 10.1111/j.1462-2920.2005.00907.x; Hogbom M, 2005, MOL CELL PROTEOMICS, V4, P827, DOI 10.1074/mcp.T400023-MCP200; Imlay JA, 2006, MOL MICROBIOL, V59, P1073, DOI 10.1111/j.1365-2958.2006.05028.x; Major TA, 2004, FEMS MICROBIOL LETT, V239, P117, DOI 10.1016/j.femsle.2004.08.027; Pierrel F, 2002, J BIOL CHEM, V277, P13367, DOI 10.1074/jbc.C100609200; Schneider D, 2005, BBA-BIOENERGETICS, V1710, P1, DOI 10.1016/j.bbabio.2005.09.003; WACHTERSHAUSER G, 2002, SCIENCE, V296, P1982; Watson AJ, 2000, NATURE, V407, P730, DOI 10.1038/35037561	17	78	81	2	70	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 4	2007	445	7123					91	94		10.1038/nature05362	http://dx.doi.org/10.1038/nature05362			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	122KG	17203061				2022-12-28	WOS:000243225100042
J	Beulens, JWJ; Rimm, EB; Ascherio, A; Spiegelman, D; Hendriks, HFJ; Mukamal, KJ				Beulens, Joline W. J.; Rimm, Eric B.; Ascherio, Alberto; Spiegelman, Donna; Hendriks, Henk F. J.; Mukamal, Kenneth J.			Alcohol consumption and risk for coronary heart disease among men with hypertension	ANNALS OF INTERNAL MEDICINE			English	Article							CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; CONFIDENCE-INTERVALS; MEASUREMENT ERROR; MORTALITY; REPRODUCIBILITY; FREQUENCY; VALIDITY; WOMEN; WINE	Background: Heavy alcohol consumption increases risk for hypertension, which is in itself a strong risk factor for cardiovascular disease (CVD). However, data on the association between alcohol consumption and CVD among individuals with hypertension are scarce. Objective: To assess whether alcohol consumption is inversely associated with CVD among men with hypertension. Design: Prospective cohort study. Setting: United States. Participants: 11 711 men with hypertension from the Health Professionals Follow-Up Study. Measurements: Alcohol consumption was assessed every 4 years by using a food-frequency questionnaire. Incident cases of nonfatal myocardial infarction (MI), fatal coronary heart disease, and stroke were documented from 1986 to 2002. Results: During follow-up, 653 patients with MI were documented. Compared with patients abstaining from alcohol, the hazard ratio for participants with MI consuming 0.1 to 4.9 grams of alcohol per day was 1.09 (95% CI, 0.86 to 1.37); consuming 5 to 9.9 grams of alcohol per day was 0.81 (CI, 0.60 to 1.08 g/d); consuming 10 to 14.9 grams of alcohol per day was 0.68 (CI, 0.51 to 0.91 g/d); consuming 15 to 29.9 grams of alcohol per day was 0.72 (CI, 0.54 to 0.97 g/d); consuming 30 to 49.9 grams of alcohol per day was 0.67 (CI, 0.48 to 0.94 g/d); and consuming 50 or more grams of alcohol per day was 0.41 (CI, 0.22 to 0.77 g/d) (P < 0.001 for trend). Associations were similar for fatal and nonfatal MI. Alcohol consumption was not associated with total death or death due to CVD. Risks for total and ischemic stroke for patients consuming 10 to 29.9 g of alcohol per day were 1.40 (CI, 0.93 to 2.12) and 1.55 (CI, 0.90 to 2.68) compared with that of abstainers. When corrected for measurement error in alcohol consumption, dietary variables, and body mass index, the hazard ratio for participants with MI per 12.5 grams per day increment of alcohol intake was 0.68 (CI, 0.46 to 1.00). Limitations: Hypertension, alcohol consumption, and CVD risk factors were assessed by self-report. Available data used to correct for measurement error were primarily restricted to dietary variables. Conclusions: In this population of men with hypertension, moderate alcohol consumption was associated with a decreased risk for MI but not with risks for total death or death due to CVD. As in the general population, men with hypertension who drink moderately and safely may not need to change their drinking habits.	Harvard Univ, Sch Med, Sch Publ Hlth, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Univ Wageningen & Res Ctr, NL-6700 HB Wageningen, Netherlands; TNO Qual Life, Zeist, Netherlands	Harvard University; Harvard Medical School; Harvard T.H. Chan School of Public Health; Harvard University; Beth Israel Deaconess Medical Center; Wageningen University & Research; Netherlands Organization Applied Science Research	Beulens, JWJ (corresponding author), Univ Utrecht, Med Ctr, Utrecht Julius Ctr Hlth Sci & Primary Care, POB 85500, NL-3508 GA Utrecht, Netherlands.	J.Beulens@umcutrecht.nl	Mukamal, Kenneth/GVR-7978-2022; Hendriks, Henk/AAU-5987-2021	Beulens, Joline/0000-0002-4181-0937	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035464] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA011181] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ASCHERIO A, 1992, CIRCULATION, V86, P1475, DOI 10.1161/01.CIR.86.5.1475; ChasanTaber S, 1996, EPIDEMIOLOGY, V7, P81, DOI 10.1097/00001648-199601000-00014; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; COLDITZ GA, 1991, AM J CLIN NUTR, V54, P49, DOI 10.1093/ajcn/54.1.49; Corrao G, 2000, ADDICTION, V95, P1505, DOI 10.1046/j.1360-0443.2000.951015056.x; Cushman WC, 1998, ARCH INTERN MED, V158, P1197, DOI 10.1001/archinte.158.11.1197; Davies MJ, 2002, JAMA-J AM MED ASSOC, V287, P2559, DOI 10.1001/jama.287.19.2559; Day NE, 2004, INT J EPIDEMIOL, V33, P1373, DOI 10.1093/ije/dyh138; DURRLEMAN S, 1989, STAT MED, V8, P551, DOI 10.1002/sim.4780080504; FESKANICH D, 1993, J AM DIET ASSOC, V93, P790, DOI 10.1016/0002-8223(93)91754-E; Fields LE, 2004, HYPERTENSION, V44, P398, DOI 10.1161/01.HYP.0000142248.54761.56; Fox MP, 2005, INT J EPIDEMIOL, V34, P1370, DOI 10.1093/ije/dyi184; FOX MP, 2006, EPIDEMIOLOGIC METHOD; Fuchs FD, 2001, HYPERTENSION, V37, P1242, DOI 10.1161/01.HYP.37.5.1242; GIOVANNUCCI E, 1994, ANN INTERN MED, V121, P241, DOI 10.7326/0003-4819-121-4-199408150-00001; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; Goldberg IJ, 2001, CIRCULATION, V103, P472; HENDRIKS HFJ, 1994, BRIT MED J, V308, P1003, DOI 10.1136/bmj.308.6935.1003; KIYOHARA Y, 1995, STROKE, V26, P368, DOI 10.1161/01.STR.26.3.368; LOGAN R, 1997, SAS BLINPLUS MACRO; MACLURE M, 1993, EPIDEMIOL REV, V15, P328, DOI 10.1093/oxfordjournals.epirev.a036124; Malinski MK, 2004, ARCH INTERN MED, V164, P623, DOI 10.1001/archinte.164.6.623; Mancia G, 2003, J HYPERTENS, V21, P1011, DOI 10.1097/01.hjh.0000059051.65882.32; MARMOT M, 1991, BMJ-BRIT MED J, V303, P565, DOI 10.1136/bmj.303.6802.565; Mukamal KJ, 2005, CIRCULATION, V112, P1406, DOI 10.1161/CIRCULATIONAHA.105.537704; Mukamal KJ, 2005, ANN INTERN MED, V142, P11, DOI 10.7326/0003-4819-142-1-200501040-00007; Mukamal KJ, 2003, NEW ENGL J MED, V348, P109, DOI 10.1056/NEJMoa022095; Ngandu NH, 1997, STAT MED, V16, P611, DOI 10.1002/(SICI)1097-0258(19970330)16:6<611::AID-SIM437>3.0.CO;2-T; PALMER AJ, 1995, J HYPERTENS, V13, P957, DOI 10.1097/00004872-199509000-00004; Rehm JT, 1997, AM J EPIDEMIOL, V146, P495, DOI 10.1093/oxfordjournals.aje.a009303; Reims HM, 2004, J HUM HYPERTENS, V18, P381, DOI 10.1038/sj.jhh.1001731; Renaud SC, 2004, AM J CLIN NUTR, V80, P621; Rimm E B, 1990, Epidemiology, V1, P466, DOI 10.1097/00001648-199011000-00009; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; Rimm EB, 1996, AM J EPIDEMIOL, V143, P1094; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; Rimm EB, 1999, BMJ-BRIT MED J, V319, P1523, DOI 10.1136/bmj.319.7224.1523; Rose G, 1982, CARDIOVASCULAR SURVE; ROSNER B, 1990, AM J EPIDEMIOL, V132, P734, DOI 10.1093/oxfordjournals.aje.a115715; ROSNER B, 1989, STAT MED, V8, P1051, DOI 10.1002/sim.4780080905; SHAPER AG, 1988, LANCET, V2, P1267; Sierksma A, 2002, EUR J CLIN NUTR, V56, P1130, DOI 10.1038/sj.ejcn.1601459; Tanasescu M, 2001, J AM COLL CARDIOL, V38, P1836, DOI 10.1016/S0735-1097(01)01655-2; Thadhani R, 2002, ARCH INTERN MED, V162, P569, DOI 10.1001/archinte.162.5.569; Therneau T, 1997, P 1 SEATTL S BIOST S, P51; Thun MJ, 1997, NEW ENGL J MED, V337, P1705, DOI 10.1056/NEJM199712113372401; Tunstall-Pedoe H, 1999, LANCET, V353, P1547, DOI 10.1016/S0140-6736(99)04021-0; WANNAMETHEE G, 1995, BRIT HEART J, V74, P324; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837	49	91	99	0	16	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 2	2007	146	1					10	W3		10.7326/0003-4819-146-1-200701020-00004	http://dx.doi.org/10.7326/0003-4819-146-1-200701020-00004			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188BK	17200217				2022-12-28	WOS:000247893300002
J	Black, DM; Schwartz, AV; Ensrud, KE; Cauley, JA; Levis, S; Quandt, SA; Satterfield, S; Wallace, RB; Bauer, DC; Palermo, L; Wehren, LE; Lombardi, A; Santora, AC; Cummings, SR				Black, Dennis M.; Schwartz, Ann V.; Ensrud, Kristine E.; Cauley, Jane A.; Levis, Silvina; Quandt, Sara A.; Satterfield, Suzanne; Wallace, Robert B.; Bauer, Douglas C.; Palermo, Lisa; Wehren, Lois E.; Lombardi, Antonio; Santora, Arthur C.; Cummings, Steven R.		FLEX Res Grp	Effects of continuing or stopping alendronate after 5 years of treatment - The Fracture Intervention Trial long-term extension (FLEX): A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BONE-MINERAL DENSITY; PREVALENT VERTEBRAL DEFORMITIES; POSTMENOPAUSAL OSTEOPOROSIS; HIP-FRACTURES; CORTICAL BONE; WOMEN; RISK; DISCONTINUATION; RISEDRONATE; EFFICACY	Context The optimal duration of treatment of women with postmenopausal osteoporosis is uncertain. Objective To compare the effects of discontinuing alendronate treatment after 5 years vs continuing for 10 years. Design and Setting Randomized, double-blind trial conducted at 10 US clinical centers that participated in the Fracture Intervention Trial ( FIT). Participants One thousand ninety-nine postmenopausal women who had been randomized to alendronate in FIT, with a mean of 5 years of prior alendronate treatment. Intervention Randomization to alendronate, 5 mg/d (n = 329) or 10 mg/d (n = 333), or placebo (n = 437) for 5 years (1998-2003). Main Outcome Measures The primary outcome measure was total hip bone mineral density (BMD); secondary measures were BMD at other sites and biochemical markers of bone remodeling. An exploratory outcome measure was fracture incidence. Results Compared with continuing alendronate, switching to placebo for 5 years resulted in declines in BMD at the total hip (- 2.4%; 95% confidence interval [CI], - 2.9% to - 1.8%; P <. 001) and spine (- 3.7%; 95% CI, - 4.5% to - 3.0%; P <. 001), but mean levels remained at or above pretreatment levels 10 years earlier. Similarly, those discontinuing alendronate had increased serum markers of bone turnover compared with continuing alendronate: 55.6% ( P <. 001) for C-telopeptide of type 1 collagen, 59.5% ( P <. 001) for serum N = propeptide of type 1 collagen, and 28.1% ( P <. 001) for bone-specific alkaline phosphatase, but after 5 years without therapy, bone marker levels remained somewhat below pretreatment levels 10 years earlier. After 5 years, the cumulative risk of nonvertebral fractures (RR, 1.00; 95% CI, 0.76-1.32) was not significantly different between those continuing (19%) and discontinuing (18.9%) alendronate. Among those who continued, there was a significantly lower risk of clinically recognized vertebral fractures (5.3% for placebo and 2.4% for alendronate; RR, 0.45; 95% CI, 0.24-0.85) but no significant reduction in morphometric vertebral fractures (11.3% for placebo and 9.8% for alendronate; RR, 0.86; 95% CI, 0.60-1.22). A small sample of 18 transilial bone biopsies did not show any qualitative abnormalities, with bone turnover ( double labeling) seen in all specimens. Conclusions Women who discontinued alendronate after 5 years showed a moderate decline in BMD and a gradual rise in biochemical markers but no higher fracture risk other than for clinical vertebral fractures compared with those who continued alendronate. These results suggest that for many women, discontinuation of alendronate for up to 5 years does not appear to significantly increase fracture risk. However, women at very high risk of clinical vertebral fractures may benefit by continuing beyond 5 years.	Univ Calif San Francisco, San Francisco Coordinating Ctr, San Francisco, CA 94107 USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA USA; Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA; VA Med Ctr, Dept Med, Minneapolis, MN USA; Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA; Univ Miami, Dept Med, Miami, FL USA; Wake Forest Univ, Sch Med, Winston Salem, NC 27109 USA; Univ Tennessee, Dept Prevent Med, Memphis, TN USA; Univ Iowa, Coll Med, Iowa City, IA USA; Merck Res Labs, Rahway, NJ USA	California Pacific Medical Center; California Pacific Medical Center Research Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; California Pacific Medical Center; California Pacific Medical Center Research Institute; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Miami; Wake Forest University; University of Tennessee System; University of Tennessee Health Science Center; University of Iowa; Merck & Company	Black, DM (corresponding author), Univ Calif San Francisco, San Francisco Coordinating Ctr, Suite 5700,Lobby 4,185 Berry St, San Francisco, CA 94107 USA.	dblack@psg.ucsf.edu	Cauley, Jane A/N-4836-2015	Cauley, Jane A/0000-0003-0752-4408; Ensrud, Kristine/0000-0002-9069-3036				Bauer DC, 2006, J BONE MINER RES, V21, P292, DOI 10.1359/JBMR.051018; BLACK DM, 1993, OSTEOPOROSIS INT, V3, pS29; Black DM, 2005, NEW ENGL J MED, V353, P555, DOI 10.1056/NEJMoa050336; BLACK DM, 1995, J BONE MINER RES, V10, P890; Black DM, 1999, J BONE MINER RES, V14, P821, DOI 10.1359/jbmr.1999.14.5.821; BLACK DM, 1991, J BONE MINER RES, V6, P883; Black DM, 2000, J CLIN ENDOCR METAB, V85, P4118, DOI 10.1210/jc.85.11.4118; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897; Burr DB, 2002, BONE, V30, P2, DOI 10.1016/S8756-3282(01)00619-6; Chesnut CH, 2004, J BONE MINER RES, V19, P1241, DOI 10.1359/JBMR.040325; Cummings SR, 1998, JAMA-J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077; Devogelaer JP, 1992, 3 BATH C OST BON MIN; EASTELL R, 1991, J BONE MINER RES, V6, P207; Eastell R, 2003, J BONE MINER RES, V18, P1051, DOI 10.1359/jbmr.2003.18.6.1051; ENSRUD KE, 1995, J BONE MINER RES, V10, P1778; Ensrud KE, 2004, J BONE MINER RES, V19, P1259, DOI 10.1359/JBMR.040326; FRANCK H, 1995, CALCIFIED TISSUE INT, V56, P192, DOI 10.1007/BF00298608; Garnero P, 2000, J BONE MINER RES, V15, P1526, DOI 10.1359/jbmr.2000.15.8.1526; Garnero P, 1996, J BONE MINER RES, V11, P1531; GENANT HK, 1993, J BONE MINER RES, V8, P1137, DOI 10.1002/jbmr.5650080915; Greenspan SL, 2002, ANN INTERN MED, V137, P875, DOI 10.7326/0003-4819-137-11-200212030-00008; Hans D, 1997, J BONE MINER RES, V12, P1289, DOI 10.1359/jbmr.1997.12.8.1289; Harris ST, 1999, JAMA-J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344; HODGSON SF, 1986, MAYO CLIN PROC, V61, P28, DOI 10.1016/S0025-6196(12)61395-0; LANDMAN JO, 1995, J CLIN ENDOCR METAB, V80, P3465, DOI 10.1210/jc.80.12.3465; LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201; Looker AC, 1998, OSTEOPOROSIS INT, V8, P468, DOI 10.1007/s001980050093; Mellstrom DD, 2004, CALCIFIED TISSUE INT, V75, P462, DOI 10.1007/s00223-004-0286-7; Miller PD, 1997, AM J MED, V103, P468, DOI 10.1016/S0002-9343(97)00278-7; Mortensen L, 1996, AM J CLIN NUTR, V63, P354, DOI 10.1093/ajcn/63.3.354; Neele SJM, 2002, BONE, V30, P599, DOI 10.1016/S8756-3282(01)00706-2; NEER M, 1993, OSTEOPOROSIS INT, V3, pS204; Papapoulos SE, 2005, OSTEOPOROSIS INT, V16, P468, DOI 10.1007/s00198-004-1725-z; Recker RR., 1983, BONE HISTOMORPHOMETR; Rodan G, 2004, CURR MED RES OPIN, V20, P1291, DOI 10.1185/030079904125004475; Roschger P, 2001, BONE, V29, P185, DOI 10.1016/S8756-3282(01)00485-9; Sobelman OS, 2004, J BIOMECH, V37, P1295, DOI 10.1016/j.jbiomech.2003.12.034; Wasnich Richard D, 2004, Menopause, V11, P622; Woo SB, 2006, ANN INTERN MED, V144, P753, DOI 10.7326/0003-4819-144-10-200605160-00009	40	946	1004	1	38	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	2006	296	24					2927	2938		10.1001/jama.296.24.2927	http://dx.doi.org/10.1001/jama.296.24.2927			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	120FD	17190893	Bronze			2022-12-28	WOS:000243069000024
J	Heathcote, E				Heathcote, Edwin			Maggie's Centres	BRITISH MEDICAL JOURNAL			English	Editorial Material									Financial Times, London, England		Heathcote, E (corresponding author), Financial Times, London, England.	edwinheathcote@hotmail.com							0	2	2	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 23	2006	333	7582					1304	1305		10.1136/bmj.39062.614132.55	http://dx.doi.org/10.1136/bmj.39062.614132.55			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121MC	17185717	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000243160700015
J	Gillies, CL; Abrams, KR; Lambert, PC; Cooper, NJ; Sutton, AJ; Hsu, RT; Khunti, K				Gillies, Clare L.; Abrams, Keith R.; Lambert, Paul C.; Cooper, Nicola J.; Sutton, Alex J.; Hsu, Ron T.; Khunti, Kamlesh			Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TRIALS	Objective To quantify the effectiveness of pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance. Data sources Medline, Embase, and the Cochrane library searched up to July 2006. Expert opinions sought and reference lists of identified studies and any relevant published reviews checked. Study selection Randomised controlled trials that evaluated interventions to delay or prevent type 2 diabetes in individuals with impaired glucose tolerance. Results 21 trials met the inclusion criteria, of which 17, with 8084 participants with impaired glucose tolerance, reported results in enough detail for inclusion in the meta-analyses. From the meta-analyses the pooled hazard ratios were 0.51 (95% confidence interval 0.44 to 0.60) for lifestyle interventions v standard advice, 0.70 (0.62 to 0.79) for oral diabetes drugs v control, 0.44 (0.28 to 0.69) for orlistat v control, and 0.32 (0.03 to 3.07) for the herbal remedy jiangtang bushen recipe v standard diabetes advice. These correspond to numbers needed to treat for benefit (NNTB) and harm (NNTH) of 6.4 for lifestyle (95% credible interval, NNTB 5.0 to NNTB 8.4), 10.8 for oral diabetes drugs (NNTB 8.1 to NNTB 15.0), 5.4 for orlistat (NNTB 4.1 to NNTB 7.6), and 4.0 for jiangtang bushen (NNTH 16.9 to NNTB 24.8). Conclusions Lifestyle and pharmacological interventions reduce the rate of progression to type 2 diabetes in people with impaired glucose tolerance. Lifestyle interventions seem to be at least as effective as drug treatment.	Univ Leicester, Ctr Biostat & Genet Epidemiol, Dept Hlth Sci, Leicester LE1 7RH, Leics, England; Univ Leicester, Clin Div Gen Practice & Primary Hlth Care, Dept Hlth Sci, Leicester LE1 7RH, Leics, England	University of Leicester; University of Leicester	Gillies, CL (corresponding author), Univ Leicester, Ctr Biostat & Genet Epidemiol, Dept Hlth Sci, Leicester LE1 7RH, Leics, England.	clg13@le.ac.uk	Abrams, Keith/AAA-2557-2020; /ABC-9527-2021; Samaan, M. Constantine/R-1456-2017	Samaan, M. Constantine/0000-0002-6403-4715; Abrams, Keith/0000-0002-7557-1567; Sutton, Alexander/0000-0002-8934-9940; Gillies, Clare/0000-0002-8417-9700; Lambert, Paul/0000-0002-5337-663X; Khunti, Kamlesh/0000-0003-2343-7099	MRC [G106/1170] Funding Source: UKRI; Medical Research Council [G106/1170] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Altman DG, 1998, BRIT MED J, V317, P1309, DOI 10.1136/bmj.317.7168.1309; Anderson DC, 2005, ANN PHARMACOTHER, V39, P102, DOI 10.1345/aph.1E081; ANGELO JB, 2005, ADV STUD MED, V5, P250; Davies MJ, 2004, DIABETIC MED, V21, P403, DOI 10.1111/j.1464-5491.2004.01176.x; de Vegt F, 2001, JAMA-J AM MED ASSOC, V285, P2109, DOI 10.1001/jama.285.16.2109; Edelstein SL, 1997, DIABETES, V46, P701, DOI 10.2337/diabetes.46.4.701; Gerstein HC, 2006, LANCET, V368, P1096, DOI 10.1016/S0140-6736(06)69420-8; Heneghan C, 2006, BRIT MED J, V333, P764, DOI 10.1136/bmj.38996.709340.BE; Ingelfinger JR, 2006, NEW ENGL J MED, V355, P1608, DOI 10.1056/NEJMe068213; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Knowler WC, 2003, DIABETES CARE, V26, P977; Norris SL, 2005, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD004096.pub2, 10.1002/14651858.CD004095.pub2, 10.1002/14651858.CD005270]; Norris SL, 2005, AM J PREV MED, V28, P126, DOI 10.1016/j.amepre.2004.08.006; Padwal R, 2004, DIABETES CARE, V27, P247, DOI 10.2337/diacare.27.1.247; Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8; Prisant LM, 2004, J CLIN PHARMACOL, V44, P406, DOI 10.1177/0091270004263018; Sharp SJ, 2000, STAT MED, V19, P3251, DOI 10.1002/1097-0258(20001215)19:23<3251::AID-SIM625>3.0.CO;2-2; Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047	18	757	771	2	75	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 10	2007	334	7588					299	302B		10.1136/bmj.39063.689375.55	http://dx.doi.org/10.1136/bmj.39063.689375.55			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	142MN	17237299	Green Published, Bronze			2022-12-28	WOS:000244654100033
J	Johnson, MD; Oldach, D; Delwiche, CF; Stoecker, DK				Johnson, Matthew D.; Oldach, David; Delwiche, Charles F.; Stoecker, Diane K.			Retention of transcriptionally active cryptophyte nuclei by the ciliate Myrionecta rubra	NATURE			English	Article							MESODINIUM-RUBRUM; GENE-TRANSFER; ULTRASTRUCTURE; CHLOROPLASTS; CRYPTOMONAD; DINOFLAGELLATE; ENDOSYMBIONT; NUCLEOMORPH; CILIOPHORA; ALGAE	It is well documented that organelles can be retained and used by predatory organisms, but in most cases such sequestrations are limited to plastids of algal prey(1). Furthermore, sequestrations of prey organelles are typically highly ephemeral(2) as a result of the inability of the organelle to remain functional in the absence of numerous nuclear-encoded genes involved in its regulation, division and function(3). The marine photosynthetic ciliate Myrionecta rubra (Lohmann 1908) Jankowski 1976 ( the same as Mesodinium rubrum)(4) is known to possess organelles of cryptophyte origin(5-9), which has led to debate concerning their status as permanent symbiotic or temporary sequestered fixtures(5-13). Recently, M. rubra has been shown to steal plastids ( that is, chloroplasts) from the cryptomonad, Geminigera cryophila, and prey nuclei were observed to accumulate after feeding(10). Here we show that cryptophyte nuclei in M. rubra are retained for up to 30 days, are transcriptionally active and service plastids derived from multiple cryptophyte cells. Expression of a cryptophyte nuclear-encoded gene involved in plastid function declined in M. rubra as the sequestered nuclei disappeared from the population. Cytokinesis, plastid performance and their replication are dependent on recurrent stealing of cryptophyte nuclei. Karyoklepty ( from Greek karydi, kernel; kleftis, thief) represents a previously unknown evolutionary strategy for acquiring biochemical potential.	Univ Maryland, Horn Point Environm Lab, Ctr Environm Sci, Cambridge, MD 21613 USA; Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA; Univ Maryland, College Pk, MD 20742 USA	University System of Maryland; University of Maryland Center for Environmental Science; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland College Park	Johnson, MD (corresponding author), Rutgers State Univ, Inst Marine & Coastal Sci, 71 Dudley Rd, New Brunswick, NJ 08901 USA.	johnson@marine.rutgers.edu	Delwiche, Charles F/C-6549-2008; stoecker, diane k/F-9341-2013; Johnson, Matthew/B-4344-2012	Delwiche, Charles F/0000-0001-7854-8584; Johnson, Matthew/0000-0003-4853-2674				BLACKBOURN DJ, 1973, J PROTOZOOL, V20, P286, DOI 10.1111/j.1550-7408.1973.tb00877.x; Deane JA, 2000, PROTIST, V151, P239, DOI 10.1078/1434-4610-00022; FIELDS SD, 1991, J PHYCOL, V27, P525, DOI 10.1111/j.0022-3646.1991.00525.x; Gast RJ, 2007, ENVIRON MICROBIOL, V9, P39, DOI 10.1111/j.1462-2920.2006.01109.x; GILLOTT MA, 1980, J PHYCOL, V16, P558; GOFF LJ, 1995, PLANT CELL, V7, P1899; Gustafson DE, 2000, NATURE, V405, P1049, DOI 10.1038/35016570; Hansen PJ, 2006, MAR BIOL RES, V2, P169, DOI 10.1080/17451000600719577; HIBBERD DJ, 1977, J MAR BIOL ASSOC UK, V57, P45, DOI 10.1017/S0025315400021226; Johnson MD, 2006, J PHYCOL, V42, P1235, DOI 10.1111/j.1529-8817.2006.00275.x; Johnson MD, 2004, PROTIST, V155, P347, DOI 10.1078/1434461041844222; Johnson MD, 2005, AQUAT MICROB ECOL, V39, P303, DOI 10.3354/ame039303; Lindholm T., 1985, Advances in Aquatic Microbiology, V3, P1; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; LYNN DH, 2000, ILLUSTRATED GUIDE PR, P477; MADDISON WP, 1992, MACCLADE ANAL PHYLOG; Martin W, 1998, NATURE, V393, P162, DOI 10.1038/30234; Miller PE, 1998, J PHYCOL, V34, P371, DOI 10.1046/j.1529-8817.1998.340371.x; OAKLEY BR, 1978, BIOSYSTEMS, V10, P361, DOI 10.1016/0303-2647(78)90019-9; Saldarriaga JF, 2003, INT J SYST EVOL MICR, V53, P355, DOI 10.1099/ijs.0.02328-0; STOECKER DK, 1990, MAR BIOL, V107, P491, DOI 10.1007/BF01313434; TAYLOR FJR, 1971, J FISH RES BOARD CAN, V28, P391, DOI 10.1139/f71-052; TAYLOR FJR, 1969, NATURE, V224, P819, DOI 10.1038/224819a0; WILCOX LW, 1984, J PHYCOL, V20, P236, DOI 10.1111/j.0022-3646.1984.00236.x	24	146	152	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 25	2007	445	7126					426	428		10.1038/nature05496	http://dx.doi.org/10.1038/nature05496			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	128WD	17251979				2022-12-28	WOS:000243689500039
J	Kuhle, J; Pohl, C; Mehling, M; Edan, G; Freedman, MS; Hartung, H; Polman, CH; Miller, DH; Montalban, X; Barkhof, F; Bauer, L; Dahms, S; Lindberg, R; Kappos, L; Sandbrink, R				Kuhle, Jens; Pohl, Christoph; Mehling, Matthias; Edan, Gilles; Freedman, Mark S.; Hartung, Hans-Peter; Polman, Chris H.; Miller, David H.; Montalban, Xavier; Barkhof, Frederik; Bauer, Lars; Dahms, Susanne; Lindberg, Raija; Kappos, Ludwig; Sandbrink, Rupert			Lack of association between antimyelin antibodies and progression to multiple sclerosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYELIN OLIGODENDROCYTE GLYCOPROTEIN; CENTRAL-NERVOUS-SYSTEM; GLYCOSYLATED NATIVE MOG; MONOCLONAL-ANTIBODY; BASIC-PROTEIN; DIAGNOSTIC-CRITERIA; DEMYELINATING EVENT; CEREBROSPINAL-FLUID; CLINICALLY DEFINITE; AUTOANTIBODIES	BACKGROUND: Patients with a single episode of neurologic dysfunction and brain magnetic resonance imaging (MRI) scans suggestive of multiple sclerosis are at high risk for clinically definite multiple sclerosis, but the outcome for individual patients is unpredictable. An increased risk of progression to clinically definite multiple sclerosis in patients with serum antibodies against myelin oligodendrocyte glycoprotein (MOG) and myelin basic protein (MBP) has been reported. METHODS: We measured serum anti-MOG and anti-MBP IgG and IgM antibodies in 462 patients with a first clinical event suggestive of multiple sclerosis and at least two clinically silent lesions on brain MRI. The patients were participating in a multicenter trial of treatment with interferon beta-1b. Antibodies were assessed by Western blot analysis at baseline, and the results compared with the time and rate of progression to clinically definite multiple sclerosis or a diagnosis of multiple sclerosis as defined by an international panel (the McDonald criteria). Regular visits were scheduled for the assessment of neurologic impairment and for MRI before treatment and at months 3, 6, 9, 12, 18, and 24. RESULTS: No associations were found between the presence of anti-MOG and anti-MBP IgM and IgG antibodies and progression to clinically definite multiple sclerosis or a diagnosis of multiple sclerosis according to the McDonald criteria, either in the entire cohort or in any subgroups of the study population. CONCLUSIONS: Serum antibodies against MOG and MBP, as detected by Western blot analysis, are not associated with an increased risk of progression to clinically definite multiple sclerosis in patients who have had a clinically isolated syndrome suggestive of multiple sclerosis.	Univ Basel Hosp, Dept Neurol & Res, Outpatient Clin Neurol Neurosurg & Clin Neuroimmu, CH-4031 Basel, Switzerland; Schering, Berlin, Germany; Univ Hosp, Dept Neurol, Bonn, Germany; Clin Neurol, Rennes, France; Ottawa Hosp, Multiple Sclerosis Res Clin, Ottawa, ON, Canada; Univ Dusseldorf, Dept Neurol, D-4000 Dusseldorf, Germany; Vrije Univ Amsterdam, Med Ctr, Dept Neurol, Amsterdam, Netherlands; Vrije Univ Amsterdam, Med Ctr, Dept Neuroradiol, Amsterdam, Netherlands; UCL Natl Hosp Neurol & Neurosurg, Inst Neurol, London WC1N 3BG, England; Hosp Valle De Hebron, Clin Neuroimmunol Unit, Barcelona, Spain	University of Basel; University of Bonn; University of Ottawa; Ottawa Hospital Research Institute; Heinrich Heine University Dusseldorf; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; Hospital Universitari Vall d'Hebron	Kappos, L (corresponding author), Univ Basel Hosp, Dept Neurol & Res, Outpatient Clin Neurol Neurosurg & Clin Neuroimmu, Petersgraben 4, CH-4031 Basel, Switzerland.	lkappos@uhbs.ch	Montalban, Xavier/J-5938-2016; Kuhle, Jens/AGE-3474-2022; Barkhof, Frederik/AAJ-6226-2020; Edan, Gilles/AAI-5944-2020	Montalban, Xavier/0000-0002-0098-9918; Barkhof, Frederik/0000-0003-3543-3706; Mehling, Matthias/0000-0001-8599-1226	Multiple Sclerosis Society [748] Funding Source: Medline	Multiple Sclerosis Society(National Multiple Sclerosis Society)		Baumann N, 2001, PHYSIOL REV, V81, P871, DOI 10.1152/physrev.2001.81.2.871; Berger T, 2003, NEW ENGL J MED, V349, P139, DOI 10.1056/NEJMoa022328; Bonifacio E, 1998, J IMMUNOL, V161, P2648; BRUNNER C, 1989, J NEUROCHEM, V52, P296, DOI 10.1111/j.1471-4159.1989.tb10930.x; DEROSBO NK, 1990, J NEUROCHEM, V55, P583; Gaertner S, 2004, NEUROLOGY, V63, P2381, DOI 10.1212/01.WNL.0000147259.34163.33; Genain CP, 1999, NAT MED, V5, P170, DOI 10.1038/5532; Kappos L, 2006, NEUROLOGY, V67, P1242, DOI 10.1212/01.wnl.0000237641.33768.8d; KUHLE J, IN PRESS J NEUROL; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Lalive PH, 2006, P NATL ACAD SCI USA, V103, P2280, DOI 10.1073/pnas.0510672103; Lampasona V, 2004, NEUROLOGY, V62, P2092, DOI 10.1212/01.WNL.0000127615.15768.AE; Lim ET, 2005, MULT SCLER J, V11, P492, DOI 10.1191/1352458505ms1187sr; LININGTON C, 1988, AM J PATHOL, V130, P443; LINNINGTON C, 1984, J NEUROIMMUNOL, V6, P387, DOI 10.1016/0165-5728(84)90064-X; Lolli F, 2005, NEUROLOGY, V65, P781, DOI 10.1212/WNL.65.5.781-b; Lucchinetti CF, 1996, BRAIN PATHOL, V6, P259, DOI 10.1111/j.1750-3639.1996.tb00854.x; Mantegazza R, 2004, INT IMMUNOL, V16, P559, DOI 10.1093/intimm/dxh056; Markovic M, 2003, J NEUROL SCI, V211, P67, DOI 10.1016/S0022-510X(03)00066-2; Marta CB, 2005, P NATL ACAD SCI USA, V102, P13992, DOI 10.1073/pnas.0504979102; McDonald WI, 2001, ANN NEUROL, V50, P121, DOI 10.1002/ana.1032; O'Connor KC, 2005, J IMMUNOL, V175, P1974, DOI 10.4049/jimmunol.175.3.1974; O'Connor KC, 2003, J NEUROIMMUNOL, V136, P140, DOI 10.1016/S0165-5728(03)00002-X; Pelayo R, 2007, NEW ENGL J MED, V356, P426, DOI 10.1056/NEJMc062467; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; Rauer S, 2006, J NEUROL NEUROSUR PS, V77, P739, DOI 10.1136/jnnp.2005.077784; Reindl M, 1999, BRAIN, V122, P2047, DOI 10.1093/brain/122.11.2047; SCHLUESENER HJ, 1987, J IMMUNOL, V139, P4016; Storch MK, 1998, BRAIN PATHOL, V8, P681, DOI 10.1111/j.1750-3639.1998.tb00194.x	29	166	176	1	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 25	2007	356	4					371	378		10.1056/NEJMoa063602	http://dx.doi.org/10.1056/NEJMoa063602			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128FT	17251533				2022-12-28	WOS:000243644300007
J	Center, JR; Bliue, D; Nguyen, TV; Eisman, JA				Center, Jacqueline R.; Bliue, Dana; Nguyen, Tuan V.; Eisman, John A.			Risk of subsequent fracture after low-trauma fracture in men and women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HIP FRACTURE; OSTEOPOROTIC FRACTURES; LIMB FRACTURES; ELDERLY-MEN; DUBBO; METAANALYSIS; MANAGEMENT; INCREASE; FOREARM; SPINE	Context There are few published long-term data on absolute risk of subsequent fracture ( refracture) following initial low-trauma fracture in women and fewer in men. Objective To examine long-term risk of subsequent fracture following initial osteoporotic fracture in men and women. Design, Setting, and Participants Prospective cohort study (Dubbo Osteoporosis Epidemiology Study) in Australia of 2245 community-dwelling women and 1760 men aged 60 years or older followed up for 16 years from July 1989 through April 2005. Main Outcome Measure Incidence of first ( initial) fracture and incidence of subsequent fracture according to sex, age group, and time since first fracture. Relative risk was determined by comparing risk of subsequent fracture with risk of initial fracture. Results There were 905 women and 337 men with an initial fracture, of whom 253 women and 71 men experienced a subsequent fracture. Relative risk (RR) of subsequent fracture in women was 1.95 (95% confidence interval [CI], 1.70-2.25) and in men was 3.47 ( 95% CI, 2.68-4.48). As a result, absolute risk of subsequent fracture was similar in women and men and at least as great as the initial fracture risk for a woman 10 years older. Thus, women and men aged 60 to 69 years had absolute refracture rates of 36/1000 person-years ( 95% CI, 26-48/1000) and 37/1000 person-years ( 95% CI, 23-59/1000), respectively. The increase in absolute fracture risk remained for up to 10 years, by which time 40% to 60% of surviving women and men experienced a subsequent fracture. All fracture locations apart from rib ( men) and ankle ( women) resulted in increased subsequent fracture risk, with highest RRs following hip ( RR, 9.97; 95% CI, 1.38-71.98) and clinical vertebral ( RR, 15.12; 95% CI, 6.06-37.69) fractures in younger men. In multivariate analyses, femoral neck bone mineral density, age, and smoking were predictors of subsequent fracture in women and femoral neck bone mineral density, physical activity, and calcium intake were predictors in men. Conclusion After an initial low-trauma fracture, absolute risk of subsequent fracture was similar for men and women. This increased risk occurred for virtually all clinical fractures and persisted for up to 10 years.	Univ New S Wales, Bone & Mineral Res Program, Garvan Inst Med Res, St Vincents Hosp, Sydney, NSW, Australia	Garvan Institute of Medical Research; St Vincents Hospital Sydney; University of New South Wales Sydney	Center, JR (corresponding author), St Vincents Hosp, Garvan Inst Med Res, 384 Victoria St, Darlinghurst, NSW 2010, Australia.	j.center@garvan.org.au	Nguyen, Tuan V/B-6147-2008; Nguyen, Tuan V./AAD-9503-2020; Center, Jacqueline/AAY-8712-2021; Bliuc, Dana/Y-7240-2018; Eisman, John A/C-2886-2014	Nguyen, Tuan V/0000-0002-3246-6281; Nguyen, Tuan V./0000-0002-3246-6281; Center, Jacqueline/0000-0002-5278-4527; Bliuc, Dana/0000-0001-9682-2313; 				Bliuc D, 2005, OSTEOPOROSIS INT, V16, P977, DOI 10.1007/s00198-004-1788-x; Briancon D, 2004, JOINT BONE SPINE, V71, P128, DOI 10.1016/S1297-319X(03)00060-5; *CARY NC, 2006, SAS 9 1 3 PROCEDURES; Center JR, 1999, LANCET, V353, P878, DOI 10.1016/S0140-6736(98)09075-8; CENTER JR, 2003, INT C MET BON DIS CO; Cuddihy MT, 1999, OSTEOPOROSIS INT, V9, P469, DOI 10.1007/s001980050172; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; Eisman J, 2004, J BONE MINER RES, V19, P1969, DOI 10.1359/JBMR.040905; Ettinger B, 2003, ARCH INTERN MED, V163, P2741, DOI 10.1001/archinte.163.22.2741; Haentjens P, 2004, J BONE MINER RES, V19, P1933, DOI 10.1359/JBMR.040917; Hasselman CT, 2003, J BONE JOINT SURG AM, V85A, P820, DOI 10.2106/00004623-200305000-00008; Ismail AA, 2006, OSTEOPOROSIS INT, V17, P41, DOI 10.1007/s00198-005-1887-3; Johnell O, 2001, OSTEOPOROSIS INT, V12, P207, DOI 10.1007/s001980170131; JONES G, 1994, OSTEOPOROSIS INT, V4, P277, DOI 10.1007/BF01623352; Kanis JA, 2004, BONE, V35, P375, DOI 10.1016/j.bone.2004.03.024; Kanis JA, 2004, OSTEOPOROSIS INT, V15, P108, DOI 10.1007/s00198-003-1516-y; Kanis JA, 2002, OSTEOPOROSIS INT, V13, P527, DOI 10.1007/s001980200069; Klotzbuecher CM, 2000, J BONE MINER RES, V15, P721, DOI 10.1359/jbmr.2000.15.4.721; LAURITZEN JB, 1993, ACTA ORTHOP SCAND, V64, P297, DOI 10.3109/17453679308993629; LORD SR, 1994, MED J AUSTRALIA, V160, P684, DOI 10.5694/j.1326-5377.1994.tb125905.x; Majumdar SR, 2005, ARCH INTERN MED, V165, P905, DOI 10.1001/archinte.165.8.905; Majumdar SR, 2004, ANN INTERN MED, V141, P366, DOI 10.7326/0003-4819-141-5-200409070-00011; MALLMIN H, 1993, CALCIFIED TISSUE INT, V52, P269, DOI 10.1007/BF00296650; Marshall D, 1996, BRIT MED J, V312, P1254, DOI 10.1136/bmj.312.7041.1254; Nguyen ND, 2005, J BONE MINER RES, V20, P1921, DOI 10.1359/JBMR.050520; NGUYEN T, 1993, BRIT MED J, V307, P1111, DOI 10.1136/bmj.307.6912.1111; Port L, 2003, OSTEOPOROSIS INT, V14, P780, DOI 10.1007/s00198-003-1452-x; SIMONS LA, 1990, AUST NZ J MED, V20, P783, DOI 10.1111/j.1445-5994.1990.tb00423.x; van Staa TP, 2002, OSTEOPOROSIS INT, V13, P624, DOI 10.1007/s001980200084; VANHELDEN S, 2005, OSTEOPOROUS INT, V24, P24	30	435	452	1	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 24	2007	297	4					387	394		10.1001/jama.297.4.387	http://dx.doi.org/10.1001/jama.297.4.387			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128GE	17244835				2022-12-28	WOS:000243645400024
J	Kamerow, D				Kamerow, Douglas			Today's doctor's dilemma	BRITISH MEDICAL JOURNAL			English	Editorial Material												dkamerow@bmj.com		Kamerow, Douglas/0000-0001-7000-9957					0	2	2	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JAN 20	2007	334	7585					126	126		10.1136/bmj.39097.516609.59	http://dx.doi.org/10.1136/bmj.39097.516609.59			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	130LP	17235092	Green Published			2022-12-28	WOS:000243801400029
J	Kolsch, V; Seher, T; Fernandez-Ballester, GJ; Serrano, L; Leptin, M				Koelsch, Verena; Seher, Thomas; Fernandez-Ballester, Gregorio J.; Serrano, Luis; Leptin, Maria			Control of Drosophila gastrulation by apical localization of adherens junctions and RhoGEF2	SCIENCE			English	Article							CELL-SHAPE CHANGES; FOLDED-GASTRULATION; SIGNALING PATHWAY; RHO-GTPASE; PROTEIN; MORPHOLOGY; EXTENSION; TARGET; FURROW	A hallmark of epithelial invagination is the constriction of cells on their apical sides. During Drosophila gastrulation, apical constrictions under the control of the transcription factor Twist lead to the invagination of the mesoderm. Twist-controlled G protein signaling is involved in mediating the invagination but is not sufficient to account for the full activity of Twist. We identified a Twist target, the transmembrane protein T48, which acts in conjunction with G protein signaling to orchestrate shape changes. Together with G protein signaling, T48 recruits adherens junctions and the cytoskeletal regulator RhoGEF2 to the sites of apical constriction, ensuring rapid and intense changes in cell shape.	Univ Cologne, Inst Genet, D-50674 Cologne, Germany; Univ Miguel Hernandez, Inst Biol Mol & Celular, Elche 03202, Spain; European Mol Biol Lab, D-69012 Heidelberg, Germany	University of Cologne; Universidad Miguel Hernandez de Elche; European Molecular Biology Laboratory (EMBL)	Leptin, M (corresponding author), Univ Cologne, Inst Genet, Zulpicher Str 47, D-50674 Cologne, Germany.	mleptin@uni-koeln.de	Serrano, Luis/B-3355-2013	Serrano, Luis/0000-0002-5276-1392				Barmchi MP, 2005, J CELL BIOL, V168, P575, DOI 10.1083/jcb.200407124; Barrett K, 1997, CELL, V91, P905, DOI 10.1016/S0092-8674(00)80482-1; COSTA M, 1994, CELL, V76, P1075, DOI 10.1016/0092-8674(94)90384-0; Dawes-Hoang RE, 2005, DEVELOPMENT, V132, P4165, DOI 10.1242/dev.01938; Grosshans J, 2005, DEVELOPMENT, V132, P1009, DOI 10.1242/dev.01669; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Izumi Y, 2004, J CELL BIOL, V164, P729, DOI 10.1083/jcb.200309162; Kwan KM, 2005, DEVELOPMENT, V132, P4599, DOI 10.1242/dev.02041; LEPTIN M, 1991, GENE DEV, V5, P1568, DOI 10.1101/gad.5.9.1568; LEPTIN M, 1990, DEVELOPMENT, V110, P73; Lin F, 2005, J CELL BIOL, V169, P777, DOI 10.1083/jcb.200501104; McGregor L, 2003, NAT GENET, V34, P203, DOI 10.1038/ng1142; Nikolaidou KK, 2004, CURR BIOL, V14, P1822, DOI 10.1016/j.cub.2004.09.080; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; Reina J, 2002, NAT STRUCT BIOL, V9, P621, DOI 10.1038/nsb815; Rogers SL, 2004, CURR BIOL, V14, P1827, DOI 10.1016/j.cub.2004.09.078; Seher TC, 2000, CURR BIOL, V10, P623, DOI 10.1016/S0960-9822(00)00502-9; STRUTT DI, 1994, MECH DEVELOP, V46, P27, DOI 10.1016/0925-4773(94)90035-3; SWEETON D, 1991, DEVELOPMENT, V112, P775; Swiercz JM, 2002, NEURON, V35, P51, DOI 10.1016/S0896-6273(02)00750-X	20	236	236	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 19	2007	315	5810					384	386		10.1126/science.1134833	http://dx.doi.org/10.1126/science.1134833			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126SI	17234948				2022-12-28	WOS:000243535400044
J	Coombes, R				Coombes, Rebecca			The week in medicine - Ashley X: a difficult moral choice	BRITISH MEDICAL JOURNAL			English	Editorial Material												rcoombes@bmjgroup.com							0	2	2	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JAN 13	2007	334	7584					72	73		10.1136/bmj.39091.555856.B7	http://dx.doi.org/10.1136/bmj.39091.555856.B7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	127DZ	17218709	Green Published			2022-12-28	WOS:000243566800026
J	Burgisser, A; Scaillet, B				Burgisser, Alain; Scaillet, Bruno			Redox evolution of a degassing magma rising to the surface	NATURE			English	Article							OXIDATION-STATE; KILAUEA-VOLCANO; OXYGEN FUGACITY; SILICATE MELTS; GAS; TEMPERATURE; SOLUBILITY; MORPHOLOGY; PRESSURE; ERUPTION	Volatiles carried by magmas, either dissolved or exsolved, have a fundamental effect on a variety of geological phenomena, such as magma dynamics(1-5) and the composition of the Earth's atmosphere(6). In particular, the redox state of volcanic gases emanating at the Earth's surface is widely believed to mirror that of the magma source, and is thought to have exerted a first-order control on the secular evolution of atmospheric oxygen(6,7). Oxygen fugacity (f(O2)) estimated from lava or related gas chemistry, however, may vary by as much as one log unit(8-10), and the reason for such differences remains obscure. Here we use a coupled chemical - physical model of conduit flow to show that the redox state evolution of an ascending magma, and thus of its coexisting gas phase, is strongly dependent on both the composition and the amount of gas in the reservoir. Magmas with no sulphur show a systematic f(O2) increase during ascent, by as much as 2 log units. Magmas with sulphur show also a change of redox state during ascent, but the direction of change depends on the initial f(O2) in the reservoir. Our calculations closely reproduce the H2S/SO2 ratios of volcanic gases observed at convergent settings, yet the difference between f(O2) in the reservoir and that at the exit of the volcanic conduit may be as much as 1.5 log units. Thus, the redox state of erupted magmas is not necessarily a good proxy of the redox state of the gases they emit. Our findings may require re-evaluation of models aimed at quantifying the role of magmatic volatiles in geological processes.	Univ Orleans, CNRS, UMR 6113, ISTO, F-45071 Orleans 2, France	Bureau de Recherches Geologiques et Minieres (BRGM); Centre National de la Recherche Scientifique (CNRS); Universite de Orleans	Burgisser, A (corresponding author), Univ Orleans, CNRS, UMR 6113, ISTO, 1a Rue Ferollerie, F-45071 Orleans 2, France.	burgisse@cnrs-orleans.fr	Scaillet, Bruno/A-5846-2012	Scaillet, Bruno/0000-0003-1561-0226; Burgisser, Alain/0000-0002-9263-622X				Burgisser A, 2004, B VOLCANOL, V67, P42, DOI 10.1007/s00445-004-0359-5; CARMICHAEL ISE, 1991, CONTRIB MINERAL PETR, V106, P129, DOI 10.1007/BF00306429; Clemente B, 2004, J PETROL, V45, P2171, DOI 10.1093/petrology/egh052; EICHELBERGER JC, 1986, NATURE, V323, P598, DOI 10.1038/323598a0; Gaillard F, 2003, GEOCHIM COSMOCHIM AC, V67, P2427, DOI 10.1016/S0016-7037(02)01407-2; Gardner JE, 2000, GEOCHIM COSMOCHIM AC, V64, P1473, DOI 10.1016/S0016-7037(99)00436-6; Gerlach TM, 2004, J VOLCANOL GEOTH RES, V134, P241, DOI 10.1016/j.jvolgeores.2004.02.004; GERLACH TM, 1993, GEOCHIM COSMOCHIM AC, V57, P795, DOI 10.1016/0016-7037(93)90169-W; Gonnermann HM, 2003, NATURE, V426, P432, DOI 10.1038/nature02138; Holland HD, 2002, GEOCHIM COSMOCHIM AC, V66, P3811, DOI 10.1016/S0016-7037(02)00950-X; HOLLOWAY JR, 1987, REV MINERAL, V17, P211; HOLTZ F, 1995, AM MINERAL, V80, P94; Huppert HE, 2002, NATURE, V420, P493, DOI 10.1038/nature01211; KASTING JF, 1993, J GEOL, V101, P245, DOI 10.1086/648219; KRESS VC, 1991, CONTRIB MINERAL PETR, V108, P82, DOI 10.1007/BF00307328; MATHEZ EA, 1984, NATURE, V310, P371, DOI 10.1038/310371a0; Moretti R, 2004, CHEM GEOL, V213, P265, DOI 10.1016/j.chemgeo.2004.08.048; Papale P, 1999, NATURE, V397, P425, DOI 10.1038/17109; Roeder PL, 2003, J VOLCANOL GEOTH RES, V123, P245, DOI 10.1016/S0377-0273(02)00508-5; Scaillet B, 2003, GEOL SOC SPEC PUBL, V213, P23, DOI 10.1144/GSL.SP.2003.213.01.03; Scaillet B, 2003, GEOPHYS MONOGR SER, V139, P11; SCAILLET B, 2004, NATURE          0728, P430, DOI DOI 10.1038/NATURE02814; SHI PF, 1992, AM MINERAL, V77, P1038; SYMONDS RB, 1994, REV MINERAL, V30, P1; Wallace PJ, 2005, J VOLCANOL GEOTH RES, V140, P217, DOI 10.1016/j.jvolgeores.2004.07.023; WALLACE PJ, 1995, NATURE, V377, P612, DOI 10.1038/377612a0; WATSON EB, 1994, REV MINERAL, V30, P371; WESTRICH HR, 1992, GEOLOGY, V20, P867, DOI 10.1130/0091-7613(1992)020<0867:MGSFTS>2.3.CO;2; WILSON L, 1980, GEOPHYS J ROY ASTR S, V63, P117, DOI 10.1111/j.1365-246X.1980.tb02613.x	29	178	179	1	61	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 11	2007	445	7124					194	197		10.1038/nature05509	http://dx.doi.org/10.1038/nature05509			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124QF	17215841	Green Submitted			2022-12-28	WOS:000243384300048
J	Guo, HY				Guo, Hangyuan			RETRACTED: Complication of central venous catheterization (Retracted Article. See vol 356, pg 1075, 2007)	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material; Retracted Publication									Shaoxing Peoples Hosp, Shaoxing 31200, Zhejiang, Peoples R China		Guo, HY (corresponding author), Shaoxing Peoples Hosp, Shaoxing 31200, Zhejiang, Peoples R China.	ghangyuan@hotmail.com							0	3	3	0	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 11	2007	356	2					E2	E2		10.1056/NEJMicm053415	http://dx.doi.org/10.1056/NEJMicm053415			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	124NE	17215525				2022-12-28	WOS:000243373700011
J	Selwitz, RH; Ismail, AI; Pitts, NB				Selwitz, Robert H.; Ismail, Amid I.; Pitts, Nigel B.			Dental caries	LANCET			English	Review							ORAL-HEALTH; OLDER-PEOPLE; CONSEQUENCES; EXPERIENCE; IMPACT; COHORT	Dental caries, otherwise known as tooth decay, is one of the most prevalent chronic diseases of people worldwide; individuals are susceptible to this disease throughout their lifetime. Dental caries forms through a complex interaction over time between acid-producing bacteria and fermentable carbohydrate, and many host factors including teeth and saliva. The disease develops in both the crowns and roots of teeth, and it can arise in early childhood as an aggressive tooth decay that affects the primary teeth of infants and toddlers. Risk for caries includes physical, biological, environmental, behavioural, and lifestyle-related factors such as high numbers of cariogenic bacteria, inadequate salivary flow, insufficient fluoride exposure, poor oral hygiene, inappropriate methods of feeding infants, and poverty. The approach to primary prevention should be based on common risk factors. Secondary prevention and treatment should focus on management of the caries process over time for individual patients, with a minimally invasive, tissue-preserving approach.	Univ Florida, Coll Dent, Dept Community Dent & Behav Sci, Gainesville, FL 32611 USA; Duval Cty Hlth Dept, Dent Program, Jacksonville, FL USA; Univ Michigan, Sch Dent, Dept Cariol Restorat Sci & Endodont, Ann Arbor, MI 48109 USA; Univ Dundee, Dent Hlth Serv Res Unit, Dundee, Scotland; Univ Dundee, Ctr Clin Innovat, Dundee, Scotland	State University System of Florida; University of Florida; University of Michigan System; University of Michigan; University of Dundee; University of Dundee	Selwitz, RH (corresponding author), DCHD, Dent Program, 515 W 6th St,MC-11, Jacksonville, FL 32206 USA.	RSelwitz@dental.ufl.edu	Weintraub, Jane A/T-8877-2019	Weintraub, Jane A/0000-0001-7178-2028; Pitts, Nigel Berry/0000-0001-6184-4213				Ahola AJ, 2002, ARCH ORAL BIOL, V47, P799, DOI 10.1016/S0003-9969(02)00112-7; Ahovuo-Saloranta A, 2004, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD001830.PUB2; Anderson Max, 2002, Pediatr Dent, V24, P377; [Anonymous], 1994, TXB CLIN CARIOLOGY; Atkinson J C, 2001, J Dent Educ, V65, P1096; Axelsson P., 2000, DIAGNOSIS RISK PREDI, V2; Bader J D, 2001, J Dent Educ, V65, P960; Bader JD, 2004, AM J PREV MED, V26, P315, DOI 10.1016/j.amepre.2003.12.001; Batchelor P, 2002, COMMUNITY DENT ORAL, V30, P302, DOI 10.1034/j.1600-0528.2002.00057.x; Baum Bruce J, 2004, J Am Coll Dent, V71, P27; Beck J D, 1993, Adv Dent Res, V7, P42; Beltran-Aguilar Eugenio D., 2005, Morbidity and Mortality Weekly Report, V54, P1; Berkowitz Robert J, 2003, J Calif Dent Assoc, V31, P135; Brown LJ, 1995, J PUBLIC HEALTH DENT, V55, P274, DOI 10.1111/j.1752-7325.1995.tb02382.x; Burt B A, 2001, J Dent Educ, V65, P1024; Caufield PW, 2000, PEDIATR CLIN N AM, V47, P1001, DOI 10.1016/S0031-3955(05)70255-8; Chesters RK, 2002, J DENT RES, V81, P637, DOI 10.1177/154405910208100912; Curzon M. E. J., 2004, Caries Research, V38, P24, DOI 10.1159/000074359; De Grauwe A, 2004, Eur J Paediatr Dent, V5, P62; Elderton R J, 1990, Adv Dent Res, V4, P4; Ettinger R L, 1999, Dent Clin North Am, V43, P679; Featherstone J D B, 2004, J Dent Res, V83 Spec No C, pC39; Featherstone JDB, 2000, J AM DENT ASSOC, V131, P887, DOI 10.14219/jada.archive.2000.0307; Featherstone John D B, 2003, J Calif Dent Assoc, V31, P257; Featherstone John D B, 2004, Oral Health Prev Dent, V2 Suppl 1, P259; Fejerskov O, 1997, COMMUNITY DENT ORAL, V25, P5, DOI 10.1111/j.1600-0528.1997.tb00894.x; Fejerskov O, 2004, CARIES RES, V38, P182, DOI 10.1159/000077753; FEJERSKOV O, 1990, RISK ASSESSMENT DENT, P00215; Fejerskov O., 2003, DENT CARIES DIS ITS; Filstrup Sara L, 2003, Pediatr Dent, V25, P431; Griffin SO, 2004, J DENT RES, V83, P634, DOI 10.1177/154405910408300810; HASSELL TM, 1995, CRIT REV ORAL BIOL M, V6, P319, DOI 10.1177/10454411950060040401; Hausen H, 1997, COMMUNITY DENT ORAL, V25, P87, DOI 10.1111/j.1600-0528.1997.tb00904.x; HEIDMANN J, 1987, CARIES RES, V21, P460, DOI 10.1159/000261052; Ismail A, 2004, CARIES RES, V38, P199, DOI 10.1159/000077755; Ismail A I, 2004, J Dent Res, V83 Spec No C, pC56; Ismail A.I., 2003, PEDIAT DENT, V25, P425; Ismail AI, 1997, COMMUNITY DENT ORAL, V25, P13, DOI 10.1111/j.1600-0528.1997.tb00895.x; Kelly M., 1998, ADULT DENT HLTH SURV; Kidd E A, 2000, Dent Update, V27, P222; Kidd E A M, 2004, J Dent Res, V83 Spec No C, pC35; KIDD EAM, 1997, ESSENTIALS DENT CARI; Konig KG, 2004, CARIES RES, V38, P168, DOI 10.1159/000077751; Krol David M, 2003, Curr Probl Pediatr Adolesc Health Care, V33, P253, DOI 10.1016/S1538-5442(03)00093-2; Locker D, 1992, Community Dent Health, V9, P109; Low Wendy, 1999, Pediatric Dentistry, V21, P325; Marinho V., 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002280; Marinho V C, 2003, Cochrane Database Syst Rev, pCD002278, DOI 10.1002/14651858.CD002278; MARINHO VC, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002279; Marsh P, 1999, ORAL MICROBIOLOGY, V4th; Marthaler TM, 2004, CARIES RES, V38, P173, DOI 10.1159/000077752; Mejare I, 2004, CARIES RES, V38, P130, DOI 10.1159/000075937; Mjor IA, 2000, QUINTESSENCE INT, V31, P165; Montalto M, 2004, DIGESTION, V69, P53, DOI 10.1159/000076559; *NAT I CLIN EXC, 19 NAT I CLIN EXC; *NHS CTR REV DISS, 1999, B EFF HLTH SERV INT; Petersen PE, 2005, COMMUNITY DENT ORAL, V33, P81, DOI 10.1111/j.1600-0528.2004.00219.x; Petersen PE, 2003, COMMUNITY DENT ORAL, V31, P3, DOI 10.1046/j..2003.com122.x; Pierce KM, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.5.e82; PITTS N, 2004, OBVIOUS DECAY EXPERI; Pitts N B, 2004, J Dent Res, V83 Spec No C, pC125; Pitts N B, 2004, J Dent Res, V83 Spec No C, pC43; Pitts NB, 1997, COMMUNITY DENT ORAL, V25, P24, DOI 10.1111/j.1600-0528.1997.tb00896.x; Pitts NB, 2005, COMMUNITY DENT HLTH, V22, P46; Pitts NB, 2004, CARIES RES, V38, P294, DOI 10.1159/000077769; Pitts Nigel, 2004, Community Dent Health, V21, P193; Poulton R, 2002, LANCET, V360, P1640, DOI 10.1016/S0140-6736(02)11602-3; Ramos-Gomez Francisco J, 2002, J Clin Pediatr Dent, V26, P165; Scheie AA, 2004, CRIT REV ORAL BIOL M, V15, P4, DOI 10.1177/154411130401500102; *SCOTT EX, 2005, ACT PLAN IMPR OR HLT, P41; Seow WK, 1998, COMMUNITY DENT ORAL, V26, P8, DOI 10.1111/j.1600-0528.1998.tb02090.x; Sheiham A, 2001, Public Health Nutr, V4, P569; *SIGN, 2000, 47 SIGN; Tagg JR, 2003, TRENDS BIOTECHNOL, V21, P217, DOI 10.1016/S0167-7799(03)00085-4; Tennant M, 2000, AUST DENT J, V45, P204, DOI 10.1111/j.1834-7819.2000.tb00558.x; Thomson WM, 2004, BRIT DENT J, V196, P89, DOI 10.1038/sj.bdj.4810900; Tinanoff Norman, 2002, Pediatr Dent, V24, P543; Touger-Decker R, 2003, AM J CLIN NUTR, V78, p881S, DOI 10.1093/ajcn/78.4.881S; Tubert-Jeannin Stephanie, 2004, Spec Care Dentist, V24, P264, DOI 10.1111/j.1754-4505.2004.tb01704.x; Tyas MJ, 2000, INT DENT J, V50, P1, DOI 10.1111/j.1875-595X.2000.tb00540.x; United States Department of Health and Human Services National Institute of Dental and Craniofacial Research, 2000, OR HLTH AM REP SURG, P308; Winn D M, 2001, J Dent Educ, V65, P306; Yee R, 2002, INT DENT J, V52, P1; Zheng CY, 2001, HUM GENE THER, V12, P2215, DOI 10.1089/10430340152710559; 2001, J DENT ED, V65, P935	85	1531	1602	30	568	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 6	2007	369	9555					51	59		10.1016/S0140-6736(07)60031-2	http://dx.doi.org/10.1016/S0140-6736(07)60031-2			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125AK	17208642				2022-12-28	WOS:000243413700029
J	Woodward, D				Woodward, David			Vote buying in the UN Security Council	LANCET			English	Editorial Material							GULF-WAR; IMF; MORTALITY; POLITICS; AID		New Econ Fdn, Ctr Global Interdependence, London SE11 5NH, England		Woodward, D (corresponding author), New Econ Fdn, Ctr Global Interdependence, London SE11 5NH, England.	david.woodward@neweconomics.org						Andersen TB, 2006, EUR ECON REV, V50, P1843, DOI 10.1016/j.euroecorev.2005.07.001; ASCHERIO A, 1992, NEW ENGL J MED, V327, P931, DOI 10.1056/NEJM199209243271306; Blane D, 2004, LANCET, V364, P1188, DOI 10.1016/S0140-6736(04)17110-9; Buira A., 2003, PROVIDING GLOBAL PUB; Burnham G, 2006, LANCET, V368, P1421, DOI 10.1016/S0140-6736(06)69491-9; Collier P, 2002, EUR ECON REV, V46, P1475, DOI 10.1016/S0014-2921(01)00187-8; Daponte BO, 2000, AM J PUBLIC HEALTH, V90, P546, DOI 10.2105/AJPH.90.4.546; Harrigan J, 2006, WORLD DEV, V34, P247, DOI 10.1016/j.worlddev.2005.07.016; HITT G, 2006, WALL STREET J   1030, P1; Kuziemko I, 2006, J POLIT ECON, V114, P905, DOI 10.1086/507155; Kwa A., 2003, SCENES WTO REAL WORL; Labonte R, 2005, HLTH SOME DEATH DIS; Smith R., 2003, GLOBAL PUBLIC GOODS; Thacker SC, 1999, WORLD POLIT, V52, P38, DOI 10.1017/S0043887100020025; Yamey G, 2002, BMJ-BRIT MED J, V325, P1251, DOI 10.1136/bmj.325.7375.1251	15	1	1	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 6	2007	369	9555					12	13		10.1016/S0140-6736(07)60009-9	http://dx.doi.org/10.1016/S0140-6736(07)60009-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	125AK	17208625	Green Published, Bronze			2022-12-28	WOS:000243413700009
J	Gillson, L; Hoffman, MT				Gillson, Lindsey; Hoffman, M. Timm			Rangeland ecology in a changing world	SCIENCE			English	Editorial Material							NONEQUILIBRIUM; ECOSYSTEMS	A synthesis of differnt models for assessing the balance between vegetation and livestock numbers in grazing lands may help policy-makers integrate human and ecosystem needs.	Univ Cape Town, Inst Plant Conservat, Dept Bot, ZA-7701 Rondebosch, South Africa	University of Cape Town	Gillson, L (corresponding author), Univ Cape Town, Inst Plant Conservat, Dept Bot, ZA-7701 Rondebosch, South Africa.	lindsey.gillson@uct.ac.za	Hoffman, Timm/K-4937-2016; Gillson, Lindsey/AAR-6531-2020	Hoffman, Timm/0000-0002-5843-2397; Gillson, Lindsey/0000-0001-9607-6760				Behnke R.H., 1993, RANGE ECOLOGY DISEQU; Benjaminsen TA, 2006, ANN ASSOC AM GEOGR, V96, P524, DOI 10.1111/j.1467-8306.2006.00704.x; Bond WJ, 2005, NEW PHYTOL, V165, P525, DOI 10.1111/j.1469-8137.2004.01252.x; Briske DD, 2003, J APPL ECOL, V40, P601, DOI 10.1046/j.1365-2664.2003.00837.x; Campbell BM, 2006, ECOL ECON, V60, P75, DOI 10.1016/j.ecolecon.2006.05.010; Chambers FM, 1999, J APPL ECOL, V36, P719, DOI 10.1046/j.1365-2664.1999.00435.x; Cingolani AM, 2005, ECOL APPL, V15, P757, DOI 10.1890/03-5272; ELLIS JE, 1988, J RANGE MANAGE, V41, P450, DOI 10.2307/3899515; Gross JE, 2006, ENVIRON MODELL SOFTW, V21, P1264, DOI 10.1016/j.envsoft.2005.04.024; HASTINGS A, 1993, ANNU REV ECOL SYST, V24, P1, DOI 10.1146/annurev.es.24.110193.000245; Illius AW, 1999, ECOL APPL, V9, P798, DOI 10.1890/1051-0761(1999)009[0798:OTRONC]2.0.CO;2; Janssen MA, 2004, J ENVIRON ECON MANAG, V47, P140, DOI 10.1016/S0095-0696(03)00069-X; Li BL, 2002, ACTA BIOTHEOR, V50, P141, DOI 10.1023/A:1016562208170; Reynolds JF, 2002, GLOBAL DESERTIFICATI, P1; SCOONES I, 1999, ANNU REV ANTHROPOL, V28, P479, DOI DOI 10.1146/ANNUREV.ANTHR0.28.1.479; Sullivan S, 2002, J BIOGEOGR, V29, P1595, DOI 10.1046/j.1365-2699.2002.00799.x; Vetter S, 2005, J ARID ENVIRON, V62, P321, DOI 10.1016/j.jaridenv.2004.11.015; WESTOBY M, 1989, J RANGE MANAGE, V42, P266, DOI 10.2307/3899492	18	114	123	1	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 5	2007	315	5808					53	54		10.1126/science.1136577	http://dx.doi.org/10.1126/science.1136577			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	122WU	17204634				2022-12-28	WOS:000243259100027
J	Yudushkin, IA; Schleifenbaum, A; Kinkhabwala, A; Neel, BG; Schultz, C; Bastiaens, PIH				Yudushkin, Ivan A.; Schleifenbaum, Andreas; Kinkhabwala, Ali; Neel, Benjamin G.; Schultz, Carsten; Bastiaens, Philippe I. H.			Live-cell Imaging of enzyme-substrate interaction reveals spatial regulation of PTP1B	SCIENCE			English	Article							PROTEIN-TYROSINE PHOSPHATASES; GROWTH-FACTOR RECEPTOR; SIGNAL-TRANSDUCTION; ENDOPLASMIC-RETICULUM; INSULIN-RECEPTOR; PHOSPHORYLATION; DEPHOSPHORYLATION; SPECIFICITY; GRADIENTS; PEPTIDES	Endoplasmic reticulum-localized protein-tyrosine phosphatase PTP1B terminates growth factor signal transduction by dephosphorylation of receptor tyrosine kinases (RTKs). But how PTP1B allows for RTK signaling in the cytoplasm is unclear. In order to test whether PTP1B activity is spatially regulated, we developed a method based on Forster resonant energy transfer for imaging enzyme-substrate (ES) intermediates in live cells. We observed the establishment of a steady-state ES gradient across the cell. This gradient exhibited robustness to cell-to-cell variability, growth factor activation, and RTK localization, which demonstrated spatial regulation of PTP1B activity. Such regulation may be important for generating distinct cellular environments that permit RTK signal transduction and that mediate its eventual termination.	European Mol Biol Lab, D-69117 Heidelberg, Germany; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Hematol Oncol,Canc Biol Program, Boston, MA 02115 USA	European Molecular Biology Laboratory (EMBL); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Bastiaens, PIH (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.	bastiaen@embl.de	Yudushkin, Ivan/ABH-9204-2020	Yudushkin, Ivan/0000-0002-6637-027X; Schultz, Carsten/0000-0002-5824-2171	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060838] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK60838] Funding Source: Medline; PHS HHS [R37 49152] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bourdeau A, 2005, CURR OPIN CELL BIOL, V17, P203, DOI 10.1016/j.ceb.2005.02.001; Boute N, 2003, EMBO REP, V4, P313, DOI 10.1038/sj.embor.embor767; Brown GC, 1999, FEBS LETT, V457, P452, DOI 10.1016/S0014-5793(99)01058-3; Chiarugi P, 2003, TRENDS BIOCHEM SCI, V28, P509, DOI 10.1016/S0968-0004(03)00174-9; Fan YX, 2004, J BIOL CHEM, V279, P38143, DOI 10.1074/jbc.M405760200; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; Guo L, 2003, J AM SOC MASS SPECTR, V14, P1022, DOI 10.1016/S1044-0305(03)00206-X; Haj FG, 2002, SCIENCE, V295, P1708, DOI 10.1126/science.1067566; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; Kholodenko BN, 2000, BIOCHEM J, V350, P901, DOI 10.1042/0264-6021:3500901; Miaczynska M, 2004, CURR OPIN CELL BIOL, V16, P400, DOI 10.1016/j.ceb.2004.06.005; Nguyen A, 2004, NAT BIOTECHNOL, V22, P993, DOI 10.1038/nbt997; Niethammer P, 2004, SCIENCE, V303, P1862, DOI 10.1126/science.1094108; Offterdinger M, 2004, J BIOL CHEM, V279, P36972, DOI 10.1074/jbc.M405830200; Ostman A, 2001, TRENDS CELL BIOL, V11, P258, DOI 10.1016/S0962-8924(01)01990-0; Romsicki Y, 2004, J BIOL CHEM, V279, P12868, DOI 10.1074/jbc.M309600200; Sawano A, 2002, DEV CELL, V3, P245, DOI 10.1016/S1534-5807(02)00224-1; Vazquez ME, 2003, J AM CHEM SOC, V125, P10150, DOI 10.1021/ja0351847; Verveer P.J., 2001, METHODS CELLULAR IMA, P273; Verveer PJ, 2000, BIOPHYS J, V78, P2127, DOI 10.1016/S0006-3495(00)76759-2; WOODFORDTHOMAS TA, 1992, J CELL BIOL, V117, P401, DOI 10.1083/jcb.117.2.401; Wouters FS, 2001, TRENDS CELL BIOL, V11, P203, DOI 10.1016/S0962-8924(01)01982-1; ZHANG ZY, 1993, P NATL ACAD SCI USA, V90, P4446, DOI 10.1073/pnas.90.10.4446; ZHANG ZY, 1993, ANAL BIOCHEM, V211, P7, DOI 10.1006/abio.1993.1224	25	111	117	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 5	2007	315	5808					115	119		10.1126/science.1134966	http://dx.doi.org/10.1126/science.1134966			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	122WU	17204654				2022-12-28	WOS:000243259100050
J	Swanson, SJ; Snider, C; Braden, CR; Boxrud, D; Wunschmann, A; Rudroff, JA; Lockett, J; Smith, KE				Swanson, Stephen J.; Snider, Cynthia; Braden, Christopher R.; Boxrud, David; Wuenschmann, Arno; Rudroff, Jo Ann; Lockett, Jana; Smith, Kirk E.			Multidrug-resistant Salmonella enterica serotype typhimurium associated with pet rodents	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	43rd Annual Meeting of the Infectious-Diseases-Society-of-America	OCT 06-09, 2005	San Francisco, CA	Infect Dis Soc Amer			NONTYPHOIDAL SALMONELLA; COLONIZATION RESISTANCE; UNITED-STATES; INFECTIONS; ILLNESS; FEED; MICE; TRANSPORTATION; OUTBREAK; BURDEN	BACKGROUND: An estimated 1.4 million salmonella infections occur annually in the United States. The majority of these infections are foodborne, but many are acquired by contact with animals. In August 2004, isolates of Salmonella enterica serotype Typhimurium, which were indistinguishable from one another by pulsed-field gel electrophoresis (PFGE), were obtained from eight hamsters from a Minnesota pet distributor. We conducted an investigation to determine whether human cases of salmonella could be linked to this rodent-borne strain. METHODS: To identify cases of human infection with S. enterica serotype Typhimurium potentially related to pet rodents, we reviewed salmonella PFGE patterns submitted to the National Molecular Subtyping Network for Foodborne Disease Surveillance. Patients with isolates matching the hamster strain were interviewed about exposure to pet rodents. Implicated rodents were traced to pet stores, distributors, and breeders. RESULTS: We identified matching S. enterica serotype Typhimurium isolates from 28 patients in whom the onset of illness occurred between December 2003 and September 2004. Of 22 patients (or in the case of children, their parents) interviewed, 13 patients (59%) in 10 states reported exposure to pet hamsters, mice, or rats, and 2 (9%) had secondary infections. The median age of the 15 patients with primary or secondary rodent exposure was 16 years, and 6 patients (40%) were hospitalized. Thirteen associated pet stores supplied by seven distributors were identified in 10 states. No single source of the rodents was identified. The outbreak strain of S. enterica serotype Typhimurium was cultured from a patient's pet mouse and from seven hamsters from pet stores. Closely related S. enterica serotype Typhimurium isolates were cultured from rodent cages and reusable transport containers at a pet distributor. Human, rodent, and environmental isolates were resistant to ampicillin, chloramphenicol, streptomycin, sulfisoxazole, and tetracycline. CONCLUSIONS: Pet rodents probably are an underrecognized source of human salmonella infection.	Ctr Dis Control & Prevent, Epidem Intelligence Serv Program, Atlanta, GA USA; Ctr Dis Control & Prevent, Foodborne & Diarrheal Dis Branch, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, Atlanta, GA USA; Minnesota Dept Hlth, Publ Hlth Lab, St Paul, MN USA; Minnesota Dept Hlth, Acute Dis Invest & Control Sect, St Paul, MN USA; Univ Minnesota, Coll Vet Med, Dept Vet Populat Med, St Paul, MN 55108 USA; Missouri Dept Hlth & Senior Serv, Jefferson City, MO USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Minnesota Department of Health (MHD); Minnesota Department of Health (MHD); University of Minnesota System; University of Minnesota Twin Cities	Swanson, SJ (corresponding author), Hennepin Cty Med Ctr, Dept Pediat, Mail Code G7,701 Pk Ave, Minneapolis, MN 55415 USA.	stephen.swanson@co.hennepin.mn.us						*AM VET MED ASS, 2004, JUD THER US ANT SCHA; Bartram MT, 1940, J INFECT DIS, V67, P222, DOI 10.1093/infdis/67.3.222; BOHNHOFF M, 1954, P SOC EXP BIOL MED, V86, P132, DOI 10.3181/00379727-86-21030; FISH NA, 1968, CAN MED ASSOC J, V99, P418; Foodborne and Diarrheal Diseases Branch DoBaMD; National Center for Infectious Diseases Centers for Disease Control and Prevention, 2000, STAND MOL SUBT FOODB; Gupte AR, 2003, APPL ENVIRON MICROB, V69, P6669, DOI 10.1128/AEM.69.11.6669-6675.2003; HABERMANN RT, 1958, J NATL CANCER I, V20, P933; Healing T D, 1991, CDR (Lond Engl Rev), V1, pR114; Helms M, 2002, EMERG INFECT DIS, V8, P490, DOI 10.3201/eid0805.010267; Isaacson RE, 1999, AM J VET RES, V60, P1155; LATOUR PB, 1981, AM J VET RES, V42, P2105; Lawson AJ, 2002, EMERG INFECT DIS, V8, P434; LIPSKY S, 1995, JAMA-J AM MED ASSOC, V274, P294; Martin LJ, 2004, J INFECT DIS, V189, P377, DOI 10.1086/381270; Mead PS, 1999, EMERG INFECT DIS, V5, P607, DOI 10.3201/eid0505.990502; Mermin J, 2004, CLIN INFECT DIS, V38, pS253, DOI 10.1086/381594; MILLER CP, 1963, J INFECT DIS, V113, P59, DOI 10.1093/infdis/113.1.59; Molbak K, 1999, NEW ENGL J MED, V341, P1420, DOI 10.1056/NEJM199911043411902; OWEN RA, 1983, AM J VET RES, V44, P46; PETRIE GF, 1910, P ROY SOC MED, V4, P70; QUE JU, 1985, INFECT IMMUN, V48, P169, DOI 10.1128/IAI.48.1.169-174.1985; Santos RL, 2001, MICROBES INFECT, V3, P1335, DOI 10.1016/S1286-4579(01)01495-2; SPARROW S, 1980, J SMALL ANIM PRACT, V21, P1, DOI 10.1111/j.1748-5827.1980.tb01208.x; STEFFEN EK, 1983, LAB ANIM SCI, V33, P454; VANDERWAAIJ D, 1968, J INFECT DIS, V118, P32, DOI 10.1093/infdis/118.1.32; VANDERWAAIJ D, 1971, J HYG-CAMB, V69, P405, DOI 10.1017/S0022172400021653; Varma JK, 2005, J INFECT DIS, V191, P554, DOI 10.1086/427263; Voetsch AC, 2004, CLIN INFECT DIS, V38, pS127, DOI 10.1086/381578; Welch H, 1941, AM J PUBLIC HEALTH N, V31, P332, DOI 10.2105/AJPH.31.4.332; WILLIAMS JE, 1978, AVIAN DIS, V22, P742, DOI 10.2307/1589652; Woodward DL, 1997, J CLIN MICROBIOL, V35, P2786, DOI 10.1128/JCM.35.11.2786-2790.1997; 2000, MMWR MORB MORTAL WKL, V49, P297; 2001, MMWR MORB MORTAL WKL, V50, P701; 2003, MMWR MORB MORTAL WKL, V52, P1206; 2005, MMWR MORB MORTAL WKL, V54, P429	35	56	65	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 4	2007	356	1					21	28		10.1056/NEJMoa060465	http://dx.doi.org/10.1056/NEJMoa060465			8	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	122EX	17202452				2022-12-28	WOS:000243209600005
J	Zanettini, R; Antonini, A; Gatto, G; Gentile, R; Tesei, S; Pezzoli, G				Zanettini, Renzo; Antonini, Angelo; Gatto, Gemma; Gentile, Rosa; Tesei, Silvana; Pezzoli, Gianni			Valvular heart disease and the use of dopamine agonists for Parkinson's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MITRAL REGURGITATION; 5-HT2B RECEPTORS; PERGOLIDE; VALVE; DETERMINANTS; VALVULOPATHY; FENFLURAMINE; DYSFUNCTION; PREVALENCE	BACKGROUND: Ergot-derived dopamine receptor agonists, often used in the treatment of Parkinson's disease, have been associated with an increased risk of valvular heart disease. METHODS: We performed an echocardiographic prevalence study in 155 patients taking dopamine agonists for Parkinson's disease (pergolide, 64 patients; cabergoline, 49; and non-ergot-derived dopamine agonists, 42) and 90 control subjects. Valve regurgitation was assessed according to American Society of Echocardiography recommendations. The mitral-valve tenting area was also measured and used as a quantitative index for leaflet stiffening and apical displacement of leaflet coaptation. RESULTS: Clinically important regurgitation (moderate to severe, grade 3 to 4) in any valve was found with significantly greater frequency in patients taking pergolide (23.4%) or cabergoline (28.6%) but not in patients taking non-ergot-derived dopamine agonists (0%), as compared with control subjects (5.6%). The relative risk for moderate or severe valve regurgitation in the pergolide group was 6.3 for mitral regurgitation (P=0.008), 4.2 for aortic regurgitation (P=0.01), and 5.6 for tricuspid regurgitation (P=0.16); corresponding relative risks in the cabergoline group were 4.6 (P=0.09), 7.3 (P<0.001), and 5.5 (P=0.12). The mean mitral tenting area was significantly greater in ergot-treated patients and showed a linear relationship with the severity of mitral regurgitation. Patients treated with ergot derivatives who had grade 3 to 4 regurgitation of any valve had received a significantly higher mean cumulative dose of pergolide or cabergoline than had patients with lower grades. CONCLUSIONS: The frequency of clinically important valve regurgitation was significantly increased in patients taking pergolide or cabergoline, but not in patients taking non-ergot-derived dopamine agonists, as compared with control subjects. These findings should be considered in evaluating the risk-benefit ratio of treatment with ergot derivatives.	Ist Clin Perfezionamento, Cardiac Rehabil Unit, I-20126 Milan, Italy; Ist Clin Perfezionamento, Parkinson Inst, I-20126 Milan, Italy		Zanettini, R (corresponding author), Ist Clin Perfezionamento, Cardiac Rehabil Unit, Via Bignami 1, I-20126 Milan, Italy.	cardriab@icp.mi.it	Antonini, Angelo/H-9726-2019	Antonini, Angelo/0000-0003-1040-2807; Pezzoli, Gianni/0000-0003-4665-6710				Baseman DG, 2004, NEUROLOGY, V63, P301, DOI 10.1212/01.WNL.0000129842.49926.07; Botero M, 2002, J CLIN ANESTH, V14, P57, DOI 10.1016/S0952-8180(01)00353-1; Chaudhuri KR, 2004, MOVEMENT DISORD, V19, P1522, DOI 10.1002/mds.20330; Flowers CM, 2003, MAYO CLIN PROC, V78, P730, DOI 10.4065/78.6.730; Horvath J, 2004, MOVEMENT DISORD, V19, P656, DOI 10.1002/mds.20201; Jahnichen S, 2005, EUR J PHARMACOL, V513, P225, DOI 10.1016/j.ejphar.2005.03.010; Jollis JG, 2000, CIRCULATION, V101, P2071, DOI 10.1161/01.CIR.101.17.2071; Lancellotti P, 2003, J AM COLL CARDIOL, V42, P1921, DOI 10.1016/j.jacc.2003.04.002; Pinero A, 2005, NEW ENGL J MED, V353, P1976, DOI 10.1056/NEJM200511033531822; Rascol O, 2004, MOVEMENT DISORD, V19, P611, DOI 10.1002/mds.20202; REDFIELD MM, 1992, ANN INTERN MED, V117, P50, DOI 10.7326/0003-4819-117-1-50; Rothman RB, 2000, CIRCULATION, V102, P2836; Serratrice Jacques, 2002, Cardiol Rev, V10, P334, DOI 10.1097/00045415-200211000-00005; Shively BK, 1999, CIRCULATION, V100, P2161, DOI 10.1161/01.CIR.100.21.2161; Srichai MB, 2005, ANN THORAC SURG, V80, P170, DOI 10.1016/j.athoracsur.2005.01.068; Van Camp G, 2003, NEUROLOGY, V61, P859, DOI 10.1212/01.WNL.0000083985.00343.F2; Van Camp G, 2004, LANCET, V363, P1179, DOI 10.1016/S0140-6736(04)15945-X; YOCK PG, 1984, CIRCULATION, V70, P657, DOI 10.1161/01.CIR.70.4.657; Zoghbi WA, 2003, J AM SOC ECHOCARDIOG, V16, P777, DOI 10.1016/S0894-7317(03)00335-3	19	575	593	0	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 4	2007	356	1					39	46		10.1056/NEJMoa054830	http://dx.doi.org/10.1056/NEJMoa054830			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	122EX	17202454	Bronze			2022-12-28	WOS:000243209600007
J	Fonarow, GC; Abraham, WT; Albert, NM; Stough, WG; Gheorghiade, M; Greenberg, BH; O'Connor, CM; Pieper, K; Sun, JL; Yancy, C; Young, JB				Fonarow, Gregg C.; Abraham, William T.; Albert, Nancy M.; Stough, Wendy Gattis; Gheorghiade, Mihai; Greenberg, Barry H.; O'Connor, Christopher M.; Pieper, Karen; Sun, Jie Lena; Yancy, Clyde; Young, James B.		OPTIMIZE-HF Investigators	Association between performance measures and clinical outcomes for patients hospitalized with heart failure	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY-OF-CARE; MORTALITY; CARVEDILOL; INFARCTION; RATES	Context Assessment of quality of care in heart failure has focused on the development and use of process-based performance measures, with the presumption that these processes are associated with improved clinical outcomes. However, this link remains largely untested. Objective To examine the relationship between current American College of Cardiology/ American Heart Association (ACC/AHA) performance measures for patients hospitalized with heart failure and relevant clinical outcomes. Design, Setting, and Patients The Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure, a registry and performance improvement program for patients hospitalized with heart failure. Sixty- to ninety-day postdischarge follow-up data were prospectively collected from 5791 patients at 91 US hospitals in a prespecified 10% sample between March 2003 and December 2004. Mean patient age was 72.0 years, 51% were male, 78% were white, and 42% had ischemic etiology. Multivariable and propensity-adjusted analyses were performed to assess the process-outcome relationship for each performance measure in eligible patients. Additionally, we evaluated the process-outcome link of a potential performance measure for beta-blockade at discharge among eligible patients hospitalized with heart failure. Main Outcome Measures Sixty- to ninety-day mortality and combined mortality/ rehospitalization rates. Results Mortality during follow-up was 8.6% and mortality/ rehospitalization was 36.2%. None of the 5 ACC/AHA heart failure performance measures was significantly associated with reduced early mortality risk, and only angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use at discharge was associated with 60- to 90-day postdischarge mortality or rehospitalization. beta-Blockade at the time of hospital discharge, currently not a heart failure performance measure, was strongly associated with reduced risk of mortality ( hazard ratio, 0.48; 95% confidence interval, 0.30-0.79; P=.004) and mortality/ rehospitalization during follow-up. Conclusions Current heart failure performance measures, aside from prescription of an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker at discharge, have little relationship to patient mortality and combined mortality/ rehospitalization in the first 60 to 90 days after discharge. Additional measures and better methods for identifying and validating heart failure performance measures may be needed to accurately assess and improve care of patients with heart failure.	Univ Calif Los Angeles, Med Ctr, Ahmanson UCLA Cardiomyopathy Ctr, Los Angeles, CA 90095 USA; Ohio State Univ, Columbus, OH 43210 USA; Cleveland Clin Fdn, Cleveland, OH 44195 USA; Duke Univ, Med Ctr, Durham, NC USA; Duke Clin Res Inst, Durham, NC USA; Campbell Univ, Sch Pharm, Dept Clin Res, Res Triangle Pk, NC USA; Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; Univ Calif San Diego, Med Ctr, San Diego, CA 92103 USA; Baylor Univ, Med Ctr, Baylor Heart & Vasc Inst, Dallas, TX USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University System of Ohio; Ohio State University; Cleveland Clinic Foundation; Duke University; Duke University; Campbell University; Northwestern University; Feinberg School of Medicine; University of California System; University of California San Diego; Baylor University; Baylor University Medical Center	Fonarow, GC (corresponding author), Univ Calif Los Angeles, Med Ctr, Ahmanson UCLA Cardiomyopathy Ctr, 10833 LeConte Ave,Room 47-123 CHS, Los Angeles, CA 90095 USA.	gfonarow@mednet.ucla.edu	Fonarow, Gregg C/D-5988-2014; Stough, Wendy G/R-4287-2016	Fonarow, Gregg C/0000-0002-3192-8093; Stough, Wendy G/0000-0001-8290-1205				American Heart Association, 2006, HEART DIS STROK STAT; [Anonymous], 2005, J AM COLL CARDIOL, V46, P1144, DOI 10.1016/j.jacc.2005.07.012; Bradley EH, 2006, JAMA-J AM MED ASSOC, V296, P72, DOI 10.1001/jama.296.1.72; Bufalino V, 2006, CIRCULATION, V113, P1151, DOI 10.1161/CIRCULATIONAHA.105.171760; Fonarow GC, 2004, AM J CARDIOL, V93, p77B, DOI 10.1016/j.amjcard.2004.01.030; Fonarow GC, 2005, ARCH INTERN MED, V165, P1469, DOI 10.1001/archinte.165.13.1469; Fonarow GC, 2004, AM HEART J, V148, P43, DOI 10.1016/j.ahj.2004.03.004; Gheorghiade M, 2006, JAMA-J AM MED ASSOC, V296, P2217, DOI 10.1001/jama.296.18.2217; Granger CB, 2005, AM J MED, V118, P858, DOI 10.1016/j.amjmed.2005.01.070; Gwadry-Sridhar FH, 2004, ARCH INTERN MED, V164, P2315, DOI 10.1001/archinte.164.21.2315; Hjalmarson A, 1999, LANCET, V353, P2001; Houston TK, 2005, AM J MED, V118, P269, DOI 10.1016/j.amjmed.2004.12.007; Hunt SA, ACC AHA 2005 GUIDELI; Jencks SF, 2003, JAMA-J AM MED ASSOC, V289, P305, DOI 10.1001/jama.289.3.305; Jencks SF, 2003, JAMA-J AM MED ASSOC, V289, P2647; *JOINT COMM ACCR H, 2006, SPEC MAN NAT HOSP QU; *JOINT COMM ACCR H, 2006, FACTS ORYX HOSP COR; Koelling TM, 2004, AM HEART J, V147, P74, DOI 10.1016/j.ahj.2003.07.021; Koelling TM, 2005, CIRCULATION, V111, P179, DOI 10.1161/01.CIR.0000151811.53450.B8; Krum H, 2003, JAMA-J AM MED ASSOC, V289, P712, DOI 10.1001/jama.289.6.712; Krumholz HM, 2000, CIRCULATION, V101, pE122, DOI 10.1161/01.CIR.101.12.e122; Lappe JM, 2004, ANN INTERN MED, V141, P446, DOI 10.7326/0003-4819-141-6-200409210-00010; Lechat P, 1999, LANCET, V353, P9; Luthi JC, 2002, INT J QUAL HEALTH C, V14, P15, DOI 10.1093/intqhc/14.1.15; Luthi JC, 2003, INT J QUAL HEALTH C, V15, P413, DOI 10.1093/intqhc/mzg055; Masoudi FA, 2004, CIRCULATION, V110, P724, DOI 10.1161/01.CIR.0000138934.28340.ED; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; Packer M, 2001, NEW ENGL J MED, V344, P1651, DOI 10.1056/NEJM200105313442201; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; Peterson ED, 2006, JAMA-J AM MED ASSOC, V295, P1912, DOI 10.1001/jama.295.16.1912; Rich Michael W, 2002, Heart Fail Rev, V7, P89; Senni M, 1999, J AM COLL CARDIOL, V33, P164, DOI 10.1016/S0735-1097(98)00523-3; Shivkumar K, 1996, PROG CARDIOVASC DIS, V38, P337, DOI 10.1016/S0033-0620(96)80018-1; Spertus JA, 2005, J AM COLL CARDIOL, V45, P1147, DOI 10.1016/j.jacc.2005.03.011	34	382	387	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 3	2007	297	1					61	70		10.1001/jama.297.1.61	http://dx.doi.org/10.1001/jama.297.1.61			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	123BS	17200476				2022-12-28	WOS:000243271900022
J	Liu, N; Bonini, NM				Liu, Nan; Bonini, Nancy M.			Hosting neurotoxicity in polyglutamine disease	CELL			English	Editorial Material							NEURODEGENERATIVE DISEASE; DROSOPHILA; PATHOGENESIS	Polyglutamine diseases are caused by an expanded glutamine domain thought to confer a toxic activity onto the respective disease proteins. In this issue, Lam et al. (2006) propose that toxicity of the polyglutamine protein Ataxin-1 may not be due to abberant protein interactions mediated by the polyglutamine expansion. Instead, they suggest that toxicity is solely due to interactions of Ataxin-1 with its normal binding partners.	Univ Penn, Dept Biol, Philadelphia, PA 19104 USA; Univ Penn, Howard Hughes Med Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania	Bonini, NM (corresponding author), Univ Penn, Dept Biol, Philadelphia, PA 19104 USA.	nbonini@sas.upenn.edu	Liu, Nan/D-8913-2011	Bonini, Nancy/0000-0003-0226-5291				Bilen J, 2005, ANNU REV GENET, V39, P153, DOI 10.1146/annurev.genet.39.110304.095804; Bilen J, 2006, MOL CELL, V24, P157, DOI 10.1016/j.molcel.2006.07.030; Eriksen JL, 2005, TRENDS MOL MED, V11, P91, DOI 10.1016/j.molmed.2005.01.001; Fernandez-Funez P, 2000, NATURE, V408, P101, DOI 10.1038/35040584; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; LAM YC, 2006, CELL; Lim J, 2006, CELL, V125, P801, DOI 10.1016/j.cell.2006.03.032; Marsh JL, 2006, NEURON, V52, P169, DOI 10.1016/j.neuron.2006.09.025; Takeyama K, 2002, NEURON, V35, P855, DOI 10.1016/S0896-6273(02)00875-9; Taylor JP, 2002, SCIENCE, V296, P1991, DOI 10.1126/science.1067122	10	4	4	0	2	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 29	2006	127	7					1299	1300		10.1016/j.cell.2006.12.012	http://dx.doi.org/10.1016/j.cell.2006.12.012			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	128WI	17190592	Bronze			2022-12-28	WOS:000243690000007
J	Loxterkamp, D				Loxterkamp, David			Living conditions	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Seaport Family Practice, Belfast, ME 04915 USA		Loxterkamp, D (corresponding author), Seaport Family Practice, Belfast, ME 04915 USA.	mclobster@verizon.net							0	0	0	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 23	2006	333	7582					1323	1325		10.1136/bmj.39057.524792.BE	http://dx.doi.org/10.1136/bmj.39057.524792.BE			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121MC	17185728	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000243160700025
J	Davis, CC; Latvis, M; Nickrent, DL; Wurdack, KJ; Baum, DA				Davis, Charles C.; Latvis, Maribeth; Nickrent, Daniel L.; Wurdack, Kenneth J.; Baum, David A.			Floral gigantism in rafflesiaceae	SCIENCE			English	Article							FLOWERING PLANTS; GENE-TRANSFER		Harvard Univ Hebaria, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA; So Illinois Univ, Dept Plant Biol, Carbondale, IL 62901 USA; Smithsonian Inst, Dept Bot, Washington, DC 20013 USA; Univ Wisconsin, Dept Bot, Madison, WI 53706 USA	Harvard University; Southern Illinois University System; Southern Illinois University; Smithsonian Institution; Smithsonian National Museum of Natural History; University of Wisconsin System; University of Wisconsin Madison	Davis, CC (corresponding author), Harvard Univ Hebaria, Dept Organism & Evolutionary Biol, 22 Divin Ave, Cambridge, MA 02138 USA.	cdavis@oeb.harvard.edu	Nickrent, Daniel/AAA-8411-2020; Baum, David/D-6804-2015	Baum, David/0000-0001-8334-6311				[Anonymous], 1969, BIOL PARASITIC FLOWE; Barkman TJ, 2004, P NATL ACAD SCI USA, V101, P787, DOI 10.1073/pnas.0305562101; BROWN R, 1822, T LINN SOC LOND, V13, P201, DOI DOI 10.1111/J.1095-8339.1821.TB00062.X; Davis CC, 2005, AM NAT, V165, pE36, DOI 10.1086/428296; Davis CC, 2004, SCIENCE, V305, P676, DOI 10.1126/science.1100671; Nickrent Daniel L., 1998, P211; Nickrent DL, 2004, BMC EVOL BIOL, V4, DOI 10.1186/1471-2148-4-40; Nickrent DL, 1997, PLANT MOL BIOL, V34, P717, DOI 10.1023/A:1005860632601; O'Meara BC, 2006, EVOLUTION, V60, P922; OMEARA BC, BROWNIE 2 06B	10	100	104	1	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 30	2007	315	5820					1812	1812		10.1126/science.1135260	http://dx.doi.org/10.1126/science.1135260			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	151HC	17218493				2022-12-28	WOS:000245280100033
J	Boyer, D; Westra, SJ; Harris, NL; Kinane, TB; Stone, JR				Boyer, Debra; Westra, Sjirk J.; Harris, Nancy Lee; Kinane, T. Bernard; Stone, James R.			A 3-year-old boy with recurrent episodes of respiratory insufficiency - Pulmonary hemorrhage and hemosiderosis, consistent with idiopathic pulmonary hemosiderosis.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTERSTITIAL LUNG-DISEASE; COMPUTED-TOMOGRAPHY FINDINGS; OF-THE-LITERATURE; CHILDREN; CT; TELANGIECTASIA; RADIOGRAPHY; MACROPHAGES; HEMOPTYSIS; MUTATIONS		Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pediat Radiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Boyer, D (corresponding author), Childrens Hosp, Div Resp Dis, 300 Longwood Ave, Boston, MA 02115 USA.							Ahrens B, 2001, J THORAC CARDIOV SUR, V122, P1021, DOI 10.1067/mtc.2001.113741; AKYAR S, 1993, RESPIRATION, V60, P63; Bullard JE, 2005, AM J RESP CRIT CARE, V172, P1026, DOI 10.1164/rccm.200503-504OC; CHRYSSANTHOPOULOS C, 1983, EUR J PEDIATR, V140, P123, DOI 10.1007/BF00441658; COLIN AA, 1993, NEW ENGL J MED, V329, P1797; Copley SJ, 2000, AM J ROENTGENOL, V174, P549, DOI 10.2214/ajr.174.2.1740549; COSSBU JA, 1997, PEDIATRICS, V100, P7; FRASER RS, 1999, FRASER PARES DIAGN D, V3, P1757; Fullmer JJ, 2005, J PEDIATR-US, V146, P376, DOI 10.1016/j.jpeds.2004.10.025; Godfrey S, 2004, PEDIATR PULM, V37, P476, DOI 10.1002/ppul.20020; Greaves K, 2003, HEART, V89, P937, DOI 10.1136/heart.89.8.937; GREBSKI E, 1992, CHEST, V102, P1794, DOI 10.1378/chest.102.6.1794; Hamvas A, 2004, AM J RESP CELL MOL, V30, P771, DOI 10.1165/rcmb.2003-0323OC; HEINER DC, 1962, AM J DIS CHILD, V103, P634, DOI 10.1001/archpedi.1962.02080020649003; KJELLMAN B, 1984, ACTA PAEDIATR SCAND, V73, P584, DOI 10.1111/j.1651-2227.1984.tb09978.x; Kocakoc E, 2003, MED PRIN PRACT, V12, P129, DOI 10.1159/000069112; LYNCH DA, 1990, RADIOLOGY, V176, P243, DOI 10.1148/radiology.176.1.2353097; MCCOY KS, 1999, PEDIAT RESP MED, P835; Moraes TJ, 2003, PEDIATR PULM, V35, P318, DOI 10.1002/ppul.10249; Pradhan M, 2000, PEDIATR NEPHROL, V14, P862, DOI 10.1007/PL00013445; Saeed MM, 1999, CHEST, V116, P721, DOI 10.1378/chest.116.3.721; Seely JM, 1997, AM J ROENTGENOL, V168, P1269, DOI 10.2214/ajr.168.5.9129425; SHERMAN JM, 1984, CHEST, V86, P409, DOI 10.1378/chest.86.3.409; Shovlin CL, 2000, AM J MED GENET, V91, P66, DOI 10.1002/(SICI)1096-8628(20000306)91:1<66::AID-AJMG12>3.0.CO;2-P; Shulenin S, 2004, NEW ENGL J MED, V350, P1296, DOI 10.1056/NEJMoa032178; Silverman ES, 2002, NEW ENGL J MED, V347, P1693, DOI 10.1056/NEJMcpc020020; SNIDER GL, 1988, NEW ENGL J MED, V319, P227; SOERGEL KH, 1962, AM REV RESPIR DIS, V85, P540; SOERGEL KH, 1962, AM J MED, V32, P499, DOI 10.1016/0002-9343(62)90051-7; States LJ, 1998, SEMIN ROENTGENOL, V33, P174, DOI 10.1016/S0037-198X(98)80021-7; Trembath RC, 2001, NEW ENGL J MED, V345, P325, DOI 10.1056/NEJM200108023450503; von Vigier RO, 2000, PEDIATR PULM, V29, P382, DOI 10.1002/(SICI)1099-0496(200005)29:5<382::AID-PPUL7>3.0.CO;2-D; Wu CY, 2001, LUPUS, V10, P879, DOI 10.1191/096120301701548544; 2004, MMWR MORB MORTAL WKL, V53, P817	34	3	4	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 25	2007	356	4					398	407		10.1056/NEJMcpc069033	http://dx.doi.org/10.1056/NEJMcpc069033			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128FT	17251537				2022-12-28	WOS:000243644300012
J	Young, DW; Hassan, MQ; Pratap, J; Galindo, M; Zaidi, SK; Lee, SH; Yang, XQ; Xie, RL; Javed, A; Underwood, JM; Furcinitti, P; Imbalzano, AN; Penman, S; Nickerson, JA; Montecino, MA; Lian, JB; Stein, JL; van Wijnen, AJ; Stein, GS				Young, Daniel W.; Hassan, Mohammad Q.; Pratap, Jitesh; Galindo, Mario; Zaidi, Sayyed K.; Lee, Suk-hee; Yang, Xiaoqing; Xie, Ronglin; Javed, Amjad; Underwood, Jean M.; Furcinitti, Paul; Imbalzano, Anthony N.; Penman, Sheldon; Nickerson, Jeffrey A.; Montecino, Martin A.; Lian, Jane B.; Stein, Janet L.; van Wijnen, Andre J.; Stein, Gary S.			Mitotic occupancy and lineage-specific transcriptional control of rRNA genes by Runx2	NATURE			English	Article							POLYMERASE-I TRANSCRIPTION; CELL-CYCLE; RDNA TRANSCRIPTION; NUCLEAR-MATRIX; UBF; PROTEINS; DNA; RB; DIFFERENTIATION; CHROMOSOMES	Regulation of ribosomal RNA genes is a fundamental process that supports the growth of cells and is tightly coupled with cell differentiation. Although rRNA transcriptional control by RNA polymerase I (Pol I) and associated factors is well studied, the lineage-specific mechanisms governing rRNA expression remain elusive(1). Runt-related transcription factors Runx1, Runx2 and Runx3 establish and maintain cell identity(2), and convey phenotypic information through successive cell divisions for regulatory events that determine cell cycle progression or exit in progeny cells(3). Here we establish that mammalian Runx2 not only controls lineage commitment and cell proliferation by regulating genes transcribed by RNA Pol II, but also acts as a repressor of RNA Pol I mediated rRNA synthesis. Within the condensed mitotic chromosomes we find that Runx2 is retained in large discrete foci at nucleolar organizing regions where rRNA genes reside. These Runx2 chromosomal foci are associated with open chromatin, colocalize with the RNA Pol I transcription factor UBF1, and undergo transition into nucleoli at sites of rRNA synthesis during interphase. Ribosomal RNA transcription and protein synthesis are enhanced by Runx2 deficiency that results from gene ablation or RNA interference, whereas induction of Runx2 specifically and directly represses rDNA promoter activity. Runx2 forms complexes containing the RNA Pol I transcription factors UBF1 and SL1, co-occupies the rRNA gene promoter with these factors in vivo, and affects local chromatin histone modifications at rDNA regulatory regions. Thus Runx2 is a critical mechanistic link between cell fate, proliferation and growth control. Our results suggest that lineage-specific control of ribosomal biogenesis may be a fundamental function of transcription factors that govern cell fate.	Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Ctr Canc, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01655 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Univ Concepcion, Dept Biol Mol, Fac Ciencias Biol, Concepcion, Chile	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Massachusetts Institute of Technology (MIT); Universidad de Concepcion	Stein, GS (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA.	gary.stein@umassmed.edu	van Wijnen, Andre J./AAG-3578-2019; Hassan, Mohammad/GZA-7507-2022; Zaidi, Sayyed Kaleem/I-5596-2019	van Wijnen, Andre J./0000-0002-4458-0946; Hassan, Mohammad/0000-0002-1712-0004; Zaidi, Sayyed Kaleem/0000-0001-6664-5168; Javed, Amjad/0000-0002-0847-8266	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049069] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR049069] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Arabi A, 2005, NAT CELL BIOL, V7, P303, DOI 10.1038/ncb1225; Blyth K, 2005, NAT REV CANCER, V5, P376, DOI 10.1038/nrc1607; Budde A, 1999, ONCOGENE, V18, P1119, DOI 10.1038/sj.onc.1202402; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; Cheutin T, 2002, J CELL SCI, V115, P3297; Galindo M, 2005, J BIOL CHEM, V280, P20274, DOI 10.1074/jbc.M413665200; GebraneYounes J, 1997, J CELL SCI, V110, P2429; Gonzalez IL, 2001, GENOMICS, V73, P255, DOI 10.1006/geno.2001.6540; Grandori C, 2005, NAT CELL BIOL, V7, P311, DOI 10.1038/ncb1224; Hannan KM, 2000, ONCOGENE, V19, P3487, DOI 10.1038/sj.onc.1203690; Hannan KM, 2000, ONCOGENE, V19, P4988, DOI 10.1038/sj.onc.1203875; Hovhannisyan H, 2003, MOL CELL BIOL, V23, P1460, DOI 10.1128/MCB.23.4.1460-1469.2003; Javed A, 2005, P NATL ACAD SCI USA, V102, P1454, DOI 10.1073/pnas.0409121102; Javed A, 2000, J CELL SCI, V113, P2221; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Mais C, 2005, GENE DEV, V19, P50, DOI 10.1101/gad.310705; Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761; MARTINEZBALBAS MA, 1995, CELL, V83, P29, DOI 10.1016/0092-8674(95)90231-7; Muchardt C, 1996, EMBO J, V15, P3394, DOI 10.1002/j.1460-2075.1996.tb00705.x; NICKERSON JA, 1990, P NATL ACAD SCI USA, V87, P2259, DOI 10.1073/pnas.87.6.2259; Nuthall HN, 2002, J BIOL CHEM, V277, P51049, DOI 10.1074/jbc.M111660200; Otto F, 2002, HUM MUTAT, V19, P209, DOI 10.1002/humu.10043; Poortinga G, 2004, EMBO J, V23, P3325, DOI 10.1038/sj.emboj.7600335; Prasanth KV, 2003, MOL BIOL CELL, V14, P1043, DOI 10.1091/mbc.E02-10-0669; ROUSSEL P, 1993, J CELL SCI, V104, P327; Russell J, 2005, TRENDS BIOCHEM SCI, V30, P87, DOI 10.1016/j.tibs.2004.12.008; Valdez BC, 2004, P NATL ACAD SCI USA, V101, P10709, DOI 10.1073/pnas.0402492101; Voit R, 1997, MOL CELL BIOL, V17, P4230, DOI 10.1128/MCB.17.8.4230; Zaidi SK, 2001, J CELL SCI, V114, P3093; Zaidi SK, 2003, P NATL ACAD SCI USA, V100, P14852, DOI 10.1073/pnas.2533076100	30	182	187	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 25	2007	445	7126					442	446		10.1038/nature05473	http://dx.doi.org/10.1038/nature05473			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	128WD	17251981				2022-12-28	WOS:000243689500043
J	Kullnat, MW				Kullnat, Megan Wills			Boundaries	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												megwills@hotmail.com							0	4	4	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 24	2007	297	4					343	344		10.1001/jama.297.4.343	http://dx.doi.org/10.1001/jama.297.4.343			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128GE	17244822				2022-12-28	WOS:000243645400001
J	Abramson, J; Wright, JM				Abramson, J.; Wright, J. M.			Are lipid-lowering guidelines evidence-based?	LANCET			English	Editorial Material							CORONARY-HEART-DISEASE; WOMEN; MEN		Univ British Columbia, Dept Anesthesiol Pharmacol & Therapeut & Med, Vancouver, BC V6T 1Z3, Canada; Harvard Univ, Sch Med, Cambridge, MA 02138 USA	University of British Columbia; Harvard University	Wright, JM (corresponding author), Univ British Columbia, Dept Anesthesiol Pharmacol & Therapeut & Med, Vancouver, BC V6T 1Z3, Canada.	jmwright@interchange.ubc.ca						Baigent C, 2005, LANCET, V366, P1267, DOI 10.1016/S0140-6736(05)67394-1; Chiuve SE, 2006, CIRCULATION, V114, P160, DOI 10.1161/CIRCULATIONAHA.106.621417; JAUCA C, 2003, INT SOC DRUG B NEWSL, V17, P7; Manuel DG, 2006, BMJ-BRIT MED J, V332, P1419, DOI 10.1136/bmj.38849.487546.DE; National Cholesterol Education Program (NCEP), 2002, 3 NCEP; Savoie I, 2002, J CLIN EPIDEMIOL, V55, P95, DOI 10.1016/S0895-4356(01)00436-X; Shepherd J, 2002, LANCET, V360, P1623, DOI 10.1016/S0140-6736(02)11600-X; Walsh JME, 2004, JAMA-J AM MED ASSOC, V291, P2243, DOI 10.1001/jama.291.18.2243	8	93	95	1	14	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 20	2007	369	9557					168	169		10.1016/S0140-6736(07)60084-1	http://dx.doi.org/10.1016/S0140-6736(07)60084-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128XG	17240267				2022-12-28	WOS:000243692400006
J	Fomenko, DE; Xing, WB; Adair, BM; Thomas, DJ; Gladyshev, VN				Fomenko, Dmitri E.; Xing, Weibing; Adair, Blakely M.; Thomas, David J.; Gladyshev, Vadim N.			High-throughput identification of catalytic redox-active cysteine residues	SCIENCE			English	Article							SELENOCYSTEINE INSERTION; ESCHERICHIA-COLI; PROTEIN; METHYLTRANSFERASE; OXIDATION; INSIGHT; CLUSTER	Cysteine (Cys) residues often play critical roles in proteins; however, identification of their specific functions has been limited to case-by-case experimental approaches. We developed a procedure for high-throughput identification of catalytic redox-active Cys in proteins by searching for sporadic selenocysteine-Cys pairs in sequence databases. This method is independent of protein family, structure, and taxon. We used it to selectively detect the majority of known proteins with redox-active Cys and to make additional predictions, one of which was verified. Rapid accumulation of sequence information from genomic and metagenomic projects should allow detection of many additional oxidoreductase families as well as identification of redox-active Cys in these proteins.	Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA; Univ N Carolina, Curriculum Toxicol, Chapel Hill, NC 27599 USA; US EPA, Expt Toxicol Div, Natl Hlth & Environm Effects Res Lab, Res Triangle Pk, NC 27711 USA	University of Nebraska System; University of Nebraska Lincoln; University of North Carolina; University of North Carolina Chapel Hill; United States Environmental Protection Agency	Gladyshev, VN (corresponding author), Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA.	vgladyshev1@unl.edu	Gladyshev, Vadim N/J-6187-2013; Gladyshev, Vadim N/A-9894-2013	Gladyshev, Vadim/0000-0002-0372-7016	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061603] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021518] Funding Source: NIH RePORTER; NIA NIH HHS [AG021518] Funding Source: Medline; NIGMS NIH HHS [GM061603] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adair BM, 2005, ENVIRON CHEM, V2, P161, DOI 10.1071/EN05054; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Beeby M, 2005, PLOS BIOL, V3, P1549, DOI 10.1371/journal.pbio.0030309; Bordo D, 2002, EMBO REP, V3, P741, DOI 10.1093/embo-reports/kvf150; Copeland PR, 2001, MOL CELL BIOL, V21, P1491, DOI 10.1128/MCB.21.5.1491-1498.2001; Cupp-Vickery JR, 2004, J MOL BIOL, V338, P127, DOI 10.1016/j.jmb.2004.02.027; Dahl C, 2005, J BACTERIOL, V187, P1392, DOI 10.1128/JB.187.4.1392-1404.2005; Fetrow JS, 2001, PROTEIN SCI, V10, P1005, DOI 10.1110/ps.49201; Fomenko DE, 2003, BIOCHEMISTRY-US, V42, P11214, DOI 10.1021/bi034459s; Hatfield D.L., 2002, SELENIUM ITS MOL BIO, V36, P235, DOI 10.1080/10715760290006394; Hayes JD, 2005, ANNU REV PHARMACOL, V45, P51, DOI 10.1146/annurev.pharmtox.45.120403.095857; Kim HY, 2005, PLOS BIOL, V3, P2080, DOI 10.1371/journal.pbio.0030375; Kryukov GV, 2003, SCIENCE, V300, P1439, DOI 10.1126/science.1083516; Leichert LI, 2004, PLOS BIOL, V2, P1723, DOI 10.1371/journal.pbio.0020333; Leimkuhler S, 2001, J BIOL CHEM, V276, P34695, DOI 10.1074/jbc.M102787200; Li JX, 2005, TOXICOL APPL PHARM, V204, P164, DOI 10.1016/j.taap.2004.12.002; Madadi-Kahkesh S, 2001, EUR J BIOCHEM, V268, P2566, DOI 10.1046/j.1432-1327.2001.02141.x; Novoselov SV, 2002, EMBO J, V21, P3681, DOI 10.1093/emboj/cdf372; Rosen BP, 2002, FEBS LETT, V529, P86, DOI 10.1016/S0014-5793(02)03186-1; Tringe SG, 2005, SCIENCE, V308, P554, DOI 10.1126/science.1107851; Tujebajeva RM, 2000, EMBO REP, V1, P158, DOI 10.1093/embo-reports/kvd033; Waters SB, 2004, CHEM RES TOXICOL, V17, P404, DOI 10.1021/tx0342161	22	147	152	1	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 19	2007	315	5810					387	389		10.1126/science.1133114	http://dx.doi.org/10.1126/science.1133114			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126SI	17234949	Green Submitted			2022-12-28	WOS:000243535400045
J	Dahn, RD; Davis, MC; Pappano, WN; Shubin, NH				Dahn, Randall D.; Davis, Marcus C.; Pappano, William N.; Shubin, Neil H.			Sonic hedgehog function in chondrichthyan fins and the evolution of appendage patterning	NATURE			English	Article							RETINOIC ACID; PECTORAL FIN; POLARIZING ACTIVITY; POLYODON-SPATHULA; LIMB; EXPRESSION; ZEBRAFISH; RANGE; SHH; ENHANCER	The genetic mechanisms regulating tetrapod limb development are well characterized, but how they were assembled during evolution and their function in basal vertebrates is poorly understood. Initial studies report that chondrichthyans, the most primitive extant vertebrates with paired appendages, differ from ray-finned fish and tetrapods in having Sonic hedgehog (Shh)-independent patterning of the appendage skeleton(1). Here we demonstrate that chondrichthyans share patterns of appendage Shh expression, Shh appendage-specific regulatory DNA, and Shh function with ray-finned fish and tetrapods(2-10). These studies demonstrate that some aspects of Shh function are deeply conserved in vertebrate phylogeny, but also highlight how the evolution of Shh regulation may underlie major morphological changes during appendage evolution.	Univ Chicago, Dept Organismal Biol & Anat, Chicago, IL 60637 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Howard Hughes Med Inst, Baltimore, MD 21205 USA; Field Museum Nat Hist, Chicago, IL 60605 USA	University of Chicago; Howard Hughes Medical Institute; Johns Hopkins University; Field Museum of Natural History (Chicago)	Shubin, NH (corresponding author), Univ Chicago, Dept Organismal Biol & Anat, 1025 E 57th St, Chicago, IL 60637 USA.	nshubin@uchicago.edu		Pappano, William/0000-0003-2848-2219; Davis, Marcus/0000-0002-2462-0138				AKIMENKO MA, 1995, DEV BIOL, V170, P243, DOI 10.1006/dbio.1995.1211; BALLARD WW, 1993, J EXP ZOOL, V267, P318, DOI 10.1002/jez.1402670309; BEMIS WE, 1992, J MORPHOL, V213, P47, DOI 10.1002/jmor.1052130106; Chiang C, 2001, DEV BIOL, V236, P421, DOI 10.1006/dbio.2001.0346; Dahn RD, 2000, SCIENCE, V289, P438, DOI 10.1126/science.289.5478.438; Davis MC, 2004, J MORPHOL, V262, P608, DOI 10.1002/jmor.10264; Gritli-Linde A, 2001, DEV BIOL, V236, P364, DOI 10.1006/dbio.2001.0336; Hoffman L, 2002, INT J DEV BIOL, V46, P949; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; Lettice LA, 2003, HUM MOL GENET, V12, P1725, DOI 10.1093/hmg/ddg180; Maas SA, 2005, DEV DYNAM, V232, P345, DOI 10.1002/dvdy.20254; Pearse RV, 2001, DEV BIOL, V239, P15, DOI 10.1006/dbio.2001.0430; Prince VE, 1998, DEVELOPMENT, V125, P407; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; Ros MA, 2003, DEVELOPMENT, V130, P527, DOI 10.1242/dev.00245; Sagai T, 2005, DEVELOPMENT, V132, P797, DOI 10.1242/dev.01613; Sagai T, 2004, MAMM GENOME, V15, P23, DOI 10.1007/s00335-033-2317-5; Saunders J. W., 1968, EPITHELIAL MESENCHYM, P78; Tanaka M, 2002, NATURE, V416, P527, DOI 10.1038/416527a; TICKLE C, 1982, NATURE, V296, P564, DOI 10.1038/296564a0; Vandersea MW, 1998, DEV GENES EVOL, V208, P61, DOI 10.1007/s004270050155	21	102	107	1	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 18	2007	445	7125					311	314		10.1038/nature05436	http://dx.doi.org/10.1038/nature05436			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126HT	17187056				2022-12-28	WOS:000243504700044
J	Pimpinella, G; Malgarini, RB				Pimpinella, G.; Malgarini, R. Bertini			Increased transparency in EU pharmaceutical code	LANCET			English	Editorial Material									Agenzia Italiana Farm, I-00144 Rome, Italy		Pimpinella, G (corresponding author), Agenzia Italiana Farm, I-00144 Rome, Italy.	g.pimpinella@aifa.gov.it						Abraham J, 1998, LANCET, V352, P480, DOI 10.1016/S0140-6736(97)11282-X; *EUR MED AG, IND CENTR AUTH MED P; European Medicines Agency, 2005, ICH TOP E2E PHARM PL; Garattini S, 2003, LANCET, V362, P1078, DOI 10.1016/S0140-6736(03)14424-8; Horton R, 2004, LANCET, V364, P1995, DOI 10.1016/S0140-6736(04)17523-5; Maxwell SRJ, 2005, LANCET, V365, P449	6	2	2	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 13	2007	369	9556					88	90		10.1016/S0140-6736(07)60047-6	http://dx.doi.org/10.1016/S0140-6736(07)60047-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	126TK	17223456				2022-12-28	WOS:000243538200009
J	Blondin, JM; Mezzacappa, A				Blondin, John M.; Mezzacappa, Anthony			Pulsar spins from an instability in the accretion shock of supernovae	NATURE			English	Article							BIRTH; EVOLUTION; STARS; STATE	Rotation-powered radio pulsars are born with inferred initial rotation periods(1) of order 300 ms ( some as short as 20 ms) in core-collapse supernovae. In the traditional picture, this fast rotation is the result of conservation of angular momentum during the collapse of a rotating stellar core. This leads to the inevitable conclusion that pulsar spin is directly correlated with the rotation of the progenitor star(2). So far, however, stellar theory has not been able to explain the distribution of pulsar spins, suggesting that the birth rotation is either too slow(3) or too fast(2,4). Here we report a robust instability of the stalled accretion shock in core-collapse supernovae that is able to generate a strong rotational flow in the vicinity of the accreting proto-neutron star. Sufficient angular momentum is deposited on the proto-neutron star to generate a final spin period consistent with observations, even beginning with spherically symmetrical initial conditions. This provides a new mechanism for the generation of neutron star spin and weakens, if not breaks, the assumed correlation between the rotational periods of supernova progenitor cores and pulsar spin.	N Carolina State Univ, Dept Phys, Raleigh, NC 27695 USA; Oak Ridge Natl Lab, Div Phys, Oak Ridge, TN 37831 USA	University of North Carolina; North Carolina State University; United States Department of Energy (DOE); Oak Ridge National Laboratory	Blondin, JM (corresponding author), N Carolina State Univ, Dept Phys, Raleigh, NC 27695 USA.	john_blondin@ncsu.edu	Mezzacappa, Anthony/B-3163-2017	Mezzacappa, Anthony/0000-0001-9816-9741; Blondin, John/0000-0001-9691-6803				Blondin JM, 2006, ASTROPHYS J, V642, P401, DOI 10.1086/500817; Blondin JM, 2003, ASTROPHYS J, V584, P971, DOI 10.1086/345812; Faucher-Giguere CA, 2006, ASTROPHYS J, V643, P332, DOI 10.1086/501516; Heger A, 2005, ASTROPHYS J, V626, P350, DOI 10.1086/429868; Janka HT, 2005, NUCL PHYS A, V758, p19C, DOI 10.1016/j.nuclphysa.2005.05.008; Lattimer JM, 2001, ASTROPHYS J, V550, P426, DOI 10.1086/319702; Liebendorfer M, 2001, PHYS REV D, V63, DOI 10.1103/PhysRevD.63.103004; Mezzacappa A, 2005, ANNU REV NUCL PART S, V55, P467, DOI 10.1146/annurev.nucl.55.090704.151608; Ohnishi N, 2006, ASTROPHYS J, V641, P1018, DOI 10.1086/500554; Ott CD, 2006, ASTROPHYS J SUPPL S, V164, P130, DOI 10.1086/500832; Scheck L, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.011103; Spruit H, 1998, NATURE, V393, P139, DOI 10.1038/30168; WHITHAM GB, 1974, LINEAR NONLINEAR WAV, P289	13	183	185	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 4	2007	445	7123					58	60		10.1038/nature05428	http://dx.doi.org/10.1038/nature05428			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	122KG	17203055				2022-12-28	WOS:000243225100034
J	Stofan, ER; Elachi, C; Lunine, JI; Lorenz, RD; Stiles, B; Mitchell, KL; Ostro, S; Soderblom, L; Wood, C; Zebker, H; Wall, S; Janssen, M; Kirk, R; Lopes, R; Paganelli, F; Radebaugh, J; Wye, L; Anderson, Y; Allison, M; Boehmer, R; Callahan, P; Encrenaz, P; Flamini, E; Francescetti, G; Gim, Y; Hamilton, G; Hensley, S; Johnson, WTK; Kelleher, K; Muhleman, D; Paillou, P; Picardi, G; Posa, F; Roth, L; Seu, R; Shaffer, S; Vetrella, S; West, R				Stofan, E. R.; Elachi, C.; Lunine, J. I.; Lorenz, R. D.; Stiles, B.; Mitchell, K. L.; Ostro, S.; Soderblom, L.; Wood, C.; Zebker, H.; Wall, S.; Janssen, M.; Kirk, R.; Lopes, R.; Paganelli, F.; Radebaugh, J.; Wye, L.; Anderson, Y.; Allison, M.; Boehmer, R.; Callahan, P.; Encrenaz, P.; Flamini, E.; Francescetti, G.; Gim, Y.; Hamilton, G.; Hensley, S.; Johnson, W. T. K.; Kelleher, K.; Muhleman, D.; Paillou, P.; Picardi, G.; Posa, F.; Roth, L.; Seu, R.; Shaffer, S.; Vetrella, S.; West, R.			The lakes of Titan	NATURE			English	Article							RADAR MAPPER; METHANE; SURFACE; CLOUDS	The surface of Saturn's haze-shrouded moon Titan has long been proposed to have oceans or lakes, on the basis of the stability of liquid methane at the surface(1,2). Initial visible(3) and radar(4,5) imaging failed to find any evidence of an ocean, although abundant evidence was found that flowing liquids have existed on the surface(5,6). Here we provide definitive evidence for the presence of lakes on the surface of Titan, obtained during the Cassini Radar flyby of Titan on 22 July 2006 (T-16). The radar imaging polewards of 70 degrees north shows more than 75 circular to irregular radar-dark patches, in a region where liquid methane and ethane are expected to be abundant and stable on the surface(2,7). The radar-dark patches are interpreted as lakes on the basis of their very low radar reflectivity and morphological similarities to lakes, including associated channels and location in topographic depressions. Some of the lakes do not completely fill the depressions in which they lie, and apparently dry depressions are present. We interpret this to indicate that lakes are present in a number of states, including partly dry and liquid-filled. These northern-hemisphere lakes constitute the strongest evidence yet that a condensable-liquid hydrological cycle is active in Titan's surface and atmosphere, in which the lakes are filled through rainfall and/or intersection with the subsurface 'liquid methane' table.	Proxemy Res, Rectortown, VA 20140 USA; UCL, Dept Earth Sci, London WC1E 6BT, England; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA; Johns Hopkins Univ, Appl Phys Lab, Space Dept, Laurel, MD 20723 USA; US Geol Survey, Flagstaff, AZ 86001 USA; Wheeling Jesuit Univ, Tucson, AZ 85719 USA; Planetary Sci Inst, Tucson, AZ 85719 USA; Stanford Univ, Stanford, CA 94305 USA; NASA, Goddard Inst Space Studies, New York, NY 10025 USA; Observ Paris, F-92195 Meudon, France; Alenia Aerospazio, I-00131 Rome, Italy; Fac Ingn, I-80125 Naples, Italy; CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA; Observ Aquitain Sci Univers UMR 5804, F-33270 Floirac, France; Univ Roma La Sapienza, I-00184 Rome, Italy; Politecn Bari, Dipartimento Interateneo Fis, I-70126 Bari, Italy	University of London; University College London; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of Arizona; Johns Hopkins University; Johns Hopkins University Applied Physics Laboratory; United States Department of the Interior; United States Geological Survey; Wheeling University; Stanford University; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; Leonardo; California Institute of Technology; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); Sapienza University Rome; Politecnico di Bari	Stofan, ER (corresponding author), Proxemy Res, Rectortown, VA 20140 USA.	estofan@proxemy.com	Lorenz, Ralph D/B-8759-2016; Mitchell, Karl Leon/AAG-3821-2020; Lopes, Rosaly M.C./D-1608-2016; Mitchell, Karl Leon/AGL-9516-2022	Lorenz, Ralph D/0000-0001-8528-4644; Mitchell, Karl Leon/0000-0003-1093-8441; Lopes, Rosaly M.C./0000-0002-7928-3167; Lunine, Jonathan/0000-0003-2279-4131; zebker, howard/0000-0001-9931-5237				Elachi C, 2006, NATURE, V441, P709, DOI 10.1038/nature04786; ELACHI C, 1991, P IEEE, V79, P867, DOI 10.1109/5.90164; Elachi C, 2005, SCIENCE, V308, P970, DOI 10.1126/science.1109919; Fulchignoni M, 2005, NATURE, V438, P785, DOI 10.1038/nature04314; Hueso R, 2006, NATURE, V442, P428, DOI 10.1038/nature04933; LOPES RMC, IN PRESS ICARUS; Lorenz RD, 2006, MON NOT R ASTRON SOC, V369, P1683, DOI 10.1111/j.1365-2966.2006.10405.x; Lorenz RD, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2004GL021415; Lorenz RD, 2005, ICARUS, V175, P556, DOI 10.1016/j.icarus.2004.11.019; Lorenz RD, 1996, ICARUS, V122, P79, DOI 10.1006/icar.1996.0110; LORENZ RD, UNPUB PLANET SPACE S; LUNINE JI, 1983, SCIENCE, V222, P1229, DOI 10.1126/science.222.4629.1229; LUNINE JL, UNPUB ICARUS; MITRI G, IN PRESS ICARUS; Porco CC, 2005, NATURE, V434, P159, DOI 10.1038/nature03436; Rannou P, 2006, SCIENCE, V311, P201, DOI 10.1126/science.1118424; Samuelson RE, 1997, PLANET SPACE SCI, V45, P959, DOI 10.1016/S0032-0633(97)00090-1; Samuelson RE, 1997, PLANET SPACE SCI, V45, P941, DOI 10.1016/S0032-0633(97)00088-3; Sotin C, 2005, NATURE, V435, P786, DOI 10.1038/nature03596; STOFAN ER, IN PRESS ICARUS; Tobie G, 2006, NATURE, V440, P61, DOI 10.1038/nature04497; Tokano T, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL024456; Tokano T, 2006, NATURE, V442, P432, DOI 10.1038/nature04948; Tomasko MG, 2005, NATURE, V438, P765, DOI 10.1038/nature04126; West RA, 2005, NATURE, V436, P670, DOI 10.1038/nature03824; YUNG YL, 1984, ASTROPHYS J SUPPL S, V55, P465, DOI 10.1086/190963; [No title captured]	27	397	406	2	110	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 4	2007	445	7123					61	64		10.1038/nature05438	http://dx.doi.org/10.1038/nature05438			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	122KG	17203056				2022-12-28	WOS:000243225100035
J	Szutorisz, H; Georgiou, A; Tora, L; Dillon, N				Szutorisz, Henrietta; Georgiou, Andrew; Tora, Laszlo; Dillon, Niall			The proteasome restricts permissive transcription at tissue-specific gene loci in embryonic stem cells	CELL			English	Article							RNA-POLYMERASE-II; PROTEIN-DEGRADATION; REGULATORY PARTICLE; 20S PROTEASOME; CHROMATIN; COMPLEX; COACTIVATOR; RECRUITMENT; TURNOVER; DOMAIN	The ability of stem cells to activate different gene expression programs requires the choreographed assembly of trans-acting factors at enhancers and promoters during cell differentiation. In this study, we show that the proteasome acts on specific regulatory regions in embryonic stem (ES) cells to prevent incorrect transcriptional initiation. Chemical or siRNA-mediated inhibition of proteasome activity results in increased transcription factor and RNA polymerase II binding and leads to activation of cryptic promoters. Analysis of the binding profiles of different proteasome subunits in normal ES cells and following RNAi knockdown of individual subunits provides evidence for a targeted assembly of the 26S proteasome at specific regulatory elements. Our results suggest that the proteasome promotes a dynamic turnover of transcription factor and Pol II binding at tissue-specific gene domains in ES cells, thereby restricting permissive transcriptional activity and keeping the genes in a potentiated state, ready for activation at later stages.	Univ London Imperial Coll Sci & Technol, Gene Regulat & Chromatin Grp, MRC Clin Sci Ctr, Fac Med, London W12 0NN, England; ULP, INSERM, IGBMC, CNRS,UMR 7104, F-67404 Illkirch Graffenstaden, France	Imperial College London; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Szutorisz, H (corresponding author), Stowers Inst Med Res, 1000 E 50th St, Kansas City, MO 64110 USA.	henrietta.szutorisz@csc.mrc.ac.uk; niall.dillon@csc.mrc.ac.uk	Tora, Laszlo/E-9999-2018	Tora, Laszlo/0000-0001-7398-2250	MRC [MC_U120036884] Funding Source: UKRI; Medical Research Council [MC_U120036884] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Asher G, 2006, BIOESSAYS, V28, P844, DOI 10.1002/bies.20447; AUID KL, 2006, CELL, V21, P861; Babbitt SE, 2005, CELL, V121, P553, DOI 10.1016/j.cell.2005.03.028; Baugh JM, 2004, MOL CELL, V16, P575, DOI 10.1016/j.molcel.2004.10.017; Black JC, 2006, MOL CELL, V23, P809, DOI 10.1016/j.molcel.2006.07.018; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Bulger M, 2005, J BIOL CHEM, V280, P21689, DOI 10.1074/jbc.R500004200; Carrozza MJ, 2005, CELL, V123, P581, DOI 10.1016/j.cell.2005.10.023; Collins GA, 2006, CURR OPIN GENET DEV, V16, P197, DOI 10.1016/j.gde.2006.02.009; Ferdous A, 2001, MOL CELL, V7, P981, DOI 10.1016/S1097-2765(01)00250-7; Frank SR, 2003, EMBO REP, V4, P575, DOI 10.1038/sj.embor.embor861; Gillette TG, 2004, P NATL ACAD SCI USA, V101, P5904, DOI 10.1073/pnas.0305411101; Groll M, 2005, CHEMBIOCHEM, V6, P222, DOI 10.1002/cbic.200400313; Kang ZG, 2002, J BIOL CHEM, V277, P48366, DOI 10.1074/jbc.M209074200; Lee DY, 2005, CELL, V123, P423, DOI 10.1016/j.cell.2005.08.015; Li XT, 2006, CELL, V124, P381, DOI 10.1016/j.cell.2005.11.037; Lipford JR, 2005, NATURE, V438, P113, DOI 10.1038/nature04098; Liu CW, 2003, SCIENCE, V299, P408, DOI 10.1126/science.1079293; Liu XH, 2003, J BIOL CHEM, V278, P20405, DOI 10.1074/jbc.M211795200; Meshorer E, 2006, NAT REV MOL CELL BIO, V7, P540, DOI 10.1038/nrm1938; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Minaee S, 2005, MOL IMMUNOL, V42, P1283, DOI 10.1016/j.molimm.2005.01.003; Muchardt C, 2001, ONCOGENE, V20, P3067, DOI 10.1038/sj.onc.1204331; Muller F, 2004, EMBO J, V23, P2, DOI 10.1038/sj.emboj.7600027; Muratani M, 2005, CELL, V120, P887, DOI 10.1016/j.cell.2004.12.025; Perissi V, 2005, NAT REV MOL CELL BIO, V6, P542, DOI 10.1038/nrm1680; Perry P, 2004, CELL CYCLE, V3, P1645; Pickart CM, 2004, NAT REV MOL CELL BIO, V5, P177, DOI 10.1038/nrm1336; Rastegar M, 2004, MOL CELL BIOL, V24, P8090, DOI 10.1128/MCB.24.18.8090-8103.2004; Rasti M, 2006, EMBO J, V25, P2710, DOI 10.1038/sj.emboj.7601169; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Routledge SJE, 2002, J MOL BIOL, V323, P601, DOI 10.1016/S0022-2836(02)01011-2; Sabbattini P, 2005, SEMIN IMMUNOL, V17, P121, DOI 10.1016/j.smim.2005.01.004; Sikder D, 2006, J BIOL CHEM, V281, P27346, DOI 10.1074/jbc.M604706200; Somesh BP, 2005, CELL, V121, P913, DOI 10.1016/j.cell.2005.04.010; Stommel JM, 2005, CELL CYCLE, V4, P411, DOI 10.4161/cc.4.3.1522; Szutorisz H, 2005, BIOESSAYS, V27, P1286, DOI 10.1002/bies.20330; Szutorisz H, 2005, TRENDS BIOCHEM SCI, V30, P593, DOI 10.1016/j.tibs.2005.08.006; Szutorisz H, 2005, MOL CELL BIOL, V25, P1804, DOI 10.1128/MCB.25.5.1804-1820.2005; Vieira KF, 2004, J BIOL CHEM, V279, P50350, DOI 10.1074/jbc.M408883200; Wilkinson CRM, 2000, J BIOL CHEM, V275, P15182, DOI 10.1074/jbc.275.20.15182; Yudkovsky N, 2000, NATURE, V408, P225, DOI 10.1038/35041603	42	96	99	0	9	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 29	2006	127	7					1375	1388		10.1016/j.cell.2006.10.045	http://dx.doi.org/10.1016/j.cell.2006.10.045			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	128WI	17190601	Bronze			2022-12-28	WOS:000243690000017
J	Sethi, D; Racioppi, F; Baumgarten, I; Bertollini, R				Sethi, Dinesh; Racioppi, Francesca; Baumgarten, Inge; Bertollini, Roberto			Reducing inequalities from injuries in Europe	LANCET			English	Article							ALCOHOL-CONSUMPTION; SOCIOECONOMIC INEQUALITIES; EASTERN-EUROPE; PUBLIC-HEALTH; GLOBAL BURDEN; POLICY-MAKING; CHILD INJURY; SOCIAL-CLASS; MORTALITY; RUSSIA	Injuries cause 9% of deaths and 14% of ill health in the WHO European Region. This problem is neglected; injuries are often seen as part of everyday life. However, although western Europe has good safety levels, death and disability from injury are rising in eastern Europe. People in low-to-middle-income countries in the Region are 3.6 times more likely to die from injuries than those in high-income countries. Economic and political change have led to unemployment, income inequalities, increased traffic, reduced restrictions on alcohol, and loss of social support. Risks such as movement of vulnerable populations and transfer of lifestyles and products between countries also need attention. In many countries, the public-health response has been inadequate, yet the cost is devastating to individuals and health-service budgets. More than half a million lives could be saved annually in the Region if recent knowledge could be used to prevent injuries and thus redress social injustice in this area.	WHO European Ctr Environm & Hlth, Special Programme Hlth & Environm, WHO Reg Off Europe, Accid Transport & Hlth, I-00187 Rome, Italy; WHO Reg Off Europe, Special Programme Hlth & Environm, Copenhagen, Denmark; WHO Reg Off Europe, Violence Prevent, Copenhagen, Denmark	World Health Organization; World Health Organization	Sethi, D (corresponding author), WHO European Ctr Environm & Hlth, Special Programme Hlth & Environm, WHO Reg Off Europe, Accid Transport & Hlth, I-00187 Rome, Italy.	din@ecr.euro.who.int		Racioppi, Francesca/0000-0002-7287-9603				*AD HOC COMM, 1996, AD HOC COMM HLTH RES; Andreev EM, 2003, INT J EPIDEMIOL, V32, P437, DOI 10.1093/ije/dyg085; Bauer Robert, 2005, Int J Inj Contr Saf Promot, V12, P57, DOI 10.1080/15660970412331289715; Bobak M, 1999, ANN EPIDEMIOL, V9, P335; Boland M, 2005, INJURY PREV, V11, P38, DOI 10.1136/ip.2004.005371; Breen J, 2004, BRIT MED J, V328, P888, DOI 10.1136/bmj.328.7444.888; Chenet L, 2001, INT J EPIDEMIOL, V30, P743, DOI 10.1093/ije/30.4.743; Chisholm D, 2004, J STUD ALCOHOL, V65, P782, DOI 10.15288/jsa.2004.65.782; Choi BCK, 2005, J EPIDEMIOL COMMUN H, V59, P632, DOI 10.1136/jech.2004.031765; Coker RJ, 2004, LANCET, V363, P1389, DOI 10.1016/S0140-6736(04)16053-4; Cubbin C, 2002, ANNU REV PUBL HEALTH, V23, P349, DOI 10.1146/annurev.publhealth.23.100901.140548; *DEP TRANSP, 2004, BACKGR PARTN DEM PRO; Department of Health, 1999, RED HLTH IN ACT REP; DIMITROV P, 2004, OVERVIEW ENV HLTH EF; *EUR C MIN TRANSP, 2006, ROAD SAF PERF NAT PE; *EUR COMM, 2001, CONS MEMB STAT EL PR; European Commission, 2001, WHIT PAP EUR TRANSP; FOXCROFT DR, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003024; *FRENCH NAT OBS RO, FRANC REC DEV ROAD S; Fustukian S., 2002, HLTH POLICY GLOBALIS, P208; *GOV RUSS FED, FED TARG PROGR ENH R; GUSTAFSSON LH, 1979, PAEDIATRICIAN, V8, P181; HIBBEL B, 2004, 2003 ESPAD REPORT AL; Holder Y., 2001, INJURY SURVEILLANCE; HOWSON CP, 1998, ADLV, V351, P586; Hyder AA, 2003, LANCET, V362, P2034, DOI 10.1016/S0140-6736(03)15145-8; JENKINS R, 2005, BMJ-BRIT MED J, V34, P1203; KOUPILOVA I, 2002, 29 EUR ENV AG, P130; Krug EG, 2000, AM J PUBLIC HEALTH, V90, P523, DOI 10.2105/AJPH.90.4.523; LAFLAMME L, 1998, SOCIAL INEQUALITY IN; Leon DA, 1997, LANCET, V350, P383, DOI 10.1016/S0140-6736(97)03360-6; Macintyre S, 2003, BRIT MED J, V326, P5, DOI 10.1136/bmj.326.7379.5; Mackenbach JP, 2003, INT J EPIDEMIOL, V32, P830, DOI 10.1093/ije/dyg209; MCALLISTER JFO, 2005, TIME            1219; McKee M, 2000, LANCET, V356, P665, DOI 10.1016/S0140-6736(00)02616-7; McKee M, 2000, HEALTH POLICY PLANN, V15, P263, DOI 10.1093/heapol/15.3.263; McKee M, 1999, ALCOHOL ALCOHOLISM, V34, P824, DOI 10.1093/alcalc/34.6.824; McKee M, 2004, BRIT MED J, V329, P1428, DOI 10.1136/bmj.329.7480.1428; Mckee M, 2005, ADDICTION, V100, P1205, DOI 10.1111/j.1360-0443.2005.01162.x; McKee M, 2004, BRIT MED J, V328, P1025, DOI 10.1136/bmj.328.7447.1025; MCKEE M, 2005, INT J EPIDEMIOL, V1093, P1; Men T, 2003, BRIT MED J, V327, P964, DOI 10.1136/bmj.327.7421.964; Miller TR, 2000, MED CARE, V38, P562, DOI 10.1097/00005650-200006000-00003; *MIN HLTH, 2003, MORT POP RUSS FED 20; Mock C, 2005, B WORLD HEALTH ORGAN, V83, P294; MULRHAD N, 2004, GAMBIT C P GDANSK; *NAT CTR INJ PREV, 2000, WORK PREV CONTR INJ; Nemtsov A, 2003, DRUG ALCOHOL DEPEN, V71, P161, DOI 10.1016/S0376-8716(03)00094-2; Nemtsov AV, 1998, ADDICTION, V93, P1501, DOI 10.1046/j.1360-0443.1998.931015016.x; Peden M, 2002, INJURY LEADING CAUSE; Peden M., 2004, WORLD REPORT ROAD TR; Pomerleau J, 2005, ADDICTION, V100, P1647, DOI 10.1111/j.1360-0443.2005.01233.x; Powles JW, 2005, BMC PUBLIC HEALTH, V5, DOI 10.1186/1471-2458-5-116; Pridemore WA, 2002, AM J PUBLIC HEALTH, V92, P1921, DOI 10.2105/AJPH.92.12.1921; Racioppi F., 2004, PREVENTING ROAD TRAF; Rehm J, 2004, COMP QUANTIFICATION, P959; Roberts I, 1996, BRIT MED J, V313, P784; Roberts I, 1997, J EPIDEMIOL COMMUN H, V51, P334, DOI 10.1136/jech.51.3.334; Roberts I, 2004, INJURY PREV, V10, P65, DOI 10.1136/ip.2004.005140; Room R, 2005, ADDICTION, V100, P579, DOI 10.1111/rp10.1017-S1367943003213238; Room R, 2005, LANCET, V365, P519, DOI 10.1016/S0140-6736(05)70276-2; Ross L, 2001, J VIROL METHODS, V96, P1, DOI 10.1016/S0166-0934(00)00275-5; SETHI D, 1999, HLTH MORTALITY ISSUE, P412; SETHI D, IN PRESS INJURIES VI; Shkolnikov V, 2001, LANCET, V357, P917, DOI 10.1016/S0140-6736(00)04212-4; Shkolnikov VM, 1998, SOC SCI MED, V47, P357, DOI 10.1016/S0277-9536(98)00096-3; *SURESTART, ACC INJ; *TEACH VIP, 2005, US MAN; Towner Elizabeth, 2005, Int J Inj Contr Saf Promot, V12, P79, DOI 10.1080/15660970500073682; *UN, 2004, 58289 UN; Walberg P, 1998, BRIT MED J, V317, P312, DOI 10.1136/bmj.317.7154.312; Walby S., 2004, COST DOMESTIC VIOLEN; Watt K, 2004, ADDICTION, V99, P1262, DOI 10.1111/j.1360-0443.2004.00823.x; Watts C, 2002, LANCET, V359, P1232, DOI 10.1016/S0140-6736(02)08221-1; *WHO, 2005, MORT 67 CAUS DEATH A; *WHO, 2003, WHA5624 WHO; WHO, 2004, WHA5710 WHO; *WHO, 2005, STAT INF SYST WHOSIS; *WHO, GBD EST; WHO, 2000, EUR ALC ACT PLAN 200, piii; *WHO EUR MIN C MEN, MENT HLTH ACT PLAN E; *WHO REG COMM, 2005, EURRC5510 WHO REG CO; *WHO REG COMM EUR, 2005, EURRC55R9 WHO REG CO; Wilkinson RG, 2003, SOCIAL DETERMINANTS; *WORLD BANK, 2002, TRANS 1 10 YEARS AN; World Bank, 2005, DYING TOO YOUNG ADDR; *WORLD BANK, 2002, COUNTR CLASS CLASS E; World Health Organization, 2002, WORLD REPORT VIOLENC; World Health Organization, 1996, WHA4925 WHO; ZWI A, 2002, POVERTY INEQUALITY H, P263	90	49	52	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 23	2006	368	9554					2243	2250		10.1016/S0140-6736(06)68895-8	http://dx.doi.org/10.1016/S0140-6736(06)68895-8			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	120HY	17189036				2022-12-28	WOS:000243076800032
J	McManus, P; Iheanacho, I				McManus, Paul; Iheanacho, Ike			Don't use minocycline as first line oral antibiotic in acne	BRITISH MEDICAL JOURNAL			English	Article									Drug & Therapeut Bulletin, London WC1H 9JR, England		McManus, P (corresponding author), Drug & Therapeut Bulletin, BMA House, London WC1H 9JR, England.	PMcManus@bmjgroup.com							0	15	15	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JAN 20	2007	334	7585					154	154		10.1136/bmj.39048.540394.BE	http://dx.doi.org/10.1136/bmj.39048.540394.BE			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	130LP	17235098	Green Published			2022-12-28	WOS:000243801400038
J	't Hoen, EFM; Dukes, MNG				't Hoen, Ellen F. M.; Dukes, M. N. Graham			Compensation for diethylstilbestrol injury	LANCET			English	Editorial Material									Univ Amsterdam, Amsterdam Sch Social Sci Res, NL-1012 CX Amsterdam, Netherlands; Univ Oslo, N-0316 Oslo, Norway	University of Amsterdam; University of Oslo	't Hoen, EFM (corresponding author), Univ Amsterdam, Amsterdam Sch Social Sci Res, NL-1012 CX Amsterdam, Netherlands.	ellen.t.hoen@orange.fr		't Hoen, Ellen/0000-0003-4477-6866				BUITENDIJK S, 1984, 13 EUR S CLIN PHARM; *DES, 2005, REP RUL GOV COMP INJ; DIECKMANN WJ, 1953, AM J OBSTET GYNECOL, V66, P1062; Dodds EC, 1938, NATURE, V141, P247, DOI 10.1038/141247b0; Dukes M. N. G., 2005, LAW ETHICS PHARM IND; *GRANT CHEM CO INC, 1957, AM J OBSTET GYNECOL; Hatch EE, 2006, AM J EPIDEMIOL, V164, P682, DOI 10.1093/aje/kwj257; Palmer JR, 2006, CANCER EPIDEM BIOMAR, V15, P1509, DOI 10.1158/1055-9965.EPI-06-0109; SMITH OW, 1948, AM J OBSTET GYNECOL, V56, P821; *US NCI, DES RES UPD 1999 CUR	10	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 20	2007	369	9557					173	174		10.1016/S0140-6736(07)60087-7	http://dx.doi.org/10.1016/S0140-6736(07)60087-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128XG	17240270				2022-12-28	WOS:000243692400009
J	DeVries, GA; Brunnbauer, M; Hu, Y; Jackson, AM; Long, B; Neltner, BT; Uzun, O; Wunsch, BH; Stellacci, F				DeVries, Gretchen A.; Brunnbauer, Markus; Hu, Ying; Jackson, Alicia M.; Long, Brenda; Neltner, Brian T.; Uzun, Oktay; Wunsch, Benjamin H.; Stellacci, Francesco			Divalent metal nanoparticles	SCIENCE			English	Article							SELF-ASSEMBLED MONOLAYERS; GOLD NANOPARTICLES; DNA; DYNAMICS; FUNCTIONALIZATION	Nanoparticles can be used as the building blocks for materials such as supracrystals or ionic liquids. However, they lack the ability to bond along specific directions as atoms and molecules do. We report a simple method to place target molecules specifically at two diametrically opposed positions in the molecular coating of metal nanoparticles. The approach is based on the functionalization of the polar singularities that must form when a curved surface is coated with ordered monolayers, such as a phase-separated mixture of ligands. The molecules placed at these polar defects have been used as chemical handles to form nanoparticle chains that in turn can generate self-standing films.	MIT, Dept Mat Sci & Engn, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Stellacci, F (corresponding author), MIT, Dept Mat Sci & Engn, Cambridge, MA 02139 USA.	frstella@mit.edu	Stellacci, Francesco/B-1990-2008; Uzun, Oktay/AAI-7018-2021; Hu, Ying/F-3949-2010	Stellacci, Francesco/0000-0003-4635-6080; Neltner, Brian/0000-0002-3770-5288				Bachand GD, 2004, NANO LETT, V4, P817, DOI 10.1021/nl049811h; Bourlinos AB, 2006, EUR PHYS J E, V20, P109, DOI 10.1140/epje/i2006-10007-3; Donkers RL, 2004, LANGMUIR, V20, P4703, DOI 10.1021/la0497494; EISENBERG M, 1979, AM MATH MON, V86, P572; Fu AH, 2004, J AM CHEM SOC, V126, P10832, DOI 10.1021/ja046747x; Hostetler MJ, 1999, LANGMUIR, V15, P3782, DOI 10.1021/la981598f; Huo FW, 2006, ADV MATER, V18, P2304, DOI 10.1002/adma.200601178; Jackson AM, 2006, J AM CHEM SOC, V128, P11135, DOI 10.1021/ja061545h; Jackson AM, 2004, NAT MATER, V3, P330, DOI 10.1038/nmat1116; Katz E, 2004, ANGEW CHEM INT EDIT, V43, P6042, DOI 10.1002/anie.200400651; Love JC, 2005, CHEM REV, V105, P1103, DOI 10.1021/cr0300789; Luedtke WD, 1998, J PHYS CHEM B, V102, P6566, DOI 10.1021/jp981745i; Maier SA, 2001, ADV MATER, V13, P1501, DOI 10.1002/1521-4095(200110)13:19<1501::AID-ADMA1501>3.0.CO;2-Z; Nelson DR, 2002, NANO LETT, V2, P1125, DOI [10.1021/nl0202096, 10.1021/n10202096]; Novak JP, 2000, J AM CHEM SOC, V122, P12029, DOI 10.1021/ja003129h; Poincar?, 1885, J MATH PURE APPL, V4, P167; Praharaj S, 2004, LANGMUIR, V20, P9889, DOI 10.1021/la0486281; Rosi NL, 2004, ANGEW CHEM INT EDIT, V43, P5500, DOI 10.1002/anie.200460905; Schreiber F, 2000, PROG SURF SCI, V65, P151, DOI 10.1016/S0079-6816(00)00024-1; Shevchenko EV, 2006, NATURE, V439, P55, DOI 10.1038/nature04414; Smith RK, 2001, J PHYS CHEM B, V105, P1119, DOI 10.1021/jp0035129; Song Y, 2002, J AM CHEM SOC, V124, P7096, DOI 10.1021/ja0174985; Sung KM, 2004, J AM CHEM SOC, V126, P5064, DOI 10.1021/ja049578p; Tang ZY, 2005, ADV MATER, V17, P951, DOI 10.1002/adma.200401593; Thomas KG, 2004, J PHYS CHEM B, V108, P13066, DOI 10.1021/jp049167v; Wang GL, 2004, NANO LETT, V4, P95, DOI 10.1021/nl034922m; Warner MG, 2003, NAT MATER, V2, P272, DOI 10.1038/nmat853; Worden JG, 2004, CHEM COMMUN, P518, DOI 10.1039/b312819a	28	538	543	2	267	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 19	2007	315	5810					358	361		10.1126/science.1133162	http://dx.doi.org/10.1126/science.1133162			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126SI	17234943	Green Submitted, Green Published			2022-12-28	WOS:000243535400036
J	Parton, W; Silver, WL; Burke, IC; Grassens, L; Harmon, ME; Currie, WS; King, JY; Adair, EC; Brandt, LA; Hart, SC; Fasth, B				Parton, William; Silver, Whendee L.; Burke, Ingrid C.; Grassens, Leo; Harmon, Mark E.; Currie, William S.; King, Jennifer Y.; Adair, E. Carol; Brandt, Leslie A.; Hart, Stephen C.; Fasth, Becky			Global-scale similarities in nitrogen release patterns during long-term decomposition	SCIENCE			English	Article							FINE-ROOT DECOMPOSITION; ULTRAVIOLET-B RADIATION; LITTER DECOMPOSITION; ORGANIC-MATTER; FOREST SOILS; LEAF-LITTER; MASS-LOSS; DYNAMICS; ECOSYSTEM; CLIMATE	Litter decomposition provides the primary source of mineral nitrogen (N) for biological activity in most terrestrial ecosystems. A 10-year decomposition experiment in 21 sites from seven biomes found that net N release from leaf litter is dominantly driven by the initial tissue N concentration and mass remaining regardless of climate, edaphic conditions, or biota. Arid grasslands exposed to high ultraviolet radiation were an exception, where net N release was insensitive to initial N. Roots released N linearly with decomposition and exhibited little net N immobilization. We suggest that fundamental constraints on decomposer physiologies lead to predictable global-scale patterns in net N release during decomposition.	Colorado State Univ, Nat Resource Ecol Lab, Ft Collins, CO 80523 USA; Univ Calif Berkeley, Dept Environm Sci Policy & Management, Ecosyst Sci Div, Berkeley, CA 94720 USA; Colorado State Univ, Dept Forest Rangeland & Watershed Stewardship, Ft Collins, CO 80523 USA; Colorado State Univ, Grad Degree Program Ecol, Ft Collins, CO 80523 USA; LSI Log Inc, Loveland, CO 80227 USA; Oregon State Univ, Dept Forest Sci, Corvallis, OR 97331 USA; Univ Michigan, Sch Nat Resources & Environm, Ann Arbor, MI 48103 USA; Univ Minnesota, Dept Soil Water & Climate, St Paul, MN 55108 USA; Univ Minnesota, Dept Ecol Evolut & Behav, St Paul, MN 55108 USA; No Arizona Univ, Sch Forestry, Flagstaff, AZ 86011 USA; No Arizona Univ, Merriam Powell Ctr Environm Res, Flagstaff, AZ 86011 USA	Colorado State University; University of California System; University of California Berkeley; Colorado State University; Colorado State University; Oregon State University; University of Michigan System; University of Michigan; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Northern Arizona University; Northern Arizona University	Parton, W (corresponding author), Colorado State Univ, Nat Resource Ecol Lab, 200 W Lake,Campus Mail 1499, Ft Collins, CO 80523 USA.		Burke, Ingrid/A-1420-2009; King, Jennifer Y./I-5986-2015; Silver, Whendee L./H-1118-2012	Burke, Ingrid/0000-0003-4717-6399; King, Jennifer Y./0000-0003-3433-5952; Silver, Whendee L./0000-0003-0372-8745; Adair, E. Carol/0000-0002-8567-9045; Fasth, Becky/0000-0001-5006-6727				ABER JD, 1985, OECOLOGIA, V66, P317, DOI 10.1007/BF00378292; ABER JD, 1990, CAN J BOT, V68, P2201, DOI 10.1139/b90-287; ABER JD, 1982, CAN J BOT, V60, P2263, DOI 10.1139/b82-277; Aerts R, 1997, OIKOS, V79, P439, DOI 10.2307/3546886; Austin AT, 2006, NATURE, V442, P555, DOI 10.1038/nature05038; Barrett JE, 2002, J VEG SCI, V13, P383, DOI 10.1111/j.1654-1103.2002.tb02062.x; BEARE MH, 1992, ECOL MONOGR, V62, P569, DOI 10.2307/2937317; Berg B, 2000, FOREST ECOL MANAG, V133, P13, DOI 10.1016/S0378-1127(99)00294-7; BERG B, 1989, CAN J BOT, V67, P1148, DOI 10.1139/b89-150; Cadisch G., 1997, DRIVEN NATURE PLANT; Chen H, 2002, CAN J FOREST RES, V32, P320, DOI 10.1139/X01-202; Currie WS, 2003, GLOBAL CHANGE BIOL, V9, P919, DOI 10.1046/j.1365-2486.2003.00637.x; Dornbush ME, 2002, ECOLOGY, V83, P2985, DOI 10.1890/0012-9658(2002)083[2985:QFRDAA]2.0.CO;2; Frey SD, 2000, SOIL BIOL BIOCHEM, V32, P689, DOI 10.1016/S0038-0717(99)00205-9; Frey SD, 2004, FOREST ECOL MANAG, V196, P159, DOI 10.1016/j.foreco.2004.03.018; Gholz HL, 2000, GLOBAL CHANGE BIOL, V6, P751, DOI 10.1046/j.1365-2486.2000.00349.x; Hobbie SE, 2000, ECOLOGY, V81, P1867, DOI 10.1890/0012-9658(2000)081[1867:NLODIH]2.0.CO;2; *LIDET, 1995, PUBLICATION US LONG, V19; LOUSIER JD, 1979, CAN J FOREST RES, V9, P449, DOI 10.1139/x79-073; Moody SA, 2001, PLANT ECOL, V154, P27, DOI 10.1023/A:1012965610170; MOORE B, 1994, AMBIO, V23, P4; Moore TR, 2006, ECOSYSTEMS, V9, P46, DOI 10.1007/s10021-004-0026-x; Moorhead DL, 1999, GLOBAL BIOGEOCHEM CY, V13, P575, DOI 10.1029/1998GB900014; Pancotto VA, 2005, GLOBAL CHANGE BIOL, V11, P1982, DOI 10.1111/j.1365-2486.2005.01027.x; Parton W.J., 1994, SSSA SPECIAL PUBLICA, V39, P147, DOI DOI 10.2136/SSSASPECPUB39.C9; Post WM, 1996, CLIMATIC CHANGE, V34, P253, DOI 10.1007/BF00224636; Prentice IC, 2001, CLIMATE CHANGE 2001: THE SCIENTIFIC BASIS, P183; Richards EH, 1931, BIOCHEM J, V25, P1769, DOI 10.1042/bj0251769; Rozema J, 1997, PLANT ECOL, V128, P284; SCHIMEL DS, 1991, ECOLOGY, V72, P672, DOI 10.2307/2937207; SEASTEDT TR, 1992, CAN J BOT, V70, P384, DOI 10.1139/b92-052; Silver WL, 2001, OECOLOGIA, V129, P407, DOI 10.1007/s004420100740; Silver WL, 2005, GLOBAL CHANGE BIOL, V11, P290, DOI 10.1111/j.1365-2486.2005.00903.x; SILVER WL, 1993, J ECOL, V81, P729, DOI 10.2307/2261670; Verhoef HA, 2000, BIOL FERT SOILS, V31, P366, DOI 10.1007/s003749900181; VITOUSEK PM, 1991, BIOGEOCHEMISTRY, V13, P87	36	817	941	39	573	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 19	2007	315	5810					361	364		10.1126/science.1134853	http://dx.doi.org/10.1126/science.1134853			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126SI	17234944				2022-12-28	WOS:000243535400037
J	Liu, R; Wang, XH; Chen, GY; Dalerba, P; Gurney, A; Hoey, T; Sherlock, G; Lewicki, J; Shedden, K; Clarke, MF				Liu, Rui; Wang, Xinhao; Chen, Grace Y.; Dalerba, Piero; Gurney, Austin; Hoey, Timothy; Sherlock, Gavin; Lewicki, John; Shedden, Kerby; Clarke, Michael F.			The prognostic role of a gene signature from tumorigenic breast-cancer cells.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EXPRESSION SIGNATURE; IDENTIFICATION; METASTASIS; SURVIVAL; PATTERNS; THERAPY	BACKGROUND: Breast cancers contain a minority population of cancer cells characterized by CD44 expression but low or undetectable levels of CD24 (CD44+CD24-/low) that have higher tumorigenic capacity than other subtypes of cancer cells. METHODS: We compared the gene-expression profile of CD44+CD24-/low tumorigenic breast-cancer cells with that of normal breast epithelium. Differentially expressed genes were used to generate a 186-gene ``invasiveness'' gene signature (IGS), which was evaluated for its association with overall survival and metastasis-free survival in patients with breast cancer or other types of cancer. RESULTS: There was a significant association between the IGS and both overall and metastasis-free survival (P<0.001, for both) in patients with breast cancer, which was independent of established clinical and pathological variables. When combined with the prognostic criteria of the National Institutes of Health, the IGS was used to stratify patients with high-risk early breast cancer into prognostic categories (good or poor); among patients with a good prognosis, the 10-year rate of metastasis-free survival was 81%, and among those with a poor prognosis, it was 57%. The IGS was also associated with the prognosis in medulloblastoma (P=0.004), lung cancer (P=0.03), and prostate cancer (P=0.01). The prognostic power of the IGS was increased when combined with the wound-response (WR) signature. CONCLUSIONS: The IGS is strongly associated with metastasis-free survival and overall survival for four different types of tumors. This genetic signature of tumorigenic breast-cancer cells was even more strongly associated with clinical outcomes when combined with the WR signature in breast cancer.	Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Stat, Ann Arbor, MI 48109 USA; Oncomed Pharmaceut, Mountain View, CA USA; Stanford Inst Stem Cell Biol & Regenerat Med, Palo Alto, CA USA; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Stanford University	Liu, R (corresponding author), Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA.		Dalerba, Piero/E-2543-2018; Sherlock, Gavin J/B-1831-2009; Sherlock, Gavin J/E-9110-2012	Dalerba, Piero/0000-0002-8815-4981; Sherlock, Gavin/0000-0002-1692-4983	NCI NIH HHS [CA126524, CA104987, T32 CA009357] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U54CA126524, T32CA009357, R01CA104987] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P6890, DOI 10.1073/pnas.1131491100; Chang HY, 2005, P NATL ACAD SCI USA, V102, P3738, DOI 10.1073/pnas.0409462102; Chang HY, 2004, PLOS BIOL, V2, P206, DOI 10.1371/journal.pbio.0020007; de Hoon MJL, 2004, BIOINFORMATICS, V20, P1453, DOI 10.1093/bioinformatics/bth078; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fan C, 2006, NEW ENGL J MED, V355, P560, DOI 10.1056/NEJMoa052933; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412; Goldhirsch A, 2005, ANN ONCOL, V16, P1569, DOI 10.1093/annonc/mdi326; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1	18	773	839	0	39	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 18	2007	356	3					217	226		10.1056/NEJMoa063994	http://dx.doi.org/10.1056/NEJMoa063994			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	126BV	17229949	Bronze			2022-12-28	WOS:000243488100004
J	Phillips, AN; Gazzard, BG; Clumeck, N; Losso, MH; Lundgren, JD				Phillips, Andrew N.; Gazzard, Brian G.; Clumeck, Nathan; Losso, Marcelo H.; Lundgren, Jens D.			When should antiretroviral therapy for HIV be started?	BRITISH MEDICAL JOURNAL			English	Editorial Material							VIROLOGICAL RESPONSE; PROTEASE INHIBITOR; CLINICAL-PRACTICE; INFECTION; RISK; COUNTS; ADULTS; TIME		UCL Royal Free & Univ Coll Med Sch, Dept Primary Care & Populat Sci, London NW3 2PF, England; Chelsea & Westminster Hosp, London, England; Hosp St Pierre, Dept Infect Dis, Brussels, Belgium; Hosp JM Ramos Mejia, Serv Inmunocomprometidos, Buenos Aires, DF, Argentina; Hvidovre Univ Hosp, Copenhagen HIV Programme, Copenhagen, Denmark	University of London; University College London; UCL Medical School; Imperial College London; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Hospital Ramos Mejia; University of Buenos Aires; University of Copenhagen	Phillips, AN (corresponding author), UCL Royal Free & Univ Coll Med Sch, Dept Primary Care & Populat Sci, London NW3 2PF, England.	a.phillips@pcps.ucl.ac.uk	Lundgren, Jens/AAE-6876-2019; Phillips, Andrew N/B-4427-2008	Phillips, Andrew N/0000-0003-2384-4807; Lundgren, Jens/0000-0001-8901-7850				Bannister WP, 2006, JAIDS-J ACQ IMM DEF, V42, P229, DOI 10.1097/01.qai.0000214815.95786.31; Beral V, 2004, AIDS, V18, P51, DOI [10.1097/00002030-200401020-00006, 10.1097/01.aids.0000096908.73209.5d]; Blackham J, 2005, AIDS, V19, P487; BURMAN W, 2006, 16 INT AIDS C; Burman WJ, 1998, JAMA-J AM MED ASSOC, V280, P93, DOI 10.1001/jama.280.1.93; Carr A, 2000, AIDS, V14, pF25, DOI 10.1097/00002030-200002180-00001; Carr A, 1998, NEW ENGL J MED, V339, P1296, DOI 10.1056/NEJM199810293391806; Egger M, 2002, LANCET, V360, P119, DOI 10.1016/S0140-6736(02)09411-4; El-Sadr WM, 2006, NEW ENGL J MED, V355, P2283, DOI 10.1056/NEJMoa062360; Fellay J, 2001, LANCET, V358, P1322, DOI 10.1016/S0140-6736(01)06413-3; Friis-Moller N, 2003, NEW ENGL J MED, V349, P1993, DOI 10.1056/NEJMoa030218; FRIISMOLLER N, 2006, 13 C RETR OPP INF; Gazzard B, 2005, HIV MED, V6, P1, DOI 10.1111/j.1468-1293.2005.0311b.x; GRINSZTEJN B, 2006, 13 C RETR OPP INF DE; Holmberg SD, 2004, CLIN INFECT DIS, V39, P1699, DOI 10.1086/425743; Lampe FC, 2006, ARCH INTERN MED, V166, P521, DOI 10.1001/archinte.166.5.521; Maini MK, 1996, GENITOURIN MED, V72, P27; Moore RD, 2005, JAIDS-J ACQ IMM DEF, V39, P195; Nolan David, 2005, Sex Health, V2, P153, DOI 10.1071/SH04058; *PAN CLIN PRACT TR, 2006, GUID US ANT AG HIV 1; Phillips AN, 2003, AIDS, V17, P1863, DOI 10.1097/00002030-200309050-00004; Podlekareva D, 2006, J INFECT DIS, V194, P633, DOI 10.1086/506366; Walker BD, 1998, JAMA-J AM MED ASSOC, V280, P91, DOI 10.1001/jama.280.1.91; WEBER R, 2005, 12 C RETR OPP INF	24	58	59	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JAN 13	2007	334	7584					76	78		10.1136/bmj.39064.406389.94	http://dx.doi.org/10.1136/bmj.39064.406389.94			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	127DZ	17218713	Green Published			2022-12-28	WOS:000243566800029
J	Ayala, R; Shu, TZ; Tsai, LH				Ayala, Ramses; Shu, Tianzhi; Tsai, Li-Huei			Trekking across the brain: The journey of neuronal migration	CELL			English	Review							DOUBLECORTIN-LIKE-KINASE; CYTOPLASMIC DYNEIN; RADIAL MIGRATION; CELL-MIGRATION; TYROSINE PHOSPHORYLATION; LISSENCEPHALY GENE; DIRECTIONAL GUIDANCE; ADULT NEUROGENESIS; P35/CDK5 KINASE; REELIN	The correct positioning of neurons during development -achieved through directed migration-is the basis for proper brain function. Several decades of research have yielded a comprehensive map illustrating the temporal and spatial events underlying neurogenesis and neuronal migration during development. The discovery of distinct migration modes and pathways has been accompanied by the identification of a large interwoven molecular network that transmits extracellular signals into the cell. Moreover, recent work has shed new light on how the cytoskeleton is regulated and coordinated at the molecular and cellular level to execute neuronal migration.	MIT, Howard Hughes Med Inst, Picower Inst Learning & Memory, Dept Brain & Cognit Sci,RIKEN,Neurosci Res Ctr, Cambridge, MA 02139 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Northwell Health; RIKEN	Tsai, LH (corresponding author), MIT, Howard Hughes Med Inst, Picower Inst Learning & Memory, Dept Brain & Cognit Sci,RIKEN,Neurosci Res Ctr, 77 Massachusetts Ave,Bldg 46,Room 4235A, Cambridge, MA 02139 USA.	lhtsai@mit.edu						Alberti S, 2005, P NATL ACAD SCI USA, V102, P6148, DOI 10.1073/pnas.0501191102; Alcantara S, 2000, DEVELOPMENT, V127, P1359; Arnaud L, 2003, CURR BIOL, V13, P9, DOI 10.1016/S0960-9822(02)01397-0; Assadi AH, 2003, NAT GENET, V35, P270, DOI 10.1038/ng1257; AVILA J, 1994, INT J DEV BIOL, V38, P13; Bagri A, 2002, ADV EXP MED BIOL, V515, P13; Bai JL, 2003, NAT NEUROSCI, V6, P1277, DOI 10.1038/nn1153; Banerjee M, 2002, CURR BIOL, V12, P1233, DOI 10.1016/S0960-9822(02)00956-9; Beffert U, 2004, J NEUROSCI, V24, P1897, DOI 10.1523/JNEUROSCI.4084-03.2004; Behar TN, 2001, CEREB CORTEX, V11, P744, DOI 10.1093/cercor/11.8.744; Behar TN, 1997, EUR J NEUROSCI, V9, P2561, DOI 10.1111/j.1460-9568.1997.tb01685.x; Bellion A, 2005, J NEUROSCI, V25, P5691, DOI 10.1523/JNEUROSCI.1030-05.2005; Bock HH, 2003, J BIOL CHEM, V278, P38772, DOI 10.1074/jbc.M306416200; Bock HH, 2003, CURR BIOL, V13, P18, DOI 10.1016/S0960-9822(02)01403-3; Borghesani PR, 2002, DEVELOPMENT, V129, P1435; Cajal S.R., 1911, HISTOLOGY NERVOUS SY; Caspi M, 2000, HUM MOL GENET, V9, P2205, DOI 10.1093/oxfordjournals.hmg.a018911; CAVINESS VS, 1995, BRAIN DEV-JPN, V17, P159, DOI 10.1016/0387-7604(95)00029-B; Conover JC, 2000, NAT NEUROSCI, V3, P1091, DOI 10.1038/80606; de Rouvroit CL, 2001, MECH DEVELOP, V105, P47, DOI 10.1016/S0925-4773(01)00396-3; Dehmelt L, 2004, J NEUROBIOL, V58, P18, DOI 10.1002/neu.10284; Del Rio JA, 2004, CURR BIOL, V14, P840, DOI 10.1016/j.cub.2004.04.046; Deuel TAS, 2006, NEURON, V49, P41, DOI 10.1016/j.neuron.2005.10.038; Dhavan R, 2001, NAT REV MOL CELL BIO, V2, P749, DOI 10.1038/35096019; Doetsch F, 2005, CURR OPIN NEUROBIOL, V15, P121, DOI 10.1016/j.conb.2005.01.018; Dulabon L, 2000, NEURON, V27, P33, DOI 10.1016/S0896-6273(00)00007-6; Faulkner NE, 2000, NAT CELL BIOL, V2, P784, DOI 10.1038/35041020; Feng YY, 2004, NEURON, V44, P279, DOI 10.1016/j.neuron.2004.09.023; Forster E, 2002, P NATL ACAD SCI USA, V99, P13178, DOI 10.1073/pnas.202035899; Fox JW, 1998, NEURON, V21, P1315, DOI 10.1016/S0896-6273(00)80651-0; Gambello MJ, 2003, J NEUROSCI, V23, P1719; Ge WH, 2006, P NATL ACAD SCI USA, V103, P1319, DOI 10.1073/pnas.0510419103; Gheusi C, 2000, P NATL ACAD SCI USA, V97, P1823, DOI 10.1073/pnas.97.4.1823; Gonzalez-Billault C, 2005, CEREB CORTEX, V15, P1134, DOI 10.1093/cercor/bhh213; Gressens P, 2005, J CHILD NEUROL, V20, P968, DOI 10.1177/08830738050200120701; Guo J, 2006, MOL BIOL CELL, V17, P680, DOI 10.1091/mbc.E05-04-0360; Gupta A, 2002, NAT REV GENET, V3, P342, DOI 10.1038/nrg799; Gupta A, 2003, NAT NEUROSCI, V6, P1284, DOI 10.1038/nn1151; Handler M, 2000, DEVELOPMENT, V127, P2593; Hartfuss E, 2003, DEVELOPMENT, V130, P4597, DOI 10.1242/dev.00654; Hatten ME, 1999, ANNU REV NEUROSCI, V22, P511, DOI 10.1146/annurev.neuro.22.1.511; Hiesberger T, 1999, NEURON, V24, P481, DOI 10.1016/S0896-6273(00)80861-2; Hirai S, 2002, DEVELOPMENT, V129, P4483; Hirotsune S, 1998, NAT GENET, V19, P333, DOI 10.1038/1221; Hong SE, 2000, NAT GENET, V26, P93, DOI 10.1038/79246; Howell BW, 2000, CURR BIOL, V10, P877, DOI 10.1016/S0960-9822(00)00608-4; Hu HY, 2001, NAT NEUROSCI, V4, P695, DOI 10.1038/89482; HunterSchaedle KE, 1997, J NEUROBIOL, V33, P459, DOI 10.1002/(SICI)1097-4695(199710)33:4<459::AID-NEU9>3.0.CO;2-9; Kamiya A, 2005, NAT CELL BIOL, V7, P1167, DOI 10.1038/ncb1328; Kato G, 1999, J BIOCHEM-TOKYO, V126, P957, DOI 10.1093/oxfordjournals.jbchem.a022540; Kawauchi T, 2005, BIOCHEM BIOPH RES CO, V331, P50, DOI 10.1016/j.bbrc.2005.03.132; Kawauchi T, 2006, NAT CELL BIOL, V8, P17, DOI 10.1038/ncb1338; Keshvara L, 2002, J NEUROSCI, V22, P4869, DOI 10.1523/JNEUROSCI.22-12-04869.2002; Kholmanskikh SS, 2006, NAT NEUROSCI, V9, P50, DOI 10.1038/nn1619; Kholmanskikh SS, 2003, J NEUROSCI, V23, P8673; Koizumi H, 2006, NEURON, V49, P55, DOI 10.1016/j.neuron.2005.10.040; KOMURO H, 1993, SCIENCE, V260, P95, DOI 10.1126/science.8096653; Konno D, 2005, J BIOL CHEM, V280, P5082, DOI 10.1074/jbc.M408251200; Krause M, 2003, ANNU REV CELL DEV BI, V19, P541, DOI 10.1146/annurev.cellbio.19.050103.103356; Kriegstein AR, 2004, TRENDS NEUROSCI, V27, P392, DOI 10.1016/j.tins.2004.05.001; Kruger RR, 2005, NAT REV MOL CELL BIO, V6, P789, DOI 10.1038/nrm1740; Kuo G, 2005, J NEUROSCI, V25, P8578, DOI 10.1523/JNEUROSCI.1656-05.2005; Leuner B, 2006, HIPPOCAMPUS, V16, P216, DOI 10.1002/hipo.20153; Li J, 2005, NAT CELL BIOL, V7, P686, DOI 10.1038/ncb1273; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; Ma XF, 2004, MOL BIOL CELL, V15, P2568, DOI 10.1091/mbc.E03-11-0836; Magdaleno S, 2002, NEURON, V33, P573, DOI 10.1016/S0896-6273(02)00582-2; Marin O, 2003, ANNU REV NEUROSCI, V26, P441, DOI 10.1146/annurev.neuro.26.041002.131058; Marin O, 2003, DEVELOPMENT, V130, P1889, DOI 10.1242/dev.00417; Marin O, 2001, NAT REV NEUROSCI, V2, P780, DOI 10.1038/35097509; Martinez-Lopez MJ, 2005, MOL CELL NEUROSCI, V28, P599, DOI 10.1016/j.mcn.2004.09.016; Mattar P, 2004, DEV BIOL, V273, P373, DOI 10.1016/j.ydbio.2004.06.013; Mesngon MT, 2006, J NEUROSCI, V26, P2132, DOI 10.1523/JNEUROSCI.5095-05.2006; Millar JK, 2000, HUM MOL GENET, V9, P1415, DOI 10.1093/hmg/9.9.1415; Ming GL, 2005, ANNU REV NEUROSCI, V28, P223, DOI 10.1146/annurev.neuro.28.051804.101459; Moores CA, 2004, MOL CELL, V14, P833, DOI 10.1016/j.molcel.2004.06.009; Morris NR, 1998, TRENDS CELL BIOL, V8, P467, DOI 10.1016/S0962-8924(98)01389-0; Nadarajah B, 2001, NAT NEUROSCI, V4, P143, DOI 10.1038/83967; Nagano T, 2004, J NEUROSCI, V24, P9648, DOI 10.1523/JNEUROSCI.2363-04.2004; Nagano T, 2002, NAT CELL BIOL, V4, P495, DOI 10.1038/ncb808; Nikolic M, 1998, NATURE, V395, P194, DOI 10.1038/26034; Olson EC, 2006, J NEUROSCI, V26, P1767, DOI 10.1523/JNEUROSCI.3000-05.2006; Ozmen M, 2000, TURKISH J PEDIATR, V42, P210; Paglini G, 1998, J NEUROSCI, V18, P9858; Porteous DJ, 2006, TRENDS MOL MED, V12, P255, DOI 10.1016/j.molmed.2006.04.009; RAKIC P, 1982, NEUROSCI RES PROG B, V20, P429; Rashid T, 2001, J BIOL CHEM, V276, P49043, DOI 10.1074/jbc.M105599200; REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0; Rice DS, 2001, ANNU REV NEUROSCI, V24, P1005, DOI 10.1146/annurev.neuro.24.1.1005; RIVAS RJ, 1995, J NEUROSCI, V15, P981; Sanada K, 2004, NEURON, V42, P197, DOI 10.1016/S0896-6273(04)00222-3; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; Sapir T, 1997, EMBO J, V16, P6977, DOI 10.1093/emboj/16.23.6977; Sasaki S, 2005, MOL CELL BIOL, V25, P7812, DOI 10.1128/MCB.25.17.7812-7827.2005; Schaar BT, 2005, P NATL ACAD SCI USA, V102, P13652, DOI 10.1073/pnas.0506008102; Schaar BT, 2004, NEURON, V41, P203, DOI 10.1016/S0896-6273(03)00843-2; Schaefer AW, 2002, J CELL BIOL, V158, P139, DOI 10.1083/jcb.200203038; Schmid RS, 2005, CEREB CORTEX, V15, P1632, DOI 10.1093/cercor/bhi041; Senzaki K, 1999, CELL, V99, P635, DOI 10.1016/S0092-8674(00)81552-4; Serafini T, 1996, CELL, V87, P1001, DOI 10.1016/S0092-8674(00)81795-X; Shmueli A, 2006, MOL CELL NEUROSCI, V32, P15, DOI 10.1016/j.mcn.2006.01.014; Shu TZ, 2004, NEURON, V44, P263, DOI 10.1016/j.neuron.2004.09.030; Shu TZ, 2006, NEURON, V49, P25, DOI 10.1016/j.neuron.2005.10.039; SIMO S, 2006, CEREB CORTEX; Solecki DJ, 2004, NAT NEUROSCI, V7, P1195, DOI 10.1038/nn1332; Stossel TP, 2001, NAT REV MOL CELL BIO, V2, P138, DOI 10.1038/35052082; Tai CY, 2002, J CELL BIOL, V156, P959, DOI 10.1083/jcb.200109046; Takahashi S, 2003, J BIOL CHEM, V278, P10506, DOI 10.1074/jbc.M211964200; Tanaka T, 2004, NEURON, V41, P215, DOI 10.1016/S0896-6273(03)00852-3; Taylor KR, 2000, J BIOL CHEM, V275, P34442, DOI 10.1074/jbc.M007078200; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Toyo-oka K, 2003, NAT GENET, V34, P274, DOI 10.1038/ng1169; Tsai JW, 2005, J CELL BIOL, V170, P935, DOI 10.1083/jcb.200505166; Tsai LH, 2005, NEURON, V46, P383, DOI 10.1016/j.neuron.2005.04.013; Tsukada M, 2005, J BIOL CHEM, V280, P11361, DOI 10.1074/jbc.M405525200; Tullio AN, 2001, J COMP NEUROL, V433, P62, DOI 10.1002/cne.1125; Uchida Y, 2005, GENES CELLS, V10, P165, DOI 10.1111/j.1365-2443.2005.00827.x; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Ward M, 2003, J NEUROSCI, V23, P5170; Wong K, 2001, CELL, V107, P209, DOI 10.1016/S0092-8674(01)00530-X; Xie ZG, 2003, CELL, V114, P469, DOI 10.1016/S0092-8674(03)00605-6; Yan XM, 2003, MOL CELL BIOL, V23, P1239, DOI 10.1128/MCB.23.4.1239-1250.2003; Yee KT, 1999, NEURON, V24, P607, DOI 10.1016/S0896-6273(00)81116-2; Yoshida A, 2001, DEV CELL, V1, P717, DOI 10.1016/S1534-5807(01)00070-3; Zukerberg LR, 2000, NEURON, V26, P633, DOI 10.1016/S0896-6273(00)81200-3	127	441	456	1	47	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 12	2007	128	1					29	43		10.1016/j.cell.2006.12.021	http://dx.doi.org/10.1016/j.cell.2006.12.021			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	139GN	17218253	Bronze			2022-12-28	WOS:000244420400011
J	Mukhopadhyay, D; Riezman, H				Mukhopadhyay, Debdyuti; Riezman, Howard			Proteasome-independent functions of ubiquitin in endocytosis and signaling	SCIENCE			English	Review							RECEPTOR TYROSINE KINASES; KAPPA-B ACTIVATION; TGF-BETA RECEPTOR; DOWN-REGULATION; POLYUBIQUITIN CHAINS; MEMBRANE-PROTEIN; BINDING PROTEINS; DEGRADATION; LIGASE; MONOUBIQUITINATION	Ubiquitination is a reversible posttranslational modification of cellular proteins, in which a 76-amino acid polypeptide, ubiquitin, is primarily attached to the epsilon-amino group of lysines in target proteins. Ubiquitination is a major player in regulating a broad host of cellular processes, including cell division, differentiation, signal transduction, protein trafficking, and quality control. Aberrations in the ubiquitination system are implicated in pathogenesis of some diseases, certain malignancies, neurodegenerative disorders, and pathologies of the inflammatory immune response. Here, we discuss the proteasome-independent roles of ubiquitination in signaling and endocytosis.	Univ Geneva, Dept Biochem, CH-1211 Geneva, Switzerland	University of Geneva	Riezman, H (corresponding author), Univ Geneva, Dept Biochem, 30 Quai Ernest Ansermet, CH-1211 Geneva, Switzerland.	Howard.Riezman@biochem.unige.ch		Riezman, Howard/0000-0003-4680-9422				Abrami L, 2006, J CELL BIOL, V172, P309, DOI 10.1083/jcb.200507067; Adhikary S, 2005, CELL, V123, P409, DOI 10.1016/j.cell.2005.08.016; Arevalo JC, 2006, NEURON, V50, P549, DOI 10.1016/j.neuron.2006.03.044; Bienko M, 2005, SCIENCE, V310, P1821, DOI 10.1126/science.1120615; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Cadwell K, 2005, SCIENCE, V309, P127, DOI 10.1126/science.1110340; Chen H, 2005, P NATL ACAD SCI USA, V102, P2766, DOI 10.1073/pnas.0409719102; Clague MJ, 2003, TRENDS CELL BIOL, V13, P603, DOI 10.1016/j.tcb.2003.10.002; Daniel JA, 2004, J BIOL CHEM, V279, P1867, DOI 10.1074/jbc.C300494200; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Duncan LM, 2006, EMBO J, V25, P1635, DOI 10.1038/sj.emboj.7601056; Dupre S, 2001, MOL CELL BIOL, V21, P4482, DOI 10.1128/MCB.21.14.4482-4494.2001; Elsasser S, 2005, NAT CELL BIOL, V7, P742, DOI 10.1038/ncb0805-742; Fallon L, 2006, NAT CELL BIOL, V8, P834, DOI 10.1038/ncb1441; Flick K, 2004, NAT CELL BIOL, V6, P634, DOI 10.1038/ncb1143; Flick K, 2006, NAT CELL BIOL, V8, P509, DOI 10.1038/ncb1402; Friedberg EC, 2005, MOL CELL, V18, P499, DOI 10.1016/j.molcel.2005.03.032; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; Geetha T, 2005, MOL CELL, V20, P301, DOI 10.1016/j.molcel.2005.09.014; Gupta-Rossi N, 2004, J CELL BIOL, V166, P73, DOI 10.1083/jcb.200310098; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hicke L, 2005, NAT REV MOL CELL BIO, V6, P610, DOI 10.1038/nrm1701; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hicke L, 2001, CELL, V106, P527, DOI 10.1016/S0092-8674(01)00485-8; Hoeller D, 2006, NAT CELL BIOL, V8, P163, DOI 10.1038/ncb1354; Huang FT, 2006, MOL CELL, V21, P737, DOI 10.1016/j.molcel.2006.02.018; Hurley JH, 2006, ANNU REV BIOPH BIOM, V35, P277, DOI 10.1146/annurev.biophys.35.040405.102126; Itoh T, 2001, SCIENCE, V291, P1047, DOI 10.1126/science.291.5506.1047; Kanayama A, 2004, MOL CELL, V15, P535, DOI 10.1016/j.molcel.2004.08.008; Kannouche PL, 2004, MOL CELL, V14, P491, DOI 10.1016/S1097-2765(04)00259-X; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kishida S, 2005, GENES CELLS, V10, P447, DOI 10.1111/j.1365-2443.2005.00852.x; Komada M, 2005, J BIOCHEM, V137, P1, DOI 10.1093/jb/mvi001; KOTLING R, 1994, EMBO J, V13, P3261; Lai EC, 2005, DEVELOPMENT, V132, P2319, DOI 10.1242/dev.01825; Lim KL, 2005, J NEUROSCI, V25, P2002, DOI 10.1523/JNEUROSCI.4474-04.2005; McCullough J, 2004, J CELL BIOL, V166, P487, DOI 10.1083/jcb.200401141; Mizuno E, 2005, MOL BIOL CELL, V16, P5163, DOI 10.1091/mbc.E05-06-0560; Mosesson Y, 2003, J BIOL CHEM, V278, P21323, DOI 10.1074/jbc.C300096200; Pickart CM, 2004, CURR OPIN CHEM BIOL, V8, P610, DOI 10.1016/j.cbpa.2004.09.009; Pickart CM, 2004, BBA-MOL CELL RES, V1695, P55, DOI 10.1016/j.bbamcr.2004.09.019; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Rotin D, 2001, AM J PHYSIOL-RENAL, V281, pF391, DOI 10.1152/ajprenal.2001.281.3.F391; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Sigismund S, 2005, P NATL ACAD SCI USA, V102, P2760, DOI 10.1073/pnas.0409817102; Springael JY, 1999, J CELL SCI, V112, P1375; Stelter P, 2003, NATURE, V425, P188, DOI 10.1038/nature01965; Strous GJ, 2004, CURR TOP MICROBIOL, V286, P81; Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9; Terrell J, 1998, MOL CELL, V1, P193, DOI 10.1016/S1097-2765(00)80020-9; Varadan R, 2004, J BIOL CHEM, V279, P7055, DOI 10.1074/jbc.M309184200; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Wu CJ, 2006, NAT CELL BIOL, V8, P398, DOI 10.1038/ncb1384; Zhang YZ, 2000, J NEUROSCI, V20, P5671, DOI 10.1523/JNEUROSCI.20-15-05671.2000; Zhou HL, 2005, J EXP MED, V202, P1327, DOI 10.1084/jem.20051194; Zhou HL, 2004, NATURE, V427, P167, DOI 10.1038/nature02273	59	909	962	4	175	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 12	2007	315	5809					201	205		10.1126/science.1127085	http://dx.doi.org/10.1126/science.1127085			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124XZ	17218518				2022-12-28	WOS:000243407400035
J	Trotman, LC; Wang, XJ; Alimonti, A; Chen, ZB; Teruya-Feldstein, J; Yang, HJ; Pavletich, NP; Carver, BS; Cordon-Cardo, C; Erdjument-Bromage, H; Tempst, P; Chi, SG; Kim, HJ; Misteli, T; Jiang, XJ; Pandolfi, PP				Trotman, Lloyd C.; Wang, Xinjiang; Alimonti, Andrea; Chen, Zhenbang; Teruya-Feldstein, Julie; Yang, Haijuan; Pavletich, Nikola P.; Carver, Brett S.; Cordon-Cardo, Carlos; Erdjument-Bromage, Hediye; Tempst, Paul; Chi, Sung-Gil; Kim, Hyo-Jong; Misteli, Tom; Jiang, Xuejun; Pandolfi, Pier Paolo			Ubiquitination regulates PTEN nuclear import and tumor suppression	CELL			English	Article							PTEN/MMAC1 GENE; PROSTATE-CANCER; COWDEN-DISEASE; P53; MUTATIONS; PATHWAY; IDENTIFICATION; EXPRESSION; SYSTEM; ROLES	The PTEN tumor suppressor is frequently affected in cancer cells, and inherited PTEN mutation causes cancer-susceptibility conditions such as Cowden syndrome. PTEN acts as a plasma-membrane lipid-phosphatase antagonizing the phosphoinositide 3-kinase/AKT cell survival pathway. However, PTEN is also found in cell nuclei, but mechanism, function, and relevance of nuclear localization remain unclear. We show that nuclear PTEN is essential for tumor suppression and that PTEN nuclear import is mediated by its monoubiquitination. A lysine mutant of PTEN, K289E associated with Cowden syndrome, retains catalytic activity but fails to accumulate in nuclei of patient tissue due to an import defect. We identify this and another lysine residue as major monoubiquitination sites essential for PTEN import. While nuclear PTEN is stable, polyubiquitination leads to its degradation in the cytoplasm. Thus, we identify cancer-associated mutations of PTEN that target its posttranslational modification and demonstrate how a discrete molecular mechanism dictates tumor progression by differentiating between degradation and protection of IPTEN.	Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Canc Biol & Genet Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Dept Pathol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Cell Biol Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Struct Biol Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Howard Hughes Med Inst, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Dept Urol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA; Korea Univ, Sch Life Sci & Biotechnol, Seoul 136701, South Korea; Kyung Hee Univ, Sch Med, Seoul 130701, South Korea; NCI, NIH, Bethesda, MD 20892 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Korea University; Kyung Hee University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Pandolfi, PP (corresponding author), Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Canc Biol & Genet Program, 1275 York Ave, New York, NY 10021 USA.	p-pandolfi@ski.mskcc.org	高, 雨莉/HGU-8187-2022	Alimonti, Andrea/0000-0002-9362-2313; Tempst, Paul/0000-0002-6680-3987; Erdjument-Bromage, Hediye/0000-0003-0224-3594	Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [R01 CA137050, R01 CA082328, R01-CA-82328, P30-CA-08748, P30 CA008748] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082328, P30CA008748, R01CA137050, Z01BC010309] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bonneau D, 2000, HUM MUTAT, V16, P109, DOI 10.1002/1098-1004(200008)16:2<109::AID-HUMU3>3.0.CO;2-0; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Chi SG, 1998, GASTROENTEROLOGY, V115, P1084, DOI 10.1016/S0016-5085(98)70078-2; Chook YM, 2001, CURR OPIN STRUC BIOL, V11, P703, DOI 10.1016/S0959-440X(01)00264-0; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; Ciechanover A, 2005, NAT REV MOL CELL BIO, V6, P79, DOI 10.1038/nrm1552; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Duerr EM, 1998, ONCOGENE, V16, P2259, DOI 10.1038/sj.onc.1201756; Eng C, 2003, HUM MUTAT, V22, P183, DOI 10.1002/humu.10257; Georgescu MM, 2000, CANCER RES, V60, P7033; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hoeller D, 2006, NAT REV CANCER, V6, P776, DOI 10.1038/nrc1994; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Leslie NR, 2004, BIOCHEM J, V382, P1, DOI 10.1042/BJ20040825; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Lian ZL, 2005, ONCOGENE, V24, P7394, DOI 10.1038/sj.onc.1209089; Lohrum MAE, 2001, MOL CELL BIOL, V21, P8521, DOI 10.1128/MCB.21.24.8521-8532.2001; Ma L, 2005, GENE DEV, V19, P1779, DOI 10.1101/gad.1314405; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Massoumi R, 2006, CELL, V125, P665, DOI 10.1016/j.cell.2006.03.041; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Nagy R, 2004, ONCOGENE, V23, P6445, DOI 10.1038/sj.onc.1207714; Nelen MR, 1997, HUM MOL GENET, V6, P1383, DOI 10.1093/hmg/6.8.1383; Plafker SM, 2004, J CELL BIOL, V167, P649, DOI 10.1083/jcb.200406001; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Sansal I, 2004, J CLIN ONCOL, V22, P2954, DOI 10.1200/jco.2004.02.141; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Trotman LC, 2003, PLOS BIOL, V1, P385, DOI 10.1371/journal.pbio.0000059; Trotman LC, 2003, CANCER CELL, V3, P97, DOI 10.1016/S1535-6108(03)00022-9; Trotman LC, 2006, NATURE, V441, P523, DOI 10.1038/nature04809; Walker SM, 2004, BIOCHEM J, V379, P301, DOI 10.1042/BJ20031839; Wang XJ, 2007, CELL, V128, P129, DOI 10.1016/j.cell.2006.11.039; Whiteman DC, 2002, INT J CANCER, V99, P63, DOI 10.1002/ijc.10294; Zhou XP, 2002, AM J PATHOL, V161, P439, DOI 10.1016/S0002-9440(10)64200-9	43	554	600	0	44	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 12	2007	128	1					141	156		10.1016/j.cell.2006.11.040	http://dx.doi.org/10.1016/j.cell.2006.11.040			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	139GN	17218261	Green Accepted, Bronze			2022-12-28	WOS:000244420400019
J	Wang, XJ; Trotman, LC; Koppie, T; Alimonti, A; Chen, ZB; Gao, ZH; Wang, JR; Erdjument-Bromage, H; Tempst, P; Cordon-Cardo, C; Pandolfi, PP; Jiang, XJ				Wang, Xinjiang; Trotman, Lloyd C.; Koppie, Theresa; Alimonti, Andrea; Chen, Zhenbang; Gao, Zhonghua; Wang, Junru; Erdjument-Bromage, Hediye; Tempst, Paul; Cordon-Cardo, Carlos; Pandolfi, Pier Paolo; Jiang, Xuejun			NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN	CELL			English	Article							TUMOR-SUPPRESSOR PTEN; PROSTATE-CANCER; PROTEIN-DEGRADATION; CELL-MIGRATION; PATHWAY; GENE; PHOSPHORYLATION; DOMAIN; P53; RECRUITMENT	The tumor suppressor PTEN, a critical regulator for multiple cellular processes, is mutated or deleted frequently in various human cancers. Subtle reductions in PTEN expression levels have profound impacts on carcinogenesis. Here we show that PTEN level is regulated by ubiquitin-mediated proteasomal degradation, and purified its ubiquitin ligase as HECT-domain protein NEDD4-1. In cells NEDD4-1 negatively regulates PTEN stability by catalyzing PTEN polyubiquitination. Consistent with the tumor-suppressive role of PTEN, overexpression of NEDD4-1 potentiated cellular transformation. Strikingly, in a mouse cancer model and multiple human cancer samples where the genetic background of PTEN was normal but its protein levels were low, NEDD4-1 was highly expressed, suggesting that aberrant upregulation of NEDD4-1 can posttranslationally suppress PTEN in cancers. Elimination of NEDD4-1 expression inhibited xenotransplanted tumor growth in a PTENdependent manner. Therefore, NEDD4-1 is a potential proto-oncogene that negatively regulates PTEN via ubiquitination, a paradigm analogous to that of Mdm2 and p53.	Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Cell Biol Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Cenc Biol & Genet Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Dept Pathol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Jiang, XJ (corresponding author), Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Cell Biol Program, 1275 York Ave,Box 522, New York, NY 10021 USA.	jiangx@mskcc.org	高, 雨莉/HGU-8187-2022	Tempst, Paul/0000-0002-6680-3987; Alimonti, Andrea/0000-0002-9362-2313; Erdjument-Bromage, Hediye/0000-0003-0224-3594	NCI NIH HHS [R01 CA137050, R01 CA113890] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA113890, R01CA137050] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adey NB, 2000, CANCER RES, V60, P35; Bakkers J, 2005, CELL CYCLE, V4, P790, DOI 10.4161/cc.4.6.1694; Blot V, 2004, J CELL SCI, V117, P2357, DOI 10.1242/jcs.01095; Bond GL, 2005, CURR CANCER DRUG TAR, V5, P3, DOI 10.2174/1568009053332627; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; CIECHANOVER A, 1984, J CELL BIOCHEM, V24, P27, DOI 10.1002/jcb.240240104; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Fostier M, 1998, GENETICS, V150, P1477; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gray IC, 1998, BRIT J CANCER, V78, P1296, DOI 10.1038/bjc.1998.674; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Ingham RJ, 2004, ONCOGENE, V23, P1972, DOI 10.1038/sj.onc.1207436; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Kamynina E, 2001, AM J PHYSIOL-RENAL, V281, pF469, DOI 10.1152/ajprenal.2001.281.3.F469; Kim RH, 2005, CANCER CELL, V7, P263, DOI 10.1016/j.ccr.2005.02.010; Kwabi-Addo B, 2001, P NATL ACAD SCI USA, V98, P11563, DOI 10.1073/pnas.201167798; Leslie NR, 2004, BIOCHEM J, V382, P1, DOI 10.1042/BJ20040825; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Maehama T, 2001, ANNU REV BIOCHEM, V70, P247, DOI 10.1146/annurev.biochem.70.1.247; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; Nagase T, 1995, DNA Res, V2, P37, DOI 10.1093/dnares/2.1.37; Pao W, 2003, P NATL ACAD SCI USA, V100, P8764, DOI 10.1073/pnas.1133333100; Raftopoulou M, 2004, SCIENCE, V303, P1179, DOI 10.1126/science.1092089; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Rougier JS, 2005, AM J PHYSIOL-CELL PH, V288, pC692, DOI 10.1152/ajpcell.00460.2004; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; Sansal I, 2004, J CLIN ONCOL, V22, P2954, DOI 10.1200/jco.2004.02.141; Shen WH, 2007, CELL, V128, P157, DOI 10.1016/j.cell.2006.11.042; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Strack B, 2000, P NATL ACAD SCI USA, V97, P13063, DOI 10.1073/pnas.97.24.13063; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Trotman LC, 2003, PLOS BIOL, V1, P385, DOI 10.1371/journal.pbio.0000059; Trotman LC, 2007, CELL, V128, P141, DOI 10.1016/j.cell.2006.11.040; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Wu WD, 2003, J BIOL CHEM, V278, P28258, DOI 10.1074/jbc.M303318200	42	513	546	0	34	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 12	2007	128	1					129	139		10.1016/j.cell.2006.11.039	http://dx.doi.org/10.1016/j.cell.2006.11.039			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	139GN	17218260	Green Accepted, Bronze			2022-12-28	WOS:000244420400018
J	Gomez-Consarnau, L; Gonzalez, JM; Coll-Llado, M; Gourdon, P; Pascher, T; Neutze, R; Pedros-Alio, C; Pinhassi, J				Gomez-Consarnau, Laura; Gonzalez, Jose M.; Coll-Llado, Montserrat; Gourdon, Pontus; Pascher, Torbjoern; Neutze, Richard; Pedros-Alio, Carlos; Pinhassi, Jarone			Light stimulates growth of proteorhodopsin-containing marine Flavobacteria	NATURE			English	Article							OCEAN; PHOTOTROPHY; BACTERIUM; SAR11; SEA	Proteorhodopsins are bacterial light-dependent proton pumps. Their discovery within genomic material from uncultivated marine bacterioplankton caused considerable excitement because it indicated a potential phototrophic function within these organisms, which had previously been considered strictly chemotrophic(1). Subsequent studies established that sequences encoding proteorhodopsin are broadly distributed throughout the world's oceans(2-5). Nevertheless, the role of proteorhodopsins in native marine bacteria is still unknown(6). Here we show, from an analysis of the complete genomes of three marine Flavobacteria, that cultivated bacteria in the phylum Bacteroidetes, one of the principal components of marine bacterioplankton, contain proteorhodopsin. Moreover, growth experiments in both natural and artificial seawater ( low in labile organic matter, which is typical of the world's oceans) establish that exposure to light results in a marked increase in the cell yield of one such bacterium (Dokdonia sp. strain MED134) when compared with cells grown in darkness. Thus, our results show that the phototrophy conferred by proteorhodopsin can provide critical amounts of energy, not only for respiration and maintenance but also for active growth of marine bacterioplankton in their natural environment.	Univ Kalmar, Dept Biol & Environm Sci, SE-39182 KAlmar, Sweden; Univ La Laguna, Dept Microbiol & Cell Biol, ES-38206 Tenerife, Spain; CSIC, CMIMA, Inst Ciencies Mar, ES-08003 Barcelona, Spain; Chalmers, Dept Biol & Chem Engn, SE-41296 Gothenburg, Sweden; Lund Univ, Kemictr, SE-22100 Lund, Sweden; Univ Gothenburg, Dept Chem Biochem & Biophys, SE-40530 Gothenburg, Sweden	Linnaeus University; University of Kalmar; Universidad de la Laguna; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Mediterraneo de Investigaciones Marinas y Ambientales (CMIMA); CSIC - Instituto de Ciencias del Mar (ICM); Chalmers University of Technology; Lund University; University of Gothenburg	Pinhassi, J (corresponding author), Univ Kalmar, Dept Biol & Environm Sci, SE-39182 KAlmar, Sweden.	jarone.pinhassi@hik.se	Gomez-Consarnau, Laura/AAM-1319-2021; Gonzalez, Jose M./C-3333-2013; Gourdon, Pontus/HCI-8898-2022; Neutze, Richard/A-7573-2010; Gourdon, Pontus/E-1076-2014; Pedrós-Alió, Carlos/H-1222-2011	Gonzalez, Jose M./0000-0002-9926-3323; Neutze, Richard/0000-0003-0986-6153; Gourdon, Pontus/0000-0002-8631-3539; Pedrós-Alió, Carlos/0000-0003-1009-4277; Coll-Llado, Montserrat/0000-0003-0169-4107				Abell GCJ, 2005, FEMS MICROBIOL ECOL, V51, P265, DOI 10.1016/j.femsec.2004.09.001; Beja O, 2002, NATURE, V415, P630, DOI 10.1038/415630a; Beja O, 2000, SCIENCE, V289, P1902, DOI 10.1126/science.289.5486.1902; Beja O, 2001, NATURE, V411, P786, DOI 10.1038/35081051; Bielawski JP, 2004, P NATL ACAD SCI USA, V101, P14824, DOI 10.1073/pnas.0403999101; de la Torre JR, 2003, P NATL ACAD SCI USA, V100, P12830, DOI 10.1073/pnas.2133554100; Dioumaev AK, 2002, BIOCHEMISTRY-US, V41, P5348, DOI 10.1021/bi025563x; Frigaard NU, 2006, NATURE, V439, P847, DOI 10.1038/nature04435; Giovannoni SJ, 2005, NATURE, V438, P82, DOI 10.1038/nature04032; Giovannoni SJ., 2000, MICROBIAL ECOLOGY OC, P47; Glockner FO, 1999, APPL ENVIRON MICROB, V65, P3721; Hagstrom A, 2002, APPL ENVIRON MICROB, V68, P3628, DOI 10.1128/AEM.68.7.3628-3633.2002; Kirchman DL, 2002, FEMS MICROBIOL ECOL, V39, P91, DOI 10.1111/j.1574-6941.2002.tb00910.x; Kolber ZS, 2000, NATURE, V407, P177, DOI 10.1038/35025044; Man DL, 2003, EMBO J, V22, P1725, DOI 10.1093/emboj/cdg183; Neutze R, 2002, BBA-BIOMEMBRANES, V1565, P144, DOI 10.1016/S0005-2736(02)00566-7; Pinhassi J, 2004, APPL ENVIRON MICROB, V70, P6753, DOI 10.1128/AEM.70.11.6753-6766.2004; Rappe MS, 2002, NATURE, V418, P630, DOI 10.1038/nature00917; Riemann L, 2000, APPL ENVIRON MICROB, V66, P578, DOI 10.1128/AEM.66.2.578-587.2000; Sabehi G, 2005, PLOS BIOL, V3, P1409, DOI 10.1371/journal.pbio.0030273; Sabehi G, 2004, ENVIRON MICROBIOL, V6, P903, DOI 10.1111/j.1462-2920.2004.00676.x; Sabehi G, 2003, ENVIRON MICROBIOL, V5, P842, DOI 10.1046/j.1462-2920.2003.00493.x; SHIBA T, 1979, APPL ENVIRON MICROB, V38, P43, DOI 10.1128/AEM.38.1.43-45.1979; Teramoto M, 2003, FEBS LETT, V545, P120, DOI 10.1016/S0014-5793(03)00513-1; Venter JC, 2004, SCIENCE, V304, P66, DOI 10.1126/science.1093857; Wang WW, 2003, J BIOL CHEM, V278, P33985, DOI 10.1074/jbc.M305716200	26	266	279	4	78	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 11	2007	445	7124					210	213		10.1038/nature05381	http://dx.doi.org/10.1038/nature05381			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124QF	17215843				2022-12-28	WOS:000243384300052
J	Platt, MJ; Cans, C; Johnson, A; Surman, G; Topp, M; Torrioli, MG; Krageloh-Mann, I				Platt, Mary Jane; Cans, Christine; Johnson, Ann; Surman, Geraldine; Topp, Monica; Torrioli, Maria Giulia; Krageloh-Mann, Inge			Trends in cerebral palsy among of very low birthweight (< 1500 g) or born prematurely (< 32 weeks) in 16 European centres: a database study	LANCET			English	Article							BRAIN-INJURY; INFANTS; POPULATION; PREVALENCE; ULTRASOUND; SURVIVAL; OUTCOMES; SWEDEN; RATES; GRAMS	Background The risk of cerebral palsy, the commonest physical disability of children in western Europe, is higher in infants of very low birthweight (VLBW)-those born weighing less than 1500 g-and those from multiple pregnancies than in infants of normal birthweight. An increasing proportion of infants from both of these groups survive into childhood. This paper describes changes in the frequency and distribution of cerebral palsy by sex and neurological subtype in infants with a birthweight below 1000 g and 1000-1499 g in the period 1980-96. Methods A group of 16 European centres, Surveillance of Cerebral Palsy in Europe, agreed a standard definition of cerebral palsy and inclusion and exclusion criteria. Data for children with cerebral palsy born in the years 1980-96 were pooled. The data were analysed to describe the distribution and prevalence of cerebral palsy in VLBW infants. Prevalence trends were expressed as both per 1000 livebirths and per 1000 neonatal survivors. Findings There were 1575 VLBW infants born with cerebral palsy; 414 (26%) were of birthweight less than 1000 g and 317 (20%) were from multiple pregnancies. 1426 (94%) had spastic cerebral palsy, which was unilateral (hemiplegic) in 336 (24%). The birth prevalence fell from 60.6 (99% CI 37.8-91.4) per 1000 liveborn VLBW infants in 1980 to 39.5 (28.6-53.0) per 1000 VLBW infants in 1996. This decline was related to a reduction in the frequency of bilateral spastic cerebral palsy among infants of birthweight 1000-1499 g. The frequency of cerebral palsy was higher in male than female babies in the group of birthweight 1000-1499 g (61.0 [53.8-68.2] vs 49.5 [42.8-56.2] per 1000 livebirths; p=0.0025) but not in the group of birthweight below 1000 g. Interpretation These data from a large population base provide evidence that the prevalence of cerebral palsy in children of birthweight less than 1500 g has fallen, which has important implications for parents, health services, and society.	Univ Liverpool, Div Publ Hlth, Liverpool L69 3GB, Merseyside, England; Registre Handicaps Enfant, Grenoble, France; Observ Perinatal Technol Imagerie Modelisat & Cog, Grenoble, France; Univ Oxford, Natl Perinatal Epidemiol Unit, Oxford, England; Natl Inst Publ Hlth, Cerebral Palsy Registry, Copenhagen, Denmark; Hvidovre Univ Hosp, Dept Obstet & Gynaecol, Copenhagen, Denmark; Univ Cattolica Sacro Cuore, Fac Med & Chirurg Augostino Gemelli, Rome, Italy; Univ Childrens Hosp, Dept Child Neurol, Tubingen, Germany	University of Liverpool; University of Oxford; University of Copenhagen; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Eberhard Karls University of Tubingen; TUBINGEN UNIVERSITY CHILDRENS HOSPITAL; University of Hamburg; University Medical Center Hamburg-Eppendorf	Platt, MJ (corresponding author), Univ Liverpool, Div Publ Hlth, Whelan Bldg, Liverpool L69 3GB, Merseyside, England.	mjplatt@liv.ac.uk	Cans, Christine/M-6153-2014; Platt, MJ/K-4588-2012	Cans, Christine/0000-0003-3071-9959; Platt, MJ/0000-0002-9372-9575; Johnson, Anne/0000-0003-1330-7100				[Anonymous], 1997, Arch Dis Child Fetal Neonatal Ed, V77, pF91; Bell R, 2004, ARCH DIS CHILD-FETAL, V89, pF531, DOI 10.1136/adc.2003.038414; Breart G, 2003, EUR J OBSTET GYN R B, V111, pS45, DOI 10.1016/j.ejogrb.2003.09.005; Cans C, 2002, DEV MED CHILD NEUROL, V44, P633; Cans C, 2000, DEV MED CHILD NEUROL, V42, P816, DOI 10.1111/j.1469-8749.2000.tb00695.x; Clark SL, 2003, AM J OBSTET GYNECOL, V188, P628, DOI 10.1067/mob.2003.204; Colver AF, 2000, ARCH DIS CHILD-FETAL, V83, pF7, DOI 10.1136/fn.83.1.F7; Cooke RWI, 1999, ARCH DIS CHILD-FETAL, V80, pF115, DOI 10.1136/fn.80.2.F115; Doyle LW, 2000, J PAEDIATR CHILD H, V36, P7, DOI 10.1046/j.1440-1754.2000.00452.x; ENSDOKKUM ME, 1994, ARCH DIS CHILD-FETAL, V70, P96; Hamrick SEG, 2004, J PEDIATR-US, V145, P593, DOI 10.1016/j.jpeds.2004.05.042; Himmelmann K, 2005, ACTA PAEDIATR, V94, P287, DOI 10.1111/j.1651-2227.2005.tb03071.x; Krageloh-Mann I, 2004, EXP NEUROL, V190, pS84, DOI 10.1016/j.expneurol.2004.05.037; KRAGELOHMANN I, 1994, DEV MED CHILD NEUROL, V36, P473; Laptook AR, 2005, PEDIATRICS, V115, P673, DOI 10.1542/peds.2004-0667; OShea TM, 1997, PEDIATRICS, V100, P982, DOI 10.1542/peds.100.6.982; Piecuch RE, 1997, PEDIATRICS, V100, P633, DOI 10.1542/peds.100.4.633; Pison G, 2006, TWIN RES HUM GENET, V9, P250, DOI 10.1375/twin.9.2.250; Scher AI, 2002, PEDIATR RES, V52, P671, DOI [10.1203/00006450-200211000-00011, 10.1203/01.PDR.0000032159.88318.5B]; Shankaran S, 2004, AM J OBSTET GYNECOL, V191, P1084, DOI 10.1016/j.ajog.2004.05.032; Stanley F, 2000, CLIN DEV MED; Surman G, 2003, DEV MED CHILD NEUROL, V45, P456, DOI 10.1017/S0012162203000859; Tin W, 1997, BRIT J OBSTET GYNAEC, V104, P180, DOI 10.1111/j.1471-0528.1997.tb11041.x; Topp M, 2004, ACTA OBSTET GYN SCAN, V83, P548, DOI 10.1111/j.0001-6349.2004.00545.x; Topp M, 2001, PAEDIATR PERINAT EP, V15, P271, DOI 10.1046/j.1365-3016.2001.00354.x; Vohr BR, 1997, SEMIN PERINATOL, V21, P202, DOI 10.1016/S0146-0005(97)80064-X; Watson L, 1999, REPORT W AUSTR CEREB; Winter S, 2002, PEDIATRICS, V110, P1220, DOI 10.1542/peds.110.6.1220	28	270	294	0	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 6	2007	369	9555					43	50		10.1016/S0140-6736(07)60030-0	http://dx.doi.org/10.1016/S0140-6736(07)60030-0			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125AK	17208641				2022-12-28	WOS:000243413700028
J	Roth, BL				Roth, Bryan L.			Focus on research - Drug and valvular heart disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							FENFLURAMINE		Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Pharm, Dept Med Chem, Chapel Hill, NC USA; Univ N Carolina, NIMH, Psychoact Drug Screening Program, Chapel Hill, NC USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); University of North Carolina; University of North Carolina Chapel Hill	Roth, BL (corresponding author), Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA.		Roth, Bryan/ABE-7032-2020; Roth, Bryan L/F-3928-2010	Roth, Bryan/0000-0002-0561-6520; 				Connolly HM, 1997, NEW ENGL J MED, V337, P1783; Devereux RB, 1998, NEW ENGL J MED, V339, P765, DOI 10.1056/NEJM199809103391109; Rothman RB, 2000, CIRCULATION, V102, P2836; Setola V, 2003, MOL PHARMACOL, V63, P1223, DOI 10.1124/mol.63.6.1223; Setola Vincent, 2005, Expert Opin Drug Metab Toxicol, V1, P377, DOI 10.1517/17425255.1.3.377	5	343	354	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 4	2007	356	1					6	9		10.1056/NEJMp068265	http://dx.doi.org/10.1056/NEJMp068265			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	122EX	17202450				2022-12-28	WOS:000243209600003
J	Van Dyke, T				Van Dyke, Terry			p53 and tumor suppression	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							DNA-DAMAGE		Univ N Carolina, Sch Med, Dept Genet, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Van Dyke, T (corresponding author), Univ N Carolina, Sch Med, Dept Genet, Chapel Hill, NC 27599 USA.							Christophorou MA, 2006, NATURE, V443, P214, DOI 10.1038/nature05077; Christophorou MA, 2005, NAT GENET, V37, P718, DOI 10.1038/ng1572; Efeyan A, 2006, NATURE, V443, P159, DOI 10.1038/443159a; Garcia-Cao I, 2002, EMBO J, V21, P6225, DOI 10.1093/emboj/cdf595	4	22	24	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 4	2007	356	1					79	81		10.1056/NEJMcibr066301	http://dx.doi.org/10.1056/NEJMcibr066301			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	122EX	17202460				2022-12-28	WOS:000243209600014
J	Ganz, DA; Bao, Y; Shekelle, PG; Rubenstein, LZ				Ganz, David A.; Bao, Yeran; Shekelle, Paul G.; Rubenstein, Laurence Z.			Will my patient fall?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK-FACTORS; RECURRENT FALLS; OLDER-PEOPLE; COMMUNITY; PREDICTORS; METAANALYSIS; OSTEOARTHRITIS; MOBILITY; DRUGS	Context Effective multifactorial interventions reduce the frequent falling rate of older patients by 30% to 40%. However, clinical consensus suggests reserving these interventions for high-risk patients. Limiting fall prevention programs to high-risk patients implies that clinicians must recognize features that predict future falls. Objective To identify the prognostic value of risk factors for future falls among older patients. Data Sources and Study Selection Search of MEDLINE ( 1966-September 2004), CINAHL (1982-September 2004), and authors' own files to identify prospective cohort studies of risk factors for falls that performed a multivariate analysis of such factors. Data Extraction Two reviewers independently determined inclusion of articles and assessed study quality. Disagreements were resolved by consensus. Included studies were those identifying the prognostic value of risk factors for future falls among community-dwelling persons 65 years and older. Clinically identifiable risk factors were identified across 6 domains: orthostatic hypotension, visual impairment, impairment of gait or balance, medication use, limitations in basic or instrumental activities of daily living, and cognitive impairment. Data Synthesis Eighteen studies met inclusion criteria and provided a multivariate analysis including at least 1 of the risk factor domains. The estimated pretest probability of falling at least once in any given year for individuals 65 years and older was 27% (95% confidence interval, 19%-36%). Patients who have fallen in the past year are more likely to fall again [ likelihood ratio range, 2.3-2.8]. The most consistent predictors of future falls are clinically detected abnormalities of gait or balance ( likelihood ratio range, 1.7-2.4). Visual impairment, medication variables, decreased activities of daily living, and impaired cognition did not consistently predict falls across studies. Orthostatic hypotension did not predict falls after controlling for other factors. Conclusions Screening for risk of falling during the clinical examination begins with determining if the patient has fallen in the past year. For patients who have not previously fallen, screening consists of an assessment of gait and balance. Patients who have fallen or who have a gait or balance problem are at higher risk of future falls.	Vet Affairs Greater Los Angeles Hlth Care Syst, Vet Affairs Geriatr Res Educ & Clin Ctr 11G, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, Multicampus Program Geriatr Med & Gerontol, Los Angeles, CA USA; Robert Wood Johnson Clin Scholars Program, Los Angeles, CA USA; RAND Hlth, Santa Monica, CA USA	Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of California System; University of California Los Angeles; RAND Corporation	Ganz, DA (corresponding author), Vet Affairs Greater Los Angeles Hlth Care Syst, Vet Affairs Geriatr Res Educ & Clin Ctr 11G, 11301 Wilshire Blvd,Bldg 220,Room 308, Los Angeles, CA 90073 USA.	dganz@mednet.ucla.edu		Rubenstein, Laurence/0000-0001-5910-0266				[Anonymous], 1996, CLIN AUTON RES, V6, P125; Arden NK, 1999, ARTHRITIS RHEUM, V42, P1378, DOI 10.1002/1529-0131(199907)42:7<1378::AID-ANR11>3.0.CO;2-I; Bergland A, 2003, AGING CLIN EXP RES, V15, P43; Brotman DJ, 2005, ARCH INTERN MED, V165, P138, DOI 10.1001/archinte.165.2.138; CAMPBELL AJ, 1990, J CLIN EPIDEMIOL, V43, P1415, DOI 10.1016/0895-4356(90)90110-B; CAMPBELL AJ, 1989, J GERONTOL, V44, pM112, DOI 10.1093/geronj/44.4.m112; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P1019; Chang JT, 2004, BRIT MED J, V328, P680, DOI 10.1136/bmj.328.7441.680; Chu LW, 1999, J GERONTOL A-BIOL, V54, pM38, DOI 10.1093/gerona/54.1.M38; Chu LW, 2005, ANN ACAD MED SINGAP, V34, P60; Coleman AL, 2004, OPHTHALMOLOGY, V111, P857, DOI 10.1016/j.ophtha.2003.09.033; CUMMINGS SR, 1988, J AM GERIATR SOC, V36, P613, DOI 10.1111/j.1532-5415.1988.tb06155.x; DUNCAN PW, 1992, J GERONTOL, V47, pM93, DOI 10.1093/geronj/47.3.M93; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FORMAN MD, 1983, J RHEUMATOL, V10, P282; Gerdhem P, 2005, J CLIN EPIDEMIOL, V58, P226, DOI 10.1016/j.jclinepi.2004.06.013; Gillespie Lesley D, 2012, Cochrane Database Syst Rev, pCD007146, DOI 10.1002/14651858.CD007146.pub3; Guideline for the prevention of falls in older persons, 2001, J AM GERIATR SOC, V49, P664, DOI DOI 10.1046/J.1532-5415.2001.49115.X; Holleman DR, 1997, J GEN INTERN MED, V12, P165, DOI 10.1007/s11606-006-5024-6; Horton JC, 1997, SURV OPHTHALMOL, V42, P169, DOI 10.1016/S0039-6257(97)00055-6; Ioannidis JPA, 2005, PLOS MED, V2, P696, DOI 10.1371/journal.pmed.0020124; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; Leipzig RM, 1999, J AM GERIATR SOC, V47, P40, DOI 10.1111/j.1532-5415.1999.tb01899.x; Leipzig RM, 1999, J AM GERIATR SOC, V47, P30, DOI 10.1111/j.1532-5415.1999.tb01898.x; Lin MR, 2004, J AM GERIATR SOC, V52, P1343, DOI 10.1111/j.1532-5415.2004.52366.x; LUUKINEN H, 1995, SCAND J PRIM HEALTH, V13, P294, DOI 10.3109/02813439508996778; Luukinen H, 1996, PUBLIC HEALTH, V110, P115, DOI 10.1016/S0033-3506(96)80057-6; McGee S, 1999, JAMA-J AM MED ASSOC, V281, P1022, DOI 10.1001/jama.281.11.1022; *NAT I CLIN EXC, ASS PREV FALLS OLD P; OLOUGHLIN JL, 1994, J EPIDEMIOL COMMUN H, V48, P488, DOI 10.1136/jech.48.5.488; OLOUGHLIN JL, 1993, AM J EPIDEMIOL, V137, P342, DOI 10.1093/oxfordjournals.aje.a116681; PFEIFFER E, 1975, J AM GERIATR SOC, V23, P433, DOI 10.1111/j.1532-5415.1975.tb00927.x; REEVES RA, 1995, JAMA-J AM MED ASSOC, V273, P1211, DOI 10.1001/jama.1995.03520390071036; REUBEN DB, GERIATRICS YOUR FING; Rubenstein LZ, 2002, CLIN GERIATR MED, V18, P141, DOI 10.1016/S0749-0690(02)00002-2; SIMEL DL, 1991, J CLIN EPIDEMIOL, V44, P763, DOI 10.1016/0895-4356(91)90128-V; Stalenhoef PA, 1997, EUR J PUBLIC HEALTH, V7, P328, DOI 10.1093/eurpub/7.3.328; Stalenhoef PA, 2002, J CLIN EPIDEMIOL, V55, P1088, DOI 10.1016/S0895-4356(02)00502-4; STUDENSKI S, 1994, J AM GERIATR SOC, V42, P297, DOI 10.1111/j.1532-5415.1994.tb01755.x; TENO J, 1990, J AM GERIATR SOC, V38, P1321, DOI 10.1111/j.1532-5415.1990.tb03455.x; THETTI ME, 1995, JAMA-J AM MED ASSOC, V273, P1348; Tinetti ME, 2003, NEW ENGL J MED, V348, P42, DOI 10.1056/NEJMcp020719; TINETTI ME, 1993, JAMA-J AM MED ASSOC, V269, P65, DOI 10.1001/jama.269.1.65; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; Tinetti ME, 1997, NEW ENGL J MED, V337, P1279, DOI 10.1056/NEJM199710303371806; TINETTI ME, 1986, J AM GERIATR SOC, V34, P119, DOI 10.1111/j.1532-5415.1986.tb05480.x; Tromp AM, 2001, J CLIN EPIDEMIOL, V54, P837, DOI 10.1016/S0895-4356(01)00349-3; *UCLA MED CTR GER, PREV QUEST IN VIS; van Bemmel T, 2005, J CLIN EPIDEMIOL, V58, P63, DOI 10.1016/j.jclinepi.2004.06.007; Weiner DK, 1998, GERONTOLOGY, V44, P217, DOI 10.1159/000022013; Zhang HG, 2004, ARCH GERONTOL GERIAT, V38, P145, DOI 10.1016/j.archger.2003.09.001	51	554	580	3	54	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 3	2007	297	1					77	86		10.1001/jama.297.1.77	http://dx.doi.org/10.1001/jama.297.1.77			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	123BS	17200478				2022-12-28	WOS:000243271900024
J	Nigrovic, LE; Kuppermann, N; Macias, CG; Cannavino, CR; Moro-Sutherland, DM; Schremmer, RD; Schwab, SH; Agrawal, D; Mansour, KM; Bennett, JE; Katsogridakis, YL; Mohseni, MM; Bulloch, B; Steele, DW; Kaplan, RL; Herman, MI; Bandyopadhyay, S; Dayan, P; Truong, UT; Wang, VJ; Bonsu, BK; Chapman, JL; Kanegaye, JT; Malley, R				Nigrovic, Lise E.; Kuppermann, Nathan; Macias, Charles G.; Cannavino, Christopher R.; Moro-Sutherland, Donna M.; Schremmer, Robert D.; Schwab, Sandra H.; Agrawal, Dewesh; Mansour, Karim M.; Bennett, Jonathan E.; Katsogridakis, Yiannis L.; Mohseni, Michael M.; Bulloch, Blake; Steele, Dale W.; Kaplan, Ron L.; Herman, Martin I.; Bandyopadhyay, Subhankar; Dayan, Peter; Truong, Uyen T.; Wang, Vincent J.; Bonsu, Bema K.; Chapman, Jennifer L.; Kanegaye, John T.; Malley, Richard		Amer Acad Pediat	Clinical prediction rule for identifying children with cerebrospinal fluid pleocytosis at very low risk of bacterial meningitis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PNEUMOCOCCAL CONJUGATE VACCINE; DECISION RULES; DISTINGUISH; VALIDATION; DIAGNOSIS; DISEASE; MODEL	Context Children with cerebrospinal fluid (CSF) pleocytosis are routinely admitted to the hospital and treated with parenteral antibiotics, although few have bacterial meningitis. We previously developed a clinical prediction rule, the Bacterial Meningitis Score, that classifies patients at very low risk of bacterial meningitis if they lack all of the following criteria: positive CSF Gram stain, CSF absolute neutrophil count (ANC) of at least 1000 cells/mu L, CSF protein of at least 80 mg/dL, peripheral blood ANC of at least 10 000 cells/mu L, and a history of seizure before or at the time of presentation. Objective To validate the Bacterial Meningitis Score in the era of widespread pneumococcal conjugate vaccination. Design, Setting, and Patients A multicenter, retrospective cohort study conducted in emergency departments of 20 US academic medical centers through the Pediatric Emergency Medicine Collaborative Research Committee of the American Academy of Pediatrics. All children aged 29 days to 19 years who presented at participating emergency departments between January 1, 2001, and June 30, 2004, with CSF pleocytosis ( CSF white blood cells >= 10 cells/mu L) and who had not received antibiotic treatment before lumbar puncture. Main Outcome Measure The sensitivity and negative predictive value of the Bacterial Meningitis Score. Results Among 3295 patients with CSF pleocytosis, 121 (3.7%; 95% confidence interval [CI], 3.1%-4.4%) had bacterial meningitis and 3174 (96.3%; 95% CI, 95.5%-96.9%) had aseptic meningitis. Of the 1714 patients categorized as very low risk for bacterial meningitis by the Bacterial Meningitis Score, only 2 had bacterial meningitis ( sensitivity, 98.3%; 95% CI, 94.2%-99.8%; negative predictive value, 99.9%; 95% CI, 99.6%-100%), and both were younger than 2 months old. A total of 2518 patients (80%) with aseptic meningitis were hospitalized. Conclusions This large multicenter study validates the Bacterial Meningitis Score prediction rule in the era of conjugate pneumococcal vaccine as an accurate decision support tool. The risk of bacterial meningitis is very low (0.1%) in patients with none of the criteria. The Bacterial Meningitis Score may be helpful to guide clinical decision making for the management of children presenting to emergency departments with CSF pleocytosis.	Childrens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Univ Calif Davis, Med Ctr, Dept Emergency Med, Sacramento, CA 95817 USA; Univ Calif Davis, Med Ctr, Dept Pediat, Sacramento, CA 95817 USA; Univ Calif Davis, Sch Med, Davis, CA 95616 USA; Texas Childrens Hosp, Dept Pediat, Houston, TX 77030 USA; Baylor Coll Med, Houston, TX 77030 USA; Rady Childrens Hosp San Diego Med Ctr, Dept Emergency Med, San Diego, CA USA; Univ Calif San Diego, Sch Med, Dept Pediat, San Diego, CA 92103 USA; Wake Emergency Phys PA, Raleigh, NC USA; WakeMed Hlth & Hosp, Raleigh, NC USA; Childrens Mercy Hosp & Clin, Dept Pediat, Kansas City, MO USA; Univ Missouri, Sch Med, Kansas City, MO 64108 USA; Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA; Univ Penn, Philadelphia, PA 19104 USA; Childrens Natl Med Ctr, Dept Emergency Med, Washington, DC 20010 USA; George Washington Univ, Sch Med, Washington, DC USA; Childrens Hosp & Res Ctr Oakland, Dept Emergency Med, Oakland, CA USA; Alfred I duPont Hosp Children, Dept Pediat, Wilmington, DE USA; Thomas Jefferson Med Coll, Wilmington, DE USA; Childrens Mem Hosp, Dept Pediat, Chicago, IL 60614 USA; Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; Childrens Med Ctr, Dept Emergency Med, Augusta, GA USA; Med Coll Georgia, Augusta, GA 30912 USA; Phoenix Childrens Hosp, Dept Emergency Med, Phoenix, AZ USA; Univ Arizona, Coll Med, Phoenix, AZ USA; Hasbro Childrens Hosp, Dept Emergency Med, Providence, RI USA; Hasbro Childrens Hosp, Dept Pediat, Providence, RI USA; Brown Med Sch, Providence, RI USA; Childrens Hosp & Reg Med Ctr, Dept Emergency Med, Seattle, WA USA; Univ Washington, Sch Med, Seattle, WA USA; Lebonheur Childrens Hosp & Med Ctr, Dept Pediat, Memphis, TN USA; Univ Tennessee, Ctr Hlth Sci, Coll Med, Memphis, TN 38163 USA; Childrens Hosp Wisconsin, Dept Emergency Med, Milwaukee, WI 53201 USA; Med Coll Wisconsin, Milwaukee, WI 53226 USA; Scottish Rite, Childrens Healthcare Atlanta, Pediat Emergency Med Associates LLC, Atlanta, GA USA; Morgan Stanley Childrens Hosp New York Presbyteri, Dept Emergency Med, New York, NY USA; Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; Childrens Hosp Los Angeles, Dept Pediat, Los Angeles, CA 90027 USA; Univ So Calif, Keck Sch Med, Los Angeles, CA USA; Columbus Childrens Hosp, Dept Emergency Med, Columbus, OH USA; Ohio State Univ, Columbus, OH 43210 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; Baylor College of Medicine; Baylor College of Medicine; Rady Childrens Hospital San Diego; University of California System; University of California San Diego; Children's Mercy Hospital; University of Missouri System; University of Missouri Kansas City; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Children's National Health System; George Washington University; Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; Nemours Alfred I. duPont Hospital for Children; Jefferson University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; University System of Georgia; Augusta University; Phoenix Children's Hospital; University of Arizona; Hasbro Children's Hospital; Hasbro Children's Hospital; Brown University; Seattle Children's Hospital; University of Washington; University of Washington Seattle; University of Tennessee System; University of Tennessee Health Science Center; Children's Hospital of Wisconsin; Medical College of Wisconsin; Children's Healthcare of Atlanta (CHOA); NewYork-Presbyterian Hospital; Morgan Stanley Children's Hospital; Columbia University; Children's Hospital Los Angeles; University of Southern California; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; University System of Ohio; Ohio State University	Nigrovic, LE (corresponding author), Childrens Hosp, Dept Med, 300 Longwood Ave, Boston, MA 02115 USA.	lise.nigrovic@childrens.harvard.edu	Steele, Dale W./D-8304-2015	Steele, Dale W./0000-0002-5689-0255; Nigrovic, Lise/0000-0002-6369-3997; Agrawal, Dewesh/0000-0001-5897-5976	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD040128] Funding Source: NIH RePORTER; NICHD NIH HHS [T32 HD40128-01] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Black S, 2004, PEDIATR INFECT DIS J, V23, P485, DOI 10.1097/01.inf.0000129685.04847.94; Black S, 2000, PEDIATR INFECT DIS J, V19, P187, DOI 10.1097/00006454-200003000-00003; BLAZER S, 1983, AM J CLIN PATHOL, V80, P386, DOI 10.1093/ajcp/80.3.386; Bonsu BK, 2004, PEDIATR INFECT DIS J, V23, P511, DOI 10.1097/01.inf.0000129689.58211.9e; Bonsu BK, 2004, PEDIATR INFECT DIS J, V23, P893, DOI 10.1097/01.inf.0000137586.42248.00; Breiman L., 1994, CLASSIFICATION REGRE; *CDCP, 2003, MMWR-MORBID MORTAL W, V52, P761; CHARLSON ME, 1987, ARCH INTERN MED, V147, P2155, DOI 10.1001/archinte.147.12.2155; Chavez-Bueno S, 2005, PEDIATR CLIN N AM, V52, P795, DOI 10.1016/j.pcl.2005.02.011; Dubos F, 2006, ARCH DIS CHILD, V91, P647, DOI 10.1136/adc.2005.085704; FLEISHER GR, 2006, TXB PEDIAT EMERGENCY, P788; Freedman SB, 2001, ARCH PEDIAT ADOL MED, V155, P1301, DOI 10.1001/archpedi.155.12.1301; Jansen GJ, 2000, J CLIN MICROBIOL, V38, P814, DOI 10.1128/JCM.38.2.814-817.2000; KAPLAN SL, 1986, PEDIATR INFECT DIS J, V5, P626, DOI 10.1097/00006454-198611000-00005; Kaplan SL, 2004, PEDIATRICS, V113, P443, DOI 10.1542/peds.113.3.443; Kyaw MH, 2006, NEW ENGL J MED, V354, P1455, DOI 10.1056/NEJMoa051642; Laupacis A, 1997, JAMA-J AM MED ASSOC, V277, P488, DOI 10.1001/jama.277.6.488; Martin TP, 1997, ANN EMERG MED, V29, P459, DOI 10.1016/S0196-0644(97)70217-8; MAYEFSKY JH, 1987, AM J MED, V82, P1175, DOI 10.1016/0002-9343(87)90221-X; McGinn TG, 2000, JAMA-J AM MED ASSOC, V284, P79, DOI 10.1001/jama.284.1.79; *MICR, 2003, MICR ACC COMP PROGR; Negrini B, 2000, PEDIATRICS, V105, P316, DOI 10.1542/peds.105.2.316; Nigrovic LE, 2002, PEDIATRICS, V110, P712, DOI 10.1542/peds.110.4.712; Oostenbrink R, 2002, ARCH PEDIAT ADOL MED, V156, P1189, DOI 10.1001/archpedi.156.12.1189; Oostenbrink R, 2004, EUR J EPIDEMIOL, V19, P109, DOI 10.1023/B:EJEP.0000017828.13995.76; Oostenbrink R, 2004, PEDIATR INFECT DIS J, V23, P1070, DOI 10.1097/01.inf.0000143501.15066.db; Peltola H, 2005, BMJ-BRIT MED J, V330, P18, DOI 10.1136/bmj.38301.657014.79; Pierart J, 2006, Rev Med Liege, V61, P581; Poppert S, 2005, J CLIN MICROBIOL, V43, P3390, DOI 10.1128/JCM.43.7.3390-3397.2005; Reilly BM, 2006, ANN INTERN MED, V144, P201, DOI 10.7326/0003-4819-144-3-200602070-00009; RUBENSTEIN JS, 1985, J PEDIATR-US, V107, P249, DOI 10.1016/S0022-3476(85)80137-2; Schuchat A, 1997, NEW ENGL J MED, V337, P970, DOI 10.1056/NEJM199710023371404; SPANOS A, 1989, JAMA-J AM MED ASSOC, V262, P2700, DOI 10.1001/jama.262.19.2700; *SPSS INC, 2003, SPSS WIND COMP PROGR; *STAT SOFTW INC, 2005, CART WIND COMP PROGR; Stiell IG, 1999, ANN EMERG MED, V33, P437, DOI 10.1016/S0196-0644(99)70309-4; Wasson JH, 1996, JAMA-J AM MED ASSOC, V275, P641, DOI 10.1001/jama.275.8.641; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; Whitney CG, 2003, NEW ENGL J MED, V348, P1737, DOI 10.1056/NEJMoa022823	39	200	209	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 3	2007	297	1					52	60		10.1001/jama.297.1.52	http://dx.doi.org/10.1001/jama.297.1.52			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	123BS	17200475				2022-12-28	WOS:000243271900021
J	Vanhollebeke, B; Truc, P; Poelvoorde, P; Pays, A; Joshi, PP; Katti, R; Jannin, JG; Pays, E				Vanhollebeke, Benoit; Truc, Philippe; Poelvoorde, Philippe; Pays, Annette; Joshi, Prashant P.; Katti, Ravindra; Jannin, Jean G.; Pays, Etienne			Brief report: Human Trypanosoma evansi infection linked to a lack of apolipoprotein L-I	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN SERUM; RHODESIENSE; RESISTANCE; PROTEIN; INDIA; GENE	Humans have innate immunity against Trypanosoma brucei brucei that is known to involve apolipoprotein L-I (APOL1). Recently, a case of T. evansi infection in a human was identified in India. We investigated whether the APOL1 pathway was involved in this occurrence. The serum of the infected patient was found to have no trypanolytic activity, and the finding was linked to the lack of APOL1, which was due to frameshift mutations in both APOL1 alleles. Trypanolytic activity was restored by the addition of recombinant APOL1. The lack of APOL1 explained the patient's infection with T. evansi.	Univ Libre Bruxelles, IBMM, Mol Parasitol Lab, B-6041 Gosselies, Belgium; Inst Rech Dev, Unite Rech Trypanosomoses Africaines 117, Montpellier, France; Govt Med Coll, Dept Med, Nagpur, Maharashtra, India; Directorate Hlth Serv, Bombay, Maharashtra, India; WHO, Communicable Dis Control Prevent & Eradicat, CH-1211 Geneva, Switzerland	Universite Libre de Bruxelles; Institut de Recherche pour le Developpement (IRD); World Health Organization	Pays, E (corresponding author), Univ Libre Bruxelles, IBMM, Mol Parasitol Lab, 12 Rue Professeurs Jeener & Brachet, B-6041 Gosselies, Belgium.	epays@ulb.ac.be		Vanhollebeke, Benoit/0000-0002-0353-365X				Gibson WC, 2005, PARASITOLOGY, V131, P143, DOI 10.1017/S0031182005007560; HAWKING F, 1978, T ROY SOC TROP MED H, V72, P405, DOI 10.1016/0035-9203(78)90136-0; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; Joshi PP, 2006, T ROY SOC TROP MED H, V100, P989, DOI 10.1016/j.trstmh.2005.11.003; Joshi PP, 2005, AM J TROP MED HYG, V73, P491, DOI 10.4269/ajtmh.2005.73.491; Juyal P. D., 1998, Journal of Parasitic Diseases, V22, P67; LAVERAN A, 1912, TRYPANOSOMES TRPANOS, P379; Pays E, 2006, NAT REV MICROBIOL, V4, P477, DOI 10.1038/nrmicro1428; Perez-Morga D, 2005, SCIENCE, V309, P469, DOI 10.1126/science.1114566; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; TRUC P, IN PRESS INFECT GENE; Vanhamme L, 2003, NATURE, V422, P83, DOI 10.1038/nature01461; Xong HV, 1998, CELL, V95, P839, DOI 10.1016/S0092-8674(00)81706-7	13	131	141	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 28	2006	355	26					2752	2756		10.1056/NEJMoa063265	http://dx.doi.org/10.1056/NEJMoa063265			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	120UA	17192540				2022-12-28	WOS:000243110500007
J	Johnson, C; Goodman, NW				Johnson, Chris; Goodman, Neville W.			Time to stop sniffing the air: snapshot survey	BRITISH MEDICAL JOURNAL			English	Editorial Material									Southmead Gen Hosp, Bristol BS10 5NB, Avon, England	Southmead Hospital	Goodman, NW (corresponding author), Southmead Gen Hosp, Bristol BS10 5NB, Avon, England.	nev.w.goodman@bris.ac.uk						Cattermole GN, 2002, ANAESTHESIA, V57, P411; GOLDSACK N, 1999, STUDENT BMJ, V7; LIM SL, 1994, ANAESTHESIA, V49, P255; Pinnock C, 1999, FUNDAMENTALS ANAESTH, P49	4	5	5	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 23	2006	333	7582					1295	1296		10.1136/bmj.39015.726690.47	http://dx.doi.org/10.1136/bmj.39015.726690.47			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121MC	17185713	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000243160700011
J	Weingart, SN; Flug, J; Brouillard, D; Morwayl, L; Partridge, A; Bartel, S; Shulman, LN; Connor, M				Weingart, Saul N.; Flug, Jonathan; Brouillard, Daniela; Morway, Laurinda; Partridge, Ann; Bartel, Sylvia; Shulman, Lawrence N.; Connor, Maureen			Oral chemotherapy safety practices at US cancer centres: questionnaire survey	BRITISH MEDICAL JOURNAL			English	Article								Objective To characterise current safety practices forth e use of oral chemotherapy. Design Written questionnaire survey of pharmacy directors of cancer centres. Setting Comprehensive cancer centres in the United States. Results Respondents from 42 (78%) of 54 eligible centres completed the survey, after consulting with 89 colleagues. Clinicians at 29 centres used handwritten prescriptions, two used preprinted paper prescriptions, and six used electronic systems for most oral chemotherapy prescribing. For six commonly used oral chemotherapies, on average 10 centres required a diagnosis on the prescription, 11 required the protocol number, four required the cycle number, nine required double checking by a second clinician, 14 required a calculation of body surface area, and 14 required a calculation of dose per square metre of body surface area. Only a third of centres requested patients' written informed consent when oral chemotherapy was given off protocol. Nearly a quarter (10) of centres had no formal process for monitoring patients' adherence. In the past year respondents at 10 centres reported at least one serious adverse drug event related to oral chemotherapy, and respondents at 13 centres reported a serious near miss. Conclusion Few of the safeguards routinely used for infusion chemotherapy have been adopted for oral chemotherapy at US cancer centres. There is currently no consensus at these centres about safe medication practices for oral chemotherapy.	Dana Farber Canc Inst, Ctr Patient Safety, Boston, MA 02115 USA; Tufts Univ, Sch Med, Boston, MA 02111 USA	Harvard University; Dana-Farber Cancer Institute; Tufts University	Weingart, SN (corresponding author), Dana Farber Canc Inst, Ctr Patient Safety, Boston, MA 02115 USA.	saul_weingart@dfci.harvard.edu			AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [K08HS011644] Funding Source: NIH RePORTER; AHRQ HHS [1 K08 HS 11644] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Bedell Cindi Holt, 2003, Clin J Oncol Nurs, V7, P5, DOI 10.1188/03.CJON.S6.5-9; Birner Ann, 2003, Clin J Oncol Nurs, V7, P158, DOI 10.1188/03.CJON.158-162; DeMario MD, 1998, J CLIN ONCOL, V16, P2557, DOI 10.1200/JCO.1998.16.7.2557; Faithfull Sara, 2004, Eur J Oncol Nurs, V8 Suppl 1, pS54, DOI 10.1016/j.ejon.2004.06.009; Griffin Elaine, 2003, Clin J Oncol Nurs, V7, P25, DOI 10.1188/03.CJON.S6.25-29; Hartigan Kristine, 2003, Clin J Oncol Nurs, V7, P21, DOI 10.1188/03.CJON.S6.21-24; O'Neill VJ, 2002, BRIT J CANCER, V87, P933, DOI 10.1038/sj.bjc.6600591; Partridge AH, 2002, JNCI-J NATL CANCER I, V94, P652; Schulmeister Lisa, 2005, Clin J Oncol Nurs, V9, P201, DOI 10.1188/05.CJON.201-205; Sharma S, 2001, Oncology (Williston Park), V15, P33; Taylor JA, 2006, CANCER-AM CANCER SOC, V107, P1400, DOI 10.1002/cncr.22131	11	75	78	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	FEB 24	2007	334	7590					407	409		10.1136/bmj.39069.489757.55	http://dx.doi.org/10.1136/bmj.39069.489757.55			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	142MQ	17223629	Green Published, Bronze			2022-12-28	WOS:000244654400032
J	Labandeira-Rey, M; Couzon, F; Boisset, S; Brown, EL; Bes, M; Benito, Y; Barbu, EM; Vazquez, V; Hook, M; Etienne, J; Vandenesch, F; Bowden, MG				Labandeira-Rey, Maria; Couzon, Florence; Boisset, Sandrine; Brown, Eric L.; Bes, Michele; Benito, Yvonne; Barbu, Elena M.; Vazquez, Vanessa; Hoeoek, Magnus; Etienne, Jerome; Vandenesch, Francois; Bowden, M. Gabriela			Staphylococcus aureus Panton-Valentine leukocidin causes necrotizing pneumonia	SCIENCE			English	Article							PROTEIN-A; EXPRESSION; RESISTANCE; REGULATOR; SIGMA(B); STRAINS; GENE	The Staphylococcus aureus Panton-Valentine leukocidin (PVL) is a pore-forming toxin secreted by strains epidemiologically associated with the current outbreak of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) and with the often-lethal necrotizing pneumonia. To investigate the role of PVL in pulmonary disease, we tested the pathogenicity of clinical isolates, isogenic PVL-negative and PVL-positive S. aureus strains, as well as purified PVL, in a mouse acute pneumonia model. Here we show that PVL is sufficient to cause pneumonia and that the expression of this leukotoxin induces global changes in transcriptional levels of genes encoding secreted and cell wall-anchored staphylococcal proteins, including the lung inflammatory factor staphylococcal protein A ( Spa).	Univ Lyon, F-69008 Lyon, France; Texas A&M Univ Syst, Hlth Sci Ctr, Inst Biosci & Technol, Ctr Extracellular Matrix Biol, Houston, TX 77030 USA; Univ Lyon 1, Fac Laennec, F-69008 Lyon, France; INSERM, Natl Reference Staphylocoques, E0230, F-69008 Lyon, France; Hop Edouard Herriot, Hosp Civils Lyon, F-69003 Lyon, France	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Lyon	Vandenesch, F (corresponding author), Univ Lyon, F-69008 Lyon, France.	denesch@univ-lyon1.fr; gbowden@ibt.tamhsc.edu	Boisset, Sandrine/C-3106-2011; Sarathy, Vanessa V./U-7803-2019; ETIENNE, Jerome/C-5471-2014; Vandenesch, Francois/C-7209-2014; Boisset, Sandrine SB/D-8144-2014	Sarathy, Vanessa V./0000-0002-1262-2101; ETIENNE, Jerome/0000-0002-3348-3315; Vandenesch, Francois/0000-0001-9412-7106; Boisset, Sandrine SB/0000-0001-8717-8749	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020624] Funding Source: NIH RePORTER; NIAID NIH HHS [AI020624] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Chambers HF, 2005, NEW ENGL J MED, V352, P1485, DOI 10.1056/NEJMe058023; Cheung AL, 1997, INFECT IMMUN, V65, P2243, DOI 10.1128/IAI.65.6.2243-2249.1997; de Bentzmann S, 2004, J INFECT DIS, V190, P1506, DOI 10.1086/424521; Foster TJ, 2005, NAT REV MICROBIOL, V3, P948, DOI 10.1038/nrmicro1289; Foster TJ, 1998, TRENDS MICROBIOL, V6, P484, DOI 10.1016/S0966-842X(98)01400-0; Genestier AL, 2005, J CLIN INVEST, V115, P3117, DOI 10.1172/JCI22684; Gillet Y, 2002, LANCET, V359, P753, DOI 10.1016/S0140-6736(02)07877-7; Gomez MI, 2004, NAT MED, V10, P842, DOI 10.1038/nm1079; Horsburgh MJ, 2002, J BACTERIOL, V184, P5457, DOI 10.1128/JB.184.19.5457-5467.2002; Huntzinger E, 2005, EMBO J, V24, P824, DOI 10.1038/sj.emboj.7600572; KONIG B, 1995, J INFECT DIS, V171, P607, DOI 10.1093/infdis/171.3.607; Kullik I, 1998, J BACTERIOL, V180, P4814, DOI 10.1128/JB.180.18.4814-4820.1998; OBrien L, 2002, MOL MICROBIOL, V44, P1033, DOI 10.1046/j.1365-2958.2002.02935.x; Oscarsson J, 2005, INT J MED MICROBIOL, V295, P253, DOI 10.1016/j.ijmm.2005.05.003; Palmqvist N, 2002, MICROB PATHOGENESIS, V33, P239, DOI 10.1006/mpat.2002.0533; Panton PN, 1932, LANCET, V1, P506; Said-Salim B, 2005, J CLIN MICROBIOL, V43, P3373, DOI 10.1128/JCM.43.7.3373-3379.2005; Thomas P, 2003, PEDIATR INFECT DIS J, V22, P201; Vojtov N, 2002, P NATL ACAD SCI USA, V99, P10102, DOI 10.1073/pnas.152152499	19	554	601	0	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 23	2007	315	5815					1130	1133		10.1126/science.1137165	http://dx.doi.org/10.1126/science.1137165			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	138UA	17234914				2022-12-28	WOS:000244387600038
J	Wan, YSY; Flavell, RA				Wan, Yisong Y.; Flavell, Richard A.			Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression	NATURE			English	Article							IMMUNOLOGICAL SELF-TOLERANCE; TRANSCRIPTION FACTOR FOXP3; SCURFY MOUSE; INTERLEUKIN-2; INFLAMMATION; CD25(+); PROTEIN	The naturally occurring regulatory T cell (T-R) is the pivotal cell type that maintains self-tolerance and exerts active immune suppression. The development and function of T-R cells is controlled by Foxp3 (refs 1, 2), a lack of which results in loss of T-R cells and massive multi-organ autoimmunity in scurfy mice and IPEX ( immune dysregulation, polyendocrinopathy, enteropathy, X-linked) patients(3,4). It is generally thought that, through a binary mechanism, Foxp3 expression serves as an on-and-off switch to regulate positively the physiology of T-R cells; however, emerging evidence associates decreased Foxp3 expression in T-R cells with various immune disorders(5-7). We hypothesized that Foxp3 regulates T(R)cell development and function in a dose-dependent, nonbinary manner, and that decreased Foxp3 expression can cause immune disease. Here, by generating a mouse model in which endogenous Foxp3 gene expression is attenuated in T-R cells, we show that decreased Foxp3 expression results in the development of an aggressive autoimmune syndrome similar to that of scurfy mice, but does not affect thymic development, homeostatic expansion/maintenance or transforming-growth-factor-beta-induced de novo generation of Foxp3-expressing cells. The immune-suppressive activities of T cells with attenuated Foxp3 expression were nearly abolished in vitro and in vivo, whereas their anergic properties in vitro were maintained. This was accompanied by decreased expression of T(R)cell 'signature genes'. Notably, T cells expressing decreased Foxp3 preferentially became T-helper 2 (T(H)2)-type effectors even in a T(H)1-polarizing environment. These cells instructed T(H)2 differentiation of conventional T cells, which contributed to the immune diseases observed in these mice. Thus, decreased Foxp3 expression causes immune disease by subverting the suppressive function of T-R cells and converting T-R cells into effector cells; these findings are important for understanding the regulation of T-R cell function and the aetiology of various human immune diseases.	Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06520 USA; Howard Hughes Med Inst, New Haven, CT 06520 USA	Yale University; Howard Hughes Medical Institute	Flavell, RA (corresponding author), Yale Univ, Sch Med, Immunobiol Sect, 300 Cedar St, New Haven, CT 06520 USA.	richard.flavell@yale.edu	Wan, Yisong/ABE-1200-2021	Wan, Yisong/0000-0003-4346-9717				Balandina A, 2005, BLOOD, V105, P735, DOI 10.1182/blood-2003-11-3900; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; D'Cruz LM, 2005, NAT IMMUNOL, V6, P1152, DOI 10.1038/ni1264; Fontenot JD, 2005, NAT IMMUNOL, V6, P331, DOI 10.1038/ni1179; Fontenot JD, 2005, NAT IMMUNOL, V6, P1142, DOI 10.1038/ni1263; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; Furtado GC, 2002, J EXP MED, V196, P851, DOI 10.1084/jem.20020190; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Hsieh CS, 2006, NAT IMMUNOL, V7, P401, DOI 10.1038/ni1318; Hsieh CS, 2004, IMMUNITY, V21, P267, DOI 10.1016/j.immuni.2004.07.009; Huan J, 2005, J NEUROSCI RES, V81, P45, DOI 10.1002/jnr.20522; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; LYON MF, 1990, P NATL ACAD SCI USA, V87, P2433, DOI 10.1073/pnas.87.7.2433; Miura Y, 2004, BLOOD, V104, P2187, DOI 10.1182/blood-2004-03-1040; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Ono M, 2006, J IMMUNOL, V176, P4748, DOI 10.4049/jimmunol.176.8.4748; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Sakaguchi S, 2000, CELL, V101, P455, DOI 10.1016/S0092-8674(00)80856-9; Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Shevach EM, 2000, ANNU REV IMMUNOL, V18, P423, DOI 10.1146/annurev.immunol.18.1.423; Takahashi T, 2000, J EXP MED, V192, P303, DOI 10.1084/jem.192.2.303; Wan YSY, 2005, P NATL ACAD SCI USA, V102, P5126, DOI 10.1073/pnas.0501701102; Wildin RS, 2001, NAT GENET, V27, P18, DOI 10.1038/83707	27	660	710	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 15	2007	445	7129					766	770		10.1038/nature05479	http://dx.doi.org/10.1038/nature05479			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	136EK	17220876	Bronze			2022-12-28	WOS:000244205200045
J	Christeson, GL; McIntosh, KD; Karson, JA				Christeson, Gail L.; McIntosh, Kirk D.; Karson, Jeffrey A.			Inconsistent correlation of seismic layer 2a and lava layer thickness in oceanic crust	NATURE			English	Article							EAST PACIFIC RISE; HYDROTHERMAL ALTERATION; EMPLACEMENT PROCESSES; HESS DEEP; EVOLUTION; SECTION; 9-DEGREES-N; CONSTRAINTS; RIDGE; ZONE	At mid-ocean ridges with fast to intermediate spreading rates, the upper section of oceanic crust is composed of lavas overlying a sheeted dyke complex. These units are formed by dykes intruding into rocks overlying a magma chamber, with lavas erupting at the ocean floor. Seismic reflection data acquired over young oceanic crust commonly image a reflector known as 'layer 2A', which is typically interpreted as defining the geologic boundary between lavas and dykes(1-3). An alternative hypothesis is that the reflector is associated with an alteration boundary within the lava unit(4-6). Many studies have used mapped variability in layer 2A thickness to make inferences regarding the geology of the oceanic crust, including volcanic construction, dyke intrusion and faulting(7-10). However, there has been no link between the geologic and seismological structure of oceanic crust except at a few deep drill holes. Here we show that, although the layer 2A reflector is imaged near the top of the sheeted dyke complex at fast-spreading crust located adjacent to the Hess Deep rift, it is imaged significantly above the sheeted dykes section at intermediate-spreading crust located near the Blanco transform fault. Although the lavas and underlying transition zone thicknesses differ by about a factor of two, the shallow seismic structure is remarkably similar at the two locations. This implies that seismic layer 2A cannot be used reliably to map the boundary between lavas and dykes in young oceanic crust. Instead we argue that the seismic layer 2A reflector corresponds to an alteration boundary that can be located either within the lava section or near the top of the sheeted dyke complex of oceanic crust.	Univ Texas, Inst Geophys, Jackson Sch Geosci, Austin, TX 78758 USA; Syracuse Univ, Dept Earth Sci, Syracuse, NY 13244 USA	University of Texas System; University of Texas Austin; Syracuse University	Christeson, GL (corresponding author), Univ Texas, Inst Geophys, Jackson Sch Geosci, JJ Pickle Res Campus,Mail Code R2200,10100 Burnet, Austin, TX 78758 USA.	gail@ig.utexas.edu	McIntosh, Kirk/G-6143-2010; Christeson, Gail/B-9967-2008; Christeson, Gail/R-3777-2019	Christeson, Gail/0000-0002-4749-4429; Christeson, Gail/0000-0002-4749-4429				Alt J., 1996, P ODP SCI RES, V148, P417; ALT JC, 1986, J GEOPHYS RES-SOLID, V91, P309, DOI 10.1029/JB091iB10p10309; Buck WR, 1997, GEOLOGY, V25, P935; Canales JP, 2005, J GEOPHYS RES-SOL EA, V110, DOI 10.1029/2005JB003630; Carbotte S, 1998, GEOLOGY, V26, P455, DOI 10.1130/0091-7613(1998)026<0455:IOMSAS>2.3.CO;2; CARESS DW, 1992, J GEOPHYS RES-SOL EA, V97, P9243, DOI 10.1029/92JB00287; CHRISTESON GL, 1994, J GEOPHYS RES-SOL EA, V99, P17957, DOI 10.1029/94JB01252; CHRISTESON GL, 1992, GEOPHYS RES LETT, V19, P1045, DOI 10.1029/91GL00971; DELANEY JR, 1981, J GEOPHYS RES, V86, P1747, DOI 10.1029/JB086iB12p11747; FRANCHETEAU J, 1990, EARTH PLANET SC LETT, V101, P281, DOI 10.1016/0012-821X(90)90160-Y; FRANCHETEAU J, 1992, EARTH PLANET SC LETT, V111, P109, DOI 10.1016/0012-821X(92)90173-S; GILLIS KM, 1995, EARTH PLANET SC LETT, V134, P473, DOI 10.1016/0012-821X(95)00137-2; HARDING AJ, 1989, J GEOPHYS RES-SOLID, V94, P12163, DOI 10.1029/JB094iB09p12163; HARDING AJ, 1993, J GEOPHYS RES-SOL EA, V98, P13925, DOI 10.1029/93JB00886; HERRON TJ, 1982, GEOPHYS RES LETT, V9, P17, DOI 10.1029/GL009i001p00017; Hooft EEE, 1996, EARTH PLANET SC LETT, V142, P289, DOI 10.1016/0012-821X(96)00101-X; JUTEAU T, 1995, MAR GEOPHYS RES, V17, P399, DOI 10.1007/BF01371786; Karson JA, 2002, GEOCHEM GEOPHY GEOSY, V3, DOI 10.1029/2001GC000155; Karson JA, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2000JB000051; Karson JA, 2003, HETEROGENEITY IN THE CRUST AND UPPER MANTLE: NATURE, SCALING AND SEISMIC PROPERTIES, P99; KENT GM, 1994, J GEOPHYS RES-SOL EA, V99, P9097, DOI 10.1029/93JB02872; LONSDALE P, 1988, J GEOPHYS RES-SOLID, V93, P13551, DOI 10.1029/JB093iB11p13551; ROHR KMM, 1988, GEOLOGY, V16, P533, DOI 10.1130/0091-7613(1988)016<0533:ADCSAT>2.3.CO;2; Schouten H, 1999, EARTH PLANET SC LETT, V169, P37, DOI 10.1016/S0012-821X(99)00063-1; SEARLE RC, 1986, MAR GEOPHYS RES, V8, P95; Tivey MA, 1998, GEOPHYS RES LETT, V25, P3631, DOI 10.1029/98GL02752; TOOMEY DR, 1990, NATURE, V347, P639, DOI 10.1038/347639a0; VERA EE, 1994, J GEOPHYS RES-SOL EA, V99, P3031, DOI 10.1029/93JB02107; VERA EE, 1990, J GEOPHYS RES-SOLID, V95, P15529, DOI 10.1029/JB095iB10p15529; 2006, IODP PRELIM REP, V312, P45	30	60	60	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 25	2007	445	7126					418	421		10.1038/nature05517	http://dx.doi.org/10.1038/nature05517			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	128WD	17251977				2022-12-28	WOS:000243689500037
J	Engle, PL; Black, MM; Behrman, JR; de Mello, MC; Gertler, PJ; Kapiriri, L; Martorell, R; Young, ME				Engle, Patrice L.; Black, Maureen M.; Behrman, Jere R.; Cabral de Mello, Meena; Gertler, Paul J.; Kapiriri, Lydia; Martorell, Reynaldo; Eming Young, Mary		Int Child Dev Steering Grp	Child development in developing countries 3 - Strategies to avoid the loss of developmental potential in more than 200 million children in the developing world	LANCET			English	Review							NUTRITIONAL SUPPLEMENTATION; PSYCHOSOCIAL STIMULATION; COGNITIVE-DEVELOPMENT; MATERNAL DEPRESSION; PRESCHOOL-CHILDREN; EARLY INTERVENTION; MOTOR DEVELOPMENT; CONTROLLED-TRIAL; HOME VISITATION; YOUNG-CHILDREN	This paper is the third in the Child Development Series. The first paper showed that more than 200 million children under 5 years of age in developing countries do not reach their developmental potential. The second paper identified four well-documented risks: stunting, iodine deficiency, iron deficiency anaemia, and inadequate cognitive stimulation, plus four potential risks based on epidemiological evidence: maternal depression, violence exposure, environmental contamination, and malaria. This paper assesses strategies to promote child development and to prevent or ameliorate the loss of developmental potential. The most effective early child development programmes provide direct learning experiences to children and families, are targeted toward younger and disadvantaged children, are of longer duration, high quality, and high intensity, and are integrated with family support, health, nutrition, or educational systems and services. Despite convincing evidence, programme coverage is low. To achieve the Millennium Development Goals of reducing poverty and ensuring primary school completion for both girls and boys, governments and civil society should consider expanding high quality, cost-effective early child development programmes.	Univ Maryland, Dept Pediat, Baltimore, MD 21201 USA; UNICEF, New York, NY USA; Univ Penn, Dept Econ, Philadelphia, PA 19104 USA; WHO, CH-1211 Geneva, Switzerland; World Bank, Washington, DC 20433 USA; Univ Calif Berkeley, Haas Sch Business, Berkeley, CA 94720 USA; Univ Toronto, Toronto, ON, Canada; Emory Univ, Rollins Sch PUbl Hlth, Hubert Dept Global Hlth, Atlanta, GA 30322 USA	University System of Maryland; University of Maryland Baltimore; UNICEF; University of Pennsylvania; World Health Organization; The World Bank; University of California System; University of California Berkeley; University of Toronto; Emory University; Rollins School Public Health	Engle, PL (corresponding author), Calif Polytech State Univ San Luis Obispo, Dept Psychol & Child Dev, San Luis Obispo, CA 93407 USA.	Pengle@calpoly.edu	Behrman, Jere R/A-9734-2009; Martorell, Reynaldo/I-2539-2012	Black, Maureen/0000-0002-6427-4639				ABOUD F, IN PRESS J HLTH POPU; Aboud FE, 2006, EARLY CHILD RES Q, V21, P46, DOI 10.1016/j.ecresq.2006.01.008; ALDERMAN H, IN PRESS SYNERGY NUT; Allhusen V, 2002, AM EDUC RES J, V39, P133; Als H, 2004, PEDIATRICS, V113, P846, DOI 10.1542/peds.113.4.846; Araya R, 2003, LANCET, V361, P995, DOI 10.1016/S0140-6736(03)12825-5; Armecin G., 2006, EARLY CHILDHOOD DEV; Armstrong KL, 1999, J PAEDIATR CHILD H, V35, P237, DOI 10.1046/j.1440-1754.1999.00348.x; Armstrong KL, 2000, J PAEDIATR CHILD H, V36, P555, DOI 10.1046/j.1440-1754.2000.00591.x; Baker-Henningham H, 2005, ARCH DIS CHILD, V90, P1230, DOI 10.1136/adc.2005.073015; Behrman J. R., 2004, GLOBAL CRISES GLOBAL, P363; Behrman JR, 2005, OXFORD B ECON STAT, V67, P547, DOI 10.1111/j.1468-0084.2005.00131.x; Behrman JR, 2004, REV ECON STAT, V86, P108, DOI 10.1162/003465304323023714; Berlinski S., 2006, EFFECT PREPRIMARY ED; Bolton P, 2003, JAMA-J AM MED ASSOC, V289, P3117, DOI 10.1001/jama.289.23.3117; Brooks-Gunn J, 2003, EARLY CHILD DEV 21 C; Bross DC, 2000, WORLD PERSPECTIVES C; Chen CH, 2000, J PSYCHOSOM RES, V49, P395, DOI 10.1016/S0022-3999(00)00180-X; CHOPRA M, 2001, ASSESSMENT PARTICIPA; COLLETTA N, 1993, EARLY CHILD DEV CARE, V96, P161; COOPER P, 1999, BRIT J PSYCHIAT, P554; Cueto S, 1999, REV PSICOLOGIA, V17, P74; Currie J, 2001, J ECON PERSPECT, V15, P213, DOI 10.1257/jep.15.2.213; Currie J, 2001, RES LABOR E, V20, P103; Dewey KG, 2002, J NUTR, V132, P3249, DOI 10.1093/jn/132.11.3249; Dewey KG, 2001, J NUTR, V131, P262, DOI 10.1093/jn/131.2.262; Doryan EA, 2002, FROM EARLY CHILD DEVELOPMENT TO HUMAN DEVELOPMENT, P375; DOSSANTOS I, 1999, PILOT TEST CHILD DEV; *EFA GLOB MON REP, 2006, EFA GLOB MON REP 200; Engle PL, 2000, P NUTR SOC, V59, P25, DOI 10.1017/S0029665100000045; ENGLE PL, IN PRESS ECD AFRICA; ENGLE PL, 2001, PROMOTING GROWTH DEV, P23; Ertem IO, 2006, PEDIATRICS, V118, pE124, DOI 10.1542/peds.2005-2704; Faber M, 2005, AM J CLIN NUTR, V82, P1032, DOI 10.1093/ajcn/82.5.1032; GERTLER P, 2004, MEDIUM TERM IMPACT O; Ghuman S, 2005, ECON DEV CULT CHANGE, V54, P129, DOI 10.1086/431258; GHUMAN S, 2006, CHILDRENS NUTR SCH Q; Gillespie S, 2002, PUBLIC HEALTH NUTR, V5, P513, DOI 10.1979/PHN2002351; *GLOB MON REP TEAM, 2005, GLOB MON REP 2006; *GLOB MON REP TEAM, 2004, EFA GLOB MON REP 200; Grantham-McGregor S, 2002, LANCET, V359, P542, DOI 10.1016/S0140-6736(02)07719-X; Grantham-McGregor S, 2007, LANCET, V369, P60, DOI 10.1016/S0140-6736(07)60032-4; GRANTHAMMCGREGOR SM, 1991, LANCET, V338, P1, DOI 10.1016/0140-6736(91)90001-6; Gunnar MR, 2001, DEV PSYCHOPATHOL, V13, P611, DOI 10.1017/S095457940100311X; Haas JD, 2005, J NUTR, V135, P2823, DOI 10.1093/jn/135.12.2823; HALL DMB, 1996, HLTH ALL CHILDREN RE; Hamadani JD, 2006, J NUTR, V136, P2645, DOI 10.1093/jn/136.10.2645; Heaver R., 2005, STRENGTHENING COUNTR; Heckman JJ, 2006, SCIENCE, V312, P1900, DOI 10.1126/science.1128898; Hiscock H, 2002, BRIT MED J, V324, P1062, DOI 10.1136/bmj.324.7345.1062; Hoddinott J, 2004, ECON DEV CULT CHANGE, V53, P37, DOI 10.1086/423252; Holding PA, 2004, AM J TROP MED HYG, V71, P71, DOI 10.4269/ajtmh.2004.71.2_suppl.0700071; Jaramillo A., 2003, EARLY CHILDHOOD CARE; JARAMILLO A, 2002, EARLY CHILDHOOD DEV; Jukes Matthew, 2005, Food and Nutrition Bulletin, V26, pS193; Kagitcibasi C, 2001, J APPL DEV PSYCHOL, V22, P333, DOI 10.1016/S0193-3973(01)00071-5; Karoly L. A., 1998, INVESTING OUR CHILDR; Karoly LA., 2005, EARLY CHILDHOOD INTE; Knowles JC., 2005, EC RETURNS INVESTING; Kohli T., 1990, INDIAN J DISABIL REH, V4, P65; Landrigan Philip J, 2004, Int J Occup Med Environ Health, V17, P175; Landry SH, 2006, DEV PSYCHOL, V42, P627, DOI 10.1037/0012-1649.42.4.627; Lanphear BP, 2005, ENVIRON HEALTH PERSP, V113, P894, DOI 10.1289/ehp.7688; Li HJ, 2003, PEDIATRICS, V112, P1156, DOI 10.1542/peds.112.5.1156; LIEN NM, 1977, AM J CLIN NUTR, V30, P1734, DOI 10.1093/ajcn/30.10.1734; Love JM, 2005, DEV PSYCHOL, V41, P885, DOI 10.1037/0012-1649.41.6.885; Lozoff B, 2000, PEDIATRICS, V105, DOI 10.1542/peds.105.4.e51; MacMillan HL, 2005, LANCET, V365, P1786, DOI 10.1016/S0140-6736(05)66388-X; Magnuson KA, 2005, FUTURE CHILD, V15, P169, DOI 10.1353/foc.2005.0005; Majumdar I, 2003, J TROP PEDIATRICS, V49, P84, DOI 10.1093/tropej/49.2.84; Malekpour M, 2004, BRIT J DEV DISABIL, V50, P79; MALUCCIO J, 2006, 207 INT FOOD POL RES; Manary MJ, 2002, ANN TROP PAEDIATR, V22, P133, DOI 10.1179/027249302125000850; Marshall NL, 2004, CURR DIR PSYCHOL SCI, V13, P165, DOI 10.1111/j.0963-7214.2004.00299.x; Martorell Reynaldo, 2005, Food and Nutrition Bulletin, V26, pS5; McCormick MC, 2006, PEDIATRICS, V117, P771, DOI 10.1542/peds.2005-1316; MCKAY H, 1978, SCIENCE, V200, P270, DOI 10.1126/science.635585; Mehansho H, 2006, J NUTR, V136, P1059, DOI 10.1093/jn/136.4.1059; *MINED UNICEF CELE, ED YOUR CHILD CUB EX; Minkovitz CS, 2003, JAMA-J AM MED ASSOC, V290, P3081, DOI 10.1001/jama.290.23.3081; Montie JE, 2006, EARLY CHILD RES Q, V21, P313, DOI 10.1016/j.ecresq.2006.07.007; Morenza L., 2005, EVALUACION PROYECTO, P1; Morris SS, 2004, J NUTR, V134, P2336, DOI 10.1093/jn/134.9.2336; Murray L, 1997, ARCH DIS CHILD, V77, P99, DOI 10.1136/adc.77.2.99; MUSTARD J, 1999, EARLY YEARS STUDY RE, P1; Myers R., 1992, 12 WHO SURVIVE; Nair M K C, 2004, Indian Pediatr, V41, P227; *NIPCCD, 1992, NAT EV ICDS; Noble KG, 2005, FUTURE CHILD, V15, P71, DOI 10.1353/foc.2005.0006; Olds D, 1998, JAMA-J AM MED ASSOC, V280, P1238, DOI 10.1001/jama.280.14.1238; PANTHURAAMPHORN C, 1998, J PRENATAL PERINATAL, V12, P163; Parker SW, 2005, DEV PSYCHOPATHOL, V17, P621, DOI 10.1017/S0954579405050303; Pelto GH., 1999, NUTR ANTHR, V22, P21, DOI [10.1525/nua.1999.22.2.21, DOI 10.1525/NUA.1999.22.2.21]; PHATAK P, 2000, PSYCHOL STUD, V45, P83; Pollitt E, 1993, Monogr Soc Res Child Dev, V58, P1; POLLITT E, DEV TIMING MODERATOR; POWELL C, 1989, Pediatrics, V84, P157; Powell C, 2004, BMJ-BRIT MED J, V329, P89, DOI 10.1136/bmj.38132.503472.7C; Powell C., 2004, EVALUATION ROVING CA; PSACHAROPOULOS G, 1994, INDIGENOUS PEOPLE PO; Rahman A, 2003, PSYCHOL MED, V33, P1161, DOI 10.1017/S0033291703008286; RAO N, 2004, IMPACT INTEGRATED CH; Rao N., 2005, INT J EARLY CHILDH, V37, P15, DOI [10.1007/BF03168343, DOI 10.1007/BF03168343]; RAO N, 2002, INT DEV EARLY CHILDH, P97; Rogan WJ, 2001, NEW ENGL J MED, V344, P1421, DOI 10.1056/NEJM200105103441902; Rutter M, 2004, DEV PSYCHOL, V40, P81, DOI 10.1037/0012-1649.40.1.81; *SAV CHILDR, 2003, WHATS DIFF IMP EARL; *SAV CHILDR MYANM, 2004, EAR CHILDH CAR DEV P; Sazawal S, 2006, LANCET, V367, P133, DOI 10.1016/S0140-6736(06)67962-2; SCHROEDER DG, 1995, J NUTR, V125, pS1051; SUPER CM, 1990, CHILD DEV, V61, P29, DOI 10.2307/1131045; Sweet MA, 2004, CHILD DEV, V75, P1435, DOI 10.1111/j.1467-8624.2004.00750.x; Tchibindat F, 2004, J HEALTH POPUL NUTR, V22, P59; *UNAIDS, UNAIDS0620E; *UNICEF, 2005, GLOB THEM REP INT EA; *UNICEF, 1997, CHILDR VIOL; *UNICEF, 2005, ANN REP; *UNICEF UNAIDS USA, 2004, CHILDR BRINK; Vazir S., 1999, J INDIAN ACAD APPL P, V25, P11; VICTORA MD, 1990, CHILD CARE HLTH DEV, V16, P151, DOI 10.1111/j.1365-2214.1990.tb00647.x; WABER DP, 1981, AM J CLIN NUTR, V34, P807, DOI 10.1093/ajcn/34.4.807; Walker SP, 2007, LANCET, V369, P145, DOI 10.1016/S0140-6736(07)60076-2; Watanabe K, 2005, J NUTR, V135, P1918, DOI 10.1093/jn/135.8.1918; WHO/UNICEF, 2005, WORLD MAL REP; WINICK M, 1975, SCIENCE, V190, P1173, DOI 10.1126/science.1198103; Wolf AW, 2002, SOC PSYCH PSYCH EPID, V37, P169, DOI 10.1007/s001270200011; *WORLD BANK, 2002, IND CHALL DEV OV SEC; World Bank, 2006, REP NUTR CENTR DEV; Young M. E., 2002, EARLY CHILD DEV HUMA; Zlotkin S, 2002, AM J CLIN NUTR, V76, P693, DOI 10.1093/ajcn/76.3.693; Zlotkin Stanley H., 2004, Indian Journal of Pediatrics, V71, P1015, DOI 10.1007/BF02828118	131	601	615	1	104	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 20	2007	369	9557					229	242		10.1016/S0140-6736(07)60112-3	http://dx.doi.org/10.1016/S0140-6736(07)60112-3			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	128XG	17240290	Green Submitted			2022-12-28	WOS:000243692400032
J	Headlam, D; Brown, M				Headlam, Dave; Brown, Matthew			Comment on "The geometry of musical chords"	SCIENCE			English	Editorial Material									Univ Rochester, Eastman Sch Mus, Rochester, NY 14604 USA	University of Rochester	Headlam, D (corresponding author), Univ Rochester, Eastman Sch Mus, 26 Gibbs St, Rochester, NY 14604 USA.	dheadlam@esm.rochester.edu						FOX JJ, 1971, GRADUS PARNASSUM; FUX JJ, 1725, GRADUS PARNASSUM; MANN A, 1987, THEORY PRACTICE GREA; ROSNER BS, 1992, MUSIC PERCEPT, V9, P383; SCHENKER H, 2001, COUNTERPOINT, V2, P11; Schenker H., 1922, KONTRAPUNKT; Schenker Heinrich, 1979, FREE COMPOSITION; Tymoczko D, 2006, SCIENCE, V313, P72, DOI 10.1126/science.1126287	8	3	3	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 19	2007	315	5810								10.1126/science.1134013	http://dx.doi.org/10.1126/science.1134013			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126SI	17234932				2022-12-28	WOS:000243535400019
J	Kobasa, D; Jones, SM; Shinya, K; Kash, JC; Copps, J; Ebihara, H; Hatta, Y; Kim, JH; Halfmann, P; Hatta, M; Feldmann, F; Alimonti, JB; Fernando, L; Li, Y; Katze, MG; Feldmann, H; Kawaoka, Y				Kobasa, Darwyn; Jones, Steven M.; Shinya, Kyoko; Kash, John C.; Copps, John; Ebihara, Hideki; Hatta, Yasuko; Kim, Jin Hyun; Halfmann, Peter; Hatta, Masato; Feldmann, Friederike; Alimonti, Judie B.; Fernando, Lisa; Li, Yan; Katze, Michael G.; Feldmann, Heinz; Kawaoka, Yoshihiro			Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus	NATURE			English	Article							A VIRUSES; HEMAGGLUTININ; EXPRESSION; DISEASE; ORIGIN; GENES; ROLES	The 1918 influenza pandemic was unusually severe, resulting in about 50 million deaths worldwide(1). The 1918 virus is also highly pathogenic in mice, and studies have identified a multigenic origin of this virulent phenotype in mice(2-4). However, these initial characterizations of the 1918 virus did not address the question of its pathogenic potential in primates. Here we demonstrate that the 1918 virus caused a highly pathogenic respiratory infection in a cynomolgus macaque model that culminated in acute respiratory distress and a fatal outcome. Furthermore, infected animals mounted an immune response, characterized by dysregulation of the antiviral response, that was insufficient for protection, indicating that atypical host innate immune responses may contribute to lethality. The ability of influenza viruses to modulate host immune responses, such as that demonstrated for the avian H5N1 influenza viruses(5), may be a feature shared by the virulent influenza viruses.	Univ Tokyo, Dept Microbiol & Immunol, Div Virol, Tokyo 1088639, Japan; Publ Hlth Agcy Canada, Special Pathogens Program Natl Microbiol Lab, Winnipeg, MB R3E 3R2, Canada; Univ Manitoba, Dept Immunol, Winnipeg, MB R3E 3R2, Canada; Univ Manitoba, Dept Med Microbiol, Winnipeg, MB R3E 3R2, Canada; Tottori Univ, Avian Zoonosis Res Ctr, Tottori 6808550, Japan; Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA; Univ Washington, Washington Natl Primate Res Ctr, Seattle, WA 98195 USA; Canadian Food Inspect Agcy, Natl Ctr Foreign Anim Dis, Canadian Sci Ctr Human & Anim Hlth, Winnipeg, MB R3E 3M4, Canada; Univ Tokyo, Inst Med Sci, Int Res Ctr Infect Dis, Tokyo 1088639, Japan; Japan Sci & Technol Agcy, CREST, Saitama 3220012, Japan; Univ Wisconsin, Dept Pathobiol Sci, Madison, WI 53706 USA	University of Tokyo; Public Health Agency of Canada; University of Manitoba; University of Manitoba; Tottori University; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Canadian Food Inspection Agency; Canadian Science Centre for Human & Animal Health; University of Tokyo; Japan Science & Technology Agency (JST); University of Wisconsin System; University of Wisconsin Madison	Kawaoka, Y (corresponding author), Univ Tokyo, Dept Microbiol & Immunol, Div Virol, Tokyo 1088639, Japan.	kawaokay@svm.vetmed.wisc.edu	Kash, John/ABE-8280-2021; Halfmann, Peter/W-8084-2019	Ebihara, Hideki/0000-0002-2576-9735				Al-Shahrour F, 2005, NUCLEIC ACIDS RES, V33, pW460, DOI 10.1093/nar/gki456; Baas T, 2006, J VIROL, V80, P10813, DOI 10.1128/JVI.00851-06; Basler CF, 2001, P NATL ACAD SCI USA, V98, P2746, DOI 10.1073/pnas.031575198; Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365; de Jong MD, 2006, NAT MED, V12, P1203, DOI 10.1038/nm1477; Garcia-Sastre A, 1998, VIROLOGY, V252, P324, DOI 10.1006/viro.1998.9508; Hayden FG, 1998, J CLIN INVEST, V101, P643, DOI 10.1172/JCI1355; Johnson NPAS, 2002, B HIST MED, V76, P105, DOI 10.1353/bhm.2002.0022; Kash JC, 2006, J VIROL, V80, P3009, DOI 10.1128/JVI.80.6.3009-3020.2006; Kash JC, 2006, NATURE, V443, P578, DOI 10.1038/nature05181; Kato H, 2006, NATURE, V441, P101, DOI 10.1038/nature04734; Kobasa D, 2004, NATURE, V431, P703, DOI 10.1038/nature02951; Krug RM, 2003, VIROLOGY, V309, P181, DOI 10.1016/S0042-6822(03)00119-3; Kuiken T, 2003, VET PATHOL, V40, P304, DOI 10.1354/vp.40-3-304; Li SD, 2006, VIROLOGY, V349, P13, DOI 10.1016/j.virol.2006.01.005; Matikainen S, 2006, J VIROL, V80, P3515, DOI 10.1128/JVI.80.7.3515-3522.2006; Neumann G, 1999, P NATL ACAD SCI USA, V96, P9345, DOI 10.1073/pnas.96.16.9345; Pichlmair A, 2006, SCIENCE, V314, P997, DOI 10.1126/science.1132998; REED L. J., 1938, AMER JOUR HYG, V27, P493; Reid AH, 2000, P NATL ACAD SCI USA, V97, P6785, DOI 10.1073/pnas.100140097; Reid AH, 2004, J VIROL, V78, P12462, DOI 10.1128/JVI.78.22.12462-12470.2004; Reid AH, 1999, P NATL ACAD SCI USA, V96, P1651, DOI 10.1073/pnas.96.4.1651; Reid AH, 2002, J VIROL, V76, P10717, DOI 10.1128/JVI.76.21.10717-10723.2002; Rimmelzwaan GF, 2001, J VIROL, V75, P6687, DOI 10.1128/JVI.75.14.6687-6691.2001; Seo SH, 2002, NAT MED, V8, P950, DOI 10.1038/nm757; Skoner DP, 1999, J INFECT DIS, V180, P10, DOI 10.1086/314823; Taubenberger JK, 2005, NATURE, V437, P889, DOI 10.1038/nature04230; Tumpey TM, 2005, SCIENCE, V310, P77, DOI 10.1126/science.1119392; Tumpey TM, 2002, P NATL ACAD SCI USA, V99, P13849, DOI 10.1073/pnas.212519699; Winternitz MC, 1920, PATHOLOGY INFLUENZA	30	730	768	0	74	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 18	2007	445	7125					319	323		10.1038/nature05495	http://dx.doi.org/10.1038/nature05495			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126HT	17230189				2022-12-28	WOS:000243504700046
J	Ledford, H				Ledford, Heidi			Turning back the clock	NATURE			English	News Item																			0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 18	2007	445	7125					249	249		10.1038/445249a	http://dx.doi.org/10.1038/445249a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126HT	17230164				2022-12-28	WOS:000243504700013
J	Willett, WC; Collins, FS; Manolio, TA				Willett, Walter C.; Collins, Francis S.; Manolio, Teri A.			Merging and emerging cohorts	NATURE			English	Editorial Material							PROSTATE-CANCER; GENE; BREAST		Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Willett, WC (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.	walter.willett@channing.harvard.edu	Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [R01 CA092447] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092447] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amundadottir LT, 2006, NAT GENET, V38, P652, DOI 10.1038/ng1808; Collins FS, 2004, NATURE, V429, P475, DOI 10.1038/nature02628; Feigelson HS, 2006, CANCER RES, V66, P2468, DOI 10.1158/0008-5472.CAN-05-3574; Hunter DJ, 2005, NAT REV CANCER, V5, P977, DOI 10.1038/nrc1754; Land CE, 2003, RADIAT RES, V160, P707, DOI 10.1667/RR3082; LANGHOLZ B, 1999, MONOGR NATL CANC I, V26, P39; National Heart Lung and Blood Institute, NAT HEART LUNG BLOOD; Samet JM, 1998, EPIDEMIOL REV, V20, P1; Smith-Warner SA, 2006, AM J EPIDEMIOL, V163, P1053, DOI 10.1093/aje/kwj127; Spivey A, 2006, ENVIRON HEALTH PERSP, V114, pA466, DOI 10.1289/ehp.114-a466; Watts G, 2006, BRIT MED J, V332, P1052	11	56	61	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 18	2007	445	7125					257	258		10.1038/445257a	http://dx.doi.org/10.1038/445257a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126HT	17230171				2022-12-28	WOS:000243504700021
J	Hutton, W				Hutton, Will			Why the NHS needs people power	BRITISH MEDICAL JOURNAL			English	Article												WHutton@theworkfoundation.com						Barrett A, 2006, BRIT MED J, V333, P1118, DOI 10.1136/bmj.39008.624051.BE; HORNER L, 2007, DELIBERATIVE DEMOCRA; MOORE M, 1995, CREATING PUBLIC VALU, P114; *NHS HLTH SOC CAR, NHS IMM STAT 2004 5; *SOC ISS RES CTR, 1999, B SOCIAL ISSUES 0823; TAYLOR R, 2005, STAND BE COUNTED	6	3	3	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JAN 13	2007	334	7584					69	70		10.1136/bmj.39080.574699.47	http://dx.doi.org/10.1136/bmj.39080.574699.47			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	127DZ	17218707	Green Published			2022-12-28	WOS:000243566800024
J	Walker, SP; Wachs, TD; Gardner, JM; Lozoff, B; Wasserman, GA; Pollitt, E; Carter, JA				Walker, Susan P.; Wachs, Theodore D.; Gardner, Julie Meeks; Lozoff, Betsy; Wasserman, Gail A.; Pollitt, Ernesto; Carter, Julie A.		Int Child Dev Steering Grp	Child development in developing countries 2 - Child development: risk factors for adverse outcomes in developing countries	LANCET			English	Review							IRON-DEFICIENCY ANEMIA; LOW-BIRTH-WEIGHT; RANDOMIZED CONTROLLED-TRIAL; MOTHER-INFANT RELATIONSHIP; SEVERE FALCIPARUM-MALARIA; FOR-GESTATIONAL-AGE; COGNITIVE-DEVELOPMENT; MOTOR DEVELOPMENT; NUTRITIONAL SUPPLEMENTATION; PSYCHOSOCIAL STIMULATION	Poverty and associated health, nutrition, and social factors prevent at least 200 million children in developing countries from attaining their developmental potential. We review the evidence linking compromised development with modifiable biological and psychosocial risks encountered by children from birth to 5 years of age. We identify four key risk factors where the need for intervention is urgent: stunting, inadequate cognitive stimulation, iodine deficiency, and iron deficiency anaemia. The evidence is also sufficient to warrant interventions for malaria, intrauterine growth restriction, maternal depression, exposure to violence, and exposure to heavy metals. We discuss the research needed to clarify the effect of other potential risk factors on child development. The prevalence of the risk factors and their effect on development and human potential are substantial. Furthermore, risks often occur together or cumulatively, with concomitant increased adverse effects on the development of the world's poorest children.	Univ W Indies, Res Inst Trop Med, Epidemiol Res Unit, Kingston 7, Jamaica; Purdue Univ, Dept Psychol Sci, W Lafayette, IN 47907 USA; Univ W Indies, Caribbean Child Dev Ctr, Mona, Jamaica; Univ Michigan, Ctr Human Growth & Dev, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pediat & Communicable Dis, Ann Arbor, MI 48109 USA; Columbia Univ, Div Child & Adolescent Psychiat, New York, NY USA; Univ Calif Davis, Davis, CA 95616 USA; UCL, Inst Child Hlth, Ctr Int Hlth & Dev, London, England	University West Indies Mona Jamaica; Purdue University System; Purdue University; Purdue University West Lafayette Campus; University West Indies Mona Jamaica; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Columbia University; University of California System; University of California Davis; University of London; University College London	Walker, SP (corresponding author), Univ W Indies, Res Inst Trop Med, Epidemiol Res Unit, Kingston 7, Jamaica.	susan.walker@uwimona.edu.jm						ADAIR LS, 1985, AM J CLIN NUTR, V41, P948, DOI 10.1093/ajcn/41.5.948; Affonso DD, 2000, J PSYCHOSOM RES, V49, P207, DOI 10.1016/S0022-3999(00)00176-8; AGARWAL D K, 1992, Indian Pediatrics, V29, P467; Akman M, 2004, ACTA PAEDIATR, V93, P1391, DOI 10.1080/08035250410030946; Anderson JW, 1999, AM J CLIN NUTR, V70, P525; Bao XL, 1999, CHINESE MED J-PEKING, V112, P520; Barbarin OA, 2001, AM J ORTHOPSYCHIAT, V71, P16, DOI 10.1037/0002-9432.71.1.16; Barenbaum J, 2004, J CHILD PSYCHOL PSYC, V45, P41, DOI 10.1046/j.0021-9630.2003.00304.x; BARRETT DE, 1982, DEV PSYCHOL, V18, P541, DOI 10.1037/0012-1649.18.4.541; Berkman DS, 2002, LANCET, V359, P564, DOI 10.1016/S0140-6736(02)07744-9; Black MM, 2004, AM J CLIN NUTR, V80, P903, DOI 10.1093/ajcn/80.4.903; Black MM, 2004, PEDIATRICS, V113, P1297, DOI 10.1542/peds.113.5.1297; Black MM, 2003, J NUTR, V133, p3927S, DOI 10.1093/jn/133.11.3927S; BLACK MM, 2002, PEDIATR RES, V51, P2565; Blair C, 2002, AM PSYCHOL, V57, P111, DOI 10.1037//0003-066X.57.2.111; Bleichrodt N., 1987, PREVENTION CONTROL I, P65; Boivin MJ, 2002, J DEV BEHAV PEDIATR, V23, P353, DOI 10.1097/00004703-200210000-00010; Bradley RH, 2005, INT J BEHAV DEV, V29, P468, DOI 10.1080/01650250500146925; Brown LK, 2000, J CHILD PSYCHOL PSYC, V41, P81, DOI 10.1111/1469-7610.00550; Bryan J, 2004, NUTR REV, V62, P295, DOI 10.1301/nr.2004.aug.295-306; Calderon J, 2001, ENVIRON RES, V85, P69, DOI 10.1006/enrs.2000.4106; Callender JE, 1998, ACTA PAEDIATR, V87, P1247, DOI 10.1080/080352598750030924; CAO XY, 1994, NEW ENGL J MED, V331, P1739, DOI 10.1056/NEJM199412293312603; Carter JA, 2006, DEV MED CHILD NEUROL, V48, P51, DOI 10.1017/S0012162206000107; Carter JA, 2005, J NEUROL NEUROSUR PS, V76, P476, DOI 10.1136/jnnp.2004.043893; Carter JA, 2003, BRAIN RES REV, V43, P57, DOI 10.1016/S0165-0173(03)00192-9; Chang SM, 2002, J CHILD PSYCHOL PSYC, V43, P775, DOI 10.1111/1469-7610.00088; Choudhury N, 2003, J NUTR, V133, P3162, DOI 10.1093/jn/133.10.3162; Clark KM, 2006, AMBUL PEDIATR, V6, P65, DOI 10.1016/j.ambp.2005.11.003; Cohen J., 2013, STAT POWER ANAL BEHA, DOI DOI 10.4324/9780203771587; Cooper PJ, 2002, BRIT J PSYCHIAT, V180, P76, DOI 10.1192/bjp.180.1.76; Cooper PJ, 1999, BRIT J PSYCHIAT, V175, P554, DOI 10.1192/bjp.175.6.554; Daniels MC, 2005, J NUTR, V135, P2589, DOI 10.1093/jn/135.11.2589; Daniels MC, 2004, J NUTR, V134, P1439, DOI 10.1093/jn/134.6.1439; Davidson PW, 1998, JAMA-J AM MED ASSOC, V280, P701, DOI 10.1001/jama.280.8.701; de Onis M, 1998, EUR J CLIN NUTR, V52, pS5; Dewey KG, 2001, J NUTR, V131, P262, DOI 10.1093/jn/131.2.262; Dybdahl R, 2001, CHILD DEV, V72, P1214, DOI 10.1111/1467-8624.00343; Eickmann SH, 2003, DEV MED CHILD NEUROL, V45, P536, DOI 10.1017/S0012162203000987; Factor-Litvak P, 1999, ENVIRON HEALTH PERSP, V107, P9, DOI 10.2307/3434284; Fernando SD, 2003, AM J TROP MED HYG, V69, P582, DOI 10.4269/ajtmh.2003.69.582; Friel JK, 2003, J PEDIATR-US, V143, P582, DOI 10.1067/S0022-3476(03)00301-9; GALLER JR, 1989, J AM ACAD CHILD PSY, V28, P254, DOI 10.1097/00004583-198903000-00018; Galler JR, 2000, J CHILD PSYCHOL PSYC, V41, P747, DOI 10.1017/S0021963099005910; Gardner JM, 2003, J PEDIATR-US, V143, P634, DOI 10.1067/S0022-3476(03)00455-4; Gardner JMM, 2005, AM J CLIN NUTR, V82, P399, DOI 10.1093/ajcn/82.2.399; Gardner JMM, 1999, J CHILD PSYCHOL PSYC, V40, P819, DOI 10.1111/1469-7610.00497; Golub MS, 2006, NEUROTOXICOL TERATOL, V28, P3, DOI 10.1016/j.ntt.2005.10.005; Gorman KS, 1996, CHILD DEV, V67, P314; GORMAN KS, 1992, INFANT BEHAV DEV, V15, P279, DOI 10.1016/0163-6383(92)80001-B; Grandjean P, 1997, NEUROTOXICOL TERATOL, V19, P417, DOI 10.1016/S0892-0362(97)00097-4; Grantham-McGregor S, 2001, J NUTR, V131, p649S, DOI 10.1093/jn/131.2.649S; Grantham-McGregor S, 2007, LANCET, V369, P60, DOI 10.1016/S0140-6736(07)60032-4; Grantham-McGregor Sally M., 1999, Food and Nutrition Bulletin, V20, P53; Grantham-McGregor Sally M., 1999, Food and Nutrition Bulletin, V20, P76; Grantham-McGregor SM, 1998, J PEDIATR-US, V132, P661, DOI 10.1016/S0022-3476(98)70357-9; GRANTHAMMCGREGOR S, 1995, J NUTR, V125, pS2233; GRANTHAMMCGREGOR SM, 1991, LANCET, V338, P1, DOI 10.1016/0140-6736(91)90001-6; GRAVES PL, 1978, AM J CLIN NUTR, V31, P541, DOI 10.1093/ajcn/31.3.541; Guerrant DI, 1999, AM J TROP MED HYG, V61, P707, DOI 10.4269/ajtmh.1999.61.707; Hasanbegovic Edo, 2004, Med Arh, V58, P227; Holding PA, 1999, T ROY SOC TROP MED H, V93, P529, DOI 10.1016/S0035-9203(99)90368-1; HUSAINI MA, 1991, AM J CLIN NUTR, V54, P799, DOI 10.1093/ajcn/54.5.799; *I MED NAT RES COU, 2000, NEUR NEIGHB SCI EARL; IDJRADINATA P, 1993, LANCET, V341, P1, DOI 10.1016/0140-6736(93)92477-B; International Zinc Consultative Group, 2004, FOOD NUTR BULL, V25, pS99, DOI DOI 10.1177/15648265040251S205; Jain A, 2002, PEDIATRICS, V109, P1044, DOI 10.1542/peds.109.6.1044; Kagitcibasi C, 2001, J APPL DEV PSYCHOL, V22, P333, DOI 10.1016/S0193-3973(01)00071-5; Kihara M, 2006, TROP MED INT HEALTH, V11, P386, DOI 10.1111/j.1365-3156.2006.01579.x; KURUGANTI K, 2005, CHILD YOUTH ENV, V15, P83; Lanphear BP, 2005, ENVIRON HEALTH PERSP, V113, P894, DOI 10.1289/ehp.7688; Laor N, 1996, ARCH GEN PSYCHIAT, V53, P416, DOI 10.1001/archpsyc.1996.01830050052008; Li HJ, 2004, EARLY HUM DEV, V76, P1, DOI 10.1016/j.earlhumdev.2003.09.007; LIDDELL C, 1994, INT J BEHAV DEV, V17, P613, DOI 10.1177/016502549401700403; Lima AAM, 2004, CLIN INFECT DIS, V38, P1552, DOI 10.1086/420827; Lind T, 2003, AM J CLIN NUTR, V77, P883, DOI 10.1093/ajcn/77.4.883; Liu XC, 2001, PSYCHIAT RES, V101, P115, DOI 10.1016/S0165-1781(00)00244-4; Lozoff B, 1998, CHILD DEV, V69, P24, DOI 10.1111/j.1467-8624.1998.tb06130.x; Lozoff B, 2003, PEDIATRICS, V112, P846; LOZOFF B, 1987, PEDIATRICS, V79, P981; Lozoff B, 1996, J PEDIATR-US, V129, P382, DOI 10.1016/S0022-3476(96)70070-7; Lozoff B, 2000, PEDIATRICS, V105, DOI 10.1542/peds.105.4.e51; Lozoff B, 2006, ARCH PEDIAT ADOL MED, V160, P1108, DOI 10.1001/archpedi.160.11.1108; Lozoff B, 2006, NUTR REV, V64, pS34, DOI 10.1301/nr.2006.may.S34-S43; Lustig SL, 2004, J AM ACAD CHILD PSY, V43, P24, DOI 10.1097/00004583-200401000-00012; MAGWAZA A S, 1991, South African Journal of Psychology, V21, P21; MAGWAZA AS, 1993, CHILD ABUSE NEGLECT, V17, P795, DOI 10.1016/S0145-2134(08)80010-5; Mara DD, 2003, PUBLIC HEALTH, V117, P452, DOI 10.1016/S0033-3506(03)00143-4; MARSH K, 1995, NEW ENGL J MED, V332, P1399, DOI 10.1056/NEJM199505253322102; Martorell R, 1992, HUMAN GROWTH BASIC C, P143; Masten A, 2003, RESILIENCE VULNERABI, P1; MCKAY H, 1978, SCIENCE, V200, P270, DOI 10.1126/science.635585; Mendez MA, 1999, J NUTR, V129, P1555, DOI 10.1093/jn/129.8.1555; MOFFATT MEK, 1994, J PEDIATR-US, V125, P527, DOI 10.1016/S0022-3476(94)70003-6; MORA JO, 1979, DHEW PUB NIH, P255; Morley R, 1999, ARCH DIS CHILD, V81, P247, DOI 10.1136/adc.81.3.247; Murray L, 1997, PSYCHOL MED, V27, P253, DOI 10.1017/S0033291796004564; Niehaus MD, 2002, AM J TROP MED HYG, V66, P590, DOI 10.4269/ajtmh.2002.66.590; O'Donnell KJ, 2002, DEV MED CHILD NEUROL, V44, P76, DOI 10.1017/S0012162201001712; Oberhelman RA, 1998, AM J TROP MED HYG, V58, P470, DOI 10.4269/ajtmh.1998.58.470; Patel V, 2003, ARCH DIS CHILD, V88, P34, DOI 10.1136/adc.88.1.34; PENG H, 1994, CHINESE J PREV MED, V28, P216; PHAROAH POD, 1995, DEV MED CHILD NEUROL, V37, P744; Pollitt E, 2000, EUR J CLIN NUTR, V54, pS2, DOI 10.1038/sj.ejcn.1600999; Pollitt E, 1997, AM J CLIN NUTR, V66, P1357, DOI 10.1093/ajcn/66.6.1357; Pollitt E, 1993, Monogr Soc Res Child Dev, V58, P1; POLLITT E, 1991, FUTURE DIRECTIONS IN, P43; Posada G, 2002, DEV PSYCHOL, V38, P67, DOI 10.1037//0012-1649.38.1.67; Posada G, 1999, DEV PSYCHOL, V35, P1379, DOI 10.1037/0012-1649.35.6.1379; Qian M, 2005, ASIA PAC J CLIN NUTR, V14, P32; Rahman A, 2002, CHILD CARE HLTH DEV, V28, P51, DOI 10.1046/j.1365-2214.2002.00239.x; RICHARDSON SA, 1972, J HEALTH SOC BEHAV, V13, P276, DOI 10.2307/2136764; RICHTER L, 2000, INT PERSPECTIVES CHI, V1, P160; Sachdev HPS, 2005, PUBLIC HEALTH NUTR, V8, P117, DOI 10.1079/PHN2004677; Shaw JA, 2003, CLIN CHILD FAM PSYCH, V6, P237, DOI 10.1023/B:CCFP.0000006291.10180.bd; Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342; Stoltzfus RJ, 2001, BRIT MED J, V323, P1389, DOI 10.1136/bmj.323.7326.1389; STOLTZFUS RJ, 2005, IRON DEFICIENCY ANAE, V1, P163; Strauss RS, 2000, JAMA-J AM MED ASSOC, V283, P625, DOI 10.1001/jama.283.5.625; Tomlinson M, 2005, CHILD DEV, V76, P1044, DOI 10.1111/j.1467-8624.2005.00896.x; Tsai SY, 2003, NEUROTOXICOLOGY, V24, P747, DOI 10.1016/S0161-813X(03)00029-9; UNICEF, 2004, STAT WORLDS CHILDR 2; *US GEOL SURV, NAT WAT QUAL ASS PRO; Valenzuela M, 1997, DEV PSYCHOL, V33, P845, DOI 10.1037/0012-1649.33.5.845; VILLAR J, 1984, PEDIATRICS, V74, P783; von der Lippe AL, 1999, INT J BEHAV DEV, V23, P703, DOI 10.1080/016502599383766; WABER DP, 1981, AM J CLIN NUTR, V34, P807, DOI 10.1093/ajcn/34.4.807; Wachs T., 2000, NECESSARY NOT SUFFIC; Wachs Theodore D., 2005, Food and Nutrition Bulletin, V26, pS159; Walker SP, 2005, LANCET, V366, P1804, DOI 10.1016/S0140-6736(05)67574-5; Walker SP, 2004, J NUTR, V134, P1417, DOI 10.1093/jn/134.6.1417; WALTER T, 1989, PEDIATRICS, V84, P7; Wasserman GA, 2006, ENVIRON HEALTH PERSP, V114, P124, DOI 10.1289/ehp.8030; Wasserman GA, 2004, ENVIRON HEALTH PERSP, V112, P1329, DOI 10.1289/ehp.6964; Watanabe K, 2005, J NUTR, V135, P1918, DOI 10.1093/jn/135.8.1918; Watkins WE, 1997, PSYCHOL BULL, V121, P171, DOI 10.1037/0033-2909.121.2.171; Wendland-Carro J, 1999, CHILD DEV, V70, P713, DOI 10.1111/1467-8624.00051; *WHO, 2004, IOD STAT WORLDW 2004; *WHO, ARS CONT GROUND WAT; WHO, 2002, RED RISKS PROM HLTH; Williams J, 1999, BRIT MED J, V318, P693, DOI 10.1136/bmj.318.7185.693; WOLFF PH, 1995, J CHILD PSYCHOL PSYC, V36, P633, DOI 10.1111/j.1469-7610.1995.tb02318.x	142	1180	1232	4	204	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 13	2007	369	9556					145	157		10.1016/S0140-6736(07)60076-2	http://dx.doi.org/10.1016/S0140-6736(07)60076-2			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	126TK	17223478				2022-12-28	WOS:000243538200034
J	Cuchel, M; Bloedon, LT; Szapary, PO; Kolansky, DM; Wolfe, ML; Sarkis, A; Millar, JS; Ikewaki, K; Siegelman, ES; Gregg, RE; Rader, DJ				Cuchel, Marina; Bloedon, LeAnne T.; Szapary, Philippe O.; Kolansky, Daniel M.; Wolfe, Megan L.; Sarkis, Antoine; Millar, John S.; Ikewaki, Katsunori; Siegelman, Evan S.; Gregg, Richard E.; Rader, Daniel J.			Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DENSITY-LIPOPROTEIN APHERESIS; LDL APHERESIS; ABETALIPOPROTEINEMIA; INSIGHTS; RECEPTOR; GENE	BACKGROUND: Patients with homozygous familial hypercholesterolemia have markedly elevated cholesterol levels, which respond poorly to drug therapy, and a very high risk of premature cardiovascular disease. Inhibition of the microsomal triglyceride transfer protein may be effective in reducing cholesterol levels in these patients. METHODS: We conducted a dose-escalation study to examine the safety, tolerability, and effects on lipid levels of BMS-201038, an inhibitor of the microsomal triglyceride transfer protein, in six patients with homozygous familial hypercholesterolemia. All lipid-lowering therapies were suspended 4 weeks before treatment. The patients received BMS-201038 at four different doses (0.03, 0.1, 0.3, and 1.0 mg per kilogram of body weight per day), each for 4 weeks, and returned for a final visit after a 4-week drug washout period. Analysis of lipid levels, safety laboratory analyses, and magnetic resonance imaging of the liver for fat content were performed throughout the study. RESULTS: All patients tolerated titration to the highest dose, 1.0 mg per kilogram per day. Treatment at this dose decreased low-density lipoprotein (LDL) cholesterol levels by 50.9% and apolipoprotein B levels by 55.6% from baseline (P<0.001 for both comparisons). Kinetic studies showed a marked reduction in the production of apolipoprotein B. The most serious adverse events were elevation of liver aminotransferase levels and accumulation of hepatic fat, which at the highest dose ranged from less than 10% to more than 40%. CONCLUSIONS: Inhibition of the microsomal triglyceride transfer protein by BMS-201038 resulted in the reduction of LDL cholesterol levels in patients with homozygous familial hypercholesterolemia, owing to reduced production of apolipoprotein B. However, the therapy was associated with elevated liver aminotransferase levels and hepatic fat accumulation.	Univ Penn, Med Ctr, Sch Med, BRBII III Labs 654, Philadelphia, PA 19104 USA; St Joseph Univ, Hotel Dieu France Hosp, Beirut, Lebanon; Jikei Univ, Sch Med, Tokyo, Japan; Bristol Myers Squibb Co, Pharmaceut Res Inst, Lawrenceville, NJ USA	University of Pennsylvania; Jikei University; Bristol-Myers Squibb	Rader, DJ (corresponding author), Univ Penn, Med Ctr, Sch Med, BRBII III Labs 654, 421 Curie Blvd, Philadelphia, PA 19104 USA.	rader@mail.med.upenn.edu			NCRR NIH HHS [M01-RR00040, K12-RR017625] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [K12RR017625, M01RR000040] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Berriot-Varoqueaux N, 2000, ANNU REV NUTR, V20, P663, DOI 10.1146/annurev.nutr.20.1.663; Cole TG, 2001, CLIN CHEM, V47, P712; Fishbein M, 2005, J CLIN GASTROENTEROL, V39, P619, DOI 10.1097/00004836-200508000-00012; Goldstein JL, 2001, METABOLIC MOL BASES, V8th, P2863; Gordon BR, 1998, AM J CARDIOL, V81, P407, DOI 10.1016/S0002-9149(97)00947-8; Hobbs Helen H., 1992, Human Mutation, V1, P445, DOI 10.1002/humu.1380010602; Hudgins LC, 2002, CARDIOVASC DRUG REV, V20, P271; ILLINGWORTH DR, 1980, ARCH NEUROL-CHICAGO, V37, P659, DOI 10.1001/archneur.1980.00500590083015; Kane J, 2001, METAB MOL BASES INHE, P2717; Liao W, 2003, J LIPID RES, V44, P978, DOI 10.1194/jlr.M300020-JLR200; Mabuchi H, 1998, AM J CARDIOL, V82, P1489, DOI 10.1016/S0002-9149(98)00692-4; Millar JS, 2005, ARTERIOSCL THROM VAS, V25, P560, DOI 10.1161/01.ATV.0000155323.18856.a2; Otvos James D, 2002, Clin Lab, V48, P171; Rader DJ, 2003, J CLIN INVEST, V111, P1795, DOI 10.1172/JCI200318925; RADER DJ, 1993, JAMA-J AM MED ASSOC, V270, P865, DOI 10.1001/jama.270.7.865; Rinella, 2003, LIVER TRANSPLANT, V9, P1230; Rinella ME, 2003, LIVER TRANSPLANT, V9, P851, DOI 10.1053/jlts.2003.50153; Sachais BS, 2005, J CLIN APHERESIS, V20, P252, DOI 10.1002/jca.20036; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; Thompson GR, 2003, ATHEROSCLEROSIS, V167, P1, DOI 10.1016/S0021-9150(02)00251-4; WETTERAU JR, 1992, SCIENCE, V258, P999; Wetterau JR, 1998, SCIENCE, V282, P751, DOI 10.1126/science.282.5389.751; Wetterau JR, 1997, BBA-LIPID LIPID MET, V1345, P136, DOI 10.1016/S0005-2760(96)00168-3	23	399	431	1	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 11	2007	356	2					148	156		10.1056/NEJMoa061189	http://dx.doi.org/10.1056/NEJMoa061189			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	124NE	17215532				2022-12-28	WOS:000243373700007
J	Ropper, AH; Gorson, KC				Ropper, Allan H.; Gorson, Kenneth C.			Concussion	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MILD HEAD-INJURY; TRAUMATIC BRAIN-INJURY; COLLEGIATE FOOTBALL PLAYERS; SPORT-RELATED CONCUSSION; NEW-ORLEANS CRITERIA; NCAA CONCUSSION; MANAGEMENT; DIAGNOSIS; RECOVERY; GUIDELINES	A 64-year-old woman slipped on an icy walk, falling forward and striking her forehead. She had a brief convulsion immediately after the fall, was unresponsive for less than 1 minute, and awakened with a severe generalized headache and nausea but no vomiting. In addition to being perplexed about the circumstances of the fall, she could not recall the previous few hours. She was awake and oriented and had no abnormalities on neurologic examination. Tenderness and a scalp contusion were apparent at the site of the impact, and there were abrasions on her right cheek. What is the expected course, and how should her case be managed?	Caritas St Elizabeths Med Ctr, Dept Neurol, Boston, MA 02135 USA; Tufts Univ, Sch Med, Boston, MA 02111 USA	St. Elizabeth's Medical Center; Tufts University	Ropper, AH (corresponding author), Caritas St Elizabeths Med Ctr, Dept Neurol, 736 Cambridge St, Boston, MA 02135 USA.							Asplund CA, 2004, CLIN J SPORT MED, V14, P339, DOI 10.1097/00042752-200411000-00003; Bailes JE, 2001, NEUROSURGERY, V48, P26, DOI 10.1097/00006123-200101000-00005; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Blostein P, 2003, J TRAUMA, V55, P450, DOI 10.1097/01.TA.0000038545.24879.4D; BURTON HL, 1931, P ROY SOC MED, V24, P1405; Collie A, 2006, BRIT J SPORT MED, V40, P550, DOI 10.1136/bjsm.2005.019802; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; Ernst A, 2005, OTOLARYNG HEAD NECK, V132, P554, DOI 10.1016/j.otohns.2004.09.034; Evans RW., 1992, PROGNOSIS NEUROLOGIC, P97; FISHER CM, 1966, NEUROLOGY, V16, P826, DOI 10.1212/WNL.16.8.826; Goadsby PJ, 2006, BMJ-BRIT MED J, V332, P25, DOI 10.1136/bmj.332.7532.25; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Hofman PAM, 2000, J NEUROL NEUROSUR PS, V68, P416, DOI 10.1136/jnnp.68.4.416; Ibanez J, 2004, J NEUROSURG, V100, P825, DOI 10.3171/jns.2004.100.5.0825; JENNETT B, 1992, DIS NERVOUS SYSTEM C, P1229; Johnston KM, 2000, CLIN J SPORT MED, V10, P209; Kelly JP, 1997, NEUROLOGY, V48, P581; Lloyd DA, 1997, LANCET, V349, P821, DOI 10.1016/S0140-6736(96)09356-7; McAllister TW, 2002, NEUROREHABILITATION, V17, P265; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; McCrory PR, 1998, SPORTS MED, V25, P131, DOI 10.2165/00007256-199825020-00005; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; Mickeviciene D, 2002, EUR J NEUROL, V9, P581, DOI 10.1046/j.1468-1331.2002.00497.x; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Perron AD, 2001, ACAD EMERG MED, V8, P296, DOI 10.1111/j.1553-2712.2001.tb01312.x; POVLISHOCK JT, 1995, NEUROTRAUMA, P1325; QUIGLEY T B, 1959, Med Times, V87, P1241; Rutherford A, 2005, J CLIN EXP NEUROPSYC, V27, P299, DOI 10.1080/13803390490515504; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Sakas DE, 1997, MED HYPOTHESES, V48, P431, DOI 10.1016/S0306-9877(97)90042-6; SARAN A, 1988, INT J PSYCHIAT MED, V18, P75, DOI 10.2190/15AH-JB7Q-U94T-JEAF; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; SNOEK JW, 1984, BRAIN, V107, P15, DOI 10.1093/brain/107.1.15; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Sturmi JE, 1998, SPORTS MED, V25, P351, DOI 10.2165/00007256-199825060-00001	45	135	140	0	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 11	2007	356	2					166	172		10.1056/NEJMcp064645	http://dx.doi.org/10.1056/NEJMcp064645			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	124NE	17215534				2022-12-28	WOS:000243373700009
J	Masoud, MT; Shaikh, MY				Masoud, Mohammad Tahir; Shaikh, M. Yusuf			Subconjunctival swelling - Prolapse of orbital fat	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Stirling Royal Infirm, Stirling FK8 2AU, Scotland		Masoud, MT (corresponding author), Stirling Royal Infirm, Stirling FK8 2AU, Scotland.	seham_tm@hotmail.com							0	6	6	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 4	2007	356	1					67	67		10.1056/NEJMicm054986	http://dx.doi.org/10.1056/NEJMicm054986			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	122EX	17202457				2022-12-28	WOS:000243209600010
J	Wadman, M				Wadman, Meredith			When the party's over	NATURE			English	News Item																		Wadman M, 2005, NATURE, V437, P618, DOI 10.1038/437618a; [No title captured]	2	8	8	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 4	2007	445	7123					13	13		10.1038/445013a	http://dx.doi.org/10.1038/445013a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	122KG	17203035				2022-12-28	WOS:000243225100009
J	Durga, J; Verhoef, P; Anteunis, LJC; Schouten, E; Kok, FJ				Durga, Jane; Verhoef, Petra; Anteunis, Lucien J. C.; Schouten, Evert; Kok, Frans J.			Effects of folic acid supplementation on hearing in older adults - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							CARDIOVASCULAR RISK; HOMOCYSTEINE; FOLATE; VITAMIN-B-12; ASSOCIATION; THRESHOLDS; IMPAIRMENT; DISEASE	Background: Age-related hearing loss is a common chronic condition of elderly persons. Low folate status has been associated with poor hearing. Objective: To determine whether folic acid supplementation slows age-related hearing loss. Design: Double-blind, randomized, placebo-controlled trial conducted from September 2000 to December 2004. Setting: The Netherlands. Participants: 728 older men and women recruited from municipal and blood bank registries with plasma total homocysteine concentrations 13 mu mol/L or greater serum and vitamin B-12 concentrations 200 pmol/L or greater at screening, and no middle ear dysfunction, unilateral hearing loss, or pathologic ear conditions unrelated to aging. Intervention: Daily oral folic acid (800 mu g) or placebo supplementation for 3 years. Measurements: 3-year change in hearing thresholds, assessed as the average of the pure-tone air conduction thresholds of both ears of the low (0.5-kHz, 1-kHz, and 2-kHz) and high (4-kHz, 6-kHz, and 8-kHz) frequencies. Results: Initial median hearing thresholds were 11.7 dB (interquartile range, 7.5 to 17.5 dB) for low frequencies and 34.2 dB (interquartile range, 22.5 to 50.0 dB) for high frequencies. Sixteen participants (2%) were lost to follow-up. After 3 years, thresholds of the low frequencies increased by 1.0 dB (95% CI, 0.6 to 1.4 dB) in the folic acid group and by 1.7 dB (CI, 1.3 to 2.1 dB) in the placebo group (difference, -0.7 dB [CI, -1.2 to -0.1 dB]; P = 0.020). Folic acid supplementation did not affect the decline in hearing high frequencies. Limitations: The strict criterion for participation on the basis of serum homocysteine concentrations limits extrapolation to the general population. Folic acid fortification of food was prohibited in the Netherlands during the study, so baseline folate levels in participants were about half of those found in the U. S. population. Conclusions: Folic acid supplementation slowed the decline in hearing of the speech frequencies associated with aging in a population from a country without folic acid fortification of food. The effect requires confirmation, especially in populations from countries with folic acid fortification programs.	Univ Wageningen & Res Ctr, NL-6700 HB Wageningen, Netherlands; Wageningen Ctr Food Sci, Wageningen, Netherlands; Univ Hosp Maastricht, Maastricht, Netherlands	Wageningen University & Research; Wageningen University & Research; Maastricht University; Maastricht University Medical Centre (MUMC)	Durga, J (corresponding author), Nestle Res Ctr, Cognit Sci Grp, Nutr & Hlth Dept, POB 44, CH-1000 Lausanne 26, Switzerland.	jane.durga@rdls.nestle.com		Verhoef, Petra/0000-0002-6927-6182				Berner B, 2000, ACTA OTO-LARYNGOL, V120, P633, DOI 10.1080/000164800750000469; Bonding P, 2004, OTOL NEUROTOL, V25, P610, DOI 10.1097/00129492-200407000-00032; BRANT LJ, 1990, J ACOUST SOC AM, V88, P813, DOI 10.1121/1.399731; Brattstrom L, 1998, BMJ-BRIT MED J, V316, P894, DOI 10.1136/bmj.316.7135.894; Cadoni G, 2004, ACTA OTO-LARYNGOL, V124, P608, DOI 10.1080/00016480410016216; CHIODO AA, 1994, EUR ARCH OTO-RHINO-L, V251, P375; Chisolm TH, 2003, INT J AUDIOL S2, V42, p2S3, DOI 10.3109/14992020309074637; Clarke R, 2000, SEMIN THROMB HEMOST, V26, P341, DOI 10.1055/s-2000-8101; COOPER JC, 1991, EAR HEARING, V12, P304, DOI 10.1097/00003446-199110000-00002; de Bree A, 2001, AM J CLIN NUTR, V73, P1027; DEBIE SE, 1987, PROPOSAL UNIFROMIZAT; Divenyi PL, 2005, J ACOUST SOC AM, V118, P1089, DOI 10.1121/1.1953207; Durga J, 2006, NEUROBIOL AGING, V27, P482, DOI 10.1016/j.neurobiolaging.2005.03.002; FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111; Ganji V, 2006, J NUTR, V136, P153, DOI 10.1093/jn/136.1.153; GATES GA, 1993, ARCH OTOLARYNGOL, V119, P156; Gates GA, 2002, J AM GERIATR SOC, V50, P482, DOI 10.1046/j.1532-5415.2002.50114.x; Gok U, 2004, AURIS NASUS LARYNX, V31, P19, DOI 10.1016/j.anl.2003.09.001; *HLTH COUNC NETH, 2003, 200304 HLTH COUNC NE; Houston DK, 1999, AM J CLIN NUTR, V69, P564; Hughson W., 1944, T AM ACAD OPHTHALMOL, V48, P1; Institute of Medicine Food and Nutrition Board., 1998, DIETARY REFERENCE IN, P150; International Organization for Standardization, 2000, 7029 ISO; Kim JM, 2002, J NUTR, V132, P3418, DOI 10.1093/jn/132.11.3418; Kumar M, 2003, CLIN OTOLARYNGOL, V28, P183, DOI 10.1046/j.1365-2273.2003.00682.x; Lee H, 2005, J NUTR, V135, P544, DOI 10.1093/jn/135.3.544; Marcucci R, 2005, J THROMB HAEMOST, V3, P929, DOI 10.1111/j.1538-7836.2005.01310.x; MULROW CD, 1990, ANN INTERN MED, V113, P188, DOI 10.7326/0003-4819-113-3-188; OZTURK H, 2005, NED TIJDSCHR KLIN CH, V30, P208; Ramaekers VT, 2004, DEV MED CHILD NEUROL, V46, P843, DOI 10.1017/S0012162204001471; Refsum H, 2004, CLIN CHEM, V50, P3, DOI 10.1373/clinchem.2003.021634; ROMAN GC, 1994, J NEUROL SCI, V127, P11, DOI 10.1016/0022-510X(94)90130-9; SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693; UBBINK JB, 1985, J CHROMATOGR, V342, P277, DOI 10.1016/S0378-4347(00)84518-1; UBBINK JB, 1991, J CHROMATOGR-BIOMED, V565, P441, DOI 10.1016/0378-4347(91)80407-4; *US CENS BUR, 1994, STAT ABSTR US; Vermeulen EGJ, 2004, EUR J CLIN INVEST, V34, P256, DOI 10.1111/j.1365-2362.2004.01332.x; [No title captured]	38	103	107	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 2	2007	146	1					1	W2		10.7326/0003-4819-146-1-200701020-00003	http://dx.doi.org/10.7326/0003-4819-146-1-200701020-00003			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188BK	17200216				2022-12-28	WOS:000247893300001
J	Turner, ML				Turner, Marc L.			Prion reduction filters	LANCET			English	Editorial Material							TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES; CREUTZFELDT-JAKOB-DISEASE; INFECTIVITY; BLOOD; PROTEIN; REMOVAL; CELLS; VCJD; UK		Royal Infirm Edinburgh NHS Trust, Edinburgh Blood Transfus Ctr, Edinburgh EH16 45A, Midlothian, Scotland	Royal Infirmary of Edinburgh	Turner, ML (corresponding author), Royal Infirm Edinburgh NHS Trust, Edinburgh Blood Transfus Ctr, Edinburgh EH16 45A, Midlothian, Scotland.	Marc.Turner@snbts.csa.scot.nhs.uk						Bishop MT, 2006, LANCET NEUROL, V5, P393, DOI 10.1016/S1474-4422(06)70413-6; Brandel JP, 2003, LANCET, V362, P128, DOI 10.1016/S0140-6736(03)13867-6; Brown P, 1998, TRANSFUSION, V38, P810, DOI 10.1046/j.1537-2995.1998.38998408999.x; Clarke P, 2005, J R SOC INTERFACE, V2, P19, DOI 10.1098/rsif.2004.0017; Collinge J, 2006, LANCET, V367, P2068, DOI 10.1016/S0140-6736(06)68930-7; Gregori L, 2004, LANCET, V364, P529, DOI 10.1016/S0140-6736(04)16812-8; Gregori L, 2006, TRANSFUSION, V46, P1152, DOI 10.1111/j.1537-2995.2006.00865.x; Gregori L, 2006, LANCET, V368, P2226, DOI 10.1016/S0140-6736(06)69897-8; Hilton DA, 2004, J PATHOL, V203, P733, DOI 10.1002/path.1580; Ironside JW, 2006, BRIT MED J, V332, P1186, DOI 10.1136/bmj.38804.511644.55; Llewelyn CA, 2004, LANCET, V363, P417, DOI 10.1016/S0140-6736(04)15486-X; Peden AH, 2004, LANCET, V364, P527, DOI 10.1016/S0140-6736(04)16811-6; Sowemimo-Coker S, 2005, TRANSFUSION, V45, P1839, DOI 10.1111/j.1537-2995.2005.00640.x; Sowemimo-Coker SO, 2006, VOX SANG, V90, P265, DOI 10.1111/j.1423-0410.2006.00765.x; *U ED, 2006, UK C JAK DIS SURV UN; Wadsworth JDF, 2004, SCIENCE, V306, P1793, DOI 10.1126/science.1103932	16	6	6	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 23	2006	368	9554					2190	2191		10.1016/S0140-6736(06)69872-3	http://dx.doi.org/10.1016/S0140-6736(06)69872-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	120HY	17189014				2022-12-28	WOS:000243076800006
J	Kim, PM; Lu, LJ; Xia, Y; Gerstein, MB				Kim, Philip M.; Lu, Long J.; Xia, Yu; Gerstein, Mark B.			Relating three-dimensional structures to protein networks provides evolutionary insights	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; NUMBER; MODULARITY; DEPENDENCE; DATABASE; BIOLOGY; GENOME	Most studies of protein networks operate on a high level of abstraction, neglecting structural and chemical aspects of each interaction. Here, we characterize interactions by using atomic-resolution information from three-dimensional protein structures. We find that some previously recognized relationships between network topology and genomic features ( e. g., hubs tending to be essential proteins) are actually more reflective of a structural quantity, the number of distinct binding interfaces. Subdividing hubs with respect to this quantity provides insight into their evolutionary rate and indicates that additional mechanisms of network growth are active in evolution ( beyond effective preferential attachment through gene duplication).	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Comp Sci, New Haven, CT 06520 USA; Yale Univ, Program Computat Biol & Bioinformat, New Haven, CT 06520 USA; Boston Univ, Dept Chem, Boston, MA 02215 USA	Yale University; Yale University; Yale University; Boston University	Gerstein, MB (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA.	mark.gerstein@yale.edu	lu, lu/HGA-0894-2022; Xia, Yu/W-6150-2019; lu, lu/HII-7530-2022	Xia, Yu/0000-0002-5596-5518; 	NCRR NIH HHS [RR19895] Funding Source: Medline; NHLBI NIH HHS [N01-HV-28186] Funding Source: Medline; DIVISION OF HEART AND VASCULAR DISEASES [N01HV028186] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR019895] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF HEART AND VASCULAR DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Albert R, 2002, REV MOD PHYS, V74, P47, DOI 10.1103/RevModPhys.74.47; Aloy P, 2006, NAT REV MOL CELL BIO, V7, P188, DOI 10.1038/nrm1859; Aloy P, 2004, NAT BIOTECHNOL, V22, P1317, DOI 10.1038/nbt1018; Bader GD, 2002, NAT BIOTECHNOL, V20, P991, DOI 10.1038/nbt1002-991; Barabasi AL, 2004, NAT REV GENET, V5, P101, DOI 10.1038/nrg1272; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Bloom JD, 2003, BMC EVOL BIOL, V3, DOI 10.1186/1471-2148-3-21; de Lichtenberg U, 2005, SCIENCE, V307, P724, DOI 10.1126/science.1105103; Eisenberg E, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.138701; Espadaler J, 2005, P NATL ACAD SCI USA, V102, P7151, DOI 10.1073/pnas.0500831102; Finn RD, 2005, BIOINFORMATICS, V21, P410, DOI 10.1093/bioinformatics/bti011; Fraser HB, 2002, SCIENCE, V296, P750, DOI 10.1126/science.1068696; Fraser HB, 2004, BMC EVOL BIOL, V4, DOI 10.1186/1471-2148-4-13; Gavin AC, 2006, NATURE, V440, P631, DOI 10.1038/nature04532; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Han JDJ, 2004, NATURE, V430, P88, DOI 10.1038/nature02555; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Issel-Tarver L, 2002, METHOD ENZYMOL, V350, P329, DOI 10.1016/S0076-6879(02)50972-1; Jansen R, 2003, SCIENCE, V302, P449, DOI 10.1126/science.1087361; Jeong H, 2001, NATURE, V411, P41, DOI 10.1038/35075138; Jordan IK, 2003, BMC EVOL BIOL, V3, DOI 10.1186/1471-2148-3-1; Kelley R, 2005, NAT BIOTECHNOL, V23, P561, DOI 10.1038/nbt1096; KIM PM, 2003, THESIS MIT CAMBRIDGE, P1; Lee I, 2004, SCIENCE, V306, P1555, DOI 10.1126/science.1099511; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Valdar WSJ, 2001, PROTEINS, V42, P108; VAZQUEZ A, 2003, PHYS REV E, V67; Wagner A, 2003, P ROY SOC B-BIOL SCI, V270, P457, DOI 10.1098/rspb.2002.2269; Wall DP, 2005, P NATL ACAD SCI USA, V102, P5483, DOI 10.1073/pnas.0501761102; Wuchty S, 2004, GENOME RES, V14, P1310, DOI 10.1101/gr.2300204	30	380	383	1	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 22	2006	314	5807					1938	1941		10.1126/science.1136174	http://dx.doi.org/10.1126/science.1136174			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	119EY	17185604				2022-12-28	WOS:000242996800053
J	Braithwaite, RS; Roberts, MS; Justice, AC				Braithwaite, R. Scott; Roberts, Mark S.; Justice, Amy C.			Incorporating quality of evidence into decision analytic modeling	ANNALS OF INTERNAL MEDICINE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; COST-EFFECTIVENESS ANALYSIS; SELF-ADMINISTERED THERAPY; INFECTED DRUG-USERS; HIV-INFECTION; ADHERENCE; WOMEN; TUBERCULOSIS; METAANALYSIS; UNCERTAINTY	Our objective was to illustrate the effects of using stricter standards for the quality of evidence used in decision analytic modeling. We created a simple 10-parameter probabilistic Markov model to estimate the cost-effectiveness of directly observed therapy (DOT) for individuals with newly diagnosed HIV infection. We evaluated quality of evidence on the basis of U.S. Preventive Services Task Force methods, which specified 3 separate domains: study design, internal validity, and external validity. We varied the evidence criteria for each of these domains individually and collectively. We used published research as a source of data only if the quality of the research met specified criteria; otherwise, we specified the parameter by randomly choosing a number from a range within which every number has the same probability of being selected (a uniform distribution). When we did not eliminate poor-quality evidence, DOT improved health 99% of the time and cost less than $100 000 per additional quality-adjusted life-year (QALY) 85% of the time. The confidence ellipse was extremely narrow, suggesting high precision. When we used the most rigorous standards of evidence, we could use fewer than one fifth of the data sources, and DOT improved health only 49% of the time and cost less than $100 000 per additional QALY only 4% of the time. The confidence ellipse became much larger, showing that the results were less precise. We conclude that the results of decision modeling may vary dramatically depending on the stringency of the criteria for selecting evidence to use in the model.	Yale Univ, Sch Med, Vet Affairs Connecticut Healthcare Syst, West Haven, CT 06516 USA; Univ Pittsburgh, Sch Med, Pittsburgh, PA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Yale University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Braithwaite, RS (corresponding author), Yale Univ, Sch Med, Vet Affairs Connecticut Healthcare Syst, Mailstop 11 ACSLG,950 Campbell Ave, West Haven, CT 06516 USA.	ronald.braithwaite@va.gov		Braithwaite, Ronald Scott/0000-0001-7067-3655	NIAAA NIH HHS [K23 AA14483-01] Funding Source: Medline; NIAAA NIH HHS [U24 AA020794, K23 AA14483-01, K23 AA014483] Funding Source: Medline	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Altice FL, 2004, CLIN INFECT DIS, V38, pS376, DOI 10.1086/421400; Anderson K, 2006, ANN INTERN MED, V144, P397, DOI 10.7326/0003-4819-144-6-200603210-00006; Arias Elizabeth, 2004, Natl Vital Stat Rep, V53, P1; Arnsten JH, 2002, J GEN INTERN MED, V17, P377, DOI 10.1007/s11606-002-0044-3; Bozzette SA, 2001, NEW ENGL J MED, V344, P817, DOI 10.1056/NEJM200103153441107; Braithwaite RS, 2006, J ANTIMICROB CHEMOTH, V58, P1036, DOI 10.1093/jac/dkl386; Braithwaite RS, 2005, AM J MED, V118, P890, DOI 10.1016/j.amjmed.2004.12.034; BRAITHWAITE RS, IN PRESS VALUE HLTH; Burman WJ, 1997, CHEST, V112, P63, DOI 10.1378/chest.112.1.63; Burstrom K, 2001, QUAL LIFE RES, V10, P621, DOI 10.1023/A:1013171831202; Claxton K, 2005, HEALTH ECON, V14, P339, DOI 10.1002/hec.985; *COCHR COLL, 2002, REV MAN 4 2 WIND; Cooper NJ, 2002, STAT METHODS MED RES, V11, P491, DOI 10.1191/0962280202sm306ra; Doubilet P, 1985, Med Decis Making, V5, P157, DOI 10.1177/0272989X8500500205; EDDY DM, 1990, MED DECIS MAKING, V10, P15, DOI 10.1177/0272989X9001000104; Egger M, 2002, LANCET, V360, P119, DOI 10.1016/S0140-6736(02)09411-4; Enger C, 1996, JAMA-J AM MED ASSOC, V275, P1329, DOI 10.1001/jama.275.17.1329; Fenwick E, 2001, HEALTH ECON, V10, P779, DOI 10.1002/hec.635; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Freedberg KA, 1998, JAMA-J AM MED ASSOC, V279, P130, DOI 10.1001/jama.279.2.130; Gold MR, 1996, COST EFFECTIVENESS H; Goldie SJ, 2003, AM J MED, V115, P632, DOI 10.1016/j.amjmed.2003.07.007; Greenland S, 2005, J R STAT SOC A STAT, V168, P267, DOI 10.1111/j.1467-985X.2004.00349.x; Guyatt GH, 2000, JAMA-J AM MED ASSOC, V284, P1290, DOI 10.1001/jama.284.10.1290; Harris RP, 2001, AM J PREV MED, V20, P21, DOI 10.1016/S0749-3797(01)00261-6; Haubrich RH, 1999, AIDS, V13, P1099, DOI 10.1097/00002030-199906180-00014; Howard AA, 2002, AIDS, V16, P2175, DOI 10.1097/00002030-200211080-00010; Juni P, 1999, JAMA-J AM MED ASSOC, V282, P1054, DOI 10.1001/jama.282.11.1054; Kanis JA, 2004, OSTEOPOROSIS INT, V15, P20, DOI 10.1007/s00198-003-1463-7; Leibson CL, 2002, J AM GERIATR SOC, V50, P1644, DOI 10.1046/j.1532-5415.2002.50455.x; Lohr KN, 2004, INT J QUAL HEALTH C, V16, P9, DOI 10.1093/intqhc/mzh005; Moore RD, 1996, AM J RESP CRIT CARE, V154, P1013, DOI 10.1164/ajrccm.154.4.8887600; Neumann PJ, 2004, AM J MANAG CARE, V10, P308; Palmer C S, 1998, J Public Health Manag Pract, V4, P1; Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004; Rothwell PM, 2005, LANCET, V365, P82, DOI 10.1016/S0140-6736(04)17670-8; Schousboe JT, 2005, ANN INTERN MED, V142, P734, DOI 10.7326/0003-4819-142-9-200505030-00008; Spiegelhalter DJ, 2003, STAT MED, V22, P3687, DOI 10.1002/sim.1586	38	54	54	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 16	2007	146	2					133	141		10.7326/0003-4819-146-2-200701160-00008	http://dx.doi.org/10.7326/0003-4819-146-2-200701160-00008			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	131WF	17227937	Green Accepted			2022-12-28	WOS:000243901000007
